
PMID- 24569914
OWN - NLM
STAT- MEDLINE
DCOM- 20141209
LR  - 20161017
IS  - 1569-8041 (Electronic)
IS  - 0923-7534 (Linking)
VI  - 25
IP  - 5
DP  - 2014 May
TI  - Phase III placebo-controlled double-blind randomized trial of radiotherapy for
      stage IIB-IVA cervical cancer with or without immunomodulator Z-100: a JGOG
      study.
PG  - 1011-7
LID - 10.1093/annonc/mdu057 [doi]
AB  - BACKGROUND: Based on the result of our previous study showing better overall
      survival (OS) at the lower dose (0.2 microg) of immunomodulator Z-100 than higher
      dose (40 microg) in patients with locally advanced cervical cancer who received
      radiotherapy, we conducted a placebo-controlled double-blind randomized trial.
      PATIENTS AND METHODS: Patients of stages IIB-IVA squamous cell carcinoma of the
      uterine cervix were randomly assigned to receive Z-100 at 0.2 microg (Z) or
      placebo (P). The study agent was given subcutaneously twice a week during the
      radiotherapy, followed by maintenance therapy by administering once every 2 weeks
      until disease progression. Primary end point was OS, and secondary end points
      were recurrence-free survival, and toxicity. RESULTS: A total of 249 patients
      were randomized. Death events occurred extremely slower than expected, and
      Independent Data Monitoring Committee recommended to analyze the survival result 
      prematurely. The 5-year OS rate was 75.7% [95% confidence interval (CI) 66.4% to 
      82.8%] for Arm Z and 65.8% (95% CI 56.2% to 73.8%) for Arm P (P = 0.07); hazard
      ratio was 0.65 (95% CI 0.40-1.04). Survival benefit in Arm Z was observed
      regardless of chemoradiation or radiation alone. There was no trend in
      recurrence-free survival between the two arms. Side-effects were not different
      between two arms. CONCLUSION: Z-100 showed a trend of improvement on OS in
      locally advanced cervical cancer, although the statistical power was less than
      anticipated because survival rates were unexpectedly higher than expected for
      both arms. Validation of potential survival benefit of immune modulation should
      be made. TRIAL REGISTRATION: umin.ac.jp/ctr Identifier: C000000221.
FAU - Sugiyama, T
AU  - Sugiyama T
AD  - Department of Obstetrics and Gynecology, Iwate Medical University School of
      Medicine, Morioka.
FAU - Fujiwara, K
AU  - Fujiwara K
FAU - Ohashi, Y
AU  - Ohashi Y
FAU - Yokota, H
AU  - Yokota H
FAU - Hatae, M
AU  - Hatae M
FAU - Ohno, T
AU  - Ohno T
FAU - Nagai, Y
AU  - Nagai Y
FAU - Mitsuhashi, N
AU  - Mitsuhashi N
FAU - Ochiai, K
AU  - Ochiai K
FAU - Noda, K
AU  - Noda K
LA  - eng
PT  - Clinical Trial, Phase III
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20140225
PL  - England
TA  - Ann Oncol
JT  - Annals of oncology : official journal of the European Society for Medical
      Oncology
JID - 9007735
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Lipids)
RN  - 0 (Mannans)
RN  - 0 (specific substance maruyama)
SB  - IM
MH  - Adjuvants, Immunologic/*therapeutic use
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/*therapeutic use
MH  - Carcinoma, Squamous Cell/mortality/pathology/*therapy
MH  - Chemoradiotherapy
MH  - Disease-Free Survival
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Lipids/*therapeutic use
MH  - Mannans/*therapeutic use
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Proportional Hazards Models
MH  - Uterine Cervical Neoplasms/mortality/pathology/*therapy
OTO - NOTNLM
OT  - Z-100
OT  - cervical cancer of the uterus
OT  - chemoradiotherapy
OT  - dose of immunomodulator
OT  - immunotherapy
OT  - radiotherapy
EDAT- 2014/02/27 06:00
MHDA- 2014/12/15 06:00
CRDT- 2014/02/27 06:00
PHST- 2014/02/27 06:00 [entrez]
PHST- 2014/02/27 06:00 [pubmed]
PHST- 2014/12/15 06:00 [medline]
AID - mdu057 [pii]
AID - 10.1093/annonc/mdu057 [doi]
PST - ppublish
SO  - Ann Oncol. 2014 May;25(5):1011-7. doi: 10.1093/annonc/mdu057. Epub 2014 Feb 25.

PMID- 29211679
OWN - NLM
STAT- MEDLINE
DCOM- 20171215
LR  - 20171215
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 377
IP  - 23
DP  - 2017 Dec 7
TI  - Contemporary Hormonal Contraception and the Risk of Breast Cancer.
PG  - 2228-2239
LID - 10.1056/NEJMoa1700732 [doi]
AB  - BACKGROUND: Little is known about whether contemporary hormonal contraception is 
      associated with an increased risk of breast cancer. METHODS: We assessed
      associations between the use of hormonal contraception and the risk of invasive
      breast cancer in a nationwide prospective cohort study involving all women in
      Denmark between 15 and 49 years of age who had not had cancer or venous
      thromboembolism and who had not received treatment for infertility. Nationwide
      registries provided individually updated information about the use of hormonal
      contraception, breast-cancer diagnoses, and potential confounders. RESULTS: Among
      1.8 million women who were followed on average for 10.9 years (a total of 19.6
      million person-years), 11,517 cases of breast cancer occurred. As compared with
      women who had never used hormonal contraception, the relative risk of breast
      cancer among all current and recent users of hormonal contraception was 1.20 (95%
      confidence interval [CI], 1.14 to 1.26). This risk increased from 1.09 (95% CI,
      0.96 to 1.23) with less than 1 year of use to 1.38 (95% CI, 1.26 to 1.51) with
      more than 10 years of use (P=0.002). After discontinuation of hormonal
      contraception, the risk of breast cancer was still higher among the women who had
      used hormonal contraceptives for 5 years or more than among women who had not
      used hormonal contraceptives. Risk estimates associated with current or recent
      use of various oral combination (estrogen-progestin) contraceptives varied
      between 1.0 and 1.6. Women who currently or recently used the progestin-only
      intrauterine system also had a higher risk of breast cancer than women who had
      never used hormonal contraceptives (relative risk, 1.21; 95% CI, 1.11 to 1.33).
      The overall absolute increase in breast cancers diagnosed among current and
      recent users of any hormonal contraceptive was 13 (95% CI, 10 to 16) per 100,000 
      person-years, or approximately 1 extra breast cancer for every 7690 women using
      hormonal contraception for 1 year. CONCLUSIONS: The risk of breast cancer was
      higher among women who currently or recently used contemporary hormonal
      contraceptives than among women who had never used hormonal contraceptives, and
      this risk increased with longer durations of use; however, absolute increases in 
      risk were small. (Funded by the Novo Nordisk Foundation.).
FAU - Morch, Lina S
AU  - Morch LS
AD  - From Rigshospitalet, the Juliane Marie Center, Department of Gynecology,
      University of Copenhagen, Copenhagen (L.S.M., C.W.S., O.L.); and Academic Primary
      Care (P.C.H., L.I.) and Medical Statistics (S.F.), Institute of Applied Health
      Sciences, University of Aberdeen, Aberdeen, United Kingdom.
FAU - Skovlund, Charlotte W
AU  - Skovlund CW
AD  - From Rigshospitalet, the Juliane Marie Center, Department of Gynecology,
      University of Copenhagen, Copenhagen (L.S.M., C.W.S., O.L.); and Academic Primary
      Care (P.C.H., L.I.) and Medical Statistics (S.F.), Institute of Applied Health
      Sciences, University of Aberdeen, Aberdeen, United Kingdom.
FAU - Hannaford, Philip C
AU  - Hannaford PC
AD  - From Rigshospitalet, the Juliane Marie Center, Department of Gynecology,
      University of Copenhagen, Copenhagen (L.S.M., C.W.S., O.L.); and Academic Primary
      Care (P.C.H., L.I.) and Medical Statistics (S.F.), Institute of Applied Health
      Sciences, University of Aberdeen, Aberdeen, United Kingdom.
FAU - Iversen, Lisa
AU  - Iversen L
AD  - From Rigshospitalet, the Juliane Marie Center, Department of Gynecology,
      University of Copenhagen, Copenhagen (L.S.M., C.W.S., O.L.); and Academic Primary
      Care (P.C.H., L.I.) and Medical Statistics (S.F.), Institute of Applied Health
      Sciences, University of Aberdeen, Aberdeen, United Kingdom.
FAU - Fielding, Shona
AU  - Fielding S
AD  - From Rigshospitalet, the Juliane Marie Center, Department of Gynecology,
      University of Copenhagen, Copenhagen (L.S.M., C.W.S., O.L.); and Academic Primary
      Care (P.C.H., L.I.) and Medical Statistics (S.F.), Institute of Applied Health
      Sciences, University of Aberdeen, Aberdeen, United Kingdom.
FAU - Lidegaard, Ojvind
AU  - Lidegaard O
AD  - From Rigshospitalet, the Juliane Marie Center, Department of Gynecology,
      University of Copenhagen, Copenhagen (L.S.M., C.W.S., O.L.); and Academic Primary
      Care (P.C.H., L.I.) and Medical Statistics (S.F.), Institute of Applied Health
      Sciences, University of Aberdeen, Aberdeen, United Kingdom.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Contraceptives, Oral, Hormonal)
RN  - 0 (Estrogens)
RN  - 0 (Progestins)
RN  - 4TI98Z838E (Estradiol)
SB  - AIM
SB  - IM
CIN - N Engl J Med. 2017 Dec 7;377(23 ):2276-2277. PMID: 29211666
MH  - Adolescent
MH  - Adult
MH  - Age Distribution
MH  - Breast Neoplasms/*chemically induced/epidemiology
MH  - Contraceptives, Oral, Hormonal/*adverse effects
MH  - Denmark/epidemiology
MH  - Estradiol/adverse effects
MH  - Estrogens/adverse effects
MH  - Female
MH  - Humans
MH  - Intrauterine Devices, Medicated/*adverse effects
MH  - Progestins/adverse effects
MH  - Prospective Studies
MH  - Registries
MH  - Risk
MH  - Risk Assessment
MH  - Time Factors
MH  - Young Adult
EDAT- 2017/12/07 06:00
MHDA- 2017/12/16 06:00
CRDT- 2017/12/07 06:00
PHST- 2017/12/07 06:00 [entrez]
PHST- 2017/12/07 06:00 [pubmed]
PHST- 2017/12/16 06:00 [medline]
AID - 10.1056/NEJMoa1700732 [doi]
PST - ppublish
SO  - N Engl J Med. 2017 Dec 7;377(23):2228-2239. doi: 10.1056/NEJMoa1700732.

PMID- 29056346
OWN - NLM
STAT- MEDLINE
DCOM- 20171215
LR  - 20171219
IS  - 1097-4172 (Electronic)
IS  - 0092-8674 (Linking)
VI  - 171
IP  - 5
DP  - 2017 Nov 16
TI  - Universal Patterns of Selection in Cancer and Somatic Tissues.
PG  - 1029-1041.e21
LID - S0092-8674(17)31136-4 [pii]
LID - 10.1016/j.cell.2017.09.042 [doi]
AB  - Cancer develops as a result of somatic mutation and clonal selection, but
      quantitative measures of selection in cancer evolution are lacking. We adapted
      methods from molecular evolution and applied them to 7,664 tumors across 29
      cancer types. Unlike species evolution, positive selection outweighs negative
      selection during cancer development. On average, <1 coding base
      substitution/tumor is lost through negative selection, with purifying selection
      almost absent outside homozygous loss of essential genes. This allows exome-wide 
      enumeration of all driver coding mutations, including outside known cancer genes.
      On average, tumors carry approximately 4 coding substitutions under positive
      selection, ranging from <1/tumor in thyroid and testicular cancers to >10/tumor
      in endometrial and colorectal cancers. Half of driver substitutions occur in
      yet-to-be-discovered cancer genes. With increasing mutation burden, numbers of
      driver mutations increase, but not linearly. We systematically catalog cancer
      genes and show that genes vary extensively in what proportion of mutations are
      drivers versus passengers.
CI  - Copyright (c) 2017 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Martincorena, Inigo
AU  - Martincorena I
AD  - Wellcome Trust Sanger Institute, Hinxton CB10 1SA, Cambridgeshire, UK. Electronic
      address: im3@sanger.ac.uk.
FAU - Raine, Keiran M
AU  - Raine KM
AD  - Wellcome Trust Sanger Institute, Hinxton CB10 1SA, Cambridgeshire, UK.
FAU - Gerstung, Moritz
AU  - Gerstung M
AD  - European Molecular Biology Laboratory, European Bioinformatics Institute
      EMBL-EBI, Hinxton CB10 1SD, UK.
FAU - Dawson, Kevin J
AU  - Dawson KJ
AD  - Wellcome Trust Sanger Institute, Hinxton CB10 1SA, Cambridgeshire, UK.
FAU - Haase, Kerstin
AU  - Haase K
AD  - The Francis Crick Institute, London NW1 1AT, UK.
FAU - Van Loo, Peter
AU  - Van Loo P
AD  - The Francis Crick Institute, London NW1 1AT, UK; Department of Human Genetics,
      University of Leuven, Leuven 3000, Belgium.
FAU - Davies, Helen
AU  - Davies H
AD  - Wellcome Trust Sanger Institute, Hinxton CB10 1SA, Cambridgeshire, UK.
FAU - Stratton, Michael R
AU  - Stratton MR
AD  - Wellcome Trust Sanger Institute, Hinxton CB10 1SA, Cambridgeshire, UK.
FAU - Campbell, Peter J
AU  - Campbell PJ
AD  - Wellcome Trust Sanger Institute, Hinxton CB10 1SA, Cambridgeshire, UK; Department
      of Haematology, University of Cambridge, Cambridge CB2 2XY, UK. Electronic
      address: pc8@sanger.ac.uk.
LA  - eng
GR  - Wellcome Trust/United Kingdom
PT  - Journal Article
DEP - 20171019
PL  - United States
TA  - Cell
JT  - Cell
JID - 0413066
SB  - IM
MH  - Humans
MH  - INDEL Mutation
MH  - Microsatellite Instability
MH  - Models, Genetic
MH  - Mutation Rate
MH  - Neoplasms/*genetics/immunology/*pathology
MH  - Point Mutation
MH  - Polymorphism, Single Nucleotide
MH  - Selection, Genetic
PMC - PMC5720395
OTO - NOTNLM
OT  - cancer
OT  - evolution
OT  - genomics
OT  - mutations
OT  - selection
EDAT- 2017/10/24 06:00
MHDA- 2017/12/16 06:00
CRDT- 2017/10/24 06:00
PHST- 2017/04/13 00:00 [received]
PHST- 2017/08/09 00:00 [revised]
PHST- 2017/09/22 00:00 [accepted]
PHST- 2017/10/24 06:00 [pubmed]
PHST- 2017/12/16 06:00 [medline]
PHST- 2017/10/24 06:00 [entrez]
AID - S0092-8674(17)31136-4 [pii]
AID - 10.1016/j.cell.2017.09.042 [doi]
PST - ppublish
SO  - Cell. 2017 Nov 16;171(5):1029-1041.e21. doi: 10.1016/j.cell.2017.09.042. Epub
      2017 Oct 19.

PMID- 29117498
OWN - NLM
STAT- MEDLINE
DCOM- 20171116
LR  - 20180106
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 377
IP  - 19
DP  - 2017 Nov 9
TI  - 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5
      Years.
PG  - 1836-1846
LID - 10.1056/NEJMoa1701830 [doi]
AB  - BACKGROUND: The administration of endocrine therapy for 5 years substantially
      reduces recurrence rates during and after treatment in women with early-stage,
      estrogen-receptor (ER)-positive breast cancer. Extending such therapy beyond 5
      years offers further protection but has additional side effects. Obtaining data
      on the absolute risk of subsequent distant recurrence if therapy stops at 5 years
      could help determine whether to extend treatment. METHODS: In this meta-analysis 
      of the results of 88 trials involving 62,923 women with ER-positive breast cancer
      who were disease-free after 5 years of scheduled endocrine therapy, we used
      Kaplan-Meier and Cox regression analyses, stratified according to trial and
      treatment, to assess the associations of tumor diameter and nodal status (TN),
      tumor grade, and other factors with patients' outcomes during the period from 5
      to 20 years. RESULTS: Breast-cancer recurrences occurred at a steady rate
      throughout the study period from 5 to 20 years. The risk of distant recurrence
      was strongly correlated with the original TN status. Among the patients with
      stage T1 disease, the risk of distant recurrence was 13% with no nodal
      involvement (T1N0), 20% with one to three nodes involved (T1N1-3), and 34% with
      four to nine nodes involved (T1N4-9); among those with stage T2 disease, the
      risks were 19% with T2N0, 26% with T2N1-3, and 41% with T2N4-9. The risk of death
      from breast cancer was similarly dependent on TN status, but the risk of
      contralateral breast cancer was not. Given the TN status, the factors of tumor
      grade (available in 43,590 patients) and Ki-67 status (available in 7692
      patients), which are strongly correlated with each other, were of only moderate
      independent predictive value for distant recurrence, but the status regarding the
      progesterone receptor (in 54,115 patients) and human epidermal growth factor
      receptor type 2 (HER2) (in 15,418 patients in trials with no use of trastuzumab) 
      was not predictive. During the study period from 5 to 20 years, the absolute risk
      of distant recurrence among patients with T1N0 breast cancer was 10% for
      low-grade disease, 13% for moderate-grade disease, and 17% for high-grade
      disease; the corresponding risks of any recurrence or a contralateral breast
      cancer were 17%, 22%, and 26%, respectively. CONCLUSIONS: After 5 years of
      adjuvant endocrine therapy, breast-cancer recurrences continued to occur steadily
      throughout the study period from 5 to 20 years. The risk of distant recurrence
      was strongly correlated with the original TN status, with risks ranging from 10
      to 41%, depending on TN status and tumor grade. (Funded by Cancer Research UK and
      others.).
FAU - Pan, Hongchao
AU  - Pan H
AD  - From the Medical Research Council Population Health Research Unit, Nuffield
      Department of Population Health, University of Oxford, Oxford (H.P., R.G., J.
      Braybrooke, C.D., C.T., P.M., R.P.), and Royal Marsden Hospital and Institute of 
      Cancer Research, London (M.D.) - both in the United Kingdom; Sunnybrook Health
      Sciences Centre and the University of Toronto, Toronto (K.I.P.); Karolinska
      Institutet and Karolinska University Hospital, Stockholm (J. Bergh); and the
      University of Michigan Comprehensive Cancer Center, Ann Arbor (D.F.H.).
FAU - Gray, Richard
AU  - Gray R
AD  - From the Medical Research Council Population Health Research Unit, Nuffield
      Department of Population Health, University of Oxford, Oxford (H.P., R.G., J.
      Braybrooke, C.D., C.T., P.M., R.P.), and Royal Marsden Hospital and Institute of 
      Cancer Research, London (M.D.) - both in the United Kingdom; Sunnybrook Health
      Sciences Centre and the University of Toronto, Toronto (K.I.P.); Karolinska
      Institutet and Karolinska University Hospital, Stockholm (J. Bergh); and the
      University of Michigan Comprehensive Cancer Center, Ann Arbor (D.F.H.).
FAU - Braybrooke, Jeremy
AU  - Braybrooke J
AD  - From the Medical Research Council Population Health Research Unit, Nuffield
      Department of Population Health, University of Oxford, Oxford (H.P., R.G., J.
      Braybrooke, C.D., C.T., P.M., R.P.), and Royal Marsden Hospital and Institute of 
      Cancer Research, London (M.D.) - both in the United Kingdom; Sunnybrook Health
      Sciences Centre and the University of Toronto, Toronto (K.I.P.); Karolinska
      Institutet and Karolinska University Hospital, Stockholm (J. Bergh); and the
      University of Michigan Comprehensive Cancer Center, Ann Arbor (D.F.H.).
FAU - Davies, Christina
AU  - Davies C
AD  - From the Medical Research Council Population Health Research Unit, Nuffield
      Department of Population Health, University of Oxford, Oxford (H.P., R.G., J.
      Braybrooke, C.D., C.T., P.M., R.P.), and Royal Marsden Hospital and Institute of 
      Cancer Research, London (M.D.) - both in the United Kingdom; Sunnybrook Health
      Sciences Centre and the University of Toronto, Toronto (K.I.P.); Karolinska
      Institutet and Karolinska University Hospital, Stockholm (J. Bergh); and the
      University of Michigan Comprehensive Cancer Center, Ann Arbor (D.F.H.).
FAU - Taylor, Carolyn
AU  - Taylor C
AD  - From the Medical Research Council Population Health Research Unit, Nuffield
      Department of Population Health, University of Oxford, Oxford (H.P., R.G., J.
      Braybrooke, C.D., C.T., P.M., R.P.), and Royal Marsden Hospital and Institute of 
      Cancer Research, London (M.D.) - both in the United Kingdom; Sunnybrook Health
      Sciences Centre and the University of Toronto, Toronto (K.I.P.); Karolinska
      Institutet and Karolinska University Hospital, Stockholm (J. Bergh); and the
      University of Michigan Comprehensive Cancer Center, Ann Arbor (D.F.H.).
FAU - McGale, Paul
AU  - McGale P
AD  - From the Medical Research Council Population Health Research Unit, Nuffield
      Department of Population Health, University of Oxford, Oxford (H.P., R.G., J.
      Braybrooke, C.D., C.T., P.M., R.P.), and Royal Marsden Hospital and Institute of 
      Cancer Research, London (M.D.) - both in the United Kingdom; Sunnybrook Health
      Sciences Centre and the University of Toronto, Toronto (K.I.P.); Karolinska
      Institutet and Karolinska University Hospital, Stockholm (J. Bergh); and the
      University of Michigan Comprehensive Cancer Center, Ann Arbor (D.F.H.).
FAU - Peto, Richard
AU  - Peto R
AD  - From the Medical Research Council Population Health Research Unit, Nuffield
      Department of Population Health, University of Oxford, Oxford (H.P., R.G., J.
      Braybrooke, C.D., C.T., P.M., R.P.), and Royal Marsden Hospital and Institute of 
      Cancer Research, London (M.D.) - both in the United Kingdom; Sunnybrook Health
      Sciences Centre and the University of Toronto, Toronto (K.I.P.); Karolinska
      Institutet and Karolinska University Hospital, Stockholm (J. Bergh); and the
      University of Michigan Comprehensive Cancer Center, Ann Arbor (D.F.H.).
FAU - Pritchard, Kathleen I
AU  - Pritchard KI
AD  - From the Medical Research Council Population Health Research Unit, Nuffield
      Department of Population Health, University of Oxford, Oxford (H.P., R.G., J.
      Braybrooke, C.D., C.T., P.M., R.P.), and Royal Marsden Hospital and Institute of 
      Cancer Research, London (M.D.) - both in the United Kingdom; Sunnybrook Health
      Sciences Centre and the University of Toronto, Toronto (K.I.P.); Karolinska
      Institutet and Karolinska University Hospital, Stockholm (J. Bergh); and the
      University of Michigan Comprehensive Cancer Center, Ann Arbor (D.F.H.).
FAU - Bergh, Jonas
AU  - Bergh J
AD  - From the Medical Research Council Population Health Research Unit, Nuffield
      Department of Population Health, University of Oxford, Oxford (H.P., R.G., J.
      Braybrooke, C.D., C.T., P.M., R.P.), and Royal Marsden Hospital and Institute of 
      Cancer Research, London (M.D.) - both in the United Kingdom; Sunnybrook Health
      Sciences Centre and the University of Toronto, Toronto (K.I.P.); Karolinska
      Institutet and Karolinska University Hospital, Stockholm (J. Bergh); and the
      University of Michigan Comprehensive Cancer Center, Ann Arbor (D.F.H.).
FAU - Dowsett, Mitch
AU  - Dowsett M
AD  - From the Medical Research Council Population Health Research Unit, Nuffield
      Department of Population Health, University of Oxford, Oxford (H.P., R.G., J.
      Braybrooke, C.D., C.T., P.M., R.P.), and Royal Marsden Hospital and Institute of 
      Cancer Research, London (M.D.) - both in the United Kingdom; Sunnybrook Health
      Sciences Centre and the University of Toronto, Toronto (K.I.P.); Karolinska
      Institutet and Karolinska University Hospital, Stockholm (J. Bergh); and the
      University of Michigan Comprehensive Cancer Center, Ann Arbor (D.F.H.).
FAU - Hayes, Daniel F
AU  - Hayes DF
AD  - From the Medical Research Council Population Health Research Unit, Nuffield
      Department of Population Health, University of Oxford, Oxford (H.P., R.G., J.
      Braybrooke, C.D., C.T., P.M., R.P.), and Royal Marsden Hospital and Institute of 
      Cancer Research, London (M.D.) - both in the United Kingdom; Sunnybrook Health
      Sciences Centre and the University of Toronto, Toronto (K.I.P.); Karolinska
      Institutet and Karolinska University Hospital, Stockholm (J. Bergh); and the
      University of Michigan Comprehensive Cancer Center, Ann Arbor (D.F.H.).
CN  - EBCTCG
LA  - eng
GR  - K12 HD055929/HD/NICHD NIH HHS/United States
GR  - P30 AG028740/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Estrogen Antagonists)
RN  - 0 (Receptors, Estrogen)
SB  - AIM
SB  - IM
MH  - Adult
MH  - Aged
MH  - *Breast Neoplasms/drug therapy/mortality/pathology
MH  - Chemotherapy, Adjuvant
MH  - Drug Administration Schedule
MH  - Estrogen Antagonists/*therapeutic use
MH  - Female
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Lymphatic Metastasis
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Neoplasm Metastasis
MH  - Neoplasm Recurrence, Local
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Receptors, Estrogen
MH  - Recurrence
MH  - Risk
PMC - PMC5734609
MID - EMS75008
IR  - Albain K
FIR - Albain, K
IR  - Anderson S
FIR - Anderson, S
IR  - Arriagada R
FIR - Arriagada, R
IR  - Barlow W
FIR - Barlow, W
IR  - Bartlett J
FIR - Bartlett, J
IR  - Bergsten-Nordstrom E
FIR - Bergsten-Nordstrom, E
IR  - Bliss J
FIR - Bliss, J
IR  - Boccardo F
FIR - Boccardo, F
IR  - Bradley R
FIR - Bradley, R
IR  - Brain E
FIR - Brain, E
IR  - Cameron D
FIR - Cameron, D
IR  - Clarke M
FIR - Clarke, M
IR  - Coates A
FIR - Coates, A
IR  - Coleman R
FIR - Coleman, R
IR  - Correa C
FIR - Correa, C
IR  - Costantino J
FIR - Costantino, J
IR  - Cuzick J
FIR - Cuzick, J
IR  - Davidson N
FIR - Davidson, N
IR  - Dodwell D
FIR - Dodwell, D
IR  - Di Leo A
FIR - Di Leo, A
IR  - Ewertz M
FIR - Ewertz, M
IR  - Forbes J
FIR - Forbes, J
IR  - Gelber R
FIR - Gelber, R
IR  - Gnant M
FIR - Gnant, M
IR  - Goldhirsch A
FIR - Goldhirsch, A
IR  - Goodwin P
FIR - Goodwin, P
IR  - Hill C
FIR - Hill, C
IR  - Ingle J
FIR - Ingle, J
IR  - Jagsi R
FIR - Jagsi, R
IR  - Janni W
FIR - Janni, W
IR  - Loibl S
FIR - Loibl, S
IR  - MacKinnon E
FIR - MacKinnon, E
IR  - Martin M
FIR - Martin, M
IR  - Mukai H
FIR - Mukai, H
IR  - Norton L
FIR - Norton, L
IR  - Ohashi Y
FIR - Ohashi, Y
IR  - Paik S
FIR - Paik, S
IR  - Perez E
FIR - Perez, E
IR  - Piccart M
FIR - Piccart, M
IR  - Pierce L
FIR - Pierce, L
IR  - Poortmans P
FIR - Poortmans, P
IR  - Raina V
FIR - Raina, V
IR  - Ravdin P
FIR - Ravdin, P
IR  - Regan M
FIR - Regan, M
IR  - Robertson J
FIR - Robertson, J
IR  - Rutgers E
FIR - Rutgers, E
IR  - Slamon D
FIR - Slamon, D
IR  - Sparano J
FIR - Sparano, J
IR  - Swain S
FIR - Swain, S
IR  - Tutt A
FIR - Tutt, A
IR  - Viale G
FIR - Viale, G
IR  - von Minckwitz G
FIR - von Minckwitz, G
IR  - Wang X
FIR - Wang, X
IR  - Whelan T
FIR - Whelan, T
IR  - Wilcken N
FIR - Wilcken, N
IR  - Winer E
FIR - Winer, E
IR  - Wolmark N
FIR - Wolmark, N
IR  - Wood W
FIR - Wood, W
IR  - Zambetti M
FIR - Zambetti, M
IR  - Alberro JA
FIR - Alberro, J A
IR  - Ballester B
FIR - Ballester, B
IR  - Deulofeu P
FIR - Deulofeu, P
IR  - Fabregas R
FIR - Fabregas, R
IR  - Fraile M
FIR - Fraile, M
IR  - Gubern JM
FIR - Gubern, J M
IR  - Janer J
FIR - Janer, J
IR  - Moral A
FIR - Moral, A
IR  - de Pablo JL
FIR - de Pablo, J L
IR  - Penalva G
FIR - Penalva, G
IR  - Puig P
FIR - Puig, P
IR  - Ramos M
FIR - Ramos, M
IR  - Rojo R
FIR - Rojo, R
IR  - Santesteban P
FIR - Santesteban, P
IR  - Serra C
FIR - Serra, C
IR  - Sola M
FIR - Sola, M
IR  - Solarnau L
FIR - Solarnau, L
IR  - Solsona J
FIR - Solsona, J
IR  - Veloso E
FIR - Veloso, E
IR  - Vidal S
FIR - Vidal, S
IR  - Abe O
FIR - Abe, O
IR  - Abe R
FIR - Abe, R
IR  - Enomoto K
FIR - Enomoto, K
IR  - Kikuchi K
FIR - Kikuchi, K
IR  - Koyama H
FIR - Koyama, H
IR  - Masuda H
FIR - Masuda, H
IR  - Nomura Y
FIR - Nomura, Y
IR  - Sakai K
FIR - Sakai, K
IR  - Sugimachi K
FIR - Sugimachi, K
IR  - Toi M
FIR - Toi, M
IR  - Tominaga T
FIR - Tominaga, T
IR  - Uchino J
FIR - Uchino, J
IR  - Yoshida M
FIR - Yoshida, M
IR  - Haybittle JL
FIR - Haybittle, J L
IR  - Leonard CF
FIR - Leonard, C F
IR  - Calais G
FIR - Calais, G
IR  - Garaud P
FIR - Garaud, P
IR  - Collett V
FIR - Collett, V
IR  - Delmestri A
FIR - Delmestri, A
IR  - Sayer J
FIR - Sayer, J
IR  - Harvey VJ
FIR - Harvey, V J
IR  - Holdaway IM
FIR - Holdaway, I M
IR  - Kay RG
FIR - Kay, R G
IR  - Mason BH
FIR - Mason, B H
IR  - Forbes JF
FIR - Forbes, J F
IR  - Balic M
FIR - Balic, M
IR  - Bartsch R
FIR - Bartsch, R
IR  - Fesl C
FIR - Fesl, C
IR  - Fitzal F
FIR - Fitzal, F
IR  - Fohler H
FIR - Fohler, H
IR  - Greil R
FIR - Greil, R
IR  - Jakesz R
FIR - Jakesz, R
IR  - Marth C
FIR - Marth, C
IR  - Mlineritsch B
FIR - Mlineritsch, B
IR  - Pfeiler G
FIR - Pfeiler, G
IR  - Singer CF
FIR - Singer, C F
IR  - Steger GG
FIR - Steger, G G
IR  - Stoger H
FIR - Stoger, H
IR  - Canney P
FIR - Canney, P
IR  - Yosef HMA
FIR - Yosef, H M A
IR  - Focan C
FIR - Focan, C
IR  - Peek U
FIR - Peek, U
IR  - Oates GD
FIR - Oates, G D
IR  - Powell J
FIR - Powell, J
IR  - Durand M
FIR - Durand, M
IR  - Mauriac L
FIR - Mauriac, L
IR  - Dolci S
FIR - Dolci, S
IR  - Larsimont D
FIR - Larsimont, D
IR  - Nogaret JM
FIR - Nogaret, J M
IR  - Philippson C
FIR - Philippson, C
IR  - Piccart MJ
FIR - Piccart, M J
IR  - Masood MB
FIR - Masood, M B
IR  - Parker D
FIR - Parker, D
IR  - Price JJ
FIR - Price, J J
IR  - Lindsay MA
FIR - Lindsay, M A
IR  - Mackey J
FIR - Mackey, J
IR  - Hupperets PSGJ
FIR - Hupperets, P S G J
IR  - Bates T
FIR - Bates, T
IR  - Blamey RW
FIR - Blamey, R W
IR  - Chetty U
FIR - Chetty, U
IR  - Ellis IO
FIR - Ellis, I O
IR  - Mallon E
FIR - Mallon, E
IR  - Morgan DAL
FIR - Morgan, D A L
IR  - Patnick J
FIR - Patnick, J
IR  - Pinder S
FIR - Pinder, S
IR  - Lohrisch C
FIR - Lohrisch, C
IR  - Nichol A
FIR - Nichol, A
IR  - Bramwell VH
FIR - Bramwell, V H
IR  - Chen BE
FIR - Chen, B E
IR  - Gelmon K
FIR - Gelmon, K
IR  - Goss PE
FIR - Goss, P E
IR  - Levine MN
FIR - Levine, M N
IR  - Parulekar W
FIR - Parulekar, W
IR  - Pater JL
FIR - Pater, J L
IR  - Shepherd LE
FIR - Shepherd, L E
IR  - Tu D
FIR - Tu, D
IR  - Berry D
FIR - Berry, D
IR  - Broadwater G
FIR - Broadwater, G
IR  - Cirrincione C
FIR - Cirrincione, C
IR  - Muss H
FIR - Muss, H
IR  - Weiss RB
FIR - Weiss, R B
IR  - Abu-Zahra HT
FIR - Abu-Zahra, H T
IR  - Portnoj SM
FIR - Portnoj, S M
IR  - Bowden S
FIR - Bowden, S
IR  - Brookes C
FIR - Brookes, C
IR  - Dunn J
FIR - Dunn, J
IR  - Fernando I
FIR - Fernando, I
IR  - Lee M
FIR - Lee, M
IR  - Poole C
FIR - Poole, C
IR  - Rea D
FIR - Rea, D
IR  - Spooner D
FIR - Spooner, D
IR  - Barrett-Lee PJ
FIR - Barrett-Lee, P J
IR  - Mansel RE
FIR - Mansel, R E
IR  - Monypenny IJ
FIR - Monypenny, I J
IR  - Gordon NH
FIR - Gordon, N H
IR  - Davis HL
FIR - Davis, H L
IR  - Sestak I
FIR - Sestak, I
IR  - Lehingue Y
FIR - Lehingue, Y
IR  - Romestaing P
FIR - Romestaing, P
IR  - Dubois JB
FIR - Dubois, J B
IR  - Delozier T
FIR - Delozier, T
IR  - Griffon B
FIR - Griffon, B
IR  - Mace Lesec'h J
FIR - Mace Lesec'h, J
IR  - de La Lande B
FIR - de La Lande, B
IR  - Mouret-Fourme E
FIR - Mouret-Fourme, E
IR  - Mustacchi G
FIR - Mustacchi, G
IR  - Petruzelka L
FIR - Petruzelka, L
IR  - Pribylova O
FIR - Pribylova, O
IR  - Owen JR
FIR - Owen, J R
IR  - Harbeck N
FIR - Harbeck, N
IR  - Janicke F
FIR - Janicke, F
IR  - Meisner C
FIR - Meisner, C
IR  - Schmitt M
FIR - Schmitt, M
IR  - Thomssen C
FIR - Thomssen, C
IR  - Meier P
FIR - Meier, P
IR  - Shan Y
FIR - Shan, Y
IR  - Shao YF
FIR - Shao, Y F
IR  - Zhao DB
FIR - Zhao, D B
IR  - Chen ZM
FIR - Chen, Z M
IR  - Howell A
FIR - Howell, A
IR  - Swindell R
FIR - Swindell, R
IR  - Boddington C
FIR - Boddington, C
IR  - Burrett JA
FIR - Burrett, J A
IR  - Cutter D
FIR - Cutter, D
IR  - Duane F
FIR - Duane, F
IR  - Evans V
FIR - Evans, V
IR  - Gettins L
FIR - Gettins, L
IR  - Godwin J
FIR - Godwin, J
IR  - James S
FIR - James, S
IR  - Kerr A
FIR - Kerr, A
IR  - Liu H
FIR - Liu, H
IR  - Mannu G
FIR - Mannu, G
IR  - McHugh T
FIR - McHugh, T
IR  - Morris P
FIR - Morris, P
IR  - Read S
FIR - Read, S
IR  - Wang Y
FIR - Wang, Y
IR  - Wang Z
FIR - Wang, Z
IR  - Albano J
FIR - Albano, J
IR  - de Oliveira CF
FIR - de Oliveira, C F
IR  - Gervasio H
FIR - Gervasio, H
IR  - Gordilho J
FIR - Gordilho, J
IR  - Ejlertsen B
FIR - Ejlertsen, B
IR  - Jensen MB
FIR - Jensen, M B
IR  - Johansen H
FIR - Johansen, H
IR  - Mouridsen H
FIR - Mouridsen, H
IR  - Palshof T
FIR - Palshof, T
IR  - Gelman RS
FIR - Gelman, R S
IR  - Harris JR
FIR - Harris, J R
IR  - Henderson C
FIR - Henderson, C
IR  - Shapiro CL
FIR - Shapiro, C L
IR  - Christiansen P
FIR - Christiansen, P
IR  - Mouridsen HT
FIR - Mouridsen, H T
IR  - Fehm T
FIR - Fehm, T
IR  - Trampisch HJ
FIR - Trampisch, H J
IR  - Dalesio O
FIR - Dalesio, O
IR  - de Vries EGE
FIR - de Vries, E G E
IR  - Rodenhuis S
FIR - Rodenhuis, S
IR  - van Tinteren H
FIR - van Tinteren, H
IR  - Comis RL
FIR - Comis, R L
IR  - Davidson NE
FIR - Davidson, N E
IR  - Robert N
FIR - Robert, N
IR  - Sledge G
FIR - Sledge, G
IR  - Solin LJ
FIR - Solin, L J
IR  - Sparano JA
FIR - Sparano, J A
IR  - Tormey DC
FIR - Tormey, D C
IR  - Dixon JM
FIR - Dixon, J M
IR  - Forrest P
FIR - Forrest, P
IR  - Jack W
FIR - Jack, W
IR  - Kunkler I
FIR - Kunkler, I
IR  - Rossbach J
FIR - Rossbach, J
IR  - Klijn JGM
FIR - Klijn, J G M
IR  - Treurniet-Donker AD
FIR - Treurniet-Donker, A D
IR  - van Putten WLJ
FIR - van Putten, W L J
IR  - Rotmensz N
FIR - Rotmensz, N
IR  - Veronesi U
FIR - Veronesi, U
IR  - Bartelink H
FIR - Bartelink, H
IR  - Bijker N
FIR - Bijker, N
IR  - Bogaerts J
FIR - Bogaerts, J
IR  - Cardoso F
FIR - Cardoso, F
IR  - Cufer T
FIR - Cufer, T
IR  - Julien JP
FIR - Julien, J P
IR  - van de Velde CJH
FIR - van de Velde, C J H
IR  - Cunningham MP
FIR - Cunningham, M P
IR  - Brufsky AM
FIR - Brufsky, A M
IR  - Coleman RE
FIR - Coleman, R E
IR  - Llombart HA
FIR - Llombart, H A
IR  - Huovinen R
FIR - Huovinen, R
IR  - Joensuu H
FIR - Joensuu, H
IR  - Costa A
FIR - Costa, A
IR  - Bonadonna G
FIR - Bonadonna, G
IR  - Gianni L
FIR - Gianni, L
IR  - Valagussa P
FIR - Valagussa, P
IR  - Goldstein LJ
FIR - Goldstein, L J
IR  - Bonneterre J
FIR - Bonneterre, J
IR  - Fargeot P
FIR - Fargeot, P
IR  - Fumoleau P
FIR - Fumoleau, P
IR  - Kerbrat P
FIR - Kerbrat, P
IR  - Luporsi E
FIR - Luporsi, E
IR  - Namer M
FIR - Namer, M
IR  - Carrasco E
FIR - Carrasco, E
IR  - Segui MA
FIR - Segui, M A
IR  - Eiermann W
FIR - Eiermann, W
IR  - Hilfrich J
FIR - Hilfrich, J
IR  - Jonat W
FIR - Jonat, W
IR  - Kaufmann M
FIR - Kaufmann, M
IR  - Kreienberg R
FIR - Kreienberg, R
IR  - Schumacher M
FIR - Schumacher, M
IR  - Bastert G
FIR - Bastert, G
IR  - Rauschecker H
FIR - Rauschecker, H
IR  - Sauer R
FIR - Sauer, R
IR  - Sauerbrei W
FIR - Sauerbrei, W
IR  - Schauer A
FIR - Schauer, A
IR  - Blohmer JU
FIR - Blohmer, J U
IR  - Costa SD
FIR - Costa, S D
IR  - Eidtmann H
FIR - Eidtmann, H
IR  - Gerber B
FIR - Gerber, B
IR  - Jackisch C
FIR - Jackisch, C
IR  - de Schryver A
FIR - de Schryver, A
IR  - Vakaet L
FIR - Vakaet, L
IR  - Belfiglio M
FIR - Belfiglio, M
IR  - Nicolucci A
FIR - Nicolucci, A
IR  - Pellegrini F
FIR - Pellegrini, F
IR  - Pirozzoli MC
FIR - Pirozzoli, M C
IR  - Sacco M
FIR - Sacco, M
IR  - Valentini M
FIR - Valentini, M
IR  - McArdle CS
FIR - McArdle, C S
IR  - Smith DC
FIR - Smith, D C
IR  - Stallard S
FIR - Stallard, S
IR  - Dent DM
FIR - Dent, D M
IR  - Gudgeon CA
FIR - Gudgeon, C A
IR  - Hacking A
FIR - Hacking, A
IR  - Murray E
FIR - Murray, E
IR  - Panieri E
FIR - Panieri, E
IR  - Werner ID
FIR - Werner, I D
IR  - Galligioni E
FIR - Galligioni, E
IR  - Leone B
FIR - Leone, B
IR  - Vallejo CT
FIR - Vallejo, C T
IR  - Zwenger A
FIR - Zwenger, A
IR  - Lopez M
FIR - Lopez, M
IR  - Erazo A
FIR - Erazo, A
IR  - Medina JY
FIR - Medina, J Y
IR  - Horiguchi J
FIR - Horiguchi, J
IR  - Takei H
FIR - Takei, H
IR  - Fentiman IS
FIR - Fentiman, I S
IR  - Hayward JL
FIR - Hayward, J L
IR  - Rubens RD
FIR - Rubens, R D
IR  - Skilton D
FIR - Skilton, D
IR  - Scheurlen H
FIR - Scheurlen, H
IR  - Sohn HC
FIR - Sohn, H C
IR  - Untch M
FIR - Untch, M
IR  - Dafni U
FIR - Dafni, U
IR  - Markopoulos C
FIR - Markopoulos, C
IR  - Fountzilas G
FIR - Fountzilas, G
IR  - Mavroudis D
FIR - Mavroudis, D
IR  - Klefstrom P
FIR - Klefstrom, P
IR  - Blomqvist C
FIR - Blomqvist, C
IR  - Saarto T
FIR - Saarto, T
IR  - Gallen M
FIR - Gallen, M
IR  - Tinterri C
FIR - Tinterri, C
IR  - Margreiter R
FIR - Margreiter, R
IR  - de Lafontan B
FIR - de Lafontan, B
IR  - Mihura J
FIR - Mihura, J
IR  - Roche H
FIR - Roche, H
IR  - Asselain B
FIR - Asselain, B
IR  - Salmon RJ
FIR - Salmon, R J
IR  - Vilcoq JR
FIR - Vilcoq, J R
IR  - Andre F
FIR - Andre, F
IR  - Delaloge S
FIR - Delaloge, S
IR  - Koscielny S
FIR - Koscielny, S
IR  - Michiels S
FIR - Michiels, S
IR  - Rubino C
FIR - Rubino, C
IR  - A'Hern R
FIR - A'Hern, R
IR  - Ellis P
FIR - Ellis, P
IR  - Kilburn L
FIR - Kilburn, L
IR  - Yarnold JR
FIR - Yarnold, J R
IR  - Benraadt J
FIR - Benraadt, J
IR  - Kooi M
FIR - Kooi, M
IR  - van de Velde AO
FIR - van de Velde, A O
IR  - van Dongen JA
FIR - van Dongen, J A
IR  - Vermorken JB
FIR - Vermorken, J B
IR  - Castiglione M
FIR - Castiglione, M
IR  - Colleoni M
FIR - Colleoni, M
IR  - Collins J
FIR - Collins, J
IR  - Gelber RD
FIR - Gelber, R D
IR  - Lindtner J
FIR - Lindtner, J
IR  - Price KN
FIR - Price, K N
IR  - Regan MM
FIR - Regan, M M
IR  - Rudenstam CM
FIR - Rudenstam, C M
IR  - Senn HJ
FIR - Senn, H J
IR  - Thuerlimann B
FIR - Thuerlimann, B
IR  - Bliss JM
FIR - Bliss, J M
IR  - Chilvers CED
FIR - Chilvers, C E D
IR  - Coombes RC
FIR - Coombes, R C
IR  - Hall E
FIR - Hall, E
IR  - Marty M
FIR - Marty, M
IR  - Buyse M
FIR - Buyse, M
IR  - Possinger K
FIR - Possinger, K
IR  - Schmid P
FIR - Schmid, P
IR  - Wallwiener D
FIR - Wallwiener, D
IR  - Bighin C
FIR - Bighin, C
IR  - Bruzzi P
FIR - Bruzzi, P
IR  - Del Mastro L
FIR - Del Mastro, L
IR  - Dozin B
FIR - Dozin, B
IR  - Pastorino S
FIR - Pastorino, S
IR  - Pronzato P
FIR - Pronzato, P
IR  - Sertoli MR
FIR - Sertoli, M R
IR  - Foster L
FIR - Foster, L
IR  - George WD
FIR - George, W D
IR  - Stewart HJ
FIR - Stewart, H J
IR  - Stroner P
FIR - Stroner, P
IR  - Borovik R
FIR - Borovik, R
IR  - Hayat H
FIR - Hayat, H
IR  - Inbar MJ
FIR - Inbar, M J
IR  - Peretz T
FIR - Peretz, T
IR  - Robinson E
FIR - Robinson, E
IR  - Camerini T
FIR - Camerini, T
IR  - Formelli F
FIR - Formelli, F
IR  - Martelli G
FIR - Martelli, G
IR  - Di Mauro MG
FIR - Di Mauro, M G
IR  - Perrone F
FIR - Perrone, F
IR  - Amadori D
FIR - Amadori, D
IR  - Martoni A
FIR - Martoni, A
IR  - Pannuti F
FIR - Pannuti, F
IR  - Camisa R
FIR - Camisa, R
IR  - Musolino A
FIR - Musolino, A
IR  - Passalacqua R
FIR - Passalacqua, R
IR  - Iwata H
FIR - Iwata, H
IR  - Shien T
FIR - Shien, T
IR  - Ikeda T
FIR - Ikeda, T
IR  - Inokuchi K
FIR - Inokuchi, K
IR  - Sawa K
FIR - Sawa, K
IR  - Sonoo H
FIR - Sonoo, H
IR  - Sadoon M
FIR - Sadoon, M
IR  - Tulusan AH
FIR - Tulusan, A H
IR  - Kohno N
FIR - Kohno, N
IR  - Miyashita M
FIR - Miyashita, M
IR  - Takao S
FIR - Takao, S
IR  - Ahn JH
FIR - Ahn, J H
IR  - Jung KH
FIR - Jung, K H
IR  - Korzeniowski S
FIR - Korzeniowski, S
IR  - Skolyszewski J
FIR - Skolyszewski, J
IR  - Ogawa M
FIR - Ogawa, M
IR  - Yamashita J
FIR - Yamashita, J
IR  - Bastiaannet E
FIR - Bastiaannet, E
IR  - Liefers GJ
FIR - Liefers, G J
IR  - Christiaens R
FIR - Christiaens, R
IR  - Neven P
FIR - Neven, P
IR  - Paridaens R
FIR - Paridaens, R
IR  - Van den Bogaert W
FIR - Van den Bogaert, W
IR  - Braun S
FIR - Braun, S
IR  - Martin P
FIR - Martin, P
IR  - Romain S
FIR - Romain, S
IR  - Janauer M
FIR - Janauer, M
IR  - Seifert M
FIR - Seifert, M
IR  - Sevelda P
FIR - Sevelda, P
IR  - Zielinski CC
FIR - Zielinski, C C
IR  - Hakes T
FIR - Hakes, T
IR  - Hudis CA
FIR - Hudis, C A
IR  - Wittes R
FIR - Wittes, R
IR  - Giokas G
FIR - Giokas, G
IR  - Kondylis D
FIR - Kondylis, D
IR  - Lissaios B
FIR - Lissaios, B
IR  - de la Huerta R
FIR - de la Huerta, R
IR  - Sainz MG
FIR - Sainz, M G
IR  - Ro J
FIR - Ro, J
IR  - Camphausen K
FIR - Camphausen, K
IR  - Danforth D
FIR - Danforth, D
IR  - Lichter A
FIR - Lichter, A
IR  - Lippman M
FIR - Lippman, M
IR  - Smart D
FIR - Smart, D
IR  - Steinberg S
FIR - Steinberg, S
IR  - D'Amico C
FIR - D'Amico, C
IR  - Lioce M
FIR - Lioce, M
IR  - Paradiso A
FIR - Paradiso, A
IR  - Ohno S
FIR - Ohno, S
IR  - Bass G
FIR - Bass, G
IR  - Brown A
FIR - Brown, A
IR  - Bryant J
FIR - Bryant, J
IR  - Dignam J
FIR - Dignam, J
IR  - Fisher B
FIR - Fisher, B
IR  - Geyer C
FIR - Geyer, C
IR  - Mamounas EP
FIR - Mamounas, E P
IR  - Redmond C
FIR - Redmond, C
IR  - Wickerham L
FIR - Wickerham, L
IR  - Aihara T
FIR - Aihara, T
IR  - Hozumi Y
FIR - Hozumi, Y
IR  - Baum M
FIR - Baum, M
IR  - Jackson IM
FIR - Jackson, I M
IR  - Palmer MK
FIR - Palmer, M K
IR  - Ingle JN
FIR - Ingle, J N
IR  - Suman VJ
FIR - Suman, V J
IR  - Bengtsson NO
FIR - Bengtsson, N O
IR  - Emdin S
FIR - Emdin, S
IR  - Jonsson H
FIR - Jonsson, H
IR  - Venturini M
FIR - Venturini, M
IR  - Lythgoe JP
FIR - Lythgoe, J P
IR  - Kissin M
FIR - Kissin, M
IR  - Erikstein B
FIR - Erikstein, B
IR  - Hannisdal E
FIR - Hannisdal, E
IR  - Jacobsen AB
FIR - Jacobsen, A B
IR  - Reinertsen KV
FIR - Reinertsen, K V
IR  - Varhaug JE
FIR - Varhaug, J E
IR  - Gundersen S
FIR - Gundersen, S
IR  - Hauer-Jensen M
FIR - Hauer-Jensen, M
IR  - Host H
FIR - Host, H
IR  - Nissen-Meyer R
FIR - Nissen-Meyer, R
IR  - Mitchell AK
FIR - Mitchell, A K
IR  - Robertson JFR
FIR - Robertson, J F R
IR  - Ueo H
FIR - Ueo, H
IR  - Di Palma M
FIR - Di Palma, M
IR  - Mathe G
FIR - Mathe, G
IR  - Misset JL
FIR - Misset, J L
IR  - Levine M
FIR - Levine, M
IR  - Morimoto K
FIR - Morimoto, K
IR  - Takatsuka Y
FIR - Takatsuka, Y
IR  - Crossley E
FIR - Crossley, E
IR  - Harris A
FIR - Harris, A
IR  - Talbot D
FIR - Talbot, D
IR  - Taylor M
FIR - Taylor, M
IR  - Cocconi G
FIR - Cocconi, G
IR  - di Blasio B
FIR - di Blasio, B
IR  - Ivanov V
FIR - Ivanov, V
IR  - Paltuev R
FIR - Paltuev, R
IR  - Semiglazov V
FIR - Semiglazov, V
IR  - Brockschmidt J
FIR - Brockschmidt, J
IR  - Cooper MR
FIR - Cooper, M R
IR  - Falkson CI
FIR - Falkson, C I
IR  - Hadji P
FIR - Hadji, P
IR  - A'Hern R
FIR - A'Hern, R
IR  - Makris A
FIR - Makris, A
IR  - Parton M
FIR - Parton, M
IR  - Pennert K
FIR - Pennert, K
IR  - Powles TJ
FIR - Powles, T J
IR  - Smith IE
FIR - Smith, I E
IR  - Gazet JC
FIR - Gazet, J C
IR  - Browne L
FIR - Browne, L
IR  - Graham P
FIR - Graham, P
IR  - Corcoran N
FIR - Corcoran, N
IR  - Clack G
FIR - Clack, G
IR  - Van Poznak C
FIR - Van Poznak, C
IR  - Deshpande N
FIR - Deshpande, N
IR  - di Martino L
FIR - di Martino, L
IR  - Douglas P
FIR - Douglas, P
IR  - Lindtner A
FIR - Lindtner, A
IR  - Notter G
FIR - Notter, G
IR  - Bryant AJS
FIR - Bryant, A J S
IR  - Ewing GH
FIR - Ewing, G H
IR  - Firth LA
FIR - Firth, L A
IR  - Krushen-Kosloski JL
FIR - Krushen-Kosloski, J L
IR  - Anderson H
FIR - Anderson, H
IR  - Killander F
FIR - Killander, F
IR  - Malmstrom P
FIR - Malmstrom, P
IR  - Ryden L
FIR - Ryden, L
IR  - Arnesson LG
FIR - Arnesson, L G
IR  - Carstensen J
FIR - Carstensen, J
IR  - Dufmats M
FIR - Dufmats, M
IR  - Fohlin H
FIR - Fohlin, H
IR  - Nordenskjold B
FIR - Nordenskjold, B
IR  - Soderberg M
FIR - Soderberg, M
IR  - Carpenter JT
FIR - Carpenter, J T
IR  - Murray N
FIR - Murray, N
IR  - Royle GT
FIR - Royle, G T
IR  - Simmonds PD
FIR - Simmonds, P D
IR  - Crowley J
FIR - Crowley, J
IR  - Gralow J
FIR - Gralow, J
IR  - Hortobagyi G
FIR - Hortobagyi, G
IR  - Livingston R
FIR - Livingston, R
IR  - Martino S
FIR - Martino, S
IR  - Osborne CK
FIR - Osborne, C K
IR  - Ravdin PM
FIR - Ravdin, P M
IR  - Bondesson T
FIR - Bondesson, T
IR  - Celebioglu F
FIR - Celebioglu, F
IR  - Dahlberg K
FIR - Dahlberg, K
IR  - Fornander T
FIR - Fornander, T
IR  - Fredriksson I
FIR - Fredriksson, I
IR  - Frisell J
FIR - Frisell, J
IR  - Goransson E
FIR - Goransson, E
IR  - Iiristo M
FIR - Iiristo, M
IR  - Johansson U
FIR - Johansson, U
IR  - Lenner E
FIR - Lenner, E
IR  - Lofgren L
FIR - Lofgren, L
IR  - Nikolaidis P
FIR - Nikolaidis, P
IR  - Perbeck L
FIR - Perbeck, L
IR  - Rotstein S
FIR - Rotstein, S
IR  - Sandelin K
FIR - Sandelin, K
IR  - Skoog L
FIR - Skoog, L
IR  - Svane G
FIR - Svane, G
IR  - af Trampe E
FIR - af Trampe, E
IR  - Wadstrom C
FIR - Wadstrom, C
IR  - Maibach R
FIR - Maibach, R
IR  - Thurlimann B
FIR - Thurlimann, B
IR  - Holli K
FIR - Holli, K
IR  - Rouhento K
FIR - Rouhento, K
IR  - Safra T
FIR - Safra, T
IR  - Brenner H
FIR - Brenner, H
IR  - Hercbergs A
FIR - Hercbergs, A
IR  - Yoshimoto M
FIR - Yoshimoto, M
IR  - Paterson AHG
FIR - Paterson, A H G
IR  - Fyles A
FIR - Fyles, A
IR  - Meakin JW
FIR - Meakin, J W
IR  - Panzarella T
FIR - Panzarella, T
IR  - Bahi J
FIR - Bahi, J
IR  - Lemonnier J
FIR - Lemonnier, J
IR  - Martin AL
FIR - Martin, A L
IR  - Reid M
FIR - Reid, M
IR  - Spittle M
FIR - Spittle, M
IR  - Bishop H
FIR - Bishop, H
IR  - Bundred NJ
FIR - Bundred, N J
IR  - Forsyth S
FIR - Forsyth, S
IR  - Pinder SE
FIR - Pinder, S E
IR  - Deutsch GP
FIR - Deutsch, G P
IR  - Kwong DLW
FIR - Kwong, D L W
IR  - Pai VR
FIR - Pai, V R
IR  - Senanayake F
FIR - Senanayake, F
IR  - Rubagotti A
FIR - Rubagotti, A
IR  - Hackshaw A
FIR - Hackshaw, A
IR  - Houghton J
FIR - Houghton, J
IR  - Ledermann J
FIR - Ledermann, J
IR  - Monson K
FIR - Monson, K
IR  - Tobias JS
FIR - Tobias, J S
IR  - Carlomagno C
FIR - Carlomagno, C
IR  - De Laurentiis M
FIR - De Laurentiis, M
IR  - De Placido S
FIR - De Placido, S
IR  - Williams L
FIR - Williams, L
IR  - Bell R
FIR - Bell, R
IR  - Hinsley S
FIR - Hinsley, S
IR  - Marshall HC
FIR - Marshall, H C
IR  - Pierce LJ
FIR - Pierce, L J
IR  - Solomayer E
FIR - Solomayer, E
IR  - Horsman JM
FIR - Horsman, J M
IR  - Lester J
FIR - Lester, J
IR  - Winter MC
FIR - Winter, M C
IR  - Buzdar AU
FIR - Buzdar, A U
IR  - Hsu L
FIR - Hsu, L
IR  - Love RR
FIR - Love, R R
IR  - Ahlgren J
FIR - Ahlgren, J
IR  - Garmo H
FIR - Garmo, H
IR  - Holmberg L
FIR - Holmberg, L
IR  - Liljegren G
FIR - Liljegren, G
IR  - Lindman H
FIR - Lindman, H
IR  - Warnberg F
FIR - Warnberg, F
IR  - Asmar L
FIR - Asmar, L
IR  - Jones SE
FIR - Jones, S E
IR  - Aft R
FIR - Aft, R
IR  - Gluz O
FIR - Gluz, O
IR  - Liedtke C
FIR - Liedtke, C
IR  - Nitz U
FIR - Nitz, U
IR  - Litton A
FIR - Litton, A
IR  - Wallgren A
FIR - Wallgren, A
IR  - Karlsson P
FIR - Karlsson, P
IR  - Linderholm BK
FIR - Linderholm, B K
IR  - Chlebowski RT
FIR - Chlebowski, R T
IR  - Caffier H
FIR - Caffier, H
EDAT- 2017/11/09 06:00
MHDA- 2017/11/29 06:00
CRDT- 2017/11/09 06:00
PMCR- 2018/05/09 00:00
PHST- 2018/05/09 00:00 [pmc-release]
PHST- 2017/11/09 06:00 [entrez]
PHST- 2017/11/09 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
AID - 10.1056/NEJMoa1701830 [doi]
PST - ppublish
SO  - N Engl J Med. 2017 Nov 9;377(19):1836-1846. doi: 10.1056/NEJMoa1701830.

PMID- 28725912
OWN - NLM
STAT- In-Process
LR  - 20171028
IS  - 1432-0428 (Electronic)
IS  - 0012-186X (Linking)
VI  - 60
IP  - 10
DP  - 2017 Oct
TI  - SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and
      meta-analysis of randomised controlled trials.
PG  - 1862-1872
LID - 10.1007/s00125-017-4370-8 [doi]
AB  - AIMS/HYPOTHESIS: The association between sodium-glucose cotransporter 2 (SGLT2)
      inhibitors and the risk of cancer in individuals with type 2 diabetes remains
      uncertain. This study aimed to evaluate the risk of cancer associated with SGLT2 
      inhibitor treatment of type 2 diabetes. METHODS: We systematically searched
      PubMed, EMBASE, Cochrane Central Register of Controlled Trials and
      ClinicalTrials.gov from inception to 15 February 2017 to identify eligible
      randomised controlled trials (RCTs) that report cancer events in individuals with
      type 2 diabetes treated with SGLT2 inhibitors for at least 24 weeks. We performed
      pairwise and network meta-analyses as well as a cumulative meta-analysis to
      calculate ORs and 95% CIs. RESULTS: In total, 580 incidences of cancer among
      34,569 individuals were identified from 46 independent RCTs with a mean trial
      duration of 61 weeks. When compared with comparators (placebo or other active
      glucose-lowering treatments), SGLT2 inhibitors were not significantly associated 
      with an increased risk of overall cancer (OR 1.14 [95% CI 0.96, 1.36]). For
      pre-specified cancer types, the risk of bladder cancer might be increased with
      SGLT2 inhibitors (OR 3.87 [95% CI 1.48, 10.08]), especially empagliflozin (OR
      4.49 [95% CI 1.21, 16.73]). Interestingly, canagliflozin might be protective
      against gastrointestinal cancers (OR 0.15 [95% CI 0.04, 0.60]).
      CONCLUSIONS/INTERPRETATION: Current evidence from short-term RCTs did not
      indicate a significantly increased risk of overall cancer among individuals with 
      type 2 diabetes using SGLT2 inhibitors. Given the short-term trial durations and 
      uncertainty of evidence, future long-term prospective studies and post-marketing 
      surveillance studies are warranted.
FAU - Tang, Huilin
AU  - Tang H
AD  - Department of Pharmacy, Peking University Third Hospital, Beijing, People's
      Republic of China.
AD  - Department of Epidemiology, Richard M. Fairbanks School of Public Health, Indiana
      University, 1050 Wishard Blvd, Indianapolis, IN, 46202, USA.
AD  - Center for Pharmacoepidemiology, Richard M. Fairbanks School of Public Health,
      Indiana University, Indianapolis, IN, USA.
FAU - Dai, Qi
AU  - Dai Q
AD  - Department of Medicine, School of Medicine, Vanderbilt Ingram Cancer Center,
      Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN, USA.
FAU - Shi, Weilong
AU  - Shi W
AD  - Department of Pharmacy, Peking University Third Hospital, Beijing, People's
      Republic of China.
FAU - Zhai, Suodi
AU  - Zhai S
AD  - Department of Pharmacy, Peking University Third Hospital, Beijing, People's
      Republic of China.
FAU - Song, Yiqing
AU  - Song Y
AD  - Department of Epidemiology, Richard M. Fairbanks School of Public Health, Indiana
      University, 1050 Wishard Blvd, Indianapolis, IN, 46202, USA. yiqsong@iu.edu.
AD  - Center for Pharmacoepidemiology, Richard M. Fairbanks School of Public Health,
      Indiana University, Indianapolis, IN, USA. yiqsong@iu.edu.
FAU - Han, Jiali
AU  - Han J
AD  - Department of Epidemiology, Richard M. Fairbanks School of Public Health, Indiana
      University, 1050 Wishard Blvd, Indianapolis, IN, 46202, USA. jialhan@iu.edu.
AD  - Center for Pharmacoepidemiology, Richard M. Fairbanks School of Public Health,
      Indiana University, Indianapolis, IN, USA. jialhan@iu.edu.
AD  - Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN, USA.
      jialhan@iu.edu.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170719
PL  - Germany
TA  - Diabetologia
JT  - Diabetologia
JID - 0006777
OTO - NOTNLM
OT  - Cancer
OT  - Meta-analysis
OT  - Randomised controlled trials
OT  - SGLT2 inhibitors
OT  - Systematic review
OT  - Type 2 diabetes
EDAT- 2017/07/21 06:00
MHDA- 2017/07/21 06:00
CRDT- 2017/07/21 06:00
PHST- 2017/03/16 00:00 [received]
PHST- 2017/06/02 00:00 [accepted]
PHST- 2017/07/21 06:00 [pubmed]
PHST- 2017/07/21 06:00 [medline]
PHST- 2017/07/21 06:00 [entrez]
AID - 10.1007/s00125-017-4370-8 [doi]
AID - 10.1007/s00125-017-4370-8 [pii]
PST - ppublish
SO  - Diabetologia. 2017 Oct;60(10):1862-1872. doi: 10.1007/s00125-017-4370-8. Epub
      2017 Jul 19.

PMID- 29313949
OWN - NLM
STAT- In-Data-Review
LR  - 20180112
IS  - 1542-4863 (Electronic)
IS  - 0007-9235 (Linking)
VI  - 68
IP  - 1
DP  - 2018 Jan
TI  - Cancer statistics, 2018.
PG  - 7-30
LID - 10.3322/caac.21442 [doi]
AB  - Each year, the American Cancer Society estimates the numbers of new cancer cases 
      and deaths that will occur in the United States and compiles the most recent data
      on cancer incidence, mortality, and survival. Incidence data, available through
      2014, were collected by the Surveillance, Epidemiology, and End Results Program; 
      the National Program of Cancer Registries; and the North American Association of 
      Central Cancer Registries. Mortality data, available through 2015, were collected
      by the National Center for Health Statistics. In 2018, 1,735,350 new cancer cases
      and 609,640 cancer deaths are projected to occur in the United States. Over the
      past decade of data, the cancer incidence rate (2005-2014) was stable in women
      and declined by approximately 2% annually in men, while the cancer death rate
      (2006-2015) declined by about 1.5% annually in both men and women. The combined
      cancer death rate dropped continuously from 1991 to 2015 by a total of 26%,
      translating to approximately 2,378,600 fewer cancer deaths than would have been
      expected if death rates had remained at their peak. Of the 10 leading causes of
      death, only cancer declined from 2014 to 2015. In 2015, the cancer death rate was
      14% higher in non-Hispanic blacks (NHBs) than non-Hispanic whites (NHWs) overall 
      (death rate ratio [DRR], 1.14; 95% confidence interval [95% CI], 1.13-1.15), but 
      the racial disparity was much larger for individuals aged <65 years (DRR, 1.31;
      95% CI, 1.29-1.32) compared with those aged >/=65 years (DRR, 1.07; 95% CI,
      1.06-1.09) and varied substantially by state. For example, the cancer death rate 
      was lower in NHBs than NHWs in Massachusetts for all ages and in New York for
      individuals aged >/=65 years, whereas for those aged <65 years, it was 3 times
      higher in NHBs in the District of Columbia (DRR, 2.89; 95% CI, 2.16-3.91) and
      about 50% higher in Wisconsin (DRR, 1.78; 95% CI, 1.56-2.02), Kansas (DRR, 1.51; 
      95% CI, 1.25-1.81), Louisiana (DRR, 1.49; 95% CI, 1.38-1.60), Illinois (DRR,
      1.48; 95% CI, 1.39-1.57), and California (DRR, 1.45; 95% CI, 1.38-1.54). Larger
      racial inequalities in young and middle-aged adults probably partly reflect less 
      access to high-quality health care. CA Cancer J Clin 2018;68:7-30. (c) 2018
      American Cancer Society.
CI  - (c) 2018 American Cancer Society.
FAU - Siegel, Rebecca L
AU  - Siegel RL
AD  - Strategic Director, Surveillance Information Services, Surveillance and Health
      Services Research, American Cancer Society, Atlanta, GA.
FAU - Miller, Kimberly D
AU  - Miller KD
AD  - Epidemiologist, Surveillance and Health Services Research, American Cancer
      Society, Atlanta, GA.
FAU - Jemal, Ahmedin
AU  - Jemal A
AUID- ORCID: http://orcid.org/0000-0002-0000-4111
AD  - Vice President, Surveillance and Health Services Research, American Cancer
      Society, Atlanta, GA.
LA  - eng
PT  - Journal Article
DEP - 20180104
PL  - United States
TA  - CA Cancer J Clin
JT  - CA: a cancer journal for clinicians
JID - 0370647
OTO - NOTNLM
OT  - cancer cases
OT  - cancer statistics
OT  - death rates
OT  - incidence
OT  - mortality
EDAT- 2018/01/10 06:00
MHDA- 2018/01/10 06:00
CRDT- 2018/01/10 06:00
PHST- 2017/10/16 00:00 [received]
PHST- 2017/10/16 00:00 [accepted]
PHST- 2018/01/10 06:00 [pubmed]
PHST- 2018/01/10 06:00 [medline]
PHST- 2018/01/10 06:00 [entrez]
AID - 10.3322/caac.21442 [doi]
PST - ppublish
SO  - CA Cancer J Clin. 2018 Jan;68(1):7-30. doi: 10.3322/caac.21442. Epub 2018 Jan 4.

PMID- 29211715
OWN - NLM
STAT- In-Data-Review
LR  - 20171220
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 552
IP  - 7684
DP  - 2017 Dec 14
TI  - Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4.
PG  - 194-199
LID - 10.1038/nature25016 [doi]
AB  - Cancer incidence is rising and this global challenge is further exacerbated by
      tumour resistance to available medicines. A promising approach to meet the need
      for improved cancer treatment is drug repurposing. Here we highlight the
      potential for repurposing disulfiram (also known by the trade name Antabuse), an 
      old alcohol-aversion drug that has been shown to be effective against diverse
      cancer types in preclinical studies. Our nationwide epidemiological study reveals
      that patients who continuously used disulfiram have a lower risk of death from
      cancer compared to those who stopped using the drug at their diagnosis. Moreover,
      we identify the ditiocarb-copper complex as the metabolite of disulfiram that is 
      responsible for its anti-cancer effects, and provide methods to detect
      preferential accumulation of the complex in tumours and candidate biomarkers to
      analyse its effect on cells and tissues. Finally, our functional and biophysical 
      analyses reveal the molecular target of disulfiram's tumour-suppressing effects
      as NPL4, an adaptor of p97 (also known as VCP) segregase, which is essential for 
      the turnover of proteins involved in multiple regulatory and stress-response
      pathways in cells.
FAU - Skrott, Zdenek
AU  - Skrott Z
AD  - Institute of Molecular and Translational Medicine, Faculty of Medicine and
      Dentistry, Palacky University, Olomouc, Czech Republic.
FAU - Mistrik, Martin
AU  - Mistrik M
AD  - Institute of Molecular and Translational Medicine, Faculty of Medicine and
      Dentistry, Palacky University, Olomouc, Czech Republic.
FAU - Andersen, Klaus Kaae
AU  - Andersen KK
AD  - Danish Cancer Society Research Center, DK-2100 Copenhagen, Denmark.
FAU - Friis, Soren
AU  - Friis S
AD  - Danish Cancer Society Research Center, DK-2100 Copenhagen, Denmark.
FAU - Majera, Dusana
AU  - Majera D
AD  - Institute of Molecular and Translational Medicine, Faculty of Medicine and
      Dentistry, Palacky University, Olomouc, Czech Republic.
FAU - Gursky, Jan
AU  - Gursky J
AD  - Institute of Molecular and Translational Medicine, Faculty of Medicine and
      Dentistry, Palacky University, Olomouc, Czech Republic.
FAU - Ozdian, Tomas
AU  - Ozdian T
AD  - Institute of Molecular and Translational Medicine, Faculty of Medicine and
      Dentistry, Palacky University, Olomouc, Czech Republic.
FAU - Bartkova, Jirina
AU  - Bartkova J
AD  - Danish Cancer Society Research Center, DK-2100 Copenhagen, Denmark.
AD  - Science for Life Laboratory, Division of Genome Biology, Department of Medical
      Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden.
FAU - Turi, Zsofia
AU  - Turi Z
AD  - Institute of Molecular and Translational Medicine, Faculty of Medicine and
      Dentistry, Palacky University, Olomouc, Czech Republic.
FAU - Moudry, Pavel
AU  - Moudry P
AD  - Institute of Molecular and Translational Medicine, Faculty of Medicine and
      Dentistry, Palacky University, Olomouc, Czech Republic.
FAU - Kraus, Marianne
AU  - Kraus M
AD  - Kantonsspital St Gallen, Department Oncology/Hematology, St Gallen, Switzerland.
FAU - Michalova, Martina
AU  - Michalova M
AD  - Institute of Molecular and Translational Medicine, Faculty of Medicine and
      Dentistry, Palacky University, Olomouc, Czech Republic.
FAU - Vaclavkova, Jana
AU  - Vaclavkova J
AD  - Institute of Molecular and Translational Medicine, Faculty of Medicine and
      Dentistry, Palacky University, Olomouc, Czech Republic.
FAU - Dzubak, Petr
AU  - Dzubak P
AD  - Institute of Molecular and Translational Medicine, Faculty of Medicine and
      Dentistry, Palacky University, Olomouc, Czech Republic.
FAU - Vrobel, Ivo
AU  - Vrobel I
AD  - Institute of Molecular and Translational Medicine, Faculty of Medicine and
      Dentistry, Palacky University, Olomouc, Czech Republic.
FAU - Pouckova, Pavla
AU  - Pouckova P
AD  - Institute of Biophysics and Informatics, First Faculty of Medicine, Charles
      University, 120 00 Prague 2, Czech Republic.
FAU - Sedlacek, Jindrich
AU  - Sedlacek J
AD  - Department of Cell Biology & Genetics, Palacky University, Olomouc, Czech
      Republic.
FAU - Miklovicova, Andrea
AU  - Miklovicova A
AD  - Psychiatric Hospital, 785 01 Sternberk, Czech Republic.
FAU - Kutt, Anne
AU  - Kutt A
AD  - Danish Cancer Society Research Center, DK-2100 Copenhagen, Denmark.
FAU - Li, Jing
AU  - Li J
AD  - Division of Biology and Biological Engineering, Caltech, Pasadena, California
      91125, USA.
FAU - Mattova, Jana
AU  - Mattova J
AD  - Institute of Biophysics and Informatics, First Faculty of Medicine, Charles
      University, 120 00 Prague 2, Czech Republic.
FAU - Driessen, Christoph
AU  - Driessen C
AD  - Kantonsspital St Gallen, Department Oncology/Hematology, St Gallen, Switzerland.
FAU - Dou, Q Ping
AU  - Dou QP
AD  - Barbara Ann Karmanos Cancer Institute and Department of Oncology, School of
      Medicine, Wayne State University, Detroit, Michigan, USA.
AD  - School of Basic Medical Sciences, Affiliated Tumor Hospital of Guangzhou Medical 
      University, Guangzhou 511436, China.
FAU - Olsen, Jorgen
AU  - Olsen J
AD  - Danish Cancer Society Research Center, DK-2100 Copenhagen, Denmark.
FAU - Hajduch, Marian
AU  - Hajduch M
AD  - Institute of Molecular and Translational Medicine, Faculty of Medicine and
      Dentistry, Palacky University, Olomouc, Czech Republic.
FAU - Cvek, Boris
AU  - Cvek B
AD  - Department of Cell Biology & Genetics, Palacky University, Olomouc, Czech
      Republic.
FAU - Deshaies, Raymond J
AU  - Deshaies RJ
AD  - Division of Biology and Biological Engineering, Caltech, Pasadena, California
      91125, USA.
AD  - Howard Hughes Medical Institute, Caltech, Pasadena, California 91125, USA.
FAU - Bartek, Jiri
AU  - Bartek J
AD  - Danish Cancer Society Research Center, DK-2100 Copenhagen, Denmark.
AD  - Science for Life Laboratory, Division of Genome Biology, Department of Medical
      Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden.
LA  - eng
GR  - R01 CA164803/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20171206
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
PMC - PMC5730499
MID - NIHMS919071
EDAT- 2017/12/07 06:00
MHDA- 2017/12/07 06:00
CRDT- 2017/12/07 06:00
PMCR- 2018/06/06 00:00
PHST- 2015/10/01 00:00 [received]
PHST- 2017/11/08 00:00 [accepted]
PHST- 2018/06/06 00:00 [pmc-release]
PHST- 2017/12/07 06:00 [pubmed]
PHST- 2017/12/07 06:00 [medline]
PHST- 2017/12/07 06:00 [entrez]
AID - nature25016 [pii]
AID - 10.1038/nature25016 [doi]
PST - ppublish
SO  - Nature. 2017 Dec 14;552(7684):194-199. doi: 10.1038/nature25016. Epub 2017 Dec 6.

PMID- 29058716
OWN - NLM
STAT- MEDLINE
DCOM- 20171211
LR  - 20180120
IS  - 1546-1718 (Electronic)
IS  - 1061-4036 (Linking)
VI  - 49
IP  - 12
DP  - 2017 Dec
TI  - Identification of ten variants associated with risk of estrogen-receptor-negative
      breast cancer.
PG  - 1767-1778
LID - 10.1038/ng.3785 [doi]
AB  - Most common breast cancer susceptibility variants have been identified through
      genome-wide association studies (GWAS) of predominantly estrogen receptor
      (ER)-positive disease. We conducted a GWAS using 21,468 ER-negative cases and
      100,594 controls combined with 18,908 BRCA1 mutation carriers (9,414 with breast 
      cancer), all of European origin. We identified independent associations at P < 5 
      x 10(-8) with ten variants at nine new loci. At P < 0.05, we replicated
      associations with 10 of 11 variants previously reported in ER-negative disease or
      BRCA1 mutation carrier GWAS and observed consistent associations with ER-negative
      disease for 105 susceptibility variants identified by other studies. These 125
      variants explain approximately 16% of the familial risk of this breast cancer
      subtype. There was high genetic correlation (0.72) between risk of ER-negative
      breast cancer and breast cancer risk for BRCA1 mutation carriers. These findings 
      may lead to improved risk prediction and inform further fine-mapping and
      functional work to better understand the biological basis of ER-negative breast
      cancer.
FAU - Milne, Roger L
AU  - Milne RL
AUID- ORCID: http://orcid.org/0000-0001-5764-7268
AD  - Cancer Epidemiology and Intelligence Division, Cancer Council Victoria,
      Melbourne, Victoria, Australia.
AD  - Centre for Epidemiology and Biostatistics, Melbourne School of Population and
      Global Health, University of Melbourne, Melbourne, Victoria, Australia.
FAU - Kuchenbaecker, Karoline B
AU  - Kuchenbaecker KB
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary
      Care, University of Cambridge, Cambridge, UK.
AD  - Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK.
FAU - Michailidou, Kyriaki
AU  - Michailidou K
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary
      Care, University of Cambridge, Cambridge, UK.
AD  - Department of Electron Microscopy/Molecular Pathology, The Cyprus Institute of
      Neurology and Genetics, Nicosia, Cyprus.
FAU - Beesley, Jonathan
AU  - Beesley J
AD  - Cancer Division, QIMR Berghofer Medical Research Institute, Brisbane, Queensland,
      Australia.
FAU - Kar, Siddhartha
AU  - Kar S
AD  - Centre for Cancer Genetic Epidemiology, Department of Oncology, University of
      Cambridge, Cambridge, UK.
FAU - Lindstrom, Sara
AU  - Lindstrom S
AD  - Department of Epidemiology, University of Washington School of Public Health,
      Seattle, Washington, USA.
AD  - Program in Genetic Epidemiology and Statistical Genetics, Harvard T.H. Chan
      School of Public Health, Boston, Massachusetts, USA.
FAU - Hui, Shirley
AU  - Hui S
AD  - Donnelly Centre, University of Toronto, Toronto, Ontario, Canada.
FAU - Lemacon, Audrey
AU  - Lemacon A
AD  - Genomics Center, Centre Hospitalier Universitaire de Quebec Research Center,
      Laval University, Quebec City, Quebec, Canada.
FAU - Soucy, Penny
AU  - Soucy P
AD  - Genomics Center, Centre Hospitalier Universitaire de Quebec Research Center,
      Laval University, Quebec City, Quebec, Canada.
FAU - Dennis, Joe
AU  - Dennis J
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary
      Care, University of Cambridge, Cambridge, UK.
FAU - Jiang, Xia
AU  - Jiang X
AD  - Program in Genetic Epidemiology and Statistical Genetics, Harvard T.H. Chan
      School of Public Health, Boston, Massachusetts, USA.
FAU - Rostamianfar, Asha
AU  - Rostamianfar A
AD  - Donnelly Centre, University of Toronto, Toronto, Ontario, Canada.
FAU - Finucane, Hilary
AU  - Finucane H
AD  - Program in Genetic Epidemiology and Statistical Genetics, Harvard T.H. Chan
      School of Public Health, Boston, Massachusetts, USA.
AD  - Department of Mathematics, Massachusetts Institute of Technology, Cambridge,
      Massachusetts, USA.
FAU - Bolla, Manjeet K
AU  - Bolla MK
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary
      Care, University of Cambridge, Cambridge, UK.
FAU - McGuffog, Lesley
AU  - McGuffog L
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary
      Care, University of Cambridge, Cambridge, UK.
FAU - Wang, Qin
AU  - Wang Q
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary
      Care, University of Cambridge, Cambridge, UK.
FAU - Aalfs, Cora M
AU  - Aalfs CM
AD  - Department of Clinical Genetics, Academic Medical Center, Amsterdam, the
      Netherlands.
CN  - ABCTB Investigators
FAU - Adams, Marcia
AU  - Adams M
AD  - Center for Inherited Disease Research (CIDR), Institute of Genetic Medicine,
      Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
FAU - Adlard, Julian
AU  - Adlard J
AD  - Yorkshire Regional Genetics Service, Chapel Allerton Hospital, Leeds, UK.
FAU - Agata, Simona
AU  - Agata S
AD  - Immunology and Molecular Oncology Unit, Istituto Oncologico Veneto (IOV), IRCCS, 
      Padua, Italy.
FAU - Ahmed, Shahana
AU  - Ahmed S
AD  - Centre for Cancer Genetic Epidemiology, Department of Oncology, University of
      Cambridge, Cambridge, UK.
FAU - Ahsan, Habibul
AU  - Ahsan H
AD  - Center for Cancer Epidemiology and Prevention, University of Chicago, Chicago,
      Illinois, USA.
FAU - Aittomaki, Kristiina
AU  - Aittomaki K
AD  - Department of Clinical Genetics, Helsinki University Hospital, University of
      Helsinki, Helsinki, Finland.
FAU - Al-Ejeh, Fares
AU  - Al-Ejeh F
AD  - Personalised Medicine Team, QIMR Berghofer Medical Research Institute, Brisbane, 
      Queensland, Australia.
FAU - Allen, Jamie
AU  - Allen J
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary
      Care, University of Cambridge, Cambridge, UK.
FAU - Ambrosone, Christine B
AU  - Ambrosone CB
AD  - Roswell Park Cancer Institute, Buffalo, New York, USA.
FAU - Amos, Christopher I
AU  - Amos CI
AD  - Center for Genomic Medicine, Department of Biomedical Data Science, Geisel School
      of Medicine, Dartmouth College, Lebanon, New Hampshire, USA.
FAU - Andrulis, Irene L
AU  - Andrulis IL
AD  - Fred A. Litwin Center for Cancer Genetics, Lunenfeld-Tanenbaum Research Institute
      of Mount Sinai Hospital, Toronto, Ontario, Canada.
AD  - Department of Molecular Genetics, University of Toronto, Toronto, Ontario,
      Canada.
FAU - Anton-Culver, Hoda
AU  - Anton-Culver H
AD  - Department of Epidemiology, University of California, Irvine, Irvine, California,
      USA.
FAU - Antonenkova, Natalia N
AU  - Antonenkova NN
AD  - N.N. Alexandrov Research Institute of Oncology and Medical Radiology, Minsk,
      Belarus.
FAU - Arndt, Volker
AU  - Arndt V
AD  - Division of Clinical Epidemiology and Aging Research, German Cancer Research
      Center (DKFZ), Heidelberg, Germany.
FAU - Arnold, Norbert
AU  - Arnold N
AD  - Institute of Clinical Molecular Biology / Department of Gynecology and
      Obstetrics, University Hospital of Schleswig-Holstein, Campus Kiel,
      Christian-Albrechts University Kiel, Kiel, Germany.
FAU - Aronson, Kristan J
AU  - Aronson KJ
AD  - Department of Public Health Sciences and Cancer Research Institute, Queen's
      University, Kingston, Ontario, Canada.
FAU - Auber, Bernd
AU  - Auber B
AD  - Institute of Human Genetics, Hannover Medical School, Hannover, Germany.
FAU - Auer, Paul L
AU  - Auer PL
AD  - Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle,
      Washington, USA.
AD  - Zilber School of Public Health, University of Wisconsin-Milwaukee, Milwaukee,
      Wisconsin, USA.
FAU - Ausems, Margreet G E M
AU  - Ausems MGEM
AD  - Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the
      Netherlands.
FAU - Azzollini, Jacopo
AU  - Azzollini J
AD  - Unit of Medical Genetics, Department of Preventive and Predictive Medicine,
      Fondazione IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), Istituto 
      Nazionale dei Tumori (INT), Milan, Italy.
FAU - Bacot, Francois
AU  - Bacot F
AD  - McGill University and Genome Quebec Innovation Centre, Montreal, Quebec, Canada.
FAU - Balmana, Judith
AU  - Balmana J
AD  - Department of Medical Oncology, University Hospital, Vall d'Hebron, Barcelona,
      Spain.
FAU - Barile, Monica
AU  - Barile M
AD  - Division of Cancer Prevention and Genetics, Istituto Europeo di Oncologia, Milan,
      Italy.
FAU - Barjhoux, Laure
AU  - Barjhoux L
AD  - Batiment Cheney D, Centre Leon Berard, Lyon, France.
FAU - Barkardottir, Rosa B
AU  - Barkardottir RB
AD  - Laboratory of Cell Biology, Department of Pathology, Landspitali, Reykjavik,
      Iceland.
AD  - BMC (Biomedical Centre), Faculty of Medicine, University of Iceland, Reykjavik,
      Iceland.
FAU - Barrdahl, Myrto
AU  - Barrdahl M
AD  - Division of Cancer Epidemiology, German Cancer Research Center (DKFZ),
      Heidelberg, Germany.
FAU - Barnes, Daniel
AU  - Barnes D
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary
      Care, University of Cambridge, Cambridge, UK.
FAU - Barrowdale, Daniel
AU  - Barrowdale D
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary
      Care, University of Cambridge, Cambridge, UK.
FAU - Baynes, Caroline
AU  - Baynes C
AD  - Centre for Cancer Genetic Epidemiology, Department of Oncology, University of
      Cambridge, Cambridge, UK.
FAU - Beckmann, Matthias W
AU  - Beckmann MW
AD  - Department of Gynaecology and Obstetrics, University Hospital Erlangen, Friedrich
      Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center
      Erlangen-EMN, Erlangen, Germany.
FAU - Benitez, Javier
AU  - Benitez J
AD  - Human Genotyping Unit -Centro Nacional de Genotipado (CEGEN), Human Cancer
      Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid,
      Spain.
AD  - Human Genetics Group, Human Cancer Genetics Programme, Spanish National Cancer
      Centre (CNIO), Madrid, Spain.
AD  - Spanish Network on Rare Diseases (CIBERER), Madrid, Spain.
FAU - Bermisheva, Marina
AU  - Bermisheva M
AD  - Institute of Biochemistry and Genetics, Ufa Scientific Center of the Russian
      Academy of Sciences, Ufa, Russian Federation.
FAU - Bernstein, Leslie
AU  - Bernstein L
AD  - Department of Population Sciences, Beckman Research Institute of City of Hope,
      Duarte, California, USA.
FAU - Bignon, Yves-Jean
AU  - Bignon YJ
AD  - Universite Clermont Auvergne, INSERM, U1240, Imagerie Moleculaire et Strategies
      Theranostiques, Centre Jean Perrin, Clermont-Ferrand, France.
FAU - Blazer, Kathleen R
AU  - Blazer KR
AD  - Clinical Cancer Genetics, City of Hope, Duarte, California, USA.
FAU - Blok, Marinus J
AU  - Blok MJ
AD  - Department of Clinical Genetics, Maastricht University Medical Center,
      Maastricht, the Netherlands.
FAU - Blomqvist, Carl
AU  - Blomqvist C
AD  - Department of Oncology, Helsinki University Hospital, University of Helsinki,
      Helsinki, Finland.
FAU - Blot, William
AU  - Blot W
AD  - Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center,
      Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine,
      Nashville, Tennessee, USA.
AD  - International Epidemiology Institute, Rockville, Maryland, USA.
FAU - Bobolis, Kristie
AU  - Bobolis K
AD  - City of Hope Clinical Cancer Genomics Community Research Network, Duarte,
      California, USA.
FAU - Boeckx, Bram
AU  - Boeckx B
AD  - Vesalius Research Center, VIB, Leuven, Belgium.
AD  - Laboratory for Translational Genetics, Department of Oncology, University of
      Leuven, Leuven, Belgium.
FAU - Bogdanova, Natalia V
AU  - Bogdanova NV
AD  - N.N. Alexandrov Research Institute of Oncology and Medical Radiology, Minsk,
      Belarus.
AD  - Department of Radiation Oncology, Hannover Medical School, Hannover, Germany.
AD  - Gynaecology Research Unit, Hannover Medical School, Hannover, Germany.
FAU - Bojesen, Anders
AU  - Bojesen A
AD  - Department of Clinical Genetics, Vejle Hospital, Vejle, Denmark.
FAU - Bojesen, Stig E
AU  - Bojesen SE
AD  - Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen
      University Hospital, Herlev, Denmark.
AD  - Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen
      University Hospital, Herlev, Denmark.
AD  - Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen,
      Denmark.
FAU - Bonanni, Bernardo
AU  - Bonanni B
AD  - Division of Cancer Prevention and Genetics, Istituto Europeo di Oncologia, Milan,
      Italy.
FAU - Borresen-Dale, Anne-Lise
AU  - Borresen-Dale AL
AD  - Department of Cancer Genetics, Institute for Cancer Research, Oslo University
      Hospital Radiumhospitalet, Oslo, Norway.
FAU - Bozsik, Aniko
AU  - Bozsik A
AD  - Department of Molecular Genetics, National Institute of Oncology, Budapest,
      Hungary.
FAU - Bradbury, Angela R
AU  - Bradbury AR
AD  - Department of Medicine, Abramson Cancer Center, Perelman School of Medicine at
      the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
FAU - Brand, Judith S
AU  - Brand JS
AD  - Department of Medical Epidemiology and Biostatistics, Karolinska Institutet,
      Stockholm, Sweden.
FAU - Brauch, Hiltrud
AU  - Brauch H
AD  - Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart,
      Germany.
AD  - University of Tubingen, Tubingen, Germany.
AD  - German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ),
      Heidelberg, Germany.
FAU - Brenner, Hermann
AU  - Brenner H
AD  - Division of Clinical Epidemiology and Aging Research, German Cancer Research
      Center (DKFZ), Heidelberg, Germany.
AD  - German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ),
      Heidelberg, Germany.
AD  - Division of Preventive Oncology, German Cancer Research Center (DKFZ) and
      National Center for Tumor Diseases (NCT), Heidelberg, Germany.
FAU - Bressac-de Paillerets, Brigitte
AU  - Bressac-de Paillerets B
AD  - Gustave Roussy, Biopathology Department, Villejuif, France.
FAU - Brewer, Carole
AU  - Brewer C
AD  - Department of Clinical Genetics, Royal Devon and Exeter Hospital, Exeter, UK.
FAU - Brinton, Louise
AU  - Brinton L
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute,
      Rockville, Maryland, USA.
FAU - Broberg, Per
AU  - Broberg P
AD  - Department of Cancer Epidemiology, Clinical Sciences, Lund University, Lund,
      Sweden.
FAU - Brooks-Wilson, Angela
AU  - Brooks-Wilson A
AD  - Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia, Canada.
AD  - Department of Biomedical Physiology and Kinesiology, Simon Fraser University,
      Burnaby, British Columbia, Canada.
FAU - Brunet, Joan
AU  - Brunet J
AD  - Genetic Counseling Unit, Hereditary Cancer Program, IDIBGI (Institut
      d'Investigacio Biomedica de Girona), Catalan Institute of Oncology, Girona,
      Spain.
FAU - Bruning, Thomas
AU  - Bruning T
AD  - Institute for Prevention and Occupational Medicine of the German Social Accident 
      Insurance, Institute of the Ruhr University Bochum (IPA), Bochum, Germany.
FAU - Burwinkel, Barbara
AU  - Burwinkel B
AD  - Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg,
      Germany.
AD  - Molecular Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg,
      Germany.
FAU - Buys, Saundra S
AU  - Buys SS
AD  - Department of Medicine, Huntsman Cancer Institute, Salt Lake City, Utah, USA.
FAU - Byun, Jinyoung
AU  - Byun J
AD  - Center for Genomic Medicine, Department of Biomedical Data Science, Geisel School
      of Medicine, Dartmouth College, Lebanon, New Hampshire, USA.
FAU - Cai, Qiuyin
AU  - Cai Q
AD  - Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center,
      Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine,
      Nashville, Tennessee, USA.
FAU - Caldes, Trinidad
AU  - Caldes T
AD  - Medical Oncology Department, CIBERONC, Hospital Clinico San Carlos, Madrid,
      Spain.
FAU - Caligo, Maria A
AU  - Caligo MA
AD  - Section of Molecular Genetics, Department of Laboratory Medicine, University of
      Pisa and University Hospital of Pisa, Pisa, Italy.
FAU - Campbell, Ian
AU  - Campbell I
AD  - Research Department, Peter MacCallum Cancer Centre, East Melbourne, Victoria,
      Australia.
AD  - Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne,
      Victoria, Australia.
FAU - Canzian, Federico
AU  - Canzian F
AD  - Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg,
      Germany.
FAU - Caron, Olivier
AU  - Caron O
AD  - Gustave Roussy, Biopathology Department, Villejuif, France.
FAU - Carracedo, Angel
AU  - Carracedo A
AD  - Genomic Medicine Group, Galician Foundation of Genomic Medicine, Instituto de
      Investigacion Sanitaria de Santiago de Compostela (IDIS), Complejo Hospitalario
      Universitario de Santiago, Servizo Galego de Saude SERGAS, Santiago de
      Compostela, Spain.
AD  - Centro de Investigacion en Red de Enfermedades Raras (CIBERER) and Centro
      Nacional de Genotipado (CEGEN-PRB2), Universidade de Santiago de Compostela,
      Santiago de Compostela, Spain.
FAU - Carter, Brian D
AU  - Carter BD
AD  - Epidemiology Research Program, American Cancer Society, Atlanta, Georgia, USA.
FAU - Castelao, J Esteban
AU  - Castelao JE
AD  - Oncology and Genetics Unit, Instituto de Investigacion Biomedica (IBI) de
      Orense-Pontevedra-Vigo, Xerencia de Xestion Integrada de Vigo, Servizo Galego de 
      Saude SERGAS, Vigo, Spain.
FAU - Castera, Laurent
AU  - Castera L
AD  - Centre Francois Baclesse, Caen, France.
FAU - Caux-Moncoutier, Virginie
AU  - Caux-Moncoutier V
AD  - Service de Genetique Oncologique and INSERM U830, Institut Curie, Paris, France -
      Universite Paris Descartes, Sorbonne Paris Cite.
FAU - Chan, Salina B
AU  - Chan SB
FAU - Chang-Claude, Jenny
AU  - Chang-Claude J
AD  - Division of Cancer Epidemiology, German Cancer Research Center (DKFZ),
      Heidelberg, Germany.
AD  - University Cancer Center Hamburg (UCCH), University Medical Center
      Hamburg-Eppendorf, Hamburg, Germany.
FAU - Chanock, Stephen J
AU  - Chanock SJ
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute,
      Rockville, Maryland, USA.
FAU - Chen, Xiaoqing
AU  - Chen X
AD  - Cancer Division, QIMR Berghofer Medical Research Institute, Brisbane, Queensland,
      Australia.
FAU - Cheng, Ting-Yuan David
AU  - Cheng TD
AD  - Division of Cancer Prevention and Population Sciences, Roswell Park Cancer
      Institute, Buffalo, New York, USA.
FAU - Chiquette, Jocelyne
AU  - Chiquette J
AD  - Unite de Recherche en Sante des Populations, Centre des Maladies du Sein
      Deschenes-Fabia, Hopital du Saint-Sacrement, Quebec City, Quebec, Canada.
FAU - Christiansen, Hans
AU  - Christiansen H
AD  - Department of Radiation Oncology, Hannover Medical School, Hannover, Germany.
FAU - Claes, Kathleen B M
AU  - Claes KBM
AD  - Center for Medical Genetics, Ghent University, Ghent, Belgium.
FAU - Clarke, Christine L
AU  - Clarke CL
AD  - Westmead Institute for Medical Research, University of Sydney, Sydney, New South 
      Wales, Australia.
FAU - Conner, Thomas
AU  - Conner T
AD  - Huntsman Cancer Institute, Salt Lake City, Utah, USA.
FAU - Conroy, Don M
AU  - Conroy DM
AD  - Centre for Cancer Genetic Epidemiology, Department of Oncology, University of
      Cambridge, Cambridge, UK.
FAU - Cook, Jackie
AU  - Cook J
AD  - Sheffield Clinical Genetics Service, Sheffield Children's Hospital, Sheffield,
      UK.
FAU - Cordina-Duverger, Emilie
AU  - Cordina-Duverger E
AD  - Cancer and Environment Group, Center for Research in Epidemiology and Population 
      Health (CESP), INSERM, University Paris-Sud, University Paris-Saclay, Villejuif, 
      France.
FAU - Cornelissen, Sten
AU  - Cornelissen S
AD  - Division of Molecular Pathology, Netherlands Cancer Institute, Antoni van
      Leeuwenhoek Hospital, Amsterdam, the Netherlands.
FAU - Coupier, Isabelle
AU  - Coupier I
AD  - Unite d'Oncogenetique, CHU Arnaud de Villeneuve, Montpellier, France.
FAU - Cox, Angela
AU  - Cox A
AD  - Academic Unit of Molecular Oncology, Department of Oncology and Metabolism,
      University of Sheffield, Sheffield, UK.
FAU - Cox, David G
AU  - Cox DG
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Imperial
      College London, London, UK.
AD  - INSERM U1052, Cancer Research Center of Lyon, Lyon, France.
FAU - Cross, Simon S
AU  - Cross SS
AD  - Academic Unit of Pathology, Department of Neuroscience, University of Sheffield, 
      Sheffield, UK.
FAU - Cuk, Katarina
AU  - Cuk K
AD  - Division of Clinical Epidemiology and Aging Research, German Cancer Research
      Center (DKFZ), Heidelberg, Germany.
FAU - Cunningham, Julie M
AU  - Cunningham JM
AD  - Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester,
      Minnesota, USA.
FAU - Czene, Kamila
AU  - Czene K
AD  - Department of Medical Epidemiology and Biostatistics, Karolinska Institutet,
      Stockholm, Sweden.
FAU - Daly, Mary B
AU  - Daly MB
AD  - Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia,
      Pennsylvania, USA.
FAU - Damiola, Francesca
AU  - Damiola F
AD  - Batiment Cheney D, Centre Leon Berard, Lyon, France.
FAU - Darabi, Hatef
AU  - Darabi H
AD  - Department of Medical Epidemiology and Biostatistics, Karolinska Institutet,
      Stockholm, Sweden.
FAU - Davidson, Rosemarie
AU  - Davidson R
AD  - Department of Clinical Genetics, South Glasgow University Hospitals, Glasgow, UK.
FAU - De Leeneer, Kim
AU  - De Leeneer K
AD  - Center for Medical Genetics, Ghent University, Ghent, Belgium.
FAU - Devilee, Peter
AU  - Devilee P
AD  - Department of Pathology, Leiden University Medical Center, Leiden, the
      Netherlands.
AD  - Department of Human Genetics, Leiden University Medical Center, Leiden, the
      Netherlands.
FAU - Dicks, Ed
AU  - Dicks E
AD  - Centre for Cancer Genetic Epidemiology, Department of Oncology, University of
      Cambridge, Cambridge, UK.
FAU - Diez, Orland
AU  - Diez O
AD  - Oncogenetics Group, Vall d'Hebron Institute of Oncology (VHIO), Clinical and
      Molecular Genetics Area, Vall d'Hebron University Hospital, Barcelona, Spain.
FAU - Ding, Yuan Chun
AU  - Ding YC
AD  - Department of Population Sciences, Beckman Research Institute of City of Hope,
      Duarte, California, USA.
FAU - Ditsch, Nina
AU  - Ditsch N
AD  - Department of Gynecology and Obstetrics, Ludwig Maximilians University of Munich,
      Munich, Germany.
FAU - Doheny, Kimberly F
AU  - Doheny KF
AD  - Center for Inherited Disease Research (CIDR), Institute of Genetic Medicine,
      Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
FAU - Domchek, Susan M
AU  - Domchek SM
AD  - Department of Medicine, Abramson Cancer Center, Perelman School of Medicine at
      the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
FAU - Dorfling, Cecilia M
AU  - Dorfling CM
AD  - Cancer Genetics Laboratory, Department of Genetics, University of Pretoria,
      Arcadia, South Africa.
FAU - Dork, Thilo
AU  - Dork T
AD  - Gynaecology Research Unit, Hannover Medical School, Hannover, Germany.
FAU - Dos-Santos-Silva, Isabel
AU  - Dos-Santos-Silva I
AD  - Department of Non-Communicable Disease Epidemiology, London School of Hygiene and
      Tropical Medicine, London, UK.
FAU - Dubois, Stephane
AU  - Dubois S
AD  - Genomics Center, Centre Hospitalier Universitaire de Quebec Research Center,
      Laval University, Quebec City, Quebec, Canada.
FAU - Dugue, Pierre-Antoine
AU  - Dugue PA
AD  - Cancer Epidemiology and Intelligence Division, Cancer Council Victoria,
      Melbourne, Victoria, Australia.
AD  - Centre for Epidemiology and Biostatistics, Melbourne School of Population and
      Global Health, University of Melbourne, Melbourne, Victoria, Australia.
FAU - Dumont, Martine
AU  - Dumont M
AD  - Genomics Center, Centre Hospitalier Universitaire de Quebec Research Center,
      Laval University, Quebec City, Quebec, Canada.
FAU - Dunning, Alison M
AU  - Dunning AM
AD  - Centre for Cancer Genetic Epidemiology, Department of Oncology, University of
      Cambridge, Cambridge, UK.
FAU - Durcan, Lorraine
AU  - Durcan L
AD  - Southampton Clinical Trials Unit, Faculty of Medicine, University of Southampton,
      Southampton, UK.
AD  - Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton,
      Southampton, UK.
FAU - Dwek, Miriam
AU  - Dwek M
AD  - Department of Biomedical Sciences, Faculty of Science and Technology, University 
      of Westminster, London, UK.
FAU - Dworniczak, Bernd
AU  - Dworniczak B
AD  - Institute of Human Genetics, University of Munster, Munster, Germany.
FAU - Eccles, Diana
AU  - Eccles D
AD  - Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton,
      Southampton, UK.
FAU - Eeles, Ros
AU  - Eeles R
AD  - Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS
      Foundation Trust, London, UK.
FAU - Ehrencrona, Hans
AU  - Ehrencrona H
AD  - Department of Clinical Genetics, Lund University Hospital, Lund, Sweden.
FAU - Eilber, Ursula
AU  - Eilber U
AD  - Division of Cancer Epidemiology, German Cancer Research Center (DKFZ),
      Heidelberg, Germany.
FAU - Ejlertsen, Bent
AU  - Ejlertsen B
AD  - Department of Oncology, Rigshospitalet, Copenhagen University Hospital,
      Copenhagen, Denmark.
FAU - Ekici, Arif B
AU  - Ekici AB
AD  - Institute of Human Genetics, University Hospital Erlangen, Friedrich Alexander
      University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN,
      Erlangen, Germany.
FAU - Eliassen, A Heather
AU  - Eliassen AH
AD  - Channing Division of Network Medicine, Department of Medicine, Brigham and
      Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
AD  - Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston,
      Massachusetts, USA.
CN  - EMBRACE
FAU - Engel, Christoph
AU  - Engel C
AD  - Institute for Medical Informatics, Statistics and Epidemiology, University of
      Leipzig, Leipzig, Germany.
AD  - LIFE-Leipzig Research Centre for Civilization Diseases, University of Leipzig,
      Leipzig, Germany.
FAU - Eriksson, Mikael
AU  - Eriksson M
AD  - Department of Medical Epidemiology and Biostatistics, Karolinska Institutet,
      Stockholm, Sweden.
FAU - Fachal, Laura
AU  - Fachal L
AD  - Centre for Cancer Genetic Epidemiology, Department of Oncology, University of
      Cambridge, Cambridge, UK.
FAU - Faivre, Laurence
AU  - Faivre L
AD  - Genetics Department, Dijon University Hospital, Dijon, France.
AD  - Oncogenetics, Centre Georges-Francois Leclerc, Dijon, France.
FAU - Fasching, Peter A
AU  - Fasching PA
AD  - Department of Gynaecology and Obstetrics, University Hospital Erlangen, Friedrich
      Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center
      Erlangen-EMN, Erlangen, Germany.
AD  - Division of Hematology and Oncology, Department of Medicine, David Geffen School 
      of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
FAU - Faust, Ulrike
AU  - Faust U
AD  - Institute of Medical Genetics and Applied Genomics, University of Tubingen,
      Tubingen, Germany.
FAU - Figueroa, Jonine
AU  - Figueroa J
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute,
      Rockville, Maryland, USA.
AD  - Usher Institute of Population Health Sciences and Informatics, CRUK Edinburgh
      Centre, University of Edinburgh Medical School, Edinburgh, UK.
FAU - Flesch-Janys, Dieter
AU  - Flesch-Janys D
AD  - Institute for Medical Biometrics and Epidemiology, University Medical Center
      Hamburg-Eppendorf, Hamburg, Germany.
AD  - Department of Cancer Epidemiology, Clinical Cancer Registry, University Medical
      Center Hamburg-Eppendorf, Hamburg, Germany.
FAU - Fletcher, Olivia
AU  - Fletcher O
AD  - Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, 
      London, UK.
FAU - Flyger, Henrik
AU  - Flyger H
AD  - Department of Breast Surgery, Herlev and Gentofte Hospital, Copenhagen University
      Hospital, Herlev, Denmark.
FAU - Foulkes, William D
AU  - Foulkes WD
AD  - Program in Cancer Genetics, Departments of Human Genetics and Oncology, McGill
      University, Montreal, Quebec, Canada.
FAU - Friedman, Eitan
AU  - Friedman E
AD  - Susanne Levy Gertner Oncogenetics Unit, Institute of Human Genetics, Chaim Sheba 
      Medical Center, Ramat Gan, Israel.
AD  - Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel.
FAU - Fritschi, Lin
AU  - Fritschi L
AD  - School of Public Health, Curtin University, Perth, Western Australia, Australia.
FAU - Frost, Debra
AU  - Frost D
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary
      Care, University of Cambridge, Cambridge, UK.
FAU - Gabrielson, Marike
AU  - Gabrielson M
AD  - Department of Medical Epidemiology and Biostatistics, Karolinska Institutet,
      Stockholm, Sweden.
FAU - Gaddam, Pragna
AU  - Gaddam P
AD  - Clinical Cancer Genetics Laboratory, Memorial Sloan Kettering Cancer Center, New 
      York, New York, USA.
FAU - Gammon, Marilie D
AU  - Gammon MD
AD  - Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel
      Hill, North Carolina, USA.
FAU - Ganz, Patricia A
AU  - Ganz PA
AD  - Division of Cancer Prevention and Control Research, Jonsson Comprehensive Cancer 
      Center, Schools of Medicine and Public Health, University of California, Los
      Angeles, Los Angeles, California, USA.
FAU - Gapstur, Susan M
AU  - Gapstur SM
AD  - Epidemiology Research Program, American Cancer Society, Atlanta, Georgia, USA.
FAU - Garber, Judy
AU  - Garber J
AD  - Cancer Risk and Prevention Clinic, Dana-Farber Cancer Institute, Boston,
      Massachusetts, USA.
FAU - Garcia-Barberan, Vanesa
AU  - Garcia-Barberan V
AD  - Medical Oncology Department, CIBERONC, Hospital Clinico San Carlos, Madrid,
      Spain.
FAU - Garcia-Saenz, Jose A
AU  - Garcia-Saenz JA
AD  - Medical Oncology Department, CIBERONC, Hospital Clinico San Carlos, Madrid,
      Spain.
FAU - Gaudet, Mia M
AU  - Gaudet MM
AD  - Epidemiology Research Program, American Cancer Society, Atlanta, Georgia, USA.
FAU - Gauthier-Villars, Marion
AU  - Gauthier-Villars M
AD  - Service de Genetique Oncologique and INSERM U830, Institut Curie, Paris, France -
      Universite Paris Descartes, Sorbonne Paris Cite.
FAU - Gehrig, Andrea
AU  - Gehrig A
AD  - Centre of Familial Breast and Ovarian Cancer, Department of Medical Genetics,
      Institute of Human Genetics, University Wurzburg, Wurzburg, Germany.
CN  - GEMO Study Collaborators
FAU - Georgoulias, Vassilios
AU  - Georgoulias V
AD  - Department of Medical Oncology, University Hospital of Heraklion, Heraklion,
      Greece.
FAU - Gerdes, Anne-Marie
AU  - Gerdes AM
AD  - Department of Clinical Genetics, Rigshospitalet, Copenhagen, Denmark.
FAU - Giles, Graham G
AU  - Giles GG
AD  - Cancer Epidemiology and Intelligence Division, Cancer Council Victoria,
      Melbourne, Victoria, Australia.
AD  - Centre for Epidemiology and Biostatistics, Melbourne School of Population and
      Global Health, University of Melbourne, Melbourne, Victoria, Australia.
FAU - Glendon, Gord
AU  - Glendon G
AD  - Fred A. Litwin Center for Cancer Genetics, Lunenfeld-Tanenbaum Research Institute
      of Mount Sinai Hospital, Toronto, Ontario, Canada.
FAU - Godwin, Andrew K
AU  - Godwin AK
AD  - Department of Pathology and Laboratory Medicine, University of Kansas Medical
      Center, Kansas City, Kansas, USA.
FAU - Goldberg, Mark S
AU  - Goldberg MS
AD  - Department of Medicine, McGill University, Montreal, Quebec, Canada.
AD  - Division of Clinical Epidemiology, Royal Victoria Hospital, McGill University,
      Montreal, Quebec, Canada.
FAU - Goldgar, David E
AU  - Goldgar DE
AD  - Department of Dermatology, Huntsman Cancer Institute, University of Utah School
      of Medicine, Salt Lake City, Utah, USA.
FAU - Gonzalez-Neira, Anna
AU  - Gonzalez-Neira A
AD  - Human Genotyping Unit -Centro Nacional de Genotipado (CEGEN), Human Cancer
      Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid,
      Spain.
FAU - Goodfellow, Paul
AU  - Goodfellow P
AD  - Department of Obstetrics and Gynecology, Ohio State University James
      Comprehensive Cancer Center, Columbus, Ohio, USA.
FAU - Greene, Mark H
AU  - Greene MH
AD  - Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National 
      Cancer Institute, US National Institutes of Health, Bethesda, Maryland, USA.
FAU - Alnaes, Grethe I Grenaker
AU  - Alnaes GIG
AD  - Department of Cancer Genetics, Institute for Cancer Research, Oslo University
      Hospital Radiumhospitalet, Oslo, Norway.
FAU - Grip, Mervi
AU  - Grip M
AD  - Department of Surgery, Oulu University Hospital, University of Oulu, Oulu,
      Finland.
FAU - Gronwald, Jacek
AU  - Gronwald J
AD  - Department of Genetics and Pathology, Pomeranian Medical University, Szczecin,
      Poland.
FAU - Grundy, Anne
AU  - Grundy A
AD  - Centre de Recherche du Centre Hospitalier de Universite de Montreal (CHUM),
      Montreal, Quebec, Canada.
FAU - Gschwantler-Kaulich, Daphne
AU  - Gschwantler-Kaulich D
AD  - Department of Obstetrics and Gynaecology and Comprehensive Cancer Centre, Medical
      University of Vienna, Vienna, Austria.
FAU - Guenel, Pascal
AU  - Guenel P
AD  - Cancer and Environment Group, Center for Research in Epidemiology and Population 
      Health (CESP), INSERM, University Paris-Sud, University Paris-Saclay, Villejuif, 
      France.
FAU - Guo, Qi
AU  - Guo Q
AD  - Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care,
      University of Cambridge, Cambridge, UK.
FAU - Haeberle, Lothar
AU  - Haeberle L
AD  - Department of Gynaecology and Obstetrics, University Hospital Erlangen, Friedrich
      Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center
      Erlangen-EMN, Erlangen, Germany.
FAU - Hahnen, Eric
AU  - Hahnen E
AD  - Center for Familial Breast and Ovarian Cancer, University Hospital of Cologne,
      Cologne, Germany.
AD  - Center for Integrated Oncology (CIO), University Hospital of Cologne, Cologne,
      Germany.
AD  - Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne,
      Germany.
FAU - Haiman, Christopher A
AU  - Haiman CA
AD  - Department of Preventive Medicine, Keck School of Medicine, University of
      Southern California, Los Angeles, California, USA.
FAU - Hakansson, Niclas
AU  - Hakansson N
AD  - Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
FAU - Hallberg, Emily
AU  - Hallberg E
AD  - Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.
FAU - Hamann, Ute
AU  - Hamann U
AD  - Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ),
      Heidelberg, Germany.
FAU - Hamel, Nathalie
AU  - Hamel N
AD  - McGill University and Genome Quebec Innovation Centre, Montreal, Quebec, Canada.
FAU - Hankinson, Susan
AU  - Hankinson S
AD  - Department of Biostatistics and Epidemiology, University of Massachusetts,
      Amherst, Amherst, Massachusetts, USA.
FAU - Hansen, Thomas V O
AU  - Hansen TVO
AD  - Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital,
      Copenhagen, Denmark.
FAU - Harrington, Patricia
AU  - Harrington P
AD  - Centre for Cancer Genetic Epidemiology, Department of Oncology, University of
      Cambridge, Cambridge, UK.
FAU - Hart, Steven N
AU  - Hart SN
AD  - Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.
FAU - Hartikainen, Jaana M
AU  - Hartikainen JM
AD  - Translational Cancer Research Area, University of Eastern Finland, Kuopio,
      Finland.
AD  - Institute of Clinical Medicine, Pathology and Forensic Medicine, University of
      Eastern Finland, Kuopio, Finland.
AD  - Imaging Center, Department of Clinical Pathology, Kuopio University Hospital,
      Kuopio, Finland.
FAU - Healey, Catherine S
AU  - Healey CS
AD  - Centre for Cancer Genetic Epidemiology, Department of Oncology, University of
      Cambridge, Cambridge, UK.
CN  - HEBON
FAU - Hein, Alexander
AU  - Hein A
AD  - Department of Gynaecology and Obstetrics, University Hospital Erlangen, Friedrich
      Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center
      Erlangen-EMN, Erlangen, Germany.
FAU - Helbig, Sonja
AU  - Helbig S
AD  - Gynaecology Research Unit, Hannover Medical School, Hannover, Germany.
FAU - Henderson, Alex
AU  - Henderson A
AD  - Institute of Genetic Medicine, Centre for Life, Newcastle-upon-Tyne Hospitals NHS
      Trust, Newcastle-upon-Tyne, UK.
FAU - Heyworth, Jane
AU  - Heyworth J
AD  - School of Population Health, University of Western Australia, Perth, Western
      Australia, Australia.
FAU - Hicks, Belynda
AU  - Hicks B
AD  - Cancer Genomics Research Laboratory (CGR), Division of Cancer Epidemiology and
      Genetics, National Cancer Institute, Bethesda, Maryland, USA.
FAU - Hillemanns, Peter
AU  - Hillemanns P
AD  - Gynaecology Research Unit, Hannover Medical School, Hannover, Germany.
FAU - Hodgson, Shirley
AU  - Hodgson S
AD  - Medical Genetics Unit, St George's, University of London, London, UK.
FAU - Hogervorst, Frans B
AU  - Hogervorst FB
AD  - Family Cancer Clinic, Netherlands Cancer Institute, Antoni van Leeuwenhoek
      Hospital, Amsterdam, the Netherlands.
FAU - Hollestelle, Antoinette
AU  - Hollestelle A
AD  - Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer
      Institute, Rotterdam, the Netherlands.
FAU - Hooning, Maartje J
AU  - Hooning MJ
AD  - Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer
      Institute, Rotterdam, the Netherlands.
FAU - Hoover, Bob
AU  - Hoover B
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute,
      Rockville, Maryland, USA.
FAU - Hopper, John L
AU  - Hopper JL
AD  - Centre for Epidemiology and Biostatistics, Melbourne School of Population and
      Global Health, University of Melbourne, Melbourne, Victoria, Australia.
FAU - Hu, Chunling
AU  - Hu C
AD  - Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester,
      Minnesota, USA.
FAU - Huang, Guanmengqian
AU  - Huang G
AD  - Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ),
      Heidelberg, Germany.
FAU - Hulick, Peter J
AU  - Hulick PJ
AD  - Center for Medical Genetics, NorthShore University HealthSystem, Evanston,
      Illinois, USA.
AD  - Pritzker School of Medicine, University of Chicago, Evanston, Illinois, USA.
FAU - Humphreys, Keith
AU  - Humphreys K
AD  - Department of Medical Epidemiology and Biostatistics, Karolinska Institutet,
      Stockholm, Sweden.
FAU - Hunter, David J
AU  - Hunter DJ
AD  - Program in Genetic Epidemiology and Statistical Genetics, Harvard T.H. Chan
      School of Public Health, Boston, Massachusetts, USA.
AD  - Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston,
      Massachusetts, USA.
FAU - Imyanitov, Evgeny N
AU  - Imyanitov EN
AD  - N.N. Petrov Institute of Oncology, St. Petersburg, Russian Federation.
FAU - Isaacs, Claudine
AU  - Isaacs C
AD  - Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
FAU - Iwasaki, Motoki
AU  - Iwasaki M
AD  - Division of Epidemiology, Center for Public Health Sciences, National Cancer
      Center, Tokyo, Japan.
FAU - Izatt, Louise
AU  - Izatt L
AD  - Clinical Genetics, Guy's and St Thomas' NHS Foundation Trust, London, UK.
FAU - Jakubowska, Anna
AU  - Jakubowska A
AD  - Department of Genetics and Pathology, Pomeranian Medical University, Szczecin,
      Poland.
FAU - James, Paul
AU  - James P
AD  - Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne,
      Victoria, Australia.
AD  - Familial Cancer Centre, Peter MacCallum Cancer Centre, Melbourne, Victoria,
      Australia.
FAU - Janavicius, Ramunas
AU  - Janavicius R
AD  - State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania.
FAU - Janni, Wolfgang
AU  - Janni W
AD  - Department of Gynaecology and Obstetrics, University of Ulm, Ulm, Germany.
FAU - Jensen, Uffe Birk
AU  - Jensen UB
AD  - Department of Clinical Genetics, Aarhus University Hospital, Aarhus, Denmark.
FAU - John, Esther M
AU  - John EM
AD  - Department of Epidemiology, Cancer Prevention Institute of California, Fremont,
      California, USA.
AD  - Department of Health Research and Policy, Stanford University School of Medicine,
      Stanford, California, USA.
FAU - Johnson, Nichola
AU  - Johnson N
AD  - Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, 
      London, UK.
FAU - Jones, Kristine
AU  - Jones K
AD  - Cancer Genomics Research Laboratory (CGR), Division of Cancer Epidemiology and
      Genetics, National Cancer Institute, Bethesda, Maryland, USA.
FAU - Jones, Michael
AU  - Jones M
AD  - Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK.
FAU - Jukkola-Vuorinen, Arja
AU  - Jukkola-Vuorinen A
AD  - Department of Oncology, Oulu University Hospital, University of Oulu, Oulu,
      Finland.
FAU - Kaaks, Rudolf
AU  - Kaaks R
AD  - Division of Cancer Epidemiology, German Cancer Research Center (DKFZ),
      Heidelberg, Germany.
FAU - Kabisch, Maria
AU  - Kabisch M
AD  - Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ),
      Heidelberg, Germany.
FAU - Kaczmarek, Katarzyna
AU  - Kaczmarek K
AD  - Department of Genetics and Pathology, Pomeranian Medical University, Szczecin,
      Poland.
FAU - Kang, Daehee
AU  - Kang D
AD  - Department of Preventive Medicine, Seoul National University College of Medicine,
      Seoul, Republic of Korea.
AD  - Department of Biomedical Sciences, Seoul National University College of Medicine,
      Seoul, Republic of Korea.
AD  - Cancer Research Institute, Seoul National University, Seoul, Republic of Korea.
FAU - Kast, Karin
AU  - Kast K
AD  - Department of Gynecology and Obstetrics, Medical Faculty and University Hospital 
      Carl Gustav Carus, Technische Universitat Dresden, Dresden, Germany.
CN  - kConFab/AOCS Investigators
FAU - Keeman, Renske
AU  - Keeman R
AD  - Division of Molecular Pathology, Netherlands Cancer Institute, Antoni van
      Leeuwenhoek Hospital, Amsterdam, the Netherlands.
FAU - Kerin, Michael J
AU  - Kerin MJ
AD  - School of Medicine, National University of Ireland, Galway, Ireland.
FAU - Kets, Carolien M
AU  - Kets CM
AD  - Department of Human Genetics, Radboud University Nijmegen Medical Centre,
      Nijmegen, the Netherlands.
FAU - Keupers, Machteld
AU  - Keupers M
AD  - Leuven Multidisciplinary Breast Center, Department of Oncology, Leuven Cancer
      Institute, University Hospitals Leuven, Leuven, Belgium.
FAU - Khan, Sofia
AU  - Khan S
AD  - Department of Obstetrics and Gynecology, Helsinki University Hospital, University
      of Helsinki, Helsinki, Finland.
FAU - Khusnutdinova, Elza
AU  - Khusnutdinova E
AD  - Institute of Biochemistry and Genetics, Ufa Scientific Center of the Russian
      Academy of Sciences, Ufa, Russian Federation.
AD  - Department of Genetics and Fundamental Medicine, Bashkir State University, Ufa,
      Russian Federation.
FAU - Kiiski, Johanna I
AU  - Kiiski JI
AD  - Department of Obstetrics and Gynecology, Helsinki University Hospital, University
      of Helsinki, Helsinki, Finland.
FAU - Kim, Sung-Won
AU  - Kim SW
AD  - Department of Obstetrics and Gynaecology and Comprehensive Cancer Centre, Medical
      University of Vienna, Vienna, Austria.
FAU - Knight, Julia A
AU  - Knight JA
AD  - Prosserman Centre for Health Research, Lunenfeld-Tanenbaum Research Institute of 
      Mount Sinai Hospital, Toronto, Ontario, Canada.
AD  - Division of Epidemiology, Dalla Lana School of Public Health, University of
      Toronto, Toronto, Ontario, Canada.
FAU - Konstantopoulou, Irene
AU  - Konstantopoulou I
AD  - Molecular Diagnostics Laboratory, INRASTES, National Centre for Scientific
      Research 'Demokritos', Athens, Greece.
FAU - Kosma, Veli-Matti
AU  - Kosma VM
AD  - Translational Cancer Research Area, University of Eastern Finland, Kuopio,
      Finland.
AD  - Institute of Clinical Medicine, Pathology and Forensic Medicine, University of
      Eastern Finland, Kuopio, Finland.
AD  - Imaging Center, Department of Clinical Pathology, Kuopio University Hospital,
      Kuopio, Finland.
FAU - Kristensen, Vessela N
AU  - Kristensen VN
AD  - Department of Cancer Genetics, Institute for Cancer Research, Oslo University
      Hospital Radiumhospitalet, Oslo, Norway.
AD  - Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo,
      Norway.
AD  - Department of Clinical Molecular Biology, Oslo University Hospital, University of
      Oslo, Oslo, Norway.
FAU - Kruse, Torben A
AU  - Kruse TA
AD  - Department of Clinical Genetics, Odense University Hospital, Odense, Denmark.
FAU - Kwong, Ava
AU  - Kwong A
AD  - Hong Kong Hereditary Breast Cancer Family Registry, Hong Kong.
AD  - Department of Surgery, University of Hong Kong, Hong Kong.
AD  - Department of Surgery, Hong Kong Sanatorium and Hospital, Hong Kong.
FAU - Laenkholm, Anne-Vibeke
AU  - Laenkholm AV
AD  - Department of Pathology, University Hospital of Region Zealand, Division
      Slagelse, Slagelse, Denmark.
FAU - Laitman, Yael
AU  - Laitman Y
AD  - Susanne Levy Gertner Oncogenetics Unit, Institute of Human Genetics, Chaim Sheba 
      Medical Center, Ramat Gan, Israel.
FAU - Lalloo, Fiona
AU  - Lalloo F
AD  - Genetic Medicine, Manchester Academic Health Sciences Centre, Central Manchester 
      University Hospitals NHS Foundation Trust, Manchester, UK.
FAU - Lambrechts, Diether
AU  - Lambrechts D
AD  - Vesalius Research Center, VIB, Leuven, Belgium.
AD  - Laboratory for Translational Genetics, Department of Oncology, University of
      Leuven, Leuven, Belgium.
FAU - Landsman, Keren
AU  - Landsman K
AD  - Clalit National Cancer Control Center, Haifa, Israel.
FAU - Lasset, Christine
AU  - Lasset C
AD  - Unite de Prevention et d'Epidemiologie Genetique, Centre Leon Berard, Lyon,
      France.
FAU - Lazaro, Conxi
AU  - Lazaro C
AD  - Molecular Diagnostic Unit, Hereditary Cancer Program, IDIBELL (Bellvitge
      Biomedical Research Institute), Catalan Institute of Oncology, Barcelona, Spain.
FAU - Le Marchand, Loic
AU  - Le Marchand L
AD  - University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
FAU - Lecarpentier, Julie
AU  - Lecarpentier J
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary
      Care, University of Cambridge, Cambridge, UK.
FAU - Lee, Andrew
AU  - Lee A
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary
      Care, University of Cambridge, Cambridge, UK.
FAU - Lee, Eunjung
AU  - Lee E
AD  - Department of Preventive Medicine, Keck School of Medicine, University of
      Southern California, Los Angeles, California, USA.
FAU - Lee, Jong Won
AU  - Lee JW
AD  - Department of Surgery, University of Ulsan College of Medicine and Asan Medical
      Center, Seoul, Republic of Korea.
FAU - Lee, Min Hyuk
AU  - Lee MH
AD  - Department of Surgery, Soonchunhyang University and Hospital, Seoul, Republic of 
      Korea.
FAU - Lejbkowicz, Flavio
AU  - Lejbkowicz F
AD  - Clalit National Cancer Control Center, Haifa, Israel.
FAU - Lesueur, Fabienne
AU  - Lesueur F
AD  - Institut Curie, Paris, France.
AD  - PSL Research University, Paris, France.
AD  - INSERM U900, Paris, France.
AD  - Mines Paris Tech, Fontainebleau, France.
FAU - Li, Jingmei
AU  - Li J
AD  - Department of Medical Epidemiology and Biostatistics, Karolinska Institutet,
      Stockholm, Sweden.
FAU - Lilyquist, Jenna
AU  - Lilyquist J
AD  - Department of Health Sciences Research, Mayo Clinic, Scottsdale, Arizona, USA.
FAU - Lincoln, Anne
AU  - Lincoln A
AD  - Clinical Genetics Research Laboratory, Department of Medicine, Memorial Sloan
      Kettering Cancer Center, New York, New York, USA.
FAU - Lindblom, Annika
AU  - Lindblom A
AD  - Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm,
      Sweden.
FAU - Lissowska, Jolanta
AU  - Lissowska J
AD  - Department of Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial
      Cancer Center and Institute of Oncology, Warsaw, Poland.
FAU - Lo, Wing-Yee
AU  - Lo WY
AD  - Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart,
      Germany.
AD  - University of Tubingen, Tubingen, Germany.
FAU - Loibl, Sibylle
AU  - Loibl S
AD  - German Breast Group, Neu Isenburg, Germany.
FAU - Long, Jirong
AU  - Long J
AD  - Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center,
      Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine,
      Nashville, Tennessee, USA.
FAU - Loud, Jennifer T
AU  - Loud JT
AD  - Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National 
      Cancer Institute, US National Institutes of Health, Bethesda, Maryland, USA.
FAU - Lubinski, Jan
AU  - Lubinski J
AD  - Department of Genetics and Pathology, Pomeranian Medical University, Szczecin,
      Poland.
FAU - Luccarini, Craig
AU  - Luccarini C
AD  - Centre for Cancer Genetic Epidemiology, Department of Oncology, University of
      Cambridge, Cambridge, UK.
FAU - Lush, Michael
AU  - Lush M
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary
      Care, University of Cambridge, Cambridge, UK.
FAU - MacInnis, Robert J
AU  - MacInnis RJ
AD  - Cancer Epidemiology and Intelligence Division, Cancer Council Victoria,
      Melbourne, Victoria, Australia.
AD  - Centre for Epidemiology and Biostatistics, Melbourne School of Population and
      Global Health, University of Melbourne, Melbourne, Victoria, Australia.
FAU - Maishman, Tom
AU  - Maishman T
AD  - Southampton Clinical Trials Unit, Faculty of Medicine, University of Southampton,
      Southampton, UK.
AD  - Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton,
      Southampton, UK.
FAU - Makalic, Enes
AU  - Makalic E
AD  - Centre for Epidemiology and Biostatistics, Melbourne School of Population and
      Global Health, University of Melbourne, Melbourne, Victoria, Australia.
FAU - Kostovska, Ivana Maleva
AU  - Kostovska IM
AD  - Research Centre for Genetic Engineering and Biotechnology 'Georgi D. Efremov',
      Macedonian Academy of Sciences and Arts, Skopje, Macedonia.
FAU - Malone, Kathleen E
AU  - Malone KE
AD  - Division of Public Health Sciences, Epidemiology Program, Fred Hutchinson Cancer 
      Research Center, Seattle, Washington, USA.
FAU - Manoukian, Siranoush
AU  - Manoukian S
AD  - Unit of Medical Genetics, Department of Preventive and Predictive Medicine,
      Fondazione IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), Istituto 
      Nazionale dei Tumori (INT), Milan, Italy.
FAU - Manson, JoAnn E
AU  - Manson JE
AD  - Department of Medicine, Brigham and Women's Hospital, Harvard Medical School,
      Boston, Massachusetts, USA.
FAU - Margolin, Sara
AU  - Margolin S
AD  - Department of Oncology, Pathology, Karolinska Institutet, Stockholm, Sweden.
FAU - Martens, John W M
AU  - Martens JWM
AD  - Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer
      Institute, Rotterdam, the Netherlands.
FAU - Martinez, Maria Elena
AU  - Martinez ME
AD  - Moores Cancer Center, University of California, San Diego, La Jolla, California, 
      USA.
AD  - Department of Family Medicine and Public Health, University of California, San
      Diego, La Jolla, California, USA.
FAU - Matsuo, Keitaro
AU  - Matsuo K
AD  - Division of Molecular and Clinical Epidemiology, Aichi Cancer Center Research
      Institute, Nagoya, Japan.
AD  - Department of Epidemiology, Nagoya University Graduate School of Medicine,
      Nagoya, Japan.
FAU - Mavroudis, Dimitrios
AU  - Mavroudis D
AD  - Department of Medical Oncology, University Hospital of Heraklion, Heraklion,
      Greece.
FAU - Mazoyer, Sylvie
AU  - Mazoyer S
AD  - Lyon Neuroscience Research Center-CRNL, INSERM U1028, CNRS UMR 5292, University
      of Lyon, Lyon, France.
FAU - McLean, Catriona
AU  - McLean C
AD  - Anatomical Pathology, Alfred Hospital, Melbourne, Victoria, Australia.
FAU - Meijers-Heijboer, Hanne
AU  - Meijers-Heijboer H
AD  - Department of Clinical Genetics, Academic Medical Center, Amsterdam, the
      Netherlands.
AD  - Department of Clinical Genetics, VU University Medical Centre, Amsterdam, the
      Netherlands.
FAU - Menendez, Primitiva
AU  - Menendez P
AD  - Servicio de Anatomia Patologica, Hospital Monte Naranco, Oviedo, Spain.
FAU - Meyer, Jeffery
AU  - Meyer J
AD  - Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester,
      Minnesota, USA.
FAU - Miao, Hui
AU  - Miao H
AD  - Saw Swee Hock School of Public Health, National University of Singapore,
      Singapore.
FAU - Miller, Austin
AU  - Miller A
AD  - NRG Oncology, Statistics and Data Management Center, Roswell Park Cancer
      Institute, Buffalo, New York, USA.
FAU - Miller, Nicola
AU  - Miller N
AD  - School of Medicine, National University of Ireland, Galway, Ireland.
FAU - Mitchell, Gillian
AU  - Mitchell G
AD  - Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne,
      Victoria, Australia.
AD  - Familial Cancer Centre, Peter MacCallum Cancer Centre, Melbourne, Victoria,
      Australia.
FAU - Montagna, Marco
AU  - Montagna M
AD  - Immunology and Molecular Oncology Unit, Istituto Oncologico Veneto (IOV), IRCCS, 
      Padua, Italy.
FAU - Muir, Kenneth
AU  - Muir K
AD  - Institute of Population Health, University of Manchester, Manchester, UK.
AD  - Division of Health Sciences, Warwick Medical School, Warwick University,
      Coventry, UK.
FAU - Mulligan, Anna Marie
AU  - Mulligan AM
AD  - Department of Laboratory Medicine and Pathobiology, University of Toronto,
      Toronto, Ontario, Canada.
AD  - Laboratory Medicine Program, University Health Network, Toronto, Ontario, Canada.
FAU - Mulot, Claire
AU  - Mulot C
AD  - Universite Paris Sorbonne Cite, INSERM UMRS 1147, Paris, France.
FAU - Nadesan, Sue
AU  - Nadesan S
AD  - City of Hope Clinical Cancer Genomics Community Research Network, Duarte,
      California, USA.
FAU - Nathanson, Katherine L
AU  - Nathanson KL
AD  - Department of Medicine, Abramson Cancer Center, Perelman School of Medicine at
      the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
CN  - NBSC Collaborators
FAU - Neuhausen, Susan L
AU  - Neuhausen SL
AD  - Department of Population Sciences, Beckman Research Institute of City of Hope,
      Duarte, California, USA.
FAU - Nevanlinna, Heli
AU  - Nevanlinna H
AD  - Department of Obstetrics and Gynecology, Helsinki University Hospital, University
      of Helsinki, Helsinki, Finland.
FAU - Nevelsteen, Ines
AU  - Nevelsteen I
AD  - Leuven Multidisciplinary Breast Center, Department of Oncology, Leuven Cancer
      Institute, University Hospitals Leuven, Leuven, Belgium.
FAU - Niederacher, Dieter
AU  - Niederacher D
AD  - Department of Gynecology and Obstetrics, University Hospital Dusseldorf, Heinrich
      Heine University Dusseldorf, Dusseldorf, Germany.
FAU - Nielsen, Sune F
AU  - Nielsen SF
AD  - Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen
      University Hospital, Herlev, Denmark.
AD  - Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen
      University Hospital, Herlev, Denmark.
FAU - Nordestgaard, Borge G
AU  - Nordestgaard BG
AD  - Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen
      University Hospital, Herlev, Denmark.
AD  - Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen
      University Hospital, Herlev, Denmark.
AD  - Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen,
      Denmark.
FAU - Norman, Aaron
AU  - Norman A
AD  - Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.
FAU - Nussbaum, Robert L
AU  - Nussbaum RL
AD  - Department of Medicine, University of California, San Francisco,San Francisco,
      California, USA.
FAU - Olah, Edith
AU  - Olah E
AD  - Department of Molecular Genetics, National Institute of Oncology, Budapest,
      Hungary.
FAU - Olopade, Olufunmilayo I
AU  - Olopade OI
AD  - Center for Clinical Cancer Genetics and Global Health, University of Chicago,
      Chicago, Illinois, USA.
FAU - Olson, Janet E
AU  - Olson JE
AD  - Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.
FAU - Olswold, Curtis
AU  - Olswold C
AD  - Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.
FAU - Ong, Kai-Ren
AU  - Ong KR
AD  - West Midlands Regional Genetics Service, Birmingham Women's Hospital Healthcare
      NHS Trust, Edgbaston, Birmingham, UK.
FAU - Oosterwijk, Jan C
AU  - Oosterwijk JC
AD  - Department of Genetics, University Medical Center Groningen, University of
      Groningen, Groningen, the Netherlands.
FAU - Orr, Nick
AU  - Orr N
AD  - Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, 
      London, UK.
FAU - Osorio, Ana
AU  - Osorio A
AD  - Human Genetics Group, Human Cancer Genetics Programme, Spanish National Cancer
      Centre (CNIO), Madrid, Spain.
AD  - Spanish Network on Rare Diseases (CIBERER), Madrid, Spain.
FAU - Pankratz, V Shane
AU  - Pankratz VS
AD  - University of New Mexico Health Sciences Center, University of New Mexico,
      Albuquerque, New Mexico, USA.
FAU - Papi, Laura
AU  - Papi L
AD  - Unit of Medical Genetics, Department of Biomedical, Experimental and Clinical
      Sciences, University of Florence, Florence, Italy.
FAU - Park-Simon, Tjoung-Won
AU  - Park-Simon TW
AD  - Gynaecology Research Unit, Hannover Medical School, Hannover, Germany.
FAU - Paulsson-Karlsson, Ylva
AU  - Paulsson-Karlsson Y
AD  - Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala,
      Sweden.
FAU - Lloyd, Rachel
AU  - Lloyd R
AD  - Curtin UWA Centre for Genetic Origins of Health and Disease, Curtin University
      and University of Western Australia, Perth, Western Australia, Australia.
FAU - Pedersen, Inge Sokilde
AU  - Pedersen IS
AD  - Section of Molecular Diagnostics, Clinical Biochemistry, Aalborg University
      Hospital, Aalborg, Denmark.
FAU - Peissel, Bernard
AU  - Peissel B
AD  - Unit of Medical Genetics, Department of Preventive and Predictive Medicine,
      Fondazione IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), Istituto 
      Nazionale dei Tumori (INT), Milan, Italy.
FAU - Peixoto, Ana
AU  - Peixoto A
AD  - Department of Genetics, Portuguese Oncology Institute, Porto, Portugal.
FAU - Perez, Jose I A
AU  - Perez JIA
AD  - Servicio de Cirugia General y Especialidades, Hospital Monte Naranco, Oviedo,
      Spain.
FAU - Peterlongo, Paolo
AU  - Peterlongo P
AD  - IFOM, FIRC (Italian Foundation for Cancer Research) Institute of Molecular
      Oncology, Milan, Italy.
FAU - Peto, Julian
AU  - Peto J
AD  - Department of Non-Communicable Disease Epidemiology, London School of Hygiene and
      Tropical Medicine, London, UK.
FAU - Pfeiler, Georg
AU  - Pfeiler G
AD  - Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care,
      University of Cambridge, Cambridge, UK.
FAU - Phelan, Catherine M
AU  - Phelan CM
AD  - Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida, USA.
FAU - Pinchev, Mila
AU  - Pinchev M
AD  - Clalit National Cancer Control Center, Haifa, Israel.
FAU - Plaseska-Karanfilska, Dijana
AU  - Plaseska-Karanfilska D
AD  - Research Centre for Genetic Engineering and Biotechnology 'Georgi D. Efremov',
      Macedonian Academy of Sciences and Arts, Skopje, Macedonia.
FAU - Poppe, Bruce
AU  - Poppe B
AD  - Center for Medical Genetics, Ghent University, Ghent, Belgium.
FAU - Porteous, Mary E
AU  - Porteous ME
AD  - South East of Scotland Regional Genetics Service, Western General Hospital,
      Edinburgh, UK.
FAU - Prentice, Ross
AU  - Prentice R
AD  - Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle,
      Washington, USA.
FAU - Presneau, Nadege
AU  - Presneau N
AD  - Department of Biomedical Sciences, Faculty of Science and Technology, University 
      of Westminster, London, UK.
FAU - Prokofieva, Darya
AU  - Prokofieva D
AD  - Department of Genetics and Fundamental Medicine, Bashkir State University, Ufa,
      Russian Federation.
FAU - Pugh, Elizabeth
AU  - Pugh E
AD  - Center for Inherited Disease Research (CIDR), Institute of Genetic Medicine,
      Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
FAU - Pujana, Miquel Angel
AU  - Pujana MA
AD  - ProCURE, Catalan Institute of Oncology, IDIBELL (Bellvitge Biomedical Research
      Institute), Barcelona, Spain.
FAU - Pylkas, Katri
AU  - Pylkas K
AD  - Laboratory of Cancer Genetics and Tumor Biology, Cancer and Translational
      Medicine Research Unit, Biocenter Oulu, University of Oulu, Oulu, Finland.
AD  - Laboratory of Cancer Genetics and Tumor Biology, Northern Finland Laboratory
      Centre Oulu, Oulu, Finland.
FAU - Rack, Brigitte
AU  - Rack B
AD  - Department of Gynecology and Obstetrics, Ludwig Maximilians University of Munich,
      Munich, Germany.
AD  - Department of Gynaecology and Obstetrics, University of Ulm, Ulm, Germany.
FAU - Radice, Paolo
AU  - Radice P
AD  - Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of
      Preventive and Predictive Medicine, Fondazione IRCCS (Istituto di Ricovero e Cura
      a Carattere Scientifico), Istituto Nazionale dei Tumori (INT), Milan, Italy.
FAU - Rahman, Nazneen
AU  - Rahman N
AD  - Section of Cancer Genetics, The Institute of Cancer Research, London, UK.
FAU - Rantala, Johanna
AU  - Rantala J
AD  - Department of Clinical Genetics, Karolinska University Hospital, Stockholm,
      Sweden.
FAU - Rappaport-Fuerhauser, Christine
AU  - Rappaport-Fuerhauser C
AD  - Department of Obstetrics and Gynaecology and Comprehensive Cancer Centre, Medical
      University of Vienna, Vienna, Austria.
FAU - Rennert, Gad
AU  - Rennert G
AD  - Clalit National Cancer Control Center, Haifa, Israel.
AD  - Carmel Medical Center and B. Rappaport Faculty of Medicine-Technion, Haifa,
      Israel.
FAU - Rennert, Hedy S
AU  - Rennert HS
AD  - Clalit National Cancer Control Center, Haifa, Israel.
AD  - Carmel Medical Center and B. Rappaport Faculty of Medicine-Technion, Haifa,
      Israel.
FAU - Rhenius, Valerie
AU  - Rhenius V
AD  - Centre for Cancer Genetic Epidemiology, Department of Oncology, University of
      Cambridge, Cambridge, UK.
FAU - Rhiem, Kerstin
AU  - Rhiem K
AD  - Center for Familial Breast and Ovarian Cancer, University Hospital of Cologne,
      Cologne, Germany.
AD  - Center for Integrated Oncology (CIO), University Hospital of Cologne, Cologne,
      Germany.
AD  - Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne,
      Germany.
FAU - Richardson, Andrea
AU  - Richardson A
AD  - Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston,
      Massachusetts, USA.
FAU - Rodriguez, Gustavo C
AU  - Rodriguez GC
AD  - Division of Gynecologic Oncology, NorthShore University HealthSystem, University 
      of Chicago, Evanston, Illinois, USA.
FAU - Romero, Atocha
AU  - Romero A
AD  - Medical Oncology Department, CIBERONC, Hospital Clinico San Carlos, Madrid,
      Spain.
AD  - Medical Oncology Department, Hospital Universitario Puerta de Hierro, Madrid,
      Spain.
FAU - Romm, Jane
AU  - Romm J
AD  - Center for Inherited Disease Research (CIDR), Institute of Genetic Medicine,
      Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
FAU - Rookus, Matti A
AU  - Rookus MA
AD  - Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the
      Netherlands.
FAU - Rudolph, Anja
AU  - Rudolph A
AD  - Division of Cancer Epidemiology, German Cancer Research Center (DKFZ),
      Heidelberg, Germany.
FAU - Ruediger, Thomas
AU  - Ruediger T
AD  - Institute of Pathology, Staedtisches Klinikum Karlsruhe, Karlsruhe, Germany.
FAU - Saloustros, Emmanouil
AU  - Saloustros E
AD  - Hereditary Cancer Clinic, University Hospital of Heraklion, Heraklion, Greece.
FAU - Sanders, Joyce
AU  - Sanders J
AD  - Department of Pathology, Netherlands Cancer Institute, Antoni van Leeuwenhoek
      Hospital, Amsterdam, the Netherlands.
FAU - Sandler, Dale P
AU  - Sandler DP
AD  - Epidemiology Branch, National Institute of Environmental Health Sciences, US
      National Institutes of Health, Research Triangle Park, North Carolina, USA.
FAU - Sangrajrang, Suleeporn
AU  - Sangrajrang S
AD  - National Cancer Institute, Bangkok, Thailand.
FAU - Sawyer, Elinor J
AU  - Sawyer EJ
AD  - Department of Population and Quantitative Health Sciences, Case Western Reserve
      University, Cleveland, Ohio, USA.
FAU - Schmidt, Daniel F
AU  - Schmidt DF
AD  - Centre for Epidemiology and Biostatistics, Melbourne School of Population and
      Global Health, University of Melbourne, Melbourne, Victoria, Australia.
FAU - Schoemaker, Minouk J
AU  - Schoemaker MJ
AD  - Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK.
FAU - Schumacher, Fredrick
AU  - Schumacher F
AD  - Research Oncology, Guy's Hospital, King's College London, London, UK.
FAU - Schurmann, Peter
AU  - Schurmann P
AD  - Gynaecology Research Unit, Hannover Medical School, Hannover, Germany.
FAU - Schwentner, Lukas
AU  - Schwentner L
AD  - Department of Gynaecology and Obstetrics, University of Ulm, Ulm, Germany.
FAU - Scott, Christopher
AU  - Scott C
AD  - Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.
FAU - Scott, Rodney J
AU  - Scott RJ
AD  - Division of Molecular Medicine, Pathology North, John Hunter Hospital, Newcastle,
      New South Wales, Australia.
AD  - Discipline of Medical Genetics, School of Biomedical Sciences and Pharmacy,
      Faculty of Health, University of Newcastle, Callaghan, New South Wales,
      Australia.
FAU - Seal, Sheila
AU  - Seal S
AD  - Section of Cancer Genetics, The Institute of Cancer Research, London, UK.
FAU - Senter, Leigha
AU  - Senter L
AD  - Clinical Cancer Genetics Program, Division of Human Genetics, Department of
      Internal Medicine, Comprehensive Cancer Center, Ohio State University, Columbus, 
      Ohio, USA.
FAU - Seynaeve, Caroline
AU  - Seynaeve C
AD  - Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer
      Institute, Rotterdam, the Netherlands.
FAU - Shah, Mitul
AU  - Shah M
AD  - Centre for Cancer Genetic Epidemiology, Department of Oncology, University of
      Cambridge, Cambridge, UK.
FAU - Sharma, Priyanka
AU  - Sharma P
AD  - Department of Internal Medicine, University of Kansas Medical Center, Kansas
      City, Kansas, USA.
FAU - Shen, Chen-Yang
AU  - Shen CY
AD  - School of Public Health, China Medical University, Taichung, Taiwan.
AD  - Taiwan Biobank, Institute of Biomedical Sciences, Academia Sinica, Taipei,
      Taiwan.
FAU - Sheng, Xin
AU  - Sheng X
AD  - Department of Preventive Medicine, Keck School of Medicine, University of
      Southern California, Los Angeles, California, USA.
FAU - Shimelis, Hermela
AU  - Shimelis H
AD  - Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester,
      Minnesota, USA.
FAU - Shrubsole, Martha J
AU  - Shrubsole MJ
AD  - Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center,
      Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine,
      Nashville, Tennessee, USA.
FAU - Shu, Xiao-Ou
AU  - Shu XO
AD  - Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center,
      Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine,
      Nashville, Tennessee, USA.
FAU - Side, Lucy E
AU  - Side LE
AD  - North East Thames Regional Genetics Service, Great Ormond Street Hospital for
      Children NHS Trust, London, UK.
FAU - Singer, Christian F
AU  - Singer CF
AD  - Department of Obstetrics and Gynaecology and Comprehensive Cancer Centre, Medical
      University of Vienna, Vienna, Austria.
FAU - Sohn, Christof
AU  - Sohn C
AD  - National Center for Tumor Diseases, University of Heidelberg, Heidelberg,
      Germany.
FAU - Southey, Melissa C
AU  - Southey MC
AD  - Department of Pathology, University of Melbourne, Melbourne, Victoria, Australia.
FAU - Spinelli, John J
AU  - Spinelli JJ
AD  - Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
AD  - School of Population and Public Health, University of British Columbia,
      Vancouver, British Columbia, Canada.
FAU - Spurdle, Amanda B
AU  - Spurdle AB
AD  - Cancer Division, QIMR Berghofer Medical Research Institute, Brisbane, Queensland,
      Australia.
FAU - Stegmaier, Christa
AU  - Stegmaier C
AD  - Saarland Cancer Registry, Saarbrucken, Germany.
FAU - Stoppa-Lyonnet, Dominique
AU  - Stoppa-Lyonnet D
AD  - Service de Genetique Oncologique and INSERM U830, Institut Curie, Paris, France -
      Universite Paris Descartes, Sorbonne Paris Cite.
FAU - Sukiennicki, Grzegorz
AU  - Sukiennicki G
AD  - Department of Genetics and Pathology, Pomeranian Medical University, Szczecin,
      Poland.
FAU - Surowy, Harald
AU  - Surowy H
AD  - Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg,
      Germany.
AD  - Molecular Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg,
      Germany.
FAU - Sutter, Christian
AU  - Sutter C
AD  - Institute of Human Genetics, University Hospital Heidelberg, Heidelberg, Germany.
FAU - Swerdlow, Anthony
AU  - Swerdlow A
AD  - Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK.
AD  - Division of Breast Cancer Research, The Institute of Cancer Research, London, UK.
FAU - Szabo, Csilla I
AU  - Szabo CI
AD  - National Human Genome Research Institute, US National Institutes of Health,
      Bethesda, Maryland, USA.
FAU - Tamimi, Rulla M
AU  - Tamimi RM
AD  - Program in Genetic Epidemiology and Statistical Genetics, Harvard T.H. Chan
      School of Public Health, Boston, Massachusetts, USA.
AD  - Channing Division of Network Medicine, Department of Medicine, Brigham and
      Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
AD  - Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston,
      Massachusetts, USA.
FAU - Tan, Yen Y
AU  - Tan YY
AD  - Department of Obstetrics and Gynaecology and Comprehensive Cancer Centre, Medical
      University of Vienna, Vienna, Austria.
FAU - Taylor, Jack A
AU  - Taylor JA
AD  - Epidemiology Branch, National Institute of Environmental Health Sciences, US
      National Institutes of Health, Research Triangle Park, North Carolina, USA.
AD  - Epigenetic and Stem Cell Biology Laboratory, National Institute of Environmental 
      Health Sciences, US National Institutes of Health, Research Triangle Park, North 
      Carolina, USA.
FAU - Tejada, Maria-Isabel
AU  - Tejada MI
AD  - Molecular Genetics Laboratory, Clinical Genetics Service, Cruces University
      Hospital and BioCruces Health Research Institute, Barakaldo, Spain.
FAU - Tengstrom, Maria
AU  - Tengstrom M
AD  - Translational Cancer Research Area, University of Eastern Finland, Kuopio,
      Finland.
AD  - Cancer Center, Kuopio University Hospital, Kuopio, Finland.
AD  - Institute of Clinical Medicine, Oncology, University of Eastern Finland, Kuopio, 
      Finland.
FAU - Teo, Soo H
AU  - Teo SH
AD  - Cancer Research Malaysia, Subang Jaya, Malaysia.
AD  - Breast Cancer Research Unit, Cancer Research Institute, University Malaya Medical
      Centre, Kuala Lumpur, Malaysia.
FAU - Terry, Mary B
AU  - Terry MB
AD  - Department of Epidemiology, Mailman School of Public Health, Columbia University,
      New York, New York, USA.
FAU - Tessier, Daniel C
AU  - Tessier DC
AD  - McGill University and Genome Quebec Innovation Centre, Montreal, Quebec, Canada.
FAU - Teule, Alex
AU  - Teule A
AD  - Genetic Counseling Unit, Hereditary Cancer Program, IDIBELL (Bellvitge Biomedical
      Research Institute), Catalan Institute of Oncology, Barcelona, Spain.
FAU - Thone, Kathrin
AU  - Thone K
AD  - Department of Cancer Epidemiology, Clinical Cancer Registry, University Medical
      Center Hamburg-Eppendorf, Hamburg, Germany.
FAU - Thull, Darcy L
AU  - Thull DL
AD  - Magee-Womens Hospital, University of Pittsburgh School of Medicine, Pittsburgh,
      Pennsylvania, USA.
FAU - Tibiletti, Maria Grazia
AU  - Tibiletti MG
AD  - Ospedale di Circolo ASST Settelaghi, Varese, Italy.
FAU - Tihomirova, Laima
AU  - Tihomirova L
AD  - Latvian Biomedical Research and Study Centre, Riga, Latvia.
FAU - Tischkowitz, Marc
AU  - Tischkowitz M
AD  - Program in Cancer Genetics, Departments of Human Genetics and Oncology, McGill
      University, Montreal, Quebec, Canada.
AD  - Department of Medical Genetics, Addenbrooke's Treatment Centre, Addenbrooke's
      Hospital, Cambridge, UK.
FAU - Toland, Amanda E
AU  - Toland AE
AD  - Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive 
      Cancer Center, Ohio State University, Columbus, Ohio, USA.
FAU - Tollenaar, Rob A E M
AU  - Tollenaar RAEM
AD  - Department of Surgery, Leiden University Medical Center, Leiden, the Netherlands.
FAU - Tomlinson, Ian
AU  - Tomlinson I
AD  - Wellcome Trust Centre for Human Genetics and Oxford NIHR Biomedical Research
      Centre, University of Oxford, Oxford, UK.
FAU - Tong, Ling
AU  - Tong L
AD  - Center for Cancer Epidemiology and Prevention, University of Chicago, Chicago,
      Illinois, USA.
FAU - Torres, Diana
AU  - Torres D
AD  - Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ),
      Heidelberg, Germany.
AD  - Institute of Human Genetics, Pontificia Universidad Javeriana, Bogota, Colombia.
FAU - Tranchant, Martine
AU  - Tranchant M
AD  - Genomics Center, Centre Hospitalier Universitaire de Quebec Research Center,
      Laval University, Quebec City, Quebec, Canada.
FAU - Truong, Therese
AU  - Truong T
AD  - Cancer and Environment Group, Center for Research in Epidemiology and Population 
      Health (CESP), INSERM, University Paris-Sud, University Paris-Saclay, Villejuif, 
      France.
FAU - Tucker, Kathy
AU  - Tucker K
AD  - Hereditary Cancer Clinic, Department of Medical Oncology, Prince of Wales
      Hospital, Randwick, New South Wales, Australia.
FAU - Tung, Nadine
AU  - Tung N
AD  - Department of Medical Oncology, Beth Israel Deaconess Medical Center, Boston,
      Massachusetts, USA.
FAU - Tyrer, Jonathan
AU  - Tyrer J
AD  - Centre for Cancer Genetic Epidemiology, Department of Oncology, University of
      Cambridge, Cambridge, UK.
FAU - Ulmer, Hans-Ulrich
AU  - Ulmer HU
AD  - Frauenklinik der Stadtklinik Baden Baden, Baden Baden, Germany.
FAU - Vachon, Celine
AU  - Vachon C
AD  - Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.
FAU - van Asperen, Christi J
AU  - van Asperen CJ
AD  - Department of Clinical Genetics, Leiden University Medical Center, Leiden, the
      Netherlands.
FAU - Van Den Berg, David
AU  - Van Den Berg D
AD  - Department of Preventive Medicine, Keck School of Medicine, University of
      Southern California, Los Angeles, California, USA.
FAU - van den Ouweland, Ans M W
AU  - van den Ouweland AMW
AD  - Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam,
      the Netherlands.
FAU - van Rensburg, Elizabeth J
AU  - van Rensburg EJ
AD  - Cancer Genetics Laboratory, Department of Genetics, University of Pretoria,
      Arcadia, South Africa.
FAU - Varesco, Liliana
AU  - Varesco L
AD  - Unit of Hereditary Cancer, Department of Epidemiology, Prevention and Special
      Functions, IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico) AOU San
      Martino, IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy.
FAU - Varon-Mateeva, Raymonda
AU  - Varon-Mateeva R
AD  - Institute of Human Genetics, Campus Virchov Klinikum, Charite Berlin, Berlin,
      Germany.
FAU - Vega, Ana
AU  - Vega A
AD  - Fundacion Publica Galega de Medicina Xenomica, Servizo Galego de Saude SERGAS,
      Instituto de Investigaciones Sanitarias (IDIS), Santiago de Compostela, Spain.
AD  - Grupo de Medicina Xenomica, Centro de Investigacion Biomedica en Red de
      Enfermedades Raras (CIBERER), Universidade de Santiago de Compostela, Santiago de
      Compostela, Spain.
FAU - Viel, Alessandra
AU  - Viel A
AD  - Unit of Functional Onco-genomics and Genetics, CRO Aviano, National Cancer
      Institute, Aviano, Italy.
FAU - Vijai, Joseph
AU  - Vijai J
AD  - Clinical Genetics Research Laboratory, Department of Medicine, Memorial Sloan
      Kettering Cancer Center, New York, New York, USA.
FAU - Vincent, Daniel
AU  - Vincent D
AD  - McGill University and Genome Quebec Innovation Centre, Montreal, Quebec, Canada.
FAU - Vollenweider, Jason
AU  - Vollenweider J
AD  - Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester,
      Minnesota, USA.
FAU - Walker, Lisa
AU  - Walker L
AD  - Oxford Regional Genetics Service, Churchill Hospital, Oxford, UK.
FAU - Wang, Zhaoming
AU  - Wang Z
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute,
      Rockville, Maryland, USA.
AD  - Department of Computational Biology, St. Jude Children's Research Hospital,
      Memphis, Tennessee, USA.
FAU - Wang-Gohrke, Shan
AU  - Wang-Gohrke S
AD  - Department of Gynaecology and Obstetrics, University of Ulm, Ulm, Germany.
FAU - Wappenschmidt, Barbara
AU  - Wappenschmidt B
AD  - Center for Familial Breast and Ovarian Cancer, University Hospital of Cologne,
      Cologne, Germany.
AD  - Center for Integrated Oncology (CIO), University Hospital of Cologne, Cologne,
      Germany.
AD  - Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne,
      Germany.
FAU - Weinberg, Clarice R
AU  - Weinberg CR
AD  - Biostatistics and Computational Biology Branch, National Institute of
      Environmental Health Sciences, US National Institutes of Health, Research
      Triangle Park, North Carolina, USA.
FAU - Weitzel, Jeffrey N
AU  - Weitzel JN
AD  - Clinical Cancer Genetics, City of Hope, Duarte, California, USA.
FAU - Wendt, Camilla
AU  - Wendt C
AD  - Department of Oncology, Pathology, Karolinska Institutet, Stockholm, Sweden.
FAU - Wesseling, Jelle
AU  - Wesseling J
AD  - Division of Molecular Pathology, Netherlands Cancer Institute, Antoni van
      Leeuwenhoek Hospital, Amsterdam, the Netherlands.
AD  - Department of Pathology, Netherlands Cancer Institute, Antoni van Leeuwenhoek
      Hospital, Amsterdam, the Netherlands.
FAU - Whittemore, Alice S
AU  - Whittemore AS
AD  - Department of Health Research and Policy, Stanford University School of Medicine,
      Stanford, California, USA.
AD  - Department of Biomedical Data Sciences, Stanford University School of Medicine,
      Stanford, California, USA.
FAU - Wijnen, Juul T
AU  - Wijnen JT
AD  - Department of Human Genetics, Leiden University Medical Center, Leiden, the
      Netherlands.
AD  - Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam,
      the Netherlands.
FAU - Willett, Walter
AU  - Willett W
AD  - Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston,
      Massachusetts, USA.
AD  - Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston,
      Massachusetts, USA.
FAU - Winqvist, Robert
AU  - Winqvist R
AD  - Laboratory of Cancer Genetics and Tumor Biology, Cancer and Translational
      Medicine Research Unit, Biocenter Oulu, University of Oulu, Oulu, Finland.
AD  - Laboratory of Cancer Genetics and Tumor Biology, Northern Finland Laboratory
      Centre Oulu, Oulu, Finland.
FAU - Wolk, Alicja
AU  - Wolk A
AD  - Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
FAU - Wu, Anna H
AU  - Wu AH
AD  - Department of Preventive Medicine, Keck School of Medicine, University of
      Southern California, Los Angeles, California, USA.
FAU - Xia, Lucy
AU  - Xia L
AD  - Department of Preventive Medicine, Keck School of Medicine, University of
      Southern California, Los Angeles, California, USA.
FAU - Yang, Xiaohong R
AU  - Yang XR
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute,
      Rockville, Maryland, USA.
FAU - Yannoukakos, Drakoulis
AU  - Yannoukakos D
AD  - Molecular Diagnostics Laboratory, INRASTES, National Centre for Scientific
      Research 'Demokritos', Athens, Greece.
FAU - Zaffaroni, Daniela
AU  - Zaffaroni D
AD  - Unit of Medical Genetics, Department of Preventive and Predictive Medicine,
      Fondazione IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), Istituto 
      Nazionale dei Tumori (INT), Milan, Italy.
FAU - Zheng, Wei
AU  - Zheng W
AD  - Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center,
      Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine,
      Nashville, Tennessee, USA.
FAU - Zhu, Bin
AU  - Zhu B
AD  - Cancer Genomics Research Laboratory (CGR), Division of Cancer Epidemiology and
      Genetics, National Cancer Institute, Bethesda, Maryland, USA.
FAU - Ziogas, Argyrios
AU  - Ziogas A
AD  - Department of Epidemiology, University of California, Irvine, Irvine, California,
      USA.
FAU - Ziv, Elad
AU  - Ziv E
AD  - Department of Medicine, Institute for Human Genetics, UCSF Helen Diller Family
      Comprehensive Cancer Center, University of California, San Francisco, San
      Francisco, California, USA.
FAU - Zorn, Kristin K
AU  - Zorn KK
AD  - Ospedale di Circolo ASST Settelaghi, Varese, Italy.
FAU - Gago-Dominguez, Manuela
AU  - Gago-Dominguez M
AD  - Genomic Medicine Group, Galician Foundation of Genomic Medicine, Instituto de
      Investigacion Sanitaria de Santiago de Compostela (IDIS), Complejo Hospitalario
      Universitario de Santiago, Servizo Galego de Saude SERGAS, Santiago de
      Compostela, Spain.
AD  - Moores Cancer Center, University of California, San Diego, La Jolla, California, 
      USA.
FAU - Mannermaa, Arto
AU  - Mannermaa A
AD  - Translational Cancer Research Area, University of Eastern Finland, Kuopio,
      Finland.
AD  - Institute of Clinical Medicine, Pathology and Forensic Medicine, University of
      Eastern Finland, Kuopio, Finland.
AD  - Imaging Center, Department of Clinical Pathology, Kuopio University Hospital,
      Kuopio, Finland.
FAU - Olsson, Hakan
AU  - Olsson H
AD  - Department of Cancer Epidemiology, Clinical Sciences, Lund University, Lund,
      Sweden.
FAU - Teixeira, Manuel R
AU  - Teixeira MR
AD  - Department of Genetics, Portuguese Oncology Institute, Porto, Portugal.
AD  - Biomedical Sciences Institute (ICBAS), University of Porto, Porto, Portugal.
FAU - Stone, Jennifer
AU  - Stone J
AD  - Curtin UWA Centre for Genetic Origins of Health and Disease, Curtin University
      and University of Western Australia, Perth, Western Australia, Australia.
AD  - Department of Obstetrics and Gynaecology, University of Melbourne and the Royal
      Women's Hospital, Melbourne, Victoria, Australia.
FAU - Offit, Kenneth
AU  - Offit K
AD  - Clinical Genetics Research Laboratory, Cancer Biology and Genetics Program,
      Memorial Sloan Kettering Cancer Center, New York, New York, USA.
AD  - Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering
      Cancer Center, New York, New York, USA.
FAU - Ottini, Laura
AU  - Ottini L
AD  - Department of Molecular Medicine, University La Sapienza, Rome, Italy.
FAU - Park, Sue K
AU  - Park SK
AD  - Department of Preventive Medicine, Seoul National University College of Medicine,
      Seoul, Republic of Korea.
AD  - Cancer Research Institute, Seoul National University, Seoul, Republic of Korea.
FAU - Thomassen, Mads
AU  - Thomassen M
AD  - Department of Clinical Genetics, Odense University Hospital, Odense, Denmark.
FAU - Hall, Per
AU  - Hall P
AD  - Department of Medical Epidemiology and Biostatistics, Karolinska Institutet,
      Stockholm, Sweden.
AD  - Department of Oncology, South General Hospital, Stockholm, Sweden.
FAU - Meindl, Alfons
AU  - Meindl A
AD  - Division of Gynaecology and Obstetrics, Technische Universitat Munchen, Munich,
      Germany.
FAU - Schmutzler, Rita K
AU  - Schmutzler RK
AD  - Center for Familial Breast and Ovarian Cancer, University Hospital of Cologne,
      Cologne, Germany.
AD  - Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne,
      Germany.
FAU - Droit, Arnaud
AU  - Droit A
AD  - Genomics Center, Centre Hospitalier Universitaire de Quebec Research Center,
      Laval University, Quebec City, Quebec, Canada.
FAU - Bader, Gary D
AU  - Bader GD
AUID- ORCID: http://orcid.org/0000-0003-0185-8861
AD  - Donnelly Centre, University of Toronto, Toronto, Ontario, Canada.
FAU - Pharoah, Paul D P
AU  - Pharoah PDP
AUID- ORCID: http://orcid.org/0000-0001-8494-732X
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary
      Care, University of Cambridge, Cambridge, UK.
AD  - Centre for Cancer Genetic Epidemiology, Department of Oncology, University of
      Cambridge, Cambridge, UK.
FAU - Couch, Fergus J
AU  - Couch FJ
AD  - Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester,
      Minnesota, USA.
FAU - Easton, Douglas F
AU  - Easton DF
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary
      Care, University of Cambridge, Cambridge, UK.
AD  - Centre for Cancer Genetic Epidemiology, Department of Oncology, University of
      Cambridge, Cambridge, UK.
FAU - Kraft, Peter
AU  - Kraft P
AD  - Program in Genetic Epidemiology and Statistical Genetics, Harvard T.H. Chan
      School of Public Health, Boston, Massachusetts, USA.
AD  - Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston,
      Massachusetts, USA.
FAU - Chenevix-Trench, Georgia
AU  - Chenevix-Trench G
AD  - Cancer Division, QIMR Berghofer Medical Research Institute, Brisbane, Queensland,
      Australia.
FAU - Garcia-Closas, Montserrat
AU  - Garcia-Closas M
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute,
      Rockville, Maryland, USA.
FAU - Schmidt, Marjanka K
AU  - Schmidt MK
AD  - Division of Molecular Pathology, Netherlands Cancer Institute, Antoni van
      Leeuwenhoek Hospital, Amsterdam, the Netherlands.
AD  - Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute,
      Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
FAU - Antoniou, Antonis C
AU  - Antoniou AC
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary
      Care, University of Cambridge, Cambridge, UK.
FAU - Simard, Jacques
AU  - Simard J
AD  - Genomics Center, Centre Hospitalier Universitaire de Quebec Research Center,
      Laval University, Quebec City, Quebec, Canada.
LA  - eng
GR  - U01 CA199277/CA/NCI NIH HHS/United States
GR  - U10 CA180868/CA/NCI NIH HHS/United States
GR  - UM1 CA164917/CA/NCI NIH HHS/United States
GR  - R01 CA128931/CA/NCI NIH HHS/United States
GR  - U19 CA148127/CA/NCI NIH HHS/United States
GR  - P20 GM103534/GM/NIGMS NIH HHS/United States
GR  - R01 CA140323/CA/NCI NIH HHS/United States
GR  - UM1 CA164973/CA/NCI NIH HHS/United States
GR  - U41 HG006623/HG/NHGRI NIH HHS/United States
GR  - R01 CA176785/CA/NCI NIH HHS/United States
GR  - RC4 CA153828/CA/NCI NIH HHS/United States
GR  - R01 CA142996/CA/NCI NIH HHS/United States
GR  - P50 CA125183/CA/NCI NIH HHS/United States
GR  - P01 CA087969/CA/NCI NIH HHS/United States
GR  - UM1 CA164920/CA/NCI NIH HHS/United States
GR  - U01 CA194393/CA/NCI NIH HHS/United States
GR  - P30 CA168524/CA/NCI NIH HHS/United States
GR  - U01 CA161032/CA/NCI NIH HHS/United States
GR  - R01 CA097396/CA/NCI NIH HHS/United States
GR  - UM1 CA176726/CA/NCI NIH HHS/United States
GR  - P41 GM103504/GM/NIGMS NIH HHS/United States
GR  - U10 CA027469/CA/NCI NIH HHS/United States
GR  - K07 CA092044/CA/NCI NIH HHS/United States
GR  - R01 CA100374/CA/NCI NIH HHS/United States
GR  - U01 CA116167/CA/NCI NIH HHS/United States
GR  - R01 CA128978/CA/NCI NIH HHS/United States
GR  - P30 CA014089/CA/NCI NIH HHS/United States
GR  - U19 CA148537/CA/NCI NIH HHS/United States
GR  - P30 CA051008/CA/NCI NIH HHS/United States
GR  - P30 ES013508/ES/NIEHS NIH HHS/United States
GR  - R01 CA177150/CA/NCI NIH HHS/United States
GR  - P50 CA116201/CA/NCI NIH HHS/United States
GR  - U01 CA113916/CA/NCI NIH HHS/United States
GR  - U10 CA037517/CA/NCI NIH HHS/United States
GR  - UM1 CA186107/CA/NCI NIH HHS/United States
GR  - R01 CA122443/CA/NCI NIH HHS/United States
GR  - R01 CA077398/CA/NCI NIH HHS/United States
GR  - U01 CA063464/CA/NCI NIH HHS/United States
GR  - R01 CA132839/CA/NCI NIH HHS/United States
GR  - P30 CA068485/CA/NCI NIH HHS/United States
GR  - U01 CA058860/CA/NCI NIH HHS/United States
GR  - U19 CA148112/CA/NCI NIH HHS/United States
GR  - R01 CA149429/CA/NCI NIH HHS/United States
GR  - U01 CA098758/CA/NCI NIH HHS/United States
GR  - U19 CA148065/CA/NCI NIH HHS/United States
GR  - R03 CA173531/CA/NCI NIH HHS/United States
GR  - R01 CA121941/CA/NCI NIH HHS/United States
GR  - R01 CA192393/CA/NCI NIH HHS/United States
GR  - HHSN268201200008I/HL/NHLBI NIH HHS/United States
GR  - U10 CA180822/CA/NCI NIH HHS/United States
GR  - R01 CA140286/CA/NCI NIH HHS/United States
GR  - R37 CA054281/CA/NCI NIH HHS/United States
GR  - P50 CA136393/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20171023
PL  - United States
TA  - Nat Genet
JT  - Nature genetics
JID - 9216904
RN  - 0 (BRCA1 Protein)
RN  - 0 (Receptors, Estrogen)
SB  - IM
MH  - BRCA1 Protein/*genetics
MH  - Breast Neoplasms/ethnology/*genetics/metabolism
MH  - European Continental Ancestry Group/genetics
MH  - Female
MH  - Genetic Predisposition to Disease/ethnology/*genetics
MH  - Genome-Wide Association Study/methods
MH  - Heterozygote
MH  - Humans
MH  - *Mutation
MH  - *Polymorphism, Single Nucleotide
MH  - Receptors, Estrogen/metabolism
MH  - Risk Factors
EDAT- 2017/10/24 06:00
MHDA- 2017/12/12 06:00
CRDT- 2017/10/24 06:00
PHST- 2016/05/30 00:00 [received]
PHST- 2017/01/11 00:00 [accepted]
PHST- 2017/10/24 06:00 [pubmed]
PHST- 2017/12/12 06:00 [medline]
PHST- 2017/10/24 06:00 [entrez]
AID - ng.3785 [pii]
AID - 10.1038/ng.3785 [doi]
PST - ppublish
SO  - Nat Genet. 2017 Dec;49(12):1767-1778. doi: 10.1038/ng.3785. Epub 2017 Oct 23.

PMID- 29170280
OWN - NLM
STAT- MEDLINE
DCOM- 20180115
LR  - 20180115
IS  - 1095-9203 (Electronic)
IS  - 0036-8075 (Linking)
VI  - 358
IP  - 6369
DP  - 2017 Dec 15
TI  - Analysis of Fusobacterium persistence and antibiotic response in colorectal
      cancer.
PG  - 1443-1448
LID - 10.1126/science.aal5240 [doi]
AB  - Colorectal cancers comprise a complex mixture of malignant cells, nontransformed 
      cells, and microorganisms. Fusobacterium nucleatum is among the most prevalent
      bacterial species in colorectal cancer tissues. Here we show that colonization of
      human colorectal cancers with Fusobacterium and its associated
      microbiome-including Bacteroides, Selenomonas, and Prevotella species-is
      maintained in distal metastases, demonstrating microbiome stability between
      paired primary and metastatic tumors. In situ hybridization analysis revealed
      that Fusobacterium is predominantly associated with cancer cells in the
      metastatic lesions. Mouse xenografts of human primary colorectal adenocarcinomas 
      were found to retain viable Fusobacterium and its associated microbiome through
      successive passages. Treatment of mice bearing a colon cancer xenograft with the 
      antibiotic metronidazole reduced Fusobacterium load, cancer cell proliferation,
      and overall tumor growth. These observations argue for further investigation of
      antimicrobial interventions as a potential treatment for patients with
      Fusobacterium-associated colorectal cancer.
CI  - Copyright (c) 2017 The Authors, some rights reserved; exclusive licensee American
      Association for the Advancement of Science. No claim to original U.S. Government 
      Works.
FAU - Bullman, Susan
AU  - Bullman S
AUID- ORCID: 0000-0002-6978-0223
AD  - Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Pedamallu, Chandra S
AU  - Pedamallu CS
AD  - Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Sicinska, Ewa
AU  - Sicinska E
AD  - Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
FAU - Clancy, Thomas E
AU  - Clancy TE
AD  - Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
FAU - Zhang, Xiaoyang
AU  - Zhang X
AD  - Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Cai, Diana
AU  - Cai D
AD  - Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Neuberg, Donna
AU  - Neuberg D
AUID- ORCID: 0000-0003-2566-3145
AD  - Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
FAU - Huang, Katherine
AU  - Huang K
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Guevara, Fatima
AU  - Guevara F
AD  - Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
FAU - Nelson, Timothy
AU  - Nelson T
AUID- ORCID: 0000-0001-7784-9211
AD  - Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
FAU - Chipashvili, Otari
AU  - Chipashvili O
AUID- ORCID: 0000-0002-5454-2388
AD  - Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
FAU - Hagan, Timothy
AU  - Hagan T
AUID- ORCID: 0000-0002-5990-6574
AD  - Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
FAU - Walker, Mark
AU  - Walker M
AUID- ORCID: 0000-0001-6613-4560
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Ramachandran, Aruna
AU  - Ramachandran A
AD  - Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Diosdado, Begona
AU  - Diosdado B
AUID- ORCID: 0000-0001-5104-0393
AD  - Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Serna, Garazi
AU  - Serna G
AUID- ORCID: 0000-0003-2666-0982
AD  - Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology,
      Barcelona, CIBERONC, Universitat Autonoma de Barcelona, Spain.
FAU - Mulet, Nuria
AU  - Mulet N
AD  - Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology,
      Barcelona, CIBERONC, Universitat Autonoma de Barcelona, Spain.
FAU - Landolfi, Stefania
AU  - Landolfi S
AUID- ORCID: 0000-0002-1059-635X
AD  - Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology,
      Barcelona, CIBERONC, Universitat Autonoma de Barcelona, Spain.
FAU - Ramon Y Cajal, Santiago
AU  - Ramon Y Cajal S
AD  - Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology,
      Barcelona, CIBERONC, Universitat Autonoma de Barcelona, Spain.
FAU - Fasani, Roberta
AU  - Fasani R
AD  - Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology,
      Barcelona, CIBERONC, Universitat Autonoma de Barcelona, Spain.
FAU - Aguirre, Andrew J
AU  - Aguirre AJ
AD  - Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
AD  - Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
FAU - Ng, Kimmie
AU  - Ng K
AD  - Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
FAU - Elez, Elena
AU  - Elez E
AD  - Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology,
      Barcelona, CIBERONC, Universitat Autonoma de Barcelona, Spain.
FAU - Ogino, Shuji
AU  - Ogino S
AUID- ORCID: 0000-0002-3909-2323
AD  - Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
AD  - Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
AD  - Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.
FAU - Tabernero, Josep
AU  - Tabernero J
AUID- ORCID: 0000-0002-2495-8139
AD  - Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology,
      Barcelona, CIBERONC, Universitat Autonoma de Barcelona, Spain.
FAU - Fuchs, Charles S
AU  - Fuchs CS
AD  - Yale Cancer Center, Yale School of Medicine, New Haven, CT 06520, USA.
FAU - Hahn, William C
AU  - Hahn WC
AUID- ORCID: 0000-0003-2840-9791
AD  - Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
AD  - Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
FAU - Nuciforo, Paolo
AU  - Nuciforo P
AUID- ORCID: 0000-0003-1380-0990
AD  - Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology,
      Barcelona, CIBERONC, Universitat Autonoma de Barcelona, Spain.
FAU - Meyerson, Matthew
AU  - Meyerson M
AUID- ORCID: 0000-0002-9133-8108
AD  - Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
AD  - Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
LA  - eng
GR  - K07 CA148894/CA/NCI NIH HHS/United States
GR  - R35 CA197735/CA/NCI NIH HHS/United States
GR  - R01 CA118553/CA/NCI NIH HHS/United States
GR  - HHMI/Howard Hughes Medical Institute/United States
GR  - R01 CA169141/CA/NCI NIH HHS/United States
GR  - R35 CA197568/CA/NCI NIH HHS/United States
GR  - P50 CA127003/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20171123
PL  - United States
TA  - Science
JT  - Science (New York, N.Y.)
JID - 0404511
RN  - 0 (Anti-Bacterial Agents)
RN  - 140QMO216E (Metronidazole)
SB  - IM
MH  - Adenocarcinoma/*drug therapy/*microbiology/secondary
MH  - Animals
MH  - Anti-Bacterial Agents/pharmacology/*therapeutic use
MH  - Bacteroides/drug effects
MH  - Carcinogenesis
MH  - Colorectal Neoplasms/*drug therapy/*microbiology/pathology
MH  - Fusobacterium/*drug effects/genetics/isolation & purification
MH  - HT29 Cells
MH  - Humans
MH  - Liver Neoplasms/microbiology/secondary
MH  - Metronidazole/*pharmacology/therapeutic use
MH  - Mice
MH  - Microbiota/*drug effects
MH  - Prevotella/drug effects
MH  - Xenograft Model Antitumor Assays
EDAT- 2017/11/25 06:00
MHDA- 2018/01/16 06:00
CRDT- 2017/11/25 06:00
PHST- 2016/12/02 00:00 [received]
PHST- 2017/08/17 00:00 [revised]
PHST- 2017/11/13 00:00 [accepted]
PHST- 2017/11/25 06:00 [pubmed]
PHST- 2018/01/16 06:00 [medline]
PHST- 2017/11/25 06:00 [entrez]
AID - science.aal5240 [pii]
AID - 10.1126/science.aal5240 [doi]
PST - ppublish
SO  - Science. 2017 Dec 15;358(6369):1443-1448. doi: 10.1126/science.aal5240. Epub 2017
      Nov 23.

PMID- 29180808
OWN - NLM
STAT- MEDLINE
DCOM- 20171227
LR  - 20171227
IS  - 1529-2916 (Electronic)
IS  - 1529-2908 (Linking)
VI  - 19
IP  - 1
DP  - 2018 Jan
TI  - Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses
      macrophages and is a target of cancer immunotherapy.
PG  - 76-84
LID - 10.1038/s41590-017-0004-z [doi]
AB  - Exciting progress in the field of cancer immunotherapy has renewed the urgency of
      the need for basic studies of immunoregulation in both adaptive cell lineages and
      innate cell lineages. Here we found a central role for major histocompatibility
      complex (MHC) class I in controlling the phagocytic function of macrophages. Our 
      results demonstrated that expression of the common MHC class I component
      beta2-microglobulin (beta2M) by cancer cells directly protected them from
      phagocytosis. We further showed that this protection was mediated by the
      inhibitory receptor LILRB1, whose expression was upregulated on the surface of
      macrophages, including tumor-associated macrophages. Disruption of either MHC
      class I or LILRB1 potentiated phagocytosis of tumor cells both in vitro and in
      vivo, which defines the MHC class I-LILRB1 signaling axis as an important
      regulator of the effector function of innate immune cells, a potential biomarker 
      for therapeutic response to agents directed against the signal-regulatory protein
      CD47 and a potential target of anti-cancer immunotherapy.
FAU - Barkal, Amira A
AU  - Barkal AA
AD  - Institute for Stem Cell Biology and Regenerative Medicine, Stanford University
      School of Medicine, Stanford, CA, USA.
FAU - Weiskopf, Kipp
AU  - Weiskopf K
AD  - Institute for Stem Cell Biology and Regenerative Medicine, Stanford University
      School of Medicine, Stanford, CA, USA.
AD  - Brigham and Women's Hospital, Boston, MA, USA.
FAU - Kao, Kevin S
AU  - Kao KS
AD  - Institute for Stem Cell Biology and Regenerative Medicine, Stanford University
      School of Medicine, Stanford, CA, USA.
FAU - Gordon, Sydney R
AU  - Gordon SR
AD  - Institute for Stem Cell Biology and Regenerative Medicine, Stanford University
      School of Medicine, Stanford, CA, USA.
FAU - Rosental, Benyamin
AU  - Rosental B
AD  - Institute for Stem Cell Biology and Regenerative Medicine, Stanford University
      School of Medicine, Stanford, CA, USA.
FAU - Yiu, Ying Y
AU  - Yiu YY
AD  - Institute for Stem Cell Biology and Regenerative Medicine, Stanford University
      School of Medicine, Stanford, CA, USA.
FAU - George, Benson M
AU  - George BM
AD  - Institute for Stem Cell Biology and Regenerative Medicine, Stanford University
      School of Medicine, Stanford, CA, USA.
FAU - Markovic, Maxim
AU  - Markovic M
AD  - Institute for Stem Cell Biology and Regenerative Medicine, Stanford University
      School of Medicine, Stanford, CA, USA.
FAU - Ring, Nan G
AU  - Ring NG
AD  - Institute for Stem Cell Biology and Regenerative Medicine, Stanford University
      School of Medicine, Stanford, CA, USA.
FAU - Tsai, Jonathan M
AU  - Tsai JM
AD  - Institute for Stem Cell Biology and Regenerative Medicine, Stanford University
      School of Medicine, Stanford, CA, USA.
FAU - McKenna, Kelly M
AU  - McKenna KM
AD  - Institute for Stem Cell Biology and Regenerative Medicine, Stanford University
      School of Medicine, Stanford, CA, USA.
FAU - Ho, Po Yi
AU  - Ho PY
AD  - Institute for Stem Cell Biology and Regenerative Medicine, Stanford University
      School of Medicine, Stanford, CA, USA.
FAU - Cheng, Robin Z
AU  - Cheng RZ
AUID- ORCID: http://orcid.org/0000-0001-7294-8907
AD  - Institute for Stem Cell Biology and Regenerative Medicine, Stanford University
      School of Medicine, Stanford, CA, USA.
FAU - Chen, James Y
AU  - Chen JY
AD  - Institute for Stem Cell Biology and Regenerative Medicine, Stanford University
      School of Medicine, Stanford, CA, USA.
FAU - Barkal, Layla J
AU  - Barkal LJ
AUID- ORCID: http://orcid.org/0000-0002-4734-7197
AD  - Department of Biomedical Engineering, University of Wisconsin-Madison, Madison,
      WI, USA.
FAU - Ring, Aaron M
AU  - Ring AM
AD  - Department of Immunobiology, Yale University School of Medicine, New Haven, CT,
      USA.
FAU - Weissman, Irving L
AU  - Weissman IL
AUID- ORCID: http://orcid.org/0000-0002-9077-7467
AD  - Institute for Stem Cell Biology and Regenerative Medicine, Stanford University
      School of Medicine, Stanford, CA, USA. irv@stanford.edu.
AD  - Ludwig Center for Cancer Stem Cell Research and Medicine, Stanford, CA, USA.
      irv@stanford.edu.
AD  - Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, 
      USA. irv@stanford.edu.
AD  - Department of Pathology, Stanford University School of Medicine, Stanford, CA,
      USA. irv@stanford.edu.
FAU - Maute, Roy L
AU  - Maute RL
AUID- ORCID: http://orcid.org/0000-0001-7501-3285
AD  - Institute for Stem Cell Biology and Regenerative Medicine, Stanford University
      School of Medicine, Stanford, CA, USA. rmaute@stanford.edu.
AD  - Ab Initio Biotherapeutics, South San Francisco, CA, USA. rmaute@stanford.edu.
LA  - eng
GR  - T32 GM008692/GM/NIGMS NIH HHS/United States
PT  - Journal Article
DEP - 20171127
PL  - United States
TA  - Nat Immunol
JT  - Nature immunology
JID - 100941354
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Leukocyte Immunoglobulin-like Receptor B1)
SB  - IM
MH  - Animals
MH  - Cell Line, Tumor
MH  - Histocompatibility Antigens Class I/*immunology/metabolism
MH  - Humans
MH  - Immunotherapy/methods
MH  - Leukocyte Immunoglobulin-like Receptor B1/*immunology/metabolism
MH  - Macrophages/*immunology/metabolism
MH  - Mice, Inbred BALB C
MH  - Mice, Inbred C57BL
MH  - Mice, Inbred NOD
MH  - Mice, Knockout
MH  - Mice, SCID
MH  - Neoplasms/*immunology/metabolism/therapy
MH  - Neoplasms, Experimental/immunology/metabolism/therapy
MH  - Phagocytosis/*immunology
EDAT- 2017/11/29 06:00
MHDA- 2017/12/28 06:00
CRDT- 2017/11/29 06:00
PHST- 2016/06/20 00:00 [received]
PHST- 2017/10/20 00:00 [accepted]
PHST- 2017/11/29 06:00 [pubmed]
PHST- 2017/12/28 06:00 [medline]
PHST- 2017/11/29 06:00 [entrez]
AID - 10.1038/s41590-017-0004-z [doi]
AID - 10.1038/s41590-017-0004-z [pii]
PST - ppublish
SO  - Nat Immunol. 2018 Jan;19(1):76-84. doi: 10.1038/s41590-017-0004-z. Epub 2017 Nov 
      27.

PMID- 29131160
OWN - NLM
STAT- MEDLINE
DCOM- 20171226
LR  - 20171226
IS  - 1546-170X (Electronic)
IS  - 1078-8956 (Linking)
VI  - 23
IP  - 12
DP  - 2017 Dec
TI  - Human primary liver cancer-derived organoid cultures for disease modeling and
      drug screening.
PG  - 1424-1435
LID - 10.1038/nm.4438 [doi]
AB  - Human liver cancer research currently lacks in vitro models that can faithfully
      recapitulate the pathophysiology of the original tumor. We recently described a
      novel, near-physiological organoid culture system, wherein primary human healthy 
      liver cells form long-term expanding organoids that retain liver tissue function 
      and genetic stability. Here we extend this culture system to the propagation of
      primary liver cancer (PLC) organoids from three of the most common PLC subtypes: 
      hepatocellular carcinoma (HCC), cholangiocarcinoma (CC) and combined HCC/CC (CHC)
      tumors. PLC-derived organoid cultures preserve the histological architecture,
      gene expression and genomic landscape of the original tumor, allowing for
      discrimination between different tumor tissues and subtypes, even after long-term
      expansion in culture in the same medium conditions. Xenograft studies demonstrate
      that the tumorogenic potential, histological features and metastatic properties
      of PLC-derived organoids are preserved in vivo. PLC-derived organoids are
      amenable for biomarker identification and drug-screening testing and led to the
      identification of the ERK inhibitor SCH772984 as a potential therapeutic agent
      for primary liver cancer. We thus demonstrate the wide-ranging biomedical
      utilities of PLC-derived organoid models in furthering the understanding of liver
      cancer biology and in developing personalized-medicine approaches for the
      disease.
FAU - Broutier, Laura
AU  - Broutier L
AUID- ORCID: http://orcid.org/0000-0001-5163-5573
AD  - The Wellcome Trust/CRUK Gurdon Institute, University of Cambridge, Cambridge, UK.
FAU - Mastrogiovanni, Gianmarco
AU  - Mastrogiovanni G
AD  - The Wellcome Trust/CRUK Gurdon Institute, University of Cambridge, Cambridge, UK.
AD  - Wellcome Trust-Medical Research Council Stem Cell Institute, University of
      Cambridge, Cambridge, UK.
FAU - Verstegen, Monique Ma
AU  - Verstegen MM
AD  - Department of Surgery, Erasmus MC-University Medical Center, Rotterdam, the
      Netherlands.
FAU - Francies, Hayley E
AU  - Francies HE
AD  - Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK.
FAU - Gavarro, Lena Morrill
AU  - Gavarro LM
AD  - Wellcome Trust-Medical Research Council Stem Cell Institute, University of
      Cambridge, Cambridge, UK.
FAU - Bradshaw, Charles R
AU  - Bradshaw CR
AD  - The Wellcome Trust/CRUK Gurdon Institute, University of Cambridge, Cambridge, UK.
FAU - Allen, George E
AU  - Allen GE
AD  - The Wellcome Trust/CRUK Gurdon Institute, University of Cambridge, Cambridge, UK.
FAU - Arnes-Benito, Robert
AU  - Arnes-Benito R
AD  - The Wellcome Trust/CRUK Gurdon Institute, University of Cambridge, Cambridge, UK.
FAU - Sidorova, Olga
AU  - Sidorova O
AD  - The Wellcome Trust/CRUK Gurdon Institute, University of Cambridge, Cambridge, UK.
FAU - Gaspersz, Marcia P
AU  - Gaspersz MP
AD  - Department of Surgery, Erasmus MC-University Medical Center, Rotterdam, the
      Netherlands.
FAU - Georgakopoulos, Nikitas
AU  - Georgakopoulos N
AD  - Department of Surgery, University of Cambridge and NIHR Cambridge Biomedical
      Research Centre, Cambridge, UK.
FAU - Koo, Bon-Kyoung
AU  - Koo BK
AD  - Wellcome Trust-Medical Research Council Stem Cell Institute, University of
      Cambridge, Cambridge, UK.
FAU - Dietmann, Sabine
AU  - Dietmann S
AD  - Wellcome Trust-Medical Research Council Stem Cell Institute, University of
      Cambridge, Cambridge, UK.
FAU - Davies, Susan E
AU  - Davies SE
AD  - Department of Histopathology, Cambridge University Hospitals NHS Foundation
      Trust, Cambridge, UK.
FAU - Praseedom, Raaj K
AU  - Praseedom RK
AD  - Department of Hepato Pancreato Biliary Surgery, Cambridge University Hospitals
      NHS Foundation Trust, Cambridge, UK.
FAU - Lieshout, Ruby
AU  - Lieshout R
AD  - Department of Surgery, Erasmus MC-University Medical Center, Rotterdam, the
      Netherlands.
FAU - IJzermans, Jan N M
AU  - IJzermans JNM
AD  - Department of Surgery, Erasmus MC-University Medical Center, Rotterdam, the
      Netherlands.
FAU - Wigmore, Stephen J
AU  - Wigmore SJ
AD  - Department of Clinical Surgery, Royal Infirmary of Edinburgh, Edinburgh, UK.
FAU - Saeb-Parsy, Kourosh
AU  - Saeb-Parsy K
AD  - Department of Surgery, University of Cambridge and NIHR Cambridge Biomedical
      Research Centre, Cambridge, UK.
FAU - Garnett, Mathew J
AU  - Garnett MJ
AD  - Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK.
FAU - van der Laan, Luc Jw
AU  - van der Laan LJ
AD  - Department of Surgery, Erasmus MC-University Medical Center, Rotterdam, the
      Netherlands.
FAU - Huch, Meritxell
AU  - Huch M
AUID- ORCID: http://orcid.org/0000-0002-1545-5265
AD  - The Wellcome Trust/CRUK Gurdon Institute, University of Cambridge, Cambridge, UK.
AD  - Wellcome Trust-Medical Research Council Stem Cell Institute, University of
      Cambridge, Cambridge, UK.
AD  - Department of Physiology, Development and Neuroscience, University of Cambridge, 
      Cambridge, UK.
LA  - eng
PT  - Journal Article
DEP - 20171113
PL  - United States
TA  - Nat Med
JT  - Nature medicine
JID - 9502015
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/isolation & purification/therapeutic use
MH  - Bile Duct Neoplasms/drug therapy/genetics/*pathology
MH  - Carcinoma, Hepatocellular/drug therapy/genetics/*pathology
MH  - Cell Proliferation
MH  - Cholangiocarcinoma/drug therapy/genetics/*pathology
MH  - Drug Screening Assays, Antitumor/*methods
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Liver Neoplasms/drug therapy/genetics/*pathology
MH  - Male
MH  - Mice
MH  - Mice, Inbred NOD
MH  - Mice, SCID
MH  - Organoids/*pathology
MH  - Precision Medicine
MH  - Primary Cell Culture/*methods
MH  - Transcriptome
MH  - Tumor Cells, Cultured
MH  - Xenograft Model Antitumor Assays
PMC - PMC5722201
MID - EMS74480
EDAT- 2017/11/14 06:00
MHDA- 2017/12/27 06:00
CRDT- 2017/11/14 06:00
PMCR- 2018/05/13 00:00
PHST- 2016/08/08 00:00 [received]
PHST- 2017/10/11 00:00 [accepted]
PHST- 2018/05/13 00:00 [pmc-release]
PHST- 2017/11/14 06:00 [pubmed]
PHST- 2017/12/27 06:00 [medline]
PHST- 2017/11/14 06:00 [entrez]
AID - nm.4438 [pii]
AID - 10.1038/nm.4438 [doi]
PST - ppublish
SO  - Nat Med. 2017 Dec;23(12):1424-1435. doi: 10.1038/nm.4438. Epub 2017 Nov 13.

PMID- 28480532
OWN - NLM
STAT- MEDLINE
DCOM- 20170922
LR  - 20170922
IS  - 1365-2796 (Electronic)
IS  - 0954-6820 (Linking)
VI  - 282
IP  - 4
DP  - 2017 Oct
TI  - Hydrochlorothiazide use is strongly associated with risk of lip cancer.
PG  - 322-331
LID - 10.1111/joim.12629 [doi]
AB  - BACKGROUND: The diuretic hydrochlorothiazide is amongst the most frequently
      prescribed drugs in the United States and Western Europe, but there is suggestive
      evidence that hydrochlorothiazide use increases the risk of lip cancer.
      OBJECTIVES: To study the association between use of hydrochlorothiazide and
      squamous cell carcinoma of the lip. METHODS: We conducted a case-control study
      using Danish nationwide registry data. From the Cancer Registry (2004-2012), we
      identified 633 case patients with squamous cell carcinoma (SCC) of the lip and
      matched them to 63 067 population controls using a risk-set sampling strategy.
      Hydrochlorothiazide use (1995-2012) was obtained from the Prescription Registry
      and defined according to cumulative use. Applying conditional logistic
      regression, we calculated odds ratios (ORs) for SCC lip cancer associated with
      hydrochlorothiazide use, adjusting for predefined potential confounders obtained 
      from demographic, prescription and patient registries. RESULTS: Ever-use of
      hydrochlorothiazide was associated with an adjusted OR for SCC lip cancer of 2.1 
      (95% confidence interval (CI): 1.7-2.6), increasing to 3.9 (95%CI: 3.0-4.9) for
      high use (>/=25 000 mg). There was a clear dose-response effect (P < 0.001), with
      the highest cumulative dose category of hydrochlorothiazide (>/=100 000 mg)
      presenting an OR of 7.7 (95%CI: 5.7-10.5). No association with lip cancer was
      seen with use of other diuretics or nondiuretic antihypertensives. Assuming
      causality, we estimated that 11% of the SCC lip cancer cases could be attributed 
      to hydrochlorothiazide use. CONCLUSIONS: Hydrochlorothiazide use is strongly
      associated with an increased risk of lip cancer.
CI  - (c) 2017 The Authors. Journal of Internal Medicine published by John Wiley & Sons
      Ltd on behalf of Association for Publication of The Journal of Internal Medicine.
FAU - Pottegard, A
AU  - Pottegard A
AUID- ORCID: http://orcid.org/0000-0001-9314-5679
AD  - Clinical Pharmacology and Pharmacy, Department of Public Health, University of
      Southern Denmark, Odense, Denmark.
FAU - Hallas, J
AU  - Hallas J
AD  - Clinical Pharmacology and Pharmacy, Department of Public Health, University of
      Southern Denmark, Odense, Denmark.
FAU - Olesen, M
AU  - Olesen M
AD  - Clinical Pharmacology and Pharmacy, Department of Public Health, University of
      Southern Denmark, Odense, Denmark.
FAU - Svendsen, M T
AU  - Svendsen MT
AD  - Department of Dermatology and Allergy Centre, Odense University Hospital, Odense,
      Denmark.
FAU - Habel, L A
AU  - Habel LA
AD  - Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA.
FAU - Friedman, G D
AU  - Friedman GD
AD  - Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA.
FAU - Friis, S
AU  - Friis S
AD  - Danish Cancer Society, Danish Cancer Society Research Center, Copenhagen,
      Denmark.
LA  - eng
PT  - Journal Article
DEP - 20170606
PL  - England
TA  - J Intern Med
JT  - Journal of internal medicine
JID - 8904841
RN  - 0 (Diuretics)
RN  - 0J48LPH2TH (Hydrochlorothiazide)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Squamous Cell/*chemically induced/epidemiology
MH  - Case-Control Studies
MH  - Denmark/epidemiology
MH  - Diuretics/*adverse effects
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Hydrochlorothiazide/*adverse effects
MH  - Lip Neoplasms/*chemically induced/epidemiology
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Registries
OTO - NOTNLM
OT  - cancer
OT  - epidemiology
OT  - hydrochlorothiazide
OT  - pharmacology
EDAT- 2017/05/10 06:00
MHDA- 2017/09/25 06:00
CRDT- 2017/05/09 06:00
PHST- 2017/05/10 06:00 [pubmed]
PHST- 2017/09/25 06:00 [medline]
PHST- 2017/05/09 06:00 [entrez]
AID - 10.1111/joim.12629 [doi]
PST - ppublish
SO  - J Intern Med. 2017 Oct;282(4):322-331. doi: 10.1111/joim.12629. Epub 2017 Jun 6.

PMID- 29150554
OWN - NLM
STAT- In-Data-Review
LR  - 20171219
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Linking)
VI  - 114
IP  - 49
DP  - 2017 Dec 5
TI  - Cancer cells induce interleukin-22 production from memory CD4(+) T cells via
      interleukin-1 to promote tumor growth.
PG  - 12994-12999
LID - 10.1073/pnas.1705165114 [doi]
AB  - IL-22 has been identified as a cancer-promoting cytokine that is secreted by
      infiltrating immune cells in several cancer models. We hypothesized that IL-22
      regulation would occur at the interface between cancer cells and immune cells.
      Breast and lung cancer cells of murine and human origin induced IL-22 production 
      from memory CD4(+) T cells. In the present study, we found that IL-22 production 
      in humans is dependent on activation of the NLRP3 inflammasome with the
      subsequent release of IL-1beta from both myeloid and T cells. IL-1 receptor
      signaling via the transcription factors AhR and RORgammat in T cells was
      necessary and sufficient for IL-22 production. In these settings, IL-1 induced
      IL-22 production from a mixed T helper cell population comprised of Th1, Th17,
      and Th22 cells, which was abrogated by the addition of anakinra. We confirmed
      these findings in vitro and in vivo in two murine tumor models, in primary human 
      breast and lung cancer cells, and in deposited expression data. Relevant to
      ongoing clinical trials in breast cancer, we demonstrate here that the IL-1
      receptor antagonist anakinra abrogates IL-22 production and reduces tumor growth 
      in a murine breast cancer model. Thus, we describe here a previously unrecognized
      mechanism by which cancer cells induce IL-22 production from memory CD4(+) T
      cells via activation of the NLRP3 inflammasome and the release of IL-1beta to
      promote tumor growth. These findings may provide the basis for therapeutic
      interventions that affect IL-22 production by targeting IL-1 activity.
FAU - Voigt, Cornelia
AU  - Voigt C
AD  - Center of Integrated Protein Science Munich, University Hospital, Ludwig
      Maximilian University of Munich, 80337 Munich, Germany.
AD  - Division of Clinical Pharmacology, Department of Medicine IV, University
      Hospital, Ludwig Maximilian University of Munich, 80337 Munich, Germany.
AD  - Comprehensive Pneumology Center, Ludwig Maximilian University of Munich, 80337
      Munich, Germany.
AD  - Institute for Lung Biology and Disease, University Hospital, Ludwig Maximilian
      University of Munich, 80337 Munich, Germany.
AD  - Helmholtz Zentrum Munchen, 81377 Munich, Germany.
AD  - German Center for Lung Research, 81377 Munich, Germany.
FAU - May, Peter
AU  - May P
AD  - Center of Integrated Protein Science Munich, University Hospital, Ludwig
      Maximilian University of Munich, 80337 Munich, Germany.
AD  - Division of Clinical Pharmacology, Department of Medicine IV, University
      Hospital, Ludwig Maximilian University of Munich, 80337 Munich, Germany.
AD  - German Center for Lung Research, 81377 Munich, Germany.
FAU - Gottschlich, Adrian
AU  - Gottschlich A
AD  - Center of Integrated Protein Science Munich, University Hospital, Ludwig
      Maximilian University of Munich, 80337 Munich, Germany.
AD  - Division of Clinical Pharmacology, Department of Medicine IV, University
      Hospital, Ludwig Maximilian University of Munich, 80337 Munich, Germany.
AD  - German Center for Lung Research, 81377 Munich, Germany.
FAU - Markota, Anamarija
AU  - Markota A
AD  - Center of Integrated Protein Science Munich, University Hospital, Ludwig
      Maximilian University of Munich, 80337 Munich, Germany.
AD  - Division of Clinical Pharmacology, Department of Medicine IV, University
      Hospital, Ludwig Maximilian University of Munich, 80337 Munich, Germany.
AD  - German Center for Lung Research, 81377 Munich, Germany.
FAU - Wenk, Daniel
AU  - Wenk D
AD  - Center of Integrated Protein Science Munich, University Hospital, Ludwig
      Maximilian University of Munich, 80337 Munich, Germany.
AD  - Division of Clinical Pharmacology, Department of Medicine IV, University
      Hospital, Ludwig Maximilian University of Munich, 80337 Munich, Germany.
AD  - German Center for Lung Research, 81377 Munich, Germany.
FAU - Gerlach, Inga
AU  - Gerlach I
AD  - Center of Integrated Protein Science Munich, University Hospital, Ludwig
      Maximilian University of Munich, 80337 Munich, Germany.
AD  - Division of Clinical Pharmacology, Department of Medicine IV, University
      Hospital, Ludwig Maximilian University of Munich, 80337 Munich, Germany.
AD  - German Center for Lung Research, 81377 Munich, Germany.
FAU - Voigt, Sebastian
AU  - Voigt S
AD  - Brustzentrum Klinikum Dritter Orden, 80638 Munich, Germany.
FAU - Stathopoulos, Georgios T
AU  - Stathopoulos GT
AD  - Comprehensive Pneumology Center, Ludwig Maximilian University of Munich, 80337
      Munich, Germany.
AD  - Institute for Lung Biology and Disease, University Hospital, Ludwig Maximilian
      University of Munich, 80337 Munich, Germany.
AD  - German Center for Lung Research, 81377 Munich, Germany.
AD  - Laboratory for Molecular Respiratory Carcinogenesis, Department of Physiology,
      University of Patras, Rio, Achaia, 26504 Greece.
AD  - Faculty of Medicine, University of Patras, Rio, Achaia, 26504 Greece.
FAU - Arendt, Kristina A M
AU  - Arendt KAM
AD  - Comprehensive Pneumology Center, Ludwig Maximilian University of Munich, 80337
      Munich, Germany.
AD  - Institute for Lung Biology and Disease, University Hospital, Ludwig Maximilian
      University of Munich, 80337 Munich, Germany.
AD  - Helmholtz Zentrum Munchen, 81377 Munich, Germany.
AD  - German Center for Lung Research, 81377 Munich, Germany.
FAU - Heise, Constanze
AU  - Heise C
AD  - Center of Integrated Protein Science Munich, University Hospital, Ludwig
      Maximilian University of Munich, 80337 Munich, Germany.
AD  - Division of Clinical Pharmacology, Department of Medicine IV, University
      Hospital, Ludwig Maximilian University of Munich, 80337 Munich, Germany.
AD  - German Center for Lung Research, 81377 Munich, Germany.
FAU - Rataj, Felicitas
AU  - Rataj F
AD  - Center of Integrated Protein Science Munich, University Hospital, Ludwig
      Maximilian University of Munich, 80337 Munich, Germany.
AD  - Division of Clinical Pharmacology, Department of Medicine IV, University
      Hospital, Ludwig Maximilian University of Munich, 80337 Munich, Germany.
AD  - German Center for Lung Research, 81377 Munich, Germany.
FAU - Janssen, Klaus-Peter
AU  - Janssen KP
AD  - Chirurgische Klinik und Poliklinik, Klinikum rechts der Isar, Technische
      Universitat, 81675 Munich, Germany.
FAU - Konigshoff, Melanie
AU  - Konigshoff M
AD  - Comprehensive Pneumology Center, Ludwig Maximilian University of Munich, 80337
      Munich, Germany.
AD  - Institute for Lung Biology and Disease, University Hospital, Ludwig Maximilian
      University of Munich, 80337 Munich, Germany.
AD  - Helmholtz Zentrum Munchen, 81377 Munich, Germany.
AD  - German Center for Lung Research, 81377 Munich, Germany.
FAU - Winter, Hauke
AU  - Winter H
AD  - German Center for Lung Research, 81377 Munich, Germany.
AD  - Department of Thoracic Surgery, University Hospital, Ludwig Maximilian University
      of Munich, 81377 Munich, Germany.
FAU - Himsl, Isabelle
AU  - Himsl I
AD  - Brustzentrum Klinikum Dritter Orden, 80638 Munich, Germany.
FAU - Thasler, Wolfgang E
AU  - Thasler WE
AD  - Biobank, Department of General, Visceral and Transplantation Surgery, University 
      Hospital, Ludwig Maximilian University of Munich, 81377 Munich, Germany.
FAU - Schnurr, Max
AU  - Schnurr M
AD  - Center of Integrated Protein Science Munich, University Hospital, Ludwig
      Maximilian University of Munich, 80337 Munich, Germany.
AD  - Division of Clinical Pharmacology, Department of Medicine IV, University
      Hospital, Ludwig Maximilian University of Munich, 80337 Munich, Germany.
AD  - German Center for Lung Research, 81377 Munich, Germany.
FAU - Rothenfusser, Simon
AU  - Rothenfusser S
AD  - Center of Integrated Protein Science Munich, University Hospital, Ludwig
      Maximilian University of Munich, 80337 Munich, Germany.
AD  - Division of Clinical Pharmacology, Department of Medicine IV, University
      Hospital, Ludwig Maximilian University of Munich, 80337 Munich, Germany.
AD  - German Center for Lung Research, 81377 Munich, Germany.
FAU - Endres, Stefan
AU  - Endres S
AD  - Center of Integrated Protein Science Munich, University Hospital, Ludwig
      Maximilian University of Munich, 80337 Munich, Germany.
AD  - Division of Clinical Pharmacology, Department of Medicine IV, University
      Hospital, Ludwig Maximilian University of Munich, 80337 Munich, Germany.
AD  - German Center for Lung Research, 81377 Munich, Germany.
FAU - Kobold, Sebastian
AU  - Kobold S
AUID- ORCID: http://orcid.org/0000-0002-5612-4673
AD  - Center of Integrated Protein Science Munich, University Hospital, Ludwig
      Maximilian University of Munich, 80337 Munich, Germany;
      sebastian.kobold@med.uni-muenchen.de.
AD  - Division of Clinical Pharmacology, Department of Medicine IV, University
      Hospital, Ludwig Maximilian University of Munich, 80337 Munich, Germany.
AD  - German Center for Lung Research, 81377 Munich, Germany.
LA  - eng
PT  - Journal Article
DEP - 20171117
PL  - United States
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
PMC - PMC5724250
OTO - NOTNLM
OT  - anakinra
OT  - cancer immunology
OT  - inflammasome
OT  - interleukin-1
OT  - interleukin-22
COIS- The authors declare no conflict of interest.
EDAT- 2017/11/19 06:00
MHDA- 2017/11/19 06:00
CRDT- 2017/11/19 06:00
PMCR- 2018/06/05 00:00
PHST- 2018/06/05 00:00 [pmc-release]
PHST- 2017/11/19 06:00 [pubmed]
PHST- 2017/11/19 06:00 [medline]
PHST- 2017/11/19 06:00 [entrez]
AID - 1705165114 [pii]
AID - 10.1073/pnas.1705165114 [doi]
PST - ppublish
SO  - Proc Natl Acad Sci U S A. 2017 Dec 5;114(49):12994-12999. doi:
      10.1073/pnas.1705165114. Epub 2017 Nov 17.

PMID- 29198524
OWN - NLM
STAT- MEDLINE
DCOM- 20171228
LR  - 20171228
IS  - 1097-4172 (Electronic)
IS  - 0092-8674 (Linking)
VI  - 171
IP  - 7
DP  - 2017 Dec 14
TI  - Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in
      Head and Neck Cancer.
PG  - 1611-1624.e24
LID - S0092-8674(17)31270-9 [pii]
LID - 10.1016/j.cell.2017.10.044 [doi]
AB  - The diverse malignant, stromal, and immune cells in tumors affect growth,
      metastasis, and response to therapy. We profiled transcriptomes of approximately 
      6,000 single cells from 18 head and neck squamous cell carcinoma (HNSCC)
      patients, including five matched pairs of primary tumors and lymph node
      metastases. Stromal and immune cells had consistent expression programs across
      patients. Conversely, malignant cells varied within and between tumors in their
      expression of signatures related to cell cycle, stress, hypoxia, epithelial
      differentiation, and partial epithelial-to-mesenchymal transition (p-EMT). Cells 
      expressing the p-EMT program spatially localized to the leading edge of primary
      tumors. By integrating single-cell transcriptomes with bulk expression profiles
      for hundreds of tumors, we refined HNSCC subtypes by their malignant and stromal 
      composition and established p-EMT as an independent predictor of nodal
      metastasis, grade, and adverse pathologic features. Our results provide insight
      into the HNSCC ecosystem and define stromal interactions and a p-EMT program
      associated with metastasis.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Puram, Sidharth V
AU  - Puram SV
AD  - Department of Pathology and Center for Cancer Research, Massachusetts General
      Hospital and Harvard Medical School, Boston, MA 02114, USA; Broad Institute of
      Harvard and MIT, Cambridge, MA 02142, USA; Department of Otolaryngology,
      Massachusetts Eye and Ear Infirmary, Boston, MA 02114, USA; Department of Otology
      and Laryngology, Harvard Medical School, Boston, MA 02115, USA.
FAU - Tirosh, Itay
AU  - Tirosh I
AD  - Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Department of
      Molecular Cell Biology, Weizmann Institute of Science, 7610001 Rehovot, Israel.
      Electronic address: itay.tirosh@weizmann.ac.il.
FAU - Parikh, Anuraag S
AU  - Parikh AS
AD  - Department of Pathology and Center for Cancer Research, Massachusetts General
      Hospital and Harvard Medical School, Boston, MA 02114, USA; Broad Institute of
      Harvard and MIT, Cambridge, MA 02142, USA; Department of Otolaryngology,
      Massachusetts Eye and Ear Infirmary, Boston, MA 02114, USA; Department of Otology
      and Laryngology, Harvard Medical School, Boston, MA 02115, USA.
FAU - Patel, Anoop P
AU  - Patel AP
AD  - Department of Pathology and Center for Cancer Research, Massachusetts General
      Hospital and Harvard Medical School, Boston, MA 02114, USA; Broad Institute of
      Harvard and MIT, Cambridge, MA 02142, USA; Department of Neurosurgery,
      Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
FAU - Yizhak, Keren
AU  - Yizhak K
AD  - Department of Pathology and Center for Cancer Research, Massachusetts General
      Hospital and Harvard Medical School, Boston, MA 02114, USA; Broad Institute of
      Harvard and MIT, Cambridge, MA 02142, USA.
FAU - Gillespie, Shawn
AU  - Gillespie S
AD  - Department of Pathology and Center for Cancer Research, Massachusetts General
      Hospital and Harvard Medical School, Boston, MA 02114, USA; Broad Institute of
      Harvard and MIT, Cambridge, MA 02142, USA.
FAU - Rodman, Christopher
AU  - Rodman C
AD  - Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
FAU - Luo, Christina L
AU  - Luo CL
AD  - Department of Pathology and Center for Cancer Research, Massachusetts General
      Hospital and Harvard Medical School, Boston, MA 02114, USA.
FAU - Mroz, Edmund A
AU  - Mroz EA
AD  - Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Boston, MA
      02114, USA; Department of Otology and Laryngology, Harvard Medical School,
      Boston, MA 02115, USA; Department of Otolaryngology, Ohio State University,
      Columbus, OH 43210, USA.
FAU - Emerick, Kevin S
AU  - Emerick KS
AD  - Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Boston, MA
      02114, USA; Department of Otology and Laryngology, Harvard Medical School,
      Boston, MA 02115, USA.
FAU - Deschler, Daniel G
AU  - Deschler DG
AD  - Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Boston, MA
      02114, USA; Department of Otology and Laryngology, Harvard Medical School,
      Boston, MA 02115, USA.
FAU - Varvares, Mark A
AU  - Varvares MA
AD  - Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Boston, MA
      02114, USA; Department of Otology and Laryngology, Harvard Medical School,
      Boston, MA 02115, USA.
FAU - Mylvaganam, Ravi
AU  - Mylvaganam R
AD  - Department of Pathology and Center for Cancer Research, Massachusetts General
      Hospital and Harvard Medical School, Boston, MA 02114, USA.
FAU - Rozenblatt-Rosen, Orit
AU  - Rozenblatt-Rosen O
AD  - Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
FAU - Rocco, James W
AU  - Rocco JW
AD  - Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Boston, MA
      02114, USA; Department of Otology and Laryngology, Harvard Medical School,
      Boston, MA 02115, USA; Department of Otolaryngology, Ohio State University,
      Columbus, OH 43210, USA.
FAU - Faquin, William C
AU  - Faquin WC
AD  - Department of Pathology and Center for Cancer Research, Massachusetts General
      Hospital and Harvard Medical School, Boston, MA 02114, USA.
FAU - Lin, Derrick T
AU  - Lin DT
AD  - Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Boston, MA
      02114, USA; Department of Otology and Laryngology, Harvard Medical School,
      Boston, MA 02115, USA. Electronic address: derrick_lin@meei.harvard.edu.
FAU - Regev, Aviv
AU  - Regev A
AD  - Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Department of
      Biology and Koch Institute, MIT, Boston, MA 02142, USA; Howard Hughes Medical
      Institute, Chevy Chase, MD 20815, USA. Electronic address:
      aregev@broadinstitute.org.
FAU - Bernstein, Bradley E
AU  - Bernstein BE
AD  - Department of Pathology and Center for Cancer Research, Massachusetts General
      Hospital and Harvard Medical School, Boston, MA 02114, USA; Broad Institute of
      Harvard and MIT, Cambridge, MA 02142, USA. Electronic address:
      bernstein.bradley@mgh.harvard.edu.
LA  - eng
PT  - Journal Article
DEP - 20171130
PL  - United States
TA  - Cell
JT  - Cell
JID - 0413066
SB  - IM
MH  - Carcinoma, Squamous Cell/genetics/*pathology
MH  - Cells, Cultured
MH  - Epithelial-Mesenchymal Transition
MH  - Gene Expression Profiling
MH  - Head and Neck Neoplasms/genetics/*pathology
MH  - Humans
MH  - Male
MH  - Neoplasm Metastasis/*pathology
MH  - Single-Cell Analysis
MH  - Tumor Microenvironment
OTO - NOTNLM
OT  - epithelial-to-mesenchymal transition
OT  - head and neck squamous cell carcinoma
OT  - intra-tumoral heterogeneity
OT  - metastasis
OT  - scRNA-seq
OT  - single-cell RNA sequencing
OT  - tumor microenvironment
EDAT- 2017/12/05 06:00
MHDA- 2017/12/29 06:00
CRDT- 2017/12/05 06:00
PHST- 2017/04/05 00:00 [received]
PHST- 2017/08/17 00:00 [revised]
PHST- 2017/10/25 00:00 [accepted]
PHST- 2017/12/05 06:00 [pubmed]
PHST- 2017/12/29 06:00 [medline]
PHST- 2017/12/05 06:00 [entrez]
AID - S0092-8674(17)31270-9 [pii]
AID - 10.1016/j.cell.2017.10.044 [doi]
PST - ppublish
SO  - Cell. 2017 Dec 14;171(7):1611-1624.e24. doi: 10.1016/j.cell.2017.10.044. Epub
      2017 Nov 30.

PMID- 29326430
OWN - NLM
STAT- In-Data-Review
LR  - 20180129
IS  - 1474-1768 (Electronic)
IS  - 1474-175X (Linking)
VI  - 18
IP  - 2
DP  - 2018 Feb
TI  - EMT in cancer.
PG  - 128-134
LID - 10.1038/nrc.2017.118 [doi]
AB  - Similar to embryonic development, changes in cell phenotypes defined as an
      epithelial to mesenchymal transition (EMT) have been shown to play a role in the 
      tumorigenic process. Although the first description of EMT in cancer was in cell 
      cultures, evidence for its role in vivo is now widely reported but also actively 
      debated. Moreover, current research has exemplified just how complex this
      phenomenon is in cancer, leaving many exciting, open questions for researchers to
      answer in the future. With these points in mind, we asked four scientists for
      their opinions on the role of EMT in cancer and the challenges faced by
      scientists working in this fast-moving field.
FAU - Brabletz, Thomas
AU  - Brabletz T
AD  - Department of Experimental Medicine 1, Nikolaus-Fiebiger Center for Molecular
      Medicine, FAU University Erlangen-Nurnberg, Gluckstr. 6, 91054 Erlangen, Germany.
FAU - Kalluri, Raghu
AU  - Kalluri R
AD  - Department of Cancer Biology, Metastasis Research Center, University of Texas MD 
      Anderson Cancer Center, Houston, Texas 77054, USA.
FAU - Nieto, M Angela
AU  - Nieto MA
AD  - Instituto de Neurociencias CSIC-UMH, Avda. Ramon y Cajal s/n, 03550 San Juan de
      Alicante, Spain.
FAU - Weinberg, Robert A
AU  - Weinberg RA
AD  - Whitehead Institute for Biomedical Research, Ludwig Massachusetts Institute for
      Technology (MIT) Center for Molecular Oncology and MIT Department of Biology,
      Cambridge, Massachusetts 02142, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180112
PL  - England
TA  - Nat Rev Cancer
JT  - Nature reviews. Cancer
JID - 101124168
EDAT- 2018/01/13 06:00
MHDA- 2018/01/13 06:00
CRDT- 2018/01/13 06:00
PHST- 2018/01/13 06:00 [pubmed]
PHST- 2018/01/13 06:00 [medline]
PHST- 2018/01/13 06:00 [entrez]
AID - nrc.2017.118 [pii]
AID - 10.1038/nrc.2017.118 [doi]
PST - ppublish
SO  - Nat Rev Cancer. 2018 Feb;18(2):128-134. doi: 10.1038/nrc.2017.118. Epub 2018 Jan 
      12.

PMID- 29342393
OWN - NLM
STAT- MEDLINE
DCOM- 20180124
LR  - 20180124
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 378
IP  - 3
DP  - 2018 Jan 18
TI  - Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.
PG  - 230-240
LID - 10.1056/NEJMoa1708618 [doi]
AB  - BACKGROUND: Treatment of newly diagnosed advanced-stage ovarian cancer typically 
      involves cytoreductive surgery and systemic chemotherapy. We conducted a trial to
      investigate whether the addition of hyperthermic intraperitoneal chemotherapy
      (HIPEC) to interval cytoreductive surgery would improve outcomes among patients
      who were receiving neoadjuvant chemotherapy for stage III epithelial ovarian
      cancer. METHODS: In a multicenter, open-label, phase 3 trial, we randomly
      assigned 245 patients who had at least stable disease after three cycles of
      carboplatin (area under the curve of 5 to 6 mg per milliliter per minute) and
      paclitaxel (175 mg per square meter of body-surface area) to undergo interval
      cytoreductive surgery either with or without administration of HIPEC with
      cisplatin (100 mg per square meter). Randomization was performed at the time of
      surgery in cases in which surgery that would result in no visible disease
      (complete cytoreduction) or surgery after which one or more residual tumors
      measuring 10 mm or less in diameter remain (optimal cytoreduction) was deemed to 
      be feasible. Three additional cycles of carboplatin and paclitaxel were
      administered postoperatively. The primary end point was recurrence-free survival.
      Overall survival and the side-effect profile were key secondary end points.
      RESULTS: In the intention-to-treat analysis, events of disease recurrence or
      death occurred in 110 of the 123 patients (89%) who underwent cytoreductive
      surgery without HIPEC (surgery group) and in 99 of the 122 patients (81%) who
      underwent cytoreductive surgery with HIPEC (surgery-plus-HIPEC group) (hazard
      ratio for disease recurrence or death, 0.66; 95% confidence interval [CI], 0.50
      to 0.87; P=0.003). The median recurrence-free survival was 10.7 months in the
      surgery group and 14.2 months in the surgery-plus-HIPEC group. At a median
      follow-up of 4.7 years, 76 patients (62%) in the surgery group and 61 patients
      (50%) in the surgery-plus-HIPEC group had died (hazard ratio, 0.67; 95% CI, 0.48 
      to 0.94; P=0.02). The median overall survival was 33.9 months in the surgery
      group and 45.7 months in the surgery-plus-HIPEC group. The percentage of patients
      who had adverse events of grade 3 or 4 was similar in the two groups (25% in the 
      surgery group and 27% in the surgery-plus-HIPEC group, P=0.76). CONCLUSIONS:
      Among patients with stage III epithelial ovarian cancer, the addition of HIPEC to
      interval cytoreductive surgery resulted in longer recurrence-free survival and
      overall survival than surgery alone and did not result in higher rates of side
      effects. (Funded by the Dutch Cancer Society; ClinicalTrials.gov number,
      NCT00426257 ; EudraCT number, 2006-003466-34 .).
FAU - van Driel, Willemien J
AU  - van Driel WJ
AD  - From the Departments of Gynecology (W.J.D., S.N.K.), Biometrics (K.S., H.T.),
      Surgical Oncology (A.G.J.A.), Pathology (K.K.V.V.), and Medical Oncology (S.N.K.,
      G.S.S.) and the Division of Psychosocial Research and Epidemiology (J.M.K.,
      N.K.A.), the Netherlands Cancer Institute, Amsterdam, the Center for Gynecologic 
      Oncology Amsterdam, Amsterdam (W.J.D., S.N.K., J.V.), the Dutch Gynecologic
      Oncology Group (W.J.D., J.H.S.L., H.W.R.S., R.H.M.H., J.V., H.J.A., L.F.A.G.M.,
      G.S.S.), the Department of Obstetrics and Gynecology, Academic Medical Center,
      Amsterdam (J.V.), the Department of Obstetrics and Gynecology, Sint Antonius
      Hospital, Nieuwegein (J.H.S.L.), the Department of Gynecologic Oncology, UMC
      Utrecht Cancer Center, University Medical Center Utrecht, Utrecht (H.W.R.S.), the
      Departments of Gynecology and Obstetrics (R.H.M.H.) and Surgery (I.H.J.T.H.),
      Catharina Hospital, Eindhoven, the Dutch Peritoneal Oncology Group (I.H.J.T.H.,
      A.G.J.A.), the Department of Gynecologic Oncology, University of Groningen,
      University Medical Center Groningen, Groningen (H.J.A.), and the Department of
      Gynecologic Oncology, Radboud University Medical Center, Nijmegen (L.F.A.G.M.) - 
      all in the Netherlands; and the Department of Surgery, Aarhus University
      Hospital, Aarhus, Denmark (V.J.V.).
FAU - Koole, Simone N
AU  - Koole SN
AD  - From the Departments of Gynecology (W.J.D., S.N.K.), Biometrics (K.S., H.T.),
      Surgical Oncology (A.G.J.A.), Pathology (K.K.V.V.), and Medical Oncology (S.N.K.,
      G.S.S.) and the Division of Psychosocial Research and Epidemiology (J.M.K.,
      N.K.A.), the Netherlands Cancer Institute, Amsterdam, the Center for Gynecologic 
      Oncology Amsterdam, Amsterdam (W.J.D., S.N.K., J.V.), the Dutch Gynecologic
      Oncology Group (W.J.D., J.H.S.L., H.W.R.S., R.H.M.H., J.V., H.J.A., L.F.A.G.M.,
      G.S.S.), the Department of Obstetrics and Gynecology, Academic Medical Center,
      Amsterdam (J.V.), the Department of Obstetrics and Gynecology, Sint Antonius
      Hospital, Nieuwegein (J.H.S.L.), the Department of Gynecologic Oncology, UMC
      Utrecht Cancer Center, University Medical Center Utrecht, Utrecht (H.W.R.S.), the
      Departments of Gynecology and Obstetrics (R.H.M.H.) and Surgery (I.H.J.T.H.),
      Catharina Hospital, Eindhoven, the Dutch Peritoneal Oncology Group (I.H.J.T.H.,
      A.G.J.A.), the Department of Gynecologic Oncology, University of Groningen,
      University Medical Center Groningen, Groningen (H.J.A.), and the Department of
      Gynecologic Oncology, Radboud University Medical Center, Nijmegen (L.F.A.G.M.) - 
      all in the Netherlands; and the Department of Surgery, Aarhus University
      Hospital, Aarhus, Denmark (V.J.V.).
FAU - Sikorska, Karolina
AU  - Sikorska K
AD  - From the Departments of Gynecology (W.J.D., S.N.K.), Biometrics (K.S., H.T.),
      Surgical Oncology (A.G.J.A.), Pathology (K.K.V.V.), and Medical Oncology (S.N.K.,
      G.S.S.) and the Division of Psychosocial Research and Epidemiology (J.M.K.,
      N.K.A.), the Netherlands Cancer Institute, Amsterdam, the Center for Gynecologic 
      Oncology Amsterdam, Amsterdam (W.J.D., S.N.K., J.V.), the Dutch Gynecologic
      Oncology Group (W.J.D., J.H.S.L., H.W.R.S., R.H.M.H., J.V., H.J.A., L.F.A.G.M.,
      G.S.S.), the Department of Obstetrics and Gynecology, Academic Medical Center,
      Amsterdam (J.V.), the Department of Obstetrics and Gynecology, Sint Antonius
      Hospital, Nieuwegein (J.H.S.L.), the Department of Gynecologic Oncology, UMC
      Utrecht Cancer Center, University Medical Center Utrecht, Utrecht (H.W.R.S.), the
      Departments of Gynecology and Obstetrics (R.H.M.H.) and Surgery (I.H.J.T.H.),
      Catharina Hospital, Eindhoven, the Dutch Peritoneal Oncology Group (I.H.J.T.H.,
      A.G.J.A.), the Department of Gynecologic Oncology, University of Groningen,
      University Medical Center Groningen, Groningen (H.J.A.), and the Department of
      Gynecologic Oncology, Radboud University Medical Center, Nijmegen (L.F.A.G.M.) - 
      all in the Netherlands; and the Department of Surgery, Aarhus University
      Hospital, Aarhus, Denmark (V.J.V.).
FAU - Schagen van Leeuwen, Jules H
AU  - Schagen van Leeuwen JH
AD  - From the Departments of Gynecology (W.J.D., S.N.K.), Biometrics (K.S., H.T.),
      Surgical Oncology (A.G.J.A.), Pathology (K.K.V.V.), and Medical Oncology (S.N.K.,
      G.S.S.) and the Division of Psychosocial Research and Epidemiology (J.M.K.,
      N.K.A.), the Netherlands Cancer Institute, Amsterdam, the Center for Gynecologic 
      Oncology Amsterdam, Amsterdam (W.J.D., S.N.K., J.V.), the Dutch Gynecologic
      Oncology Group (W.J.D., J.H.S.L., H.W.R.S., R.H.M.H., J.V., H.J.A., L.F.A.G.M.,
      G.S.S.), the Department of Obstetrics and Gynecology, Academic Medical Center,
      Amsterdam (J.V.), the Department of Obstetrics and Gynecology, Sint Antonius
      Hospital, Nieuwegein (J.H.S.L.), the Department of Gynecologic Oncology, UMC
      Utrecht Cancer Center, University Medical Center Utrecht, Utrecht (H.W.R.S.), the
      Departments of Gynecology and Obstetrics (R.H.M.H.) and Surgery (I.H.J.T.H.),
      Catharina Hospital, Eindhoven, the Dutch Peritoneal Oncology Group (I.H.J.T.H.,
      A.G.J.A.), the Department of Gynecologic Oncology, University of Groningen,
      University Medical Center Groningen, Groningen (H.J.A.), and the Department of
      Gynecologic Oncology, Radboud University Medical Center, Nijmegen (L.F.A.G.M.) - 
      all in the Netherlands; and the Department of Surgery, Aarhus University
      Hospital, Aarhus, Denmark (V.J.V.).
FAU - Schreuder, Henk W R
AU  - Schreuder HWR
AD  - From the Departments of Gynecology (W.J.D., S.N.K.), Biometrics (K.S., H.T.),
      Surgical Oncology (A.G.J.A.), Pathology (K.K.V.V.), and Medical Oncology (S.N.K.,
      G.S.S.) and the Division of Psychosocial Research and Epidemiology (J.M.K.,
      N.K.A.), the Netherlands Cancer Institute, Amsterdam, the Center for Gynecologic 
      Oncology Amsterdam, Amsterdam (W.J.D., S.N.K., J.V.), the Dutch Gynecologic
      Oncology Group (W.J.D., J.H.S.L., H.W.R.S., R.H.M.H., J.V., H.J.A., L.F.A.G.M.,
      G.S.S.), the Department of Obstetrics and Gynecology, Academic Medical Center,
      Amsterdam (J.V.), the Department of Obstetrics and Gynecology, Sint Antonius
      Hospital, Nieuwegein (J.H.S.L.), the Department of Gynecologic Oncology, UMC
      Utrecht Cancer Center, University Medical Center Utrecht, Utrecht (H.W.R.S.), the
      Departments of Gynecology and Obstetrics (R.H.M.H.) and Surgery (I.H.J.T.H.),
      Catharina Hospital, Eindhoven, the Dutch Peritoneal Oncology Group (I.H.J.T.H.,
      A.G.J.A.), the Department of Gynecologic Oncology, University of Groningen,
      University Medical Center Groningen, Groningen (H.J.A.), and the Department of
      Gynecologic Oncology, Radboud University Medical Center, Nijmegen (L.F.A.G.M.) - 
      all in the Netherlands; and the Department of Surgery, Aarhus University
      Hospital, Aarhus, Denmark (V.J.V.).
FAU - Hermans, Ralph H M
AU  - Hermans RHM
AD  - From the Departments of Gynecology (W.J.D., S.N.K.), Biometrics (K.S., H.T.),
      Surgical Oncology (A.G.J.A.), Pathology (K.K.V.V.), and Medical Oncology (S.N.K.,
      G.S.S.) and the Division of Psychosocial Research and Epidemiology (J.M.K.,
      N.K.A.), the Netherlands Cancer Institute, Amsterdam, the Center for Gynecologic 
      Oncology Amsterdam, Amsterdam (W.J.D., S.N.K., J.V.), the Dutch Gynecologic
      Oncology Group (W.J.D., J.H.S.L., H.W.R.S., R.H.M.H., J.V., H.J.A., L.F.A.G.M.,
      G.S.S.), the Department of Obstetrics and Gynecology, Academic Medical Center,
      Amsterdam (J.V.), the Department of Obstetrics and Gynecology, Sint Antonius
      Hospital, Nieuwegein (J.H.S.L.), the Department of Gynecologic Oncology, UMC
      Utrecht Cancer Center, University Medical Center Utrecht, Utrecht (H.W.R.S.), the
      Departments of Gynecology and Obstetrics (R.H.M.H.) and Surgery (I.H.J.T.H.),
      Catharina Hospital, Eindhoven, the Dutch Peritoneal Oncology Group (I.H.J.T.H.,
      A.G.J.A.), the Department of Gynecologic Oncology, University of Groningen,
      University Medical Center Groningen, Groningen (H.J.A.), and the Department of
      Gynecologic Oncology, Radboud University Medical Center, Nijmegen (L.F.A.G.M.) - 
      all in the Netherlands; and the Department of Surgery, Aarhus University
      Hospital, Aarhus, Denmark (V.J.V.).
FAU - de Hingh, Ignace H J T
AU  - de Hingh IHJT
AD  - From the Departments of Gynecology (W.J.D., S.N.K.), Biometrics (K.S., H.T.),
      Surgical Oncology (A.G.J.A.), Pathology (K.K.V.V.), and Medical Oncology (S.N.K.,
      G.S.S.) and the Division of Psychosocial Research and Epidemiology (J.M.K.,
      N.K.A.), the Netherlands Cancer Institute, Amsterdam, the Center for Gynecologic 
      Oncology Amsterdam, Amsterdam (W.J.D., S.N.K., J.V.), the Dutch Gynecologic
      Oncology Group (W.J.D., J.H.S.L., H.W.R.S., R.H.M.H., J.V., H.J.A., L.F.A.G.M.,
      G.S.S.), the Department of Obstetrics and Gynecology, Academic Medical Center,
      Amsterdam (J.V.), the Department of Obstetrics and Gynecology, Sint Antonius
      Hospital, Nieuwegein (J.H.S.L.), the Department of Gynecologic Oncology, UMC
      Utrecht Cancer Center, University Medical Center Utrecht, Utrecht (H.W.R.S.), the
      Departments of Gynecology and Obstetrics (R.H.M.H.) and Surgery (I.H.J.T.H.),
      Catharina Hospital, Eindhoven, the Dutch Peritoneal Oncology Group (I.H.J.T.H.,
      A.G.J.A.), the Department of Gynecologic Oncology, University of Groningen,
      University Medical Center Groningen, Groningen (H.J.A.), and the Department of
      Gynecologic Oncology, Radboud University Medical Center, Nijmegen (L.F.A.G.M.) - 
      all in the Netherlands; and the Department of Surgery, Aarhus University
      Hospital, Aarhus, Denmark (V.J.V.).
FAU - van der Velden, Jacobus
AU  - van der Velden J
AD  - From the Departments of Gynecology (W.J.D., S.N.K.), Biometrics (K.S., H.T.),
      Surgical Oncology (A.G.J.A.), Pathology (K.K.V.V.), and Medical Oncology (S.N.K.,
      G.S.S.) and the Division of Psychosocial Research and Epidemiology (J.M.K.,
      N.K.A.), the Netherlands Cancer Institute, Amsterdam, the Center for Gynecologic 
      Oncology Amsterdam, Amsterdam (W.J.D., S.N.K., J.V.), the Dutch Gynecologic
      Oncology Group (W.J.D., J.H.S.L., H.W.R.S., R.H.M.H., J.V., H.J.A., L.F.A.G.M.,
      G.S.S.), the Department of Obstetrics and Gynecology, Academic Medical Center,
      Amsterdam (J.V.), the Department of Obstetrics and Gynecology, Sint Antonius
      Hospital, Nieuwegein (J.H.S.L.), the Department of Gynecologic Oncology, UMC
      Utrecht Cancer Center, University Medical Center Utrecht, Utrecht (H.W.R.S.), the
      Departments of Gynecology and Obstetrics (R.H.M.H.) and Surgery (I.H.J.T.H.),
      Catharina Hospital, Eindhoven, the Dutch Peritoneal Oncology Group (I.H.J.T.H.,
      A.G.J.A.), the Department of Gynecologic Oncology, University of Groningen,
      University Medical Center Groningen, Groningen (H.J.A.), and the Department of
      Gynecologic Oncology, Radboud University Medical Center, Nijmegen (L.F.A.G.M.) - 
      all in the Netherlands; and the Department of Surgery, Aarhus University
      Hospital, Aarhus, Denmark (V.J.V.).
FAU - Arts, Henriette J
AU  - Arts HJ
AD  - From the Departments of Gynecology (W.J.D., S.N.K.), Biometrics (K.S., H.T.),
      Surgical Oncology (A.G.J.A.), Pathology (K.K.V.V.), and Medical Oncology (S.N.K.,
      G.S.S.) and the Division of Psychosocial Research and Epidemiology (J.M.K.,
      N.K.A.), the Netherlands Cancer Institute, Amsterdam, the Center for Gynecologic 
      Oncology Amsterdam, Amsterdam (W.J.D., S.N.K., J.V.), the Dutch Gynecologic
      Oncology Group (W.J.D., J.H.S.L., H.W.R.S., R.H.M.H., J.V., H.J.A., L.F.A.G.M.,
      G.S.S.), the Department of Obstetrics and Gynecology, Academic Medical Center,
      Amsterdam (J.V.), the Department of Obstetrics and Gynecology, Sint Antonius
      Hospital, Nieuwegein (J.H.S.L.), the Department of Gynecologic Oncology, UMC
      Utrecht Cancer Center, University Medical Center Utrecht, Utrecht (H.W.R.S.), the
      Departments of Gynecology and Obstetrics (R.H.M.H.) and Surgery (I.H.J.T.H.),
      Catharina Hospital, Eindhoven, the Dutch Peritoneal Oncology Group (I.H.J.T.H.,
      A.G.J.A.), the Department of Gynecologic Oncology, University of Groningen,
      University Medical Center Groningen, Groningen (H.J.A.), and the Department of
      Gynecologic Oncology, Radboud University Medical Center, Nijmegen (L.F.A.G.M.) - 
      all in the Netherlands; and the Department of Surgery, Aarhus University
      Hospital, Aarhus, Denmark (V.J.V.).
FAU - Massuger, Leon F A G
AU  - Massuger LFAG
AD  - From the Departments of Gynecology (W.J.D., S.N.K.), Biometrics (K.S., H.T.),
      Surgical Oncology (A.G.J.A.), Pathology (K.K.V.V.), and Medical Oncology (S.N.K.,
      G.S.S.) and the Division of Psychosocial Research and Epidemiology (J.M.K.,
      N.K.A.), the Netherlands Cancer Institute, Amsterdam, the Center for Gynecologic 
      Oncology Amsterdam, Amsterdam (W.J.D., S.N.K., J.V.), the Dutch Gynecologic
      Oncology Group (W.J.D., J.H.S.L., H.W.R.S., R.H.M.H., J.V., H.J.A., L.F.A.G.M.,
      G.S.S.), the Department of Obstetrics and Gynecology, Academic Medical Center,
      Amsterdam (J.V.), the Department of Obstetrics and Gynecology, Sint Antonius
      Hospital, Nieuwegein (J.H.S.L.), the Department of Gynecologic Oncology, UMC
      Utrecht Cancer Center, University Medical Center Utrecht, Utrecht (H.W.R.S.), the
      Departments of Gynecology and Obstetrics (R.H.M.H.) and Surgery (I.H.J.T.H.),
      Catharina Hospital, Eindhoven, the Dutch Peritoneal Oncology Group (I.H.J.T.H.,
      A.G.J.A.), the Department of Gynecologic Oncology, University of Groningen,
      University Medical Center Groningen, Groningen (H.J.A.), and the Department of
      Gynecologic Oncology, Radboud University Medical Center, Nijmegen (L.F.A.G.M.) - 
      all in the Netherlands; and the Department of Surgery, Aarhus University
      Hospital, Aarhus, Denmark (V.J.V.).
FAU - Aalbers, Arend G J
AU  - Aalbers AGJ
AD  - From the Departments of Gynecology (W.J.D., S.N.K.), Biometrics (K.S., H.T.),
      Surgical Oncology (A.G.J.A.), Pathology (K.K.V.V.), and Medical Oncology (S.N.K.,
      G.S.S.) and the Division of Psychosocial Research and Epidemiology (J.M.K.,
      N.K.A.), the Netherlands Cancer Institute, Amsterdam, the Center for Gynecologic 
      Oncology Amsterdam, Amsterdam (W.J.D., S.N.K., J.V.), the Dutch Gynecologic
      Oncology Group (W.J.D., J.H.S.L., H.W.R.S., R.H.M.H., J.V., H.J.A., L.F.A.G.M.,
      G.S.S.), the Department of Obstetrics and Gynecology, Academic Medical Center,
      Amsterdam (J.V.), the Department of Obstetrics and Gynecology, Sint Antonius
      Hospital, Nieuwegein (J.H.S.L.), the Department of Gynecologic Oncology, UMC
      Utrecht Cancer Center, University Medical Center Utrecht, Utrecht (H.W.R.S.), the
      Departments of Gynecology and Obstetrics (R.H.M.H.) and Surgery (I.H.J.T.H.),
      Catharina Hospital, Eindhoven, the Dutch Peritoneal Oncology Group (I.H.J.T.H.,
      A.G.J.A.), the Department of Gynecologic Oncology, University of Groningen,
      University Medical Center Groningen, Groningen (H.J.A.), and the Department of
      Gynecologic Oncology, Radboud University Medical Center, Nijmegen (L.F.A.G.M.) - 
      all in the Netherlands; and the Department of Surgery, Aarhus University
      Hospital, Aarhus, Denmark (V.J.V.).
FAU - Verwaal, Victor J
AU  - Verwaal VJ
AD  - From the Departments of Gynecology (W.J.D., S.N.K.), Biometrics (K.S., H.T.),
      Surgical Oncology (A.G.J.A.), Pathology (K.K.V.V.), and Medical Oncology (S.N.K.,
      G.S.S.) and the Division of Psychosocial Research and Epidemiology (J.M.K.,
      N.K.A.), the Netherlands Cancer Institute, Amsterdam, the Center for Gynecologic 
      Oncology Amsterdam, Amsterdam (W.J.D., S.N.K., J.V.), the Dutch Gynecologic
      Oncology Group (W.J.D., J.H.S.L., H.W.R.S., R.H.M.H., J.V., H.J.A., L.F.A.G.M.,
      G.S.S.), the Department of Obstetrics and Gynecology, Academic Medical Center,
      Amsterdam (J.V.), the Department of Obstetrics and Gynecology, Sint Antonius
      Hospital, Nieuwegein (J.H.S.L.), the Department of Gynecologic Oncology, UMC
      Utrecht Cancer Center, University Medical Center Utrecht, Utrecht (H.W.R.S.), the
      Departments of Gynecology and Obstetrics (R.H.M.H.) and Surgery (I.H.J.T.H.),
      Catharina Hospital, Eindhoven, the Dutch Peritoneal Oncology Group (I.H.J.T.H.,
      A.G.J.A.), the Department of Gynecologic Oncology, University of Groningen,
      University Medical Center Groningen, Groningen (H.J.A.), and the Department of
      Gynecologic Oncology, Radboud University Medical Center, Nijmegen (L.F.A.G.M.) - 
      all in the Netherlands; and the Department of Surgery, Aarhus University
      Hospital, Aarhus, Denmark (V.J.V.).
FAU - Kieffer, Jacobien M
AU  - Kieffer JM
AD  - From the Departments of Gynecology (W.J.D., S.N.K.), Biometrics (K.S., H.T.),
      Surgical Oncology (A.G.J.A.), Pathology (K.K.V.V.), and Medical Oncology (S.N.K.,
      G.S.S.) and the Division of Psychosocial Research and Epidemiology (J.M.K.,
      N.K.A.), the Netherlands Cancer Institute, Amsterdam, the Center for Gynecologic 
      Oncology Amsterdam, Amsterdam (W.J.D., S.N.K., J.V.), the Dutch Gynecologic
      Oncology Group (W.J.D., J.H.S.L., H.W.R.S., R.H.M.H., J.V., H.J.A., L.F.A.G.M.,
      G.S.S.), the Department of Obstetrics and Gynecology, Academic Medical Center,
      Amsterdam (J.V.), the Department of Obstetrics and Gynecology, Sint Antonius
      Hospital, Nieuwegein (J.H.S.L.), the Department of Gynecologic Oncology, UMC
      Utrecht Cancer Center, University Medical Center Utrecht, Utrecht (H.W.R.S.), the
      Departments of Gynecology and Obstetrics (R.H.M.H.) and Surgery (I.H.J.T.H.),
      Catharina Hospital, Eindhoven, the Dutch Peritoneal Oncology Group (I.H.J.T.H.,
      A.G.J.A.), the Department of Gynecologic Oncology, University of Groningen,
      University Medical Center Groningen, Groningen (H.J.A.), and the Department of
      Gynecologic Oncology, Radboud University Medical Center, Nijmegen (L.F.A.G.M.) - 
      all in the Netherlands; and the Department of Surgery, Aarhus University
      Hospital, Aarhus, Denmark (V.J.V.).
FAU - Van de Vijver, Koen K
AU  - Van de Vijver KK
AD  - From the Departments of Gynecology (W.J.D., S.N.K.), Biometrics (K.S., H.T.),
      Surgical Oncology (A.G.J.A.), Pathology (K.K.V.V.), and Medical Oncology (S.N.K.,
      G.S.S.) and the Division of Psychosocial Research and Epidemiology (J.M.K.,
      N.K.A.), the Netherlands Cancer Institute, Amsterdam, the Center for Gynecologic 
      Oncology Amsterdam, Amsterdam (W.J.D., S.N.K., J.V.), the Dutch Gynecologic
      Oncology Group (W.J.D., J.H.S.L., H.W.R.S., R.H.M.H., J.V., H.J.A., L.F.A.G.M.,
      G.S.S.), the Department of Obstetrics and Gynecology, Academic Medical Center,
      Amsterdam (J.V.), the Department of Obstetrics and Gynecology, Sint Antonius
      Hospital, Nieuwegein (J.H.S.L.), the Department of Gynecologic Oncology, UMC
      Utrecht Cancer Center, University Medical Center Utrecht, Utrecht (H.W.R.S.), the
      Departments of Gynecology and Obstetrics (R.H.M.H.) and Surgery (I.H.J.T.H.),
      Catharina Hospital, Eindhoven, the Dutch Peritoneal Oncology Group (I.H.J.T.H.,
      A.G.J.A.), the Department of Gynecologic Oncology, University of Groningen,
      University Medical Center Groningen, Groningen (H.J.A.), and the Department of
      Gynecologic Oncology, Radboud University Medical Center, Nijmegen (L.F.A.G.M.) - 
      all in the Netherlands; and the Department of Surgery, Aarhus University
      Hospital, Aarhus, Denmark (V.J.V.).
FAU - van Tinteren, Harm
AU  - van Tinteren H
AD  - From the Departments of Gynecology (W.J.D., S.N.K.), Biometrics (K.S., H.T.),
      Surgical Oncology (A.G.J.A.), Pathology (K.K.V.V.), and Medical Oncology (S.N.K.,
      G.S.S.) and the Division of Psychosocial Research and Epidemiology (J.M.K.,
      N.K.A.), the Netherlands Cancer Institute, Amsterdam, the Center for Gynecologic 
      Oncology Amsterdam, Amsterdam (W.J.D., S.N.K., J.V.), the Dutch Gynecologic
      Oncology Group (W.J.D., J.H.S.L., H.W.R.S., R.H.M.H., J.V., H.J.A., L.F.A.G.M.,
      G.S.S.), the Department of Obstetrics and Gynecology, Academic Medical Center,
      Amsterdam (J.V.), the Department of Obstetrics and Gynecology, Sint Antonius
      Hospital, Nieuwegein (J.H.S.L.), the Department of Gynecologic Oncology, UMC
      Utrecht Cancer Center, University Medical Center Utrecht, Utrecht (H.W.R.S.), the
      Departments of Gynecology and Obstetrics (R.H.M.H.) and Surgery (I.H.J.T.H.),
      Catharina Hospital, Eindhoven, the Dutch Peritoneal Oncology Group (I.H.J.T.H.,
      A.G.J.A.), the Department of Gynecologic Oncology, University of Groningen,
      University Medical Center Groningen, Groningen (H.J.A.), and the Department of
      Gynecologic Oncology, Radboud University Medical Center, Nijmegen (L.F.A.G.M.) - 
      all in the Netherlands; and the Department of Surgery, Aarhus University
      Hospital, Aarhus, Denmark (V.J.V.).
FAU - Aaronson, Neil K
AU  - Aaronson NK
AD  - From the Departments of Gynecology (W.J.D., S.N.K.), Biometrics (K.S., H.T.),
      Surgical Oncology (A.G.J.A.), Pathology (K.K.V.V.), and Medical Oncology (S.N.K.,
      G.S.S.) and the Division of Psychosocial Research and Epidemiology (J.M.K.,
      N.K.A.), the Netherlands Cancer Institute, Amsterdam, the Center for Gynecologic 
      Oncology Amsterdam, Amsterdam (W.J.D., S.N.K., J.V.), the Dutch Gynecologic
      Oncology Group (W.J.D., J.H.S.L., H.W.R.S., R.H.M.H., J.V., H.J.A., L.F.A.G.M.,
      G.S.S.), the Department of Obstetrics and Gynecology, Academic Medical Center,
      Amsterdam (J.V.), the Department of Obstetrics and Gynecology, Sint Antonius
      Hospital, Nieuwegein (J.H.S.L.), the Department of Gynecologic Oncology, UMC
      Utrecht Cancer Center, University Medical Center Utrecht, Utrecht (H.W.R.S.), the
      Departments of Gynecology and Obstetrics (R.H.M.H.) and Surgery (I.H.J.T.H.),
      Catharina Hospital, Eindhoven, the Dutch Peritoneal Oncology Group (I.H.J.T.H.,
      A.G.J.A.), the Department of Gynecologic Oncology, University of Groningen,
      University Medical Center Groningen, Groningen (H.J.A.), and the Department of
      Gynecologic Oncology, Radboud University Medical Center, Nijmegen (L.F.A.G.M.) - 
      all in the Netherlands; and the Department of Surgery, Aarhus University
      Hospital, Aarhus, Denmark (V.J.V.).
FAU - Sonke, Gabe S
AU  - Sonke GS
AD  - From the Departments of Gynecology (W.J.D., S.N.K.), Biometrics (K.S., H.T.),
      Surgical Oncology (A.G.J.A.), Pathology (K.K.V.V.), and Medical Oncology (S.N.K.,
      G.S.S.) and the Division of Psychosocial Research and Epidemiology (J.M.K.,
      N.K.A.), the Netherlands Cancer Institute, Amsterdam, the Center for Gynecologic 
      Oncology Amsterdam, Amsterdam (W.J.D., S.N.K., J.V.), the Dutch Gynecologic
      Oncology Group (W.J.D., J.H.S.L., H.W.R.S., R.H.M.H., J.V., H.J.A., L.F.A.G.M.,
      G.S.S.), the Department of Obstetrics and Gynecology, Academic Medical Center,
      Amsterdam (J.V.), the Department of Obstetrics and Gynecology, Sint Antonius
      Hospital, Nieuwegein (J.H.S.L.), the Department of Gynecologic Oncology, UMC
      Utrecht Cancer Center, University Medical Center Utrecht, Utrecht (H.W.R.S.), the
      Departments of Gynecology and Obstetrics (R.H.M.H.) and Surgery (I.H.J.T.H.),
      Catharina Hospital, Eindhoven, the Dutch Peritoneal Oncology Group (I.H.J.T.H.,
      A.G.J.A.), the Department of Gynecologic Oncology, University of Groningen,
      University Medical Center Groningen, Groningen (H.J.A.), and the Department of
      Gynecologic Oncology, Radboud University Medical Center, Nijmegen (L.F.A.G.M.) - 
      all in the Netherlands; and the Department of Surgery, Aarhus University
      Hospital, Aarhus, Denmark (V.J.V.).
LA  - eng
SI  - ClinicalTrials.gov/NCT00426257
PT  - Clinical Trial, Phase III
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - BG3F62OND5 (Carboplatin)
RN  - P88XT4IS4D (Paclitaxel)
RN  - Q20Q21Q62J (Cisplatin)
RN  - Ovarian epithelial cancer
SB  - AIM
SB  - IM
CIN - N Engl J Med. 2018 Jan 18;378(3):293-294. PMID: 29342385
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Carboplatin/administration & dosage
MH  - Cisplatin/*administration & dosage
MH  - Combined Modality Therapy
MH  - *Cytoreduction Surgical Procedures
MH  - Female
MH  - Humans
MH  - *Hyperthermia, Induced
MH  - Intention to Treat Analysis
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Neoplasms, Glandular and Epithelial/*drug therapy/mortality/surgery
MH  - Ovarian Neoplasms/*drug therapy/mortality/surgery
MH  - Paclitaxel/administration & dosage
MH  - Survival Analysis
EDAT- 2018/01/18 06:00
MHDA- 2018/01/25 06:00
CRDT- 2018/01/18 06:00
PHST- 2018/01/18 06:00 [entrez]
PHST- 2018/01/18 06:00 [pubmed]
PHST- 2018/01/25 06:00 [medline]
AID - 10.1056/NEJMoa1708618 [doi]
PST - ppublish
SO  - N Engl J Med. 2018 Jan 18;378(3):230-240. doi: 10.1056/NEJMoa1708618.

PMID- 29295986
OWN - NLM
STAT- In-Data-Review
LR  - 20180115
IS  - 2041-1723 (Electronic)
IS  - 2041-1723 (Linking)
VI  - 9
IP  - 1
DP  - 2018 Jan 2
TI  - Macrophages orchestrate breast cancer early dissemination and metastasis.
PG  - 21
LID - 10.1038/s41467-017-02481-5 [doi]
AB  - Cancer cell dissemination during very early stages of breast cancer proceeds
      through poorly understood mechanisms. Here we show, in a mouse model of HER2(+)
      breast cancer, that a previously described sub-population of early-evolved cancer
      cells requires macrophages for early dissemination. Depletion of macrophages
      specifically during pre-malignant stages reduces early dissemination and also
      results in reduced metastatic burden at end stages of cancer progression.
      Mechanistically, we show that, in pre-malignant lesions, CCL2 produced by cancer 
      cells and myeloid cells attracts CD206(+)/Tie2(+) macrophages and induces Wnt-1
      upregulation that in turn downregulates E-cadherin junctions in the HER2(+) early
      cancer cells. We also observe macrophage-containing tumor microenvironments of
      metastasis structures in the pre-malignant lesions that can operate as portals
      for intravasation. These data support a causal role for macrophages in early
      dissemination that affects long-term metastasis development much later in cancer 
      progression. A pilot analysis on human specimens revealed intra-epithelial
      macrophages and loss of E-cadherin junctions in ductal carcinoma in situ,
      supporting a potential clinical relevance.
FAU - Linde, Nina
AU  - Linde N
AD  - Division of Hematology and Oncology, Department of Medicine, Tisch Cancer
      Institute, Black Family Stem Cell Institute, Icahn School of Medicine at Mount
      Sinai, New York, NY, 10029, USA.
AD  - Department of Otolaryngology, Tisch Cancer Institute, Black Family Stem Cell
      Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
AD  - Merck KGaA, Frankfurter Str. 250, Postcode: A025/301, Darmstadt, 64293, Germany.
FAU - Casanova-Acebes, Maria
AU  - Casanova-Acebes M
AD  - Department of Oncological Sciences, The Immunology Institute, Tisch Cancer
      Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
FAU - Sosa, Maria Soledad
AU  - Sosa MS
AD  - Division of Hematology and Oncology, Department of Medicine, Tisch Cancer
      Institute, Black Family Stem Cell Institute, Icahn School of Medicine at Mount
      Sinai, New York, NY, 10029, USA.
AD  - Department of Otolaryngology, Tisch Cancer Institute, Black Family Stem Cell
      Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
AD  - Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, 
      New York, NY, 10029, USA.
FAU - Mortha, Arthur
AU  - Mortha A
AD  - Department of Oncological Sciences, The Immunology Institute, Tisch Cancer
      Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
AD  - Department of Immunology, University of Toronto, Toronto, ON, M5S 1A8, USA.
FAU - Rahman, Adeeb
AU  - Rahman A
AD  - Human Immune Monitoring Core, Icahn School of Medicine at Mount Sinai, New York, 
      NY, 10029, USA.
FAU - Farias, Eduardo
AU  - Farias E
AD  - Division of Hematology and Oncology, Department of Medicine, Tisch Cancer
      Institute, Black Family Stem Cell Institute, Icahn School of Medicine at Mount
      Sinai, New York, NY, 10029, USA.
AD  - Department of Otolaryngology, Tisch Cancer Institute, Black Family Stem Cell
      Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
FAU - Harper, Kathryn
AU  - Harper K
AD  - Division of Hematology and Oncology, Department of Medicine, Tisch Cancer
      Institute, Black Family Stem Cell Institute, Icahn School of Medicine at Mount
      Sinai, New York, NY, 10029, USA.
AD  - Department of Otolaryngology, Tisch Cancer Institute, Black Family Stem Cell
      Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
FAU - Tardio, Ethan
AU  - Tardio E
AD  - Division of Hematology and Oncology, Department of Medicine, Tisch Cancer
      Institute, Black Family Stem Cell Institute, Icahn School of Medicine at Mount
      Sinai, New York, NY, 10029, USA.
AD  - Department of Otolaryngology, Tisch Cancer Institute, Black Family Stem Cell
      Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
FAU - Reyes Torres, Ivan
AU  - Reyes Torres I
AD  - Department of Oncological Sciences, The Immunology Institute, Tisch Cancer
      Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
FAU - Jones, Joan
AU  - Jones J
AD  - Department of Anatomy and Structural Biology, Integrated Imaging Program, Gruss
      Lipper Biophotonics Center, Albert Einstein College of Medicine, 1300 Morris Park
      Avenue, Bronx, NY, 10461, USA.
FAU - Condeelis, John
AU  - Condeelis J
AUID- ORCID: http://orcid.org/0000-0001-8826-2336
AD  - Department of Anatomy and Structural Biology, Integrated Imaging Program, Gruss
      Lipper Biophotonics Center, Albert Einstein College of Medicine, 1300 Morris Park
      Avenue, Bronx, NY, 10461, USA.
FAU - Merad, Miriam
AU  - Merad M
AD  - Department of Oncological Sciences, The Immunology Institute, Tisch Cancer
      Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
AD  - Human Immune Monitoring Core, Icahn School of Medicine at Mount Sinai, New York, 
      NY, 10029, USA.
FAU - Aguirre-Ghiso, Julio A
AU  - Aguirre-Ghiso JA
AD  - Division of Hematology and Oncology, Department of Medicine, Tisch Cancer
      Institute, Black Family Stem Cell Institute, Icahn School of Medicine at Mount
      Sinai, New York, NY, 10029, USA. julio.aguirre-ghiso@mssm.edu.
AD  - Department of Otolaryngology, Tisch Cancer Institute, Black Family Stem Cell
      Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
      julio.aguirre-ghiso@mssm.edu.
LA  - eng
GR  - S10 OD023547/OD/NIH HHS/United States
GR  - U54 CA163131/CA/NCI NIH HHS/United States
GR  - R01 CA216248/CA/NCI NIH HHS/United States
GR  - R01 CA109182/CA/NCI NIH HHS/United States
GR  - R03 CA191430/CA/NCI NIH HHS/United States
GR  - S10 RR024745/RR/NCRR NIH HHS/United States
GR  - K22 CA201054/CA/NCI NIH HHS/United States
GR  - F31 CA183185/CA/NCI NIH HHS/United States
GR  - P30 CA196521/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20180102
PL  - England
TA  - Nat Commun
JT  - Nature communications
JID - 101528555
PMC - PMC5750231
EDAT- 2018/01/04 06:00
MHDA- 2018/01/04 06:00
CRDT- 2018/01/04 06:00
PHST- 2016/09/07 00:00 [received]
PHST- 2017/12/04 00:00 [accepted]
PHST- 2018/01/04 06:00 [entrez]
PHST- 2018/01/04 06:00 [pubmed]
PHST- 2018/01/04 06:00 [medline]
AID - 10.1038/s41467-017-02481-5 [doi]
AID - 10.1038/s41467-017-02481-5 [pii]
PST - epublish
SO  - Nat Commun. 2018 Jan 2;9(1):21. doi: 10.1038/s41467-017-02481-5.

PMID- 29121666
OWN - NLM
STAT- MEDLINE
DCOM- 20171122
LR  - 20171219
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 12
IP  - 11
DP  - 2017
TI  - SOX9 is a proliferation and stem cell factor in hepatocellular carcinoma and
      possess widespread prognostic significance in different cancer types.
PG  - e0187814
LID - 10.1371/journal.pone.0187814 [doi]
AB  - SOX9 has been previously shown to be involved in hepatocellular carcinoma (HCC)
      and other types of cancer. However, prognostic studies so far involved rather
      small cohorts or lack external validation and experimental data. In this study,
      we firstly determined the histological expression pattern of SOX9 in human HCC by
      immunohistochemistry (n = 84) and evaluated its prognostic value. External
      cohorts of publicly available datasets were used to validate its prognostic
      relevance in HCC (n = 359) and other types of cancer including breast (n = 3951),
      ovarian (n = 1306), lung (n = 1926) and gastric cancer (n = 876). Functional SOX9
      knock-down studies using siRNA and cancer stem cell models were generated in a
      panel of liver and breast cancer cell lines. High level of SOX9 was associated
      with poor survival even after adjustment for other prognostic factors in
      multivariate analysis (HR = 2.103, 95%CI = 1.064 to 4.156, p = 0.021). SOX9
      prevailed a poor prognostic factor in all cancer validation cohorts (p<0.05).
      Reduced SOX9 expression by siRNA decreased the growth of liver cancer cells
      (p<0.05). SOX9 expression was associated with stem cell features in all tested
      cell lines (p<0.05). In conclusion, this study demonstrated in a large number of 
      patients from multiple cohorts that high levels of SOX9 are a consistent negative
      prognostic factor.
FAU - Richtig, Georg
AU  - Richtig G
AUID- ORCID: http://orcid.org/0000-0002-4437-4413
AD  - Institute of Experimental and Clinical Pharmacology, Medical University of Graz, 
      Graz, Austria.
FAU - Aigelsreiter, Ariane
AU  - Aigelsreiter A
AD  - Institute of Pathology, Medical University of Graz, Graz, Austria.
FAU - Schwarzenbacher, Daniela
AU  - Schwarzenbacher D
AD  - Department of Internal Medicine, Division of Oncology, Medical University of
      Graz, Graz, Austria.
AD  - Research Unit for Non-Coding RNAs and Genome Editing in Cancer, Medical
      University of Graz, Graz, Austria.
FAU - Ress, Anna Lena
AU  - Ress AL
AD  - Department of Internal Medicine, Division of Oncology, Medical University of
      Graz, Graz, Austria.
AD  - Research Unit for Non-Coding RNAs and Genome Editing in Cancer, Medical
      University of Graz, Graz, Austria.
FAU - Adiprasito, Jan Basri
AU  - Adiprasito JB
AD  - Department of Internal Medicine, Division of Oncology, Medical University of
      Graz, Graz, Austria.
AD  - Research Unit for Non-Coding RNAs and Genome Editing in Cancer, Medical
      University of Graz, Graz, Austria.
FAU - Stiegelbauer, Verena
AU  - Stiegelbauer V
AD  - Department of Internal Medicine, Division of Oncology, Medical University of
      Graz, Graz, Austria.
AD  - Research Unit for Non-Coding RNAs and Genome Editing in Cancer, Medical
      University of Graz, Graz, Austria.
FAU - Hoefler, Gerald
AU  - Hoefler G
AD  - Institute of Pathology, Medical University of Graz, Graz, Austria.
FAU - Schauer, Silvia
AU  - Schauer S
AD  - Institute of Pathology, Medical University of Graz, Graz, Austria.
FAU - Kiesslich, Tobias
AU  - Kiesslich T
AD  - Department of Internal Medicine, Paracelsus Medical University, Salzburger
      Landeskliniken, Salzburg, Austria.
AD  - Institute of Physiology and Pathophysiology, Laboratory for Tumour Biology and
      Experimental Therapies (TREAT), Paracelsus Medical University, Salzburg, Austria.
FAU - Kornprat, Peter
AU  - Kornprat P
AD  - Department of Surgery, Division of Visceral Surgery, Medical University of Graz, 
      Graz, Austria.
FAU - Winder, Thomas
AU  - Winder T
AD  - Department of Oncology, University Hospital Zurich, Zurich, Switzerland.
FAU - Eisner, Florian
AU  - Eisner F
AD  - Department of Internal Medicine, Division of Oncology, Medical University of
      Graz, Graz, Austria.
FAU - Gerger, Armin
AU  - Gerger A
AD  - Department of Internal Medicine, Division of Oncology, Medical University of
      Graz, Graz, Austria.
FAU - Stoeger, Herbert
AU  - Stoeger H
AD  - Department of Internal Medicine, Division of Oncology, Medical University of
      Graz, Graz, Austria.
FAU - Stauber, Rudolf
AU  - Stauber R
AD  - Department of Internal Medicine, Division of Gastroenterology and Hepatology,
      Medical University of Graz, Graz, Austria.
FAU - Lackner, Carolin
AU  - Lackner C
AD  - Institute of Pathology, Medical University of Graz, Graz, Austria.
FAU - Pichler, Martin
AU  - Pichler M
AD  - Department of Internal Medicine, Division of Oncology, Medical University of
      Graz, Graz, Austria.
AD  - Research Unit for Non-Coding RNAs and Genome Editing in Cancer, Medical
      University of Graz, Graz, Austria.
AD  - Department of Experimental Therapeutics, The University of Texas MD Anderson
      Cancer Center, Houston, TX, United States of America.
LA  - eng
PT  - Journal Article
DEP - 20171109
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (SOX9 Transcription Factor)
SB  - IM
MH  - Aged
MH  - Biomarkers, Tumor/metabolism
MH  - Carcinoma, Hepatocellular/*diagnosis/genetics/metabolism/*pathology
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - Cohort Studies
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Gene Knockdown Techniques
MH  - Humans
MH  - Liver Neoplasms/*diagnosis/genetics/metabolism/*pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplastic Stem Cells/*pathology
MH  - Prognosis
MH  - SOX9 Transcription Factor/genetics/*metabolism
PMC - PMC5679634
EDAT- 2017/11/10 06:00
MHDA- 2017/11/29 06:00
CRDT- 2017/11/10 06:00
PHST- 2017/08/27 00:00 [received]
PHST- 2017/10/26 00:00 [accepted]
PHST- 2017/11/10 06:00 [entrez]
PHST- 2017/11/10 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
AID - 10.1371/journal.pone.0187814 [doi]
AID - PONE-D-17-31496 [pii]
PST - epublish
SO  - PLoS One. 2017 Nov 9;12(11):e0187814. doi: 10.1371/journal.pone.0187814.
      eCollection 2017.

PMID- 29080556
OWN - NLM
STAT- In-Process
LR  - 20171219
IS  - 1945-4589 (Electronic)
IS  - 1945-4589 (Linking)
VI  - 9
IP  - 10
DP  - 2017 Oct 27
TI  - A new mutation-independent approach to cancer therapy: Inhibiting oncogenic RAS
      and MYC, by targeting mitochondrial biogenesis.
PG  - 2098-2116
LID - 10.18632/aging.101304 [doi]
AB  - Here, we used MCF7 cells as a model system to interrogate how MYC/RAS
      co-operativity contributes to metabolic flux and stemness in breast cancer cells.
      We compared the behavior of isogenic MCF7 cell lines transduced with c-Myc or
      H-Ras (G12V), either individually or in combination. Cancer stem cell (CSC)
      activity was measured using the mammosphere assay. c-Myc augmented both
      mammosphere formation and mitochondrial respiration, without any effects on
      glycolytic flux. In contrast, H-Ras (G12V) synergistically augmented both
      mammosphere formation and glycolysis, but only in combination with c-Myc,
      directly demonstrating MYC/RAS co-operativity. As c-Myc is known to exert its
      effects, in part, by stimulating mitochondrial biogenesis, we next examined the
      effects of another stimulus known to affect mitochondrial biogenesis, i.e. ROS
      production. To pharmacologically induce oxidative stress, we used Rotenone (a
      mitochondrial inhibitor) to target mitochondrial complex I. Treatment with
      Rotenone showed bi-phasic effects; low-dose Rotenone (1 to 2.5 nM) elevated
      mammosphere formation, while higher doses (10 to 100 nM) were inhibitory.
      Importantly, the stimulatory effects of Rotenone on CSC propagation were blocked 
      using a mitochondrial-specific anti-oxidant, namely Mito-tempo. Thus, "mild"
      mitochondrial oxidative stress, originating at Complex I, was sufficient to
      pheno-copy the effects of c-Myc, effectively promoting CSC propagation. To
      validate the idea that mitochondrial biogenesis is required to stimulate CSC
      propagation, we employed Doxycycline, a well-established inhibitor of
      mitochondrial protein translation. Treatment with Doxycycline was indeed
      sufficient to block the stimulatory effects of H-Ras (G12V), c-Myc, and Rotenone 
      on CSC propagation. As such, Doxycycline provides a strong rationale for
      designing new therapeutics to target mitochondrial biogenesis, suggesting a new
      "mutation-independent" approach to cancer therapy. In support of this notion,
      most currently successful anti-cancer agents therapeutically target "cell
      phenotypes", such as increased cell proliferation, rather than specific genetic
      mutations. Remarkably, we demonstrated that Doxycycline inhibits the effects of
      diverse oncogenic stimuli, of both i) genetic (MYC/RAS) and ii) environmental
      (Rotenone) origins. Finally, we discuss the advantages of our
      "Proteomics-to-Genomics (PTG)" approach for in silico validation of new
      biomarkers and novel drug targets. In this context, we developed a new Myc-based 
      Mito-Signature consisting of 3 mitochondrial genes (HSPD1; COX5B; TIMM44) for
      effectively predicting tumor recurrence (HR=4.69; p=2.4e-08) and distant
      metastasis (HR=4.94; p=2.8e-07), in ER(+) in breast cancer patients. This gene
      signature could serve as a new companion diagnostic for the early prediction of
      treatment failure in patients receiving hormonal therapy.
FAU - Ozsvari, Bela
AU  - Ozsvari B
AD  - Translational Medicine, School of Environment and Life Sciences, Biomedical
      Research Centre (BRC), University of Salford, Greater Manchester, UK.
AD  - The Paterson Institute, University of Manchester, Withington, UK.
FAU - Sotgia, Federica
AU  - Sotgia F
AD  - Translational Medicine, School of Environment and Life Sciences, Biomedical
      Research Centre (BRC), University of Salford, Greater Manchester, UK.
AD  - The Paterson Institute, University of Manchester, Withington, UK.
FAU - Lisanti, Michael P
AU  - Lisanti MP
AD  - Translational Medicine, School of Environment and Life Sciences, Biomedical
      Research Centre (BRC), University of Salford, Greater Manchester, UK.
AD  - The Paterson Institute, University of Manchester, Withington, UK.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Aging (Albany NY)
JT  - Aging
JID - 101508617
PMC - PMC5680558
OTO - NOTNLM
OT  - MYC
OT  - RAS
OT  - cancer stem cells (CSCs)
OT  - cancer therapy
OT  - mitochondrial oxidative stress
EDAT- 2017/10/29 06:00
MHDA- 2017/10/29 06:00
CRDT- 2017/10/29 06:00
PHST- 2017/09/17 00:00 [received]
PHST- 2017/10/03 00:00 [accepted]
PHST- 2017/10/29 06:00 [pubmed]
PHST- 2017/10/29 06:00 [medline]
PHST- 2017/10/29 06:00 [entrez]
AID - 101304 [pii]
AID - 10.18632/aging.101304 [doi]
PST - ppublish
SO  - Aging (Albany NY). 2017 Oct 27;9(10):2098-2116. doi: 10.18632/aging.101304.

PMID- 29107330
OWN - NLM
STAT- MEDLINE
DCOM- 20171222
LR  - 20171222
IS  - 1097-4172 (Electronic)
IS  - 0092-8674 (Linking)
VI  - 171
IP  - 6
DP  - 2017 Nov 30
TI  - Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution.
PG  - 1259-1271.e11
LID - S0092-8674(17)31185-6 [pii]
LID - 10.1016/j.cell.2017.10.001 [doi]
AB  - Immune evasion is a hallmark of cancer. Losing the ability to present neoantigens
      through human leukocyte antigen (HLA) loss may facilitate immune evasion.
      However, the polymorphic nature of the locus has precluded accurate HLA
      copy-number analysis. Here, we present loss of heterozygosity in human leukocyte 
      antigen (LOHHLA), a computational tool to determine HLA allele-specific copy
      number from sequencing data. Using LOHHLA, we find that HLA LOH occurs in 40% of 
      non-small-cell lung cancers (NSCLCs) and is associated with a high subclonal
      neoantigen burden, APOBEC-mediated mutagenesis, upregulation of cytolytic
      activity, and PD-L1 positivity. The focal nature of HLA LOH alterations, their
      subclonal frequencies, enrichment in metastatic sites, and occurrence as parallel
      events suggests that HLA LOH is an immune escape mechanism that is subject to
      strong microenvironmental selection pressures later in tumor evolution.
      Characterizing HLA LOH with LOHHLA refines neoantigen prediction and may have
      implications for our understanding of resistance mechanisms and immunotherapeutic
      approaches targeting neoantigens. VIDEO ABSTRACT.
CI  - Copyright (c) 2017 The Francis Crick Institute. Published by Elsevier Inc. All
      rights reserved.
FAU - McGranahan, Nicholas
AU  - McGranahan N
AD  - Cancer Research UK Lung Cancer Centre of Excellence, University College London
      Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6BT, UK.
      Electronic address: nicholas.mcgranahan.10@ucl.ac.uk.
FAU - Rosenthal, Rachel
AU  - Rosenthal R
AD  - Cancer Research UK Lung Cancer Centre of Excellence, University College London
      Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6BT, UK.
FAU - Hiley, Crispin T
AU  - Hiley CT
AD  - Cancer Research UK Lung Cancer Centre of Excellence, University College London
      Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6BT, UK;
      Division of Cancer Studies, King's College London, Guy's Campus, London SE1 1UL, 
      UK.
FAU - Rowan, Andrew J
AU  - Rowan AJ
AD  - Translational Cancer Therapeutics Laboratory, The Francis Crick Institute, 1
      Midland Rd, London NW1 1AT, UK.
FAU - Watkins, Thomas B K
AU  - Watkins TBK
AD  - Translational Cancer Therapeutics Laboratory, The Francis Crick Institute, 1
      Midland Rd, London NW1 1AT, UK.
FAU - Wilson, Gareth A
AU  - Wilson GA
AD  - Cancer Research UK Lung Cancer Centre of Excellence, University College London
      Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6BT, UK;
      Translational Cancer Therapeutics Laboratory, The Francis Crick Institute, 1
      Midland Rd, London NW1 1AT, UK.
FAU - Birkbak, Nicolai J
AU  - Birkbak NJ
AD  - Cancer Research UK Lung Cancer Centre of Excellence, University College London
      Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6BT, UK;
      Translational Cancer Therapeutics Laboratory, The Francis Crick Institute, 1
      Midland Rd, London NW1 1AT, UK.
FAU - Veeriah, Selvaraju
AU  - Veeriah S
AD  - Cancer Research UK Lung Cancer Centre of Excellence, University College London
      Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6BT, UK.
FAU - Van Loo, Peter
AU  - Van Loo P
AD  - Cancer Genomics Laboratory, The Francis Crick Institute, 1 Midland Rd, London NW1
      1AT, UK; Department of Human Genetics, University of Leuven, 3000 BE Leuven,
      Belgium.
FAU - Herrero, Javier
AU  - Herrero J
AD  - Bill Lyons Informatics Centre, University College London Cancer Institute, Paul
      O'Gorman Building, 72 Huntley Street, London WC1E 6BT, UK.
FAU - Swanton, Charles
AU  - Swanton C
AD  - Cancer Research UK Lung Cancer Centre of Excellence, University College London
      Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6BT, UK;
      Translational Cancer Therapeutics Laboratory, The Francis Crick Institute, 1
      Midland Rd, London NW1 1AT, UK. Electronic address: charles.swanton@crick.ac.uk.
CN  - TRACERx Consortium
LA  - eng
GR  - Wellcome Trust/United Kingdom
PT  - Journal Article
DEP - 20171026
PL  - United States
TA  - Cell
JT  - Cell
JID - 0413066
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antigen Presentation
MH  - Carcinoma, Non-Small-Cell Lung/genetics/*immunology/pathology/therapy
MH  - Cohort Studies
MH  - Female
MH  - HLA Antigens/*genetics/immunology
MH  - Humans
MH  - Loss of Heterozygosity
MH  - Lung Neoplasms/genetics/*immunology/pathology/therapy
MH  - Male
MH  - Middle Aged
MH  - Mutation
MH  - Polymorphism, Single Nucleotide
MH  - *Tumor Escape
PMC - PMC5720478
OTO - NOTNLM
OT  - bioinformatics
OT  - cancer evolution
OT  - chromosomal instability
OT  - copy number
OT  - heterogeneity
OT  - immune-editing
OT  - immune-escape
OT  - loss of heterozygosity
OT  - lung cancer
OT  - neoantigen
IR  - Swanton C
FIR - Swanton, Charles
IR  - Jamal-Hanjani M
FIR - Jamal-Hanjani, Mariam
IR  - Veeriah S
FIR - Veeriah, Selvaraju
IR  - Shafi S
FIR - Shafi, Seema
IR  - Czyzewska-Khan J
FIR - Czyzewska-Khan, Justyna
IR  - Johnson D
FIR - Johnson, Diana
IR  - Laycock J
FIR - Laycock, Joanne
IR  - Bosshard-Carter L
FIR - Bosshard-Carter, Leticia
IR  - Rosenthal R
FIR - Rosenthal, Rachel
IR  - Gorman P
FIR - Gorman, Pat
IR  - Hynds RE
FIR - Hynds, Robert E
IR  - Wilson G
FIR - Wilson, Gareth
IR  - Birkbak NJ
FIR - Birkbak, Nicolai J
IR  - Watkins TBK
FIR - Watkins, Thomas B K
IR  - McGranahan N
FIR - McGranahan, Nicholas
IR  - Horswell S
FIR - Horswell, Stuart
IR  - Mitter R
FIR - Mitter, Richard
IR  - Escudero M
FIR - Escudero, Mickael
IR  - Stewart A
FIR - Stewart, Aengus
IR  - Van Loo P
FIR - Van Loo, Peter
IR  - Rowan A
FIR - Rowan, Andrew
IR  - Xu H
FIR - Xu, Hang
IR  - Turajlic S
FIR - Turajlic, Samra
IR  - Hiley C
FIR - Hiley, Crispin
IR  - Abbosh C
FIR - Abbosh, Christopher
IR  - Goldman J
FIR - Goldman, Jacki
IR  - Stone RK
FIR - Stone, Richard Kevin
IR  - Denner T
FIR - Denner, Tamara
IR  - Matthews N
FIR - Matthews, Nik
IR  - Elgar G
FIR - Elgar, Greg
IR  - Ward S
FIR - Ward, Sophia
IR  - Costa M
FIR - Costa, Marta
IR  - Begum S
FIR - Begum, Sharmin
IR  - Phillimore B
FIR - Phillimore, Ben
IR  - Chambers T
FIR - Chambers, Tim
IR  - Nye E
FIR - Nye, Emma
IR  - Graca S
FIR - Graca, Sofia
IR  - Al Bakir M
FIR - Al Bakir, Maise
IR  - Joshi K
FIR - Joshi, Kroopa
IR  - Furness A
FIR - Furness, Andrew
IR  - Ben Aissa A
FIR - Ben Aissa, Assma
IR  - Wong YNS
FIR - Wong, Yien Ning Sophia
IR  - Georgiou A
FIR - Georgiou, Andy
IR  - Quezada S
FIR - Quezada, Sergio
IR  - Hartley JA
FIR - Hartley, John A
IR  - Lowe HL
FIR - Lowe, Helen L
IR  - Herrero J
FIR - Herrero, Javier
IR  - Lawrence D
FIR - Lawrence, David
IR  - Hayward M
FIR - Hayward, Martin
IR  - Panagiotopoulos N
FIR - Panagiotopoulos, Nikolaos
IR  - Kolvekar S
FIR - Kolvekar, Shyam
IR  - Falzon M
FIR - Falzon, Mary
IR  - Borg E
FIR - Borg, Elaine
IR  - Marafioti T
FIR - Marafioti, Teresa
IR  - Simeon C
FIR - Simeon, Celia
IR  - Hector G
FIR - Hector, Gemma
IR  - Smith A
FIR - Smith, Amy
IR  - Aranda M
FIR - Aranda, Marie
IR  - Novelli M
FIR - Novelli, Marco
IR  - Oukrif D
FIR - Oukrif, Dahmane
IR  - Janes SM
FIR - Janes, Sam M
IR  - Thakrar R
FIR - Thakrar, Ricky
IR  - Forster M
FIR - Forster, Martin
IR  - Ahmad T
FIR - Ahmad, Tanya
IR  - Lee SM
FIR - Lee, Siow Ming
IR  - Papadatos-Pastos D
FIR - Papadatos-Pastos, Dionysis
IR  - Carnell D
FIR - Carnell, Dawn
IR  - Mendes R
FIR - Mendes, Ruheena
IR  - George J
FIR - George, Jeremy
IR  - Navani N
FIR - Navani, Neal
IR  - Ahmed A
FIR - Ahmed, Asia
IR  - Taylor M
FIR - Taylor, Magali
IR  - Choudhary J
FIR - Choudhary, Junaid
IR  - Summers Y
FIR - Summers, Yvonne
IR  - Califano R
FIR - Califano, Raffaele
IR  - Taylor P
FIR - Taylor, Paul
IR  - Shah R
FIR - Shah, Rajesh
IR  - Krysiak P
FIR - Krysiak, Piotr
IR  - Rammohan K
FIR - Rammohan, Kendadai
IR  - Fontaine E
FIR - Fontaine, Eustace
IR  - Booton R
FIR - Booton, Richard
IR  - Evison M
FIR - Evison, Matthew
IR  - Crosbie P
FIR - Crosbie, Phil
IR  - Moss S
FIR - Moss, Stuart
IR  - Idries F
FIR - Idries, Faiza
IR  - Joseph L
FIR - Joseph, Leena
IR  - Bishop P
FIR - Bishop, Paul
IR  - Chaturved A
FIR - Chaturved, Anshuman
IR  - Quinn AM
FIR - Quinn, Anne Marie
IR  - Doran H
FIR - Doran, Helen
IR  - Leek A
FIR - Leek, Angela
IR  - Harrison P
FIR - Harrison, Phil
IR  - Moore K
FIR - Moore, Katrina
IR  - Waddington R
FIR - Waddington, Rachael
IR  - Novasio J
FIR - Novasio, Juliette
IR  - Blackhall F
FIR - Blackhall, Fiona
IR  - Rogan J
FIR - Rogan, Jane
IR  - Smith E
FIR - Smith, Elaine
IR  - Dive C
FIR - Dive, Caroline
IR  - Tugwood J
FIR - Tugwood, Jonathan
IR  - Brady G
FIR - Brady, Ged
IR  - Rothwell DG
FIR - Rothwell, Dominic G
IR  - Chemi F
FIR - Chemi, Francesca
IR  - Pierce J
FIR - Pierce, Jackie
IR  - Gulati S
FIR - Gulati, Sakshi
IR  - Naidu B
FIR - Naidu, Babu
IR  - Langman G
FIR - Langman, Gerald
IR  - Trotter S
FIR - Trotter, Simon
IR  - Bellamy M
FIR - Bellamy, Mary
IR  - Bancroft H
FIR - Bancroft, Hollie
IR  - Kerr A
FIR - Kerr, Amy
IR  - Kadiri S
FIR - Kadiri, Salma
IR  - Webb J
FIR - Webb, Joanne
IR  - Middleton G
FIR - Middleton, Gary
IR  - Djearaman M
FIR - Djearaman, Madava
IR  - Fennell D
FIR - Fennell, Dean
IR  - Shaw JA
FIR - Shaw, Jacqui A
IR  - Le Quesne J
FIR - Le Quesne, John
IR  - Moore D
FIR - Moore, David
IR  - Nakas A
FIR - Nakas, Apostolos
IR  - Rathinam S
FIR - Rathinam, Sridhar
IR  - Monteiro W
FIR - Monteiro, William
IR  - Marshall H
FIR - Marshall, Hilary
IR  - Nelson L
FIR - Nelson, Louise
IR  - Bennett J
FIR - Bennett, Jonathan
IR  - Riley J
FIR - Riley, Joan
IR  - Primrose L
FIR - Primrose, Lindsay
IR  - Martinson L
FIR - Martinson, Luke
IR  - Anand G
FIR - Anand, Girija
IR  - Khan S
FIR - Khan, Sajid
IR  - Amadi A
FIR - Amadi, Anita
IR  - Nicolson M
FIR - Nicolson, Marianne
IR  - Kerr K
FIR - Kerr, Keith
IR  - Palmer S
FIR - Palmer, Shirley
IR  - Remmen H
FIR - Remmen, Hardy
IR  - Miller J
FIR - Miller, Joy
IR  - Buchan K
FIR - Buchan, Keith
IR  - Chetty M
FIR - Chetty, Mahendran
IR  - Gomersall L
FIR - Gomersall, Lesley
IR  - Lester J
FIR - Lester, Jason
IR  - Edwards A
FIR - Edwards, Alison
IR  - Morgan F
FIR - Morgan, Fiona
IR  - Adams H
FIR - Adams, Haydn
IR  - Davies H
FIR - Davies, Helen
IR  - Kornaszewska M
FIR - Kornaszewska, Malgorzata
IR  - Attanoos R
FIR - Attanoos, Richard
IR  - Lock S
FIR - Lock, Sara
IR  - Verjee A
FIR - Verjee, Azmina
IR  - MacKenzie M
FIR - MacKenzie, Mairead
IR  - Wilcox M
FIR - Wilcox, Maggie
IR  - Bell H
FIR - Bell, Harriet
IR  - Hackshaw A
FIR - Hackshaw, Allan
IR  - Ngai Y
FIR - Ngai, Yenting
IR  - Smith S
FIR - Smith, Sean
IR  - Gower N
FIR - Gower, Nicole
IR  - Ottensmeier C
FIR - Ottensmeier, Christian
IR  - Chee S
FIR - Chee, Serena
IR  - Johnson B
FIR - Johnson, Benjamin
IR  - Alzetani A
FIR - Alzetani, Aiman
IR  - Shaw E
FIR - Shaw, Emily
IR  - Lim E
FIR - Lim, Eric
IR  - De Sousa P
FIR - De Sousa, Paulo
IR  - Barbosa MT
FIR - Barbosa, Monica Tavares
IR  - Bowman A
FIR - Bowman, Alex
IR  - Jordan S
FIR - Jordan, Simon
IR  - Rice A
FIR - Rice, Alexandra
IR  - Raubenheimer H
FIR - Raubenheimer, Hilgardt
IR  - Proli C
FIR - Proli, Chiara
IR  - Cufari ME
FIR - Cufari, Maria Elena
IR  - Ronquillo JC
FIR - Ronquillo, John Carlo
IR  - Kwayie A
FIR - Kwayie, Angela
IR  - Bhayani H
FIR - Bhayani, Harshil
IR  - Hamilton M
FIR - Hamilton, Morag
IR  - Bakar Y
FIR - Bakar, Yusura
IR  - Mensah N
FIR - Mensah, Natalie
IR  - Ambrose L
FIR - Ambrose, Lyn
IR  - Devaraj A
FIR - Devaraj, Anand
IR  - Buderi S
FIR - Buderi, Silviu
IR  - Finch J
FIR - Finch, Jonathan
IR  - Azcarate L
FIR - Azcarate, Leire
IR  - Chavan H
FIR - Chavan, Hema
IR  - Green S
FIR - Green, Sophie
IR  - Mashinga H
FIR - Mashinga, Hillaria
IR  - Nicholson AG
FIR - Nicholson, Andrew G
IR  - Lau K
FIR - Lau, Kelvin
IR  - Sheaff M
FIR - Sheaff, Michael
IR  - Schmid P
FIR - Schmid, Peter
IR  - Conibear J
FIR - Conibear, John
IR  - Ezhil V
FIR - Ezhil, Veni
IR  - Ismail B
FIR - Ismail, Babikir
IR  - Irvin-Sellers M
FIR - Irvin-Sellers, Melanie
IR  - Prakash V
FIR - Prakash, Vineet
IR  - Russell P
FIR - Russell, Peter
IR  - Light T
FIR - Light, Teresa
IR  - Horey T
FIR - Horey, Tracey
IR  - Danson S
FIR - Danson, Sarah
IR  - Bury J
FIR - Bury, Jonathan
IR  - Edwards J
FIR - Edwards, John
IR  - Hill J
FIR - Hill, Jennifer
IR  - Matthews S
FIR - Matthews, Sue
IR  - Kitsanta Y
FIR - Kitsanta, Yota
IR  - Suvarna K
FIR - Suvarna, Kim
IR  - Fisher P
FIR - Fisher, Patricia
IR  - Keerio AD
FIR - Keerio, Allah Dino
IR  - Shackcloth M
FIR - Shackcloth, Michael
IR  - Gosney J
FIR - Gosney, John
IR  - Postmus P
FIR - Postmus, Pieter
IR  - Feeney S
FIR - Feeney, Sarah
IR  - Asante-Siaw J
FIR - Asante-Siaw, Julius
IR  - Aerts HJWL
FIR - Aerts, Hugo J W L
IR  - Dentro S
FIR - Dentro, Stefan
IR  - Dessimoz C
FIR - Dessimoz, Christophe
EDAT- 2017/11/07 06:00
MHDA- 2017/12/23 06:00
CRDT- 2017/11/07 06:00
PHST- 2017/07/14 00:00 [received]
PHST- 2017/09/06 00:00 [revised]
PHST- 2017/09/28 00:00 [accepted]
PHST- 2017/11/07 06:00 [pubmed]
PHST- 2017/12/23 06:00 [medline]
PHST- 2017/11/07 06:00 [entrez]
AID - S0092-8674(17)31185-6 [pii]
AID - 10.1016/j.cell.2017.10.001 [doi]
PST - ppublish
SO  - Cell. 2017 Nov 30;171(6):1259-1271.e11. doi: 10.1016/j.cell.2017.10.001. Epub
      2017 Oct 26.

PMID- 29056344
OWN - NLM
STAT- MEDLINE
DCOM- 20171215
LR  - 20171219
IS  - 1097-4172 (Electronic)
IS  - 0092-8674 (Linking)
VI  - 171
IP  - 5
DP  - 2017 Nov 16
TI  - Comprehensive Analysis of Hypermutation in Human Cancer.
PG  - 1042-1056.e10
LID - S0092-8674(17)31142-X [pii]
LID - 10.1016/j.cell.2017.09.048 [doi]
AB  - We present an extensive assessment of mutation burden through sequencing analysis
      of >81,000 tumors from pediatric and adult patients, including tumors with
      hypermutation caused by chemotherapy, carcinogens, or germline alterations.
      Hypermutation was detected in tumor types not previously associated with high
      mutation burden. Replication repair deficiency was a major contributing factor.
      We uncovered new driver mutations in the replication-repair-associated DNA
      polymerases and a distinct impact of microsatellite instability and replication
      repair deficiency on the scale of mutation load. Unbiased clustering, based on
      mutational context, revealed clinically relevant subgroups regardless of the
      tumors' tissue of origin, highlighting similarities in evolutionary dynamics
      leading to hypermutation. Mutagens, such as UV light, were implicated in
      unexpected cancers, including sarcomas and lung tumors. The order of mutational
      signatures identified previous treatment and germline replication repair
      deficiency, which improved management of patients and families. These data will
      inform tumor classification, genetic testing, and clinical trial design.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Campbell, Brittany B
AU  - Campbell BB
AD  - Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, 
      ON, Canada; The Arthur and Sonia Labatt Brain Tumour Research Centre, The
      Hospital for Sick Children, Toronto, ON, Canada; Institute of Medical Science,
      Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
FAU - Light, Nicholas
AU  - Light N
AD  - Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, 
      ON, Canada; Institute of Medical Science, Faculty of Medicine, University of
      Toronto, Toronto, ON, Canada.
FAU - Fabrizio, David
AU  - Fabrizio D
AD  - Foundation Medicine, Inc., Cambridge, MA, USA.
FAU - Zatzman, Matthew
AU  - Zatzman M
AD  - Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, 
      ON, Canada; Department of Laboratory Medicine and Pathobiology, University of
      Toronto, Toronto, ON, Canada.
FAU - Fuligni, Fabio
AU  - Fuligni F
AD  - Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, 
      ON, Canada.
FAU - de Borja, Richard
AU  - de Borja R
AD  - Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, 
      ON, Canada.
FAU - Davidson, Scott
AU  - Davidson S
AD  - Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, 
      ON, Canada; Department of Paediatric Laboratory Medicine, The Hospital for Sick
      Children, Toronto, ON, Canada.
FAU - Edwards, Melissa
AU  - Edwards M
AD  - Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, 
      ON, Canada.
FAU - Elvin, Julia A
AU  - Elvin JA
AD  - Foundation Medicine, Inc., Cambridge, MA, USA.
FAU - Hodel, Karl P
AU  - Hodel KP
AD  - Department of Biochemistry and Molecular Biology, Tulane Cancer Center, Tulane
      University School of Medicine, New Orleans, LA, USA.
FAU - Zahurancik, Walter J
AU  - Zahurancik WJ
AD  - The Ohio State Biochemistry Program, The Ohio State University, Columbus, OH,
      USA; Department of Chemistry and Biochemistry, The Ohio State University,
      Columbus, OH, USA.
FAU - Suo, Zucai
AU  - Suo Z
AD  - The Ohio State Biochemistry Program, The Ohio State University, Columbus, OH,
      USA; Department of Chemistry and Biochemistry, The Ohio State University,
      Columbus, OH, USA.
FAU - Lipman, Tatiana
AU  - Lipman T
AD  - Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, 
      ON, Canada.
FAU - Wimmer, Katharina
AU  - Wimmer K
AD  - Division of Human Genetics, Medical University Innsbruck, Innsbruck, Austria.
FAU - Kratz, Christian P
AU  - Kratz CP
AD  - Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany.
FAU - Bowers, Daniel C
AU  - Bowers DC
AD  - Department of Pediatrics and Harold C. Simmons Comprehensive Cancer Center,
      University of Texas Southwestern Medical Center, Dallas, TX, USA; Pauline Allen
      Gill Center for Cancer and Blood Disorders, Children's Health, Dallas, TX, USA.
FAU - Laetsch, Theodore W
AU  - Laetsch TW
AD  - Department of Pediatrics and Harold C. Simmons Comprehensive Cancer Center,
      University of Texas Southwestern Medical Center, Dallas, TX, USA; Pauline Allen
      Gill Center for Cancer and Blood Disorders, Children's Health, Dallas, TX, USA.
FAU - Dunn, Gavin P
AU  - Dunn GP
AD  - Department of Neurological Surgery, Center for Human Immunology and Immunotherapy
      Programs, Washington University School of Medicine, St. Louis, MO, USA.
FAU - Johanns, Tanner M
AU  - Johanns TM
AD  - Department of Neurological Surgery, Center for Human Immunology and Immunotherapy
      Programs, Washington University School of Medicine, St. Louis, MO, USA; Division 
      of Oncology, Department of Medicine, Washington University School of Medicine,
      St. Louis, MO, USA.
FAU - Grimmer, Matthew R
AU  - Grimmer MR
AD  - Division of Oncology, Department of Medicine, Washington University School of
      Medicine, St. Louis, MO, USA.
FAU - Smirnov, Ivan V
AU  - Smirnov IV
AD  - Department of Neurological Surgery, University of California, San Francisco, San 
      Francisco, CA, USA; Division of Neuroepidemiology, Department of Neurological
      Surgery, University of California, San Francisco, San Francisco, CA, USA.
FAU - Larouche, Valerie
AU  - Larouche V
AD  - Department of Pediatrics, Centre Mere-enfant Soleil du CHU de Quebec, CRCHU de
      Quebec, Universite Laval, Quebec City, QC, Canada.
FAU - Samuel, David
AU  - Samuel D
AD  - Department of Hematology-Oncology, Valley Children's Hospital, Madera, CA, USA.
FAU - Bronsema, Annika
AU  - Bronsema A
AD  - Department of Pediatric Hematology and Oncology, University Medical Center
      Hamburg-Eppendorf, Hamburg, Germany.
FAU - Osborn, Michael
AU  - Osborn M
AD  - Department of Haematology and Oncology, Women's and Children's Hospital, North
      Adelaide, SA, Australia.
FAU - Stearns, Duncan
AU  - Stearns D
AD  - Department of Pediatrics-Hematology and Oncology, UH Rainbow Babies and
      Children's Hospital, Cleveland, OH, USA.
FAU - Raman, Pichai
AU  - Raman P
AD  - Division of Oncology and Center for Childhood Cancer Research, Children's
      Hospital of Philadelphia, Philadelphia, PA, USA; Perelman School of Medicine at
      the University of Pennsylvania, Philadelphia, PA, USA.
FAU - Cole, Kristina A
AU  - Cole KA
AD  - Division of Oncology and Center for Childhood Cancer Research, Children's
      Hospital of Philadelphia, Philadelphia, PA, USA; Perelman School of Medicine at
      the University of Pennsylvania, Philadelphia, PA, USA.
FAU - Storm, Phillip B
AU  - Storm PB
AD  - Division of Neurosurgery, Children's Hospital of Philadelphia, Philadelphia, PA, 
      USA.
FAU - Yalon, Michal
AU  - Yalon M
AD  - Department of Pediatric Hematology-Oncology, Sheba Medical Center, Tel Hashomer, 
      Israel.
FAU - Opocher, Enrico
AU  - Opocher E
AD  - Pediatric Oncology & Hematology, Azienda Ospedaliera-Universita degli Studi di
      Padova, Via Giustiniani n.1, Padova, Italy.
FAU - Mason, Gary
AU  - Mason G
AD  - Department of Pediatric Hematology-Oncology, Children's Hospital of Pittsburgh of
      UPMC, Pittsburgh, PA, USA.
FAU - Thomas, Gregory A
AU  - Thomas GA
AD  - Division of Pediatric Hematology-Oncology, Oregon Health & Science University,
      Portland, OR, USA.
FAU - Sabel, Magnus
AU  - Sabel M
AD  - Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy,
      University of Gothenburg & Queen Silvia Children's Hospital, Sahlgrenska
      University Hospital, Gothenburg, Sweden.
FAU - George, Ben
AU  - George B
AD  - Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI,
      USA.
FAU - Ziegler, David S
AU  - Ziegler DS
AD  - Kids Cancer Centre, Sydney Children's Hospital, Randwick, NSW, Australia;
      Children's Cancer Institute, Lowy Cancer Research Centre, University of New South
      Wales, Randwick, NSW, Australia.
FAU - Lindhorst, Scott
AU  - Lindhorst S
AD  - Neuro-Oncology, Department of Neurosurgery, and Department of Medicine, Division 
      of Hematology/Medical Oncology, Medical University of South Carolina, Charleston,
      SC, USA.
FAU - Issai, Vanan Magimairajan
AU  - Issai VM
AD  - Department of Pediatric Hematology-Oncology, Cancer Care Manitoba; Research
      Institute in Oncology and Hematology (RIOH), University of Manitoba, Winnipeg,
      MB, Canada.
FAU - Constantini, Shlomi
AU  - Constantini S
AD  - Department of Pediatric Neurosurgery, Tel Aviv Sourasky Medical Center, Tel Aviv 
      University, Tel Aviv, Israel.
FAU - Toledano, Helen
AU  - Toledano H
AD  - Department of Pediatric Neurosurgery, Tel Aviv Sourasky Medical Center, Tel Aviv 
      University, Tel Aviv, Israel.
FAU - Elhasid, Ronit
AU  - Elhasid R
AD  - Department of Hematology-Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv,
      Israel.
FAU - Farah, Roula
AU  - Farah R
AD  - Department of Pediatrics, Saint George Hospital University Medical Center,
      Beirut, Lebanon.
FAU - Dvir, Rina
AU  - Dvir R
AD  - Department of Pediatric Hematology/Oncology, Schneider Children's Medical Center 
      of Israel, Petach Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv
      University, Tel Aviv, Israel.
FAU - Dirks, Peter
AU  - Dirks P
AD  - Department of Neurosurgery, The Hospital for Sick Children, Toronto, ON, Canada.
FAU - Huang, Annie
AU  - Huang A
AD  - The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick
      Children, Toronto, ON, Canada; Division of Hematology/Oncology, The Hospital for 
      Sick Children, Toronto, ON, Canada; Department of Laboratory Medicine and
      Pathobiology, University of Toronto, Toronto, ON, Canada.
FAU - Galati, Melissa A
AU  - Galati MA
AD  - Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, 
      ON, Canada.
FAU - Chung, Jiil
AU  - Chung J
AD  - Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, 
      ON, Canada.
FAU - Ramaswamy, Vijay
AU  - Ramaswamy V
AD  - Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, ON,
      Canada.
FAU - Irwin, Meredith S
AU  - Irwin MS
AD  - Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, ON,
      Canada.
FAU - Aronson, Melyssa
AU  - Aronson M
AD  - Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, ON,
      Canada.
FAU - Durno, Carol
AU  - Durno C
AD  - Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, ON,
      Canada; Division of Gastroenterology, Hepatology and Nutrition, The Hospital for 
      Sick Children, Toronto, ON, Canada.
FAU - Taylor, Michael D
AU  - Taylor MD
AD  - Department of Neurosurgery, The Hospital for Sick Children, Toronto, ON, Canada.
FAU - Rechavi, Gideon
AU  - Rechavi G
AD  - Cancer Research Center and Wohl Institute for Translational Medicine, Sheba
      Medical Center, Tel Hashomer, Ramat Gan, Israel.
FAU - Maris, John M
AU  - Maris JM
AD  - Division of Oncology and Center for Childhood Cancer Research, Children's
      Hospital of Philadelphia, Philadelphia, PA, USA; Perelman School of Medicine at
      the University of Pennsylvania, Philadelphia, PA, USA.
FAU - Bouffet, Eric
AU  - Bouffet E
AD  - Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, ON,
      Canada.
FAU - Hawkins, Cynthia
AU  - Hawkins C
AD  - The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick
      Children, Toronto, ON, Canada.
FAU - Costello, Joseph F
AU  - Costello JF
AD  - Department of Neurological Surgery, University of California, San Francisco, San 
      Francisco, CA, USA.
FAU - Meyn, M Stephen
AU  - Meyn MS
AD  - Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada;
      Center for Human Genomics and Precision Medicine, University of Wisconsin,
      Madison, WI, USA.
FAU - Pursell, Zachary F
AU  - Pursell ZF
AD  - Department of Biochemistry and Molecular Biology, Tulane Cancer Center, Tulane
      University School of Medicine, New Orleans, LA, USA.
FAU - Malkin, David
AU  - Malkin D
AD  - Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, ON,
      Canada; Department of Pediatrics, University of Toronto, Toronto, ON, Canada.
FAU - Tabori, Uri
AU  - Tabori U
AD  - Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, 
      ON, Canada; The Arthur and Sonia Labatt Brain Tumour Research Centre, The
      Hospital for Sick Children, Toronto, ON, Canada; Division of Hematology/Oncology,
      The Hospital for Sick Children, Toronto, ON, Canada. Electronic address:
      uri.tabori@sickkids.ca.
FAU - Shlien, Adam
AU  - Shlien A
AD  - Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, 
      ON, Canada; Department of Paediatric Laboratory Medicine, The Hospital for Sick
      Children, Toronto, ON, Canada; Department of Laboratory Medicine and
      Pathobiology, University of Toronto, Toronto, ON, Canada. Electronic address:
      adam.shlien@sickkids.ca.
LA  - eng
GR  - P01 CA118816/CA/NCI NIH HHS/United States
GR  - P50 CA097257/CA/NCI NIH HHS/United States
GR  - R01 CA169316/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20171019
PL  - United States
TA  - Cell
JT  - Cell
JID - 0413066
RN  - 0 (Poly-ADP-Ribose Binding Proteins)
RN  - EC 2.7.7.- (DNA Polymerase II)
RN  - EC 2.7.7.- (DNA Polymerase III)
RN  - EC 2.7.7.- (POLD1 protein, human)
RN  - EC 2.7.7.7 (POLE protein, human)
SB  - IM
MH  - Adult
MH  - Child
MH  - Cluster Analysis
MH  - DNA Polymerase II/genetics
MH  - DNA Polymerase III/genetics
MH  - DNA Replication
MH  - Humans
MH  - Mutation
MH  - Neoplasms/classification/*genetics/pathology/therapy
MH  - Poly-ADP-Ribose Binding Proteins/genetics
OTO - NOTNLM
OT  - DNA repair
OT  - DNA replication
OT  - cancer genomics
OT  - cancer predisposition
OT  - hypermutation
OT  - immune checkpoint inhibitors
OT  - mismatch repair
OT  - mutator
EDAT- 2017/10/24 06:00
MHDA- 2017/12/16 06:00
CRDT- 2017/10/24 06:00
PHST- 2017/03/23 00:00 [received]
PHST- 2017/07/26 00:00 [revised]
PHST- 2017/09/25 00:00 [accepted]
PHST- 2017/10/24 06:00 [pubmed]
PHST- 2017/12/16 06:00 [medline]
PHST- 2017/10/24 06:00 [entrez]
AID - S0092-8674(17)31142-X [pii]
AID - 10.1016/j.cell.2017.09.048 [doi]
PST - ppublish
SO  - Cell. 2017 Nov 16;171(5):1042-1056.e10. doi: 10.1016/j.cell.2017.09.048. Epub
      2017 Oct 19.

PMID- 29151359
OWN - NLM
STAT- MEDLINE
DCOM- 20180118
LR  - 20180118
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 378
IP  - 2
DP  - 2018 Jan 11
TI  - Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
PG  - 113-125
LID - 10.1056/NEJMoa1713137 [doi]
AB  - BACKGROUND: Osimertinib is an oral, third-generation, irreversible epidermal
      growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively
      inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations. We
      compared osimertinib with standard EGFR-TKIs in patients with previously
      untreated, EGFR mutation-positive advanced non-small-cell lung cancer (NSCLC).
      METHODS: In this double-blind, phase 3 trial, we randomly assigned 556 patients
      with previously untreated, EGFR mutation-positive (exon 19 deletion or L858R)
      advanced NSCLC in a 1:1 ratio to receive either osimertinib (at a dose of 80 mg
      once daily) or a standard EGFR-TKI (gefitinib at a dose of 250 mg once daily or
      erlotinib at a dose of 150 mg once daily). The primary end point was
      investigator-assessed progression-free survival. RESULTS: The median
      progression-free survival was significantly longer with osimertinib than with
      standard EGFR-TKIs (18.9 months vs. 10.2 months; hazard ratio for disease
      progression or death, 0.46; 95% confidence interval [CI], 0.37 to 0.57; P<0.001).
      The objective response rate was similar in the two groups: 80% with osimertinib
      and 76% with standard EGFR-TKIs (odds ratio, 1.27; 95% CI, 0.85 to 1.90; P=0.24).
      The median duration of response was 17.2 months (95% CI, 13.8 to 22.0) with
      osimertinib versus 8.5 months (95% CI, 7.3 to 9.8) with standard EGFR-TKIs. Data 
      on overall survival were immature at the interim analysis (25% maturity). The
      survival rate at 18 months was 83% (95% CI, 78 to 87) with osimertinib and 71%
      (95% CI, 65 to 76) with standard EGFR-TKIs (hazard ratio for death, 0.63; 95% CI,
      0.45 to 0.88; P=0.007 [nonsignificant in the interim analysis]). Adverse events
      of grade 3 or higher were less frequent with osimertinib than with standard
      EGFR-TKIs (34% vs. 45%). CONCLUSIONS: Osimertinib showed efficacy superior to
      that of standard EGFR-TKIs in the first-line treatment of EGFR mutation-positive 
      advanced NSCLC, with a similar safety profile and lower rates of serious adverse 
      events. (Funded by AstraZeneca; FLAURA ClinicalTrials.gov number, NCT02296125 .).
FAU - Soria, Jean-Charles
AU  - Soria JC
AD  - From Gustave Roussy Cancer Campus and University Paris-Sud, Orsay, France
      (J.-C.S., D.P.); the Department of Thoracic Oncology, National Cancer Center
      Hospital, Tokyo (Y.O.), the Department of Thoracic Oncology, Osaka International 
      Cancer Institute (F.I.), and the Department of Thoracic Oncology, Kansai Medical 
      University Hospital (T.K.), Osaka, the Department of Thoracic Oncology, National 
      Hospital Organization Shikoku Cancer Center, Matsuyama (N.N.), and the Research
      Institute for Diseases of the Chest, Graduate School of Medical Science, Kyushu
      University, Fukuoka (I.O.) - all in Japan; the Respiratory Oncology Unit,
      University Hospital KU Leuven, Leuven, Belgium (J.V.); Faculty of Medicine
      Ramathibodi Hospital, Mahidol University, Bangkok (T.R.), the Oncology Unit,
      Department of Medicine, Chiang Mai University, Chiang Mai (B.C.), and the
      Division of Medical Oncology, Department of Internal Medicine, Faculty of
      Medicine, Prince of Songkla University, Hat Yai (A.D.) - all in Thailand; the
      Division of Medical Oncology, Chungbuk National University Hospital, Chungbuk
      National University College of Medicine, Cheong-ju (K.H.L.), the Division of
      Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei
      University College of Medicine, Seoul (B.C.C.), and the Division of Hematology
      and Oncology, Department of Internal Medicine, Gachon University Gil Medical
      Center, Incheon (E.K.C.) - all in South Korea; Pulmonary Hospital of Tongji
      University, Shanghai (C.Z.), and Jilin Provincial Cancer Hospital, Changchun
      (Y.C.) - both in China; Hospital Umum Sarawak, Kuching, Malaysia (P.J.V.);
      National Cheng Kung University, Tainan, Taiwan (W.-C.S.); the Department of
      Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
      (J.E.G.); the Department of Oncology, University College London Hospitals
      Biomedical Research Centre, and the Cancer Research UK Lung Cancer Centre of
      Excellence, London (S.-M.L.), and AstraZeneca, Cambridge (R.H., M.M., Y.R.) - all
      in the United Kingdom; and Emory University School of Medicine, Winship Cancer
      Institute, Atlanta (S.S.R.).
FAU - Ohe, Yuichiro
AU  - Ohe Y
AD  - From Gustave Roussy Cancer Campus and University Paris-Sud, Orsay, France
      (J.-C.S., D.P.); the Department of Thoracic Oncology, National Cancer Center
      Hospital, Tokyo (Y.O.), the Department of Thoracic Oncology, Osaka International 
      Cancer Institute (F.I.), and the Department of Thoracic Oncology, Kansai Medical 
      University Hospital (T.K.), Osaka, the Department of Thoracic Oncology, National 
      Hospital Organization Shikoku Cancer Center, Matsuyama (N.N.), and the Research
      Institute for Diseases of the Chest, Graduate School of Medical Science, Kyushu
      University, Fukuoka (I.O.) - all in Japan; the Respiratory Oncology Unit,
      University Hospital KU Leuven, Leuven, Belgium (J.V.); Faculty of Medicine
      Ramathibodi Hospital, Mahidol University, Bangkok (T.R.), the Oncology Unit,
      Department of Medicine, Chiang Mai University, Chiang Mai (B.C.), and the
      Division of Medical Oncology, Department of Internal Medicine, Faculty of
      Medicine, Prince of Songkla University, Hat Yai (A.D.) - all in Thailand; the
      Division of Medical Oncology, Chungbuk National University Hospital, Chungbuk
      National University College of Medicine, Cheong-ju (K.H.L.), the Division of
      Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei
      University College of Medicine, Seoul (B.C.C.), and the Division of Hematology
      and Oncology, Department of Internal Medicine, Gachon University Gil Medical
      Center, Incheon (E.K.C.) - all in South Korea; Pulmonary Hospital of Tongji
      University, Shanghai (C.Z.), and Jilin Provincial Cancer Hospital, Changchun
      (Y.C.) - both in China; Hospital Umum Sarawak, Kuching, Malaysia (P.J.V.);
      National Cheng Kung University, Tainan, Taiwan (W.-C.S.); the Department of
      Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
      (J.E.G.); the Department of Oncology, University College London Hospitals
      Biomedical Research Centre, and the Cancer Research UK Lung Cancer Centre of
      Excellence, London (S.-M.L.), and AstraZeneca, Cambridge (R.H., M.M., Y.R.) - all
      in the United Kingdom; and Emory University School of Medicine, Winship Cancer
      Institute, Atlanta (S.S.R.).
FAU - Vansteenkiste, Johan
AU  - Vansteenkiste J
AD  - From Gustave Roussy Cancer Campus and University Paris-Sud, Orsay, France
      (J.-C.S., D.P.); the Department of Thoracic Oncology, National Cancer Center
      Hospital, Tokyo (Y.O.), the Department of Thoracic Oncology, Osaka International 
      Cancer Institute (F.I.), and the Department of Thoracic Oncology, Kansai Medical 
      University Hospital (T.K.), Osaka, the Department of Thoracic Oncology, National 
      Hospital Organization Shikoku Cancer Center, Matsuyama (N.N.), and the Research
      Institute for Diseases of the Chest, Graduate School of Medical Science, Kyushu
      University, Fukuoka (I.O.) - all in Japan; the Respiratory Oncology Unit,
      University Hospital KU Leuven, Leuven, Belgium (J.V.); Faculty of Medicine
      Ramathibodi Hospital, Mahidol University, Bangkok (T.R.), the Oncology Unit,
      Department of Medicine, Chiang Mai University, Chiang Mai (B.C.), and the
      Division of Medical Oncology, Department of Internal Medicine, Faculty of
      Medicine, Prince of Songkla University, Hat Yai (A.D.) - all in Thailand; the
      Division of Medical Oncology, Chungbuk National University Hospital, Chungbuk
      National University College of Medicine, Cheong-ju (K.H.L.), the Division of
      Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei
      University College of Medicine, Seoul (B.C.C.), and the Division of Hematology
      and Oncology, Department of Internal Medicine, Gachon University Gil Medical
      Center, Incheon (E.K.C.) - all in South Korea; Pulmonary Hospital of Tongji
      University, Shanghai (C.Z.), and Jilin Provincial Cancer Hospital, Changchun
      (Y.C.) - both in China; Hospital Umum Sarawak, Kuching, Malaysia (P.J.V.);
      National Cheng Kung University, Tainan, Taiwan (W.-C.S.); the Department of
      Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
      (J.E.G.); the Department of Oncology, University College London Hospitals
      Biomedical Research Centre, and the Cancer Research UK Lung Cancer Centre of
      Excellence, London (S.-M.L.), and AstraZeneca, Cambridge (R.H., M.M., Y.R.) - all
      in the United Kingdom; and Emory University School of Medicine, Winship Cancer
      Institute, Atlanta (S.S.R.).
FAU - Reungwetwattana, Thanyanan
AU  - Reungwetwattana T
AD  - From Gustave Roussy Cancer Campus and University Paris-Sud, Orsay, France
      (J.-C.S., D.P.); the Department of Thoracic Oncology, National Cancer Center
      Hospital, Tokyo (Y.O.), the Department of Thoracic Oncology, Osaka International 
      Cancer Institute (F.I.), and the Department of Thoracic Oncology, Kansai Medical 
      University Hospital (T.K.), Osaka, the Department of Thoracic Oncology, National 
      Hospital Organization Shikoku Cancer Center, Matsuyama (N.N.), and the Research
      Institute for Diseases of the Chest, Graduate School of Medical Science, Kyushu
      University, Fukuoka (I.O.) - all in Japan; the Respiratory Oncology Unit,
      University Hospital KU Leuven, Leuven, Belgium (J.V.); Faculty of Medicine
      Ramathibodi Hospital, Mahidol University, Bangkok (T.R.), the Oncology Unit,
      Department of Medicine, Chiang Mai University, Chiang Mai (B.C.), and the
      Division of Medical Oncology, Department of Internal Medicine, Faculty of
      Medicine, Prince of Songkla University, Hat Yai (A.D.) - all in Thailand; the
      Division of Medical Oncology, Chungbuk National University Hospital, Chungbuk
      National University College of Medicine, Cheong-ju (K.H.L.), the Division of
      Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei
      University College of Medicine, Seoul (B.C.C.), and the Division of Hematology
      and Oncology, Department of Internal Medicine, Gachon University Gil Medical
      Center, Incheon (E.K.C.) - all in South Korea; Pulmonary Hospital of Tongji
      University, Shanghai (C.Z.), and Jilin Provincial Cancer Hospital, Changchun
      (Y.C.) - both in China; Hospital Umum Sarawak, Kuching, Malaysia (P.J.V.);
      National Cheng Kung University, Tainan, Taiwan (W.-C.S.); the Department of
      Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
      (J.E.G.); the Department of Oncology, University College London Hospitals
      Biomedical Research Centre, and the Cancer Research UK Lung Cancer Centre of
      Excellence, London (S.-M.L.), and AstraZeneca, Cambridge (R.H., M.M., Y.R.) - all
      in the United Kingdom; and Emory University School of Medicine, Winship Cancer
      Institute, Atlanta (S.S.R.).
FAU - Chewaskulyong, Busyamas
AU  - Chewaskulyong B
AD  - From Gustave Roussy Cancer Campus and University Paris-Sud, Orsay, France
      (J.-C.S., D.P.); the Department of Thoracic Oncology, National Cancer Center
      Hospital, Tokyo (Y.O.), the Department of Thoracic Oncology, Osaka International 
      Cancer Institute (F.I.), and the Department of Thoracic Oncology, Kansai Medical 
      University Hospital (T.K.), Osaka, the Department of Thoracic Oncology, National 
      Hospital Organization Shikoku Cancer Center, Matsuyama (N.N.), and the Research
      Institute for Diseases of the Chest, Graduate School of Medical Science, Kyushu
      University, Fukuoka (I.O.) - all in Japan; the Respiratory Oncology Unit,
      University Hospital KU Leuven, Leuven, Belgium (J.V.); Faculty of Medicine
      Ramathibodi Hospital, Mahidol University, Bangkok (T.R.), the Oncology Unit,
      Department of Medicine, Chiang Mai University, Chiang Mai (B.C.), and the
      Division of Medical Oncology, Department of Internal Medicine, Faculty of
      Medicine, Prince of Songkla University, Hat Yai (A.D.) - all in Thailand; the
      Division of Medical Oncology, Chungbuk National University Hospital, Chungbuk
      National University College of Medicine, Cheong-ju (K.H.L.), the Division of
      Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei
      University College of Medicine, Seoul (B.C.C.), and the Division of Hematology
      and Oncology, Department of Internal Medicine, Gachon University Gil Medical
      Center, Incheon (E.K.C.) - all in South Korea; Pulmonary Hospital of Tongji
      University, Shanghai (C.Z.), and Jilin Provincial Cancer Hospital, Changchun
      (Y.C.) - both in China; Hospital Umum Sarawak, Kuching, Malaysia (P.J.V.);
      National Cheng Kung University, Tainan, Taiwan (W.-C.S.); the Department of
      Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
      (J.E.G.); the Department of Oncology, University College London Hospitals
      Biomedical Research Centre, and the Cancer Research UK Lung Cancer Centre of
      Excellence, London (S.-M.L.), and AstraZeneca, Cambridge (R.H., M.M., Y.R.) - all
      in the United Kingdom; and Emory University School of Medicine, Winship Cancer
      Institute, Atlanta (S.S.R.).
FAU - Lee, Ki Hyeong
AU  - Lee KH
AD  - From Gustave Roussy Cancer Campus and University Paris-Sud, Orsay, France
      (J.-C.S., D.P.); the Department of Thoracic Oncology, National Cancer Center
      Hospital, Tokyo (Y.O.), the Department of Thoracic Oncology, Osaka International 
      Cancer Institute (F.I.), and the Department of Thoracic Oncology, Kansai Medical 
      University Hospital (T.K.), Osaka, the Department of Thoracic Oncology, National 
      Hospital Organization Shikoku Cancer Center, Matsuyama (N.N.), and the Research
      Institute for Diseases of the Chest, Graduate School of Medical Science, Kyushu
      University, Fukuoka (I.O.) - all in Japan; the Respiratory Oncology Unit,
      University Hospital KU Leuven, Leuven, Belgium (J.V.); Faculty of Medicine
      Ramathibodi Hospital, Mahidol University, Bangkok (T.R.), the Oncology Unit,
      Department of Medicine, Chiang Mai University, Chiang Mai (B.C.), and the
      Division of Medical Oncology, Department of Internal Medicine, Faculty of
      Medicine, Prince of Songkla University, Hat Yai (A.D.) - all in Thailand; the
      Division of Medical Oncology, Chungbuk National University Hospital, Chungbuk
      National University College of Medicine, Cheong-ju (K.H.L.), the Division of
      Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei
      University College of Medicine, Seoul (B.C.C.), and the Division of Hematology
      and Oncology, Department of Internal Medicine, Gachon University Gil Medical
      Center, Incheon (E.K.C.) - all in South Korea; Pulmonary Hospital of Tongji
      University, Shanghai (C.Z.), and Jilin Provincial Cancer Hospital, Changchun
      (Y.C.) - both in China; Hospital Umum Sarawak, Kuching, Malaysia (P.J.V.);
      National Cheng Kung University, Tainan, Taiwan (W.-C.S.); the Department of
      Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
      (J.E.G.); the Department of Oncology, University College London Hospitals
      Biomedical Research Centre, and the Cancer Research UK Lung Cancer Centre of
      Excellence, London (S.-M.L.), and AstraZeneca, Cambridge (R.H., M.M., Y.R.) - all
      in the United Kingdom; and Emory University School of Medicine, Winship Cancer
      Institute, Atlanta (S.S.R.).
FAU - Dechaphunkul, Arunee
AU  - Dechaphunkul A
AD  - From Gustave Roussy Cancer Campus and University Paris-Sud, Orsay, France
      (J.-C.S., D.P.); the Department of Thoracic Oncology, National Cancer Center
      Hospital, Tokyo (Y.O.), the Department of Thoracic Oncology, Osaka International 
      Cancer Institute (F.I.), and the Department of Thoracic Oncology, Kansai Medical 
      University Hospital (T.K.), Osaka, the Department of Thoracic Oncology, National 
      Hospital Organization Shikoku Cancer Center, Matsuyama (N.N.), and the Research
      Institute for Diseases of the Chest, Graduate School of Medical Science, Kyushu
      University, Fukuoka (I.O.) - all in Japan; the Respiratory Oncology Unit,
      University Hospital KU Leuven, Leuven, Belgium (J.V.); Faculty of Medicine
      Ramathibodi Hospital, Mahidol University, Bangkok (T.R.), the Oncology Unit,
      Department of Medicine, Chiang Mai University, Chiang Mai (B.C.), and the
      Division of Medical Oncology, Department of Internal Medicine, Faculty of
      Medicine, Prince of Songkla University, Hat Yai (A.D.) - all in Thailand; the
      Division of Medical Oncology, Chungbuk National University Hospital, Chungbuk
      National University College of Medicine, Cheong-ju (K.H.L.), the Division of
      Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei
      University College of Medicine, Seoul (B.C.C.), and the Division of Hematology
      and Oncology, Department of Internal Medicine, Gachon University Gil Medical
      Center, Incheon (E.K.C.) - all in South Korea; Pulmonary Hospital of Tongji
      University, Shanghai (C.Z.), and Jilin Provincial Cancer Hospital, Changchun
      (Y.C.) - both in China; Hospital Umum Sarawak, Kuching, Malaysia (P.J.V.);
      National Cheng Kung University, Tainan, Taiwan (W.-C.S.); the Department of
      Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
      (J.E.G.); the Department of Oncology, University College London Hospitals
      Biomedical Research Centre, and the Cancer Research UK Lung Cancer Centre of
      Excellence, London (S.-M.L.), and AstraZeneca, Cambridge (R.H., M.M., Y.R.) - all
      in the United Kingdom; and Emory University School of Medicine, Winship Cancer
      Institute, Atlanta (S.S.R.).
FAU - Imamura, Fumio
AU  - Imamura F
AD  - From Gustave Roussy Cancer Campus and University Paris-Sud, Orsay, France
      (J.-C.S., D.P.); the Department of Thoracic Oncology, National Cancer Center
      Hospital, Tokyo (Y.O.), the Department of Thoracic Oncology, Osaka International 
      Cancer Institute (F.I.), and the Department of Thoracic Oncology, Kansai Medical 
      University Hospital (T.K.), Osaka, the Department of Thoracic Oncology, National 
      Hospital Organization Shikoku Cancer Center, Matsuyama (N.N.), and the Research
      Institute for Diseases of the Chest, Graduate School of Medical Science, Kyushu
      University, Fukuoka (I.O.) - all in Japan; the Respiratory Oncology Unit,
      University Hospital KU Leuven, Leuven, Belgium (J.V.); Faculty of Medicine
      Ramathibodi Hospital, Mahidol University, Bangkok (T.R.), the Oncology Unit,
      Department of Medicine, Chiang Mai University, Chiang Mai (B.C.), and the
      Division of Medical Oncology, Department of Internal Medicine, Faculty of
      Medicine, Prince of Songkla University, Hat Yai (A.D.) - all in Thailand; the
      Division of Medical Oncology, Chungbuk National University Hospital, Chungbuk
      National University College of Medicine, Cheong-ju (K.H.L.), the Division of
      Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei
      University College of Medicine, Seoul (B.C.C.), and the Division of Hematology
      and Oncology, Department of Internal Medicine, Gachon University Gil Medical
      Center, Incheon (E.K.C.) - all in South Korea; Pulmonary Hospital of Tongji
      University, Shanghai (C.Z.), and Jilin Provincial Cancer Hospital, Changchun
      (Y.C.) - both in China; Hospital Umum Sarawak, Kuching, Malaysia (P.J.V.);
      National Cheng Kung University, Tainan, Taiwan (W.-C.S.); the Department of
      Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
      (J.E.G.); the Department of Oncology, University College London Hospitals
      Biomedical Research Centre, and the Cancer Research UK Lung Cancer Centre of
      Excellence, London (S.-M.L.), and AstraZeneca, Cambridge (R.H., M.M., Y.R.) - all
      in the United Kingdom; and Emory University School of Medicine, Winship Cancer
      Institute, Atlanta (S.S.R.).
FAU - Nogami, Naoyuki
AU  - Nogami N
AD  - From Gustave Roussy Cancer Campus and University Paris-Sud, Orsay, France
      (J.-C.S., D.P.); the Department of Thoracic Oncology, National Cancer Center
      Hospital, Tokyo (Y.O.), the Department of Thoracic Oncology, Osaka International 
      Cancer Institute (F.I.), and the Department of Thoracic Oncology, Kansai Medical 
      University Hospital (T.K.), Osaka, the Department of Thoracic Oncology, National 
      Hospital Organization Shikoku Cancer Center, Matsuyama (N.N.), and the Research
      Institute for Diseases of the Chest, Graduate School of Medical Science, Kyushu
      University, Fukuoka (I.O.) - all in Japan; the Respiratory Oncology Unit,
      University Hospital KU Leuven, Leuven, Belgium (J.V.); Faculty of Medicine
      Ramathibodi Hospital, Mahidol University, Bangkok (T.R.), the Oncology Unit,
      Department of Medicine, Chiang Mai University, Chiang Mai (B.C.), and the
      Division of Medical Oncology, Department of Internal Medicine, Faculty of
      Medicine, Prince of Songkla University, Hat Yai (A.D.) - all in Thailand; the
      Division of Medical Oncology, Chungbuk National University Hospital, Chungbuk
      National University College of Medicine, Cheong-ju (K.H.L.), the Division of
      Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei
      University College of Medicine, Seoul (B.C.C.), and the Division of Hematology
      and Oncology, Department of Internal Medicine, Gachon University Gil Medical
      Center, Incheon (E.K.C.) - all in South Korea; Pulmonary Hospital of Tongji
      University, Shanghai (C.Z.), and Jilin Provincial Cancer Hospital, Changchun
      (Y.C.) - both in China; Hospital Umum Sarawak, Kuching, Malaysia (P.J.V.);
      National Cheng Kung University, Tainan, Taiwan (W.-C.S.); the Department of
      Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
      (J.E.G.); the Department of Oncology, University College London Hospitals
      Biomedical Research Centre, and the Cancer Research UK Lung Cancer Centre of
      Excellence, London (S.-M.L.), and AstraZeneca, Cambridge (R.H., M.M., Y.R.) - all
      in the United Kingdom; and Emory University School of Medicine, Winship Cancer
      Institute, Atlanta (S.S.R.).
FAU - Kurata, Takayasu
AU  - Kurata T
AD  - From Gustave Roussy Cancer Campus and University Paris-Sud, Orsay, France
      (J.-C.S., D.P.); the Department of Thoracic Oncology, National Cancer Center
      Hospital, Tokyo (Y.O.), the Department of Thoracic Oncology, Osaka International 
      Cancer Institute (F.I.), and the Department of Thoracic Oncology, Kansai Medical 
      University Hospital (T.K.), Osaka, the Department of Thoracic Oncology, National 
      Hospital Organization Shikoku Cancer Center, Matsuyama (N.N.), and the Research
      Institute for Diseases of the Chest, Graduate School of Medical Science, Kyushu
      University, Fukuoka (I.O.) - all in Japan; the Respiratory Oncology Unit,
      University Hospital KU Leuven, Leuven, Belgium (J.V.); Faculty of Medicine
      Ramathibodi Hospital, Mahidol University, Bangkok (T.R.), the Oncology Unit,
      Department of Medicine, Chiang Mai University, Chiang Mai (B.C.), and the
      Division of Medical Oncology, Department of Internal Medicine, Faculty of
      Medicine, Prince of Songkla University, Hat Yai (A.D.) - all in Thailand; the
      Division of Medical Oncology, Chungbuk National University Hospital, Chungbuk
      National University College of Medicine, Cheong-ju (K.H.L.), the Division of
      Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei
      University College of Medicine, Seoul (B.C.C.), and the Division of Hematology
      and Oncology, Department of Internal Medicine, Gachon University Gil Medical
      Center, Incheon (E.K.C.) - all in South Korea; Pulmonary Hospital of Tongji
      University, Shanghai (C.Z.), and Jilin Provincial Cancer Hospital, Changchun
      (Y.C.) - both in China; Hospital Umum Sarawak, Kuching, Malaysia (P.J.V.);
      National Cheng Kung University, Tainan, Taiwan (W.-C.S.); the Department of
      Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
      (J.E.G.); the Department of Oncology, University College London Hospitals
      Biomedical Research Centre, and the Cancer Research UK Lung Cancer Centre of
      Excellence, London (S.-M.L.), and AstraZeneca, Cambridge (R.H., M.M., Y.R.) - all
      in the United Kingdom; and Emory University School of Medicine, Winship Cancer
      Institute, Atlanta (S.S.R.).
FAU - Okamoto, Isamu
AU  - Okamoto I
AD  - From Gustave Roussy Cancer Campus and University Paris-Sud, Orsay, France
      (J.-C.S., D.P.); the Department of Thoracic Oncology, National Cancer Center
      Hospital, Tokyo (Y.O.), the Department of Thoracic Oncology, Osaka International 
      Cancer Institute (F.I.), and the Department of Thoracic Oncology, Kansai Medical 
      University Hospital (T.K.), Osaka, the Department of Thoracic Oncology, National 
      Hospital Organization Shikoku Cancer Center, Matsuyama (N.N.), and the Research
      Institute for Diseases of the Chest, Graduate School of Medical Science, Kyushu
      University, Fukuoka (I.O.) - all in Japan; the Respiratory Oncology Unit,
      University Hospital KU Leuven, Leuven, Belgium (J.V.); Faculty of Medicine
      Ramathibodi Hospital, Mahidol University, Bangkok (T.R.), the Oncology Unit,
      Department of Medicine, Chiang Mai University, Chiang Mai (B.C.), and the
      Division of Medical Oncology, Department of Internal Medicine, Faculty of
      Medicine, Prince of Songkla University, Hat Yai (A.D.) - all in Thailand; the
      Division of Medical Oncology, Chungbuk National University Hospital, Chungbuk
      National University College of Medicine, Cheong-ju (K.H.L.), the Division of
      Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei
      University College of Medicine, Seoul (B.C.C.), and the Division of Hematology
      and Oncology, Department of Internal Medicine, Gachon University Gil Medical
      Center, Incheon (E.K.C.) - all in South Korea; Pulmonary Hospital of Tongji
      University, Shanghai (C.Z.), and Jilin Provincial Cancer Hospital, Changchun
      (Y.C.) - both in China; Hospital Umum Sarawak, Kuching, Malaysia (P.J.V.);
      National Cheng Kung University, Tainan, Taiwan (W.-C.S.); the Department of
      Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
      (J.E.G.); the Department of Oncology, University College London Hospitals
      Biomedical Research Centre, and the Cancer Research UK Lung Cancer Centre of
      Excellence, London (S.-M.L.), and AstraZeneca, Cambridge (R.H., M.M., Y.R.) - all
      in the United Kingdom; and Emory University School of Medicine, Winship Cancer
      Institute, Atlanta (S.S.R.).
FAU - Zhou, Caicun
AU  - Zhou C
AD  - From Gustave Roussy Cancer Campus and University Paris-Sud, Orsay, France
      (J.-C.S., D.P.); the Department of Thoracic Oncology, National Cancer Center
      Hospital, Tokyo (Y.O.), the Department of Thoracic Oncology, Osaka International 
      Cancer Institute (F.I.), and the Department of Thoracic Oncology, Kansai Medical 
      University Hospital (T.K.), Osaka, the Department of Thoracic Oncology, National 
      Hospital Organization Shikoku Cancer Center, Matsuyama (N.N.), and the Research
      Institute for Diseases of the Chest, Graduate School of Medical Science, Kyushu
      University, Fukuoka (I.O.) - all in Japan; the Respiratory Oncology Unit,
      University Hospital KU Leuven, Leuven, Belgium (J.V.); Faculty of Medicine
      Ramathibodi Hospital, Mahidol University, Bangkok (T.R.), the Oncology Unit,
      Department of Medicine, Chiang Mai University, Chiang Mai (B.C.), and the
      Division of Medical Oncology, Department of Internal Medicine, Faculty of
      Medicine, Prince of Songkla University, Hat Yai (A.D.) - all in Thailand; the
      Division of Medical Oncology, Chungbuk National University Hospital, Chungbuk
      National University College of Medicine, Cheong-ju (K.H.L.), the Division of
      Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei
      University College of Medicine, Seoul (B.C.C.), and the Division of Hematology
      and Oncology, Department of Internal Medicine, Gachon University Gil Medical
      Center, Incheon (E.K.C.) - all in South Korea; Pulmonary Hospital of Tongji
      University, Shanghai (C.Z.), and Jilin Provincial Cancer Hospital, Changchun
      (Y.C.) - both in China; Hospital Umum Sarawak, Kuching, Malaysia (P.J.V.);
      National Cheng Kung University, Tainan, Taiwan (W.-C.S.); the Department of
      Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
      (J.E.G.); the Department of Oncology, University College London Hospitals
      Biomedical Research Centre, and the Cancer Research UK Lung Cancer Centre of
      Excellence, London (S.-M.L.), and AstraZeneca, Cambridge (R.H., M.M., Y.R.) - all
      in the United Kingdom; and Emory University School of Medicine, Winship Cancer
      Institute, Atlanta (S.S.R.).
FAU - Cho, Byoung Chul
AU  - Cho BC
AD  - From Gustave Roussy Cancer Campus and University Paris-Sud, Orsay, France
      (J.-C.S., D.P.); the Department of Thoracic Oncology, National Cancer Center
      Hospital, Tokyo (Y.O.), the Department of Thoracic Oncology, Osaka International 
      Cancer Institute (F.I.), and the Department of Thoracic Oncology, Kansai Medical 
      University Hospital (T.K.), Osaka, the Department of Thoracic Oncology, National 
      Hospital Organization Shikoku Cancer Center, Matsuyama (N.N.), and the Research
      Institute for Diseases of the Chest, Graduate School of Medical Science, Kyushu
      University, Fukuoka (I.O.) - all in Japan; the Respiratory Oncology Unit,
      University Hospital KU Leuven, Leuven, Belgium (J.V.); Faculty of Medicine
      Ramathibodi Hospital, Mahidol University, Bangkok (T.R.), the Oncology Unit,
      Department of Medicine, Chiang Mai University, Chiang Mai (B.C.), and the
      Division of Medical Oncology, Department of Internal Medicine, Faculty of
      Medicine, Prince of Songkla University, Hat Yai (A.D.) - all in Thailand; the
      Division of Medical Oncology, Chungbuk National University Hospital, Chungbuk
      National University College of Medicine, Cheong-ju (K.H.L.), the Division of
      Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei
      University College of Medicine, Seoul (B.C.C.), and the Division of Hematology
      and Oncology, Department of Internal Medicine, Gachon University Gil Medical
      Center, Incheon (E.K.C.) - all in South Korea; Pulmonary Hospital of Tongji
      University, Shanghai (C.Z.), and Jilin Provincial Cancer Hospital, Changchun
      (Y.C.) - both in China; Hospital Umum Sarawak, Kuching, Malaysia (P.J.V.);
      National Cheng Kung University, Tainan, Taiwan (W.-C.S.); the Department of
      Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
      (J.E.G.); the Department of Oncology, University College London Hospitals
      Biomedical Research Centre, and the Cancer Research UK Lung Cancer Centre of
      Excellence, London (S.-M.L.), and AstraZeneca, Cambridge (R.H., M.M., Y.R.) - all
      in the United Kingdom; and Emory University School of Medicine, Winship Cancer
      Institute, Atlanta (S.S.R.).
FAU - Cheng, Ying
AU  - Cheng Y
AD  - From Gustave Roussy Cancer Campus and University Paris-Sud, Orsay, France
      (J.-C.S., D.P.); the Department of Thoracic Oncology, National Cancer Center
      Hospital, Tokyo (Y.O.), the Department of Thoracic Oncology, Osaka International 
      Cancer Institute (F.I.), and the Department of Thoracic Oncology, Kansai Medical 
      University Hospital (T.K.), Osaka, the Department of Thoracic Oncology, National 
      Hospital Organization Shikoku Cancer Center, Matsuyama (N.N.), and the Research
      Institute for Diseases of the Chest, Graduate School of Medical Science, Kyushu
      University, Fukuoka (I.O.) - all in Japan; the Respiratory Oncology Unit,
      University Hospital KU Leuven, Leuven, Belgium (J.V.); Faculty of Medicine
      Ramathibodi Hospital, Mahidol University, Bangkok (T.R.), the Oncology Unit,
      Department of Medicine, Chiang Mai University, Chiang Mai (B.C.), and the
      Division of Medical Oncology, Department of Internal Medicine, Faculty of
      Medicine, Prince of Songkla University, Hat Yai (A.D.) - all in Thailand; the
      Division of Medical Oncology, Chungbuk National University Hospital, Chungbuk
      National University College of Medicine, Cheong-ju (K.H.L.), the Division of
      Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei
      University College of Medicine, Seoul (B.C.C.), and the Division of Hematology
      and Oncology, Department of Internal Medicine, Gachon University Gil Medical
      Center, Incheon (E.K.C.) - all in South Korea; Pulmonary Hospital of Tongji
      University, Shanghai (C.Z.), and Jilin Provincial Cancer Hospital, Changchun
      (Y.C.) - both in China; Hospital Umum Sarawak, Kuching, Malaysia (P.J.V.);
      National Cheng Kung University, Tainan, Taiwan (W.-C.S.); the Department of
      Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
      (J.E.G.); the Department of Oncology, University College London Hospitals
      Biomedical Research Centre, and the Cancer Research UK Lung Cancer Centre of
      Excellence, London (S.-M.L.), and AstraZeneca, Cambridge (R.H., M.M., Y.R.) - all
      in the United Kingdom; and Emory University School of Medicine, Winship Cancer
      Institute, Atlanta (S.S.R.).
FAU - Cho, Eun Kyung
AU  - Cho EK
AD  - From Gustave Roussy Cancer Campus and University Paris-Sud, Orsay, France
      (J.-C.S., D.P.); the Department of Thoracic Oncology, National Cancer Center
      Hospital, Tokyo (Y.O.), the Department of Thoracic Oncology, Osaka International 
      Cancer Institute (F.I.), and the Department of Thoracic Oncology, Kansai Medical 
      University Hospital (T.K.), Osaka, the Department of Thoracic Oncology, National 
      Hospital Organization Shikoku Cancer Center, Matsuyama (N.N.), and the Research
      Institute for Diseases of the Chest, Graduate School of Medical Science, Kyushu
      University, Fukuoka (I.O.) - all in Japan; the Respiratory Oncology Unit,
      University Hospital KU Leuven, Leuven, Belgium (J.V.); Faculty of Medicine
      Ramathibodi Hospital, Mahidol University, Bangkok (T.R.), the Oncology Unit,
      Department of Medicine, Chiang Mai University, Chiang Mai (B.C.), and the
      Division of Medical Oncology, Department of Internal Medicine, Faculty of
      Medicine, Prince of Songkla University, Hat Yai (A.D.) - all in Thailand; the
      Division of Medical Oncology, Chungbuk National University Hospital, Chungbuk
      National University College of Medicine, Cheong-ju (K.H.L.), the Division of
      Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei
      University College of Medicine, Seoul (B.C.C.), and the Division of Hematology
      and Oncology, Department of Internal Medicine, Gachon University Gil Medical
      Center, Incheon (E.K.C.) - all in South Korea; Pulmonary Hospital of Tongji
      University, Shanghai (C.Z.), and Jilin Provincial Cancer Hospital, Changchun
      (Y.C.) - both in China; Hospital Umum Sarawak, Kuching, Malaysia (P.J.V.);
      National Cheng Kung University, Tainan, Taiwan (W.-C.S.); the Department of
      Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
      (J.E.G.); the Department of Oncology, University College London Hospitals
      Biomedical Research Centre, and the Cancer Research UK Lung Cancer Centre of
      Excellence, London (S.-M.L.), and AstraZeneca, Cambridge (R.H., M.M., Y.R.) - all
      in the United Kingdom; and Emory University School of Medicine, Winship Cancer
      Institute, Atlanta (S.S.R.).
FAU - Voon, Pei Jye
AU  - Voon PJ
AD  - From Gustave Roussy Cancer Campus and University Paris-Sud, Orsay, France
      (J.-C.S., D.P.); the Department of Thoracic Oncology, National Cancer Center
      Hospital, Tokyo (Y.O.), the Department of Thoracic Oncology, Osaka International 
      Cancer Institute (F.I.), and the Department of Thoracic Oncology, Kansai Medical 
      University Hospital (T.K.), Osaka, the Department of Thoracic Oncology, National 
      Hospital Organization Shikoku Cancer Center, Matsuyama (N.N.), and the Research
      Institute for Diseases of the Chest, Graduate School of Medical Science, Kyushu
      University, Fukuoka (I.O.) - all in Japan; the Respiratory Oncology Unit,
      University Hospital KU Leuven, Leuven, Belgium (J.V.); Faculty of Medicine
      Ramathibodi Hospital, Mahidol University, Bangkok (T.R.), the Oncology Unit,
      Department of Medicine, Chiang Mai University, Chiang Mai (B.C.), and the
      Division of Medical Oncology, Department of Internal Medicine, Faculty of
      Medicine, Prince of Songkla University, Hat Yai (A.D.) - all in Thailand; the
      Division of Medical Oncology, Chungbuk National University Hospital, Chungbuk
      National University College of Medicine, Cheong-ju (K.H.L.), the Division of
      Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei
      University College of Medicine, Seoul (B.C.C.), and the Division of Hematology
      and Oncology, Department of Internal Medicine, Gachon University Gil Medical
      Center, Incheon (E.K.C.) - all in South Korea; Pulmonary Hospital of Tongji
      University, Shanghai (C.Z.), and Jilin Provincial Cancer Hospital, Changchun
      (Y.C.) - both in China; Hospital Umum Sarawak, Kuching, Malaysia (P.J.V.);
      National Cheng Kung University, Tainan, Taiwan (W.-C.S.); the Department of
      Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
      (J.E.G.); the Department of Oncology, University College London Hospitals
      Biomedical Research Centre, and the Cancer Research UK Lung Cancer Centre of
      Excellence, London (S.-M.L.), and AstraZeneca, Cambridge (R.H., M.M., Y.R.) - all
      in the United Kingdom; and Emory University School of Medicine, Winship Cancer
      Institute, Atlanta (S.S.R.).
FAU - Planchard, David
AU  - Planchard D
AD  - From Gustave Roussy Cancer Campus and University Paris-Sud, Orsay, France
      (J.-C.S., D.P.); the Department of Thoracic Oncology, National Cancer Center
      Hospital, Tokyo (Y.O.), the Department of Thoracic Oncology, Osaka International 
      Cancer Institute (F.I.), and the Department of Thoracic Oncology, Kansai Medical 
      University Hospital (T.K.), Osaka, the Department of Thoracic Oncology, National 
      Hospital Organization Shikoku Cancer Center, Matsuyama (N.N.), and the Research
      Institute for Diseases of the Chest, Graduate School of Medical Science, Kyushu
      University, Fukuoka (I.O.) - all in Japan; the Respiratory Oncology Unit,
      University Hospital KU Leuven, Leuven, Belgium (J.V.); Faculty of Medicine
      Ramathibodi Hospital, Mahidol University, Bangkok (T.R.), the Oncology Unit,
      Department of Medicine, Chiang Mai University, Chiang Mai (B.C.), and the
      Division of Medical Oncology, Department of Internal Medicine, Faculty of
      Medicine, Prince of Songkla University, Hat Yai (A.D.) - all in Thailand; the
      Division of Medical Oncology, Chungbuk National University Hospital, Chungbuk
      National University College of Medicine, Cheong-ju (K.H.L.), the Division of
      Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei
      University College of Medicine, Seoul (B.C.C.), and the Division of Hematology
      and Oncology, Department of Internal Medicine, Gachon University Gil Medical
      Center, Incheon (E.K.C.) - all in South Korea; Pulmonary Hospital of Tongji
      University, Shanghai (C.Z.), and Jilin Provincial Cancer Hospital, Changchun
      (Y.C.) - both in China; Hospital Umum Sarawak, Kuching, Malaysia (P.J.V.);
      National Cheng Kung University, Tainan, Taiwan (W.-C.S.); the Department of
      Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
      (J.E.G.); the Department of Oncology, University College London Hospitals
      Biomedical Research Centre, and the Cancer Research UK Lung Cancer Centre of
      Excellence, London (S.-M.L.), and AstraZeneca, Cambridge (R.H., M.M., Y.R.) - all
      in the United Kingdom; and Emory University School of Medicine, Winship Cancer
      Institute, Atlanta (S.S.R.).
FAU - Su, Wu-Chou
AU  - Su WC
AD  - From Gustave Roussy Cancer Campus and University Paris-Sud, Orsay, France
      (J.-C.S., D.P.); the Department of Thoracic Oncology, National Cancer Center
      Hospital, Tokyo (Y.O.), the Department of Thoracic Oncology, Osaka International 
      Cancer Institute (F.I.), and the Department of Thoracic Oncology, Kansai Medical 
      University Hospital (T.K.), Osaka, the Department of Thoracic Oncology, National 
      Hospital Organization Shikoku Cancer Center, Matsuyama (N.N.), and the Research
      Institute for Diseases of the Chest, Graduate School of Medical Science, Kyushu
      University, Fukuoka (I.O.) - all in Japan; the Respiratory Oncology Unit,
      University Hospital KU Leuven, Leuven, Belgium (J.V.); Faculty of Medicine
      Ramathibodi Hospital, Mahidol University, Bangkok (T.R.), the Oncology Unit,
      Department of Medicine, Chiang Mai University, Chiang Mai (B.C.), and the
      Division of Medical Oncology, Department of Internal Medicine, Faculty of
      Medicine, Prince of Songkla University, Hat Yai (A.D.) - all in Thailand; the
      Division of Medical Oncology, Chungbuk National University Hospital, Chungbuk
      National University College of Medicine, Cheong-ju (K.H.L.), the Division of
      Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei
      University College of Medicine, Seoul (B.C.C.), and the Division of Hematology
      and Oncology, Department of Internal Medicine, Gachon University Gil Medical
      Center, Incheon (E.K.C.) - all in South Korea; Pulmonary Hospital of Tongji
      University, Shanghai (C.Z.), and Jilin Provincial Cancer Hospital, Changchun
      (Y.C.) - both in China; Hospital Umum Sarawak, Kuching, Malaysia (P.J.V.);
      National Cheng Kung University, Tainan, Taiwan (W.-C.S.); the Department of
      Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
      (J.E.G.); the Department of Oncology, University College London Hospitals
      Biomedical Research Centre, and the Cancer Research UK Lung Cancer Centre of
      Excellence, London (S.-M.L.), and AstraZeneca, Cambridge (R.H., M.M., Y.R.) - all
      in the United Kingdom; and Emory University School of Medicine, Winship Cancer
      Institute, Atlanta (S.S.R.).
FAU - Gray, Jhanelle E
AU  - Gray JE
AD  - From Gustave Roussy Cancer Campus and University Paris-Sud, Orsay, France
      (J.-C.S., D.P.); the Department of Thoracic Oncology, National Cancer Center
      Hospital, Tokyo (Y.O.), the Department of Thoracic Oncology, Osaka International 
      Cancer Institute (F.I.), and the Department of Thoracic Oncology, Kansai Medical 
      University Hospital (T.K.), Osaka, the Department of Thoracic Oncology, National 
      Hospital Organization Shikoku Cancer Center, Matsuyama (N.N.), and the Research
      Institute for Diseases of the Chest, Graduate School of Medical Science, Kyushu
      University, Fukuoka (I.O.) - all in Japan; the Respiratory Oncology Unit,
      University Hospital KU Leuven, Leuven, Belgium (J.V.); Faculty of Medicine
      Ramathibodi Hospital, Mahidol University, Bangkok (T.R.), the Oncology Unit,
      Department of Medicine, Chiang Mai University, Chiang Mai (B.C.), and the
      Division of Medical Oncology, Department of Internal Medicine, Faculty of
      Medicine, Prince of Songkla University, Hat Yai (A.D.) - all in Thailand; the
      Division of Medical Oncology, Chungbuk National University Hospital, Chungbuk
      National University College of Medicine, Cheong-ju (K.H.L.), the Division of
      Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei
      University College of Medicine, Seoul (B.C.C.), and the Division of Hematology
      and Oncology, Department of Internal Medicine, Gachon University Gil Medical
      Center, Incheon (E.K.C.) - all in South Korea; Pulmonary Hospital of Tongji
      University, Shanghai (C.Z.), and Jilin Provincial Cancer Hospital, Changchun
      (Y.C.) - both in China; Hospital Umum Sarawak, Kuching, Malaysia (P.J.V.);
      National Cheng Kung University, Tainan, Taiwan (W.-C.S.); the Department of
      Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
      (J.E.G.); the Department of Oncology, University College London Hospitals
      Biomedical Research Centre, and the Cancer Research UK Lung Cancer Centre of
      Excellence, London (S.-M.L.), and AstraZeneca, Cambridge (R.H., M.M., Y.R.) - all
      in the United Kingdom; and Emory University School of Medicine, Winship Cancer
      Institute, Atlanta (S.S.R.).
FAU - Lee, Siow-Ming
AU  - Lee SM
AD  - From Gustave Roussy Cancer Campus and University Paris-Sud, Orsay, France
      (J.-C.S., D.P.); the Department of Thoracic Oncology, National Cancer Center
      Hospital, Tokyo (Y.O.), the Department of Thoracic Oncology, Osaka International 
      Cancer Institute (F.I.), and the Department of Thoracic Oncology, Kansai Medical 
      University Hospital (T.K.), Osaka, the Department of Thoracic Oncology, National 
      Hospital Organization Shikoku Cancer Center, Matsuyama (N.N.), and the Research
      Institute for Diseases of the Chest, Graduate School of Medical Science, Kyushu
      University, Fukuoka (I.O.) - all in Japan; the Respiratory Oncology Unit,
      University Hospital KU Leuven, Leuven, Belgium (J.V.); Faculty of Medicine
      Ramathibodi Hospital, Mahidol University, Bangkok (T.R.), the Oncology Unit,
      Department of Medicine, Chiang Mai University, Chiang Mai (B.C.), and the
      Division of Medical Oncology, Department of Internal Medicine, Faculty of
      Medicine, Prince of Songkla University, Hat Yai (A.D.) - all in Thailand; the
      Division of Medical Oncology, Chungbuk National University Hospital, Chungbuk
      National University College of Medicine, Cheong-ju (K.H.L.), the Division of
      Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei
      University College of Medicine, Seoul (B.C.C.), and the Division of Hematology
      and Oncology, Department of Internal Medicine, Gachon University Gil Medical
      Center, Incheon (E.K.C.) - all in South Korea; Pulmonary Hospital of Tongji
      University, Shanghai (C.Z.), and Jilin Provincial Cancer Hospital, Changchun
      (Y.C.) - both in China; Hospital Umum Sarawak, Kuching, Malaysia (P.J.V.);
      National Cheng Kung University, Tainan, Taiwan (W.-C.S.); the Department of
      Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
      (J.E.G.); the Department of Oncology, University College London Hospitals
      Biomedical Research Centre, and the Cancer Research UK Lung Cancer Centre of
      Excellence, London (S.-M.L.), and AstraZeneca, Cambridge (R.H., M.M., Y.R.) - all
      in the United Kingdom; and Emory University School of Medicine, Winship Cancer
      Institute, Atlanta (S.S.R.).
FAU - Hodge, Rachel
AU  - Hodge R
AD  - From Gustave Roussy Cancer Campus and University Paris-Sud, Orsay, France
      (J.-C.S., D.P.); the Department of Thoracic Oncology, National Cancer Center
      Hospital, Tokyo (Y.O.), the Department of Thoracic Oncology, Osaka International 
      Cancer Institute (F.I.), and the Department of Thoracic Oncology, Kansai Medical 
      University Hospital (T.K.), Osaka, the Department of Thoracic Oncology, National 
      Hospital Organization Shikoku Cancer Center, Matsuyama (N.N.), and the Research
      Institute for Diseases of the Chest, Graduate School of Medical Science, Kyushu
      University, Fukuoka (I.O.) - all in Japan; the Respiratory Oncology Unit,
      University Hospital KU Leuven, Leuven, Belgium (J.V.); Faculty of Medicine
      Ramathibodi Hospital, Mahidol University, Bangkok (T.R.), the Oncology Unit,
      Department of Medicine, Chiang Mai University, Chiang Mai (B.C.), and the
      Division of Medical Oncology, Department of Internal Medicine, Faculty of
      Medicine, Prince of Songkla University, Hat Yai (A.D.) - all in Thailand; the
      Division of Medical Oncology, Chungbuk National University Hospital, Chungbuk
      National University College of Medicine, Cheong-ju (K.H.L.), the Division of
      Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei
      University College of Medicine, Seoul (B.C.C.), and the Division of Hematology
      and Oncology, Department of Internal Medicine, Gachon University Gil Medical
      Center, Incheon (E.K.C.) - all in South Korea; Pulmonary Hospital of Tongji
      University, Shanghai (C.Z.), and Jilin Provincial Cancer Hospital, Changchun
      (Y.C.) - both in China; Hospital Umum Sarawak, Kuching, Malaysia (P.J.V.);
      National Cheng Kung University, Tainan, Taiwan (W.-C.S.); the Department of
      Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
      (J.E.G.); the Department of Oncology, University College London Hospitals
      Biomedical Research Centre, and the Cancer Research UK Lung Cancer Centre of
      Excellence, London (S.-M.L.), and AstraZeneca, Cambridge (R.H., M.M., Y.R.) - all
      in the United Kingdom; and Emory University School of Medicine, Winship Cancer
      Institute, Atlanta (S.S.R.).
FAU - Marotti, Marcelo
AU  - Marotti M
AD  - From Gustave Roussy Cancer Campus and University Paris-Sud, Orsay, France
      (J.-C.S., D.P.); the Department of Thoracic Oncology, National Cancer Center
      Hospital, Tokyo (Y.O.), the Department of Thoracic Oncology, Osaka International 
      Cancer Institute (F.I.), and the Department of Thoracic Oncology, Kansai Medical 
      University Hospital (T.K.), Osaka, the Department of Thoracic Oncology, National 
      Hospital Organization Shikoku Cancer Center, Matsuyama (N.N.), and the Research
      Institute for Diseases of the Chest, Graduate School of Medical Science, Kyushu
      University, Fukuoka (I.O.) - all in Japan; the Respiratory Oncology Unit,
      University Hospital KU Leuven, Leuven, Belgium (J.V.); Faculty of Medicine
      Ramathibodi Hospital, Mahidol University, Bangkok (T.R.), the Oncology Unit,
      Department of Medicine, Chiang Mai University, Chiang Mai (B.C.), and the
      Division of Medical Oncology, Department of Internal Medicine, Faculty of
      Medicine, Prince of Songkla University, Hat Yai (A.D.) - all in Thailand; the
      Division of Medical Oncology, Chungbuk National University Hospital, Chungbuk
      National University College of Medicine, Cheong-ju (K.H.L.), the Division of
      Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei
      University College of Medicine, Seoul (B.C.C.), and the Division of Hematology
      and Oncology, Department of Internal Medicine, Gachon University Gil Medical
      Center, Incheon (E.K.C.) - all in South Korea; Pulmonary Hospital of Tongji
      University, Shanghai (C.Z.), and Jilin Provincial Cancer Hospital, Changchun
      (Y.C.) - both in China; Hospital Umum Sarawak, Kuching, Malaysia (P.J.V.);
      National Cheng Kung University, Tainan, Taiwan (W.-C.S.); the Department of
      Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
      (J.E.G.); the Department of Oncology, University College London Hospitals
      Biomedical Research Centre, and the Cancer Research UK Lung Cancer Centre of
      Excellence, London (S.-M.L.), and AstraZeneca, Cambridge (R.H., M.M., Y.R.) - all
      in the United Kingdom; and Emory University School of Medicine, Winship Cancer
      Institute, Atlanta (S.S.R.).
FAU - Rukazenkov, Yuri
AU  - Rukazenkov Y
AD  - From Gustave Roussy Cancer Campus and University Paris-Sud, Orsay, France
      (J.-C.S., D.P.); the Department of Thoracic Oncology, National Cancer Center
      Hospital, Tokyo (Y.O.), the Department of Thoracic Oncology, Osaka International 
      Cancer Institute (F.I.), and the Department of Thoracic Oncology, Kansai Medical 
      University Hospital (T.K.), Osaka, the Department of Thoracic Oncology, National 
      Hospital Organization Shikoku Cancer Center, Matsuyama (N.N.), and the Research
      Institute for Diseases of the Chest, Graduate School of Medical Science, Kyushu
      University, Fukuoka (I.O.) - all in Japan; the Respiratory Oncology Unit,
      University Hospital KU Leuven, Leuven, Belgium (J.V.); Faculty of Medicine
      Ramathibodi Hospital, Mahidol University, Bangkok (T.R.), the Oncology Unit,
      Department of Medicine, Chiang Mai University, Chiang Mai (B.C.), and the
      Division of Medical Oncology, Department of Internal Medicine, Faculty of
      Medicine, Prince of Songkla University, Hat Yai (A.D.) - all in Thailand; the
      Division of Medical Oncology, Chungbuk National University Hospital, Chungbuk
      National University College of Medicine, Cheong-ju (K.H.L.), the Division of
      Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei
      University College of Medicine, Seoul (B.C.C.), and the Division of Hematology
      and Oncology, Department of Internal Medicine, Gachon University Gil Medical
      Center, Incheon (E.K.C.) - all in South Korea; Pulmonary Hospital of Tongji
      University, Shanghai (C.Z.), and Jilin Provincial Cancer Hospital, Changchun
      (Y.C.) - both in China; Hospital Umum Sarawak, Kuching, Malaysia (P.J.V.);
      National Cheng Kung University, Tainan, Taiwan (W.-C.S.); the Department of
      Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
      (J.E.G.); the Department of Oncology, University College London Hospitals
      Biomedical Research Centre, and the Cancer Research UK Lung Cancer Centre of
      Excellence, London (S.-M.L.), and AstraZeneca, Cambridge (R.H., M.M., Y.R.) - all
      in the United Kingdom; and Emory University School of Medicine, Winship Cancer
      Institute, Atlanta (S.S.R.).
FAU - Ramalingam, Suresh S
AU  - Ramalingam SS
AD  - From Gustave Roussy Cancer Campus and University Paris-Sud, Orsay, France
      (J.-C.S., D.P.); the Department of Thoracic Oncology, National Cancer Center
      Hospital, Tokyo (Y.O.), the Department of Thoracic Oncology, Osaka International 
      Cancer Institute (F.I.), and the Department of Thoracic Oncology, Kansai Medical 
      University Hospital (T.K.), Osaka, the Department of Thoracic Oncology, National 
      Hospital Organization Shikoku Cancer Center, Matsuyama (N.N.), and the Research
      Institute for Diseases of the Chest, Graduate School of Medical Science, Kyushu
      University, Fukuoka (I.O.) - all in Japan; the Respiratory Oncology Unit,
      University Hospital KU Leuven, Leuven, Belgium (J.V.); Faculty of Medicine
      Ramathibodi Hospital, Mahidol University, Bangkok (T.R.), the Oncology Unit,
      Department of Medicine, Chiang Mai University, Chiang Mai (B.C.), and the
      Division of Medical Oncology, Department of Internal Medicine, Faculty of
      Medicine, Prince of Songkla University, Hat Yai (A.D.) - all in Thailand; the
      Division of Medical Oncology, Chungbuk National University Hospital, Chungbuk
      National University College of Medicine, Cheong-ju (K.H.L.), the Division of
      Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei
      University College of Medicine, Seoul (B.C.C.), and the Division of Hematology
      and Oncology, Department of Internal Medicine, Gachon University Gil Medical
      Center, Incheon (E.K.C.) - all in South Korea; Pulmonary Hospital of Tongji
      University, Shanghai (C.Z.), and Jilin Provincial Cancer Hospital, Changchun
      (Y.C.) - both in China; Hospital Umum Sarawak, Kuching, Malaysia (P.J.V.);
      National Cheng Kung University, Tainan, Taiwan (W.-C.S.); the Department of
      Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
      (J.E.G.); the Department of Oncology, University College London Hospitals
      Biomedical Research Centre, and the Cancer Research UK Lung Cancer Centre of
      Excellence, London (S.-M.L.), and AstraZeneca, Cambridge (R.H., M.M., Y.R.) - all
      in the United Kingdom; and Emory University School of Medicine, Winship Cancer
      Institute, Atlanta (S.S.R.).
CN  - FLAURA Investigators
LA  - eng
SI  - ClinicalTrials.gov/NCT02296125
PT  - Clinical Trial, Phase III
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20171118
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Piperazines)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Quinazolines)
RN  - 3C06JJ0Z2O (osimertinib)
RN  - DA87705X9K (Erlotinib Hydrochloride)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
RN  - EC 2.7.10.1 (Receptor, Epidermal Growth Factor)
RN  - S65743JHBS (gefitinib)
SB  - AIM
SB  - IM
CIN - N Engl J Med. 2018 Jan 11;378(2):192-193. PMID: 29320658
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/adverse effects/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/genetics/mortality
MH  - Disease-Free Survival
MH  - Double-Blind Method
MH  - Erlotinib Hydrochloride/therapeutic use
MH  - Female
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Lung Neoplasms/*drug therapy/genetics/mortality
MH  - Male
MH  - Middle Aged
MH  - *Mutation
MH  - Piperazines/adverse effects/*therapeutic use
MH  - Protein Kinase Inhibitors/adverse effects/*therapeutic use
MH  - Protein-Tyrosine Kinases/antagonists & inhibitors
MH  - Quinazolines/therapeutic use
MH  - Receptor, Epidermal Growth Factor/*genetics
MH  - Survival Rate
IR  - Boyer M
FIR - Boyer, Michael
IR  - Lee C
FIR - Lee, Chee
IR  - Hughes B
FIR - Hughes, Brett
IR  - O'Byrne K
FIR - O'Byrne, Kenneth
IR  - Briggs P
FIR - Briggs, Peter
IR  - Milward M
FIR - Milward, Michael
IR  - John T
FIR - John, Thomas
IR  - Demedts I
FIR - Demedts, Ingel
IR  - Bustin F
FIR - Bustin, Frederique
IR  - Barrios CH
FIR - Barrios, Carlos Henrique
IR  - Timcheva C
FIR - Timcheva, Constanta
IR  - Butts C
FIR - Butts, Charles
IR  - Goss G
FIR - Goss, Glenwood
IR  - Juergens R
FIR - Juergens, Rosalyn
IR  - Leighl N
FIR - Leighl, Natasha
IR  - Cheng S
FIR - Cheng, Susanna
IR  - Burkes R
FIR - Burkes, Ronald
IR  - Zhang H
FIR - Zhang, Helong
IR  - Shu Y
FIR - Shu, Yongqian
IR  - Zhou Q
FIR - Zhou, Qing
IR  - Li W
FIR - Li, Wei
IR  - Feng G
FIR - Feng, Guosheng
IR  - He Y
FIR - He, Yong
IR  - Wang B
FIR - Wang, Buhai
IR  - Gao H
FIR - Gao, Hongjun
IR  - Nan K
FIR - Nan, Kejun
IR  - Zhou X
FIR - Zhou, Xiangdong
IR  - Fan Y
FIR - Fan, Yun
IR  - Hunag JA
FIR - Hunag, Jian an
IR  - Hu Y
FIR - Hu, Yi
IR  - Liu YP
FIR - Liu, Yun-Peng
IR  - Liu C
FIR - Liu, Chunling
IR  - Zhang Y
FIR - Zhang, Yiping
IR  - Zhu B
FIR - Zhu, Bo
IR  - Bartek T
FIR - Bartek, Tomas
IR  - Monnet I
FIR - Monnet, Isabelle
IR  - El Kouri C
FIR - El Kouri, Claude
IR  - Perol M
FIR - Perol, Maurice
IR  - Berard H
FIR - Berard, Henri
IR  - Madelaine J
FIR - Madelaine, Jeannick
IR  - von Pawel J
FIR - von Pawel, Joachim
IR  - Grohe C
FIR - Grohe, Christian
IR  - Bohnet S
FIR - Bohnet, Sabine
IR  - Bischoff H
FIR - Bischoff, Helge
IR  - zum Buschenfelde CM
FIR - zum Buschenfelde, Christian Meyer
IR  - Ruckert A
FIR - Ruckert, Anja
IR  - Urban L
FIR - Urban, Lazlo
IR  - Papi-Szekely Z
FIR - Papi-Szekely, Zsolt
IR  - Csanky E
FIR - Csanky, Eszter
IR  - Bocskei C
FIR - Bocskei, Csaba
IR  - Tehenes S
FIR - Tehenes, Sandor
IR  - Gottfried M
FIR - Gottfried, Maya
IR  - Bar J
FIR - Bar, Jair
IR  - Peled N
FIR - Peled, Nir
IR  - Wollner M
FIR - Wollner, Mirjana
IR  - Bertolini A
FIR - Bertolini, Alessandro
IR  - Ardizzoia A
FIR - Ardizzoia, Antonio
IR  - Accettura C
FIR - Accettura, Caterina
IR  - Mitella M
FIR - Mitella, Michele
IR  - Passalacqua R
FIR - Passalacqua, Rodolfo
IR  - Novello S
FIR - Novello, Silvia
IR  - Roila F
FIR - Roila, Fausto
IR  - Tiseo M
FIR - Tiseo, Marcello
IR  - Sekine A
FIR - Sekine, Akimasa
IR  - Takahashi T
FIR - Takahashi, Toshiaki
IR  - Kasahara K
FIR - Kasahara, Kazuo
IR  - Yoh K
FIR - Yoh, Kiyotaka
IR  - Sugawara S
FIR - Sugawara, Shunichi
IR  - Kobayashi N
FIR - Kobayashi, Nobuaki
IR  - Shimokawa T
FIR - Shimokawa, Tsuneo
IR  - Okuda C
FIR - Okuda, Chiyuki
IR  - Fukuhara T
FIR - Fukuhara, Tatsuo
IR  - Sata M
FIR - Sata, Masafumi
IR  - Nagakawa K
FIR - Nagakawa, Kazuhiko
IR  - Atagi S
FIR - Atagi, Shinji
IR  - Nakahara Y
FIR - Nakahara, Yoshiro
IR  - Lee JS
FIR - Lee, Jong-Seok
IR  - Lee KY
FIR - Lee, Kye Young
IR  - Shin SW
FIR - Shin, Sang Won
IR  - Kang JH
FIR - Kang, Jin-Hyoung
IR  - How SH
FIR - How, Soon Hin
IR  - Pang YK
FIR - Pang, Yong Kek
IR  - Osorio-Sanchez JA
FIR - Osorio-Sanchez, Jemela Anne
IR  - Ladrera GEI
FIR - Ladrera, Guia Elena Imelda
IR  - Serwatowski P
FIR - Serwatowski, Piotr
IR  - Szczesna A
FIR - Szczesna, Aleksandra
IR  - Zajda K
FIR - Zajda, Katarzyna
IR  - Ramlau R
FIR - Ramlau, Rodryg
IR  - Sawka D
FIR - Sawka, Dariusz
IR  - Encarnacao Teixeira M
FIR - Encarnacao Teixeira, Maria
IR  - Almodovar T
FIR - Almodovar, Teresa
IR  - Soares M
FIR - Soares, Marta
IR  - Almeida A
FIR - Almeida, Amelia
IR  - Barroso A
FIR - Barroso, Ana
IR  - Schenker M
FIR - Schenker, Michael
IR  - Girgorescu AC
FIR - Girgorescu, Alexandru Calin
IR  - Iorga P
FIR - Iorga, Polixenia
IR  - Orlov S
FIR - Orlov, Sergey
IR  - Karaseva N
FIR - Karaseva, Nina
IR  - Moiseenko V
FIR - Moiseenko, Vladimir
IR  - Garcia Campelo R
FIR - Garcia Campelo, Rosario
IR  - Isla Casado MD
FIR - Isla Casado, Maria Dolores
IR  - Cobo Dols M
FIR - Cobo Dols, Manuel
IR  - Nadal E
FIR - Nadal, Ernest
IR  - Campayo Guillaumes M
FIR - Campayo Guillaumes, Marc
IR  - Gonzalez Larriba JL
FIR - Gonzalez Larriba, Jose Luis
IR  - Majem Tarruella M
FIR - Majem Tarruella, Margarita
IR  - Vazquez Estevez S
FIR - Vazquez Estevez, Sergio
IR  - Fuentes Pradera J
FIR - Fuentes Pradera, Jose
IR  - Marquez Medina D
FIR - Marquez Medina, Diego
IR  - Vikstrom A
FIR - Vikstrom, Anders
IR  - Gautschi O
FIR - Gautschi, Oliver
IR  - Britschgi C
FIR - Britschgi, Christian
IR  - Mueller A
FIR - Mueller, Andreas
IR  - Tsai YH
FIR - Tsai, Ying-Huang
IR  - Wu MF
FIR - Wu, Ming-Fang
IR  - Yang CT
FIR - Yang, Cheng-Ta
IR  - Lin MC
FIR - Lin, Meng Chih
IR  - Chen CH
FIR - Chen, Chao-Hsun
IR  - Srimuninnimit V
FIR - Srimuninnimit, Vichien
IR  - Laohavinij S
FIR - Laohavinij, Sudsawat
IR  - Sriuranpong V
FIR - Sriuranpong, Virote
IR  - Yildiz R
FIR - Yildiz, Ramazan
IR  - Bondarenko I
FIR - Bondarenko, Igor
IR  - Vynnychenko I
FIR - Vynnychenko, Ihor
IR  - Adamchuk H
FIR - Adamchuk, Hryhoriy
IR  - Shparyk Y
FIR - Shparyk, Yaroslav
IR  - Price A
FIR - Price, Allan
IR  - Summers Y
FIR - Summers, Yvonne
IR  - Shah R
FIR - Shah, Riyaz
IR  - Dragnev K
FIR - Dragnev, Konstantin
IR  - Maniam A
FIR - Maniam, Ajit
IR  - McCune S
FIR - McCune, Steven
IR  - Ruiz J
FIR - Ruiz, Jimmy
IR  - Janne P
FIR - Janne, Pasi
IR  - Feinstein T
FIR - Feinstein, Trevor
IR  - Hamm J
FIR - Hamm, John
IR  - Anderson I
FIR - Anderson, Ian
IR  - Khan F
FIR - Khan, Farrah
IR  - Boccia R
FIR - Boccia, Ralph
IR  - Tran N
FIR - Tran, Ngoc
IR  - Nguyen N
FIR - Nguyen, Nhung
EDAT- 2017/11/21 06:00
MHDA- 2018/01/19 06:00
CRDT- 2017/11/21 06:00
PHST- 2017/11/21 06:00 [pubmed]
PHST- 2018/01/19 06:00 [medline]
PHST- 2017/11/21 06:00 [entrez]
AID - 10.1056/NEJMoa1713137 [doi]
PST - ppublish
SO  - N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017
      Nov 18.

PMID- 29056342
OWN - NLM
STAT- MEDLINE
DCOM- 20171215
LR  - 20171215
IS  - 1097-4172 (Electronic)
IS  - 0092-8674 (Linking)
VI  - 171
IP  - 5
DP  - 2017 Nov 16
TI  - Synthetic RNA-Based Immunomodulatory Gene Circuits for Cancer Immunotherapy.
PG  - 1138-1150.e15
LID - S0092-8674(17)31143-1 [pii]
LID - 10.1016/j.cell.2017.09.049 [doi]
AB  - Despite its success in several clinical trials, cancer immunotherapy remains
      limited by the rarity of targetable tumor-specific antigens, tumor-mediated
      immune suppression, and toxicity triggered by systemic delivery of potent
      immunomodulators. Here, we present a proof-of-concept immunomodulatory gene
      circuit platform that enables tumor-specific expression of immunostimulators,
      which could potentially overcome these limitations. Our design comprised de novo 
      synthetic cancer-specific promoters and, to enhance specificity, an RNA-based AND
      gate that generates combinatorial immunomodulatory outputs only when both
      promoters are mutually active. These outputs included an immunogenic cell-surface
      protein, a cytokine, a chemokine, and a checkpoint inhibitor antibody. The
      circuits triggered selective T cell-mediated killing of cancer cells, but not of 
      normal cells, in vitro. In in vivo efficacy assays, lentiviral circuit delivery
      mediated significant tumor reduction and prolonged mouse survival. Our design
      could be adapted to drive additional immunomodulators, sense other cancers, and
      potentially treat other diseases that require precise immunological programming.
CI  - Copyright (c) 2017. Published by Elsevier Inc.
FAU - Nissim, Lior
AU  - Nissim L
AD  - Synthetic Biology Group, Research Laboratory of Electronics , Massachusetts
      Institute of Technology, Cambridge, MA 02139, USA.
FAU - Wu, Ming-Ru
AU  - Wu MR
AD  - Synthetic Biology Group, Research Laboratory of Electronics , Massachusetts
      Institute of Technology, Cambridge, MA 02139, USA.
FAU - Pery, Erez
AU  - Pery E
AD  - Synthetic Biology Group, Research Laboratory of Electronics , Massachusetts
      Institute of Technology, Cambridge, MA 02139, USA.
FAU - Binder-Nissim, Adina
AU  - Binder-Nissim A
AD  - Synthetic Biology Group, Research Laboratory of Electronics , Massachusetts
      Institute of Technology, Cambridge, MA 02139, USA.
FAU - Suzuki, Hiroshi I
AU  - Suzuki HI
AD  - David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute 
      of Technology, Cambridge, MA 02139, USA.
FAU - Stupp, Doron
AU  - Stupp D
AD  - Department of Developmental Biology and Cancer Research, The Institute for
      Medical Research Israel-Canada, and Hadassah Medical School, The Hebrew
      University of Jerusalem, 91120 Jerusalem, Israel.
FAU - Wehrspaun, Claudia
AU  - Wehrspaun C
AD  - Synthetic Biology Group, Research Laboratory of Electronics , Massachusetts
      Institute of Technology, Cambridge, MA 02139, USA.
FAU - Tabach, Yuval
AU  - Tabach Y
AD  - Department of Developmental Biology and Cancer Research, The Institute for
      Medical Research Israel-Canada, and Hadassah Medical School, The Hebrew
      University of Jerusalem, 91120 Jerusalem, Israel.
FAU - Sharp, Phillip A
AU  - Sharp PA
AD  - David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute 
      of Technology, Cambridge, MA 02139, USA; Department of Biology, Massachusetts
      Institute of Technology, Cambridge, MA 02139, USA.
FAU - Lu, Timothy K
AU  - Lu TK
AD  - Synthetic Biology Group, Research Laboratory of Electronics , Massachusetts
      Institute of Technology, Cambridge, MA 02139, USA; David H. Koch Institute for
      Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA
      02139, USA; Synthetic Biology Center, Department of Biological Engineering,
      Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of
      Electrical Engineering and Computer Science , Massachusetts Institute of
      Technology, Cambridge, MA 02139, USA; Biophysics Program, Harvard University,
      Boston, MA 02115, USA; Center for Microbiome Informatics and Therapeutics,
      Massachusetts Institute of Technology, Cambridge, MA 02139, USA. Electronic
      address: timlu@mit.edu.
LA  - eng
PT  - Journal Article
DEP - 20171019
PL  - United States
TA  - Cell
JT  - Cell
JID - 0413066
RN  - 0 (Receptors, Antigen, T-Cell)
SB  - IM
MH  - Animals
MH  - Female
MH  - *Gene Regulatory Networks
MH  - Humans
MH  - Immunomodulation
MH  - Immunotherapy/*methods
MH  - Mice
MH  - Ovarian Neoplasms/immunology/*therapy
MH  - Promoter Regions, Genetic
MH  - Receptors, Antigen, T-Cell/metabolism
MH  - T-Lymphocytes, Cytotoxic/immunology
OTO - NOTNLM
OT  - RNA-based AND gate
OT  - biology
OT  - cancer detecting circuit
OT  - cancer immunotherapy
OT  - genetic circuit
OT  - ovarian cancer
EDAT- 2017/10/24 06:00
MHDA- 2017/12/16 06:00
CRDT- 2017/10/24 06:00
PHST- 2017/06/05 00:00 [received]
PHST- 2017/08/16 00:00 [revised]
PHST- 2017/09/27 00:00 [accepted]
PHST- 2017/10/24 06:00 [pubmed]
PHST- 2017/12/16 06:00 [medline]
PHST- 2017/10/24 06:00 [entrez]
AID - S0092-8674(17)31143-1 [pii]
AID - 10.1016/j.cell.2017.09.049 [doi]
PST - ppublish
SO  - Cell. 2017 Nov 16;171(5):1138-1150.e15. doi: 10.1016/j.cell.2017.09.049. Epub
      2017 Oct 19.

PMID- 29245011
OWN - NLM
STAT- MEDLINE
DCOM- 20171228
LR  - 20171228
IS  - 1097-4172 (Electronic)
IS  - 0092-8674 (Linking)
VI  - 171
IP  - 7
DP  - 2017 Dec 14
TI  - Oncogenic Role of THOR, a Conserved Cancer/Testis Long Non-coding RNA.
PG  - 1559-1572.e20
LID - S0092-8674(17)31430-7 [pii]
LID - 10.1016/j.cell.2017.11.040 [doi]
AB  - Large-scale transcriptome sequencing efforts have vastly expanded the catalog of 
      long non-coding RNAs (lncRNAs) with varying evolutionary conservation, lineage
      expression, and cancer specificity. Here, we functionally characterize a novel
      ultraconserved lncRNA, THOR (ENSG00000226856), which exhibits expression
      exclusively in testis and a broad range of human cancers. THOR knockdown and
      overexpression in multiple cell lines and animal models alters cell or tumor
      growth supporting an oncogenic role. We discovered a conserved interaction of
      THOR with IGF2BP1 and show that THOR contributes to the mRNA stabilization
      activities of IGF2BP1. Notably, transgenic THOR knockout produced fertilization
      defects in zebrafish and also conferred a resistance to melanoma onset. Likewise,
      ectopic expression of human THOR in zebrafish accelerated the onset of melanoma. 
      THOR represents a novel class of functionally important cancer/testis lncRNAs
      whose structure and function have undergone positive evolutionary selection.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Hosono, Yasuyuki
AU  - Hosono Y
AD  - Michigan Center for Translational Pathology, University of Michigan, Ann Arbor,
      MI, USA.
FAU - Niknafs, Yashar S
AU  - Niknafs YS
AD  - Michigan Center for Translational Pathology, University of Michigan, Ann Arbor,
      MI, USA; Department of Cellular and Molecular Biology, University of Michigan,
      Ann Arbor, MI, USA.
FAU - Prensner, John R
AU  - Prensner JR
AD  - Michigan Center for Translational Pathology, University of Michigan, Ann Arbor,
      MI, USA; Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA.
FAU - Iyer, Matthew K
AU  - Iyer MK
AD  - Michigan Center for Translational Pathology, University of Michigan, Ann Arbor,
      MI, USA; Department of Computational Medicine and Bioinformatics, University of
      Michigan, Ann Arbor, MI, USA.
FAU - Dhanasekaran, Saravana M
AU  - Dhanasekaran SM
AD  - Michigan Center for Translational Pathology, University of Michigan, Ann Arbor,
      MI, USA; Department of Pathology, University of Michigan, Ann Arbor, MI, USA.
FAU - Mehra, Rohit
AU  - Mehra R
AD  - Michigan Center for Translational Pathology, University of Michigan, Ann Arbor,
      MI, USA; Department of Pathology, University of Michigan, Ann Arbor, MI, USA.
FAU - Pitchiaya, Sethuramasundaram
AU  - Pitchiaya S
AD  - Michigan Center for Translational Pathology, University of Michigan, Ann Arbor,
      MI, USA.
FAU - Tien, Jean
AU  - Tien J
AD  - Michigan Center for Translational Pathology, University of Michigan, Ann Arbor,
      MI, USA.
FAU - Escara-Wilke, June
AU  - Escara-Wilke J
AD  - Department of Urology, University of Michigan, Ann Arbor, MI, USA.
FAU - Poliakov, Anton
AU  - Poliakov A
AD  - Michigan Center for Translational Pathology, University of Michigan, Ann Arbor,
      MI, USA.
FAU - Chu, Shih-Chun
AU  - Chu SC
AD  - Michigan Center for Translational Pathology, University of Michigan, Ann Arbor,
      MI, USA.
FAU - Saleh, Sahal
AU  - Saleh S
AD  - Michigan Center for Translational Pathology, University of Michigan, Ann Arbor,
      MI, USA.
FAU - Sankar, Keerthana
AU  - Sankar K
AD  - Michigan Center for Translational Pathology, University of Michigan, Ann Arbor,
      MI, USA.
FAU - Su, Fengyun
AU  - Su F
AD  - Michigan Center for Translational Pathology, University of Michigan, Ann Arbor,
      MI, USA.
FAU - Guo, Shuling
AU  - Guo S
AD  - Ionis Pharmaceuticals, Carlsbad, CA, USA.
FAU - Qiao, Yuanyuan
AU  - Qiao Y
AD  - Michigan Center for Translational Pathology, University of Michigan, Ann Arbor,
      MI, USA.
FAU - Freier, Susan M
AU  - Freier SM
AD  - Ionis Pharmaceuticals, Carlsbad, CA, USA.
FAU - Bui, Huynh-Hoa
AU  - Bui HH
AD  - Ionis Pharmaceuticals, Carlsbad, CA, USA.
FAU - Cao, Xuhong
AU  - Cao X
AD  - Michigan Center for Translational Pathology, University of Michigan, Ann Arbor,
      MI, USA.
FAU - Malik, Rohit
AU  - Malik R
AD  - Michigan Center for Translational Pathology, University of Michigan, Ann Arbor,
      MI, USA; Department of Pathology, University of Michigan, Ann Arbor, MI, USA.
FAU - Johnson, Timothy M
AU  - Johnson TM
AD  - Department of Dermatology, University of Michigan Medical School, Ann Arbor, MI, 
      USA; Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, USA.
FAU - Beer, David G
AU  - Beer DG
AD  - Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, USA; Section 
      of Thoracic Surgery, Department of Surgery, University of Michigan, Ann Arbor,
      MI, USA.
FAU - Feng, Felix Y
AU  - Feng FY
AD  - Michigan Center for Translational Pathology, University of Michigan, Ann Arbor,
      MI, USA; Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, USA;
      Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.
FAU - Zhou, Weibin
AU  - Zhou W
AD  - Department of Pediatrics and Communicable Diseases, University of Michigan, Ann
      Arbor, MI, USA.
FAU - Chinnaiyan, Arul M
AU  - Chinnaiyan AM
AD  - Michigan Center for Translational Pathology, University of Michigan, Ann Arbor,
      MI, USA; Department of Cellular and Molecular Biology, University of Michigan,
      Ann Arbor, MI, USA; Department of Pathology, University of Michigan, Ann Arbor,
      MI, USA; Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, USA;
      Howard Hughes Medical Institute, University of Michigan, Ann Arbor, MI, USA;
      Department of Urology, University of Michigan, Ann Arbor, MI, USA. Electronic
      address: arul@med.umich.edu.
LA  - eng
GR  - U01 CA214170/CA/NCI NIH HHS/United States
GR  - R00 DK091405/DK/NIDDK NIH HHS/United States
GR  - Howard Hughes Medical Institute/United States
GR  - P30 DK081943/DK/NIDDK NIH HHS/United States
GR  - K99 DK091405/DK/NIDDK NIH HHS/United States
GR  - F30 CA200328/CA/NCI NIH HHS/United States
GR  - R01 CA154365/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cell
JT  - Cell
JID - 0413066
RN  - 0 (IMP-1 protein, human)
RN  - 0 (RNA, Long Noncoding)
RN  - 0 (RNA-Binding Proteins)
SB  - IM
MH  - Animals
MH  - Cell Line, Tumor
MH  - *Disease Models, Animal
MH  - Gene Knockout Techniques
MH  - Humans
MH  - Male
MH  - Melanoma/*metabolism
MH  - Mice
MH  - RNA, Long Noncoding/*metabolism
MH  - RNA-Binding Proteins/metabolism
MH  - Testis/metabolism
MH  - *Zebrafish
PMC - PMC5734106
MID - NIHMS922696
OTO - NOTNLM
OT  - IGF2BP1
OT  - RNA
OT  - RNA-seq
OT  - cancer
OT  - conservation
OT  - fertility
OT  - iCLIP
OT  - lncRNA
OT  - zebrafish
EDAT- 2017/12/16 06:00
MHDA- 2017/12/29 06:00
CRDT- 2017/12/16 06:00
PMCR- 2018/12/14 00:00
PHST- 2017/02/15 00:00 [received]
PHST- 2017/08/29 00:00 [revised]
PHST- 2017/11/20 00:00 [accepted]
PHST- 2018/12/14 00:00 [pmc-release]
PHST- 2017/12/16 06:00 [entrez]
PHST- 2017/12/16 06:00 [pubmed]
PHST- 2017/12/29 06:00 [medline]
AID - S0092-8674(17)31430-7 [pii]
AID - 10.1016/j.cell.2017.11.040 [doi]
PST - ppublish
SO  - Cell. 2017 Dec 14;171(7):1559-1572.e20. doi: 10.1016/j.cell.2017.11.040.

PMID- 29059683
OWN - NLM
STAT- In-Data-Review
LR  - 20180107
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 551
IP  - 7678
DP  - 2017 Nov 2
TI  - Association analysis identifies 65 new breast cancer risk loci.
PG  - 92-94
LID - 10.1038/nature24284 [doi]
AB  - Breast cancer risk is influenced by rare coding variants in susceptibility genes,
      such as BRCA1, and many common, mostly non-coding variants. However, much of the 
      genetic contribution to breast cancer risk remains unknown. Here we report the
      results of a genome-wide association study of breast cancer in 122,977 cases and 
      105,974 controls of European ancestry and 14,068 cases and 13,104 controls of
      East Asian ancestry. We identified 65 new loci that are associated with overall
      breast cancer risk at P < 5 x 10(-8). The majority of credible risk
      single-nucleotide polymorphisms in these loci fall in distal regulatory elements,
      and by integrating in silico data to predict target genes in breast cells at each
      locus, we demonstrate a strong overlap between candidate target genes and somatic
      driver genes in breast tumours. We also find that heritability of breast cancer
      due to all single-nucleotide polymorphisms in regulatory features was 2-5-fold
      enriched relative to the genome-wide average, with strong enrichment for
      particular transcription factor binding sites. These results provide further
      insight into genetic susceptibility to breast cancer and will improve the use of 
      genetic risk scores for individualized screening and prevention.
FAU - Michailidou, Kyriaki
AU  - Michailidou K
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary
      Care, University of Cambridge, Cambridge, UK.
AD  - Department of Electron Microscopy/Molecular Pathology, The Cyprus Institute of
      Neurology and Genetics, Nicosia, Cyprus.
FAU - Lindstrom, Sara
AU  - Lindstrom S
AD  - Department of Epidemiology, University of Washington School of Public Health,
      Seattle, Washington, USA.
AD  - Program in Genetic Epidemiology and Statistical Genetics, Harvard T. H. Chan
      School of Public Health, Boston, Massachusetts, USA.
FAU - Dennis, Joe
AU  - Dennis J
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary
      Care, University of Cambridge, Cambridge, UK.
FAU - Beesley, Jonathan
AU  - Beesley J
AD  - Department of Genetics and Computational Biology, QIMR Berghofer Medical Research
      Institute, Brisbane, Australia.
FAU - Hui, Shirley
AU  - Hui S
AD  - The Donnelly Centre, University of Toronto, Toronto, Ontario, Canada.
FAU - Kar, Siddhartha
AU  - Kar S
AD  - Centre for Cancer Genetic Epidemiology, Department of Oncology, University of
      Cambridge, Cambridge, UK.
FAU - Lemacon, Audrey
AU  - Lemacon A
AD  - Genomics Center, Centre Hospitalier Universitaire de Quebec Research Center,
      Laval University, Quebec City, Quebec, Canada.
FAU - Soucy, Penny
AU  - Soucy P
AD  - Genomics Center, Centre Hospitalier Universitaire de Quebec Research Center,
      Laval University, Quebec City, Quebec, Canada.
FAU - Glubb, Dylan
AU  - Glubb D
AD  - Department of Genetics and Computational Biology, QIMR Berghofer Medical Research
      Institute, Brisbane, Australia.
FAU - Rostamianfar, Asha
AU  - Rostamianfar A
AD  - The Donnelly Centre, University of Toronto, Toronto, Ontario, Canada.
FAU - Bolla, Manjeet K
AU  - Bolla MK
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary
      Care, University of Cambridge, Cambridge, UK.
FAU - Wang, Qin
AU  - Wang Q
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary
      Care, University of Cambridge, Cambridge, UK.
FAU - Tyrer, Jonathan
AU  - Tyrer J
AD  - Centre for Cancer Genetic Epidemiology, Department of Oncology, University of
      Cambridge, Cambridge, UK.
FAU - Dicks, Ed
AU  - Dicks E
AD  - Centre for Cancer Genetic Epidemiology, Department of Oncology, University of
      Cambridge, Cambridge, UK.
FAU - Lee, Andrew
AU  - Lee A
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary
      Care, University of Cambridge, Cambridge, UK.
FAU - Wang, Zhaoming
AU  - Wang Z
AD  - Department of Computational Biology, St Jude Children's Research Hospital,
      Memphis, Tennessee, USA.
AD  - Cancer Genomics Research Laboratory (CGR), Division of Cancer Epidemiology and
      Genetics, National Cancer Institute, Rockville, Maryland, USA.
FAU - Allen, Jamie
AU  - Allen J
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary
      Care, University of Cambridge, Cambridge, UK.
FAU - Keeman, Renske
AU  - Keeman R
AD  - Division of Molecular Pathology, The Netherlands Cancer Institute, Antoni van
      Leeuwenhoek Hospital, Amsterdam, The Netherlands.
FAU - Eilber, Ursula
AU  - Eilber U
AD  - Division of Cancer Epidemiology, German Cancer Research Center (DKFZ),
      Heidelberg, Germany.
FAU - French, Juliet D
AU  - French JD
AD  - Department of Genetics and Computational Biology, QIMR Berghofer Medical Research
      Institute, Brisbane, Australia.
FAU - Qing Chen, Xiao
AU  - Qing Chen X
AD  - Department of Genetics and Computational Biology, QIMR Berghofer Medical Research
      Institute, Brisbane, Australia.
FAU - Fachal, Laura
AU  - Fachal L
AD  - Centre for Cancer Genetic Epidemiology, Department of Oncology, University of
      Cambridge, Cambridge, UK.
FAU - McCue, Karen
AU  - McCue K
AD  - Department of Genetics and Computational Biology, QIMR Berghofer Medical Research
      Institute, Brisbane, Australia.
FAU - McCart Reed, Amy E
AU  - McCart Reed AE
AD  - UQ Centre for Clinical Research, The University of Queensland, Brisbane,
      Australia.
FAU - Ghoussaini, Maya
AU  - Ghoussaini M
AD  - Centre for Cancer Genetic Epidemiology, Department of Oncology, University of
      Cambridge, Cambridge, UK.
FAU - Carroll, Jason S
AU  - Carroll JS
AD  - Cancer Research UK Cambridge Research Institute, University of Cambridge, Li Ka
      Shing Centre, Cambridge, UK.
FAU - Jiang, Xia
AU  - Jiang X
AD  - Program in Genetic Epidemiology and Statistical Genetics, Harvard T. H. Chan
      School of Public Health, Boston, Massachusetts, USA.
FAU - Finucane, Hilary
AU  - Finucane H
AD  - Program in Genetic Epidemiology and Statistical Genetics, Harvard T. H. Chan
      School of Public Health, Boston, Massachusetts, USA.
AD  - Department of Mathematics, Massachusetts Institute of Technology, Cambridge,
      Massachusetts, USA.
FAU - Adams, Marcia
AU  - Adams M
AD  - Center for Inherited Disease Research (CIDR), Institute of Genetic Medicine,
      Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
FAU - Adank, Muriel A
AU  - Adank MA
AD  - Department of Clinical Genetics, VU University Medical Center, Amsterdam, The
      Netherlands.
FAU - Ahsan, Habibul
AU  - Ahsan H
AD  - Center for Cancer Epidemiology and Prevention, The University of Chicago,
      Chicago, Illinois, USA.
FAU - Aittomaki, Kristiina
AU  - Aittomaki K
AD  - Department of Clinical Genetics, Helsinki University Hospital, University of
      Helsinki, Helsinki, Finland.
FAU - Anton-Culver, Hoda
AU  - Anton-Culver H
AD  - Department of Epidemiology, University of California Irvine, Irvine, California, 
      USA.
FAU - Antonenkova, Natalia N
AU  - Antonenkova NN
AD  - N. N. Alexandrov Research Institute of Oncology and Medical Radiology, Minsk,
      Belarus.
FAU - Arndt, Volker
AU  - Arndt V
AD  - Division of Clinical Epidemiology and Aging Research, German Cancer Research
      Center (DKFZ), Heidelberg, Germany.
FAU - Aronson, Kristan J
AU  - Aronson KJ
AD  - Department of Public Health Sciences, and Cancer Research Institute, Queen's
      University, Kingston, Ontario, Canada.
FAU - Arun, Banu
AU  - Arun B
AD  - Department of Breast Medical Oncology, University of Texas MD Anderson Cancer
      Center, Houston, Texas, USA.
FAU - Auer, Paul L
AU  - Auer PL
AD  - Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle,
      Washington, USA.
AD  - Zilber School of Public Health, University of Wisconsin-Milwaukee, Milwaukee,
      Wisconsin, USA.
FAU - Bacot, Francois
AU  - Bacot F
AD  - McGill University and Genome Quebec Innovation Centre, Montreal, Quebec, Canada.
FAU - Barrdahl, Myrto
AU  - Barrdahl M
AD  - Division of Cancer Epidemiology, German Cancer Research Center (DKFZ),
      Heidelberg, Germany.
FAU - Baynes, Caroline
AU  - Baynes C
AD  - Centre for Cancer Genetic Epidemiology, Department of Oncology, University of
      Cambridge, Cambridge, UK.
FAU - Beckmann, Matthias W
AU  - Beckmann MW
AD  - Department of Gynaecology and Obstetrics, University Hospital Erlangen,
      Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center
      Erlangen-EMN, Erlangen, Germany.
FAU - Behrens, Sabine
AU  - Behrens S
AD  - Division of Cancer Epidemiology, German Cancer Research Center (DKFZ),
      Heidelberg, Germany.
FAU - Benitez, Javier
AU  - Benitez J
AD  - Human Cancer Genetics Program, Spanish National Cancer Research Centre, Madrid,
      Spain.
AD  - Centro de Investigacion en Red de Enfermedades Raras (CIBERER), Valencia, Spain.
FAU - Bermisheva, Marina
AU  - Bermisheva M
AD  - Institute of Biochemistry and Genetics, Ufa Scientific Center of Russian Academy 
      of Sciences, Ufa, Russia.
FAU - Bernstein, Leslie
AU  - Bernstein L
AD  - Department of Population Sciences, Beckman Research Institute of City of Hope,
      Duarte, California, USA.
FAU - Blomqvist, Carl
AU  - Blomqvist C
AD  - Department of Oncology, Helsinki University Hospital, University of Helsinki,
      Helsinki, Finland.
FAU - Bogdanova, Natalia V
AU  - Bogdanova NV
AD  - N. N. Alexandrov Research Institute of Oncology and Medical Radiology, Minsk,
      Belarus.
AD  - Department of Radiation Oncology, Hannover Medical School, Hannover, Germany.
AD  - Gynaecology Research Unit, Hannover Medical School, Hannover, Germany.
FAU - Bojesen, Stig E
AU  - Bojesen SE
AD  - Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen
      University Hospital, Herlev, Denmark.
AD  - Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen
      University Hospital, Herlev, Denmark.
AD  - Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen,
      Denmark.
FAU - Bonanni, Bernardo
AU  - Bonanni B
AD  - Division of Cancer Prevention and Genetics, Istituto Europeo di Oncologia, Milan,
      Italy.
FAU - Borresen-Dale, Anne-Lise
AU  - Borresen-Dale AL
AD  - Department of Cancer Genetics, Institute for Cancer Research, Oslo University
      Hospital Radiumhospitalet, Oslo, Norway.
FAU - Brand, Judith S
AU  - Brand JS
AD  - Department of Medical Epidemiology and Biostatistics, Karolinska Institutet,
      Stockholm, Sweden.
FAU - Brauch, Hiltrud
AU  - Brauch H
AD  - Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart,
      Germany.
AD  - University of Tubingen, Tubingen, Germany.
AD  - German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ),
      Heidelberg, Germany.
FAU - Brennan, Paul
AU  - Brennan P
AD  - International Agency for Research on Cancer, Lyon, France.
FAU - Brenner, Hermann
AU  - Brenner H
AD  - Division of Clinical Epidemiology and Aging Research, German Cancer Research
      Center (DKFZ), Heidelberg, Germany.
AD  - German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ),
      Heidelberg, Germany.
AD  - Division of Preventive Oncology, German Cancer Research Center (DKFZ) and
      National Center for Tumor Diseases (NCT), Heidelberg, Germany.
FAU - Brinton, Louise
AU  - Brinton L
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute,
      Rockville, Maryland, USA.
FAU - Broberg, Per
AU  - Broberg P
AD  - Department of Cancer Epidemiology, Clinical Sciences, Lund University, Lund,
      Sweden.
FAU - Brock, Ian W
AU  - Brock IW
AD  - Sheffield Institute for Nucleic Acids (SInFoNiA), Department of Oncology and
      Metabolism, University of Sheffield, Sheffield, UK.
FAU - Broeks, Annegien
AU  - Broeks A
AD  - Division of Molecular Pathology, The Netherlands Cancer Institute, Antoni van
      Leeuwenhoek Hospital, Amsterdam, The Netherlands.
FAU - Brooks-Wilson, Angela
AU  - Brooks-Wilson A
AD  - Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia, Canada.
AD  - Department of Biomedical Physiology and Kinesiology, Simon Fraser University,
      Burnaby, British Columbia, Canada.
FAU - Brucker, Sara Y
AU  - Brucker SY
AD  - Department of Gynecology and Obstetrics, University of Tubingen, Tubingen,
      Germany.
FAU - Bruning, Thomas
AU  - Bruning T
AD  - Institute for Prevention and Occupational Medicine of the German Social Accident 
      Insurance, Institute of the Ruhr University Bochum, Bochum, Germany.
FAU - Burwinkel, Barbara
AU  - Burwinkel B
AD  - Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg,
      Germany.
AD  - Molecular Epidemiology Group, C080, German Cancer Research Center (DKFZ),
      Heidelberg, Germany.
FAU - Butterbach, Katja
AU  - Butterbach K
AD  - Division of Clinical Epidemiology and Aging Research, German Cancer Research
      Center (DKFZ), Heidelberg, Germany.
FAU - Cai, Qiuyin
AU  - Cai Q
AD  - Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center,
      Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine,
      Nashville, Tennessee, USA.
FAU - Cai, Hui
AU  - Cai H
AD  - Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center,
      Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine,
      Nashville, Tennessee, USA.
FAU - Caldes, Trinidad
AU  - Caldes T
AD  - Medical Oncology Department, Hospital Clinico San Carlos, IdISSC (Centro
      Investigacion Biomedica en Red), CIBERONC (Instituto de Investigacion Sanitaria
      San Carlos), Madrid, Spain.
FAU - Canzian, Federico
AU  - Canzian F
AD  - Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg,
      Germany.
FAU - Carracedo, Angel
AU  - Carracedo A
AD  - Genomic Medicine Group, Galician Foundation of Genomic Medicine, Instituto de
      Investigacion Sanitaria de Santiago de Compostela (IDIS), Complejo Hospitalario
      Universitario de Santiago, SERGAS, Santiago De Compostela, Spain.
AD  - Centro de Investigacion en Red de Enfermedades Raras (CIBERER) y Centro Nacional 
      de Genotipado (CEGEN-PRB2), Universidad de Santiago de Compostela, Santiago De
      Compostela, Spain.
FAU - Carter, Brian D
AU  - Carter BD
AD  - Epidemiology Research Program, American Cancer Society, Atlanta, Georgia, USA.
FAU - Castelao, Jose E
AU  - Castelao JE
AD  - Oncology and Genetics Unit, Instituto de Investigacion Biomedica (IBI)
      Orense-Pontevedra-Vigo, Xerencia de Xestion Integrada de Vigo-SERGAS, Vigo,
      Spain.
FAU - Chan, Tsun L
AU  - Chan TL
AD  - Hong Kong Hereditary Breast Cancer Family Registry, Happy Valley, Hong Kong.
AD  - Department of Pathology, Hong Kong Sanatorium and Hospital, Happy Valley, Hong
      Kong.
FAU - David Cheng, Ting-Yuan
AU  - David Cheng TY
AD  - Division of Cancer Prevention and Control, Roswell Park Cancer Institute,
      Buffalo, New York, USA.
FAU - Seng Chia, Kee
AU  - Seng Chia K
AD  - Saw Swee Hock School of Public Health, National University of Singapore,
      Singapore, Singapore.
FAU - Choi, Ji-Yeob
AU  - Choi JY
AD  - Department of Biomedical Sciences, Seoul National University Graduate School,
      Seoul, South Korea.
AD  - Cancer Research Institute, Seoul National University, Seoul, South Korea.
FAU - Christiansen, Hans
AU  - Christiansen H
AD  - Department of Radiation Oncology, Hannover Medical School, Hannover, Germany.
FAU - Clarke, Christine L
AU  - Clarke CL
AD  - Westmead Institute for Medical Research, University of Sydney, Sydney, Australia.
CN  - NBCS Collaborators
FAU - Collee, Margriet
AU  - Collee M
AD  - Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam,
      The Netherlands.
FAU - Conroy, Don M
AU  - Conroy DM
AD  - Centre for Cancer Genetic Epidemiology, Department of Oncology, University of
      Cambridge, Cambridge, UK.
FAU - Cordina-Duverger, Emilie
AU  - Cordina-Duverger E
AD  - Cancer & Environment Group, Center for Research in Epidemiology and Population
      Health (CESP), INSERM, University Paris-Sud, University Paris-Saclay, Villejuif, 
      France.
FAU - Cornelissen, Sten
AU  - Cornelissen S
AD  - Division of Molecular Pathology, The Netherlands Cancer Institute, Antoni van
      Leeuwenhoek Hospital, Amsterdam, The Netherlands.
FAU - Cox, David G
AU  - Cox DG
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Imperial
      College London, London, UK.
AD  - INSERM U1052, Cancer Research Center of Lyon, Lyon, France.
FAU - Cox, Angela
AU  - Cox A
AD  - Sheffield Institute for Nucleic Acids (SInFoNiA), Department of Oncology and
      Metabolism, University of Sheffield, Sheffield, UK.
FAU - Cross, Simon S
AU  - Cross SS
AD  - Academic Unit of Pathology, Department of Neuroscience, University of Sheffield, 
      Sheffield, UK.
FAU - Cunningham, Julie M
AU  - Cunningham JM
AD  - Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester,
      Minnesota, USA.
FAU - Czene, Kamila
AU  - Czene K
AD  - Department of Medical Epidemiology and Biostatistics, Karolinska Institutet,
      Stockholm, Sweden.
FAU - Daly, Mary B
AU  - Daly MB
AD  - Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia,
      Pennsylvania, USA.
FAU - Devilee, Peter
AU  - Devilee P
AD  - Department of Pathology, Leiden University Medical Center, Leiden, The
      Netherlands.
AD  - Department of Human Genetics, Leiden University Medical Center, Leiden, The
      Netherlands.
FAU - Doheny, Kimberly F
AU  - Doheny KF
AD  - Center for Inherited Disease Research (CIDR), Institute of Genetic Medicine,
      Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
FAU - Dork, Thilo
AU  - Dork T
AD  - Gynaecology Research Unit, Hannover Medical School, Hannover, Germany.
FAU - Dos-Santos-Silva, Isabel
AU  - Dos-Santos-Silva I
AD  - Department of Non-Communicable Disease Epidemiology, London School of Hygiene and
      Tropical Medicine, London, UK.
FAU - Dumont, Martine
AU  - Dumont M
AD  - Genomics Center, Centre Hospitalier Universitaire de Quebec Research Center,
      Laval University, Quebec City, Quebec, Canada.
FAU - Durcan, Lorraine
AU  - Durcan L
AD  - Southampton Clinical Trials Unit, Faculty of Medicine, University of Southampton,
      Southampton, UK.
AD  - Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton,
      Southampton, UK.
FAU - Dwek, Miriam
AU  - Dwek M
AD  - Department of Biomedical Sciences, Faculty of Science and Technology, University 
      of Westminster, London, UK.
FAU - Eccles, Diana M
AU  - Eccles DM
AD  - Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton,
      Southampton, UK.
FAU - Ekici, Arif B
AU  - Ekici AB
AD  - Institute of Human Genetics, University Hospital Erlangen, Friedrich-Alexander
      University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN,
      Erlangen, Germany.
FAU - Eliassen, A Heather
AU  - Eliassen AH
AD  - Channing Division of Network Medicine, Department of Medicine, Brigham and
      Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
AD  - Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston,
      Massachusetts, USA.
FAU - Ellberg, Carolina
AU  - Ellberg C
AD  - Department of Cancer Epidemiology, Clinical Sciences, Lund University, Lund,
      Sweden.
AD  - Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund,
      Sweden.
FAU - Elvira, Mingajeva
AU  - Elvira M
AD  - Department of Genetics and Fundamental Medicine, Bashkir State University, Ufa,
      Russia.
FAU - Engel, Christoph
AU  - Engel C
AD  - Institute for Medical Informatics, Statistics and Epidemiology, University of
      Leipzig, Leipzig, Germany.
AD  - LIFE-Leipzig Research Centre for Civilization Diseases, University of Leipzig,
      Leipzig, Germany.
FAU - Eriksson, Mikael
AU  - Eriksson M
AD  - Department of Medical Epidemiology and Biostatistics, Karolinska Institutet,
      Stockholm, Sweden.
FAU - Fasching, Peter A
AU  - Fasching PA
AD  - Department of Gynaecology and Obstetrics, University Hospital Erlangen,
      Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center
      Erlangen-EMN, Erlangen, Germany.
AD  - David Geffen School of Medicine, Department of Medicine Division of Hematology
      and Oncology, University of California at Los Angeles, Los Angeles, California,
      USA.
FAU - Figueroa, Jonine
AU  - Figueroa J
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute,
      Rockville, Maryland, USA.
AD  - Usher Institute of Population Health Sciences and Informatics, The University of 
      Edinburgh Medical School, Edinburgh, UK.
FAU - Flesch-Janys, Dieter
AU  - Flesch-Janys D
AD  - Institute for Medical Biometrics and Epidemiology, University Medical Center
      Hamburg-Eppendorf, Hamburg, Germany.
AD  - Department of Cancer Epidemiology, Clinical Cancer Registry, University Medical
      Center Hamburg-Eppendorf, Hamburg, Germany.
FAU - Fletcher, Olivia
AU  - Fletcher O
AD  - Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, 
      London, UK.
FAU - Flyger, Henrik
AU  - Flyger H
AD  - Department of Breast Surgery, Herlev and Gentofte Hospital, Copenhagen University
      Hospital, Herlev, Denmark.
FAU - Fritschi, Lin
AU  - Fritschi L
AD  - School of Public Health, Curtin University, Perth, Australia.
FAU - Gaborieau, Valerie
AU  - Gaborieau V
AD  - International Agency for Research on Cancer, Lyon, France.
FAU - Gabrielson, Marike
AU  - Gabrielson M
AD  - Department of Medical Epidemiology and Biostatistics, Karolinska Institutet,
      Stockholm, Sweden.
FAU - Gago-Dominguez, Manuela
AU  - Gago-Dominguez M
AD  - Genomic Medicine Group, Galician Foundation of Genomic Medicine, Instituto de
      Investigacion Sanitaria de Santiago de Compostela (IDIS), Complejo Hospitalario
      Universitario de Santiago, SERGAS, Santiago De Compostela, Spain.
AD  - Moores Cancer Center, University of California San Diego, La Jolla, California,
      USA.
FAU - Gao, Yu-Tang
AU  - Gao YT
AD  - Department of Epidemiology, Shanghai Cancer Institute, Shanghai, China.
FAU - Gapstur, Susan M
AU  - Gapstur SM
AD  - Epidemiology Research Program, American Cancer Society, Atlanta, Georgia, USA.
FAU - Garcia-Saenz, Jose A
AU  - Garcia-Saenz JA
AD  - Medical Oncology Department, Hospital Clinico San Carlos, IdISSC (Centro
      Investigacion Biomedica en Red), CIBERONC (Instituto de Investigacion Sanitaria
      San Carlos), Madrid, Spain.
FAU - Gaudet, Mia M
AU  - Gaudet MM
AD  - Epidemiology Research Program, American Cancer Society, Atlanta, Georgia, USA.
FAU - Georgoulias, Vassilios
AU  - Georgoulias V
AD  - Department of Medical Oncology, University Hospital of Heraklion, Heraklion,
      Greece.
FAU - Giles, Graham G
AU  - Giles GG
AD  - Cancer Epidemiology and Intelligence Division, Cancer Council Victoria,
      Melbourne, Victoria, Australia.
AD  - Centre for Epidemiology and Biostatistics, Melbourne School of Population and
      Global Health, The University of Melbourne, Melbourne, Australia.
FAU - Glendon, Gord
AU  - Glendon G
AD  - Fred A. Litwin Center for Cancer Genetics, Lunenfeld-Tanenbaum Research Institute
      of Mount Sinai Hospital, Toronto, Ontario, Canada.
FAU - Goldberg, Mark S
AU  - Goldberg MS
AD  - Department of Medicine, McGill University, Montreal, Quebec, Canada.
AD  - Division of Clinical Epidemiology, Royal Victoria Hospital, McGill University,
      Montreal, Quebec, Canada.
FAU - Goldgar, David E
AU  - Goldgar DE
AD  - Department of Dermatology, Huntsman Cancer Institute, University of Utah School
      of Medicine, Salt Lake City, Utah, USA.
FAU - Gonzalez-Neira, Anna
AU  - Gonzalez-Neira A
AD  - Human Cancer Genetics Program, Spanish National Cancer Research Centre, Madrid,
      Spain.
FAU - Grenaker Alnaes, Grethe I
AU  - Grenaker Alnaes GI
AD  - Department of Cancer Genetics, Institute for Cancer Research, Oslo University
      Hospital Radiumhospitalet, Oslo, Norway.
FAU - Grip, Mervi
AU  - Grip M
AD  - Department of Surgery, Oulu University Hospital, University of Oulu, Oulu,
      Finland.
FAU - Gronwald, Jacek
AU  - Gronwald J
AD  - Department of Genetics and Pathology, Pomeranian Medical University, Szczecin,
      Poland.
FAU - Grundy, Anne
AU  - Grundy A
AD  - Centre de Recherche du Centre Hospitalier de Universite de Montreal (CHUM),
      Universite de Montreal, Montreal, Quebec, Canada.
FAU - Guenel, Pascal
AU  - Guenel P
AD  - Cancer & Environment Group, Center for Research in Epidemiology and Population
      Health (CESP), INSERM, University Paris-Sud, University Paris-Saclay, Villejuif, 
      France.
FAU - Haeberle, Lothar
AU  - Haeberle L
AD  - Department of Gynaecology and Obstetrics, University Hospital Erlangen,
      Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center
      Erlangen-EMN, Erlangen, Germany.
FAU - Hahnen, Eric
AU  - Hahnen E
AD  - Center for Hereditary Breast and Ovarian Cancer, University Hospital of Cologne, 
      Cologne, Germany.
AD  - Center for Integrated Oncology (CIO), University Hospital of Cologne, Cologne,
      Germany.
AD  - Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne,
      Germany.
FAU - Haiman, Christopher A
AU  - Haiman CA
AD  - Department of Preventive Medicine, Keck School of Medicine, University of
      Southern California, Los Angeles, California, USA.
FAU - Hakansson, Niclas
AU  - Hakansson N
AD  - Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
FAU - Hamann, Ute
AU  - Hamann U
AD  - Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ),
      Heidelberg, Germany.
FAU - Hamel, Nathalie
AU  - Hamel N
AD  - McGill University and Genome Quebec Innovation Centre, Montreal, Quebec, Canada.
FAU - Hankinson, Susan
AU  - Hankinson S
AD  - Department of Biostatistics & Epidemiology, University of Massachusetts, Amherst,
      Amherst, Massachusetts, USA.
FAU - Harrington, Patricia
AU  - Harrington P
AD  - Centre for Cancer Genetic Epidemiology, Department of Oncology, University of
      Cambridge, Cambridge, UK.
FAU - Hart, Steven N
AU  - Hart SN
AD  - Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.
FAU - Hartikainen, Jaana M
AU  - Hartikainen JM
AD  - Translational Cancer Research Area, University of Eastern Finland, Kuopio,
      Finland.
AD  - Institute of Clinical Medicine, Pathology and Forensic Medicine, University of
      Eastern Finland, Kuopio, Finland.
AD  - Imaging Center, Department of Clinical Pathology, Kuopio University Hospital,
      Kuopio, Finland.
FAU - Hartman, Mikael
AU  - Hartman M
AD  - Saw Swee Hock School of Public Health, National University of Singapore,
      Singapore, Singapore.
AD  - Department of Surgery, National University Health System, Singapore, Singapore.
FAU - Hein, Alexander
AU  - Hein A
AD  - Department of Gynaecology and Obstetrics, University Hospital Erlangen,
      Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center
      Erlangen-EMN, Erlangen, Germany.
FAU - Heyworth, Jane
AU  - Heyworth J
AD  - School of Population Health, University of Western Australia, Perth, Australia.
FAU - Hicks, Belynda
AU  - Hicks B
AD  - Cancer Genomics Research Laboratory (CGR), Division of Cancer Epidemiology and
      Genetics, National Cancer Institute, Rockville, Maryland, USA.
FAU - Hillemanns, Peter
AU  - Hillemanns P
AD  - Gynaecology Research Unit, Hannover Medical School, Hannover, Germany.
FAU - Ho, Dona N
AU  - Ho DN
AD  - Department of Pathology, Hong Kong Sanatorium and Hospital, Happy Valley, Hong
      Kong.
FAU - Hollestelle, Antoinette
AU  - Hollestelle A
AD  - Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer
      Institute, Rotterdam, The Netherlands.
FAU - Hooning, Maartje J
AU  - Hooning MJ
AD  - Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer
      Institute, Rotterdam, The Netherlands.
FAU - Hoover, Robert N
AU  - Hoover RN
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute,
      Rockville, Maryland, USA.
FAU - Hopper, John L
AU  - Hopper JL
AD  - Centre for Epidemiology and Biostatistics, Melbourne School of Population and
      Global Health, The University of Melbourne, Melbourne, Australia.
FAU - Hou, Ming-Feng
AU  - Hou MF
AD  - Division of Breast Surgery, Department of Surgery, Kaohsiung Medical University, 
      Kaohsiung, Taiwan.
FAU - Hsiung, Chia-Ni
AU  - Hsiung CN
AD  - Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
FAU - Huang, Guanmengqian
AU  - Huang G
AD  - Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ),
      Heidelberg, Germany.
FAU - Humphreys, Keith
AU  - Humphreys K
AD  - Department of Medical Epidemiology and Biostatistics, Karolinska Institutet,
      Stockholm, Sweden.
FAU - Ishiguro, Junko
AU  - Ishiguro J
AD  - Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, 
      Nagoya, Japan.
AD  - Department of Epidemiology, Nagoya University Graduate School of Medicine,
      Nagoya, Japan.
FAU - Ito, Hidemi
AU  - Ito H
AD  - Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, 
      Nagoya, Japan.
AD  - Department of Epidemiology, Nagoya University Graduate School of Medicine,
      Nagoya, Japan.
FAU - Iwasaki, Motoki
AU  - Iwasaki M
AD  - Division of Epidemiology, Center for Public Health Sciences, National Cancer
      Center, Tokyo, Japan.
FAU - Iwata, Hiroji
AU  - Iwata H
AD  - Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
FAU - Jakubowska, Anna
AU  - Jakubowska A
AD  - Department of Genetics and Pathology, Pomeranian Medical University, Szczecin,
      Poland.
FAU - Janni, Wolfgang
AU  - Janni W
AD  - Department of Gynecology and Obstetrics, University Hospital Ulm, Ulm, Germany.
FAU - John, Esther M
AU  - John EM
AD  - Department of Epidemiology, Cancer Prevention Institute of California, Fremont,
      California, USA.
AD  - Department of Health Research and Policy-Epidemiology, Stanford University School
      of Medicine, Stanford, California, USA.
AD  - Stanford Cancer Institute, Stanford University School of Medicine, Stanford,
      California, USA.
FAU - Johnson, Nichola
AU  - Johnson N
AD  - Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, 
      London, UK.
FAU - Jones, Kristine
AU  - Jones K
AD  - Cancer Genomics Research Laboratory (CGR), Division of Cancer Epidemiology and
      Genetics, National Cancer Institute, Rockville, Maryland, USA.
FAU - Jones, Michael
AU  - Jones M
AD  - Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK.
FAU - Jukkola-Vuorinen, Arja
AU  - Jukkola-Vuorinen A
AD  - Department of Oncology, Oulu University Hospital, University of Oulu, Oulu,
      Finland.
FAU - Kaaks, Rudolf
AU  - Kaaks R
AD  - Division of Cancer Epidemiology, German Cancer Research Center (DKFZ),
      Heidelberg, Germany.
FAU - Kabisch, Maria
AU  - Kabisch M
AD  - Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ),
      Heidelberg, Germany.
FAU - Kaczmarek, Katarzyna
AU  - Kaczmarek K
AD  - Department of Genetics and Pathology, Pomeranian Medical University, Szczecin,
      Poland.
FAU - Kang, Daehee
AU  - Kang D
AD  - Department of Biomedical Sciences, Seoul National University Graduate School,
      Seoul, South Korea.
AD  - Cancer Research Institute, Seoul National University, Seoul, South Korea.
AD  - Department of Preventive Medicine, Seoul National University College of Medicine,
      Seoul, South Korea.
FAU - Kasuga, Yoshio
AU  - Kasuga Y
AD  - Department of Surgery, Nagano Matsushiro General Hospital, Nagano, Japan.
FAU - Kerin, Michael J
AU  - Kerin MJ
AD  - School of Medicine, National University of Ireland, Galway, Ireland.
FAU - Khan, Sofia
AU  - Khan S
AD  - Department of Obstetrics and Gynecology, Helsinki University Hospital, University
      of Helsinki, Helsinki, Finland.
FAU - Khusnutdinova, Elza
AU  - Khusnutdinova E
AD  - Institute of Biochemistry and Genetics, Ufa Scientific Center of Russian Academy 
      of Sciences, Ufa, Russia.
AD  - Department of Genetics and Fundamental Medicine, Bashkir State University, Ufa,
      Russia.
FAU - Kiiski, Johanna I
AU  - Kiiski JI
AD  - Department of Obstetrics and Gynecology, Helsinki University Hospital, University
      of Helsinki, Helsinki, Finland.
FAU - Kim, Sung-Won
AU  - Kim SW
AD  - Department of Surgery, Daerim Saint Mary's Hospital, Seoul, South Korea.
FAU - Knight, Julia A
AU  - Knight JA
AD  - Prosserman Centre for Health Research, Lunenfeld-Tanenbaum Research Institute of 
      Mount Sinai Hospital, Toronto, Ontario, Canada.
AD  - Division of Epidemiology, Dalla Lana School of Public Health, University of
      Toronto, Toronto, Ontario, Canada.
FAU - Kosma, Veli-Matti
AU  - Kosma VM
AD  - Translational Cancer Research Area, University of Eastern Finland, Kuopio,
      Finland.
AD  - Institute of Clinical Medicine, Pathology and Forensic Medicine, University of
      Eastern Finland, Kuopio, Finland.
AD  - Imaging Center, Department of Clinical Pathology, Kuopio University Hospital,
      Kuopio, Finland.
FAU - Kristensen, Vessela N
AU  - Kristensen VN
AD  - Department of Cancer Genetics, Institute for Cancer Research, Oslo University
      Hospital Radiumhospitalet, Oslo, Norway.
AD  - Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo,
      Norway.
AD  - Department of Clinical Molecular Biology, Oslo University Hospital, University of
      Oslo, Oslo, Norway.
FAU - Kruger, Ute
AU  - Kruger U
AD  - Department of Cancer Epidemiology, Clinical Sciences, Lund University, Lund,
      Sweden.
FAU - Kwong, Ava
AU  - Kwong A
AD  - Hong Kong Hereditary Breast Cancer Family Registry, Happy Valley, Hong Kong.
AD  - Department of Surgery, The University of Hong Kong, Pok Fu Lam, Hong Kong.
AD  - Department of Surgery, Hong Kong Sanatorium and Hospital, Happy Valley, Hong
      Kong.
FAU - Lambrechts, Diether
AU  - Lambrechts D
AD  - Vesalius Research Center, VIB, Leuven, Belgium.
AD  - Laboratory for Translational Genetics, Department of Oncology, University of
      Leuven, Leuven, Belgium.
FAU - Le Marchand, Loic
AU  - Le Marchand L
AD  - University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
FAU - Lee, Eunjung
AU  - Lee E
AD  - Department of Preventive Medicine, Keck School of Medicine, University of
      Southern California, Los Angeles, California, USA.
FAU - Lee, Min Hyuk
AU  - Lee MH
AD  - Department of Surgery, Soonchunhyang University College of Medicine and
      Soonchunhyang University Hospital, Seoul, South Korea.
FAU - Lee, Jong Won
AU  - Lee JW
AD  - Department of Surgery, University of Ulsan College of Medicine and Asan Medical
      Center, Seoul, South Korea.
FAU - Neng Lee, Chuen
AU  - Neng Lee C
AD  - Department of Surgery, National University Health System, Singapore, Singapore.
AD  - Department of Cardiac, Thoracic and Vascular Surgery, National University Health 
      System, Singapore, Singapore.
FAU - Lejbkowicz, Flavio
AU  - Lejbkowicz F
AD  - Clalit National Cancer Control Center, Carmel Medical Center and Technion Faculty
      of Medicine, Haifa, Israel.
FAU - Li, Jingmei
AU  - Li J
AD  - Department of Medical Epidemiology and Biostatistics, Karolinska Institutet,
      Stockholm, Sweden.
FAU - Lilyquist, Jenna
AU  - Lilyquist J
AD  - Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.
FAU - Lindblom, Annika
AU  - Lindblom A
AD  - Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm,
      Sweden.
FAU - Lissowska, Jolanta
AU  - Lissowska J
AD  - Department of Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial
      Cancer Center & Institute of Oncology, Warsaw, Poland.
FAU - Lo, Wing-Yee
AU  - Lo WY
AD  - Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart,
      Germany.
AD  - University of Tubingen, Tubingen, Germany.
FAU - Loibl, Sibylle
AU  - Loibl S
AD  - German Breast Group GmbH, Neu Isenburg, Germany.
FAU - Long, Jirong
AU  - Long J
AD  - Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center,
      Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine,
      Nashville, Tennessee, USA.
FAU - Lophatananon, Artitaya
AU  - Lophatananon A
AD  - Division of Health Sciences, Warwick Medical School, Warwick University,
      Coventry, UK.
AD  - Institute of Population Health, University of Manchester, Manchester, UK.
FAU - Lubinski, Jan
AU  - Lubinski J
AD  - Department of Genetics and Pathology, Pomeranian Medical University, Szczecin,
      Poland.
FAU - Luccarini, Craig
AU  - Luccarini C
AD  - Centre for Cancer Genetic Epidemiology, Department of Oncology, University of
      Cambridge, Cambridge, UK.
FAU - Lux, Michael P
AU  - Lux MP
AD  - Department of Gynaecology and Obstetrics, University Hospital Erlangen,
      Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center
      Erlangen-EMN, Erlangen, Germany.
FAU - Ma, Edmond S K
AU  - Ma ESK
AD  - Hong Kong Hereditary Breast Cancer Family Registry, Happy Valley, Hong Kong.
AD  - Department of Pathology, Hong Kong Sanatorium and Hospital, Happy Valley, Hong
      Kong.
FAU - MacInnis, Robert J
AU  - MacInnis RJ
AD  - Cancer Epidemiology and Intelligence Division, Cancer Council Victoria,
      Melbourne, Victoria, Australia.
AD  - Centre for Epidemiology and Biostatistics, Melbourne School of Population and
      Global Health, The University of Melbourne, Melbourne, Australia.
FAU - Maishman, Tom
AU  - Maishman T
AD  - Southampton Clinical Trials Unit, Faculty of Medicine, University of Southampton,
      Southampton, UK.
AD  - Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton,
      Southampton, UK.
FAU - Makalic, Enes
AU  - Makalic E
AD  - Centre for Epidemiology and Biostatistics, Melbourne School of Population and
      Global Health, The University of Melbourne, Melbourne, Australia.
FAU - Malone, Kathleen E
AU  - Malone KE
AD  - Division of Public Health Sciences, Epidemiology Program, Fred Hutchinson Cancer 
      Research Center, Seattle, Washington, USA.
FAU - Kostovska, Ivana Maleva
AU  - Kostovska IM
AD  - Research Centre for Genetic Engineering and Biotechnology "Georgi D. Efremov",
      Macedonian Academy of Sciences and Arts, Skopje, Republic of Macedonia.
FAU - Mannermaa, Arto
AU  - Mannermaa A
AD  - Translational Cancer Research Area, University of Eastern Finland, Kuopio,
      Finland.
AD  - Institute of Clinical Medicine, Pathology and Forensic Medicine, University of
      Eastern Finland, Kuopio, Finland.
AD  - Imaging Center, Department of Clinical Pathology, Kuopio University Hospital,
      Kuopio, Finland.
FAU - Manoukian, Siranoush
AU  - Manoukian S
AD  - Unit of Medical Genetics, Department of Preventive and Predictive Medicine,
      Fondazione IRCCS (Istituto Di Ricovero e Cura a Carattere Scientifico) Istituto
      Nazionale dei Tumori (INT), Milan, Italy.
FAU - Manson, JoAnn E
AU  - Manson JE
AD  - Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston,
      Massachusetts, USA.
AD  - Department of Medicine, Brigham and Women's Hospital, Harvard Medical School,
      Boston, Massachusetts, USA.
FAU - Margolin, Sara
AU  - Margolin S
AD  - Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
FAU - Mariapun, Shivaani
AU  - Mariapun S
AD  - Cancer Research Malaysia, Subang Jaya, Selangor, Malaysia.
FAU - Martinez, Maria Elena
AU  - Martinez ME
AD  - Moores Cancer Center, University of California San Diego, La Jolla, California,
      USA.
AD  - Department of Family Medicine and Public Health, University of California San
      Diego, La Jolla, California, USA.
FAU - Matsuo, Keitaro
AU  - Matsuo K
AD  - Department of Epidemiology, Nagoya University Graduate School of Medicine,
      Nagoya, Japan.
AD  - Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya,
      Japan.
FAU - Mavroudis, Dimitrios
AU  - Mavroudis D
AD  - Department of Medical Oncology, University Hospital of Heraklion, Heraklion,
      Greece.
FAU - McKay, James
AU  - McKay J
AD  - International Agency for Research on Cancer, Lyon, France.
FAU - McLean, Catriona
AU  - McLean C
AD  - Anatomical Pathology, The Alfred Hospital, Melbourne, Australia.
FAU - Meijers-Heijboer, Hanne
AU  - Meijers-Heijboer H
AD  - Department of Clinical Genetics, VU University Medical Center, Amsterdam, The
      Netherlands.
FAU - Meindl, Alfons
AU  - Meindl A
AD  - Division of Gynaecology and Obstetrics, Technische Universitat Munchen, Munich,
      Germany.
FAU - Menendez, Primitiva
AU  - Menendez P
AD  - Servicio de Anatomia Patologica, Hospital Monte Naranco, Oviedo, Spain.
FAU - Menon, Usha
AU  - Menon U
AD  - Gynaecological Cancer Research Centre, Department of Women's Cancer, Institute
      for Women's Health, University College London, London, UK.
FAU - Meyer, Jeffery
AU  - Meyer J
AD  - Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester,
      Minnesota, USA.
FAU - Miao, Hui
AU  - Miao H
AD  - Saw Swee Hock School of Public Health, National University of Singapore,
      Singapore, Singapore.
FAU - Miller, Nicola
AU  - Miller N
AD  - School of Medicine, National University of Ireland, Galway, Ireland.
FAU - Taib, Nur Aishah Mohd
AU  - Taib NAM
AD  - Breast Cancer Research Unit, Cancer Research Institute, University Malaya Medical
      Centre, Kuala Lumpur, Malaysia.
FAU - Muir, Kenneth
AU  - Muir K
AD  - Division of Health Sciences, Warwick Medical School, Warwick University,
      Coventry, UK.
AD  - Institute of Population Health, University of Manchester, Manchester, UK.
FAU - Mulligan, Anna Marie
AU  - Mulligan AM
AD  - Department of Laboratory Medicine and Pathobiology, University of Toronto,
      Toronto, Ontario, Canada.
AD  - Laboratory Medicine Program, University Health Network, Toronto, Ontario, Canada.
FAU - Mulot, Claire
AU  - Mulot C
AD  - Universite Paris Sorbonne Cite, INSERM UMR-S1147, Paris, France.
FAU - Neuhausen, Susan L
AU  - Neuhausen SL
AD  - Department of Population Sciences, Beckman Research Institute of City of Hope,
      Duarte, California, USA.
FAU - Nevanlinna, Heli
AU  - Nevanlinna H
AD  - Department of Obstetrics and Gynecology, Helsinki University Hospital, University
      of Helsinki, Helsinki, Finland.
FAU - Neven, Patrick
AU  - Neven P
AD  - Leuven Multidisciplinary Breast Center, Department of Oncology, Leuven Cancer
      Institute, University Hospitals Leuven, Leuven, Belgium.
FAU - Nielsen, Sune F
AU  - Nielsen SF
AD  - Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen
      University Hospital, Herlev, Denmark.
AD  - Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen
      University Hospital, Herlev, Denmark.
FAU - Noh, Dong-Young
AU  - Noh DY
AD  - Department of Surgery, Seoul National University College of Medicine, Seoul,
      South Korea.
FAU - Nordestgaard, Borge G
AU  - Nordestgaard BG
AD  - Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen
      University Hospital, Herlev, Denmark.
AD  - Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen
      University Hospital, Herlev, Denmark.
AD  - Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen,
      Denmark.
FAU - Norman, Aaron
AU  - Norman A
AD  - Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.
FAU - Olopade, Olufunmilayo I
AU  - Olopade OI
AD  - Center for Clinical Cancer Genetics and Global Health, The University of Chicago,
      Chicago, Illinois, USA.
FAU - Olson, Janet E
AU  - Olson JE
AD  - Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.
FAU - Olsson, Hakan
AU  - Olsson H
AD  - Department of Cancer Epidemiology, Clinical Sciences, Lund University, Lund,
      Sweden.
FAU - Olswold, Curtis
AU  - Olswold C
AD  - Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.
FAU - Orr, Nick
AU  - Orr N
AD  - Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, 
      London, UK.
FAU - Pankratz, V Shane
AU  - Pankratz VS
AD  - University of New Mexico Health Sciences Center, University of New Mexico,
      Albuquerque, New Mexico, USA.
FAU - Park, Sue K
AU  - Park SK
AD  - Department of Biomedical Sciences, Seoul National University Graduate School,
      Seoul, South Korea.
AD  - Cancer Research Institute, Seoul National University, Seoul, South Korea.
AD  - Department of Preventive Medicine, Seoul National University College of Medicine,
      Seoul, South Korea.
FAU - Park-Simon, Tjoung-Won
AU  - Park-Simon TW
AD  - Gynaecology Research Unit, Hannover Medical School, Hannover, Germany.
FAU - Lloyd, Rachel
AU  - Lloyd R
AD  - The Curtin UWA Centre for Genetic Origins of Health and Disease, Curtin
      University and University of Western Australia, Perth, Australia.
FAU - Perez, Jose I A
AU  - Perez JIA
AD  - Servicio de Cirugia General y Especialidades, Hospital Monte Naranco, Oviedo,
      Spain.
FAU - Peterlongo, Paolo
AU  - Peterlongo P
AD  - IFOM, The FIRC (Italian Foundation for Cancer Research) Institute of Molecular
      Oncology, Milan, Italy.
FAU - Peto, Julian
AU  - Peto J
AD  - Department of Non-Communicable Disease Epidemiology, London School of Hygiene and
      Tropical Medicine, London, UK.
FAU - Phillips, Kelly-Anne
AU  - Phillips KA
AD  - Centre for Epidemiology and Biostatistics, Melbourne School of Population and
      Global Health, The University of Melbourne, Melbourne, Australia.
AD  - Peter MacCallum Cancer Center, Melbourne, Australia.
AD  - Sir Peter MacCallum Department of Oncology, The University of Melbourne,
      Melbourne, Australia.
AD  - Department of Medicine, St Vincent's Hospital, The University of Melbourne,
      Fitzroy, Australia.
FAU - Pinchev, Mila
AU  - Pinchev M
AD  - Clalit National Cancer Control Center, Carmel Medical Center and Technion Faculty
      of Medicine, Haifa, Israel.
FAU - Plaseska-Karanfilska, Dijana
AU  - Plaseska-Karanfilska D
AD  - Research Centre for Genetic Engineering and Biotechnology "Georgi D. Efremov",
      Macedonian Academy of Sciences and Arts, Skopje, Republic of Macedonia.
FAU - Prentice, Ross
AU  - Prentice R
AD  - Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle,
      Washington, USA.
FAU - Presneau, Nadege
AU  - Presneau N
AD  - Department of Biomedical Sciences, Faculty of Science and Technology, University 
      of Westminster, London, UK.
FAU - Prokofyeva, Darya
AU  - Prokofyeva D
AD  - Department of Genetics and Fundamental Medicine, Bashkir State University, Ufa,
      Russia.
FAU - Pugh, Elizabeth
AU  - Pugh E
AD  - Center for Inherited Disease Research (CIDR), Institute of Genetic Medicine,
      Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
FAU - Pylkas, Katri
AU  - Pylkas K
AD  - Laboratory of Cancer Genetics and Tumor Biology, Cancer and Translational
      Medicine Research Unit, Biocenter Oulu, University of Oulu, Oulu, Finland.
AD  - Laboratory of Cancer Genetics and Tumor Biology, Northern Finland Laboratory
      Centre Oulu, Oulu, Finland.
FAU - Rack, Brigitte
AU  - Rack B
AD  - Department of Gynecology and Obstetrics, Ludwig-Maximilians University of Munich,
      Munich, Germany.
FAU - Radice, Paolo
AU  - Radice P
AD  - Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of
      Preventive and Predictive Medicine, Fondazione IRCCS (Istituto Di Ricovero e Cura
      a Carattere Scientifico) Istituto Nazionale dei Tumori (INT), Milan, Italy.
FAU - Rahman, Nazneen
AU  - Rahman N
AD  - Section of Cancer Genetics, The Institute of Cancer Research, London, UK.
FAU - Rennert, Gadi
AU  - Rennert G
AD  - Clalit National Cancer Control Center, Carmel Medical Center and Technion Faculty
      of Medicine, Haifa, Israel.
FAU - Rennert, Hedy S
AU  - Rennert HS
AD  - Clalit National Cancer Control Center, Carmel Medical Center and Technion Faculty
      of Medicine, Haifa, Israel.
FAU - Rhenius, Valerie
AU  - Rhenius V
AD  - Centre for Cancer Genetic Epidemiology, Department of Oncology, University of
      Cambridge, Cambridge, UK.
FAU - Romero, Atocha
AU  - Romero A
AD  - Medical Oncology Department, Hospital Clinico San Carlos, IdISSC (Centro
      Investigacion Biomedica en Red), CIBERONC (Instituto de Investigacion Sanitaria
      San Carlos), Madrid, Spain.
AD  - Medical Oncology Department, Hospital Universitario Puerta de Hierro, Madrid,
      Spain.
FAU - Romm, Jane
AU  - Romm J
AD  - Center for Inherited Disease Research (CIDR), Institute of Genetic Medicine,
      Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
FAU - Ruddy, Kathryn J
AU  - Ruddy KJ
AD  - Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA.
FAU - Rudiger, Thomas
AU  - Rudiger T
AD  - Institute of Pathology, Staedtisches Klinikum Karlsruhe, Karlsruhe, Germany.
FAU - Rudolph, Anja
AU  - Rudolph A
AD  - Division of Cancer Epidemiology, German Cancer Research Center (DKFZ),
      Heidelberg, Germany.
FAU - Ruebner, Matthias
AU  - Ruebner M
AD  - Department of Gynaecology and Obstetrics, University Hospital Erlangen,
      Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center
      Erlangen-EMN, Erlangen, Germany.
FAU - Rutgers, Emiel J T
AU  - Rutgers EJT
AD  - Department of Surgery, The Netherlands Cancer Institute, Antoni van Leeuwenhoek
      Hospital, Amsterdam, The Netherlands.
FAU - Saloustros, Emmanouil
AU  - Saloustros E
AD  - Hereditary Cancer Clinic, University Hospital of Heraklion, Heraklion, Greece.
FAU - Sandler, Dale P
AU  - Sandler DP
AD  - Epidemiology Branch, National Institute of Environmental Health Sciences, NIH,
      Research Triangle Park, North Carolina, USA.
FAU - Sangrajrang, Suleeporn
AU  - Sangrajrang S
AD  - National Cancer Institute, Bangkok, Thailand.
FAU - Sawyer, Elinor J
AU  - Sawyer EJ
AD  - Research Oncology, Guy's Hospital, King's College London, London, UK.
FAU - Schmidt, Daniel F
AU  - Schmidt DF
AD  - Centre for Epidemiology and Biostatistics, Melbourne School of Population and
      Global Health, The University of Melbourne, Melbourne, Australia.
FAU - Schmutzler, Rita K
AU  - Schmutzler RK
AD  - Center for Hereditary Breast and Ovarian Cancer, University Hospital of Cologne, 
      Cologne, Germany.
AD  - Center for Integrated Oncology (CIO), University Hospital of Cologne, Cologne,
      Germany.
AD  - Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne,
      Germany.
FAU - Schneeweiss, Andreas
AU  - Schneeweiss A
AD  - Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg,
      Germany.
AD  - National Center for Tumor Diseases, University of Heidelberg, Heidelberg,
      Germany.
FAU - Schoemaker, Minouk J
AU  - Schoemaker MJ
AD  - Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK.
FAU - Schumacher, Fredrick
AU  - Schumacher F
AD  - Department of Epidemiology and Biostatistics, Case Western Reserve University,
      Cleveland, Ohio, USA.
FAU - Schurmann, Peter
AU  - Schurmann P
AD  - Gynaecology Research Unit, Hannover Medical School, Hannover, Germany.
FAU - Scott, Rodney J
AU  - Scott RJ
AD  - Division of Molecular Medicine, Pathology North, John Hunter Hospital, Newcastle,
      Australia.
AD  - Discipline of Medical Genetics, School of Biomedical Sciences and Pharmacy,
      Faculty of Health, University of Newcastle, Callaghan, Australia.
FAU - Scott, Christopher
AU  - Scott C
AD  - Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.
FAU - Seal, Sheila
AU  - Seal S
AD  - Section of Cancer Genetics, The Institute of Cancer Research, London, UK.
FAU - Seynaeve, Caroline
AU  - Seynaeve C
AD  - Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer
      Institute, Rotterdam, The Netherlands.
FAU - Shah, Mitul
AU  - Shah M
AD  - Centre for Cancer Genetic Epidemiology, Department of Oncology, University of
      Cambridge, Cambridge, UK.
FAU - Sharma, Priyanka
AU  - Sharma P
AD  - Department of Medicine, University of Kansas Medical Center, Kansas City, Kansas,
      USA.
FAU - Shen, Chen-Yang
AU  - Shen CY
AD  - School of Public Health, China Medical University, Taichung, Taiwan.
AD  - Taiwan Biobank, Institute of Biomedical Sciences, Academia Sinica, Taipei,
      Taiwan.
FAU - Sheng, Grace
AU  - Sheng G
AD  - Department of Preventive Medicine, Keck School of Medicine, University of
      Southern California, Los Angeles, California, USA.
FAU - Sherman, Mark E
AU  - Sherman ME
AD  - Division of Cancer Prevention, National Cancer Institute, Rockville, Maryland,
      USA.
FAU - Shrubsole, Martha J
AU  - Shrubsole MJ
AD  - Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center,
      Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine,
      Nashville, Tennessee, USA.
FAU - Shu, Xiao-Ou
AU  - Shu XO
AD  - Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center,
      Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine,
      Nashville, Tennessee, USA.
FAU - Smeets, Ann
AU  - Smeets A
AD  - Leuven Multidisciplinary Breast Center, Department of Oncology, Leuven Cancer
      Institute, University Hospitals Leuven, Leuven, Belgium.
FAU - Sohn, Christof
AU  - Sohn C
AD  - National Center for Tumor Diseases, University of Heidelberg, Heidelberg,
      Germany.
FAU - Southey, Melissa C
AU  - Southey MC
AD  - Genetic Epidemiology Laboratory, Department of Pathology, The University of
      Melbourne, Melbourne, Australia.
FAU - Spinelli, John J
AU  - Spinelli JJ
AD  - Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
AD  - School of Population and Public Health, University of British Columbia,
      Vancouver, British Columbia, Canada.
FAU - Stegmaier, Christa
AU  - Stegmaier C
AD  - Saarland Cancer Registry, Saarbrucken, Germany.
FAU - Stewart-Brown, Sarah
AU  - Stewart-Brown S
AD  - Division of Health Sciences, Warwick Medical School, Warwick University,
      Coventry, UK.
FAU - Stone, Jennifer
AU  - Stone J
AD  - The Curtin UWA Centre for Genetic Origins of Health and Disease, Curtin
      University and University of Western Australia, Perth, Australia.
AD  - Department of Obstetrics and Gynaecology, University of Melbourne and the Royal
      Women's Hospital, Melbourne, Australia.
FAU - Stram, Daniel O
AU  - Stram DO
AD  - Department of Preventive Medicine, Keck School of Medicine, University of
      Southern California, Los Angeles, California, USA.
FAU - Surowy, Harald
AU  - Surowy H
AD  - Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg,
      Germany.
AD  - Molecular Epidemiology Group, C080, German Cancer Research Center (DKFZ),
      Heidelberg, Germany.
FAU - Swerdlow, Anthony
AU  - Swerdlow A
AD  - Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
      UK.
AD  - Division of Breast Cancer Research, The Institute of Cancer Research, London, UK.
FAU - Tamimi, Rulla
AU  - Tamimi R
AD  - Program in Genetic Epidemiology and Statistical Genetics, Harvard T. H. Chan
      School of Public Health, Boston, Massachusetts, USA.
AD  - Channing Division of Network Medicine, Department of Medicine, Brigham and
      Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
AD  - Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston,
      Massachusetts, USA.
FAU - Taylor, Jack A
AU  - Taylor JA
AD  - Epidemiology Branch, National Institute of Environmental Health Sciences, NIH,
      Research Triangle Park, North Carolina, USA.
AD  - Epigenetic and Stem Cell Biology Laboratory, National Institute of Environmental 
      Health Sciences, NIH, Research Triangle Park, North Carolina, USA.
FAU - Tengstrom, Maria
AU  - Tengstrom M
AD  - Translational Cancer Research Area, University of Eastern Finland, Kuopio,
      Finland.
AD  - Cancer Center, Kuopio University Hospital, Kuopio, Finland.
AD  - Institute of Clinical Medicine, Oncology, University of Eastern Finland, Kuopio, 
      Finland.
FAU - Teo, Soo H
AU  - Teo SH
AD  - Cancer Research Malaysia, Subang Jaya, Selangor, Malaysia.
AD  - Breast Cancer Research Unit, Cancer Research Institute, University Malaya Medical
      Centre, Kuala Lumpur, Malaysia.
FAU - Beth Terry, Mary
AU  - Beth Terry M
AD  - Department of Epidemiology, Mailman School of Public Health, Columbia University,
      New York, New York, USA.
FAU - Tessier, Daniel C
AU  - Tessier DC
AD  - McGill University and Genome Quebec Innovation Centre, Montreal, Quebec, Canada.
FAU - Thanasitthichai, Somchai
AU  - Thanasitthichai S
AD  - National Cancer Institute, Ministry of Public Health, Nonthaburi, Thailand.
FAU - Thone, Kathrin
AU  - Thone K
AD  - Department of Cancer Epidemiology, Clinical Cancer Registry, University Medical
      Center Hamburg-Eppendorf, Hamburg, Germany.
FAU - Tollenaar, Rob A E M
AU  - Tollenaar RAEM
AD  - Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
FAU - Tomlinson, Ian
AU  - Tomlinson I
AD  - Wellcome Trust Centre for Human Genetics and Oxford NIHR Biomedical Research
      Centre, University of Oxford, Oxford, UK.
FAU - Tong, Ling
AU  - Tong L
AD  - Center for Cancer Epidemiology and Prevention, The University of Chicago,
      Chicago, Illinois, USA.
FAU - Torres, Diana
AU  - Torres D
AD  - Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ),
      Heidelberg, Germany.
AD  - Institute of Human Genetics, Pontificia Universidad Javeriana, Bogota, Colombia.
FAU - Truong, Therese
AU  - Truong T
AD  - Cancer & Environment Group, Center for Research in Epidemiology and Population
      Health (CESP), INSERM, University Paris-Sud, University Paris-Saclay, Villejuif, 
      France.
FAU - Tseng, Chiu-Chen
AU  - Tseng CC
AD  - Department of Preventive Medicine, Keck School of Medicine, University of
      Southern California, Los Angeles, California, USA.
FAU - Tsugane, Shoichiro
AU  - Tsugane S
AD  - Center for Public Health Sciences, National Cancer Center, Tokyo, Japan.
FAU - Ulmer, Hans-Ulrich
AU  - Ulmer HU
AD  - Frauenklinik der Stadtklinik Baden-Baden, Baden-Baden, Germany.
FAU - Ursin, Giske
AU  - Ursin G
AD  - Cancer Registry of Norway, Oslo, Norway.
AD  - Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo,
      Oslo, Norway.
FAU - Untch, Michael
AU  - Untch M
AD  - Department of Gynecology and Obstetrics, Helios Clinics Berlin-Buch, Berlin,
      Germany.
FAU - Vachon, Celine
AU  - Vachon C
AD  - Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.
FAU - van Asperen, Christi J
AU  - van Asperen CJ
AD  - Department of Clinical Genetics, Leiden University Medical Center, Leiden, The
      Netherlands.
FAU - Van Den Berg, David
AU  - Van Den Berg D
AD  - Department of Preventive Medicine, Keck School of Medicine, University of
      Southern California, Los Angeles, California, USA.
FAU - van den Ouweland, Ans M W
AU  - van den Ouweland AMW
AD  - Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam,
      The Netherlands.
FAU - van der Kolk, Lizet
AU  - van der Kolk L
AD  - Family Cancer Clinic, The Netherlands Cancer Institute, Antoni van Leeuwenhoek
      Hospital, Amsterdam, The Netherlands.
FAU - van der Luijt, Rob B
AU  - van der Luijt RB
AD  - Division of Biomedical Genetics, University Medical Center Utrecht, Utrecht, The 
      Netherlands.
FAU - Vincent, Daniel
AU  - Vincent D
AD  - McGill University and Genome Quebec Innovation Centre, Montreal, Quebec, Canada.
FAU - Vollenweider, Jason
AU  - Vollenweider J
AD  - Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester,
      Minnesota, USA.
FAU - Waisfisz, Quinten
AU  - Waisfisz Q
AD  - Department of Clinical Genetics, VU University Medical Center, Amsterdam, The
      Netherlands.
FAU - Wang-Gohrke, Shan
AU  - Wang-Gohrke S
AD  - Department of Gynaecology and Obstetrics, University of Ulm, Ulm, Germany.
FAU - Weinberg, Clarice R
AU  - Weinberg CR
AD  - Biostatistics and Computational Biology Branch, National Institute of
      Environmental Health Sciences, NIH, Research Triangle Park, North Carolina, USA.
FAU - Wendt, Camilla
AU  - Wendt C
AD  - Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
FAU - Whittemore, Alice S
AU  - Whittemore AS
AD  - Department of Health Research and Policy-Epidemiology, Stanford University School
      of Medicine, Stanford, California, USA.
AD  - Stanford Cancer Institute, Stanford University School of Medicine, Stanford,
      California, USA.
FAU - Wildiers, Hans
AU  - Wildiers H
AD  - Leuven Multidisciplinary Breast Center, Department of Oncology, Leuven Cancer
      Institute, University Hospitals Leuven, Leuven, Belgium.
FAU - Willett, Walter
AU  - Willett W
AD  - Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston,
      Massachusetts, USA.
AD  - Department of Nutrition, Harvard T. H. Chan School of Public Health, Boston,
      Massachusetts, USA.
FAU - Winqvist, Robert
AU  - Winqvist R
AD  - Laboratory of Cancer Genetics and Tumor Biology, Cancer and Translational
      Medicine Research Unit, Biocenter Oulu, University of Oulu, Oulu, Finland.
AD  - Laboratory of Cancer Genetics and Tumor Biology, Northern Finland Laboratory
      Centre Oulu, Oulu, Finland.
FAU - Wolk, Alicja
AU  - Wolk A
AD  - Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
FAU - Wu, Anna H
AU  - Wu AH
AD  - Department of Preventive Medicine, Keck School of Medicine, University of
      Southern California, Los Angeles, California, USA.
FAU - Xia, Lucy
AU  - Xia L
AD  - Department of Preventive Medicine, Keck School of Medicine, University of
      Southern California, Los Angeles, California, USA.
FAU - Yamaji, Taiki
AU  - Yamaji T
AD  - Division of Epidemiology, Center for Public Health Sciences, National Cancer
      Center, Tokyo, Japan.
FAU - Yang, Xiaohong R
AU  - Yang XR
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute,
      Rockville, Maryland, USA.
FAU - Har Yip, Cheng
AU  - Har Yip C
AD  - Subang Jaya Medical Centre, Subang Jaya, Selangor, Malaysia.
FAU - Yoo, Keun-Young
AU  - Yoo KY
AD  - Seoul National University College of Medicine, Seoul, South Korea.
AD  - Armed Forces Capital Hospital, Seongnam, South Korea.
FAU - Yu, Jyh-Cherng
AU  - Yu JC
AD  - Department of Surgery, Tri-Service General Hospital, National Defense Medical
      Center, Taipei, Taiwan.
FAU - Zheng, Wei
AU  - Zheng W
AD  - Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center,
      Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine,
      Nashville, Tennessee, USA.
FAU - Zheng, Ying
AU  - Zheng Y
AD  - Shanghai Municipal Center for Disease Control and Prevention, Shanghai, China.
FAU - Zhu, Bin
AU  - Zhu B
AD  - Cancer Genomics Research Laboratory (CGR), Division of Cancer Epidemiology and
      Genetics, National Cancer Institute, Rockville, Maryland, USA.
FAU - Ziogas, Argyrios
AU  - Ziogas A
AD  - Department of Epidemiology, University of California Irvine, Irvine, California, 
      USA.
FAU - Ziv, Elad
AU  - Ziv E
AD  - Department of Medicine, Institute for Human Genetics, UCSF Helen Diller Family
      Comprehensive Cancer Center, University of California San Francisco, San
      Francisco, California, USA.
CN  - ABCTB Investigators
CN  - ConFab/AOCS Investigators
FAU - Lakhani, Sunil R
AU  - Lakhani SR
AD  - UQ Centre for Clinical Research, The University of Queensland, Brisbane,
      Australia.
AD  - Pathology Queensland, The Royal Brisbane and Women's Hospital, Brisbane 4029,
      Australia.
FAU - Antoniou, Antonis C
AU  - Antoniou AC
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary
      Care, University of Cambridge, Cambridge, UK.
FAU - Droit, Arnaud
AU  - Droit A
AD  - Genomics Center, Centre Hospitalier Universitaire de Quebec Research Center,
      Laval University, Quebec City, Quebec, Canada.
FAU - Andrulis, Irene L
AU  - Andrulis IL
AD  - Fred A. Litwin Center for Cancer Genetics, Lunenfeld-Tanenbaum Research Institute
      of Mount Sinai Hospital, Toronto, Ontario, Canada.
AD  - Department of Molecular Genetics, University of Toronto, Toronto, Ontario,
      Canada.
FAU - Amos, Christopher I
AU  - Amos CI
AD  - Center for Genomic Medicine, Department of Biomedical Data Science, Geisel School
      of Medicine, Dartmouth College, Hanover, New Hampshire, USA.
FAU - Couch, Fergus J
AU  - Couch FJ
AD  - Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester,
      Minnesota, USA.
FAU - Pharoah, Paul D P
AU  - Pharoah PDP
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary
      Care, University of Cambridge, Cambridge, UK.
AD  - Centre for Cancer Genetic Epidemiology, Department of Oncology, University of
      Cambridge, Cambridge, UK.
FAU - Chang-Claude, Jenny
AU  - Chang-Claude J
AD  - Division of Cancer Epidemiology, German Cancer Research Center (DKFZ),
      Heidelberg, Germany.
AD  - University Cancer Center Hamburg (UCCH), University Medical Center
      Hamburg-Eppendorf, Hamburg, Germany.
FAU - Hall, Per
AU  - Hall P
AD  - Department of Medical Epidemiology and Biostatistics, Karolinska Institutet,
      Stockholm, Sweden.
AD  - Department of Oncology, Sodersjukhuset, Stockholm, Sweden.
FAU - Hunter, David J
AU  - Hunter DJ
AD  - Program in Genetic Epidemiology and Statistical Genetics, Harvard T. H. Chan
      School of Public Health, Boston, Massachusetts, USA.
AD  - Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston,
      Massachusetts, USA.
FAU - Milne, Roger L
AU  - Milne RL
AD  - Cancer Epidemiology and Intelligence Division, Cancer Council Victoria,
      Melbourne, Victoria, Australia.
AD  - Centre for Epidemiology and Biostatistics, Melbourne School of Population and
      Global Health, The University of Melbourne, Melbourne, Australia.
FAU - Garcia-Closas, Montserrat
AU  - Garcia-Closas M
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute,
      Rockville, Maryland, USA.
FAU - Schmidt, Marjanka K
AU  - Schmidt MK
AD  - Division of Molecular Pathology, The Netherlands Cancer Institute, Antoni van
      Leeuwenhoek Hospital, Amsterdam, The Netherlands.
AD  - Division of Psychosocial Research and Epidemiology, The Netherlands Cancer
      Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
FAU - Chanock, Stephen J
AU  - Chanock SJ
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute,
      Rockville, Maryland, USA.
FAU - Dunning, Alison M
AU  - Dunning AM
AD  - Centre for Cancer Genetic Epidemiology, Department of Oncology, University of
      Cambridge, Cambridge, UK.
FAU - Edwards, Stacey L
AU  - Edwards SL
AD  - Department of Genetics and Computational Biology, QIMR Berghofer Medical Research
      Institute, Brisbane, Australia.
FAU - Bader, Gary D
AU  - Bader GD
AD  - The Donnelly Centre, University of Toronto, Toronto, Ontario, Canada.
FAU - Chenevix-Trench, Georgia
AU  - Chenevix-Trench G
AD  - Department of Genetics and Computational Biology, QIMR Berghofer Medical Research
      Institute, Brisbane, Australia.
FAU - Simard, Jacques
AU  - Simard J
AD  - Genomics Center, Centre Hospitalier Universitaire de Quebec Research Center,
      Laval University, Quebec City, Quebec, Canada.
FAU - Kraft, Peter
AU  - Kraft P
AD  - Program in Genetic Epidemiology and Statistical Genetics, Harvard T. H. Chan
      School of Public Health, Boston, Massachusetts, USA.
AD  - Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston,
      Massachusetts, USA.
FAU - Easton, Douglas F
AU  - Easton DF
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary
      Care, University of Cambridge, Cambridge, UK.
AD  - Centre for Cancer Genetic Epidemiology, Department of Oncology, University of
      Cambridge, Cambridge, UK.
LA  - eng
GR  - U01 CA199277/CA/NCI NIH HHS/United States
GR  - UM1 CA164917/CA/NCI NIH HHS/United States
GR  - UM1 CA164973/CA/NCI NIH HHS/United States
GR  - U41 HG006623/HG/NHGRI NIH HHS/United States
GR  - R01 CA176785/CA/NCI NIH HHS/United States
GR  - R01 CA089085/CA/NCI NIH HHS/United States
GR  - P50 CA125183/CA/NCI NIH HHS/United States
GR  - P01 CA087969/CA/NCI NIH HHS/United States
GR  - UM1 CA164920/CA/NCI NIH HHS/United States
GR  - U01 CA194393/CA/NCI NIH HHS/United States
GR  - R01 CA097396/CA/NCI NIH HHS/United States
GR  - UM1 CA176726/CA/NCI NIH HHS/United States
GR  - R37 CA070867/CA/NCI NIH HHS/United States
GR  - R01 CA092447/CA/NCI NIH HHS/United States
GR  - R01 CA058860/CA/NCI NIH HHS/United States
GR  - K07 CA092044/CA/NCI NIH HHS/United States
GR  - R01 CA100374/CA/NCI NIH HHS/United States
GR  - U01 CA116167/CA/NCI NIH HHS/United States
GR  - R01 CA128978/CA/NCI NIH HHS/United States
GR  - R01 CA064277/CA/NCI NIH HHS/United States
GR  - D43 TW009112/TW/FIC NIH HHS/United States
GR  - U01 CA122171/CA/NCI NIH HHS/United States
GR  - R01 CA148667/CA/NCI NIH HHS/United States
GR  - P50 CA116201/CA/NCI NIH HHS/United States
GR  - R01 CA063464/CA/NCI NIH HHS/United States
GR  - UM1 CA186107/CA/NCI NIH HHS/United States
GR  - R01 CA077398/CA/NCI NIH HHS/United States
GR  - R01 CA054281/CA/NCI NIH HHS/United States
GR  - R01 CA132839/CA/NCI NIH HHS/United States
GR  - R01 CA159868/CA/NCI NIH HHS/United States
GR  - P30 CA068485/CA/NCI NIH HHS/United States
GR  - U01 CA098758/CA/NCI NIH HHS/United States
GR  - U19 CA148065/CA/NCI NIH HHS/United States
GR  - R01 CA121941/CA/NCI NIH HHS/United States
GR  - UM1 CA182910/CA/NCI NIH HHS/United States
GR  - R01 CA192393/CA/NCI NIH HHS/United States
GR  - R01 CA140286/CA/NCI NIH HHS/United States
GR  - R01 CA120120/CA/NCI NIH HHS/United States
GR  - K24 CA169004/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20171023
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
EDAT- 2017/10/24 06:00
MHDA- 2017/10/24 06:00
CRDT- 2017/10/24 06:00
PHST- 2016/06/21 00:00 [received]
PHST- 2017/09/17 00:00 [accepted]
PHST- 2017/10/24 06:00 [pubmed]
PHST- 2017/10/24 06:00 [medline]
PHST- 2017/10/24 06:00 [entrez]
AID - nature24284 [pii]
AID - 10.1038/nature24284 [doi]
PST - ppublish
SO  - Nature. 2017 Nov 2;551(7678):92-94. doi: 10.1038/nature24284. Epub 2017 Oct 23.

PMID- 29053400
OWN - NLM
STAT- MEDLINE
DCOM- 20171211
LR  - 20171211
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Linking)
VI  - 35
IP  - 34
DP  - 2017 Dec 1
TI  - Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical
      Assays and Clinical Implementation in Non-Small-Cell Lung Cancer.
PG  - 3867-3876
LID - 10.1200/JCO.2017.74.7642 [doi]
AB  - Purpose Three programmed death-1/programmed death-ligand 1 (PD-L1) inhibitors are
      currently approved for treatment of non-small-cell lung cancer (NSCLC). Treatment
      with pembrolizumab in NSCLC requires PD-L1 immunohistochemistry (IHC) testing.
      Nivolumab and atezolizumab are approved without PD-L1 testing, though US Food and
      Drug Administration-cleared complementary PD-L1 tests are available for both.
      PD-L1 IHC assays used to assess PD-L1 expression in patients treated with
      programmed death-1/PD-L1 inhibitors in clinical trials include PD-L1 IHC 28-8
      pharmDx (28-8), PD-L1 IHC 22C3 pharmDx (22C3), Ventana PD-L1 SP142 (SP142), and
      Ventana PD-L1 SP263 (SP263). Differences in antibodies and IHC platforms have
      raised questions about comparability among these assays and their diagnostic use.
      This review provides practical information to help physicians and pathologists
      understand analytical features and comparability of various PD-L1 IHC assays and 
      their diagnostic use. Methods We reviewed and summarized published or otherwise
      reported studies (January 2016 to January 2017) on clinical trial and
      laboratory-developed PD-L1 IHC assays (LDAs). Studies assessing the effect of
      diagnostic methods on PD-L1 expression levels were analyzed to address practical 
      issues related to tissue samples used for testing. Results High concordance and
      interobserver reproducibility were observed with the 28-8, 22C3, and SP263
      clinical trial assays for PD-L1 expression on tumor cell membranes, whereas lower
      PD-L1 expression was detected with SP142. Immune-cell PD-L1 expression was
      variable and interobserver concordance was poor. Inter- and intratumoral
      heterogeneity had variable effects on PD-L1 expression. Concordance among LDAs
      was variable. Conclusion High concordance among 28-8, 22C3, and SP263 when
      assessing PD-L1 expression on tumor cell membranes suggests possible
      interchangeability of their clinical use for NSCLC but not for assessment of
      PD-L1 expression on immune cells. Development of LDAs requires stringent
      standardization before their recommendation for routine clinical use.
FAU - Buttner, Reinhard
AU  - Buttner R
AD  - Reinhard Buttner, University Hospital Cologne, Cologne; Manfred Dietel, Charite
      Universitatsmedizin Berlin, Berlin, Germany; John R. Gosney, Royal Liverpool
      University Hospital, Liverpool; Andrew C. Wotherspoon, Royal Marsden Hospital,
      London; Keith M. Kerr, Aberdeen University Medical School and Aberdeen Royal
      Infirmary, Aberdeen, Scotland, United Kingdom; Birgit Guldhammer Skov, Copenhagen
      University Hospital, Copenhagen, Denmark; Julien Adam, Gustave Roussy Cancer
      Center, Villejuif; Frederique Penault-Llorca, Jean Perrin Comprehensive Cancer
      Center, Clermont-Ferrand, France; Noriko Motoi, National Cancer Center Hospital, 
      Tokyo, Japan; Kenneth J. Bloom, Human Longevity, San Diego, CA; John W.
      Longshore, Carolinas Pathology Group, Charlotte, NC; Fernando Lopez-Rios,
      Hospital Universitario HM Sanchinarro, Madrid, Spain; Giuseppe Viale, University 
      of Milan, Milan, Italy; and Ming-Sound Tsao, University Health Network, Princess 
      Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada.
FAU - Gosney, John R
AU  - Gosney JR
AD  - Reinhard Buttner, University Hospital Cologne, Cologne; Manfred Dietel, Charite
      Universitatsmedizin Berlin, Berlin, Germany; John R. Gosney, Royal Liverpool
      University Hospital, Liverpool; Andrew C. Wotherspoon, Royal Marsden Hospital,
      London; Keith M. Kerr, Aberdeen University Medical School and Aberdeen Royal
      Infirmary, Aberdeen, Scotland, United Kingdom; Birgit Guldhammer Skov, Copenhagen
      University Hospital, Copenhagen, Denmark; Julien Adam, Gustave Roussy Cancer
      Center, Villejuif; Frederique Penault-Llorca, Jean Perrin Comprehensive Cancer
      Center, Clermont-Ferrand, France; Noriko Motoi, National Cancer Center Hospital, 
      Tokyo, Japan; Kenneth J. Bloom, Human Longevity, San Diego, CA; John W.
      Longshore, Carolinas Pathology Group, Charlotte, NC; Fernando Lopez-Rios,
      Hospital Universitario HM Sanchinarro, Madrid, Spain; Giuseppe Viale, University 
      of Milan, Milan, Italy; and Ming-Sound Tsao, University Health Network, Princess 
      Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada.
FAU - Skov, Birgit Guldhammer
AU  - Skov BG
AD  - Reinhard Buttner, University Hospital Cologne, Cologne; Manfred Dietel, Charite
      Universitatsmedizin Berlin, Berlin, Germany; John R. Gosney, Royal Liverpool
      University Hospital, Liverpool; Andrew C. Wotherspoon, Royal Marsden Hospital,
      London; Keith M. Kerr, Aberdeen University Medical School and Aberdeen Royal
      Infirmary, Aberdeen, Scotland, United Kingdom; Birgit Guldhammer Skov, Copenhagen
      University Hospital, Copenhagen, Denmark; Julien Adam, Gustave Roussy Cancer
      Center, Villejuif; Frederique Penault-Llorca, Jean Perrin Comprehensive Cancer
      Center, Clermont-Ferrand, France; Noriko Motoi, National Cancer Center Hospital, 
      Tokyo, Japan; Kenneth J. Bloom, Human Longevity, San Diego, CA; John W.
      Longshore, Carolinas Pathology Group, Charlotte, NC; Fernando Lopez-Rios,
      Hospital Universitario HM Sanchinarro, Madrid, Spain; Giuseppe Viale, University 
      of Milan, Milan, Italy; and Ming-Sound Tsao, University Health Network, Princess 
      Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada.
FAU - Adam, Julien
AU  - Adam J
AD  - Reinhard Buttner, University Hospital Cologne, Cologne; Manfred Dietel, Charite
      Universitatsmedizin Berlin, Berlin, Germany; John R. Gosney, Royal Liverpool
      University Hospital, Liverpool; Andrew C. Wotherspoon, Royal Marsden Hospital,
      London; Keith M. Kerr, Aberdeen University Medical School and Aberdeen Royal
      Infirmary, Aberdeen, Scotland, United Kingdom; Birgit Guldhammer Skov, Copenhagen
      University Hospital, Copenhagen, Denmark; Julien Adam, Gustave Roussy Cancer
      Center, Villejuif; Frederique Penault-Llorca, Jean Perrin Comprehensive Cancer
      Center, Clermont-Ferrand, France; Noriko Motoi, National Cancer Center Hospital, 
      Tokyo, Japan; Kenneth J. Bloom, Human Longevity, San Diego, CA; John W.
      Longshore, Carolinas Pathology Group, Charlotte, NC; Fernando Lopez-Rios,
      Hospital Universitario HM Sanchinarro, Madrid, Spain; Giuseppe Viale, University 
      of Milan, Milan, Italy; and Ming-Sound Tsao, University Health Network, Princess 
      Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada.
FAU - Motoi, Noriko
AU  - Motoi N
AD  - Reinhard Buttner, University Hospital Cologne, Cologne; Manfred Dietel, Charite
      Universitatsmedizin Berlin, Berlin, Germany; John R. Gosney, Royal Liverpool
      University Hospital, Liverpool; Andrew C. Wotherspoon, Royal Marsden Hospital,
      London; Keith M. Kerr, Aberdeen University Medical School and Aberdeen Royal
      Infirmary, Aberdeen, Scotland, United Kingdom; Birgit Guldhammer Skov, Copenhagen
      University Hospital, Copenhagen, Denmark; Julien Adam, Gustave Roussy Cancer
      Center, Villejuif; Frederique Penault-Llorca, Jean Perrin Comprehensive Cancer
      Center, Clermont-Ferrand, France; Noriko Motoi, National Cancer Center Hospital, 
      Tokyo, Japan; Kenneth J. Bloom, Human Longevity, San Diego, CA; John W.
      Longshore, Carolinas Pathology Group, Charlotte, NC; Fernando Lopez-Rios,
      Hospital Universitario HM Sanchinarro, Madrid, Spain; Giuseppe Viale, University 
      of Milan, Milan, Italy; and Ming-Sound Tsao, University Health Network, Princess 
      Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada.
FAU - Bloom, Kenneth J
AU  - Bloom KJ
AD  - Reinhard Buttner, University Hospital Cologne, Cologne; Manfred Dietel, Charite
      Universitatsmedizin Berlin, Berlin, Germany; John R. Gosney, Royal Liverpool
      University Hospital, Liverpool; Andrew C. Wotherspoon, Royal Marsden Hospital,
      London; Keith M. Kerr, Aberdeen University Medical School and Aberdeen Royal
      Infirmary, Aberdeen, Scotland, United Kingdom; Birgit Guldhammer Skov, Copenhagen
      University Hospital, Copenhagen, Denmark; Julien Adam, Gustave Roussy Cancer
      Center, Villejuif; Frederique Penault-Llorca, Jean Perrin Comprehensive Cancer
      Center, Clermont-Ferrand, France; Noriko Motoi, National Cancer Center Hospital, 
      Tokyo, Japan; Kenneth J. Bloom, Human Longevity, San Diego, CA; John W.
      Longshore, Carolinas Pathology Group, Charlotte, NC; Fernando Lopez-Rios,
      Hospital Universitario HM Sanchinarro, Madrid, Spain; Giuseppe Viale, University 
      of Milan, Milan, Italy; and Ming-Sound Tsao, University Health Network, Princess 
      Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada.
FAU - Dietel, Manfred
AU  - Dietel M
AD  - Reinhard Buttner, University Hospital Cologne, Cologne; Manfred Dietel, Charite
      Universitatsmedizin Berlin, Berlin, Germany; John R. Gosney, Royal Liverpool
      University Hospital, Liverpool; Andrew C. Wotherspoon, Royal Marsden Hospital,
      London; Keith M. Kerr, Aberdeen University Medical School and Aberdeen Royal
      Infirmary, Aberdeen, Scotland, United Kingdom; Birgit Guldhammer Skov, Copenhagen
      University Hospital, Copenhagen, Denmark; Julien Adam, Gustave Roussy Cancer
      Center, Villejuif; Frederique Penault-Llorca, Jean Perrin Comprehensive Cancer
      Center, Clermont-Ferrand, France; Noriko Motoi, National Cancer Center Hospital, 
      Tokyo, Japan; Kenneth J. Bloom, Human Longevity, San Diego, CA; John W.
      Longshore, Carolinas Pathology Group, Charlotte, NC; Fernando Lopez-Rios,
      Hospital Universitario HM Sanchinarro, Madrid, Spain; Giuseppe Viale, University 
      of Milan, Milan, Italy; and Ming-Sound Tsao, University Health Network, Princess 
      Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada.
FAU - Longshore, John W
AU  - Longshore JW
AD  - Reinhard Buttner, University Hospital Cologne, Cologne; Manfred Dietel, Charite
      Universitatsmedizin Berlin, Berlin, Germany; John R. Gosney, Royal Liverpool
      University Hospital, Liverpool; Andrew C. Wotherspoon, Royal Marsden Hospital,
      London; Keith M. Kerr, Aberdeen University Medical School and Aberdeen Royal
      Infirmary, Aberdeen, Scotland, United Kingdom; Birgit Guldhammer Skov, Copenhagen
      University Hospital, Copenhagen, Denmark; Julien Adam, Gustave Roussy Cancer
      Center, Villejuif; Frederique Penault-Llorca, Jean Perrin Comprehensive Cancer
      Center, Clermont-Ferrand, France; Noriko Motoi, National Cancer Center Hospital, 
      Tokyo, Japan; Kenneth J. Bloom, Human Longevity, San Diego, CA; John W.
      Longshore, Carolinas Pathology Group, Charlotte, NC; Fernando Lopez-Rios,
      Hospital Universitario HM Sanchinarro, Madrid, Spain; Giuseppe Viale, University 
      of Milan, Milan, Italy; and Ming-Sound Tsao, University Health Network, Princess 
      Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada.
FAU - Lopez-Rios, Fernando
AU  - Lopez-Rios F
AD  - Reinhard Buttner, University Hospital Cologne, Cologne; Manfred Dietel, Charite
      Universitatsmedizin Berlin, Berlin, Germany; John R. Gosney, Royal Liverpool
      University Hospital, Liverpool; Andrew C. Wotherspoon, Royal Marsden Hospital,
      London; Keith M. Kerr, Aberdeen University Medical School and Aberdeen Royal
      Infirmary, Aberdeen, Scotland, United Kingdom; Birgit Guldhammer Skov, Copenhagen
      University Hospital, Copenhagen, Denmark; Julien Adam, Gustave Roussy Cancer
      Center, Villejuif; Frederique Penault-Llorca, Jean Perrin Comprehensive Cancer
      Center, Clermont-Ferrand, France; Noriko Motoi, National Cancer Center Hospital, 
      Tokyo, Japan; Kenneth J. Bloom, Human Longevity, San Diego, CA; John W.
      Longshore, Carolinas Pathology Group, Charlotte, NC; Fernando Lopez-Rios,
      Hospital Universitario HM Sanchinarro, Madrid, Spain; Giuseppe Viale, University 
      of Milan, Milan, Italy; and Ming-Sound Tsao, University Health Network, Princess 
      Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada.
FAU - Penault-Llorca, Frederique
AU  - Penault-Llorca F
AD  - Reinhard Buttner, University Hospital Cologne, Cologne; Manfred Dietel, Charite
      Universitatsmedizin Berlin, Berlin, Germany; John R. Gosney, Royal Liverpool
      University Hospital, Liverpool; Andrew C. Wotherspoon, Royal Marsden Hospital,
      London; Keith M. Kerr, Aberdeen University Medical School and Aberdeen Royal
      Infirmary, Aberdeen, Scotland, United Kingdom; Birgit Guldhammer Skov, Copenhagen
      University Hospital, Copenhagen, Denmark; Julien Adam, Gustave Roussy Cancer
      Center, Villejuif; Frederique Penault-Llorca, Jean Perrin Comprehensive Cancer
      Center, Clermont-Ferrand, France; Noriko Motoi, National Cancer Center Hospital, 
      Tokyo, Japan; Kenneth J. Bloom, Human Longevity, San Diego, CA; John W.
      Longshore, Carolinas Pathology Group, Charlotte, NC; Fernando Lopez-Rios,
      Hospital Universitario HM Sanchinarro, Madrid, Spain; Giuseppe Viale, University 
      of Milan, Milan, Italy; and Ming-Sound Tsao, University Health Network, Princess 
      Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada.
FAU - Viale, Giuseppe
AU  - Viale G
AD  - Reinhard Buttner, University Hospital Cologne, Cologne; Manfred Dietel, Charite
      Universitatsmedizin Berlin, Berlin, Germany; John R. Gosney, Royal Liverpool
      University Hospital, Liverpool; Andrew C. Wotherspoon, Royal Marsden Hospital,
      London; Keith M. Kerr, Aberdeen University Medical School and Aberdeen Royal
      Infirmary, Aberdeen, Scotland, United Kingdom; Birgit Guldhammer Skov, Copenhagen
      University Hospital, Copenhagen, Denmark; Julien Adam, Gustave Roussy Cancer
      Center, Villejuif; Frederique Penault-Llorca, Jean Perrin Comprehensive Cancer
      Center, Clermont-Ferrand, France; Noriko Motoi, National Cancer Center Hospital, 
      Tokyo, Japan; Kenneth J. Bloom, Human Longevity, San Diego, CA; John W.
      Longshore, Carolinas Pathology Group, Charlotte, NC; Fernando Lopez-Rios,
      Hospital Universitario HM Sanchinarro, Madrid, Spain; Giuseppe Viale, University 
      of Milan, Milan, Italy; and Ming-Sound Tsao, University Health Network, Princess 
      Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada.
FAU - Wotherspoon, Andrew C
AU  - Wotherspoon AC
AD  - Reinhard Buttner, University Hospital Cologne, Cologne; Manfred Dietel, Charite
      Universitatsmedizin Berlin, Berlin, Germany; John R. Gosney, Royal Liverpool
      University Hospital, Liverpool; Andrew C. Wotherspoon, Royal Marsden Hospital,
      London; Keith M. Kerr, Aberdeen University Medical School and Aberdeen Royal
      Infirmary, Aberdeen, Scotland, United Kingdom; Birgit Guldhammer Skov, Copenhagen
      University Hospital, Copenhagen, Denmark; Julien Adam, Gustave Roussy Cancer
      Center, Villejuif; Frederique Penault-Llorca, Jean Perrin Comprehensive Cancer
      Center, Clermont-Ferrand, France; Noriko Motoi, National Cancer Center Hospital, 
      Tokyo, Japan; Kenneth J. Bloom, Human Longevity, San Diego, CA; John W.
      Longshore, Carolinas Pathology Group, Charlotte, NC; Fernando Lopez-Rios,
      Hospital Universitario HM Sanchinarro, Madrid, Spain; Giuseppe Viale, University 
      of Milan, Milan, Italy; and Ming-Sound Tsao, University Health Network, Princess 
      Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada.
FAU - Kerr, Keith M
AU  - Kerr KM
AD  - Reinhard Buttner, University Hospital Cologne, Cologne; Manfred Dietel, Charite
      Universitatsmedizin Berlin, Berlin, Germany; John R. Gosney, Royal Liverpool
      University Hospital, Liverpool; Andrew C. Wotherspoon, Royal Marsden Hospital,
      London; Keith M. Kerr, Aberdeen University Medical School and Aberdeen Royal
      Infirmary, Aberdeen, Scotland, United Kingdom; Birgit Guldhammer Skov, Copenhagen
      University Hospital, Copenhagen, Denmark; Julien Adam, Gustave Roussy Cancer
      Center, Villejuif; Frederique Penault-Llorca, Jean Perrin Comprehensive Cancer
      Center, Clermont-Ferrand, France; Noriko Motoi, National Cancer Center Hospital, 
      Tokyo, Japan; Kenneth J. Bloom, Human Longevity, San Diego, CA; John W.
      Longshore, Carolinas Pathology Group, Charlotte, NC; Fernando Lopez-Rios,
      Hospital Universitario HM Sanchinarro, Madrid, Spain; Giuseppe Viale, University 
      of Milan, Milan, Italy; and Ming-Sound Tsao, University Health Network, Princess 
      Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada.
FAU - Tsao, Ming-Sound
AU  - Tsao MS
AD  - Reinhard Buttner, University Hospital Cologne, Cologne; Manfred Dietel, Charite
      Universitatsmedizin Berlin, Berlin, Germany; John R. Gosney, Royal Liverpool
      University Hospital, Liverpool; Andrew C. Wotherspoon, Royal Marsden Hospital,
      London; Keith M. Kerr, Aberdeen University Medical School and Aberdeen Royal
      Infirmary, Aberdeen, Scotland, United Kingdom; Birgit Guldhammer Skov, Copenhagen
      University Hospital, Copenhagen, Denmark; Julien Adam, Gustave Roussy Cancer
      Center, Villejuif; Frederique Penault-Llorca, Jean Perrin Comprehensive Cancer
      Center, Clermont-Ferrand, France; Noriko Motoi, National Cancer Center Hospital, 
      Tokyo, Japan; Kenneth J. Bloom, Human Longevity, San Diego, CA; John W.
      Longshore, Carolinas Pathology Group, Charlotte, NC; Fernando Lopez-Rios,
      Hospital Universitario HM Sanchinarro, Madrid, Spain; Giuseppe Viale, University 
      of Milan, Milan, Italy; and Ming-Sound Tsao, University Health Network, Princess 
      Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20171020
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of
      Clinical Oncology
JID - 8309333
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (B7-H1 Antigen)
RN  - 0 (CD274 protein, human)
RN  - 31YO63LBSN (nivolumab)
RN  - DPT0O3T46P (pembrolizumab)
SB  - IM
MH  - Antibodies, Monoclonal/*administration & dosage/adverse effects
MH  - Antibodies, Monoclonal, Humanized/administration & dosage/adverse effects
MH  - B7-H1 Antigen/*genetics
MH  - Biopsy, Needle
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/*genetics/mortality/pathology
MH  - Disease-Free Survival
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Immunohistochemistry
MH  - Lung Neoplasms/*drug therapy/*genetics/mortality/pathology
MH  - Male
MH  - Molecular Targeted Therapy/methods
MH  - Prognosis
MH  - Risk Assessment
MH  - Survival Rate
MH  - Treatment Outcome
EDAT- 2017/10/21 06:00
MHDA- 2017/12/12 06:00
CRDT- 2017/10/21 06:00
PHST- 2017/10/21 06:00 [pubmed]
PHST- 2017/12/12 06:00 [medline]
PHST- 2017/10/21 06:00 [entrez]
AID - 10.1200/JCO.2017.74.7642 [doi]
PST - ppublish
SO  - J Clin Oncol. 2017 Dec 1;35(34):3867-3876. doi: 10.1200/JCO.2017.74.7642. Epub
      2017 Oct 20.

PMID- 29136508
OWN - NLM
STAT- MEDLINE
DCOM- 20171127
LR  - 20171219
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 5
DP  - 2017 Nov 13
TI  - Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor
      Blockade by Inducing PMN-MDSC Infiltration of Tumors.
PG  - 654-668.e5
LID - S1535-6108(17)30458-0 [pii]
LID - 10.1016/j.ccell.2017.10.005 [doi]
AB  - Tumor-associated macrophages (TAM) contribute to all aspects of tumor
      progression. Use of CSF1R inhibitors to target TAM is therapeutically appealing, 
      but has had very limited anti-tumor effects. Here, we have identified the
      mechanism that limited the effect of CSF1R targeted therapy. We demonstrated that
      carcinoma-associated fibroblasts (CAF) are major sources of chemokines that
      recruit granulocytes to tumors. CSF1 produced by tumor cells caused
      HDAC2-mediated downregulation of granulocyte-specific chemokine expression in
      CAF, which limited migration of these cells to tumors. Treatment with CSF1R
      inhibitors disrupted this crosstalk and triggered a profound increase in
      granulocyte recruitment to tumors. Combining CSF1R inhibitor with a CXCR2
      antagonist blocked granulocyte infiltration of tumors and showed strong
      anti-tumor effects.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Kumar, Vinit
AU  - Kumar V
AD  - Immunology, Microenvironment and Metastasis Program, The Wistar Institute,
      Philadelphia, PA 19104, USA.
FAU - Donthireddy, Laxminarasimha
AU  - Donthireddy L
AD  - Immunology, Microenvironment and Metastasis Program, The Wistar Institute,
      Philadelphia, PA 19104, USA.
FAU - Marvel, Douglas
AU  - Marvel D
AD  - Immunology, Microenvironment and Metastasis Program, The Wistar Institute,
      Philadelphia, PA 19104, USA.
FAU - Condamine, Thomas
AU  - Condamine T
AD  - Immunology, Microenvironment and Metastasis Program, The Wistar Institute,
      Philadelphia, PA 19104, USA.
FAU - Wang, Fang
AU  - Wang F
AD  - Immunology, Microenvironment and Metastasis Program, The Wistar Institute,
      Philadelphia, PA 19104, USA.
FAU - Lavilla-Alonso, Sergio
AU  - Lavilla-Alonso S
AD  - Immunology, Microenvironment and Metastasis Program, The Wistar Institute,
      Philadelphia, PA 19104, USA.
FAU - Hashimoto, Ayumi
AU  - Hashimoto A
AD  - Immunology, Microenvironment and Metastasis Program, The Wistar Institute,
      Philadelphia, PA 19104, USA.
FAU - Vonteddu, Prashanthi
AU  - Vonteddu P
AD  - Immunology, Microenvironment and Metastasis Program, The Wistar Institute,
      Philadelphia, PA 19104, USA.
FAU - Behera, Reeti
AU  - Behera R
AD  - Immunology, Microenvironment and Metastasis Program, The Wistar Institute,
      Philadelphia, PA 19104, USA.
FAU - Goins, Marlee A
AU  - Goins MA
AD  - Helen F. Graham Cancer Center at Christiana Care Health System, Wilmington, DE,
      USA.
FAU - Mulligan, Charles
AU  - Mulligan C
AD  - Helen F. Graham Cancer Center at Christiana Care Health System, Wilmington, DE,
      USA.
FAU - Nam, Brian
AU  - Nam B
AD  - Helen F. Graham Cancer Center at Christiana Care Health System, Wilmington, DE,
      USA.
FAU - Hockstein, Neil
AU  - Hockstein N
AD  - Helen F. Graham Cancer Center at Christiana Care Health System, Wilmington, DE,
      USA.
FAU - Denstman, Fred
AU  - Denstman F
AD  - Helen F. Graham Cancer Center at Christiana Care Health System, Wilmington, DE,
      USA.
FAU - Shakamuri, Shanti
AU  - Shakamuri S
AD  - Helen F. Graham Cancer Center at Christiana Care Health System, Wilmington, DE,
      USA.
FAU - Speicher, David W
AU  - Speicher DW
AD  - Molecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia,
      PA 19104, USA.
FAU - Weeraratna, Ashani T
AU  - Weeraratna AT
AD  - Immunology, Microenvironment and Metastasis Program, The Wistar Institute,
      Philadelphia, PA 19104, USA.
FAU - Chao, Timothy
AU  - Chao T
AD  - University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.
FAU - Vonderheide, Robert H
AU  - Vonderheide RH
AD  - University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.
FAU - Languino, Lucia R
AU  - Languino LR
AD  - Sidney Kimmel Cancer Center, Sidney Kimmel Medical College, Thomas Jefferson
      University, Philadelphia, PA 19107, USA.
FAU - Ordentlich, Peter
AU  - Ordentlich P
AD  - Syndax Pharmaceuticals, Inc., Waltham, MA 02451, USA.
FAU - Liu, Qin
AU  - Liu Q
AD  - Immunology, Microenvironment and Metastasis Program, The Wistar Institute,
      Philadelphia, PA 19104, USA.
FAU - Xu, Xiaowei
AU  - Xu X
AD  - University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.
FAU - Lo, Albert
AU  - Lo A
AD  - University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA 19104,
      USA.
FAU - Pure, Ellen
AU  - Pure E
AD  - University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA 19104,
      USA.
FAU - Zhang, Chunsheng
AU  - Zhang C
AD  - Department of Genetics and Pharmacogenomics, MRL, Merck & Co., Inc., Boston, MA
      02115, USA.
FAU - Loboda, Andrey
AU  - Loboda A
AD  - Department of Genetics and Pharmacogenomics, MRL, Merck & Co., Inc., Boston, MA
      02115, USA.
FAU - Sepulveda, Manuel A
AU  - Sepulveda MA
AD  - Janssen R&D, Spring House, PA 19477, USA.
FAU - Snyder, Linda A
AU  - Snyder LA
AD  - Janssen R&D, Spring House, PA 19477, USA.
FAU - Gabrilovich, Dmitry I
AU  - Gabrilovich DI
AD  - Immunology, Microenvironment and Metastasis Program, The Wistar Institute,
      Philadelphia, PA 19104, USA. Electronic address: dgabrilovich@wistar.org.
LA  - eng
GR  - P01 CA114046/CA/NCI NIH HHS/United States
GR  - P01 CA140043/CA/NCI NIH HHS/United States
GR  - P30 CA010815/CA/NCI NIH HHS/United States
GR  - R01 CA084488/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Imidazoles)
RN  - 0 (JNJ-40346527)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Pyridines)
RN  - 0 (Receptors, Interleukin-8B)
RN  - 0 (SB 225002)
RN  - EC 2.7.10.1 (Receptor, Macrophage Colony-Stimulating Factor)
RN  - EC 3.5.1.98 (HDAC2 protein, human)
RN  - EC 3.5.1.98 (Histone Deacetylase 2)
SB  - IM
MH  - Animals
MH  - Cancer-Associated Fibroblasts/drug effects/*metabolism
MH  - Cell Line, Tumor
MH  - Granulocytes/metabolism
MH  - Histone Deacetylase 2
MH  - Humans
MH  - Imidazoles/pharmacology
MH  - Macrophages/metabolism
MH  - Mice, Inbred C57BL
MH  - Monocytes/*metabolism
MH  - Myeloid-Derived Suppressor Cells/*metabolism
MH  - Neoplasms, Experimental/drug therapy/*metabolism/pathology
MH  - Phenylurea Compounds/pharmacology
MH  - Pyridines/pharmacology
MH  - Receptor, Macrophage Colony-Stimulating Factor/antagonists &
      inhibitors/*metabolism
MH  - Receptors, Interleukin-8B/antagonists & inhibitors/metabolism
MH  - Tumor Burden/drug effects
OTO - NOTNLM
OT  - CSF1R
OT  - M-CSF
OT  - PMN-MDSC
OT  - fibroblasts
OT  - granulocytes
OT  - macrophages
EDAT- 2017/11/15 06:00
MHDA- 2017/11/29 06:00
CRDT- 2017/11/15 06:00
PHST- 2017/03/03 00:00 [received]
PHST- 2017/07/25 00:00 [revised]
PHST- 2017/10/09 00:00 [accepted]
PHST- 2017/11/15 06:00 [entrez]
PHST- 2017/11/15 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
AID - S1535-6108(17)30458-0 [pii]
AID - 10.1016/j.ccell.2017.10.005 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Nov 13;32(5):654-668.e5. doi: 10.1016/j.ccell.2017.10.005.

PMID- 27105432
OWN - NLM
STAT- MEDLINE
DCOM- 20170324
LR  - 20171214
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 11
IP  - 4
DP  - 2016
TI  - Genetic Factors Are Not the Major Causes of Chronic Diseases.
PG  - e0154387
LID - 10.1371/journal.pone.0154387 [doi]
AB  - The risk of acquiring a chronic disease is influenced by a person's genetics (G) 
      and exposures received during life (the 'exposome', E) plus their interactions
      (GxE). Yet, investigators use genome-wide association studies (GWAS) to
      characterize G while relying on self-reported information to classify E. If E and
      GxE dominate disease risks, this imbalance obscures important causal factors. To 
      estimate proportions of disease risk attributable to G (plus shared exposures),
      published data from Western European monozygotic (MZ) twins were used to estimate
      population attributable fractions (PAFs) for 28 chronic diseases. Genetic PAFs
      ranged from 3.4% for leukemia to 48.6% for asthma with a median value of 18.5%.
      Cancers had the lowest PAFs (median = 8.26%) while neurological (median = 26.1%) 
      and lung (median = 33.6%) diseases had the highest PAFs. These PAFs were then
      linked with Western European mortality statistics to estimate deaths attributable
      to G for heart disease and nine cancer types. Of 1.53 million Western European
      deaths in 2000, 0.25 million (16.4%) could be attributed to genetics plus shared 
      exposures. Given the modest influences of G-related factors on the risks of
      chronic diseases in MZ twins, the disparity in coverage of G and E in etiological
      research is problematic. To discover causes of disease, GWAS should be
      complemented with exposome-wide association studies (EWAS) that profile chemicals
      in biospecimens from incident disease cases and matched controls.
FAU - Rappaport, Stephen M
AU  - Rappaport SM
AD  - School of Public Health, University of California, Berkeley, California, United
      States of America.
LA  - eng
GR  - P42 ES004705/ES/NIEHS NIH HHS/United States
GR  - P42 ES005948/ES/NIEHS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20160422
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Sodium, Dietary)
SB  - IM
MH  - Air Pollution, Indoor/adverse effects
MH  - Alcohol Drinking/adverse effects
MH  - Asthma/diagnosis/*etiology/genetics/mortality
MH  - Chronic Disease
MH  - Environmental Exposure/*adverse effects
MH  - Female
MH  - Gene-Environment Interaction
MH  - Genome-Wide Association Study
MH  - Heart Diseases/diagnosis/*etiology/genetics/mortality
MH  - *Heredity
MH  - Humans
MH  - Male
MH  - Neoplasms/diagnosis/*etiology/genetics/mortality
MH  - Nervous System Diseases/diagnosis/*etiology/genetics/mortality
MH  - Smoking/adverse effects
MH  - Sodium, Dietary/adverse effects
MH  - Survival Analysis
MH  - Twins, Monozygotic/genetics
PMC - PMC4841510
OID - NLM: PMC4841510
EDAT- 2016/04/23 06:00
MHDA- 2017/03/25 06:00
CRDT- 2016/04/23 06:00
PHST- 2016/02/26 00:00 [received]
PHST- 2016/04/12 00:00 [accepted]
PHST- 2016/04/23 06:00 [entrez]
PHST- 2016/04/23 06:00 [pubmed]
PHST- 2017/03/25 06:00 [medline]
AID - 10.1371/journal.pone.0154387 [doi]
AID - PONE-D-16-08292 [pii]
PST - epublish
SO  - PLoS One. 2016 Apr 22;11(4):e0154387. doi: 10.1371/journal.pone.0154387.
      eCollection 2016.

PMID- 29083409
OWN - NLM
STAT- MEDLINE
DCOM- 20171211
LR  - 20171219
IS  - 1546-1718 (Electronic)
IS  - 1061-4036 (Linking)
VI  - 49
IP  - 12
DP  - 2017 Dec
TI  - Computational correction of copy number effect improves specificity of
      CRISPR-Cas9 essentiality screens in cancer cells.
PG  - 1779-1784
LID - 10.1038/ng.3984 [doi]
AB  - The CRISPR-Cas9 system has revolutionized gene editing both at single genes and
      in multiplexed loss-of-function screens, thus enabling precise genome-scale
      identification of genes essential for proliferation and survival of cancer cells.
      However, previous studies have reported that a gene-independent antiproliferative
      effect of Cas9-mediated DNA cleavage confounds such measurement of genetic
      dependency, thereby leading to false-positive results in copy number-amplified
      regions. We developed CERES, a computational method to estimate gene-dependency
      levels from CRISPR-Cas9 essentiality screens while accounting for the copy
      number-specific effect. In our efforts to define a cancer dependency map, we
      performed genome-scale CRISPR-Cas9 essentiality screens across 342 cancer cell
      lines and applied CERES to this data set. We found that CERES decreased
      false-positive results and estimated sgRNA activity for both this data set and
      previously published screens performed with different sgRNA libraries. We further
      demonstrate the utility of this collection of screens, after CERES correction,
      for identifying cancer-type-specific vulnerabilities.
FAU - Meyers, Robin M
AU  - Meyers RM
AUID- ORCID: http://orcid.org/0000-0002-1802-7231
AD  - Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
FAU - Bryan, Jordan G
AU  - Bryan JG
AD  - Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
FAU - McFarland, James M
AU  - McFarland JM
AD  - Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
FAU - Weir, Barbara A
AU  - Weir BA
AD  - Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
FAU - Sizemore, Ann E
AU  - Sizemore AE
AD  - Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
FAU - Xu, Han
AU  - Xu H
AD  - Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
FAU - Dharia, Neekesh V
AU  - Dharia NV
AUID- ORCID: http://orcid.org/0000-0001-5048-067X
AD  - Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
AD  - Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
AD  - Boston Children's Hospital, Boston, Massachusetts, USA.
AD  - Harvard Medical School, Boston, Massachusetts, USA.
FAU - Montgomery, Phillip G
AU  - Montgomery PG
AUID- ORCID: http://orcid.org/0000-0002-2633-1081
AD  - Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
FAU - Cowley, Glenn S
AU  - Cowley GS
AD  - Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
FAU - Pantel, Sasha
AU  - Pantel S
AD  - Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
FAU - Goodale, Amy
AU  - Goodale A
AD  - Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
FAU - Lee, Yenarae
AU  - Lee Y
AD  - Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
FAU - Ali, Levi D
AU  - Ali LD
AD  - Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
FAU - Jiang, Guozhi
AU  - Jiang G
AD  - Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
FAU - Lubonja, Rakela
AU  - Lubonja R
AD  - Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
FAU - Harrington, William F
AU  - Harrington WF
AD  - Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
FAU - Strickland, Matthew
AU  - Strickland M
AD  - Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
FAU - Wu, Ting
AU  - Wu T
AD  - Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
FAU - Hawes, Derek C
AU  - Hawes DC
AD  - Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
FAU - Zhivich, Victor A
AU  - Zhivich VA
AD  - Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
FAU - Wyatt, Meghan R
AU  - Wyatt MR
AD  - Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
FAU - Kalani, Zohra
AU  - Kalani Z
AD  - Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
FAU - Chang, Jaime J
AU  - Chang JJ
AD  - Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
FAU - Okamoto, Michael
AU  - Okamoto M
AD  - Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
FAU - Stegmaier, Kimberly
AU  - Stegmaier K
AD  - Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
AD  - Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
AD  - Boston Children's Hospital, Boston, Massachusetts, USA.
AD  - Harvard Medical School, Boston, Massachusetts, USA.
FAU - Golub, Todd R
AU  - Golub TR
AUID- ORCID: http://orcid.org/0000-0003-0113-2403
AD  - Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
AD  - Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
AD  - Boston Children's Hospital, Boston, Massachusetts, USA.
AD  - Harvard Medical School, Boston, Massachusetts, USA.
AD  - Howard Hughes Medical Institute, Chevy Chase, Maryland, USA.
FAU - Boehm, Jesse S
AU  - Boehm JS
AUID- ORCID: http://orcid.org/0000-0002-6795-6336
AD  - Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
FAU - Vazquez, Francisca
AU  - Vazquez F
AD  - Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
AD  - Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
FAU - Root, David E
AU  - Root DE
AD  - Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
FAU - Hahn, William C
AU  - Hahn WC
AUID- ORCID: http://orcid.org/0000-0003-2840-9791
AD  - Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
AD  - Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
AD  - Harvard Medical School, Boston, Massachusetts, USA.
AD  - Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
FAU - Tsherniak, Aviad
AU  - Tsherniak A
AUID- ORCID: http://orcid.org/0000-0002-3797-1877
AD  - Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
LA  - eng
GR  - P01 CA154303/CA/NCI NIH HHS/United States
GR  - U01 CA176058/CA/NCI NIH HHS/United States
GR  - U01 CA199253/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20171030
PL  - United States
TA  - Nat Genet
JT  - Nature genetics
JID - 9216904
SB  - IM
MH  - Algorithms
MH  - *CRISPR-Cas Systems
MH  - Cell Line, Tumor
MH  - Computational Biology/*methods
MH  - *DNA Copy Number Variations
MH  - Gene Dosage/*genetics
MH  - Genetic Predisposition to Disease/*genetics
MH  - Humans
MH  - Models, Genetic
MH  - Neoplasms/diagnosis/genetics
MH  - Reproducibility of Results
MH  - Sensitivity and Specificity
PMC - PMC5709193
MID - NIHMS910985
EDAT- 2017/10/31 06:00
MHDA- 2017/12/12 06:00
CRDT- 2017/10/31 06:00
PMCR- 2018/04/30 00:00
PHST- 2017/04/07 00:00 [received]
PHST- 2017/10/04 00:00 [accepted]
PHST- 2018/04/30 00:00 [pmc-release]
PHST- 2017/10/31 06:00 [pubmed]
PHST- 2017/12/12 06:00 [medline]
PHST- 2017/10/31 06:00 [entrez]
AID - ng.3984 [pii]
AID - 10.1038/ng.3984 [doi]
PST - ppublish
SO  - Nat Genet. 2017 Dec;49(12):1779-1784. doi: 10.1038/ng.3984. Epub 2017 Oct 30.

PMID- 29258294
OWN - NLM
STAT- In-Data-Review
LR  - 20180104
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 553
IP  - 7686
DP  - 2018 Jan 4
TI  - Senescence-associated reprogramming promotes cancer stemness.
PG  - 96-100
LID - 10.1038/nature25167 [doi]
AB  - Cellular senescence is a stress-responsive cell-cycle arrest program that
      terminates the further expansion of (pre-)malignant cells. Key signalling
      components of the senescence machinery, such as p16(INK4a), p21(CIP1) and p53, as
      well as trimethylation of lysine 9 at histone H3 (H3K9me3), also operate as
      critical regulators of stem-cell functions (which are collectively termed
      'stemness'). In cancer cells, a gain of stemness may have profound implications
      for tumour aggressiveness and clinical outcome. Here we investigated whether
      chemotherapy-induced senescence could change stem-cell-related properties of
      malignant cells. Gene expression and functional analyses comparing senescent and 
      non-senescent B-cell lymphomas from Emu-Myc transgenic mice revealed substantial 
      upregulation of an adult tissue stem-cell signature, activated Wnt signalling,
      and distinct stem-cell markers in senescence. Using genetically switchable models
      of senescence targeting H3K9me3 or p53 to mimic spontaneous escape from the
      arrested condition, we found that cells released from senescence re-entered the
      cell cycle with strongly enhanced and Wnt-dependent clonogenic growth potential
      compared to virtually identical populations that had been equally exposed to
      chemotherapy but had never been senescent. In vivo, these previously senescent
      cells presented with a much higher tumour initiation potential. Notably, the
      temporary enforcement of senescence in p53-regulatable models of acute
      lymphoblastic leukaemia and acute myeloid leukaemia was found to reprogram
      non-stem bulk leukaemia cells into self-renewing, leukaemia-initiating stem
      cells. Our data, which are further supported by consistent results in human
      cancer cell lines and primary samples of human haematological malignancies,
      reveal that senescence-associated stemness is an unexpected, cell-autonomous
      feature that exerts its detrimental, highly aggressive growth potential upon
      escape from cell-cycle blockade, and is enriched in relapse tumours. These
      findings have profound implications for cancer therapy, and provide new
      mechanistic insights into the plasticity of cancer cells.
FAU - Milanovic, Maja
AU  - Milanovic M
AD  - Charite - Universitatsmedizin Berlin, Medical Department of Hematology, Oncology 
      and Tumor Immunology, and Molekulares Krebsforschungszentrum - MKFZ, Virchow
      Campus, 13353 Berlin, Germany.
FAU - Fan, Dorothy N Y
AU  - Fan DNY
AD  - Charite - Universitatsmedizin Berlin, Medical Department of Hematology, Oncology 
      and Tumor Immunology, and Molekulares Krebsforschungszentrum - MKFZ, Virchow
      Campus, 13353 Berlin, Germany.
AD  - Deutsches Konsortium fur Translationale Krebsforschung (German Cancer
      Consortium), 69120 Heidelberg, Germany.
AD  - German Cancer Research Center (Deutsches Krebsforschungszentrum - DKFZ), Im
      Neuenheimer Feld 280, 69120 Heidelberg, Germany.
AD  - Deutsches Konsortium fur Translationale Krebsforschung (German Cancer
      Consortium), Partner site Berlin, Berlin, Germany.
FAU - Belenki, Dimitri
AU  - Belenki D
AD  - Charite - Universitatsmedizin Berlin, Medical Department of Hematology, Oncology 
      and Tumor Immunology, and Molekulares Krebsforschungszentrum - MKFZ, Virchow
      Campus, 13353 Berlin, Germany.
FAU - Dabritz, J Henry M
AU  - Dabritz JHM
AD  - Charite - Universitatsmedizin Berlin, Medical Department of Hematology, Oncology 
      and Tumor Immunology, and Molekulares Krebsforschungszentrum - MKFZ, Virchow
      Campus, 13353 Berlin, Germany.
FAU - Zhao, Zhen
AU  - Zhao Z
AD  - Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, 1275
      York Avenue, New York, New York 10065, USA.
FAU - Yu, Yong
AU  - Yu Y
AD  - Max-Delbruck-Center for Molecular Medicine in the Helmholtz Association,
      Robert-Rossle-Strasse 10, 13125 Berlin, Germany.
FAU - Dorr, Jan R
AU  - Dorr JR
AD  - Charite - Universitatsmedizin Berlin, Medical Department of Hematology, Oncology 
      and Tumor Immunology, and Molekulares Krebsforschungszentrum - MKFZ, Virchow
      Campus, 13353 Berlin, Germany.
FAU - Dimitrova, Lora
AU  - Dimitrova L
AD  - Charite - Universitatsmedizin Berlin, Department of Pathology, Berlin, Germany.
FAU - Lenze, Dido
AU  - Lenze D
AD  - Charite - Universitatsmedizin Berlin, Department of Pathology, Berlin, Germany.
FAU - Monteiro Barbosa, Ines A
AU  - Monteiro Barbosa IA
AD  - Institute of Molecular Pathology (IMP), Vienna Biocenter, Dr Bohr-Gasse 7, 1030
      Vienna, Austria.
FAU - Mendoza-Parra, Marco A
AU  - Mendoza-Parra MA
AD  - Equipe Labellisee Ligue Contre le Cancer, Department of Functional Genomics and
      Cancer, Institut de Genetique et de Biologie Moleculaire et Cellulaire, Centre
      National de la Recherche Scientifique, UMR7104, Institut National de la Sante et 
      de la Recherche Medicale, U964, Universite de Strasbourg, 67400 Illkirch, France.
FAU - Kanashova, Tamara
AU  - Kanashova T
AD  - Max-Delbruck-Center for Molecular Medicine in the Helmholtz Association,
      Robert-Rossle-Strasse 10, 13125 Berlin, Germany.
FAU - Metzner, Marlen
AU  - Metzner M
AD  - Charite - Universitatsmedizin Berlin, Medical Department of Hematology, Oncology 
      and Tumor Immunology, and Molekulares Krebsforschungszentrum - MKFZ, Virchow
      Campus, 13353 Berlin, Germany.
FAU - Pardon, Katharina
AU  - Pardon K
AD  - Charite - Universitatsmedizin Berlin, Medical Department of Hematology, Oncology 
      and Tumor Immunology, and Molekulares Krebsforschungszentrum - MKFZ, Virchow
      Campus, 13353 Berlin, Germany.
FAU - Reimann, Maurice
AU  - Reimann M
AD  - Charite - Universitatsmedizin Berlin, Medical Department of Hematology, Oncology 
      and Tumor Immunology, and Molekulares Krebsforschungszentrum - MKFZ, Virchow
      Campus, 13353 Berlin, Germany.
FAU - Trumpp, Andreas
AU  - Trumpp A
AD  - Deutsches Konsortium fur Translationale Krebsforschung (German Cancer
      Consortium), 69120 Heidelberg, Germany.
AD  - German Cancer Research Center (Deutsches Krebsforschungszentrum - DKFZ), Im
      Neuenheimer Feld 280, 69120 Heidelberg, Germany.
AD  - Deutsches Konsortium fur Translationale Krebsforschung (German Cancer
      Consortium), Partner site Berlin, Berlin, Germany.
AD  - Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM 
      gGmbH), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.
FAU - Dorken, Bernd
AU  - Dorken B
AD  - Charite - Universitatsmedizin Berlin, Medical Department of Hematology, Oncology 
      and Tumor Immunology, and Molekulares Krebsforschungszentrum - MKFZ, Virchow
      Campus, 13353 Berlin, Germany.
AD  - Deutsches Konsortium fur Translationale Krebsforschung (German Cancer
      Consortium), 69120 Heidelberg, Germany.
AD  - Deutsches Konsortium fur Translationale Krebsforschung (German Cancer
      Consortium), Partner site Berlin, Berlin, Germany.
AD  - Max-Delbruck-Center for Molecular Medicine in the Helmholtz Association,
      Robert-Rossle-Strasse 10, 13125 Berlin, Germany.
AD  - Berlin Institute of Health, Anna-Louisa-Karsch-Strasse 2, 10178 Berlin, Germany.
FAU - Zuber, Johannes
AU  - Zuber J
AD  - Institute of Molecular Pathology (IMP), Vienna Biocenter, Dr Bohr-Gasse 7, 1030
      Vienna, Austria.
FAU - Gronemeyer, Hinrich
AU  - Gronemeyer H
AD  - Equipe Labellisee Ligue Contre le Cancer, Department of Functional Genomics and
      Cancer, Institut de Genetique et de Biologie Moleculaire et Cellulaire, Centre
      National de la Recherche Scientifique, UMR7104, Institut National de la Sante et 
      de la Recherche Medicale, U964, Universite de Strasbourg, 67400 Illkirch, France.
FAU - Hummel, Michael
AU  - Hummel M
AD  - Deutsches Konsortium fur Translationale Krebsforschung (German Cancer
      Consortium), 69120 Heidelberg, Germany.
AD  - Deutsches Konsortium fur Translationale Krebsforschung (German Cancer
      Consortium), Partner site Berlin, Berlin, Germany.
AD  - Charite - Universitatsmedizin Berlin, Department of Pathology, Berlin, Germany.
AD  - Berlin Institute of Health, Anna-Louisa-Karsch-Strasse 2, 10178 Berlin, Germany.
FAU - Dittmar, Gunnar
AU  - Dittmar G
AD  - Max-Delbruck-Center for Molecular Medicine in the Helmholtz Association,
      Robert-Rossle-Strasse 10, 13125 Berlin, Germany.
AD  - Luxembourg Institute of Health, 1A-B rue Thomas Edison, L-1455 Strassen,
      Luxembourg.
FAU - Lee, Soyoung
AU  - Lee S
AD  - Charite - Universitatsmedizin Berlin, Medical Department of Hematology, Oncology 
      and Tumor Immunology, and Molekulares Krebsforschungszentrum - MKFZ, Virchow
      Campus, 13353 Berlin, Germany.
AD  - Deutsches Konsortium fur Translationale Krebsforschung (German Cancer
      Consortium), 69120 Heidelberg, Germany.
AD  - Deutsches Konsortium fur Translationale Krebsforschung (German Cancer
      Consortium), Partner site Berlin, Berlin, Germany.
AD  - Max-Delbruck-Center for Molecular Medicine in the Helmholtz Association,
      Robert-Rossle-Strasse 10, 13125 Berlin, Germany.
FAU - Schmitt, Clemens A
AU  - Schmitt CA
AD  - Charite - Universitatsmedizin Berlin, Medical Department of Hematology, Oncology 
      and Tumor Immunology, and Molekulares Krebsforschungszentrum - MKFZ, Virchow
      Campus, 13353 Berlin, Germany.
AD  - Deutsches Konsortium fur Translationale Krebsforschung (German Cancer
      Consortium), 69120 Heidelberg, Germany.
AD  - Deutsches Konsortium fur Translationale Krebsforschung (German Cancer
      Consortium), Partner site Berlin, Berlin, Germany.
AD  - Max-Delbruck-Center for Molecular Medicine in the Helmholtz Association,
      Robert-Rossle-Strasse 10, 13125 Berlin, Germany.
AD  - Berlin Institute of Health, Anna-Louisa-Karsch-Strasse 2, 10178 Berlin, Germany.
LA  - eng
PT  - Journal Article
DEP - 20171220
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
EDAT- 2017/12/21 06:00
MHDA- 2017/12/21 06:00
CRDT- 2017/12/21 06:00
PHST- 2014/02/16 00:00 [received]
PHST- 2017/11/24 00:00 [accepted]
PHST- 2017/12/21 06:00 [pubmed]
PHST- 2017/12/21 06:00 [medline]
PHST- 2017/12/21 06:00 [entrez]
AID - nature25167 [pii]
AID - 10.1038/nature25167 [doi]
PST - ppublish
SO  - Nature. 2018 Jan 4;553(7686):96-100. doi: 10.1038/nature25167. Epub 2017 Dec 20.

PMID- 29088702
OWN - NLM
STAT- In-Data-Review
LR  - 20171219
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 551
IP  - 7679
DP  - 2017 Nov 9
TI  - Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition.
PG  - 247-250
LID - 10.1038/nature24297 [doi]
AB  - Acquired drug resistance prevents cancer therapies from achieving stable and
      complete responses. Emerging evidence implicates a key role for non-mutational
      drug resistance mechanisms underlying the survival of residual cancer 'persister'
      cells. The persister cell pool constitutes a reservoir from which drug-resistant 
      tumours may emerge. Targeting persister cells therefore presents a therapeutic
      opportunity to impede tumour relapse. We previously found that cancer cells in a 
      high mesenchymal therapy-resistant cell state are dependent on the lipid
      hydroperoxidase GPX4 for survival. Here we show that a similar therapy-resistant 
      cell state underlies the behaviour of persister cells derived from a wide range
      of cancers and drug treatments. Consequently, we demonstrate that persister cells
      acquire a dependency on GPX4. Loss of GPX4 function results in selective
      persister cell ferroptotic death in vitro and prevents tumour relapse in mice.
      These findings suggest that targeting of GPX4 may represent a therapeutic
      strategy to prevent acquired drug resistance.
FAU - Hangauer, Matthew J
AU  - Hangauer MJ
AD  - Department of Microbiology and Immunology, University of California San
      Francisco, 513 Parnassus Avenue, San Francisco, California 94143, USA.
AD  - UCSF Diabetes Center, University of California San Francisco, 513 Parnassus
      Avenue, San Francisco, California 94143, USA.
AD  - UCSF Helen Diller Family Comprehensive Cancer Center, University of California
      San Francisco, 1450 3rd Street, San Francisco, California 94143, USA.
FAU - Viswanathan, Vasanthi S
AU  - Viswanathan VS
AD  - Broad Institute, 415 Main Street, Cambridge, Massachusetts 02142, USA.
FAU - Ryan, Matthew J
AU  - Ryan MJ
AD  - Broad Institute, 415 Main Street, Cambridge, Massachusetts 02142, USA.
FAU - Bole, Dhruv
AU  - Bole D
AD  - UCSF Helen Diller Family Comprehensive Cancer Center, University of California
      San Francisco, 1450 3rd Street, San Francisco, California 94143, USA.
FAU - Eaton, John K
AU  - Eaton JK
AD  - Broad Institute, 415 Main Street, Cambridge, Massachusetts 02142, USA.
FAU - Matov, Alexandre
AU  - Matov A
AD  - DataSet Analysis LLC, 155 Jackson Street, San Francisco, California 94111, USA.
FAU - Galeas, Jacqueline
AU  - Galeas J
AD  - UCSF Helen Diller Family Comprehensive Cancer Center, University of California
      San Francisco, 1450 3rd Street, San Francisco, California 94143, USA.
FAU - Dhruv, Harshil D
AU  - Dhruv HD
AD  - Cancer and Cell Biology Division, The Translational Genomics Research Institute, 
      445 N 5th Street, Phoenix, Arizona 85004, USA.
FAU - Berens, Michael E
AU  - Berens ME
AD  - Cancer and Cell Biology Division, The Translational Genomics Research Institute, 
      445 N 5th Street, Phoenix, Arizona 85004, USA.
FAU - Schreiber, Stuart L
AU  - Schreiber SL
AD  - Broad Institute, 415 Main Street, Cambridge, Massachusetts 02142, USA.
AD  - Howard Hughes Medical Institute, Chevy Chase, Maryland 20815, USA.
AD  - Department of Chemistry and Chemical Biology, Harvard University, 12 Oxford
      Street, Cambridge, Massachusetts 02138, USA.
FAU - McCormick, Frank
AU  - McCormick F
AD  - UCSF Helen Diller Family Comprehensive Cancer Center, University of California
      San Francisco, 1450 3rd Street, San Francisco, California 94143, USA.
FAU - McManus, Michael T
AU  - McManus MT
AD  - Department of Microbiology and Immunology, University of California San
      Francisco, 513 Parnassus Avenue, San Francisco, California 94143, USA.
AD  - UCSF Diabetes Center, University of California San Francisco, 513 Parnassus
      Avenue, San Francisco, California 94143, USA.
LA  - eng
PT  - Journal Article
DEP - 20171101
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
EDAT- 2017/11/02 06:00
MHDA- 2017/11/02 06:00
CRDT- 2017/11/02 06:00
PHST- 2016/07/20 00:00 [received]
PHST- 2017/09/19 00:00 [accepted]
PHST- 2017/11/02 06:00 [pubmed]
PHST- 2017/11/02 06:00 [medline]
PHST- 2017/11/02 06:00 [entrez]
AID - nature24297 [pii]
AID - 10.1038/nature24297 [doi]
PST - ppublish
SO  - Nature. 2017 Nov 9;551(7679):247-250. doi: 10.1038/nature24297. Epub 2017 Nov 1.

PMID- 29150967
OWN - NLM
STAT- In-Process
LR  - 20180109
IS  - 1600-0781 (Electronic)
IS  - 0905-4383 (Linking)
VI  - 34
IP  - 1
DP  - 2018 Jan
TI  - Drug delivery strategies for chemoprevention of UVB-induced skin cancer: A
      review.
PG  - 60-68
LID - 10.1111/phpp.12368 [doi]
AB  - Annually, more skin cancer cases are diagnosed than the collective incidence of
      the colon, lung, breast, and prostate cancer. Persistent contact with sunlight is
      a primary cause for all the skin malignancies. UVB radiation induces reactive
      oxygen species (ROS) production in the skin which eventually leads to DNA damage 
      and mutation. Various delivery approaches for the skin cancer
      treatment/prevention have been evolving and are directed toward improvements in
      terms of delivery modes, therapeutic agents, and site-specificity of therapeutics
      delivery. The effective chemoprevention activity achieved is based on the
      efficiency of the delivery system used and the amount of the therapeutic molecule
      deposited in the skin. In this article, we have discussed different studies
      performed specifically for the chemoprevention of UVB-induced skin cancer.
      Ultra-flexible nanocarriers, transethosomes nanocarriers, silica nanoparticles,
      silver nanoparticles, nanocapsule suspensions, microemulsion, nanoemulsion, and
      polymeric nanoparticles which have been used so far to deliver the desired drug
      molecule for preventing the UVB-induced skin cancer.
CI  - (c) 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Bagde, Arvind
AU  - Bagde A
AD  - College of Pharmacy and Pharmaceutical Sciences, Florida A&M University,
      Tallahassee, FL, USA.
FAU - Mondal, Arindam
AU  - Mondal A
AD  - College of Pharmacy and Pharmaceutical Sciences, Florida A&M University,
      Tallahassee, FL, USA.
FAU - Singh, Mandip
AU  - Singh M
AUID- ORCID: http://orcid.org/0000-0001-9192-8143
AD  - College of Pharmacy and Pharmaceutical Sciences, Florida A&M University,
      Tallahassee, FL, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Photodermatol Photoimmunol Photomed
JT  - Photodermatology, photoimmunology & photomedicine
JID - 9013641
OTO - NOTNLM
OT  - UVB radiation
OT  - chemoprevention
OT  - drug delivery strategy
OT  - skin cancer
EDAT- 2017/11/19 06:00
MHDA- 2017/11/19 06:00
CRDT- 2017/11/19 06:00
PHST- 2017/11/10 00:00 [accepted]
PHST- 2017/11/19 06:00 [pubmed]
PHST- 2017/11/19 06:00 [medline]
PHST- 2017/11/19 06:00 [entrez]
AID - 10.1111/phpp.12368 [doi]
PST - ppublish
SO  - Photodermatol Photoimmunol Photomed. 2018 Jan;34(1):60-68. doi:
      10.1111/phpp.12368.

PMID- 29138276
OWN - NLM
STAT- MEDLINE
DCOM- 20171205
LR  - 20171222
IS  - 1549-5477 (Electronic)
IS  - 0890-9369 (Linking)
VI  - 31
IP  - 20
DP  - 2017 Oct 15
TI  - Metabolic reprogramming ensures cancer cell survival despite oncogenic signaling 
      blockade.
PG  - 2067-2084
LID - 10.1101/gad.305292.117 [doi]
AB  - There is limited knowledge about the metabolic reprogramming induced by cancer
      therapies and how this contributes to therapeutic resistance. Here we show that
      although inhibition of PI3K-AKT-mTOR signaling markedly decreased glycolysis and 
      restrained tumor growth, these signaling and metabolic restrictions triggered
      autophagy, which supplied the metabolites required for the maintenance of
      mitochondrial respiration and redox homeostasis. Specifically, we found that
      survival of cancer cells was critically dependent on phospholipase A2 (PLA2) to
      mobilize lysophospholipids and free fatty acids to sustain fatty acid oxidation
      and oxidative phosphorylation. Consistent with this, we observed significantly
      increased lipid droplets, with subsequent mobilization to mitochondria. These
      changes were abrogated in cells deficient for the essential autophagy gene ATG5
      Accordingly, inhibition of PLA2 significantly decreased lipid droplets, decreased
      oxidative phosphorylation, and increased apoptosis. Together, these results
      describe how treatment-induced autophagy provides nutrients for cancer cell
      survival and identifies novel cotreatment strategies to override this survival
      advantage.
CI  - (c) 2017 Lue et al.; Published by Cold Spring Harbor Laboratory Press.
FAU - Lue, Hui-Wen
AU  - Lue HW
AD  - Knight Comprehensive Cancer Institute, Oregon Health and Science University,
      Portland, Oregon 97239, USA.
FAU - Podolak, Jennifer
AU  - Podolak J
AD  - Knight Comprehensive Cancer Institute, Oregon Health and Science University,
      Portland, Oregon 97239, USA.
FAU - Kolahi, Kevin
AU  - Kolahi K
AD  - Knight Cardiovascular Institute, Oregon Health and Science University, Portland, 
      Oregon 97239, USA.
FAU - Cheng, Larry
AU  - Cheng L
AD  - Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New
      Jersey, New Brunswick, New Jersey 08903, USA.
FAU - Rao, Soumya
AU  - Rao S
AD  - Knight Comprehensive Cancer Institute, Oregon Health and Science University,
      Portland, Oregon 97239, USA.
FAU - Garg, Devin
AU  - Garg D
AD  - Knight Comprehensive Cancer Institute, Oregon Health and Science University,
      Portland, Oregon 97239, USA.
FAU - Xue, Chang-Hui
AU  - Xue CH
AD  - Knight Comprehensive Cancer Institute, Oregon Health and Science University,
      Portland, Oregon 97239, USA.
FAU - Rantala, Juha K
AU  - Rantala JK
AD  - Knight Comprehensive Cancer Institute, Oregon Health and Science University,
      Portland, Oregon 97239, USA.
FAU - Tyner, Jeffrey W
AU  - Tyner JW
AD  - Knight Comprehensive Cancer Institute, Oregon Health and Science University,
      Portland, Oregon 97239, USA.
FAU - Thornburg, Kent L
AU  - Thornburg KL
AD  - Knight Cardiovascular Institute, Oregon Health and Science University, Portland, 
      Oregon 97239, USA.
FAU - Martinez-Acevedo, Ann
AU  - Martinez-Acevedo A
AD  - Department of Urology, Oregon Health and Science University, Portland, Oregon
      97239, USA.
FAU - Liu, Jen-Jane
AU  - Liu JJ
AD  - Department of Urology, Oregon Health and Science University, Portland, Oregon
      97239, USA.
FAU - Amling, Christopher L
AU  - Amling CL
AD  - Department of Urology, Oregon Health and Science University, Portland, Oregon
      97239, USA.
FAU - Truillet, Charles
AU  - Truillet C
AD  - Department of Radiology, University of California at San Francisco School of
      Medicine, San Francisco, California 94107, USA.
FAU - Louie, Sharon M
AU  - Louie SM
AD  - University of California at Berkeley, Berkeley, California 94720, USA.
FAU - Anderson, Kimberly E
AU  - Anderson KE
AD  - University of California at Berkeley, Berkeley, California 94720, USA.
FAU - Evans, Michael J
AU  - Evans MJ
AD  - Department of Radiology, University of California at San Francisco School of
      Medicine, San Francisco, California 94107, USA.
FAU - O'Donnell, Valerie B
AU  - O'Donnell VB
AD  - Systems Immunity Research Institute, Cardiff University, Cardiff CF14 4XN, United
      Kingdom.
FAU - Nomura, Daniel K
AU  - Nomura DK
AD  - University of California at Berkeley, Berkeley, California 94720, USA.
FAU - Drake, Justin M
AU  - Drake JM
AD  - Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New
      Jersey, New Brunswick, New Jersey 08903, USA.
FAU - Ritz, Anna
AU  - Ritz A
AD  - Department of Biology, Reed College, Portland, Oregon 97202, USA.
FAU - Thomas, George V
AU  - Thomas GV
AUID- ORCID: http://orcid.org/0000-0001-7416-8840
AD  - Knight Comprehensive Cancer Institute, Oregon Health and Science University,
      Portland, Oregon 97239, USA.
AD  - Department of Pathology and Laboratory Medicine, Oregon Health and Science
      University, Portland, Oregon 97239, USA.
LA  - eng
GR  - R01 CA176671/CA/NCI NIH HHS/United States
GR  - T32 GM008339/GM/NIGMS NIH HHS/United States
GR  - R00 CA172695/CA/NCI NIH HHS/United States
GR  - R01 CA169172/CA/NCI NIH HHS/United States
GR  - P30 CA069533/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20171114
PL  - United States
TA  - Genes Dev
JT  - Genes & development
JID - 8711660
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Benzamides)
RN  - 0 (Heterocyclic Compounds, 3-Ring)
RN  - 0 (MK 2206)
RN  - 0 (Phospholipase A2 Inhibitors)
RN  - 0 (Phospholipids)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyrimidines)
RN  - 6O01GMS00P
      (N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide)
RN  - EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*pharmacology
MH  - Apoptosis
MH  - Autophagy
MH  - Benzamides/pharmacology
MH  - Cell Line, Tumor
MH  - Cell Respiration/drug effects
MH  - Cell Survival
MH  - Heterocyclic Compounds, 3-Ring/pharmacology
MH  - Humans
MH  - Lipid Droplets/metabolism
MH  - Mice
MH  - Mitochondria/drug effects/metabolism
MH  - Neoplasms/enzymology/*metabolism/pathology
MH  - Phosphatidylinositol 3-Kinases/antagonists & inhibitors/metabolism
MH  - Phospholipase A2 Inhibitors/pharmacology
MH  - Phospholipids/metabolism
MH  - Protein Kinase Inhibitors/pharmacology
MH  - Proto-Oncogene Proteins c-akt/antagonists & inhibitors/metabolism
MH  - Pyrimidines/pharmacology
MH  - Signal Transduction/*drug effects
MH  - Tumor Cells, Cultured
PMC - PMC5733498
OTO - NOTNLM
OT  - autophagy
OT  - cancer
OT  - metabolism
OT  - phospholipid
OT  - resistance
OT  - signaling
EDAT- 2017/11/16 06:00
MHDA- 2017/12/06 06:00
CRDT- 2017/11/16 06:00
PMCR- 2018/04/15 00:00
PHST- 2017/07/25 00:00 [received]
PHST- 2017/10/26 00:00 [accepted]
PHST- 2018/04/15 00:00 [pmc-release]
PHST- 2017/11/16 06:00 [pubmed]
PHST- 2017/12/06 06:00 [medline]
PHST- 2017/11/16 06:00 [entrez]
AID - gad.305292.117 [pii]
AID - 10.1101/gad.305292.117 [doi]
PST - ppublish
SO  - Genes Dev. 2017 Oct 15;31(20):2067-2084. doi: 10.1101/gad.305292.117. Epub 2017
      Nov 14.

PMID- 29202431
OWN - NLM
STAT- MEDLINE
DCOM- 20180102
LR  - 20180102
IS  - 1532-1967 (Electronic)
IS  - 0305-7372 (Linking)
VI  - 62
DP  - 2018 Jan
TI  - Triple negative breast cancer: Emerging therapeutic modalities and novel
      combination therapies.
PG  - 110-122
LID - S0305-7372(17)30188-3 [pii]
LID - 10.1016/j.ctrv.2017.11.003 [doi]
AB  - Triple negative breast cancer (TNBC) is a complex and aggressive subtype of
      breast cancer which lacks oestrogen receptors, progesterone receptors and HER2
      amplification, thereby making it difficult to target therapeutically. In
      addition, TNBC has the highest rates of metastatic disease and the poorest
      overall survival of all breast cancer subtypes. Resultantly, development of
      targeted therapies for TNBC is urgently needed. Recent efforts aimed at molecular
      characterisation of TNBCs have revealed various emerging therapeutic targets
      including PARP1, receptor and non-receptor tyrosine kinases, immune-checkpoints, 
      androgen receptor and epigenetic proteins. Key successes include that of the PARP
      inhibitor, olaparib, which prolonged progression-free survival in a trial of
      BRCA-mutated breast cancer and for which clinical approval (in this setting)
      appears imminent. Nevertheless, the heterogeneity of TNBC has limited the
      clinical benefits of many trialled therapies in 'unselected' patients. Further,
      drug resistance develops following use of many targeted monotherapies due to
      upregulation of compensatory signalling pathways. In this review, we evaluate the
      current status of investigational targeted treatments and present evidence for
      the role of novel biomarkers and combination therapies in increasing response
      rates and circumventing drug-induced resistance. Additionally, we discuss
      promising novel targets in metastatic TNBC identified through preclinical and/or 
      epidemiological studies.
CI  - Crown Copyright (c) 2017. Published by Elsevier Ltd. All rights reserved.
FAU - Lee, Alice
AU  - Lee A
AD  - Faculty of Medicine, Imperial College London, South Kensington Campus, London SW7
      2AZ, UK.
FAU - Djamgoz, Mustafa B A
AU  - Djamgoz MBA
AD  - Neuroscience Solution to Cancer Research Group, Department of Life Sciences,
      Faculty of Natural Sciences, Sir Alexander Fleming Building, Imperial College
      London, South Kensington Campus, London SW7 2AZ, UK. Electronic address:
      m.djamgoz@imperial.ac.uk.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20171113
PL  - Netherlands
TA  - Cancer Treat Rev
JT  - Cancer treatment reviews
JID - 7502030
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Androgen Receptor Antagonists)
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - 0 (Histone Deacetylase Inhibitors)
RN  - 0 (Poly(ADP-ribose) Polymerase Inhibitors)
RN  - 0 (Protein Kinase Inhibitors)
SB  - IM
MH  - Adrenergic beta-Antagonists/*therapeutic use
MH  - Androgen Receptor Antagonists/*therapeutic use
MH  - Angiogenesis Inhibitors/*therapeutic use
MH  - Antineoplastic Agents, Immunological/*therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Carcinoma/*drug therapy
MH  - Histone Deacetylase Inhibitors/*therapeutic use
MH  - Humans
MH  - Poly(ADP-ribose) Polymerase Inhibitors/*therapeutic use
MH  - Protein Kinase Inhibitors/*therapeutic use
MH  - Triple Negative Breast Neoplasms/*drug therapy
OTO - NOTNLM
OT  - Biomarkers
OT  - Combination therapy
OT  - Targeted therapy
OT  - Triple-negative breast cancer
EDAT- 2017/12/05 06:00
MHDA- 2018/01/03 06:00
CRDT- 2017/12/05 06:00
PHST- 2017/07/26 00:00 [received]
PHST- 2017/11/01 00:00 [revised]
PHST- 2017/11/03 00:00 [accepted]
PHST- 2017/12/05 06:00 [pubmed]
PHST- 2018/01/03 06:00 [medline]
PHST- 2017/12/05 06:00 [entrez]
AID - S0305-7372(17)30188-3 [pii]
AID - 10.1016/j.ctrv.2017.11.003 [doi]
PST - ppublish
SO  - Cancer Treat Rev. 2018 Jan;62:110-122. doi: 10.1016/j.ctrv.2017.11.003. Epub 2017
      Nov 13.

PMID- 29353450
OWN - NLM
STAT- Publisher
LR  - 20180121
IS  - 1432-0827 (Electronic)
IS  - 0171-967X (Linking)
DP  - 2018 Jan 20
TI  - Cancer Treatment and Bone Health.
LID - 10.1007/s00223-017-0369-x [doi]
AB  - Considerable advances in oncology over recent decades have led to improved
      survival, while raising concerns about long-term consequences of anticancer
      treatments. In patients with breast or prostate malignancies, bone health is a
      major issue due to the high risk of bone metastases and the frequent prolonged
      use of hormone therapies that alter physiological bone turnover, leading to
      increased fracture risk. Thus, the onset of cancer treatment-induced bone loss
      (CTIBL) should be considered by clinicians and recent guidelines should be
      routinely applied to these patients. In particular, baseline and periodic
      follow-up evaluations of bone health parameters enable the identification of
      patients at high risk of osteoporosis and fractures, which can be prevented by
      the use of bone-targeting agents (BTAs), calcium and vitamin D supplementation
      and modifications of lifestyle. This review will focus upon the pathophysiology
      of breast and prostate cancer treatment-induced bone loss and the most recent
      evidence about effective preventive and therapeutic strategies.
FAU - Handforth, Catherine
AU  - Handforth C
AD  - Department of Oncology and Metabolism, Academic Unit of Clinical Oncology, Weston
      Park Hospital, University of Sheffield, Sheffield, UK.
FAU - D'Oronzo, Stella
AU  - D'Oronzo S
AD  - Department of Oncology and Metabolism, Academic Unit of Clinical Oncology, Weston
      Park Hospital, University of Sheffield, Sheffield, UK.
FAU - Coleman, Robert
AU  - Coleman R
AD  - Department of Oncology and Metabolism, Academic Unit of Clinical Oncology, Weston
      Park Hospital, University of Sheffield, Sheffield, UK.
FAU - Brown, Janet
AU  - Brown J
AD  - Department of Oncology and Metabolism, Academic Unit of Clinical Oncology, Weston
      Park Hospital, University of Sheffield, Sheffield, UK. j.e.brown@sheffield.ac.uk.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180120
PL  - United States
TA  - Calcif Tissue Int
JT  - Calcified tissue international
JID - 7905481
OTO - NOTNLM
OT  - BMD
OT  - Breast cancer
OT  - Cancer treatment
OT  - Osteoporosis
OT  - Prostate cancer
EDAT- 2018/01/22 06:00
MHDA- 2018/01/22 06:00
CRDT- 2018/01/22 06:00
PHST- 2017/09/23 00:00 [received]
PHST- 2017/11/23 00:00 [accepted]
PHST- 2018/01/22 06:00 [entrez]
PHST- 2018/01/22 06:00 [pubmed]
PHST- 2018/01/22 06:00 [medline]
AID - 10.1007/s00223-017-0369-x [doi]
AID - 10.1007/s00223-017-0369-x [pii]
PST - aheadofprint
SO  - Calcif Tissue Int. 2018 Jan 20. pii: 10.1007/s00223-017-0369-x. doi:
      10.1007/s00223-017-0369-x.

PMID- 29329556
OWN - NLM
STAT- In-Data-Review
LR  - 20180119
IS  - 1756-8722 (Electronic)
IS  - 1756-8722 (Linking)
VI  - 11
IP  - 1
DP  - 2018 Jan 12
TI  - Cancer immunotherapy beyond immune checkpoint inhibitors.
PG  - 8
LID - 10.1186/s13045-017-0552-6 [doi]
AB  - Malignant cells have the capacity to rapidly grow exponentially and spread in
      part by suppressing, evading, and exploiting the host immune system.
      Immunotherapy is a form of oncologic treatment directed towards enhancing the
      host immune system against cancer. In recent years, manipulation of immune
      checkpoints or pathways has emerged as an important and effective form of
      immunotherapy. Agents that target cytotoxic T lymphocyte-associated molecule-4
      (CTLA-4), programmed cell death receptor-1 (PD-1), and programmed cell death
      ligand-1 (PD-L1) are the most widely studied and recognized. Immunotherapy,
      however, extends beyond immune checkpoint therapy by using new molecules such as 
      chimeric monoclonal antibodies and antibody drug conjugates that target malignant
      cells and promote their destruction. Genetically modified T cells expressing
      chimeric antigen receptors are able to recognize specific antigens on cancer
      cells and subsequently activate the immune system. Native or genetically modified
      viruses with oncolytic activity are of great interest as, besides destroying
      malignant cells, they can increase anti-tumor activity in response to the release
      of new antigens and danger signals as a result of infection and tumor cell lysis.
      Vaccines are also being explored, either in the form of autologous or allogenic
      tumor peptide antigens, genetically modified dendritic cells that express tumor
      peptides, or even in the use of RNA, DNA, bacteria, or virus as vectors of
      specific tumor markers. Most of these agents are yet under development, but they 
      promise to be important options to boost the host immune system to control and
      eliminate malignancy. In this review, we have provided detailed discussion of
      different forms of immunotherapy agents other than checkpoint-modifying drugs.
      The specific focus of this manuscript is to include first-in-human phase I and
      phase I/II clinical trials intended to allow the identification of those drugs
      that most likely will continue to develop and possibly join the immunotherapeutic
      arsenal in a near future.
FAU - Marin-Acevedo, Julian A
AU  - Marin-Acevedo JA
AD  - Department of Internal Medicine, Mayo Clinic, Jacksonville, FL, USA.
FAU - Soyano, Aixa E
AU  - Soyano AE
AD  - Department of Hematology and Oncology, Mayo Clinic, 4500 San Pablo Road,
      Jacksonville, FL, 32224, USA.
FAU - Dholaria, Bhagirathbhai
AU  - Dholaria B
AD  - Department of Hematology and Oncology, Mayo Clinic, 4500 San Pablo Road,
      Jacksonville, FL, 32224, USA.
AD  - Current address: Department of Blood and Marrow Transplant and Cellular
      Immunotherapy, Moffitt Cancer Center, Tampa, FL, USA.
FAU - Knutson, Keith L
AU  - Knutson KL
AD  - Department of Immunology, Mayo Clinic, Jacksonville, FL, USA.
FAU - Lou, Yanyan
AU  - Lou Y
AUID- ORCID: http://orcid.org/0000-0001-6207-9461
AD  - Department of Hematology and Oncology, Mayo Clinic, 4500 San Pablo Road,
      Jacksonville, FL, 32224, USA. lou.yanyan@mayo.edu.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180112
PL  - England
TA  - J Hematol Oncol
JT  - Journal of hematology & oncology
JID - 101468937
PMC - PMC5767051
OTO - NOTNLM
OT  - Antibody drug conjugates
OT  - Chimeric antigen receptor therapy
OT  - Immunotherapy
OT  - Oncolytic viruses
OT  - Tumor vaccines
OT  - Tumor-directed monoclonal antibodies
OT  - Viral gene therapy
EDAT- 2018/01/14 06:00
MHDA- 2018/01/14 06:00
CRDT- 2018/01/14 06:00
PHST- 2017/11/01 00:00 [received]
PHST- 2017/12/28 00:00 [accepted]
PHST- 2018/01/14 06:00 [entrez]
PHST- 2018/01/14 06:00 [pubmed]
PHST- 2018/01/14 06:00 [medline]
AID - 10.1186/s13045-017-0552-6 [doi]
AID - 10.1186/s13045-017-0552-6 [pii]
PST - epublish
SO  - J Hematol Oncol. 2018 Jan 12;11(1):8. doi: 10.1186/s13045-017-0552-6.

PMID- 29245013
OWN - NLM
STAT- MEDLINE
DCOM- 20171228
LR  - 20171228
IS  - 1097-4172 (Electronic)
IS  - 0092-8674 (Linking)
VI  - 171
IP  - 7
DP  - 2017 Dec 14
TI  - Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability 
      without Drug Additivity or Synergy.
PG  - 1678-1691.e13
LID - S0092-8674(17)31318-1 [pii]
LID - 10.1016/j.cell.2017.11.009 [doi]
AB  - Combination cancer therapies aim to improve the probability and magnitude of
      therapeutic responses and reduce the likelihood of acquired resistance in an
      individual patient. However, drugs are tested in clinical trials on genetically
      diverse patient populations. We show here that patient-to-patient variability and
      independent drug action are sufficient to explain the superiority of many
      FDA-approved drug combinations in the absence of drug synergy or additivity. This
      is also true for combinations tested in patient-derived tumor xenografts. In a
      combination exhibiting independent drug action, each patient benefits solely from
      the drug to which his or her tumor is most sensitive, with no added benefit from 
      other drugs. Even when drug combinations exhibit additivity or synergy in
      pre-clinical models, patient-to-patient variability and low cross-resistance make
      independent action the dominant mechanism in clinical populations. This insight
      represents a different way to interpret trial data and a different way to design 
      combination therapies.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Palmer, Adam C
AU  - Palmer AC
AD  - Laboratory of Systems Pharmacology, Program in Therapeutic Science, Harvard
      Medical School, Boston, MA 02115, USA.
FAU - Sorger, Peter K
AU  - Sorger PK
AD  - Laboratory of Systems Pharmacology, Program in Therapeutic Science, Harvard
      Medical School, Boston, MA 02115, USA. Electronic address:
      peter_sorger@hms.harvard.edu.
LA  - eng
GR  - P50 GM107618/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cell
JT  - Cell
JID - 0413066
SB  - IM
MH  - Animals
MH  - *Antineoplastic Combined Chemotherapy Protocols
MH  - Biological Variation, Individual
MH  - Clinical Trials as Topic
MH  - Drug Delivery Systems
MH  - Drug Interactions
MH  - Drug Resistance, Neoplasm
MH  - Heterografts
MH  - Humans
MH  - Immunotherapy
MH  - Neoplasm Transplantation
MH  - Neoplasms/*drug therapy
PMC - PMC5741091
MID - NIHMS918569
OTO - NOTNLM
OT  - cancer
OT  - clinical trials
OT  - combination therapy
OT  - drug synergy
OT  - mathematical modeling
OT  - patient-derived tumor xenograft
OT  - pharmacology
OT  - systems biology
OT  - tumor heterogeneity
EDAT- 2017/12/16 06:00
MHDA- 2017/12/29 06:00
CRDT- 2017/12/16 06:00
PMCR- 2018/12/14 00:00
PHST- 2017/03/12 00:00 [received]
PHST- 2017/07/26 00:00 [revised]
PHST- 2017/10/31 00:00 [accepted]
PHST- 2018/12/14 00:00 [pmc-release]
PHST- 2017/12/16 06:00 [entrez]
PHST- 2017/12/16 06:00 [pubmed]
PHST- 2017/12/29 06:00 [medline]
AID - S0092-8674(17)31318-1 [pii]
AID - 10.1016/j.cell.2017.11.009 [doi]
PST - ppublish
SO  - Cell. 2017 Dec 14;171(7):1678-1691.e13. doi: 10.1016/j.cell.2017.11.009.

PMID- 29132146
OWN - NLM
STAT- In-Data-Review
LR  - 20171219
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 551
IP  - 7681
DP  - 2017 Nov 23
TI  - Identification of unique neoantigen qualities in long-term survivors of
      pancreatic cancer.
PG  - 512-516
LID - 10.1038/nature24462 [doi]
AB  - Pancreatic ductal adenocarcinoma is a lethal cancer with fewer than 7% of
      patients surviving past 5 years. T-cell immunity has been linked to the
      exceptional outcome of the few long-term survivors, yet the relevant antigens
      remain unknown. Here we use genetic, immunohistochemical and transcriptional
      immunoprofiling, computational biophysics, and functional assays to identify
      T-cell antigens in long-term survivors of pancreatic cancer. Using whole-exome
      sequencing and in silico neoantigen prediction, we found that tumours with both
      the highest neoantigen number and the most abundant CD8(+) T-cell infiltrates,
      but neither alone, stratified patients with the longest survival. Investigating
      the specific neoantigen qualities promoting T-cell activation in long-term
      survivors, we discovered that these individuals were enriched in neoantigen
      qualities defined by a fitness model, and neoantigens in the tumour antigen MUC16
      (also known as CA125). A neoantigen quality fitness model conferring greater
      immunogenicity to neoantigens with differential presentation and homology to
      infectious disease-derived peptides identified long-term survivors in two
      independent datasets, whereas a neoantigen quantity model ascribing greater
      immunogenicity to increasing neoantigen number alone did not. We detected
      intratumoural and lasting circulating T-cell reactivity to both high-quality and 
      MUC16 neoantigens in long-term survivors of pancreatic cancer, including clones
      with specificity to both high-quality neoantigens and predicted cross-reactive
      microbial epitopes, consistent with neoantigen molecular mimicry. Notably, we
      observed selective loss of high-quality and MUC16 neoantigenic clones on
      metastatic progression, suggesting neoantigen immunoediting. Our results identify
      neoantigens with unique qualities as T-cell targets in pancreatic ductal
      adenocarcinoma. More broadly, we identify neoantigen quality as a biomarker for
      immunogenic tumours that may guide the application of immunotherapies.
FAU - Balachandran, Vinod P
AU  - Balachandran VP
AD  - Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New
      York, USA.
AD  - David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan
      Kettering Cancer Center, New York, New York, USA.
AD  - Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer
      Center, New York, New York, USA.
FAU - Luksza, Marta
AU  - Luksza M
AD  - The Simons Center for Systems Biology, Institute for Advanced Study, Princeton,
      New Jersey, USA.
FAU - Zhao, Julia N
AU  - Zhao JN
AD  - Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New
      York, USA.
AD  - David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan
      Kettering Cancer Center, New York, New York, USA.
AD  - Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer
      Center, New York, New York, USA.
FAU - Makarov, Vladimir
AU  - Makarov V
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, New York, USA.
AD  - Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer
      Center, New York, New York, USA.
FAU - Moral, John Alec
AU  - Moral JA
AD  - Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New
      York, USA.
AD  - David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan
      Kettering Cancer Center, New York, New York, USA.
AD  - Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer
      Center, New York, New York, USA.
FAU - Remark, Romain
AU  - Remark R
AD  - Tisch Cancer Institute, Immunology Institute, Icahn School of Medicine at Mount
      Sinai, New York, New York, USA.
FAU - Herbst, Brian
AU  - Herbst B
AD  - David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan
      Kettering Cancer Center, New York, New York, USA.
FAU - Askan, Gokce
AU  - Askan G
AD  - David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan
      Kettering Cancer Center, New York, New York, USA.
AD  - Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New
      York, USA.
FAU - Bhanot, Umesh
AU  - Bhanot U
AD  - Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New
      York, USA.
FAU - Senbabaoglu, Yasin
AU  - Senbabaoglu Y
AD  - Swim Across America/Ludwig Collaborative Laboratory, New York, New York, USA.
FAU - Wells, Daniel K
AU  - Wells DK
AD  - Parker Institute for Cancer Immunotherapy, San Francisco, California, USA.
FAU - Cary, Charles Ian Ormsby
AU  - Cary CIO
AD  - Parker Institute for Cancer Immunotherapy, San Francisco, California, USA.
FAU - Grbovic-Huezo, Olivera
AU  - Grbovic-Huezo O
AD  - David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan
      Kettering Cancer Center, New York, New York, USA.
FAU - Attiyeh, Marc
AU  - Attiyeh M
AD  - Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New
      York, USA.
AD  - David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan
      Kettering Cancer Center, New York, New York, USA.
FAU - Medina, Benjamin
AU  - Medina B
AD  - Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New
      York, USA.
FAU - Zhang, Jennifer
AU  - Zhang J
AD  - Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New
      York, USA.
FAU - Loo, Jennifer
AU  - Loo J
AD  - Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New
      York, USA.
FAU - Saglimbeni, Joseph
AU  - Saglimbeni J
AD  - David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan
      Kettering Cancer Center, New York, New York, USA.
FAU - Abu-Akeel, Mohsen
AU  - Abu-Akeel M
AD  - Swim Across America/Ludwig Collaborative Laboratory, New York, New York, USA.
FAU - Zappasodi, Roberta
AU  - Zappasodi R
AD  - Swim Across America/Ludwig Collaborative Laboratory, New York, New York, USA.
FAU - Riaz, Nadeem
AU  - Riaz N
AD  - Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer
      Center, New York, New York, USA.
AD  - Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New
      York, New York, USA.
FAU - Smoragiewicz, Martin
AU  - Smoragiewicz M
AD  - Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing
      Centre, Cambridge, UK.
FAU - Kelley, Z Larkin
AU  - Kelley ZL
AD  - Cold Spring Harbor Laboratory, New York, New York, USA.
AD  - Department of Microbiology and Immunology, Weill Cornell Medical School, New
      York, New York, USA.
FAU - Basturk, Olca
AU  - Basturk O
AD  - Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New
      York, USA.
CN  - Australian Pancreatic Cancer Genome Initiative
CN  - Garvan Institute of Medical Research
CN  - Prince of Wales Hospital
CN  - Royal North Shore Hospital
CN  - University of Glasgow
CN  - St Vincent's Hospital
CN  - QIMR Berghofer Medical Research Institute
CN  - University of Melbourne, Centre for Cancer Research
CN  - University of Queensland, Institute for Molecular Bioscience
CN  - Bankstown Hospital
CN  - Liverpool Hospital
CN  - Royal Prince Alfred Hospital, Chris O'Brien Lifehouse
CN  - Westmead Hospital
CN  - Fremantle Hospital
CN  - St John of God Healthcare
CN  - Royal Adelaide Hospital
CN  - Flinders Medical Centre
CN  - Envoi Pathology
CN  - Princess Alexandria Hospital
CN  - Austin Hospital
CN  - Johns Hopkins Medical Institutes
CN  - ARC-Net Centre for Applied Research on Cancer
FAU - Gonen, Mithat
AU  - Gonen M
AD  - Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York,
      New York, USA.
FAU - Levine, Arnold J
AU  - Levine AJ
AD  - The Simons Center for Systems Biology, Institute for Advanced Study, Princeton,
      New Jersey, USA.
FAU - Allen, Peter J
AU  - Allen PJ
AD  - Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New
      York, USA.
AD  - David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan
      Kettering Cancer Center, New York, New York, USA.
FAU - Fearon, Douglas T
AU  - Fearon DT
AD  - Cold Spring Harbor Laboratory, New York, New York, USA.
AD  - Department of Microbiology and Immunology, Weill Cornell Medical School, New
      York, New York, USA.
FAU - Merad, Miriam
AU  - Merad M
AD  - Tisch Cancer Institute, Immunology Institute, Icahn School of Medicine at Mount
      Sinai, New York, New York, USA.
FAU - Gnjatic, Sacha
AU  - Gnjatic S
AD  - Tisch Cancer Institute, Immunology Institute, Icahn School of Medicine at Mount
      Sinai, New York, New York, USA.
FAU - Iacobuzio-Donahue, Christine A
AU  - Iacobuzio-Donahue CA
AD  - David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan
      Kettering Cancer Center, New York, New York, USA.
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, New York, USA.
AD  - Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New
      York, USA.
FAU - Wolchok, Jedd D
AU  - Wolchok JD
AD  - Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer
      Center, New York, New York, USA.
AD  - Swim Across America/Ludwig Collaborative Laboratory, New York, New York, USA.
AD  - Melanoma and Immunotherapeutics Service, Department of Medicine, Memorial Sloan
      Kettering Cancer Center, New York, New York, USA.
AD  - Weill Cornell Medical College, Cornell University, New York, New York, USA.
AD  - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New
      York, USA.
FAU - DeMatteo, Ronald P
AU  - DeMatteo RP
AD  - Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New
      York, USA.
AD  - David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan
      Kettering Cancer Center, New York, New York, USA.
FAU - Chan, Timothy A
AU  - Chan TA
AD  - Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer
      Center, New York, New York, USA.
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, New York, USA.
AD  - Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer
      Center, New York, New York, USA.
AD  - Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New
      York, New York, USA.
FAU - Greenbaum, Benjamin D
AU  - Greenbaum BD
AD  - Tisch Cancer Institute, Departments of Medicine, Hematology and Medical Oncology,
      Oncological Sciences, and Pathology, Icahn School of Medicine at Mount Sinai, New
      York, New York, USA.
FAU - Merghoub, Taha
AU  - Merghoub T
AD  - Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer
      Center, New York, New York, USA.
AD  - Swim Across America/Ludwig Collaborative Laboratory, New York, New York, USA.
AD  - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New
      York, USA.
FAU - Leach, Steven D
AU  - Leach SD
AD  - Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New
      York, USA.
AD  - David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan
      Kettering Cancer Center, New York, New York, USA.
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, New York, USA.
AD  - Dartmouth Norris Cotton Cancer Center, Lebanon, New Hampshire, USA.
LA  - eng
PT  - Journal Article
DEP - 20171108
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
IR  - Johns AL
FIR - Johns, Amber L
IR  - Mead RS
FIR - Mead, R Scott
IR  - Gill AJ
FIR - Gill, Anthony J
IR  - Chang DK
FIR - Chang, David K
IR  - McKay SH
FIR - McKay, Skye H
IR  - Chantrill LA
FIR - Chantrill, Lorraine A
IR  - Chin VT
FIR - Chin, Venessa T
IR  - Chou A
FIR - Chou, Angela
IR  - Humphris JL
FIR - Humphris, Jeremy L
IR  - Pajic M
FIR - Pajic, Marina
IR  - Steinmann A
FIR - Steinmann, Angela
IR  - Arshi M
FIR - Arshi, Mehreen
IR  - Drury A
FIR - Drury, Ali
IR  - Froio D
FIR - Froio, Danielle
IR  - Morgan A
FIR - Morgan, Ashleigh
IR  - Timpson P
FIR - Timpson, Paul
IR  - Hermann D
FIR - Hermann, David
IR  - Vennin C
FIR - Vennin, Claire
IR  - Warren S
FIR - Warren, Sean
IR  - Pinese M
FIR - Pinese, Mark
IR  - Wu J
FIR - Wu, Jianmin
IR  - Pinho AV
FIR - Pinho, Andreia V
IR  - Mead RS
FIR - Mead, R Scott
IR  - Tucker K
FIR - Tucker, Katherine
IR  - Andrews L
FIR - Andrews, Lesley
IR  - Gill AJ
FIR - Gill, Anthony J
IR  - Samra JS
FIR - Samra, Jaswinder S
IR  - Arena J
FIR - Arena, Jennifer
IR  - Pavlakis N
FIR - Pavlakis, Nick
IR  - High HA
FIR - High, Hilda A
IR  - Mittal A
FIR - Mittal, Anubhav
IR  - Chang DK
FIR - Chang, David K
IR  - Biankin AV
FIR - Biankin, Andrew V
IR  - Bailey P
FIR - Bailey, Peter
IR  - Martin S
FIR - Martin, Sancha
IR  - Musgrove EA
FIR - Musgrove, Elizabeth A
IR  - Jones MD
FIR - Jones, Marc D
IR  - Nourse C
FIR - Nourse, Craig
IR  - Jamieson NB
FIR - Jamieson, Nigel B
IR  - Chou A
FIR - Chou, Angela
IR  - Chantrill LA
FIR - Chantrill, Lorraine A
IR  - Stoita A
FIR - Stoita, Alina
IR  - Williams D
FIR - Williams, David
IR  - Spigelman A
FIR - Spigelman, Allan
IR  - Waddell N
FIR - Waddell, Nicola
IR  - Pearson JV
FIR - Pearson, John V
IR  - Patch AM
FIR - Patch, Ann-Marie
IR  - Nones K
FIR - Nones, Katia
IR  - Newell F
FIR - Newell, Felicity
IR  - Mukhopadhyay P
FIR - Mukhopadhyay, Pamela
IR  - Addala V
FIR - Addala, Venkateswar
IR  - Kazakoff S
FIR - Kazakoff, Stephen
IR  - Holmes O
FIR - Holmes, Oliver
IR  - Leonard C
FIR - Leonard, Conrad
IR  - Wood S
FIR - Wood, Scott
IR  - Xu C
FIR - Xu, Christina
IR  - Grimmond SM
FIR - Grimmond, Sean M
IR  - Hofmann O
FIR - Hofmann, Oliver
IR  - Wilson PJ
FIR - Wilson, Peter J
IR  - Christ A
FIR - Christ, Angelika
IR  - Bruxner T
FIR - Bruxner, Tim
IR  - Asghari R
FIR - Asghari, Ray
IR  - Merrett ND
FIR - Merrett, Neil D
IR  - Pavey D
FIR - Pavey, Darren
IR  - Das A
FIR - Das, Amitabha
IR  - Goodwin A
FIR - Goodwin, Annabel
IR  - Cosman PH
FIR - Cosman, Peter H
IR  - Ismail K
FIR - Ismail, Kasim
IR  - O'Connor C
FIR - O'Connor, Chelsie
IR  - Cooper CL
FIR - Cooper, Caroline L
IR  - Goodwin A
FIR - Goodwin, Annabel
IR  - Grimison P
FIR - Grimison, Peter
IR  - Kench JG
FIR - Kench, James G
IR  - Sandroussi C
FIR - Sandroussi, Charbel
IR  - Lam VW
FIR - Lam, Vincent W
IR  - McLeod D
FIR - McLeod, Duncan
IR  - Nagrial AM
FIR - Nagrial, Adnan M
IR  - Kirk J
FIR - Kirk, Judy
IR  - James V
FIR - James, Virginia
IR  - Texler M
FIR - Texler, Michael
IR  - Forest C
FIR - Forest, Cindy
IR  - Epari KP
FIR - Epari, Krishna P
IR  - Ballal M
FIR - Ballal, Mo
IR  - Fletcher DR
FIR - Fletcher, David R
IR  - Mukhedkar S
FIR - Mukhedkar, Sanjay
IR  - Zeps N
FIR - Zeps, Nikolajs
IR  - Beilin M
FIR - Beilin, Maria
IR  - Feeney K
FIR - Feeney, Kynan
IR  - Nguyen NQ
FIR - Nguyen, Nan Q
IR  - Ruszkiewicz AR
FIR - Ruszkiewicz, Andrew R
IR  - Worthley C
FIR - Worthley, Chris
IR  - Chen J
FIR - Chen, John
IR  - Brooke-Smith ME
FIR - Brooke-Smith, Mark E
IR  - Papangelis V
FIR - Papangelis, Virginia
IR  - Clouston AD
FIR - Clouston, Andrew D
IR  - Martin P
FIR - Martin, Patrick
IR  - Barbour AP
FIR - Barbour, Andrew P
IR  - O'Rourke TJ
FIR - O'Rourke, Thomas J
IR  - Fawcett JW
FIR - Fawcett, Jonathan W
IR  - Slater K
FIR - Slater, Kellee
IR  - Hatzifotis M
FIR - Hatzifotis, Michael
IR  - Hodgkinson P
FIR - Hodgkinson, Peter
IR  - Nikfarjam M
FIR - Nikfarjam, Mehrdad
IR  - Eshleman JR
FIR - Eshleman, James R
IR  - Hruban RH
FIR - Hruban, Ralph H
IR  - Wolfgang CL
FIR - Wolfgang, Christopher L
IR  - Hodgin M
FIR - Hodgin, Mary
IR  - Scarpa A
FIR - Scarpa, Aldo
IR  - Lawlor RT
FIR - Lawlor, Rita T
IR  - Beghelli S
FIR - Beghelli, Stefania
IR  - Corbo V
FIR - Corbo, Vincenzo
IR  - Scardoni M
FIR - Scardoni, Maria
IR  - Bassi C
FIR - Bassi, Claudio
IR  - Scarpa A
FIR - Scarpa, Aldo
IR  - Lawlor RT
FIR - Lawlor, Rita T
IR  - Beghelli S
FIR - Beghelli, Stefania
IR  - Corbo V
FIR - Corbo, Vincenzo
IR  - Scardoni M
FIR - Scardoni, Maria
IR  - Bassi C
FIR - Bassi, Claudio
EDAT- 2017/11/14 06:00
MHDA- 2017/11/14 06:00
CRDT- 2017/11/14 06:00
PHST- 2016/11/21 00:00 [received]
PHST- 2017/10/02 00:00 [accepted]
PHST- 2017/11/14 06:00 [pubmed]
PHST- 2017/11/14 06:00 [medline]
PHST- 2017/11/14 06:00 [entrez]
AID - nature24462 [pii]
AID - 10.1038/nature24462 [doi]
PST - ppublish
SO  - Nature. 2017 Nov 23;551(7681):512-516. doi: 10.1038/nature24462. Epub 2017 Nov 8.

PMID- 29217585
OWN - NLM
STAT- Publisher
LR  - 20180119
IS  - 1095-9203 (Electronic)
IS  - 0036-8075 (Linking)
DP  - 2017 Dec 7
TI  - Patient HLA class I genotype influences cancer response to checkpoint blockade
      immunotherapy.
LID - eaao4572 [pii]
LID - 10.1126/science.aao4572 [doi]
AB  - CD8(+) T cell-dependent killing of cancer cells requires efficient presentation
      of tumor antigens by human leukocyte antigen class I (HLA-I) molecules. However, 
      the extent to which patient-specific HLA-I genotype influences response to
      anti-PD-1 or anti-CTLA-4 is currently unknown. We determined the HLA-I genotype
      of 1,535 advanced cancer patients treated with immune checkpoint blockade (ICB). 
      Maximal heterozygosity at HLA-I loci (A, B, and C) improved overall survival
      after ICB compared to patients who were homozygous for at least one HLA locus. In
      two independent melanoma cohorts, patients with the HLA-B44 supertype had
      extended survival, whereas the HLA-B62 supertype (including HLA-B*15:01) or
      somatic loss of heterozygosity at HLA-I, was associated with poor outcome.
      Molecular dynamics simulations of HLA-B*15:01 revealed unique elements that may
      impair CD8(+) T cell recognition of neoantigens. Our results have important
      implications for predicting response to ICB and for the design of
      neoantigen-based therapeutic vaccines.
CI  - Copyright (c) 2017, American Association for the Advancement of Science.
FAU - Chowell, Diego
AU  - Chowell D
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
AD  - Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer
      Center, New York, NY 10065. USA.
FAU - Morris, Luc G T
AU  - Morris LGT
AUID- ORCID: http://orcid.org/0000-0002-4417-2280
AD  - Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer
      Center, New York, NY 10065. USA.
AD  - Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA.
FAU - Grigg, Claud M
AU  - Grigg CM
AUID- ORCID: http://orcid.org/0000-0001-8847-5366
AD  - NewYork-Presbyterian/Columbia University Medical Center, 177 Fort Washington
      Ave., New York, NY 10032, USA.
FAU - Weber, Jeffrey K
AU  - Weber JK
AD  - IBM Thomas J. Watson Research Center, Yorktown Heights, NY 10598, USA.
FAU - Samstein, Robert M
AU  - Samstein RM
AUID- ORCID: http://orcid.org/0000-0001-6860-2401
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
AD  - Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer
      Center, New York, NY 10065. USA.
FAU - Makarov, Vladimir
AU  - Makarov V
AUID- ORCID: http://orcid.org/0000-0001-8026-824X
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
AD  - Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer
      Center, New York, NY 10065. USA.
FAU - Kuo, Fengshen
AU  - Kuo F
AUID- ORCID: http://orcid.org/0000-0003-1797-2896
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
AD  - Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer
      Center, New York, NY 10065. USA.
FAU - Kendall, Sviatoslav M
AU  - Kendall SM
AUID- ORCID: http://orcid.org/0000-0002-5368-5109
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
AD  - Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer
      Center, New York, NY 10065. USA.
FAU - Requena, David
AU  - Requena D
AUID- ORCID: http://orcid.org/0000-0002-5968-1133
AD  - The Rockefeller University, New York, NY 10065, USA.
FAU - Riaz, Nadeem
AU  - Riaz N
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
AD  - Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer
      Center, New York, NY 10065. USA.
AD  - Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New
      York, NY 10065, USA.
FAU - Greenbaum, Benjamin
AU  - Greenbaum B
AD  - Tisch Cancer Institute, Departments of Medicine, Oncological Sciences, and
      Pathology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
FAU - Carroll, James
AU  - Carroll J
AUID- ORCID: http://orcid.org/0000-0002-3061-0761
AD  - David Geffen School of Medicine at UCLA, 2825 Santa Monica Boulevard, Suite 200, 
      Santa Monica, CA 90404, USA.
FAU - Garon, Edward
AU  - Garon E
AD  - David Geffen School of Medicine at UCLA, 2825 Santa Monica Boulevard, Suite 200, 
      Santa Monica, CA 90404, USA.
FAU - Hyman, David M
AU  - Hyman DM
AUID- ORCID: http://orcid.org/0000-0001-8150-9762
AD  - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA.
AD  - Weill Cornell School of Medicine, New York, NY 10065, USA.
FAU - Zehir, Ahmet
AU  - Zehir A
AUID- ORCID: http://orcid.org/0000-0001-5406-4104
AD  - Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA.
FAU - Solit, David
AU  - Solit D
AUID- ORCID: http://orcid.org/0000-0002-6614-802X
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
AD  - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA.
AD  - Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA.
FAU - Berger, Michael
AU  - Berger M
AUID- ORCID: http://orcid.org/0000-0003-3882-5000
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
AD  - Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA.
AD  - Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA.
FAU - Zhou, Ruhong
AU  - Zhou R
AUID- ORCID: http://orcid.org/0000-0001-8624-5591
AD  - IBM Thomas J. Watson Research Center, Yorktown Heights, NY 10598, USA.
AD  - Deartment of Chemistry, Columbia University, New York, NY 10027, USA.
FAU - Rizvi, Naiyer A
AU  - Rizvi NA
AUID- ORCID: http://orcid.org/0000-0002-1134-7494
AD  - NewYork-Presbyterian/Columbia University Medical Center, 177 Fort Washington
      Ave., New York, NY 10032, USA. chant@mskcc.org nar2144@cumc.columbia.edu.
FAU - Chan, Timothy A
AU  - Chan TA
AUID- ORCID: http://orcid.org/0000-0002-9265-0283
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA. chant@mskcc.org nar2144@cumc.columbia.edu.
AD  - Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer
      Center, New York, NY 10065. USA.
AD  - Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New
      York, NY 10065, USA.
AD  - Weill Cornell School of Medicine, New York, NY 10065, USA.
LA  - eng
GR  - P30 CA008748/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20171207
PL  - United States
TA  - Science
JT  - Science (New York, N.Y.)
JID - 0404511
EDAT- 2017/12/09 06:00
MHDA- 2017/12/09 06:00
CRDT- 2017/12/09 06:00
PHST- 2017/07/24 00:00 [received]
PHST- 2017/11/29 00:00 [accepted]
PHST- 2017/12/09 06:00 [entrez]
PHST- 2017/12/09 06:00 [pubmed]
PHST- 2017/12/09 06:00 [medline]
AID - science.aao4572 [pii]
AID - 10.1126/science.aao4572 [doi]
PST - aheadofprint
SO  - Science. 2017 Dec 7. pii: science.aao4572. doi: 10.1126/science.aao4572.

PMID- 29191879
OWN - NLM
STAT- In-Process
LR  - 20171220
IS  - 1095-9203 (Electronic)
IS  - 0036-8075 (Linking)
VI  - 358
IP  - 6367
DP  - 2017 Dec 1
TI  - Osteoblasts remotely supply lung tumors with cancer-promoting SiglecF(high)
      neutrophils.
LID - eaal5081 [pii]
LID - 10.1126/science.aal5081 [doi]
AB  - Bone marrow-derived myeloid cells can accumulate within tumors and foster cancer 
      outgrowth. Local immune-neoplastic interactions have been intensively
      investigated, but the contribution of the systemic host environment to tumor
      growth remains poorly understood. Here, we show in mice and cancer patients (n = 
      70) that lung adenocarcinomas increase bone stromal activity in the absence of
      bone metastasis. Animal studies reveal that the cancer-induced bone phenotype
      involves bone-resident osteocalcin-expressing (Ocn(+)) osteoblastic cells. These 
      cells promote cancer by remotely supplying a distinct subset of
      tumor-infiltrating SiglecF(high) neutrophils, which exhibit cancer-promoting
      properties. Experimentally reducing Ocn(+) cell numbers suppresses the neutrophil
      response and lung tumor outgrowth. These observations posit osteoblasts as remote
      regulators of lung cancer and identify SiglecF(high) neutrophils as myeloid cell 
      effectors of the osteoblast-driven protumoral response.
CI  - Copyright (c) 2017 The Authors, some rights reserved; exclusive licensee American
      Association for the Advancement of Science. No claim to original U.S. Government 
      Works.
FAU - Engblom, Camilla
AU  - Engblom C
AD  - Center for Systems Biology, Massachusetts General Hospital Research Institute and
      Harvard Medical School, Boston, MA 02114, USA.
AD  - Graduate Program in Immunology, Harvard Medical School, Boston, MA 02115, USA.
FAU - Pfirschke, Christina
AU  - Pfirschke C
AUID- ORCID: 0000-0001-9434-4485
AD  - Center for Systems Biology, Massachusetts General Hospital Research Institute and
      Harvard Medical School, Boston, MA 02114, USA.
FAU - Zilionis, Rapolas
AU  - Zilionis R
AUID- ORCID: 0000-0002-9697-2431
AD  - Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA.
AD  - Institute of Biotechnology, Vilnius University, Vilnius, LT 10257, Lithuania.
FAU - Da Silva Martins, Janaina
AU  - Da Silva Martins J
AUID- ORCID: 0000-0001-8249-7011
AD  - Endocrine Unit, Massachusetts General Hospital, Harvard Medical School, Boston,
      MA 02114, USA.
FAU - Bos, Stijn A
AU  - Bos SA
AD  - Department of Radiology, Massachusetts General Hospital, MA 02114, USA.
FAU - Courties, Gabriel
AU  - Courties G
AD  - Center for Systems Biology, Massachusetts General Hospital Research Institute and
      Harvard Medical School, Boston, MA 02114, USA.
FAU - Rickelt, Steffen
AU  - Rickelt S
AUID- ORCID: 0000-0002-5224-7764
AD  - Howard Hughes Medical Institute, Koch Institute for Integrative Cancer Research, 
      Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
FAU - Severe, Nicolas
AU  - Severe N
AUID- ORCID: 0000-0003-1971-337X
AD  - Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA
      02114, USA.
FAU - Baryawno, Ninib
AU  - Baryawno N
AUID- ORCID: 0000-0001-8211-8368
AD  - Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA
      02114, USA.
FAU - Faget, Julien
AU  - Faget J
AUID- ORCID: 0000-0003-0848-7135
AD  - Swiss Institute for Experimental Cancer Research, School of Life Sciences, Ecole 
      Polytechnique Federale de Lausanne, 1015 Lausanne, Switzerland.
FAU - Savova, Virginia
AU  - Savova V
AD  - Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA.
FAU - Zemmour, David
AU  - Zemmour D
AUID- ORCID: 0000-0002-0990-217X
AD  - Graduate Program in Immunology, Harvard Medical School, Boston, MA 02115, USA.
AD  - Division of Immunology, Department of Microbiology and Immunobiology, Harvard
      Medical School, Boston, MA 02115, USA.
FAU - Kline, Jaclyn
AU  - Kline J
AUID- ORCID: 0000-0002-6897-5520
AD  - Center for Systems Biology, Massachusetts General Hospital Research Institute and
      Harvard Medical School, Boston, MA 02114, USA.
FAU - Siwicki, Marie
AU  - Siwicki M
AD  - Center for Systems Biology, Massachusetts General Hospital Research Institute and
      Harvard Medical School, Boston, MA 02114, USA.
AD  - Graduate Program in Immunology, Harvard Medical School, Boston, MA 02115, USA.
FAU - Garris, Christopher
AU  - Garris C
AUID- ORCID: 0000-0002-5764-6203
AD  - Center for Systems Biology, Massachusetts General Hospital Research Institute and
      Harvard Medical School, Boston, MA 02114, USA.
AD  - Graduate Program in Immunology, Harvard Medical School, Boston, MA 02115, USA.
FAU - Pucci, Ferdinando
AU  - Pucci F
AUID- ORCID: 0000-0002-1300-9931
AD  - Center for Systems Biology, Massachusetts General Hospital Research Institute and
      Harvard Medical School, Boston, MA 02114, USA.
FAU - Liao, Hsin-Wei
AU  - Liao HW
AUID- ORCID: 0000-0002-5905-2601
AD  - Center for Systems Biology, Massachusetts General Hospital Research Institute and
      Harvard Medical School, Boston, MA 02114, USA.
FAU - Lin, Yi-Jang
AU  - Lin YJ
AUID- ORCID: 0000-0002-1850-4245
AD  - Center for Systems Biology, Massachusetts General Hospital Research Institute and
      Harvard Medical School, Boston, MA 02114, USA.
FAU - Newton, Andita
AU  - Newton A
AUID- ORCID: 0000-0003-0180-9824
AD  - Center for Systems Biology, Massachusetts General Hospital Research Institute and
      Harvard Medical School, Boston, MA 02114, USA.
FAU - Yaghi, Omar K
AU  - Yaghi OK
AD  - Center for Systems Biology, Massachusetts General Hospital Research Institute and
      Harvard Medical School, Boston, MA 02114, USA.
AD  - Graduate Program in Immunology, Harvard Medical School, Boston, MA 02115, USA.
FAU - Iwamoto, Yoshiko
AU  - Iwamoto Y
AD  - Center for Systems Biology, Massachusetts General Hospital Research Institute and
      Harvard Medical School, Boston, MA 02114, USA.
FAU - Tricot, Benoit
AU  - Tricot B
AD  - Center for Systems Biology, Massachusetts General Hospital Research Institute and
      Harvard Medical School, Boston, MA 02114, USA.
FAU - Wojtkiewicz, Gregory R
AU  - Wojtkiewicz GR
AUID- ORCID: 0000-0002-3148-8411
AD  - Center for Systems Biology, Massachusetts General Hospital Research Institute and
      Harvard Medical School, Boston, MA 02114, USA.
FAU - Nahrendorf, Matthias
AU  - Nahrendorf M
AUID- ORCID: 0000-0002-4021-1887
AD  - Center for Systems Biology, Massachusetts General Hospital Research Institute and
      Harvard Medical School, Boston, MA 02114, USA.
FAU - Cortez-Retamozo, Virna
AU  - Cortez-Retamozo V
AUID- ORCID: 0000-0002-3549-7390
AD  - Center for Systems Biology, Massachusetts General Hospital Research Institute and
      Harvard Medical School, Boston, MA 02114, USA.
FAU - Meylan, Etienne
AU  - Meylan E
AD  - Swiss Institute for Experimental Cancer Research, School of Life Sciences, Ecole 
      Polytechnique Federale de Lausanne, 1015 Lausanne, Switzerland.
FAU - Hynes, Richard O
AU  - Hynes RO
AUID- ORCID: 0000-0001-7603-8396
AD  - Howard Hughes Medical Institute, Koch Institute for Integrative Cancer Research, 
      Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
FAU - Demay, Marie
AU  - Demay M
AUID- ORCID: 0000-0001-5845-5479
AD  - Endocrine Unit, Massachusetts General Hospital, Harvard Medical School, Boston,
      MA 02114, USA.
FAU - Klein, Allon
AU  - Klein A
AUID- ORCID: 0000-0001-8913-7879
AD  - Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA.
FAU - Bredella, Miriam A
AU  - Bredella MA
AD  - Department of Radiology, Massachusetts General Hospital, MA 02114, USA.
FAU - Scadden, David T
AU  - Scadden DT
AUID- ORCID: 0000-0001-9821-7133
AD  - Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA
      02114, USA.
FAU - Weissleder, Ralph
AU  - Weissleder R
AUID- ORCID: 0000-0003-0828-4143
AD  - Center for Systems Biology, Massachusetts General Hospital Research Institute and
      Harvard Medical School, Boston, MA 02114, USA.
AD  - Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA.
AD  - Department of Radiology, Massachusetts General Hospital, MA 02114, USA.
FAU - Pittet, Mikael J
AU  - Pittet MJ
AUID- ORCID: 0000-0002-2060-4691
AD  - Center for Systems Biology, Massachusetts General Hospital Research Institute and
      Harvard Medical School, Boston, MA 02114, USA. mpittet@mgh.harvard.edu.
AD  - Department of Radiology, Massachusetts General Hospital, MA 02114, USA.
LA  - eng
GR  - R01 CA206890/CA/NCI NIH HHS/United States
GR  - P50 CA086355/CA/NCI NIH HHS/United States
GR  - HHMI/Howard Hughes Medical Institute/United States
GR  - T32 GM007753/GM/NIGMS NIH HHS/United States
GR  - R01 AI084880/AI/NIAID NIH HHS/United States
GR  - P50 CA148110/CA/NCI NIH HHS/United States
GR  - U54 CA163109/CA/NCI NIH HHS/United States
GR  - P30 AR066261/AR/NIAMS NIH HHS/United States
GR  - U54 CA126515/CA/NCI NIH HHS/United States
GR  - R33 CA212697/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Science
JT  - Science (New York, N.Y.)
JID - 0404511
CIN - Science. 2017 Dec 1;358(6367):1127-1128. PMID: 29191891
EDAT- 2017/12/02 06:00
MHDA- 2017/12/02 06:00
CRDT- 2017/12/02 06:00
PHST- 2016/11/30 00:00 [received]
PHST- 2017/08/16 00:00 [revised]
PHST- 2017/10/17 00:00 [accepted]
PHST- 2017/12/02 06:00 [entrez]
PHST- 2017/12/02 06:00 [pubmed]
PHST- 2017/12/02 06:00 [medline]
AID - 358/6367/eaal5081 [pii]
AID - 10.1126/science.aal5081 [doi]
PST - ppublish
SO  - Science. 2017 Dec 1;358(6367). pii: 358/6367/eaal5081. doi:
      10.1126/science.aal5081.

PMID- 29342230
OWN - NLM
STAT- Publisher
LR  - 20180117
IS  - 1745-7270 (Electronic)
IS  - 1672-9145 (Linking)
DP  - 2017 Oct 7
TI  - Metformin as an anti-cancer agent: actions and mechanisms targeting cancer stem
      cells.
PG  - 1-11
LID - 10.1093/abbs/gmx106 [doi]
AB  - Metformin, a first line medication for type II diabetes, initially entered the
      spotlight as a promising anti-cancer agent due to epidemiologic reports that
      found reduced cancer risk and improved clinical outcomes in diabetic patients
      taking metformin. To uncover the anti-cancer mechanisms of metformin, preclinical
      studies determined that metformin impairs cellular metabolism and suppresses
      oncogenic signaling pathways, including receptor tyrosine kinase, PI3K/Akt, and
      mTOR pathways. Recently, the anti-cancer potential of metformin has gained
      increasing interest due to its inhibitory effects on cancer stem cells (CSCs),
      which are associated with tumor metastasis, drug resistance, and relapse. Studies
      using various cancer models, including breast, pancreatic, prostate, and colon,
      have demonstrated the potency of metformin in attenuating CSCs through the
      targeting of specific pathways involved in cell differentiation, renewal,
      metastasis, and metabolism. In this review, we provide a comprehensive overview
      of the anti-cancer actions and mechanisms of metformin, including the regulation 
      of CSCs and related pathways. We also discuss the potential anti-cancer
      applications of metformin as mono- or combination therapies.
CI  - (c) The Author 2017. Published by Oxford University Press on behalf of the
      Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological
      Sciences, Chinese Academy of Sciences. All rights reserved. For permissions,
      please e-mail: journals.permissions@oup.com.
FAU - Saini, Nipun
AU  - Saini N
AD  - Julius L. Chambers Biomedical/Biotechnology Research Institute, Department of
      Biological and Biomedical Sciences, North Carolina Central University, North
      Carolina Research Campus, Kannapolis, NC 28081, USA.
FAU - Yang, Xiaohe
AU  - Yang X
AD  - Julius L. Chambers Biomedical/Biotechnology Research Institute, Department of
      Biological and Biomedical Sciences, North Carolina Central University, North
      Carolina Research Campus, Kannapolis, NC 28081, USA.
LA  - eng
PT  - Journal Article
DEP - 20171007
PL  - China
TA  - Acta Biochim Biophys Sin (Shanghai)
JT  - Acta biochimica et biophysica Sinica
JID - 101206716
OTO - NOTNLM
OT  - AMPK/mTOR pathway
OT  - anti-cancer drugs
OT  - cancer stem cells
OT  - cellular metabolism
OT  - metformin
EDAT- 2018/01/18 06:00
MHDA- 2018/01/18 06:00
CRDT- 2018/01/18 06:00
PHST- 2017/05/10 00:00 [received]
PHST- 2017/09/14 00:00 [accepted]
PHST- 2018/01/18 06:00 [entrez]
PHST- 2018/01/18 06:00 [pubmed]
PHST- 2018/01/18 06:00 [medline]
AID - 4371596 [pii]
AID - 10.1093/abbs/gmx106 [doi]
PST - aheadofprint
SO  - Acta Biochim Biophys Sin (Shanghai). 2017 Oct 7:1-11. doi: 10.1093/abbs/gmx106.

PMID- 29234806
OWN - NLM
STAT- MEDLINE
DCOM- 20171222
LR  - 20171222
IS  - 1538-3598 (Electronic)
IS  - 0098-7484 (Linking)
VI  - 318
IP  - 22
DP  - 2017 Dec 12
TI  - Diagnostic Assessment of Deep Learning Algorithms for Detection of Lymph Node
      Metastases in Women With Breast Cancer.
PG  - 2199-2210
LID - 10.1001/jama.2017.14585 [doi]
AB  - Importance: Application of deep learning algorithms to whole-slide pathology
      images can potentially improve diagnostic accuracy and efficiency. Objective:
      Assess the performance of automated deep learning algorithms at detecting
      metastases in hematoxylin and eosin-stained tissue sections of lymph nodes of
      women with breast cancer and compare it with pathologists' diagnoses in a
      diagnostic setting. Design, Setting, and Participants: Researcher challenge
      competition (CAMELYON16) to develop automated solutions for detecting lymph node 
      metastases (November 2015-November 2016). A training data set of whole-slide
      images from 2 centers in the Netherlands with (n = 110) and without (n = 160)
      nodal metastases verified by immunohistochemical staining were provided to
      challenge participants to build algorithms. Algorithm performance was evaluated
      in an independent test set of 129 whole-slide images (49 with and 80 without
      metastases). The same test set of corresponding glass slides was also evaluated
      by a panel of 11 pathologists with time constraint (WTC) from the Netherlands to 
      ascertain likelihood of nodal metastases for each slide in a flexible 2-hour
      session, simulating routine pathology workflow, and by 1 pathologist without time
      constraint (WOTC). Exposures: Deep learning algorithms submitted as part of a
      challenge competition or pathologist interpretation. Main Outcomes and Measures: 
      The presence of specific metastatic foci and the absence vs presence of lymph
      node metastasis in a slide or image using receiver operating characteristic curve
      analysis. The 11 pathologists participating in the simulation exercise rated
      their diagnostic confidence as definitely normal, probably normal, equivocal,
      probably tumor, or definitely tumor. Results: The area under the receiver
      operating characteristic curve (AUC) for the algorithms ranged from 0.556 to
      0.994. The top-performing algorithm achieved a lesion-level, true-positive
      fraction comparable with that of the pathologist WOTC (72.4% [95% CI,
      64.3%-80.4%]) at a mean of 0.0125 false-positives per normal whole-slide image.
      For the whole-slide image classification task, the best algorithm (AUC, 0.994
      [95% CI, 0.983-0.999]) performed significantly better than the pathologists WTC
      in a diagnostic simulation (mean AUC, 0.810 [range, 0.738-0.884]; P < .001). The 
      top 5 algorithms had a mean AUC that was comparable with the pathologist
      interpreting the slides in the absence of time constraints (mean AUC, 0.960
      [range, 0.923-0.994] for the top 5 algorithms vs 0.966 [95% CI, 0.927-0.998] for 
      the pathologist WOTC). Conclusions and Relevance: In the setting of a challenge
      competition, some deep learning algorithms achieved better diagnostic performance
      than a panel of 11 pathologists participating in a simulation exercise designed
      to mimic routine pathology workflow; algorithm performance was comparable with an
      expert pathologist interpreting whole-slide images without time constraints.
      Whether this approach has clinical utility will require evaluation in a clinical 
      setting.
FAU - Ehteshami Bejnordi, Babak
AU  - Ehteshami Bejnordi B
AD  - Diagnostic Image Analysis Group, Department of Radiology and Nuclear Medicine,
      Radboud University Medical Center, Nijmegen, the Netherlands.
FAU - Veta, Mitko
AU  - Veta M
AD  - Medical Image Analysis Group, Eindhoven University of Technology, Eindhoven, the 
      Netherlands.
FAU - Johannes van Diest, Paul
AU  - Johannes van Diest P
AD  - Department of Pathology, University Medical Center Utrecht, Utrecht, the
      Netherlands.
FAU - van Ginneken, Bram
AU  - van Ginneken B
AD  - Diagnostic Image Analysis Group, Department of Radiology and Nuclear Medicine,
      Radboud University Medical Center, Nijmegen, the Netherlands.
FAU - Karssemeijer, Nico
AU  - Karssemeijer N
AD  - Diagnostic Image Analysis Group, Department of Radiology and Nuclear Medicine,
      Radboud University Medical Center, Nijmegen, the Netherlands.
FAU - Litjens, Geert
AU  - Litjens G
AD  - Department of Pathology, Radboud University Medical Center, Nijmegen, the
      Netherlands.
FAU - van der Laak, Jeroen A W M
AU  - van der Laak JAWM
AD  - Department of Pathology, Radboud University Medical Center, Nijmegen, the
      Netherlands.
CN  - the CAMELYON16 Consortium
FAU - Hermsen, Meyke
AU  - Hermsen M
AD  - Department of Pathology, Radboud University Medical Center, Nijmegen, the
      Netherlands.
FAU - Manson, Quirine F
AU  - Manson QF
AD  - Department of Pathology, University Medical Center Utrecht, Utrecht, the
      Netherlands.
FAU - Balkenhol, Maschenka
AU  - Balkenhol M
AD  - Department of Pathology, Radboud University Medical Center, Nijmegen, the
      Netherlands.
FAU - Geessink, Oscar
AU  - Geessink O
AD  - Department of Pathology, Radboud University Medical Center, Nijmegen, the
      Netherlands.
AD  - Laboratorium Pathologie Oost Nederland, Hengelo, the Netherlands.
FAU - Stathonikos, Nikolaos
AU  - Stathonikos N
AD  - Department of Pathology, University Medical Center Utrecht, Utrecht, the
      Netherlands.
FAU - van Dijk, Marcory Crf
AU  - van Dijk MC
AD  - Rijnstate Hospital, Arnhem, the Netherlands.
FAU - Bult, Peter
AU  - Bult P
AD  - Department of Pathology, Radboud University Medical Center, Nijmegen, the
      Netherlands.
FAU - Beca, Francisco
AU  - Beca F
AD  - BeckLab, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston,
      Massachusetts.
FAU - Beck, Andrew H
AU  - Beck AH
AD  - BeckLab, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston,
      Massachusetts.
AD  - PathAI, Cambridge, Massachusetts.
FAU - Wang, Dayong
AU  - Wang D
AD  - BeckLab, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston,
      Massachusetts.
AD  - PathAI, Cambridge, Massachusetts.
FAU - Khosla, Aditya
AU  - Khosla A
AD  - PathAI, Cambridge, Massachusetts.
AD  - Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute 
      of Technology, Cambridge, Massachusetts.
FAU - Gargeya, Rishab
AU  - Gargeya R
AD  - Harker School, San Jose, California.
FAU - Irshad, Humayun
AU  - Irshad H
AD  - BeckLab, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston,
      Massachusetts.
FAU - Zhong, Aoxiao
AU  - Zhong A
AD  - Center for Clinical Data Science, Gordon Center for Medical Imaging,
      Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
FAU - Dou, Qi
AU  - Dou Q
AD  - Center for Clinical Data Science, Gordon Center for Medical Imaging,
      Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
AD  - Chinese University of Hong Kong, Hong Kong, China.
FAU - Li, Quanzheng
AU  - Li Q
AD  - Center for Clinical Data Science, Gordon Center for Medical Imaging,
      Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
FAU - Chen, Hao
AU  - Chen H
AD  - Chinese University of Hong Kong, Hong Kong, China.
FAU - Lin, Huang-Jing
AU  - Lin HJ
AD  - Chinese University of Hong Kong, Hong Kong, China.
FAU - Heng, Pheng-Ann
AU  - Heng PA
AD  - Chinese University of Hong Kong, Hong Kong, China.
FAU - Hass, Christian
AU  - Hass C
AD  - ExB Research and Development GmbH, Munich, Germany.
FAU - Bruni, Elia
AU  - Bruni E
AD  - ExB Research and Development GmbH, Munich, Germany.
FAU - Wong, Quincy
AU  - Wong Q
AD  - Munich Business School, Munich, Germany.
FAU - Halici, Ugur
AU  - Halici U
AD  - Department of Electrical and Electronics Engineering, Middle East Technical
      University, Ankara, Turkey.
AD  - Neuroscience and Neurotechnology, Graduate School of Natural and Applied
      Sciences, Middle East Technical University, Ankara, Turkey.
FAU - Oner, Mustafa Umit
AU  - Oner MU
AD  - Department of Electrical and Electronics Engineering, Middle East Technical
      University, Ankara, Turkey.
FAU - Cetin-Atalay, Rengul
AU  - Cetin-Atalay R
AD  - Cancer System Biology Laboratory, Graduate School of Informatics, Middle East
      Technical University, Ankara, Turkey.
FAU - Berseth, Matt
AU  - Berseth M
AD  - NLP LOGIX, Jacksonville, Florida.
FAU - Khvatkov, Vitali
AU  - Khvatkov V
AD  - Smart Imaging Technologies, Houston, Texas.
FAU - Vylegzhanin, Alexei
AU  - Vylegzhanin A
AD  - Smart Imaging Technologies, Houston, Texas.
FAU - Kraus, Oren
AU  - Kraus O
AD  - Department of Electrical and Computer Engineering, University of Toronto,
      Toronto, Ontario, Canada.
FAU - Shaban, Muhammad
AU  - Shaban M
AD  - Tissue Image Analytics Lab, Department of Computer Science, University of
      Warwick, Coventry, United Kingdom.
FAU - Rajpoot, Nasir
AU  - Rajpoot N
AD  - Tissue Image Analytics Lab, Department of Computer Science, University of
      Warwick, Coventry, United Kingdom.
AD  - Department of Pathology, University Hospitals Coventry and Warwickshire National 
      Health Service Foundation Trust, Coventry, United Kingdom.
FAU - Awan, Ruqayya
AU  - Awan R
AD  - Department of Computer Science and Engineering, Qatar University, Doha, Qatar.
FAU - Sirinukunwattana, Korsuk
AU  - Sirinukunwattana K
AD  - Tissue Image Analytics Lab, Department of Computer Science, University of
      Warwick, Coventry, United Kingdom.
FAU - Qaiser, Talha
AU  - Qaiser T
AD  - Tissue Image Analytics Lab, Department of Computer Science, University of
      Warwick, Coventry, United Kingdom.
FAU - Tsang, Yee-Wah
AU  - Tsang YW
AD  - Department of Pathology, University Hospitals Coventry and Warwickshire National 
      Health Service Foundation Trust, Coventry, United Kingdom.
FAU - Tellez, David
AU  - Tellez D
AD  - Department of Pathology, Radboud University Medical Center, Nijmegen, the
      Netherlands.
FAU - Annuscheit, Jonas
AU  - Annuscheit J
AD  - Hochschule fur Technik und Wirtschaft, Berlin, Germany.
FAU - Hufnagl, Peter
AU  - Hufnagl P
AD  - Hochschule fur Technik und Wirtschaft, Berlin, Germany.
FAU - Valkonen, Mira
AU  - Valkonen M
AD  - BioMediTech Institute and Faculty of Medicine and Life Sciences, Tampere
      University of Technology, Tampere, Finland.
FAU - Kartasalo, Kimmo
AU  - Kartasalo K
AD  - Hochschule fur Technik und Wirtschaft, Berlin, Germany.
AD  - BioMediTech Institute and Faculty of Biomedical Science and Engineering, Tampere 
      University of Technology, Tampere, Finland.
FAU - Latonen, Leena
AU  - Latonen L
AD  - Prostate Cancer Research Center, Faculty of Medicine and Life Sciences and
      BioMediTech, University of Tampere, Tampere, Finland.
FAU - Ruusuvuori, Pekka
AU  - Ruusuvuori P
AD  - Hochschule fur Technik und Wirtschaft, Berlin, Germany.
AD  - Faculty of Computing and Electrical Engineering, Tampere University of
      Technology, Pori, Finland.
FAU - Liimatainen, Kaisa
AU  - Liimatainen K
AD  - Hochschule fur Technik und Wirtschaft, Berlin, Germany.
FAU - Albarqouni, Shadi
AU  - Albarqouni S
AD  - Technical University of Munich, Munich, Germany.
FAU - Mungal, Bharti
AU  - Mungal B
AD  - Technical University of Munich, Munich, Germany.
FAU - George, Ami
AU  - George A
AD  - Technical University of Munich, Munich, Germany.
FAU - Demirci, Stefanie
AU  - Demirci S
AD  - Technical University of Munich, Munich, Germany.
FAU - Navab, Nassir
AU  - Navab N
AD  - Technical University of Munich, Munich, Germany.
FAU - Watanabe, Seiryo
AU  - Watanabe S
AD  - Department of Bioinformatic Engineering, Osaka University.
FAU - Seno, Shigeto
AU  - Seno S
AD  - Department of Bioinformatic Engineering, Osaka University.
FAU - Takenaka, Yoichi
AU  - Takenaka Y
AD  - Department of Bioinformatic Engineering, Osaka University.
FAU - Matsuda, Hideo
AU  - Matsuda H
AD  - Department of Bioinformatic Engineering, Osaka University.
FAU - Ahmady Phoulady, Hady
AU  - Ahmady Phoulady H
AD  - University of South Florida, Tampa, Florida.
FAU - Kovalev, Vassili
AU  - Kovalev V
AD  - Biomedical Image Analysis Department, United Institute of Informatics Problems,
      Belarus National Academy of Sciences, Minsk, Belarus.
FAU - Kalinovsky, Alexander
AU  - Kalinovsky A
AD  - Biomedical Image Analysis Department, United Institute of Informatics Problems,
      Belarus National Academy of Sciences, Minsk, Belarus.
FAU - Liauchuk, Vitali
AU  - Liauchuk V
AD  - Biomedical Image Analysis Department, United Institute of Informatics Problems,
      Belarus National Academy of Sciences, Minsk, Belarus.
FAU - Bueno, Gloria
AU  - Bueno G
AD  - Visilab, University of Castilla-La Mancha, Ciudad Real, Spain.
FAU - Fernandez-Carrobles, M Milagro
AU  - Fernandez-Carrobles MM
AD  - Visilab, University of Castilla-La Mancha, Ciudad Real, Spain.
FAU - Serrano, Ismael
AU  - Serrano I
AD  - Visilab, University of Castilla-La Mancha, Ciudad Real, Spain.
FAU - Deniz, Oscar
AU  - Deniz O
AD  - Visilab, University of Castilla-La Mancha, Ciudad Real, Spain.
FAU - Racoceanu, Daniel
AU  - Racoceanu D
AD  - INSERM, Laboratoire d'Imagerie Biomedicale, Sorbonne Universites, Pierre and
      Marie Curie University, Paris, France.
AD  - Pontifical Catholic University of Peru, San Miguel, Lima, Peru.
FAU - Venancio, Rui
AU  - Venancio R
AD  - Sorbonne University, Pierre and Marie Curie University, Paris, France.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
SB  - AIM
SB  - IM
CIN - JAMA. 2017 Dec 12;318(22):2184-2186. PMID: 29234791
CIN - JAMA. 2017 Dec 12;318(22):2250-2251. PMID: 29234793
MH  - Algorithms
MH  - Breast Neoplasms/*pathology
MH  - Female
MH  - Humans
MH  - Lymphatic Metastasis/*diagnosis/pathology
MH  - *Machine Learning
MH  - *Pathologists
MH  - Pathology, Clinical
MH  - ROC Curve
EDAT- 2017/12/14 06:00
MHDA- 2017/12/23 06:00
CRDT- 2017/12/14 06:00
PHST- 2017/12/14 06:00 [entrez]
PHST- 2017/12/14 06:00 [pubmed]
PHST- 2017/12/23 06:00 [medline]
AID - 2665774 [pii]
AID - 10.1001/jama.2017.14585 [doi]
PST - ppublish
SO  - JAMA. 2017 Dec 12;318(22):2199-2210. doi: 10.1001/jama.2017.14585.

PMID- 29274927
OWN - NLM
STAT- Publisher
LR  - 20171224
IS  - 1879-0852 (Electronic)
IS  - 0959-8049 (Linking)
VI  - 90
DP  - 2017 Dec 21
TI  - Red and processed meat consumption and breast cancer: UK Biobank cohort study and
      meta-analysis.
PG  - 73-82
LID - S0959-8049(17)31430-2 [pii]
LID - 10.1016/j.ejca.2017.11.022 [doi]
AB  - AIM: Red and processed meat may be risk factors for breast cancer due to their
      iron content, administration of oestrogens to cattle or mutagens created during
      cooking. We studied the associations in UK Biobank and then included the results 
      in a meta-analysis of published cohort studies. METHODS: UK Biobank, a general
      population cohort study, recruited participants aged 40-69 years. Incident breast
      cancer was ascertained via linkage to routine hospital admission, cancer registry
      and death certificate data. Univariate and multivariable Cox proportional hazard 
      models were used to explore the associations between red and processed meat
      consumption and breast cancer. Previously published cohort studies were
      identified from a systematic review using PubMed and Ovid and a meta-analysis
      conducted using a random effects model. RESULTS: Over a median of 7 years
      follow-up, 4819 of the 262,195 women developed breast cancer. The risk was
      increased in the highest tertile (>9 g/day) of processed meat consumption
      (adjusted hazard ratio [HR] 1.21, 95% confidence interval [CI] 1.08-1.35, p =
      0.001). Collation with 10 previous cohort studies provided data on 40,257
      incident breast cancers in 1.65 million women. On meta-analysis, processed meat
      consumption was associated with overall (relative risk [RR] 1.06, 95% CI
      1.01-1.11) and post-menopausal (RR 1.09, 95% CI 1.03-1.15), but not
      pre-menopausal (RR 0.99, 95% CI 0.88-1.10), breast cancer. In UK Biobank and the 
      meta-analysis, red meat consumption was not associated with breast cancer
      (adjusted HR 0.99 95% CI 0.88-1.12 and RR 1.03, 95% CI 0.99-1.08, respectively). 
      CONCLUSIONS: Consumption of processed meat, but not red meat, may increase the
      risk of breast cancer.
CI  - Crown Copyright (c) 2017. Published by Elsevier Ltd. All rights reserved.
FAU - Anderson, Jana J
AU  - Anderson JJ
AD  - Institute of Health and Wellbeing, University of Glasgow, 1 Lilybank Gardens,
      Glasgow, UK.
FAU - Darwis, Narisa D M
AU  - Darwis NDM
AD  - Institute of Health and Wellbeing, University of Glasgow, 1 Lilybank Gardens,
      Glasgow, UK.
FAU - Mackay, Daniel F
AU  - Mackay DF
AD  - Institute of Health and Wellbeing, University of Glasgow, 1 Lilybank Gardens,
      Glasgow, UK.
FAU - Celis-Morales, Carlos A
AU  - Celis-Morales CA
AD  - Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow,
      UK.
FAU - Lyall, Donald M
AU  - Lyall DM
AD  - Institute of Health and Wellbeing, University of Glasgow, 1 Lilybank Gardens,
      Glasgow, UK.
FAU - Sattar, Naveed
AU  - Sattar N
AD  - Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow,
      UK.
FAU - Gill, Jason M R
AU  - Gill JMR
AD  - Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow,
      UK.
FAU - Pell, Jill P
AU  - Pell JP
AD  - Institute of Health and Wellbeing, University of Glasgow, 1 Lilybank Gardens,
      Glasgow, UK. Electronic address: jill.pell@glasgow.ac.uk.
LA  - eng
PT  - Journal Article
DEP - 20171221
PL  - England
TA  - Eur J Cancer
JT  - European journal of cancer (Oxford, England : 1990)
JID - 9005373
OTO - NOTNLM
OT  - Breast cancer
OT  - Diet
OT  - Post-menopausal
OT  - Pre-menopausal
OT  - Processed meat
OT  - Red meat
OT  - UK Biobank
EDAT- 2017/12/25 06:00
MHDA- 2017/12/25 06:00
CRDT- 2017/12/25 06:00
PHST- 2017/08/22 00:00 [received]
PHST- 2017/10/25 00:00 [revised]
PHST- 2017/11/22 00:00 [accepted]
PHST- 2017/12/25 06:00 [entrez]
PHST- 2017/12/25 06:00 [pubmed]
PHST- 2017/12/25 06:00 [medline]
AID - S0959-8049(17)31430-2 [pii]
AID - 10.1016/j.ejca.2017.11.022 [doi]
PST - aheadofprint
SO  - Eur J Cancer. 2017 Dec 21;90:73-82. doi: 10.1016/j.ejca.2017.11.022.

PMID- 29190829
OWN - NLM
STAT- MEDLINE
DCOM- 20171226
LR  - 20171226
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 12
IP  - 11
DP  - 2017
TI  - A comprehensive analysis of breast cancer microbiota and host gene expression.
PG  - e0188873
LID - 10.1371/journal.pone.0188873 [doi]
AB  - The inflammatory tumoral-immune response alters the physiology of the tumor
      microenvironment, which may attenuate genomic instability. In addition to
      inducing inflammatory immune responses, several pathogenic bacteria produce
      genotoxins. However the extent of microbial contribution to the tumor
      microenvironment biology remains unknown. We utilized The Cancer Genome Atlas,
      (TCGA) breast cancer data to perform a novel experiment utilizing unmapped and
      mapped RNA sequencing read evidence to minimize laboratory costs and effort. Our 
      objective was to characterize the microbiota and associate the microbiota with
      the tumor expression profiles, for 668 breast tumor tissues and 72 non-cancerous 
      adjacent tissues. The prominent presence of Proteobacteria was increased in the
      tumor tissues and conversely Actinobacteria abundance increase in non-cancerous
      adjacent tissues. Further, geneset enrichment suggests Listeria spp to be
      associated with the expression profiles of genes involved with epithelial to
      mesenchymal transitions. Moreover, evidence suggests H. influenza may reside in
      the surrounding stromal material and was significantly associated with the
      proliferative pathways: G2M checkpoint, E2F transcription factors, and mitotic
      spindle assembly. In summary, further unraveling this complicated interplay
      should enable us to better diagnose and treat breast cancer patients.
FAU - Thompson, Kevin J
AU  - Thompson KJ
AUID- ORCID: http://orcid.org/0000-0002-9348-4686
AD  - Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, United
      States of America.
AD  - Department of Center for Individualized Medicine, Mayo Clinic, Rochester,
      Minnesota, United States of America.
FAU - Ingle, James N
AU  - Ingle JN
AD  - Department of Oncology, Mayo Clinic, Rochester, Minnesota, United States of
      America.
FAU - Tang, Xiaojia
AU  - Tang X
AD  - Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, United
      States of America.
AD  - Department of Center for Individualized Medicine, Mayo Clinic, Rochester,
      Minnesota, United States of America.
FAU - Chia, Nicholas
AU  - Chia N
AD  - Department of Center for Individualized Medicine, Mayo Clinic, Rochester,
      Minnesota, United States of America.
AD  - Department of Surgery, Mayo Clinic, Rochester, Minnesota, United States of
      America.
FAU - Jeraldo, Patricio R
AU  - Jeraldo PR
AD  - Department of Center for Individualized Medicine, Mayo Clinic, Rochester,
      Minnesota, United States of America.
AD  - Department of Surgery, Mayo Clinic, Rochester, Minnesota, United States of
      America.
FAU - Walther-Antonio, Marina R
AU  - Walther-Antonio MR
AD  - Department of Center for Individualized Medicine, Mayo Clinic, Rochester,
      Minnesota, United States of America.
AD  - Department of Surgery, Mayo Clinic, Rochester, Minnesota, United States of
      America.
FAU - Kandimalla, Karunya K
AU  - Kandimalla KK
AD  - Department of Pharmaceutics, University of Minnesota, Minneapolis, MN, United
      States of America.
FAU - Johnson, Stephen
AU  - Johnson S
AD  - Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, United
      States of America.
AD  - Department of Center for Individualized Medicine, Mayo Clinic, Rochester,
      Minnesota, United States of America.
FAU - Yao, Janet Z
AU  - Yao JZ
AD  - Department of Center for Individualized Medicine, Mayo Clinic, Rochester,
      Minnesota, United States of America.
FAU - Harrington, Sean C
AU  - Harrington SC
AD  - Department of Center for Individualized Medicine, Mayo Clinic, Rochester,
      Minnesota, United States of America.
FAU - Suman, Vera J
AU  - Suman VJ
AD  - Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, United
      States of America.
FAU - Wang, Liewei
AU  - Wang L
AD  - Department of Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic,
      Rochester, Minnesota, United States of America.
FAU - Weinshilboum, Richard L
AU  - Weinshilboum RL
AD  - Department of Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic,
      Rochester, Minnesota, United States of America.
FAU - Boughey, Judy C
AU  - Boughey JC
AD  - Department of Surgery, Mayo Clinic, Rochester, Minnesota, United States of
      America.
FAU - Kocher, Jean-Pierre
AU  - Kocher JP
AD  - Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, United
      States of America.
AD  - Department of Center for Individualized Medicine, Mayo Clinic, Rochester,
      Minnesota, United States of America.
FAU - Nelson, Heidi
AU  - Nelson H
AD  - Department of Surgery, Mayo Clinic, Rochester, Minnesota, United States of
      America.
FAU - Goetz, Matthew P
AU  - Goetz MP
AD  - Department of Oncology, Mayo Clinic, Rochester, Minnesota, United States of
      America.
FAU - Kalari, Krishna R
AU  - Kalari KR
AD  - Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, United
      States of America.
AD  - Department of Center for Individualized Medicine, Mayo Clinic, Rochester,
      Minnesota, United States of America.
LA  - eng
PT  - Journal Article
DEP - 20171130
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (RNA, Ribosomal, 16S)
SB  - IM
MH  - Breast Neoplasms/genetics/immunology/*microbiology/pathology
MH  - Female
MH  - *Gene Expression
MH  - Humans
MH  - Proteobacteria
MH  - RNA, Ribosomal, 16S/genetics
MH  - Sequence Analysis, RNA
MH  - Tumor Microenvironment
PMC - PMC5708741
EDAT- 2017/12/01 06:00
MHDA- 2017/12/27 06:00
CRDT- 2017/12/01 06:00
PHST- 2017/04/16 00:00 [received]
PHST- 2017/11/14 00:00 [accepted]
PHST- 2017/12/01 06:00 [entrez]
PHST- 2017/12/01 06:00 [pubmed]
PHST- 2017/12/27 06:00 [medline]
AID - 10.1371/journal.pone.0188873 [doi]
AID - PONE-D-17-14737 [pii]
PST - epublish
SO  - PLoS One. 2017 Nov 30;12(11):e0188873. doi: 10.1371/journal.pone.0188873.
      eCollection 2017.

PMID- 29149612
OWN - NLM
STAT- In-Process
LR  - 20171117
IS  - 1097-4172 (Electronic)
IS  - 0092-8674 (Linking)
VI  - 171
IP  - 5
DP  - 2017 Nov 16
TI  - Cancer Evolution: No Room for Negative Selection.
PG  - 987-989
LID - S0092-8674(17)31265-5 [pii]
LID - 10.1016/j.cell.2017.10.039 [doi]
AB  - In this issue of Cell, Martincorena et al. and Campbell et al. interrogated the
      selection dynamics during tumor evolution using large-scale genomics datasets.
      They found that somatic mutations in cancer are largely neutral, highlighting a
      near-complete absence of negative selection. Neutral evolution enables tolerance 
      of hypermutation, which defines a surprisingly large fraction of adult cancer.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Bakhoum, Samuel F
AU  - Bakhoum SF
AD  - Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New
      York, NY 10065, USA; Sandra and Edward Meyer Cancer Center, Weill Cornell
      Medicine, New York, NY 10065, USA.
FAU - Landau, Dan A
AU  - Landau DA
AD  - Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY
      10065, USA; Division of Hematology and Medical Oncology, Institute for
      Computational Biomedicine, Weill Cornell Medicine, New York, NY 10065, USA; New
      York Genome Center, New York, NY 10013, USA. Electronic address:
      dlandau@nygenome.org.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cell
JT  - Cell
JID - 0413066
EDAT- 2017/11/18 06:00
MHDA- 2017/11/18 06:00
CRDT- 2017/11/18 06:00
PHST- 2017/11/18 06:00 [entrez]
PHST- 2017/11/18 06:00 [pubmed]
PHST- 2017/11/18 06:00 [medline]
AID - S0092-8674(17)31265-5 [pii]
AID - 10.1016/j.cell.2017.10.039 [doi]
PST - ppublish
SO  - Cell. 2017 Nov 16;171(5):987-989. doi: 10.1016/j.cell.2017.10.039.

PMID- 29160310
OWN - NLM
STAT- In-Data-Review
LR  - 20180106
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 553
IP  - 7686
DP  - 2018 Jan 4
TI  - Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer
      immune surveillance.
PG  - 91-95
LID - 10.1038/nature25015 [doi]
AB  - Treatments that target immune checkpoints, such as the one mediated by programmed
      cell death protein 1 (PD-1) and its ligand PD-L1, have been approved for treating
      human cancers with durable clinical benefit. However, many patients with cancer
      fail to respond to compounds that target the PD-1 and PD-L1 interaction, and the 
      underlying mechanism(s) is not well understood. Recent studies revealed that
      response to PD-1-PD-L1 blockade might correlate with PD-L1 expression levels in
      tumour cells. Hence, it is important to understand the mechanistic pathways that 
      control PD-L1 protein expression and stability, which can offer a molecular basis
      to improve the clinical response rate and efficacy of PD-1-PD-L1 blockade in
      patients with cancer. Here we show that PD-L1 protein abundance is regulated by
      cyclin D-CDK4 and the cullin 3-SPOP E3 ligase via proteasome-mediated
      degradation. Inhibition of CDK4 and CDK6 (hereafter CDK4/6) in vivo increases
      PD-L1 protein levels by impeding cyclin D-CDK4-mediated phosphorylation of
      speckle-type POZ protein (SPOP) and thereby promoting SPOP degradation by the
      anaphase-promoting complex activator FZR1. Loss-of-function mutations in SPOP
      compromise ubiquitination-mediated PD-L1 degradation, leading to increased PD-L1 
      levels and reduced numbers of tumour-infiltrating lymphocytes in mouse tumours
      and in primary human prostate cancer specimens. Notably, combining CDK4/6
      inhibitor treatment with anti-PD-1 immunotherapy enhances tumour regression and
      markedly improves overall survival rates in mouse tumour models. Our study
      uncovers a novel molecular mechanism for regulating PD-L1 protein stability by a 
      cell cycle kinase and reveals the potential for using combination treatment with 
      CDK4/6 inhibitors and PD-1-PD-L1 immune checkpoint blockade to enhance
      therapeutic efficacy for human cancers.
FAU - Zhang, Jinfang
AU  - Zhang J
AD  - Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical
      School, Boston, Massachusetts 02215, USA.
FAU - Bu, Xia
AU  - Bu X
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical
      School, Boston, Massachusetts 02215, USA.
FAU - Wang, Haizhen
AU  - Wang H
AD  - Department of Cancer Biology, Dana-Farber Cancer Institute and Department of
      Genetics, Harvard Medical School, Boston, Massachusetts 02215, USA.
FAU - Zhu, Yasheng
AU  - Zhu Y
AD  - Department of Urology, Shanghai Changhai Hospital, Second Military Medical
      University, Shanghai 200433, China.
FAU - Geng, Yan
AU  - Geng Y
AD  - Department of Cancer Biology, Dana-Farber Cancer Institute and Department of
      Genetics, Harvard Medical School, Boston, Massachusetts 02215, USA.
FAU - Nihira, Naoe Taira
AU  - Nihira NT
AD  - Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical
      School, Boston, Massachusetts 02215, USA.
FAU - Tan, Yuyong
AU  - Tan Y
AD  - Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical
      School, Boston, Massachusetts 02215, USA.
AD  - Department of Gastroenterology, the Second Xiangya Hospital of Central South
      University, Changsha 410011, China.
FAU - Ci, Yanpeng
AU  - Ci Y
AD  - Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical
      School, Boston, Massachusetts 02215, USA.
AD  - School of Life Science and Technology, Harbin Institute of Technology, Harbin
      150001, China.
FAU - Wu, Fei
AU  - Wu F
AD  - Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical
      School, Boston, Massachusetts 02215, USA.
AD  - Department of Urology, Huashan Hospital, Fudan University, Shanghai 200040,
      China.
FAU - Dai, Xiangpeng
AU  - Dai X
AD  - Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical
      School, Boston, Massachusetts 02215, USA.
FAU - Guo, Jianping
AU  - Guo J
AD  - Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical
      School, Boston, Massachusetts 02215, USA.
FAU - Huang, Yu-Han
AU  - Huang YH
AD  - Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical
      School, Boston, Massachusetts 02215, USA.
FAU - Fan, Caoqi
AU  - Fan C
AD  - Department of Cancer Biology, Dana-Farber Cancer Institute and Department of
      Genetics, Harvard Medical School, Boston, Massachusetts 02215, USA.
AD  - Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary 
      Studies, School of Life Sciences, Peking University, Beijing 100871, China.
FAU - Ren, Shancheng
AU  - Ren S
AD  - Department of Urology, Shanghai Changhai Hospital, Second Military Medical
      University, Shanghai 200433, China.
FAU - Sun, Yinghao
AU  - Sun Y
AD  - Department of Urology, Shanghai Changhai Hospital, Second Military Medical
      University, Shanghai 200433, China.
FAU - Freeman, Gordon J
AU  - Freeman GJ
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical
      School, Boston, Massachusetts 02215, USA.
FAU - Sicinski, Piotr
AU  - Sicinski P
AD  - Department of Cancer Biology, Dana-Farber Cancer Institute and Department of
      Genetics, Harvard Medical School, Boston, Massachusetts 02215, USA.
FAU - Wei, Wenyi
AU  - Wei W
AD  - Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical
      School, Boston, Massachusetts 02215, USA.
LA  - eng
GR  - R01 CA083688/CA/NCI NIH HHS/United States
GR  - P01 CA080111/CA/NCI NIH HHS/United States
GR  - P50 CA101942/CA/NCI NIH HHS/United States
GR  - R01 GM094777/GM/NIGMS NIH HHS/United States
GR  - R01 CA202634/CA/NCI NIH HHS/United States
GR  - K99 CA212292/CA/NCI NIH HHS/United States
GR  - R01 CA177910/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20171116
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
PMC - PMC5754234
MID - NIHMS919072
EDAT- 2017/11/22 06:00
MHDA- 2017/11/22 06:00
CRDT- 2017/11/22 06:00
PMCR- 2018/05/16 00:00
PHST- 2017/07/12 00:00 [received]
PHST- 2017/11/08 00:00 [accepted]
PHST- 2018/05/16 00:00 [pmc-release]
PHST- 2017/11/22 06:00 [pubmed]
PHST- 2017/11/22 06:00 [medline]
PHST- 2017/11/22 06:00 [entrez]
AID - nature25015 [pii]
AID - 10.1038/nature25015 [doi]
PST - ppublish
SO  - Nature. 2018 Jan 4;553(7686):91-95. doi: 10.1038/nature25015. Epub 2017 Nov 16.

PMID- 29305909
OWN - NLM
STAT- Publisher
LR  - 20180114
IS  - 1096-1186 (Electronic)
IS  - 1043-6618 (Linking)
DP  - 2018 Jan 4
TI  - Targeting oncogenic transcription factors by polyphenols: A novel approach for
      cancer therapy.
LID - S1043-6618(17)30968-4 [pii]
LID - 10.1016/j.phrs.2017.12.034 [doi]
AB  - Inflammation is one of the major causative factor of cancer and chronic
      inflammation is involved in all the major steps of cancer initiation, progression
      metastasis and drug resistance. The molecular mechanism of inflammation driven
      cancer is the complex interplay between oncogenic and tumor suppressive
      transcription factors which include FOXM1, NF-kB, STAT3, Wnt/beta- Catenin,
      HIF-1alpha, NRF2, androgen and estrogen receptors. Several products derived from 
      natural sources modulate the expression and activity of multiple transcription
      factors in various tumor models as evident from studies conducted in cell lines, 
      pre-clinical models and clinical samples. Further combination of these natural
      products along with currently approved cancer therapies added an additional
      advantage and they considered as promising targets for prevention and treatment
      of inflammation and cancer. In this review we discuss the application of
      multi-targeting natural products by analyzing the literature and future
      directions for their plausible applications in drug discovery.
CI  - Copyright (c) 2018 Elsevier Ltd. All rights reserved.
FAU - Rajagopal, Chitra
AU  - Rajagopal C
AD  - Cancer Research Program, Rajiv Gandhi Centre for Biotechnology,
      Thiruvananthapuram 695014, Kerala, India.
FAU - Lankadasari, Manendra Babu
AU  - Lankadasari MB
AD  - Cancer Research Program, Rajiv Gandhi Centre for Biotechnology,
      Thiruvananthapuram 695014, Kerala, India.
FAU - Aranjani, Jesil Mathew
AU  - Aranjani JM
AD  - Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, 
      Manipal 576104, Karnataka, India.
FAU - Harikumar, K B
AU  - Harikumar KB
AD  - Cancer Research Program, Rajiv Gandhi Centre for Biotechnology,
      Thiruvananthapuram 695014, Kerala, India. Electronic address:
      harikumar@rgcb.res.in.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180104
PL  - Netherlands
TA  - Pharmacol Res
JT  - Pharmacological research
JID - 8907422
OTO - NOTNLM
OT  - 4- Shogaol (PubChem CID: 9794897)
OT  - 6- Shogaol (PubChem CID: 5281794)
OT  - Apigenin (PubChem CID: 5280443)
OT  - Berberine (PubChem CID: 2353)
OT  - Bergamottin (PubChem CID: 5471349)
OT  - Caffeic acid (PubChem CID: 689043)Capsaicin (PubChem CID: 1548943)
OT  - Cancer
OT  - Cardamonin (PubChem CID: 641785)
OT  - Casticin(PubChem CID: 5315263)
OT  - Chrysin (PubChem CID: 5281607)
OT  - Cryptotanshinone (PubChem CID: 160254)
OT  - Cucurbitacin (PubChem CID: 5281319)
OT  - Curcumin (PubChem CID: 969516)
OT  - EGCG (PubChem CID: 65064)
OT  - Ellagic acid (PubChem CID: 5281855)
OT  - Escin (PubChem CID: 16211024)
OT  - Fistein (PubChem CID: 5281614)
OT  - Gambogic acid (PubChem CID: 16072310)
OT  - Gingerol (PubChem CID: 442793)
OT  - Gossypin (PubChem CID: 5281621)
OT  - Honokiol (PubChem CID: 72303)
OT  - Inflammation
OT  - Luteolin (PubChem CID: 5280445)
OT  - Mangiferin (PubChem CID: 5281647)
OT  - Metastasis
OT  - Natural compounds
OT  - Piperlongumine (PubChem CID: 637858)
OT  - Polyphenols
OT  - Pterostilbene (PubChem CID: 5281727)
OT  - Quercetin (PubChem CID: 5280343)
OT  - Resveratrol (PubChem CID: 445154)
OT  - Rutin (PubChem CID: 5280805)
OT  - Sesamin (PubChem CID: 72307)
OT  - Transcription factors
OT  - Ursolic acid (PubChem CID: 64945)
OT  - Wogonin (PubChem CID: 5281703)
OT  - Xanthohumol (PubChem CID: 639665)
EDAT- 2018/01/07 06:00
MHDA- 2018/01/07 06:00
CRDT- 2018/01/07 06:00
PHST- 2017/07/31 00:00 [received]
PHST- 2017/11/30 00:00 [revised]
PHST- 2017/12/31 00:00 [accepted]
PHST- 2018/01/07 06:00 [pubmed]
PHST- 2018/01/07 06:00 [medline]
PHST- 2018/01/07 06:00 [entrez]
AID - S1043-6618(17)30968-4 [pii]
AID - 10.1016/j.phrs.2017.12.034 [doi]
PST - aheadofprint
SO  - Pharmacol Res. 2018 Jan 4. pii: S1043-6618(17)30968-4. doi:
      10.1016/j.phrs.2017.12.034.

PMID- 29293244
OWN - NLM
STAT- In-Data-Review
LR  - 20180102
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 552
IP  - 7685
DP  - 2017 Dec 21
TI  - Cancer immunotherapy.
PG  - S61
LID - 10.1038/d41586-017-08699-z [doi]
FAU - Bender, Eric
AU  - Bender E
LA  - eng
PT  - Journal Article
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
EDAT- 2018/01/03 06:00
MHDA- 2018/01/03 06:00
CRDT- 2018/01/03 06:00
PHST- 2018/01/03 06:00 [entrez]
PHST- 2018/01/03 06:00 [pubmed]
PHST- 2018/01/03 06:00 [medline]
AID - d41586-017-08699-z [pii]
AID - 10.1038/d41586-017-08699-z [doi]
PST - ppublish
SO  - Nature. 2017 Dec 21;552(7685):S61. doi: 10.1038/d41586-017-08699-z.

PMID- 29100071
OWN - NLM
STAT- In-Process
LR  - 20180107
IS  - 1097-4172 (Electronic)
IS  - 0092-8674 (Linking)
VI  - 171
IP  - 4
DP  - 2017 Nov 2
TI  - Cancer Evolution during Immunotherapy.
PG  - 740-742
LID - S0092-8674(17)31249-7 [pii]
LID - 10.1016/j.cell.2017.10.027 [doi]
AB  - Immune checkpoint blockade has revolutionized cancer treatment. In this issue of 
      Cell, insights from a longitudinal multi-omics analysis of the largest
      yet-reported cohort of melanoma patients reveal how tumor and immunity co-evolve 
      during anti-PD-1 therapy.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Andrews, M C
AU  - Andrews MC
AD  - Department of Surgical Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, USA.
FAU - Wargo, J A
AU  - Wargo JA
AD  - Department of Surgical Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, USA; Department of Genomic Medicine, The University of Texas MD 
      Anderson Cancer Center, Houston, USA. Electronic address: jwargo@mdanderson.org.
LA  - eng
GR  - K08 CA160692/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cell
JT  - Cell
JID - 0413066
PMC - PMC5755374
MID - NIHMS927793
EDAT- 2017/11/04 06:00
MHDA- 2017/11/04 06:00
CRDT- 2017/11/04 06:00
PMCR- 2018/11/02 00:00
PHST- 2018/11/02 00:00 [pmc-release]
PHST- 2017/11/04 06:00 [entrez]
PHST- 2017/11/04 06:00 [pubmed]
PHST- 2017/11/04 06:00 [medline]
AID - S0092-8674(17)31249-7 [pii]
AID - 10.1016/j.cell.2017.10.027 [doi]
PST - ppublish
SO  - Cell. 2017 Nov 2;171(4):740-742. doi: 10.1016/j.cell.2017.10.027.

PMID- 29224780
OWN - NLM
STAT- In-Data-Review
LR  - 20180112
IS  - 1097-4172 (Electronic)
IS  - 0092-8674 (Linking)
VI  - 172
IP  - 1-2
DP  - 2018 Jan 11
TI  - A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity.
PG  - 373-386.e10
LID - S0092-8674(17)31319-3 [pii]
LID - 10.1016/j.cell.2017.11.010 [doi]
AB  - Breast cancer (BC) comprises multiple distinct subtypes that differ genetically, 
      pathologically, and clinically. Here, we describe a robust protocol for long-term
      culturing of human mammary epithelial organoids. Using this protocol, >100
      primary and metastatic BC organoid lines were generated, broadly recapitulating
      the diversity of the disease. BC organoid morphologies typically matched the
      histopathology, hormone receptor status, and HER2 status of the original tumor.
      DNA copy number variations as well as sequence changes were consistent within
      tumor-organoid pairs and largely retained even after extended passaging. BC
      organoids furthermore populated all major gene-expression-based classification
      groups and allowed in vitro drug screens that were consistent with in vivo
      xeno-transplantations and patient response. This study describes a representative
      collection of well-characterized BC organoids available for cancer research and
      drug development, as well as a strategy to assess in vitro drug response in a
      personalized fashion.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Sachs, Norman
AU  - Sachs N
AD  - Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences and University
      Medical Center Utrecht, Uppsalalaan 8, 3584 CT Utrecht, the Netherlands;
      Foundation Hubrecht Organoid Technology (HUB), Yalelaan 62, 3584 CM Utrecht, the 
      Netherlands; Cancer Genomics Netherlands, Oncode Institute, 3584 CG Utrecht, the 
      Netherlands.
FAU - de Ligt, Joep
AU  - de Ligt J
AD  - Center for Molecular Medicine, Department of Genetics, University Medical Center 
      Utrecht, Utrecht University, Universiteitsweg 100, 3584 CG Utrecht, the
      Netherlands; Cancer Genomics Netherlands, Oncode Institute, 3584 CG Utrecht, the 
      Netherlands.
FAU - Kopper, Oded
AU  - Kopper O
AD  - Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences and University
      Medical Center Utrecht, Uppsalalaan 8, 3584 CT Utrecht, the Netherlands; Cancer
      Genomics Netherlands, Oncode Institute, 3584 CG Utrecht, the Netherlands.
FAU - Gogola, Ewa
AU  - Gogola E
AD  - Division of Molecular Pathology, Netherlands Cancer Institute, Plesmanlaan 121,
      1066 CX Amsterdam, the Netherlands.
FAU - Bounova, Gergana
AU  - Bounova G
AD  - Division of Molecular Carcinogenesis, Netherlands Cancer Institute, Plesmanlaan
      121, 1066 CX Amsterdam, the Netherlands; Cancer Genomics Netherlands, Oncode
      Institute, 3584 CG Utrecht, the Netherlands.
FAU - Weeber, Fleur
AU  - Weeber F
AD  - Division of Molecular Oncology and Immunology, Netherlands Cancer Institute,
      Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands.
FAU - Balgobind, Anjali Vanita
AU  - Balgobind AV
AD  - Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences and University
      Medical Center Utrecht, Uppsalalaan 8, 3584 CT Utrecht, the Netherlands;
      Foundation Hubrecht Organoid Technology (HUB), Yalelaan 62, 3584 CM Utrecht, the 
      Netherlands.
FAU - Wind, Karin
AU  - Wind K
AD  - Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences and University
      Medical Center Utrecht, Uppsalalaan 8, 3584 CT Utrecht, the Netherlands.
FAU - Gracanin, Ana
AU  - Gracanin A
AD  - Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences and University
      Medical Center Utrecht, Uppsalalaan 8, 3584 CT Utrecht, the Netherlands.
FAU - Begthel, Harry
AU  - Begthel H
AD  - Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences and University
      Medical Center Utrecht, Uppsalalaan 8, 3584 CT Utrecht, the Netherlands.
FAU - Korving, Jeroen
AU  - Korving J
AD  - Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences and University
      Medical Center Utrecht, Uppsalalaan 8, 3584 CT Utrecht, the Netherlands.
FAU - van Boxtel, Ruben
AU  - van Boxtel R
AD  - Center for Molecular Medicine, Department of Genetics, University Medical Center 
      Utrecht, Utrecht University, Universiteitsweg 100, 3584 CG Utrecht, the
      Netherlands; Cancer Genomics Netherlands, Oncode Institute, 3584 CG Utrecht, the 
      Netherlands.
FAU - Duarte, Alexandra Alves
AU  - Duarte AA
AD  - Division of Molecular Pathology, Netherlands Cancer Institute, Plesmanlaan 121,
      1066 CX Amsterdam, the Netherlands.
FAU - Lelieveld, Daphne
AU  - Lelieveld D
AD  - Cell Screening Core, Department of Cell Biology, Center for Molecular Medicine,
      University Medical Center, Heidelberglaan 100, 3584 CX Utrecht, the Netherlands.
FAU - van Hoeck, Arne
AU  - van Hoeck A
AD  - Center for Molecular Medicine, Department of Genetics, University Medical Center 
      Utrecht, Utrecht University, Universiteitsweg 100, 3584 CG Utrecht, the
      Netherlands; Cancer Genomics Netherlands, Oncode Institute, 3584 CG Utrecht, the 
      Netherlands.
FAU - Ernst, Robert Frans
AU  - Ernst RF
AD  - Center for Molecular Medicine, Department of Genetics, University Medical Center 
      Utrecht, Utrecht University, Universiteitsweg 100, 3584 CG Utrecht, the
      Netherlands; Cancer Genomics Netherlands, Oncode Institute, 3584 CG Utrecht, the 
      Netherlands.
FAU - Blokzijl, Francis
AU  - Blokzijl F
AD  - Center for Molecular Medicine, Department of Genetics, University Medical Center 
      Utrecht, Utrecht University, Universiteitsweg 100, 3584 CG Utrecht, the
      Netherlands; Cancer Genomics Netherlands, Oncode Institute, 3584 CG Utrecht, the 
      Netherlands.
FAU - Nijman, Isaac Johannes
AU  - Nijman IJ
AD  - Center for Molecular Medicine, Department of Genetics, University Medical Center 
      Utrecht, Utrecht University, Universiteitsweg 100, 3584 CG Utrecht, the
      Netherlands; Cancer Genomics Netherlands, Oncode Institute, 3584 CG Utrecht, the 
      Netherlands.
FAU - Hoogstraat, Marlous
AU  - Hoogstraat M
AD  - Division of Molecular Carcinogenesis, Netherlands Cancer Institute, Plesmanlaan
      121, 1066 CX Amsterdam, the Netherlands.
FAU - van de Ven, Marieke
AU  - van de Ven M
AD  - Mouse Clinic for Cancer and Aging (MCCA), Preclinical Intervention Unit,
      Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the
      Netherlands.
FAU - Egan, David Anthony
AU  - Egan DA
AD  - Cell Screening Core, Department of Cell Biology, Center for Molecular Medicine,
      University Medical Center, Heidelberglaan 100, 3584 CX Utrecht, the Netherlands.
FAU - Zinzalla, Vittoria
AU  - Zinzalla V
AD  - Pharmacology and Translational Research, Boehringer Ingelheim RCV GmbH & Co KG,
      Dr. Boehringer-Gasse 5-11, 1121 Vienna, Austria.
FAU - Moll, Jurgen
AU  - Moll J
AD  - Pharmacology and Translational Research, Boehringer Ingelheim RCV GmbH & Co KG,
      Dr. Boehringer-Gasse 5-11, 1121 Vienna, Austria.
FAU - Boj, Sylvia Fernandez
AU  - Boj SF
AD  - Foundation Hubrecht Organoid Technology (HUB), Yalelaan 62, 3584 CM Utrecht, the 
      Netherlands; Cancer Genomics Netherlands, Oncode Institute, 3584 CG Utrecht, the 
      Netherlands.
FAU - Voest, Emile Eugene
AU  - Voest EE
AD  - Division of Molecular Oncology and Immunology, Netherlands Cancer Institute,
      Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands.
FAU - Wessels, Lodewyk
AU  - Wessels L
AD  - Division of Molecular Pathology, Netherlands Cancer Institute, Plesmanlaan 121,
      1066 CX Amsterdam, the Netherlands; Cancer Genomics Netherlands, Oncode
      Institute, 3584 CG Utrecht, the Netherlands; Faculty of EEMCS, Delft University
      of Technology, Delft, the Netherlands.
FAU - van Diest, Paul Joannes
AU  - van Diest PJ
AD  - Department of Pathology, University Medical Center Utrecht, Heidelberglaan 100,
      3584 CX Utrecht, the Netherlands.
FAU - Rottenberg, Sven
AU  - Rottenberg S
AD  - Division of Molecular Pathology, Netherlands Cancer Institute, Plesmanlaan 121,
      1066 CX Amsterdam, the Netherlands; Institute of Animal Pathology, Vetsuisse
      Faculty, University of Bern, Langgassstrasse 122, 3012 Bern, Switzerland.
FAU - Vries, Robert Gerhardus Jacob
AU  - Vries RGJ
AD  - Foundation Hubrecht Organoid Technology (HUB), Yalelaan 62, 3584 CM Utrecht, the 
      Netherlands; Cancer Genomics Netherlands, Oncode Institute, 3584 CG Utrecht, the 
      Netherlands.
FAU - Cuppen, Edwin
AU  - Cuppen E
AD  - Center for Molecular Medicine, Department of Genetics, University Medical Center 
      Utrecht, Utrecht University, Universiteitsweg 100, 3584 CG Utrecht, the
      Netherlands; Cancer Genomics Netherlands, Oncode Institute, 3584 CG Utrecht, the 
      Netherlands.
FAU - Clevers, Hans
AU  - Clevers H
AD  - Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences and University
      Medical Center Utrecht, Uppsalalaan 8, 3584 CT Utrecht, the Netherlands; Cancer
      Genomics Netherlands, Oncode Institute, 3584 CG Utrecht, the Netherlands.
      Electronic address: h.clevers@hubrecht.eu.
LA  - eng
PT  - Journal Article
DEP - 20171207
PL  - United States
TA  - Cell
JT  - Cell
JID - 0413066
OTO - NOTNLM
OT  - basal
OT  - biobank
OT  - breast cancer
OT  - luminal
OT  - organoids
OT  - precision medicine
OT  - triple negative
EDAT- 2017/12/12 06:00
MHDA- 2017/12/12 06:00
CRDT- 2017/12/12 06:00
PHST- 2016/11/20 00:00 [received]
PHST- 2017/10/06 00:00 [revised]
PHST- 2017/11/03 00:00 [accepted]
PHST- 2017/12/12 06:00 [pubmed]
PHST- 2017/12/12 06:00 [medline]
PHST- 2017/12/12 06:00 [entrez]
AID - S0092-8674(17)31319-3 [pii]
AID - 10.1016/j.cell.2017.11.010 [doi]
PST - ppublish
SO  - Cell. 2018 Jan 11;172(1-2):373-386.e10. doi: 10.1016/j.cell.2017.11.010. Epub
      2017 Dec 7.

PMID- 29231094
OWN - NLM
STAT- Publisher
LR  - 20171212
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
DP  - 2017 Dec 12
TI  - Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.
LID - 10.1056/NEJMoa1711948 [doi]
AB  - Background Low-molecular-weight heparin is the standard treatment for
      cancer-associated venous thromboembolism. The role of treatment with direct oral 
      anticoagulant agents is unclear. Methods In this open-label, noninferiority
      trial, we randomly assigned patients with cancer who had acute symptomatic or
      incidental venous thromboembolism to receive either low-molecular-weight heparin 
      for at least 5 days followed by oral edoxaban at a dose of 60 mg once daily
      (edoxaban group) or subcutaneous dalteparin at a dose of 200 IU per kilogram of
      body weight once daily for 1 month followed by dalteparin at a dose of 150 IU per
      kilogram once daily (dalteparin group). Treatment was given for at least 6 months
      and up to 12 months. The primary outcome was a composite of recurrent venous
      thromboembolism or major bleeding during the 12 months after randomization,
      regardless of treatment duration. Results Of the 1050 patients who underwent
      randomization, 1046 were included in the modified intention-to-treat analysis. A 
      primary-outcome event occurred in 67 of the 522 patients (12.8%) in the edoxaban 
      group as compared with 71 of the 524 patients (13.5%) in the dalteparin group
      (hazard ratio, 0.97; 95% confidence interval [CI], 0.70 to 1.36; P=0.006 for
      noninferiority; P=0.87 for superiority). Recurrent venous thromboembolism
      occurred in 41 patients (7.9%) in the edoxaban group and in 59 patients (11.3%)
      in the dalteparin group (difference in risk, -3.4 percentage points; 95% CI, -7.0
      to 0.2). Major bleeding occurred in 36 patients (6.9%) in the edoxaban group and 
      in 21 patients (4.0%) in the dalteparin group (difference in risk, 2.9 percentage
      points; 95% CI, 0.1 to 5.6). Conclusions Oral edoxaban was noninferior to
      subcutaneous dalteparin with respect to the composite outcome of recurrent venous
      thromboembolism or major bleeding. The rate of recurrent venous thromboembolism
      was lower but the rate of major bleeding was higher with edoxaban than with
      dalteparin. (Funded by Daiichi Sankyo; Hokusai VTE Cancer ClinicalTrials.gov
      number, NCT02073682 .).
FAU - Raskob, Gary E
AU  - Raskob GE
AD  - From the University of Oklahoma Health Sciences Center, College of Public Health,
      Oklahoma City (G.E.R.); the Department of Vascular Medicine, Academic Medical
      Center, University of Amsterdam (N.E., H.R.B.), and ITREAS, Academic Research
      Organization (A.S.) - both in Amsterdam; the Department of Vascular Medicine and 
      Hemostasis, University Hospitals Leuven, Leuven, Belgium (P.V.); Ottawa Hospital 
      Research Institute, Ottawa (M.C.), London Health Sciences Centre-Victoria
      Hospital, London, ON (M.J.K.), University Health Network, University of Toronto, 
      Toronto (E.Y.), and McMaster University and the Thrombosis and Atherosclerosis
      Research Institute, Hamilton, ON (J.I.W.) - all in Canada; the Department of
      Medicine and Aging Sciences, University G. D'Annunzio, Chieti, Italy (M.D.N.);
      the Department of Medicine, Division of Hematology, University of Washington,
      Seattle (D.G.); Daiichi Sankyo Pharma Development, Basking Ridge, NJ (M.A.G.,
      M.F.M., M.S., G.Z.); Thrombosis Research Institute and University College London,
      London (A.K.K.); the Department of Respiratory Disease, Hopital Europeen
      Georges-Pompidou, Assistance Publique-Hopitaux de Paris, Paris (G.M.); the
      Department of Internal Medicine, Division of Hematology, Ohio State University
      Wexner Medical Center, Columbus (T.-F.W.); and Beth Israel Deaconess Medical
      Center, Harvard Medical School, Boston (J.I.Z.).
FAU - van Es, Nick
AU  - van Es N
AD  - From the University of Oklahoma Health Sciences Center, College of Public Health,
      Oklahoma City (G.E.R.); the Department of Vascular Medicine, Academic Medical
      Center, University of Amsterdam (N.E., H.R.B.), and ITREAS, Academic Research
      Organization (A.S.) - both in Amsterdam; the Department of Vascular Medicine and 
      Hemostasis, University Hospitals Leuven, Leuven, Belgium (P.V.); Ottawa Hospital 
      Research Institute, Ottawa (M.C.), London Health Sciences Centre-Victoria
      Hospital, London, ON (M.J.K.), University Health Network, University of Toronto, 
      Toronto (E.Y.), and McMaster University and the Thrombosis and Atherosclerosis
      Research Institute, Hamilton, ON (J.I.W.) - all in Canada; the Department of
      Medicine and Aging Sciences, University G. D'Annunzio, Chieti, Italy (M.D.N.);
      the Department of Medicine, Division of Hematology, University of Washington,
      Seattle (D.G.); Daiichi Sankyo Pharma Development, Basking Ridge, NJ (M.A.G.,
      M.F.M., M.S., G.Z.); Thrombosis Research Institute and University College London,
      London (A.K.K.); the Department of Respiratory Disease, Hopital Europeen
      Georges-Pompidou, Assistance Publique-Hopitaux de Paris, Paris (G.M.); the
      Department of Internal Medicine, Division of Hematology, Ohio State University
      Wexner Medical Center, Columbus (T.-F.W.); and Beth Israel Deaconess Medical
      Center, Harvard Medical School, Boston (J.I.Z.).
FAU - Verhamme, Peter
AU  - Verhamme P
AD  - From the University of Oklahoma Health Sciences Center, College of Public Health,
      Oklahoma City (G.E.R.); the Department of Vascular Medicine, Academic Medical
      Center, University of Amsterdam (N.E., H.R.B.), and ITREAS, Academic Research
      Organization (A.S.) - both in Amsterdam; the Department of Vascular Medicine and 
      Hemostasis, University Hospitals Leuven, Leuven, Belgium (P.V.); Ottawa Hospital 
      Research Institute, Ottawa (M.C.), London Health Sciences Centre-Victoria
      Hospital, London, ON (M.J.K.), University Health Network, University of Toronto, 
      Toronto (E.Y.), and McMaster University and the Thrombosis and Atherosclerosis
      Research Institute, Hamilton, ON (J.I.W.) - all in Canada; the Department of
      Medicine and Aging Sciences, University G. D'Annunzio, Chieti, Italy (M.D.N.);
      the Department of Medicine, Division of Hematology, University of Washington,
      Seattle (D.G.); Daiichi Sankyo Pharma Development, Basking Ridge, NJ (M.A.G.,
      M.F.M., M.S., G.Z.); Thrombosis Research Institute and University College London,
      London (A.K.K.); the Department of Respiratory Disease, Hopital Europeen
      Georges-Pompidou, Assistance Publique-Hopitaux de Paris, Paris (G.M.); the
      Department of Internal Medicine, Division of Hematology, Ohio State University
      Wexner Medical Center, Columbus (T.-F.W.); and Beth Israel Deaconess Medical
      Center, Harvard Medical School, Boston (J.I.Z.).
FAU - Carrier, Marc
AU  - Carrier M
AD  - From the University of Oklahoma Health Sciences Center, College of Public Health,
      Oklahoma City (G.E.R.); the Department of Vascular Medicine, Academic Medical
      Center, University of Amsterdam (N.E., H.R.B.), and ITREAS, Academic Research
      Organization (A.S.) - both in Amsterdam; the Department of Vascular Medicine and 
      Hemostasis, University Hospitals Leuven, Leuven, Belgium (P.V.); Ottawa Hospital 
      Research Institute, Ottawa (M.C.), London Health Sciences Centre-Victoria
      Hospital, London, ON (M.J.K.), University Health Network, University of Toronto, 
      Toronto (E.Y.), and McMaster University and the Thrombosis and Atherosclerosis
      Research Institute, Hamilton, ON (J.I.W.) - all in Canada; the Department of
      Medicine and Aging Sciences, University G. D'Annunzio, Chieti, Italy (M.D.N.);
      the Department of Medicine, Division of Hematology, University of Washington,
      Seattle (D.G.); Daiichi Sankyo Pharma Development, Basking Ridge, NJ (M.A.G.,
      M.F.M., M.S., G.Z.); Thrombosis Research Institute and University College London,
      London (A.K.K.); the Department of Respiratory Disease, Hopital Europeen
      Georges-Pompidou, Assistance Publique-Hopitaux de Paris, Paris (G.M.); the
      Department of Internal Medicine, Division of Hematology, Ohio State University
      Wexner Medical Center, Columbus (T.-F.W.); and Beth Israel Deaconess Medical
      Center, Harvard Medical School, Boston (J.I.Z.).
FAU - Di Nisio, Marcello
AU  - Di Nisio M
AD  - From the University of Oklahoma Health Sciences Center, College of Public Health,
      Oklahoma City (G.E.R.); the Department of Vascular Medicine, Academic Medical
      Center, University of Amsterdam (N.E., H.R.B.), and ITREAS, Academic Research
      Organization (A.S.) - both in Amsterdam; the Department of Vascular Medicine and 
      Hemostasis, University Hospitals Leuven, Leuven, Belgium (P.V.); Ottawa Hospital 
      Research Institute, Ottawa (M.C.), London Health Sciences Centre-Victoria
      Hospital, London, ON (M.J.K.), University Health Network, University of Toronto, 
      Toronto (E.Y.), and McMaster University and the Thrombosis and Atherosclerosis
      Research Institute, Hamilton, ON (J.I.W.) - all in Canada; the Department of
      Medicine and Aging Sciences, University G. D'Annunzio, Chieti, Italy (M.D.N.);
      the Department of Medicine, Division of Hematology, University of Washington,
      Seattle (D.G.); Daiichi Sankyo Pharma Development, Basking Ridge, NJ (M.A.G.,
      M.F.M., M.S., G.Z.); Thrombosis Research Institute and University College London,
      London (A.K.K.); the Department of Respiratory Disease, Hopital Europeen
      Georges-Pompidou, Assistance Publique-Hopitaux de Paris, Paris (G.M.); the
      Department of Internal Medicine, Division of Hematology, Ohio State University
      Wexner Medical Center, Columbus (T.-F.W.); and Beth Israel Deaconess Medical
      Center, Harvard Medical School, Boston (J.I.Z.).
FAU - Garcia, David
AU  - Garcia D
AD  - From the University of Oklahoma Health Sciences Center, College of Public Health,
      Oklahoma City (G.E.R.); the Department of Vascular Medicine, Academic Medical
      Center, University of Amsterdam (N.E., H.R.B.), and ITREAS, Academic Research
      Organization (A.S.) - both in Amsterdam; the Department of Vascular Medicine and 
      Hemostasis, University Hospitals Leuven, Leuven, Belgium (P.V.); Ottawa Hospital 
      Research Institute, Ottawa (M.C.), London Health Sciences Centre-Victoria
      Hospital, London, ON (M.J.K.), University Health Network, University of Toronto, 
      Toronto (E.Y.), and McMaster University and the Thrombosis and Atherosclerosis
      Research Institute, Hamilton, ON (J.I.W.) - all in Canada; the Department of
      Medicine and Aging Sciences, University G. D'Annunzio, Chieti, Italy (M.D.N.);
      the Department of Medicine, Division of Hematology, University of Washington,
      Seattle (D.G.); Daiichi Sankyo Pharma Development, Basking Ridge, NJ (M.A.G.,
      M.F.M., M.S., G.Z.); Thrombosis Research Institute and University College London,
      London (A.K.K.); the Department of Respiratory Disease, Hopital Europeen
      Georges-Pompidou, Assistance Publique-Hopitaux de Paris, Paris (G.M.); the
      Department of Internal Medicine, Division of Hematology, Ohio State University
      Wexner Medical Center, Columbus (T.-F.W.); and Beth Israel Deaconess Medical
      Center, Harvard Medical School, Boston (J.I.Z.).
FAU - Grosso, Michael A
AU  - Grosso MA
AD  - From the University of Oklahoma Health Sciences Center, College of Public Health,
      Oklahoma City (G.E.R.); the Department of Vascular Medicine, Academic Medical
      Center, University of Amsterdam (N.E., H.R.B.), and ITREAS, Academic Research
      Organization (A.S.) - both in Amsterdam; the Department of Vascular Medicine and 
      Hemostasis, University Hospitals Leuven, Leuven, Belgium (P.V.); Ottawa Hospital 
      Research Institute, Ottawa (M.C.), London Health Sciences Centre-Victoria
      Hospital, London, ON (M.J.K.), University Health Network, University of Toronto, 
      Toronto (E.Y.), and McMaster University and the Thrombosis and Atherosclerosis
      Research Institute, Hamilton, ON (J.I.W.) - all in Canada; the Department of
      Medicine and Aging Sciences, University G. D'Annunzio, Chieti, Italy (M.D.N.);
      the Department of Medicine, Division of Hematology, University of Washington,
      Seattle (D.G.); Daiichi Sankyo Pharma Development, Basking Ridge, NJ (M.A.G.,
      M.F.M., M.S., G.Z.); Thrombosis Research Institute and University College London,
      London (A.K.K.); the Department of Respiratory Disease, Hopital Europeen
      Georges-Pompidou, Assistance Publique-Hopitaux de Paris, Paris (G.M.); the
      Department of Internal Medicine, Division of Hematology, Ohio State University
      Wexner Medical Center, Columbus (T.-F.W.); and Beth Israel Deaconess Medical
      Center, Harvard Medical School, Boston (J.I.Z.).
FAU - Kakkar, Ajay K
AU  - Kakkar AK
AD  - From the University of Oklahoma Health Sciences Center, College of Public Health,
      Oklahoma City (G.E.R.); the Department of Vascular Medicine, Academic Medical
      Center, University of Amsterdam (N.E., H.R.B.), and ITREAS, Academic Research
      Organization (A.S.) - both in Amsterdam; the Department of Vascular Medicine and 
      Hemostasis, University Hospitals Leuven, Leuven, Belgium (P.V.); Ottawa Hospital 
      Research Institute, Ottawa (M.C.), London Health Sciences Centre-Victoria
      Hospital, London, ON (M.J.K.), University Health Network, University of Toronto, 
      Toronto (E.Y.), and McMaster University and the Thrombosis and Atherosclerosis
      Research Institute, Hamilton, ON (J.I.W.) - all in Canada; the Department of
      Medicine and Aging Sciences, University G. D'Annunzio, Chieti, Italy (M.D.N.);
      the Department of Medicine, Division of Hematology, University of Washington,
      Seattle (D.G.); Daiichi Sankyo Pharma Development, Basking Ridge, NJ (M.A.G.,
      M.F.M., M.S., G.Z.); Thrombosis Research Institute and University College London,
      London (A.K.K.); the Department of Respiratory Disease, Hopital Europeen
      Georges-Pompidou, Assistance Publique-Hopitaux de Paris, Paris (G.M.); the
      Department of Internal Medicine, Division of Hematology, Ohio State University
      Wexner Medical Center, Columbus (T.-F.W.); and Beth Israel Deaconess Medical
      Center, Harvard Medical School, Boston (J.I.Z.).
FAU - Kovacs, Michael J
AU  - Kovacs MJ
AD  - From the University of Oklahoma Health Sciences Center, College of Public Health,
      Oklahoma City (G.E.R.); the Department of Vascular Medicine, Academic Medical
      Center, University of Amsterdam (N.E., H.R.B.), and ITREAS, Academic Research
      Organization (A.S.) - both in Amsterdam; the Department of Vascular Medicine and 
      Hemostasis, University Hospitals Leuven, Leuven, Belgium (P.V.); Ottawa Hospital 
      Research Institute, Ottawa (M.C.), London Health Sciences Centre-Victoria
      Hospital, London, ON (M.J.K.), University Health Network, University of Toronto, 
      Toronto (E.Y.), and McMaster University and the Thrombosis and Atherosclerosis
      Research Institute, Hamilton, ON (J.I.W.) - all in Canada; the Department of
      Medicine and Aging Sciences, University G. D'Annunzio, Chieti, Italy (M.D.N.);
      the Department of Medicine, Division of Hematology, University of Washington,
      Seattle (D.G.); Daiichi Sankyo Pharma Development, Basking Ridge, NJ (M.A.G.,
      M.F.M., M.S., G.Z.); Thrombosis Research Institute and University College London,
      London (A.K.K.); the Department of Respiratory Disease, Hopital Europeen
      Georges-Pompidou, Assistance Publique-Hopitaux de Paris, Paris (G.M.); the
      Department of Internal Medicine, Division of Hematology, Ohio State University
      Wexner Medical Center, Columbus (T.-F.W.); and Beth Israel Deaconess Medical
      Center, Harvard Medical School, Boston (J.I.Z.).
FAU - Mercuri, Michele F
AU  - Mercuri MF
AD  - From the University of Oklahoma Health Sciences Center, College of Public Health,
      Oklahoma City (G.E.R.); the Department of Vascular Medicine, Academic Medical
      Center, University of Amsterdam (N.E., H.R.B.), and ITREAS, Academic Research
      Organization (A.S.) - both in Amsterdam; the Department of Vascular Medicine and 
      Hemostasis, University Hospitals Leuven, Leuven, Belgium (P.V.); Ottawa Hospital 
      Research Institute, Ottawa (M.C.), London Health Sciences Centre-Victoria
      Hospital, London, ON (M.J.K.), University Health Network, University of Toronto, 
      Toronto (E.Y.), and McMaster University and the Thrombosis and Atherosclerosis
      Research Institute, Hamilton, ON (J.I.W.) - all in Canada; the Department of
      Medicine and Aging Sciences, University G. D'Annunzio, Chieti, Italy (M.D.N.);
      the Department of Medicine, Division of Hematology, University of Washington,
      Seattle (D.G.); Daiichi Sankyo Pharma Development, Basking Ridge, NJ (M.A.G.,
      M.F.M., M.S., G.Z.); Thrombosis Research Institute and University College London,
      London (A.K.K.); the Department of Respiratory Disease, Hopital Europeen
      Georges-Pompidou, Assistance Publique-Hopitaux de Paris, Paris (G.M.); the
      Department of Internal Medicine, Division of Hematology, Ohio State University
      Wexner Medical Center, Columbus (T.-F.W.); and Beth Israel Deaconess Medical
      Center, Harvard Medical School, Boston (J.I.Z.).
FAU - Meyer, Guy
AU  - Meyer G
AD  - From the University of Oklahoma Health Sciences Center, College of Public Health,
      Oklahoma City (G.E.R.); the Department of Vascular Medicine, Academic Medical
      Center, University of Amsterdam (N.E., H.R.B.), and ITREAS, Academic Research
      Organization (A.S.) - both in Amsterdam; the Department of Vascular Medicine and 
      Hemostasis, University Hospitals Leuven, Leuven, Belgium (P.V.); Ottawa Hospital 
      Research Institute, Ottawa (M.C.), London Health Sciences Centre-Victoria
      Hospital, London, ON (M.J.K.), University Health Network, University of Toronto, 
      Toronto (E.Y.), and McMaster University and the Thrombosis and Atherosclerosis
      Research Institute, Hamilton, ON (J.I.W.) - all in Canada; the Department of
      Medicine and Aging Sciences, University G. D'Annunzio, Chieti, Italy (M.D.N.);
      the Department of Medicine, Division of Hematology, University of Washington,
      Seattle (D.G.); Daiichi Sankyo Pharma Development, Basking Ridge, NJ (M.A.G.,
      M.F.M., M.S., G.Z.); Thrombosis Research Institute and University College London,
      London (A.K.K.); the Department of Respiratory Disease, Hopital Europeen
      Georges-Pompidou, Assistance Publique-Hopitaux de Paris, Paris (G.M.); the
      Department of Internal Medicine, Division of Hematology, Ohio State University
      Wexner Medical Center, Columbus (T.-F.W.); and Beth Israel Deaconess Medical
      Center, Harvard Medical School, Boston (J.I.Z.).
FAU - Segers, Annelise
AU  - Segers A
AD  - From the University of Oklahoma Health Sciences Center, College of Public Health,
      Oklahoma City (G.E.R.); the Department of Vascular Medicine, Academic Medical
      Center, University of Amsterdam (N.E., H.R.B.), and ITREAS, Academic Research
      Organization (A.S.) - both in Amsterdam; the Department of Vascular Medicine and 
      Hemostasis, University Hospitals Leuven, Leuven, Belgium (P.V.); Ottawa Hospital 
      Research Institute, Ottawa (M.C.), London Health Sciences Centre-Victoria
      Hospital, London, ON (M.J.K.), University Health Network, University of Toronto, 
      Toronto (E.Y.), and McMaster University and the Thrombosis and Atherosclerosis
      Research Institute, Hamilton, ON (J.I.W.) - all in Canada; the Department of
      Medicine and Aging Sciences, University G. D'Annunzio, Chieti, Italy (M.D.N.);
      the Department of Medicine, Division of Hematology, University of Washington,
      Seattle (D.G.); Daiichi Sankyo Pharma Development, Basking Ridge, NJ (M.A.G.,
      M.F.M., M.S., G.Z.); Thrombosis Research Institute and University College London,
      London (A.K.K.); the Department of Respiratory Disease, Hopital Europeen
      Georges-Pompidou, Assistance Publique-Hopitaux de Paris, Paris (G.M.); the
      Department of Internal Medicine, Division of Hematology, Ohio State University
      Wexner Medical Center, Columbus (T.-F.W.); and Beth Israel Deaconess Medical
      Center, Harvard Medical School, Boston (J.I.Z.).
FAU - Shi, Minggao
AU  - Shi M
AD  - From the University of Oklahoma Health Sciences Center, College of Public Health,
      Oklahoma City (G.E.R.); the Department of Vascular Medicine, Academic Medical
      Center, University of Amsterdam (N.E., H.R.B.), and ITREAS, Academic Research
      Organization (A.S.) - both in Amsterdam; the Department of Vascular Medicine and 
      Hemostasis, University Hospitals Leuven, Leuven, Belgium (P.V.); Ottawa Hospital 
      Research Institute, Ottawa (M.C.), London Health Sciences Centre-Victoria
      Hospital, London, ON (M.J.K.), University Health Network, University of Toronto, 
      Toronto (E.Y.), and McMaster University and the Thrombosis and Atherosclerosis
      Research Institute, Hamilton, ON (J.I.W.) - all in Canada; the Department of
      Medicine and Aging Sciences, University G. D'Annunzio, Chieti, Italy (M.D.N.);
      the Department of Medicine, Division of Hematology, University of Washington,
      Seattle (D.G.); Daiichi Sankyo Pharma Development, Basking Ridge, NJ (M.A.G.,
      M.F.M., M.S., G.Z.); Thrombosis Research Institute and University College London,
      London (A.K.K.); the Department of Respiratory Disease, Hopital Europeen
      Georges-Pompidou, Assistance Publique-Hopitaux de Paris, Paris (G.M.); the
      Department of Internal Medicine, Division of Hematology, Ohio State University
      Wexner Medical Center, Columbus (T.-F.W.); and Beth Israel Deaconess Medical
      Center, Harvard Medical School, Boston (J.I.Z.).
FAU - Wang, Tzu-Fei
AU  - Wang TF
AD  - From the University of Oklahoma Health Sciences Center, College of Public Health,
      Oklahoma City (G.E.R.); the Department of Vascular Medicine, Academic Medical
      Center, University of Amsterdam (N.E., H.R.B.), and ITREAS, Academic Research
      Organization (A.S.) - both in Amsterdam; the Department of Vascular Medicine and 
      Hemostasis, University Hospitals Leuven, Leuven, Belgium (P.V.); Ottawa Hospital 
      Research Institute, Ottawa (M.C.), London Health Sciences Centre-Victoria
      Hospital, London, ON (M.J.K.), University Health Network, University of Toronto, 
      Toronto (E.Y.), and McMaster University and the Thrombosis and Atherosclerosis
      Research Institute, Hamilton, ON (J.I.W.) - all in Canada; the Department of
      Medicine and Aging Sciences, University G. D'Annunzio, Chieti, Italy (M.D.N.);
      the Department of Medicine, Division of Hematology, University of Washington,
      Seattle (D.G.); Daiichi Sankyo Pharma Development, Basking Ridge, NJ (M.A.G.,
      M.F.M., M.S., G.Z.); Thrombosis Research Institute and University College London,
      London (A.K.K.); the Department of Respiratory Disease, Hopital Europeen
      Georges-Pompidou, Assistance Publique-Hopitaux de Paris, Paris (G.M.); the
      Department of Internal Medicine, Division of Hematology, Ohio State University
      Wexner Medical Center, Columbus (T.-F.W.); and Beth Israel Deaconess Medical
      Center, Harvard Medical School, Boston (J.I.Z.).
FAU - Yeo, Erik
AU  - Yeo E
AD  - From the University of Oklahoma Health Sciences Center, College of Public Health,
      Oklahoma City (G.E.R.); the Department of Vascular Medicine, Academic Medical
      Center, University of Amsterdam (N.E., H.R.B.), and ITREAS, Academic Research
      Organization (A.S.) - both in Amsterdam; the Department of Vascular Medicine and 
      Hemostasis, University Hospitals Leuven, Leuven, Belgium (P.V.); Ottawa Hospital 
      Research Institute, Ottawa (M.C.), London Health Sciences Centre-Victoria
      Hospital, London, ON (M.J.K.), University Health Network, University of Toronto, 
      Toronto (E.Y.), and McMaster University and the Thrombosis and Atherosclerosis
      Research Institute, Hamilton, ON (J.I.W.) - all in Canada; the Department of
      Medicine and Aging Sciences, University G. D'Annunzio, Chieti, Italy (M.D.N.);
      the Department of Medicine, Division of Hematology, University of Washington,
      Seattle (D.G.); Daiichi Sankyo Pharma Development, Basking Ridge, NJ (M.A.G.,
      M.F.M., M.S., G.Z.); Thrombosis Research Institute and University College London,
      London (A.K.K.); the Department of Respiratory Disease, Hopital Europeen
      Georges-Pompidou, Assistance Publique-Hopitaux de Paris, Paris (G.M.); the
      Department of Internal Medicine, Division of Hematology, Ohio State University
      Wexner Medical Center, Columbus (T.-F.W.); and Beth Israel Deaconess Medical
      Center, Harvard Medical School, Boston (J.I.Z.).
FAU - Zhang, George
AU  - Zhang G
AD  - From the University of Oklahoma Health Sciences Center, College of Public Health,
      Oklahoma City (G.E.R.); the Department of Vascular Medicine, Academic Medical
      Center, University of Amsterdam (N.E., H.R.B.), and ITREAS, Academic Research
      Organization (A.S.) - both in Amsterdam; the Department of Vascular Medicine and 
      Hemostasis, University Hospitals Leuven, Leuven, Belgium (P.V.); Ottawa Hospital 
      Research Institute, Ottawa (M.C.), London Health Sciences Centre-Victoria
      Hospital, London, ON (M.J.K.), University Health Network, University of Toronto, 
      Toronto (E.Y.), and McMaster University and the Thrombosis and Atherosclerosis
      Research Institute, Hamilton, ON (J.I.W.) - all in Canada; the Department of
      Medicine and Aging Sciences, University G. D'Annunzio, Chieti, Italy (M.D.N.);
      the Department of Medicine, Division of Hematology, University of Washington,
      Seattle (D.G.); Daiichi Sankyo Pharma Development, Basking Ridge, NJ (M.A.G.,
      M.F.M., M.S., G.Z.); Thrombosis Research Institute and University College London,
      London (A.K.K.); the Department of Respiratory Disease, Hopital Europeen
      Georges-Pompidou, Assistance Publique-Hopitaux de Paris, Paris (G.M.); the
      Department of Internal Medicine, Division of Hematology, Ohio State University
      Wexner Medical Center, Columbus (T.-F.W.); and Beth Israel Deaconess Medical
      Center, Harvard Medical School, Boston (J.I.Z.).
FAU - Zwicker, Jeffrey I
AU  - Zwicker JI
AD  - From the University of Oklahoma Health Sciences Center, College of Public Health,
      Oklahoma City (G.E.R.); the Department of Vascular Medicine, Academic Medical
      Center, University of Amsterdam (N.E., H.R.B.), and ITREAS, Academic Research
      Organization (A.S.) - both in Amsterdam; the Department of Vascular Medicine and 
      Hemostasis, University Hospitals Leuven, Leuven, Belgium (P.V.); Ottawa Hospital 
      Research Institute, Ottawa (M.C.), London Health Sciences Centre-Victoria
      Hospital, London, ON (M.J.K.), University Health Network, University of Toronto, 
      Toronto (E.Y.), and McMaster University and the Thrombosis and Atherosclerosis
      Research Institute, Hamilton, ON (J.I.W.) - all in Canada; the Department of
      Medicine and Aging Sciences, University G. D'Annunzio, Chieti, Italy (M.D.N.);
      the Department of Medicine, Division of Hematology, University of Washington,
      Seattle (D.G.); Daiichi Sankyo Pharma Development, Basking Ridge, NJ (M.A.G.,
      M.F.M., M.S., G.Z.); Thrombosis Research Institute and University College London,
      London (A.K.K.); the Department of Respiratory Disease, Hopital Europeen
      Georges-Pompidou, Assistance Publique-Hopitaux de Paris, Paris (G.M.); the
      Department of Internal Medicine, Division of Hematology, Ohio State University
      Wexner Medical Center, Columbus (T.-F.W.); and Beth Israel Deaconess Medical
      Center, Harvard Medical School, Boston (J.I.Z.).
FAU - Weitz, Jeffrey I
AU  - Weitz JI
AD  - From the University of Oklahoma Health Sciences Center, College of Public Health,
      Oklahoma City (G.E.R.); the Department of Vascular Medicine, Academic Medical
      Center, University of Amsterdam (N.E., H.R.B.), and ITREAS, Academic Research
      Organization (A.S.) - both in Amsterdam; the Department of Vascular Medicine and 
      Hemostasis, University Hospitals Leuven, Leuven, Belgium (P.V.); Ottawa Hospital 
      Research Institute, Ottawa (M.C.), London Health Sciences Centre-Victoria
      Hospital, London, ON (M.J.K.), University Health Network, University of Toronto, 
      Toronto (E.Y.), and McMaster University and the Thrombosis and Atherosclerosis
      Research Institute, Hamilton, ON (J.I.W.) - all in Canada; the Department of
      Medicine and Aging Sciences, University G. D'Annunzio, Chieti, Italy (M.D.N.);
      the Department of Medicine, Division of Hematology, University of Washington,
      Seattle (D.G.); Daiichi Sankyo Pharma Development, Basking Ridge, NJ (M.A.G.,
      M.F.M., M.S., G.Z.); Thrombosis Research Institute and University College London,
      London (A.K.K.); the Department of Respiratory Disease, Hopital Europeen
      Georges-Pompidou, Assistance Publique-Hopitaux de Paris, Paris (G.M.); the
      Department of Internal Medicine, Division of Hematology, Ohio State University
      Wexner Medical Center, Columbus (T.-F.W.); and Beth Israel Deaconess Medical
      Center, Harvard Medical School, Boston (J.I.Z.).
FAU - Buller, Harry R
AU  - Buller HR
AD  - From the University of Oklahoma Health Sciences Center, College of Public Health,
      Oklahoma City (G.E.R.); the Department of Vascular Medicine, Academic Medical
      Center, University of Amsterdam (N.E., H.R.B.), and ITREAS, Academic Research
      Organization (A.S.) - both in Amsterdam; the Department of Vascular Medicine and 
      Hemostasis, University Hospitals Leuven, Leuven, Belgium (P.V.); Ottawa Hospital 
      Research Institute, Ottawa (M.C.), London Health Sciences Centre-Victoria
      Hospital, London, ON (M.J.K.), University Health Network, University of Toronto, 
      Toronto (E.Y.), and McMaster University and the Thrombosis and Atherosclerosis
      Research Institute, Hamilton, ON (J.I.W.) - all in Canada; the Department of
      Medicine and Aging Sciences, University G. D'Annunzio, Chieti, Italy (M.D.N.);
      the Department of Medicine, Division of Hematology, University of Washington,
      Seattle (D.G.); Daiichi Sankyo Pharma Development, Basking Ridge, NJ (M.A.G.,
      M.F.M., M.S., G.Z.); Thrombosis Research Institute and University College London,
      London (A.K.K.); the Department of Respiratory Disease, Hopital Europeen
      Georges-Pompidou, Assistance Publique-Hopitaux de Paris, Paris (G.M.); the
      Department of Internal Medicine, Division of Hematology, Ohio State University
      Wexner Medical Center, Columbus (T.-F.W.); and Beth Israel Deaconess Medical
      Center, Harvard Medical School, Boston (J.I.Z.).
CN  - Hokusai VTE Cancer Investigators
LA  - eng
PT  - Journal Article
DEP - 20171212
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
EDAT- 2017/12/13 06:00
MHDA- 2017/12/13 06:00
CRDT- 2017/12/13 06:00
PHST- 2017/12/13 06:00 [entrez]
PHST- 2017/12/13 06:00 [pubmed]
PHST- 2017/12/13 06:00 [medline]
AID - 10.1056/NEJMoa1711948 [doi]
PST - aheadofprint
SO  - N Engl J Med. 2017 Dec 12. doi: 10.1056/NEJMoa1711948.

PMID- 29298051
OWN - NLM
STAT- Publisher
LR  - 20180122
IS  - 1520-4812 (Electronic)
IS  - 1043-1802 (Linking)
DP  - 2018 Jan 22
TI  - CRISPRed Macrophages for Cell-Based Cancer Immunotherapy.
LID - 10.1021/acs.bioconjchem.7b00768 [doi]
AB  - We present here an integrated nanotechnology/biology strategy for cancer
      immunotherapy that uses arginine nanoparticles (ArgNPs) to deliver CRISPR-Cas9
      gene editing machinery into cells to generate SIRP-alpha knockout macrophages.
      The NP system efficiently codelivers single guide RNA (sgRNA) and Cas9 protein
      required for editing to knock out the "don't eat me signal" in macrophages that
      prevents phagocytosis of cancer cells. Turning off this signal increased the
      innate phagocytic capabilities of the macrophages by 4-fold. This improved attack
      and elimination of cancer cells makes this strategy promising for the creation of
      "weaponized" macrophages for cancer immunotherapy.
FAU - Ray, Moumita
AU  - Ray M
AD  - Department of Chemistry, University of Massachusetts , 710 North Pleasant Street,
      Amherst, Massachusetts 01003, United States.
FAU - Lee, Yi-Wei
AU  - Lee YW
AD  - Department of Chemistry, University of Massachusetts , 710 North Pleasant Street,
      Amherst, Massachusetts 01003, United States.
FAU - Hardie, Joseph
AU  - Hardie J
AD  - Department of Chemistry, University of Massachusetts , 710 North Pleasant Street,
      Amherst, Massachusetts 01003, United States.
FAU - Mout, Rubul
AU  - Mout R
AUID- ORCID: http://orcid.org/0000-0001-6125-5873
AD  - Department of Chemistry, University of Massachusetts , 710 North Pleasant Street,
      Amherst, Massachusetts 01003, United States.
FAU - Yesilbag Tonga, Gulen
AU  - Yesilbag Tonga G
AD  - Department of Chemistry, University of Massachusetts , 710 North Pleasant Street,
      Amherst, Massachusetts 01003, United States.
FAU - Farkas, Michelle E
AU  - Farkas ME
AUID- ORCID: http://orcid.org/0000-0001-5824-1243
AD  - Department of Chemistry, University of Massachusetts , 710 North Pleasant Street,
      Amherst, Massachusetts 01003, United States.
FAU - Rotello, Vincent M
AU  - Rotello VM
AUID- ORCID: http://orcid.org/0000-0002-5184-5439
AD  - Department of Chemistry, University of Massachusetts , 710 North Pleasant Street,
      Amherst, Massachusetts 01003, United States.
LA  - eng
PT  - Journal Article
DEP - 20180122
PL  - United States
TA  - Bioconjug Chem
JT  - Bioconjugate chemistry
JID - 9010319
EDAT- 2018/01/04 06:00
MHDA- 2018/01/04 06:00
CRDT- 2018/01/04 06:00
PHST- 2018/01/04 06:00 [pubmed]
PHST- 2018/01/04 06:00 [medline]
PHST- 2018/01/04 06:00 [entrez]
AID - 10.1021/acs.bioconjchem.7b00768 [doi]
PST - aheadofprint
SO  - Bioconjug Chem. 2018 Jan 22. doi: 10.1021/acs.bioconjchem.7b00768.

PMID- 29143822
OWN - NLM
STAT- In-Data-Review
LR  - 20171219
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 552
IP  - 7683
DP  - 2017 Dec 7
TI  - Cancer immunotherapy: The dark side of PD-1 receptor inhibition.
PG  - 41-42
LID - 10.1038/nature24759 [doi]
FAU - Ludin, Aya
AU  - Ludin A
AD  - the Department of Stem Cell and Regenerative Biology, Harvard Stem Cell
      Institute, Harvard University, Cambridge, Massachusetts 02138, USA.
FAU - Zon, Leonard I
AU  - Zon LI
AD  - the Department of Stem Cell and Regenerative Biology, Harvard Stem Cell
      Institute, Harvard University, Cambridge, Massachusetts 02138, USA.
AD  - the Stem Cell Program and Division of Hematology/Oncology, Boston Children's
      Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts, and at the
      Howard Hughes Medical Institute, Boston.
LA  - eng
PT  - Journal Article
DEP - 20171115
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
EDAT- 2017/11/17 06:00
MHDA- 2017/11/17 06:00
CRDT- 2017/11/17 06:00
PHST- 2017/11/17 06:00 [pubmed]
PHST- 2017/11/17 06:00 [medline]
PHST- 2017/11/17 06:00 [entrez]
AID - nature24759 [pii]
AID - 10.1038/nature24759 [doi]
PST - ppublish
SO  - Nature. 2017 Dec 7;552(7683):41-42. doi: 10.1038/nature24759. Epub 2017 Nov 15.

PMID- 29048660
OWN - NLM
STAT- In-Process
LR  - 20171219
IS  - 1791-2423 (Electronic)
IS  - 1019-6439 (Linking)
VI  - 51
IP  - 5
DP  - 2017 Nov
TI  - Canonical and non-canonical WNT signaling in cancer stem cells and their niches: 
      Cellular heterogeneity, omics reprogramming, targeted therapy and tumor
      plasticity (Review).
PG  - 1357-1369
LID - 10.3892/ijo.2017.4129 [doi]
AB  - Cancer stem cells (CSCs), which have the potential for self-renewal,
      differentiation and de-differentiation, undergo epigenetic,
      epithelial-mesenchymal, immunological and metabolic reprogramming to adapt to the
      tumor microenvironment and survive host defense or therapeutic insults.
      Intra-tumor heterogeneity and cancer-cell plasticity give rise to therapeutic
      resistance and recurrence through clonal replacement and reactivation of dormant 
      CSCs, respectively. WNT signaling cascades cross-talk with the FGF, Notch,
      Hedgehog and TGFbeta/BMP signaling cascades and regulate expression of functional
      CSC markers, such as CD44, CD133 (PROM1), EPCAM and LGR5 (GPR49). Aberrant
      canonical and non-canonical WNT signaling in human malignancies, including
      breast, colorectal, gastric, lung, ovary, pancreatic, prostate and uterine
      cancers, leukemia and melanoma, are involved in CSC survival, bulk-tumor
      expansion and invasion/metastasis. WNT signaling-targeted therapeutics, such as
      anti-FZD1/2/5/7/8 monoclonal antibody (mAb) (vantictumab), anti-LGR5
      antibody-drug conjugate (ADC) (mAb-mc-vc-PAB-MMAE), anti-PTK7 ADC (PF-06647020), 
      anti-ROR1 mAb (cirmtuzumab), anti-RSPO3 mAb (rosmantuzumab), small-molecule
      porcupine inhibitors (ETC-159, WNT-C59 and WNT974), tankyrase inhibitors (AZ1366,
      G007-LK, NVP-TNKS656 and XAV939) and beta-catenin inhibitors (BC2059, CWP232228, 
      ICG-001 and PRI-724), are in clinical trials or preclinical studies for the
      treatment of patients with WNT-driven cancers. WNT signaling-targeted
      therapeutics are applicable for combination therapy with BCR-ABL, EGFR, FLT3, KIT
      or RET inhibitors to treat a subset of tyrosine kinase-driven cancers because WNT
      and tyrosine kinase signaling cascades converge to beta-catenin for the
      maintenance and expansion of CSCs. WNT signaling-targeted therapeutics might also
      be applicable for combination therapy with immune checkpoint blockers, such as
      atezolizumab, avelumab, durvalumab, ipilimumab, nivolumab and pembrolizumab, to
      treat cancers with immune evasion, although the context-dependent effects of WNT 
      signaling on immunity should be carefully assessed. Omics monitoring, such as
      genome sequencing and transcriptome tests, immunohistochemical analyses on PD-L1 
      (CD274), PD-1 (PDCD1), ROR1 and nuclear beta-catenin and organoid-based drug
      screening, is necessary to determine the appropriate WNT signaling-targeted
      therapeutics for cancer patients.
FAU - Katoh, Masaru
AU  - Katoh M
AD  - Department of Omics Network, National Cancer Center, Tokyo 104-0045, Japan.
LA  - eng
PT  - Journal Article
DEP - 20170919
PL  - Greece
TA  - Int J Oncol
JT  - International journal of oncology
JID - 9306042
PMC - PMC5642388
EDAT- 2017/10/20 06:00
MHDA- 2017/10/20 06:00
CRDT- 2017/10/20 06:00
PHST- 2017/07/30 00:00 [received]
PHST- 2017/09/15 00:00 [accepted]
PHST- 2017/10/20 06:00 [pubmed]
PHST- 2017/10/20 06:00 [medline]
PHST- 2017/10/20 06:00 [entrez]
AID - 10.3892/ijo.2017.4129 [doi]
PST - ppublish
SO  - Int J Oncol. 2017 Nov;51(5):1357-1369. doi: 10.3892/ijo.2017.4129. Epub 2017 Sep 
      19.

PMID- 29150934
OWN - NLM
STAT- Publisher
LR  - 20171118
IS  - 1097-4652 (Electronic)
IS  - 0021-9541 (Linking)
DP  - 2017 Nov 18
TI  - The current status and perspectives regarding the clinical implication of
      intracellular calcium in breast cancer.
LID - 10.1002/jcp.26277 [doi]
AB  - Calcium ions (Ca(2+) ) act as second messengers in intracellular signaling.
      Ca(2+) pumps, channels, sensors, and calcium binding proteins, regulate the
      concentrations of intracellular Ca(2+) as a key regulator of important cellular
      processes such as gene expression, proliferation, differentiation, DNA repair,
      apoptosis, metastasis, and hormone secretion. Intracellular Ca(2+) also
      influences the functions of several organelles, that include: the endoplasmic
      reticulum, mitochondria, the Golgi, and cell membrane both in normal and breast
      cancer cells. In breast cancer, the disruption of intracellular: Ca(2+)
      homeostasis may cause tumor progression by affecting key factors/pathways
      including phospholipase C (PLC), inositol 1,4,5-trisphosphate (IP3), calmodulin
      (CaM), nuclear factor of activated T-cells (NFAT), calpain, calmodulin-dependent 
      protein kinase II (CaMKII), mitogen-activated protein kinase (MAPK),
      epithelial-mesenchymal transition (EMT), vascular endothelial growth factor
      (VEGF), poly (ADP-Ribose) polymerase-1 (PARP1), estrogen, and estrogen receptor. 
      Because the foregoing molecules play crucial roles in breast cancer, the
      factors/pathways influencing intracellular Ca(2+) concentrations are putative
      targets for cancer treatment, using drugs such as Mephebrindole, Tilapia piscidin
      4, Nifetepimine, Paricalcitol, and Prednisolone. We have explored the
      factors/pathways which are related to breast cancer and Ca(2+) homeostasis and
      signaling in this review, and also discussed their potential as biomarkers for
      breast cancer staging, prognosis, and therapy.
CI  - This article is protected by copyright. All rights reserved.
FAU - Tajbakhsh, Amir
AU  - Tajbakhsh A
AD  - Department of Modern Sciences and Technologies, School of Medicine, Mashhad
      University of Medical Sciences, Mashhad, Iran.
AD  - Student Research Committee, Faculty of Medicine, Mashhad University of Medical
      Sciences, Mashhad, IR, Iran.
FAU - Pasdar, Alireza
AU  - Pasdar A
AD  - Department of Modern Sciences and Technologies, School of Medicine, Mashhad
      University of Medical Sciences, Mashhad, Iran.
FAU - Rezaee, Mehdi
AU  - Rezaee M
AD  - Department of Medical Biotechnology, Faculty of Medicine, Mashhad University of
      Medical Sciences, Mashhad, Iran.
AD  - Student Research Committee, Faculty of Medicine, Mashhad University of Medical
      Sciences, Mashhad, IR, Iran.
FAU - Fazeli, Mostafa
AU  - Fazeli M
AD  - Department of Modern Sciences and Technologies, School of Medicine, Mashhad
      University of Medical Sciences, Mashhad, Iran.
AD  - Student Research Committee, Faculty of Medicine, Mashhad University of Medical
      Sciences, Mashhad, IR, Iran.
FAU - Soleimanpour, Saman
AU  - Soleimanpour S
AD  - Department of Microbiology and Virology, School of Medicine, Mashhad University
      of Medical Sciences, Mashhad, Iran.
FAU - Hassanian, Seyed Mahdi
AU  - Hassanian SM
AD  - Metabolic Syndrome Research Center, Mashhad University of Medical Sciences,
      Mashhad, Iran.
FAU - FarshchiyanYazdi, Zahra
AU  - FarshchiyanYazdi Z
AD  - Student Research Committee, Faculty of Medicine, Mashhad University of Medical
      Sciences, Mashhad, IR, Iran.
AD  - Department of Laboratory Sciences, Faculty of Paramedical Sciences, Mashhad
      University of Medical Sciences, Mashhad, Iran.
FAU - Rad, Tayebe Younesi
AU  - Rad TY
AD  - Student Research Committee, Faculty of Medicine, Mashhad University of Medical
      Sciences, Mashhad, IR, Iran.
AD  - Department of Laboratory Sciences, Faculty of Paramedical Sciences, Mashhad
      University of Medical Sciences, Mashhad, Iran.
FAU - Ferns, Gordon A
AU  - Ferns GA
AD  - Brighton & Sussex Medical School, Division of Medical Education, Falmer,
      Brighton, Sussex BN1 9PH, UK.
FAU - Avan, Amir
AU  - Avan A
AD  - Metabolic Syndrome Research Center, Mashhad University of Medical Sciences,
      Mashhad, Iran.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20171118
PL  - United States
TA  - J Cell Physiol
JT  - Journal of cellular physiology
JID - 0050222
OTO - NOTNLM
OT  - Calcium homeostasis
OT  - breast neoplasms
OT  - calcium influx pathways
OT  - calcium signaling
OT  - cancer metastasis
OT  - pharmacological modulators
EDAT- 2017/11/19 06:00
MHDA- 2017/11/19 06:00
CRDT- 2017/11/19 06:00
PHST- 2017/08/01 00:00 [received]
PHST- 2017/10/18 00:00 [revised]
PHST- 2017/11/06 00:00 [accepted]
PHST- 2017/11/19 06:00 [entrez]
PHST- 2017/11/19 06:00 [pubmed]
PHST- 2017/11/19 06:00 [medline]
AID - 10.1002/jcp.26277 [doi]
PST - aheadofprint
SO  - J Cell Physiol. 2017 Nov 18. doi: 10.1002/jcp.26277.

PMID- 29144460
OWN - NLM
STAT- In-Data-Review
LR  - 20171219
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 551
IP  - 7680
DP  - 2017 Nov 16
TI  - Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity.
PG  - 340-345
LID - 10.1038/nature24302 [doi]
AB  - The role of adaptive immunity in early cancer development is controversial. Here 
      we show that chronic inflammation and fibrosis in humans and mice with
      non-alcoholic fatty liver disease is accompanied by accumulation of
      liver-resident immunoglobulin-A-producing (IgA(+)) cells. These cells also
      express programmed death ligand 1 (PD-L1) and interleukin-10, and directly
      suppress liver cytotoxic CD8(+) T lymphocytes, which prevent emergence of
      hepatocellular carcinoma and express a limited repertoire of T-cell receptors
      against tumour-associated antigens. Whereas CD8(+) T-cell ablation accelerates
      hepatocellular carcinoma, genetic or pharmacological interference with IgA(+)
      cell generation attenuates liver carcinogenesis and induces cytotoxic
      T-lymphocyte-mediated regression of established hepatocellular carcinoma. These
      findings establish the importance of inflammation-induced suppression of
      cytotoxic CD8(+) T-lymphocyte activation as a tumour-promoting mechanism.
FAU - Shalapour, Shabnam
AU  - Shalapour S
AD  - Laboratory of Gene Regulation and Signal Transduction, Department of
      Pharmacology, School of Medicine, University of California San Diego (UCSD), 9500
      Gilman Drive, La Jolla, California 92093, USA.
FAU - Lin, Xue-Jia
AU  - Lin XJ
AD  - Laboratory of Gene Regulation and Signal Transduction, Department of
      Pharmacology, School of Medicine, University of California San Diego (UCSD), 9500
      Gilman Drive, La Jolla, California 92093, USA.
AD  - Biomedical Translational Research Institute and The First Affiliated Hospital,
      Jinan University, Guangzhou 510632, China.
FAU - Bastian, Ingmar N
AU  - Bastian IN
AD  - Laboratory of Gene Regulation and Signal Transduction, Department of
      Pharmacology, School of Medicine, University of California San Diego (UCSD), 9500
      Gilman Drive, La Jolla, California 92093, USA.
FAU - Brain, John
AU  - Brain J
AD  - Liver Research Group, Institute of Cellular Medicine, The Medical School,
      Newcastle University, Newcastle upon Tyne NE2 4HH, UK.
FAU - Burt, Alastair D
AU  - Burt AD
AD  - Faculty of Health and Medical Sciences, University of Adelaide, South Australia
      5005, Australia.
FAU - Aksenov, Alexander A
AU  - Aksenov AA
AD  - Collaborative Mass Spectrometry Innovation Center, Skaggs School of Pharmacy and 
      Pharmaceutical Sciences, University of California San Diego (UCSD), 9500 Gilman
      Drive, La Jolla, California 92093, USA.
FAU - Vrbanac, Alison F
AU  - Vrbanac AF
AD  - Departments of Pediatrics and Computer Science & Engineering, University of
      California San Diego (UCSD), 9500 Gilman Drive, La Jolla, California 92093, USA.
FAU - Li, Weihua
AU  - Li W
AD  - Laboratory of Gene Regulation and Signal Transduction, Department of
      Pharmacology, School of Medicine, University of California San Diego (UCSD), 9500
      Gilman Drive, La Jolla, California 92093, USA.
FAU - Perkins, Andres
AU  - Perkins A
AD  - Laboratory of Gene Regulation and Signal Transduction, Department of
      Pharmacology, School of Medicine, University of California San Diego (UCSD), 9500
      Gilman Drive, La Jolla, California 92093, USA.
FAU - Matsutani, Takaji
AU  - Matsutani T
AD  - R&D Department, Repertoire Genesis Incorporation, Ibaraki, Osaka 567-0085, Japan.
FAU - Zhong, Zhenyu
AU  - Zhong Z
AD  - Laboratory of Gene Regulation and Signal Transduction, Department of
      Pharmacology, School of Medicine, University of California San Diego (UCSD), 9500
      Gilman Drive, La Jolla, California 92093, USA.
FAU - Dhar, Debanjan
AU  - Dhar D
AD  - Laboratory of Gene Regulation and Signal Transduction, Department of
      Pharmacology, School of Medicine, University of California San Diego (UCSD), 9500
      Gilman Drive, La Jolla, California 92093, USA.
FAU - Navas-Molina, Jose A
AU  - Navas-Molina JA
AD  - Departments of Pediatrics and Computer Science & Engineering, University of
      California San Diego (UCSD), 9500 Gilman Drive, La Jolla, California 92093, USA.
FAU - Xu, Jun
AU  - Xu J
AD  - Department of Medicine, University of California San Diego (UCSD), 9500 Gilman
      Drive, La Jolla, California 92093, USA.
FAU - Loomba, Rohit
AU  - Loomba R
AD  - NAFLD Research Center, Division of Gastroenterology, Department of Medicine,
      University of California San Diego (UCSD), La Jolla, California 92093, USA.
FAU - Downes, Michael
AU  - Downes M
AD  - Gene Expression Laboratory, Howard Hughes Medical Institute, Salk Institute for
      Biological Studies, 10010 North Torrey Pines Road, La Jolla, California 92037,
      USA.
FAU - Yu, Ruth T
AU  - Yu RT
AD  - Gene Expression Laboratory, Howard Hughes Medical Institute, Salk Institute for
      Biological Studies, 10010 North Torrey Pines Road, La Jolla, California 92037,
      USA.
FAU - Evans, Ronald M
AU  - Evans RM
AD  - Gene Expression Laboratory, Howard Hughes Medical Institute, Salk Institute for
      Biological Studies, 10010 North Torrey Pines Road, La Jolla, California 92037,
      USA.
FAU - Dorrestein, Pieter C
AU  - Dorrestein PC
AD  - Collaborative Mass Spectrometry Innovation Center, Skaggs School of Pharmacy and 
      Pharmaceutical Sciences, University of California San Diego (UCSD), 9500 Gilman
      Drive, La Jolla, California 92093, USA.
AD  - Center for Microbiome Innovation, University of California San Diego (UCSD), La
      Jolla, California 92093, USA.
FAU - Knight, Rob
AU  - Knight R
AD  - Departments of Pediatrics and Computer Science & Engineering, University of
      California San Diego (UCSD), 9500 Gilman Drive, La Jolla, California 92093, USA.
AD  - Center for Microbiome Innovation, University of California San Diego (UCSD), La
      Jolla, California 92093, USA.
FAU - Benner, Christopher
AU  - Benner C
AD  - Department of Medicine, University of California San Diego (UCSD), 9500 Gilman
      Drive, La Jolla, California 92093, USA.
FAU - Anstee, Quentin M
AU  - Anstee QM
AD  - Liver Research Group, Institute of Cellular Medicine, The Medical School,
      Newcastle University, Newcastle upon Tyne NE2 4HH, UK.
FAU - Karin, Michael
AU  - Karin M
AD  - Laboratory of Gene Regulation and Signal Transduction, Department of
      Pharmacology, School of Medicine, University of California San Diego (UCSD), 9500
      Gilman Drive, La Jolla, California 92093, USA.
AD  - Center for Microbiome Innovation, University of California San Diego (UCSD), La
      Jolla, California 92093, USA.
LA  - eng
GR  - P01 HL088093/HL/NHLBI NIH HHS/United States
GR  - P42 ES010337/ES/NIEHS NIH HHS/United States
PT  - Journal Article
DEP - 20171108
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
EIN - Nature. 2017 Nov 22;:. PMID: 29168501
EDAT- 2017/11/17 06:00
MHDA- 2017/11/17 06:00
CRDT- 2017/11/17 06:00
PHST- 2016/11/10 00:00 [received]
PHST- 2017/09/22 00:00 [accepted]
PHST- 2017/11/17 06:00 [entrez]
PHST- 2017/11/17 06:00 [pubmed]
PHST- 2017/11/17 06:00 [medline]
AID - nature24302 [pii]
AID - 10.1038/nature24302 [doi]
PST - ppublish
SO  - Nature. 2017 Nov 16;551(7680):340-345. doi: 10.1038/nature24302. Epub 2017 Nov 8.

PMID- 29087384
OWN - NLM
STAT- MEDLINE
DCOM- 20171107
LR  - 20171219
IS  - 1476-4679 (Electronic)
IS  - 1465-7392 (Linking)
VI  - 19
IP  - 11
DP  - 2017 Oct 31
TI  - PARPi focus the spotlight on replication fork protection in cancer.
PG  - 1309-1310
LID - 10.1038/ncb3638 [doi]
AB  - PARP inhibitors (PARPi) kill BRCA1/2-mutated cancers, which become resistant when
      DNA repair functions are restored. Now, MUS81 nuclease inhibition due to EZH2
      downregulation is found to restore DNA replication fork protection but not
      repair, leading to PARPi-resistance in mutant BRCA2 cells and patients. This
      challenges the DNA repair dominance in synthetic lethality.
FAU - Schlacher, Katharina
AU  - Schlacher K
AD  - Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas 77030, USA.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Nat Cell Biol
JT  - Nature cell biology
JID - 100890575
RN  - 0 (BRCA1 Protein)
RN  - 0 (BRCA1 protein, human)
RN  - 0 (BRCA2 Protein)
RN  - 0 (BRCA2 protein, human)
RN  - 0 (Poly(ADP-ribose) Polymerase Inhibitors)
RN  - EC 2.1.1.43 (EZH2 protein, human)
RN  - EC 2.1.1.43 (Enhancer of Zeste Homolog 2 Protein)
RN  - EC 2.4.2.30 (Poly(ADP-ribose) Polymerases)
SB  - IM
MH  - BRCA1 Protein/genetics
MH  - BRCA2 Protein/genetics
MH  - DNA Damage/drug effects/genetics
MH  - DNA Repair/drug effects/genetics
MH  - DNA Replication/*drug effects/genetics
MH  - Down-Regulation/drug effects/genetics
MH  - Enhancer of Zeste Homolog 2 Protein/genetics
MH  - Humans
MH  - Neoplasms/*drug therapy/*genetics/metabolism
MH  - Poly(ADP-ribose) Polymerase Inhibitors/*pharmacology
MH  - Poly(ADP-ribose) Polymerases/*metabolism
EDAT- 2017/11/01 06:00
MHDA- 2017/11/08 06:00
CRDT- 2017/11/01 06:00
PHST- 2017/11/01 06:00 [entrez]
PHST- 2017/11/01 06:00 [pubmed]
PHST- 2017/11/08 06:00 [medline]
AID - ncb3638 [pii]
AID - 10.1038/ncb3638 [doi]
PST - ppublish
SO  - Nat Cell Biol. 2017 Oct 31;19(11):1309-1310. doi: 10.1038/ncb3638.

PMID- 29202474
OWN - NLM
STAT- In-Data-Review
LR  - 20180102
IS  - 1558-8238 (Electronic)
IS  - 0021-9738 (Linking)
VI  - 128
IP  - 1
DP  - 2018 Jan 2
TI  - ADHFE1 is a breast cancer oncogene and induces metabolic reprogramming.
PG  - 323-340
LID - 10.1172/JCI93815 [doi]
LID - 93815 [pii]
AB  - Metabolic reprogramming in breast tumors is linked to increases in putative
      oncogenic metabolites that may contribute to malignant transformation. We
      previously showed that accumulation of the oncometabolite, 2-hydroxyglutarate
      (2HG), in breast tumors was associated with MYC signaling, but not with
      isocitrate dehydrogenase (IDH) mutations, suggesting a distinct mechanism for
      increased 2HG in breast cancer. Here, we determined that D-2HG is the predominant
      enantiomer in human breast tumors and show that the D-2HG-producing mitochondrial
      enzyme, alcohol dehydrogenase, iron-containing protein 1 (ADHFE1), is a breast
      cancer oncogene that decreases patient survival. We found that MYC upregulates
      ADHFE1 through changes in iron metabolism while coexpression of both ADHFE1 and
      MYC strongly enhanced orthotopic tumor growth in MCF7 cells. Moreover, ADHFE1
      promoted metabolic reprogramming with increased formation of D-2HG and reactive
      oxygen, a reductive glutamine metabolism, and modifications of the epigenetic
      landscape, leading to cellular dedifferentiation, enhanced mesenchymal
      transition, and phenocopying alterations that occur with high D-2HG levels in
      cancer cells with IDH mutations. Together, our data support the hypothesis that
      ADHFE1 and MYC signaling contribute to D-2HG accumulation in breast tumors and
      show that D-2HG is an oncogenic metabolite and potential driver of disease
      progression.
FAU - Mishra, Prachi
AU  - Mishra P
AD  - Laboratory of Human Carcinogenesis, Center for Cancer Research (CCR), National
      Cancer Institute (NCI), NIH, Bethesda, Maryland, USA.
FAU - Tang, Wei
AU  - Tang W
AD  - Laboratory of Human Carcinogenesis, Center for Cancer Research (CCR), National
      Cancer Institute (NCI), NIH, Bethesda, Maryland, USA.
FAU - Putluri, Vasanta
AU  - Putluri V
AD  - Department of Molecular and Cell Biology, Verna and Marrs McLean Department of
      Biochemistry and Alkek Center for Molecular Discovery, and.
AD  - Advanced Technology Core, Baylor College of Medicine, Houston, Texas, USA.
FAU - Dorsey, Tiffany H
AU  - Dorsey TH
AD  - Laboratory of Human Carcinogenesis, Center for Cancer Research (CCR), National
      Cancer Institute (NCI), NIH, Bethesda, Maryland, USA.
FAU - Jin, Feng
AU  - Jin F
AD  - Department of Molecular and Cell Biology, Verna and Marrs McLean Department of
      Biochemistry and Alkek Center for Molecular Discovery, and.
AD  - Advanced Technology Core, Baylor College of Medicine, Houston, Texas, USA.
FAU - Wang, Fang
AU  - Wang F
AD  - Agios Pharmaceuticals, Cambridge, Massachusetts, USA.
FAU - Zhu, Donewei
AU  - Zhu D
AD  - Agios Pharmaceuticals, Cambridge, Massachusetts, USA.
FAU - Amable, Lauren
AU  - Amable L
AD  - National Institute of Minority Health and Health Disparities.
FAU - Deng, Tao
AU  - Deng T
AD  - Protein Section, Laboratory of Metabolism, CCR, NCI, and.
FAU - Zhang, Shaofei
AU  - Zhang S
AD  - Protein Section, Laboratory of Metabolism, CCR, NCI, and.
FAU - Killian, J Keith
AU  - Killian JK
AD  - Genetics Branch, CCR, and Clinical Molecular Profiling Core, NCI, NIH, Bethesda, 
      Maryland, USA.
FAU - Wang, Yonghong
AU  - Wang Y
AD  - Genetics Branch, CCR, and Clinical Molecular Profiling Core, NCI, NIH, Bethesda, 
      Maryland, USA.
FAU - Minas, Tsion Z
AU  - Minas TZ
AD  - Laboratory of Human Carcinogenesis, Center for Cancer Research (CCR), National
      Cancer Institute (NCI), NIH, Bethesda, Maryland, USA.
FAU - Yfantis, Harry G
AU  - Yfantis HG
AD  - Pathology and Laboratory Medicine, Baltimore Veterans Affairs Medical Center,
      Baltimore, Maryland, USA.
FAU - Lee, Dong H
AU  - Lee DH
AD  - Pathology and Laboratory Medicine, Baltimore Veterans Affairs Medical Center,
      Baltimore, Maryland, USA.
FAU - Sreekumar, Arun
AU  - Sreekumar A
AD  - Department of Molecular and Cell Biology, Verna and Marrs McLean Department of
      Biochemistry and Alkek Center for Molecular Discovery, and.
FAU - Bustin, Michael
AU  - Bustin M
AD  - Protein Section, Laboratory of Metabolism, CCR, NCI, and.
FAU - Liu, Wei
AU  - Liu W
AD  - Agios Pharmaceuticals, Cambridge, Massachusetts, USA.
FAU - Putluri, Nagireddy
AU  - Putluri N
AD  - Department of Molecular and Cell Biology, Verna and Marrs McLean Department of
      Biochemistry and Alkek Center for Molecular Discovery, and.
AD  - Advanced Technology Core, Baylor College of Medicine, Houston, Texas, USA.
FAU - Ambs, Stefan
AU  - Ambs S
AD  - Laboratory of Human Carcinogenesis, Center for Cancer Research (CCR), National
      Cancer Institute (NCI), NIH, Bethesda, Maryland, USA.
LA  - eng
PT  - Journal Article
DEP - 20171127
PL  - United States
TA  - J Clin Invest
JT  - The Journal of clinical investigation
JID - 7802877
OTO - NOTNLM
OT  - Breast cancer
OT  - Metabolism
OT  - Oncogenes
OT  - Oncology
EDAT- 2017/12/05 06:00
MHDA- 2017/12/05 06:00
CRDT- 2017/12/05 06:00
PHST- 2017/03/08 00:00 [received]
PHST- 2017/10/17 00:00 [accepted]
PHST- 2017/12/05 06:00 [pubmed]
PHST- 2017/12/05 06:00 [medline]
PHST- 2017/12/05 06:00 [entrez]
AID - 93815 [pii]
AID - 10.1172/JCI93815 [doi]
PST - ppublish
SO  - J Clin Invest. 2018 Jan 2;128(1):323-340. doi: 10.1172/JCI93815. Epub 2017 Nov
      27.

PMID- 29211666
OWN - NLM
STAT- MEDLINE
DCOM- 20171208
LR  - 20171208
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 377
IP  - 23
DP  - 2017 Dec 7
TI  - Oral Contraceptives and the Small Increased Risk of Breast Cancer.
PG  - 2276-2277
LID - 10.1056/NEJMe1709636 [doi]
FAU - Hunter, David J
AU  - Hunter DJ
AD  - From the Nuffield Department of Population Health, University of Oxford, Oxford, 
      United Kingdom.
LA  - eng
PT  - Editorial
PT  - Comment
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Contraceptives, Oral)
SB  - AIM
SB  - IM
CON - N Engl J Med. 2017 Dec 7;377(23 ):2228-2239. PMID: 29211679
MH  - *Breast Neoplasms
MH  - *Contraceptives, Oral
MH  - Female
MH  - Humans
MH  - Risk
MH  - Risk Factors
EDAT- 2017/12/07 06:00
MHDA- 2017/12/09 06:00
CRDT- 2017/12/07 06:00
PHST- 2017/12/07 06:00 [entrez]
PHST- 2017/12/07 06:00 [pubmed]
PHST- 2017/12/09 06:00 [medline]
AID - 10.1056/NEJMe1709636 [doi]
PST - ppublish
SO  - N Engl J Med. 2017 Dec 7;377(23):2276-2277. doi: 10.1056/NEJMe1709636.

PMID- 29230043
OWN - NLM
STAT- In-Data-Review
LR  - 20180113
IS  - 1748-3395 (Electronic)
IS  - 1748-3387 (Linking)
VI  - 13
IP  - 1
DP  - 2018 Jan
TI  - Nanoparticle orientation to control RNA loading and ligand display on
      extracellular vesicles for cancer regression.
PG  - 82-89
LID - 10.1038/s41565-017-0012-z [doi]
AB  - Nanotechnology offers many benefits, and here we report an advantage of applying 
      RNA nanotechnology for directional control. The orientation of arrow-shaped RNA
      was altered to control ligand display on extracellular vesicle membranes for
      specific cell targeting, or to regulate intracellular trafficking of small
      interfering RNA (siRNA) or microRNA (miRNA). Placing membrane-anchoring
      cholesterol at the tail of the arrow results in display of RNA aptamer or folate 
      on the outer surface of the extracellular vesicle. In contrast, placing the
      cholesterol at the arrowhead results in partial loading of RNA nanoparticles into
      the extracellular vesicles. Taking advantage of the RNA ligand for specific
      targeting and extracellular vesicles for efficient membrane fusion, the resulting
      ligand-displaying extracellular vesicles were capable of specific delivery of
      siRNA to cells, and efficiently blocked tumour growth in three cancer models.
      Extracellular vesicles displaying an aptamer that binds to prostate-specific
      membrane antigen, and loaded with survivin siRNA, inhibited prostate cancer
      xenograft. The same extracellular vesicle instead displaying epidermal
      growth-factor receptor aptamer inhibited orthotopic breast cancer models.
      Likewise, survivin siRNA-loaded and folate-displaying extracellular vesicles
      inhibited patient-derived colorectal cancer xenograft.
FAU - Pi, Fengmei
AU  - Pi F
AD  - College of Pharmacy, The Ohio State University, Columbus, OH, USA.
AD  - Center for RNA Nanobiotechnology and Nanomedicine, The Ohio State University,
      Columbus, OH, USA.
AD  - Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
AD  - Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University,
      Columbus, OH, USA.
FAU - Binzel, Daniel W
AU  - Binzel DW
AD  - College of Pharmacy, The Ohio State University, Columbus, OH, USA.
AD  - Center for RNA Nanobiotechnology and Nanomedicine, The Ohio State University,
      Columbus, OH, USA.
AD  - Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
AD  - Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University,
      Columbus, OH, USA.
FAU - Lee, Tae Jin
AU  - Lee TJ
AD  - Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
AD  - Department of Cancer Biology and Genetics, College of Medicine, The Ohio State
      University, Columbus, OH, USA.
AD  - Department of Neurosurgery, McGovern Medical School, University of Texas Health
      Science Center at Houston, Houston, TX, USA.
FAU - Li, Zhefeng
AU  - Li Z
AD  - College of Pharmacy, The Ohio State University, Columbus, OH, USA.
AD  - Center for RNA Nanobiotechnology and Nanomedicine, The Ohio State University,
      Columbus, OH, USA.
AD  - Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
AD  - Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University,
      Columbus, OH, USA.
FAU - Sun, Meiyan
AU  - Sun M
AD  - Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy,
      University of Houston, Houston, TX, USA.
FAU - Rychahou, Piotr
AU  - Rychahou P
AD  - Markey Cancer Center, Department of Surgery, University of Kentucky, Lexington,
      KY, USA.
FAU - Li, Hui
AU  - Li H
AD  - College of Pharmacy, The Ohio State University, Columbus, OH, USA.
AD  - Center for RNA Nanobiotechnology and Nanomedicine, The Ohio State University,
      Columbus, OH, USA.
AD  - Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
AD  - Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University,
      Columbus, OH, USA.
FAU - Haque, Farzin
AU  - Haque F
AD  - College of Pharmacy, The Ohio State University, Columbus, OH, USA.
AD  - Center for RNA Nanobiotechnology and Nanomedicine, The Ohio State University,
      Columbus, OH, USA.
AD  - Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
AD  - Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University,
      Columbus, OH, USA.
FAU - Wang, Shaoying
AU  - Wang S
AD  - College of Pharmacy, The Ohio State University, Columbus, OH, USA.
AD  - Center for RNA Nanobiotechnology and Nanomedicine, The Ohio State University,
      Columbus, OH, USA.
AD  - Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
AD  - Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University,
      Columbus, OH, USA.
FAU - Croce, Carlo M
AU  - Croce CM
AD  - Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
AD  - Department of Cancer Biology and Genetics, College of Medicine, The Ohio State
      University, Columbus, OH, USA.
FAU - Guo, Bin
AU  - Guo B
AD  - Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy,
      University of Houston, Houston, TX, USA.
FAU - Evers, B Mark
AU  - Evers BM
AD  - Markey Cancer Center, Department of Surgery, University of Kentucky, Lexington,
      KY, USA.
FAU - Guo, Peixuan
AU  - Guo P
AD  - College of Pharmacy, The Ohio State University, Columbus, OH, USA.
      guo.1091@osu.edu.
AD  - Center for RNA Nanobiotechnology and Nanomedicine, The Ohio State University,
      Columbus, OH, USA. guo.1091@osu.edu.
AD  - Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
      guo.1091@osu.edu.
AD  - Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University,
      Columbus, OH, USA. guo.1091@osu.edu.
AD  - Department of Cancer Biology and Genetics, College of Medicine, The Ohio State
      University, Columbus, OH, USA. guo.1091@osu.edu.
LA  - eng
GR  - UH3 TR000875/TR/NCATS NIH HHS/United States
GR  - R35 CA197706/CA/NCI NIH HHS/United States
GR  - U01 CA207946/CA/NCI NIH HHS/United States
GR  - P30 CA177558/CA/NCI NIH HHS/United States
GR  - R01 CA186100/CA/NCI NIH HHS/United States
GR  - R01 CA195573/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20171211
PL  - England
TA  - Nat Nanotechnol
JT  - Nature nanotechnology
JID - 101283273
PMC - PMC5762263
MID - NIHMS910986
EDAT- 2017/12/13 06:00
MHDA- 2017/12/13 06:00
CRDT- 2017/12/13 06:00
PMCR- 2018/06/11 00:00
PHST- 2016/05/10 00:00 [received]
PHST- 2017/10/04 00:00 [accepted]
PHST- 2018/06/11 00:00 [pmc-release]
PHST- 2017/12/13 06:00 [pubmed]
PHST- 2017/12/13 06:00 [medline]
PHST- 2017/12/13 06:00 [entrez]
AID - 10.1038/s41565-017-0012-z [doi]
AID - 10.1038/s41565-017-0012-z [pii]
PST - ppublish
SO  - Nat Nanotechnol. 2018 Jan;13(1):82-89. doi: 10.1038/s41565-017-0012-z. Epub 2017 
      Dec 11.

PMID- 29195073
OWN - NLM
STAT- MEDLINE
DCOM- 20171222
LR  - 20180127
IS  - 1097-4172 (Electronic)
IS  - 0092-8674 (Linking)
VI  - 171
IP  - 6
DP  - 2017 Nov 30
TI  - Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating
      Lung Cancer.
PG  - 1284-1300.e21
LID - S0092-8674(17)31244-8 [pii]
LID - 10.1016/j.cell.2017.10.022 [doi]
AB  - Combining DNA-demethylating agents (DNA methyltransferase inhibitors [DNMTis])
      with histone deacetylase inhibitors (HDACis) holds promise for enhancing cancer
      immune therapy. Herein, pharmacologic and isoform specificity of HDACis are
      investigated to guide their addition to a DNMTi, thus devising a new, low-dose,
      sequential regimen that imparts a robust anti-tumor effect for non-small-cell
      lung cancer (NSCLC). Using in-vitro-treated NSCLC cell lines, we elucidate an
      interferon alpha/beta-based transcriptional program with accompanying
      upregulation of antigen presentation machinery, mediated in part through
      double-stranded RNA (dsRNA) induction. This is accompanied by suppression of MYC 
      signaling and an increase in the T cell chemoattractant CCL5. Use of this
      combination treatment schema in mouse models of NSCLC reverses tumor immune
      evasion and modulates T cell exhaustion state towards memory and effector T cell 
      phenotypes. Key correlative science metrics emerge for an upcoming clinical
      trial, testing enhancement of immune checkpoint therapy for NSCLC.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Topper, Michael J
AU  - Topper MJ
AD  - Department of Oncology, The Johns Hopkins School of Medicine, The Sidney Kimmel
      Comprehensive Cancer Center, Baltimore, MD 21287, USA; The Graduate Program in
      Cellular and Molecular Medicine, Johns Hopkins University School of Medicine,
      Baltimore, MD 21287, USA.
FAU - Vaz, Michelle
AU  - Vaz M
AD  - Department of Oncology, The Johns Hopkins School of Medicine, The Sidney Kimmel
      Comprehensive Cancer Center, Baltimore, MD 21287, USA.
FAU - Chiappinelli, Katherine B
AU  - Chiappinelli KB
AD  - Department of Microbiology, Immunology, and Tropical Medicine, The George
      Washington University Cancer Center, Washington, DC 20052, USA.
FAU - DeStefano Shields, Christina E
AU  - DeStefano Shields CE
AD  - Department of Oncology, The Johns Hopkins School of Medicine, The Sidney Kimmel
      Comprehensive Cancer Center, Baltimore, MD 21287, USA.
FAU - Niknafs, Noushin
AU  - Niknafs N
AD  - Department of Oncology, The Johns Hopkins School of Medicine, The Sidney Kimmel
      Comprehensive Cancer Center, Baltimore, MD 21287, USA.
FAU - Yen, Ray-Whay Chiu
AU  - Yen RC
AD  - Department of Oncology, The Johns Hopkins School of Medicine, The Sidney Kimmel
      Comprehensive Cancer Center, Baltimore, MD 21287, USA.
FAU - Wenzel, Alyssa
AU  - Wenzel A
AD  - The Johns Hopkins University, Baltimore, MD 21218, USA.
FAU - Hicks, Jessica
AU  - Hicks J
AD  - Department of Urologic Pathology, The Johns Hopkins School of Medicine, The
      Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287, USA.
FAU - Ballew, Matthew
AU  - Ballew M
AD  - Department of Radiation Oncology & Molecular Radiation Sciences, The Johns
      Hopkins School of Medicine, The Sidney Kimmel Comprehensive Cancer Center,
      Baltimore, MD 21287, USA.
FAU - Stone, Meredith
AU  - Stone M
AD  - Department of Oncology, The Johns Hopkins School of Medicine, The Sidney Kimmel
      Comprehensive Cancer Center, Baltimore, MD 21287, USA; The Graduate Program in
      Cellular and Molecular Medicine, Johns Hopkins University School of Medicine,
      Baltimore, MD 21287, USA.
FAU - Tran, Phuoc T
AU  - Tran PT
AD  - Department of Radiation Oncology & Molecular Radiation Sciences, The Johns
      Hopkins School of Medicine, The Sidney Kimmel Comprehensive Cancer Center,
      Baltimore, MD 21287, USA.
FAU - Zahnow, Cynthia A
AU  - Zahnow CA
AD  - Department of Oncology, The Johns Hopkins School of Medicine, The Sidney Kimmel
      Comprehensive Cancer Center, Baltimore, MD 21287, USA.
FAU - Hellmann, Matthew D
AU  - Hellmann MD
AD  - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA.
FAU - Anagnostou, Valsamo
AU  - Anagnostou V
AD  - Department of Oncology, The Johns Hopkins School of Medicine, The Sidney Kimmel
      Comprehensive Cancer Center, Baltimore, MD 21287, USA.
FAU - Strissel, Pamela L
AU  - Strissel PL
AD  - Department of Gynecology and Obstetrics, Laboratory for Molecular Medicine,
      University-Clinic Erlangen, 91054 Erlangen, Germany.
FAU - Strick, Reiner
AU  - Strick R
AD  - Department of Gynecology and Obstetrics, Laboratory for Molecular Medicine,
      University-Clinic Erlangen, 91054 Erlangen, Germany.
FAU - Velculescu, Victor E
AU  - Velculescu VE
AD  - Department of Oncology, The Johns Hopkins School of Medicine, The Sidney Kimmel
      Comprehensive Cancer Center, Baltimore, MD 21287, USA.
FAU - Baylin, Stephen B
AU  - Baylin SB
AD  - Department of Oncology, The Johns Hopkins School of Medicine, The Sidney Kimmel
      Comprehensive Cancer Center, Baltimore, MD 21287, USA. Electronic address:
      sbaylin@jhmi.edu.
LA  - eng
GR  - P30 CA006973/CA/NCI NIH HHS/United States
GR  - R01 CA121113/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cell
JT  - Cell
JID - 0413066
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Histone Deacetylase Inhibitors)
RN  - 0 (Hydroxamic Acids)
RN  - M801H13NRU (Azacitidine)
RN  - Z02132R2QQ (givinostat hydrochloride)
SB  - IM
MH  - Animals
MH  - Antigen Presentation/drug effects
MH  - Antineoplastic Agents/therapeutic use
MH  - Azacitidine/therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/genetics/immunology/*therapy
MH  - Cell Line, Tumor
MH  - *Drug Therapy, Combination
MH  - Histone Deacetylase Inhibitors/therapeutic use
MH  - Hydroxamic Acids/therapeutic use
MH  - Immunotherapy
MH  - Lung Neoplasms/genetics/immunology/*therapy
MH  - Mice
MH  - T-Lymphocytes/immunology
MH  - Transcriptome
MH  - Tumor Escape/*drug effects
MH  - Tumor Microenvironment
OTO - NOTNLM
OT  - HDAC
OT  - ITF-2357
OT  - MYC
OT  - NSCLC
OT  - azacitidine
OT  - immune response
OT  - lung cancer
OT  - memory T cells
EDAT- 2017/12/02 06:00
MHDA- 2017/12/23 06:00
CRDT- 2017/12/02 06:00
PHST- 2017/03/22 00:00 [received]
PHST- 2017/08/07 00:00 [revised]
PHST- 2017/10/13 00:00 [accepted]
PHST- 2017/12/02 06:00 [entrez]
PHST- 2017/12/02 06:00 [pubmed]
PHST- 2017/12/23 06:00 [medline]
AID - S0092-8674(17)31244-8 [pii]
AID - 10.1016/j.cell.2017.10.022 [doi]
PST - ppublish
SO  - Cell. 2017 Nov 30;171(6):1284-1300.e21. doi: 10.1016/j.cell.2017.10.022.

PMID- 29065440
OWN - NLM
STAT- Publisher
LR  - 20171219
IS  - 1440-1746 (Electronic)
IS  - 0815-9319 (Linking)
DP  - 2017 Oct 24
TI  - Individual and combined effects of hepatitis B surface antigen level and viral
      load on liver cancer risk.
LID - 10.1111/jgh.14032 [doi]
AB  - BACKGROUND: Hepatitis B surface antigen (HBsAg) and viral load are both hallmarks
      of hepatitis B virus (HBV) infection and have potential to stratify liver cancer 
      risk. METHODS: We carried out a nested case-control study including 211 liver
      cancer cases and 221 controls who were sero-positive for HBsAg within two
      population-based cohorts in Shanghai. Logistic regression was performed to
      estimate the odds ratios (ORs) and 95% confidence intervals (CIs). RESULTS: Risk 
      of liver cancer was positively related to increasing levels of HBV DNA and HBsAg 
      in dose-response manners. Compared to subjects with HBV DNA<2,000IU/ml, the
      adjusted ORs increased from 2.11 (95%CI: 0.99-4.50) to 10.47 (95%CI: 5.06-21.68) 
      for those with HBV DNA level at 2,000-19,999 IU/ml to>/=20,000 IU/ml. Compared to
      subjects at a low level of HBsAg (0.05-99 IU/ml), the adjusted ORs increased from
      1.82 (95%CI: 0.90-3.68) to 2.21 (95%CI: 1.10-4.43) for those with HBsAg level at 
      100-999 IU/ml to >/=1,000 IU/ml. Compared to subjects with HBV DNA<2,000 IU/ml
      and HBsAg<100IU/ml, the adjusted ORs were increased from 2.20 (95%CI: 1.07-4.49) 
      for those with HBV DNA<2,000IU/ml and HBsAg>/=100IU/ml to 6.94 (95%CI:
      3.39-14.23) for those with HBVDNA>/=2,000IU/ml and HBsAg<1,000IU/ml, and 16.15
      (95%CI: 7.60-34.32) for those with HBVDNA>/=2,000IU/ml and HBsAg>/=1,000IU/ml.
      CONCLUSION: Elevated levels of HBV DNA and HBsAg are associated with increased
      risks of liver cancer. Chronic HBsAg carriers may be suggested to simultaneously 
      lower the viral load to <2,000 IU/ml and HBsAg level to <100 IU/ml to lower their
      liver cancer risk.
CI  - This article is protected by copyright. All rights reserved.
FAU - Yang, Yang
AU  - Yang Y
AD  - State Key Laboratory of Oncogene and Related Genes, Shanghai Cancer Institute,
      Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai,
      200032, China.
AD  - Department of Epidemiology, Shanghai Cancer Institute, Renji Hospital, Shanghai
      Jiaotong University School of Medicine, Shanghai, 200032, China.
FAU - Gao, Jing
AU  - Gao J
AD  - State Key Laboratory of Oncogene and Related Genes, Shanghai Cancer Institute,
      Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai,
      200032, China.
AD  - Department of Epidemiology, Shanghai Cancer Institute, Renji Hospital, Shanghai
      Jiaotong University School of Medicine, Shanghai, 200032, China.
FAU - Tan, Yu-Ting
AU  - Tan YT
AD  - State Key Laboratory of Oncogene and Related Genes, Shanghai Cancer Institute,
      Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai,
      200032, China.
AD  - Department of Epidemiology, Shanghai Cancer Institute, Renji Hospital, Shanghai
      Jiaotong University School of Medicine, Shanghai, 200032, China.
FAU - Li, Hong-Lan
AU  - Li HL
AD  - State Key Laboratory of Oncogene and Related Genes, Shanghai Cancer Institute,
      Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai,
      200032, China.
AD  - Department of Epidemiology, Shanghai Cancer Institute, Renji Hospital, Shanghai
      Jiaotong University School of Medicine, Shanghai, 200032, China.
FAU - Wang, Jing
AU  - Wang J
AD  - State Key Laboratory of Oncogene and Related Genes, Shanghai Cancer Institute,
      Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai,
      200032, China.
AD  - Department of Epidemiology, Shanghai Cancer Institute, Renji Hospital, Shanghai
      Jiaotong University School of Medicine, Shanghai, 200032, China.
FAU - Ma, Xiao
AU  - Ma X
AD  - State Key Laboratory of Oncogene and Related Genes, Shanghai Cancer Institute,
      Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai,
      200032, China.
AD  - Department of Epidemiology, Shanghai Cancer Institute, Renji Hospital, Shanghai
      Jiaotong University School of Medicine, Shanghai, 200032, China.
FAU - Zheng, Wei
AU  - Zheng W
AD  - Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center,
      Vanderbilt University Medicine Center, Nashville, TN, 37203-1738, USA.
FAU - Shu, Xiao-Ou
AU  - Shu XO
AD  - Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center,
      Vanderbilt University Medicine Center, Nashville, TN, 37203-1738, USA.
FAU - Xiang, Yong-Bing
AU  - Xiang YB
AD  - State Key Laboratory of Oncogene and Related Genes, Shanghai Cancer Institute,
      Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai,
      200032, China.
AD  - Department of Epidemiology, Shanghai Cancer Institute, Renji Hospital, Shanghai
      Jiaotong University School of Medicine, Shanghai, 200032, China.
LA  - eng
GR  - UM1 CA173640/CA/NCI NIH HHS/United States
GR  - UM1 CA182910/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20171024
PL  - Australia
TA  - J Gastroenterol Hepatol
JT  - Journal of gastroenterology and hepatology
JID - 8607909
OTO - NOTNLM
OT  - Hepatitis B surface antigen
OT  - HepatitisB virus
OT  - Liver cancer
OT  - Prospective study
OT  - Viral load
EDAT- 2017/10/25 06:00
MHDA- 2017/10/25 06:00
CRDT- 2017/10/25 06:00
PHST- 2017/07/31 00:00 [received]
PHST- 2017/09/11 00:00 [revised]
PHST- 2017/10/16 00:00 [accepted]
PHST- 2017/10/25 06:00 [entrez]
PHST- 2017/10/25 06:00 [pubmed]
PHST- 2017/10/25 06:00 [medline]
AID - 10.1111/jgh.14032 [doi]
PST - aheadofprint
SO  - J Gastroenterol Hepatol. 2017 Oct 24. doi: 10.1111/jgh.14032.

PMID- 29333111
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20180119
IS  - 1556-3790 (Print)
IS  - 1556-3790 (Linking)
VI  - 13
IP  - 6
DP  - 2017 Dec
TI  - Diet, Gut Microbiota, and Colorectal Cancer Prevention: A Review of Potential
      Mechanisms and Promising Targets for Future Research.
PG  - 429-439
LID - 10.1007/s11888-017-0389-y [doi]
AB  - Diet plays an important role in the development of colorectal cancer. Emerging
      data have implicated the gut microbiota in colorectal cancer. Diet is a major
      determinant for the gut microbial structure and function. Therefore, it has been 
      hypothesized that alterations in gut microbes and their metabolites may
      contribute to the influence of diet on the development of colorectal cancer. We
      review several major dietary factors that have been linked to gut microbiota and 
      colorectal cancer, including major dietary patterns, fiber, red meat and sulfur, 
      and obesity. Most of the epidemiologic evidence derives from cross-sectional or
      short-term, highly controlled feeding studies that are limited in size.
      Therefore, high-quality large-scale prospective studies with dietary data
      collected over the life course and comprehensive gut microbial composition and
      function assessed well prior to neoplastic occurrence are critically needed to
      identify microbiome-based interventions that may complement or optimize current
      diet-based strategies for colorectal cancer prevention and management.
FAU - Song, Mingyang
AU  - Song M
AD  - Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and 
      Harvard Medical School, Boston, MA.
AD  - Division of Gastroenterology, Massachusetts General Hospital, Boston, MA.
AD  - Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA.
FAU - Chan, Andrew T
AU  - Chan AT
AD  - Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and 
      Harvard Medical School, Boston, MA.
AD  - Division of Gastroenterology, Massachusetts General Hospital, Boston, MA.
AD  - Channing Division of Network Medicine, Department of Medicine, Brigham and
      Women's Hospital, and Harvard Medical School, Boston, MA.
AD  - Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, 
      MA.
LA  - eng
GR  - K24 DK098311/DK/NIDDK NIH HHS/United States
GR  - R01 CA137178/CA/NCI NIH HHS/United States
GR  - R01 CA202704/CA/NCI NIH HHS/United States
GR  - U01 CA182367/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20170904
PL  - United States
TA  - Curr Colorectal Cancer Rep
JT  - Current colorectal cancer reports
JID - 101253272
PMC - PMC5761320
MID - NIHMS903991
OTO - NOTNLM
OT  - Fusobacterium nucleatum
OT  - Gut microbiome
OT  - antibiotics
OT  - colorectal neoplasia
OT  - dietary pattern
OT  - fiber
OT  - hydrogen sulfide
OT  - obesity
OT  - processed meat
OT  - red meat
OT  - short-chain fatty acid
OT  - sulfur
OT  - sulfur-reducing bacteria
EDAT- 2018/01/16 06:00
MHDA- 2018/01/16 06:01
CRDT- 2018/01/16 06:00
PMCR- 2018/12/01 00:00
PHST- 2018/12/01 00:00 [pmc-release]
PHST- 2018/01/16 06:00 [entrez]
PHST- 2018/01/16 06:00 [pubmed]
PHST- 2018/01/16 06:01 [medline]
AID - 10.1007/s11888-017-0389-y [doi]
PST - ppublish
SO  - Curr Colorectal Cancer Rep. 2017 Dec;13(6):429-439. doi:
      10.1007/s11888-017-0389-y. Epub 2017 Sep 4.

PMID- 27458904
OWN - NLM
STAT- MEDLINE
DCOM- 20171226
LR  - 20171226
IS  - 1879-0445 (Electronic)
IS  - 0960-9822 (Linking)
VI  - 26
IP  - 14
DP  - 2016 Jul 25
TI  - Epigenetics, cellular memory and gene regulation.
PG  - R644-8
LID - 10.1016/j.cub.2016.06.011 [doi]
LID - S0960-9822(16)30623-6 [pii]
AB  - The field described as 'epigenetics' has captured the imagination of scientists
      and the lay public. Advances in our understanding of chromatin and gene
      regulatory mechanisms have had impact on drug development, fueling excitement in 
      the lay public about the prospects of applying this knowledge to address health
      issues. However, when describing these scientific advances as 'epigenetic', we
      encounter the problem that this term means different things to different people, 
      starting within the scientific community and amplified in the popular press. To
      help researchers understand some of the misconceptions in the field and to
      communicate the science accurately to each other and the lay audience, here we
      review the basis for many of the assumptions made about what are currently
      referred to as epigenetic processes.
CI  - Copyright (c) 2016 Elsevier Ltd. All rights reserved.
FAU - Henikoff, Steven
AU  - Henikoff S
AD  - Howard Hughes Medical Institute and Basic Sciences Division, Fred Hutchinson
      Cancer Research Center, 1100 Fairview Avenue North, Seattle, WA 98109, USA.
      Electronic address: steveh@fredhutch.org.
FAU - Greally, John M
AU  - Greally JM
AD  - Department of Genetics, Albert Einstein College of Medicine, Bronx, NY 10461, USA
      and Department of Genetics, Center for Epigenomics and Division of Computational 
      Genetics, Albert Einstein College of Medicine, 1301 Morris Park Avenue, Bronx, NY
      10461, USA. Electronic address: john.greally@einstein.yu.edu.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Curr Biol
JT  - Current biology : CB
JID - 9107782
SB  - IM
MH  - *Epigenesis, Genetic
MH  - *Epigenomics
MH  - *Gene Expression Regulation
MH  - Humans
MH  - Terminology as Topic
EDAT- 2016/07/28 06:00
MHDA- 2017/12/27 06:00
CRDT- 2016/07/27 06:00
PHST- 2016/07/27 06:00 [entrez]
PHST- 2016/07/28 06:00 [pubmed]
PHST- 2017/12/27 06:00 [medline]
AID - S0960-9822(16)30623-6 [pii]
AID - 10.1016/j.cub.2016.06.011 [doi]
PST - ppublish
SO  - Curr Biol. 2016 Jul 25;26(14):R644-8. doi: 10.1016/j.cub.2016.06.011.

PMID- 29045907
OWN - NLM
STAT- MEDLINE
DCOM- 20171106
LR  - 20171106
IS  - 1097-4180 (Electronic)
IS  - 1074-7613 (Linking)
VI  - 47
IP  - 4
DP  - 2017 Oct 17
TI  - Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET
      Limit Cancer Immunotherapy.
PG  - 789-802.e9
LID - S1074-7613(17)30423-5 [pii]
LID - 10.1016/j.immuni.2017.09.012 [doi]
AB  - Inhibitors of the receptor tyrosine kinase c-MET are currently used in the clinic
      to target oncogenic signaling in tumor cells. We found that concomitant c-MET
      inhibition promoted adoptive T cell transfer and checkpoint immunotherapies in
      murine cancer models by increasing effector T cell infiltration in tumors. This
      therapeutic effect was independent of tumor cell-intrinsic c-MET dependence.
      Mechanistically, c-MET inhibition impaired the reactive mobilization and
      recruitment of neutrophils into tumors and draining lymph nodes in response to
      cytotoxic immunotherapies. In the absence of c-MET inhibition, neutrophils
      recruited to T cell-inflamed microenvironments rapidly acquired immunosuppressive
      properties, restraining T cell expansion and effector functions. In cancer
      patients, high serum levels of the c-MET ligand HGF correlated with increasing
      neutrophil counts and poor responses to checkpoint blockade therapies. Our
      findings reveal a role for the HGF/c-MET pathway in neutrophil recruitment and
      function and suggest that c-MET inhibitor co-treatment may improve responses to
      cancer immunotherapy in settings beyond c-MET-dependent tumors.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Glodde, Nicole
AU  - Glodde N
AD  - Laboratory of Experimental Dermatology, Department of Dermatology, University of 
      Magdeburg, 39120 Magdeburg, Germany; Laboratory of Experimental Dermatology,
      Department of Dermatology and Allergy, University of Bonn, 53105 Bonn, Germany;
      Unit for RNA Biology, Department of Clinical Chemistry and Clinical Pharmacology,
      University of Bonn, 53105 Bonn, Germany.
FAU - Bald, Tobias
AU  - Bald T
AD  - Laboratory of Experimental Dermatology, Department of Dermatology, University of 
      Magdeburg, 39120 Magdeburg, Germany; Laboratory of Experimental Dermatology,
      Department of Dermatology and Allergy, University of Bonn, 53105 Bonn, Germany;
      Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research
      Institute, Herston, QLD 4006, Australia. Electronic address:
      tobias.bald@qimrberghofer.edu.au.
FAU - van den Boorn-Konijnenberg, Debby
AU  - van den Boorn-Konijnenberg D
AD  - Unit for RNA Biology, Department of Clinical Chemistry and Clinical Pharmacology,
      University of Bonn, 53105 Bonn, Germany.
FAU - Nakamura, Kyohei
AU  - Nakamura K
AD  - Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research
      Institute, Herston, QLD 4006, Australia.
FAU - O'Donnell, Jake S
AU  - O'Donnell JS
AD  - Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research
      Institute, Herston, QLD 4006, Australia; Cancer Immunoregulation and
      Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD
      4006, Australia; School of Medicine, The University of Queensland, Herston, QLD
      4006, Australia.
FAU - Szczepanski, Sabrina
AU  - Szczepanski S
AD  - Department of Internal Medicine III, Hematology/Oncology/Rheumatology, University
      of Bonn, 53105 Bonn, Germany.
FAU - Brandes, Maria
AU  - Brandes M
AD  - Department of Internal Medicine III, Hematology/Oncology/Rheumatology, University
      of Bonn, 53105 Bonn, Germany.
FAU - Eickhoff, Sarah
AU  - Eickhoff S
AD  - Laboratory for Cellular Interactions and Immunimaging, Institute of Experimental 
      Immunology, University of Bonn, 53105 Bonn, Germany.
FAU - Das, Indrajit
AU  - Das I
AD  - Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research
      Institute, Herston, QLD 4006, Australia.
FAU - Shridhar, Naveen
AU  - Shridhar N
AD  - Laboratory of Experimental Dermatology, Department of Dermatology, University of 
      Magdeburg, 39120 Magdeburg, Germany; Laboratory of Experimental Dermatology,
      Department of Dermatology and Allergy, University of Bonn, 53105 Bonn, Germany.
FAU - Hinze, Daniel
AU  - Hinze D
AD  - Unit for RNA Biology, Department of Clinical Chemistry and Clinical Pharmacology,
      University of Bonn, 53105 Bonn, Germany.
FAU - Rogava, Meri
AU  - Rogava M
AD  - Laboratory of Experimental Dermatology, Department of Dermatology, University of 
      Magdeburg, 39120 Magdeburg, Germany; Laboratory of Experimental Dermatology,
      Department of Dermatology and Allergy, University of Bonn, 53105 Bonn, Germany.
FAU - van der Sluis, Tetje C
AU  - van der Sluis TC
AD  - Laboratory of Experimental Dermatology, Department of Dermatology, University of 
      Magdeburg, 39120 Magdeburg, Germany; Laboratory of Experimental Dermatology,
      Department of Dermatology and Allergy, University of Bonn, 53105 Bonn, Germany.
FAU - Ruotsalainen, Janne J
AU  - Ruotsalainen JJ
AD  - Laboratory of Experimental Dermatology, Department of Dermatology, University of 
      Magdeburg, 39120 Magdeburg, Germany; Laboratory of Experimental Dermatology,
      Department of Dermatology and Allergy, University of Bonn, 53105 Bonn, Germany.
FAU - Gaffal, Evelyn
AU  - Gaffal E
AD  - Laboratory of Experimental Dermatology, Department of Dermatology, University of 
      Magdeburg, 39120 Magdeburg, Germany; Laboratory of Experimental Dermatology,
      Department of Dermatology and Allergy, University of Bonn, 53105 Bonn, Germany.
FAU - Landsberg, Jennifer
AU  - Landsberg J
AD  - Laboratory of Experimental Dermatology, Department of Dermatology and Allergy,
      University of Bonn, 53105 Bonn, Germany.
FAU - Ludwig, Kerstin U
AU  - Ludwig KU
AD  - Institute of Human Genetics, University of Bonn, 53127 Bonn, Germany; Department 
      of Genomics, Life & Brain Center, University of Bonn, 53127 Bonn, Germany.
FAU - Wilhelm, Christoph
AU  - Wilhelm C
AD  - Unit for Immunopathology, Department of Clinical Chemistry and Clinical
      Pharmacology, University of Bonn, 53105 Bonn, Germany.
FAU - Riek-Burchardt, Monika
AU  - Riek-Burchardt M
AD  - Institute of Molecular and Clinical Immunology, University of Magdeburg, 39120
      Magdeburg, Germany.
FAU - Muller, Andreas J
AU  - Muller AJ
AD  - Institute of Molecular and Clinical Immunology, University of Magdeburg, 39120
      Magdeburg, Germany; Helmholtz Centre for Infection Research (HZI), 38124
      Braunschweig, Germany.
FAU - Gebhardt, Christoffer
AU  - Gebhardt C
AD  - Skin Cancer Unit, German Cancer Research Center, Heidelberg and Department of
      Dermatology, Venereology and Allergology, University Medical Center Mannheim,
      Ruprecht Karl University of Heidelberg, 69121 Heidelberg, Germany.
FAU - Scolyer, Richard A
AU  - Scolyer RA
AD  - Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred
      Hospital, Sydney, NSW 2050, Australia; Melanoma Institute Australia and Sydney
      Medical School, The University of Sydney, Sydney, NSW 2065, Australia.
FAU - Long, Georgina V
AU  - Long GV
AD  - Melanoma Institute Australia and Sydney Medical School, The University of Sydney,
      Sydney, NSW 2065, Australia.
FAU - Janzen, Viktor
AU  - Janzen V
AD  - Department of Internal Medicine III, Hematology/Oncology/Rheumatology, University
      of Bonn, 53105 Bonn, Germany.
FAU - Teng, Michele W L
AU  - Teng MWL
AD  - Cancer Immunoregulation and Immunotherapy Laboratory, QIMR Berghofer Medical
      Research Institute, Herston, QLD 4006, Australia; School of Medicine, The
      University of Queensland, Herston, QLD 4006, Australia.
FAU - Kastenmuller, Wolfgang
AU  - Kastenmuller W
AD  - Laboratory for Cellular Interactions and Immunimaging, Institute of Experimental 
      Immunology, University of Bonn, 53105 Bonn, Germany.
FAU - Mazzone, Massimiliano
AU  - Mazzone M
AD  - Laboratory of Molecular Oncology and Angiogenesis, Vesalius Research Center, VIB,
      Leuven B3000, Belgium; Laboratory of Molecular Oncology and Angiogenesis,
      Vesalius Research Center, Department of Oncology, KU Leuven, Leuven B3000,
      Belgium.
FAU - Smyth, Mark J
AU  - Smyth MJ
AD  - Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research
      Institute, Herston, QLD 4006, Australia; School of Medicine, The University of
      Queensland, Herston, QLD 4006, Australia.
FAU - Tuting, Thomas
AU  - Tuting T
AD  - Laboratory of Experimental Dermatology, Department of Dermatology, University of 
      Magdeburg, 39120 Magdeburg, Germany; Laboratory of Experimental Dermatology,
      Department of Dermatology and Allergy, University of Bonn, 53105 Bonn, Germany.
      Electronic address: thomas.tueting@med.ovgu.de.
FAU - Holzel, Michael
AU  - Holzel M
AD  - Unit for RNA Biology, Department of Clinical Chemistry and Clinical Pharmacology,
      University of Bonn, 53105 Bonn, Germany. Electronic address:
      michael.hoelzel@ukbonn.de.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Immunity
JT  - Immunity
JID - 9432918
RN  - 82115-62-6 (Interferon-gamma)
RN  - EC 2.7.10.1 (Proto-Oncogene Proteins c-met)
SB  - IM
MH  - Animals
MH  - Cell Line, Tumor
MH  - Cell Proliferation/genetics
MH  - Gene Expression Profiling/methods
MH  - Gene Expression Regulation, Neoplastic/immunology
MH  - Immunotherapy/*methods
MH  - Interferon-gamma/immunology/metabolism
MH  - Kaplan-Meier Estimate
MH  - Mice, Inbred BALB C
MH  - Mice, Inbred C57BL
MH  - Mice, Knockout
MH  - Mice, Transgenic
MH  - Neoplasms, Experimental/immunology/metabolism/*therapy
MH  - Neutrophils/*immunology/metabolism
MH  - Proto-Oncogene Proteins c-met/genetics/*immunology/metabolism
MH  - Signal Transduction/genetics/immunology
MH  - T-Lymphocytes/immunology/metabolism
MH  - Tumor Microenvironment/genetics/immunology
OTO - NOTNLM
OT  - HGF
OT  - T cells
OT  - bone marrow
OT  - c-MET
OT  - cancer immunotherapy
OT  - lymph node
OT  - melanoma
OT  - neutrophils
OT  - plasticity
OT  - therapy resistance
EDAT- 2017/10/19 06:00
MHDA- 2017/11/07 06:00
CRDT- 2017/10/19 06:00
PHST- 2016/09/26 00:00 [received]
PHST- 2017/07/05 00:00 [revised]
PHST- 2017/09/20 00:00 [accepted]
PHST- 2017/10/19 06:00 [entrez]
PHST- 2017/10/19 06:00 [pubmed]
PHST- 2017/11/07 06:00 [medline]
AID - S1074-7613(17)30423-5 [pii]
AID - 10.1016/j.immuni.2017.09.012 [doi]
PST - ppublish
SO  - Immunity. 2017 Oct 17;47(4):789-802.e9. doi: 10.1016/j.immuni.2017.09.012.

PMID- 29025772
OWN - NLM
STAT- In-Process
LR  - 20171219
IS  - 2159-8290 (Electronic)
IS  - 2159-8274 (Linking)
VI  - 7
IP  - 12
DP  - 2017 Dec
TI  - Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of
      Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer.
PG  - 1420-1435
LID - 10.1158/2159-8290.CD-17-0593 [doi]
AB  - Mechanisms of acquired resistance to immune checkpoint inhibitors (ICI) are
      poorly understood. We leveraged a collection of 14 ICI-resistant lung cancer
      samples to investigate whether alterations in genes encoding HLA Class I antigen 
      processing and presentation machinery (APM) components or interferon signaling
      play a role in acquired resistance to PD-1 or PD-L1 antagonistic antibodies.
      Recurrent mutations or copy-number changes were not detected in our cohort. In
      one case, we found acquired homozygous loss of B2M that caused lack of
      cell-surface HLA Class I expression in the tumor and a matched patient-derived
      xenograft (PDX). Downregulation of B2M was also found in two additional PDXs
      established from ICI-resistant tumors. CRISPR-mediated knockout of B2m in an
      immunocompetent lung cancer mouse model conferred resistance to PD-1 blockade in 
      vivo, proving its role in resistance to ICIs. These results indicate that HLA
      Class I APM disruption can mediate escape from ICIs in lung cancer.Significance: 
      As programmed death 1 axis inhibitors are becoming more established in standard
      treatment algorithms for diverse malignancies, acquired resistance to these
      therapies is increasingly being encountered. Here, we found that defective
      antigen processing and presentation can serve as a mechanism of such resistance
      in lung cancer. Cancer Discov; 7(12); 1420-35. (c)2017 AACR.This article is
      highlighted in the In This Issue feature, p. 1355.
CI  - (c)2017 American Association for Cancer Research.
FAU - Gettinger, Scott
AU  - Gettinger S
AD  - Department of Medicine (Section of Medical Oncology), Yale University School of
      Medicine, New Haven, Connecticut. katerina.politi@yale.edu
      scott.gettinger@yale.edu.
AD  - Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut.
FAU - Choi, Jungmin
AU  - Choi J
AD  - Department of Genetics, Yale University School of Medicine, New Haven,
      Connecticut.
FAU - Hastings, Katherine
AU  - Hastings K
AD  - Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut.
FAU - Truini, Anna
AU  - Truini A
AD  - Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut.
FAU - Datar, Ila
AU  - Datar I
AD  - Department of Pathology, Yale University School of Medicine, New Haven,
      Connecticut.
FAU - Sowell, Ryan
AU  - Sowell R
AD  - Department of Immunobiology, Yale University School of Medicine, New Haven,
      Connecticut.
FAU - Wurtz, Anna
AU  - Wurtz A
AD  - Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut.
FAU - Dong, Weilai
AU  - Dong W
AD  - Department of Genetics, Yale University School of Medicine, New Haven,
      Connecticut.
FAU - Cai, Guoping
AU  - Cai G
AD  - Department of Pathology, Yale University School of Medicine, New Haven,
      Connecticut.
FAU - Melnick, Mary Ann
AU  - Melnick MA
AD  - Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut.
FAU - Du, Victor Y
AU  - Du VY
AD  - Department of Immunobiology, Yale University School of Medicine, New Haven,
      Connecticut.
FAU - Schlessinger, Joseph
AU  - Schlessinger J
AD  - Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut.
AD  - Department of Pharmacology, Yale University School of Medicine, New Haven,
      Connecticut.
FAU - Goldberg, Sarah B
AU  - Goldberg SB
AD  - Department of Medicine (Section of Medical Oncology), Yale University School of
      Medicine, New Haven, Connecticut.
AD  - Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut.
FAU - Chiang, Anne
AU  - Chiang A
AD  - Department of Medicine (Section of Medical Oncology), Yale University School of
      Medicine, New Haven, Connecticut.
AD  - Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut.
FAU - Sanmamed, Miguel F
AU  - Sanmamed MF
AD  - Department of Immunobiology, Yale University School of Medicine, New Haven,
      Connecticut.
FAU - Melero, Ignacio
AU  - Melero I
AD  - CIMA and Clinica Universidad de Navarra, Pamplona, Spain.
AD  - Centro de Investigacion Biomedica en red de Oncologia CIBERONC, Madrid, Spain.
FAU - Agorreta, Jackeline
AU  - Agorreta J
AD  - CIMA and Clinica Universidad de Navarra, Pamplona, Spain.
AD  - Centro de Investigacion Biomedica en red de Oncologia CIBERONC, Madrid, Spain.
FAU - Montuenga, Luis M
AU  - Montuenga LM
AD  - CIMA and Clinica Universidad de Navarra, Pamplona, Spain.
AD  - Centro de Investigacion Biomedica en red de Oncologia CIBERONC, Madrid, Spain.
FAU - Lifton, Richard
AU  - Lifton R
AD  - Department of Genetics, Yale University School of Medicine, New Haven,
      Connecticut.
FAU - Ferrone, Soldano
AU  - Ferrone S
AD  - Department of Surgery, Massachusetts General Hospital, Harvard Medical School,
      Boston, Massachusetts.
FAU - Kavathas, Paula
AU  - Kavathas P
AD  - Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut.
AD  - Department of Immunobiology, Yale University School of Medicine, New Haven,
      Connecticut.
AD  - Department of Laboratory Medicine, Yale University School of Medicine, New Haven,
      Connecticut.
FAU - Rimm, David L
AU  - Rimm DL
AD  - Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut.
AD  - Department of Pathology, Yale University School of Medicine, New Haven,
      Connecticut.
FAU - Kaech, Susan M
AU  - Kaech SM
AD  - Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut.
AD  - Department of Immunobiology, Yale University School of Medicine, New Haven,
      Connecticut.
FAU - Schalper, Kurt
AU  - Schalper K
AD  - Department of Medicine (Section of Medical Oncology), Yale University School of
      Medicine, New Haven, Connecticut.
AD  - Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut.
AD  - Department of Pathology, Yale University School of Medicine, New Haven,
      Connecticut.
FAU - Herbst, Roy S
AU  - Herbst RS
AD  - Department of Medicine (Section of Medical Oncology), Yale University School of
      Medicine, New Haven, Connecticut.
AD  - Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut.
AD  - Department of Pharmacology, Yale University School of Medicine, New Haven,
      Connecticut.
FAU - Politi, Katerina
AU  - Politi K
AD  - Department of Medicine (Section of Medical Oncology), Yale University School of
      Medicine, New Haven, Connecticut. katerina.politi@yale.edu
      scott.gettinger@yale.edu.
AD  - Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut.
AD  - Department of Pathology, Yale University School of Medicine, New Haven,
      Connecticut.
LA  - eng
GR  - R01 CA195720/CA/NCI NIH HHS/United States
GR  - F32 CA210516/CA/NCI NIH HHS/United States
GR  - P30 CA016359/CA/NCI NIH HHS/United States
GR  - T32 HL007974/HL/NHLBI NIH HHS/United States
GR  - P50 CA196530/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20171012
PL  - United States
TA  - Cancer Discov
JT  - Cancer discovery
JID - 101561693
PMC - PMC5718941
MID - NIHMS911262
EDAT- 2017/10/14 06:00
MHDA- 2017/10/14 06:00
CRDT- 2017/10/14 06:00
PMCR- 2018/12/01 00:00
PHST- 2017/05/30 00:00 [received]
PHST- 2017/08/25 00:00 [revised]
PHST- 2017/09/29 00:00 [accepted]
PHST- 2018/12/01 00:00 [pmc-release]
PHST- 2017/10/14 06:00 [pubmed]
PHST- 2017/10/14 06:00 [medline]
PHST- 2017/10/14 06:00 [entrez]
AID - 2159-8290.CD-17-0593 [pii]
AID - 10.1158/2159-8290.CD-17-0593 [doi]
PST - ppublish
SO  - Cancer Discov. 2017 Dec;7(12):1420-1435. doi: 10.1158/2159-8290.CD-17-0593. Epub 
      2017 Oct 12.

PMID- 29171881
OWN - NLM
STAT- Publisher
LR  - 20171124
IS  - 1527-3350 (Electronic)
IS  - 0270-9139 (Linking)
DP  - 2017 Nov 24
TI  - RNA N6-methyladenosine methyltransferase METTL3 promotes liver cancer progression
      through YTHDF2 dependent post-transcriptional silencing of SOCS2.
LID - 10.1002/hep.29683 [doi]
AB  - Epigenetic alterations immensely contributed to human carcinogenesis.
      Conventional epigenetic studies predominantly focused on DNA methylation, histone
      modifications, and chromatin remodeling. Recently, diverse and reversible
      chemical modifications on RNAs emerge as a new layer of epigenetic regulation.
      N6-methyladenosine (m6A) is the most abundant chemical modification on eukaryotic
      mRNA and is important to the regulation of mRNA stability, splicing, and
      translation. Using transcriptome sequencing, we discovered that METTL3
      (methyltransferase like 3), a major RNA N6-adenosine methyltransferase, was
      significantly up-regulated in human hepatocellular carcinoma (HCC) and multiple
      solid tumors. Clinically, overexpression of METTL3 was associated with poor
      prognosis of HCC patients. Functionally, we proved that knockdown of METTL3
      drastically reduced HCC cell proliferation, migration and colony formation in
      vitro. Knockout of METTL3 remarkably suppressed HCC tumorigenicity and lung
      metastasis in vivo. On the other hand, using CRISPR/dCas9-VP64 activation system,
      we demonstrated that overexpression of METTL3 significantly promoted HCC growth
      both in vitro and in vivo. Through transcriptome sequencing, m6A-Seq and m6A
      MeRIP qRT-PCR, we identified SOCS2 (suppressor of cytokine signaling 2) as a
      target of METTL3-mediated m6A modification. Knockdown of METTL3 substantially
      abolished SOCS2 mRNA m6A modification and augmented SOCS2 mRNA expression. We
      also showed that m6A-mediated SOCS2 mRNA degradation relied on m6A "reader"
      protein YTHDF2 dependent pathway. In conclusion, we demonstrated that METTL3 was 
      frequently up-regulated in human HCC and contributed to HCC progression. METTL3
      repressed SOCS2 expression in HCC via the m6A-YTHDF2 dependent mechanism. Thus,
      our findings suggested a new dimension of epigenetic alteration in liver
      carcinogenesis. This article is protected by copyright. All rights reserved.
CI  - (c) 2017 by the American Association for the Study of Liver Diseases.
FAU - Chen, Mengnuo
AU  - Chen M
AD  - State Key Laboratory for Liver Research and Department of Pathology, Li Ka Shing 
      Faculty of Medicine, the University of Hong Kong.
FAU - Wei, Lai
AU  - Wei L
AD  - State Key Laboratory for Liver Research and Department of Pathology, Li Ka Shing 
      Faculty of Medicine, the University of Hong Kong.
FAU - Law, Cheuk-Ting
AU  - Law CT
AD  - State Key Laboratory for Liver Research and Department of Pathology, Li Ka Shing 
      Faculty of Medicine, the University of Hong Kong.
FAU - Tsang, Felice Ho-Ching
AU  - Tsang FH
AD  - State Key Laboratory for Liver Research and Department of Pathology, Li Ka Shing 
      Faculty of Medicine, the University of Hong Kong.
FAU - Shen, Jialing
AU  - Shen J
AD  - State Key Laboratory for Liver Research and Department of Pathology, Li Ka Shing 
      Faculty of Medicine, the University of Hong Kong.
FAU - Cheng, Carol Lai-Hung
AU  - Cheng CL
AD  - State Key Laboratory for Liver Research and Department of Pathology, Li Ka Shing 
      Faculty of Medicine, the University of Hong Kong.
FAU - Tsang, Long-Hin
AU  - Tsang LH
AD  - State Key Laboratory for Liver Research and Department of Pathology, Li Ka Shing 
      Faculty of Medicine, the University of Hong Kong.
FAU - Ho, Daniel Wai-Hung
AU  - Ho DW
AD  - State Key Laboratory for Liver Research and Department of Pathology, Li Ka Shing 
      Faculty of Medicine, the University of Hong Kong.
FAU - Chiu, David Kung-Chun
AU  - Chiu DK
AD  - State Key Laboratory for Liver Research and Department of Pathology, Li Ka Shing 
      Faculty of Medicine, the University of Hong Kong.
FAU - Lee, Joyce Man-Fong
AU  - Lee JM
AD  - State Key Laboratory for Liver Research and Department of Pathology, Li Ka Shing 
      Faculty of Medicine, the University of Hong Kong.
FAU - Wong, Carmen Chak-Lui
AU  - Wong CC
AD  - State Key Laboratory for Liver Research and Department of Pathology, Li Ka Shing 
      Faculty of Medicine, the University of Hong Kong.
FAU - Ng, Irene Oi-Lin
AU  - Ng IO
AD  - State Key Laboratory for Liver Research and Department of Pathology, Li Ka Shing 
      Faculty of Medicine, the University of Hong Kong.
FAU - Wong, Chun-Ming
AU  - Wong CM
AUID- ORCID: http://orcid.org/0000-0002-2497-7858
AD  - State Key Laboratory for Liver Research and Department of Pathology, Li Ka Shing 
      Faculty of Medicine, the University of Hong Kong.
LA  - eng
PT  - Journal Article
DEP - 20171124
PL  - United States
TA  - Hepatology
JT  - Hepatology (Baltimore, Md.)
JID - 8302946
OTO - NOTNLM
OT  - Epigenetics
OT  - Hepatocellular carcinoma
OT  - METTL3
OT  - N6-methyladenosine
OT  - SOCS2
OT  - YTHDF2
EDAT- 2017/11/25 06:00
MHDA- 2017/11/25 06:00
CRDT- 2017/11/25 06:00
PHST- 2017/02/09 00:00 [received]
PHST- 2017/11/08 00:00 [revised]
PHST- 2017/11/21 00:00 [accepted]
PHST- 2017/11/25 06:00 [entrez]
PHST- 2017/11/25 06:00 [pubmed]
PHST- 2017/11/25 06:00 [medline]
AID - 10.1002/hep.29683 [doi]
PST - aheadofprint
SO  - Hepatology. 2017 Nov 24. doi: 10.1002/hep.29683.

PMID- 29039115
OWN - NLM
STAT- In-Process
LR  - 20171219
IS  - 1558-822X (Electronic)
IS  - 1558-8211 (Linking)
VI  - 12
IP  - 6
DP  - 2017 Dec
TI  - Genome-Editing Technologies in Adoptive T Cell Immunotherapy for Cancer.
PG  - 522-529
LID - 10.1007/s11899-017-0417-7 [doi]
AB  - PURPOSE OF REVIEW: In this review, we discuss the most recent developments in
      gene-editing technology and discuss their application to adoptive T cell
      immunotherapy. RECENT FINDINGS: Engineered T cell therapies targeting cancer
      antigens have demonstrated significant efficacy in specific patient populations. 
      Most impressively, CD19-directed chimeric antigen receptor T cells (CART19) have 
      led to impressive responses in patients with B-cell leukemia and lymphoma.
      CTL019, or KYMRIAH (tisagenlecleucel), a CD19 CAR T cell product developed by
      Novartis and the University of Pennsylvania, was recently approved for clinical
      use by the Food and Drug Administration, representing a landmark in the
      application of adoptive T cell therapies. As CART19 enters routine clinical use, 
      improving the efficacy of this exciting platform is the next step in broader
      application. Novel gene-editing technologies like CRISPR-Cas9 allow facile
      editing of specific genes within the genome, generating a powerful platform to
      further optimize the activity of engineered T cells.
FAU - Singh, Nathan
AU  - Singh N
AD  - Center for Cellular Immunotherapies, Perelman School of Medicine at the
      University of Pennsylvania, Philadelphia, PA, USA.
AD  - Division of Hematology and Oncology, University of Pennsylvania, Philadelphia,
      PA, USA.
AD  - Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
FAU - Shi, Junwei
AU  - Shi J
AD  - Department of Pathology and Laboratory Medicine, Perelman School of Medicine at
      the University of Pennsylvania, Philadelphia, PA, USA.
FAU - June, Carl H
AU  - June CH
AD  - Center for Cellular Immunotherapies, Perelman School of Medicine at the
      University of Pennsylvania, Philadelphia, PA, USA.
AD  - Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
AD  - Department of Pathology and Laboratory Medicine, Perelman School of Medicine at
      the University of Pennsylvania, Philadelphia, PA, USA.
AD  - Parker Institute for Cancer Immunotherapy, University of Pennsylvania,
      Philadelphia, PA, USA.
FAU - Ruella, Marco
AU  - Ruella M
AD  - Center for Cellular Immunotherapies, Perelman School of Medicine at the
      University of Pennsylvania, Philadelphia, PA, USA. marco.ruella@uphs.upenn.edu.
AD  - Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
      marco.ruella@uphs.upenn.edu.
AD  - Department of Pathology and Laboratory Medicine, Perelman School of Medicine at
      the University of Pennsylvania, Philadelphia, PA, USA.
      marco.ruella@uphs.upenn.edu.
LA  - eng
GR  - K99 CA212302/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Hematol Malig Rep
JT  - Current hematologic malignancy reports
JID - 101262565
PMC - PMC5709224
MID - NIHMS913516
OTO - NOTNLM
OT  - Adoptive cell therapy
OT  - CRISPR-Cas9
OT  - Chimeric antigen receptor T cells (CART)
OT  - Gene-editing
OT  - Immunotherapy
OT  - PD-1
OT  - TALEN
OT  - Zinc-finger nucleases
EDAT- 2017/10/19 06:00
MHDA- 2017/10/19 06:00
CRDT- 2017/10/18 06:00
PMCR- 2018/12/01 00:00
PHST- 2018/12/01 00:00 [pmc-release]
PHST- 2017/10/19 06:00 [pubmed]
PHST- 2017/10/19 06:00 [medline]
PHST- 2017/10/18 06:00 [entrez]
AID - 10.1007/s11899-017-0417-7 [doi]
AID - 10.1007/s11899-017-0417-7 [pii]
PST - ppublish
SO  - Curr Hematol Malig Rep. 2017 Dec;12(6):522-529. doi: 10.1007/s11899-017-0417-7.

PMID- 29061641
OWN - NLM
STAT- In-Data-Review
LR  - 20180104
IS  - 1078-0432 (Print)
IS  - 1078-0432 (Linking)
VI  - 24
IP  - 1
DP  - 2018 Jan 1
TI  - Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively
      Targets HER2(+) Breast Cancer Metastasis to the Brain.
PG  - 95-105
LID - 10.1158/1078-0432.CCR-17-2041 [doi]
AB  - Purpose: Metastasis to the brain from breast cancer remains a significant
      clinical challenge, and may be targeted with CAR-based immunotherapy. CAR design 
      optimization for solid tumors is crucial due to the absence of truly restricted
      antigen expression and potential safety concerns with "on-target off-tumor"
      activity. Here, we have optimized HER2-CAR T cells for the treatment of breast to
      brain metastases, and determined optimal second-generation CAR design and route
      of administration for xenograft mouse models of breast metastatic brain tumors,
      including multifocal and leptomeningeal disease.Experimental Design: HER2-CAR
      constructs containing either CD28 or 4-1BB intracellular costimulatory signaling 
      domains were compared for functional activity in vitro by measuring cytokine
      production, T-cell proliferation, and tumor killing capacity. We also evaluated
      HER2-CAR T cells delivered by intravenous, local intratumoral, or regional
      intraventricular routes of administration using in vivo human xenograft models of
      breast cancer that have metastasized to the brain.Results: Here, we have shown
      that HER2-CARs containing the 4-1BB costimulatory domain confer improved tumor
      targeting with reduced T-cell exhaustion phenotype and enhanced proliferative
      capacity compared with HER2-CARs containing the CD28 costimulatory domain. Local 
      intracranial delivery of HER2-CARs showed potent in vivo antitumor activity in
      orthotopic xenograft models. Importantly, we demonstrated robust antitumor
      efficacy following regional intraventricular delivery of HER2-CAR T cells for the
      treatment of multifocal brain metastases and leptomeningeal disease.Conclusions: 
      Our study shows the importance of CAR design in defining an optimized CAR T cell,
      and highlights intraventricular delivery of HER2-CAR T cells for treating
      multifocal brain metastases. Clin Cancer Res; 24(1); 95-105. (c)2017 AACR.
CI  - (c)2017 American Association for Cancer Research.
FAU - Priceman, Saul J
AU  - Priceman SJ
AD  - Department of Hematology and Hematopoietic Cell Transplantation, City of Hope,
      Duarte, California.
AD  - T Cell Therapeutics Research Laboratory, City of Hope, Duarte, California.
FAU - Tilakawardane, Dileshni
AU  - Tilakawardane D
AD  - Department of Hematology and Hematopoietic Cell Transplantation, City of Hope,
      Duarte, California.
AD  - T Cell Therapeutics Research Laboratory, City of Hope, Duarte, California.
FAU - Jeang, Brook
AU  - Jeang B
AD  - Department of Hematology and Hematopoietic Cell Transplantation, City of Hope,
      Duarte, California.
AD  - T Cell Therapeutics Research Laboratory, City of Hope, Duarte, California.
FAU - Aguilar, Brenda
AU  - Aguilar B
AD  - Department of Hematology and Hematopoietic Cell Transplantation, City of Hope,
      Duarte, California.
AD  - T Cell Therapeutics Research Laboratory, City of Hope, Duarte, California.
FAU - Murad, John P
AU  - Murad JP
AD  - Department of Hematology and Hematopoietic Cell Transplantation, City of Hope,
      Duarte, California.
AD  - T Cell Therapeutics Research Laboratory, City of Hope, Duarte, California.
FAU - Park, Anthony K
AU  - Park AK
AD  - Department of Hematology and Hematopoietic Cell Transplantation, City of Hope,
      Duarte, California.
AD  - T Cell Therapeutics Research Laboratory, City of Hope, Duarte, California.
FAU - Chang, Wen-Chung
AU  - Chang WC
AD  - Department of Hematology and Hematopoietic Cell Transplantation, City of Hope,
      Duarte, California.
AD  - T Cell Therapeutics Research Laboratory, City of Hope, Duarte, California.
FAU - Ostberg, Julie R
AU  - Ostberg JR
AD  - Department of Hematology and Hematopoietic Cell Transplantation, City of Hope,
      Duarte, California.
AD  - T Cell Therapeutics Research Laboratory, City of Hope, Duarte, California.
FAU - Neman, Josh
AU  - Neman J
AD  - Department of Neurosurgery, Keck School of Medicine at University of Southern
      California, Los Angeles, California.
FAU - Jandial, Rahul
AU  - Jandial R
AD  - Division of Neurosurgery, Beckman Research Institute, City of Hope, Duarte,
      California.
FAU - Portnow, Jana
AU  - Portnow J
AD  - Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte,
      California.
FAU - Forman, Stephen J
AU  - Forman SJ
AD  - Department of Hematology and Hematopoietic Cell Transplantation, City of Hope,
      Duarte, California. sforman@coh.org cbrown@coh.org.
AD  - T Cell Therapeutics Research Laboratory, City of Hope, Duarte, California.
FAU - Brown, Christine E
AU  - Brown CE
AD  - Department of Hematology and Hematopoietic Cell Transplantation, City of Hope,
      Duarte, California. sforman@coh.org cbrown@coh.org.
AD  - T Cell Therapeutics Research Laboratory, City of Hope, Duarte, California.
LA  - eng
PT  - Journal Article
DEP - 20171023
PL  - United States
TA  - Clin Cancer Res
JT  - Clinical cancer research : an official journal of the American Association for
      Cancer Research
JID - 9502500
EDAT- 2017/10/25 06:00
MHDA- 2017/10/25 06:00
CRDT- 2017/10/25 06:00
PHST- 2017/07/19 00:00 [received]
PHST- 2017/09/13 00:00 [revised]
PHST- 2017/10/16 00:00 [accepted]
PHST- 2017/10/25 06:00 [pubmed]
PHST- 2017/10/25 06:00 [medline]
PHST- 2017/10/25 06:00 [entrez]
AID - 1078-0432.CCR-17-2041 [pii]
AID - 10.1158/1078-0432.CCR-17-2041 [doi]
PST - ppublish
SO  - Clin Cancer Res. 2018 Jan 1;24(1):95-105. doi: 10.1158/1078-0432.CCR-17-2041.
      Epub 2017 Oct 23.

PMID- 29147629
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20171219
IS  - 2162-4011 (Print)
IS  - 2162-4011 (Linking)
VI  - 6
IP  - 11
DP  - 2017
TI  - Trial watch: Immune checkpoint blockers for cancer therapy.
PG  - e1373237
LID - 10.1080/2162402X.2017.1373237 [doi]
AB  - Immune checkpoint blockers (ICBs) are literally revolutionizing the clinical
      management of an ever more diversified panel of oncological indications. Although
      considerable attention persists around the inhibition of cytotoxic T
      lymphocyte-associated protein 4 (CTLA4) and programmed cell death 1 (PDCD1, best 
      known as PD-1) signaling, several other co-inhibitory T-cell receptors are being 
      evaluated as potential targets for the development of novel ICBs. Moreover,
      substantial efforts are being devoted to the identification of biomarkers that
      reliably predict the likelihood of each patient to obtain clinical benefits from 
      ICBs in the absence of severe toxicity. Tailoring the delivery of specific ICBs
      or combinations thereof to selected patient populations in the context of
      precision medicine programs constitutes indeed a major objective of the future of
      ICB-based immunotherapy. Here, we discuss recent preclinical and clinical
      advances on the development of ICBs for oncological indications.
FAU - Vanpouille-Box, Claire
AU  - Vanpouille-Box C
AD  - Department of Radiation Oncology, Weill Cornell Medical College, New York, NY,
      USA.
FAU - Lhuillier, Claire
AU  - Lhuillier C
AD  - Department of Radiation Oncology, Weill Cornell Medical College, New York, NY,
      USA.
FAU - Bezu, Lucillia
AU  - Bezu L
AD  - Universite Paris Descartes/Paris V, Paris, France.
AD  - Universite Pierre et Marie Curie/Paris VI, Paris, France.
AD  - Equipe 11 labellisee Ligue contre le Cancer, Centre de Recherche des Cordeliers, 
      Paris, France.
AD  - INSERM, U1138, Paris, France.
AD  - Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer
      Institute, Villejuif, France.
FAU - Aranda, Fernando
AU  - Aranda F
AD  - Immunoreceptors of the Innate and Adaptive System Group, Institut
      d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
FAU - Yamazaki, Takahiro
AU  - Yamazaki T
AD  - Department of Radiation Oncology, Weill Cornell Medical College, New York, NY,
      USA.
FAU - Kepp, Oliver
AU  - Kepp O
AD  - Universite Paris Descartes/Paris V, Paris, France.
AD  - Universite Pierre et Marie Curie/Paris VI, Paris, France.
AD  - Equipe 11 labellisee Ligue contre le Cancer, Centre de Recherche des Cordeliers, 
      Paris, France.
AD  - INSERM, U1138, Paris, France.
AD  - Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer
      Institute, Villejuif, France.
FAU - Fucikova, Jitka
AU  - Fucikova J
AD  - Sotio a.c., Prague, Czech Republic.
AD  - Dept. of Immunology, 2nd Faculty of Medicine and University Hospital Motol,
      Charles University, Prague, Czech Republic.
FAU - Spisek, Radek
AU  - Spisek R
AD  - Sotio a.c., Prague, Czech Republic.
AD  - Dept. of Immunology, 2nd Faculty of Medicine and University Hospital Motol,
      Charles University, Prague, Czech Republic.
FAU - Demaria, Sandra
AU  - Demaria S
AD  - Department of Radiation Oncology, Weill Cornell Medical College, New York, NY,
      USA.
AD  - Sandra and Edward Meyer Cancer Center, New York, NY, USA.
FAU - Formenti, Silvia C
AU  - Formenti SC
AD  - Department of Radiation Oncology, Weill Cornell Medical College, New York, NY,
      USA.
AD  - Sandra and Edward Meyer Cancer Center, New York, NY, USA.
FAU - Zitvogel, Laurence
AU  - Zitvogel L
AD  - Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.
AD  - INSERM, U1015, Villejuif, France.
AD  - Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428,
      Villejuif, France.
AD  - Universite Paris Sud/Paris XI, Le Kremlin-Bicetre, France.
FAU - Kroemer, Guido
AU  - Kroemer G
AD  - Universite Paris Descartes/Paris V, Paris, France.
AD  - Universite Pierre et Marie Curie/Paris VI, Paris, France.
AD  - Equipe 11 labellisee Ligue contre le Cancer, Centre de Recherche des Cordeliers, 
      Paris, France.
AD  - INSERM, U1138, Paris, France.
AD  - Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer
      Institute, Villejuif, France.
AD  - Department of Women's and Children's Health, Karolinska Institute, Karolinska
      University Hospital, Stockholm, Sweden.
AD  - Pole de Biologie, Hopital Europeen George Pompidou, AP-HP, Paris, France.
FAU - Galluzzi, Lorenzo
AU  - Galluzzi L
AD  - Department of Radiation Oncology, Weill Cornell Medical College, New York, NY,
      USA.
AD  - Universite Paris Descartes/Paris V, Paris, France.
AD  - Sandra and Edward Meyer Cancer Center, New York, NY, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170831
PL  - United States
TA  - Oncoimmunology
JT  - Oncoimmunology
JID - 101570526
PMC - PMC5674958
OTO - NOTNLM
OT  - Atezolizumab
OT  - avelumab
OT  - durvalumab
OT  - ipilimumab
OT  - nivolumab
OT  - pembrolizumab
EDAT- 2017/11/18 06:00
MHDA- 2017/11/18 06:01
CRDT- 2017/11/18 06:00
PMCR- 2018/08/31 00:00
PHST- 2017/08/23 00:00 [received]
PHST- 2017/08/25 00:00 [accepted]
PHST- 2018/08/31 00:00 [pmc-release]
PHST- 2017/11/18 06:00 [entrez]
PHST- 2017/11/18 06:00 [pubmed]
PHST- 2017/11/18 06:01 [medline]
AID - 10.1080/2162402X.2017.1373237 [doi]
AID - 1373237 [pii]
PST - epublish
SO  - Oncoimmunology. 2017 Aug 31;6(11):e1373237. doi: 10.1080/2162402X.2017.1373237.
      eCollection 2017.

PMID- 29335551
OWN - NLM
STAT- In-Process
LR  - 20180123
IS  - 2041-1723 (Electronic)
IS  - 2041-1723 (Linking)
VI  - 9
IP  - 1
DP  - 2018 Jan 15
TI  - Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast
      activation to foster lung metastasis of liver cancer.
PG  - 191
LID - 10.1038/s41467-017-02583-0 [doi]
AB  - The communication between tumor-derived elements and stroma in the metastatic
      niche has a critical role in facilitating cancer metastasis. Yet, the mechanisms 
      tumor cells use to control metastatic niche formation are not fully understood.
      Here we report that in the lung metastatic niche, high-metastatic hepatocellular 
      carcinoma (HCC) cells exhibit a greater capacity to convert normal fibroblasts to
      cancer-associated fibroblasts (CAFs) than low-metastatic HCC cells. We show
      high-metastatic HCC cells secrete exosomal miR-1247-3p that directly targets
      B4GALT3, leading to activation of beta1-integrin-NF-kappaB signaling in
      fibroblasts. Activated CAFs further promote cancer progression by secreting
      pro-inflammatory cytokines, including IL-6 and IL-8. Clinical data show high
      serum exosomal miR-1247-3p levels correlate with lung metastasis in HCC patients.
      These results demonstrate intercellular crosstalk between tumor cells and
      fibroblasts is mediated by tumor-derived exosomes that control lung metastasis of
      HCC, providing potential targets for prevention and treatment of cancer
      metastasis.
FAU - Fang, Tian
AU  - Fang T
AD  - International Co-operation Laboratory on Signal Transduction, Eastern
      Hepatobiliary Surgery Institute, Second Military Medical University, Shanghai,
      200438, China.
FAU - Lv, Hongwei
AU  - Lv H
AD  - International Co-operation Laboratory on Signal Transduction, Eastern
      Hepatobiliary Surgery Institute, Second Military Medical University, Shanghai,
      200438, China.
FAU - Lv, Guishuai
AU  - Lv G
AD  - International Co-operation Laboratory on Signal Transduction, Eastern
      Hepatobiliary Surgery Institute, Second Military Medical University, Shanghai,
      200438, China.
AD  - National Center for Liver Cancer, Shanghai, 201805, China.
FAU - Li, Ting
AU  - Li T
AD  - International Co-operation Laboratory on Signal Transduction, Eastern
      Hepatobiliary Surgery Institute, Second Military Medical University, Shanghai,
      200438, China.
FAU - Wang, Changzheng
AU  - Wang C
AD  - International Co-operation Laboratory on Signal Transduction, Eastern
      Hepatobiliary Surgery Institute, Second Military Medical University, Shanghai,
      200438, China.
FAU - Han, Qin
AU  - Han Q
AD  - International Co-operation Laboratory on Signal Transduction, Eastern
      Hepatobiliary Surgery Institute, Second Military Medical University, Shanghai,
      200438, China.
FAU - Yu, Lexing
AU  - Yu L
AD  - International Co-operation Laboratory on Signal Transduction, Eastern
      Hepatobiliary Surgery Institute, Second Military Medical University, Shanghai,
      200438, China.
AD  - National Center for Liver Cancer, Shanghai, 201805, China.
FAU - Su, Bo
AU  - Su B
AD  - Central Laboratory, Shanghai Pulmonary Hospital, School of Medicine, Tongji
      University, Shanghai, 200433, China.
FAU - Guo, Linna
AU  - Guo L
AD  - International Co-operation Laboratory on Signal Transduction, Eastern
      Hepatobiliary Surgery Institute, Second Military Medical University, Shanghai,
      200438, China.
AD  - National Center for Liver Cancer, Shanghai, 201805, China.
FAU - Huang, Shanna
AU  - Huang S
AD  - International Co-operation Laboratory on Signal Transduction, Eastern
      Hepatobiliary Surgery Institute, Second Military Medical University, Shanghai,
      200438, China.
AD  - National Center for Liver Cancer, Shanghai, 201805, China.
FAU - Cao, Dan
AU  - Cao D
AD  - International Co-operation Laboratory on Signal Transduction, Eastern
      Hepatobiliary Surgery Institute, Second Military Medical University, Shanghai,
      200438, China.
AD  - National Center for Liver Cancer, Shanghai, 201805, China.
FAU - Tang, Liang
AU  - Tang L
AD  - International Co-operation Laboratory on Signal Transduction, Eastern
      Hepatobiliary Surgery Institute, Second Military Medical University, Shanghai,
      200438, China.
AD  - National Center for Liver Cancer, Shanghai, 201805, China.
FAU - Tang, Shanhua
AU  - Tang S
AD  - International Co-operation Laboratory on Signal Transduction, Eastern
      Hepatobiliary Surgery Institute, Second Military Medical University, Shanghai,
      200438, China.
AD  - National Center for Liver Cancer, Shanghai, 201805, China.
FAU - Wu, Mengchao
AU  - Wu M
AD  - International Co-operation Laboratory on Signal Transduction, Eastern
      Hepatobiliary Surgery Institute, Second Military Medical University, Shanghai,
      200438, China.
AD  - National Center for Liver Cancer, Shanghai, 201805, China.
FAU - Yang, Wen
AU  - Yang W
AD  - International Co-operation Laboratory on Signal Transduction, Eastern
      Hepatobiliary Surgery Institute, Second Military Medical University, Shanghai,
      200438, China. woodeasy66@hotmail.com.
AD  - National Center for Liver Cancer, Shanghai, 201805, China.
      woodeasy66@hotmail.com.
FAU - Wang, Hongyang
AU  - Wang H
AD  - International Co-operation Laboratory on Signal Transduction, Eastern
      Hepatobiliary Surgery Institute, Second Military Medical University, Shanghai,
      200438, China. hywangk@vip.sina.com.
AD  - National Center for Liver Cancer, Shanghai, 201805, China. hywangk@vip.sina.com.
AD  - State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute,
      Renji Hospital, Shanghai Jiaotong University, Shanghai, 200032, China.
      hywangk@vip.sina.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180115
PL  - England
TA  - Nat Commun
JT  - Nature communications
JID - 101528555
PMC - PMC5768693
EDAT- 2018/01/18 06:00
MHDA- 2018/01/18 06:00
CRDT- 2018/01/17 06:00
PHST- 2017/03/30 00:00 [received]
PHST- 2017/12/11 00:00 [accepted]
PHST- 2018/01/17 06:00 [entrez]
PHST- 2018/01/18 06:00 [pubmed]
PHST- 2018/01/18 06:00 [medline]
AID - 10.1038/s41467-017-02583-0 [doi]
AID - 10.1038/s41467-017-02583-0 [pii]
PST - epublish
SO  - Nat Commun. 2018 Jan 15;9(1):191. doi: 10.1038/s41467-017-02583-0.

PMID- 29156509
OWN - NLM
STAT- Publisher
LR  - 20171120
IS  - 1440-1746 (Electronic)
IS  - 0815-9319 (Linking)
DP  - 2017 Nov 20
TI  - The Role of Exosomes on Colorectal Cancer: a Review.
LID - 10.1111/jgh.14049 [doi]
AB  - Exosomes are extracellular microvesicles released from cells, which are involved 
      in many biological and pathological processes, mainly due to their role in
      intercellular communication. Exosomes derived from colorectal cancer (CRC) cells 
      are related to oncogenesis, tumor cell survival, chemo-resistance and metastasis.
      The role of the exosomes in these processes involves the transfer of proteins,
      RNAs or mutant versions of proto-oncogenes to the target cells. In recent years, 
      great efforts have been made to identify useful biomarkers in CRC exosomes for
      diagnosis, prediction of prognosis and treatment response. This review focuses on
      recent studies on CRC exosomes, considering isolation, cargo, biomarkers and the 
      effects of exosomes on the development and progression of CRC, including
      resistance to antitumor therapy.
CI  - This article is protected by copyright. All rights reserved.
FAU - Ruiz-Lopez, Lidia
AU  - Ruiz-Lopez L
AD  - Institute of Biopathology and Regenerative Medicine (IBIMER), University of
      Granada, Granada, Spain.
FAU - Blancas, Isabel
AU  - Blancas I
AD  - Institute of Biopathology and Regenerative Medicine (IBIMER), University of
      Granada, Granada, Spain.
AD  - Biosanitary Research Institute of Granada (ibs.GRANADA), Granada, Spain.
AD  - Department of Oncology, San Cecilio University Hospital, Granada, Spain.
FAU - Garrido, Jose M
AU  - Garrido JM
AD  - Institute of Biopathology and Regenerative Medicine (IBIMER), University of
      Granada, Granada, Spain.
AD  - Biosanitary Research Institute of Granada (ibs.GRANADA), Granada, Spain.
AD  - Department of Cardiovascular Surgery, Virgen de las Nieves University Hospital,
      Granada, Spain.
FAU - Mut-Salud, Nuria
AU  - Mut-Salud N
AD  - Institute of Biopathology and Regenerative Medicine (IBIMER), University of
      Granada, Granada, Spain.
FAU - Moya-Jodar, Marta
AU  - Moya-Jodar M
AD  - Institute of Biopathology and Regenerative Medicine (IBIMER), University of
      Granada, Granada, Spain.
FAU - Osuna, Antonio
AU  - Osuna A
AD  - Molecular Biochemistry and Parasitology Research Group, Department of
      Parasitology, Institute of Biotechnology, Faculty of Sciences, University of
      Granada, Granada, Spain.
FAU - Rodriguez-Serrano, Fernando
AU  - Rodriguez-Serrano F
AUID- ORCID: http://orcid.org/0000-0002-7105-4060
AD  - Institute of Biopathology and Regenerative Medicine (IBIMER), University of
      Granada, Granada, Spain.
AD  - Biosanitary Research Institute of Granada (ibs.GRANADA), Granada, Spain.
AD  - Department of Human Anatomy and Embryology, University of Granada, Granada,
      Spain.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20171120
PL  - Australia
TA  - J Gastroenterol Hepatol
JT  - Journal of gastroenterology and hepatology
JID - 8607909
OTO - NOTNLM
OT  - Exosomes
OT  - biomarkers
OT  - colorectal cancer
OT  - intercellular communication
OT  - oncogenic transformation
EDAT- 2017/11/21 06:00
MHDA- 2017/11/21 06:00
CRDT- 2017/11/21 06:00
PHST- 2017/03/05 00:00 [received]
PHST- 2017/11/09 00:00 [revised]
PHST- 2017/11/10 00:00 [accepted]
PHST- 2017/11/21 06:00 [entrez]
PHST- 2017/11/21 06:00 [pubmed]
PHST- 2017/11/21 06:00 [medline]
AID - 10.1111/jgh.14049 [doi]
PST - aheadofprint
SO  - J Gastroenterol Hepatol. 2017 Nov 20. doi: 10.1111/jgh.14049.

PMID- 29172863
OWN - NLM
STAT- Publisher
LR  - 20171127
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Linking)
DP  - 2017 Nov 27
TI  - Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer:
      American Society of Clinical Oncology Clinical Practice Guideline Update.
PG  - JCO2017757385
LID - 10.1200/JCO.2017.75.7385 [doi]
AB  - Purpose To update the guideline recommendations on the use of larynx-preservation
      strategies in the treatment of laryngeal cancer. Methods An Expert Panel updated 
      the systematic review of the literature for the period from January 2005 to May
      2017. Results The panel confirmed that the use of a larynx-preservation approach 
      for appropriately selected patients does not compromise survival. No
      larynx-preservation approach offered a survival advantage compared with total
      laryngectomy and adjuvant therapy as indicated. Changes were supported for the
      use of endoscopic surgical resection in patients with limited disease (T1, T2)
      and for initial total laryngectomy in patients with T4a disease or with severe
      pretreatment laryngeal dysfunction. New recommendations for positron emission
      tomography imaging for the evaluation of regional nodes after treatment and best 
      measures for evaluating voice and swallowing function were added. Recommendations
      Patients with T1, T2 laryngeal cancer should be treated initially with intent to 
      preserve the larynx by using endoscopic resection or radiation therapy, with
      either leading to similar outcomes. For patients with locally advanced (T3, T4)
      disease, organ-preservation surgery, combined chemotherapy and radiation, or
      radiation alone offer the potential for larynx preservation without compromising 
      overall survival. For selected patients with extensive T3 or large T4a lesions
      and/or poor pretreatment laryngeal function, better survival rates and quality of
      life may be achieved with total laryngectomy. Patients with clinically involved
      regional cervical nodes (N+) who have a complete clinical and radiologic imaging 
      response after chemoradiation do not require elective neck dissection. All
      patients should undergo a pretreatment baseline assessment of voice and
      swallowing function and receive counseling with regard to the potential impact of
      treatment options on voice, swallowing, and quality of life. Additional
      information is available at www.asco.org/head-neck-cancer-guidelines and
      www.asco.org/guidelineswiki .
FAU - Forastiere, Arlene A
AU  - Forastiere AA
AD  - Arlene A. Forastiere, The Sidney Kimmel Comprehensive Cancer Center at Johns
      Hopkins, Baltimore, MD; Nofisat Ismaila, American Society of Clinical Oncology,
      Alexandria, VA; Jan S. Lewin and Randy Weber, The University of Texas MD Anderson
      Cancer Center, Houston, TX; Cherie Ann Nathan, LSU Health, Shreveport, LA; David 
      J. Adelstein, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Avraham
      Eisbruch and Gregory T. Wolf, University of Michigan, Ann Arbor, MI; Gail Fass,
      Support for People With Oral Head and Neck Cancer, Locust Valley; Bernard
      O'Malley, Snehal Patel, and David G. Pfister, Memorial Sloan Kettering Cancer
      Center; Anthony F. Provenzano, New York-Presbyterian Lawrence Hospital, New York,
      NY; Susan G. Fisher, Temple University; Gregory S. Weinstein, University of
      Pennsylvania School of Medicine, Philadelphia, PA; Scott A. Laurie, The Ottawa
      Hospital Cancer Centre, Ottawa, Ontario, Canada; Quynh-Thu Le, Stanford
      University, Stanford, CA; and William M. Mendenhall, University of Florida,
      Gainesville, FL.
FAU - Ismaila, Nofisat
AU  - Ismaila N
AD  - Arlene A. Forastiere, The Sidney Kimmel Comprehensive Cancer Center at Johns
      Hopkins, Baltimore, MD; Nofisat Ismaila, American Society of Clinical Oncology,
      Alexandria, VA; Jan S. Lewin and Randy Weber, The University of Texas MD Anderson
      Cancer Center, Houston, TX; Cherie Ann Nathan, LSU Health, Shreveport, LA; David 
      J. Adelstein, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Avraham
      Eisbruch and Gregory T. Wolf, University of Michigan, Ann Arbor, MI; Gail Fass,
      Support for People With Oral Head and Neck Cancer, Locust Valley; Bernard
      O'Malley, Snehal Patel, and David G. Pfister, Memorial Sloan Kettering Cancer
      Center; Anthony F. Provenzano, New York-Presbyterian Lawrence Hospital, New York,
      NY; Susan G. Fisher, Temple University; Gregory S. Weinstein, University of
      Pennsylvania School of Medicine, Philadelphia, PA; Scott A. Laurie, The Ottawa
      Hospital Cancer Centre, Ottawa, Ontario, Canada; Quynh-Thu Le, Stanford
      University, Stanford, CA; and William M. Mendenhall, University of Florida,
      Gainesville, FL.
FAU - Lewin, Jan S
AU  - Lewin JS
AD  - Arlene A. Forastiere, The Sidney Kimmel Comprehensive Cancer Center at Johns
      Hopkins, Baltimore, MD; Nofisat Ismaila, American Society of Clinical Oncology,
      Alexandria, VA; Jan S. Lewin and Randy Weber, The University of Texas MD Anderson
      Cancer Center, Houston, TX; Cherie Ann Nathan, LSU Health, Shreveport, LA; David 
      J. Adelstein, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Avraham
      Eisbruch and Gregory T. Wolf, University of Michigan, Ann Arbor, MI; Gail Fass,
      Support for People With Oral Head and Neck Cancer, Locust Valley; Bernard
      O'Malley, Snehal Patel, and David G. Pfister, Memorial Sloan Kettering Cancer
      Center; Anthony F. Provenzano, New York-Presbyterian Lawrence Hospital, New York,
      NY; Susan G. Fisher, Temple University; Gregory S. Weinstein, University of
      Pennsylvania School of Medicine, Philadelphia, PA; Scott A. Laurie, The Ottawa
      Hospital Cancer Centre, Ottawa, Ontario, Canada; Quynh-Thu Le, Stanford
      University, Stanford, CA; and William M. Mendenhall, University of Florida,
      Gainesville, FL.
FAU - Nathan, Cherie Ann
AU  - Nathan CA
AD  - Arlene A. Forastiere, The Sidney Kimmel Comprehensive Cancer Center at Johns
      Hopkins, Baltimore, MD; Nofisat Ismaila, American Society of Clinical Oncology,
      Alexandria, VA; Jan S. Lewin and Randy Weber, The University of Texas MD Anderson
      Cancer Center, Houston, TX; Cherie Ann Nathan, LSU Health, Shreveport, LA; David 
      J. Adelstein, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Avraham
      Eisbruch and Gregory T. Wolf, University of Michigan, Ann Arbor, MI; Gail Fass,
      Support for People With Oral Head and Neck Cancer, Locust Valley; Bernard
      O'Malley, Snehal Patel, and David G. Pfister, Memorial Sloan Kettering Cancer
      Center; Anthony F. Provenzano, New York-Presbyterian Lawrence Hospital, New York,
      NY; Susan G. Fisher, Temple University; Gregory S. Weinstein, University of
      Pennsylvania School of Medicine, Philadelphia, PA; Scott A. Laurie, The Ottawa
      Hospital Cancer Centre, Ottawa, Ontario, Canada; Quynh-Thu Le, Stanford
      University, Stanford, CA; and William M. Mendenhall, University of Florida,
      Gainesville, FL.
FAU - Adelstein, David J
AU  - Adelstein DJ
AD  - Arlene A. Forastiere, The Sidney Kimmel Comprehensive Cancer Center at Johns
      Hopkins, Baltimore, MD; Nofisat Ismaila, American Society of Clinical Oncology,
      Alexandria, VA; Jan S. Lewin and Randy Weber, The University of Texas MD Anderson
      Cancer Center, Houston, TX; Cherie Ann Nathan, LSU Health, Shreveport, LA; David 
      J. Adelstein, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Avraham
      Eisbruch and Gregory T. Wolf, University of Michigan, Ann Arbor, MI; Gail Fass,
      Support for People With Oral Head and Neck Cancer, Locust Valley; Bernard
      O'Malley, Snehal Patel, and David G. Pfister, Memorial Sloan Kettering Cancer
      Center; Anthony F. Provenzano, New York-Presbyterian Lawrence Hospital, New York,
      NY; Susan G. Fisher, Temple University; Gregory S. Weinstein, University of
      Pennsylvania School of Medicine, Philadelphia, PA; Scott A. Laurie, The Ottawa
      Hospital Cancer Centre, Ottawa, Ontario, Canada; Quynh-Thu Le, Stanford
      University, Stanford, CA; and William M. Mendenhall, University of Florida,
      Gainesville, FL.
FAU - Eisbruch, Avraham
AU  - Eisbruch A
AD  - Arlene A. Forastiere, The Sidney Kimmel Comprehensive Cancer Center at Johns
      Hopkins, Baltimore, MD; Nofisat Ismaila, American Society of Clinical Oncology,
      Alexandria, VA; Jan S. Lewin and Randy Weber, The University of Texas MD Anderson
      Cancer Center, Houston, TX; Cherie Ann Nathan, LSU Health, Shreveport, LA; David 
      J. Adelstein, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Avraham
      Eisbruch and Gregory T. Wolf, University of Michigan, Ann Arbor, MI; Gail Fass,
      Support for People With Oral Head and Neck Cancer, Locust Valley; Bernard
      O'Malley, Snehal Patel, and David G. Pfister, Memorial Sloan Kettering Cancer
      Center; Anthony F. Provenzano, New York-Presbyterian Lawrence Hospital, New York,
      NY; Susan G. Fisher, Temple University; Gregory S. Weinstein, University of
      Pennsylvania School of Medicine, Philadelphia, PA; Scott A. Laurie, The Ottawa
      Hospital Cancer Centre, Ottawa, Ontario, Canada; Quynh-Thu Le, Stanford
      University, Stanford, CA; and William M. Mendenhall, University of Florida,
      Gainesville, FL.
FAU - Fass, Gail
AU  - Fass G
AD  - Arlene A. Forastiere, The Sidney Kimmel Comprehensive Cancer Center at Johns
      Hopkins, Baltimore, MD; Nofisat Ismaila, American Society of Clinical Oncology,
      Alexandria, VA; Jan S. Lewin and Randy Weber, The University of Texas MD Anderson
      Cancer Center, Houston, TX; Cherie Ann Nathan, LSU Health, Shreveport, LA; David 
      J. Adelstein, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Avraham
      Eisbruch and Gregory T. Wolf, University of Michigan, Ann Arbor, MI; Gail Fass,
      Support for People With Oral Head and Neck Cancer, Locust Valley; Bernard
      O'Malley, Snehal Patel, and David G. Pfister, Memorial Sloan Kettering Cancer
      Center; Anthony F. Provenzano, New York-Presbyterian Lawrence Hospital, New York,
      NY; Susan G. Fisher, Temple University; Gregory S. Weinstein, University of
      Pennsylvania School of Medicine, Philadelphia, PA; Scott A. Laurie, The Ottawa
      Hospital Cancer Centre, Ottawa, Ontario, Canada; Quynh-Thu Le, Stanford
      University, Stanford, CA; and William M. Mendenhall, University of Florida,
      Gainesville, FL.
FAU - Fisher, Susan G
AU  - Fisher SG
AD  - Arlene A. Forastiere, The Sidney Kimmel Comprehensive Cancer Center at Johns
      Hopkins, Baltimore, MD; Nofisat Ismaila, American Society of Clinical Oncology,
      Alexandria, VA; Jan S. Lewin and Randy Weber, The University of Texas MD Anderson
      Cancer Center, Houston, TX; Cherie Ann Nathan, LSU Health, Shreveport, LA; David 
      J. Adelstein, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Avraham
      Eisbruch and Gregory T. Wolf, University of Michigan, Ann Arbor, MI; Gail Fass,
      Support for People With Oral Head and Neck Cancer, Locust Valley; Bernard
      O'Malley, Snehal Patel, and David G. Pfister, Memorial Sloan Kettering Cancer
      Center; Anthony F. Provenzano, New York-Presbyterian Lawrence Hospital, New York,
      NY; Susan G. Fisher, Temple University; Gregory S. Weinstein, University of
      Pennsylvania School of Medicine, Philadelphia, PA; Scott A. Laurie, The Ottawa
      Hospital Cancer Centre, Ottawa, Ontario, Canada; Quynh-Thu Le, Stanford
      University, Stanford, CA; and William M. Mendenhall, University of Florida,
      Gainesville, FL.
FAU - Laurie, Scott A
AU  - Laurie SA
AD  - Arlene A. Forastiere, The Sidney Kimmel Comprehensive Cancer Center at Johns
      Hopkins, Baltimore, MD; Nofisat Ismaila, American Society of Clinical Oncology,
      Alexandria, VA; Jan S. Lewin and Randy Weber, The University of Texas MD Anderson
      Cancer Center, Houston, TX; Cherie Ann Nathan, LSU Health, Shreveport, LA; David 
      J. Adelstein, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Avraham
      Eisbruch and Gregory T. Wolf, University of Michigan, Ann Arbor, MI; Gail Fass,
      Support for People With Oral Head and Neck Cancer, Locust Valley; Bernard
      O'Malley, Snehal Patel, and David G. Pfister, Memorial Sloan Kettering Cancer
      Center; Anthony F. Provenzano, New York-Presbyterian Lawrence Hospital, New York,
      NY; Susan G. Fisher, Temple University; Gregory S. Weinstein, University of
      Pennsylvania School of Medicine, Philadelphia, PA; Scott A. Laurie, The Ottawa
      Hospital Cancer Centre, Ottawa, Ontario, Canada; Quynh-Thu Le, Stanford
      University, Stanford, CA; and William M. Mendenhall, University of Florida,
      Gainesville, FL.
FAU - Le, Quynh-Thu
AU  - Le QT
AD  - Arlene A. Forastiere, The Sidney Kimmel Comprehensive Cancer Center at Johns
      Hopkins, Baltimore, MD; Nofisat Ismaila, American Society of Clinical Oncology,
      Alexandria, VA; Jan S. Lewin and Randy Weber, The University of Texas MD Anderson
      Cancer Center, Houston, TX; Cherie Ann Nathan, LSU Health, Shreveport, LA; David 
      J. Adelstein, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Avraham
      Eisbruch and Gregory T. Wolf, University of Michigan, Ann Arbor, MI; Gail Fass,
      Support for People With Oral Head and Neck Cancer, Locust Valley; Bernard
      O'Malley, Snehal Patel, and David G. Pfister, Memorial Sloan Kettering Cancer
      Center; Anthony F. Provenzano, New York-Presbyterian Lawrence Hospital, New York,
      NY; Susan G. Fisher, Temple University; Gregory S. Weinstein, University of
      Pennsylvania School of Medicine, Philadelphia, PA; Scott A. Laurie, The Ottawa
      Hospital Cancer Centre, Ottawa, Ontario, Canada; Quynh-Thu Le, Stanford
      University, Stanford, CA; and William M. Mendenhall, University of Florida,
      Gainesville, FL.
FAU - O'Malley, Bernard
AU  - O'Malley B
AD  - Arlene A. Forastiere, The Sidney Kimmel Comprehensive Cancer Center at Johns
      Hopkins, Baltimore, MD; Nofisat Ismaila, American Society of Clinical Oncology,
      Alexandria, VA; Jan S. Lewin and Randy Weber, The University of Texas MD Anderson
      Cancer Center, Houston, TX; Cherie Ann Nathan, LSU Health, Shreveport, LA; David 
      J. Adelstein, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Avraham
      Eisbruch and Gregory T. Wolf, University of Michigan, Ann Arbor, MI; Gail Fass,
      Support for People With Oral Head and Neck Cancer, Locust Valley; Bernard
      O'Malley, Snehal Patel, and David G. Pfister, Memorial Sloan Kettering Cancer
      Center; Anthony F. Provenzano, New York-Presbyterian Lawrence Hospital, New York,
      NY; Susan G. Fisher, Temple University; Gregory S. Weinstein, University of
      Pennsylvania School of Medicine, Philadelphia, PA; Scott A. Laurie, The Ottawa
      Hospital Cancer Centre, Ottawa, Ontario, Canada; Quynh-Thu Le, Stanford
      University, Stanford, CA; and William M. Mendenhall, University of Florida,
      Gainesville, FL.
FAU - Mendenhall, William M
AU  - Mendenhall WM
AD  - Arlene A. Forastiere, The Sidney Kimmel Comprehensive Cancer Center at Johns
      Hopkins, Baltimore, MD; Nofisat Ismaila, American Society of Clinical Oncology,
      Alexandria, VA; Jan S. Lewin and Randy Weber, The University of Texas MD Anderson
      Cancer Center, Houston, TX; Cherie Ann Nathan, LSU Health, Shreveport, LA; David 
      J. Adelstein, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Avraham
      Eisbruch and Gregory T. Wolf, University of Michigan, Ann Arbor, MI; Gail Fass,
      Support for People With Oral Head and Neck Cancer, Locust Valley; Bernard
      O'Malley, Snehal Patel, and David G. Pfister, Memorial Sloan Kettering Cancer
      Center; Anthony F. Provenzano, New York-Presbyterian Lawrence Hospital, New York,
      NY; Susan G. Fisher, Temple University; Gregory S. Weinstein, University of
      Pennsylvania School of Medicine, Philadelphia, PA; Scott A. Laurie, The Ottawa
      Hospital Cancer Centre, Ottawa, Ontario, Canada; Quynh-Thu Le, Stanford
      University, Stanford, CA; and William M. Mendenhall, University of Florida,
      Gainesville, FL.
FAU - Patel, Snehal
AU  - Patel S
AD  - Arlene A. Forastiere, The Sidney Kimmel Comprehensive Cancer Center at Johns
      Hopkins, Baltimore, MD; Nofisat Ismaila, American Society of Clinical Oncology,
      Alexandria, VA; Jan S. Lewin and Randy Weber, The University of Texas MD Anderson
      Cancer Center, Houston, TX; Cherie Ann Nathan, LSU Health, Shreveport, LA; David 
      J. Adelstein, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Avraham
      Eisbruch and Gregory T. Wolf, University of Michigan, Ann Arbor, MI; Gail Fass,
      Support for People With Oral Head and Neck Cancer, Locust Valley; Bernard
      O'Malley, Snehal Patel, and David G. Pfister, Memorial Sloan Kettering Cancer
      Center; Anthony F. Provenzano, New York-Presbyterian Lawrence Hospital, New York,
      NY; Susan G. Fisher, Temple University; Gregory S. Weinstein, University of
      Pennsylvania School of Medicine, Philadelphia, PA; Scott A. Laurie, The Ottawa
      Hospital Cancer Centre, Ottawa, Ontario, Canada; Quynh-Thu Le, Stanford
      University, Stanford, CA; and William M. Mendenhall, University of Florida,
      Gainesville, FL.
FAU - Pfister, David G
AU  - Pfister DG
AD  - Arlene A. Forastiere, The Sidney Kimmel Comprehensive Cancer Center at Johns
      Hopkins, Baltimore, MD; Nofisat Ismaila, American Society of Clinical Oncology,
      Alexandria, VA; Jan S. Lewin and Randy Weber, The University of Texas MD Anderson
      Cancer Center, Houston, TX; Cherie Ann Nathan, LSU Health, Shreveport, LA; David 
      J. Adelstein, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Avraham
      Eisbruch and Gregory T. Wolf, University of Michigan, Ann Arbor, MI; Gail Fass,
      Support for People With Oral Head and Neck Cancer, Locust Valley; Bernard
      O'Malley, Snehal Patel, and David G. Pfister, Memorial Sloan Kettering Cancer
      Center; Anthony F. Provenzano, New York-Presbyterian Lawrence Hospital, New York,
      NY; Susan G. Fisher, Temple University; Gregory S. Weinstein, University of
      Pennsylvania School of Medicine, Philadelphia, PA; Scott A. Laurie, The Ottawa
      Hospital Cancer Centre, Ottawa, Ontario, Canada; Quynh-Thu Le, Stanford
      University, Stanford, CA; and William M. Mendenhall, University of Florida,
      Gainesville, FL.
FAU - Provenzano, Anthony F
AU  - Provenzano AF
AD  - Arlene A. Forastiere, The Sidney Kimmel Comprehensive Cancer Center at Johns
      Hopkins, Baltimore, MD; Nofisat Ismaila, American Society of Clinical Oncology,
      Alexandria, VA; Jan S. Lewin and Randy Weber, The University of Texas MD Anderson
      Cancer Center, Houston, TX; Cherie Ann Nathan, LSU Health, Shreveport, LA; David 
      J. Adelstein, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Avraham
      Eisbruch and Gregory T. Wolf, University of Michigan, Ann Arbor, MI; Gail Fass,
      Support for People With Oral Head and Neck Cancer, Locust Valley; Bernard
      O'Malley, Snehal Patel, and David G. Pfister, Memorial Sloan Kettering Cancer
      Center; Anthony F. Provenzano, New York-Presbyterian Lawrence Hospital, New York,
      NY; Susan G. Fisher, Temple University; Gregory S. Weinstein, University of
      Pennsylvania School of Medicine, Philadelphia, PA; Scott A. Laurie, The Ottawa
      Hospital Cancer Centre, Ottawa, Ontario, Canada; Quynh-Thu Le, Stanford
      University, Stanford, CA; and William M. Mendenhall, University of Florida,
      Gainesville, FL.
FAU - Weber, Randy
AU  - Weber R
AD  - Arlene A. Forastiere, The Sidney Kimmel Comprehensive Cancer Center at Johns
      Hopkins, Baltimore, MD; Nofisat Ismaila, American Society of Clinical Oncology,
      Alexandria, VA; Jan S. Lewin and Randy Weber, The University of Texas MD Anderson
      Cancer Center, Houston, TX; Cherie Ann Nathan, LSU Health, Shreveport, LA; David 
      J. Adelstein, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Avraham
      Eisbruch and Gregory T. Wolf, University of Michigan, Ann Arbor, MI; Gail Fass,
      Support for People With Oral Head and Neck Cancer, Locust Valley; Bernard
      O'Malley, Snehal Patel, and David G. Pfister, Memorial Sloan Kettering Cancer
      Center; Anthony F. Provenzano, New York-Presbyterian Lawrence Hospital, New York,
      NY; Susan G. Fisher, Temple University; Gregory S. Weinstein, University of
      Pennsylvania School of Medicine, Philadelphia, PA; Scott A. Laurie, The Ottawa
      Hospital Cancer Centre, Ottawa, Ontario, Canada; Quynh-Thu Le, Stanford
      University, Stanford, CA; and William M. Mendenhall, University of Florida,
      Gainesville, FL.
FAU - Weinstein, Gregory S
AU  - Weinstein GS
AD  - Arlene A. Forastiere, The Sidney Kimmel Comprehensive Cancer Center at Johns
      Hopkins, Baltimore, MD; Nofisat Ismaila, American Society of Clinical Oncology,
      Alexandria, VA; Jan S. Lewin and Randy Weber, The University of Texas MD Anderson
      Cancer Center, Houston, TX; Cherie Ann Nathan, LSU Health, Shreveport, LA; David 
      J. Adelstein, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Avraham
      Eisbruch and Gregory T. Wolf, University of Michigan, Ann Arbor, MI; Gail Fass,
      Support for People With Oral Head and Neck Cancer, Locust Valley; Bernard
      O'Malley, Snehal Patel, and David G. Pfister, Memorial Sloan Kettering Cancer
      Center; Anthony F. Provenzano, New York-Presbyterian Lawrence Hospital, New York,
      NY; Susan G. Fisher, Temple University; Gregory S. Weinstein, University of
      Pennsylvania School of Medicine, Philadelphia, PA; Scott A. Laurie, The Ottawa
      Hospital Cancer Centre, Ottawa, Ontario, Canada; Quynh-Thu Le, Stanford
      University, Stanford, CA; and William M. Mendenhall, University of Florida,
      Gainesville, FL.
FAU - Wolf, Gregory T
AU  - Wolf GT
AD  - Arlene A. Forastiere, The Sidney Kimmel Comprehensive Cancer Center at Johns
      Hopkins, Baltimore, MD; Nofisat Ismaila, American Society of Clinical Oncology,
      Alexandria, VA; Jan S. Lewin and Randy Weber, The University of Texas MD Anderson
      Cancer Center, Houston, TX; Cherie Ann Nathan, LSU Health, Shreveport, LA; David 
      J. Adelstein, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Avraham
      Eisbruch and Gregory T. Wolf, University of Michigan, Ann Arbor, MI; Gail Fass,
      Support for People With Oral Head and Neck Cancer, Locust Valley; Bernard
      O'Malley, Snehal Patel, and David G. Pfister, Memorial Sloan Kettering Cancer
      Center; Anthony F. Provenzano, New York-Presbyterian Lawrence Hospital, New York,
      NY; Susan G. Fisher, Temple University; Gregory S. Weinstein, University of
      Pennsylvania School of Medicine, Philadelphia, PA; Scott A. Laurie, The Ottawa
      Hospital Cancer Centre, Ottawa, Ontario, Canada; Quynh-Thu Le, Stanford
      University, Stanford, CA; and William M. Mendenhall, University of Florida,
      Gainesville, FL.
LA  - eng
PT  - Journal Article
DEP - 20171127
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of
      Clinical Oncology
JID - 8309333
EDAT- 2017/11/28 06:00
MHDA- 2017/11/28 06:00
CRDT- 2017/11/28 06:00
PHST- 2017/11/28 06:00 [entrez]
PHST- 2017/11/28 06:00 [pubmed]
PHST- 2017/11/28 06:00 [medline]
AID - 10.1200/JCO.2017.75.7385 [doi]
PST - aheadofprint
SO  - J Clin Oncol. 2017 Nov 27:JCO2017757385. doi: 10.1200/JCO.2017.75.7385.

PMID- 29320658
OWN - NLM
STAT- MEDLINE
DCOM- 20180112
LR  - 20180112
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 378
IP  - 2
DP  - 2018 Jan 11
TI  - Osimertinib as First-Line Treatment in EGFR-Mutated Non-Small-Cell Lung Cancer.
PG  - 192-193
LID - 10.1056/NEJMe1714580 [doi]
FAU - Popat, Sanjay
AU  - Popat S
AD  - From the Department of Medicine, Royal Marsden Hospital, and the Section of
      Genomic Medicine, National Heart and Lung Institute, Imperial College, London.
LA  - eng
PT  - Editorial
PT  - Comment
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Piperazines)
RN  - 3C06JJ0Z2O (osimertinib)
RN  - EC 2.7.10.1 (Receptor, Epidermal Growth Factor)
SB  - AIM
SB  - IM
CON - N Engl J Med. 2018 Jan 11;378(2):113-125. PMID: 29151359
MH  - *Carcinoma, Non-Small-Cell Lung
MH  - Humans
MH  - *Lung Neoplasms
MH  - Piperazines
MH  - Receptor, Epidermal Growth Factor
EDAT- 2018/01/11 06:00
MHDA- 2018/01/13 06:00
CRDT- 2018/01/11 06:00
PHST- 2018/01/11 06:00 [entrez]
PHST- 2018/01/11 06:00 [pubmed]
PHST- 2018/01/13 06:00 [medline]
AID - 10.1056/NEJMe1714580 [doi]
PST - ppublish
SO  - N Engl J Med. 2018 Jan 11;378(2):192-193. doi: 10.1056/NEJMe1714580.

PMID- 29136387
OWN - NLM
STAT- In-Data-Review
LR  - 20180129
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Linking)
VI  - 36
IP  - 4
DP  - 2018 Feb 1
TI  - Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus
      Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast
      Cancer: SWOG S1202.
PG  - 326-332
LID - 10.1200/JCO.2017.74.6651 [doi]
AB  - Purpose Adherence to aromatase inhibitor (AI) therapy for early-stage breast
      cancer is limited by AI-associated musculoskeletal symptoms (AIMSS). Duloxetine
      is US Food and Drug Administration approved for treatment of multiple chronic
      pain disorders. We hypothesized that treatment of AIMSS with duloxetine would
      improve average joint pain compared with placebo. Methods This randomized,
      double-blind, phase III trial included AI-treated postmenopausal women with
      early-stage breast cancer and who had average joint pain score of >/= 4 out of 10
      that developed or worsened since AI therapy initiation. Patients were randomly
      assigned 1:1 to duloxetine or placebo for 13 weeks. The primary end point was
      average joint pain through 12 weeks, examined using multivariable linear mixed
      models, adjusted for stratification factors (baseline pain score of 4 to 6 v 7 to
      10 and prior taxane use). Clinically significant change in average pain was
      defined as a >/= 2-point decrease from baseline. Results Of 299 enrolled
      patients, 127 patients treated with duloxetine and 128 who received placebo were 
      evaluable for the primary analysis. By 12 weeks, the average joint pain score was
      0.82 points lower for patients who received duloxetine compared with those who
      received placebo (95% CI, -1.24 to -0.40; P = .0002). Similar patterns were
      observed for worst joint pain, joint stiffness, pain interference, and
      functioning. Rates of adverse events of any grade were higher in the
      duloxetine-treated group (78% v 50%); rates of grade 3 adverse events were
      similar. Conclusion Results of treatment with duloxetine for AIMSS were superior 
      to those of placebo among women with early-stage breast cancer, although it
      resulted in more frequent low-grade toxicities.
FAU - Henry, N Lynn
AU  - Henry NL
AD  - N. Lynn Henry and Anne F. Schott, University of Michigan, Ann Arbor, MI; N. Lynn 
      Henry, University of Utah Huntsman Cancer Institute, Salt Lake City, UT; Joseph
      M. Unger, Anna Moseley, and Danika L. Lew, Southwest Oncology Group Statistical
      Center and Fred Hutchinson Cancer Research Center; Carol M. Moinpour, Fred
      Hutchinson Cancer Research Center, Seattle, WA; Louis Fehrenbacher, Kaiser
      Permanente National Cancer Institute Community Oncology Research Program,
      Oakland, CA; Patrick J. Flynn, Metro Minnesota Community Clinical Oncology
      Program/Minnesota Oncology, St Louis Park, MN; Debra M. Prow, William R. Bliss
      Cancer Center, Ames, IA; Carl W. Sharer, Phoenixville Cancer Center,
      Phoenixville, PA; Gary V. Burton, Louisiana State University Health Science
      Center-Shreveport, Shreveport, LA; Charles S. Kuzma, FirstHealth of the
      Carolinas, Pinehurst, NC; Michael J. Fisch, AIM Specialty Health, Chicago, IL;
      Dawn L. Hershman, Columbia University, New York, NY; and James L. Wade III,
      Heartland National Cancer Institute Community Oncology Research Program, Decatur,
      IL.
FAU - Unger, Joseph M
AU  - Unger JM
AD  - N. Lynn Henry and Anne F. Schott, University of Michigan, Ann Arbor, MI; N. Lynn 
      Henry, University of Utah Huntsman Cancer Institute, Salt Lake City, UT; Joseph
      M. Unger, Anna Moseley, and Danika L. Lew, Southwest Oncology Group Statistical
      Center and Fred Hutchinson Cancer Research Center; Carol M. Moinpour, Fred
      Hutchinson Cancer Research Center, Seattle, WA; Louis Fehrenbacher, Kaiser
      Permanente National Cancer Institute Community Oncology Research Program,
      Oakland, CA; Patrick J. Flynn, Metro Minnesota Community Clinical Oncology
      Program/Minnesota Oncology, St Louis Park, MN; Debra M. Prow, William R. Bliss
      Cancer Center, Ames, IA; Carl W. Sharer, Phoenixville Cancer Center,
      Phoenixville, PA; Gary V. Burton, Louisiana State University Health Science
      Center-Shreveport, Shreveport, LA; Charles S. Kuzma, FirstHealth of the
      Carolinas, Pinehurst, NC; Michael J. Fisch, AIM Specialty Health, Chicago, IL;
      Dawn L. Hershman, Columbia University, New York, NY; and James L. Wade III,
      Heartland National Cancer Institute Community Oncology Research Program, Decatur,
      IL.
FAU - Schott, Anne F
AU  - Schott AF
AD  - N. Lynn Henry and Anne F. Schott, University of Michigan, Ann Arbor, MI; N. Lynn 
      Henry, University of Utah Huntsman Cancer Institute, Salt Lake City, UT; Joseph
      M. Unger, Anna Moseley, and Danika L. Lew, Southwest Oncology Group Statistical
      Center and Fred Hutchinson Cancer Research Center; Carol M. Moinpour, Fred
      Hutchinson Cancer Research Center, Seattle, WA; Louis Fehrenbacher, Kaiser
      Permanente National Cancer Institute Community Oncology Research Program,
      Oakland, CA; Patrick J. Flynn, Metro Minnesota Community Clinical Oncology
      Program/Minnesota Oncology, St Louis Park, MN; Debra M. Prow, William R. Bliss
      Cancer Center, Ames, IA; Carl W. Sharer, Phoenixville Cancer Center,
      Phoenixville, PA; Gary V. Burton, Louisiana State University Health Science
      Center-Shreveport, Shreveport, LA; Charles S. Kuzma, FirstHealth of the
      Carolinas, Pinehurst, NC; Michael J. Fisch, AIM Specialty Health, Chicago, IL;
      Dawn L. Hershman, Columbia University, New York, NY; and James L. Wade III,
      Heartland National Cancer Institute Community Oncology Research Program, Decatur,
      IL.
FAU - Fehrenbacher, Louis
AU  - Fehrenbacher L
AD  - N. Lynn Henry and Anne F. Schott, University of Michigan, Ann Arbor, MI; N. Lynn 
      Henry, University of Utah Huntsman Cancer Institute, Salt Lake City, UT; Joseph
      M. Unger, Anna Moseley, and Danika L. Lew, Southwest Oncology Group Statistical
      Center and Fred Hutchinson Cancer Research Center; Carol M. Moinpour, Fred
      Hutchinson Cancer Research Center, Seattle, WA; Louis Fehrenbacher, Kaiser
      Permanente National Cancer Institute Community Oncology Research Program,
      Oakland, CA; Patrick J. Flynn, Metro Minnesota Community Clinical Oncology
      Program/Minnesota Oncology, St Louis Park, MN; Debra M. Prow, William R. Bliss
      Cancer Center, Ames, IA; Carl W. Sharer, Phoenixville Cancer Center,
      Phoenixville, PA; Gary V. Burton, Louisiana State University Health Science
      Center-Shreveport, Shreveport, LA; Charles S. Kuzma, FirstHealth of the
      Carolinas, Pinehurst, NC; Michael J. Fisch, AIM Specialty Health, Chicago, IL;
      Dawn L. Hershman, Columbia University, New York, NY; and James L. Wade III,
      Heartland National Cancer Institute Community Oncology Research Program, Decatur,
      IL.
FAU - Flynn, Patrick J
AU  - Flynn PJ
AD  - N. Lynn Henry and Anne F. Schott, University of Michigan, Ann Arbor, MI; N. Lynn 
      Henry, University of Utah Huntsman Cancer Institute, Salt Lake City, UT; Joseph
      M. Unger, Anna Moseley, and Danika L. Lew, Southwest Oncology Group Statistical
      Center and Fred Hutchinson Cancer Research Center; Carol M. Moinpour, Fred
      Hutchinson Cancer Research Center, Seattle, WA; Louis Fehrenbacher, Kaiser
      Permanente National Cancer Institute Community Oncology Research Program,
      Oakland, CA; Patrick J. Flynn, Metro Minnesota Community Clinical Oncology
      Program/Minnesota Oncology, St Louis Park, MN; Debra M. Prow, William R. Bliss
      Cancer Center, Ames, IA; Carl W. Sharer, Phoenixville Cancer Center,
      Phoenixville, PA; Gary V. Burton, Louisiana State University Health Science
      Center-Shreveport, Shreveport, LA; Charles S. Kuzma, FirstHealth of the
      Carolinas, Pinehurst, NC; Michael J. Fisch, AIM Specialty Health, Chicago, IL;
      Dawn L. Hershman, Columbia University, New York, NY; and James L. Wade III,
      Heartland National Cancer Institute Community Oncology Research Program, Decatur,
      IL.
FAU - Prow, Debra M
AU  - Prow DM
AD  - N. Lynn Henry and Anne F. Schott, University of Michigan, Ann Arbor, MI; N. Lynn 
      Henry, University of Utah Huntsman Cancer Institute, Salt Lake City, UT; Joseph
      M. Unger, Anna Moseley, and Danika L. Lew, Southwest Oncology Group Statistical
      Center and Fred Hutchinson Cancer Research Center; Carol M. Moinpour, Fred
      Hutchinson Cancer Research Center, Seattle, WA; Louis Fehrenbacher, Kaiser
      Permanente National Cancer Institute Community Oncology Research Program,
      Oakland, CA; Patrick J. Flynn, Metro Minnesota Community Clinical Oncology
      Program/Minnesota Oncology, St Louis Park, MN; Debra M. Prow, William R. Bliss
      Cancer Center, Ames, IA; Carl W. Sharer, Phoenixville Cancer Center,
      Phoenixville, PA; Gary V. Burton, Louisiana State University Health Science
      Center-Shreveport, Shreveport, LA; Charles S. Kuzma, FirstHealth of the
      Carolinas, Pinehurst, NC; Michael J. Fisch, AIM Specialty Health, Chicago, IL;
      Dawn L. Hershman, Columbia University, New York, NY; and James L. Wade III,
      Heartland National Cancer Institute Community Oncology Research Program, Decatur,
      IL.
FAU - Sharer, Carl W
AU  - Sharer CW
AD  - N. Lynn Henry and Anne F. Schott, University of Michigan, Ann Arbor, MI; N. Lynn 
      Henry, University of Utah Huntsman Cancer Institute, Salt Lake City, UT; Joseph
      M. Unger, Anna Moseley, and Danika L. Lew, Southwest Oncology Group Statistical
      Center and Fred Hutchinson Cancer Research Center; Carol M. Moinpour, Fred
      Hutchinson Cancer Research Center, Seattle, WA; Louis Fehrenbacher, Kaiser
      Permanente National Cancer Institute Community Oncology Research Program,
      Oakland, CA; Patrick J. Flynn, Metro Minnesota Community Clinical Oncology
      Program/Minnesota Oncology, St Louis Park, MN; Debra M. Prow, William R. Bliss
      Cancer Center, Ames, IA; Carl W. Sharer, Phoenixville Cancer Center,
      Phoenixville, PA; Gary V. Burton, Louisiana State University Health Science
      Center-Shreveport, Shreveport, LA; Charles S. Kuzma, FirstHealth of the
      Carolinas, Pinehurst, NC; Michael J. Fisch, AIM Specialty Health, Chicago, IL;
      Dawn L. Hershman, Columbia University, New York, NY; and James L. Wade III,
      Heartland National Cancer Institute Community Oncology Research Program, Decatur,
      IL.
FAU - Burton, Gary V
AU  - Burton GV
AD  - N. Lynn Henry and Anne F. Schott, University of Michigan, Ann Arbor, MI; N. Lynn 
      Henry, University of Utah Huntsman Cancer Institute, Salt Lake City, UT; Joseph
      M. Unger, Anna Moseley, and Danika L. Lew, Southwest Oncology Group Statistical
      Center and Fred Hutchinson Cancer Research Center; Carol M. Moinpour, Fred
      Hutchinson Cancer Research Center, Seattle, WA; Louis Fehrenbacher, Kaiser
      Permanente National Cancer Institute Community Oncology Research Program,
      Oakland, CA; Patrick J. Flynn, Metro Minnesota Community Clinical Oncology
      Program/Minnesota Oncology, St Louis Park, MN; Debra M. Prow, William R. Bliss
      Cancer Center, Ames, IA; Carl W. Sharer, Phoenixville Cancer Center,
      Phoenixville, PA; Gary V. Burton, Louisiana State University Health Science
      Center-Shreveport, Shreveport, LA; Charles S. Kuzma, FirstHealth of the
      Carolinas, Pinehurst, NC; Michael J. Fisch, AIM Specialty Health, Chicago, IL;
      Dawn L. Hershman, Columbia University, New York, NY; and James L. Wade III,
      Heartland National Cancer Institute Community Oncology Research Program, Decatur,
      IL.
FAU - Kuzma, Charles S
AU  - Kuzma CS
AD  - N. Lynn Henry and Anne F. Schott, University of Michigan, Ann Arbor, MI; N. Lynn 
      Henry, University of Utah Huntsman Cancer Institute, Salt Lake City, UT; Joseph
      M. Unger, Anna Moseley, and Danika L. Lew, Southwest Oncology Group Statistical
      Center and Fred Hutchinson Cancer Research Center; Carol M. Moinpour, Fred
      Hutchinson Cancer Research Center, Seattle, WA; Louis Fehrenbacher, Kaiser
      Permanente National Cancer Institute Community Oncology Research Program,
      Oakland, CA; Patrick J. Flynn, Metro Minnesota Community Clinical Oncology
      Program/Minnesota Oncology, St Louis Park, MN; Debra M. Prow, William R. Bliss
      Cancer Center, Ames, IA; Carl W. Sharer, Phoenixville Cancer Center,
      Phoenixville, PA; Gary V. Burton, Louisiana State University Health Science
      Center-Shreveport, Shreveport, LA; Charles S. Kuzma, FirstHealth of the
      Carolinas, Pinehurst, NC; Michael J. Fisch, AIM Specialty Health, Chicago, IL;
      Dawn L. Hershman, Columbia University, New York, NY; and James L. Wade III,
      Heartland National Cancer Institute Community Oncology Research Program, Decatur,
      IL.
FAU - Moseley, Anna
AU  - Moseley A
AD  - N. Lynn Henry and Anne F. Schott, University of Michigan, Ann Arbor, MI; N. Lynn 
      Henry, University of Utah Huntsman Cancer Institute, Salt Lake City, UT; Joseph
      M. Unger, Anna Moseley, and Danika L. Lew, Southwest Oncology Group Statistical
      Center and Fred Hutchinson Cancer Research Center; Carol M. Moinpour, Fred
      Hutchinson Cancer Research Center, Seattle, WA; Louis Fehrenbacher, Kaiser
      Permanente National Cancer Institute Community Oncology Research Program,
      Oakland, CA; Patrick J. Flynn, Metro Minnesota Community Clinical Oncology
      Program/Minnesota Oncology, St Louis Park, MN; Debra M. Prow, William R. Bliss
      Cancer Center, Ames, IA; Carl W. Sharer, Phoenixville Cancer Center,
      Phoenixville, PA; Gary V. Burton, Louisiana State University Health Science
      Center-Shreveport, Shreveport, LA; Charles S. Kuzma, FirstHealth of the
      Carolinas, Pinehurst, NC; Michael J. Fisch, AIM Specialty Health, Chicago, IL;
      Dawn L. Hershman, Columbia University, New York, NY; and James L. Wade III,
      Heartland National Cancer Institute Community Oncology Research Program, Decatur,
      IL.
FAU - Lew, Danika L
AU  - Lew DL
AD  - N. Lynn Henry and Anne F. Schott, University of Michigan, Ann Arbor, MI; N. Lynn 
      Henry, University of Utah Huntsman Cancer Institute, Salt Lake City, UT; Joseph
      M. Unger, Anna Moseley, and Danika L. Lew, Southwest Oncology Group Statistical
      Center and Fred Hutchinson Cancer Research Center; Carol M. Moinpour, Fred
      Hutchinson Cancer Research Center, Seattle, WA; Louis Fehrenbacher, Kaiser
      Permanente National Cancer Institute Community Oncology Research Program,
      Oakland, CA; Patrick J. Flynn, Metro Minnesota Community Clinical Oncology
      Program/Minnesota Oncology, St Louis Park, MN; Debra M. Prow, William R. Bliss
      Cancer Center, Ames, IA; Carl W. Sharer, Phoenixville Cancer Center,
      Phoenixville, PA; Gary V. Burton, Louisiana State University Health Science
      Center-Shreveport, Shreveport, LA; Charles S. Kuzma, FirstHealth of the
      Carolinas, Pinehurst, NC; Michael J. Fisch, AIM Specialty Health, Chicago, IL;
      Dawn L. Hershman, Columbia University, New York, NY; and James L. Wade III,
      Heartland National Cancer Institute Community Oncology Research Program, Decatur,
      IL.
FAU - Fisch, Michael J
AU  - Fisch MJ
AD  - N. Lynn Henry and Anne F. Schott, University of Michigan, Ann Arbor, MI; N. Lynn 
      Henry, University of Utah Huntsman Cancer Institute, Salt Lake City, UT; Joseph
      M. Unger, Anna Moseley, and Danika L. Lew, Southwest Oncology Group Statistical
      Center and Fred Hutchinson Cancer Research Center; Carol M. Moinpour, Fred
      Hutchinson Cancer Research Center, Seattle, WA; Louis Fehrenbacher, Kaiser
      Permanente National Cancer Institute Community Oncology Research Program,
      Oakland, CA; Patrick J. Flynn, Metro Minnesota Community Clinical Oncology
      Program/Minnesota Oncology, St Louis Park, MN; Debra M. Prow, William R. Bliss
      Cancer Center, Ames, IA; Carl W. Sharer, Phoenixville Cancer Center,
      Phoenixville, PA; Gary V. Burton, Louisiana State University Health Science
      Center-Shreveport, Shreveport, LA; Charles S. Kuzma, FirstHealth of the
      Carolinas, Pinehurst, NC; Michael J. Fisch, AIM Specialty Health, Chicago, IL;
      Dawn L. Hershman, Columbia University, New York, NY; and James L. Wade III,
      Heartland National Cancer Institute Community Oncology Research Program, Decatur,
      IL.
FAU - Moinpour, Carol M
AU  - Moinpour CM
AD  - N. Lynn Henry and Anne F. Schott, University of Michigan, Ann Arbor, MI; N. Lynn 
      Henry, University of Utah Huntsman Cancer Institute, Salt Lake City, UT; Joseph
      M. Unger, Anna Moseley, and Danika L. Lew, Southwest Oncology Group Statistical
      Center and Fred Hutchinson Cancer Research Center; Carol M. Moinpour, Fred
      Hutchinson Cancer Research Center, Seattle, WA; Louis Fehrenbacher, Kaiser
      Permanente National Cancer Institute Community Oncology Research Program,
      Oakland, CA; Patrick J. Flynn, Metro Minnesota Community Clinical Oncology
      Program/Minnesota Oncology, St Louis Park, MN; Debra M. Prow, William R. Bliss
      Cancer Center, Ames, IA; Carl W. Sharer, Phoenixville Cancer Center,
      Phoenixville, PA; Gary V. Burton, Louisiana State University Health Science
      Center-Shreveport, Shreveport, LA; Charles S. Kuzma, FirstHealth of the
      Carolinas, Pinehurst, NC; Michael J. Fisch, AIM Specialty Health, Chicago, IL;
      Dawn L. Hershman, Columbia University, New York, NY; and James L. Wade III,
      Heartland National Cancer Institute Community Oncology Research Program, Decatur,
      IL.
FAU - Hershman, Dawn L
AU  - Hershman DL
AD  - N. Lynn Henry and Anne F. Schott, University of Michigan, Ann Arbor, MI; N. Lynn 
      Henry, University of Utah Huntsman Cancer Institute, Salt Lake City, UT; Joseph
      M. Unger, Anna Moseley, and Danika L. Lew, Southwest Oncology Group Statistical
      Center and Fred Hutchinson Cancer Research Center; Carol M. Moinpour, Fred
      Hutchinson Cancer Research Center, Seattle, WA; Louis Fehrenbacher, Kaiser
      Permanente National Cancer Institute Community Oncology Research Program,
      Oakland, CA; Patrick J. Flynn, Metro Minnesota Community Clinical Oncology
      Program/Minnesota Oncology, St Louis Park, MN; Debra M. Prow, William R. Bliss
      Cancer Center, Ames, IA; Carl W. Sharer, Phoenixville Cancer Center,
      Phoenixville, PA; Gary V. Burton, Louisiana State University Health Science
      Center-Shreveport, Shreveport, LA; Charles S. Kuzma, FirstHealth of the
      Carolinas, Pinehurst, NC; Michael J. Fisch, AIM Specialty Health, Chicago, IL;
      Dawn L. Hershman, Columbia University, New York, NY; and James L. Wade III,
      Heartland National Cancer Institute Community Oncology Research Program, Decatur,
      IL.
FAU - Wade, James L 3rd
AU  - Wade JL 3rd
AD  - N. Lynn Henry and Anne F. Schott, University of Michigan, Ann Arbor, MI; N. Lynn 
      Henry, University of Utah Huntsman Cancer Institute, Salt Lake City, UT; Joseph
      M. Unger, Anna Moseley, and Danika L. Lew, Southwest Oncology Group Statistical
      Center and Fred Hutchinson Cancer Research Center; Carol M. Moinpour, Fred
      Hutchinson Cancer Research Center, Seattle, WA; Louis Fehrenbacher, Kaiser
      Permanente National Cancer Institute Community Oncology Research Program,
      Oakland, CA; Patrick J. Flynn, Metro Minnesota Community Clinical Oncology
      Program/Minnesota Oncology, St Louis Park, MN; Debra M. Prow, William R. Bliss
      Cancer Center, Ames, IA; Carl W. Sharer, Phoenixville Cancer Center,
      Phoenixville, PA; Gary V. Burton, Louisiana State University Health Science
      Center-Shreveport, Shreveport, LA; Charles S. Kuzma, FirstHealth of the
      Carolinas, Pinehurst, NC; Michael J. Fisch, AIM Specialty Health, Chicago, IL;
      Dawn L. Hershman, Columbia University, New York, NY; and James L. Wade III,
      Heartland National Cancer Institute Community Oncology Research Program, Decatur,
      IL.
LA  - eng
GR  - U10 CA180818/CA/NCI NIH HHS/United States
GR  - UG1 CA189974/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20171114
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of
      Clinical Oncology
JID - 8309333
EDAT- 2017/11/15 06:00
MHDA- 2017/11/15 06:00
CRDT- 2017/11/15 06:00
PHST- 2017/11/15 06:00 [pubmed]
PHST- 2017/11/15 06:00 [medline]
PHST- 2017/11/15 06:00 [entrez]
AID - 10.1200/JCO.2017.74.6651 [doi]
PST - ppublish
SO  - J Clin Oncol. 2018 Feb 1;36(4):326-332. doi: 10.1200/JCO.2017.74.6651. Epub 2017 
      Nov 14.

PMID- 29320480
OWN - NLM
STAT- In-Data-Review
LR  - 20180120
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 553
IP  - 7688
DP  - 2018 Jan 18
TI  - Pharmacological activation of REV-ERBs is lethal in cancer and oncogene-induced
      senescence.
PG  - 351-355
LID - 10.1038/nature25170 [doi]
AB  - The circadian clock imposes daily rhythms in cell proliferation, metabolism,
      inflammation and DNA damage response. Perturbations of these processes are
      hallmarks of cancer and chronic circadian rhythm disruption predisposes
      individuals to tumour development. This raises the hypothesis that
      pharmacological modulation of the circadian machinery may be an effective
      therapeutic strategy for combating cancer. REV-ERBs, the nuclear hormone
      receptors REV-ERBalpha (also known as NR1D1) and REV-ERBbeta (also known as
      NR1D2), are essential components of the circadian clock. Here we show that two
      agonists of REV-ERBs-SR9009 and SR9011-are specifically lethal to cancer cells
      and oncogene-induced senescent cells, including melanocytic naevi, and have no
      effect on the viability of normal cells or tissues. The anticancer activity of
      SR9009 and SR9011 affects a number of oncogenic drivers (such as HRAS, BRAF,
      PIK3CA and others) and persists in the absence of p53 and under hypoxic
      conditions. The regulation of autophagy and de novo lipogenesis by SR9009 and
      SR9011 has a critical role in evoking an apoptotic response in malignant cells.
      Notably, the selective anticancer properties of these REV-ERB agonists impair
      glioblastoma growth in vivo and improve survival without causing overt toxicity
      in mice. These results indicate that pharmacological modulation of circadian
      regulators is an effective antitumour strategy, identifying a class of anticancer
      agents with a wide therapeutic window. We propose that REV-ERB agonists are
      inhibitors of autophagy and de novo lipogenesis, with selective activity towards 
      malignant and benign neoplasms.
FAU - Sulli, Gabriele
AU  - Sulli G
AD  - Regulatory Biology Laboratory, Salk Institute for Biological Studies, La Jolla,
      California 92037, USA.
FAU - Rommel, Amy
AU  - Rommel A
AD  - Laboratory of Genetics, Salk Institute for Biological Studies, La Jolla,
      California 92037, USA.
FAU - Wang, Xiaojie
AU  - Wang X
AD  - Department of Developmental and Cell Biology, University of California, Irvine,
      Irvine, California 92697, USA.
FAU - Kolar, Matthew J
AU  - Kolar MJ
AD  - Clayton Foundation Laboratories of Peptide Biology, Salk Institute for Biological
      Studies, La Jolla, California 92037, USA.
FAU - Puca, Francesca
AU  - Puca F
AD  - Department of Genomic Medicine, The University of Texas MD, Anderson Cancer
      Center, Houston, Texas 77030, USA.
FAU - Saghatelian, Alan
AU  - Saghatelian A
AD  - Clayton Foundation Laboratories of Peptide Biology, Salk Institute for Biological
      Studies, La Jolla, California 92037, USA.
FAU - Plikus, Maksim V
AU  - Plikus MV
AD  - Department of Developmental and Cell Biology, University of California, Irvine,
      Irvine, California 92697, USA.
FAU - Verma, Inder M
AU  - Verma IM
AD  - Laboratory of Genetics, Salk Institute for Biological Studies, La Jolla,
      California 92037, USA.
FAU - Panda, Satchidananda
AU  - Panda S
AD  - Regulatory Biology Laboratory, Salk Institute for Biological Studies, La Jolla,
      California 92037, USA.
LA  - eng
GR  - R01 AR067273/AR/NIAMS NIH HHS/United States
PT  - Journal Article
DEP - 20180110
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
EDAT- 2018/01/11 06:00
MHDA- 2018/01/11 06:00
CRDT- 2018/01/11 06:00
PHST- 2016/09/12 00:00 [received]
PHST- 2017/11/24 00:00 [accepted]
PHST- 2018/01/11 06:00 [pubmed]
PHST- 2018/01/11 06:00 [medline]
PHST- 2018/01/11 06:00 [entrez]
AID - nature25170 [pii]
AID - 10.1038/nature25170 [doi]
PST - ppublish
SO  - Nature. 2018 Jan 18;553(7688):351-355. doi: 10.1038/nature25170. Epub 2018 Jan
      10.

PMID- 29306042
OWN - NLM
STAT- Publisher
LR  - 20180106
IS  - 1542-7714 (Electronic)
IS  - 1542-3565 (Linking)
DP  - 2018 Jan 3
TI  - Associations Between Molecular Classifications of Colorectal Cancer and Patient
      Survival: a Systematic Review.
LID - S1542-3565(17)31536-7 [pii]
LID - 10.1016/j.cgh.2017.12.038 [doi]
AB  - BACKGROUND & AIMS: Colorectal cancer (CRC) is a heterogeneous disease with
      different mechanisms of pathogenesis. Classification systems have been proposed
      based on molecular features of tumors, but none are used in clinical practice. We
      performed a systematic review of studies on the associations between molecular
      classifications of CRC and patient survival. METHODS: We searched the PubMed,
      Embase, Cochrane, and Web of Science databases for combinations of terms related 
      to CRC, molecular markers, subtype classifications, and survival (overall
      survival, disease-specific survival, disease-free survival). We included only
      studies that used at least 3 molecular markers to classify tumors and provided an
      estimate of survival associated with each subtype. Data extraction and quality
      assessment were performed independently by 2 reviewers. RESULTS: We identified 6 
      studies that fulfilled the inclusion criteria. In these studies, molecular
      subtypes were assigned based on pathways associated with tumor development or
      findings from gene expression clustering analyses. Most studies proposed
      classification systems with 5 subtypes, including information on microsatellite
      instability, mutations in BRAF, and mutations in KRAS. None of the studies
      included TNM stage in their classification system. Three classification systems
      used similar definitions. Only 3 studies provided internal or external validation
      of the proposed classification schemes. Tumors with microsatellite stability and 
      mutations in KRAS or BRAF were associated with decreased survival times, compared
      to tumors with microsatellite stability and no mutations. CONCLUSION: In a
      systematic review of studies of molecular classifications of CRC and patient
      survival, we found that most subtypes were not significantly or not
      differentially associated with survival. None of the systems integrated TNM
      staging. Further research and validation are needed to develop molecular subtype 
      classification systems for clinical practice.
CI  - Copyright (c) 2018 AGA Institute. Published by Elsevier Inc. All rights reserved.
FAU - Alwers, Elizabeth
AU  - Alwers E
AD  - Division of Clinical Epidemiology and Aging Research, German Cancer Research
      Center (DKFZ), Im Neuenheimer Feld 581, Heidelberg, Germany.
FAU - Jia, Min
AU  - Jia M
AD  - Division of Clinical Epidemiology and Aging Research, German Cancer Research
      Center (DKFZ), Im Neuenheimer Feld 581, Heidelberg, Germany.
FAU - Kloor, Matthias
AU  - Kloor M
AD  - Department of Applied Tumor Biology, Institute of Pathology, University of
      Heidelberg, Im Neuenheimer Feld 220, Heidelberg, Germany.
FAU - Blaker, Hendrik
AU  - Blaker H
AD  - Department of General Pathology, Institute of Pathology, Charite University
      Medicine Hospital, Chariteplatz 1, Berlin, Germany.
FAU - Brenner, Hermann
AU  - Brenner H
AD  - Division of Clinical Epidemiology and Aging Research, German Cancer Research
      Center (DKFZ), Im Neuenheimer Feld 581, Heidelberg, Germany; Division of
      Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for
      Tumor Diseases (NCT), Heidelberg, Germany; German Cancer Consortium (DKTK),
      German Cancer Research Center (DKFZ), Heidelberg, Germany.
FAU - Hoffmeister, Michael
AU  - Hoffmeister M
AD  - Division of Clinical Epidemiology and Aging Research, German Cancer Research
      Center (DKFZ), Im Neuenheimer Feld 581, Heidelberg, Germany. Electronic address: 
      m.hoffmeister@dkfz-heidelberg.de.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180103
PL  - United States
TA  - Clin Gastroenterol Hepatol
JT  - Clinical gastroenterology and hepatology : the official clinical practice journal
      of the American Gastroenterological Association
JID - 101160775
OTO - NOTNLM
OT  - biomarker
OT  - colon cancer
OT  - genetics
OT  - msi
EDAT- 2018/01/07 06:00
MHDA- 2018/01/07 06:00
CRDT- 2018/01/07 06:00
PHST- 2017/10/25 00:00 [received]
PHST- 2017/12/19 00:00 [revised]
PHST- 2017/12/21 00:00 [accepted]
PHST- 2018/01/07 06:00 [entrez]
PHST- 2018/01/07 06:00 [pubmed]
PHST- 2018/01/07 06:00 [medline]
AID - S1542-3565(17)31536-7 [pii]
AID - 10.1016/j.cgh.2017.12.038 [doi]
PST - aheadofprint
SO  - Clin Gastroenterol Hepatol. 2018 Jan 3. pii: S1542-3565(17)31536-7. doi:
      10.1016/j.cgh.2017.12.038.

PMID- 29089348
OWN - NLM
STAT- MEDLINE
DCOM- 20171107
LR  - 20171220
IS  - 1756-1833 (Electronic)
IS  - 0959-535X (Linking)
VI  - 359
DP  - 2017 Oct 31
TI  - Circulating vitamin D concentration and risk of seven cancers: Mendelian
      randomisation study.
PG  - j4761
LID - 10.1136/bmj.j4761 [doi]
AB  - Objective To determine if circulating concentrations of vitamin D are causally
      associated with risk of cancer.Design Mendelian randomisation study.Setting Large
      genetic epidemiology networks (the Genetic Associations and Mechanisms in
      Oncology (GAME-ON), the Genetic and Epidemiology of Colorectal Cancer Consortium 
      (GECCO), and the Prostate Cancer Association Group to Investigate Cancer
      Associated Alterations in the Genome (PRACTICAL) consortiums, and the MR-Base
      platform).Participants 70 563 cases of cancer (22 898 prostate cancer, 15 748
      breast cancer, 12 537 lung cancer, 11 488 colorectal cancer, 4369 ovarian cancer,
      1896 pancreatic cancer, and 1627 neuroblastoma) and 84 418 controls.Exposures
      Four single nucleotide polymorphisms (rs2282679, rs10741657, rs12785878 and
      rs6013897) associated with vitamin D were used to define a multi-polymorphism
      score for circulating 25-hydroxyvitamin D (25(OH)D) concentrations.Main outcomes 
      measures The primary outcomes were the risk of incident colorectal, breast,
      prostate, ovarian, lung, and pancreatic cancer and neuroblastoma, which was
      evaluated with an inverse variance weighted average of the associations with
      specific polymorphisms and a likelihood based approach. Secondary outcomes based 
      on cancer subtypes by sex, anatomic location, stage, and histology were also
      examined.Results There was little evidence that the multi-polymorphism score of
      25(OH)D was associated with risk of any of the seven cancers or their subtypes.
      Specifically, the odds ratios per 25 nmol/L increase in genetically determined
      25(OH)D concentrations were 0.92 (95% confidence interval 0.76 to 1.10) for
      colorectal cancer, 1.05 (0.89 to 1.24) for breast cancer, 0.89 (0.77 to 1.02) for
      prostate cancer, and 1.03 (0.87 to 1.23) for lung cancer. The results were
      consistent with the two different analytical approaches, and the study was
      powered to detect relative effect sizes of moderate magnitude (for example,
      1.20-1.50 per 25 nmol/L decrease in 25(OH)D for most primary cancer outcomes. The
      Mendelian randomisation assumptions did not seem to be violated.Conclusions There
      is little evidence for a linear causal association between circulating vitamin D 
      concentration and risk of various types of cancer, though the existence of causal
      clinically relevant effects of low magnitude cannot be ruled out. These results, 
      in combination with previous literature, provide evidence that population-wide
      screening for vitamin D deficiency and subsequent widespread vitamin D
      supplementation should not currently be recommended as a strategy for primary
      cancer prevention.
CI  - Published by the BMJ Publishing Group Limited. For permission to use (where not
      already granted under a licence) please go to
      http://group.bmj.com/group/rights-licensing/permissions.
FAU - Dimitrakopoulou, Vasiliki I
AU  - Dimitrakopoulou VI
AD  - Department of Hygiene and Epidemiology, School of Medicine, University of
      Ioannina, Ioannina, Greece.
AD  - School of Mathematics and Statistics, University College Dublin, Dublin, Ireland.
FAU - Tsilidis, Konstantinos K
AU  - Tsilidis KK
AD  - Department of Hygiene and Epidemiology, School of Medicine, University of
      Ioannina, Ioannina, Greece ktsilidi@cc.uoi.gr.
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Imperial
      College London, London, UK.
FAU - Haycock, Philip C
AU  - Haycock PC
AD  - School of Social and Community Medicine, University of Bristol, Bristol, UK.
AD  - MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK.
FAU - Dimou, Niki L
AU  - Dimou NL
AD  - Department of Hygiene and Epidemiology, School of Medicine, University of
      Ioannina, Ioannina, Greece.
FAU - Al-Dabhani, Kawthar
AU  - Al-Dabhani K
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Imperial
      College London, London, UK.
FAU - Martin, Richard M
AU  - Martin RM
AD  - School of Social and Community Medicine, University of Bristol, Bristol, UK.
AD  - National Institute for Health Research (NIHR) Bristol Nutritional Biomedical
      Research Unit, University Hospitals Bristol NHS Foundation Trust and the
      University of Bristol, Bristol, UK.
FAU - Lewis, Sarah J
AU  - Lewis SJ
AD  - School of Social and Community Medicine, University of Bristol, Bristol, UK.
AD  - MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK.
FAU - Gunter, Marc J
AU  - Gunter MJ
AD  - International Agency for Research on Cancer, Lyon, France.
FAU - Mondul, Alison
AU  - Mondul A
AD  - Department of Epidemiology, University of Michigan School of Public Health, Ann
      Arbor, MI, USA.
FAU - Shui, Irene M
AU  - Shui IM
AD  - Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA.
FAU - Theodoratou, Evropi
AU  - Theodoratou E
AD  - Centre of Global Health Research, Usher Institute for Population Health Sciences 
      and Informatics, University of Edinburg, Edinburgh, UK.
FAU - Nimptsch, Katharina
AU  - Nimptsch K
AD  - Molecular Epidemiology Research Group, Max Delbruck Centre for Molecular Medicine
      (MDC), Berlin, Germany.
FAU - Lindstrom, Sara
AU  - Lindstrom S
AD  - Department of Epidemiology, University of Washington, Seattle, WA, USA.
FAU - Albanes, Demetrius
AU  - Albanes D
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute,
      Bethesda, MD, USA.
FAU - Kuhn, Tilman
AU  - Kuhn T
AD  - Division of Cancer Epidemiology, German Cancer Research Centre (DKFZ),
      Heidelberg, Germany.
FAU - Key, Timothy J
AU  - Key TJ
AD  - Cancer Epidemiology Unit, Nuffield Department of Population Health, University of
      Oxford, Oxford, UK.
FAU - Travis, Ruth C
AU  - Travis RC
AD  - Cancer Epidemiology Unit, Nuffield Department of Population Health, University of
      Oxford, Oxford, UK.
FAU - Vimaleswaran, Karani Santhanakrishnan
AU  - Vimaleswaran KS
AD  - Department of Food and Nutritional Sciences, Hugh Sinclair Unit of Human
      Nutrition and Institute for Cardiovascular and Metabolic Research (ICMR),
      University of Reading, Reading, UK.
CN  - GECCO Consortium
CN  - PRACTICAL Consortium
CN  - GAME-ON Network (CORECT, DRIVE, ELLIPSE, FOCI-OCAC, TRICL-ILCCO)
FAU - Kraft, Peter
AU  - Kraft P
AD  - Program in Genetic Epidemiology and Statistical Genetics, Department of
      Epidemiology, Harvard School of Public Health, Boston, MA, USA.
FAU - Pierce, Brandon L
AU  - Pierce BL
AD  - Department of Public Health Sciences, University of Chicago, Chicago, IL, USA.
AD  - Department of Human Genetics, University of Chicago, Chicago, IL, USA.
FAU - Schildkraut, Joellen M
AU  - Schildkraut JM
AD  - Department of Public Health Sciences, University of Virginia, Charlottesville,
      VA, USA.
LA  - eng
GR  - U01 CA164930/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20171031
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
RN  - 1406-16-2 (Vitamin D)
RN  - 64719-49-9 (25-hydroxyvitamin D)
SB  - AIM
SB  - IM
CIN - BMJ. 2017 Oct 31;359:j4952. PMID: 29089329
MH  - Breast Neoplasms/blood/epidemiology/genetics
MH  - Case-Control Studies
MH  - Colorectal Neoplasms/blood/epidemiology/genetics
MH  - Female
MH  - Genetic Predisposition to Disease
MH  - Genetic Variation
MH  - Genome-Wide Association Study
MH  - Humans
MH  - Incidence
MH  - Lung Neoplasms/blood/epidemiology/genetics
MH  - Male
MH  - Mendelian Randomization Analysis
MH  - Neoplasms/*blood/epidemiology/genetics
MH  - Neuroblastoma/blood/epidemiology/genetics
MH  - Ovarian Neoplasms/blood/epidemiology/genetics
MH  - Pancreatic Neoplasms/blood/epidemiology/genetics
MH  - Polymorphism, Single Nucleotide
MH  - Prostatic Neoplasms/blood/epidemiology/genetics
MH  - Risk Assessment/methods
MH  - Vitamin D/*analogs & derivatives/blood
MH  - Vitamin D Deficiency/blood/epidemiology/genetics
PMC - PMC5666592
COIS- Competing interests: All authors have completed the ICMJE uniform disclosure form
      at www.icmje.org/coi_disclosure.pdf and declare: no undeclared support from any
      organisation for the submitted work; no financial relationships with any
      organisations that might have an interest in the submitted work in the previous
      three years; no other relationships or activities that could appear to have
      influenced the submitted work.
IR  - Raskin L
FIR - Raskin, Leonid
IR  - Chan CT
FIR - Chan, Chan T
IR  - Song M
FIR - Song, Mingyang
IR  - Joshi AD
FIR - Joshi, Amit D
IR  - Xiang YB
FIR - Xiang, Yong Bing
IR  - Ha Jee S
FIR - Ha Jee, Sun
IR  - Ulrich CM
FIR - Ulrich, Cornelia M
IR  - Baron JA
FIR - Baron, John A
IR  - Giles GG
FIR - Giles, Graham G
IR  - MacInnis RJ
FIR - MacInnis, Robert J
IR  - Southey MC
FIR - Southey, Melissa C
IR  - Figueiredo JC
FIR - Figueiredo, Jane C
IR  - Li L
FIR - Li, Li
IR  - Haiman CA
FIR - Haiman, Christopher A
IR  - Landi MT
FIR - Landi, Maria Teresa
IR  - Stevens V
FIR - Stevens, Victoria
IR  - Caporaso N
FIR - Caporaso, Neil
IR  - Brennan P
FIR - Brennan, Paul
IR  - Amos CI
FIR - Amos, Christopher I
IR  - Wu X
FIR - Wu, Xifeng
IR  - Hung RJ
FIR - Hung, Rayjean J
IR  - Bickeboller H
FIR - Bickeboller, Heike
IR  - Risch A
FIR - Risch, Angela
IR  - Wichmann HE
FIR - Wichmann, H Erich
IR  - Houlston R
FIR - Houlston, Richard
IR  - Banbury BL
FIR - Banbury, Barbara L
IR  - Berndt SI
FIR - Berndt, Sonja I
IR  - Bezieau S
FIR - Bezieau, Stephane
IR  - Brenner H
FIR - Brenner, Hermann
IR  - Campbell PT
FIR - Campbell, Peter T
IR  - Casey G
FIR - Casey, Graham
IR  - Chang-Claude J
FIR - Chang-Claude, Jenny
IR  - Gallinger SJ
FIR - Gallinger, Steven J
IR  - Hoffmeister M
FIR - Hoffmeister, Michael
IR  - Jenkins MA
FIR - Jenkins, Mark A
IR  - Marchand L
FIR - Marchand, Loic Le
IR  - Newcomb PA
FIR - Newcomb, Polly A
IR  - Peters U
FIR - Peters, Ulrike
IR  - Slattery ML
FIR - Slattery, Martha L
IR  - White E
FIR - White, Emily
IR  - Ahsan H
FIR - Ahsan, Habibul
IR  - Kraft P
FIR - Kraft, Peter
IR  - Brandon L P
FIR - Brandon L, Pierce
IR  - Schildkraut JM
FIR - Schildkraut, Joellen M
IR  - Eeles R
FIR - Eeles, Rosalind
IR  - Easton D
FIR - Easton, Doug
IR  - Kote-Jarai Z
FIR - Kote-Jarai, Zsofia
IR  - Al Olama AA
FIR - Al Olama, Ali Amin
IR  - Benlloch S
FIR - Benlloch, Sara
IR  - Muir K
FIR - Muir, Kenneth
IR  - Giles GG
FIR - Giles, Graham G
IR  - Wiklund F
FIR - Wiklund, Fredrik
IR  - Gronberg H
FIR - Gronberg, Henrik
IR  - Haiman CA
FIR - Haiman, Christopher A
IR  - Schleutker J
FIR - Schleutker, Johanna
IR  - Weischer M
FIR - Weischer, Maren
IR  - Travis RC
FIR - Travis, Ruth C
IR  - Neal D
FIR - Neal, David
IR  - Pharoah P
FIR - Pharoah, Paul
IR  - Khaw KT
FIR - Khaw, Kay-Tee
IR  - Stanford JL
FIR - Stanford, Janet L
IR  - Blot WJ
FIR - Blot, William J
IR  - Thibodeau S
FIR - Thibodeau, Stephen
IR  - Maier C
FIR - Maier, Christiane
IR  - Kibel AS
FIR - Kibel, Adam S
IR  - Cybulski C
FIR - Cybulski, Cezary
IR  - Cannon-Albright L
FIR - Cannon-Albright, Lisa
IR  - Brenner H
FIR - Brenner, Hermann
IR  - Park J
FIR - Park, Jong
IR  - Kaneva R
FIR - Kaneva, Radka
IR  - Batra J
FIR - Batra, Jyotsna
IR  - Teixeira MR
FIR - Teixeira, Manuel R
IR  - Pandha H
FIR - Pandha, Hardev
IR  - Lu YJ
FIR - Lu, Yong-Jie
EDAT- 2017/11/02 06:00
MHDA- 2017/11/08 06:00
CRDT- 2017/11/02 06:00
PHST- 2017/11/02 06:00 [entrez]
PHST- 2017/11/02 06:00 [pubmed]
PHST- 2017/11/08 06:00 [medline]
PST - epublish
SO  - BMJ. 2017 Oct 31;359:j4761.

PMID- 29346757
OWN - NLM
STAT- In-Data-Review
LR  - 20180118
IS  - 2211-1247 (Electronic)
VI  - 22
IP  - 3
DP  - 2018 Jan 16
TI  - p53 Suppresses Metabolic Stress-Induced Ferroptosis in Cancer Cells.
PG  - 569-575
LID - S2211-1247(17)31914-9 [pii]
LID - 10.1016/j.celrep.2017.12.077 [doi]
AB  - How cancer cells respond to nutrient deprivation remains poorly understood. In
      certain cancer cells, deprivation of cystine induces a non-apoptotic,
      iron-dependent form of cell death termed ferroptosis. Recent evidence suggests
      that ferroptosis sensitivity may be modulated by the stress-responsive
      transcription factor and canonical tumor suppressor protein p53. Using
      CRISPR/Cas9 genome editing, small-molecule probes, and high-resolution,
      time-lapse imaging, we find that stabilization of wild-type p53 delays the onset 
      of ferroptosis in response to cystine deprivation. This delay requires the p53
      transcriptional target CDKN1A (encoding p21) and is associated with both slower
      depletion of intracellular glutathione and a reduced accumulation of toxic
      lipid-reactive oxygen species (ROS). Thus, the p53-p21 axis may help cancer cells
      cope with metabolic stress induced by cystine deprivation by delaying the onset
      of non-apoptotic cell death.
CI  - Copyright (c) 2017 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Tarangelo, Amy
AU  - Tarangelo A
AD  - Program in Cancer Biology, Stanford University School of Medicine, 291 Campus
      Drive, Stanford, CA 94305, USA.
FAU - Magtanong, Leslie
AU  - Magtanong L
AD  - Department of Biology, Stanford University, 337 Campus Drive, Stanford, CA 94305,
      USA.
FAU - Bieging-Rolett, Kathryn T
AU  - Bieging-Rolett KT
AD  - Department of Radiation Oncology, Stanford University School of Medicine, 291
      Campus Drive, Stanford, CA 94305, USA.
FAU - Li, Yang
AU  - Li Y
AD  - Program in Cancer Biology, Stanford University School of Medicine, 291 Campus
      Drive, Stanford, CA 94305, USA; Department of Radiation Oncology, Stanford
      University School of Medicine, 291 Campus Drive, Stanford, CA 94305, USA.
FAU - Ye, Jiangbin
AU  - Ye J
AD  - Program in Cancer Biology, Stanford University School of Medicine, 291 Campus
      Drive, Stanford, CA 94305, USA; Department of Radiation Oncology, Stanford
      University School of Medicine, 291 Campus Drive, Stanford, CA 94305, USA.
FAU - Attardi, Laura D
AU  - Attardi LD
AD  - Program in Cancer Biology, Stanford University School of Medicine, 291 Campus
      Drive, Stanford, CA 94305, USA; Department of Radiation Oncology, Stanford
      University School of Medicine, 291 Campus Drive, Stanford, CA 94305, USA;
      Department of Genetics, Stanford University School of Medicine, 291 Campus Drive,
      Stanford, CA 94305, USA.
FAU - Dixon, Scott J
AU  - Dixon SJ
AD  - Program in Cancer Biology, Stanford University School of Medicine, 291 Campus
      Drive, Stanford, CA 94305, USA; Department of Biology, Stanford University, 337
      Campus Drive, Stanford, CA 94305, USA. Electronic address: sjdixon@stanford.edu.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cell Rep
JT  - Cell reports
JID - 101573691
OTO - NOTNLM
OT  - cancer
OT  - cell death
OT  - cystine
OT  - ferroptosis
OT  - glutathione
OT  - metabolism
OT  - p53
OT  - reactive oxygen species
EDAT- 2018/01/19 06:00
MHDA- 2018/01/19 06:00
CRDT- 2018/01/19 06:00
PHST- 2017/06/26 00:00 [received]
PHST- 2017/11/15 00:00 [revised]
PHST- 2017/12/21 00:00 [accepted]
PHST- 2018/01/19 06:00 [entrez]
PHST- 2018/01/19 06:00 [pubmed]
PHST- 2018/01/19 06:00 [medline]
AID - S2211-1247(17)31914-9 [pii]
AID - 10.1016/j.celrep.2017.12.077 [doi]
PST - ppublish
SO  - Cell Rep. 2018 Jan 16;22(3):569-575. doi: 10.1016/j.celrep.2017.12.077.

PMID- 29294371
OWN - NLM
STAT- Publisher
LR  - 20180126
IS  - 1096-3650 (Electronic)
IS  - 1044-579X (Linking)
DP  - 2017 Dec 30
TI  - Targeting the Warburg effect for cancer treatment: Ketogenic diets for management
      of glioma.
LID - S1044-579X(17)30124-4 [pii]
LID - 10.1016/j.semcancer.2017.12.011 [doi]
AB  - Gliomas are a highly heterogeneous tumor, refractory to treatment and the most
      frequently diagnosed primary brain tumor. Although the current WHO grading system
      (2016) demonstrates promise towards identifying novel treatment modalities and
      better prediction of prognosis over time, to date, existing targeted and mono
      therapy approaches have failed to elicit a robust impact on disease progression
      and patient survival. It is possible that tumor heterogeneity as well as
      specifically targeted agents fail because redundant molecular pathways in the
      tumor make it refractory to such approaches. Additionally, the underlying
      metabolic pathology, which is significantly altered during neoplastic
      transformation and tumor progression, is unaccounted for. With several molecular 
      and metabolic pathways implicated in the carcinogenesis of CNS tumors, including 
      glioma, we postulate that a systemic, broad spectrum approach to produce robust
      targeting of relevant and multiple molecular and metabolic regulation of growth
      and survival pathways, critical to the modulation of hallmarks of carcinogenesis,
      without clinically limiting toxicity, may provide a more sustained impact on
      clinical outcomes compared to the modalities of treatment evaluated to date. The 
      objective of this review is to examine the emerging hallmark of reprogramming
      energy metabolism of the tumor cells and the tumor microenvironment during
      carcinogenesis, and to provide a rationale for exploiting this hallmark and its
      biological capabilities as a target for secondary chemoprevention and treatment
      of glioma. This review will primarily focus on interventions to induce ketosis to
      target the glycolytic phenotype of many cancers, with specific application to
      secondary chemoprevention of low grade glioma- to halt the progression of lower
      grade tumors to more aggressive subtypes, as evidenced by reduction in validated 
      intermediate endpoints of disease progression including clinical symptoms.
CI  - Copyright (c) 2018 Elsevier Ltd. All rights reserved.
FAU - Poff, Angela
AU  - Poff A
AD  - The University of South Florida, Department of Molecular Pharmacology and
      Physiology, 12901 Bruce B. Downs Blvd, MDC 8, Tampa, FL 33612, United States.
      Electronic address: abennett@health.usf.edu.
FAU - Koutnik, Andrew P
AU  - Koutnik AP
AD  - The University of South Florida, Department of Molecular Pharmacology and
      Physiology, 12901 Bruce B. Downs Blvd, MDC 8, Tampa, FL 33612, United States.
      Electronic address: akoutnik@health.usf.edu.
FAU - Egan, Kathleen M
AU  - Egan KM
AD  - Moffitt Cancer Center, H. Lee Moffitt Cancer Center and Research Institute,
      Department of Cancer Epidemiology, 12902 Magnolia Drive, MRC/CANCONT, Tampa, FL
      22612-9497, United States. Electronic address: katheleen.egan@moffitt.org.
FAU - Sahebjam, Solmaz
AU  - Sahebjam S
AD  - Department of Neuro-Oncology, H. Lee Moffitt Cancer Center and Research
      Institute, Department of Cancer Epidemiology, 12902 Magnolia Drive, Tampa, FL
      22612-9497, United States. Electronic address: solmaz.sahebjam@moffitt.org.
FAU - D'Agostino, Dominic
AU  - D'Agostino D
AD  - The University of South Florida, Department of Molecular Pharmacology and
      Physiology, 12901 Bruce B. Downs Blvd, MDC 8, Tampa, FL 33612, United States.
      Electronic address: ddagosti@health.usf.edu.
FAU - Kumar, Nagi B
AU  - Kumar NB
AD  - Moffitt Cancer Center, H. Lee Moffitt Cancer Center and Research Institute,
      Department of Cancer Epidemiology, 12902 Magnolia Drive, MRC/CANCONT, Tampa, FL
      22612-9497, United States. Electronic address: nagi.kumar@moffitt.org.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20171230
PL  - England
TA  - Semin Cancer Biol
JT  - Seminars in cancer biology
JID - 9010218
OTO - NOTNLM
OT  - Aerobic glycolysis
OT  - Energy metabolism
OT  - Gliomas
OT  - Glucose
OT  - Insulin
OT  - Kecondary chemoprevention
OT  - Ketogenic diet
OT  - Ketosis
OT  - Metabolic pathways
OT  - Molecular pathways
EDAT- 2018/01/03 06:00
MHDA- 2018/01/03 06:00
CRDT- 2018/01/03 06:00
PHST- 2017/06/01 00:00 [received]
PHST- 2017/12/07 00:00 [revised]
PHST- 2017/12/29 00:00 [accepted]
PHST- 2018/01/03 06:00 [pubmed]
PHST- 2018/01/03 06:00 [medline]
PHST- 2018/01/03 06:00 [entrez]
AID - S1044-579X(17)30124-4 [pii]
AID - 10.1016/j.semcancer.2017.12.011 [doi]
PST - aheadofprint
SO  - Semin Cancer Biol. 2017 Dec 30. pii: S1044-579X(17)30124-4. doi:
      10.1016/j.semcancer.2017.12.011.

PMID- 29061961
OWN - NLM
STAT- In-Data-Review
LR  - 20171219
IS  - 2041-1723 (Electronic)
IS  - 2041-1723 (Linking)
VI  - 8
IP  - 1
DP  - 2017 Oct 23
TI  - Survival of pancreatic cancer cells lacking KRAS function.
PG  - 1090
LID - 10.1038/s41467-017-00942-5 [doi]
AB  - Activating mutations in the proto-oncogene KRAS are a hallmark of pancreatic
      ductal adenocarcinoma (PDAC), an aggressive malignancy with few effective
      therapeutic options. Despite efforts to develop KRAS-targeted drugs, the absolute
      dependence of PDAC cells on KRAS remains incompletely understood. Here we model
      complete KRAS inhibition using CRISPR/Cas-mediated genome editing and demonstrate
      that KRAS is dispensable in a subset of human and mouse PDAC cells. Remarkably,
      nearly all KRAS deficient cells exhibit phosphoinositide 3-kinase
      (PI3K)-dependent mitogen-activated protein kinase (MAPK) signaling and induced
      sensitivity to PI3K inhibitors. Furthermore, comparison of gene expression
      profiles of PDAC cells retaining or lacking KRAS reveal a role of KRAS in the
      suppression of metastasis-related genes. Collectively, these data underscore the 
      potential for PDAC resistance to even the very best KRAS inhibitors and provide
      insights into mechanisms of response and resistance to KRAS inhibition.
FAU - Muzumdar, Mandar Deepak
AU  - Muzumdar MD
AD  - David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute 
      of Technology, Cambridge, MA, 02139, USA.
AD  - Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
AD  - Harvard Medical School, Boston, MA, 02215, USA.
FAU - Chen, Pan-Yu
AU  - Chen PY
AD  - David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute 
      of Technology, Cambridge, MA, 02139, USA.
AD  - Department of Biology, Massachusetts Institute of Technology, Cambridge, MA,
      02139, USA.
FAU - Dorans, Kimberly Judith
AU  - Dorans KJ
AD  - David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute 
      of Technology, Cambridge, MA, 02139, USA.
FAU - Chung, Katherine Minjee
AU  - Chung KM
AD  - David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute 
      of Technology, Cambridge, MA, 02139, USA.
FAU - Bhutkar, Arjun
AU  - Bhutkar A
AD  - David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute 
      of Technology, Cambridge, MA, 02139, USA.
FAU - Hong, Erin
AU  - Hong E
AD  - David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute 
      of Technology, Cambridge, MA, 02139, USA.
FAU - Noll, Elisa M
AU  - Noll EM
AUID- ORCID: http://orcid.org/0000-0001-6334-129X
AD  - Heidelberg Institute for Stem Cell Technology and Experimental Medicine
      (HI-STEM), Heidelberg, 69120, Germany.
AD  - Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ),
      Heidelberg, 69120, Germany.
FAU - Sprick, Martin R
AU  - Sprick MR
AUID- ORCID: http://orcid.org/0000-0001-9691-7574
AD  - Heidelberg Institute for Stem Cell Technology and Experimental Medicine
      (HI-STEM), Heidelberg, 69120, Germany.
AD  - Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ),
      Heidelberg, 69120, Germany.
FAU - Trumpp, Andreas
AU  - Trumpp A
AD  - Heidelberg Institute for Stem Cell Technology and Experimental Medicine
      (HI-STEM), Heidelberg, 69120, Germany.
AD  - Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ),
      Heidelberg, 69120, Germany.
FAU - Jacks, Tyler
AU  - Jacks T
AD  - David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute 
      of Technology, Cambridge, MA, 02139, USA. tjacks@mit.edu.
AD  - Department of Biology, Massachusetts Institute of Technology, Cambridge, MA,
      02139, USA. tjacks@mit.edu.
AD  - Howard Hughes Medical Institute, Massachusetts Institute of Technology,
      Cambridge, MA, 02139, USA. tjacks@mit.edu.
LA  - eng
GR  - KL2 TR001100/TR/NCATS NIH HHS/United States
GR  - P30 CA014051/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20171023
PL  - England
TA  - Nat Commun
JT  - Nature communications
JID - 101528555
PMC - PMC5653666
EDAT- 2017/10/25 06:00
MHDA- 2017/10/25 06:00
CRDT- 2017/10/25 06:00
PHST- 2017/06/18 00:00 [received]
PHST- 2017/08/07 00:00 [accepted]
PHST- 2017/10/25 06:00 [entrez]
PHST- 2017/10/25 06:00 [pubmed]
PHST- 2017/10/25 06:00 [medline]
AID - 10.1038/s41467-017-00942-5 [doi]
AID - 10.1038/s41467-017-00942-5 [pii]
PST - epublish
SO  - Nat Commun. 2017 Oct 23;8(1):1090. doi: 10.1038/s41467-017-00942-5.

PMID- 29149457
OWN - NLM
STAT- Publisher
LR  - 20180113
IS  - 1527-3350 (Electronic)
IS  - 0270-9139 (Linking)
DP  - 2017 Nov 17
TI  - HMGB1 Controls Liver Cancer Initiation through YAP-dependent Aerobic Glycolysis.
LID - 10.1002/hep.29663 [doi]
AB  - Emerging studies have suggested that the Hippo pathway is involved in the
      tumorigenesis of hepatocellular carcinoma (HCC). However, the key regulator of
      the Hippo pathway in liver tumor metabolic reprogramming remains elusive. Here,
      we provide evidence to support that high mobility group box 1 (HMGB1), a
      chromosomal protein, plays a role in the regulation of the Hippo pathway during
      liver tumorigenesis. Cre/loxP recombination-mediated HMGB1 depletion in
      hepatocytes blocks diethylnitrosamine-induced liver cancer initiation in mice,
      whereas shRNA-mediated gene silencing of HMGB1 inhibits HCC cell proliferation.
      Mechanistically, the binding of HMGB1 to GA-binding protein alpha (GABPalpha)
      promotes the expression of yes-associated protein (YAP), a major downstream
      effector of the Hippo pathway, which contributes to liver tumorigenesis by
      inducing hypoxia-inducible factor 1alpha (HIF1alpha)-dependent aerobic
      glycolysis. Like wild type YAP-cDNA, YAP-5SA-S94A can restore HIF1alpha DNA
      binding activity, glycolysis-associated gene expression, and HIF1alpha-YAP
      complex formation in YAP-knockdown HCC cell lines. In contrast, verteporfin, a
      reagent targeting the interface between YAP and TEA domain transcription factor
      (TEAD), has the ability to block YAP-HIF1alpha complex formation. Notably,
      genetic or pharmacological inhibition of the HMGB1-YAP-HIF1alpha pathway confers 
      protection against excessive glycolysis and tumor growth in mice. CONCLUSION:
      These findings uncover that HMGB1 plays a novel role in modulating the
      YAP-dependent HIF1alpha pathway and sheds light on the development of
      metabolism-targeting therapeutics for HCC chemoprevention. This article is
      protected by copyright. All rights reserved.
CI  - (c) 2017 by the American Association for the Study of Liver Diseases.
FAU - Chen, Ruochan
AU  - Chen R
AD  - The Third Affiliated Hospital, Center for DAMP Biology, Key Laboratory for Major 
      Obstetric Diseases of Guangdong Province, Key Laboratory of Reproduction and
      Genetics of Guangdong Higher Education Institutes, Protein Modification and
      Degradation Laboratory, Guangzhou Medical University, Guangzhou, Guangdong,
      510510, China.
AD  - Department of Infectious Diseases and State Key Lab of Viral Hepatitis, Xiangya
      Hospital, Central South University, Changsha, Hunan, 410008, China.
AD  - Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, 15213,
      USA.
FAU - Zhu, Shan
AU  - Zhu S
AD  - The Third Affiliated Hospital, Center for DAMP Biology, Key Laboratory for Major 
      Obstetric Diseases of Guangdong Province, Key Laboratory of Reproduction and
      Genetics of Guangdong Higher Education Institutes, Protein Modification and
      Degradation Laboratory, Guangzhou Medical University, Guangzhou, Guangdong,
      510510, China.
FAU - Fan, Xue-Gong
AU  - Fan XG
AD  - Department of Infectious Diseases and State Key Lab of Viral Hepatitis, Xiangya
      Hospital, Central South University, Changsha, Hunan, 410008, China.
FAU - Wang, Haichao
AU  - Wang H
AD  - Laboratory of Emergency Medicine, North Shore University Hospital and The
      Feinstein Institute for Medical Research, Manhasset, New York, 11030, USA.
FAU - Lotze, Michael T
AU  - Lotze MT
AD  - Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, 15213,
      USA.
FAU - Zeh, Herbert J 3rd
AU  - Zeh HJ 3rd
AD  - Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, 15213,
      USA.
FAU - Billiar, Timothy R
AU  - Billiar TR
AD  - Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, 15213,
      USA.
FAU - Kang, Rui
AU  - Kang R
AD  - Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, 15213,
      USA.
FAU - Tang, Daolin
AU  - Tang D
AD  - The Third Affiliated Hospital, Center for DAMP Biology, Key Laboratory for Major 
      Obstetric Diseases of Guangdong Province, Key Laboratory of Reproduction and
      Genetics of Guangdong Higher Education Institutes, Protein Modification and
      Degradation Laboratory, Guangzhou Medical University, Guangzhou, Guangdong,
      510510, China.
AD  - Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, 15213,
      USA.
LA  - eng
GR  - R01 AT005076/AT/NCCIH NIH HHS/United States
GR  - R01 CA160417/CA/NCI NIH HHS/United States
GR  - R01 GM063075/GM/NIGMS NIH HHS/United States
GR  - R01 GM115366/GM/NIGMS NIH HHS/United States
PT  - Journal Article
DEP - 20171117
PL  - United States
TA  - Hepatology
JT  - Hepatology (Baltimore, Md.)
JID - 8302946
OTO - NOTNLM
OT  - HMGB1
OT  - Warburg effect
OT  - YAP
OT  - hepatocellular carcinoma
EDAT- 2017/11/18 06:00
MHDA- 2017/11/18 06:00
CRDT- 2017/11/18 06:00
PHST- 2017/04/27 00:00 [received]
PHST- 2017/09/01 00:00 [revised]
PHST- 2017/11/13 00:00 [accepted]
PHST- 2017/11/18 06:00 [entrez]
PHST- 2017/11/18 06:00 [pubmed]
PHST- 2017/11/18 06:00 [medline]
AID - 10.1002/hep.29663 [doi]
PST - aheadofprint
SO  - Hepatology. 2017 Nov 17. doi: 10.1002/hep.29663.

PMID- 29236593
OWN - NLM
STAT- In-Data-Review
LR  - 20180129
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Linking)
VI  - 36
IP  - 4
DP  - 2018 Feb 1
TI  - Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate
      Cancer Consensus Conference 2017.
PG  - 414-424
LID - 10.1200/JCO.2017.74.1173 [doi]
AB  - Purpose Guidelines are limited for genetic testing for prostate cancer (PCA). The
      goal of this conference was to develop an expert consensus-driven working
      framework for comprehensive genetic evaluation of inherited PCA in the multigene 
      testing era addressing genetic counseling, testing, and genetically informed
      management. Methods An expert consensus conference was convened including key
      stakeholders to address genetic counseling and testing, PCA screening, and
      management informed by evidence review. Results Consensus was strong that
      patients should engage in shared decision making for genetic testing. There was
      strong consensus to test HOXB13 for suspected hereditary PCA, BRCA1/2 for
      suspected hereditary breast and ovarian cancer, and DNA mismatch repair genes for
      suspected Lynch syndrome. There was strong consensus to factor BRCA2 mutations
      into PCA screening discussions. BRCA2 achieved moderate consensus for factoring
      into early-stage management discussion, with stronger consensus in
      high-risk/advanced and metastatic setting. Agreement was moderate to test all men
      with metastatic castration-resistant PCA, regardless of family history, with
      stronger agreement to test BRCA1/2 and moderate agreement to test ATM to inform
      prognosis and targeted therapy. Conclusion To our knowledge, this is the first
      comprehensive, multidisciplinary consensus statement to address a genetic
      evaluation framework for inherited PCA in the multigene testing era. Future
      research should focus on developing a working definition of familial PCA for
      clinical genetic testing, expanding understanding of genetic contribution to
      aggressive PCA, exploring clinical use of genetic testing for PCA management,
      genetic testing of African American males, and addressing the value framework of 
      genetic evaluation and testing men at risk for PCA-a clinically heterogeneous
      disease.
FAU - Giri, Veda N
AU  - Giri VN
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Knudsen, Karen E
AU  - Knudsen KE
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Kelly, William K
AU  - Kelly WK
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Abida, Wassim
AU  - Abida W
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Andriole, Gerald L
AU  - Andriole GL
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Bangma, Chris H
AU  - Bangma CH
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Bekelman, Justin E
AU  - Bekelman JE
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Benson, Mitchell C
AU  - Benson MC
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Blanco, Amie
AU  - Blanco A
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Burnett, Arthur
AU  - Burnett A
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Catalona, William J
AU  - Catalona WJ
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Cooney, Kathleen A
AU  - Cooney KA
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Cooperberg, Matthew
AU  - Cooperberg M
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Crawford, David E
AU  - Crawford DE
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Den, Robert B
AU  - Den RB
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Dicker, Adam P
AU  - Dicker AP
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Eggener, Scott
AU  - Eggener S
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Fleshner, Neil
AU  - Fleshner N
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Freedman, Matthew L
AU  - Freedman ML
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Hamdy, Freddie C
AU  - Hamdy FC
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Hoffman-Censits, Jean
AU  - Hoffman-Censits J
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Hurwitz, Mark D
AU  - Hurwitz MD
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Hyatt, Colette
AU  - Hyatt C
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Isaacs, William B
AU  - Isaacs WB
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Kane, Christopher J
AU  - Kane CJ
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Kantoff, Philip
AU  - Kantoff P
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Karnes, R Jeffrey
AU  - Karnes RJ
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Karsh, Lawrence I
AU  - Karsh LI
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Klein, Eric A
AU  - Klein EA
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Lin, Daniel W
AU  - Lin DW
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Loughlin, Kevin R
AU  - Loughlin KR
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Lu-Yao, Grace
AU  - Lu-Yao G
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Malkowicz, S Bruce
AU  - Malkowicz SB
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Mann, Mark J
AU  - Mann MJ
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Mark, James R
AU  - Mark JR
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - McCue, Peter A
AU  - McCue PA
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Miner, Martin M
AU  - Miner MM
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Morgan, Todd
AU  - Morgan T
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Moul, Judd W
AU  - Moul JW
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Myers, Ronald E
AU  - Myers RE
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Nielsen, Sarah M
AU  - Nielsen SM
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Obeid, Elias
AU  - Obeid E
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Pavlovich, Christian P
AU  - Pavlovich CP
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Peiper, Stephen C
AU  - Peiper SC
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Penson, David F
AU  - Penson DF
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Petrylak, Daniel
AU  - Petrylak D
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Pettaway, Curtis A
AU  - Pettaway CA
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Pilarski, Robert
AU  - Pilarski R
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Pinto, Peter A
AU  - Pinto PA
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Poage, Wendy
AU  - Poage W
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Raj, Ganesh V
AU  - Raj GV
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Rebbeck, Timothy R
AU  - Rebbeck TR
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Robson, Mark E
AU  - Robson ME
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Rosenberg, Matt T
AU  - Rosenberg MT
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Sandler, Howard
AU  - Sandler H
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Sartor, Oliver
AU  - Sartor O
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Schaeffer, Edward
AU  - Schaeffer E
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Schwartz, Gordon F
AU  - Schwartz GF
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Shahin, Mark S
AU  - Shahin MS
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Shore, Neal D
AU  - Shore ND
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Shuch, Brian
AU  - Shuch B
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Soule, Howard R
AU  - Soule HR
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Tomlins, Scott A
AU  - Tomlins SA
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Trabulsi, Edouard J
AU  - Trabulsi EJ
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Uzzo, Robert
AU  - Uzzo R
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Vander Griend, Donald J
AU  - Vander Griend DJ
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Walsh, Patrick C
AU  - Walsh PC
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Weil, Carol J
AU  - Weil CJ
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Wender, Richard
AU  - Wender R
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
FAU - Gomella, Leonard G
AU  - Gomella LG
AD  - Veda N. Giri, Karen E. Knudsen, William K. Kelly, Robert B. Den, Adam P. Dicker, 
      Jean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, Grace Lu-Yao, Mark J. Mann,
      James R. Mark, Peter A. McCue, Ronald E. Myers, Stephen C. Peiper, Edouard J.
      Trabulsi, and Leonard G. Gomella, Jefferson Sidney Kimmel Cancer Center; Justin
      E. Bekelman, University of Pennsylvania Perelman School of Medicine; S. Bruce
      Malkowicz, University of Pennsylvania; Elias Obeid and Robert Uzzo, Fox Chase
      Cancer Center; Gordon F. Schwartz, Foundation for Breast and Prostate Health,
      Philadelphia; Mark S. Shahin, Hanjani Institute for Gynecologic Oncology,
      Abington Hospital-Jefferson Health, Abington, PA; Wassim Abida, Philip Kantoff,
      and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mitchell C. Benson,
      Columbia University, New York, NY; Gerald L. Andriole, Washington University
      School of Medicine, St Louis, MO; Chris H. Bangma, Erasmus Medical Center,
      Rotterdam, the Netherlands; Amie Blanco, and Matthew Cooperberg, University of
      California, San Francisco Helen Diller Family Comprehensive Cancer Center, San
      Francisco; Christopher J. Kane, University of California San Diego, San Diego;
      Howard Sandler, Cedars-Sinai Medical Center, Los Angeles; Howard R. Soule,
      Prostate Cancer Foundation, Santa Monica, CA; Arthur Burnett, William B. Isaacs, 
      Christian P. Pavlovich, and Patrick C. Walsh, Johns Hopkins Medical Institutions,
      Baltimore; Peter A. Pinto and Carol J. Weil, National Cancer Institute, Bethesda,
      MD; William J. Catalona and Edward Schaeffer, Northwestern University Feinberg
      School of Medicine; Scott Eggener, Sarah M. Nielsen, and Donald J. Vander Griend,
      University of Chicago, Chicago, IL; Kathleen A. Cooney, University of Utah School
      of Medicine, Salt Lake City, UT; David E. Crawford, University of Colorado,
      Aurora; Lawrence I. Karsh, The Urology Center of Colorado, Denver; Wendy Poage,
      Prostate Conditions Education Council, Elizabeth, CO; Neil Fleshner, University
      of Toronto Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Matthew L. 
      Freedman, Kevin R. Loughlin, and Timothy R. Rebbeck, Dana Farber Cancer
      Institute, and Harvard TH Chan School of Public Health, Boston, MA; Freddie C.
      Hamdy, University of Oxford, Oxford, England; R. Jeffrey Karnes, Mayo Clinic,
      Rochester, MN; Eric A. Klein, Cleveland Clinic, Cleveland; Robert Pilarski, The
      Ohio State University, Columbus, OH; Daniel W. Lin, University of Washington,
      Seattle, WA; Martin M. Miner, Brown University, Providence, RI; Todd Morgan and
      Scott A. Tomlins, University of Michigan, Ann Arbor; Matt T. Rosenberg,
      Mid-Michigan Health Center, Jackson, MI; Judd W. Moul, Duke University, Duke
      Cancer Institute, Durham, NC; David F. Penson, Vanderbilt University Medical
      Center, Nashville, TN; Daniel Petrylak and Brian Shuch, Yale University, New
      Haven, CT; Curtis A. Pettaway, The University of Texas MD Anderson Cancer Center,
      Houston; Ganesh V. Raj, University of Texas Southwestern Medical Center at
      Dallas, Dallas, TX; Oliver Sartor, Tulane University Medical School, New Orleans,
      LA; Neal D. Shore, Atlantic Urology Clinics/Carolina Urologic Research Center,
      Myrtle Beach, SC; and Richard Wender, American Cancer Society, Atlanta, GA.
LA  - eng
PT  - Journal Article
DEP - 20171213
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of
      Clinical Oncology
JID - 8309333
EDAT- 2017/12/14 06:00
MHDA- 2017/12/14 06:00
CRDT- 2017/12/14 06:00
PHST- 2017/12/14 06:00 [pubmed]
PHST- 2017/12/14 06:00 [medline]
PHST- 2017/12/14 06:00 [entrez]
AID - 10.1200/JCO.2017.74.1173 [doi]
PST - ppublish
SO  - J Clin Oncol. 2018 Feb 1;36(4):414-424. doi: 10.1200/JCO.2017.74.1173. Epub 2017 
      Dec 13.

PMID- 29129028
OWN - NLM
STAT- In-Process
LR  - 20180111
IS  - 1573-2584 (Electronic)
IS  - 0301-1623 (Linking)
VI  - 50
IP  - 1
DP  - 2018 Jan
TI  - Improved cancer-specific free survival and overall free survival in contemporary 
      metastatic prostate cancer patients: a population-based study.
PG  - 71-78
LID - 10.1007/s11255-017-1744-2 [doi]
AB  - OBJECTIVES: Over the past decade, several systemic agents as docetaxel,
      cabazitaxel, sipuleucel-T, abiraterone and enzalutamide have improved overall
      survival (OS) in metastatic prostate cancer (mPCa) patients. However, to date the
      OS benefit was not demonstrated in population-based analysis. METHODS: Between
      2004 and 2014, 19,047 men with de novo mPCa were identified within the
      Surveillance Epidemiology and End Results database. Median year of diagnosis
      resulted in two groups: historical (2004-2008) and contemporary (2009-2014). Due 
      to potentially important differences according to year of diagnosis, we relied on
      propensity score matching. Propensity-score-matched Kaplan-Meier analyses and Cox
      regression models (CRMs) tested cancer-specific mortality (CSM) free survival and
      overall mortality (OM) free survival according to treatment period. RESULTS: The 
      propensity-score-matched cohort consisted of 8596 patients with mPCa. Of those,
      4298 (50.0%) were historical (2004-2008) and 4298 (50.0%) were contemporary
      (2009-2014). CSM free survival rates and OM free survival rate were 32 versus 36 
      months (p < 0.0001) and 26 versus 29 months (p < 0.0001) for, respectively,
      historical and contemporary patients. In multivariable CRMs, patients diagnosed
      in contemporary years had lower CSM (HR 0.88; CI 0.82-0.93) and OM (HR 0.88; CI
      0.84-0.93) risks compared to historical counterpart (all p < 0.0001). CONCLUSION:
      This population-based study provides the first evidence of improved CSM free
      survival and OM free survival in patients with de novo mPCa since the
      introduction of several systemic agents for CRPC patients.
FAU - Bandini, Marco
AU  - Bandini M
AUID- ORCID: http://orcid.org/0000-0002-1462-1698
AD  - Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Via
      Olgettina 60, 20132, Milan, MI, Italy. marco.bandini.zoli@gmail.com.
AD  - Vita-Salute San Raffaele University, Milan, Italy. marco.bandini.zoli@gmail.com.
AD  - Cancer Prognostics and Health Outcomes Unit, University of Montreal Health
      Center, Montreal, QC, Canada. marco.bandini.zoli@gmail.com.
FAU - Pompe, Raisa S
AU  - Pompe RS
AD  - Cancer Prognostics and Health Outcomes Unit, University of Montreal Health
      Center, Montreal, QC, Canada.
AD  - Martini Klinik, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
FAU - Marchioni, Michele
AU  - Marchioni M
AD  - Cancer Prognostics and Health Outcomes Unit, University of Montreal Health
      Center, Montreal, QC, Canada.
AD  - Department of Urology, SS Annunziata Hospital, "G. D'Annunzio" University of
      Chieti, Chieti, Italy.
FAU - Zaffuto, Emanuele
AU  - Zaffuto E
AD  - Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Via
      Olgettina 60, 20132, Milan, MI, Italy.
AD  - Vita-Salute San Raffaele University, Milan, Italy.
FAU - Gandaglia, Giorgio
AU  - Gandaglia G
AD  - Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Via
      Olgettina 60, 20132, Milan, MI, Italy.
AD  - Vita-Salute San Raffaele University, Milan, Italy.
FAU - Fossati, Nicola
AU  - Fossati N
AD  - Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Via
      Olgettina 60, 20132, Milan, MI, Italy.
AD  - Vita-Salute San Raffaele University, Milan, Italy.
FAU - Cindolo, Luca
AU  - Cindolo L
AD  - Department of Urology, ASL Abruzzo 2, Chieti, Italy.
FAU - Montorsi, Francesco
AU  - Montorsi F
AD  - Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Via
      Olgettina 60, 20132, Milan, MI, Italy.
AD  - Vita-Salute San Raffaele University, Milan, Italy.
FAU - Briganti, Alberto
AU  - Briganti A
AD  - Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Via
      Olgettina 60, 20132, Milan, MI, Italy.
AD  - Vita-Salute San Raffaele University, Milan, Italy.
FAU - Saad, Fred
AU  - Saad F
AD  - Cancer Prognostics and Health Outcomes Unit, University of Montreal Health
      Center, Montreal, QC, Canada.
FAU - Karakiewicz, Pierre I
AU  - Karakiewicz PI
AD  - Cancer Prognostics and Health Outcomes Unit, University of Montreal Health
      Center, Montreal, QC, Canada.
LA  - eng
PT  - Journal Article
DEP - 20171111
PL  - Netherlands
TA  - Int Urol Nephrol
JT  - International urology and nephrology
JID - 0262521
OTO - NOTNLM
OT  - Adjuvant therapy
OT  - Castration-resistant prostate cancer
OT  - Metastatic prostate cancer
OT  - SEER Program
OT  - Systemic agents
OT  - Urology
EDAT- 2017/11/13 06:00
MHDA- 2017/11/13 06:00
CRDT- 2017/11/13 06:00
PHST- 2017/08/29 00:00 [received]
PHST- 2017/11/06 00:00 [accepted]
PHST- 2017/11/13 06:00 [pubmed]
PHST- 2017/11/13 06:00 [medline]
PHST- 2017/11/13 06:00 [entrez]
AID - 10.1007/s11255-017-1744-2 [doi]
AID - 10.1007/s11255-017-1744-2 [pii]
PST - ppublish
SO  - Int Urol Nephrol. 2018 Jan;50(1):71-78. doi: 10.1007/s11255-017-1744-2. Epub 2017
      Nov 11.

PMID- 29256493
OWN - NLM
STAT- Publisher
LR  - 20180129
IS  - 1548-7105 (Electronic)
IS  - 1548-7091 (Linking)
DP  - 2017 Dec 11
TI  - BRCA-deficient mouse mammary tumor organoids to study cancer-drug resistance.
LID - 10.1038/nmeth.4535 [doi]
AB  - Poly(ADP-ribose) polymerase inhibition (PARPi) is a promising new therapeutic
      approach for the treatment of cancers that show homologous recombination
      deficiency (HRD). Despite the success of PARPi in targeting HRD in tumors that
      lack the tumor suppressor function of BRCA1 or BRCA2, drug resistance poses a
      major obstacle. We developed three-dimensional cancer organoids derived from
      genetically engineered mouse models (GEMMs) for BRCA1- and BRCA2-deficient
      cancers. Unlike conventional cell lines or mammospheres, organoid cultures can be
      efficiently derived and rapidly expanded in vitro. Orthotopically transplanted
      organoids give rise to mammary tumors that recapitulate the epithelial morphology
      and preserve the drug response of the original tumor. Notably, GEMM-tumor-derived
      organoids can be easily genetically modified, making them a powerful tool for
      genetic studies of tumor biology and drug resistance.
FAU - Duarte, Alexandra A
AU  - Duarte AA
AD  - Division of Molecular Pathology and Cancer Genomics Netherlands, The Netherlands 
      Cancer Institute, Amsterdam, The Netherlands.
FAU - Gogola, Ewa
AU  - Gogola E
AD  - Division of Molecular Pathology and Cancer Genomics Netherlands, The Netherlands 
      Cancer Institute, Amsterdam, The Netherlands.
FAU - Sachs, Norman
AU  - Sachs N
AUID- ORCID: http://orcid.org/0000-0002-5467-7151
AD  - Hubrecht Institute for Developmental Biology and Stem Cell Research, University
      Medical Centre Utrecht, Utrecht, The Netherlands.
FAU - Barazas, Marco
AU  - Barazas M
AD  - Division of Molecular Pathology and Cancer Genomics Netherlands, The Netherlands 
      Cancer Institute, Amsterdam, The Netherlands.
FAU - Annunziato, Stefano
AU  - Annunziato S
AD  - Division of Molecular Pathology and Cancer Genomics Netherlands, The Netherlands 
      Cancer Institute, Amsterdam, The Netherlands.
FAU - R de Ruiter, Julian
AU  - R de Ruiter J
AD  - Division of Molecular Pathology and Cancer Genomics Netherlands, The Netherlands 
      Cancer Institute, Amsterdam, The Netherlands.
AD  - Division of Molecular Carcinogenesis, The Netherlands Cancer Institute,
      Amsterdam, The Netherlands.
FAU - Velds, Arno
AU  - Velds A
AD  - Genomics Core Facility, The Netherlands Cancer Institute, Amsterdam, The
      Netherlands.
FAU - Blatter, Sohvi
AU  - Blatter S
AD  - Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, Bern,
      Switzerland.
FAU - Houthuijzen, Julia M
AU  - Houthuijzen JM
AD  - Division of Molecular Pathology and Cancer Genomics Netherlands, The Netherlands 
      Cancer Institute, Amsterdam, The Netherlands.
FAU - van de Ven, Marieke
AU  - van de Ven M
AD  - Mouse Clinic for Cancer and Aging (MCCA), Preclinical Intervention Unit, The
      Netherlands Cancer Institute, Amsterdam, The Netherlands.
FAU - Clevers, Hans
AU  - Clevers H
AD  - Hubrecht Institute for Developmental Biology and Stem Cell Research, University
      Medical Centre Utrecht, Utrecht, The Netherlands.
FAU - Borst, Piet
AU  - Borst P
AD  - Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, the 
      Netherlands.
FAU - Jonkers, Jos
AU  - Jonkers J
AD  - Division of Molecular Pathology and Cancer Genomics Netherlands, The Netherlands 
      Cancer Institute, Amsterdam, The Netherlands.
FAU - Rottenberg, Sven
AU  - Rottenberg S
AUID- ORCID: http://orcid.org/0000-0003-2044-9844
AD  - Division of Molecular Pathology and Cancer Genomics Netherlands, The Netherlands 
      Cancer Institute, Amsterdam, The Netherlands.
AD  - Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, Bern,
      Switzerland.
LA  - eng
PT  - Journal Article
DEP - 20171211
PL  - United States
TA  - Nat Methods
JT  - Nature methods
JID - 101215604
EDAT- 2017/12/20 06:00
MHDA- 2017/12/20 06:00
CRDT- 2017/12/20 06:00
PHST- 2017/04/05 00:00 [received]
PHST- 2017/10/17 00:00 [accepted]
PHST- 2017/12/20 06:00 [pubmed]
PHST- 2017/12/20 06:00 [medline]
PHST- 2017/12/20 06:00 [entrez]
AID - nmeth.4535 [pii]
AID - 10.1038/nmeth.4535 [doi]
PST - aheadofprint
SO  - Nat Methods. 2017 Dec 11. pii: nmeth.4535. doi: 10.1038/nmeth.4535.

PMID- 29346775
OWN - NLM
STAT- In-Data-Review
LR  - 20180118
IS  - 2211-1247 (Electronic)
VI  - 22
IP  - 3
DP  - 2018 Jan 16
TI  - BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene
      Rearrangements in Prostate Cancer.
PG  - 796-808
LID - S2211-1247(17)31915-0 [pii]
LID - 10.1016/j.celrep.2017.12.078 [doi]
AB  - BRD4 belongs to the bromodomain and extraterminal (BET) family of chromatin
      reader proteins that bind acetylated histones and regulate gene expression.
      Pharmacological inhibition of BRD4 by BET inhibitors (BETi) has indicated
      antitumor activity against multiple cancer types. We show that BRD4 is essential 
      for the repair of DNA double-strand breaks (DSBs) and mediates the formation of
      oncogenic gene rearrangements by engaging the non-homologous end joining (NHEJ)
      pathway. Mechanistically, genome-wide DNA breaks are associated with enhanced
      acetylation of histone H4, leading to BRD4 recruitment, and stable establishment 
      of the DNA repair complex. In support of this, we also show that, in clinical
      tumor samples, BRD4 protein levels are negatively associated with outcome after
      prostate cancer (PCa) radiation therapy. Thus, in addition to regulating gene
      expression, BRD4 is also a central player in the repair of DNA DSBs, with
      significant implications for cancer therapy.
CI  - Copyright (c) 2018 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Li, Xiangyi
AU  - Li X
AD  - Department of Pathology, UT Southwestern Medical Center, Dallas, TX 75390, USA.
FAU - Baek, GuemHee
AU  - Baek G
AD  - Department of Pathology, UT Southwestern Medical Center, Dallas, TX 75390, USA.
FAU - Ramanand, Susmita G
AU  - Ramanand SG
AD  - Department of Pathology, UT Southwestern Medical Center, Dallas, TX 75390, USA.
FAU - Sharp, Adam
AU  - Sharp A
AD  - Prostate Cancer Targeted Therapy and Cancer Biomarkers Group, Institute of Cancer
      Research and The Royal Marsden NHS Foundation Trust, Sutton, UK.
FAU - Gao, Yunpeng
AU  - Gao Y
AD  - Department of Pathology, UT Southwestern Medical Center, Dallas, TX 75390, USA.
FAU - Yuan, Wei
AU  - Yuan W
AD  - Prostate Cancer Targeted Therapy and Cancer Biomarkers Group, Institute of Cancer
      Research and The Royal Marsden NHS Foundation Trust, Sutton, UK.
FAU - Welti, Jon
AU  - Welti J
AD  - Prostate Cancer Targeted Therapy and Cancer Biomarkers Group, Institute of Cancer
      Research and The Royal Marsden NHS Foundation Trust, Sutton, UK.
FAU - Rodrigues, Daniel N
AU  - Rodrigues DN
AD  - Prostate Cancer Targeted Therapy and Cancer Biomarkers Group, Institute of Cancer
      Research and The Royal Marsden NHS Foundation Trust, Sutton, UK.
FAU - Dolling, David
AU  - Dolling D
AD  - Clinical Trials and Statistics Unit, Institute of Cancer Research, London SM2
      5NG, UK.
FAU - Figueiredo, Ines
AU  - Figueiredo I
AD  - Prostate Cancer Targeted Therapy and Cancer Biomarkers Group, Institute of Cancer
      Research and The Royal Marsden NHS Foundation Trust, Sutton, UK.
FAU - Sumanasuriya, Semini
AU  - Sumanasuriya S
AD  - Prostate Cancer Targeted Therapy and Cancer Biomarkers Group, Institute of Cancer
      Research and The Royal Marsden NHS Foundation Trust, Sutton, UK.
FAU - Crespo, Mateus
AU  - Crespo M
AD  - Prostate Cancer Targeted Therapy and Cancer Biomarkers Group, Institute of Cancer
      Research and The Royal Marsden NHS Foundation Trust, Sutton, UK.
FAU - Aslam, Adam
AU  - Aslam A
AD  - Department of Pathology, UT Southwestern Medical Center, Dallas, TX 75390, USA.
FAU - Li, Rui
AU  - Li R
AD  - Department of Urology, UT Southwestern Medical Center, Dallas, TX 75390, USA.
FAU - Yin, Yi
AU  - Yin Y
AD  - Department of Urology, UT Southwestern Medical Center, Dallas, TX 75390, USA.
FAU - Mukherjee, Bipasha
AU  - Mukherjee B
AD  - Department of Radiation Oncology, UT Southwestern Medical Center, Dallas, TX
      75390, USA.
FAU - Kanchwala, Mohammed
AU  - Kanchwala M
AD  - Eugene McDermott Center for Human Growth & Development, UT Southwestern Medical
      Center, Dallas, TX 75390, USA.
FAU - Hughes, Ashley M
AU  - Hughes AM
AD  - Target Sciences, GlaxoSmithKline, Collegeville, PA 19426, USA.
FAU - Halsey, Wendy S
AU  - Halsey WS
AD  - Target Sciences, GlaxoSmithKline, Collegeville, PA 19426, USA.
FAU - Chiang, Cheng-Ming
AU  - Chiang CM
AD  - Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center,
      Dallas, TX 75390, USA; Department of Biochemistry, UT Southwestern Medical
      Center, Dallas, TX 75390, USA; Department of Pharmacology, UT Southwestern
      Medical Center, Dallas, TX 75390, USA.
FAU - Xing, Chao
AU  - Xing C
AD  - Eugene McDermott Center for Human Growth & Development, UT Southwestern Medical
      Center, Dallas, TX 75390, USA.
FAU - Raj, Ganesh V
AU  - Raj GV
AD  - Department of Urology, UT Southwestern Medical Center, Dallas, TX 75390, USA.
FAU - Burma, Sandeep
AU  - Burma S
AD  - Department of Radiation Oncology, UT Southwestern Medical Center, Dallas, TX
      75390, USA.
FAU - de Bono, Johann
AU  - de Bono J
AD  - Prostate Cancer Targeted Therapy and Cancer Biomarkers Group, Institute of Cancer
      Research and The Royal Marsden NHS Foundation Trust, Sutton, UK.
FAU - Mani, Ram S
AU  - Mani RS
AD  - Department of Pathology, UT Southwestern Medical Center, Dallas, TX 75390, USA;
      Department of Urology, UT Southwestern Medical Center, Dallas, TX 75390, USA;
      Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center,
      Dallas, TX 75390, USA. Electronic address: ram.mani@utsouthwestern.edu.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cell Rep
JT  - Cell reports
JID - 101573691
OTO - NOTNLM
OT  - BRD2
OT  - BRD4
OT  - CRPC
OT  - DNA repair
OT  - NHEJ
OT  - TMPRSS2-ERG
OT  - gene fusion
OT  - genomic rearrangements
OT  - non-homologous end joining
OT  - prostate cancer
EDAT- 2018/01/19 06:00
MHDA- 2018/01/19 06:00
CRDT- 2018/01/19 06:00
PHST- 2017/07/05 00:00 [received]
PHST- 2017/11/06 00:00 [revised]
PHST- 2017/12/21 00:00 [accepted]
PHST- 2018/01/19 06:00 [entrez]
PHST- 2018/01/19 06:00 [pubmed]
PHST- 2018/01/19 06:00 [medline]
AID - S2211-1247(17)31915-0 [pii]
AID - 10.1016/j.celrep.2017.12.078 [doi]
PST - ppublish
SO  - Cell Rep. 2018 Jan 16;22(3):796-808. doi: 10.1016/j.celrep.2017.12.078.

PMID- 29181191
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20171219
IS  - 2059-7029 (Print)
IS  - 2059-7029 (Linking)
VI  - 2
IP  - 3
DP  - 2017
TI  - Anti-PD-1/anti-PD-L1 immunotherapy versus docetaxel for previously treated
      advanced non-small cell lung cancer: a systematic review and meta-analysis of
      randomised clinical trials.
PG  - e000236
LID - 10.1136/esmoopen-2017-000236 [doi]
AB  - Background: To compare the efficacy and toxicity of anti-programmed cell death
      receptor 1 (PD-1) and anti-programmed cell death ligand 1 (PD-L1) versus
      docetaxel in previously treated patients with advanced non-small cell lung cancer
      (NSCLC). Materials and methods: Phase III randomised clinical trials (RCTs) were 
      identified after systematic review of databases and conference proceedings. A
      random-effect model was used to determine the pooled HR for overall survival
      (OS), progression-free survival (PFS) and duration of response. The pooled OR for
      overall response and treatment-related side effects were calculated using the
      inverse-variance method. Heterogeneity was measured using the tau(2) and I(2)
      statistics. Results: After the systematic review, we included four phase III RCTs
      (n=2737) in this meta-analysis. The use of anti-PD-1/anti-PD-L1 agents
      (atezolizumab, nivolumab and pembrolizumab) was associated with better OS in
      comparison with docetaxel alone (HR: 0.69; 95% CI 0.63 to 0.75; p<0.00001).
      Similarly, the PFS and duration of response was significantly longer for patients
      receiving immunotherapy (HR: 0.85; 95% CI 0.75 to 0.96; p=0.007 and HR:0.32; 95% 
      CI 0.24 to 0.43; p<0.00001, respectively) versus single agent chemotherapy. The
      overall response rate was also higher for patients who received any
      anti-PD-1/anti-PD-L1 therapy in comparison with docetaxel (OR: 1.77; 95% CI 1.26 
      to 2.50; p=0.001). Regarding treatment-related side effects grade 3 or higher,
      patients who received immunotherapy experienced less events than patients
      allocated to docetaxel (OR: 0.19; 95% CI 0.12 to 0.30; p<0.00001). Conclusion:
      The use of anti-PD-1/anti-PD-L1 therapy in patients with progressive advanced
      NSCLC is significantly better than the use of docetaxel in terms of OS, PFS,
      duration of response and overall response rate.
FAU - Ramos-Esquivel, Allan
AU  - Ramos-Esquivel A
AD  - Departamento de Oncologia Medica, Hospital San Juan de Dios, Universidad de Costa
      Rica, San Jose, Costa Rica.
FAU - van der Laat, Alicia
AU  - van der Laat A
AD  - Departamento de Oncologia Medica, Hospital Mexico, San Jose, Costa Rica.
FAU - Rojas-Vigott, Raquel
AU  - Rojas-Vigott R
AD  - Departamento de Oncologia Medica, Hospital Mexico, San Jose, Costa Rica.
FAU - Juarez, Melissa
AU  - Juarez M
AD  - Departamento de Oncologia Medica, Hospital San Juan de Dios, Universidad de Costa
      Rica, San Jose, Costa Rica.
FAU - Corrales-Rodriguez, Luis
AU  - Corrales-Rodriguez L
AD  - Department of Medical Oncology, Centro de Investigacion y Manejo del Cancer
      CIMCA, San Jose, Costa Rica.
LA  - eng
PT  - Journal Article
DEP - 20170831
PL  - England
TA  - ESMO Open
JT  - ESMO open
JID - 101690685
PMC - PMC5699523
OTO - NOTNLM
OT  - atezolizumab
OT  - meta-analysis
OT  - nivolumab
OT  - non-small-cell lung cancer
OT  - pembrolizumab
COIS- Competing interests: None declared.
EDAT- 2017/11/29 06:00
MHDA- 2017/11/29 06:01
CRDT- 2017/11/29 06:00
PHST- 2017/06/23 00:00 [received]
PHST- 2017/07/13 00:00 [revised]
PHST- 2017/07/18 00:00 [accepted]
PHST- 2017/11/29 06:00 [entrez]
PHST- 2017/11/29 06:00 [pubmed]
PHST- 2017/11/29 06:01 [medline]
AID - 10.1136/esmoopen-2017-000236 [doi]
AID - esmoopen-2017-000236 [pii]
PST - epublish
SO  - ESMO Open. 2017 Aug 31;2(3):e000236. doi: 10.1136/esmoopen-2017-000236.
      eCollection 2017.

PMID- 29334375
OWN - NLM
STAT- Publisher
LR  - 20180129
IS  - 1546-170X (Electronic)
IS  - 1078-8956 (Linking)
DP  - 2018 Jan 15
TI  - A small-molecule inhibitor of the ubiquitin activating enzyme for cancer
      treatment.
LID - 10.1038/nm.4474 [doi]
AB  - The ubiquitin-proteasome system (UPS) comprises a network of enzymes that is
      responsible for maintaining cellular protein homeostasis. The therapeutic
      potential of this pathway has been validated by the clinical successes of a
      number of UPS modulators, including proteasome inhibitors and immunomodulatory
      imide drugs (IMiDs). Here we identified TAK-243 (formerly known as MLN7243) as a 
      potent, mechanism-based small-molecule inhibitor of the ubiquitin activating
      enzyme (UAE), the primary mammalian E1 enzyme that regulates the ubiquitin
      conjugation cascade. TAK-243 treatment caused depletion of cellular ubiquitin
      conjugates, resulting in disruption of signaling events, induction of proteotoxic
      stress, and impairment of cell cycle progression and DNA damage repair pathways. 
      TAK-243 treatment caused death of cancer cells and, in primary human xenograft
      studies, demonstrated antitumor activity at tolerated doses. Due to its
      specificity and potency, TAK-243 allows for interrogation of ubiquitin biology
      and for assessment of UAE inhibition as a new approach for cancer treatment.
FAU - Hyer, Marc L
AU  - Hyer ML
AD  - Takeda Pharmaceuticals Inc., Cambridge, Massachusetts, USA.
FAU - Milhollen, Michael A
AU  - Milhollen MA
AD  - Takeda Pharmaceuticals Inc., Cambridge, Massachusetts, USA.
FAU - Ciavarri, Jeff
AU  - Ciavarri J
AD  - Takeda Pharmaceuticals Inc., Cambridge, Massachusetts, USA.
FAU - Fleming, Paul
AU  - Fleming P
AD  - Takeda Pharmaceuticals Inc., Cambridge, Massachusetts, USA.
FAU - Traore, Tary
AU  - Traore T
AD  - Takeda Pharmaceuticals Inc., Cambridge, Massachusetts, USA.
FAU - Sappal, Darshan
AU  - Sappal D
AD  - Takeda Pharmaceuticals Inc., Cambridge, Massachusetts, USA.
FAU - Huck, Jessica
AU  - Huck J
AD  - Takeda Pharmaceuticals Inc., Cambridge, Massachusetts, USA.
FAU - Shi, Judy
AU  - Shi J
AD  - Takeda Pharmaceuticals Inc., Cambridge, Massachusetts, USA.
FAU - Gavin, James
AU  - Gavin J
AD  - Takeda Pharmaceuticals Inc., Cambridge, Massachusetts, USA.
FAU - Brownell, Jim
AU  - Brownell J
AD  - Takeda Pharmaceuticals Inc., Cambridge, Massachusetts, USA.
FAU - Yang, Yu
AU  - Yang Y
AD  - Takeda Pharmaceuticals Inc., Cambridge, Massachusetts, USA.
FAU - Stringer, Bradley
AU  - Stringer B
AD  - Takeda Pharmaceuticals Inc., Cambridge, Massachusetts, USA.
FAU - Griffin, Robert
AU  - Griffin R
AD  - Takeda Pharmaceuticals Inc., Cambridge, Massachusetts, USA.
FAU - Bruzzese, Frank
AU  - Bruzzese F
AD  - Takeda Pharmaceuticals Inc., Cambridge, Massachusetts, USA.
FAU - Soucy, Teresa
AU  - Soucy T
AD  - Takeda Pharmaceuticals Inc., Cambridge, Massachusetts, USA.
FAU - Duffy, Jennifer
AU  - Duffy J
AD  - Takeda Pharmaceuticals Inc., Cambridge, Massachusetts, USA.
FAU - Rabino, Claudia
AU  - Rabino C
AD  - Takeda Pharmaceuticals Inc., Cambridge, Massachusetts, USA.
FAU - Riceberg, Jessica
AU  - Riceberg J
AD  - Takeda Pharmaceuticals Inc., Cambridge, Massachusetts, USA.
FAU - Hoar, Kara
AU  - Hoar K
AD  - Takeda Pharmaceuticals Inc., Cambridge, Massachusetts, USA.
FAU - Lublinsky, Anya
AU  - Lublinsky A
AD  - Takeda Pharmaceuticals Inc., Cambridge, Massachusetts, USA.
FAU - Menon, Saurabh
AU  - Menon S
AD  - Takeda Pharmaceuticals Inc., Cambridge, Massachusetts, USA.
FAU - Sintchak, Michael
AU  - Sintchak M
AD  - Takeda Pharmaceuticals Inc., Cambridge, Massachusetts, USA.
FAU - Bump, Nancy
AU  - Bump N
AD  - Takeda Pharmaceuticals Inc., Cambridge, Massachusetts, USA.
FAU - Pulukuri, Sai M
AU  - Pulukuri SM
AD  - Takeda Pharmaceuticals Inc., Cambridge, Massachusetts, USA.
FAU - Langston, Steve
AU  - Langston S
AD  - Takeda Pharmaceuticals Inc., Cambridge, Massachusetts, USA.
FAU - Tirrell, Stephen
AU  - Tirrell S
AD  - Takeda Pharmaceuticals Inc., Cambridge, Massachusetts, USA.
FAU - Kuranda, Mike
AU  - Kuranda M
AD  - Takeda Pharmaceuticals Inc., Cambridge, Massachusetts, USA.
FAU - Veiby, Petter
AU  - Veiby P
AD  - Takeda Pharmaceuticals Inc., Cambridge, Massachusetts, USA.
FAU - Newcomb, John
AU  - Newcomb J
AD  - Takeda Pharmaceuticals Inc., Cambridge, Massachusetts, USA.
FAU - Li, Ping
AU  - Li P
AD  - Takeda Pharmaceuticals Inc., Cambridge, Massachusetts, USA.
FAU - Wu, Jing Tao
AU  - Wu JT
AD  - Takeda Pharmaceuticals Inc., Cambridge, Massachusetts, USA.
FAU - Powe, Josh
AU  - Powe J
AD  - Takeda Pharmaceuticals Inc., Cambridge, Massachusetts, USA.
FAU - Dick, Lawrence R
AU  - Dick LR
AUID- ORCID: http://orcid.org/0000-0002-6880-0405
AD  - Takeda Pharmaceuticals Inc., Cambridge, Massachusetts, USA.
FAU - Greenspan, Paul
AU  - Greenspan P
AD  - Takeda Pharmaceuticals Inc., Cambridge, Massachusetts, USA.
FAU - Galvin, Katherine
AU  - Galvin K
AD  - Takeda Pharmaceuticals Inc., Cambridge, Massachusetts, USA.
FAU - Manfredi, Mark
AU  - Manfredi M
AD  - Takeda Pharmaceuticals Inc., Cambridge, Massachusetts, USA.
FAU - Claiborne, Chris
AU  - Claiborne C
AD  - Takeda Pharmaceuticals Inc., Cambridge, Massachusetts, USA.
FAU - Amidon, Benjamin S
AU  - Amidon BS
AD  - Takeda Pharmaceuticals Inc., Cambridge, Massachusetts, USA.
FAU - Bence, Neil F
AU  - Bence NF
AD  - Takeda Pharmaceuticals Inc., Cambridge, Massachusetts, USA.
LA  - eng
PT  - Journal Article
DEP - 20180115
PL  - United States
TA  - Nat Med
JT  - Nature medicine
JID - 9502015
EDAT- 2018/01/16 06:00
MHDA- 2018/01/16 06:00
CRDT- 2018/01/16 06:00
PHST- 2016/09/30 00:00 [received]
PHST- 2017/12/19 00:00 [accepted]
PHST- 2018/01/16 06:00 [pubmed]
PHST- 2018/01/16 06:00 [medline]
PHST- 2018/01/16 06:00 [entrez]
AID - nm.4474 [pii]
AID - 10.1038/nm.4474 [doi]
PST - aheadofprint
SO  - Nat Med. 2018 Jan 15. pii: nm.4474. doi: 10.1038/nm.4474.

PMID- 29323298
OWN - NLM
STAT- In-Data-Review
LR  - 20180120
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 553
IP  - 7687
DP  - 2018 Jan 11
TI  - A metabolic function of FGFR3-TACC3 gene fusions in cancer.
PG  - 222-227
LID - 10.1038/nature25171 [doi]
AB  - Chromosomal translocations that generate in-frame oncogenic gene fusions are
      notable examples of the success of targeted cancer therapies. We have previously 
      described gene fusions of FGFR3-TACC3 (F3-T3) in 3% of human glioblastoma cases. 
      Subsequent studies have reported similar frequencies of F3-T3 in many other
      cancers, indicating that F3-T3 is a commonly occuring fusion across all tumour
      types. F3-T3 fusions are potent oncogenes that confer sensitivity to FGFR
      inhibitors, but the downstream oncogenic signalling pathways remain unknown. Here
      we show that human tumours with F3-T3 fusions cluster within transcriptional
      subgroups that are characterized by the activation of mitochondrial functions.
      F3-T3 activates oxidative phosphorylation and mitochondrial biogenesis and
      induces sensitivity to inhibitors of oxidative metabolism. Phosphorylation of the
      phosphopeptide PIN4 is an intermediate step in the signalling pathway of the
      activation of mitochondrial metabolism. The F3-T3-PIN4 axis triggers the
      biogenesis of peroxisomes and the synthesis of new proteins. The anabolic
      response converges on the PGC1alpha coactivator through the production of
      intracellular reactive oxygen species, which enables mitochondrial respiration
      and tumour growth. These data illustrate the oncogenic circuit engaged by F3-T3
      and show that F3-T3-positive tumours rely on mitochondrial respiration,
      highlighting this pathway as a therapeutic opportunity for the treatment of
      tumours with F3-T3 fusions. We also provide insights into the genetic alterations
      that initiate the chain of metabolic responses that drive mitochondrial
      metabolism in cancer.
FAU - Frattini, Veronique
AU  - Frattini V
AD  - Institute for Cancer Genetics, Columbia University Medical Center, New York, New 
      York 10032, USA.
FAU - Pagnotta, Stefano M
AU  - Pagnotta SM
AD  - Institute for Cancer Genetics, Columbia University Medical Center, New York, New 
      York 10032, USA.
AD  - Department of Science and Technology, Universita' degli Studi del Sannio,
      Benevento 82100, Italy.
FAU - Tala
AU  - Tala
AD  - Institute for Cancer Genetics, Columbia University Medical Center, New York, New 
      York 10032, USA.
FAU - Fan, Jerry J
AU  - Fan JJ
AD  - The Arthur and Sonia Labatt Brain Tumour Research Centre, Program in
      Developmental and Stem Cell Biology, The Hospital for Sick Children, Toronto,
      Ontario M5G 1A4, Canada.
AD  - Department of Molecular Genetics, University of Toronto, Toronto, Ontario M5S
      1A8, Canada.
FAU - Russo, Marco V
AU  - Russo MV
AD  - Institute for Cancer Genetics, Columbia University Medical Center, New York, New 
      York 10032, USA.
FAU - Lee, Sang Bae
AU  - Lee SB
AD  - Institute for Cancer Genetics, Columbia University Medical Center, New York, New 
      York 10032, USA.
FAU - Garofano, Luciano
AU  - Garofano L
AD  - Institute for Cancer Genetics, Columbia University Medical Center, New York, New 
      York 10032, USA.
AD  - Department of Science and Technology, Universita' degli Studi del Sannio,
      Benevento 82100, Italy.
AD  - BIOGEM Istituto di Ricerche Genetiche 'G. Salvatore', Campo Reale, 83031 Ariano
      Irpino, Italy.
FAU - Zhang, Jing
AU  - Zhang J
AD  - Institute for Cancer Genetics, Columbia University Medical Center, New York, New 
      York 10032, USA.
FAU - Shi, Peiguo
AU  - Shi P
AD  - Institute for Cancer Genetics, Columbia University Medical Center, New York, New 
      York 10032, USA.
FAU - Lewis, Genevieve
AU  - Lewis G
AD  - Institute for Cancer Genetics, Columbia University Medical Center, New York, New 
      York 10032, USA.
FAU - Sanson, Heloise
AU  - Sanson H
AD  - Institute for Cancer Genetics, Columbia University Medical Center, New York, New 
      York 10032, USA.
FAU - Frederick, Vanessa
AU  - Frederick V
AD  - Institute for Cancer Genetics, Columbia University Medical Center, New York, New 
      York 10032, USA.
FAU - Castano, Angelica M
AU  - Castano AM
AD  - Institute for Cancer Genetics, Columbia University Medical Center, New York, New 
      York 10032, USA.
FAU - Cerulo, Luigi
AU  - Cerulo L
AD  - Department of Science and Technology, Universita' degli Studi del Sannio,
      Benevento 82100, Italy.
AD  - BIOGEM Istituto di Ricerche Genetiche 'G. Salvatore', Campo Reale, 83031 Ariano
      Irpino, Italy.
FAU - Rolland, Delphine C M
AU  - Rolland DCM
AD  - Department of Pathology and Laboratory Medicine, Perelman School of Medicine at
      University of Pennsylvania, Philadelphia, Pennsylvania 19104-6100, USA.
FAU - Mall, Raghvendra
AU  - Mall R
AD  - Qatar Computing Research Institute (QCRI), Hamad Bin Khalifa University, Doha,
      Qatar.
FAU - Mokhtari, Karima
AU  - Mokhtari K
AD  - Sorbonne Universites UPMC Univ Paris 06, UMR S 1127, Inserm U 1127, CNRS UMR
      7225, ICM, Paris 75013, France.
AD  - AP-HP, Groupe Hospitalier Pitie Salpetriere, Laboratoire de Neuropathologie R
      Escourolle, Paris 75013, France.
AD  - Onconeurotek, AP-HP, Paris 75013, France.
FAU - Elenitoba-Johnson, Kojo S J
AU  - Elenitoba-Johnson KSJ
AD  - Department of Pathology and Laboratory Medicine, Perelman School of Medicine at
      University of Pennsylvania, Philadelphia, Pennsylvania 19104-6100, USA.
FAU - Sanson, Marc
AU  - Sanson M
AD  - Sorbonne Universites UPMC Univ Paris 06, UMR S 1127, Inserm U 1127, CNRS UMR
      7225, ICM, Paris 75013, France.
AD  - Onconeurotek, AP-HP, Paris 75013, France.
AD  - AP-HP, Hopital de la Pitie-Salpetriere, Service de Neurologie 2, Paris 75013,
      France.
FAU - Huang, Xi
AU  - Huang X
AD  - The Arthur and Sonia Labatt Brain Tumour Research Centre, Program in
      Developmental and Stem Cell Biology, The Hospital for Sick Children, Toronto,
      Ontario M5G 1A4, Canada.
AD  - Department of Molecular Genetics, University of Toronto, Toronto, Ontario M5S
      1A8, Canada.
FAU - Ceccarelli, Michele
AU  - Ceccarelli M
AD  - Department of Science and Technology, Universita' degli Studi del Sannio,
      Benevento 82100, Italy.
AD  - BIOGEM Istituto di Ricerche Genetiche 'G. Salvatore', Campo Reale, 83031 Ariano
      Irpino, Italy.
FAU - Lasorella, Anna
AU  - Lasorella A
AD  - Institute for Cancer Genetics, Columbia University Medical Center, New York, New 
      York 10032, USA.
AD  - Department of Pathology and Cell Biology, Columbia University Medical Center, New
      York, New York 10032, USA.
AD  - Department of Pediatrics, Columbia University Medical Center, New York, New York 
      10032, USA.
FAU - Iavarone, Antonio
AU  - Iavarone A
AD  - Institute for Cancer Genetics, Columbia University Medical Center, New York, New 
      York 10032, USA.
AD  - Department of Pathology and Cell Biology, Columbia University Medical Center, New
      York, New York 10032, USA.
AD  - Department of Neurology, Columbia University Medical Center, New York, New York
      10032, USA.
LA  - eng
GR  - R01 CA179044/CA/NCI NIH HHS/United States
GR  - R01 CA131126/CA/NCI NIH HHS/United States
GR  - R01 CA178546/CA/NCI NIH HHS/United States
GR  - R01 CA190891/CA/NCI NIH HHS/United States
GR  - R01 CA101644/CA/NCI NIH HHS/United States
GR  - T32 CA009503/CA/NCI NIH HHS/United States
GR  - U54 CA193313/CA/NCI NIH HHS/United States
GR  - R01 NS061776/NS/NINDS NIH HHS/United States
PT  - Journal Article
DEP - 20180103
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
PMC - PMC5771419
MID - NIHMS922777
EDAT- 2018/01/13 06:00
MHDA- 2018/01/13 06:00
CRDT- 2018/01/12 06:00
PMCR- 2018/07/03 00:00
PHST- 2016/12/11 00:00 [received]
PHST- 2017/11/24 00:00 [accepted]
PHST- 2018/07/03 00:00 [pmc-release]
PHST- 2018/01/12 06:00 [entrez]
PHST- 2018/01/13 06:00 [pubmed]
PHST- 2018/01/13 06:00 [medline]
AID - nature25171 [pii]
AID - 10.1038/nature25171 [doi]
PST - ppublish
SO  - Nature. 2018 Jan 11;553(7687):222-227. doi: 10.1038/nature25171. Epub 2018 Jan 3.

PMID- 29336888
OWN - NLM
STAT- Publisher
LR  - 20180116
IS  - 1097-4172 (Electronic)
IS  - 0092-8674 (Linking)
DP  - 2018 Jan 9
TI  - LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer.
LID - S0092-8674(17)31506-4 [pii]
LID - 10.1016/j.cell.2017.12.026 [doi]
AB  - Therapeutic harnessing of adaptive immunity via checkpoint inhibition has
      transformed the treatment of many cancers. Despite unprecedented long-term
      responses, most patients do not respond to these therapies. Immunotherapy
      non-responders often harbor high levels of circulating myeloid-derived suppressor
      cells (MDSCs)-an immunosuppressive innate cell population. Through genetic and
      pharmacological approaches, we uncovered a pathway governing MDSC abundance in
      multiple cancer types. Therapeutic liver-X nuclear receptor (LXR) agonism reduced
      MDSC abundance in murine models and in patients treated in a first-in-human dose 
      escalation phase 1 trial. MDSC depletion was associated with activation of
      cytotoxic T lymphocyte (CTL) responses in mice and patients. The LXR
      transcriptional target ApoE mediated these effects in mice, where LXR/ApoE
      activation therapy elicited robust anti-tumor responses and also enhanced T cell 
      activation during various immune-based therapies. We implicate the LXR/ApoE axis 
      in the regulation of innate immune suppression and as a target for enhancing the 
      efficacy of cancer immunotherapy in patients.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Tavazoie, Masoud F
AU  - Tavazoie MF
AD  - Laboratory of Systems Cancer Biology, The Rockefeller University, New York, NY,
      USA. Electronic address: mtavazoie@mail.rockefeller.edu.
FAU - Pollack, Ilana
AU  - Pollack I
AD  - Laboratory of Systems Cancer Biology, The Rockefeller University, New York, NY,
      USA.
FAU - Tanqueco, Raissa
AU  - Tanqueco R
AD  - Laboratory of Systems Cancer Biology, The Rockefeller University, New York, NY,
      USA.
FAU - Ostendorf, Benjamin N
AU  - Ostendorf BN
AD  - Laboratory of Systems Cancer Biology, The Rockefeller University, New York, NY,
      USA.
FAU - Reis, Bernardo S
AU  - Reis BS
AD  - Laboratory of Mucosal Immunology, The Rockefeller University, New York, NY, USA.
FAU - Gonsalves, Foster C
AU  - Gonsalves FC
AD  - Rgenix, New York, NY, USA.
FAU - Kurth, Isabel
AU  - Kurth I
AD  - Rgenix, New York, NY, USA.
FAU - Andreu-Agullo, Celia
AU  - Andreu-Agullo C
AD  - Rgenix, New York, NY, USA.
FAU - Derbyshire, Mark L
AU  - Derbyshire ML
AD  - Laboratory of Systems Cancer Biology, The Rockefeller University, New York, NY,
      USA.
FAU - Posada, Jessica
AU  - Posada J
AD  - Laboratory of Systems Cancer Biology, The Rockefeller University, New York, NY,
      USA.
FAU - Takeda, Shugaku
AU  - Takeda S
AD  - Rgenix, New York, NY, USA.
FAU - Tafreshian, Kimia N
AU  - Tafreshian KN
AD  - Laboratory of Systems Cancer Biology, The Rockefeller University, New York, NY,
      USA.
FAU - Rowinsky, Eric
AU  - Rowinsky E
AD  - Rgenix, New York, NY, USA.
FAU - Szarek, Michael
AU  - Szarek M
AD  - Rgenix, New York, NY, USA; School of Public Health, Downstate Medical Center,
      Brooklyn, NY, USA.
FAU - Waltzman, Roger J
AU  - Waltzman RJ
AD  - Rgenix, New York, NY, USA.
FAU - Mcmillan, Elizabeth A
AU  - Mcmillan EA
AD  - Laboratory of Systems Cancer Biology, The Rockefeller University, New York, NY,
      USA.
FAU - Zhao, Connie
AU  - Zhao C
AD  - Laboratory of Systems Cancer Biology, The Rockefeller University, New York, NY,
      USA.
FAU - Mita, Monica
AU  - Mita M
AD  - Cedars-Sinai Medical Center, Los Angeles, CA, USA.
FAU - Mita, Alain
AU  - Mita A
AD  - Cedars-Sinai Medical Center, Los Angeles, CA, USA.
FAU - Chmielowski, Bartosz
AU  - Chmielowski B
AD  - Department of Medicine, University of California, Los Angeles, CA, USA.
FAU - Postow, Michael A
AU  - Postow MA
AD  - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY,
      USA; Weill Cornell Medical College, New York, NY, USA.
FAU - Ribas, Antoni
AU  - Ribas A
AD  - Department of Medicine, University of California, Los Angeles, CA, USA.
FAU - Mucida, Daniel
AU  - Mucida D
AD  - Laboratory of Mucosal Immunology, The Rockefeller University, New York, NY, USA. 
      Electronic address: mucida@mail.rockefeller.edu.
FAU - Tavazoie, Sohail F
AU  - Tavazoie SF
AD  - Laboratory of Systems Cancer Biology, The Rockefeller University, New York, NY,
      USA. Electronic address: stavazoie@mail.rockefeller.edu.
LA  - eng
PT  - Journal Article
DEP - 20180109
PL  - United States
TA  - Cell
JT  - Cell
JID - 0413066
OTO - NOTNLM
OT  - ApoE
OT  - LRP8
OT  - LXR
OT  - MDSC
OT  - cancer
OT  - clinical trial
OT  - immune therapy
OT  - myeloid
OT  - nuclear hormone receptor
OT  - tumor immunology
EDAT- 2018/01/18 06:00
MHDA- 2018/01/18 06:00
CRDT- 2018/01/17 06:00
PHST- 2017/08/25 00:00 [received]
PHST- 2017/11/14 00:00 [revised]
PHST- 2017/12/19 00:00 [accepted]
PHST- 2018/01/17 06:00 [entrez]
PHST- 2018/01/18 06:00 [pubmed]
PHST- 2018/01/18 06:00 [medline]
AID - S0092-8674(17)31506-4 [pii]
AID - 10.1016/j.cell.2017.12.026 [doi]
PST - aheadofprint
SO  - Cell. 2018 Jan 9. pii: S0092-8674(17)31506-4. doi: 10.1016/j.cell.2017.12.026.

PMID- 29036752
OWN - NLM
STAT- In-Data-Review
LR  - 20171016
IS  - 1806-9339 (Electronic)
IS  - 0100-7203 (Linking)
VI  - 39
IP  - 10
DP  - 2017 Oct
TI  - Breast Cancer Screening: Updated Recommendations of the Brazilian College of
      Radiology and Diagnostic Imaging, Brazilian Breast Disease Society, and Brazilian
      Federation of Gynecological and Obstetrical Associations.
PG  - 569-575
LID - 10.1055/s-0037-1606348 [doi]
FAU - Urban, Linei Augusta Brolini Delle
AU  - Urban LABD
AD  - Coordinator of the National Mammography Commission, Colegio Brasileiro de
      Radiologia e Diagnostico por Imagem (CBR), Sao Paulo, SP, Brazil.
FAU - Chala, Luciano Fernandes
AU  - Chala LF
AD  - Member of the National Mammography Commission, Representative of the Colegio
      Brasileiro de Radiologia e Diagnostico por Imagem (CBR), Sao Paulo, SP, Brazil.
FAU - Bauab, Selma di Pace
AU  - Bauab SDP
AD  - Member of the National Mammography Commission, Representative of the Colegio
      Brasileiro de Radiologia e Diagnostico por Imagem (CBR), Sao Paulo, SP, Brazil.
FAU - Schaefer, Marcela Brisighelli
AU  - Schaefer MB
AD  - Member of the National Mammography Commission, Representative of the Colegio
      Brasileiro de Radiologia e Diagnostico por Imagem (CBR), Sao Paulo, SP, Brazil.
FAU - Santos, Radia Pereira Dos
AU  - Santos RPD
AD  - Member of the National Mammography Commission, Representative of the Colegio
      Brasileiro de Radiologia e Diagnostico por Imagem (CBR), Sao Paulo, SP, Brazil.
FAU - Maranhao, Norma Medicis de Albuquerque
AU  - Maranhao NMA
AD  - Member of the National Mammography Commission, Representative of the Colegio
      Brasileiro de Radiologia e Diagnostico por Imagem (CBR), Sao Paulo, SP, Brazil.
FAU - Kefalas, Ana Lucia
AU  - Kefalas AL
AD  - Member of the National Mammography Commission, Representative of the Colegio
      Brasileiro de Radiologia e Diagnostico por Imagem (CBR), Sao Paulo, SP, Brazil.
FAU - Kalaf, Jose Michel
AU  - Kalaf JM
AD  - Member of the National Mammography Commission, Representative of the Colegio
      Brasileiro de Radiologia e Diagnostico por Imagem (CBR), Sao Paulo, SP, Brazil.
FAU - Ferreira, Carlos Alberto Pecci
AU  - Ferreira CAP
AD  - Member of the National Mammography Commission, Representative of the Colegio
      Brasileiro de Radiologia e Diagnostico por Imagem (CBR), Sao Paulo, SP, Brazil.
FAU - Canella, Ellyete de Oliveira
AU  - Canella EO
AD  - Member of the National Mammography Commission, Representative of the Colegio
      Brasileiro de Radiologia e Diagnostico por Imagem (CBR), Sao Paulo, SP, Brazil.
FAU - Peixoto, Joao Emilio
AU  - Peixoto JE
AD  - Member of the National Mammography Commission, Representative of the Colegio
      Brasileiro de Radiologia e Diagnostico por Imagem (CBR), Sao Paulo, SP, Brazil.
FAU - Amorim, Heverton Leal Ernesto de
AU  - Amorim HLE
AD  - Member of the National Mammography Commission, Representative of the Sociedade
      Brasileira de Mastologia (SBM), Sao Paulo, SP, Brazil.
FAU - Camargo Junior, Helio Sebastiao Amancio de
AU  - Camargo Junior HSA
AD  - Member of the National Mammography Commission, Representative of the Federacao
      Brasileira das Associacoes de Ginecologia e Obstetricia (Febrasgo), Rio de
      Janeiro, RJ, Brazil.
LA  - eng
PT  - Journal Article
TT  - Recomendacoes do Colegio Brasileiro de Radiologia e Diagnostico por Imagem, da
      Sociedade Brasileira de Mastologia e da Federacao Brasileira de Ginecologia e
      Obstetricia para o rastreamento do cancer de mama.
DEP - 20171016
PL  - Brazil
TA  - Rev Bras Ginecol Obstet
JT  - Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira
      das Sociedades de Ginecologia e Obstetricia
JID - 9214757
COIS- Conflicts to Interest: Study conducted by the National Mammography Commission of 
      the Colegio Brasileiro de Radiologia e Diagnostico por Imagem (CBR), Sao Paulo,
      SP, by the Sociedade Brasileira de Mastologia (SBM), Sao Paulo, SP, and by the
      Nacional Mammography Commission of Federacao Brasileira das Associacoes de
      Ginecologia e Obstetricia (Febrasgo), Rio de Janeiro, RJ, Brazil. This article,
      which is the product of a joint effort of the CBR, SBM, and Febrasgo, will be
      published in all three of the respective journals.
EDAT- 2017/10/17 06:00
MHDA- 2017/10/17 06:00
CRDT- 2017/10/17 06:00
PHST- 2017/10/17 06:00 [entrez]
PHST- 2017/10/17 06:00 [pubmed]
PHST- 2017/10/17 06:00 [medline]
AID - 10.1055/s-0037-1606348 [doi]
PST - ppublish
SO  - Rev Bras Ginecol Obstet. 2017 Oct;39(10):569-575. doi: 10.1055/s-0037-1606348.
      Epub 2017 Oct 16.

PMID- 29170499
OWN - NLM
STAT- In-Data-Review
LR  - 20171219
IS  - 2041-1723 (Electronic)
IS  - 2041-1723 (Linking)
VI  - 8
IP  - 1
DP  - 2017 Nov 24
TI  - DNA double-strand break repair pathway regulates PD-L1 expression in cancer
      cells.
PG  - 1751
LID - 10.1038/s41467-017-01883-9 [doi]
AB  - Accumulating evidence suggests that exogenous cellular stress induces PD-L1
      upregulation in cancer. A DNA double-strand break (DSB) is the most critical type
      of genotoxic stress, but the involvement of DSB repair in PD-L1 expression has
      not been investigated. Here we show that PD-L1 expression in cancer cells is
      upregulated in response to DSBs. This upregulation requires ATM/ATR/Chk1 kinases.
      Using an siRNA library targeting DSB repair genes, we discover that BRCA2
      depletion enhances Chk1-dependent PD-L1 upregulation after X-rays or PARP
      inhibition. In addition, we show that Ku70/80 depletion substantially enhances
      PD-L1 upregulation after X-rays. The upregulation by Ku80 depletion requires Chk1
      activation following DNA end-resection by Exonuclease 1. DSBs activate STAT1 and 
      STAT3 signalling, and IRF1 is required for DSB-dependent PD-L1 upregulation.
      Thus, our findings reveal the involvement of DSB repair in PD-L1 expression and
      provide mechanistic insight into how PD-L1 expression is regulated after DSBs.
FAU - Sato, Hiro
AU  - Sato H
AD  - Department of Radiation Oncology, Gunma University Graduate School of Medicine,
      Maebashi, Gunma, 371-8511, Japan.
FAU - Niimi, Atsuko
AU  - Niimi A
AD  - Research Program for Heavy Ion Therapy, Division of Integrated Oncology Research,
      Gunma University Initiative for Advanced Research (GIAR), Maebashi, Gunma,
      371-8511, Japan.
FAU - Yasuhara, Takaaki
AU  - Yasuhara T
AUID- ORCID: http://orcid.org/0000-0002-6719-5709
AD  - Laboratory of Molecular Radiology, Center for Disease Biology and Integrative
      Medicine, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo,
      113-8655, Japan.
FAU - Permata, Tiara Bunga Mayang
AU  - Permata TBM
AD  - Department of Radiation Oncology, Gunma University Graduate School of Medicine,
      Maebashi, Gunma, 371-8511, Japan.
FAU - Hagiwara, Yoshihiko
AU  - Hagiwara Y
AD  - Department of Radiation Oncology, Gunma University Graduate School of Medicine,
      Maebashi, Gunma, 371-8511, Japan.
FAU - Isono, Mayu
AU  - Isono M
AD  - Advanced Scientific Research Leaders Development Unit, Gunma University,
      Maebashi, Gunma, 371-8511, Japan.
FAU - Nuryadi, Endang
AU  - Nuryadi E
AD  - Department of Radiation Oncology, Gunma University Graduate School of Medicine,
      Maebashi, Gunma, 371-8511, Japan.
FAU - Sekine, Ryota
AU  - Sekine R
AD  - Advanced Scientific Research Leaders Development Unit, Gunma University,
      Maebashi, Gunma, 371-8511, Japan.
FAU - Oike, Takahiro
AU  - Oike T
AD  - Department of Radiation Oncology, Gunma University Graduate School of Medicine,
      Maebashi, Gunma, 371-8511, Japan.
FAU - Kakoti, Sangeeta
AU  - Kakoti S
AD  - Department of Radiation Oncology, Gunma University Graduate School of Medicine,
      Maebashi, Gunma, 371-8511, Japan.
FAU - Yoshimoto, Yuya
AU  - Yoshimoto Y
AD  - Department of Radiation Oncology, Gunma University Graduate School of Medicine,
      Maebashi, Gunma, 371-8511, Japan.
FAU - Held, Kathryn D
AU  - Held KD
AD  - Department of Radiation Oncology, Massachusetts General Hospital/Harvard Medical 
      School, Boston, MA, 02114, USA.
AD  - International Open Laboratory, Gunma University Initiative for Advanced Research 
      (GIAR), Maebashi, Gunma, 371-8511, Japan.
FAU - Suzuki, Yoshiyuki
AU  - Suzuki Y
AD  - Department of Radiation Oncology, Fukushima Medical University, Fukushima,
      960-1295, Japan.
FAU - Kono, Koji
AU  - Kono K
AD  - Department of Gastrointestinal Tract Surgery, Fukushima Medical University,
      Fukushima, 960-1295, Japan.
FAU - Miyagawa, Kiyoshi
AU  - Miyagawa K
AD  - Laboratory of Molecular Radiology, Center for Disease Biology and Integrative
      Medicine, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo,
      113-8655, Japan.
FAU - Nakano, Takashi
AU  - Nakano T
AD  - Department of Radiation Oncology, Gunma University Graduate School of Medicine,
      Maebashi, Gunma, 371-8511, Japan.
AD  - Research Program for Heavy Ion Therapy, Division of Integrated Oncology Research,
      Gunma University Initiative for Advanced Research (GIAR), Maebashi, Gunma,
      371-8511, Japan.
FAU - Shibata, Atsushi
AU  - Shibata A
AD  - Advanced Scientific Research Leaders Development Unit, Gunma University,
      Maebashi, Gunma, 371-8511, Japan. shibata.at@gunma-u.ac.jp.
AD  - Education and Research Support Center, Graduate School of Medicine, Gunma
      University, Maebashi, Gunma, 371-8511, Japan. shibata.at@gunma-u.ac.jp.
LA  - eng
PT  - Journal Article
DEP - 20171124
PL  - England
TA  - Nat Commun
JT  - Nature communications
JID - 101528555
PMC - PMC5701012
EDAT- 2017/11/25 06:00
MHDA- 2017/11/25 06:00
CRDT- 2017/11/25 06:00
PHST- 2017/01/23 00:00 [received]
PHST- 2017/10/23 00:00 [accepted]
PHST- 2017/11/25 06:00 [entrez]
PHST- 2017/11/25 06:00 [pubmed]
PHST- 2017/11/25 06:00 [medline]
AID - 10.1038/s41467-017-01883-9 [doi]
AID - 10.1038/s41467-017-01883-9 [pii]
PST - epublish
SO  - Nat Commun. 2017 Nov 24;8(1):1751. doi: 10.1038/s41467-017-01883-9.

PMID- 29305587
OWN - NLM
STAT- Publisher
LR  - 20180106
IS  - 1476-5403 (Electronic)
IS  - 1350-9047 (Linking)
DP  - 2018 Jan 5
TI  - Consensus molecular subtypes of colorectal cancer are recapitulated in in vitro
      and in vivo models.
LID - 10.1038/s41418-017-0011-5 [doi]
AB  - Colorectal cancer (CRC) is a highly heterogeneous disease both from a molecular
      and clinical perspective. Several distinct molecular entities, such as
      microsatellite instability (MSI), have been defined that make up biologically
      distinct subgroups with their own clinical course. Recent data indicated that CRC
      can be best segregated into four groups called consensus molecular subtypes
      (CMS1-4), each of which has a unique biology and gene expression pattern. In
      order to develop improved, subtype-specific therapies and to gain insight into
      the molecular wiring and origin of these subtypes, reliable models are needed.
      This study was designed to determine the heterogeneity and identify the presence 
      of CMSs in a large panel of CRC cell lines, primary cultures and patient-derived 
      xenografts (PDX). We provide a repository encompassing this heterogeneity and
      moreover describe that a large part of the models can be robustly assigned to one
      of the four CMSs, independent of the stromal contribution. We subsequently
      validate our CMS stratification by functional analysis which for instance shows
      mesenchymal enrichment in CMS4 and metabolic dysregulation in CMS3. Finally, we
      observe a clear difference in sensitivity to chemotherapy-induced apoptosis,
      specifically between CMS2 and CMS4. This relates to the in vivo efficacy of
      chemotherapy, which delays outgrowth of CMS2, but not CMS4 xenografts. Combined
      our data indicate that molecular subtypes are faithfully modelled in CRC cell
      cultures and PDXs, representing tumour cell intrinsic and stable features. This
      repository provides researchers with a platform to study CRC using the existing
      heterogeneity.
FAU - Linnekamp, Janneke F
AU  - Linnekamp JF
AD  - Cancer Center Amsterdam, Laboratory of Experimental Oncology and Radiobiology
      (LEXOR), CEMM, Academic Medical Center, Meibergdreef 9, 1105AZ, Amsterdam, The
      Netherlands.
AD  - Cancer Genomics Netherlands, Utrecht, The Netherlands.
FAU - Hooff, Sander R van
AU  - Hooff SRV
AD  - Cancer Center Amsterdam, Laboratory of Experimental Oncology and Radiobiology
      (LEXOR), CEMM, Academic Medical Center, Meibergdreef 9, 1105AZ, Amsterdam, The
      Netherlands.
AD  - Cancer Genomics Netherlands, Utrecht, The Netherlands.
FAU - Prasetyanti, Pramudita R
AU  - Prasetyanti PR
AD  - Cancer Center Amsterdam, Laboratory of Experimental Oncology and Radiobiology
      (LEXOR), CEMM, Academic Medical Center, Meibergdreef 9, 1105AZ, Amsterdam, The
      Netherlands.
AD  - Cancer Genomics Netherlands, Utrecht, The Netherlands.
FAU - Kandimalla, Raju
AU  - Kandimalla R
AD  - Cancer Center Amsterdam, Laboratory of Experimental Oncology and Radiobiology
      (LEXOR), CEMM, Academic Medical Center, Meibergdreef 9, 1105AZ, Amsterdam, The
      Netherlands.
AD  - Cancer Genomics Netherlands, Utrecht, The Netherlands.
FAU - Buikhuisen, Joyce Y
AU  - Buikhuisen JY
AD  - Cancer Center Amsterdam, Laboratory of Experimental Oncology and Radiobiology
      (LEXOR), CEMM, Academic Medical Center, Meibergdreef 9, 1105AZ, Amsterdam, The
      Netherlands.
AD  - Cancer Genomics Netherlands, Utrecht, The Netherlands.
FAU - Fessler, Evelyn
AU  - Fessler E
AD  - Cancer Center Amsterdam, Laboratory of Experimental Oncology and Radiobiology
      (LEXOR), CEMM, Academic Medical Center, Meibergdreef 9, 1105AZ, Amsterdam, The
      Netherlands.
AD  - Cancer Genomics Netherlands, Utrecht, The Netherlands.
AD  - Gene Center and Department of Biochemistry, Ludwig-Maximilians-Universitat
      Munchen, Feodor-Lynen-Strasse 25, 81377, Munich, Germany.
FAU - Ramesh, Prashanthi
AU  - Ramesh P
AD  - Cancer Center Amsterdam, Laboratory of Experimental Oncology and Radiobiology
      (LEXOR), CEMM, Academic Medical Center, Meibergdreef 9, 1105AZ, Amsterdam, The
      Netherlands.
AD  - Cancer Genomics Netherlands, Utrecht, The Netherlands.
FAU - Lee, Kelly A S T
AU  - Lee KAST
AD  - Cancer Center Amsterdam, Laboratory of Experimental Oncology and Radiobiology
      (LEXOR), CEMM, Academic Medical Center, Meibergdreef 9, 1105AZ, Amsterdam, The
      Netherlands.
AD  - Cancer Genomics Netherlands, Utrecht, The Netherlands.
FAU - Bochove, Grehor G W
AU  - Bochove GGW
AD  - Cancer Center Amsterdam, Laboratory of Experimental Oncology and Radiobiology
      (LEXOR), CEMM, Academic Medical Center, Meibergdreef 9, 1105AZ, Amsterdam, The
      Netherlands.
AD  - Cancer Genomics Netherlands, Utrecht, The Netherlands.
FAU - de Jong, Johan H
AU  - de Jong JH
AD  - Cancer Center Amsterdam, Laboratory of Experimental Oncology and Radiobiology
      (LEXOR), CEMM, Academic Medical Center, Meibergdreef 9, 1105AZ, Amsterdam, The
      Netherlands.
AD  - Cancer Genomics Netherlands, Utrecht, The Netherlands.
FAU - Cameron, Kate
AU  - Cameron K
AD  - Cancer Center Amsterdam, Laboratory of Experimental Oncology and Radiobiology
      (LEXOR), CEMM, Academic Medical Center, Meibergdreef 9, 1105AZ, Amsterdam, The
      Netherlands.
AD  - Cancer Genomics Netherlands, Utrecht, The Netherlands.
FAU - Leersum, Ronald van
AU  - Leersum RV
AD  - Cancer Center Amsterdam, Laboratory of Experimental Oncology and Radiobiology
      (LEXOR), CEMM, Academic Medical Center, Meibergdreef 9, 1105AZ, Amsterdam, The
      Netherlands.
AD  - Cancer Genomics Netherlands, Utrecht, The Netherlands.
FAU - Rodermond, Hans M
AU  - Rodermond HM
AD  - Cancer Center Amsterdam, Laboratory of Experimental Oncology and Radiobiology
      (LEXOR), CEMM, Academic Medical Center, Meibergdreef 9, 1105AZ, Amsterdam, The
      Netherlands.
AD  - Cancer Genomics Netherlands, Utrecht, The Netherlands.
FAU - Franitza, Marek
AU  - Franitza M
AD  - Cologne Center for Genomics (CCG), University of Cologne, Cologne, Germany.
AD  - Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated
      Diseases (CECAD), University of Cologne, Cologne, Germany.
FAU - Nurnberg, Peter
AU  - Nurnberg P
AD  - Cologne Center for Genomics (CCG), University of Cologne, Cologne, Germany.
AD  - Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated
      Diseases (CECAD), University of Cologne, Cologne, Germany.
FAU - Mangiapane, Laura R
AU  - Mangiapane LR
AD  - Cellular and Molecular Pathophysiology Laboratory, Department of Surgical and
      Oncological Sciences, University of Palermo, Via del Vespro 131, Palermo, 90134, 
      Italy.
FAU - Wang, Xin
AU  - Wang X
AD  - Department of Biomedical Sciences, City University of Hong Kong, Kowloon Tong,
      Hong Kong.
FAU - Clevers, Hans
AU  - Clevers H
AD  - Cancer Genomics Netherlands, Utrecht, The Netherlands.
AD  - Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW) and
      University Medical Centre (UMC), 3584 CT, Utrecht, The Netherlands.
AD  - Princess Maxima Centre for Pediatric Oncology, Utrecht, 3584 CT, The Netherlands.
FAU - Vermeulen, Louis
AU  - Vermeulen L
AUID- ORCID: http://orcid.org/0000-0002-6066-789X
AD  - Cancer Center Amsterdam, Laboratory of Experimental Oncology and Radiobiology
      (LEXOR), CEMM, Academic Medical Center, Meibergdreef 9, 1105AZ, Amsterdam, The
      Netherlands.
FAU - Stassi, Giorgio
AU  - Stassi G
AD  - Cellular and Molecular Pathophysiology Laboratory, Department of Surgical and
      Oncological Sciences, University of Palermo, Via del Vespro 131, Palermo, 90134, 
      Italy.
FAU - Medema, Jan Paul
AU  - Medema JP
AD  - Cancer Center Amsterdam, Laboratory of Experimental Oncology and Radiobiology
      (LEXOR), CEMM, Academic Medical Center, Meibergdreef 9, 1105AZ, Amsterdam, The
      Netherlands. j.p.medema@amc.nl.
AD  - Cancer Genomics Netherlands, Utrecht, The Netherlands. j.p.medema@amc.nl.
LA  - eng
PT  - Journal Article
DEP - 20180105
PL  - England
TA  - Cell Death Differ
JT  - Cell death and differentiation
JID - 9437445
EDAT- 2018/01/07 06:00
MHDA- 2018/01/07 06:00
CRDT- 2018/01/07 06:00
PHST- 2017/06/23 00:00 [received]
PHST- 2017/10/09 00:00 [accepted]
PHST- 2017/10/02 00:00 [revised]
PHST- 2018/01/07 06:00 [entrez]
PHST- 2018/01/07 06:00 [pubmed]
PHST- 2018/01/07 06:00 [medline]
AID - 10.1038/s41418-017-0011-5 [doi]
AID - 10.1038/s41418-017-0011-5 [pii]
PST - aheadofprint
SO  - Cell Death Differ. 2018 Jan 5. pii: 10.1038/s41418-017-0011-5. doi:
      10.1038/s41418-017-0011-5.

PMID- 29341833
OWN - NLM
STAT- Publisher
LR  - 20180117
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Linking)
DP  - 2018 Jan 17
TI  - Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining
      Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy.
PG  - JCO2017751644
LID - 10.1200/JCO.2017.75.1644 [doi]
AB  - Purpose Treating solid tumors with cancer immunotherapy (CIT) can result in
      unconventional responses and overall survival (OS) benefits that are not
      adequately captured by Response Evaluation Criteria In Solid Tumors (RECIST)
      v1.1. We describe immune-modified RECIST (imRECIST) criteria, designed to better 
      capture CIT responses. Patients and Methods Atezolizumab data from clinical
      trials in non-small-cell lung cancer, metastatic urothelial carcinoma, renal cell
      carcinoma, and melanoma were evaluated. Modifications to imRECIST versus RECIST
      v1.1 included allowance for best overall response after progressive disease (PD) 
      and changes in PD definitions per new lesions (NLs) and nontarget lesions.
      imRECIST progression-free survival (PFS) did not count initial PD as an event if 
      the subsequent scan showed disease control. OS was evaluated using conditional
      landmarks in patients whose PFS differed by imRECIST versus RECIST v1.1. Results 
      The best overall response was 1% to 2% greater, the disease control rate was 8%
      to 13% greater, and the median PFS was 0.5 to 1.5 months longer per imRECIST
      versus RECIST v1.1. Extension of imRECIST PFS versus RECIST v1.1 PFS was
      associated with longer or similar OS. Patterns of progression analysis revealed
      that patients who developed NLs without target lesion (TL) progression had a
      similar or shorter OS compared with patients with RECIST v1.1 TL progression.
      Patients infrequently experienced a spike pattern (TLs increase, then decrease)
      but had longer OS than patients without TL reversion. Conclusion Evaluation of
      PFS and patterns of response and progression revealed that allowance for TL
      reversion from PD per imRECIST may better identify patients with OS benefit.
      Progression defined by the isolated appearance of NLs, however, is not associated
      with longer OS. These results may inform additional modifications to radiographic
      criteria (including imRECIST) to better reflect efficacy with CIT agents.
FAU - Hodi, F Stephen
AU  - Hodi FS
AD  - F. Stephen Hodi and Mizuki Nishino, Dana-Farber Cancer Institute, Boston, MA;
      Marcus Ballinger, Benjamin Lyons, Chris McKenna, Ina Rhee, Gregg Fine, Nathan
      Winslow, and Daniel S. Chen, Genentech, South San Francisco, CA; Jean-Charles
      Soria, AstraZeneca, Gaithersburg, MD; Josep Tabernero, Universitat Autonoma de
      Barcelona, Barcelona, Spain; Thomas Powles, Queen Mary University of London,
      London, United Kingdom; David Smith, Compass Oncology, Vancouver, WA; Axel Hoos, 
      GlaxoSmithKline, Collegeville, PA; Ulrich Beyer, Roche Innovation Center, Basel, 
      Switzerland; and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New
      York, NY.
FAU - Ballinger, Marcus
AU  - Ballinger M
AD  - F. Stephen Hodi and Mizuki Nishino, Dana-Farber Cancer Institute, Boston, MA;
      Marcus Ballinger, Benjamin Lyons, Chris McKenna, Ina Rhee, Gregg Fine, Nathan
      Winslow, and Daniel S. Chen, Genentech, South San Francisco, CA; Jean-Charles
      Soria, AstraZeneca, Gaithersburg, MD; Josep Tabernero, Universitat Autonoma de
      Barcelona, Barcelona, Spain; Thomas Powles, Queen Mary University of London,
      London, United Kingdom; David Smith, Compass Oncology, Vancouver, WA; Axel Hoos, 
      GlaxoSmithKline, Collegeville, PA; Ulrich Beyer, Roche Innovation Center, Basel, 
      Switzerland; and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New
      York, NY.
FAU - Lyons, Benjamin
AU  - Lyons B
AD  - F. Stephen Hodi and Mizuki Nishino, Dana-Farber Cancer Institute, Boston, MA;
      Marcus Ballinger, Benjamin Lyons, Chris McKenna, Ina Rhee, Gregg Fine, Nathan
      Winslow, and Daniel S. Chen, Genentech, South San Francisco, CA; Jean-Charles
      Soria, AstraZeneca, Gaithersburg, MD; Josep Tabernero, Universitat Autonoma de
      Barcelona, Barcelona, Spain; Thomas Powles, Queen Mary University of London,
      London, United Kingdom; David Smith, Compass Oncology, Vancouver, WA; Axel Hoos, 
      GlaxoSmithKline, Collegeville, PA; Ulrich Beyer, Roche Innovation Center, Basel, 
      Switzerland; and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New
      York, NY.
FAU - Soria, Jean-Charles
AU  - Soria JC
AD  - F. Stephen Hodi and Mizuki Nishino, Dana-Farber Cancer Institute, Boston, MA;
      Marcus Ballinger, Benjamin Lyons, Chris McKenna, Ina Rhee, Gregg Fine, Nathan
      Winslow, and Daniel S. Chen, Genentech, South San Francisco, CA; Jean-Charles
      Soria, AstraZeneca, Gaithersburg, MD; Josep Tabernero, Universitat Autonoma de
      Barcelona, Barcelona, Spain; Thomas Powles, Queen Mary University of London,
      London, United Kingdom; David Smith, Compass Oncology, Vancouver, WA; Axel Hoos, 
      GlaxoSmithKline, Collegeville, PA; Ulrich Beyer, Roche Innovation Center, Basel, 
      Switzerland; and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New
      York, NY.
FAU - Nishino, Mizuki
AU  - Nishino M
AD  - F. Stephen Hodi and Mizuki Nishino, Dana-Farber Cancer Institute, Boston, MA;
      Marcus Ballinger, Benjamin Lyons, Chris McKenna, Ina Rhee, Gregg Fine, Nathan
      Winslow, and Daniel S. Chen, Genentech, South San Francisco, CA; Jean-Charles
      Soria, AstraZeneca, Gaithersburg, MD; Josep Tabernero, Universitat Autonoma de
      Barcelona, Barcelona, Spain; Thomas Powles, Queen Mary University of London,
      London, United Kingdom; David Smith, Compass Oncology, Vancouver, WA; Axel Hoos, 
      GlaxoSmithKline, Collegeville, PA; Ulrich Beyer, Roche Innovation Center, Basel, 
      Switzerland; and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New
      York, NY.
FAU - Tabernero, Josep
AU  - Tabernero J
AD  - F. Stephen Hodi and Mizuki Nishino, Dana-Farber Cancer Institute, Boston, MA;
      Marcus Ballinger, Benjamin Lyons, Chris McKenna, Ina Rhee, Gregg Fine, Nathan
      Winslow, and Daniel S. Chen, Genentech, South San Francisco, CA; Jean-Charles
      Soria, AstraZeneca, Gaithersburg, MD; Josep Tabernero, Universitat Autonoma de
      Barcelona, Barcelona, Spain; Thomas Powles, Queen Mary University of London,
      London, United Kingdom; David Smith, Compass Oncology, Vancouver, WA; Axel Hoos, 
      GlaxoSmithKline, Collegeville, PA; Ulrich Beyer, Roche Innovation Center, Basel, 
      Switzerland; and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New
      York, NY.
FAU - Powles, Thomas
AU  - Powles T
AD  - F. Stephen Hodi and Mizuki Nishino, Dana-Farber Cancer Institute, Boston, MA;
      Marcus Ballinger, Benjamin Lyons, Chris McKenna, Ina Rhee, Gregg Fine, Nathan
      Winslow, and Daniel S. Chen, Genentech, South San Francisco, CA; Jean-Charles
      Soria, AstraZeneca, Gaithersburg, MD; Josep Tabernero, Universitat Autonoma de
      Barcelona, Barcelona, Spain; Thomas Powles, Queen Mary University of London,
      London, United Kingdom; David Smith, Compass Oncology, Vancouver, WA; Axel Hoos, 
      GlaxoSmithKline, Collegeville, PA; Ulrich Beyer, Roche Innovation Center, Basel, 
      Switzerland; and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New
      York, NY.
FAU - Smith, David
AU  - Smith D
AD  - F. Stephen Hodi and Mizuki Nishino, Dana-Farber Cancer Institute, Boston, MA;
      Marcus Ballinger, Benjamin Lyons, Chris McKenna, Ina Rhee, Gregg Fine, Nathan
      Winslow, and Daniel S. Chen, Genentech, South San Francisco, CA; Jean-Charles
      Soria, AstraZeneca, Gaithersburg, MD; Josep Tabernero, Universitat Autonoma de
      Barcelona, Barcelona, Spain; Thomas Powles, Queen Mary University of London,
      London, United Kingdom; David Smith, Compass Oncology, Vancouver, WA; Axel Hoos, 
      GlaxoSmithKline, Collegeville, PA; Ulrich Beyer, Roche Innovation Center, Basel, 
      Switzerland; and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New
      York, NY.
FAU - Hoos, Axel
AU  - Hoos A
AD  - F. Stephen Hodi and Mizuki Nishino, Dana-Farber Cancer Institute, Boston, MA;
      Marcus Ballinger, Benjamin Lyons, Chris McKenna, Ina Rhee, Gregg Fine, Nathan
      Winslow, and Daniel S. Chen, Genentech, South San Francisco, CA; Jean-Charles
      Soria, AstraZeneca, Gaithersburg, MD; Josep Tabernero, Universitat Autonoma de
      Barcelona, Barcelona, Spain; Thomas Powles, Queen Mary University of London,
      London, United Kingdom; David Smith, Compass Oncology, Vancouver, WA; Axel Hoos, 
      GlaxoSmithKline, Collegeville, PA; Ulrich Beyer, Roche Innovation Center, Basel, 
      Switzerland; and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New
      York, NY.
FAU - McKenna, Chris
AU  - McKenna C
AD  - F. Stephen Hodi and Mizuki Nishino, Dana-Farber Cancer Institute, Boston, MA;
      Marcus Ballinger, Benjamin Lyons, Chris McKenna, Ina Rhee, Gregg Fine, Nathan
      Winslow, and Daniel S. Chen, Genentech, South San Francisco, CA; Jean-Charles
      Soria, AstraZeneca, Gaithersburg, MD; Josep Tabernero, Universitat Autonoma de
      Barcelona, Barcelona, Spain; Thomas Powles, Queen Mary University of London,
      London, United Kingdom; David Smith, Compass Oncology, Vancouver, WA; Axel Hoos, 
      GlaxoSmithKline, Collegeville, PA; Ulrich Beyer, Roche Innovation Center, Basel, 
      Switzerland; and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New
      York, NY.
FAU - Beyer, Ulrich
AU  - Beyer U
AD  - F. Stephen Hodi and Mizuki Nishino, Dana-Farber Cancer Institute, Boston, MA;
      Marcus Ballinger, Benjamin Lyons, Chris McKenna, Ina Rhee, Gregg Fine, Nathan
      Winslow, and Daniel S. Chen, Genentech, South San Francisco, CA; Jean-Charles
      Soria, AstraZeneca, Gaithersburg, MD; Josep Tabernero, Universitat Autonoma de
      Barcelona, Barcelona, Spain; Thomas Powles, Queen Mary University of London,
      London, United Kingdom; David Smith, Compass Oncology, Vancouver, WA; Axel Hoos, 
      GlaxoSmithKline, Collegeville, PA; Ulrich Beyer, Roche Innovation Center, Basel, 
      Switzerland; and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New
      York, NY.
FAU - Rhee, Ina
AU  - Rhee I
AD  - F. Stephen Hodi and Mizuki Nishino, Dana-Farber Cancer Institute, Boston, MA;
      Marcus Ballinger, Benjamin Lyons, Chris McKenna, Ina Rhee, Gregg Fine, Nathan
      Winslow, and Daniel S. Chen, Genentech, South San Francisco, CA; Jean-Charles
      Soria, AstraZeneca, Gaithersburg, MD; Josep Tabernero, Universitat Autonoma de
      Barcelona, Barcelona, Spain; Thomas Powles, Queen Mary University of London,
      London, United Kingdom; David Smith, Compass Oncology, Vancouver, WA; Axel Hoos, 
      GlaxoSmithKline, Collegeville, PA; Ulrich Beyer, Roche Innovation Center, Basel, 
      Switzerland; and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New
      York, NY.
FAU - Fine, Gregg
AU  - Fine G
AD  - F. Stephen Hodi and Mizuki Nishino, Dana-Farber Cancer Institute, Boston, MA;
      Marcus Ballinger, Benjamin Lyons, Chris McKenna, Ina Rhee, Gregg Fine, Nathan
      Winslow, and Daniel S. Chen, Genentech, South San Francisco, CA; Jean-Charles
      Soria, AstraZeneca, Gaithersburg, MD; Josep Tabernero, Universitat Autonoma de
      Barcelona, Barcelona, Spain; Thomas Powles, Queen Mary University of London,
      London, United Kingdom; David Smith, Compass Oncology, Vancouver, WA; Axel Hoos, 
      GlaxoSmithKline, Collegeville, PA; Ulrich Beyer, Roche Innovation Center, Basel, 
      Switzerland; and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New
      York, NY.
FAU - Winslow, Nathan
AU  - Winslow N
AD  - F. Stephen Hodi and Mizuki Nishino, Dana-Farber Cancer Institute, Boston, MA;
      Marcus Ballinger, Benjamin Lyons, Chris McKenna, Ina Rhee, Gregg Fine, Nathan
      Winslow, and Daniel S. Chen, Genentech, South San Francisco, CA; Jean-Charles
      Soria, AstraZeneca, Gaithersburg, MD; Josep Tabernero, Universitat Autonoma de
      Barcelona, Barcelona, Spain; Thomas Powles, Queen Mary University of London,
      London, United Kingdom; David Smith, Compass Oncology, Vancouver, WA; Axel Hoos, 
      GlaxoSmithKline, Collegeville, PA; Ulrich Beyer, Roche Innovation Center, Basel, 
      Switzerland; and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New
      York, NY.
FAU - Chen, Daniel S
AU  - Chen DS
AD  - F. Stephen Hodi and Mizuki Nishino, Dana-Farber Cancer Institute, Boston, MA;
      Marcus Ballinger, Benjamin Lyons, Chris McKenna, Ina Rhee, Gregg Fine, Nathan
      Winslow, and Daniel S. Chen, Genentech, South San Francisco, CA; Jean-Charles
      Soria, AstraZeneca, Gaithersburg, MD; Josep Tabernero, Universitat Autonoma de
      Barcelona, Barcelona, Spain; Thomas Powles, Queen Mary University of London,
      London, United Kingdom; David Smith, Compass Oncology, Vancouver, WA; Axel Hoos, 
      GlaxoSmithKline, Collegeville, PA; Ulrich Beyer, Roche Innovation Center, Basel, 
      Switzerland; and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New
      York, NY.
FAU - Wolchok, Jedd D
AU  - Wolchok JD
AD  - F. Stephen Hodi and Mizuki Nishino, Dana-Farber Cancer Institute, Boston, MA;
      Marcus Ballinger, Benjamin Lyons, Chris McKenna, Ina Rhee, Gregg Fine, Nathan
      Winslow, and Daniel S. Chen, Genentech, South San Francisco, CA; Jean-Charles
      Soria, AstraZeneca, Gaithersburg, MD; Josep Tabernero, Universitat Autonoma de
      Barcelona, Barcelona, Spain; Thomas Powles, Queen Mary University of London,
      London, United Kingdom; David Smith, Compass Oncology, Vancouver, WA; Axel Hoos, 
      GlaxoSmithKline, Collegeville, PA; Ulrich Beyer, Roche Innovation Center, Basel, 
      Switzerland; and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New
      York, NY.
LA  - eng
PT  - Journal Article
DEP - 20180117
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of
      Clinical Oncology
JID - 8309333
EDAT- 2018/01/18 06:00
MHDA- 2018/01/18 06:00
CRDT- 2018/01/18 06:00
PHST- 2018/01/18 06:00 [entrez]
PHST- 2018/01/18 06:00 [pubmed]
PHST- 2018/01/18 06:00 [medline]
AID - 10.1200/JCO.2017.75.1644 [doi]
PST - aheadofprint
SO  - J Clin Oncol. 2018 Jan 17:JCO2017751644. doi: 10.1200/JCO.2017.75.1644.

PMID- 29298117
OWN - NLM
STAT- Publisher
LR  - 20180103
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Linking)
DP  - 2018 Jan 3
TI  - Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations
      With Survival in Metastatic Triple-Negative Breast Cancer.
PG  - JCO2017760033
LID - 10.1200/JCO.2017.76.0033 [doi]
AB  - Purpose Cell-free DNA (cfDNA) offers the potential for minimally invasive
      genome-wide profiling of tumor alterations without tumor biopsy and may be
      associated with patient prognosis. Triple-negative breast cancer (TNBC) is
      characterized by few mutations but extensive somatic copy number alterations
      (SCNAs), yet little is known regarding SCNAs in metastatic TNBC. We sought to
      evaluate SCNAs in metastatic TNBC exclusively via cfDNA and determine if cfDNA
      tumor fraction is associated with overall survival in metastatic TNBC. Patients
      and Methods In this retrospective cohort study, we identified 164 patients with
      biopsy-proven metastatic TNBC at a single tertiary care institution who received 
      prior chemotherapy in the (neo)adjuvant or metastatic setting. We performed
      low-coverage genome-wide sequencing of cfDNA from plasma. Results Without prior
      knowledge of tumor mutations, we determined tumor fraction of cfDNA for 96.3% of 
      patients and SCNAs for 63.9% of patients. Copy number profiles and percent genome
      altered were remarkably similar between metastatic and primary TNBCs. Certain
      SCNAs were more frequent in metastatic TNBCs relative to paired primary tumors
      and primary TNBCs in publicly available data sets The Cancer Genome Atlas and
      METABRIC, including chromosomal gains in drivers NOTCH2, AKT2, and AKT3.
      Prespecified cfDNA tumor fraction threshold of >/= 10% was associated with
      significantly worse metastatic survival (median, 6.4 v 15.9 months) and remained 
      significant independent of clinicopathologic factors (hazard ratio, 2.14; 95% CI,
      1.4 to 3.8; P < .001). Conclusion We present the largest genomic characterization
      of metastatic TNBC to our knowledge, exclusively from cfDNA. Evaluation of cfDNA 
      tumor fraction was feasible for nearly all patients, and tumor fraction >/= 10%
      is associated with significantly worse survival in this large metastatic TNBC
      cohort. Specific SCNAs are enriched and prognostic in metastatic TNBC, with
      implications for metastasis, resistance, and novel therapeutic approaches.
FAU - Stover, Daniel G
AU  - Stover DG
AD  - Daniel G. Stover, Ohio State University Comprehensive Cancer Center, Columbus,
      OH; Heather A. Parsons, Gavin Ha, William T. Barry, Hao Guo, Atish D. Choudhury, 
      Melissa E. Hughes, Deborah A. Dillon, Ann H. Partridge, Nikhil Wagle, Ian E.
      Krop, Todd R. Golub, Eric P. Winer, Sara M. Tolaney, and Nancy U. Lin,
      Dana-Farber Cancer Institute; Gad Getz, Massachusetts General Hospital, Boston;
      Gavin Ha, Samuel S. Freeman, Atish D. Choudhury, Gregory Gydush, Sarah C. Reed,
      Justin Rhoades, Denisse Rotem, Nikhil Wagle, Gad Getz, Todd R. Golub, and Viktor 
      A. Adalsteinsson, Broad Institute of Harvard and Massachusetts Institute of
      Technology; and J. Christopher Love, Massachusetts Institute of Technology,
      Cambridge, MA.
FAU - Parsons, Heather A
AU  - Parsons HA
AD  - Daniel G. Stover, Ohio State University Comprehensive Cancer Center, Columbus,
      OH; Heather A. Parsons, Gavin Ha, William T. Barry, Hao Guo, Atish D. Choudhury, 
      Melissa E. Hughes, Deborah A. Dillon, Ann H. Partridge, Nikhil Wagle, Ian E.
      Krop, Todd R. Golub, Eric P. Winer, Sara M. Tolaney, and Nancy U. Lin,
      Dana-Farber Cancer Institute; Gad Getz, Massachusetts General Hospital, Boston;
      Gavin Ha, Samuel S. Freeman, Atish D. Choudhury, Gregory Gydush, Sarah C. Reed,
      Justin Rhoades, Denisse Rotem, Nikhil Wagle, Gad Getz, Todd R. Golub, and Viktor 
      A. Adalsteinsson, Broad Institute of Harvard and Massachusetts Institute of
      Technology; and J. Christopher Love, Massachusetts Institute of Technology,
      Cambridge, MA.
FAU - Ha, Gavin
AU  - Ha G
AD  - Daniel G. Stover, Ohio State University Comprehensive Cancer Center, Columbus,
      OH; Heather A. Parsons, Gavin Ha, William T. Barry, Hao Guo, Atish D. Choudhury, 
      Melissa E. Hughes, Deborah A. Dillon, Ann H. Partridge, Nikhil Wagle, Ian E.
      Krop, Todd R. Golub, Eric P. Winer, Sara M. Tolaney, and Nancy U. Lin,
      Dana-Farber Cancer Institute; Gad Getz, Massachusetts General Hospital, Boston;
      Gavin Ha, Samuel S. Freeman, Atish D. Choudhury, Gregory Gydush, Sarah C. Reed,
      Justin Rhoades, Denisse Rotem, Nikhil Wagle, Gad Getz, Todd R. Golub, and Viktor 
      A. Adalsteinsson, Broad Institute of Harvard and Massachusetts Institute of
      Technology; and J. Christopher Love, Massachusetts Institute of Technology,
      Cambridge, MA.
FAU - Freeman, Samuel S
AU  - Freeman SS
AD  - Daniel G. Stover, Ohio State University Comprehensive Cancer Center, Columbus,
      OH; Heather A. Parsons, Gavin Ha, William T. Barry, Hao Guo, Atish D. Choudhury, 
      Melissa E. Hughes, Deborah A. Dillon, Ann H. Partridge, Nikhil Wagle, Ian E.
      Krop, Todd R. Golub, Eric P. Winer, Sara M. Tolaney, and Nancy U. Lin,
      Dana-Farber Cancer Institute; Gad Getz, Massachusetts General Hospital, Boston;
      Gavin Ha, Samuel S. Freeman, Atish D. Choudhury, Gregory Gydush, Sarah C. Reed,
      Justin Rhoades, Denisse Rotem, Nikhil Wagle, Gad Getz, Todd R. Golub, and Viktor 
      A. Adalsteinsson, Broad Institute of Harvard and Massachusetts Institute of
      Technology; and J. Christopher Love, Massachusetts Institute of Technology,
      Cambridge, MA.
FAU - Barry, William T
AU  - Barry WT
AD  - Daniel G. Stover, Ohio State University Comprehensive Cancer Center, Columbus,
      OH; Heather A. Parsons, Gavin Ha, William T. Barry, Hao Guo, Atish D. Choudhury, 
      Melissa E. Hughes, Deborah A. Dillon, Ann H. Partridge, Nikhil Wagle, Ian E.
      Krop, Todd R. Golub, Eric P. Winer, Sara M. Tolaney, and Nancy U. Lin,
      Dana-Farber Cancer Institute; Gad Getz, Massachusetts General Hospital, Boston;
      Gavin Ha, Samuel S. Freeman, Atish D. Choudhury, Gregory Gydush, Sarah C. Reed,
      Justin Rhoades, Denisse Rotem, Nikhil Wagle, Gad Getz, Todd R. Golub, and Viktor 
      A. Adalsteinsson, Broad Institute of Harvard and Massachusetts Institute of
      Technology; and J. Christopher Love, Massachusetts Institute of Technology,
      Cambridge, MA.
FAU - Guo, Hao
AU  - Guo H
AD  - Daniel G. Stover, Ohio State University Comprehensive Cancer Center, Columbus,
      OH; Heather A. Parsons, Gavin Ha, William T. Barry, Hao Guo, Atish D. Choudhury, 
      Melissa E. Hughes, Deborah A. Dillon, Ann H. Partridge, Nikhil Wagle, Ian E.
      Krop, Todd R. Golub, Eric P. Winer, Sara M. Tolaney, and Nancy U. Lin,
      Dana-Farber Cancer Institute; Gad Getz, Massachusetts General Hospital, Boston;
      Gavin Ha, Samuel S. Freeman, Atish D. Choudhury, Gregory Gydush, Sarah C. Reed,
      Justin Rhoades, Denisse Rotem, Nikhil Wagle, Gad Getz, Todd R. Golub, and Viktor 
      A. Adalsteinsson, Broad Institute of Harvard and Massachusetts Institute of
      Technology; and J. Christopher Love, Massachusetts Institute of Technology,
      Cambridge, MA.
FAU - Choudhury, Atish D
AU  - Choudhury AD
AD  - Daniel G. Stover, Ohio State University Comprehensive Cancer Center, Columbus,
      OH; Heather A. Parsons, Gavin Ha, William T. Barry, Hao Guo, Atish D. Choudhury, 
      Melissa E. Hughes, Deborah A. Dillon, Ann H. Partridge, Nikhil Wagle, Ian E.
      Krop, Todd R. Golub, Eric P. Winer, Sara M. Tolaney, and Nancy U. Lin,
      Dana-Farber Cancer Institute; Gad Getz, Massachusetts General Hospital, Boston;
      Gavin Ha, Samuel S. Freeman, Atish D. Choudhury, Gregory Gydush, Sarah C. Reed,
      Justin Rhoades, Denisse Rotem, Nikhil Wagle, Gad Getz, Todd R. Golub, and Viktor 
      A. Adalsteinsson, Broad Institute of Harvard and Massachusetts Institute of
      Technology; and J. Christopher Love, Massachusetts Institute of Technology,
      Cambridge, MA.
FAU - Gydush, Gregory
AU  - Gydush G
AD  - Daniel G. Stover, Ohio State University Comprehensive Cancer Center, Columbus,
      OH; Heather A. Parsons, Gavin Ha, William T. Barry, Hao Guo, Atish D. Choudhury, 
      Melissa E. Hughes, Deborah A. Dillon, Ann H. Partridge, Nikhil Wagle, Ian E.
      Krop, Todd R. Golub, Eric P. Winer, Sara M. Tolaney, and Nancy U. Lin,
      Dana-Farber Cancer Institute; Gad Getz, Massachusetts General Hospital, Boston;
      Gavin Ha, Samuel S. Freeman, Atish D. Choudhury, Gregory Gydush, Sarah C. Reed,
      Justin Rhoades, Denisse Rotem, Nikhil Wagle, Gad Getz, Todd R. Golub, and Viktor 
      A. Adalsteinsson, Broad Institute of Harvard and Massachusetts Institute of
      Technology; and J. Christopher Love, Massachusetts Institute of Technology,
      Cambridge, MA.
FAU - Reed, Sarah C
AU  - Reed SC
AD  - Daniel G. Stover, Ohio State University Comprehensive Cancer Center, Columbus,
      OH; Heather A. Parsons, Gavin Ha, William T. Barry, Hao Guo, Atish D. Choudhury, 
      Melissa E. Hughes, Deborah A. Dillon, Ann H. Partridge, Nikhil Wagle, Ian E.
      Krop, Todd R. Golub, Eric P. Winer, Sara M. Tolaney, and Nancy U. Lin,
      Dana-Farber Cancer Institute; Gad Getz, Massachusetts General Hospital, Boston;
      Gavin Ha, Samuel S. Freeman, Atish D. Choudhury, Gregory Gydush, Sarah C. Reed,
      Justin Rhoades, Denisse Rotem, Nikhil Wagle, Gad Getz, Todd R. Golub, and Viktor 
      A. Adalsteinsson, Broad Institute of Harvard and Massachusetts Institute of
      Technology; and J. Christopher Love, Massachusetts Institute of Technology,
      Cambridge, MA.
FAU - Rhoades, Justin
AU  - Rhoades J
AD  - Daniel G. Stover, Ohio State University Comprehensive Cancer Center, Columbus,
      OH; Heather A. Parsons, Gavin Ha, William T. Barry, Hao Guo, Atish D. Choudhury, 
      Melissa E. Hughes, Deborah A. Dillon, Ann H. Partridge, Nikhil Wagle, Ian E.
      Krop, Todd R. Golub, Eric P. Winer, Sara M. Tolaney, and Nancy U. Lin,
      Dana-Farber Cancer Institute; Gad Getz, Massachusetts General Hospital, Boston;
      Gavin Ha, Samuel S. Freeman, Atish D. Choudhury, Gregory Gydush, Sarah C. Reed,
      Justin Rhoades, Denisse Rotem, Nikhil Wagle, Gad Getz, Todd R. Golub, and Viktor 
      A. Adalsteinsson, Broad Institute of Harvard and Massachusetts Institute of
      Technology; and J. Christopher Love, Massachusetts Institute of Technology,
      Cambridge, MA.
FAU - Rotem, Denisse
AU  - Rotem D
AD  - Daniel G. Stover, Ohio State University Comprehensive Cancer Center, Columbus,
      OH; Heather A. Parsons, Gavin Ha, William T. Barry, Hao Guo, Atish D. Choudhury, 
      Melissa E. Hughes, Deborah A. Dillon, Ann H. Partridge, Nikhil Wagle, Ian E.
      Krop, Todd R. Golub, Eric P. Winer, Sara M. Tolaney, and Nancy U. Lin,
      Dana-Farber Cancer Institute; Gad Getz, Massachusetts General Hospital, Boston;
      Gavin Ha, Samuel S. Freeman, Atish D. Choudhury, Gregory Gydush, Sarah C. Reed,
      Justin Rhoades, Denisse Rotem, Nikhil Wagle, Gad Getz, Todd R. Golub, and Viktor 
      A. Adalsteinsson, Broad Institute of Harvard and Massachusetts Institute of
      Technology; and J. Christopher Love, Massachusetts Institute of Technology,
      Cambridge, MA.
FAU - Hughes, Melissa E
AU  - Hughes ME
AD  - Daniel G. Stover, Ohio State University Comprehensive Cancer Center, Columbus,
      OH; Heather A. Parsons, Gavin Ha, William T. Barry, Hao Guo, Atish D. Choudhury, 
      Melissa E. Hughes, Deborah A. Dillon, Ann H. Partridge, Nikhil Wagle, Ian E.
      Krop, Todd R. Golub, Eric P. Winer, Sara M. Tolaney, and Nancy U. Lin,
      Dana-Farber Cancer Institute; Gad Getz, Massachusetts General Hospital, Boston;
      Gavin Ha, Samuel S. Freeman, Atish D. Choudhury, Gregory Gydush, Sarah C. Reed,
      Justin Rhoades, Denisse Rotem, Nikhil Wagle, Gad Getz, Todd R. Golub, and Viktor 
      A. Adalsteinsson, Broad Institute of Harvard and Massachusetts Institute of
      Technology; and J. Christopher Love, Massachusetts Institute of Technology,
      Cambridge, MA.
FAU - Dillon, Deborah A
AU  - Dillon DA
AD  - Daniel G. Stover, Ohio State University Comprehensive Cancer Center, Columbus,
      OH; Heather A. Parsons, Gavin Ha, William T. Barry, Hao Guo, Atish D. Choudhury, 
      Melissa E. Hughes, Deborah A. Dillon, Ann H. Partridge, Nikhil Wagle, Ian E.
      Krop, Todd R. Golub, Eric P. Winer, Sara M. Tolaney, and Nancy U. Lin,
      Dana-Farber Cancer Institute; Gad Getz, Massachusetts General Hospital, Boston;
      Gavin Ha, Samuel S. Freeman, Atish D. Choudhury, Gregory Gydush, Sarah C. Reed,
      Justin Rhoades, Denisse Rotem, Nikhil Wagle, Gad Getz, Todd R. Golub, and Viktor 
      A. Adalsteinsson, Broad Institute of Harvard and Massachusetts Institute of
      Technology; and J. Christopher Love, Massachusetts Institute of Technology,
      Cambridge, MA.
FAU - Partridge, Ann H
AU  - Partridge AH
AD  - Daniel G. Stover, Ohio State University Comprehensive Cancer Center, Columbus,
      OH; Heather A. Parsons, Gavin Ha, William T. Barry, Hao Guo, Atish D. Choudhury, 
      Melissa E. Hughes, Deborah A. Dillon, Ann H. Partridge, Nikhil Wagle, Ian E.
      Krop, Todd R. Golub, Eric P. Winer, Sara M. Tolaney, and Nancy U. Lin,
      Dana-Farber Cancer Institute; Gad Getz, Massachusetts General Hospital, Boston;
      Gavin Ha, Samuel S. Freeman, Atish D. Choudhury, Gregory Gydush, Sarah C. Reed,
      Justin Rhoades, Denisse Rotem, Nikhil Wagle, Gad Getz, Todd R. Golub, and Viktor 
      A. Adalsteinsson, Broad Institute of Harvard and Massachusetts Institute of
      Technology; and J. Christopher Love, Massachusetts Institute of Technology,
      Cambridge, MA.
FAU - Wagle, Nikhil
AU  - Wagle N
AD  - Daniel G. Stover, Ohio State University Comprehensive Cancer Center, Columbus,
      OH; Heather A. Parsons, Gavin Ha, William T. Barry, Hao Guo, Atish D. Choudhury, 
      Melissa E. Hughes, Deborah A. Dillon, Ann H. Partridge, Nikhil Wagle, Ian E.
      Krop, Todd R. Golub, Eric P. Winer, Sara M. Tolaney, and Nancy U. Lin,
      Dana-Farber Cancer Institute; Gad Getz, Massachusetts General Hospital, Boston;
      Gavin Ha, Samuel S. Freeman, Atish D. Choudhury, Gregory Gydush, Sarah C. Reed,
      Justin Rhoades, Denisse Rotem, Nikhil Wagle, Gad Getz, Todd R. Golub, and Viktor 
      A. Adalsteinsson, Broad Institute of Harvard and Massachusetts Institute of
      Technology; and J. Christopher Love, Massachusetts Institute of Technology,
      Cambridge, MA.
FAU - Krop, Ian E
AU  - Krop IE
AD  - Daniel G. Stover, Ohio State University Comprehensive Cancer Center, Columbus,
      OH; Heather A. Parsons, Gavin Ha, William T. Barry, Hao Guo, Atish D. Choudhury, 
      Melissa E. Hughes, Deborah A. Dillon, Ann H. Partridge, Nikhil Wagle, Ian E.
      Krop, Todd R. Golub, Eric P. Winer, Sara M. Tolaney, and Nancy U. Lin,
      Dana-Farber Cancer Institute; Gad Getz, Massachusetts General Hospital, Boston;
      Gavin Ha, Samuel S. Freeman, Atish D. Choudhury, Gregory Gydush, Sarah C. Reed,
      Justin Rhoades, Denisse Rotem, Nikhil Wagle, Gad Getz, Todd R. Golub, and Viktor 
      A. Adalsteinsson, Broad Institute of Harvard and Massachusetts Institute of
      Technology; and J. Christopher Love, Massachusetts Institute of Technology,
      Cambridge, MA.
FAU - Getz, Gad
AU  - Getz G
AD  - Daniel G. Stover, Ohio State University Comprehensive Cancer Center, Columbus,
      OH; Heather A. Parsons, Gavin Ha, William T. Barry, Hao Guo, Atish D. Choudhury, 
      Melissa E. Hughes, Deborah A. Dillon, Ann H. Partridge, Nikhil Wagle, Ian E.
      Krop, Todd R. Golub, Eric P. Winer, Sara M. Tolaney, and Nancy U. Lin,
      Dana-Farber Cancer Institute; Gad Getz, Massachusetts General Hospital, Boston;
      Gavin Ha, Samuel S. Freeman, Atish D. Choudhury, Gregory Gydush, Sarah C. Reed,
      Justin Rhoades, Denisse Rotem, Nikhil Wagle, Gad Getz, Todd R. Golub, and Viktor 
      A. Adalsteinsson, Broad Institute of Harvard and Massachusetts Institute of
      Technology; and J. Christopher Love, Massachusetts Institute of Technology,
      Cambridge, MA.
FAU - Golub, Todd R
AU  - Golub TR
AD  - Daniel G. Stover, Ohio State University Comprehensive Cancer Center, Columbus,
      OH; Heather A. Parsons, Gavin Ha, William T. Barry, Hao Guo, Atish D. Choudhury, 
      Melissa E. Hughes, Deborah A. Dillon, Ann H. Partridge, Nikhil Wagle, Ian E.
      Krop, Todd R. Golub, Eric P. Winer, Sara M. Tolaney, and Nancy U. Lin,
      Dana-Farber Cancer Institute; Gad Getz, Massachusetts General Hospital, Boston;
      Gavin Ha, Samuel S. Freeman, Atish D. Choudhury, Gregory Gydush, Sarah C. Reed,
      Justin Rhoades, Denisse Rotem, Nikhil Wagle, Gad Getz, Todd R. Golub, and Viktor 
      A. Adalsteinsson, Broad Institute of Harvard and Massachusetts Institute of
      Technology; and J. Christopher Love, Massachusetts Institute of Technology,
      Cambridge, MA.
FAU - Love, J Christopher
AU  - Love JC
AD  - Daniel G. Stover, Ohio State University Comprehensive Cancer Center, Columbus,
      OH; Heather A. Parsons, Gavin Ha, William T. Barry, Hao Guo, Atish D. Choudhury, 
      Melissa E. Hughes, Deborah A. Dillon, Ann H. Partridge, Nikhil Wagle, Ian E.
      Krop, Todd R. Golub, Eric P. Winer, Sara M. Tolaney, and Nancy U. Lin,
      Dana-Farber Cancer Institute; Gad Getz, Massachusetts General Hospital, Boston;
      Gavin Ha, Samuel S. Freeman, Atish D. Choudhury, Gregory Gydush, Sarah C. Reed,
      Justin Rhoades, Denisse Rotem, Nikhil Wagle, Gad Getz, Todd R. Golub, and Viktor 
      A. Adalsteinsson, Broad Institute of Harvard and Massachusetts Institute of
      Technology; and J. Christopher Love, Massachusetts Institute of Technology,
      Cambridge, MA.
FAU - Winer, Eric P
AU  - Winer EP
AD  - Daniel G. Stover, Ohio State University Comprehensive Cancer Center, Columbus,
      OH; Heather A. Parsons, Gavin Ha, William T. Barry, Hao Guo, Atish D. Choudhury, 
      Melissa E. Hughes, Deborah A. Dillon, Ann H. Partridge, Nikhil Wagle, Ian E.
      Krop, Todd R. Golub, Eric P. Winer, Sara M. Tolaney, and Nancy U. Lin,
      Dana-Farber Cancer Institute; Gad Getz, Massachusetts General Hospital, Boston;
      Gavin Ha, Samuel S. Freeman, Atish D. Choudhury, Gregory Gydush, Sarah C. Reed,
      Justin Rhoades, Denisse Rotem, Nikhil Wagle, Gad Getz, Todd R. Golub, and Viktor 
      A. Adalsteinsson, Broad Institute of Harvard and Massachusetts Institute of
      Technology; and J. Christopher Love, Massachusetts Institute of Technology,
      Cambridge, MA.
FAU - Tolaney, Sara M
AU  - Tolaney SM
AD  - Daniel G. Stover, Ohio State University Comprehensive Cancer Center, Columbus,
      OH; Heather A. Parsons, Gavin Ha, William T. Barry, Hao Guo, Atish D. Choudhury, 
      Melissa E. Hughes, Deborah A. Dillon, Ann H. Partridge, Nikhil Wagle, Ian E.
      Krop, Todd R. Golub, Eric P. Winer, Sara M. Tolaney, and Nancy U. Lin,
      Dana-Farber Cancer Institute; Gad Getz, Massachusetts General Hospital, Boston;
      Gavin Ha, Samuel S. Freeman, Atish D. Choudhury, Gregory Gydush, Sarah C. Reed,
      Justin Rhoades, Denisse Rotem, Nikhil Wagle, Gad Getz, Todd R. Golub, and Viktor 
      A. Adalsteinsson, Broad Institute of Harvard and Massachusetts Institute of
      Technology; and J. Christopher Love, Massachusetts Institute of Technology,
      Cambridge, MA.
FAU - Lin, Nancy U
AU  - Lin NU
AD  - Daniel G. Stover, Ohio State University Comprehensive Cancer Center, Columbus,
      OH; Heather A. Parsons, Gavin Ha, William T. Barry, Hao Guo, Atish D. Choudhury, 
      Melissa E. Hughes, Deborah A. Dillon, Ann H. Partridge, Nikhil Wagle, Ian E.
      Krop, Todd R. Golub, Eric P. Winer, Sara M. Tolaney, and Nancy U. Lin,
      Dana-Farber Cancer Institute; Gad Getz, Massachusetts General Hospital, Boston;
      Gavin Ha, Samuel S. Freeman, Atish D. Choudhury, Gregory Gydush, Sarah C. Reed,
      Justin Rhoades, Denisse Rotem, Nikhil Wagle, Gad Getz, Todd R. Golub, and Viktor 
      A. Adalsteinsson, Broad Institute of Harvard and Massachusetts Institute of
      Technology; and J. Christopher Love, Massachusetts Institute of Technology,
      Cambridge, MA.
FAU - Adalsteinsson, Viktor A
AU  - Adalsteinsson VA
AD  - Daniel G. Stover, Ohio State University Comprehensive Cancer Center, Columbus,
      OH; Heather A. Parsons, Gavin Ha, William T. Barry, Hao Guo, Atish D. Choudhury, 
      Melissa E. Hughes, Deborah A. Dillon, Ann H. Partridge, Nikhil Wagle, Ian E.
      Krop, Todd R. Golub, Eric P. Winer, Sara M. Tolaney, and Nancy U. Lin,
      Dana-Farber Cancer Institute; Gad Getz, Massachusetts General Hospital, Boston;
      Gavin Ha, Samuel S. Freeman, Atish D. Choudhury, Gregory Gydush, Sarah C. Reed,
      Justin Rhoades, Denisse Rotem, Nikhil Wagle, Gad Getz, Todd R. Golub, and Viktor 
      A. Adalsteinsson, Broad Institute of Harvard and Massachusetts Institute of
      Technology; and J. Christopher Love, Massachusetts Institute of Technology,
      Cambridge, MA.
LA  - eng
PT  - Journal Article
DEP - 20180103
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of
      Clinical Oncology
JID - 8309333
EDAT- 2018/01/04 06:00
MHDA- 2018/01/04 06:00
CRDT- 2018/01/04 06:00
PHST- 2018/01/04 06:00 [entrez]
PHST- 2018/01/04 06:00 [pubmed]
PHST- 2018/01/04 06:00 [medline]
AID - 10.1200/JCO.2017.76.0033 [doi]
PST - aheadofprint
SO  - J Clin Oncol. 2018 Jan 3:JCO2017760033. doi: 10.1200/JCO.2017.76.0033.

PMID- 29309643
OWN - NLM
STAT- Publisher
LR  - 20180108
IS  - 1362-4962 (Electronic)
IS  - 0305-1048 (Linking)
DP  - 2018 Jan 4
TI  - Androgen receptor splice variants bind to constitutively open chromatin and
      promote abiraterone-resistant growth of prostate cancer.
LID - 10.1093/nar/gkx1306 [doi]
AB  - Androgen receptor (AR) splice variants (ARVs) are implicated in development of
      castration-resistant prostate cancer (CRPC). Upregulation of ARVs often
      correlates with persistent AR activity after androgen deprivation therapy (ADT). 
      However, the genomic and epigenomic characteristics of ARV-dependent cistrome and
      the disease relevance of ARV-mediated transcriptome remain elusive. Through
      integrated chromatin immunoprecipitation coupled sequencing (ChIP-seq) and RNA
      sequencing (RNA-seq) analysis, we identified ARV-preferential-binding sites
      (ARV-PBS) and a set of genes preferentially transactivated by ARVs in CRPC cells.
      ARVs preferentially bind to enhancers located in nucleosome-depleted regions
      harboring the full AR-response element (AREfull), while full-length AR (ARFL)-PBS
      are enhancers resided in closed chromatin regions containing the composite
      FOXA1-nnnn-AREhalf motif. ARV-PBS exclusively overlapped with AR binding sites in
      castration-resistant (CR) tumors in patients and ARV-preferentially activated
      genes were up-regulated in abiraterone-resistant patient specimens. Expression of
      ARV-PBS target genes, such as oncogene RAP2A and cell cycle gene E2F7, were
      significantly associated with castration resistance, poor survival and tumor
      progression. We uncover distinct genomic and epigenomic features of ARV-PBS,
      highlighting that ARVs are useful tools to depict AR-regulated oncogenic genome
      and epigenome landscapes in prostate cancer. Our data also suggest that the
      ARV-preferentially activated transcriptional program could be targeted for
      effective treatment of CRPC.
CI  - (c) The Author(s) 2018. Published by Oxford University Press on behalf of Nucleic
      Acids Research.
FAU - He, Yundong
AU  - He Y
AD  - Department of Biochemistry and Molecular Biology, Mayo Clinic College of
      Medicine, Rochester, MN 55905, USA.
FAU - Lu, Ji
AU  - Lu J
AD  - Department of Biochemistry and Molecular Biology, Mayo Clinic College of
      Medicine, Rochester, MN 55905, USA.
FAU - Ye, Zhenqing
AU  - Ye Z
AD  - Division of Biomedical Statistics and Informatics, Mayo Clinic College of
      Medicine, Rochester, MN 55905, USA.
FAU - Hao, Siyuan
AU  - Hao S
AD  - Department of Urology, University of Kansas Medical Center, Kansas City, KS
      66160, USA.
FAU - Wang, Liewei
AU  - Wang L
AD  - Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic
      College of Medicine, Rochester, MN 55905, USA.
FAU - Kohli, Manish
AU  - Kohli M
AD  - Department of Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905,
      USA.
FAU - Tindall, Donald J
AU  - Tindall DJ
AD  - Department of Biochemistry and Molecular Biology, Mayo Clinic College of
      Medicine, Rochester, MN 55905, USA.
AD  - Department of Urology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
FAU - Li, Benyi
AU  - Li B
AD  - Department of Urology, University of Kansas Medical Center, Kansas City, KS
      66160, USA.
FAU - Zhu, Runzhi
AU  - Zhu R
AD  - Department of Urology, University of Kansas Medical Center, Kansas City, KS
      66160, USA.
AD  - Center for Cell Therapy, The Affiliated Hospital of Jiangsu University,
      Zhenjiang, Jiangsu 212001, China.
FAU - Wang, Liguo
AU  - Wang L
AD  - Division of Biomedical Statistics and Informatics, Mayo Clinic College of
      Medicine, Rochester, MN 55905, USA.
FAU - Huang, Haojie
AU  - Huang H
AD  - Department of Biochemistry and Molecular Biology, Mayo Clinic College of
      Medicine, Rochester, MN 55905, USA.
AD  - Department of Urology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
AD  - Mayo Clinic Cancer Center, Mayo Clinic College of Medicine, Rochester, MN 55905, 
      USA.
LA  - eng
PT  - Journal Article
DEP - 20180104
PL  - England
TA  - Nucleic Acids Res
JT  - Nucleic acids research
JID - 0411011
EDAT- 2018/01/09 06:00
MHDA- 2018/01/09 06:00
CRDT- 2018/01/09 06:00
PHST- 2017/10/09 00:00 [received]
PHST- 2017/12/20 00:00 [accepted]
PHST- 2018/01/09 06:00 [entrez]
PHST- 2018/01/09 06:00 [pubmed]
PHST- 2018/01/09 06:00 [medline]
AID - 4788350 [pii]
AID - 10.1093/nar/gkx1306 [doi]
PST - aheadofprint
SO  - Nucleic Acids Res. 2018 Jan 4. pii: 4788350. doi: 10.1093/nar/gkx1306.

PMID- 29290541
OWN - NLM
STAT- In-Data-Review
LR  - 20180109
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 33
IP  - 1
DP  - 2018 Jan 8
TI  - Genomic and Epigenomic Profiling of High-Risk Intestinal Metaplasia Reveals
      Molecular Determinants of Progression to Gastric Cancer.
PG  - 137-150.e5
LID - S1535-6108(17)30521-4 [pii]
LID - 10.1016/j.ccell.2017.11.018 [doi]
AB  - Intestinal metaplasia (IM) is a pre-malignant condition of the gastric mucosa
      associated with increased gastric cancer (GC) risk. We performed (epi)genomic
      profiling of 138 IMs from 148 cancer-free patients, recruited through a 10-year
      prospective study. Compared with GCs, IMs exhibit low mutational burdens,
      recurrent mutations in certain tumor suppressors (FBXW7) but not others (TP53,
      ARID1A), chromosome 8q amplification, and shortened telomeres. Sequencing
      identified more IM patients with active Helicobacter pylori infection compared
      with histopathology (11%-27%). Several IMs exhibited hypermethylation at DNA
      methylation valleys; however, IMs generally lack intragenic hypomethylation
      signatures of advanced malignancy. IM patients with shortened telomeres and
      chromosomal alterations were associated with subsequent dysplasia or GC;
      conversely patients exhibiting normal-like epigenomic patterns were associated
      with regression.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Huang, Kie Kyon
AU  - Huang KK
AD  - Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore
      169857, Singapore.
FAU - Ramnarayanan, Kalpana
AU  - Ramnarayanan K
AD  - Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore
      169857, Singapore.
FAU - Zhu, Feng
AU  - Zhu F
AD  - Department of Medicine, Yong Loo Lin School of Medicine, National University of
      Singapore, Singapore 119228, Singapore.
FAU - Srivastava, Supriya
AU  - Srivastava S
AD  - Department of Medicine, Yong Loo Lin School of Medicine, National University of
      Singapore, Singapore 119228, Singapore; Department of Pathology, National
      University of Singapore, Singapore 119228, Singapore.
FAU - Xu, Chang
AU  - Xu C
AD  - Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore
      169857, Singapore; Cancer Science Institute of Singapore, National University of 
      Singapore, Singapore 117599, Singapore.
FAU - Tan, Angie Lay Keng
AU  - Tan ALK
AD  - Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore
      169857, Singapore.
FAU - Lee, Minghui
AU  - Lee M
AD  - Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore
      169857, Singapore.
FAU - Tay, Suting
AU  - Tay S
AD  - Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore
      169857, Singapore.
FAU - Das, Kakoli
AU  - Das K
AD  - Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore
      169857, Singapore.
FAU - Xing, Manjie
AU  - Xing M
AD  - Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore
      169857, Singapore; NUS Graduate School for Integrative Sciences and Engineering, 
      Singapore 117456, Singapore; Cancer Therapeutics and Stratified Oncology, Genome 
      Institute of Singapore, Singapore 138672, Singapore.
FAU - Fatehullah, Aliya
AU  - Fatehullah A
AD  - Institute of Medical Biology, A-STAR, Singapore 138648, Singapore.
FAU - Alkaff, Syed Muhammad Fahmy
AU  - Alkaff SMF
AD  - Department of Anatomical Pathology, Singapore General Hospital, Singapore 169608,
      Singapore.
FAU - Lim, Tony Kiat Hon
AU  - Lim TKH
AD  - Department of Anatomical Pathology, Singapore General Hospital, Singapore 169608,
      Singapore.
FAU - Lee, Jonathan
AU  - Lee J
AD  - Department of Gastroenterology and Hepatology, National University Health System,
      Singapore 119074, Singapore.
FAU - Ho, Khek Yu
AU  - Ho KY
AD  - Department of Medicine, Yong Loo Lin School of Medicine, National University of
      Singapore, Singapore 119228, Singapore; Department of Gastroenterology and
      Hepatology, National University Health System, Singapore 119074, Singapore.
FAU - Rozen, Steven George
AU  - Rozen SG
AD  - Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore
      169857, Singapore.
FAU - Teh, Bin Tean
AU  - Teh BT
AD  - Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore
      169857, Singapore.
FAU - Barker, Nick
AU  - Barker N
AD  - Institute of Medical Biology, A-STAR, Singapore 138648, Singapore; Centre for
      Regenerative Medicine, Edinburgh EH16 4UU, UK.
FAU - Chia, Chung King
AU  - Chia CK
AD  - Department of Gastroenterology and Hepatology, Tan Tock Seng Hospital, Singapore 
      308433, Singapore.
FAU - Khor, Christopher
AU  - Khor C
AD  - Department of Gastroenterology and Hepatology, Singapore General Hospital,
      Singapore 169854, Singapore.
FAU - Ooi, Choon Jin
AU  - Ooi CJ
AD  - Department of Gastroenterology and Hepatology, Singapore General Hospital,
      Singapore 169854, Singapore.
FAU - Fock, Kwong Ming
AU  - Fock KM
AD  - Department of Gastroenterology and Hepatology, Changi General Hospital, Singapore
      529889, Singapore.
FAU - So, Jimmy
AU  - So J
AD  - Department of Surgery, National University of Singapore, Singapore 119228,
      Singapore.
FAU - Lim, Wee Chian
AU  - Lim WC
AD  - Department of Gastroenterology and Hepatology, Tan Tock Seng Hospital, Singapore 
      308433, Singapore.
FAU - Ling, Khoon Lin
AU  - Ling KL
AD  - Department of Gastroenterology and Hepatology, Singapore General Hospital,
      Singapore 169854, Singapore.
FAU - Ang, Tiing Leong
AU  - Ang TL
AD  - Department of Gastroenterology and Hepatology, Changi General Hospital, Singapore
      529889, Singapore.
FAU - Wong, Andrew
AU  - Wong A
AD  - Department of Surgery, Changi General Hospital, Singapore 529889, Singapore.
FAU - Rao, Jaideepraj
AU  - Rao J
AD  - Department of Surgery, Tan Tock Seng Hospital, Singapore 308433, Singapore.
FAU - Rajnakova, Andrea
AU  - Rajnakova A
AD  - Mt. Elizabeth Medical Centre, Singapore 228510, Singapore.
FAU - Lim, Lee Guan
AU  - Lim LG
AD  - Raffles Hospital, Singapore 188770, Singapore.
FAU - Yap, Wai Ming
AU  - Yap WM
AD  - Department of Pathology, Tan Tock Seng Hospital, Singapore 308433, Singapore.
FAU - Teh, Ming
AU  - Teh M
AD  - Department of Pathology, National University of Singapore, Singapore 119228,
      Singapore. Electronic address: pattehm@nus.edu.sg.
FAU - Yeoh, Khay Guan
AU  - Yeoh KG
AD  - Department of Medicine, Yong Loo Lin School of Medicine, National University of
      Singapore, Singapore 119228, Singapore; Department of Gastroenterology and
      Hepatology, National University Health System, Singapore 119074, Singapore;
      Singapore Gastric Cancer Consortium, Singapore 119074, Singapore. Electronic
      address: mdcykg@nus.edu.sg.
FAU - Tan, Patrick
AU  - Tan P
AD  - Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore
      169857, Singapore; Cancer Science Institute of Singapore, National University of 
      Singapore, Singapore 117599, Singapore; Cancer Therapeutics and Stratified
      Oncology, Genome Institute of Singapore, Singapore 138672, Singapore;
      SingHealth/Duke-NUS Institute of Precision Medicine, National Heart Centre
      Singapore, Singapore 169856, Singapore; Cellular and Molecular Research, National
      Cancer Centre, Singapore 169610, Singapore; Singapore Gastric Cancer Consortium, 
      Singapore 119074, Singapore. Electronic address: gmstanp@duke-nus.edu.sg.
LA  - eng
PT  - Journal Article
DEP - 20171228
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
OTO - NOTNLM
OT  - Helicobacter pylori
OT  - cancer genomics
OT  - gastric cancer
OT  - intestinal metaplasia
OT  - risk stratification
EDAT- 2018/01/02 06:00
MHDA- 2018/01/02 06:00
CRDT- 2018/01/02 06:00
PHST- 2017/06/09 00:00 [received]
PHST- 2017/10/02 00:00 [revised]
PHST- 2017/11/28 00:00 [accepted]
PHST- 2018/01/02 06:00 [pubmed]
PHST- 2018/01/02 06:00 [medline]
PHST- 2018/01/02 06:00 [entrez]
AID - S1535-6108(17)30521-4 [pii]
AID - 10.1016/j.ccell.2017.11.018 [doi]
PST - ppublish
SO  - Cancer Cell. 2018 Jan 8;33(1):137-150.e5. doi: 10.1016/j.ccell.2017.11.018. Epub 
      2017 Dec 28.

PMID- 29130474
OWN - NLM
STAT- MEDLINE
DCOM- 20180111
LR  - 20180111
IS  - 1469-493X (Electronic)
IS  - 1361-6137 (Linking)
VI  - 11
DP  - 2017 Nov 13
TI  - Interventions for the reduction of prescribed opioid use in chronic non-cancer
      pain.
PG  - CD010323
LID - 10.1002/14651858.CD010323.pub3 [doi]
AB  - BACKGROUND: This is the first update of the original Cochrane Review published in
      2013. The conclusions of this review have not changed from the 2013 publication. 
      People with chronic non-cancer pain who are prescribed and are taking opioids can
      have a history of long-term, high-dose opioid use without effective pain relief. 
      In those without good pain relief, reduction of prescribed opioid dose may be the
      desired and shared goal of both patient and clinician. Simple, unsupervised
      reduction of opioid use is clinically challenging, and very difficult to achieve 
      and maintain. OBJECTIVES: To investigate the effectiveness of different methods
      designed to achieve reduction or cessation of prescribed opioid use for the
      management of chronic non-cancer pain in adults compared to controls. SEARCH
      METHODS: For this update we searched CENTRAL, MEDLINE, and Embase in January
      2017, as well as bibliographies and citation searches of included studies. We
      also searched one trial registry for ongoing trials. SELECTION CRITERIA: Included
      studies had to be randomised controlled trials comparing opioid users receiving
      an intervention with a control group receiving treatment as usual, active
      control, or placebo. The aim of the study had to include a treatment goal of dose
      reduction or cessation of opioid medication. DATA COLLECTION AND ANALYSIS: Two
      review authors independently extracted data and assessed risk of bias. We sought 
      data relating to prescribed opioid use, adverse events of opioid reduction, pain,
      and psychological and physical function. We planned to assess the certainty of
      the evidence using the GRADE approach, however, due to the heterogeneity of
      studies, we were unable to combine outcomes in a meta-analysis and therefore we
      did not assess the evidence with GRADE. MAIN RESULTS: Three studies are new to
      this update, resulting in five included studies in total (278 participants).
      Participants were primarily women (mean age 49.63 years, SD = 11.74) with
      different chronic pain conditions. We judged the studies too heterogeneous to
      pool data in a meta-analysis, so we have summarised the results from each study
      qualitatively. The studies included acupuncture, mindfulness, and cognitive
      behavioral therapy interventions aimed at reducing opioid consumption, misuse of 
      opioids, or maintenance of chronic pain management treatments. We found mixed
      results from the studies. Three of the five studies reported opioid consumption
      at post-treatment and follow-up. Two studies that delivered 'Mindfulness-Oriented
      Recovery Enhancement' or 'Therapeutic Interactive Voice Response' found a
      significant difference between groups at post-treatment and follow-up in opioid
      consumption. The remaining study found reduction in opioid consumption in both
      treatment and control groups, and between-group differences were not significant.
      Three studies reported adverse events related to the study and two studies did
      not have study-related adverse events. We also found mixed findings for pain
      intensity and physical functioning. The interventions did not show between-group 
      differences for psychological functioning across all studies. Overall, the risk
      of bias was mixed across studies. All studies included sample sizes of fewer than
      100 and so we judged all studies as high risk of bias for that category. AUTHORS'
      CONCLUSIONS: There is no evidence for the efficacy or safety of methods for
      reducing prescribed opioid use in chronic pain. There is a small number of
      randomised controlled trials investigating opioid reduction, which means our
      conclusions are limited regarding the benefit of psychological, pharmacological, 
      or other types of interventions for people with chronic pain trying to reduce
      their opioid consumption. The findings to date are mixed: there were reductions
      in opioid consumption after intervention, and often in control groups too.
FAU - Eccleston, Christopher
AU  - Eccleston C
AD  - Centre for Pain Research, University of Bath, Claverton Down, Bath, UK.
FAU - Fisher, Emma
AU  - Fisher E
FAU - Thomas, Kyla H
AU  - Thomas KH
FAU - Hearn, Leslie
AU  - Hearn L
FAU - Derry, Sheena
AU  - Derry S
FAU - Stannard, Cathy
AU  - Stannard C
FAU - Knaggs, Roger
AU  - Knaggs R
FAU - Moore, R Andrew
AU  - Moore RA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20171113
PL  - England
TA  - Cochrane Database Syst Rev
JT  - The Cochrane database of systematic reviews
JID - 100909747
RN  - 0 (Analgesics, Opioid)
SB  - IM
UOF - Cochrane Database Syst Rev. 2013 Sep 01;(9):CD010323. PMID: 23996347
MH  - Analgesics, Opioid/*administration & dosage
MH  - Chronic Pain/drug therapy/etiology/*therapy
MH  - Cognitive Therapy/*methods
MH  - Drug Tolerance
MH  - Electroacupuncture/*methods
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mindfulness
MH  - Observational Studies as Topic
MH  - Randomized Controlled Trials as Topic
MH  - Therapy, Computer-Assisted/methods
EDAT- 2017/11/14 06:00
MHDA- 2018/01/13 06:00
CRDT- 2017/11/14 06:00
PHST- 2017/11/14 06:00 [pubmed]
PHST- 2018/01/13 06:00 [medline]
PHST- 2017/11/14 06:00 [entrez]
AID - 10.1002/14651858.CD010323.pub3 [doi]
PST - epublish
SO  - Cochrane Database Syst Rev. 2017 Nov 13;11:CD010323. doi:
      10.1002/14651858.CD010323.pub3.

PMID- 29083399
OWN - NLM
STAT- MEDLINE
DCOM- 20171204
LR  - 20180119
IS  - 1529-2916 (Electronic)
IS  - 1529-2908 (Linking)
VI  - 18
IP  - 12
DP  - 2017 Dec
TI  - Oxidative stress controls regulatory T cell apoptosis and suppressor activity and
      PD-L1-blockade resistance in tumor.
PG  - 1332-1341
LID - 10.1038/ni.3868 [doi]
AB  - Live regulatory T cells (Treg cells) suppress antitumor immunity, but how Treg
      cells behave in the metabolically abnormal tumor microenvironment remains
      unknown. Here we show that tumor Treg cells undergo apoptosis, and such apoptotic
      Treg cells abolish spontaneous and PD-L1-blockade-mediated antitumor T cell
      immunity. Biochemical and functional analyses show that adenosine, but not
      typical suppressive factors such as PD-L1, CTLA-4, TGF-beta, IL-35, and IL-10,
      contributes to apoptotic Treg-cell-mediated immunosuppression. Mechanistically,
      apoptotic Treg cells release and convert a large amount of ATP to adenosine via
      CD39 and CD73, and mediate immunosuppression via the adenosine and A2A pathways. 
      Apoptosis in Treg cells is attributed to their weak NRF2-associated antioxidant
      system and high vulnerability to free oxygen species in the tumor
      microenvironment. Thus, the data support a model wherein tumor Treg cells sustain
      and amplify their suppressor capacity through inadvertent death via oxidative
      stress. This work highlights the oxidative pathway as a metabolic checkpoint that
      controls Treg cell behavior and affects the efficacy of therapeutics targeting
      cancer checkpoints.
FAU - Maj, Tomasz
AU  - Maj T
AD  - Department of Surgery, University of Michigan School of Medicine, Ann Arbor,
      Michigan, USA.
FAU - Wang, Wei
AU  - Wang W
AD  - Department of Surgery, University of Michigan School of Medicine, Ann Arbor,
      Michigan, USA.
AD  - Department of Immunology and Key Laboratory of Medical Immunology of the Ministry
      of Public Health, School of Basic Medical Sciences, Peking University Health
      Science Center, Beijing, China.
FAU - Crespo, Joel
AU  - Crespo J
AD  - Department of Surgery, University of Michigan School of Medicine, Ann Arbor,
      Michigan, USA.
AD  - Rackham Graduate School, University of Michigan, Ann Arbor, Michigan, USA.
FAU - Zhang, Hongjuan
AU  - Zhang H
AD  - Department of Surgery, University of Michigan School of Medicine, Ann Arbor,
      Michigan, USA.
FAU - Wang, Weimin
AU  - Wang W
AD  - Department of Surgery, University of Michigan School of Medicine, Ann Arbor,
      Michigan, USA.
AD  - Department of Obstetrics and Gynecology, University of Michigan School of
      Medicine, Ann Arbor, Michigan, USA.
FAU - Wei, Shuang
AU  - Wei S
AD  - Department of Surgery, University of Michigan School of Medicine, Ann Arbor,
      Michigan, USA.
FAU - Zhao, Lili
AU  - Zhao L
AD  - Department of Biostatistics, University of Michigan School of Medicine, Ann
      Arbor, Michigan, USA.
FAU - Vatan, Linda
AU  - Vatan L
AD  - Department of Surgery, University of Michigan School of Medicine, Ann Arbor,
      Michigan, USA.
FAU - Shao, Irene
AU  - Shao I
AD  - Department of Surgery, University of Michigan School of Medicine, Ann Arbor,
      Michigan, USA.
FAU - Szeliga, Wojciech
AU  - Szeliga W
AD  - Department of Surgery, University of Michigan School of Medicine, Ann Arbor,
      Michigan, USA.
FAU - Lyssiotis, Costas
AU  - Lyssiotis C
AD  - Department of Molecular and Integrative Physiology, University of Michigan School
      of Medicine, Ann Arbor, Michigan, USA.
AD  - The University of Michigan Comprehensive Cancer Center, University of Michigan,
      Ann Arbor, Michigan, USA.
FAU - Liu, J Rebecca
AU  - Liu JR
AD  - Department of Obstetrics and Gynecology, University of Michigan School of
      Medicine, Ann Arbor, Michigan, USA.
FAU - Kryczek, Ilona
AU  - Kryczek I
AD  - Department of Surgery, University of Michigan School of Medicine, Ann Arbor,
      Michigan, USA.
FAU - Zou, Weiping
AU  - Zou W
AUID- ORCID: http://orcid.org/0000-0001-7952-3549
AD  - Department of Surgery, University of Michigan School of Medicine, Ann Arbor,
      Michigan, USA.
AD  - Rackham Graduate School, University of Michigan, Ann Arbor, Michigan, USA.
AD  - The University of Michigan Comprehensive Cancer Center, University of Michigan,
      Ann Arbor, Michigan, USA.
AD  - Department of Pathology, University of Michigan School of Medicine, Ann Arbor,
      Michigan, USA.
LA  - eng
GR  - R01 CA193136/CA/NCI NIH HHS/United States
GR  - P30 CA046592/CA/NCI NIH HHS/United States
GR  - R01 CA171306/CA/NCI NIH HHS/United States
GR  - R01 CA156685/CA/NCI NIH HHS/United States
GR  - R01 CA190176/CA/NCI NIH HHS/United States
GR  - R01 CA211016/CA/NCI NIH HHS/United States
GR  - R01 CA123088/CA/NCI NIH HHS/United States
GR  - R01 CA099985/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20171030
PL  - United States
TA  - Nat Immunol
JT  - Nature immunology
JID - 100941354
RN  - 0 (Antigens, CD)
RN  - 0 (B7-H1 Antigen)
RN  - 0 (CD274 protein, human)
RN  - 0 (CTLA-4 Antigen)
RN  - 0 (CTLA4 protein, human)
RN  - 0 (GPI-Linked Proteins)
RN  - 0 (IL10 protein, human)
RN  - 0 (Interleukins)
RN  - 0 (NF-E2-Related Factor 2)
RN  - 0 (NFE2L2 protein, human)
RN  - 0 (Receptor, Adenosine A2A)
RN  - 0 (Transforming Growth Factor beta)
RN  - 0 (interleukin-35, human)
RN  - 130068-27-8 (Interleukin-10)
RN  - EC 3.1.3.5 (5'-Nucleotidase)
RN  - EC 3.1.3.5 (Nt5e protein, mouse)
RN  - EC 3.6.1.5 (Apyrase)
RN  - EC 3.6.1.5 (CD39 antigen)
RN  - K72T3FS567 (Adenosine)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - 5'-Nucleotidase/genetics/metabolism
MH  - Adenosine/metabolism
MH  - Animals
MH  - Antigens, CD/metabolism
MH  - Apoptosis/*immunology
MH  - Apyrase/metabolism
MH  - B7-H1 Antigen/*metabolism
MH  - CTLA-4 Antigen/metabolism
MH  - Female
MH  - GPI-Linked Proteins/genetics
MH  - Humans
MH  - Immune Tolerance/*immunology
MH  - Interleukin-10/metabolism
MH  - Interleukins/metabolism
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Knockout
MH  - NF-E2-Related Factor 2/metabolism
MH  - Ovarian Neoplasms/*immunology
MH  - Oxidative Stress/*physiology
MH  - Oxygen/metabolism
MH  - Receptor, Adenosine A2A/metabolism
MH  - T-Lymphocytes, Regulatory/*immunology
MH  - Transforming Growth Factor beta/metabolism
MH  - Tumor Cells, Cultured
MH  - Tumor Microenvironment/immunology
PMC - PMC5770150
MID - NIHMS930217
EDAT- 2017/10/31 06:00
MHDA- 2017/12/05 06:00
CRDT- 2017/10/31 06:00
PHST- 2017/09/20 00:00 [received]
PHST- 2017/10/05 00:00 [accepted]
PHST- 2017/10/31 06:00 [pubmed]
PHST- 2017/12/05 06:00 [medline]
PHST- 2017/10/31 06:00 [entrez]
AID - ni.3868 [pii]
AID - 10.1038/ni.3868 [doi]
PST - ppublish
SO  - Nat Immunol. 2017 Dec;18(12):1332-1341. doi: 10.1038/ni.3868. Epub 2017 Oct 30.

PMID- 29223605
OWN - NLM
STAT- Publisher
LR  - 20171227
IS  - 1873-7560 (Electronic)
IS  - 0302-2838 (Linking)
DP  - 2017 Dec 7
TI  - Updated European Association of Urology Guidelines Recommendations for the
      Treatment of First-line Metastatic Clear Cell Renal Cancer.
LID - S0302-2838(17)31001-1 [pii]
LID - 10.1016/j.eururo.2017.11.016 [doi]
AB  - The randomised phase III clinical trial Checkmate-214 showed a survival
      superiority for the combination of ipilimumab and nivolumab when compared with
      the previous standard of care in first-line metastatic/advanced clear cell renal 
      cell carcinoma (RCC) (Escudier B, Tannir NM, McDermott DF, et al. CheckMate 214: 
      efficacy and safety of nivolumab plus ipilimumab vs sunitinib for treatment-naive
      advanced or metastatic renal cell carcinoma, including IMDC risk and PD-L1
      expression subgroups. LBA5, ESMO 2017, 2017). These results change the frontline 
      standard of care for this disease and have implications for the selection of
      subsequent therapies. For this reason the European Association of Urology RCC
      guidelines have been updated. PATIENT SUMMARY: The European Association of
      Urology guidelines will be updated based on the results of the phase III
      Checkmate-214 clinical trial. The trial showed superior survival for a
      combination of ipilimumab and nivolumab (IN), compared with the previous standard
      of care, in intermediate- and poor-risk patients with metastatic clear cell renal
      cell carcinoma. When IN is not safe or feasible, alternative agents such as
      sunitinib, pazopanib, and cabozantinib should be considered. Furthermore, at
      present, the data from the trial are immature in favourable-risk patients.
      Therefore, sunitinib or pazopanib remains the favoured agent for this subgroup of
      patients.
CI  - Copyright (c) 2017 European Association of Urology. Published by Elsevier B.V.
      All rights reserved.
FAU - Powles, Thomas
AU  - Powles T
AD  - The Royal Free NHS Trust and Barts Cancer Institute, Queen Mary University of
      London, London, UK. Electronic address: Thomas.Powles@bartshealth.nhs.uk.
FAU - Albiges, Laurence
AU  - Albiges L
AD  - Department of Cancer Medicine, Institut Gustave Roussy, Villejuif, France.
FAU - Staehler, Michael
AU  - Staehler M
AD  - Department of Urology, Ludwig-Maximilians University, Munich, Germany.
FAU - Bensalah, Karim
AU  - Bensalah K
AD  - Department of Urology, University of Rennes, Rennes, France.
FAU - Dabestani, Saeed
AU  - Dabestani S
AD  - Department of Clinical Sciences Lund, Lund University, Skane University Hospital,
      Lund, Sweden.
FAU - Giles, Rachel H
AU  - Giles RH
AD  - Patient Advocacy, International Kidney Cancer Coalition, Duivendrecht, The
      Netherlands; University Medical Center Utrecht, Department of Nephrology and
      Hypertension, Regenerative Medicine Center Utrecht, University of Utrecht, The
      Netherlands.
FAU - Hofmann, Fabian
AU  - Hofmann F
AD  - Department of Urology, Sunderby Hospital, Sunderby, Sweden.
FAU - Hora, Milan
AU  - Hora M
AD  - Faculty Hospital Plzen and Faculty of Medicine in Plzen, Charles University,
      Czech Republic.
FAU - Kuczyk, Markus A
AU  - Kuczyk MA
AD  - Department of Urology and Urologic Oncology, Hannover Medical School, Hannover,
      Germany.
FAU - Lam, Thomas B
AU  - Lam TB
AD  - Department of Urology, Aberdeen Royal Infirmary, Aberdeen, UK; Academic Urology
      Unit, University of Aberdeen, Aberdeen, UK.
FAU - Marconi, Lorenzo
AU  - Marconi L
AD  - Department of Urology, Coimbra University Hospital, Coimbra, Portugal.
FAU - Merseburger, Axel S
AU  - Merseburger AS
AD  - Department of Urology, University Hospital Schleswig-Holstein, Lubeck, Germany.
FAU - Fernandez-Pello, Sergio
AU  - Fernandez-Pello S
AD  - Department of Urology, Cabuenes Hospital, Gijon, Spain.
FAU - Tahbaz, Rana
AU  - Tahbaz R
AD  - Department of Urology, University Hospital Hamburg Eppendorf, Hamburg, Germany.
FAU - Volpe, Alessandro
AU  - Volpe A
AD  - Division of Urology, Maggiore Della Carita Hospital, University of Eastern
      Piedmont, Novara, Italy.
FAU - Ljungberg, Borje
AU  - Ljungberg B
AD  - Department of Surgical and Perioperative Sciences, Urology and Andrology, Umea
      University, Umea, Sweden.
FAU - Bex, Axel
AU  - Bex A
AD  - Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek
      Hospital, Amsterdam, The Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20171207
PL  - Switzerland
TA  - Eur Urol
JT  - European urology
JID - 7512719
OTO - NOTNLM
OT  - European Association of Urology guidelines
OT  - Ipilimumab
OT  - Nivolumab
OT  - Renal cell carcinoma
EDAT- 2017/12/11 06:00
MHDA- 2017/12/11 06:00
CRDT- 2017/12/11 06:00
PHST- 2017/11/09 00:00 [received]
PHST- 2017/11/17 00:00 [accepted]
PHST- 2017/12/11 06:00 [pubmed]
PHST- 2017/12/11 06:00 [medline]
PHST- 2017/12/11 06:00 [entrez]
AID - S0302-2838(17)31001-1 [pii]
AID - 10.1016/j.eururo.2017.11.016 [doi]
PST - aheadofprint
SO  - Eur Urol. 2017 Dec 7. pii: S0302-2838(17)31001-1. doi:
      10.1016/j.eururo.2017.11.016.

PMID- 29045397
OWN - NLM
STAT- In-Data-Review
LR  - 20171219
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 551
IP  - 7678
DP  - 2017 Nov 2
TI  - Glucose feeds the TCA cycle via circulating lactate.
PG  - 115-118
LID - 10.1038/nature24057 [doi]
AB  - Mammalian tissues are fuelled by circulating nutrients, including glucose, amino 
      acids, and various intermediary metabolites. Under aerobic conditions, glucose is
      generally assumed to be burned fully by tissues via the tricarboxylic acid cycle 
      (TCA cycle) to carbon dioxide. Alternatively, glucose can be catabolized
      anaerobically via glycolysis to lactate, which is itself also a potential
      nutrient for tissues and tumours. The quantitative relevance of circulating
      lactate or other metabolic intermediates as fuels remains unclear. Here we
      systematically examine the fluxes of circulating metabolites in mice, and find
      that lactate can be a primary source of carbon for the TCA cycle and thus of
      energy. Intravenous infusions of (13)C-labelled nutrients reveal that, on a molar
      basis, the circulatory turnover flux of lactate is the highest of all metabolites
      and exceeds that of glucose by 1.1-fold in fed mice and 2.5-fold in fasting mice;
      lactate is made primarily from glucose but also from other sources. In both fed
      and fasted mice, (13)C-lactate extensively labels TCA cycle intermediates in all 
      tissues. Quantitative analysis reveals that during the fasted state, the
      contribution of glucose to tissue TCA metabolism is primarily indirect (via
      circulating lactate) in all tissues except the brain. In genetically engineered
      lung and pancreatic cancer tumours in fasted mice, the contribution of
      circulating lactate to TCA cycle intermediates exceeds that of glucose, with
      glutamine making a larger contribution than lactate in pancreatic cancer. Thus,
      glycolysis and the TCA cycle are uncoupled at the level of lactate, which is a
      primary circulating TCA substrate in most tissues and tumours.
FAU - Hui, Sheng
AU  - Hui S
AD  - Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton,
      New Jersey 08544, USA.
AD  - Department of Chemistry, Princeton University, Princeton, New Jersey 08544, USA.
FAU - Ghergurovich, Jonathan M
AU  - Ghergurovich JM
AD  - Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton,
      New Jersey 08544, USA.
AD  - Department of Molecular Biology, Princeton University, Princeton, New Jersey
      08544, USA.
FAU - Morscher, Raphael J
AU  - Morscher RJ
AD  - Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton,
      New Jersey 08544, USA.
AD  - Department of Chemistry, Princeton University, Princeton, New Jersey 08544, USA.
FAU - Jang, Cholsoon
AU  - Jang C
AD  - Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton,
      New Jersey 08544, USA.
AD  - Department of Chemistry, Princeton University, Princeton, New Jersey 08544, USA.
FAU - Teng, Xin
AU  - Teng X
AD  - Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton,
      New Jersey 08544, USA.
AD  - Department of Chemistry, Princeton University, Princeton, New Jersey 08544, USA.
FAU - Lu, Wenyun
AU  - Lu W
AD  - Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton,
      New Jersey 08544, USA.
AD  - Department of Chemistry, Princeton University, Princeton, New Jersey 08544, USA.
FAU - Esparza, Lourdes A
AU  - Esparza LA
AD  - Departments of Pharmacology and Medicine, Moores Cancer Center, University of
      California San Diego School of Medicine, La Jolla, California 92093, USA.
FAU - Reya, Tannishtha
AU  - Reya T
AD  - Departments of Pharmacology and Medicine, Moores Cancer Center, University of
      California San Diego School of Medicine, La Jolla, California 92093, USA.
FAU - Le Zhan
AU  - Le Zhan
AD  - Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey 08903, USA.
AD  - Department of Molecular Biology and Biochemistry, Rutgers University, Piscataway,
      New Jersey, 08854, USA.
FAU - Yanxiang Guo, Jessie
AU  - Yanxiang Guo J
AD  - Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey 08903, USA.
AD  - Department of Medicine, Rutgers Robert Wood Johnson Medical School, New
      Brunswick, New Jersey 08901, USA.
AD  - Department of Chemical Biology, Rutgers Ernest Mario School of Pharmacy,
      Piscataway, New Jersey 08854, USA.
FAU - White, Eileen
AU  - White E
AD  - Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey 08903, USA.
AD  - Department of Molecular Biology and Biochemistry, Rutgers University, Piscataway,
      New Jersey, 08854, USA.
FAU - Rabinowitz, Joshua D
AU  - Rabinowitz JD
AD  - Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton,
      New Jersey 08544, USA.
AD  - Department of Chemistry, Princeton University, Princeton, New Jersey 08544, USA.
AD  - Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey 08903, USA.
LA  - eng
GR  - R35 CA197699/CA/NCI NIH HHS/United States
GR  - R50 CA211437/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20171018
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
EDAT- 2017/10/19 06:00
MHDA- 2017/10/19 06:00
CRDT- 2017/10/19 06:00
PHST- 2016/12/23 00:00 [received]
PHST- 2017/09/04 00:00 [accepted]
PHST- 2017/10/19 06:00 [pubmed]
PHST- 2017/10/19 06:00 [medline]
PHST- 2017/10/19 06:00 [entrez]
AID - nature24057 [pii]
AID - 10.1038/nature24057 [doi]
PST - ppublish
SO  - Nature. 2017 Nov 2;551(7678):115-118. doi: 10.1038/nature24057. Epub 2017 Oct 18.

PMID- 29316426
OWN - NLM
STAT- In-Data-Review
LR  - 20180114
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 33
IP  - 1
DP  - 2018 Jan 8
TI  - Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal
      Cancer.
PG  - 125-136.e3
LID - S1535-6108(17)30556-1 [pii]
LID - 10.1016/j.ccell.2017.12.004 [doi]
AB  - Metastatic colorectal cancers (mCRCs) are clinically heterogeneous, but the
      genomic basis of this variability remains poorly understood. We performed
      prospective targeted sequencing of 1,134 CRCs. We identified splice alterations
      in intronic regions of APC and large in-frame deletions in CTNNB1, increasing
      oncogenic WNT pathway alterations to 96% of CRCs. Right-sided primary site in
      microsatellite stable mCRC was associated with shorter survival, older age at
      diagnosis, increased mutations, and enrichment of oncogenic alterations in KRAS, 
      BRAF, PIK3CA, AKT1, RNF43, and SMAD4 compared with left-sided primaries.
      Left-sided tumors frequently had no identifiable genetic alteration in mitogenic 
      signaling, but exhibited higher mitogenic ligand expression. Our results suggest 
      different pathways to tumorigenesis in right- and left-sided microsatellite
      stable CRC that may underlie clinical differences.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Yaeger, Rona
AU  - Yaeger R
AD  - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA.
FAU - Chatila, Walid K
AU  - Chatila WK
AD  - Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA.
FAU - Lipsyc, Marla D
AU  - Lipsyc MD
AD  - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA.
FAU - Hechtman, Jaclyn F
AU  - Hechtman JF
AD  - Departments of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA.
FAU - Cercek, Andrea
AU  - Cercek A
AD  - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA.
FAU - Sanchez-Vega, Francisco
AU  - Sanchez-Vega F
AD  - Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA.
FAU - Jayakumaran, Gowtham
AU  - Jayakumaran G
AD  - Departments of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA.
FAU - Middha, Sumit
AU  - Middha S
AD  - Departments of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA.
FAU - Zehir, Ahmet
AU  - Zehir A
AD  - Departments of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA.
FAU - Donoghue, Mark T A
AU  - Donoghue MTA
AD  - Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA.
FAU - You, Daoqi
AU  - You D
AD  - Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA.
FAU - Viale, Agnes
AU  - Viale A
AD  - Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA.
FAU - Kemeny, Nancy
AU  - Kemeny N
AD  - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA.
FAU - Segal, Neil H
AU  - Segal NH
AD  - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA.
FAU - Stadler, Zsofia K
AU  - Stadler ZK
AD  - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA.
FAU - Varghese, Anna M
AU  - Varghese AM
AD  - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA.
FAU - Kundra, Ritika
AU  - Kundra R
AD  - Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA.
FAU - Gao, Jianjiong
AU  - Gao J
AD  - Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA.
FAU - Syed, Aijazuddin
AU  - Syed A
AD  - Departments of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA.
FAU - Hyman, David M
AU  - Hyman DM
AD  - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA.
FAU - Vakiani, Efsevia
AU  - Vakiani E
AD  - Departments of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA.
FAU - Rosen, Neal
AU  - Rosen N
AD  - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA.
FAU - Taylor, Barry S
AU  - Taylor BS
AD  - Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA; Departments of Epidemiology and
      Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA;
      Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Ladanyi, Marc
AU  - Ladanyi M
AD  - Departments of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering
      Cancer Center, New York, NY 10065, USA.
FAU - Berger, Michael F
AU  - Berger MF
AD  - Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA; Departments of Pathology,
      Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Human Oncology
      and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA.
FAU - Solit, David B
AU  - Solit DB
AD  - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA; Marie-Josee and Henry R. Kravis Center for Molecular Oncology,
      Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Human Oncology
      and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA.
FAU - Shia, Jinru
AU  - Shia J
AD  - Departments of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA.
FAU - Saltz, Leonard
AU  - Saltz L
AD  - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA.
FAU - Schultz, Nikolaus
AU  - Schultz N
AD  - Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA; Departments of Epidemiology and
      Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA;
      Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA. Electronic address: schultzn@mskcc.org.
LA  - eng
GR  - P30 CA008748/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
PMC - PMC5765991
MID - NIHMS928716
OTO - NOTNLM
OT  - APC
OT  - CTNNB1
OT  - colorectal cancer
OT  - integrative genomics analysis
OT  - intronic alterations
OT  - location
OT  - prognosis
EDAT- 2018/01/10 06:00
MHDA- 2018/01/10 06:00
CRDT- 2018/01/10 06:00
PMCR- 2019/01/08 00:00
PHST- 2017/08/02 00:00 [received]
PHST- 2017/10/26 00:00 [revised]
PHST- 2017/12/09 00:00 [accepted]
PHST- 2019/01/08 00:00 [pmc-release]
PHST- 2018/01/10 06:00 [entrez]
PHST- 2018/01/10 06:00 [pubmed]
PHST- 2018/01/10 06:00 [medline]
AID - S1535-6108(17)30556-1 [pii]
AID - 10.1016/j.ccell.2017.12.004 [doi]
PST - ppublish
SO  - Cancer Cell. 2018 Jan 8;33(1):125-136.e3. doi: 10.1016/j.ccell.2017.12.004.

PMID- 29316433
OWN - NLM
STAT- In-Data-Review
LR  - 20180113
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 33
IP  - 1
DP  - 2018 Jan 8
TI  - TIM-3 Regulates CD103(+) Dendritic Cell Function and Response to Chemotherapy in 
      Breast Cancer.
PG  - 60-74.e6
LID - S1535-6108(17)30523-8 [pii]
LID - 10.1016/j.ccell.2017.11.019 [doi]
AB  - Intratumoral CD103(+) dendritic cells (DCs) are necessary for anti-tumor
      immunity. Here we evaluated the expression of immune regulators by CD103(+) DCs
      in a murine model of breast cancer and identified expression of TIM-3 as a target
      for therapy. Anti-TIM-3 antibody improved response to paclitaxel chemotherapy in 
      models of triple-negative and luminal B disease, with no evidence of toxicity.
      Combined efficacy was CD8(+) T cell dependent and associated with increased
      granzyme B expression; however, TIM-3 expression was predominantly localized to
      myeloid cells in both human and murine tumors. Gene expression analysis
      identified upregulation of Cxcl9 within intratumoral DCs during combination
      therapy, and therapeutic efficacy was ablated by CXCR3 blockade, Batf3
      deficiency, or Irf8 deficiency.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - de Mingo Pulido, Alvaro
AU  - de Mingo Pulido A
AD  - Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute,
      12902 Magnolia Drive SRB-2, Tampa, FL 33612, USA.
FAU - Gardner, Alycia
AU  - Gardner A
AD  - Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute,
      12902 Magnolia Drive SRB-2, Tampa, FL 33612, USA; Cancer Biology PhD Program,
      University of South Florida, Tampa, FL 33620, USA.
FAU - Hiebler, Shandi
AU  - Hiebler S
AD  - Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute,
      12902 Magnolia Drive SRB-2, Tampa, FL 33612, USA.
FAU - Soliman, Hatem
AU  - Soliman H
AD  - Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute,
      12902 Magnolia Drive SRB-2, Tampa, FL 33612, USA; Department of Breast Oncology, 
      H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
FAU - Rugo, Hope S
AU  - Rugo HS
AD  - Department of Medicine and Helen Diller Family Comprehensive Cancer Center,
      University of California, San Francisco, CA 94143, USA.
FAU - Krummel, Matthew F
AU  - Krummel MF
AD  - Department of Pathology, University of California, San Francisco, CA 94143, USA.
FAU - Coussens, Lisa M
AU  - Coussens LM
AD  - Department of Cell, Developmental & Cancer Biology, and Knight Cancer Institute, 
      Oregon Health & Science University, Portland, OR 97239, USA.
FAU - Ruffell, Brian
AU  - Ruffell B
AD  - Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute,
      12902 Magnolia Drive SRB-2, Tampa, FL 33612, USA; Department of Breast Oncology, 
      H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
      Electronic address: brian.ruffell@moffitt.org.
LA  - eng
GR  - R00 CA185325/CA/NCI NIH HHS/United States
GR  - R01 CA155331/CA/NCI NIH HHS/United States
GR  - P30 CA076292/CA/NCI NIH HHS/United States
GR  - U54 CA163123/CA/NCI NIH HHS/United States
GR  - K99 CA185325/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
PMC - PMC5764109
MID - NIHMS925918
OTO - NOTNLM
OT  - TIM-3
OT  - breast cancer
OT  - chemotherapy
OT  - dendritic cells
OT  - galectin-9
OT  - immunotherapy
OT  - paclitaxel
EDAT- 2018/01/10 06:00
MHDA- 2018/01/10 06:00
CRDT- 2018/01/10 06:00
PMCR- 2019/01/08 00:00
PHST- 2017/04/13 00:00 [received]
PHST- 2017/08/13 00:00 [revised]
PHST- 2017/11/29 00:00 [accepted]
PHST- 2019/01/08 00:00 [pmc-release]
PHST- 2018/01/10 06:00 [entrez]
PHST- 2018/01/10 06:00 [pubmed]
PHST- 2018/01/10 06:00 [medline]
AID - S1535-6108(17)30523-8 [pii]
AID - 10.1016/j.ccell.2017.11.019 [doi]
PST - ppublish
SO  - Cancer Cell. 2018 Jan 8;33(1):60-74.e6. doi: 10.1016/j.ccell.2017.11.019.

PMID- 29364867
OWN - NLM
STAT- Publisher
LR  - 20180124
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
DP  - 2018 Jan 24
TI  - Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes.
LID - 10.1038/nature25459 [doi]
AB  - The poor correlation of mutational landscapes with phenotypes limits our
      understanding of the pathogenesis and metastasis of pancreatic ductal
      adenocarcinoma (PDAC). Here we show that oncogenic dosage-variation has a
      critical role in PDAC biology and phenotypic diversification. We find an increase
      in gene dosage of mutant KRAS in human PDAC precursors, which drives both early
      tumorigenesis and metastasis and thus rationalizes early PDAC dissemination. To
      overcome the limitations posed to gene dosage studies by the stromal richness of 
      PDAC, we have developed large cell culture resources of metastatic mouse PDAC.
      Integration of cell culture genomes, transcriptomes and tumour phenotypes with
      functional studies and human data reveals additional widespread effects of
      oncogenic dosage variation on cell morphology and plasticity, histopathology and 
      clinical outcome, with the highest Kras(MUT) levels underlying aggressive
      undifferentiated phenotypes. We also identify alternative oncogenic gains (Myc,
      Yap1 or Nfkb2), which collaborate with heterozygous Kras(MUT) in driving
      tumorigenesis, but have lower metastatic potential. Mechanistically, different
      oncogenic gains and dosages evolve along distinct evolutionary routes, licensed
      by defined allelic states and/or combinations of hallmark tumour suppressor
      alterations (Cdkn2a, Trp53, Tgfbeta-pathway). Thus, evolutionary constraints and 
      contingencies direct oncogenic dosage gain and variation along defined routes to 
      drive the early progression of PDAC and shape its downstream biology. Our study
      uncovers universal principles of Ras-driven oncogenesis that have potential
      relevance beyond pancreatic cancer.
FAU - Mueller, Sebastian
AU  - Mueller S
AD  - Center for Translational Cancer Research (TranslaTUM), Technische Universitat
      Munchen, 81675 Munich, Germany.
AD  - Department of Medicine II, Klinikum rechts der Isar, Technische Universitat
      Munchen, 81675 Munich, Germany.
FAU - Engleitner, Thomas
AU  - Engleitner T
AD  - Center for Translational Cancer Research (TranslaTUM), Technische Universitat
      Munchen, 81675 Munich, Germany.
AD  - Department of Medicine II, Klinikum rechts der Isar, Technische Universitat
      Munchen, 81675 Munich, Germany.
AD  - German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120
      Heidelberg, Germany.
FAU - Maresch, Roman
AU  - Maresch R
AD  - Center for Translational Cancer Research (TranslaTUM), Technische Universitat
      Munchen, 81675 Munich, Germany.
AD  - Department of Medicine II, Klinikum rechts der Isar, Technische Universitat
      Munchen, 81675 Munich, Germany.
AD  - German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120
      Heidelberg, Germany.
FAU - Zukowska, Magdalena
AU  - Zukowska M
AD  - Center for Translational Cancer Research (TranslaTUM), Technische Universitat
      Munchen, 81675 Munich, Germany.
AD  - Department of Medicine II, Klinikum rechts der Isar, Technische Universitat
      Munchen, 81675 Munich, Germany.
FAU - Lange, Sebastian
AU  - Lange S
AD  - Center for Translational Cancer Research (TranslaTUM), Technische Universitat
      Munchen, 81675 Munich, Germany.
AD  - Department of Medicine II, Klinikum rechts der Isar, Technische Universitat
      Munchen, 81675 Munich, Germany.
FAU - Kaltenbacher, Thorsten
AU  - Kaltenbacher T
AD  - Center for Translational Cancer Research (TranslaTUM), Technische Universitat
      Munchen, 81675 Munich, Germany.
AD  - Department of Medicine II, Klinikum rechts der Isar, Technische Universitat
      Munchen, 81675 Munich, Germany.
AD  - German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120
      Heidelberg, Germany.
FAU - Konukiewitz, Bjorn
AU  - Konukiewitz B
AD  - Institute of Pathology, Technische Universitat Munchen, 81675 Munich, Germany.
FAU - Ollinger, Rupert
AU  - Ollinger R
AD  - Center for Translational Cancer Research (TranslaTUM), Technische Universitat
      Munchen, 81675 Munich, Germany.
AD  - Department of Medicine II, Klinikum rechts der Isar, Technische Universitat
      Munchen, 81675 Munich, Germany.
FAU - Zwiebel, Maximilian
AU  - Zwiebel M
AD  - Department of Medicine II, Klinikum rechts der Isar, Technische Universitat
      Munchen, 81675 Munich, Germany.
FAU - Strong, Alex
AU  - Strong A
AD  - The Wellcome Trust Sanger Institute, Genome Campus, Hinxton, Cambridge CB10 1SA, 
      UK.
FAU - Yen, Hsi-Yu
AU  - Yen HY
AD  - German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120
      Heidelberg, Germany.
AD  - Comparative Experimental Pathology, Technische Universitat Munchen, 81675 Munich,
      Germany.
FAU - Banerjee, Ruby
AU  - Banerjee R
AD  - The Wellcome Trust Sanger Institute, Genome Campus, Hinxton, Cambridge CB10 1SA, 
      UK.
FAU - Louzada, Sandra
AU  - Louzada S
AD  - The Wellcome Trust Sanger Institute, Genome Campus, Hinxton, Cambridge CB10 1SA, 
      UK.
FAU - Fu, Beiyuan
AU  - Fu B
AD  - The Wellcome Trust Sanger Institute, Genome Campus, Hinxton, Cambridge CB10 1SA, 
      UK.
FAU - Seidler, Barbara
AU  - Seidler B
AD  - Center for Translational Cancer Research (TranslaTUM), Technische Universitat
      Munchen, 81675 Munich, Germany.
AD  - Department of Medicine II, Klinikum rechts der Isar, Technische Universitat
      Munchen, 81675 Munich, Germany.
FAU - Gotzfried, Juliana
AU  - Gotzfried J
AD  - Department of Medicine II, Klinikum rechts der Isar, Technische Universitat
      Munchen, 81675 Munich, Germany.
FAU - Schuck, Kathleen
AU  - Schuck K
AD  - Department of Medicine II, Klinikum rechts der Isar, Technische Universitat
      Munchen, 81675 Munich, Germany.
FAU - Hassan, Zonera
AU  - Hassan Z
AD  - Department of Medicine II, Klinikum rechts der Isar, Technische Universitat
      Munchen, 81675 Munich, Germany.
FAU - Arbeiter, Andreas
AU  - Arbeiter A
AD  - Department of Medicine II, Klinikum rechts der Isar, Technische Universitat
      Munchen, 81675 Munich, Germany.
FAU - Schonhuber, Nina
AU  - Schonhuber N
AD  - Center for Translational Cancer Research (TranslaTUM), Technische Universitat
      Munchen, 81675 Munich, Germany.
AD  - Department of Medicine II, Klinikum rechts der Isar, Technische Universitat
      Munchen, 81675 Munich, Germany.
FAU - Klein, Sabine
AU  - Klein S
AD  - Center for Translational Cancer Research (TranslaTUM), Technische Universitat
      Munchen, 81675 Munich, Germany.
AD  - Department of Medicine II, Klinikum rechts der Isar, Technische Universitat
      Munchen, 81675 Munich, Germany.
FAU - Veltkamp, Christian
AU  - Veltkamp C
AD  - Center for Translational Cancer Research (TranslaTUM), Technische Universitat
      Munchen, 81675 Munich, Germany.
AD  - Department of Medicine II, Klinikum rechts der Isar, Technische Universitat
      Munchen, 81675 Munich, Germany.
FAU - Friedrich, Mathias
AU  - Friedrich M
AD  - The Wellcome Trust Sanger Institute, Genome Campus, Hinxton, Cambridge CB10 1SA, 
      UK.
FAU - Rad, Lena
AU  - Rad L
AD  - Department of Medicine II, Klinikum rechts der Isar, Technische Universitat
      Munchen, 81675 Munich, Germany.
FAU - Barenboim, Maxim
AU  - Barenboim M
AD  - Department of Medicine II, Klinikum rechts der Isar, Technische Universitat
      Munchen, 81675 Munich, Germany.
AD  - German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120
      Heidelberg, Germany.
FAU - Ziegenhain, Christoph
AU  - Ziegenhain C
AD  - Anthropology & Human Genomics, Department of Biology II, Ludwig-Maximilians
      Universitat, 82152 Martinsried, Germany.
FAU - Hess, Julia
AU  - Hess J
AD  - Helmholtz Zentrum Munchen, Research Unit Radiation Cytogenetics, 85764
      Neuherberg, Germany.
FAU - Dovey, Oliver M
AU  - Dovey OM
AD  - The Wellcome Trust Sanger Institute, Genome Campus, Hinxton, Cambridge CB10 1SA, 
      UK.
FAU - Eser, Stefan
AU  - Eser S
AD  - Department of Medicine II, Klinikum rechts der Isar, Technische Universitat
      Munchen, 81675 Munich, Germany.
FAU - Parekh, Swati
AU  - Parekh S
AD  - Anthropology & Human Genomics, Department of Biology II, Ludwig-Maximilians
      Universitat, 82152 Martinsried, Germany.
FAU - Constantino-Casas, Fernando
AU  - Constantino-Casas F
AD  - Department of Veterinary Medicine, University of Cambridge, Cambridge CB3 0ES,
      UK.
FAU - de la Rosa, Jorge
AU  - de la Rosa J
AD  - The Wellcome Trust Sanger Institute, Genome Campus, Hinxton, Cambridge CB10 1SA, 
      UK.
AD  - Instituto de Medicina Oncologica y Molecular de Asturias (IMOMA), 33193 Oviedo,
      Spain.
AD  - Departamento de Bioquimica y Biologia Molecular, Facultad de Medicina, Instituto 
      Universitario de Oncologia (IUOPA), Universidad de Oviedo, 33006 Oviedo, Spain.
FAU - Sierra, Marta I
AU  - Sierra MI
AD  - Institute of Oncology of Asturias (IUOPA), HUCA, Universidad de Oviedo, 33011
      Oviedo, Spain.
FAU - Fraga, Mario
AU  - Fraga M
AD  - Institute of Oncology of Asturias (IUOPA), HUCA, Universidad de Oviedo, 33011
      Oviedo, Spain.
AD  - Nanomaterials and Nanotechnology Research Center (CINN-CSIC), Universidad de
      Oviedo, 33940 El Entrego, Spain.
FAU - Mayerle, Julia
AU  - Mayerle J
AD  - Medizinische Klinik und Poliklinik II, Klinikum der LMU Munchen-Grosshadern,
      81377 Munich, Germany.
FAU - Kloppel, Gunter
AU  - Kloppel G
AD  - Institute of Pathology, Technische Universitat Munchen, 81675 Munich, Germany.
FAU - Cadinanos, Juan
AU  - Cadinanos J
AD  - The Wellcome Trust Sanger Institute, Genome Campus, Hinxton, Cambridge CB10 1SA, 
      UK.
AD  - Instituto de Medicina Oncologica y Molecular de Asturias (IMOMA), 33193 Oviedo,
      Spain.
FAU - Liu, Pentao
AU  - Liu P
AD  - The Wellcome Trust Sanger Institute, Genome Campus, Hinxton, Cambridge CB10 1SA, 
      UK.
FAU - Vassiliou, George
AU  - Vassiliou G
AD  - The Wellcome Trust Sanger Institute, Genome Campus, Hinxton, Cambridge CB10 1SA, 
      UK.
FAU - Weichert, Wilko
AU  - Weichert W
AD  - German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120
      Heidelberg, Germany.
AD  - Institute of Pathology, Technische Universitat Munchen, 81675 Munich, Germany.
FAU - Steiger, Katja
AU  - Steiger K
AD  - Institute of Pathology, Technische Universitat Munchen, 81675 Munich, Germany.
AD  - Comparative Experimental Pathology, Technische Universitat Munchen, 81675 Munich,
      Germany.
FAU - Enard, Wolfgang
AU  - Enard W
AD  - Anthropology & Human Genomics, Department of Biology II, Ludwig-Maximilians
      Universitat, 82152 Martinsried, Germany.
FAU - Schmid, Roland M
AU  - Schmid RM
AD  - Department of Medicine II, Klinikum rechts der Isar, Technische Universitat
      Munchen, 81675 Munich, Germany.
AD  - German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120
      Heidelberg, Germany.
FAU - Yang, Fengtang
AU  - Yang F
AD  - The Wellcome Trust Sanger Institute, Genome Campus, Hinxton, Cambridge CB10 1SA, 
      UK.
FAU - Unger, Kristian
AU  - Unger K
AD  - Helmholtz Zentrum Munchen, Research Unit Radiation Cytogenetics, 85764
      Neuherberg, Germany.
FAU - Schneider, Gunter
AU  - Schneider G
AD  - Department of Medicine II, Klinikum rechts der Isar, Technische Universitat
      Munchen, 81675 Munich, Germany.
AD  - German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120
      Heidelberg, Germany.
FAU - Varela, Ignacio
AU  - Varela I
AD  - Instituto de Biomedicina y Biotecnologia de Cantabria (UC-CSIC), 39012 Santander,
      Spain.
FAU - Bradley, Allan
AU  - Bradley A
AD  - The Wellcome Trust Sanger Institute, Genome Campus, Hinxton, Cambridge CB10 1SA, 
      UK.
FAU - Saur, Dieter
AU  - Saur D
AD  - Center for Translational Cancer Research (TranslaTUM), Technische Universitat
      Munchen, 81675 Munich, Germany.
AD  - Department of Medicine II, Klinikum rechts der Isar, Technische Universitat
      Munchen, 81675 Munich, Germany.
AD  - German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120
      Heidelberg, Germany.
FAU - Rad, Roland
AU  - Rad R
AD  - Center for Translational Cancer Research (TranslaTUM), Technische Universitat
      Munchen, 81675 Munich, Germany.
AD  - Department of Medicine II, Klinikum rechts der Isar, Technische Universitat
      Munchen, 81675 Munich, Germany.
AD  - German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120
      Heidelberg, Germany.
LA  - eng
PT  - Journal Article
DEP - 20180124
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
EDAT- 2018/01/25 06:00
MHDA- 2018/01/25 06:00
CRDT- 2018/01/25 06:00
PHST- 2017/05/02 00:00 [received]
PHST- 2017/12/20 00:00 [accepted]
PHST- 2018/01/25 06:00 [entrez]
PHST- 2018/01/25 06:00 [pubmed]
PHST- 2018/01/25 06:00 [medline]
AID - nature25459 [pii]
AID - 10.1038/nature25459 [doi]
PST - aheadofprint
SO  - Nature. 2018 Jan 24. pii: nature25459. doi: 10.1038/nature25459.

PMID- 29033130
OWN - NLM
STAT- MEDLINE
DCOM- 20171121
LR  - 20180104
IS  - 1097-4172 (Electronic)
IS  - 0092-8674 (Linking)
VI  - 171
IP  - 4
DP  - 2017 Nov 2
TI  - Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.
PG  - 934-949.e15
LID - S0092-8674(17)31122-4 [pii]
LID - 10.1016/j.cell.2017.09.028 [doi]
AB  - The mechanisms by which immune checkpoint blockade modulates tumor evolution
      during therapy are unclear. We assessed genomic changes in tumors from 68
      patients with advanced melanoma, who progressed on ipilimumab or were
      ipilimumab-naive, before and after nivolumab initiation (CA209-038 study). Tumors
      were analyzed by whole-exome, transcriptome, and/or T cell receptor (TCR)
      sequencing. In responding patients, mutation and neoantigen load were reduced
      from baseline, and analysis of intratumoral heterogeneity during therapy
      demonstrated differential clonal evolution within tumors and putative selection
      against neoantigenic mutations on-therapy. Transcriptome analyses before and
      during nivolumab therapy revealed increases in distinct immune cell subsets,
      activation of specific transcriptional networks, and upregulation of immune
      checkpoint genes that were more pronounced in patients with response. Temporal
      changes in intratumoral TCR repertoire revealed expansion of T cell clones in the
      setting of neoantigen loss. Comprehensive genomic profiling data in this study
      provide insight into nivolumab's mechanism of action.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Riaz, Nadeem
AU  - Riaz N
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA; Department of Radiation Oncology, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA; Immunogenomics and Precision
      Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY 10065,
      USA.
FAU - Havel, Jonathan J
AU  - Havel JJ
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Makarov, Vladimir
AU  - Makarov V
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA; Immunogenomics and Precision Oncology Platform, Memorial
      Sloan Kettering Cancer Center, New York, NY 10065, USA.
FAU - Desrichard, Alexis
AU  - Desrichard A
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Urba, Walter J
AU  - Urba WJ
AD  - Earle A. Chiles Research Institute, Providence Cancer Center, Portland, OR 97213,
      USA.
FAU - Sims, Jennifer S
AU  - Sims JS
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA; Immunogenomics and Precision Oncology Platform, Memorial
      Sloan Kettering Cancer Center, New York, NY 10065, USA.
FAU - Hodi, F Stephen
AU  - Hodi FS
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Martin-Algarra, Salvador
AU  - Martin-Algarra S
AD  - Medical Oncology, Clinica Universidad de Navarra, Instituto de Investigacion
      Sanitaria de Navarra, 31008 Pamplona, Spain.
FAU - Mandal, Rajarsi
AU  - Mandal R
AD  - Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY
      10065, USA.
FAU - Sharfman, William H
AU  - Sharfman WH
AD  - Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of
      Medicine, Baltimore, MD 21287, USA.
FAU - Bhatia, Shailender
AU  - Bhatia S
AD  - Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA
      98105, USA.
FAU - Hwu, Wen-Jen
AU  - Hwu WJ
AD  - Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Gajewski, Thomas F
AU  - Gajewski TF
AD  - Department of Medicine, Section of Hematology/Oncology, University of Chicago,
      Chicago, IL 60637, USA.
FAU - Slingluff, Craig L Jr
AU  - Slingluff CL Jr
AD  - Department of Surgery and University of Virginia Cancer Center, University of
      Virginia School of Medicine, Charlottesville, VA 22908, USA.
FAU - Chowell, Diego
AU  - Chowell D
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA; Immunogenomics and Precision Oncology Platform, Memorial
      Sloan Kettering Cancer Center, New York, NY 10065, USA.
FAU - Kendall, Sviatoslav M
AU  - Kendall SM
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA; Immunogenomics and Precision Oncology Platform, Memorial
      Sloan Kettering Cancer Center, New York, NY 10065, USA.
FAU - Chang, Han
AU  - Chang H
AD  - Bristol-Myers Squibb, Princeton, NJ 08648, USA.
FAU - Shah, Rachna
AU  - Shah R
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA.
FAU - Kuo, Fengshen
AU  - Kuo F
AD  - Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer
      Center, New York, NY 10065, USA.
FAU - Morris, Luc G T
AU  - Morris LGT
AD  - Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer
      Center, New York, NY 10065, USA; Department of Surgery, Memorial Sloan Kettering 
      Cancer Center, New York, NY 10065, USA.
FAU - Sidhom, John-William
AU  - Sidhom JW
AD  - Department of Biomedical Engineering, Johns Hopkins University School of
      Medicine, Baltimore, MD 21205, USA.
FAU - Schneck, Jonathan P
AU  - Schneck JP
AD  - Department of Biomedical Engineering, Johns Hopkins University School of
      Medicine, Baltimore, MD 21205, USA.
FAU - Horak, Christine E
AU  - Horak CE
AD  - Bristol-Myers Squibb, Princeton, NJ 08648, USA.
FAU - Weinhold, Nils
AU  - Weinhold N
AD  - Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New
      York, NY 10065, USA. Electronic address: weinholn@mskcc.org.
FAU - Chan, Timothy A
AU  - Chan TA
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA; Department of Radiation Oncology, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA; Immunogenomics and Precision
      Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY 10065,
      USA. Electronic address: chant@mskcc.org.
LA  - eng
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - R01 CA177828/CA/NCI NIH HHS/United States
GR  - R01 CA205426/CA/NCI NIH HHS/United States
GR  - T32 CA009685/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20171012
PL  - United States
TA  - Cell
JT  - Cell
JID - 0413066
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Programmed Cell Death 1 Receptor)
RN  - 31YO63LBSN (nivolumab)
SB  - IM
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Antineoplastic Agents/*therapeutic use
MH  - Genome-Wide Association Study
MH  - Humans
MH  - *Immunotherapy
MH  - Melanoma/genetics/immunology/*therapy
MH  - Programmed Cell Death 1 Receptor/antagonists & inhibitors
MH  - T-Lymphocytes
MH  - Transcriptome
MH  - *Tumor Microenvironment
PMC - PMC5685550
MID - NIHMS907788
OTO - NOTNLM
OT  - T cell receptor repertoire
OT  - clonal evolution/clonal selection
OT  - immunotherapy
OT  - ipilimumab
OT  - melanoma
OT  - neoantigen load
OT  - nivolumab
OT  - tumor immune evasion
OT  - tumor microenvironment
OT  - tumor mutation load/tumor mutation burden
EDAT- 2017/10/17 06:00
MHDA- 2017/11/29 06:00
CRDT- 2017/10/17 06:00
PMCR- 2018/11/02 00:00
PHST- 2017/02/17 00:00 [received]
PHST- 2017/07/11 00:00 [revised]
PHST- 2017/09/18 00:00 [accepted]
PHST- 2018/11/02 00:00 [pmc-release]
PHST- 2017/10/17 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
PHST- 2017/10/17 06:00 [entrez]
AID - S0092-8674(17)31122-4 [pii]
AID - 10.1016/j.cell.2017.09.028 [doi]
PST - ppublish
SO  - Cell. 2017 Nov 2;171(4):934-949.e15. doi: 10.1016/j.cell.2017.09.028. Epub 2017
      Oct 12.

PMID- 29141249
OWN - NLM
STAT- MEDLINE
DCOM- 20180118
LR  - 20180118
IS  - 1421-9778 (Electronic)
IS  - 1015-8987 (Linking)
VI  - 44
IP  - 2
DP  - 2017
TI  - beta-Catenin Cooperates with CREB Binding Protein to Promote the Growth of Tumor 
      Cells.
PG  - 467-478
LID - 10.1159/000485013 [doi]
AB  - BACKGROUND/AIMS: beta-catenin is an integral component of the canonical Wnt
      signaling pathway, and its mutations are an autosomal recessive cause of
      colorectal cancer (CRC), medulloblastoma (MDB), and ovarian cancer. Nevertheless,
      little is known about its function in lung cancers. METHODS: We first knocked
      down beta-catenin by siRNA to investigate its effects on lung cancer cell
      proliferation, migration and apoptosis. Then we verified the interaction between 
      beta-catenin and CREB binding protein (CBP) by immunofluoresence and
      co-immunoprecipition assays. Finally, the expression of beta-catenin and CBP in
      human lung adenocarcinoma specimens were analyzed by immunohistochemistry assay. 
      RESULTS: beta-catenin knockdown inhibited cell proliferation, promoted apoptosis 
      and suppressed cell migration in A549 and H460 cells accompanied by the decreased
      expression of Myc, PCNA, VEGF, CD44, MMP-9, MMP-13 and activated bax/caspase-3
      pathway. Furthermore, co-immunoprecipition and immunofluoresence analyses
      revealed that CBP interacted with beta-catenin and contributed to
      beta-catenin-mediated lung cancer cell growth. Abolishment of their interaction
      by the Wnt/beta-catenin inhibitor ICG-001 remarkably suppressed cell
      proliferation. Immunohistochemistry assay of tissue microarrays from patients
      with lung cancer indicated that both CBP and beta-catenin were highly expressed
      in tumor tissues and predicted poor prognosis in lung adenocarcinoma patients.
      CONCLUSIONS: Our study has provided new evidence for the role of beta-catenin in 
      promoting the growth of lung cancer cells through cooperation with CBP, and
      suggested that dual targeting of beta-catenin and CBP could be a potential
      therapeutic strategy in lung cancer treatment.
CI  - (c) 2017 The Author(s). Published by S. Karger AG, Basel.
FAU - Yu, Wendan
AU  - Yu W
AD  - Institute of Cancer Stem Cell & The Second Affiliated Hospital, Dalian Medical
      University, Dalian, China.
FAU - Li, Liren
AU  - Li L
AD  - Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South
      China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.
FAU - Zheng, Fufu
AU  - Zheng F
AD  - The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
FAU - Yang, Wenjing
AU  - Yang W
AD  - Institute of Cancer Stem Cell & The Second Affiliated Hospital, Dalian Medical
      University, Dalian, China.
FAU - Zhao, Shilei
AU  - Zhao S
AD  - Institute of Cancer Stem Cell & The Second Affiliated Hospital, Dalian Medical
      University, Dalian, China.
FAU - Tian, Chunfang
AU  - Tian C
AD  - Institute of Cancer Stem Cell & The Second Affiliated Hospital, Dalian Medical
      University, Dalian, China.
FAU - Yin, Wenwen
AU  - Yin W
AD  - Institute of Cancer Stem Cell & The Second Affiliated Hospital, Dalian Medical
      University, Dalian, China.
FAU - Chen, Yiming
AU  - Chen Y
AD  - Institute of Cancer Stem Cell & The Second Affiliated Hospital, Dalian Medical
      University, Dalian, China.
FAU - Guo, Wei
AU  - Guo W
AD  - Institute of Cancer Stem Cell & The Second Affiliated Hospital, Dalian Medical
      University, Dalian, China.
FAU - Zou, Lijuan
AU  - Zou L
AD  - Institute of Cancer Stem Cell & The Second Affiliated Hospital, Dalian Medical
      University, Dalian, China.
FAU - Deng, Wuguo
AU  - Deng W
AD  - Institute of Cancer Stem Cell & The Second Affiliated Hospital, Dalian Medical
      University, Dalian, China.
AD  - Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South
      China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20171115
PL  - Switzerland
TA  - Cell Physiol Biochem
JT  - Cellular physiology and biochemistry : international journal of experimental
      cellular physiology, biochemistry, and pharmacology
JID - 9113221
RN  - 0 (Bridged Bicyclo Compounds, Heterocyclic)
RN  - 0 (ICG 001)
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
RN  - 0 (Pyrimidinones)
RN  - 0 (RNA, Small Interfering)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 0 (bcl-2-Associated X Protein)
RN  - 0 (beta Catenin)
RN  - EC 2.3.1.48 (CREB-Binding Protein)
RN  - EC 3.4.22.- (Caspase 3)
RN  - EC 3.4.24.- (Matrix Metalloproteinase 13)
RN  - EC 3.4.24.35 (Matrix Metalloproteinase 9)
SB  - IM
MH  - A549 Cells
MH  - Adenocarcinoma/metabolism/mortality/*pathology
MH  - Aged
MH  - Apoptosis/drug effects
MH  - Bridged Bicyclo Compounds, Heterocyclic/toxicity
MH  - CREB-Binding Protein/antagonists & inhibitors/genetics/*metabolism
MH  - Caspase 3/metabolism
MH  - Cell Line, Tumor
MH  - Cell Movement/drug effects
MH  - Cell Proliferation/drug effects
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - Kaplan-Meier Estimate
MH  - Lung Neoplasms/metabolism/mortality/*pathology
MH  - Male
MH  - Matrix Metalloproteinase 13/metabolism
MH  - Matrix Metalloproteinase 9/metabolism
MH  - Microscopy, Fluorescence
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Proto-Oncogene Proteins c-bcl-2/metabolism
MH  - Pyrimidinones/toxicity
MH  - RNA Interference
MH  - RNA, Small Interfering/metabolism
MH  - Vascular Endothelial Growth Factor A/metabolism
MH  - Wnt Signaling Pathway/drug effects
MH  - bcl-2-Associated X Protein/metabolism
MH  - beta Catenin/antagonists & inhibitors/genetics/*metabolism
OTO - NOTNLM
OT  - CBP
OT  - Lung cancer
OT  - Prognosis
OT  - beta-catenin
EDAT- 2017/11/16 06:00
MHDA- 2018/01/19 06:00
CRDT- 2017/11/16 06:00
PHST- 2017/07/21 00:00 [received]
PHST- 2017/09/09 00:00 [accepted]
PHST- 2017/11/16 06:00 [pubmed]
PHST- 2018/01/19 06:00 [medline]
PHST- 2017/11/16 06:00 [entrez]
AID - 000485013 [pii]
AID - 10.1159/000485013 [doi]
PST - ppublish
SO  - Cell Physiol Biochem. 2017;44(2):467-478. doi: 10.1159/000485013. Epub 2017 Nov
      15.

PMID- 29058718
OWN - NLM
STAT- MEDLINE
DCOM- 20171107
LR  - 20171219
IS  - 1476-4679 (Electronic)
IS  - 1465-7392 (Linking)
VI  - 19
IP  - 11
DP  - 2017 Nov
TI  - PKM2 methylation by CARM1 activates aerobic glycolysis to promote tumorigenesis.
PG  - 1358-1370
LID - 10.1038/ncb3630 [doi]
AB  - Metabolic reprogramming is a hallmark of cancer. Herein we discover that the key 
      glycolytic enzyme pyruvate kinase M2 isoform (PKM2), but not the related isoform 
      PKM1, is methylated by co-activator-associated arginine methyltransferase 1
      (CARM1). PKM2 methylation reversibly shifts the balance of metabolism from
      oxidative phosphorylation to aerobic glycolysis in breast cancer cells. Oxidative
      phosphorylation depends on mitochondrial calcium concentration, which becomes
      critical for cancer cell survival when PKM2 methylation is blocked. By
      interacting with and suppressing the expression of inositol-1,4,5-trisphosphate
      receptors (InsP3Rs), methylated PKM2 inhibits the influx of calcium from the
      endoplasmic reticulum to mitochondria. Inhibiting PKM2 methylation with a
      competitive peptide delivered by nanoparticles perturbs the metabolic energy
      balance in cancer cells, leading to a decrease in cell proliferation, migration
      and metastasis. Collectively, the CARM1-PKM2 axis serves as a metabolic
      reprogramming mechanism in tumorigenesis, and inhibiting PKM2 methylation
      generates metabolic vulnerability to InsP3R-dependent mitochondrial functions.
FAU - Liu, Fabao
AU  - Liu F
AD  - McArdle Laboratory for Cancer Research, University of Wisconsin-Madison, Madison,
      Wisconsin 53705, USA.
FAU - Ma, Fengfei
AU  - Ma F
AD  - School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin 53705,
      USA.
FAU - Wang, Yuyuan
AU  - Wang Y
AD  - Department of Materials Science and Engineering and Wisconsin Institute for
      Discovery, University of Wisconsin-Madison, Madison, Wisconsin 53715, USA.
FAU - Hao, Ling
AU  - Hao L
AUID- ORCID: http://orcid.org/0000-0002-0106-5266
AD  - School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin 53705,
      USA.
FAU - Zeng, Hao
AU  - Zeng H
AUID- ORCID: http://orcid.org/0000-0003-4967-9555
AD  - McArdle Laboratory for Cancer Research, University of Wisconsin-Madison, Madison,
      Wisconsin 53705, USA.
FAU - Jia, Chenxi
AU  - Jia C
AD  - School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin 53705,
      USA.
FAU - Wang, Yidan
AU  - Wang Y
AD  - McArdle Laboratory for Cancer Research, University of Wisconsin-Madison, Madison,
      Wisconsin 53705, USA.
FAU - Liu, Peng
AU  - Liu P
AD  - Department of Biostatistics and Medical Informatics, University of
      Wisconsin-Madison, Madison, Wisconsin 53705, USA.
AD  - UW Carbone Cancer Center, School of Medicine and Public Health, University of
      Wisconsin-Madison, Madison, Wisconsin 53705, USA.
FAU - Ong, Irene M
AU  - Ong IM
AD  - Department of Biostatistics and Medical Informatics, University of
      Wisconsin-Madison, Madison, Wisconsin 53705, USA.
AD  - UW Carbone Cancer Center, School of Medicine and Public Health, University of
      Wisconsin-Madison, Madison, Wisconsin 53705, USA.
FAU - Li, Baobin
AU  - Li B
AD  - School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin 53705,
      USA.
FAU - Chen, Guojun
AU  - Chen G
AD  - Department of Materials Science and Engineering and Wisconsin Institute for
      Discovery, University of Wisconsin-Madison, Madison, Wisconsin 53715, USA.
FAU - Jiang, Jiaoyang
AU  - Jiang J
AD  - School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin 53705,
      USA.
FAU - Gong, Shaoqin
AU  - Gong S
AUID- ORCID: http://orcid.org/0000-0001-9447-2938
AD  - Department of Materials Science and Engineering and Wisconsin Institute for
      Discovery, University of Wisconsin-Madison, Madison, Wisconsin 53715, USA.
AD  - Department of Biomedical Engineering, University of Wisconsin-Madison, Madison,
      Wisconsin 53706, USA.
FAU - Li, Lingjun
AU  - Li L
AUID- ORCID: http://orcid.org/0000-0003-0056-3869
AD  - School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin 53705,
      USA.
AD  - Department of Chemistry, University of Wisconsin-Madison, Madison, Wisconsin
      53706, USA.
AD  - School of Life Sciences, Tianjin University, No. 92 Weijin Road, Nankai District,
      Tianjin 300072, China.
FAU - Xu, Wei
AU  - Xu W
AUID- ORCID: http://orcid.org/0000-0003-3808-0045
AD  - McArdle Laboratory for Cancer Research, University of Wisconsin-Madison, Madison,
      Wisconsin 53705, USA.
LA  - eng
GR  - R01 CA213293/CA/NCI NIH HHS/United States
GR  - R21 CA196653/CA/NCI NIH HHS/United States
GR  - P30 CA014520/CA/NCI NIH HHS/United States
GR  - S10 OD018039/OD/NIH HHS/United States
GR  - S10 RR029531/RR/NCRR NIH HHS/United States
GR  - P41 GM108538/GM/NIGMS NIH HHS/United States
GR  - R01 DK071801/DK/NIDDK NIH HHS/United States
PT  - Journal Article
DEP - 20171023
PL  - England
TA  - Nat Cell Biol
JT  - Nature cell biology
JID - 100890575
RN  - 0 (CARD Signaling Adaptor Proteins)
RN  - 0 (Carrier Proteins)
RN  - 0 (Inositol 1,4,5-Trisphosphate Receptors)
RN  - 0 (Membrane Proteins)
RN  - 0 (Thyroid Hormones)
RN  - 0 (thyroid hormone-binding proteins)
RN  - EC 4.6.1.2 (CARD11 protein, human)
RN  - EC 4.6.1.2 (Guanylate Cyclase)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Animals
MH  - CARD Signaling Adaptor Proteins/*metabolism
MH  - Calcium/metabolism
MH  - Carcinogenesis/*metabolism/*pathology
MH  - Carrier Proteins/*metabolism
MH  - Cell Line
MH  - Cell Line, Tumor
MH  - Cell Movement/physiology
MH  - Cell Proliferation/physiology
MH  - Endoplasmic Reticulum/metabolism
MH  - Female
MH  - Glycolysis/*physiology
MH  - Guanylate Cyclase/*metabolism
MH  - HEK293 Cells
MH  - Humans
MH  - Inositol 1,4,5-Trisphosphate Receptors/metabolism
MH  - MCF-7 Cells
MH  - Membrane Proteins/*metabolism
MH  - Methylation
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Nude
MH  - Mitochondria/metabolism
MH  - Neoplasm Metastasis/pathology
MH  - Oxidative Phosphorylation
MH  - Thyroid Hormones/*metabolism
PMC - PMC5683091
MID - NIHMS907098
EDAT- 2017/10/24 06:00
MHDA- 2017/11/08 06:00
CRDT- 2017/10/24 06:00
PMCR- 2018/04/23 00:00
PHST- 2017/01/19 00:00 [received]
PHST- 2017/09/18 00:00 [accepted]
PHST- 2018/04/23 00:00 [pmc-release]
PHST- 2017/10/24 06:00 [pubmed]
PHST- 2017/11/08 06:00 [medline]
PHST- 2017/10/24 06:00 [entrez]
AID - ncb3630 [pii]
AID - 10.1038/ncb3630 [doi]
PST - ppublish
SO  - Nat Cell Biol. 2017 Nov;19(11):1358-1370. doi: 10.1038/ncb3630. Epub 2017 Oct 23.

PMID- 29337640
OWN - NLM
STAT- Publisher
LR  - 20180116
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Linking)
DP  - 2018 Jan 16
TI  - Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and
      Anti-Programmed Death-Ligand (PD-L)-Ligand 1 Blockade in Patients With
      Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.
PG  - JCO2017753384
LID - 10.1200/JCO.2017.75.3384 [doi]
AB  - Purpose Treatment of advanced non-small-cell lung cancer with immune checkpoint
      inhibitors (ICIs) is characterized by durable responses and improved survival in 
      a subset of patients. Clinically available tools to optimize use of ICIs and
      understand the molecular determinants of response are needed. Targeted
      next-generation sequencing (NGS) is increasingly routine, but its role in
      identifying predictors of response to ICIs is not known. Methods Detailed
      clinical annotation and response data were collected for patients with advanced
      non-small-cell lung cancer treated with anti-programmed death-1 or
      anti-programmed death-ligand 1 [anti-programmed cell death (PD)-1] therapy and
      profiled by targeted NGS (MSK-IMPACT; n = 240). Efficacy was assessed by Response
      Evaluation Criteria in Solid Tumors (RECIST) version 1.1, and durable clinical
      benefit (DCB) was defined as partial response/stable disease that lasted > 6
      months. Tumor mutation burden (TMB), fraction of copy number-altered genome, and 
      gene alterations were compared among patients with DCB and no durable benefit
      (NDB). Whole-exome sequencing (WES) was performed for 49 patients to compare
      quantification of TMB by targeted NGS versus WES. Results Estimates of TMB by
      targeted NGS correlated well with WES (rho = 0.86; P < .001). TMB was greater in 
      patients with DCB than with NDB ( P = .006). DCB was more common, and
      progression-free survival was longer in patients at increasing thresholds above
      versus below the 50th percentile of TMB (38.6% v 25.1%; P < .001; hazard ratio,
      1.38; P = .024). The fraction of copy number-altered genome was highest in those 
      with NDB. Variants in EGFR and STK11 associated with a lack of benefit. TMB and
      PD-L1 expression were independent variables, and a composite of TMB plus PD-L1
      further enriched for benefit to ICIs. Conclusion Targeted NGS accurately
      estimates TMB and elevated TMB further improved likelihood of benefit to ICIs.
      TMB did not correlate with PD-L1 expression; both variables had similar
      predictive capacity. The incorporation of both TMB and PD-L1 expression into
      multivariable predictive models should result in greater predictive power.
FAU - Rizvi, Hira
AU  - Rizvi H
AD  - Hira Rizvi, Francisco Sanchez-Vega, Konnor La, Walid Chatila, Philip Jonsson,
      Darragh Halpenny, Andrew Plodkowski, Niamh Long, Jennifer L. Sauter, Natasha
      Rekhtman, Travis Hollmann, Ronglai Shen, Ai Ni, Kathryn C. Arbour, Taha Merghoub,
      Jedd Wolchok, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Nicholas D. Socci, 
      Michael F. Berger, Barry S. Taylor, Ahmet Zehir, David B. Solit, Maria E. Arcila,
      Marc Ladanyi, Gregory J. Riely, Nikolaus Schultz, and Matthew D. Hellmann,
      Memorial Sloan Kettering Cancer Center; Taha Merghoub, Jedd Wolchok, Alexandra
      Snyder, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Gregory J. Riely, and
      Matthew D. Hellmann, Weill Cornell Medical College, New York, NY; Kurt A.
      Schalper, Yale School of Medicine, New Haven, CT; Justin F. Gainor, Massachusetts
      General Hospital, Boston, MA; and Alexandra Snyder, Adaptive Biotechnologies,
      Seattle, WA.
FAU - Sanchez-Vega, Francisco
AU  - Sanchez-Vega F
AD  - Hira Rizvi, Francisco Sanchez-Vega, Konnor La, Walid Chatila, Philip Jonsson,
      Darragh Halpenny, Andrew Plodkowski, Niamh Long, Jennifer L. Sauter, Natasha
      Rekhtman, Travis Hollmann, Ronglai Shen, Ai Ni, Kathryn C. Arbour, Taha Merghoub,
      Jedd Wolchok, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Nicholas D. Socci, 
      Michael F. Berger, Barry S. Taylor, Ahmet Zehir, David B. Solit, Maria E. Arcila,
      Marc Ladanyi, Gregory J. Riely, Nikolaus Schultz, and Matthew D. Hellmann,
      Memorial Sloan Kettering Cancer Center; Taha Merghoub, Jedd Wolchok, Alexandra
      Snyder, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Gregory J. Riely, and
      Matthew D. Hellmann, Weill Cornell Medical College, New York, NY; Kurt A.
      Schalper, Yale School of Medicine, New Haven, CT; Justin F. Gainor, Massachusetts
      General Hospital, Boston, MA; and Alexandra Snyder, Adaptive Biotechnologies,
      Seattle, WA.
FAU - La, Konnor
AU  - La K
AD  - Hira Rizvi, Francisco Sanchez-Vega, Konnor La, Walid Chatila, Philip Jonsson,
      Darragh Halpenny, Andrew Plodkowski, Niamh Long, Jennifer L. Sauter, Natasha
      Rekhtman, Travis Hollmann, Ronglai Shen, Ai Ni, Kathryn C. Arbour, Taha Merghoub,
      Jedd Wolchok, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Nicholas D. Socci, 
      Michael F. Berger, Barry S. Taylor, Ahmet Zehir, David B. Solit, Maria E. Arcila,
      Marc Ladanyi, Gregory J. Riely, Nikolaus Schultz, and Matthew D. Hellmann,
      Memorial Sloan Kettering Cancer Center; Taha Merghoub, Jedd Wolchok, Alexandra
      Snyder, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Gregory J. Riely, and
      Matthew D. Hellmann, Weill Cornell Medical College, New York, NY; Kurt A.
      Schalper, Yale School of Medicine, New Haven, CT; Justin F. Gainor, Massachusetts
      General Hospital, Boston, MA; and Alexandra Snyder, Adaptive Biotechnologies,
      Seattle, WA.
FAU - Chatila, Walid
AU  - Chatila W
AD  - Hira Rizvi, Francisco Sanchez-Vega, Konnor La, Walid Chatila, Philip Jonsson,
      Darragh Halpenny, Andrew Plodkowski, Niamh Long, Jennifer L. Sauter, Natasha
      Rekhtman, Travis Hollmann, Ronglai Shen, Ai Ni, Kathryn C. Arbour, Taha Merghoub,
      Jedd Wolchok, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Nicholas D. Socci, 
      Michael F. Berger, Barry S. Taylor, Ahmet Zehir, David B. Solit, Maria E. Arcila,
      Marc Ladanyi, Gregory J. Riely, Nikolaus Schultz, and Matthew D. Hellmann,
      Memorial Sloan Kettering Cancer Center; Taha Merghoub, Jedd Wolchok, Alexandra
      Snyder, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Gregory J. Riely, and
      Matthew D. Hellmann, Weill Cornell Medical College, New York, NY; Kurt A.
      Schalper, Yale School of Medicine, New Haven, CT; Justin F. Gainor, Massachusetts
      General Hospital, Boston, MA; and Alexandra Snyder, Adaptive Biotechnologies,
      Seattle, WA.
FAU - Jonsson, Philip
AU  - Jonsson P
AD  - Hira Rizvi, Francisco Sanchez-Vega, Konnor La, Walid Chatila, Philip Jonsson,
      Darragh Halpenny, Andrew Plodkowski, Niamh Long, Jennifer L. Sauter, Natasha
      Rekhtman, Travis Hollmann, Ronglai Shen, Ai Ni, Kathryn C. Arbour, Taha Merghoub,
      Jedd Wolchok, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Nicholas D. Socci, 
      Michael F. Berger, Barry S. Taylor, Ahmet Zehir, David B. Solit, Maria E. Arcila,
      Marc Ladanyi, Gregory J. Riely, Nikolaus Schultz, and Matthew D. Hellmann,
      Memorial Sloan Kettering Cancer Center; Taha Merghoub, Jedd Wolchok, Alexandra
      Snyder, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Gregory J. Riely, and
      Matthew D. Hellmann, Weill Cornell Medical College, New York, NY; Kurt A.
      Schalper, Yale School of Medicine, New Haven, CT; Justin F. Gainor, Massachusetts
      General Hospital, Boston, MA; and Alexandra Snyder, Adaptive Biotechnologies,
      Seattle, WA.
FAU - Halpenny, Darragh
AU  - Halpenny D
AD  - Hira Rizvi, Francisco Sanchez-Vega, Konnor La, Walid Chatila, Philip Jonsson,
      Darragh Halpenny, Andrew Plodkowski, Niamh Long, Jennifer L. Sauter, Natasha
      Rekhtman, Travis Hollmann, Ronglai Shen, Ai Ni, Kathryn C. Arbour, Taha Merghoub,
      Jedd Wolchok, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Nicholas D. Socci, 
      Michael F. Berger, Barry S. Taylor, Ahmet Zehir, David B. Solit, Maria E. Arcila,
      Marc Ladanyi, Gregory J. Riely, Nikolaus Schultz, and Matthew D. Hellmann,
      Memorial Sloan Kettering Cancer Center; Taha Merghoub, Jedd Wolchok, Alexandra
      Snyder, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Gregory J. Riely, and
      Matthew D. Hellmann, Weill Cornell Medical College, New York, NY; Kurt A.
      Schalper, Yale School of Medicine, New Haven, CT; Justin F. Gainor, Massachusetts
      General Hospital, Boston, MA; and Alexandra Snyder, Adaptive Biotechnologies,
      Seattle, WA.
FAU - Plodkowski, Andrew
AU  - Plodkowski A
AD  - Hira Rizvi, Francisco Sanchez-Vega, Konnor La, Walid Chatila, Philip Jonsson,
      Darragh Halpenny, Andrew Plodkowski, Niamh Long, Jennifer L. Sauter, Natasha
      Rekhtman, Travis Hollmann, Ronglai Shen, Ai Ni, Kathryn C. Arbour, Taha Merghoub,
      Jedd Wolchok, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Nicholas D. Socci, 
      Michael F. Berger, Barry S. Taylor, Ahmet Zehir, David B. Solit, Maria E. Arcila,
      Marc Ladanyi, Gregory J. Riely, Nikolaus Schultz, and Matthew D. Hellmann,
      Memorial Sloan Kettering Cancer Center; Taha Merghoub, Jedd Wolchok, Alexandra
      Snyder, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Gregory J. Riely, and
      Matthew D. Hellmann, Weill Cornell Medical College, New York, NY; Kurt A.
      Schalper, Yale School of Medicine, New Haven, CT; Justin F. Gainor, Massachusetts
      General Hospital, Boston, MA; and Alexandra Snyder, Adaptive Biotechnologies,
      Seattle, WA.
FAU - Long, Niamh
AU  - Long N
AD  - Hira Rizvi, Francisco Sanchez-Vega, Konnor La, Walid Chatila, Philip Jonsson,
      Darragh Halpenny, Andrew Plodkowski, Niamh Long, Jennifer L. Sauter, Natasha
      Rekhtman, Travis Hollmann, Ronglai Shen, Ai Ni, Kathryn C. Arbour, Taha Merghoub,
      Jedd Wolchok, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Nicholas D. Socci, 
      Michael F. Berger, Barry S. Taylor, Ahmet Zehir, David B. Solit, Maria E. Arcila,
      Marc Ladanyi, Gregory J. Riely, Nikolaus Schultz, and Matthew D. Hellmann,
      Memorial Sloan Kettering Cancer Center; Taha Merghoub, Jedd Wolchok, Alexandra
      Snyder, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Gregory J. Riely, and
      Matthew D. Hellmann, Weill Cornell Medical College, New York, NY; Kurt A.
      Schalper, Yale School of Medicine, New Haven, CT; Justin F. Gainor, Massachusetts
      General Hospital, Boston, MA; and Alexandra Snyder, Adaptive Biotechnologies,
      Seattle, WA.
FAU - Sauter, Jennifer L
AU  - Sauter JL
AD  - Hira Rizvi, Francisco Sanchez-Vega, Konnor La, Walid Chatila, Philip Jonsson,
      Darragh Halpenny, Andrew Plodkowski, Niamh Long, Jennifer L. Sauter, Natasha
      Rekhtman, Travis Hollmann, Ronglai Shen, Ai Ni, Kathryn C. Arbour, Taha Merghoub,
      Jedd Wolchok, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Nicholas D. Socci, 
      Michael F. Berger, Barry S. Taylor, Ahmet Zehir, David B. Solit, Maria E. Arcila,
      Marc Ladanyi, Gregory J. Riely, Nikolaus Schultz, and Matthew D. Hellmann,
      Memorial Sloan Kettering Cancer Center; Taha Merghoub, Jedd Wolchok, Alexandra
      Snyder, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Gregory J. Riely, and
      Matthew D. Hellmann, Weill Cornell Medical College, New York, NY; Kurt A.
      Schalper, Yale School of Medicine, New Haven, CT; Justin F. Gainor, Massachusetts
      General Hospital, Boston, MA; and Alexandra Snyder, Adaptive Biotechnologies,
      Seattle, WA.
FAU - Rekhtman, Natasha
AU  - Rekhtman N
AD  - Hira Rizvi, Francisco Sanchez-Vega, Konnor La, Walid Chatila, Philip Jonsson,
      Darragh Halpenny, Andrew Plodkowski, Niamh Long, Jennifer L. Sauter, Natasha
      Rekhtman, Travis Hollmann, Ronglai Shen, Ai Ni, Kathryn C. Arbour, Taha Merghoub,
      Jedd Wolchok, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Nicholas D. Socci, 
      Michael F. Berger, Barry S. Taylor, Ahmet Zehir, David B. Solit, Maria E. Arcila,
      Marc Ladanyi, Gregory J. Riely, Nikolaus Schultz, and Matthew D. Hellmann,
      Memorial Sloan Kettering Cancer Center; Taha Merghoub, Jedd Wolchok, Alexandra
      Snyder, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Gregory J. Riely, and
      Matthew D. Hellmann, Weill Cornell Medical College, New York, NY; Kurt A.
      Schalper, Yale School of Medicine, New Haven, CT; Justin F. Gainor, Massachusetts
      General Hospital, Boston, MA; and Alexandra Snyder, Adaptive Biotechnologies,
      Seattle, WA.
FAU - Hollmann, Travis
AU  - Hollmann T
AD  - Hira Rizvi, Francisco Sanchez-Vega, Konnor La, Walid Chatila, Philip Jonsson,
      Darragh Halpenny, Andrew Plodkowski, Niamh Long, Jennifer L. Sauter, Natasha
      Rekhtman, Travis Hollmann, Ronglai Shen, Ai Ni, Kathryn C. Arbour, Taha Merghoub,
      Jedd Wolchok, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Nicholas D. Socci, 
      Michael F. Berger, Barry S. Taylor, Ahmet Zehir, David B. Solit, Maria E. Arcila,
      Marc Ladanyi, Gregory J. Riely, Nikolaus Schultz, and Matthew D. Hellmann,
      Memorial Sloan Kettering Cancer Center; Taha Merghoub, Jedd Wolchok, Alexandra
      Snyder, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Gregory J. Riely, and
      Matthew D. Hellmann, Weill Cornell Medical College, New York, NY; Kurt A.
      Schalper, Yale School of Medicine, New Haven, CT; Justin F. Gainor, Massachusetts
      General Hospital, Boston, MA; and Alexandra Snyder, Adaptive Biotechnologies,
      Seattle, WA.
FAU - Schalper, Kurt A
AU  - Schalper KA
AD  - Hira Rizvi, Francisco Sanchez-Vega, Konnor La, Walid Chatila, Philip Jonsson,
      Darragh Halpenny, Andrew Plodkowski, Niamh Long, Jennifer L. Sauter, Natasha
      Rekhtman, Travis Hollmann, Ronglai Shen, Ai Ni, Kathryn C. Arbour, Taha Merghoub,
      Jedd Wolchok, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Nicholas D. Socci, 
      Michael F. Berger, Barry S. Taylor, Ahmet Zehir, David B. Solit, Maria E. Arcila,
      Marc Ladanyi, Gregory J. Riely, Nikolaus Schultz, and Matthew D. Hellmann,
      Memorial Sloan Kettering Cancer Center; Taha Merghoub, Jedd Wolchok, Alexandra
      Snyder, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Gregory J. Riely, and
      Matthew D. Hellmann, Weill Cornell Medical College, New York, NY; Kurt A.
      Schalper, Yale School of Medicine, New Haven, CT; Justin F. Gainor, Massachusetts
      General Hospital, Boston, MA; and Alexandra Snyder, Adaptive Biotechnologies,
      Seattle, WA.
FAU - Gainor, Justin F
AU  - Gainor JF
AD  - Hira Rizvi, Francisco Sanchez-Vega, Konnor La, Walid Chatila, Philip Jonsson,
      Darragh Halpenny, Andrew Plodkowski, Niamh Long, Jennifer L. Sauter, Natasha
      Rekhtman, Travis Hollmann, Ronglai Shen, Ai Ni, Kathryn C. Arbour, Taha Merghoub,
      Jedd Wolchok, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Nicholas D. Socci, 
      Michael F. Berger, Barry S. Taylor, Ahmet Zehir, David B. Solit, Maria E. Arcila,
      Marc Ladanyi, Gregory J. Riely, Nikolaus Schultz, and Matthew D. Hellmann,
      Memorial Sloan Kettering Cancer Center; Taha Merghoub, Jedd Wolchok, Alexandra
      Snyder, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Gregory J. Riely, and
      Matthew D. Hellmann, Weill Cornell Medical College, New York, NY; Kurt A.
      Schalper, Yale School of Medicine, New Haven, CT; Justin F. Gainor, Massachusetts
      General Hospital, Boston, MA; and Alexandra Snyder, Adaptive Biotechnologies,
      Seattle, WA.
FAU - Shen, Ronglai
AU  - Shen R
AD  - Hira Rizvi, Francisco Sanchez-Vega, Konnor La, Walid Chatila, Philip Jonsson,
      Darragh Halpenny, Andrew Plodkowski, Niamh Long, Jennifer L. Sauter, Natasha
      Rekhtman, Travis Hollmann, Ronglai Shen, Ai Ni, Kathryn C. Arbour, Taha Merghoub,
      Jedd Wolchok, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Nicholas D. Socci, 
      Michael F. Berger, Barry S. Taylor, Ahmet Zehir, David B. Solit, Maria E. Arcila,
      Marc Ladanyi, Gregory J. Riely, Nikolaus Schultz, and Matthew D. Hellmann,
      Memorial Sloan Kettering Cancer Center; Taha Merghoub, Jedd Wolchok, Alexandra
      Snyder, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Gregory J. Riely, and
      Matthew D. Hellmann, Weill Cornell Medical College, New York, NY; Kurt A.
      Schalper, Yale School of Medicine, New Haven, CT; Justin F. Gainor, Massachusetts
      General Hospital, Boston, MA; and Alexandra Snyder, Adaptive Biotechnologies,
      Seattle, WA.
FAU - Ni, Ai
AU  - Ni A
AD  - Hira Rizvi, Francisco Sanchez-Vega, Konnor La, Walid Chatila, Philip Jonsson,
      Darragh Halpenny, Andrew Plodkowski, Niamh Long, Jennifer L. Sauter, Natasha
      Rekhtman, Travis Hollmann, Ronglai Shen, Ai Ni, Kathryn C. Arbour, Taha Merghoub,
      Jedd Wolchok, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Nicholas D. Socci, 
      Michael F. Berger, Barry S. Taylor, Ahmet Zehir, David B. Solit, Maria E. Arcila,
      Marc Ladanyi, Gregory J. Riely, Nikolaus Schultz, and Matthew D. Hellmann,
      Memorial Sloan Kettering Cancer Center; Taha Merghoub, Jedd Wolchok, Alexandra
      Snyder, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Gregory J. Riely, and
      Matthew D. Hellmann, Weill Cornell Medical College, New York, NY; Kurt A.
      Schalper, Yale School of Medicine, New Haven, CT; Justin F. Gainor, Massachusetts
      General Hospital, Boston, MA; and Alexandra Snyder, Adaptive Biotechnologies,
      Seattle, WA.
FAU - Arbour, Kathryn C
AU  - Arbour KC
AD  - Hira Rizvi, Francisco Sanchez-Vega, Konnor La, Walid Chatila, Philip Jonsson,
      Darragh Halpenny, Andrew Plodkowski, Niamh Long, Jennifer L. Sauter, Natasha
      Rekhtman, Travis Hollmann, Ronglai Shen, Ai Ni, Kathryn C. Arbour, Taha Merghoub,
      Jedd Wolchok, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Nicholas D. Socci, 
      Michael F. Berger, Barry S. Taylor, Ahmet Zehir, David B. Solit, Maria E. Arcila,
      Marc Ladanyi, Gregory J. Riely, Nikolaus Schultz, and Matthew D. Hellmann,
      Memorial Sloan Kettering Cancer Center; Taha Merghoub, Jedd Wolchok, Alexandra
      Snyder, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Gregory J. Riely, and
      Matthew D. Hellmann, Weill Cornell Medical College, New York, NY; Kurt A.
      Schalper, Yale School of Medicine, New Haven, CT; Justin F. Gainor, Massachusetts
      General Hospital, Boston, MA; and Alexandra Snyder, Adaptive Biotechnologies,
      Seattle, WA.
FAU - Merghoub, Taha
AU  - Merghoub T
AD  - Hira Rizvi, Francisco Sanchez-Vega, Konnor La, Walid Chatila, Philip Jonsson,
      Darragh Halpenny, Andrew Plodkowski, Niamh Long, Jennifer L. Sauter, Natasha
      Rekhtman, Travis Hollmann, Ronglai Shen, Ai Ni, Kathryn C. Arbour, Taha Merghoub,
      Jedd Wolchok, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Nicholas D. Socci, 
      Michael F. Berger, Barry S. Taylor, Ahmet Zehir, David B. Solit, Maria E. Arcila,
      Marc Ladanyi, Gregory J. Riely, Nikolaus Schultz, and Matthew D. Hellmann,
      Memorial Sloan Kettering Cancer Center; Taha Merghoub, Jedd Wolchok, Alexandra
      Snyder, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Gregory J. Riely, and
      Matthew D. Hellmann, Weill Cornell Medical College, New York, NY; Kurt A.
      Schalper, Yale School of Medicine, New Haven, CT; Justin F. Gainor, Massachusetts
      General Hospital, Boston, MA; and Alexandra Snyder, Adaptive Biotechnologies,
      Seattle, WA.
FAU - Wolchok, Jedd
AU  - Wolchok J
AD  - Hira Rizvi, Francisco Sanchez-Vega, Konnor La, Walid Chatila, Philip Jonsson,
      Darragh Halpenny, Andrew Plodkowski, Niamh Long, Jennifer L. Sauter, Natasha
      Rekhtman, Travis Hollmann, Ronglai Shen, Ai Ni, Kathryn C. Arbour, Taha Merghoub,
      Jedd Wolchok, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Nicholas D. Socci, 
      Michael F. Berger, Barry S. Taylor, Ahmet Zehir, David B. Solit, Maria E. Arcila,
      Marc Ladanyi, Gregory J. Riely, Nikolaus Schultz, and Matthew D. Hellmann,
      Memorial Sloan Kettering Cancer Center; Taha Merghoub, Jedd Wolchok, Alexandra
      Snyder, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Gregory J. Riely, and
      Matthew D. Hellmann, Weill Cornell Medical College, New York, NY; Kurt A.
      Schalper, Yale School of Medicine, New Haven, CT; Justin F. Gainor, Massachusetts
      General Hospital, Boston, MA; and Alexandra Snyder, Adaptive Biotechnologies,
      Seattle, WA.
FAU - Snyder, Alexandra
AU  - Snyder A
AD  - Hira Rizvi, Francisco Sanchez-Vega, Konnor La, Walid Chatila, Philip Jonsson,
      Darragh Halpenny, Andrew Plodkowski, Niamh Long, Jennifer L. Sauter, Natasha
      Rekhtman, Travis Hollmann, Ronglai Shen, Ai Ni, Kathryn C. Arbour, Taha Merghoub,
      Jedd Wolchok, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Nicholas D. Socci, 
      Michael F. Berger, Barry S. Taylor, Ahmet Zehir, David B. Solit, Maria E. Arcila,
      Marc Ladanyi, Gregory J. Riely, Nikolaus Schultz, and Matthew D. Hellmann,
      Memorial Sloan Kettering Cancer Center; Taha Merghoub, Jedd Wolchok, Alexandra
      Snyder, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Gregory J. Riely, and
      Matthew D. Hellmann, Weill Cornell Medical College, New York, NY; Kurt A.
      Schalper, Yale School of Medicine, New Haven, CT; Justin F. Gainor, Massachusetts
      General Hospital, Boston, MA; and Alexandra Snyder, Adaptive Biotechnologies,
      Seattle, WA.
FAU - Chaft, Jamie E
AU  - Chaft JE
AD  - Hira Rizvi, Francisco Sanchez-Vega, Konnor La, Walid Chatila, Philip Jonsson,
      Darragh Halpenny, Andrew Plodkowski, Niamh Long, Jennifer L. Sauter, Natasha
      Rekhtman, Travis Hollmann, Ronglai Shen, Ai Ni, Kathryn C. Arbour, Taha Merghoub,
      Jedd Wolchok, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Nicholas D. Socci, 
      Michael F. Berger, Barry S. Taylor, Ahmet Zehir, David B. Solit, Maria E. Arcila,
      Marc Ladanyi, Gregory J. Riely, Nikolaus Schultz, and Matthew D. Hellmann,
      Memorial Sloan Kettering Cancer Center; Taha Merghoub, Jedd Wolchok, Alexandra
      Snyder, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Gregory J. Riely, and
      Matthew D. Hellmann, Weill Cornell Medical College, New York, NY; Kurt A.
      Schalper, Yale School of Medicine, New Haven, CT; Justin F. Gainor, Massachusetts
      General Hospital, Boston, MA; and Alexandra Snyder, Adaptive Biotechnologies,
      Seattle, WA.
FAU - Kris, Mark G
AU  - Kris MG
AD  - Hira Rizvi, Francisco Sanchez-Vega, Konnor La, Walid Chatila, Philip Jonsson,
      Darragh Halpenny, Andrew Plodkowski, Niamh Long, Jennifer L. Sauter, Natasha
      Rekhtman, Travis Hollmann, Ronglai Shen, Ai Ni, Kathryn C. Arbour, Taha Merghoub,
      Jedd Wolchok, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Nicholas D. Socci, 
      Michael F. Berger, Barry S. Taylor, Ahmet Zehir, David B. Solit, Maria E. Arcila,
      Marc Ladanyi, Gregory J. Riely, Nikolaus Schultz, and Matthew D. Hellmann,
      Memorial Sloan Kettering Cancer Center; Taha Merghoub, Jedd Wolchok, Alexandra
      Snyder, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Gregory J. Riely, and
      Matthew D. Hellmann, Weill Cornell Medical College, New York, NY; Kurt A.
      Schalper, Yale School of Medicine, New Haven, CT; Justin F. Gainor, Massachusetts
      General Hospital, Boston, MA; and Alexandra Snyder, Adaptive Biotechnologies,
      Seattle, WA.
FAU - Rudin, Charles M
AU  - Rudin CM
AD  - Hira Rizvi, Francisco Sanchez-Vega, Konnor La, Walid Chatila, Philip Jonsson,
      Darragh Halpenny, Andrew Plodkowski, Niamh Long, Jennifer L. Sauter, Natasha
      Rekhtman, Travis Hollmann, Ronglai Shen, Ai Ni, Kathryn C. Arbour, Taha Merghoub,
      Jedd Wolchok, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Nicholas D. Socci, 
      Michael F. Berger, Barry S. Taylor, Ahmet Zehir, David B. Solit, Maria E. Arcila,
      Marc Ladanyi, Gregory J. Riely, Nikolaus Schultz, and Matthew D. Hellmann,
      Memorial Sloan Kettering Cancer Center; Taha Merghoub, Jedd Wolchok, Alexandra
      Snyder, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Gregory J. Riely, and
      Matthew D. Hellmann, Weill Cornell Medical College, New York, NY; Kurt A.
      Schalper, Yale School of Medicine, New Haven, CT; Justin F. Gainor, Massachusetts
      General Hospital, Boston, MA; and Alexandra Snyder, Adaptive Biotechnologies,
      Seattle, WA.
FAU - Socci, Nicholas D
AU  - Socci ND
AD  - Hira Rizvi, Francisco Sanchez-Vega, Konnor La, Walid Chatila, Philip Jonsson,
      Darragh Halpenny, Andrew Plodkowski, Niamh Long, Jennifer L. Sauter, Natasha
      Rekhtman, Travis Hollmann, Ronglai Shen, Ai Ni, Kathryn C. Arbour, Taha Merghoub,
      Jedd Wolchok, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Nicholas D. Socci, 
      Michael F. Berger, Barry S. Taylor, Ahmet Zehir, David B. Solit, Maria E. Arcila,
      Marc Ladanyi, Gregory J. Riely, Nikolaus Schultz, and Matthew D. Hellmann,
      Memorial Sloan Kettering Cancer Center; Taha Merghoub, Jedd Wolchok, Alexandra
      Snyder, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Gregory J. Riely, and
      Matthew D. Hellmann, Weill Cornell Medical College, New York, NY; Kurt A.
      Schalper, Yale School of Medicine, New Haven, CT; Justin F. Gainor, Massachusetts
      General Hospital, Boston, MA; and Alexandra Snyder, Adaptive Biotechnologies,
      Seattle, WA.
FAU - Berger, Michael F
AU  - Berger MF
AD  - Hira Rizvi, Francisco Sanchez-Vega, Konnor La, Walid Chatila, Philip Jonsson,
      Darragh Halpenny, Andrew Plodkowski, Niamh Long, Jennifer L. Sauter, Natasha
      Rekhtman, Travis Hollmann, Ronglai Shen, Ai Ni, Kathryn C. Arbour, Taha Merghoub,
      Jedd Wolchok, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Nicholas D. Socci, 
      Michael F. Berger, Barry S. Taylor, Ahmet Zehir, David B. Solit, Maria E. Arcila,
      Marc Ladanyi, Gregory J. Riely, Nikolaus Schultz, and Matthew D. Hellmann,
      Memorial Sloan Kettering Cancer Center; Taha Merghoub, Jedd Wolchok, Alexandra
      Snyder, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Gregory J. Riely, and
      Matthew D. Hellmann, Weill Cornell Medical College, New York, NY; Kurt A.
      Schalper, Yale School of Medicine, New Haven, CT; Justin F. Gainor, Massachusetts
      General Hospital, Boston, MA; and Alexandra Snyder, Adaptive Biotechnologies,
      Seattle, WA.
FAU - Taylor, Barry S
AU  - Taylor BS
AD  - Hira Rizvi, Francisco Sanchez-Vega, Konnor La, Walid Chatila, Philip Jonsson,
      Darragh Halpenny, Andrew Plodkowski, Niamh Long, Jennifer L. Sauter, Natasha
      Rekhtman, Travis Hollmann, Ronglai Shen, Ai Ni, Kathryn C. Arbour, Taha Merghoub,
      Jedd Wolchok, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Nicholas D. Socci, 
      Michael F. Berger, Barry S. Taylor, Ahmet Zehir, David B. Solit, Maria E. Arcila,
      Marc Ladanyi, Gregory J. Riely, Nikolaus Schultz, and Matthew D. Hellmann,
      Memorial Sloan Kettering Cancer Center; Taha Merghoub, Jedd Wolchok, Alexandra
      Snyder, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Gregory J. Riely, and
      Matthew D. Hellmann, Weill Cornell Medical College, New York, NY; Kurt A.
      Schalper, Yale School of Medicine, New Haven, CT; Justin F. Gainor, Massachusetts
      General Hospital, Boston, MA; and Alexandra Snyder, Adaptive Biotechnologies,
      Seattle, WA.
FAU - Zehir, Ahmet
AU  - Zehir A
AD  - Hira Rizvi, Francisco Sanchez-Vega, Konnor La, Walid Chatila, Philip Jonsson,
      Darragh Halpenny, Andrew Plodkowski, Niamh Long, Jennifer L. Sauter, Natasha
      Rekhtman, Travis Hollmann, Ronglai Shen, Ai Ni, Kathryn C. Arbour, Taha Merghoub,
      Jedd Wolchok, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Nicholas D. Socci, 
      Michael F. Berger, Barry S. Taylor, Ahmet Zehir, David B. Solit, Maria E. Arcila,
      Marc Ladanyi, Gregory J. Riely, Nikolaus Schultz, and Matthew D. Hellmann,
      Memorial Sloan Kettering Cancer Center; Taha Merghoub, Jedd Wolchok, Alexandra
      Snyder, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Gregory J. Riely, and
      Matthew D. Hellmann, Weill Cornell Medical College, New York, NY; Kurt A.
      Schalper, Yale School of Medicine, New Haven, CT; Justin F. Gainor, Massachusetts
      General Hospital, Boston, MA; and Alexandra Snyder, Adaptive Biotechnologies,
      Seattle, WA.
FAU - Solit, David B
AU  - Solit DB
AD  - Hira Rizvi, Francisco Sanchez-Vega, Konnor La, Walid Chatila, Philip Jonsson,
      Darragh Halpenny, Andrew Plodkowski, Niamh Long, Jennifer L. Sauter, Natasha
      Rekhtman, Travis Hollmann, Ronglai Shen, Ai Ni, Kathryn C. Arbour, Taha Merghoub,
      Jedd Wolchok, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Nicholas D. Socci, 
      Michael F. Berger, Barry S. Taylor, Ahmet Zehir, David B. Solit, Maria E. Arcila,
      Marc Ladanyi, Gregory J. Riely, Nikolaus Schultz, and Matthew D. Hellmann,
      Memorial Sloan Kettering Cancer Center; Taha Merghoub, Jedd Wolchok, Alexandra
      Snyder, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Gregory J. Riely, and
      Matthew D. Hellmann, Weill Cornell Medical College, New York, NY; Kurt A.
      Schalper, Yale School of Medicine, New Haven, CT; Justin F. Gainor, Massachusetts
      General Hospital, Boston, MA; and Alexandra Snyder, Adaptive Biotechnologies,
      Seattle, WA.
FAU - Arcila, Maria E
AU  - Arcila ME
AD  - Hira Rizvi, Francisco Sanchez-Vega, Konnor La, Walid Chatila, Philip Jonsson,
      Darragh Halpenny, Andrew Plodkowski, Niamh Long, Jennifer L. Sauter, Natasha
      Rekhtman, Travis Hollmann, Ronglai Shen, Ai Ni, Kathryn C. Arbour, Taha Merghoub,
      Jedd Wolchok, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Nicholas D. Socci, 
      Michael F. Berger, Barry S. Taylor, Ahmet Zehir, David B. Solit, Maria E. Arcila,
      Marc Ladanyi, Gregory J. Riely, Nikolaus Schultz, and Matthew D. Hellmann,
      Memorial Sloan Kettering Cancer Center; Taha Merghoub, Jedd Wolchok, Alexandra
      Snyder, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Gregory J. Riely, and
      Matthew D. Hellmann, Weill Cornell Medical College, New York, NY; Kurt A.
      Schalper, Yale School of Medicine, New Haven, CT; Justin F. Gainor, Massachusetts
      General Hospital, Boston, MA; and Alexandra Snyder, Adaptive Biotechnologies,
      Seattle, WA.
FAU - Ladanyi, Marc
AU  - Ladanyi M
AD  - Hira Rizvi, Francisco Sanchez-Vega, Konnor La, Walid Chatila, Philip Jonsson,
      Darragh Halpenny, Andrew Plodkowski, Niamh Long, Jennifer L. Sauter, Natasha
      Rekhtman, Travis Hollmann, Ronglai Shen, Ai Ni, Kathryn C. Arbour, Taha Merghoub,
      Jedd Wolchok, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Nicholas D. Socci, 
      Michael F. Berger, Barry S. Taylor, Ahmet Zehir, David B. Solit, Maria E. Arcila,
      Marc Ladanyi, Gregory J. Riely, Nikolaus Schultz, and Matthew D. Hellmann,
      Memorial Sloan Kettering Cancer Center; Taha Merghoub, Jedd Wolchok, Alexandra
      Snyder, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Gregory J. Riely, and
      Matthew D. Hellmann, Weill Cornell Medical College, New York, NY; Kurt A.
      Schalper, Yale School of Medicine, New Haven, CT; Justin F. Gainor, Massachusetts
      General Hospital, Boston, MA; and Alexandra Snyder, Adaptive Biotechnologies,
      Seattle, WA.
FAU - Riely, Gregory J
AU  - Riely GJ
AD  - Hira Rizvi, Francisco Sanchez-Vega, Konnor La, Walid Chatila, Philip Jonsson,
      Darragh Halpenny, Andrew Plodkowski, Niamh Long, Jennifer L. Sauter, Natasha
      Rekhtman, Travis Hollmann, Ronglai Shen, Ai Ni, Kathryn C. Arbour, Taha Merghoub,
      Jedd Wolchok, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Nicholas D. Socci, 
      Michael F. Berger, Barry S. Taylor, Ahmet Zehir, David B. Solit, Maria E. Arcila,
      Marc Ladanyi, Gregory J. Riely, Nikolaus Schultz, and Matthew D. Hellmann,
      Memorial Sloan Kettering Cancer Center; Taha Merghoub, Jedd Wolchok, Alexandra
      Snyder, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Gregory J. Riely, and
      Matthew D. Hellmann, Weill Cornell Medical College, New York, NY; Kurt A.
      Schalper, Yale School of Medicine, New Haven, CT; Justin F. Gainor, Massachusetts
      General Hospital, Boston, MA; and Alexandra Snyder, Adaptive Biotechnologies,
      Seattle, WA.
FAU - Schultz, Nikolaus
AU  - Schultz N
AD  - Hira Rizvi, Francisco Sanchez-Vega, Konnor La, Walid Chatila, Philip Jonsson,
      Darragh Halpenny, Andrew Plodkowski, Niamh Long, Jennifer L. Sauter, Natasha
      Rekhtman, Travis Hollmann, Ronglai Shen, Ai Ni, Kathryn C. Arbour, Taha Merghoub,
      Jedd Wolchok, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Nicholas D. Socci, 
      Michael F. Berger, Barry S. Taylor, Ahmet Zehir, David B. Solit, Maria E. Arcila,
      Marc Ladanyi, Gregory J. Riely, Nikolaus Schultz, and Matthew D. Hellmann,
      Memorial Sloan Kettering Cancer Center; Taha Merghoub, Jedd Wolchok, Alexandra
      Snyder, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Gregory J. Riely, and
      Matthew D. Hellmann, Weill Cornell Medical College, New York, NY; Kurt A.
      Schalper, Yale School of Medicine, New Haven, CT; Justin F. Gainor, Massachusetts
      General Hospital, Boston, MA; and Alexandra Snyder, Adaptive Biotechnologies,
      Seattle, WA.
FAU - Hellmann, Matthew D
AU  - Hellmann MD
AD  - Hira Rizvi, Francisco Sanchez-Vega, Konnor La, Walid Chatila, Philip Jonsson,
      Darragh Halpenny, Andrew Plodkowski, Niamh Long, Jennifer L. Sauter, Natasha
      Rekhtman, Travis Hollmann, Ronglai Shen, Ai Ni, Kathryn C. Arbour, Taha Merghoub,
      Jedd Wolchok, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Nicholas D. Socci, 
      Michael F. Berger, Barry S. Taylor, Ahmet Zehir, David B. Solit, Maria E. Arcila,
      Marc Ladanyi, Gregory J. Riely, Nikolaus Schultz, and Matthew D. Hellmann,
      Memorial Sloan Kettering Cancer Center; Taha Merghoub, Jedd Wolchok, Alexandra
      Snyder, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Gregory J. Riely, and
      Matthew D. Hellmann, Weill Cornell Medical College, New York, NY; Kurt A.
      Schalper, Yale School of Medicine, New Haven, CT; Justin F. Gainor, Massachusetts
      General Hospital, Boston, MA; and Alexandra Snyder, Adaptive Biotechnologies,
      Seattle, WA.
LA  - eng
PT  - Journal Article
DEP - 20180116
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of
      Clinical Oncology
JID - 8309333
EDAT- 2018/01/18 06:00
MHDA- 2018/01/18 06:00
CRDT- 2018/01/17 06:00
PHST- 2018/01/17 06:00 [entrez]
PHST- 2018/01/18 06:00 [pubmed]
PHST- 2018/01/18 06:00 [medline]
AID - 10.1200/JCO.2017.75.3384 [doi]
PST - aheadofprint
SO  - J Clin Oncol. 2018 Jan 16:JCO2017753384. doi: 10.1200/JCO.2017.75.3384.

PMID- 29107334
OWN - NLM
STAT- MEDLINE
DCOM- 20171222
LR  - 20171222
IS  - 1097-4172 (Electronic)
IS  - 0092-8674 (Linking)
VI  - 171
IP  - 6
DP  - 2017 Nov 30
TI  - MHC-I Genotype Restricts the Oncogenic Mutational Landscape.
PG  - 1272-1283.e15
LID - S0092-8674(17)31144-3 [pii]
LID - 10.1016/j.cell.2017.09.050 [doi]
AB  - MHC-I molecules expose the intracellular protein content on the cell surface,
      allowing T cells to detect foreign or mutated peptides. The combination of six
      MHC-I alleles each individual carries defines the sub-peptidome that can be
      effectively presented. We applied this concept to human cancer, hypothesizing
      that oncogenic mutations could arise in gaps in personal MHC-I presentation. To
      validate this hypothesis, we developed and applied a residue-centric patient
      presentation score to 9,176 cancer patients across 1,018 recurrent oncogenic
      mutations. We found that patient MHC-I genotype-based scores could predict which 
      mutations were more likely to emerge in their tumor. Accordingly, poor
      presentation of a mutation across patients was correlated with higher frequency
      among tumors. These results support that MHC-I genotype-restricted immunoediting 
      during tumor formation shapes the landscape of oncogenic mutations observed in
      clinically diagnosed tumors and paves the way for predicting personal cancer
      susceptibilities from knowledge of MHC-I genotype.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Marty, Rachel
AU  - Marty R
AD  - Department of Medicine, Division of Medical Genetics, University of California
      San Diego, La Jolla, CA 92093, USA; Bioinformatics and Systems Biology Program,
      University of California San Diego, La Jolla, CA 92093, USA.
FAU - Kaabinejadian, Saghar
AU  - Kaabinejadian S
AD  - Department of Microbiology and Immunology, University of Oklahoma Health Sciences
      Center, Oklahoma City, OK 73104, USA.
FAU - Rossell, David
AU  - Rossell D
AD  - Department of Economics & Business, Universitat Pompeu Fabra, 08002 Barcelona,
      Spain.
FAU - Slifker, Michael J
AU  - Slifker MJ
AD  - Biostatistics and Bioinformatics Facility, Fox Chase Cancer Center, 333 Cottman
      Avenue, Philadelphia, PA 19111, USA.
FAU - van de Haar, Joris
AU  - van de Haar J
AD  - Department of Medicine, Division of Medical Genetics, University of California
      San Diego, La Jolla, CA 92093, USA; Division of Molecular Oncology & Immunology, 
      the Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the
      Netherlands.
FAU - Engin, Hatice Billur
AU  - Engin HB
AD  - Department of Medicine, Division of Medical Genetics, University of California
      San Diego, La Jolla, CA 92093, USA.
FAU - de Prisco, Nicola
AU  - de Prisco N
AD  - Cancer Biology Program, Fox Chase Cancer Center, 333 Cottman Avenue,
      Philadelphia, PA 19111, USA.
FAU - Ideker, Trey
AU  - Ideker T
AD  - Department of Medicine, Division of Medical Genetics, University of California
      San Diego, La Jolla, CA 92093, USA; Bioinformatics and Systems Biology Program,
      University of California San Diego, La Jolla, CA 92093, USA; Moores Cancer
      Center, University of California San Diego, La Jolla, CA 92093, USA; Cancer Cell 
      Map Initiative (CCMI), University of California San Diego, La Jolla, CA 92093,
      USA; Department of Computer Science, University of California San Diego, La
      Jolla, CA 92093, USA.
FAU - Hildebrand, William H
AU  - Hildebrand WH
AD  - Department of Microbiology and Immunology, University of Oklahoma Health Sciences
      Center, Oklahoma City, OK 73104, USA.
FAU - Font-Burgada, Joan
AU  - Font-Burgada J
AD  - Department of Pharmacology, School of Medicine, University of California San
      Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA; Cancer Biology Program, Fox
      Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA. Electronic 
      address: joan.font-burgada@fccc.edu.
FAU - Carter, Hannah
AU  - Carter H
AD  - Department of Medicine, Division of Medical Genetics, University of California
      San Diego, La Jolla, CA 92093, USA; Bioinformatics and Systems Biology Program,
      University of California San Diego, La Jolla, CA 92093, USA; Moores Cancer
      Center, University of California San Diego, La Jolla, CA 92093, USA; Cancer Cell 
      Map Initiative (CCMI), University of California San Diego, La Jolla, CA 92093,
      USA.
LA  - eng
GR  - U54 CA209891/CA/NCI NIH HHS/United States
GR  - DP5 OD017937/OD/NIH HHS/United States
GR  - R00 CA191152/CA/NCI NIH HHS/United States
GR  - U24 CA184427/CA/NCI NIH HHS/United States
GR  - K99 CA191152/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20171026
PL  - United States
TA  - Cell
JT  - Cell
JID - 0413066
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Proteome)
SB  - IM
MH  - *Antigen Presentation
MH  - Cell Line, Tumor
MH  - Computer Simulation
MH  - Female
MH  - HeLa Cells
MH  - Histocompatibility Antigens Class I/*genetics/*immunology
MH  - Humans
MH  - Male
MH  - Monitoring, Immunologic
MH  - *Mutation
MH  - Neoplasms/*immunology
MH  - Proteome
PMC - PMC5711564
MID - NIHMS909948
OTO - NOTNLM
OT  - antigen presentation
OT  - cancer
OT  - cancer predisposition
OT  - cancer susceptibility prediction
OT  - human leukocyte antigen
OT  - immunoediting
OT  - immunology
OT  - immunotherapy
OT  - major histocompatibility complex
OT  - neoantigens
EDAT- 2017/11/07 06:00
MHDA- 2017/12/23 06:00
CRDT- 2017/11/07 06:00
PMCR- 2018/11/30 00:00
PHST- 2017/03/20 00:00 [received]
PHST- 2017/07/14 00:00 [revised]
PHST- 2017/09/27 00:00 [accepted]
PHST- 2018/11/30 00:00 [pmc-release]
PHST- 2017/11/07 06:00 [pubmed]
PHST- 2017/12/23 06:00 [medline]
PHST- 2017/11/07 06:00 [entrez]
AID - S0092-8674(17)31144-3 [pii]
AID - 10.1016/j.cell.2017.09.050 [doi]
PST - ppublish
SO  - Cell. 2017 Nov 30;171(6):1272-1283.e15. doi: 10.1016/j.cell.2017.09.050. Epub
      2017 Oct 26.

PMID- 29106400
OWN - NLM
STAT- MEDLINE
DCOM- 20171226
LR  - 20171226
IS  - 1546-170X (Electronic)
IS  - 1078-8956 (Linking)
VI  - 23
IP  - 12
DP  - 2017 Dec
TI  - The activated conformation of integrin beta7 is a novel multiple myeloma-specific
      target for CAR T cell therapy.
PG  - 1436-1443
LID - 10.1038/nm.4431 [doi]
AB  - Cancer-specific cell-surface antigens are ideal targets for monoclonal antibody
      (mAb)-based immunotherapy but are likely to have previously been identified in
      transcriptome or proteome analyses. Here, we show that the active conformer of an
      integrin can serve as a specific therapeutic target for multiple myeloma (MM). We
      screened >10,000 anti-MM mAb clones and identified MMG49 as an MM-specific mAb
      specifically recognizing a subset of integrin beta7 molecules. The MMG49 epitope,
      in the N-terminal region of the beta7 chain, is predicted to be inaccessible in
      the resting integrin conformer but exposed in the active conformation. Elevated
      expression and constitutive activation of integrin beta7 conferred high MMG49
      reactivity on MM cells, whereas MMG49 binding was scarcely detectable in other
      cell types including normal integrin beta7(+) lymphocytes. T cells transduced
      with MMG49-derived chimeric antigen receptor (CAR) exerted anti-MM effects
      without damaging normal hematopoietic cells. Thus, MMG49 CAR T cell therapy is
      promising for MM, and a receptor protein with a rare but physiologically relevant
      conformation can serve as a cancer immunotherapy target.
FAU - Hosen, Naoki
AU  - Hosen N
AUID- ORCID: http://orcid.org/0000-0001-9570-0947
AD  - Department of Cancer Stem Cell Biology, Osaka University Graduate School of
      Medicine, Osaka, Japan.
AD  - Department of Respiratory Medicine and Clinical Immunology, Osaka University
      Graduate School of Medicine, Osaka, Japan.
AD  - WPI Immunology Frontier Research Center, Osaka University, Osaka, Japan.
FAU - Matsunaga, Yukiko
AU  - Matsunaga Y
AD  - Laboratory of Protein Synthesis and Expression, Institute for Protein Research,
      Osaka University, Osaka, Japan.
FAU - Hasegawa, Kana
AU  - Hasegawa K
AD  - Department of Cancer Stem Cell Biology, Osaka University Graduate School of
      Medicine, Osaka, Japan.
FAU - Matsuno, Hiroshi
AU  - Matsuno H
AD  - Department of Gastroenterological Surgery, Osaka University Graduate School of
      Medicine, Osaka, Japan.
FAU - Nakamura, Yuki
AU  - Nakamura Y
AD  - Department of Cancer Stem Cell Biology, Osaka University Graduate School of
      Medicine, Osaka, Japan.
FAU - Makita, Mio
AU  - Makita M
AD  - Department of Cancer Stem Cell Biology, Osaka University Graduate School of
      Medicine, Osaka, Japan.
FAU - Watanabe, Kouki
AU  - Watanabe K
AD  - Department of Cancer Stem Cell Biology, Osaka University Graduate School of
      Medicine, Osaka, Japan.
FAU - Yoshida, Mikako
AU  - Yoshida M
AD  - Department of Cancer Stem Cell Biology, Osaka University Graduate School of
      Medicine, Osaka, Japan.
FAU - Satoh, Kei
AU  - Satoh K
AD  - Department of Cancer Stem Cell Biology, Osaka University Graduate School of
      Medicine, Osaka, Japan.
FAU - Morimoto, Soyoko
AU  - Morimoto S
AD  - Department of Cancer Immunotherapy, Osaka University Graduate School of Medicine,
      Osaka, Japan.
FAU - Fujiki, Fumihiro
AU  - Fujiki F
AD  - Department of Cancer Immunology, Osaka University Graduate School of Medicine,
      Osaka, Japan.
FAU - Nakajima, Hiroko
AU  - Nakajima H
AD  - Department of Cancer Immunology, Osaka University Graduate School of Medicine,
      Osaka, Japan.
FAU - Nakata, Jun
AU  - Nakata J
AD  - Department of Cancer Immunotherapy, Osaka University Graduate School of Medicine,
      Osaka, Japan.
FAU - Nishida, Sumiyuki
AU  - Nishida S
AD  - Department of Respiratory Medicine and Clinical Immunology, Osaka University
      Graduate School of Medicine, Osaka, Japan.
FAU - Tsuboi, Akihiro
AU  - Tsuboi A
AD  - Department of Cancer Immunotherapy, Osaka University Graduate School of Medicine,
      Osaka, Japan.
FAU - Oka, Yoshihiro
AU  - Oka Y
AD  - Department of Cancer Stem Cell Biology, Osaka University Graduate School of
      Medicine, Osaka, Japan.
AD  - Department of Respiratory Medicine and Clinical Immunology, Osaka University
      Graduate School of Medicine, Osaka, Japan.
AD  - WPI Immunology Frontier Research Center, Osaka University, Osaka, Japan.
FAU - Manabe, Masahiro
AU  - Manabe M
AD  - Department of Hematology, Osaka General Hospital of West Japan Railway Company,
      Osaka, Japan.
FAU - Ichihara, Hiroyoshi
AU  - Ichihara H
AD  - Department of Hematology, Fuchu Hospital, Osaka, Japan.
FAU - Aoyama, Yasutaka
AU  - Aoyama Y
AD  - Department of Hematology, Fuchu Hospital, Osaka, Japan.
FAU - Mugitani, Atsuko
AU  - Mugitani A
AD  - Department of Hematology, Fuchu Hospital, Osaka, Japan.
FAU - Nakao, Takafumi
AU  - Nakao T
AD  - Department of Hematology, Osaka City General Hospital, Osaka, Japan.
FAU - Hino, Masayuki
AU  - Hino M
AD  - Department of Hematology and Oncology, Osaka City University Graduate School of
      Medicine, Osaka, Japan.
FAU - Uchibori, Ryosuke
AU  - Uchibori R
AD  - Division of Immuno-Gene & Cell Therapy (Takara Bio), Jichi Medical University,
      Tochigi, Japan.
FAU - Ozawa, Keiya
AU  - Ozawa K
AD  - Division of Immuno-Gene & Cell Therapy (Takara Bio), Jichi Medical University,
      Tochigi, Japan.
AD  - Institute of Medical Science, University of Tokyo, Tokyo, Japan.
FAU - Baba, Yoshihiro
AU  - Baba Y
AD  - Division of Immunology and Genome Biology, Medical Institute of Bioregulation,
      Kyushu University, Fukuoka, Japan.
FAU - Terakura, Seitaro
AU  - Terakura S
AUID- ORCID: http://orcid.org/0000-0002-1194-8046
AD  - Department of Hematology and Oncology, Nagoya University Graduate School of
      Medicine, Nagoya, Japan.
FAU - Wada, Naoki
AU  - Wada N
AD  - Department of Pathology, Osaka University Graduate School of Medicine, Osaka,
      Japan.
FAU - Morii, Eiichi
AU  - Morii E
AD  - Department of Pathology, Osaka University Graduate School of Medicine, Osaka,
      Japan.
FAU - Nishimura, Junichi
AU  - Nishimura J
AD  - Department of Gastroenterological Surgery, Osaka University Graduate School of
      Medicine, Osaka, Japan.
FAU - Takeda, Kiyoshi
AU  - Takeda K
AD  - WPI Immunology Frontier Research Center, Osaka University, Osaka, Japan.
AD  - Department of Microbiology and Immunology, Osaka University Graduate School of
      Medicine, Osaka, Japan.
AD  - Japan Agency for Medical Research and Development-Core Research for Evolutional
      Science and Technology (AMED-CREST), Japan.
FAU - Oji, Yusuke
AU  - Oji Y
AD  - Department of Functional Diagnostic Science, Osaka University Graduate School of 
      Medicine, Osaka, Japan.
FAU - Sugiyama, Haruo
AU  - Sugiyama H
AD  - Department of Cancer Immunology, Osaka University Graduate School of Medicine,
      Osaka, Japan.
FAU - Takagi, Junichi
AU  - Takagi J
AD  - Laboratory of Protein Synthesis and Expression, Institute for Protein Research,
      Osaka University, Osaka, Japan.
FAU - Kumanogoh, Atsushi
AU  - Kumanogoh A
AD  - Department of Respiratory Medicine and Clinical Immunology, Osaka University
      Graduate School of Medicine, Osaka, Japan.
AD  - WPI Immunology Frontier Research Center, Osaka University, Osaka, Japan.
AD  - Japan Agency for Medical Research and Development-Core Research for Evolutional
      Science and Technology (AMED-CREST), Japan.
LA  - eng
PT  - Journal Article
DEP - 20171106
PL  - United States
TA  - Nat Med
JT  - Nature medicine
JID - 9502015
RN  - 0 (Integrin beta Chains)
RN  - 0 (Receptors, Antigen, T-Cell)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 0 (integrin beta7)
SB  - IM
MH  - Animals
MH  - Cell Line, Tumor
MH  - Female
MH  - HEK293 Cells
MH  - Humans
MH  - Immunotherapy, Adoptive/*methods
MH  - Integrin beta Chains/*chemistry/*metabolism
MH  - K562 Cells
MH  - Mice
MH  - Mice, Inbred NOD
MH  - Mice, SCID
MH  - Mice, Transgenic
MH  - Multiple Myeloma/immunology/metabolism/*therapy
MH  - Protein Conformation
MH  - Receptors, Antigen, T-Cell/*immunology
MH  - Recombinant Fusion Proteins/*immunology
MH  - T-Lymphocytes/immunology/transplantation
MH  - Xenograft Model Antitumor Assays
EDAT- 2017/11/07 06:00
MHDA- 2017/12/27 06:00
CRDT- 2017/11/07 06:00
PHST- 2017/03/18 00:00 [received]
PHST- 2017/10/02 00:00 [accepted]
PHST- 2017/11/07 06:00 [pubmed]
PHST- 2017/12/27 06:00 [medline]
PHST- 2017/11/07 06:00 [entrez]
AID - nm.4431 [pii]
AID - 10.1038/nm.4431 [doi]
PST - ppublish
SO  - Nat Med. 2017 Dec;23(12):1436-1443. doi: 10.1038/nm.4431. Epub 2017 Nov 6.

PMID- 29226764
OWN - NLM
STAT- MEDLINE
DCOM- 20180115
LR  - 20180120
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 377
IP  - 26
DP  - 2017 Dec 28
TI  - Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.
PG  - 2545-2554
LID - 10.1056/NEJMoa1708566 [doi]
AB  - BACKGROUND: Patients with diffuse large B-cell lymphoma or follicular lymphoma
      that is refractory to or that relapses after immunochemotherapy and
      transplantation have a poor prognosis. High response rates have been reported
      with the use of T cells modified by chimeric antigen receptor (CAR) that target
      CD19 in B-cell cancers, although data regarding B-cell lymphomas are limited.
      METHODS: We used autologous T cells that express a CD19-directed CAR (CTL019) to 
      treat patients with diffuse large B-cell lymphoma or follicular lymphoma that had
      relapsed or was refractory to previous treatments. Patients were monitored for
      response to treatment, toxic effects, the expansion and persistence of CTL019
      cells in vivo, and immune recovery. RESULTS: A total of 28 adult patients with
      lymphoma received CTL019 cells, and 18 of 28 had a response (64%; 95% confidence 
      interval [CI], 44 to 81). Complete remission occurred in 6 of 14 patients with
      diffuse large B-cell lymphoma (43%; 95% CI, 18 to 71) and 10 of 14 patients with 
      follicular lymphoma (71%; 95% CI, 42 to 92). CTL019 cells proliferated in vivo
      and were detectable in the blood and bone marrow of patients who had a response
      and patients who did not have a response. Sustained remissions were achieved, and
      at a median follow-up of 28.6 months, 86% of patients with diffuse large B-cell
      lymphoma who had a response (95% CI, 33 to 98) and 89% of patients with
      follicular lymphoma who had a response (95% CI, 43 to 98) had maintained the
      response. Severe cytokine-release syndrome occurred in 5 patients (18%). Serious 
      encephalopathy occurred in 3 patients (11%); 2 cases were self-limiting and 1
      case was fatal. All patients in complete remission by 6 months remained in
      remission at 7.7 to 37.9 months (median, 29.3 months) after induction, with a
      sustained reappearance of B cells in 8 of 16 patients and with improvement in
      levels of IgG in 4 of 10 patients and of IgM in 6 of 10 patients at 6 months or
      later and in levels of IgA in 3 of 10 patients at 18 months or later.
      CONCLUSIONS: CTL019 cells can be effective in the treatment of relapsed or
      refractory diffuse large B-cell lymphoma and follicular lymphoma. High rates of
      durable remission were observed, with recovery of B cells and immunoglobulins in 
      some patients. Transient encephalopathy developed in approximately one in three
      patients and severe cytokine-release syndrome developed in one in five patients. 
      (Funded by Novartis and others; ClinicalTrials.gov number, NCT02030834 .).
FAU - Schuster, Stephen J
AU  - Schuster SJ
AD  - From the Lymphoma Program at the Abramson Cancer Center and the Division of
      Hematology-Oncology (S.J.S., J.S., E.A.C., S.D.N., A.R.M., D.L., D.L.P.), and the
      Department of Pathology and Laboratory Medicine (V.B., M.W., B.L.L., S.F.L.,
      J.J.M., C.H.J.), Perelman School of Medicine, University of Pennsylvania,
      Philadelphia; Novartis Pharmaceuticals, Basel, Switzerland (O.A.); and Novartis
      Institutes for BioMedical Research, Cambridge, MA (J.L.B., I.P-M.).
FAU - Svoboda, Jakub
AU  - Svoboda J
AD  - From the Lymphoma Program at the Abramson Cancer Center and the Division of
      Hematology-Oncology (S.J.S., J.S., E.A.C., S.D.N., A.R.M., D.L., D.L.P.), and the
      Department of Pathology and Laboratory Medicine (V.B., M.W., B.L.L., S.F.L.,
      J.J.M., C.H.J.), Perelman School of Medicine, University of Pennsylvania,
      Philadelphia; Novartis Pharmaceuticals, Basel, Switzerland (O.A.); and Novartis
      Institutes for BioMedical Research, Cambridge, MA (J.L.B., I.P-M.).
FAU - Chong, Elise A
AU  - Chong EA
AD  - From the Lymphoma Program at the Abramson Cancer Center and the Division of
      Hematology-Oncology (S.J.S., J.S., E.A.C., S.D.N., A.R.M., D.L., D.L.P.), and the
      Department of Pathology and Laboratory Medicine (V.B., M.W., B.L.L., S.F.L.,
      J.J.M., C.H.J.), Perelman School of Medicine, University of Pennsylvania,
      Philadelphia; Novartis Pharmaceuticals, Basel, Switzerland (O.A.); and Novartis
      Institutes for BioMedical Research, Cambridge, MA (J.L.B., I.P-M.).
FAU - Nasta, Sunita D
AU  - Nasta SD
AD  - From the Lymphoma Program at the Abramson Cancer Center and the Division of
      Hematology-Oncology (S.J.S., J.S., E.A.C., S.D.N., A.R.M., D.L., D.L.P.), and the
      Department of Pathology and Laboratory Medicine (V.B., M.W., B.L.L., S.F.L.,
      J.J.M., C.H.J.), Perelman School of Medicine, University of Pennsylvania,
      Philadelphia; Novartis Pharmaceuticals, Basel, Switzerland (O.A.); and Novartis
      Institutes for BioMedical Research, Cambridge, MA (J.L.B., I.P-M.).
FAU - Mato, Anthony R
AU  - Mato AR
AD  - From the Lymphoma Program at the Abramson Cancer Center and the Division of
      Hematology-Oncology (S.J.S., J.S., E.A.C., S.D.N., A.R.M., D.L., D.L.P.), and the
      Department of Pathology and Laboratory Medicine (V.B., M.W., B.L.L., S.F.L.,
      J.J.M., C.H.J.), Perelman School of Medicine, University of Pennsylvania,
      Philadelphia; Novartis Pharmaceuticals, Basel, Switzerland (O.A.); and Novartis
      Institutes for BioMedical Research, Cambridge, MA (J.L.B., I.P-M.).
FAU - Anak, Ozlem
AU  - Anak O
AD  - From the Lymphoma Program at the Abramson Cancer Center and the Division of
      Hematology-Oncology (S.J.S., J.S., E.A.C., S.D.N., A.R.M., D.L., D.L.P.), and the
      Department of Pathology and Laboratory Medicine (V.B., M.W., B.L.L., S.F.L.,
      J.J.M., C.H.J.), Perelman School of Medicine, University of Pennsylvania,
      Philadelphia; Novartis Pharmaceuticals, Basel, Switzerland (O.A.); and Novartis
      Institutes for BioMedical Research, Cambridge, MA (J.L.B., I.P-M.).
FAU - Brogdon, Jennifer L
AU  - Brogdon JL
AD  - From the Lymphoma Program at the Abramson Cancer Center and the Division of
      Hematology-Oncology (S.J.S., J.S., E.A.C., S.D.N., A.R.M., D.L., D.L.P.), and the
      Department of Pathology and Laboratory Medicine (V.B., M.W., B.L.L., S.F.L.,
      J.J.M., C.H.J.), Perelman School of Medicine, University of Pennsylvania,
      Philadelphia; Novartis Pharmaceuticals, Basel, Switzerland (O.A.); and Novartis
      Institutes for BioMedical Research, Cambridge, MA (J.L.B., I.P-M.).
FAU - Pruteanu-Malinici, Iulian
AU  - Pruteanu-Malinici I
AD  - From the Lymphoma Program at the Abramson Cancer Center and the Division of
      Hematology-Oncology (S.J.S., J.S., E.A.C., S.D.N., A.R.M., D.L., D.L.P.), and the
      Department of Pathology and Laboratory Medicine (V.B., M.W., B.L.L., S.F.L.,
      J.J.M., C.H.J.), Perelman School of Medicine, University of Pennsylvania,
      Philadelphia; Novartis Pharmaceuticals, Basel, Switzerland (O.A.); and Novartis
      Institutes for BioMedical Research, Cambridge, MA (J.L.B., I.P-M.).
FAU - Bhoj, Vijay
AU  - Bhoj V
AD  - From the Lymphoma Program at the Abramson Cancer Center and the Division of
      Hematology-Oncology (S.J.S., J.S., E.A.C., S.D.N., A.R.M., D.L., D.L.P.), and the
      Department of Pathology and Laboratory Medicine (V.B., M.W., B.L.L., S.F.L.,
      J.J.M., C.H.J.), Perelman School of Medicine, University of Pennsylvania,
      Philadelphia; Novartis Pharmaceuticals, Basel, Switzerland (O.A.); and Novartis
      Institutes for BioMedical Research, Cambridge, MA (J.L.B., I.P-M.).
FAU - Landsburg, Daniel
AU  - Landsburg D
AD  - From the Lymphoma Program at the Abramson Cancer Center and the Division of
      Hematology-Oncology (S.J.S., J.S., E.A.C., S.D.N., A.R.M., D.L., D.L.P.), and the
      Department of Pathology and Laboratory Medicine (V.B., M.W., B.L.L., S.F.L.,
      J.J.M., C.H.J.), Perelman School of Medicine, University of Pennsylvania,
      Philadelphia; Novartis Pharmaceuticals, Basel, Switzerland (O.A.); and Novartis
      Institutes for BioMedical Research, Cambridge, MA (J.L.B., I.P-M.).
FAU - Wasik, Mariusz
AU  - Wasik M
AD  - From the Lymphoma Program at the Abramson Cancer Center and the Division of
      Hematology-Oncology (S.J.S., J.S., E.A.C., S.D.N., A.R.M., D.L., D.L.P.), and the
      Department of Pathology and Laboratory Medicine (V.B., M.W., B.L.L., S.F.L.,
      J.J.M., C.H.J.), Perelman School of Medicine, University of Pennsylvania,
      Philadelphia; Novartis Pharmaceuticals, Basel, Switzerland (O.A.); and Novartis
      Institutes for BioMedical Research, Cambridge, MA (J.L.B., I.P-M.).
FAU - Levine, Bruce L
AU  - Levine BL
AD  - From the Lymphoma Program at the Abramson Cancer Center and the Division of
      Hematology-Oncology (S.J.S., J.S., E.A.C., S.D.N., A.R.M., D.L., D.L.P.), and the
      Department of Pathology and Laboratory Medicine (V.B., M.W., B.L.L., S.F.L.,
      J.J.M., C.H.J.), Perelman School of Medicine, University of Pennsylvania,
      Philadelphia; Novartis Pharmaceuticals, Basel, Switzerland (O.A.); and Novartis
      Institutes for BioMedical Research, Cambridge, MA (J.L.B., I.P-M.).
FAU - Lacey, Simon F
AU  - Lacey SF
AD  - From the Lymphoma Program at the Abramson Cancer Center and the Division of
      Hematology-Oncology (S.J.S., J.S., E.A.C., S.D.N., A.R.M., D.L., D.L.P.), and the
      Department of Pathology and Laboratory Medicine (V.B., M.W., B.L.L., S.F.L.,
      J.J.M., C.H.J.), Perelman School of Medicine, University of Pennsylvania,
      Philadelphia; Novartis Pharmaceuticals, Basel, Switzerland (O.A.); and Novartis
      Institutes for BioMedical Research, Cambridge, MA (J.L.B., I.P-M.).
FAU - Melenhorst, Jan J
AU  - Melenhorst JJ
AD  - From the Lymphoma Program at the Abramson Cancer Center and the Division of
      Hematology-Oncology (S.J.S., J.S., E.A.C., S.D.N., A.R.M., D.L., D.L.P.), and the
      Department of Pathology and Laboratory Medicine (V.B., M.W., B.L.L., S.F.L.,
      J.J.M., C.H.J.), Perelman School of Medicine, University of Pennsylvania,
      Philadelphia; Novartis Pharmaceuticals, Basel, Switzerland (O.A.); and Novartis
      Institutes for BioMedical Research, Cambridge, MA (J.L.B., I.P-M.).
FAU - Porter, David L
AU  - Porter DL
AD  - From the Lymphoma Program at the Abramson Cancer Center and the Division of
      Hematology-Oncology (S.J.S., J.S., E.A.C., S.D.N., A.R.M., D.L., D.L.P.), and the
      Department of Pathology and Laboratory Medicine (V.B., M.W., B.L.L., S.F.L.,
      J.J.M., C.H.J.), Perelman School of Medicine, University of Pennsylvania,
      Philadelphia; Novartis Pharmaceuticals, Basel, Switzerland (O.A.); and Novartis
      Institutes for BioMedical Research, Cambridge, MA (J.L.B., I.P-M.).
FAU - June, Carl H
AU  - June CH
AD  - From the Lymphoma Program at the Abramson Cancer Center and the Division of
      Hematology-Oncology (S.J.S., J.S., E.A.C., S.D.N., A.R.M., D.L., D.L.P.), and the
      Department of Pathology and Laboratory Medicine (V.B., M.W., B.L.L., S.F.L.,
      J.J.M., C.H.J.), Perelman School of Medicine, University of Pennsylvania,
      Philadelphia; Novartis Pharmaceuticals, Basel, Switzerland (O.A.); and Novartis
      Institutes for BioMedical Research, Cambridge, MA (J.L.B., I.P-M.).
LA  - eng
SI  - ClinicalTrials.gov/NCT02030834
GR  - R01 CA165206/CA/NCI NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20171210
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Antigens, CD19)
RN  - 0 (Biomarkers)
RN  - 0 (CTL019 chimeric antigen receptor)
RN  - 0 (Receptors, Antigen, T-Cell)
SB  - AIM
SB  - IM
CIN - N Engl J Med. 2017 Dec 28;377(26):2593-2596. PMID: 29226781
MH  - Adult
MH  - Aged
MH  - Antigens, CD19
MH  - B-Lymphocytes/immunology
MH  - Biomarkers/analysis
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - *Immunotherapy, Adoptive
MH  - Lymphoma, Follicular/mortality/*therapy
MH  - Lymphoma, Large B-Cell, Diffuse/mortality/*therapy
MH  - Male
MH  - Middle Aged
MH  - Receptors, Antigen, T-Cell/*therapeutic use
MH  - Remission Induction
MH  - Survival Analysis
MH  - T-Lymphocytes/immunology
EDAT- 2017/12/12 06:00
MHDA- 2018/01/16 06:00
CRDT- 2017/12/12 06:00
PHST- 2017/12/12 06:00 [pubmed]
PHST- 2018/01/16 06:00 [medline]
PHST- 2017/12/12 06:00 [entrez]
AID - 10.1056/NEJMoa1708566 [pii]
AID - 10.1056/NEJMoa1708566 [doi]
PST - ppublish
SO  - N Engl J Med. 2017 Dec 28;377(26):2545-2554. doi: 10.1056/NEJMoa1708566. Epub
      2017 Dec 10.

PMID- 29054911
OWN - NLM
STAT- MEDLINE
DCOM- 20171227
LR  - 20180116
IS  - 1528-0020 (Electronic)
IS  - 0006-4971 (Linking)
VI  - 130
IP  - 24
DP  - 2017 Dec 14
TI  - Ixazomib significantly prolongs progression-free survival in high-risk
      relapsed/refractory myeloma patients.
PG  - 2610-2618
LID - 10.1182/blood-2017-06-791228 [doi]
AB  - Certain cytogenetic abnormalities are known to adversely impact outcomes in
      patients with multiple myeloma (MM). The phase 3 TOURMALINE-MM1 study
      demonstrated a significant improvement in progression-free survival (PFS) with
      ixazomib-lenalidomide-dexamethasone (IRd) compared with
      placebo-lenalidomide-dexamethasone (placebo-Rd). This preplanned analysis
      assessed the efficacy and safety of IRd vs placebo-Rd according to cytogenetic
      risk, as assessed using fluorescence in situ hybridization. High-risk cytogenetic
      abnormalities were defined as del(17p), t(4;14), and/or t(14;16); additionally,
      patients were assessed for 1q21 amplification. Of 722 randomized patients, 552
      had cytogenetic results; 137 (25%) had high-risk cytogenetic abnormalities and
      172 (32%) had 1q21 amplification alone. PFS was improved with IRd vs placebo-Rd
      in both high-risk and standard-risk cytogenetics subgroups: in high-risk
      patients, the hazard ratio (HR) was 0.543 (95% confidence interval [CI],
      0.321-0.918; P = .021), with median PFS of 21.4 vs 9.7 months; in standard-risk
      patients, HR was 0.640 (95% CI, 0.462-0.888; P = .007), with median PFS of 20.6
      vs 15.6 months. This PFS benefit was consistent across subgroups with individual 
      high-risk cytogenetic abnormalities, including patients with del(17p) (HR, 0.596;
      95% CI, 0.286-1.243). PFS was also longer with IRd vs placebo-Rd in patients with
      1q21 amplification (HR, 0.781; 95% CI, 0.492-1.240), and in the "expanded
      high-risk" group, defined as those with high-risk cytogenetic abnormalities
      and/or 1q21 amplification (HR, 0.664; 95% CI, 0.474-0.928). IRd demonstrated
      substantial benefit compared with placebo-Rd in relapsed and/or refractory MM
      (RRMM) patients with high-risk and standard-risk cytogenetics, and improves the
      poor PFS associated with high-risk cytogenetic abnormalities. This trial was
      registered at www.clinicaltrials.gov as #NCT01564537.
CI  - (c) 2017 by The American Society of Hematology.
FAU - Avet-Loiseau, Herve
AU  - Avet-Loiseau H
AD  - Laboratory for Genomics in Myeloma, University Cancer Center of Toulouse Institut
      National de la Sante, Toulouse, France.
FAU - Bahlis, Nizar J
AU  - Bahlis NJ
AD  - Southern Alberta Cancer Research Institute, University of Calgary, Calgary, AB,
      Canada.
FAU - Chng, Wee-Joo
AU  - Chng WJ
AD  - Department of Hematology-Oncology, National University Cancer Institute,
      Singapore.
FAU - Masszi, Tamas
AU  - Masszi T
AD  - St. Istvan, St. Laszlo Hospital, Budapest, Hungary.
AD  - 3rd Department of Internal Medicine, Semmelweis University, Budapest, Hungary.
FAU - Viterbo, Luisa
AU  - Viterbo L
AD  - Instituto Portugues de Oncologia do Porto Francisco Gentil, Entidade Publica
      Empresarial (IPOPFG, EPE), Porto, Portugal.
FAU - Pour, Ludek
AU  - Pour L
AD  - Department of Internal Medicine, Hematology and Oncology, University Hospital
      Brno, Brno, Czech Republic.
FAU - Ganly, Peter
AU  - Ganly P
AD  - Department of Haematology, Christchurch Hospital, Christchurch, New Zealand.
FAU - Palumbo, Antonio
AU  - Palumbo A
AD  - Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria
      (AOU) S. Giovanni Battista, Torino, Italy.
FAU - Cavo, Michele
AU  - Cavo M
AD  - "Seragnoli" Institute of Hematology, University of Bologna, Bologna, Italy.
FAU - Langer, Christian
AU  - Langer C
AD  - Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.
FAU - Pluta, Andrzej
AU  - Pluta A
AD  - Department of Hematological Oncology, Oncology Specialist Hospital, Brzozow,
      Poland.
FAU - Nagler, Arnon
AU  - Nagler A
AD  - Hematology Division, Chaim Sheba Medical Center, Tel Hashomer, Israel.
FAU - Kumar, Shaji
AU  - Kumar S
AD  - Mayo Clinic, Rochester, MN.
FAU - Ben-Yehuda, Dina
AU  - Ben-Yehuda D
AD  - Hadassah Medical Center, Kiryat Hadassah, Jerusalem, Israel.
FAU - Rajkumar, S Vincent
AU  - Rajkumar SV
AD  - Mayo Clinic, Rochester, MN.
FAU - San-Miguel, Jesus
AU  - San-Miguel J
AD  - Clinica Universidad de Navarra, Centro Investigacion Medica Aplicada (CIMA),
      Instituto de Investigacion Sanitaria de Navarra (IDISNA), Centro de Investigacion
      Biomedica en Red de Cancer (CIBERONC), Pamplona, Spain.
FAU - Berg, Deborah
AU  - Berg D
AD  - Millennium Pharmaceuticals Inc, a wholly owned subsidiary of Takeda
      Pharmaceutical Company Limited, Cambridge, MA.
FAU - Lin, Jianchang
AU  - Lin J
AD  - Millennium Pharmaceuticals Inc, a wholly owned subsidiary of Takeda
      Pharmaceutical Company Limited, Cambridge, MA.
FAU - van de Velde, Helgi
AU  - van de Velde H
AD  - Millennium Pharmaceuticals Inc, a wholly owned subsidiary of Takeda
      Pharmaceutical Company Limited, Cambridge, MA.
FAU - Esseltine, Dixie-Lee
AU  - Esseltine DL
AD  - Millennium Pharmaceuticals Inc, a wholly owned subsidiary of Takeda
      Pharmaceutical Company Limited, Cambridge, MA.
FAU - di Bacco, Alessandra
AU  - di Bacco A
AD  - Millennium Pharmaceuticals Inc, a wholly owned subsidiary of Takeda
      Pharmaceutical Company Limited, Cambridge, MA.
FAU - Moreau, Philippe
AU  - Moreau P
AD  - Hematology Department, University Hospital Hotel Dieu, Nantes, France; and.
FAU - Richardson, Paul G
AU  - Richardson PG
AD  - Dana-Farber Cancer Institute, Boston, MA.
LA  - eng
SI  - ClinicalTrials.gov/NCT01564537
PT  - Clinical Trial, Phase III
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20171020
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (Boron Compounds)
RN  - 4Z8R6ORS6L (Thalidomide)
RN  - 71050168A2 (ixazomib)
RN  - 7S5I7G3JQL (Dexamethasone)
RN  - F0P408N6V4 (lenalidomide)
RN  - TE7660XO1C (Glycine)
SB  - AIM
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Boron Compounds/administration & dosage
MH  - *Chromosome Aberrations
MH  - Dexamethasone/administration & dosage
MH  - Disease-Free Survival
MH  - Double-Blind Method
MH  - Drug Resistance, Neoplasm
MH  - Female
MH  - Glycine/administration & dosage/analogs & derivatives
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Multiple Myeloma/*drug therapy/*genetics
MH  - Neoplasm Recurrence, Local
MH  - Outcome Assessment (Health Care)/methods/statistics & numerical data
MH  - Proportional Hazards Models
MH  - Thalidomide/administration & dosage/analogs & derivatives
EDAT- 2017/10/22 06:00
MHDA- 2017/12/28 06:00
CRDT- 2017/10/22 06:00
PHST- 2017/06/22 00:00 [received]
PHST- 2017/10/09 00:00 [accepted]
PHST- 2017/10/22 06:00 [pubmed]
PHST- 2017/12/28 06:00 [medline]
PHST- 2017/10/22 06:00 [entrez]
AID - blood-2017-06-791228 [pii]
AID - 10.1182/blood-2017-06-791228 [doi]
PST - ppublish
SO  - Blood. 2017 Dec 14;130(24):2610-2618. doi: 10.1182/blood-2017-06-791228. Epub
      2017 Oct 20.

PMID- 29035367
OWN - NLM
STAT- MEDLINE
DCOM- 20171226
LR  - 20171226
IS  - 1546-170X (Electronic)
IS  - 1078-8956 (Linking)
VI  - 23
IP  - 11
DP  - 2017 Nov
TI  - Targeting glioma stem cells through combined BMI1 and EZH2 inhibition.
PG  - 1352-1361
LID - 10.1038/nm.4415 [doi]
AB  - Glioblastomas are lethal cancers defined by angiogenesis and pseudopalisading
      necrosis. Here, we demonstrate that these histological features are associated
      with distinct transcriptional programs, with vascular regions showing a proneural
      profile, and hypoxic regions showing a mesenchymal pattern. As these regions
      harbor glioma stem cells (GSCs), we investigated the epigenetic regulation of
      these two niches. Proneural, perivascular GSCs activated EZH2, whereas
      mesenchymal GSCs in hypoxic regions expressed BMI1 protein, which promoted
      cellular survival under stress due to downregulation of the E3 ligase RNF144A.
      Using both genetic and pharmacologic inhibition, we found that proneural GSCs are
      preferentially sensitive to EZH2 disruption, whereas mesenchymal GSCs are more
      sensitive to BMI1 inhibition. Given that glioblastomas contain both proneural and
      mesenchymal GSCs, combined EZH2 and BMI1 targeting proved more effective than
      either agent alone both in culture and in vivo, suggesting that strategies that
      simultaneously target multiple epigenetic regulators within glioblastomas may be 
      effective in overcoming therapy resistance caused by intratumoral heterogeneity.
FAU - Jin, Xun
AU  - Jin X
AUID- ORCID: http://orcid.org/0000-0002-1550-2199
AD  - Department of Stem Cell Biology and Regenerative Medicine, Lerner Research
      Institute, Cleveland Clinic, Cleveland, Ohio, USA.
AD  - Tianjin Medical University Cancer Institute and Hospital, Tianjin, P.R. China.
AD  - First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, P.R. 
      China.
FAU - Kim, Leo J Y
AU  - Kim LJY
AD  - Department of Stem Cell Biology and Regenerative Medicine, Lerner Research
      Institute, Cleveland Clinic, Cleveland, Ohio, USA.
AD  - Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USA.
AD  - Medical Scientist Training Program, School of Medicine, Case Western Reserve
      University, Cleveland, Ohio, USA.
AD  - Division of Regenerative Medicine, Department of Medicine, University of San
      Diego, San Diego, California, USA.
FAU - Wu, Qiulian
AU  - Wu Q
AD  - Department of Stem Cell Biology and Regenerative Medicine, Lerner Research
      Institute, Cleveland Clinic, Cleveland, Ohio, USA.
AD  - Division of Regenerative Medicine, Department of Medicine, University of San
      Diego, San Diego, California, USA.
FAU - Wallace, Lisa C
AU  - Wallace LC
AD  - Department of Stem Cell Biology and Regenerative Medicine, Lerner Research
      Institute, Cleveland Clinic, Cleveland, Ohio, USA.
FAU - Prager, Briana C
AU  - Prager BC
AD  - Department of Stem Cell Biology and Regenerative Medicine, Lerner Research
      Institute, Cleveland Clinic, Cleveland, Ohio, USA.
AD  - Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USA.
AD  - Medical Scientist Training Program, School of Medicine, Case Western Reserve
      University, Cleveland, Ohio, USA.
AD  - Division of Regenerative Medicine, Department of Medicine, University of San
      Diego, San Diego, California, USA.
AD  - Cleveland Clinic Lerner College of Medicine of Case Western Reserve University,
      Cleveland, Ohio, USA.
FAU - Sanvoranart, Tanwarat
AU  - Sanvoranart T
AD  - Department of Stem Cell Biology and Regenerative Medicine, Lerner Research
      Institute, Cleveland Clinic, Cleveland, Ohio, USA.
FAU - Gimple, Ryan C
AU  - Gimple RC
AD  - Department of Stem Cell Biology and Regenerative Medicine, Lerner Research
      Institute, Cleveland Clinic, Cleveland, Ohio, USA.
AD  - Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USA.
AD  - Medical Scientist Training Program, School of Medicine, Case Western Reserve
      University, Cleveland, Ohio, USA.
AD  - Division of Regenerative Medicine, Department of Medicine, University of San
      Diego, San Diego, California, USA.
FAU - Wang, Xiuxing
AU  - Wang X
AD  - Department of Stem Cell Biology and Regenerative Medicine, Lerner Research
      Institute, Cleveland Clinic, Cleveland, Ohio, USA.
AD  - Division of Regenerative Medicine, Department of Medicine, University of San
      Diego, San Diego, California, USA.
FAU - Mack, Stephen C
AU  - Mack SC
AUID- ORCID: http://orcid.org/0000-0001-9620-4742
AD  - Department of Stem Cell Biology and Regenerative Medicine, Lerner Research
      Institute, Cleveland Clinic, Cleveland, Ohio, USA.
AD  - Department of Pediatrics, Division of Pediatric Hematology and Oncology, Baylor
      College of Medicine, Houston, Texas, USA.
FAU - Miller, Tyler E
AU  - Miller TE
AD  - Department of Stem Cell Biology and Regenerative Medicine, Lerner Research
      Institute, Cleveland Clinic, Cleveland, Ohio, USA.
AD  - Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USA.
AD  - Medical Scientist Training Program, School of Medicine, Case Western Reserve
      University, Cleveland, Ohio, USA.
FAU - Huang, Ping
AU  - Huang P
AD  - Department of Stem Cell Biology and Regenerative Medicine, Lerner Research
      Institute, Cleveland Clinic, Cleveland, Ohio, USA.
FAU - Valentim, Claudia L
AU  - Valentim CL
AD  - Department of Stem Cell Biology and Regenerative Medicine, Lerner Research
      Institute, Cleveland Clinic, Cleveland, Ohio, USA.
FAU - Zhou, Qi-Gang
AU  - Zhou QG
AD  - Department of Stem Cell Biology and Regenerative Medicine, Lerner Research
      Institute, Cleveland Clinic, Cleveland, Ohio, USA.
FAU - Barnholtz-Sloan, Jill S
AU  - Barnholtz-Sloan JS
AD  - Case Comprehensive Cancer Center, Case Western Reserve University School of
      Medicine, Cleveland, Ohio, USA.
FAU - Bao, Shideng
AU  - Bao S
AD  - Department of Stem Cell Biology and Regenerative Medicine, Lerner Research
      Institute, Cleveland Clinic, Cleveland, Ohio, USA.
AD  - Cleveland Clinic Lerner College of Medicine of Case Western Reserve University,
      Cleveland, Ohio, USA.
AD  - Case Comprehensive Cancer Center, Case Western Reserve University School of
      Medicine, Cleveland, Ohio, USA.
FAU - Sloan, Andrew E
AU  - Sloan AE
AD  - Case Comprehensive Cancer Center, Case Western Reserve University School of
      Medicine, Cleveland, Ohio, USA.
AD  - Department of Neurological Surgery, University Hospitals-Cleveland Medical
      Center, Cleveland, Ohio, USA.
FAU - Rich, Jeremy N
AU  - Rich JN
AD  - Department of Stem Cell Biology and Regenerative Medicine, Lerner Research
      Institute, Cleveland Clinic, Cleveland, Ohio, USA.
AD  - Division of Regenerative Medicine, Department of Medicine, University of San
      Diego, San Diego, California, USA.
AD  - Cleveland Clinic Lerner College of Medicine of Case Western Reserve University,
      Cleveland, Ohio, USA.
AD  - Case Comprehensive Cancer Center, Case Western Reserve University School of
      Medicine, Cleveland, Ohio, USA.
LA  - eng
GR  - R01 CA169117/CA/NCI NIH HHS/United States
GR  - F30 CA217065/CA/NCI NIH HHS/United States
GR  - R01 CA171652/CA/NCI NIH HHS/United States
GR  - R01 NS089272/NS/NINDS NIH HHS/United States
GR  - F30 CA217066/CA/NCI NIH HHS/United States
GR  - R01 NS087913/NS/NINDS NIH HHS/United States
GR  - R35 CA197718/CA/NCI NIH HHS/United States
GR  - F30 CA183510/CA/NCI NIH HHS/United States
GR  - R01 CA154130/CA/NCI NIH HHS/United States
GR  - F30 CA203101/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20171009
PL  - United States
TA  - Nat Med
JT  - Nature medicine
JID - 9502015
RN  - 0 (BMI1 protein, human)
RN  - EC 2.1.1.43 (EZH2 protein, human)
RN  - EC 2.1.1.43 (Enhancer of Zeste Homolog 2 Protein)
RN  - EC 2.3.2.27 (Polycomb Repressive Complex 1)
SB  - IM
MH  - Animals
MH  - Brain Neoplasms/*pathology
MH  - Enhancer of Zeste Homolog 2 Protein/*antagonists & inhibitors
MH  - Epigenesis, Genetic
MH  - Glioblastoma/*pathology
MH  - Humans
MH  - Mice
MH  - Neoplastic Stem Cells/*drug effects
MH  - Polycomb Repressive Complex 1/*antagonists & inhibitors
MH  - Reverse Transcriptase Polymerase Chain Reaction
PMC - PMC5679732
MID - NIHMS904707
EDAT- 2017/10/17 06:00
MHDA- 2017/12/27 06:00
CRDT- 2017/10/17 06:00
PMCR- 2018/04/09 00:00
PHST- 2016/09/23 00:00 [received]
PHST- 2017/09/06 00:00 [accepted]
PHST- 2018/04/09 00:00 [pmc-release]
PHST- 2017/10/17 06:00 [pubmed]
PHST- 2017/12/27 06:00 [medline]
PHST- 2017/10/17 06:00 [entrez]
AID - nm.4415 [pii]
AID - 10.1038/nm.4415 [doi]
PST - ppublish
SO  - Nat Med. 2017 Nov;23(11):1352-1361. doi: 10.1038/nm.4415. Epub 2017 Oct 9.

PMID- 29046282
OWN - NLM
STAT- MEDLINE
DCOM- 20171218
LR  - 20180116
IS  - 1528-0020 (Electronic)
IS  - 0006-4971 (Linking)
VI  - 130
IP  - 22
DP  - 2017 Nov 30
TI  - Clonality in context: hematopoietic clones in their marrow environment.
PG  - 2363-2372
LID - 10.1182/blood-2017-07-794362 [doi]
AB  - Clonal hematopoiesis occurs normally, especially with aging, and in the setting
      of disease, not only in myeloid cancers but in bone marrow failure as well. In
      cancer, malignant clones are characterized by recurrent somatic mutations in
      specific sets of genes, but the direct relationship of such mutations to
      leukemogenesis, when they occur in cells of an apparently healthy older
      individual or after recovery from immune aplastic anemia, is uncertain. Here we
      emphasize a view of clonal evolution that stresses natural selection over
      deterministic ontogeny, and we stress the selective role of the environment of
      the marrow and organism. Clonal hematopoieses after chemotherapy, in marrow
      failure, and with aging serve as models. We caution against the
      overinterpretation of clinical results of genomic testing in the absence of a
      better understanding of clonal selection and evolution.
FAU - Cooper, James N
AU  - Cooper JN
AD  - Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes
      of Health, Bethesda, MD.
FAU - Young, Neal S
AU  - Young NS
AD  - Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes
      of Health, Bethesda, MD.
LA  - eng
PT  - Journal Article
DEP - 20171018
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
SB  - AIM
SB  - IM
MH  - Aging
MH  - Anemia, Aplastic/*genetics/pathology
MH  - Animals
MH  - Bone Marrow/metabolism/*pathology
MH  - *Clonal Evolution
MH  - *Hematopoiesis
MH  - Humans
MH  - Leukemia/*genetics/pathology
MH  - Mutation
MH  - Myelodysplastic Syndromes/*genetics/pathology
PMC - PMC5709788
EDAT- 2017/10/20 06:00
MHDA- 2017/12/19 06:00
CRDT- 2017/10/20 06:00
PMCR- 2018/11/30 00:00
PHST- 2017/07/07 00:00 [received]
PHST- 2017/10/04 00:00 [accepted]
PHST- 2018/11/30 00:00 [pmc-release]
PHST- 2017/10/20 06:00 [pubmed]
PHST- 2017/12/19 06:00 [medline]
PHST- 2017/10/20 06:00 [entrez]
AID - blood-2017-07-794362 [pii]
AID - 10.1182/blood-2017-07-794362 [doi]
PST - ppublish
SO  - Blood. 2017 Nov 30;130(22):2363-2372. doi: 10.1182/blood-2017-07-794362. Epub
      2017 Oct 18.

PMID- 29156447
OWN - NLM
STAT- MEDLINE
DCOM- 20180102
LR  - 20180102
IS  - 1532-1967 (Electronic)
IS  - 0305-7372 (Linking)
VI  - 62
DP  - 2018 Jan
TI  - PD-1 blockade in advanced NSCLC: A focus on pembrolizumab.
PG  - 39-49
LID - S0305-7372(17)30158-5 [pii]
LID - 10.1016/j.ctrv.2017.10.002 [doi]
AB  - Non-small cell lung cancer (NSCLC) is one of the most prevalent cancers and is
      responsible for a large proportion of all cancer-related deaths. Current
      treatment options are inadequate, reflecting a substantial unmet clinical need.
      Increasing knowledge regarding the mechanisms and genetic aberrations underlying 
      tumor development and growth has heralded a new era of therapy in oncology,
      moving away from indiscriminate cytotoxic chemotherapy toward more finely
      focused, targeted medicine. The development of small-molecule drugs and
      monoclonal antibodies directed toward specific components of dysfunctional
      molecular or immune pathways, and mutated genes specific to particular cancer
      types, is leading the field to more personalized and less toxic treatment
      options, many of which have demonstrated greater efficacy and survival benefits
      than their chemotherapeutic counterparts. Particularly successful examples are
      agents that interfere with the programmed death 1 (PD-1) pathway, which many
      tumors can hijack to avoid immune surveillance and editing. Pembrolizumab, a
      monoclonal antibody directed at PD-1 that blocks the engagement between PD-1 and 
      its ligands, has been explored as a treatment for solid tumors, and demonstrated 
      survival benefits in several studies. The use of PD-1 inhibitors such as
      nivolumab and pembrolizumab in advanced cancers is widespread, and pembrolizumab 
      is available in more than 60 countries for at least one of the following:
      advanced melanoma, PD-L1-expressing NSCLC, head and neck squamous cell carcinoma,
      and adult and pediatric patients with refractory classical Hodgkin's lymphoma.
      This work provides a brief overview of the role of pembrolizumab in the treatment
      of advanced (recurrent/metastatic) NSCLC.
CI  - Copyright (c) 2017 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Peters, Solange
AU  - Peters S
AD  - Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Bureau
      BH09/733 Rue du Bugnon 46, CH-1011 Lausanne, Switzerland. Electronic address:
      Solange.Peters@chuv.ch.
FAU - Kerr, Keith M
AU  - Kerr KM
AD  - Department of Pathology, Aberdeen University Medical School and Aberdeen Royal
      Infirmary, Polwarth Building, Foresterhill, Aberdeen AB25 2ZD, UK. Electronic
      address: k.kerr@abdn.ac.uk.
FAU - Stahel, Rolf
AU  - Stahel R
AD  - Department of Oncology, University Hospital Zurich, Ramistrasse 100, 8091 Zurich,
      Switzerland. Electronic address: rolf.stahel@usz.ch.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20171023
PL  - Netherlands
TA  - Cancer Treat Rev
JT  - Cancer treatment reviews
JID - 7502030
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - 0 (PDCD1 protein, human)
RN  - 0 (Programmed Cell Death 1 Receptor)
RN  - DPT0O3T46P (pembrolizumab)
SB  - IM
MH  - Antibodies, Monoclonal, Humanized/*therapeutic use
MH  - Antineoplastic Agents, Immunological/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/immunology/pathology
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/immunology/pathology
MH  - Programmed Cell Death 1 Receptor/antagonists & inhibitors/immunology
OTO - NOTNLM
OT  - Anti-PD-1 antibody
OT  - Non-small cell lung cancer
OT  - PD-L1
OT  - Pembrolizumab
EDAT- 2017/11/21 06:00
MHDA- 2018/01/03 06:00
CRDT- 2017/11/21 06:00
PHST- 2017/10/05 00:00 [received]
PHST- 2017/10/15 00:00 [accepted]
PHST- 2017/11/21 06:00 [pubmed]
PHST- 2018/01/03 06:00 [medline]
PHST- 2017/11/21 06:00 [entrez]
AID - S0305-7372(17)30158-5 [pii]
AID - 10.1016/j.ctrv.2017.10.002 [doi]
PST - ppublish
SO  - Cancer Treat Rev. 2018 Jan;62:39-49. doi: 10.1016/j.ctrv.2017.10.002. Epub 2017
      Oct 23.

PMID- 29131157
OWN - NLM
STAT- MEDLINE
DCOM- 20171226
LR  - 20171226
IS  - 1546-170X (Electronic)
IS  - 1078-8956 (Linking)
VI  - 23
IP  - 12
DP  - 2017 Dec
TI  - Targeting the T cell receptor beta-chain constant region for immunotherapy of T
      cell malignancies.
PG  - 1416-1423
LID - 10.1038/nm.4444 [doi]
AB  - Mature T cell cancers are typically aggressive, treatment resistant and
      associated with poor prognosis. Clinical application of immunotherapeutic
      approaches has been limited by a lack of target antigens that discriminate
      malignant from healthy (normal) T cells. Unlike B cell depletion, pan-T cell
      aplasia is prohibitively toxic. We report a new targeting strategy based on the
      mutually exclusive expression of T cell receptor beta-chain constant domains 1
      and 2 (TRBC1 and TRBC2). We identify an antibody with unique TRBC1 specificity
      and use it to demonstrate that normal and virus-specific T cell populations
      contain both TRBC1(+) and TRBC2(+) compartments, whereas malignancies are
      restricted to only one. As proof of concept for anti-TRBC immunotherapy, we
      developed anti-TRBC1 chimeric antigen receptor (CAR) T cells, which recognized
      and killed normal and malignant TRBC1(+), but not TRBC2(+), T cells in vitro and 
      in a disseminated mouse model of leukemia. Unlike nonselective approaches
      targeting the entire T cell population, TRBC-targeted immunotherapy could
      eradicate a T cell malignancy while preserving sufficient normal T cells to
      maintain cellular immunity.
FAU - Maciocia, Paul M
AU  - Maciocia PM
AD  - Cancer Institute, University College London, London, UK.
FAU - Wawrzyniecka, Patrycja A
AU  - Wawrzyniecka PA
AD  - Cancer Institute, University College London, London, UK.
FAU - Philip, Brian
AU  - Philip B
AD  - Cancer Institute, University College London, London, UK.
FAU - Ricciardelli, Ida
AU  - Ricciardelli I
AD  - Institute of Child Health, University College London, London, UK.
FAU - Akarca, Ayse U
AU  - Akarca AU
AD  - Cancer Institute, University College London, London, UK.
FAU - Onuoha, Shimobi C
AU  - Onuoha SC
AD  - Autolus, Ltd., London, UK.
FAU - Legut, Mateusz
AU  - Legut M
AD  - Division of Infection and Immunity, Cardiff University School of Medicine,
      Cardiff, UK.
FAU - Cole, David K
AU  - Cole DK
AD  - Division of Infection and Immunity, Cardiff University School of Medicine,
      Cardiff, UK.
FAU - Sewell, Andrew K
AU  - Sewell AK
AUID- ORCID: http://orcid.org/0000-0003-3194-3135
AD  - Division of Infection and Immunity, Cardiff University School of Medicine,
      Cardiff, UK.
FAU - Gritti, Giuseppe
AU  - Gritti G
AD  - Hematology and Bone Marrow Transplant Units, Papa Giovanni XXIII Hospital,
      Bergamo, Italy.
FAU - Somja, Joan
AU  - Somja J
AD  - Department of Anatomy and Cellular Pathology, University of Liege, Liege,
      Belgium.
FAU - Piris, Miguel A
AU  - Piris MA
AD  - Department of Pathology, Fundacion Jimenez Diaz, Centro de Investigacion
      Biomedica en Red de Cancer (CIBERONC), Madrid, Spain.
FAU - Peggs, Karl S
AU  - Peggs KS
AD  - Cancer Institute, University College London, London, UK.
FAU - Linch, David C
AU  - Linch DC
AD  - Cancer Institute, University College London, London, UK.
FAU - Marafioti, Teresa
AU  - Marafioti T
AD  - Cancer Institute, University College London, London, UK.
FAU - Pule, Martin A
AU  - Pule MA
AUID- ORCID: http://orcid.org/0000-0002-8347-9867
AD  - Cancer Institute, University College London, London, UK.
AD  - Autolus, Ltd., London, UK.
LA  - eng
PT  - Journal Article
PT  - Validation Studies
DEP - 20171113
PL  - United States
TA  - Nat Med
JT  - Nature medicine
JID - 9502015
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - 0 (Receptors, Antigen, T-Cell, alpha-beta)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents, Immunological/*therapeutic use
MH  - Cells, Cultured
MH  - HEK293 Cells
MH  - Humans
MH  - Immunotherapy, Adoptive/*methods
MH  - Jurkat Cells
MH  - K562 Cells
MH  - Leukemia, T-Cell/immunology/*therapy
MH  - Male
MH  - Mice
MH  - Molecular Targeted Therapy/methods
MH  - Receptors, Antigen, T-Cell, alpha-beta/*immunology
MH  - T-Lymphocytes/immunology
EDAT- 2017/11/14 06:00
MHDA- 2017/12/27 06:00
CRDT- 2017/11/14 06:00
PHST- 2016/07/20 00:00 [received]
PHST- 2017/10/18 00:00 [accepted]
PHST- 2017/11/14 06:00 [pubmed]
PHST- 2017/12/27 06:00 [medline]
PHST- 2017/11/14 06:00 [entrez]
AID - nm.4444 [pii]
AID - 10.1038/nm.4444 [doi]
PST - ppublish
SO  - Nat Med. 2017 Dec;23(12):1416-1423. doi: 10.1038/nm.4444. Epub 2017 Nov 13.

PMID- 29232555
OWN - NLM
STAT- MEDLINE
DCOM- 20171220
LR  - 20171220
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 6
DP  - 2017 Dec 11
TI  - mTORC2 Promotes Tumorigenesis via Lipid Synthesis.
PG  - 807-823.e12
LID - S1535-6108(17)30514-7 [pii]
LID - 10.1016/j.ccell.2017.11.011 [doi]
AB  - Dysregulated mammalian target of rapamycin (mTOR) promotes cancer, but underlying
      mechanisms are poorly understood. We describe an mTOR-driven mouse model that
      displays hepatosteatosis progressing to hepatocellular carcinoma (HCC).
      Longitudinal proteomic, lipidomics, and metabolomic analyses revealed that
      hepatic mTORC2 promotes de novo fatty acid and lipid synthesis, leading to
      steatosis and tumor development. In particular, mTORC2 stimulated sphingolipid
      (glucosylceramide) and glycerophospholipid (cardiolipin) synthesis. Inhibition of
      fatty acid or sphingolipid synthesis prevented tumor development, indicating a
      causal effect in tumorigenesis. Increased levels of cardiolipin were associated
      with tubular mitochondria and enhanced oxidative phosphorylation. Furthermore,
      increased lipogenesis correlated with elevated mTORC2 activity and HCC in human
      patients. Thus, mTORC2 promotes cancer via formation of lipids essential for
      growth and energy production.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Guri, Yakir
AU  - Guri Y
AD  - Biozentrum, University of Basel, 4056 Basel, Switzerland.
FAU - Colombi, Marco
AU  - Colombi M
AD  - Biozentrum, University of Basel, 4056 Basel, Switzerland.
FAU - Dazert, Eva
AU  - Dazert E
AD  - Biozentrum, University of Basel, 4056 Basel, Switzerland.
FAU - Hindupur, Sravanth K
AU  - Hindupur SK
AD  - Biozentrum, University of Basel, 4056 Basel, Switzerland.
FAU - Roszik, Jason
AU  - Roszik J
AD  - Departments of Melanoma Medical Oncology and Genomic Medicine, The University of 
      Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Moes, Suzette
AU  - Moes S
AD  - Biozentrum, University of Basel, 4056 Basel, Switzerland.
FAU - Jenoe, Paul
AU  - Jenoe P
AD  - Biozentrum, University of Basel, 4056 Basel, Switzerland.
FAU - Heim, Markus H
AU  - Heim MH
AD  - Department of Biomedicine, University Hospital Basel, 4031 Basel, Switzerland.
FAU - Riezman, Isabelle
AU  - Riezman I
AD  - NCCR Chemical Biology, Department of Biochemistry, University of Geneva, 1211
      Geneva, Switzerland.
FAU - Riezman, Howard
AU  - Riezman H
AD  - NCCR Chemical Biology, Department of Biochemistry, University of Geneva, 1211
      Geneva, Switzerland.
FAU - Hall, Michael N
AU  - Hall MN
AD  - Biozentrum, University of Basel, 4056 Basel, Switzerland. Electronic address:
      m.hall@unibas.ch.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Lipids)
RN  - EC 2.7.11.1 (Mechanistic Target of Rapamycin Complex 2)
SB  - IM
MH  - Animals
MH  - Carcinogenesis/*metabolism
MH  - Carcinoma, Hepatocellular/etiology/*metabolism
MH  - Cell Transformation, Neoplastic/metabolism
MH  - Fatty Liver/complications/*metabolism
MH  - Humans
MH  - Lipids/biosynthesis
MH  - Lipogenesis/*physiology
MH  - Liver Neoplasms/etiology/*metabolism
MH  - Mechanistic Target of Rapamycin Complex 2/*metabolism
MH  - Mice
MH  - Mice, Knockout
OTO - NOTNLM
OT  - NAFLD
OT  - NASH
OT  - cardiolipin
OT  - glycosphingolipid
OT  - hepatocellular carcinoma
OT  - hepatosteatosis
OT  - mTOR
OT  - mitochondria
OT  - oxidative phosphorylation
OT  - sphingolipid
EDAT- 2017/12/13 06:00
MHDA- 2017/12/21 06:00
CRDT- 2017/12/13 06:00
PHST- 2016/10/28 00:00 [received]
PHST- 2017/08/06 00:00 [revised]
PHST- 2017/11/14 00:00 [accepted]
PHST- 2017/12/13 06:00 [entrez]
PHST- 2017/12/13 06:00 [pubmed]
PHST- 2017/12/21 06:00 [medline]
AID - S1535-6108(17)30514-7 [pii]
AID - 10.1016/j.ccell.2017.11.011 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Dec 11;32(6):807-823.e12. doi: 10.1016/j.ccell.2017.11.011.

PMID- 29128997
OWN - NLM
STAT- MEDLINE
DCOM- 20180111
LR  - 20180111
IS  - 1432-0584 (Electronic)
IS  - 0939-5555 (Linking)
VI  - 97
IP  - 2
DP  - 2018 Feb
TI  - PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas.
PG  - 229-237
LID - 10.1007/s00277-017-3176-6 [doi]
AB  - Tumor cells can evade immune surveillance through overexpressing the ligands of
      checkpoint receptors on tumor cells or adjacent cells, leading T cells to anergy 
      or exhaustion. Growing evidence of the interaction between tumor cells and
      microenvironment promoted the emergence of immune-checkpoint blockade. By
      targeting programmed cell death-1 (PD-1) pathway, cytotoxic activity of T cell is
      enhanced significantly and tumor cell lysis is induced subsequently. Currently,
      various antibodies against PD-1 and programmed death-ligand 1 (PD-L1) are under
      clinical studies in lymphomas. In this review, we outline the rationale for
      investigation of PD-1-PD-L1 immune-checkpoint blockade in lymphomas and discuss
      their prospect of applications in clinical treatment.
FAU - Wang, Yi
AU  - Wang Y
AD  - National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention
      and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical
      University Cancer Institute and Hospital, Tianjin, 300060, China.
FAU - Wu, Ling
AU  - Wu L
AD  - National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention
      and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical
      University Cancer Institute and Hospital, Tianjin, 300060, China.
FAU - Tian, Chen
AU  - Tian C
AD  - National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention
      and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical
      University Cancer Institute and Hospital, Tianjin, 300060, China.
      tcgirl2001@sina.com.
FAU - Zhang, Yizhuo
AU  - Zhang Y
AD  - National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention
      and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical
      University Cancer Institute and Hospital, Tianjin, 300060, China.
      yizhuozhang111@163.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20171111
PL  - Germany
TA  - Ann Hematol
JT  - Annals of hematology
JID - 9107334
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (B7-H1 Antigen)
RN  - 0 (CD274 protein, human)
RN  - 0 (PDCD1 protein, human)
RN  - 0 (Programmed Cell Death 1 Receptor)
RN  - 31YO63LBSN (nivolumab)
RN  - DPT0O3T46P (pembrolizumab)
SB  - IM
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Antibodies, Monoclonal, Humanized/therapeutic use
MH  - Antineoplastic Agents/*therapeutic use
MH  - B7-H1 Antigen/antagonists & inhibitors/genetics/*immunology
MH  - Clinical Trials as Topic
MH  - Clonal Anergy/genetics
MH  - Cytotoxicity, Immunologic/drug effects
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Lymphoma/*drug therapy/genetics/immunology/pathology
MH  - Programmed Cell Death 1 Receptor/antagonists & inhibitors/genetics/*immunology
MH  - Signal Transduction
MH  - T-Lymphocytes/*drug effects/immunology/pathology
MH  - Tumor Escape
MH  - Tumor Microenvironment/genetics/immunology
OTO - NOTNLM
OT  - Immune checkpoint
OT  - Lymphoma
OT  - Nivolumab
OT  - PD-1
OT  - PD-L1
OT  - Pembrolizumab
EDAT- 2017/11/13 06:00
MHDA- 2018/01/13 06:00
CRDT- 2017/11/13 06:00
PHST- 2017/07/13 00:00 [received]
PHST- 2017/11/07 00:00 [accepted]
PHST- 2017/11/13 06:00 [pubmed]
PHST- 2018/01/13 06:00 [medline]
PHST- 2017/11/13 06:00 [entrez]
AID - 10.1007/s00277-017-3176-6 [doi]
AID - 10.1007/s00277-017-3176-6 [pii]
PST - ppublish
SO  - Ann Hematol. 2018 Feb;97(2):229-237. doi: 10.1007/s00277-017-3176-6. Epub 2017
      Nov 11.

PMID- 29226797
OWN - NLM
STAT- MEDLINE
DCOM- 20180115
LR  - 20180115
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 377
IP  - 26
DP  - 2017 Dec 28
TI  - Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
PG  - 2531-2544
LID - 10.1056/NEJMoa1707447 [doi]
AB  - BACKGROUND: In a phase 1 trial, axicabtagene ciloleucel (axi-cel), an autologous 
      anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, showed efficacy in
      patients with refractory large B-cell lymphoma after the failure of conventional 
      therapy. METHODS: In this multicenter, phase 2 trial, we enrolled 111 patients
      with diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, or
      transformed follicular lymphoma who had refractory disease despite undergoing
      recommended prior therapy. Patients received a target dose of 2x10(6) anti-CD19
      CAR T cells per kilogram of body weight after receiving a conditioning regimen of
      low-dose cyclophosphamide and fludarabine. The primary end point was the rate of 
      objective response (calculated as the combined rates of complete response and
      partial response). Secondary end points included overall survival, safety, and
      biomarker assessments. RESULTS: Among the 111 patients who were enrolled, axi-cel
      was successfully manufactured for 110 (99%) and administered to 101 (91%). The
      objective response rate was 82%, and the complete response rate was 54%.With a
      median follow-up of 15.4 months, 42% of the patients continued to have a
      response, with 40% continuing to have a complete response. The overall rate of
      survival at 18 months was 52%. The most common adverse events of grade 3 or
      higher during treatment were neutropenia (in 78% of the patients), anemia (in
      43%), and thrombocytopenia (in 38%). Grade 3 or higher cytokine release syndrome 
      and neurologic events occurred in 13% and 28% of the patients, respectively.
      Three of the patients died during treatment. Higher CAR T-cell levels in blood
      were associated with response. CONCLUSIONS: In this multicenter study, patients
      with refractory large B-cell lymphoma who received CAR T-cell therapy with
      axi-cel had high levels of durable response, with a safety profile that included 
      myelosuppression, the cytokine release syndrome, and neurologic events. (Funded
      by Kite Pharma and the Leukemia and Lymphoma Society Therapy Acceleration
      Program; ZUMA-1 ClinicalTrials.gov number, NCT02348216 .).
FAU - Neelapu, Sattva S
AU  - Neelapu SS
AD  - From the University of Texas M.D. Anderson Cancer Center, Houston (S.S.N.,
      J.R.W.); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (F.L.L., 
      J.C.C.); Washington University and Siteman Cancer Center, St. Louis (N.L.B., A.
      Ghobadi); University of Miami, Miami (L.J.L., K.V.K.); Stanford University,
      Stanford (D.B.M., R.L.), City of Hope National Medical Center, Duarte (T.S.),
      University of California at Los Angeles, Los Angeles (J.M.T.), University of
      California at San Diego, San Diego (J.E.C.), and Kite Pharma, Santa Monica (A.B.,
      J.R., L.N., Y.J., J.A., M.E., D.C., J.W., W.Y.G.) - all in California;
      Dana-Farber Cancer Institute, Boston (C.A.J., E.D.J.); Montefiore Medical Center,
      Bronx (I.B.), and the University of Rochester School of Medicine, Rochester
      (J.W.F., P.R.) - both in New York; Vanderbilt University Medical Center (O.O.O.) 
      and the Sarah Cannon Research Institute and Tennessee Oncology (I.W.F.),
      Nashville; Mayo Clinic, Rochester, MN (Y.L., T.E.W.); Loyola University Medical
      Center, Maywood, IL (P.J.S.); John Theurer Cancer Center, Hackensack University
      Medical Center, Hackensack, NJ (A. Goy); Cleveland Clinic, Cleveland (B.T.H.,
      M.R.S.); Karmanos Cancer Center, Wayne State University, Detroit (A.D.);
      University of Iowa Carver College of Medicine, Iowa City (U.F.); Colorado Blood
      Cancer Institute, Denver (P.M.S.); Banner M.D. Anderson Cancer Center, Gilbert,
      AZ (J.M.); and Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel
      Aviv University, Tel Aviv, Israel (I.A.).
FAU - Locke, Frederick L
AU  - Locke FL
AD  - From the University of Texas M.D. Anderson Cancer Center, Houston (S.S.N.,
      J.R.W.); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (F.L.L., 
      J.C.C.); Washington University and Siteman Cancer Center, St. Louis (N.L.B., A.
      Ghobadi); University of Miami, Miami (L.J.L., K.V.K.); Stanford University,
      Stanford (D.B.M., R.L.), City of Hope National Medical Center, Duarte (T.S.),
      University of California at Los Angeles, Los Angeles (J.M.T.), University of
      California at San Diego, San Diego (J.E.C.), and Kite Pharma, Santa Monica (A.B.,
      J.R., L.N., Y.J., J.A., M.E., D.C., J.W., W.Y.G.) - all in California;
      Dana-Farber Cancer Institute, Boston (C.A.J., E.D.J.); Montefiore Medical Center,
      Bronx (I.B.), and the University of Rochester School of Medicine, Rochester
      (J.W.F., P.R.) - both in New York; Vanderbilt University Medical Center (O.O.O.) 
      and the Sarah Cannon Research Institute and Tennessee Oncology (I.W.F.),
      Nashville; Mayo Clinic, Rochester, MN (Y.L., T.E.W.); Loyola University Medical
      Center, Maywood, IL (P.J.S.); John Theurer Cancer Center, Hackensack University
      Medical Center, Hackensack, NJ (A. Goy); Cleveland Clinic, Cleveland (B.T.H.,
      M.R.S.); Karmanos Cancer Center, Wayne State University, Detroit (A.D.);
      University of Iowa Carver College of Medicine, Iowa City (U.F.); Colorado Blood
      Cancer Institute, Denver (P.M.S.); Banner M.D. Anderson Cancer Center, Gilbert,
      AZ (J.M.); and Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel
      Aviv University, Tel Aviv, Israel (I.A.).
FAU - Bartlett, Nancy L
AU  - Bartlett NL
AD  - From the University of Texas M.D. Anderson Cancer Center, Houston (S.S.N.,
      J.R.W.); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (F.L.L., 
      J.C.C.); Washington University and Siteman Cancer Center, St. Louis (N.L.B., A.
      Ghobadi); University of Miami, Miami (L.J.L., K.V.K.); Stanford University,
      Stanford (D.B.M., R.L.), City of Hope National Medical Center, Duarte (T.S.),
      University of California at Los Angeles, Los Angeles (J.M.T.), University of
      California at San Diego, San Diego (J.E.C.), and Kite Pharma, Santa Monica (A.B.,
      J.R., L.N., Y.J., J.A., M.E., D.C., J.W., W.Y.G.) - all in California;
      Dana-Farber Cancer Institute, Boston (C.A.J., E.D.J.); Montefiore Medical Center,
      Bronx (I.B.), and the University of Rochester School of Medicine, Rochester
      (J.W.F., P.R.) - both in New York; Vanderbilt University Medical Center (O.O.O.) 
      and the Sarah Cannon Research Institute and Tennessee Oncology (I.W.F.),
      Nashville; Mayo Clinic, Rochester, MN (Y.L., T.E.W.); Loyola University Medical
      Center, Maywood, IL (P.J.S.); John Theurer Cancer Center, Hackensack University
      Medical Center, Hackensack, NJ (A. Goy); Cleveland Clinic, Cleveland (B.T.H.,
      M.R.S.); Karmanos Cancer Center, Wayne State University, Detroit (A.D.);
      University of Iowa Carver College of Medicine, Iowa City (U.F.); Colorado Blood
      Cancer Institute, Denver (P.M.S.); Banner M.D. Anderson Cancer Center, Gilbert,
      AZ (J.M.); and Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel
      Aviv University, Tel Aviv, Israel (I.A.).
FAU - Lekakis, Lazaros J
AU  - Lekakis LJ
AD  - From the University of Texas M.D. Anderson Cancer Center, Houston (S.S.N.,
      J.R.W.); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (F.L.L., 
      J.C.C.); Washington University and Siteman Cancer Center, St. Louis (N.L.B., A.
      Ghobadi); University of Miami, Miami (L.J.L., K.V.K.); Stanford University,
      Stanford (D.B.M., R.L.), City of Hope National Medical Center, Duarte (T.S.),
      University of California at Los Angeles, Los Angeles (J.M.T.), University of
      California at San Diego, San Diego (J.E.C.), and Kite Pharma, Santa Monica (A.B.,
      J.R., L.N., Y.J., J.A., M.E., D.C., J.W., W.Y.G.) - all in California;
      Dana-Farber Cancer Institute, Boston (C.A.J., E.D.J.); Montefiore Medical Center,
      Bronx (I.B.), and the University of Rochester School of Medicine, Rochester
      (J.W.F., P.R.) - both in New York; Vanderbilt University Medical Center (O.O.O.) 
      and the Sarah Cannon Research Institute and Tennessee Oncology (I.W.F.),
      Nashville; Mayo Clinic, Rochester, MN (Y.L., T.E.W.); Loyola University Medical
      Center, Maywood, IL (P.J.S.); John Theurer Cancer Center, Hackensack University
      Medical Center, Hackensack, NJ (A. Goy); Cleveland Clinic, Cleveland (B.T.H.,
      M.R.S.); Karmanos Cancer Center, Wayne State University, Detroit (A.D.);
      University of Iowa Carver College of Medicine, Iowa City (U.F.); Colorado Blood
      Cancer Institute, Denver (P.M.S.); Banner M.D. Anderson Cancer Center, Gilbert,
      AZ (J.M.); and Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel
      Aviv University, Tel Aviv, Israel (I.A.).
FAU - Miklos, David B
AU  - Miklos DB
AD  - From the University of Texas M.D. Anderson Cancer Center, Houston (S.S.N.,
      J.R.W.); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (F.L.L., 
      J.C.C.); Washington University and Siteman Cancer Center, St. Louis (N.L.B., A.
      Ghobadi); University of Miami, Miami (L.J.L., K.V.K.); Stanford University,
      Stanford (D.B.M., R.L.), City of Hope National Medical Center, Duarte (T.S.),
      University of California at Los Angeles, Los Angeles (J.M.T.), University of
      California at San Diego, San Diego (J.E.C.), and Kite Pharma, Santa Monica (A.B.,
      J.R., L.N., Y.J., J.A., M.E., D.C., J.W., W.Y.G.) - all in California;
      Dana-Farber Cancer Institute, Boston (C.A.J., E.D.J.); Montefiore Medical Center,
      Bronx (I.B.), and the University of Rochester School of Medicine, Rochester
      (J.W.F., P.R.) - both in New York; Vanderbilt University Medical Center (O.O.O.) 
      and the Sarah Cannon Research Institute and Tennessee Oncology (I.W.F.),
      Nashville; Mayo Clinic, Rochester, MN (Y.L., T.E.W.); Loyola University Medical
      Center, Maywood, IL (P.J.S.); John Theurer Cancer Center, Hackensack University
      Medical Center, Hackensack, NJ (A. Goy); Cleveland Clinic, Cleveland (B.T.H.,
      M.R.S.); Karmanos Cancer Center, Wayne State University, Detroit (A.D.);
      University of Iowa Carver College of Medicine, Iowa City (U.F.); Colorado Blood
      Cancer Institute, Denver (P.M.S.); Banner M.D. Anderson Cancer Center, Gilbert,
      AZ (J.M.); and Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel
      Aviv University, Tel Aviv, Israel (I.A.).
FAU - Jacobson, Caron A
AU  - Jacobson CA
AD  - From the University of Texas M.D. Anderson Cancer Center, Houston (S.S.N.,
      J.R.W.); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (F.L.L., 
      J.C.C.); Washington University and Siteman Cancer Center, St. Louis (N.L.B., A.
      Ghobadi); University of Miami, Miami (L.J.L., K.V.K.); Stanford University,
      Stanford (D.B.M., R.L.), City of Hope National Medical Center, Duarte (T.S.),
      University of California at Los Angeles, Los Angeles (J.M.T.), University of
      California at San Diego, San Diego (J.E.C.), and Kite Pharma, Santa Monica (A.B.,
      J.R., L.N., Y.J., J.A., M.E., D.C., J.W., W.Y.G.) - all in California;
      Dana-Farber Cancer Institute, Boston (C.A.J., E.D.J.); Montefiore Medical Center,
      Bronx (I.B.), and the University of Rochester School of Medicine, Rochester
      (J.W.F., P.R.) - both in New York; Vanderbilt University Medical Center (O.O.O.) 
      and the Sarah Cannon Research Institute and Tennessee Oncology (I.W.F.),
      Nashville; Mayo Clinic, Rochester, MN (Y.L., T.E.W.); Loyola University Medical
      Center, Maywood, IL (P.J.S.); John Theurer Cancer Center, Hackensack University
      Medical Center, Hackensack, NJ (A. Goy); Cleveland Clinic, Cleveland (B.T.H.,
      M.R.S.); Karmanos Cancer Center, Wayne State University, Detroit (A.D.);
      University of Iowa Carver College of Medicine, Iowa City (U.F.); Colorado Blood
      Cancer Institute, Denver (P.M.S.); Banner M.D. Anderson Cancer Center, Gilbert,
      AZ (J.M.); and Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel
      Aviv University, Tel Aviv, Israel (I.A.).
FAU - Braunschweig, Ira
AU  - Braunschweig I
AD  - From the University of Texas M.D. Anderson Cancer Center, Houston (S.S.N.,
      J.R.W.); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (F.L.L., 
      J.C.C.); Washington University and Siteman Cancer Center, St. Louis (N.L.B., A.
      Ghobadi); University of Miami, Miami (L.J.L., K.V.K.); Stanford University,
      Stanford (D.B.M., R.L.), City of Hope National Medical Center, Duarte (T.S.),
      University of California at Los Angeles, Los Angeles (J.M.T.), University of
      California at San Diego, San Diego (J.E.C.), and Kite Pharma, Santa Monica (A.B.,
      J.R., L.N., Y.J., J.A., M.E., D.C., J.W., W.Y.G.) - all in California;
      Dana-Farber Cancer Institute, Boston (C.A.J., E.D.J.); Montefiore Medical Center,
      Bronx (I.B.), and the University of Rochester School of Medicine, Rochester
      (J.W.F., P.R.) - both in New York; Vanderbilt University Medical Center (O.O.O.) 
      and the Sarah Cannon Research Institute and Tennessee Oncology (I.W.F.),
      Nashville; Mayo Clinic, Rochester, MN (Y.L., T.E.W.); Loyola University Medical
      Center, Maywood, IL (P.J.S.); John Theurer Cancer Center, Hackensack University
      Medical Center, Hackensack, NJ (A. Goy); Cleveland Clinic, Cleveland (B.T.H.,
      M.R.S.); Karmanos Cancer Center, Wayne State University, Detroit (A.D.);
      University of Iowa Carver College of Medicine, Iowa City (U.F.); Colorado Blood
      Cancer Institute, Denver (P.M.S.); Banner M.D. Anderson Cancer Center, Gilbert,
      AZ (J.M.); and Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel
      Aviv University, Tel Aviv, Israel (I.A.).
FAU - Oluwole, Olalekan O
AU  - Oluwole OO
AD  - From the University of Texas M.D. Anderson Cancer Center, Houston (S.S.N.,
      J.R.W.); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (F.L.L., 
      J.C.C.); Washington University and Siteman Cancer Center, St. Louis (N.L.B., A.
      Ghobadi); University of Miami, Miami (L.J.L., K.V.K.); Stanford University,
      Stanford (D.B.M., R.L.), City of Hope National Medical Center, Duarte (T.S.),
      University of California at Los Angeles, Los Angeles (J.M.T.), University of
      California at San Diego, San Diego (J.E.C.), and Kite Pharma, Santa Monica (A.B.,
      J.R., L.N., Y.J., J.A., M.E., D.C., J.W., W.Y.G.) - all in California;
      Dana-Farber Cancer Institute, Boston (C.A.J., E.D.J.); Montefiore Medical Center,
      Bronx (I.B.), and the University of Rochester School of Medicine, Rochester
      (J.W.F., P.R.) - both in New York; Vanderbilt University Medical Center (O.O.O.) 
      and the Sarah Cannon Research Institute and Tennessee Oncology (I.W.F.),
      Nashville; Mayo Clinic, Rochester, MN (Y.L., T.E.W.); Loyola University Medical
      Center, Maywood, IL (P.J.S.); John Theurer Cancer Center, Hackensack University
      Medical Center, Hackensack, NJ (A. Goy); Cleveland Clinic, Cleveland (B.T.H.,
      M.R.S.); Karmanos Cancer Center, Wayne State University, Detroit (A.D.);
      University of Iowa Carver College of Medicine, Iowa City (U.F.); Colorado Blood
      Cancer Institute, Denver (P.M.S.); Banner M.D. Anderson Cancer Center, Gilbert,
      AZ (J.M.); and Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel
      Aviv University, Tel Aviv, Israel (I.A.).
FAU - Siddiqi, Tanya
AU  - Siddiqi T
AD  - From the University of Texas M.D. Anderson Cancer Center, Houston (S.S.N.,
      J.R.W.); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (F.L.L., 
      J.C.C.); Washington University and Siteman Cancer Center, St. Louis (N.L.B., A.
      Ghobadi); University of Miami, Miami (L.J.L., K.V.K.); Stanford University,
      Stanford (D.B.M., R.L.), City of Hope National Medical Center, Duarte (T.S.),
      University of California at Los Angeles, Los Angeles (J.M.T.), University of
      California at San Diego, San Diego (J.E.C.), and Kite Pharma, Santa Monica (A.B.,
      J.R., L.N., Y.J., J.A., M.E., D.C., J.W., W.Y.G.) - all in California;
      Dana-Farber Cancer Institute, Boston (C.A.J., E.D.J.); Montefiore Medical Center,
      Bronx (I.B.), and the University of Rochester School of Medicine, Rochester
      (J.W.F., P.R.) - both in New York; Vanderbilt University Medical Center (O.O.O.) 
      and the Sarah Cannon Research Institute and Tennessee Oncology (I.W.F.),
      Nashville; Mayo Clinic, Rochester, MN (Y.L., T.E.W.); Loyola University Medical
      Center, Maywood, IL (P.J.S.); John Theurer Cancer Center, Hackensack University
      Medical Center, Hackensack, NJ (A. Goy); Cleveland Clinic, Cleveland (B.T.H.,
      M.R.S.); Karmanos Cancer Center, Wayne State University, Detroit (A.D.);
      University of Iowa Carver College of Medicine, Iowa City (U.F.); Colorado Blood
      Cancer Institute, Denver (P.M.S.); Banner M.D. Anderson Cancer Center, Gilbert,
      AZ (J.M.); and Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel
      Aviv University, Tel Aviv, Israel (I.A.).
FAU - Lin, Yi
AU  - Lin Y
AD  - From the University of Texas M.D. Anderson Cancer Center, Houston (S.S.N.,
      J.R.W.); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (F.L.L., 
      J.C.C.); Washington University and Siteman Cancer Center, St. Louis (N.L.B., A.
      Ghobadi); University of Miami, Miami (L.J.L., K.V.K.); Stanford University,
      Stanford (D.B.M., R.L.), City of Hope National Medical Center, Duarte (T.S.),
      University of California at Los Angeles, Los Angeles (J.M.T.), University of
      California at San Diego, San Diego (J.E.C.), and Kite Pharma, Santa Monica (A.B.,
      J.R., L.N., Y.J., J.A., M.E., D.C., J.W., W.Y.G.) - all in California;
      Dana-Farber Cancer Institute, Boston (C.A.J., E.D.J.); Montefiore Medical Center,
      Bronx (I.B.), and the University of Rochester School of Medicine, Rochester
      (J.W.F., P.R.) - both in New York; Vanderbilt University Medical Center (O.O.O.) 
      and the Sarah Cannon Research Institute and Tennessee Oncology (I.W.F.),
      Nashville; Mayo Clinic, Rochester, MN (Y.L., T.E.W.); Loyola University Medical
      Center, Maywood, IL (P.J.S.); John Theurer Cancer Center, Hackensack University
      Medical Center, Hackensack, NJ (A. Goy); Cleveland Clinic, Cleveland (B.T.H.,
      M.R.S.); Karmanos Cancer Center, Wayne State University, Detroit (A.D.);
      University of Iowa Carver College of Medicine, Iowa City (U.F.); Colorado Blood
      Cancer Institute, Denver (P.M.S.); Banner M.D. Anderson Cancer Center, Gilbert,
      AZ (J.M.); and Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel
      Aviv University, Tel Aviv, Israel (I.A.).
FAU - Timmerman, John M
AU  - Timmerman JM
AD  - From the University of Texas M.D. Anderson Cancer Center, Houston (S.S.N.,
      J.R.W.); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (F.L.L., 
      J.C.C.); Washington University and Siteman Cancer Center, St. Louis (N.L.B., A.
      Ghobadi); University of Miami, Miami (L.J.L., K.V.K.); Stanford University,
      Stanford (D.B.M., R.L.), City of Hope National Medical Center, Duarte (T.S.),
      University of California at Los Angeles, Los Angeles (J.M.T.), University of
      California at San Diego, San Diego (J.E.C.), and Kite Pharma, Santa Monica (A.B.,
      J.R., L.N., Y.J., J.A., M.E., D.C., J.W., W.Y.G.) - all in California;
      Dana-Farber Cancer Institute, Boston (C.A.J., E.D.J.); Montefiore Medical Center,
      Bronx (I.B.), and the University of Rochester School of Medicine, Rochester
      (J.W.F., P.R.) - both in New York; Vanderbilt University Medical Center (O.O.O.) 
      and the Sarah Cannon Research Institute and Tennessee Oncology (I.W.F.),
      Nashville; Mayo Clinic, Rochester, MN (Y.L., T.E.W.); Loyola University Medical
      Center, Maywood, IL (P.J.S.); John Theurer Cancer Center, Hackensack University
      Medical Center, Hackensack, NJ (A. Goy); Cleveland Clinic, Cleveland (B.T.H.,
      M.R.S.); Karmanos Cancer Center, Wayne State University, Detroit (A.D.);
      University of Iowa Carver College of Medicine, Iowa City (U.F.); Colorado Blood
      Cancer Institute, Denver (P.M.S.); Banner M.D. Anderson Cancer Center, Gilbert,
      AZ (J.M.); and Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel
      Aviv University, Tel Aviv, Israel (I.A.).
FAU - Stiff, Patrick J
AU  - Stiff PJ
AD  - From the University of Texas M.D. Anderson Cancer Center, Houston (S.S.N.,
      J.R.W.); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (F.L.L., 
      J.C.C.); Washington University and Siteman Cancer Center, St. Louis (N.L.B., A.
      Ghobadi); University of Miami, Miami (L.J.L., K.V.K.); Stanford University,
      Stanford (D.B.M., R.L.), City of Hope National Medical Center, Duarte (T.S.),
      University of California at Los Angeles, Los Angeles (J.M.T.), University of
      California at San Diego, San Diego (J.E.C.), and Kite Pharma, Santa Monica (A.B.,
      J.R., L.N., Y.J., J.A., M.E., D.C., J.W., W.Y.G.) - all in California;
      Dana-Farber Cancer Institute, Boston (C.A.J., E.D.J.); Montefiore Medical Center,
      Bronx (I.B.), and the University of Rochester School of Medicine, Rochester
      (J.W.F., P.R.) - both in New York; Vanderbilt University Medical Center (O.O.O.) 
      and the Sarah Cannon Research Institute and Tennessee Oncology (I.W.F.),
      Nashville; Mayo Clinic, Rochester, MN (Y.L., T.E.W.); Loyola University Medical
      Center, Maywood, IL (P.J.S.); John Theurer Cancer Center, Hackensack University
      Medical Center, Hackensack, NJ (A. Goy); Cleveland Clinic, Cleveland (B.T.H.,
      M.R.S.); Karmanos Cancer Center, Wayne State University, Detroit (A.D.);
      University of Iowa Carver College of Medicine, Iowa City (U.F.); Colorado Blood
      Cancer Institute, Denver (P.M.S.); Banner M.D. Anderson Cancer Center, Gilbert,
      AZ (J.M.); and Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel
      Aviv University, Tel Aviv, Israel (I.A.).
FAU - Friedberg, Jonathan W
AU  - Friedberg JW
AD  - From the University of Texas M.D. Anderson Cancer Center, Houston (S.S.N.,
      J.R.W.); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (F.L.L., 
      J.C.C.); Washington University and Siteman Cancer Center, St. Louis (N.L.B., A.
      Ghobadi); University of Miami, Miami (L.J.L., K.V.K.); Stanford University,
      Stanford (D.B.M., R.L.), City of Hope National Medical Center, Duarte (T.S.),
      University of California at Los Angeles, Los Angeles (J.M.T.), University of
      California at San Diego, San Diego (J.E.C.), and Kite Pharma, Santa Monica (A.B.,
      J.R., L.N., Y.J., J.A., M.E., D.C., J.W., W.Y.G.) - all in California;
      Dana-Farber Cancer Institute, Boston (C.A.J., E.D.J.); Montefiore Medical Center,
      Bronx (I.B.), and the University of Rochester School of Medicine, Rochester
      (J.W.F., P.R.) - both in New York; Vanderbilt University Medical Center (O.O.O.) 
      and the Sarah Cannon Research Institute and Tennessee Oncology (I.W.F.),
      Nashville; Mayo Clinic, Rochester, MN (Y.L., T.E.W.); Loyola University Medical
      Center, Maywood, IL (P.J.S.); John Theurer Cancer Center, Hackensack University
      Medical Center, Hackensack, NJ (A. Goy); Cleveland Clinic, Cleveland (B.T.H.,
      M.R.S.); Karmanos Cancer Center, Wayne State University, Detroit (A.D.);
      University of Iowa Carver College of Medicine, Iowa City (U.F.); Colorado Blood
      Cancer Institute, Denver (P.M.S.); Banner M.D. Anderson Cancer Center, Gilbert,
      AZ (J.M.); and Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel
      Aviv University, Tel Aviv, Israel (I.A.).
FAU - Flinn, Ian W
AU  - Flinn IW
AD  - From the University of Texas M.D. Anderson Cancer Center, Houston (S.S.N.,
      J.R.W.); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (F.L.L., 
      J.C.C.); Washington University and Siteman Cancer Center, St. Louis (N.L.B., A.
      Ghobadi); University of Miami, Miami (L.J.L., K.V.K.); Stanford University,
      Stanford (D.B.M., R.L.), City of Hope National Medical Center, Duarte (T.S.),
      University of California at Los Angeles, Los Angeles (J.M.T.), University of
      California at San Diego, San Diego (J.E.C.), and Kite Pharma, Santa Monica (A.B.,
      J.R., L.N., Y.J., J.A., M.E., D.C., J.W., W.Y.G.) - all in California;
      Dana-Farber Cancer Institute, Boston (C.A.J., E.D.J.); Montefiore Medical Center,
      Bronx (I.B.), and the University of Rochester School of Medicine, Rochester
      (J.W.F., P.R.) - both in New York; Vanderbilt University Medical Center (O.O.O.) 
      and the Sarah Cannon Research Institute and Tennessee Oncology (I.W.F.),
      Nashville; Mayo Clinic, Rochester, MN (Y.L., T.E.W.); Loyola University Medical
      Center, Maywood, IL (P.J.S.); John Theurer Cancer Center, Hackensack University
      Medical Center, Hackensack, NJ (A. Goy); Cleveland Clinic, Cleveland (B.T.H.,
      M.R.S.); Karmanos Cancer Center, Wayne State University, Detroit (A.D.);
      University of Iowa Carver College of Medicine, Iowa City (U.F.); Colorado Blood
      Cancer Institute, Denver (P.M.S.); Banner M.D. Anderson Cancer Center, Gilbert,
      AZ (J.M.); and Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel
      Aviv University, Tel Aviv, Israel (I.A.).
FAU - Goy, Andre
AU  - Goy A
AD  - From the University of Texas M.D. Anderson Cancer Center, Houston (S.S.N.,
      J.R.W.); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (F.L.L., 
      J.C.C.); Washington University and Siteman Cancer Center, St. Louis (N.L.B., A.
      Ghobadi); University of Miami, Miami (L.J.L., K.V.K.); Stanford University,
      Stanford (D.B.M., R.L.), City of Hope National Medical Center, Duarte (T.S.),
      University of California at Los Angeles, Los Angeles (J.M.T.), University of
      California at San Diego, San Diego (J.E.C.), and Kite Pharma, Santa Monica (A.B.,
      J.R., L.N., Y.J., J.A., M.E., D.C., J.W., W.Y.G.) - all in California;
      Dana-Farber Cancer Institute, Boston (C.A.J., E.D.J.); Montefiore Medical Center,
      Bronx (I.B.), and the University of Rochester School of Medicine, Rochester
      (J.W.F., P.R.) - both in New York; Vanderbilt University Medical Center (O.O.O.) 
      and the Sarah Cannon Research Institute and Tennessee Oncology (I.W.F.),
      Nashville; Mayo Clinic, Rochester, MN (Y.L., T.E.W.); Loyola University Medical
      Center, Maywood, IL (P.J.S.); John Theurer Cancer Center, Hackensack University
      Medical Center, Hackensack, NJ (A. Goy); Cleveland Clinic, Cleveland (B.T.H.,
      M.R.S.); Karmanos Cancer Center, Wayne State University, Detroit (A.D.);
      University of Iowa Carver College of Medicine, Iowa City (U.F.); Colorado Blood
      Cancer Institute, Denver (P.M.S.); Banner M.D. Anderson Cancer Center, Gilbert,
      AZ (J.M.); and Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel
      Aviv University, Tel Aviv, Israel (I.A.).
FAU - Hill, Brian T
AU  - Hill BT
AD  - From the University of Texas M.D. Anderson Cancer Center, Houston (S.S.N.,
      J.R.W.); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (F.L.L., 
      J.C.C.); Washington University and Siteman Cancer Center, St. Louis (N.L.B., A.
      Ghobadi); University of Miami, Miami (L.J.L., K.V.K.); Stanford University,
      Stanford (D.B.M., R.L.), City of Hope National Medical Center, Duarte (T.S.),
      University of California at Los Angeles, Los Angeles (J.M.T.), University of
      California at San Diego, San Diego (J.E.C.), and Kite Pharma, Santa Monica (A.B.,
      J.R., L.N., Y.J., J.A., M.E., D.C., J.W., W.Y.G.) - all in California;
      Dana-Farber Cancer Institute, Boston (C.A.J., E.D.J.); Montefiore Medical Center,
      Bronx (I.B.), and the University of Rochester School of Medicine, Rochester
      (J.W.F., P.R.) - both in New York; Vanderbilt University Medical Center (O.O.O.) 
      and the Sarah Cannon Research Institute and Tennessee Oncology (I.W.F.),
      Nashville; Mayo Clinic, Rochester, MN (Y.L., T.E.W.); Loyola University Medical
      Center, Maywood, IL (P.J.S.); John Theurer Cancer Center, Hackensack University
      Medical Center, Hackensack, NJ (A. Goy); Cleveland Clinic, Cleveland (B.T.H.,
      M.R.S.); Karmanos Cancer Center, Wayne State University, Detroit (A.D.);
      University of Iowa Carver College of Medicine, Iowa City (U.F.); Colorado Blood
      Cancer Institute, Denver (P.M.S.); Banner M.D. Anderson Cancer Center, Gilbert,
      AZ (J.M.); and Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel
      Aviv University, Tel Aviv, Israel (I.A.).
FAU - Smith, Mitchell R
AU  - Smith MR
AD  - From the University of Texas M.D. Anderson Cancer Center, Houston (S.S.N.,
      J.R.W.); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (F.L.L., 
      J.C.C.); Washington University and Siteman Cancer Center, St. Louis (N.L.B., A.
      Ghobadi); University of Miami, Miami (L.J.L., K.V.K.); Stanford University,
      Stanford (D.B.M., R.L.), City of Hope National Medical Center, Duarte (T.S.),
      University of California at Los Angeles, Los Angeles (J.M.T.), University of
      California at San Diego, San Diego (J.E.C.), and Kite Pharma, Santa Monica (A.B.,
      J.R., L.N., Y.J., J.A., M.E., D.C., J.W., W.Y.G.) - all in California;
      Dana-Farber Cancer Institute, Boston (C.A.J., E.D.J.); Montefiore Medical Center,
      Bronx (I.B.), and the University of Rochester School of Medicine, Rochester
      (J.W.F., P.R.) - both in New York; Vanderbilt University Medical Center (O.O.O.) 
      and the Sarah Cannon Research Institute and Tennessee Oncology (I.W.F.),
      Nashville; Mayo Clinic, Rochester, MN (Y.L., T.E.W.); Loyola University Medical
      Center, Maywood, IL (P.J.S.); John Theurer Cancer Center, Hackensack University
      Medical Center, Hackensack, NJ (A. Goy); Cleveland Clinic, Cleveland (B.T.H.,
      M.R.S.); Karmanos Cancer Center, Wayne State University, Detroit (A.D.);
      University of Iowa Carver College of Medicine, Iowa City (U.F.); Colorado Blood
      Cancer Institute, Denver (P.M.S.); Banner M.D. Anderson Cancer Center, Gilbert,
      AZ (J.M.); and Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel
      Aviv University, Tel Aviv, Israel (I.A.).
FAU - Deol, Abhinav
AU  - Deol A
AD  - From the University of Texas M.D. Anderson Cancer Center, Houston (S.S.N.,
      J.R.W.); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (F.L.L., 
      J.C.C.); Washington University and Siteman Cancer Center, St. Louis (N.L.B., A.
      Ghobadi); University of Miami, Miami (L.J.L., K.V.K.); Stanford University,
      Stanford (D.B.M., R.L.), City of Hope National Medical Center, Duarte (T.S.),
      University of California at Los Angeles, Los Angeles (J.M.T.), University of
      California at San Diego, San Diego (J.E.C.), and Kite Pharma, Santa Monica (A.B.,
      J.R., L.N., Y.J., J.A., M.E., D.C., J.W., W.Y.G.) - all in California;
      Dana-Farber Cancer Institute, Boston (C.A.J., E.D.J.); Montefiore Medical Center,
      Bronx (I.B.), and the University of Rochester School of Medicine, Rochester
      (J.W.F., P.R.) - both in New York; Vanderbilt University Medical Center (O.O.O.) 
      and the Sarah Cannon Research Institute and Tennessee Oncology (I.W.F.),
      Nashville; Mayo Clinic, Rochester, MN (Y.L., T.E.W.); Loyola University Medical
      Center, Maywood, IL (P.J.S.); John Theurer Cancer Center, Hackensack University
      Medical Center, Hackensack, NJ (A. Goy); Cleveland Clinic, Cleveland (B.T.H.,
      M.R.S.); Karmanos Cancer Center, Wayne State University, Detroit (A.D.);
      University of Iowa Carver College of Medicine, Iowa City (U.F.); Colorado Blood
      Cancer Institute, Denver (P.M.S.); Banner M.D. Anderson Cancer Center, Gilbert,
      AZ (J.M.); and Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel
      Aviv University, Tel Aviv, Israel (I.A.).
FAU - Farooq, Umar
AU  - Farooq U
AD  - From the University of Texas M.D. Anderson Cancer Center, Houston (S.S.N.,
      J.R.W.); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (F.L.L., 
      J.C.C.); Washington University and Siteman Cancer Center, St. Louis (N.L.B., A.
      Ghobadi); University of Miami, Miami (L.J.L., K.V.K.); Stanford University,
      Stanford (D.B.M., R.L.), City of Hope National Medical Center, Duarte (T.S.),
      University of California at Los Angeles, Los Angeles (J.M.T.), University of
      California at San Diego, San Diego (J.E.C.), and Kite Pharma, Santa Monica (A.B.,
      J.R., L.N., Y.J., J.A., M.E., D.C., J.W., W.Y.G.) - all in California;
      Dana-Farber Cancer Institute, Boston (C.A.J., E.D.J.); Montefiore Medical Center,
      Bronx (I.B.), and the University of Rochester School of Medicine, Rochester
      (J.W.F., P.R.) - both in New York; Vanderbilt University Medical Center (O.O.O.) 
      and the Sarah Cannon Research Institute and Tennessee Oncology (I.W.F.),
      Nashville; Mayo Clinic, Rochester, MN (Y.L., T.E.W.); Loyola University Medical
      Center, Maywood, IL (P.J.S.); John Theurer Cancer Center, Hackensack University
      Medical Center, Hackensack, NJ (A. Goy); Cleveland Clinic, Cleveland (B.T.H.,
      M.R.S.); Karmanos Cancer Center, Wayne State University, Detroit (A.D.);
      University of Iowa Carver College of Medicine, Iowa City (U.F.); Colorado Blood
      Cancer Institute, Denver (P.M.S.); Banner M.D. Anderson Cancer Center, Gilbert,
      AZ (J.M.); and Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel
      Aviv University, Tel Aviv, Israel (I.A.).
FAU - McSweeney, Peter
AU  - McSweeney P
AD  - From the University of Texas M.D. Anderson Cancer Center, Houston (S.S.N.,
      J.R.W.); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (F.L.L., 
      J.C.C.); Washington University and Siteman Cancer Center, St. Louis (N.L.B., A.
      Ghobadi); University of Miami, Miami (L.J.L., K.V.K.); Stanford University,
      Stanford (D.B.M., R.L.), City of Hope National Medical Center, Duarte (T.S.),
      University of California at Los Angeles, Los Angeles (J.M.T.), University of
      California at San Diego, San Diego (J.E.C.), and Kite Pharma, Santa Monica (A.B.,
      J.R., L.N., Y.J., J.A., M.E., D.C., J.W., W.Y.G.) - all in California;
      Dana-Farber Cancer Institute, Boston (C.A.J., E.D.J.); Montefiore Medical Center,
      Bronx (I.B.), and the University of Rochester School of Medicine, Rochester
      (J.W.F., P.R.) - both in New York; Vanderbilt University Medical Center (O.O.O.) 
      and the Sarah Cannon Research Institute and Tennessee Oncology (I.W.F.),
      Nashville; Mayo Clinic, Rochester, MN (Y.L., T.E.W.); Loyola University Medical
      Center, Maywood, IL (P.J.S.); John Theurer Cancer Center, Hackensack University
      Medical Center, Hackensack, NJ (A. Goy); Cleveland Clinic, Cleveland (B.T.H.,
      M.R.S.); Karmanos Cancer Center, Wayne State University, Detroit (A.D.);
      University of Iowa Carver College of Medicine, Iowa City (U.F.); Colorado Blood
      Cancer Institute, Denver (P.M.S.); Banner M.D. Anderson Cancer Center, Gilbert,
      AZ (J.M.); and Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel
      Aviv University, Tel Aviv, Israel (I.A.).
FAU - Munoz, Javier
AU  - Munoz J
AD  - From the University of Texas M.D. Anderson Cancer Center, Houston (S.S.N.,
      J.R.W.); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (F.L.L., 
      J.C.C.); Washington University and Siteman Cancer Center, St. Louis (N.L.B., A.
      Ghobadi); University of Miami, Miami (L.J.L., K.V.K.); Stanford University,
      Stanford (D.B.M., R.L.), City of Hope National Medical Center, Duarte (T.S.),
      University of California at Los Angeles, Los Angeles (J.M.T.), University of
      California at San Diego, San Diego (J.E.C.), and Kite Pharma, Santa Monica (A.B.,
      J.R., L.N., Y.J., J.A., M.E., D.C., J.W., W.Y.G.) - all in California;
      Dana-Farber Cancer Institute, Boston (C.A.J., E.D.J.); Montefiore Medical Center,
      Bronx (I.B.), and the University of Rochester School of Medicine, Rochester
      (J.W.F., P.R.) - both in New York; Vanderbilt University Medical Center (O.O.O.) 
      and the Sarah Cannon Research Institute and Tennessee Oncology (I.W.F.),
      Nashville; Mayo Clinic, Rochester, MN (Y.L., T.E.W.); Loyola University Medical
      Center, Maywood, IL (P.J.S.); John Theurer Cancer Center, Hackensack University
      Medical Center, Hackensack, NJ (A. Goy); Cleveland Clinic, Cleveland (B.T.H.,
      M.R.S.); Karmanos Cancer Center, Wayne State University, Detroit (A.D.);
      University of Iowa Carver College of Medicine, Iowa City (U.F.); Colorado Blood
      Cancer Institute, Denver (P.M.S.); Banner M.D. Anderson Cancer Center, Gilbert,
      AZ (J.M.); and Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel
      Aviv University, Tel Aviv, Israel (I.A.).
FAU - Avivi, Irit
AU  - Avivi I
AD  - From the University of Texas M.D. Anderson Cancer Center, Houston (S.S.N.,
      J.R.W.); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (F.L.L., 
      J.C.C.); Washington University and Siteman Cancer Center, St. Louis (N.L.B., A.
      Ghobadi); University of Miami, Miami (L.J.L., K.V.K.); Stanford University,
      Stanford (D.B.M., R.L.), City of Hope National Medical Center, Duarte (T.S.),
      University of California at Los Angeles, Los Angeles (J.M.T.), University of
      California at San Diego, San Diego (J.E.C.), and Kite Pharma, Santa Monica (A.B.,
      J.R., L.N., Y.J., J.A., M.E., D.C., J.W., W.Y.G.) - all in California;
      Dana-Farber Cancer Institute, Boston (C.A.J., E.D.J.); Montefiore Medical Center,
      Bronx (I.B.), and the University of Rochester School of Medicine, Rochester
      (J.W.F., P.R.) - both in New York; Vanderbilt University Medical Center (O.O.O.) 
      and the Sarah Cannon Research Institute and Tennessee Oncology (I.W.F.),
      Nashville; Mayo Clinic, Rochester, MN (Y.L., T.E.W.); Loyola University Medical
      Center, Maywood, IL (P.J.S.); John Theurer Cancer Center, Hackensack University
      Medical Center, Hackensack, NJ (A. Goy); Cleveland Clinic, Cleveland (B.T.H.,
      M.R.S.); Karmanos Cancer Center, Wayne State University, Detroit (A.D.);
      University of Iowa Carver College of Medicine, Iowa City (U.F.); Colorado Blood
      Cancer Institute, Denver (P.M.S.); Banner M.D. Anderson Cancer Center, Gilbert,
      AZ (J.M.); and Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel
      Aviv University, Tel Aviv, Israel (I.A.).
FAU - Castro, Januario E
AU  - Castro JE
AD  - From the University of Texas M.D. Anderson Cancer Center, Houston (S.S.N.,
      J.R.W.); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (F.L.L., 
      J.C.C.); Washington University and Siteman Cancer Center, St. Louis (N.L.B., A.
      Ghobadi); University of Miami, Miami (L.J.L., K.V.K.); Stanford University,
      Stanford (D.B.M., R.L.), City of Hope National Medical Center, Duarte (T.S.),
      University of California at Los Angeles, Los Angeles (J.M.T.), University of
      California at San Diego, San Diego (J.E.C.), and Kite Pharma, Santa Monica (A.B.,
      J.R., L.N., Y.J., J.A., M.E., D.C., J.W., W.Y.G.) - all in California;
      Dana-Farber Cancer Institute, Boston (C.A.J., E.D.J.); Montefiore Medical Center,
      Bronx (I.B.), and the University of Rochester School of Medicine, Rochester
      (J.W.F., P.R.) - both in New York; Vanderbilt University Medical Center (O.O.O.) 
      and the Sarah Cannon Research Institute and Tennessee Oncology (I.W.F.),
      Nashville; Mayo Clinic, Rochester, MN (Y.L., T.E.W.); Loyola University Medical
      Center, Maywood, IL (P.J.S.); John Theurer Cancer Center, Hackensack University
      Medical Center, Hackensack, NJ (A. Goy); Cleveland Clinic, Cleveland (B.T.H.,
      M.R.S.); Karmanos Cancer Center, Wayne State University, Detroit (A.D.);
      University of Iowa Carver College of Medicine, Iowa City (U.F.); Colorado Blood
      Cancer Institute, Denver (P.M.S.); Banner M.D. Anderson Cancer Center, Gilbert,
      AZ (J.M.); and Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel
      Aviv University, Tel Aviv, Israel (I.A.).
FAU - Westin, Jason R
AU  - Westin JR
AD  - From the University of Texas M.D. Anderson Cancer Center, Houston (S.S.N.,
      J.R.W.); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (F.L.L., 
      J.C.C.); Washington University and Siteman Cancer Center, St. Louis (N.L.B., A.
      Ghobadi); University of Miami, Miami (L.J.L., K.V.K.); Stanford University,
      Stanford (D.B.M., R.L.), City of Hope National Medical Center, Duarte (T.S.),
      University of California at Los Angeles, Los Angeles (J.M.T.), University of
      California at San Diego, San Diego (J.E.C.), and Kite Pharma, Santa Monica (A.B.,
      J.R., L.N., Y.J., J.A., M.E., D.C., J.W., W.Y.G.) - all in California;
      Dana-Farber Cancer Institute, Boston (C.A.J., E.D.J.); Montefiore Medical Center,
      Bronx (I.B.), and the University of Rochester School of Medicine, Rochester
      (J.W.F., P.R.) - both in New York; Vanderbilt University Medical Center (O.O.O.) 
      and the Sarah Cannon Research Institute and Tennessee Oncology (I.W.F.),
      Nashville; Mayo Clinic, Rochester, MN (Y.L., T.E.W.); Loyola University Medical
      Center, Maywood, IL (P.J.S.); John Theurer Cancer Center, Hackensack University
      Medical Center, Hackensack, NJ (A. Goy); Cleveland Clinic, Cleveland (B.T.H.,
      M.R.S.); Karmanos Cancer Center, Wayne State University, Detroit (A.D.);
      University of Iowa Carver College of Medicine, Iowa City (U.F.); Colorado Blood
      Cancer Institute, Denver (P.M.S.); Banner M.D. Anderson Cancer Center, Gilbert,
      AZ (J.M.); and Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel
      Aviv University, Tel Aviv, Israel (I.A.).
FAU - Chavez, Julio C
AU  - Chavez JC
AD  - From the University of Texas M.D. Anderson Cancer Center, Houston (S.S.N.,
      J.R.W.); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (F.L.L., 
      J.C.C.); Washington University and Siteman Cancer Center, St. Louis (N.L.B., A.
      Ghobadi); University of Miami, Miami (L.J.L., K.V.K.); Stanford University,
      Stanford (D.B.M., R.L.), City of Hope National Medical Center, Duarte (T.S.),
      University of California at Los Angeles, Los Angeles (J.M.T.), University of
      California at San Diego, San Diego (J.E.C.), and Kite Pharma, Santa Monica (A.B.,
      J.R., L.N., Y.J., J.A., M.E., D.C., J.W., W.Y.G.) - all in California;
      Dana-Farber Cancer Institute, Boston (C.A.J., E.D.J.); Montefiore Medical Center,
      Bronx (I.B.), and the University of Rochester School of Medicine, Rochester
      (J.W.F., P.R.) - both in New York; Vanderbilt University Medical Center (O.O.O.) 
      and the Sarah Cannon Research Institute and Tennessee Oncology (I.W.F.),
      Nashville; Mayo Clinic, Rochester, MN (Y.L., T.E.W.); Loyola University Medical
      Center, Maywood, IL (P.J.S.); John Theurer Cancer Center, Hackensack University
      Medical Center, Hackensack, NJ (A. Goy); Cleveland Clinic, Cleveland (B.T.H.,
      M.R.S.); Karmanos Cancer Center, Wayne State University, Detroit (A.D.);
      University of Iowa Carver College of Medicine, Iowa City (U.F.); Colorado Blood
      Cancer Institute, Denver (P.M.S.); Banner M.D. Anderson Cancer Center, Gilbert,
      AZ (J.M.); and Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel
      Aviv University, Tel Aviv, Israel (I.A.).
FAU - Ghobadi, Armin
AU  - Ghobadi A
AD  - From the University of Texas M.D. Anderson Cancer Center, Houston (S.S.N.,
      J.R.W.); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (F.L.L., 
      J.C.C.); Washington University and Siteman Cancer Center, St. Louis (N.L.B., A.
      Ghobadi); University of Miami, Miami (L.J.L., K.V.K.); Stanford University,
      Stanford (D.B.M., R.L.), City of Hope National Medical Center, Duarte (T.S.),
      University of California at Los Angeles, Los Angeles (J.M.T.), University of
      California at San Diego, San Diego (J.E.C.), and Kite Pharma, Santa Monica (A.B.,
      J.R., L.N., Y.J., J.A., M.E., D.C., J.W., W.Y.G.) - all in California;
      Dana-Farber Cancer Institute, Boston (C.A.J., E.D.J.); Montefiore Medical Center,
      Bronx (I.B.), and the University of Rochester School of Medicine, Rochester
      (J.W.F., P.R.) - both in New York; Vanderbilt University Medical Center (O.O.O.) 
      and the Sarah Cannon Research Institute and Tennessee Oncology (I.W.F.),
      Nashville; Mayo Clinic, Rochester, MN (Y.L., T.E.W.); Loyola University Medical
      Center, Maywood, IL (P.J.S.); John Theurer Cancer Center, Hackensack University
      Medical Center, Hackensack, NJ (A. Goy); Cleveland Clinic, Cleveland (B.T.H.,
      M.R.S.); Karmanos Cancer Center, Wayne State University, Detroit (A.D.);
      University of Iowa Carver College of Medicine, Iowa City (U.F.); Colorado Blood
      Cancer Institute, Denver (P.M.S.); Banner M.D. Anderson Cancer Center, Gilbert,
      AZ (J.M.); and Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel
      Aviv University, Tel Aviv, Israel (I.A.).
FAU - Komanduri, Krishna V
AU  - Komanduri KV
AD  - From the University of Texas M.D. Anderson Cancer Center, Houston (S.S.N.,
      J.R.W.); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (F.L.L., 
      J.C.C.); Washington University and Siteman Cancer Center, St. Louis (N.L.B., A.
      Ghobadi); University of Miami, Miami (L.J.L., K.V.K.); Stanford University,
      Stanford (D.B.M., R.L.), City of Hope National Medical Center, Duarte (T.S.),
      University of California at Los Angeles, Los Angeles (J.M.T.), University of
      California at San Diego, San Diego (J.E.C.), and Kite Pharma, Santa Monica (A.B.,
      J.R., L.N., Y.J., J.A., M.E., D.C., J.W., W.Y.G.) - all in California;
      Dana-Farber Cancer Institute, Boston (C.A.J., E.D.J.); Montefiore Medical Center,
      Bronx (I.B.), and the University of Rochester School of Medicine, Rochester
      (J.W.F., P.R.) - both in New York; Vanderbilt University Medical Center (O.O.O.) 
      and the Sarah Cannon Research Institute and Tennessee Oncology (I.W.F.),
      Nashville; Mayo Clinic, Rochester, MN (Y.L., T.E.W.); Loyola University Medical
      Center, Maywood, IL (P.J.S.); John Theurer Cancer Center, Hackensack University
      Medical Center, Hackensack, NJ (A. Goy); Cleveland Clinic, Cleveland (B.T.H.,
      M.R.S.); Karmanos Cancer Center, Wayne State University, Detroit (A.D.);
      University of Iowa Carver College of Medicine, Iowa City (U.F.); Colorado Blood
      Cancer Institute, Denver (P.M.S.); Banner M.D. Anderson Cancer Center, Gilbert,
      AZ (J.M.); and Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel
      Aviv University, Tel Aviv, Israel (I.A.).
FAU - Levy, Ronald
AU  - Levy R
AD  - From the University of Texas M.D. Anderson Cancer Center, Houston (S.S.N.,
      J.R.W.); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (F.L.L., 
      J.C.C.); Washington University and Siteman Cancer Center, St. Louis (N.L.B., A.
      Ghobadi); University of Miami, Miami (L.J.L., K.V.K.); Stanford University,
      Stanford (D.B.M., R.L.), City of Hope National Medical Center, Duarte (T.S.),
      University of California at Los Angeles, Los Angeles (J.M.T.), University of
      California at San Diego, San Diego (J.E.C.), and Kite Pharma, Santa Monica (A.B.,
      J.R., L.N., Y.J., J.A., M.E., D.C., J.W., W.Y.G.) - all in California;
      Dana-Farber Cancer Institute, Boston (C.A.J., E.D.J.); Montefiore Medical Center,
      Bronx (I.B.), and the University of Rochester School of Medicine, Rochester
      (J.W.F., P.R.) - both in New York; Vanderbilt University Medical Center (O.O.O.) 
      and the Sarah Cannon Research Institute and Tennessee Oncology (I.W.F.),
      Nashville; Mayo Clinic, Rochester, MN (Y.L., T.E.W.); Loyola University Medical
      Center, Maywood, IL (P.J.S.); John Theurer Cancer Center, Hackensack University
      Medical Center, Hackensack, NJ (A. Goy); Cleveland Clinic, Cleveland (B.T.H.,
      M.R.S.); Karmanos Cancer Center, Wayne State University, Detroit (A.D.);
      University of Iowa Carver College of Medicine, Iowa City (U.F.); Colorado Blood
      Cancer Institute, Denver (P.M.S.); Banner M.D. Anderson Cancer Center, Gilbert,
      AZ (J.M.); and Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel
      Aviv University, Tel Aviv, Israel (I.A.).
FAU - Jacobsen, Eric D
AU  - Jacobsen ED
AD  - From the University of Texas M.D. Anderson Cancer Center, Houston (S.S.N.,
      J.R.W.); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (F.L.L., 
      J.C.C.); Washington University and Siteman Cancer Center, St. Louis (N.L.B., A.
      Ghobadi); University of Miami, Miami (L.J.L., K.V.K.); Stanford University,
      Stanford (D.B.M., R.L.), City of Hope National Medical Center, Duarte (T.S.),
      University of California at Los Angeles, Los Angeles (J.M.T.), University of
      California at San Diego, San Diego (J.E.C.), and Kite Pharma, Santa Monica (A.B.,
      J.R., L.N., Y.J., J.A., M.E., D.C., J.W., W.Y.G.) - all in California;
      Dana-Farber Cancer Institute, Boston (C.A.J., E.D.J.); Montefiore Medical Center,
      Bronx (I.B.), and the University of Rochester School of Medicine, Rochester
      (J.W.F., P.R.) - both in New York; Vanderbilt University Medical Center (O.O.O.) 
      and the Sarah Cannon Research Institute and Tennessee Oncology (I.W.F.),
      Nashville; Mayo Clinic, Rochester, MN (Y.L., T.E.W.); Loyola University Medical
      Center, Maywood, IL (P.J.S.); John Theurer Cancer Center, Hackensack University
      Medical Center, Hackensack, NJ (A. Goy); Cleveland Clinic, Cleveland (B.T.H.,
      M.R.S.); Karmanos Cancer Center, Wayne State University, Detroit (A.D.);
      University of Iowa Carver College of Medicine, Iowa City (U.F.); Colorado Blood
      Cancer Institute, Denver (P.M.S.); Banner M.D. Anderson Cancer Center, Gilbert,
      AZ (J.M.); and Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel
      Aviv University, Tel Aviv, Israel (I.A.).
FAU - Witzig, Thomas E
AU  - Witzig TE
AD  - From the University of Texas M.D. Anderson Cancer Center, Houston (S.S.N.,
      J.R.W.); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (F.L.L., 
      J.C.C.); Washington University and Siteman Cancer Center, St. Louis (N.L.B., A.
      Ghobadi); University of Miami, Miami (L.J.L., K.V.K.); Stanford University,
      Stanford (D.B.M., R.L.), City of Hope National Medical Center, Duarte (T.S.),
      University of California at Los Angeles, Los Angeles (J.M.T.), University of
      California at San Diego, San Diego (J.E.C.), and Kite Pharma, Santa Monica (A.B.,
      J.R., L.N., Y.J., J.A., M.E., D.C., J.W., W.Y.G.) - all in California;
      Dana-Farber Cancer Institute, Boston (C.A.J., E.D.J.); Montefiore Medical Center,
      Bronx (I.B.), and the University of Rochester School of Medicine, Rochester
      (J.W.F., P.R.) - both in New York; Vanderbilt University Medical Center (O.O.O.) 
      and the Sarah Cannon Research Institute and Tennessee Oncology (I.W.F.),
      Nashville; Mayo Clinic, Rochester, MN (Y.L., T.E.W.); Loyola University Medical
      Center, Maywood, IL (P.J.S.); John Theurer Cancer Center, Hackensack University
      Medical Center, Hackensack, NJ (A. Goy); Cleveland Clinic, Cleveland (B.T.H.,
      M.R.S.); Karmanos Cancer Center, Wayne State University, Detroit (A.D.);
      University of Iowa Carver College of Medicine, Iowa City (U.F.); Colorado Blood
      Cancer Institute, Denver (P.M.S.); Banner M.D. Anderson Cancer Center, Gilbert,
      AZ (J.M.); and Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel
      Aviv University, Tel Aviv, Israel (I.A.).
FAU - Reagan, Patrick
AU  - Reagan P
AD  - From the University of Texas M.D. Anderson Cancer Center, Houston (S.S.N.,
      J.R.W.); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (F.L.L., 
      J.C.C.); Washington University and Siteman Cancer Center, St. Louis (N.L.B., A.
      Ghobadi); University of Miami, Miami (L.J.L., K.V.K.); Stanford University,
      Stanford (D.B.M., R.L.), City of Hope National Medical Center, Duarte (T.S.),
      University of California at Los Angeles, Los Angeles (J.M.T.), University of
      California at San Diego, San Diego (J.E.C.), and Kite Pharma, Santa Monica (A.B.,
      J.R., L.N., Y.J., J.A., M.E., D.C., J.W., W.Y.G.) - all in California;
      Dana-Farber Cancer Institute, Boston (C.A.J., E.D.J.); Montefiore Medical Center,
      Bronx (I.B.), and the University of Rochester School of Medicine, Rochester
      (J.W.F., P.R.) - both in New York; Vanderbilt University Medical Center (O.O.O.) 
      and the Sarah Cannon Research Institute and Tennessee Oncology (I.W.F.),
      Nashville; Mayo Clinic, Rochester, MN (Y.L., T.E.W.); Loyola University Medical
      Center, Maywood, IL (P.J.S.); John Theurer Cancer Center, Hackensack University
      Medical Center, Hackensack, NJ (A. Goy); Cleveland Clinic, Cleveland (B.T.H.,
      M.R.S.); Karmanos Cancer Center, Wayne State University, Detroit (A.D.);
      University of Iowa Carver College of Medicine, Iowa City (U.F.); Colorado Blood
      Cancer Institute, Denver (P.M.S.); Banner M.D. Anderson Cancer Center, Gilbert,
      AZ (J.M.); and Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel
      Aviv University, Tel Aviv, Israel (I.A.).
FAU - Bot, Adrian
AU  - Bot A
AD  - From the University of Texas M.D. Anderson Cancer Center, Houston (S.S.N.,
      J.R.W.); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (F.L.L., 
      J.C.C.); Washington University and Siteman Cancer Center, St. Louis (N.L.B., A.
      Ghobadi); University of Miami, Miami (L.J.L., K.V.K.); Stanford University,
      Stanford (D.B.M., R.L.), City of Hope National Medical Center, Duarte (T.S.),
      University of California at Los Angeles, Los Angeles (J.M.T.), University of
      California at San Diego, San Diego (J.E.C.), and Kite Pharma, Santa Monica (A.B.,
      J.R., L.N., Y.J., J.A., M.E., D.C., J.W., W.Y.G.) - all in California;
      Dana-Farber Cancer Institute, Boston (C.A.J., E.D.J.); Montefiore Medical Center,
      Bronx (I.B.), and the University of Rochester School of Medicine, Rochester
      (J.W.F., P.R.) - both in New York; Vanderbilt University Medical Center (O.O.O.) 
      and the Sarah Cannon Research Institute and Tennessee Oncology (I.W.F.),
      Nashville; Mayo Clinic, Rochester, MN (Y.L., T.E.W.); Loyola University Medical
      Center, Maywood, IL (P.J.S.); John Theurer Cancer Center, Hackensack University
      Medical Center, Hackensack, NJ (A. Goy); Cleveland Clinic, Cleveland (B.T.H.,
      M.R.S.); Karmanos Cancer Center, Wayne State University, Detroit (A.D.);
      University of Iowa Carver College of Medicine, Iowa City (U.F.); Colorado Blood
      Cancer Institute, Denver (P.M.S.); Banner M.D. Anderson Cancer Center, Gilbert,
      AZ (J.M.); and Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel
      Aviv University, Tel Aviv, Israel (I.A.).
FAU - Rossi, John
AU  - Rossi J
AD  - From the University of Texas M.D. Anderson Cancer Center, Houston (S.S.N.,
      J.R.W.); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (F.L.L., 
      J.C.C.); Washington University and Siteman Cancer Center, St. Louis (N.L.B., A.
      Ghobadi); University of Miami, Miami (L.J.L., K.V.K.); Stanford University,
      Stanford (D.B.M., R.L.), City of Hope National Medical Center, Duarte (T.S.),
      University of California at Los Angeles, Los Angeles (J.M.T.), University of
      California at San Diego, San Diego (J.E.C.), and Kite Pharma, Santa Monica (A.B.,
      J.R., L.N., Y.J., J.A., M.E., D.C., J.W., W.Y.G.) - all in California;
      Dana-Farber Cancer Institute, Boston (C.A.J., E.D.J.); Montefiore Medical Center,
      Bronx (I.B.), and the University of Rochester School of Medicine, Rochester
      (J.W.F., P.R.) - both in New York; Vanderbilt University Medical Center (O.O.O.) 
      and the Sarah Cannon Research Institute and Tennessee Oncology (I.W.F.),
      Nashville; Mayo Clinic, Rochester, MN (Y.L., T.E.W.); Loyola University Medical
      Center, Maywood, IL (P.J.S.); John Theurer Cancer Center, Hackensack University
      Medical Center, Hackensack, NJ (A. Goy); Cleveland Clinic, Cleveland (B.T.H.,
      M.R.S.); Karmanos Cancer Center, Wayne State University, Detroit (A.D.);
      University of Iowa Carver College of Medicine, Iowa City (U.F.); Colorado Blood
      Cancer Institute, Denver (P.M.S.); Banner M.D. Anderson Cancer Center, Gilbert,
      AZ (J.M.); and Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel
      Aviv University, Tel Aviv, Israel (I.A.).
FAU - Navale, Lynn
AU  - Navale L
AD  - From the University of Texas M.D. Anderson Cancer Center, Houston (S.S.N.,
      J.R.W.); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (F.L.L., 
      J.C.C.); Washington University and Siteman Cancer Center, St. Louis (N.L.B., A.
      Ghobadi); University of Miami, Miami (L.J.L., K.V.K.); Stanford University,
      Stanford (D.B.M., R.L.), City of Hope National Medical Center, Duarte (T.S.),
      University of California at Los Angeles, Los Angeles (J.M.T.), University of
      California at San Diego, San Diego (J.E.C.), and Kite Pharma, Santa Monica (A.B.,
      J.R., L.N., Y.J., J.A., M.E., D.C., J.W., W.Y.G.) - all in California;
      Dana-Farber Cancer Institute, Boston (C.A.J., E.D.J.); Montefiore Medical Center,
      Bronx (I.B.), and the University of Rochester School of Medicine, Rochester
      (J.W.F., P.R.) - both in New York; Vanderbilt University Medical Center (O.O.O.) 
      and the Sarah Cannon Research Institute and Tennessee Oncology (I.W.F.),
      Nashville; Mayo Clinic, Rochester, MN (Y.L., T.E.W.); Loyola University Medical
      Center, Maywood, IL (P.J.S.); John Theurer Cancer Center, Hackensack University
      Medical Center, Hackensack, NJ (A. Goy); Cleveland Clinic, Cleveland (B.T.H.,
      M.R.S.); Karmanos Cancer Center, Wayne State University, Detroit (A.D.);
      University of Iowa Carver College of Medicine, Iowa City (U.F.); Colorado Blood
      Cancer Institute, Denver (P.M.S.); Banner M.D. Anderson Cancer Center, Gilbert,
      AZ (J.M.); and Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel
      Aviv University, Tel Aviv, Israel (I.A.).
FAU - Jiang, Yizhou
AU  - Jiang Y
AD  - From the University of Texas M.D. Anderson Cancer Center, Houston (S.S.N.,
      J.R.W.); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (F.L.L., 
      J.C.C.); Washington University and Siteman Cancer Center, St. Louis (N.L.B., A.
      Ghobadi); University of Miami, Miami (L.J.L., K.V.K.); Stanford University,
      Stanford (D.B.M., R.L.), City of Hope National Medical Center, Duarte (T.S.),
      University of California at Los Angeles, Los Angeles (J.M.T.), University of
      California at San Diego, San Diego (J.E.C.), and Kite Pharma, Santa Monica (A.B.,
      J.R., L.N., Y.J., J.A., M.E., D.C., J.W., W.Y.G.) - all in California;
      Dana-Farber Cancer Institute, Boston (C.A.J., E.D.J.); Montefiore Medical Center,
      Bronx (I.B.), and the University of Rochester School of Medicine, Rochester
      (J.W.F., P.R.) - both in New York; Vanderbilt University Medical Center (O.O.O.) 
      and the Sarah Cannon Research Institute and Tennessee Oncology (I.W.F.),
      Nashville; Mayo Clinic, Rochester, MN (Y.L., T.E.W.); Loyola University Medical
      Center, Maywood, IL (P.J.S.); John Theurer Cancer Center, Hackensack University
      Medical Center, Hackensack, NJ (A. Goy); Cleveland Clinic, Cleveland (B.T.H.,
      M.R.S.); Karmanos Cancer Center, Wayne State University, Detroit (A.D.);
      University of Iowa Carver College of Medicine, Iowa City (U.F.); Colorado Blood
      Cancer Institute, Denver (P.M.S.); Banner M.D. Anderson Cancer Center, Gilbert,
      AZ (J.M.); and Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel
      Aviv University, Tel Aviv, Israel (I.A.).
FAU - Aycock, Jeff
AU  - Aycock J
AD  - From the University of Texas M.D. Anderson Cancer Center, Houston (S.S.N.,
      J.R.W.); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (F.L.L., 
      J.C.C.); Washington University and Siteman Cancer Center, St. Louis (N.L.B., A.
      Ghobadi); University of Miami, Miami (L.J.L., K.V.K.); Stanford University,
      Stanford (D.B.M., R.L.), City of Hope National Medical Center, Duarte (T.S.),
      University of California at Los Angeles, Los Angeles (J.M.T.), University of
      California at San Diego, San Diego (J.E.C.), and Kite Pharma, Santa Monica (A.B.,
      J.R., L.N., Y.J., J.A., M.E., D.C., J.W., W.Y.G.) - all in California;
      Dana-Farber Cancer Institute, Boston (C.A.J., E.D.J.); Montefiore Medical Center,
      Bronx (I.B.), and the University of Rochester School of Medicine, Rochester
      (J.W.F., P.R.) - both in New York; Vanderbilt University Medical Center (O.O.O.) 
      and the Sarah Cannon Research Institute and Tennessee Oncology (I.W.F.),
      Nashville; Mayo Clinic, Rochester, MN (Y.L., T.E.W.); Loyola University Medical
      Center, Maywood, IL (P.J.S.); John Theurer Cancer Center, Hackensack University
      Medical Center, Hackensack, NJ (A. Goy); Cleveland Clinic, Cleveland (B.T.H.,
      M.R.S.); Karmanos Cancer Center, Wayne State University, Detroit (A.D.);
      University of Iowa Carver College of Medicine, Iowa City (U.F.); Colorado Blood
      Cancer Institute, Denver (P.M.S.); Banner M.D. Anderson Cancer Center, Gilbert,
      AZ (J.M.); and Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel
      Aviv University, Tel Aviv, Israel (I.A.).
FAU - Elias, Meg
AU  - Elias M
AD  - From the University of Texas M.D. Anderson Cancer Center, Houston (S.S.N.,
      J.R.W.); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (F.L.L., 
      J.C.C.); Washington University and Siteman Cancer Center, St. Louis (N.L.B., A.
      Ghobadi); University of Miami, Miami (L.J.L., K.V.K.); Stanford University,
      Stanford (D.B.M., R.L.), City of Hope National Medical Center, Duarte (T.S.),
      University of California at Los Angeles, Los Angeles (J.M.T.), University of
      California at San Diego, San Diego (J.E.C.), and Kite Pharma, Santa Monica (A.B.,
      J.R., L.N., Y.J., J.A., M.E., D.C., J.W., W.Y.G.) - all in California;
      Dana-Farber Cancer Institute, Boston (C.A.J., E.D.J.); Montefiore Medical Center,
      Bronx (I.B.), and the University of Rochester School of Medicine, Rochester
      (J.W.F., P.R.) - both in New York; Vanderbilt University Medical Center (O.O.O.) 
      and the Sarah Cannon Research Institute and Tennessee Oncology (I.W.F.),
      Nashville; Mayo Clinic, Rochester, MN (Y.L., T.E.W.); Loyola University Medical
      Center, Maywood, IL (P.J.S.); John Theurer Cancer Center, Hackensack University
      Medical Center, Hackensack, NJ (A. Goy); Cleveland Clinic, Cleveland (B.T.H.,
      M.R.S.); Karmanos Cancer Center, Wayne State University, Detroit (A.D.);
      University of Iowa Carver College of Medicine, Iowa City (U.F.); Colorado Blood
      Cancer Institute, Denver (P.M.S.); Banner M.D. Anderson Cancer Center, Gilbert,
      AZ (J.M.); and Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel
      Aviv University, Tel Aviv, Israel (I.A.).
FAU - Chang, David
AU  - Chang D
AD  - From the University of Texas M.D. Anderson Cancer Center, Houston (S.S.N.,
      J.R.W.); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (F.L.L., 
      J.C.C.); Washington University and Siteman Cancer Center, St. Louis (N.L.B., A.
      Ghobadi); University of Miami, Miami (L.J.L., K.V.K.); Stanford University,
      Stanford (D.B.M., R.L.), City of Hope National Medical Center, Duarte (T.S.),
      University of California at Los Angeles, Los Angeles (J.M.T.), University of
      California at San Diego, San Diego (J.E.C.), and Kite Pharma, Santa Monica (A.B.,
      J.R., L.N., Y.J., J.A., M.E., D.C., J.W., W.Y.G.) - all in California;
      Dana-Farber Cancer Institute, Boston (C.A.J., E.D.J.); Montefiore Medical Center,
      Bronx (I.B.), and the University of Rochester School of Medicine, Rochester
      (J.W.F., P.R.) - both in New York; Vanderbilt University Medical Center (O.O.O.) 
      and the Sarah Cannon Research Institute and Tennessee Oncology (I.W.F.),
      Nashville; Mayo Clinic, Rochester, MN (Y.L., T.E.W.); Loyola University Medical
      Center, Maywood, IL (P.J.S.); John Theurer Cancer Center, Hackensack University
      Medical Center, Hackensack, NJ (A. Goy); Cleveland Clinic, Cleveland (B.T.H.,
      M.R.S.); Karmanos Cancer Center, Wayne State University, Detroit (A.D.);
      University of Iowa Carver College of Medicine, Iowa City (U.F.); Colorado Blood
      Cancer Institute, Denver (P.M.S.); Banner M.D. Anderson Cancer Center, Gilbert,
      AZ (J.M.); and Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel
      Aviv University, Tel Aviv, Israel (I.A.).
FAU - Wiezorek, Jeff
AU  - Wiezorek J
AD  - From the University of Texas M.D. Anderson Cancer Center, Houston (S.S.N.,
      J.R.W.); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (F.L.L., 
      J.C.C.); Washington University and Siteman Cancer Center, St. Louis (N.L.B., A.
      Ghobadi); University of Miami, Miami (L.J.L., K.V.K.); Stanford University,
      Stanford (D.B.M., R.L.), City of Hope National Medical Center, Duarte (T.S.),
      University of California at Los Angeles, Los Angeles (J.M.T.), University of
      California at San Diego, San Diego (J.E.C.), and Kite Pharma, Santa Monica (A.B.,
      J.R., L.N., Y.J., J.A., M.E., D.C., J.W., W.Y.G.) - all in California;
      Dana-Farber Cancer Institute, Boston (C.A.J., E.D.J.); Montefiore Medical Center,
      Bronx (I.B.), and the University of Rochester School of Medicine, Rochester
      (J.W.F., P.R.) - both in New York; Vanderbilt University Medical Center (O.O.O.) 
      and the Sarah Cannon Research Institute and Tennessee Oncology (I.W.F.),
      Nashville; Mayo Clinic, Rochester, MN (Y.L., T.E.W.); Loyola University Medical
      Center, Maywood, IL (P.J.S.); John Theurer Cancer Center, Hackensack University
      Medical Center, Hackensack, NJ (A. Goy); Cleveland Clinic, Cleveland (B.T.H.,
      M.R.S.); Karmanos Cancer Center, Wayne State University, Detroit (A.D.);
      University of Iowa Carver College of Medicine, Iowa City (U.F.); Colorado Blood
      Cancer Institute, Denver (P.M.S.); Banner M.D. Anderson Cancer Center, Gilbert,
      AZ (J.M.); and Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel
      Aviv University, Tel Aviv, Israel (I.A.).
FAU - Go, William Y
AU  - Go WY
AD  - From the University of Texas M.D. Anderson Cancer Center, Houston (S.S.N.,
      J.R.W.); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (F.L.L., 
      J.C.C.); Washington University and Siteman Cancer Center, St. Louis (N.L.B., A.
      Ghobadi); University of Miami, Miami (L.J.L., K.V.K.); Stanford University,
      Stanford (D.B.M., R.L.), City of Hope National Medical Center, Duarte (T.S.),
      University of California at Los Angeles, Los Angeles (J.M.T.), University of
      California at San Diego, San Diego (J.E.C.), and Kite Pharma, Santa Monica (A.B.,
      J.R., L.N., Y.J., J.A., M.E., D.C., J.W., W.Y.G.) - all in California;
      Dana-Farber Cancer Institute, Boston (C.A.J., E.D.J.); Montefiore Medical Center,
      Bronx (I.B.), and the University of Rochester School of Medicine, Rochester
      (J.W.F., P.R.) - both in New York; Vanderbilt University Medical Center (O.O.O.) 
      and the Sarah Cannon Research Institute and Tennessee Oncology (I.W.F.),
      Nashville; Mayo Clinic, Rochester, MN (Y.L., T.E.W.); Loyola University Medical
      Center, Maywood, IL (P.J.S.); John Theurer Cancer Center, Hackensack University
      Medical Center, Hackensack, NJ (A. Goy); Cleveland Clinic, Cleveland (B.T.H.,
      M.R.S.); Karmanos Cancer Center, Wayne State University, Detroit (A.D.);
      University of Iowa Carver College of Medicine, Iowa City (U.F.); Colorado Blood
      Cancer Institute, Denver (P.M.S.); Banner M.D. Anderson Cancer Center, Gilbert,
      AZ (J.M.); and Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel
      Aviv University, Tel Aviv, Israel (I.A.).
LA  - eng
SI  - ClinicalTrials.gov/NCT02348216
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20171210
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Antigens, CD19)
RN  - 0 (Biomarkers)
RN  - 0 (Interleukins)
RN  - 0 (Receptors, Antigen, T-Cell)
SB  - AIM
SB  - IM
CIN - N Engl J Med. 2017 Dec 28;377(26):2593-2596. PMID: 29226781
MH  - Adult
MH  - Aged
MH  - Antigens, CD19
MH  - Biomarkers/blood
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - *Immunotherapy, Adoptive
MH  - Interleukins/blood
MH  - Lymphoma, Large B-Cell, Diffuse/mortality/*therapy
MH  - Male
MH  - Middle Aged
MH  - Nervous System Diseases/chemically induced
MH  - Neutropenia/chemically induced
MH  - Receptors, Antigen, T-Cell/blood/*therapeutic use
MH  - Survival Rate
MH  - T-Lymphocytes/immunology/*transplantation
MH  - Young Adult
EDAT- 2017/12/12 06:00
MHDA- 2018/01/16 06:00
CRDT- 2017/12/12 06:00
PHST- 2017/12/12 06:00 [pubmed]
PHST- 2018/01/16 06:00 [medline]
PHST- 2017/12/12 06:00 [entrez]
AID - 10.1056/NEJMoa1707447 [pii]
AID - 10.1056/NEJMoa1707447 [doi]
PST - ppublish
SO  - N Engl J Med. 2017 Dec 28;377(26):2531-2544. doi: 10.1056/NEJMoa1707447. Epub
      2017 Dec 10.

PMID- 29186113
OWN - NLM
STAT- In-Data-Review
LR  - 20171219
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 552
IP  - 7683
DP  - 2017 Dec 7
TI  - Inactivation of DNA repair triggers neoantigen generation and impairs tumour
      growth.
PG  - 116-120
LID - 10.1038/nature24673 [doi]
AB  - Molecular alterations in genes involved in DNA mismatch repair (MMR) promote
      cancer initiation and foster tumour progression. Cancers deficient in MMR
      frequently show favourable prognosis and indolent progression. The functional
      basis of the clinical outcome of patients with tumours that are deficient in MMR 
      is not clear. Here we genetically inactivate MutL homologue 1 (MLH1) in
      colorectal, breast and pancreatic mouse cancer cells. The growth of MMR-deficient
      cells was comparable to their proficient counterparts in vitro and on
      transplantation in immunocompromised mice. By contrast, MMR-deficient cancer
      cells grew poorly when transplanted in syngeneic mice. The inactivation of MMR
      increased the mutational burden and led to dynamic mutational profiles, which
      resulted in the persistent renewal of neoantigens in vitro and in vivo, whereas
      MMR-proficient cells exhibited stable mutational load and neoantigen profiles
      over time. Immune surveillance improved when cancer cells, in which MLH1 had been
      inactivated, accumulated neoantigens for several generations. When restricted to 
      a clonal population, the dynamic generation of neoantigens driven by MMR further 
      increased immune surveillance. Inactivation of MMR, driven by acquired resistance
      to the clinical agent temozolomide, increased mutational load, promoted
      continuous renewal of neoantigens in human colorectal cancers and triggered
      immune surveillance in mouse models. These results suggest that targeting DNA
      repair processes can increase the burden of neoantigens in tumour cells; this has
      the potential to be exploited in therapeutic approaches.
FAU - Germano, Giovanni
AU  - Germano G
AD  - Candiolo Cancer Institute - FPO, IRCCS, Candiolo 10060, Turin, Italy.
AD  - University of Turin, Department of Oncology, Candiolo 10060, Turin, Italy.
FAU - Lamba, Simona
AU  - Lamba S
AD  - Candiolo Cancer Institute - FPO, IRCCS, Candiolo 10060, Turin, Italy.
FAU - Rospo, Giuseppe
AU  - Rospo G
AD  - Candiolo Cancer Institute - FPO, IRCCS, Candiolo 10060, Turin, Italy.
FAU - Barault, Ludovic
AU  - Barault L
AD  - Candiolo Cancer Institute - FPO, IRCCS, Candiolo 10060, Turin, Italy.
AD  - University of Turin, Department of Oncology, Candiolo 10060, Turin, Italy.
FAU - Magri, Alessandro
AU  - Magri A
AD  - Candiolo Cancer Institute - FPO, IRCCS, Candiolo 10060, Turin, Italy.
AD  - University of Turin, Department of Oncology, Candiolo 10060, Turin, Italy.
FAU - Maione, Federica
AU  - Maione F
AD  - Candiolo Cancer Institute - FPO, IRCCS, Candiolo 10060, Turin, Italy.
FAU - Russo, Mariangela
AU  - Russo M
AD  - Candiolo Cancer Institute - FPO, IRCCS, Candiolo 10060, Turin, Italy.
AD  - University of Turin, Department of Oncology, Candiolo 10060, Turin, Italy.
FAU - Crisafulli, Giovanni
AU  - Crisafulli G
AD  - Candiolo Cancer Institute - FPO, IRCCS, Candiolo 10060, Turin, Italy.
AD  - University of Turin, Department of Oncology, Candiolo 10060, Turin, Italy.
FAU - Bartolini, Alice
AU  - Bartolini A
AD  - Candiolo Cancer Institute - FPO, IRCCS, Candiolo 10060, Turin, Italy.
FAU - Lerda, Giulia
AU  - Lerda G
AD  - Candiolo Cancer Institute - FPO, IRCCS, Candiolo 10060, Turin, Italy.
AD  - University of Turin, Department of Oncology, Candiolo 10060, Turin, Italy.
FAU - Siravegna, Giulia
AU  - Siravegna G
AD  - Candiolo Cancer Institute - FPO, IRCCS, Candiolo 10060, Turin, Italy.
AD  - University of Turin, Department of Oncology, Candiolo 10060, Turin, Italy.
FAU - Mussolin, Benedetta
AU  - Mussolin B
AD  - Candiolo Cancer Institute - FPO, IRCCS, Candiolo 10060, Turin, Italy.
FAU - Frapolli, Roberta
AU  - Frapolli R
AD  - IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan 20156, Italy.
FAU - Montone, Monica
AU  - Montone M
AD  - Candiolo Cancer Institute - FPO, IRCCS, Candiolo 10060, Turin, Italy.
FAU - Morano, Federica
AU  - Morano F
AD  - Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori,
      Milan 20133, Italy.
FAU - de Braud, Filippo
AU  - de Braud F
AD  - Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori,
      Milan 20133, Italy.
AD  - Department of Oncology and Hemat-Oncology Universita degli Studi di Milano, Milan
      20122, Italy.
FAU - Amirouchene-Angelozzi, Nabil
AU  - Amirouchene-Angelozzi N
AD  - Candiolo Cancer Institute - FPO, IRCCS, Candiolo 10060, Turin, Italy.
AD  - FIRC Institute of Molecular Oncology (IFOM), Milan 20139, Italy.
FAU - Marsoni, Silvia
AU  - Marsoni S
AD  - Candiolo Cancer Institute - FPO, IRCCS, Candiolo 10060, Turin, Italy.
FAU - D'Incalci, Maurizio
AU  - D'Incalci M
AD  - IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan 20156, Italy.
FAU - Orlandi, Armando
AU  - Orlandi A
AD  - Policlinico Universitario A. Gemelli, Roma 00168, Italy.
FAU - Giraudo, Enrico
AU  - Giraudo E
AD  - Candiolo Cancer Institute - FPO, IRCCS, Candiolo 10060, Turin, Italy.
AD  - University of Torino, Department of Science and Drug Technology, Turin 10125,
      Italy.
FAU - Sartore-Bianchi, Andrea
AU  - Sartore-Bianchi A
AD  - Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan 20142,
      Italy.
FAU - Siena, Salvatore
AU  - Siena S
AD  - Department of Oncology and Hemat-Oncology Universita degli Studi di Milano, Milan
      20122, Italy.
AD  - Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan 20142,
      Italy.
FAU - Pietrantonio, Filippo
AU  - Pietrantonio F
AD  - Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori,
      Milan 20133, Italy.
FAU - Di Nicolantonio, Federica
AU  - Di Nicolantonio F
AD  - Candiolo Cancer Institute - FPO, IRCCS, Candiolo 10060, Turin, Italy.
AD  - University of Turin, Department of Oncology, Candiolo 10060, Turin, Italy.
FAU - Bardelli, Alberto
AU  - Bardelli A
AD  - Candiolo Cancer Institute - FPO, IRCCS, Candiolo 10060, Turin, Italy.
AD  - University of Turin, Department of Oncology, Candiolo 10060, Turin, Italy.
LA  - eng
PT  - Journal Article
DEP - 20171129
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
EDAT- 2017/12/01 06:00
MHDA- 2017/12/01 06:00
CRDT- 2017/11/30 06:00
PHST- 2016/05/03 00:00 [received]
PHST- 2017/10/19 00:00 [accepted]
PHST- 2017/12/01 06:00 [pubmed]
PHST- 2017/12/01 06:00 [medline]
PHST- 2017/11/30 06:00 [entrez]
AID - nature24673 [pii]
AID - 10.1038/nature24673 [doi]
PST - ppublish
SO  - Nature. 2017 Dec 7;552(7683):116-120. doi: 10.1038/nature24673. Epub 2017 Nov 29.

PMID- 29245005
OWN - NLM
STAT- MEDLINE
DCOM- 20171228
LR  - 20171228
IS  - 1097-4172 (Electronic)
IS  - 0092-8674 (Linking)
VI  - 171
IP  - 7
DP  - 2017 Dec 14
TI  - CD19 CAR T Cells.
PG  - 1471
LID - S0092-8674(17)31444-7 [pii]
LID - 10.1016/j.cell.2017.12.002 [doi]
AB  - CARs are synthetic receptors that reprogram immune cells for therapeutic
      purposes. They comprise three canonical domains for antigen recognition, T cell
      activation, and costimulation. The CAR cDNA is genetically integrated in the T
      cell genome. Autologous CAR T cells are generated from the patient's peripheral
      blood T cells and expand in the recipient to eliminate the targeted tumor. To
      view this Bench to Bedside, open or download the PDF.
CI  - Copyright (c) 2017. Published by Elsevier Inc.
FAU - Sadelain, Michel
AU  - Sadelain M
AD  - Center for Cell Engineering, Memorial Sloan Kettering Cancer Center (MSKCC), New 
      York, NY 10065, USA. Electronic address: m-sadelain@ski.mskcc.org.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cell
JT  - Cell
JID - 0413066
RN  - 0 (Antigens, CD19)
RN  - 0 (Receptors, Antigen, T-Cell)
SB  - IM
MH  - Antigens, CD19/immunology
MH  - Autografts
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Lymphocyte Activation
MH  - Precursor Cell Lymphoblastic Leukemia-Lymphoma/*immunology/*therapy
MH  - Receptors, Antigen, T-Cell/immunology
MH  - T-Lymphocytes/*immunology
EDAT- 2017/12/16 06:00
MHDA- 2017/12/29 06:00
CRDT- 2017/12/16 06:00
PHST- 2017/12/16 06:00 [entrez]
PHST- 2017/12/16 06:00 [pubmed]
PHST- 2017/12/29 06:00 [medline]
AID - S0092-8674(17)31444-7 [pii]
AID - 10.1016/j.cell.2017.12.002 [doi]
PST - ppublish
SO  - Cell. 2017 Dec 14;171(7):1471. doi: 10.1016/j.cell.2017.12.002.

PMID- 29035371
OWN - NLM
STAT- MEDLINE
DCOM- 20171226
LR  - 20171226
IS  - 1546-170X (Electronic)
IS  - 1078-8956 (Linking)
VI  - 23
IP  - 11
DP  - 2017 Nov
TI  - lncRNA MIR100HG-derived miR-100 and miR-125b mediate cetuximab resistance via
      Wnt/beta-catenin signaling.
PG  - 1331-1341
LID - 10.1038/nm.4424 [doi]
AB  - De novo and acquired resistance, which are largely attributed to genetic
      alterations, are barriers to effective anti-epidermal-growth-factor-receptor
      (EGFR) therapy. To generate cetuximab-resistant cells, we exposed
      cetuximab-sensitive colorectal cancer cells to cetuximab in three-dimensional
      culture. Using whole-exome sequencing and transcriptional profiling, we found
      that the long non-coding RNA MIR100HG and two embedded microRNAs, miR-100 and
      miR-125b, were overexpressed in the absence of known genetic events linked to
      cetuximab resistance. MIR100HG, miR-100 and miR-125b overexpression was also
      observed in cetuximab-resistant colorectal cancer and head and neck squamous cell
      cancer cell lines and in tumors from colorectal cancer patients that progressed
      on cetuximab. miR-100 and miR-125b coordinately repressed five Wnt/beta-catenin
      negative regulators, resulting in increased Wnt signaling, and Wnt inhibition in 
      cetuximab-resistant cells restored cetuximab responsiveness. Our results describe
      a double-negative feedback loop between MIR100HG and the transcription factor
      GATA6, whereby GATA6 represses MIR100HG, but this repression is relieved by
      miR-125b targeting of GATA6. These findings identify a clinically actionable,
      epigenetic cause of cetuximab resistance.
FAU - Lu, Yuanyuan
AU  - Lu Y
AD  - Department of Medicine, Vanderbilt University Medical Center, Nashville,
      Tennessee, USA.
AD  - State Key Laboratory of Cancer Biology, National Clinical Research Center for
      Digestive Diseases and Xijing Hospital of Digestive Diseases, Fourth Military
      Medical University, Xi'an, China.
FAU - Zhao, Xiaodi
AU  - Zhao X
AUID- ORCID: http://orcid.org/0000-0002-1817-803X
AD  - Department of Medicine, Vanderbilt University Medical Center, Nashville,
      Tennessee, USA.
AD  - State Key Laboratory of Cancer Biology, National Clinical Research Center for
      Digestive Diseases and Xijing Hospital of Digestive Diseases, Fourth Military
      Medical University, Xi'an, China.
FAU - Liu, Qi
AU  - Liu Q
AD  - Department of Biomedical Informatics and Center for Quantitative Sciences,
      Vanderbilt University Medical Center, Nashville, Tennessee, USA.
FAU - Li, Cunxi
AU  - Li C
AD  - Jiaen Genetics Laboratory, Beijing Jiaen Hospital, Beijing, China, and Molecular 
      Pathology, Cancer Research Center, Medical College of Xiamen University, Xiamen, 
      China.
FAU - Graves-Deal, Ramona
AU  - Graves-Deal R
AD  - Department of Medicine, Vanderbilt University Medical Center, Nashville,
      Tennessee, USA.
FAU - Cao, Zheng
AU  - Cao Z
AD  - Department of Medicine, Vanderbilt University Medical Center, Nashville,
      Tennessee, USA.
FAU - Singh, Bhuminder
AU  - Singh B
AD  - Department of Medicine, Vanderbilt University Medical Center, Nashville,
      Tennessee, USA.
FAU - Franklin, Jeffrey L
AU  - Franklin JL
AD  - Department of Medicine, Vanderbilt University Medical Center, Nashville,
      Tennessee, USA.
FAU - Wang, Jing
AU  - Wang J
AD  - Department of Biomedical Informatics and Center for Quantitative Sciences,
      Vanderbilt University Medical Center, Nashville, Tennessee, USA.
FAU - Hu, Huaying
AU  - Hu H
AD  - Jiaen Genetics Laboratory, Beijing Jiaen Hospital, Beijing, China, and Molecular 
      Pathology, Cancer Research Center, Medical College of Xiamen University, Xiamen, 
      China.
FAU - Wei, Tianying
AU  - Wei T
AD  - Jiaen Genetics Laboratory, Beijing Jiaen Hospital, Beijing, China, and Molecular 
      Pathology, Cancer Research Center, Medical College of Xiamen University, Xiamen, 
      China.
FAU - Yang, Mingli
AU  - Yang M
AD  - Gibbs Cancer Center & Research Institute, Spartanburg, South Carolina, USA.
FAU - Yeatman, Timothy J
AU  - Yeatman TJ
AD  - Gibbs Cancer Center & Research Institute, Spartanburg, South Carolina, USA.
FAU - Lee, Ethan
AU  - Lee E
AD  - Department of Cell and Developmental Biology and Vanderbilt Ingram Cancer Center,
      Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
FAU - Saito-Diaz, Kenyi
AU  - Saito-Diaz K
AD  - Department of Cell and Developmental Biology and Vanderbilt Ingram Cancer Center,
      Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
FAU - Hinger, Scott
AU  - Hinger S
AD  - Department of Biological Sciences, Vanderbilt University School of Medicine,
      Nashville, Tennessee, USA.
FAU - Patton, James G
AU  - Patton JG
AD  - Department of Biological Sciences, Vanderbilt University School of Medicine,
      Nashville, Tennessee, USA.
FAU - Chung, Christine H
AU  - Chung CH
AD  - Moffitt Cancer Center & Research Institute, Tampa, Florida, USA.
FAU - Emmrich, Stephan
AU  - Emmrich S
AD  - Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany.
FAU - Klusmann, Jan-Henning
AU  - Klusmann JH
AD  - Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany.
FAU - Fan, Daiming
AU  - Fan D
AD  - State Key Laboratory of Cancer Biology, National Clinical Research Center for
      Digestive Diseases and Xijing Hospital of Digestive Diseases, Fourth Military
      Medical University, Xi'an, China.
FAU - Coffey, Robert J
AU  - Coffey RJ
AUID- ORCID: http://orcid.org/0000-0002-2180-3844
AD  - Department of Medicine, Vanderbilt University Medical Center, Nashville,
      Tennessee, USA.
AD  - Department of Veterans Affairs Medical Center, Nashville, Tennessee, USA.
LA  - eng
PT  - Journal Article
DEP - 20171016
PL  - United States
TA  - Nat Med
JT  - Nature medicine
JID - 9502015
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - 0 (GATA6 Transcription Factor)
RN  - 0 (GATA6 protein, human)
RN  - 0 (MIRN100 microRNA, human)
RN  - 0 (MIRN1260 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (RNA, Long Noncoding)
RN  - 0 (Wnt Proteins)
RN  - 0 (beta Catenin)
RN  - PQX0D8J21J (Cetuximab)
SB  - IM
MH  - Antineoplastic Agents, Immunological/*pharmacology
MH  - Cell Line, Tumor
MH  - Cetuximab/*pharmacology
MH  - Disease Progression
MH  - Drug Resistance, Neoplasm/*genetics
MH  - Epigenesis, Genetic
MH  - GATA6 Transcription Factor/metabolism
MH  - Humans
MH  - MicroRNAs/*genetics
MH  - RNA, Long Noncoding/*genetics
MH  - *Signal Transduction
MH  - Wnt Proteins/metabolism
MH  - beta Catenin/*metabolism
EDAT- 2017/10/17 06:00
MHDA- 2017/12/27 06:00
CRDT- 2017/10/17 06:00
PHST- 2016/12/08 00:00 [received]
PHST- 2017/09/08 00:00 [accepted]
PHST- 2017/10/17 06:00 [pubmed]
PHST- 2017/12/27 06:00 [medline]
PHST- 2017/10/17 06:00 [entrez]
AID - nm.4424 [pii]
AID - 10.1038/nm.4424 [doi]
PST - ppublish
SO  - Nat Med. 2017 Nov;23(11):1331-1341. doi: 10.1038/nm.4424. Epub 2017 Oct 16.

PMID- 29132144
OWN - NLM
STAT- In-Data-Review
LR  - 20171219
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 551
IP  - 7681
DP  - 2017 Nov 23
TI  - A neoantigen fitness model predicts tumour response to checkpoint blockade
      immunotherapy.
PG  - 517-520
LID - 10.1038/nature24473 [doi]
AB  - Checkpoint blockade immunotherapies enable the host immune system to recognize
      and destroy tumour cells. Their clinical activity has been correlated with
      activated T-cell recognition of neoantigens, which are tumour-specific, mutated
      peptides presented on the surface of cancer cells. Here we present a fitness
      model for tumours based on immune interactions of neoantigens that predicts
      response to immunotherapy. Two main factors determine neoantigen fitness: the
      likelihood of neoantigen presentation by the major histocompatibility complex
      (MHC) and subsequent recognition by T cells. We estimate these components using
      the relative MHC binding affinity of each neoantigen to its wild type and a
      nonlinear dependence on sequence similarity of neoantigens to known antigens. To 
      describe the evolution of a heterogeneous tumour, we evaluate its fitness as a
      weighted effect of dominant neoantigens in the subclones of the tumour. Our model
      predicts survival in anti-CTLA-4-treated patients with melanoma and
      anti-PD-1-treated patients with lung cancer. Importantly, low-fitness neoantigens
      identified by our method may be leveraged for developing novel immunotherapies.
      By using an immune fitness model to study immunotherapy, we reveal broad
      similarities between the evolution of tumours and rapidly evolving pathogens.
FAU - Luksza, Marta
AU  - Luksza M
AD  - The Simons Center for Systems Biology, Institute for Advanced Study, Princeton,
      New Jersey, USA.
FAU - Riaz, Nadeem
AU  - Riaz N
AD  - Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New
      York, New York, USA.
AD  - Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer
      Center, New York, New York, USA.
FAU - Makarov, Vladimir
AU  - Makarov V
AD  - Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer
      Center, New York, New York, USA.
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, New York, USA.
FAU - Balachandran, Vinod P
AU  - Balachandran VP
AD  - Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New
      York, USA.
AD  - David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan
      Kettering Cancer Center, New York, New York, USA.
AD  - Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer
      Center, New York, New York, USA.
FAU - Hellmann, Matthew D
AU  - Hellmann MD
AD  - Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer
      Center, New York, New York, USA.
AD  - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New
      York, USA.
AD  - Department of Medicine, Weill Cornell Medical College, Cornell University, New
      York, New York, USA.
FAU - Solovyov, Alexander
AU  - Solovyov A
AD  - Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New
      York, USA.
AD  - Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine
      at Mount Sinai, New York, New York, USA.
AD  - Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New 
      York, New York, USA.
AD  - Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, New
      York, USA.
FAU - Rizvi, Naiyer A
AU  - Rizvi NA
AD  - Department of Medicine, Columbia University Medical Center, New York, New York,
      USA.
FAU - Merghoub, Taha
AU  - Merghoub T
AD  - Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer
      Center, New York, New York, USA.
AD  - Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering
      Cancer Center, New York, New York, USA.
AD  - Melanoma and Immunotherapeutics Service, Department of Medicine, Memorial Sloan
      Kettering Cancer Center, New York, New York, USA.
FAU - Levine, Arnold J
AU  - Levine AJ
AD  - The Simons Center for Systems Biology, Institute for Advanced Study, Princeton,
      New Jersey, USA.
FAU - Chan, Timothy A
AU  - Chan TA
AD  - Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New
      York, New York, USA.
AD  - Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer
      Center, New York, New York, USA.
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, New York, USA.
AD  - Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer
      Center, New York, New York, USA.
FAU - Wolchok, Jedd D
AU  - Wolchok JD
AD  - Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer
      Center, New York, New York, USA.
AD  - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New
      York, USA.
AD  - Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering
      Cancer Center, New York, New York, USA.
AD  - Melanoma and Immunotherapeutics Service, Department of Medicine, Memorial Sloan
      Kettering Cancer Center, New York, New York, USA.
FAU - Greenbaum, Benjamin D
AU  - Greenbaum BD
AD  - Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New
      York, USA.
AD  - Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine
      at Mount Sinai, New York, New York, USA.
AD  - Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New 
      York, New York, USA.
AD  - Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, New
      York, USA.
LA  - eng
PT  - Journal Article
DEP - 20171108
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
EDAT- 2017/11/14 06:00
MHDA- 2017/11/14 06:00
CRDT- 2017/11/14 06:00
PHST- 2017/01/22 00:00 [received]
PHST- 2017/10/09 00:00 [accepted]
PHST- 2017/11/14 06:00 [pubmed]
PHST- 2017/11/14 06:00 [medline]
PHST- 2017/11/14 06:00 [entrez]
AID - nature24473 [pii]
AID - 10.1038/nature24473 [doi]
PST - ppublish
SO  - Nature. 2017 Nov 23;551(7681):517-520. doi: 10.1038/nature24473. Epub 2017 Nov 8.

PMID- 29046434
OWN - NLM
STAT- In-Process
LR  - 20171019
IS  - 1946-6242 (Electronic)
IS  - 1946-6234 (Linking)
VI  - 9
IP  - 412
DP  - 2017 Oct 18
TI  - Aristolochic acids and their derivatives are widely implicated in liver cancers
      in Taiwan and throughout Asia.
LID - eaan6446 [pii]
LID - 10.1126/scitranslmed.aan6446 [doi]
AB  - Many traditional pharmacopeias include Aristolochia and related plants, which
      contain nephrotoxins and mutagens in the form of aristolochic acids and similar
      compounds (collectively, AA). AA is implicated in multiple cancer types,
      sometimes with very high mutational burdens, especially in upper tract urothelial
      cancers (UTUCs). AA-associated kidney failure and UTUCs are prevalent in Taiwan, 
      but AA's role in hepatocellular carcinomas (HCCs) there remains unexplored.
      Therefore, we sequenced the whole exomes of 98 HCCs from two hospitals in Taiwan 
      and found that 78% showed the distinctive mutational signature of AA exposure,
      accounting for most of the nonsilent mutations in known cancer driver genes. We
      then searched for the AA signature in 1400 HCCs from diverse geographic regions. 
      Consistent with exposure through known herbal medicines, 47% of Chinese HCCs
      showed the signature, albeit with lower mutation loads than in Taiwan. In
      addition, 29% of HCCs from Southeast Asia showed the signature. The AA signature 
      was also detected in 13 and 2.7% of HCCs from Korea and Japan as well as in 4.8
      and 1.7% of HCCs from North America and Europe, respectively, excluding one U.S. 
      hospital where 22% of 87 "Asian" HCCs had the signature. Thus, AA exposure is
      geographically widespread. Asia, especially Taiwan, appears to be much more
      extensively affected, which is consistent with other evidence of patterns of AA
      exposure. We propose that additional measures aimed at primary prevention through
      avoidance of AA exposure and investigation of possible approaches to secondary
      prevention are warranted.
CI  - Copyright (c) 2017 The Authors, some rights reserved; exclusive licensee American
      Association for the Advancement of Science. No claim to original U.S. Government 
      Works.
FAU - Ng, Alvin W T
AU  - Ng AWT
AUID- ORCID: http://orcid.org/0000-0003-4672-0815
AD  - Centre for Computational Biology, Duke-NUS Medical School, Singapore 169857,
      Singapore.
AD  - Programme in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore
      169857, Singapore.
AD  - NUS Graduate School for Integrative Sciences and Engineering, Singapore 117456,
      Singapore.
FAU - Poon, Song Ling
AU  - Poon SL
AUID- ORCID: http://orcid.org/0000-0001-6906-3497
AD  - Laboratory of Cancer Epigenome, Division of Medical Science, National Cancer
      Centre Singapore, Singapore 169610, Singapore.
FAU - Huang, Mi Ni
AU  - Huang MN
AD  - Centre for Computational Biology, Duke-NUS Medical School, Singapore 169857,
      Singapore.
AD  - Programme in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore
      169857, Singapore.
FAU - Lim, Jing Quan
AU  - Lim JQ
AUID- ORCID: http://orcid.org/0000-0003-3732-8707
AD  - Laboratory of Cancer Epigenome, Division of Medical Science, National Cancer
      Centre Singapore, Singapore 169610, Singapore.
AD  - Lymphoma Genomic Translational Research Laboratory, Division of Medical Oncology,
      National Cancer Centre Singapore, Singapore 169610, Singapore.
FAU - Boot, Arnoud
AU  - Boot A
AUID- ORCID: http://orcid.org/0000-0002-7717-7416
AD  - Centre for Computational Biology, Duke-NUS Medical School, Singapore 169857,
      Singapore.
AD  - Programme in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore
      169857, Singapore.
FAU - Yu, Willie
AU  - Yu W
AUID- ORCID: http://orcid.org/0000-0002-1230-3426
AD  - Centre for Computational Biology, Duke-NUS Medical School, Singapore 169857,
      Singapore.
AD  - Programme in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore
      169857, Singapore.
FAU - Suzuki, Yuka
AU  - Suzuki Y
AUID- ORCID: http://orcid.org/0000-0002-5688-5472
AD  - Centre for Computational Biology, Duke-NUS Medical School, Singapore 169857,
      Singapore.
AD  - Programme in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore
      169857, Singapore.
FAU - Thangaraju, Saranya
AU  - Thangaraju S
AUID- ORCID: http://orcid.org/0000-0003-4952-2902
AD  - Laboratory of Cancer Epigenome, Division of Medical Science, National Cancer
      Centre Singapore, Singapore 169610, Singapore.
FAU - Ng, Cedric C Y
AU  - Ng CCY
AUID- ORCID: http://orcid.org/0000-0002-7150-4674
AD  - Laboratory of Cancer Epigenome, Division of Medical Science, National Cancer
      Centre Singapore, Singapore 169610, Singapore.
FAU - Tan, Patrick
AU  - Tan P
AD  - Programme in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore
      169857, Singapore.
AD  - Cancer Science Institute of Singapore, National University of Singapore,
      Singapore 117599, Singapore.
AD  - SingHealth/Duke-NUS Precision Medicine Institute, Singapore 169609, Singapore.
AD  - Genome Institute of Singapore, Singapore 138672, Singapore.
FAU - Pang, See-Tong
AU  - Pang ST
AD  - Division of Urooncology, Department of Urology, Chang Gung University and
      Memorial Hospital, Linkou, Taoyuan 33305, Taiwan.
FAU - Huang, Hao-Yi
AU  - Huang HY
AD  - Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital,
      Linkou, Taoyuan 33305, Taiwan.
FAU - Yu, Ming-Chin
AU  - Yu MC
AUID- ORCID: http://orcid.org/0000-0002-6980-7123
AD  - Department of General Surgery, Chang Gung Memorial Hospital, Linkou, Taoyuan
      33305, Taiwan.
FAU - Lee, Po-Huang
AU  - Lee PH
AD  - Department of Surgery, National Taiwan University, Taipei 10051, Taiwan.
FAU - Hsieh, Sen-Yung
AU  - Hsieh SY
AUID- ORCID: http://orcid.org/0000-0002-1723-7261
AD  - Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital,
      Linkou, Taoyuan 33305, Taiwan. siming.shia@msa.hinet.net alexchang@imc.jhmi.edu
      teh.bin.tean@singhealth.com.sg steve.rozen@duke-nus.edu.sg.
FAU - Chang, Alex Y
AU  - Chang AY
AUID- ORCID: http://orcid.org/0000-0002-9578-0323
AD  - Johns Hopkins Singapore, Singapore 308433, Singapore. siming.shia@msa.hinet.net
      alexchang@imc.jhmi.edu teh.bin.tean@singhealth.com.sg
      steve.rozen@duke-nus.edu.sg.
FAU - Teh, Bin T
AU  - Teh BT
AUID- ORCID: http://orcid.org/0000-0003-1514-1124
AD  - Programme in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore
      169857, Singapore. siming.shia@msa.hinet.net alexchang@imc.jhmi.edu
      teh.bin.tean@singhealth.com.sg steve.rozen@duke-nus.edu.sg.
AD  - Laboratory of Cancer Epigenome, Division of Medical Science, National Cancer
      Centre Singapore, Singapore 169610, Singapore.
AD  - SingHealth/Duke-NUS Precision Medicine Institute, Singapore 169609, Singapore.
AD  - Institute of Molecular and Cell Biology, Singapore 138673, Singapore.
FAU - Rozen, Steven G
AU  - Rozen SG
AUID- ORCID: http://orcid.org/0000-0002-4288-0056
AD  - Centre for Computational Biology, Duke-NUS Medical School, Singapore 169857,
      Singapore. siming.shia@msa.hinet.net alexchang@imc.jhmi.edu
      teh.bin.tean@singhealth.com.sg steve.rozen@duke-nus.edu.sg.
AD  - Programme in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore
      169857, Singapore.
AD  - NUS Graduate School for Integrative Sciences and Engineering, Singapore 117456,
      Singapore.
AD  - SingHealth/Duke-NUS Precision Medicine Institute, Singapore 169609, Singapore.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Sci Transl Med
JT  - Science translational medicine
JID - 101505086
EDAT- 2017/10/20 06:00
MHDA- 2017/10/20 06:00
CRDT- 2017/10/20 06:00
PHST- 2017/05/12 00:00 [received]
PHST- 2017/07/31 00:00 [revised]
PHST- 2017/09/25 00:00 [accepted]
PHST- 2017/10/20 06:00 [entrez]
PHST- 2017/10/20 06:00 [pubmed]
PHST- 2017/10/20 06:00 [medline]
AID - 9/412/eaan6446 [pii]
AID - 10.1126/scitranslmed.aan6446 [doi]
PST - ppublish
SO  - Sci Transl Med. 2017 Oct 18;9(412). pii: 9/412/eaan6446. doi:
      10.1126/scitranslmed.aan6446.

PMID- 29195078
OWN - NLM
STAT- MEDLINE
DCOM- 20171222
LR  - 20171222
IS  - 1097-4172 (Electronic)
IS  - 0092-8674 (Linking)
VI  - 171
IP  - 6
DP  - 2017 Nov 30
TI  - A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000
      Profiles.
PG  - 1437-1452.e17
LID - S0092-8674(17)31309-0 [pii]
LID - 10.1016/j.cell.2017.10.049 [doi]
AB  - We previously piloted the concept of a Connectivity Map (CMap), whereby genes,
      drugs, and disease states are connected by virtue of common gene-expression
      signatures. Here, we report more than a 1,000-fold scale-up of the CMap as part
      of the NIH LINCS Consortium, made possible by a new, low-cost, high-throughput
      reduced representation expression profiling method that we term L1000. We show
      that L1000 is highly reproducible, comparable to RNA sequencing, and suitable for
      computational inference of the expression levels of 81% of non-measured
      transcripts. We further show that the expanded CMap can be used to discover
      mechanism of action of small molecules, functionally annotate genetic variants of
      disease genes, and inform clinical trials. The 1.3 million L1000 profiles
      described here, as well as tools for their analysis, are available at
      https://clue.io.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Subramanian, Aravind
AU  - Subramanian A
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Narayan, Rajiv
AU  - Narayan R
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Corsello, Steven M
AU  - Corsello SM
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of
      Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard
      Medical School, Boston, MA 02115, USA.
FAU - Peck, David D
AU  - Peck DD
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Natoli, Ted E
AU  - Natoli TE
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Lu, Xiaodong
AU  - Lu X
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Gould, Joshua
AU  - Gould J
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Davis, John F
AU  - Davis JF
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Tubelli, Andrew A
AU  - Tubelli AA
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Asiedu, Jacob K
AU  - Asiedu JK
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Lahr, David L
AU  - Lahr DL
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Hirschman, Jodi E
AU  - Hirschman JE
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Liu, Zihan
AU  - Liu Z
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Donahue, Melanie
AU  - Donahue M
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Julian, Bina
AU  - Julian B
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Khan, Mariya
AU  - Khan M
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Wadden, David
AU  - Wadden D
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Smith, Ian C
AU  - Smith IC
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Lam, Daniel
AU  - Lam D
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Liberzon, Arthur
AU  - Liberzon A
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Toder, Courtney
AU  - Toder C
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Bagul, Mukta
AU  - Bagul M
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Orzechowski, Marek
AU  - Orzechowski M
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Enache, Oana M
AU  - Enache OM
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Piccioni, Federica
AU  - Piccioni F
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Johnson, Sarah A
AU  - Johnson SA
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Lyons, Nicholas J
AU  - Lyons NJ
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Berger, Alice H
AU  - Berger AH
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of
      Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard
      Medical School, Boston, MA 02115, USA.
FAU - Shamji, Alykhan F
AU  - Shamji AF
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Brooks, Angela N
AU  - Brooks AN
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of
      Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard
      Medical School, Boston, MA 02115, USA.
FAU - Vrcic, Anita
AU  - Vrcic A
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Flynn, Corey
AU  - Flynn C
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Rosains, Jacqueline
AU  - Rosains J
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Takeda, David Y
AU  - Takeda DY
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of
      Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard
      Medical School, Boston, MA 02115, USA.
FAU - Hu, Roger
AU  - Hu R
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Davison, Desiree
AU  - Davison D
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Lamb, Justin
AU  - Lamb J
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Ardlie, Kristin
AU  - Ardlie K
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Hogstrom, Larson
AU  - Hogstrom L
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Greenside, Peyton
AU  - Greenside P
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Gray, Nathanael S
AU  - Gray NS
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard Medical
      School, Boston, MA 02115, USA; Department of Cancer Biology, Dana-Farber Cancer
      Institute, Boston, MA 02215, USA.
FAU - Clemons, Paul A
AU  - Clemons PA
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Silver, Serena
AU  - Silver S
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Wu, Xiaoyun
AU  - Wu X
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Zhao, Wen-Ning
AU  - Zhao WN
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard Medical
      School, Boston, MA 02115, USA; Department of Neurology, Massachusetts General
      Hospital, Boston, MA 02114, USA.
FAU - Read-Button, Willis
AU  - Read-Button W
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Wu, Xiaohua
AU  - Wu X
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Haggarty, Stephen J
AU  - Haggarty SJ
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard Medical
      School, Boston, MA 02115, USA; Department of Neurology, Massachusetts General
      Hospital, Boston, MA 02114, USA.
FAU - Ronco, Lucienne V
AU  - Ronco LV
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Boehm, Jesse S
AU  - Boehm JS
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Schreiber, Stuart L
AU  - Schreiber SL
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of
      Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138, USA;
      Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.
FAU - Doench, John G
AU  - Doench JG
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Bittker, Joshua A
AU  - Bittker JA
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Root, David E
AU  - Root DE
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Wong, Bang
AU  - Wong B
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
FAU - Golub, Todd R
AU  - Golub TR
AD  - Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard Medical
      School, Boston, MA 02115, USA; Howard Hughes Medical Institute, Chevy Chase, MD
      20815, USA; Department of Pediatric Oncology, Dana-Farber Cancer Institute,
      Boston, MA 02215, USA. Electronic address: golub@broadinstitute.org.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cell
JT  - Cell
JID - 0413066
RN  - 0 (Pharmaceutical Preparations)
RN  - 0 (Small Molecule Libraries)
SB  - IM
MH  - Cell Line, Tumor
MH  - Drug Resistance, Neoplasm
MH  - Gene Expression Profiling/economics/*methods
MH  - Humans
MH  - Neoplasms/drug therapy
MH  - Organ Specificity
MH  - Pharmaceutical Preparations/metabolism
MH  - Sequence Analysis, RNA/economics/methods
MH  - Small Molecule Libraries
OTO - NOTNLM
OT  - Functional genomics
OT  - chemical biology
OT  - gene expression profiling
EDAT- 2017/12/02 06:00
MHDA- 2017/12/23 06:00
CRDT- 2017/12/02 06:00
PHST- 2017/05/09 00:00 [received]
PHST- 2017/07/25 00:00 [revised]
PHST- 2017/10/27 00:00 [accepted]
PHST- 2017/12/02 06:00 [entrez]
PHST- 2017/12/02 06:00 [pubmed]
PHST- 2017/12/23 06:00 [medline]
AID - S0092-8674(17)31309-0 [pii]
AID - 10.1016/j.cell.2017.10.049 [doi]
PST - ppublish
SO  - Cell. 2017 Nov 30;171(6):1437-1452.e17. doi: 10.1016/j.cell.2017.10.049.

PMID- 29045388
OWN - NLM
STAT- In-Data-Review
LR  - 20171219
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 550
IP  - 7677
DP  - 2017 Oct 26
TI  - Inflammatory memory sensitizes skin epithelial stem cells to tissue damage.
PG  - 475-480
LID - 10.1038/nature24271 [doi]
AB  - The skin barrier is the body's first line of defence against environmental
      assaults, and is maintained by epithelial stem cells (EpSCs). Despite the
      vulnerability of EpSCs to inflammatory pressures, neither the primary response to
      inflammation nor its enduring consequences are well understood. Here we report a 
      prolonged memory to acute inflammation that enables mouse EpSCs to hasten barrier
      restoration after subsequent tissue damage. This functional adaptation does not
      require skin-resident macrophages or T cells. Instead, EpSCs maintain chromosomal
      accessibility at key stress response genes that are activated by the primary
      stimulus. Upon a secondary challenge, genes governed by these domains are
      transcribed rapidly. Fuelling this memory is Aim2, which encodes an activator of 
      the inflammasome. The absence of AIM2 or its downstream effectors, caspase-1 and 
      interleukin-1beta, erases the ability of EpSCs to recollect inflammation.
      Although EpSCs benefit from inflammatory tuning by heightening their
      responsiveness to subsequent stressors, this enhanced sensitivity probably
      increases their susceptibility to autoimmune and hyperproliferative disorders,
      including cancer.
FAU - Naik, Shruti
AU  - Naik S
AD  - Robin Chemers Neustein Laboratory of Mammalian Cell Biology and Development,
      Howard Hughes Medical Institute, The Rockefeller University, New York, New York
      10065, USA.
FAU - Larsen, Samantha B
AU  - Larsen SB
AD  - Robin Chemers Neustein Laboratory of Mammalian Cell Biology and Development,
      Howard Hughes Medical Institute, The Rockefeller University, New York, New York
      10065, USA.
FAU - Gomez, Nicholas C
AU  - Gomez NC
AD  - Robin Chemers Neustein Laboratory of Mammalian Cell Biology and Development,
      Howard Hughes Medical Institute, The Rockefeller University, New York, New York
      10065, USA.
FAU - Alaverdyan, Kirill
AU  - Alaverdyan K
AD  - Robin Chemers Neustein Laboratory of Mammalian Cell Biology and Development,
      Howard Hughes Medical Institute, The Rockefeller University, New York, New York
      10065, USA.
FAU - Sendoel, Ataman
AU  - Sendoel A
AD  - Robin Chemers Neustein Laboratory of Mammalian Cell Biology and Development,
      Howard Hughes Medical Institute, The Rockefeller University, New York, New York
      10065, USA.
FAU - Yuan, Shaopeng
AU  - Yuan S
AD  - Robin Chemers Neustein Laboratory of Mammalian Cell Biology and Development,
      Howard Hughes Medical Institute, The Rockefeller University, New York, New York
      10065, USA.
FAU - Polak, Lisa
AU  - Polak L
AD  - Robin Chemers Neustein Laboratory of Mammalian Cell Biology and Development,
      Howard Hughes Medical Institute, The Rockefeller University, New York, New York
      10065, USA.
FAU - Kulukian, Anita
AU  - Kulukian A
AD  - Robin Chemers Neustein Laboratory of Mammalian Cell Biology and Development,
      Howard Hughes Medical Institute, The Rockefeller University, New York, New York
      10065, USA.
FAU - Chai, Sophia
AU  - Chai S
AD  - Robin Chemers Neustein Laboratory of Mammalian Cell Biology and Development,
      Howard Hughes Medical Institute, The Rockefeller University, New York, New York
      10065, USA.
FAU - Fuchs, Elaine
AU  - Fuchs E
AD  - Robin Chemers Neustein Laboratory of Mammalian Cell Biology and Development,
      Howard Hughes Medical Institute, The Rockefeller University, New York, New York
      10065, USA.
LA  - eng
GR  - R01 AR031737/AR/NIAMS NIH HHS/United States
GR  - R01 AR050452/AR/NIAMS NIH HHS/United States
PT  - Journal Article
DEP - 20171018
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
EDAT- 2017/10/19 06:00
MHDA- 2017/10/19 06:00
CRDT- 2017/10/19 06:00
PHST- 2016/12/29 00:00 [received]
PHST- 2017/09/14 00:00 [accepted]
PHST- 2017/10/19 06:00 [pubmed]
PHST- 2017/10/19 06:00 [medline]
PHST- 2017/10/19 06:00 [entrez]
AID - nature24271 [pii]
AID - 10.1038/nature24271 [doi]
PST - ppublish
SO  - Nature. 2017 Oct 26;550(7677):475-480. doi: 10.1038/nature24271. Epub 2017 Oct
      18.

PMID- 29056339
OWN - NLM
STAT- MEDLINE
DCOM- 20171215
LR  - 20171215
IS  - 1097-4172 (Electronic)
IS  - 0092-8674 (Linking)
VI  - 171
IP  - 5
DP  - 2017 Nov 16
TI  - Wild Mouse Gut Microbiota Promotes Host Fitness and Improves Disease Resistance.
PG  - 1015-1028.e13
LID - S0092-8674(17)31065-6 [pii]
LID - 10.1016/j.cell.2017.09.016 [doi]
AB  - Laboratory mice, while paramount for understanding basic biological phenomena,
      are limited in modeling complex diseases of humans and other free-living mammals.
      Because the microbiome is a major factor in mammalian physiology, we aimed to
      identify a naturally evolved reference microbiome to better recapitulate
      physiological phenomena relevant in the natural world outside the laboratory.
      Among 21 distinct mouse populations worldwide, we identified a closely related
      wild relative to standard laboratory mouse strains. Its bacterial gut microbiome 
      differed significantly from its laboratory mouse counterpart and was transferred 
      to and maintained in laboratory mice over several generations. Laboratory mice
      reconstituted with natural microbiota exhibited reduced inflammation and
      increased survival following influenza virus infection and improved resistance
      against mutagen/inflammation-induced colorectal tumorigenesis. By demonstrating
      the host fitness-promoting traits of natural microbiota, our findings should
      enable the discovery of protective mechanisms relevant in the natural world and
      improve the modeling of complex diseases of free-living mammals. VIDEO ABSTRACT.
CI  - Published by Elsevier Inc.
FAU - Rosshart, Stephan P
AU  - Rosshart SP
AD  - Immunology Section, Diseases Branch, National Institute of Diabetes and Digestive
      and Kidney Diseases, National Institutes of Health, DHHS, Bethesda, MD 20892,
      USA. Electronic address: stephanpatrick.rosshart@nih.gov.
FAU - Vassallo, Brian G
AU  - Vassallo BG
AD  - Immunology Section, Diseases Branch, National Institute of Diabetes and Digestive
      and Kidney Diseases, National Institutes of Health, DHHS, Bethesda, MD 20892,
      USA.
FAU - Angeletti, Davide
AU  - Angeletti D
AD  - Laboratory of Viral Diseases, National Institute of Allergy and Infectious
      Diseases, National Institutes of Health, DHHS, Bethesda, MD 20892, USA.
FAU - Hutchinson, Diane S
AU  - Hutchinson DS
AD  - Alkek Center for Metagenomics and Microbiome Research, Department of Molecular
      Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA.
FAU - Morgan, Andrew P
AU  - Morgan AP
AD  - Department of Genetics, Lineberger Comprehensive Cancer Center, The University of
      North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
FAU - Takeda, Kazuyo
AU  - Takeda K
AD  - Microscopy and Imaging Core Facility, Center for Biologics Evaluation and
      Research, Food and Drug Administration, Silver Spring, MD 20993-0002, USA.
FAU - Hickman, Heather D
AU  - Hickman HD
AD  - Laboratory of Viral Diseases, National Institute of Allergy and Infectious
      Diseases, National Institutes of Health, DHHS, Bethesda, MD 20892, USA.
FAU - McCulloch, John A
AU  - McCulloch JA
AD  - Cancer and Inflammation Program, Center for Cancer Research, National Cancer
      Institute, National Institutes of Health, DHHS, Bethesda, MD 20892, USA.
FAU - Badger, Jonathan H
AU  - Badger JH
AD  - Cancer and Inflammation Program, Center for Cancer Research, National Cancer
      Institute, National Institutes of Health, DHHS, Bethesda, MD 20892, USA.
FAU - Ajami, Nadim J
AU  - Ajami NJ
AD  - Alkek Center for Metagenomics and Microbiome Research, Department of Molecular
      Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA.
FAU - Trinchieri, Giorgio
AU  - Trinchieri G
AD  - Cancer and Inflammation Program, Center for Cancer Research, National Cancer
      Institute, National Institutes of Health, DHHS, Bethesda, MD 20892, USA.
FAU - Pardo-Manuel de Villena, Fernando
AU  - Pardo-Manuel de Villena F
AD  - Department of Genetics, Lineberger Comprehensive Cancer Center, The University of
      North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
FAU - Yewdell, Jonathan W
AU  - Yewdell JW
AD  - Laboratory of Viral Diseases, National Institute of Allergy and Infectious
      Diseases, National Institutes of Health, DHHS, Bethesda, MD 20892, USA.
FAU - Rehermann, Barbara
AU  - Rehermann B
AD  - Immunology Section, Diseases Branch, National Institute of Diabetes and Digestive
      and Kidney Diseases, National Institutes of Health, DHHS, Bethesda, MD 20892,
      USA. Electronic address: rehermann@nih.gov.
LA  - eng
PT  - Journal Article
DEP - 20171019
PL  - United States
TA  - Cell
JT  - Cell
JID - 0413066
SB  - IM
MH  - Animals
MH  - Animals, Laboratory
MH  - Animals, Wild
MH  - Carcinogenesis/immunology
MH  - Disease Resistance
MH  - Female
MH  - *Gastrointestinal Microbiome
MH  - Male
MH  - Maryland
MH  - Mice/*classification/immunology/*microbiology
MH  - Mice, Inbred C57BL
MH  - Peromyscus
MH  - Virus Diseases/immunology
OTO - NOTNLM
OT  - bacteria
OT  - colorectal cancer
OT  - cytokine
OT  - gut
OT  - inflammation
OT  - influenza
OT  - innate
OT  - microbiome
OT  - virus
OT  - wild mouse
EDAT- 2017/10/24 06:00
MHDA- 2017/12/16 06:00
CRDT- 2017/10/24 06:00
PHST- 2017/04/09 00:00 [received]
PHST- 2017/06/12 00:00 [revised]
PHST- 2017/09/09 00:00 [accepted]
PHST- 2017/10/24 06:00 [pubmed]
PHST- 2017/12/16 06:00 [medline]
PHST- 2017/10/24 06:00 [entrez]
AID - S0092-8674(17)31065-6 [pii]
AID - 10.1016/j.cell.2017.09.016 [doi]
PST - ppublish
SO  - Cell. 2017 Nov 16;171(5):1015-1028.e13. doi: 10.1016/j.cell.2017.09.016. Epub
      2017 Oct 19.

PMID- 29246442
OWN - NLM
STAT- MEDLINE
DCOM- 20171226
LR  - 20180104
IS  - 1097-4180 (Electronic)
IS  - 1074-7613 (Linking)
VI  - 47
IP  - 6
DP  - 2017 Dec 19
TI  - Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1
      mRNA.
PG  - 1083-1099.e6
LID - S1074-7613(17)30517-4 [pii]
LID - 10.1016/j.immuni.2017.11.016 [doi]
AB  - The immunosuppressive protein PD-L1 is upregulated in many cancers and
      contributes to evasion of the host immune system. The relative importance of the 
      tumor microenvironment and cancer cell-intrinsic signaling in the regulation of
      PD-L1 expression remains unclear. We report that oncogenic RAS signaling can
      upregulate tumor cell PD-L1 expression through a mechanism involving increases in
      PD-L1 mRNA stability via modulation of the AU-rich element-binding protein
      tristetraprolin (TTP). TTP negatively regulates PD-L1 expression through AU-rich 
      elements in the 3' UTR of PD-L1 mRNA. MEK signaling downstream of RAS leads to
      phosphorylation and inhibition of TTP by the kinase MK2. In human lung and
      colorectal tumors, RAS pathway activation is associated with elevated PD-L1
      expression. In vivo, restoration of TTP expression enhances anti-tumor immunity
      dependent on degradation of PD-L1 mRNA. We demonstrate that RAS can drive
      cell-intrinsic PD-L1 expression, thus presenting therapeutic opportunities to
      reverse the innately immunoresistant phenotype of RAS mutant cancers.
CI  - Copyright (c) 2017 The Author(s). Published by Elsevier Inc. All rights reserved.
FAU - Coelho, Matthew A
AU  - Coelho MA
AD  - Oncogene Biology, The Francis Crick Institute, 1 Midland Road, London NW1 1AT,
      UK.
FAU - de Carne Trecesson, Sophie
AU  - de Carne Trecesson S
AD  - Oncogene Biology, The Francis Crick Institute, 1 Midland Road, London NW1 1AT,
      UK.
FAU - Rana, Sareena
AU  - Rana S
AD  - Lung Cancer Group, Division of Molecular Pathology, The Institute of Cancer
      Research, 237 Fulham Road, London SW3 6JB, UK.
FAU - Zecchin, Davide
AU  - Zecchin D
AD  - Oncogene Biology, The Francis Crick Institute, 1 Midland Road, London NW1 1AT,
      UK.
FAU - Moore, Christopher
AU  - Moore C
AD  - Oncogene Biology, The Francis Crick Institute, 1 Midland Road, London NW1 1AT,
      UK.
FAU - Molina-Arcas, Miriam
AU  - Molina-Arcas M
AD  - Oncogene Biology, The Francis Crick Institute, 1 Midland Road, London NW1 1AT,
      UK.
FAU - East, Philip
AU  - East P
AD  - Computational Biology, The Francis Crick Institute, 1 Midland Road, London NW1
      1AT, UK.
FAU - Spencer-Dene, Bradley
AU  - Spencer-Dene B
AD  - Experimental Histopathology, The Francis Crick Institute, 1 Midland Road, London 
      NW1 1AT, UK.
FAU - Nye, Emma
AU  - Nye E
AD  - Experimental Histopathology, The Francis Crick Institute, 1 Midland Road, London 
      NW1 1AT, UK.
FAU - Barnouin, Karin
AU  - Barnouin K
AD  - Protein Analysis and Proteomics Laboratories, The Francis Crick Institute, 1
      Midland Road, London NW1 1AT, UK.
FAU - Snijders, Ambrosius P
AU  - Snijders AP
AD  - Protein Analysis and Proteomics Laboratories, The Francis Crick Institute, 1
      Midland Road, London NW1 1AT, UK.
FAU - Lai, Wi S
AU  - Lai WS
AD  - Signal Transduction Laboratory, National Institute of Environmental Health
      Sciences, Research Triangle Park, NC 27709, USA.
FAU - Blackshear, Perry J
AU  - Blackshear PJ
AD  - Signal Transduction Laboratory, National Institute of Environmental Health
      Sciences, Research Triangle Park, NC 27709, USA; Departments of Medicine and
      Biochemistry, Duke University Medical Center, Durham, NC 27703, USA.
FAU - Downward, Julian
AU  - Downward J
AD  - Oncogene Biology, The Francis Crick Institute, 1 Midland Road, London NW1 1AT,
      UK; Lung Cancer Group, Division of Molecular Pathology, The Institute of Cancer
      Research, 237 Fulham Road, London SW3 6JB, UK. Electronic address:
      julian.downward@crick.ac.uk.
LA  - eng
GR  - Wellcome Trust/United Kingdom
PT  - Journal Article
DEP - 20171212
PL  - United States
TA  - Immunity
JT  - Immunity
JID - 9432918
RN  - 0 (B7-H1 Antigen)
RN  - 0 (Cd274 protein, mouse)
RN  - 0 (Intracellular Signaling Peptides and Proteins)
RN  - 0 (RNA, Messenger)
RN  - 0 (Tristetraprolin)
RN  - 0 (Zfp36 protein, mouse)
RN  - EC 2.7.1.- (MAP-kinase-activated kinase 2)
RN  - EC 2.7.11.1 (Protein-Serine-Threonine Kinases)
RN  - EC 2.7.11.25 (MAP Kinase Kinase Kinases)
RN  - EC 3.6.5.2 (Kras2 protein, mouse)
RN  - EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras))
SB  - IM
MH  - Animals
MH  - B7-H1 Antigen/genetics/*immunology
MH  - Cell Line, Tumor
MH  - Colorectal Neoplasms/genetics/*immunology/pathology
MH  - Epithelial Cells/immunology/pathology
MH  - Female
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Intracellular Signaling Peptides and Proteins/genetics/immunology
MH  - Lung Neoplasms/genetics/*immunology/pathology
MH  - MAP Kinase Kinase Kinases/genetics/immunology
MH  - Male
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Inbred C57BL
MH  - Neoplasm Transplantation
MH  - Protein Binding
MH  - Protein-Serine-Threonine Kinases/genetics/immunology
MH  - Proto-Oncogene Proteins p21(ras)/genetics/*immunology
MH  - RNA Cleavage
MH  - RNA Stability
MH  - RNA, Messenger/genetics/immunology
MH  - Signal Transduction
MH  - Tristetraprolin/genetics/*immunology
MH  - *Tumor Escape
PMC - PMC5746170
OTO - NOTNLM
OT  - KRAS
OT  - PD-L1
OT  - RAS
OT  - TTP
OT  - immunotherapy
OT  - tristetraprolin
EDAT- 2017/12/17 06:00
MHDA- 2017/12/27 06:00
CRDT- 2017/12/17 06:00
PHST- 2016/10/14 00:00 [received]
PHST- 2017/06/06 00:00 [revised]
PHST- 2017/11/20 00:00 [accepted]
PHST- 2017/12/17 06:00 [pubmed]
PHST- 2017/12/27 06:00 [medline]
PHST- 2017/12/17 06:00 [entrez]
AID - S1074-7613(17)30517-4 [pii]
AID - 10.1016/j.immuni.2017.11.016 [doi]
PST - ppublish
SO  - Immunity. 2017 Dec 19;47(6):1083-1099.e6. doi: 10.1016/j.immuni.2017.11.016. Epub
      2017 Dec 12.

PMID- 29232556
OWN - NLM
STAT- MEDLINE
DCOM- 20171220
LR  - 20171224
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 6
DP  - 2017 Dec 11
TI  - MST4 Phosphorylation of ATG4B Regulates Autophagic Activity, Tumorigenicity, and 
      Radioresistance in Glioblastoma.
PG  - 840-855.e8
LID - S1535-6108(17)30508-1 [pii]
LID - 10.1016/j.ccell.2017.11.005 [doi]
AB  - ATG4B stimulates autophagy by promoting autophagosome formation through
      reversible modification of ATG8. We identify ATG4B as a substrate of mammalian
      sterile20-like kinase (STK) 26/MST4. MST4 phosphorylates ATG4B at serine residue 
      383, which stimulates ATG4B activity and increases autophagic flux. Inhibition of
      MST4 or ATG4B activities using genetic approaches or an inhibitor of ATG4B
      suppresses autophagy and the tumorigenicity of glioblastoma (GBM) cells.
      Furthermore, radiation induces MST4 expression, ATG4B phosphorylation, and
      autophagy. Inhibiting ATG4B in combination with radiotherapy in treating mice
      with intracranial GBM xenograft markedly slows tumor growth and provides a
      significant survival benefit. Our work describes an MST4-ATG4B signaling axis
      that influences GBM autophagy and malignancy, and whose therapeutic targeting
      enhances the anti-tumor effects of radiotherapy.
CI  - Copyright (c) 2017 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Huang, Tianzhi
AU  - Huang T
AD  - Ken & Ruth Davee Department of Neurology, Northwestern University Feinberg School
      of Medicine, Chicago, IL 60611, USA; The Lou and Jean Malnati Brain Tumor
      Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern
      University Feinberg School of Medicine, Chicago, IL 60611, USA.
FAU - Kim, Chung Kwon
AU  - Kim CK
AD  - Ken & Ruth Davee Department of Neurology, Northwestern University Feinberg School
      of Medicine, Chicago, IL 60611, USA; The Lou and Jean Malnati Brain Tumor
      Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern
      University Feinberg School of Medicine, Chicago, IL 60611, USA.
FAU - Alvarez, Angel A
AU  - Alvarez AA
AD  - Ken & Ruth Davee Department of Neurology, Northwestern University Feinberg School
      of Medicine, Chicago, IL 60611, USA; The Lou and Jean Malnati Brain Tumor
      Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern
      University Feinberg School of Medicine, Chicago, IL 60611, USA.
FAU - Pangeni, Rajendra P
AU  - Pangeni RP
AD  - Ken & Ruth Davee Department of Neurology, Northwestern University Feinberg School
      of Medicine, Chicago, IL 60611, USA; The Lou and Jean Malnati Brain Tumor
      Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern
      University Feinberg School of Medicine, Chicago, IL 60611, USA.
FAU - Wan, Xuechao
AU  - Wan X
AD  - Ken & Ruth Davee Department of Neurology, Northwestern University Feinberg School
      of Medicine, Chicago, IL 60611, USA; The Lou and Jean Malnati Brain Tumor
      Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern
      University Feinberg School of Medicine, Chicago, IL 60611, USA.
FAU - Song, Xiao
AU  - Song X
AD  - Ken & Ruth Davee Department of Neurology, Northwestern University Feinberg School
      of Medicine, Chicago, IL 60611, USA; The Lou and Jean Malnati Brain Tumor
      Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern
      University Feinberg School of Medicine, Chicago, IL 60611, USA.
FAU - Shi, Taiping
AU  - Shi T
AD  - Ken & Ruth Davee Department of Neurology, Northwestern University Feinberg School
      of Medicine, Chicago, IL 60611, USA; The Lou and Jean Malnati Brain Tumor
      Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern
      University Feinberg School of Medicine, Chicago, IL 60611, USA.
FAU - Yang, Yongyong
AU  - Yang Y
AD  - Ken & Ruth Davee Department of Neurology, Northwestern University Feinberg School
      of Medicine, Chicago, IL 60611, USA; The Lou and Jean Malnati Brain Tumor
      Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern
      University Feinberg School of Medicine, Chicago, IL 60611, USA.
FAU - Sastry, Namratha
AU  - Sastry N
AD  - Ken & Ruth Davee Department of Neurology, Northwestern University Feinberg School
      of Medicine, Chicago, IL 60611, USA; The Lou and Jean Malnati Brain Tumor
      Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern
      University Feinberg School of Medicine, Chicago, IL 60611, USA.
FAU - Horbinski, Craig M
AU  - Horbinski CM
AD  - The Lou and Jean Malnati Brain Tumor Institute, The Robert H. Lurie Comprehensive
      Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL
      60611, USA; Department of Neurological Surgery, Northwestern University Feinberg 
      School of Medicine, Chicago, IL 60611, USA.
FAU - Lu, Songjian
AU  - Lu S
AD  - Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA
      15206, USA.
FAU - Stupp, Roger
AU  - Stupp R
AD  - Ken & Ruth Davee Department of Neurology, Northwestern University Feinberg School
      of Medicine, Chicago, IL 60611, USA; The Lou and Jean Malnati Brain Tumor
      Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern
      University Feinberg School of Medicine, Chicago, IL 60611, USA.
FAU - Kessler, John A
AU  - Kessler JA
AD  - Ken & Ruth Davee Department of Neurology, Northwestern University Feinberg School
      of Medicine, Chicago, IL 60611, USA; The Lou and Jean Malnati Brain Tumor
      Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern
      University Feinberg School of Medicine, Chicago, IL 60611, USA.
FAU - Nishikawa, Ryo
AU  - Nishikawa R
AD  - Department of Neuro-Oncology/Neurosurgery, Saitama Medical University
      International Medical Center, Saitama 350-1298, Japan.
FAU - Nakano, Ichiro
AU  - Nakano I
AD  - Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL
      35294, USA.
FAU - Sulman, Erik P
AU  - Sulman EP
AD  - Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer
      Center, 1515 Holcombe Boulevard, Unit 97, Houston, TX 77030, USA.
FAU - Lu, Xinghua
AU  - Lu X
AD  - Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA
      15206, USA.
FAU - James, Charles David
AU  - James CD
AD  - The Lou and Jean Malnati Brain Tumor Institute, The Robert H. Lurie Comprehensive
      Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL
      60611, USA; Department of Neurological Surgery, Northwestern University Feinberg 
      School of Medicine, Chicago, IL 60611, USA.
FAU - Yin, Xiao-Ming
AU  - Yin XM
AD  - Department of Pathology & Laboratory Medicine, Indiana University, Indianapolis, 
      IN 46202, USA.
FAU - Hu, Bo
AU  - Hu B
AD  - Ken & Ruth Davee Department of Neurology, Northwestern University Feinberg School
      of Medicine, Chicago, IL 60611, USA; The Lou and Jean Malnati Brain Tumor
      Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern
      University Feinberg School of Medicine, Chicago, IL 60611, USA. Electronic
      address: bo.hu@northwestern.edu.
FAU - Cheng, Shi-Yuan
AU  - Cheng SY
AD  - Ken & Ruth Davee Department of Neurology, Northwestern University Feinberg School
      of Medicine, Chicago, IL 60611, USA; The Lou and Jean Malnati Brain Tumor
      Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern
      University Feinberg School of Medicine, Chicago, IL 60611, USA. Electronic
      address: shiyuan.cheng@northwestern.edu.
LA  - eng
GR  - L32 MD010147/MD/NIMHD NIH HHS/United States
GR  - R01 NS083767/NS/NINDS NIH HHS/United States
GR  - R01 NS080619/NS/NINDS NIH HHS/United States
GR  - R01 NS095634/NS/NINDS NIH HHS/United States
GR  - K99 LM011673/LM/NLM NIH HHS/United States
GR  - R21 CA175875/CA/NCI NIH HHS/United States
GR  - R01 NS102669/NS/NINDS NIH HHS/United States
GR  - R01 CA159467/CA/NCI NIH HHS/United States
GR  - P30 NS081774/NS/NINDS NIH HHS/United States
GR  - R01 NS093843/NS/NINDS NIH HHS/United States
GR  - R01 AA021751/AA/NIAAA NIH HHS/United States
GR  - T32 CA070085/CA/NCI NIH HHS/United States
GR  - P01 CA163205/CA/NCI NIH HHS/United States
GR  - R00 LM011673/LM/NLM NIH HHS/United States
GR  - R01 LM012011/LM/NLM NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Autophagy-Related Proteins)
RN  - EC 2.7.1.- (MST4 protein, human)
RN  - EC 2.7.11.1 (Protein-Serine-Threonine Kinases)
RN  - EC 3.4.22.- (ATG4B protein, human)
RN  - EC 3.4.22.- (Cysteine Endopeptidases)
SB  - IM
MH  - Animals
MH  - Autophagy/*physiology
MH  - Autophagy-Related Proteins/*metabolism
MH  - Brain Neoplasms/metabolism/*pathology
MH  - Carcinogenesis/metabolism
MH  - Cell Line, Tumor
MH  - Cysteine Endopeptidases/*metabolism
MH  - Glioblastoma/metabolism/*pathology
MH  - Humans
MH  - Mice
MH  - Mice, Nude
MH  - Phosphorylation
MH  - Protein-Serine-Threonine Kinases/*metabolism
MH  - Radiation Tolerance
MH  - Xenograft Model Antitumor Assays
PMC - PMC5734934
OTO - NOTNLM
OT  - ATG4B
OT  - ATG4B inhibitor NSC185058
OT  - MST4/STK26
OT  - autophagy
OT  - combination therapy
OT  - glioblastoma
OT  - glioma stem-like cells
OT  - phosphorylation
OT  - tumor response to radiation
OT  - tumorigenicity
EDAT- 2017/12/13 06:00
MHDA- 2017/12/21 06:00
CRDT- 2017/12/13 06:00
PHST- 2017/05/12 00:00 [received]
PHST- 2017/09/11 00:00 [revised]
PHST- 2017/11/07 00:00 [accepted]
PHST- 2017/12/13 06:00 [entrez]
PHST- 2017/12/13 06:00 [pubmed]
PHST- 2017/12/21 06:00 [medline]
AID - S1535-6108(17)30508-1 [pii]
AID - 10.1016/j.ccell.2017.11.005 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Dec 11;32(6):840-855.e8. doi: 10.1016/j.ccell.2017.11.005.

PMID- 29100075
OWN - NLM
STAT- MEDLINE
DCOM- 20171121
LR  - 20171219
IS  - 1097-4172 (Electronic)
IS  - 0092-8674 (Linking)
VI  - 171
IP  - 4
DP  - 2017 Nov 2
TI  - Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue
      Sarcomas.
PG  - 950-965.e28
LID - S0092-8674(17)31203-5 [pii]
LID - 10.1016/j.cell.2017.10.014 [doi]
AB  - Sarcomas are a broad family of mesenchymal malignancies exhibiting remarkable
      histologic diversity. We describe the multi-platform molecular landscape of 206
      adult soft tissue sarcomas representing 6 major types. Along with novel insights 
      into the biology of individual sarcoma types, we report three overarching
      findings: (1) unlike most epithelial malignancies, these sarcomas (excepting
      synovial sarcoma) are characterized predominantly by copy-number changes, with
      low mutational loads and only a few genes (TP53, ATRX, RB1) highly recurrently
      mutated across sarcoma types; (2) within sarcoma types, genomic and regulomic
      diversity of driver pathways defines molecular subtypes associated with patient
      outcome; and (3) the immune microenvironment, inferred from DNA methylation and
      mRNA profiles, associates with outcome and may inform clinical trials of immune
      checkpoint inhibitors. Overall, this large-scale analysis reveals previously
      unappreciated sarcoma-type-specific changes in copy number, methylation, RNA, and
      protein, providing insights into refining sarcoma therapy and relationships to
      other cancer types.
CI  - Copyright (c) 2017 The Authors. Published by Elsevier Inc. All rights reserved.
CN  - Cancer Genome Atlas Research Network. Electronic address:
      elizabeth.demicco@sinaihealthsystem.ca
AD  - Cancer Genome Atlas Program Office, National Cancer Institute at NIH, 31 Center
      Drive, Bldg. 31, Suite 3A20, Bethesda, MD 20892, USA.
CN  - Cancer Genome Atlas Research Network
LA  - eng
GR  - P30 CA016672/CA/NCI NIH HHS/United States
GR  - U24 CA143882/CA/NCI NIH HHS/United States
GR  - U54 HG003067/HG/NHGRI NIH HHS/United States
GR  - U24 CA143835/CA/NCI NIH HHS/United States
GR  - U24 CA143866/CA/NCI NIH HHS/United States
GR  - U24 CA143845/CA/NCI NIH HHS/United States
GR  - U24 CA143799/CA/NCI NIH HHS/United States
GR  - U54 HG003273/HG/NHGRI NIH HHS/United States
GR  - U24 CA144025/CA/NCI NIH HHS/United States
GR  - U24 CA143840/CA/NCI NIH HHS/United States
GR  - U24 CA143843/CA/NCI NIH HHS/United States
GR  - U24 CA143858/CA/NCI NIH HHS/United States
GR  - U24 CA143848/CA/NCI NIH HHS/United States
GR  - U24 CA126543/CA/NCI NIH HHS/United States
GR  - U54 HG003079/HG/NHGRI NIH HHS/United States
GR  - U24 CA143883/CA/NCI NIH HHS/United States
GR  - U24 CA143867/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cell
JT  - Cell
JID - 0413066
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Cluster Analysis
MH  - DNA Copy Number Variations
MH  - Epigenomics
MH  - Genome, Human
MH  - Genome-Wide Association Study
MH  - Humans
MH  - Middle Aged
MH  - Mutation
MH  - Sarcoma/diagnosis/*genetics/pathology
MH  - Young Adult
PMC - PMC5693358
MID - NIHMS912614
OTO - NOTNLM
OT  - DNA methylation
OT  - The Cancer Genome Atlas
OT  - dedifferentiated liposarcoma
OT  - genomics
OT  - immune infiltration
OT  - leiomyosarcoma
OT  - molecular subtype
OT  - myxofibrosarcoma
OT  - pleomorphism
OT  - undifferentiated pleomorphic sarcoma
IR  - Abeshouse A
FIR - Abeshouse, Adam
IR  - Adebamowo C
FIR - Adebamowo, Clement
IR  - Adebamowo SN
FIR - Adebamowo, Sally N
IR  - Akbani R
FIR - Akbani, Rehan
IR  - Akeredolu T
FIR - Akeredolu, Teniola
IR  - Ally A
FIR - Ally, Adrian
IR  - Anderson ML
FIR - Anderson, Matthew L
IR  - Anur P
FIR - Anur, Pavana
IR  - Appelbaum EL
FIR - Appelbaum, Elizabeth L
IR  - Armenia J
FIR - Armenia, Joshua
IR  - Auman JT
FIR - Auman, J Todd
IR  - Bailey MH
FIR - Bailey, Matthew H
IR  - Baker L
FIR - Baker, Laurence
IR  - Balasundaram M
FIR - Balasundaram, Miruna
IR  - Balu S
FIR - Balu, Saianand
IR  - Barthel FP
FIR - Barthel, Floris P
IR  - Bartlett J
FIR - Bartlett, John
IR  - Baylin SB
FIR - Baylin, Stephen B
IR  - Behera M
FIR - Behera, Madhusmita
IR  - Belyaev D
FIR - Belyaev, Dmitry
IR  - Bennett J
FIR - Bennett, Joesph
IR  - Benz C
FIR - Benz, Christopher
IR  - Beroukhim R
FIR - Beroukhim, Rameen
IR  - Birrer M
FIR - Birrer, Michael
IR  - Bocklage T
FIR - Bocklage, Therese
IR  - Bodenheimer T
FIR - Bodenheimer, Tom
IR  - Boice L
FIR - Boice, Lori
IR  - Bootwalla MS
FIR - Bootwalla, Moiz S
IR  - Bowen J
FIR - Bowen, Jay
IR  - Bowlby R
FIR - Bowlby, Reanne
IR  - Boyd J
FIR - Boyd, Jeff
IR  - Brohl AS
FIR - Brohl, Andrew S
IR  - Brooks D
FIR - Brooks, Denise
IR  - Byers L
FIR - Byers, Lauren
IR  - Carlsen R
FIR - Carlsen, Rebecca
IR  - Castro P
FIR - Castro, Patricia
IR  - Chen HW
FIR - Chen, Hsiao-Wei
IR  - Cherniack AD
FIR - Cherniack, Andrew D
IR  - Chibon F
FIR - Chibon, Frederic
IR  - Chin L
FIR - Chin, Lynda
IR  - Cho J
FIR - Cho, Juok
IR  - Chuah E
FIR - Chuah, Eric
IR  - Chudamani S
FIR - Chudamani, Sudha
IR  - Cibulskis C
FIR - Cibulskis, Carrie
IR  - Cooper LAD
FIR - Cooper, Lee A D
IR  - Cope L
FIR - Cope, Leslie
IR  - Cordes MG
FIR - Cordes, Matthew G
IR  - Crain D
FIR - Crain, Daniel
IR  - Curley E
FIR - Curley, Erin
IR  - Danilova L
FIR - Danilova, Ludmila
IR  - Dao F
FIR - Dao, Fanny
IR  - Davis IJ
FIR - Davis, Ian J
IR  - Davis LE
FIR - Davis, Lara E
IR  - Defreitas T
FIR - Defreitas, Timothy
IR  - Delman K
FIR - Delman, Keith
IR  - Demchok JA
FIR - Demchok, John A
IR  - Demetri GD
FIR - Demetri, George D
IR  - Demicco EG
FIR - Demicco, Elizabeth G
IR  - Dhalla N
FIR - Dhalla, Noreen
IR  - Diao L
FIR - Diao, Lixia
IR  - Ding L
FIR - Ding, Li
IR  - DiSaia P
FIR - DiSaia, Phil
IR  - Dottino P
FIR - Dottino, Peter
IR  - Doyle LA
FIR - Doyle, Leona A
IR  - Drill E
FIR - Drill, Esther
IR  - Dubina M
FIR - Dubina, Michael
IR  - Eschbacher J
FIR - Eschbacher, Jennifer
IR  - Fedosenko K
FIR - Fedosenko, Konstantin
IR  - Felau I
FIR - Felau, Ina
IR  - Ferguson ML
FIR - Ferguson, Martin L
IR  - Frazer S
FIR - Frazer, Scott
IR  - Fronick CC
FIR - Fronick, Catrina C
IR  - Fulidou V
FIR - Fulidou, Victoria
IR  - Fulton LA
FIR - Fulton, Lucinda A
IR  - Fulton RS
FIR - Fulton, Robert S
IR  - Gabriel SB
FIR - Gabriel, Stacey B
IR  - Gao J
FIR - Gao, Jianjiong
IR  - Gao Q
FIR - Gao, Qingsong
IR  - Gardner J
FIR - Gardner, Johanna
IR  - Gastier-Foster JM
FIR - Gastier-Foster, Julie M
IR  - Gay CM
FIR - Gay, Carl M
IR  - Gehlenborg N
FIR - Gehlenborg, Nils
IR  - Gerken M
FIR - Gerken, Mark
IR  - Getz G
FIR - Getz, Gad
IR  - Godwin AK
FIR - Godwin, Andrew K
IR  - Godwin EM
FIR - Godwin, Eryn M
IR  - Gordienko E
FIR - Gordienko, Elena
IR  - Grilley-Olson JE
FIR - Grilley-Olson, Juneko E
IR  - Gutman DA
FIR - Gutman, David A
IR  - Gutmann DH
FIR - Gutmann, David H
IR  - Hayes DN
FIR - Hayes, D Neil
IR  - Hegde AM
FIR - Hegde, Apurva M
IR  - Heiman DI
FIR - Heiman, David I
IR  - Heins Z
FIR - Heins, Zachary
IR  - Helsel C
FIR - Helsel, Carmen
IR  - Hepperla AJ
FIR - Hepperla, Austin J
IR  - Higgins K
FIR - Higgins, Kelly
IR  - Hoadley KA
FIR - Hoadley, Katherine A
IR  - Hobensack S
FIR - Hobensack, Shital
IR  - Holt RA
FIR - Holt, Robert A
IR  - Hoon DB
FIR - Hoon, Dave B
IR  - Hornick JL
FIR - Hornick, Jason L
IR  - Hoyle AP
FIR - Hoyle, Alan P
IR  - Hu X
FIR - Hu, Xin
IR  - Huang M
FIR - Huang, Mei
IR  - Hutter CM
FIR - Hutter, Carolyn M
IR  - Iacocca M
FIR - Iacocca, Mary
IR  - Ingram DR
FIR - Ingram, Davis R
IR  - Ittmann M
FIR - Ittmann, Michael
IR  - Iype L
FIR - Iype, Lisa
IR  - Jefferys SR
FIR - Jefferys, Stuart R
IR  - Jones KB
FIR - Jones, Kevin B
IR  - Jones CD
FIR - Jones, Corbin D
IR  - Jones SJM
FIR - Jones, Steven J M
IR  - Kalir T
FIR - Kalir, Tamara
IR  - Karlan BY
FIR - Karlan, Beth Y
IR  - Karseladze A
FIR - Karseladze, Apollon
IR  - Kasaian K
FIR - Kasaian, Katayoon
IR  - Kim J
FIR - Kim, Jaegil
IR  - Kundra R
FIR - Kundra, Ritika
IR  - Kuo H
FIR - Kuo, Hanluen
IR  - Ladanyi M
FIR - Ladanyi, Marc
IR  - Lai PH
FIR - Lai, Phillip H
IR  - Laird PW
FIR - Laird, Peter W
IR  - Larsson E
FIR - Larsson, Erik
IR  - Lawrence MS
FIR - Lawrence, Michael S
IR  - Lazar AJ
FIR - Lazar, Alexander J
IR  - Lee S
FIR - Lee, Sanghoon
IR  - Lee D
FIR - Lee, Darlene
IR  - Lehmann KV
FIR - Lehmann, Kjong-Van
IR  - Leraas KM
FIR - Leraas, Kristen M
IR  - Lester J
FIR - Lester, Jenny
IR  - Levine DA
FIR - Levine, Douglas A
IR  - Li I
FIR - Li, Irene
IR  - Lichtenberg TM
FIR - Lichtenberg, Tara M
IR  - Lin P
FIR - Lin, Pei
IR  - Liu J
FIR - Liu, Jia
IR  - Liu W
FIR - Liu, Wenbin
IR  - Liu EM
FIR - Liu, Eric Minwei
IR  - Lolla L
FIR - Lolla, Laxmi
IR  - Lu Y
FIR - Lu, Yiling
IR  - Ma Y
FIR - Ma, Yussanne
IR  - Madan R
FIR - Madan, Rashna
IR  - Maglinte DT
FIR - Maglinte, Dennis T
IR  - Magliocco A
FIR - Magliocco, Anthony
IR  - Maki RG
FIR - Maki, Robert G
IR  - Mallery D
FIR - Mallery, David
IR  - Manikhas G
FIR - Manikhas, Georgy
IR  - Mardis ER
FIR - Mardis, Elaine R
IR  - Mariamidze A
FIR - Mariamidze, Armaz
IR  - Marra MA
FIR - Marra, Marco A
IR  - Martignetti JA
FIR - Martignetti, John A
IR  - Martinez C
FIR - Martinez, Cathleen
IR  - Mayo M
FIR - Mayo, Michael
IR  - McLellan MD
FIR - McLellan, Michael D
IR  - Meier S
FIR - Meier, Sam
IR  - Meng S
FIR - Meng, Shaowu
IR  - Meyerson M
FIR - Meyerson, Matthew
IR  - Mieczkowski PA
FIR - Mieczkowski, Piotr A
IR  - Miller CA
FIR - Miller, Christopher A
IR  - Mills GB
FIR - Mills, Gordon B
IR  - Moore RA
FIR - Moore, Richard A
IR  - Morris S
FIR - Morris, Scott
IR  - Mose LE
FIR - Mose, Lisle E
IR  - Mozgovoy E
FIR - Mozgovoy, Evgeny
IR  - Mungall AJ
FIR - Mungall, Andrew J
IR  - Mungall K
FIR - Mungall, Karen
IR  - Nalisnik M
FIR - Nalisnik, Michael
IR  - Naresh R
FIR - Naresh, Rashi
IR  - Newton Y
FIR - Newton, Yulia
IR  - Noble MS
FIR - Noble, Michael S
IR  - Novak JE
FIR - Novak, Janet E
IR  - Ochoa A
FIR - Ochoa, Angelica
IR  - Olvera N
FIR - Olvera, Narciso
IR  - Owonikoko TK
FIR - Owonikoko, Taofeek K
IR  - Paklina O
FIR - Paklina, Oxana
IR  - Parfitt J
FIR - Parfitt, Jeremy
IR  - Parker JS
FIR - Parker, Joel S
IR  - Pastore A
FIR - Pastore, Alessandro
IR  - Paulauskis J
FIR - Paulauskis, Joseph
IR  - Penny R
FIR - Penny, Robert
IR  - Pereira E
FIR - Pereira, Elena
IR  - Perou CM
FIR - Perou, Charles M
IR  - Perou AH
FIR - Perou, Amy H
IR  - Pihl T
FIR - Pihl, Todd
IR  - Pollock RE
FIR - Pollock, Raphael E
IR  - Potapova O
FIR - Potapova, Olga
IR  - Radenbaugh AJ
FIR - Radenbaugh, Amie J
IR  - Ramalingam SS
FIR - Ramalingam, Suresh S
IR  - Ramirez NC
FIR - Ramirez, Nilsa C
IR  - Rathmell WK
FIR - Rathmell, W Kimryn
IR  - Raut CP
FIR - Raut, Chandrajit P
IR  - Riedel RF
FIR - Riedel, Richard F
IR  - Reilly C
FIR - Reilly, Colleen
IR  - Reynolds SM
FIR - Reynolds, Sheila M
IR  - Roach J
FIR - Roach, Jeffrey
IR  - Robertson AG
FIR - Robertson, A Gordon
IR  - Roszik J
FIR - Roszik, Jason
IR  - Rubin BP
FIR - Rubin, Brian P
IR  - Sadeghi S
FIR - Sadeghi, Sara
IR  - Saksena G
FIR - Saksena, Gordon
IR  - Salner A
FIR - Salner, Andrew
IR  - Sanchez-Vega F
FIR - Sanchez-Vega, Francisco
IR  - Sander C
FIR - Sander, Chris
IR  - Schein JE
FIR - Schein, Jacqueline E
IR  - Schmidt HK
FIR - Schmidt, Heather K
IR  - Schultz N
FIR - Schultz, Nikolaus
IR  - Schumacher SE
FIR - Schumacher, Steven E
IR  - Sekhon H
FIR - Sekhon, Harman
IR  - Senbabaoglu Y
FIR - Senbabaoglu, Yasin
IR  - Setdikova G
FIR - Setdikova, Galiya
IR  - Shelton C
FIR - Shelton, Candace
IR  - Shelton T
FIR - Shelton, Troy
IR  - Shen R
FIR - Shen, Ronglai
IR  - Shi Y
FIR - Shi, Yan
IR  - Shih J
FIR - Shih, Juliann
IR  - Shmulevich I
FIR - Shmulevich, Ilya
IR  - Sica GL
FIR - Sica, Gabriel L
IR  - Simons JV
FIR - Simons, Janae V
IR  - Singer S
FIR - Singer, Samuel
IR  - Sipahimalani P
FIR - Sipahimalani, Payal
IR  - Skelly T
FIR - Skelly, Tara
IR  - Socci N
FIR - Socci, Nicholas
IR  - Sofia HJ
FIR - Sofia, Heidi J
IR  - Soloway MG
FIR - Soloway, Matthew G
IR  - Spellman P
FIR - Spellman, Paul
IR  - Sun Q
FIR - Sun, Qiang
IR  - Swanson P
FIR - Swanson, Patricia
IR  - Tam A
FIR - Tam, Angela
IR  - Tan D
FIR - Tan, Donghui
IR  - Tarnuzzer R
FIR - Tarnuzzer, Roy
IR  - Thiessen N
FIR - Thiessen, Nina
IR  - Thompson E
FIR - Thompson, Eric
IR  - Thorne LB
FIR - Thorne, Leigh B
IR  - Tong P
FIR - Tong, Pan
IR  - Torres KE
FIR - Torres, Keila E
IR  - van de Rijn M
FIR - van de Rijn, Matt
IR  - Van Den Berg DJ
FIR - Van Den Berg, David J
IR  - Van Tine BA
FIR - Van Tine, Brian A
IR  - Veluvolu U
FIR - Veluvolu, Umadevi
IR  - Verhaak R
FIR - Verhaak, Roel
IR  - Voet D
FIR - Voet, Doug
IR  - Voronina O
FIR - Voronina, Olga
IR  - Wan Y
FIR - Wan, Yunhu
IR  - Wang Z
FIR - Wang, Zhining
IR  - Wang J
FIR - Wang, Jing
IR  - Weinstein JN
FIR - Weinstein, John N
IR  - Weisenberger DJ
FIR - Weisenberger, Daniel J
IR  - Wilkerson MD
FIR - Wilkerson, Matthew D
IR  - Wilson RK
FIR - Wilson, Richard K
IR  - Wise L
FIR - Wise, Lisa
IR  - Wong T
FIR - Wong, Tina
IR  - Wong W
FIR - Wong, Winghing
IR  - Wrangle J
FIR - Wrangle, John
IR  - Wu Y
FIR - Wu, Ye
IR  - Wyczalkowski M
FIR - Wyczalkowski, Matthew
IR  - Yang L
FIR - Yang, Liming
IR  - Yau C
FIR - Yau, Christina
IR  - Yellapantula V
FIR - Yellapantula, Venkata
IR  - Zenklusen JC
FIR - Zenklusen, Jean C
IR  - Zhang JJ
FIR - Zhang, Jiashan Julia
IR  - Zhang H
FIR - Zhang, Hailei
IR  - Zhang H
FIR - Zhang, Hongxin
IR  - Zmuda E
FIR - Zmuda, Erik
EDAT- 2017/11/04 06:00
MHDA- 2017/11/29 06:00
CRDT- 2017/11/04 06:00
PMCR- 2018/11/02 00:00
PHST- 2017/03/17 00:00 [received]
PHST- 2017/07/07 00:00 [revised]
PHST- 2017/10/05 00:00 [accepted]
PHST- 2018/11/02 00:00 [pmc-release]
PHST- 2017/11/04 06:00 [entrez]
PHST- 2017/11/04 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
AID - S0092-8674(17)31203-5 [pii]
AID - 10.1016/j.cell.2017.10.014 [doi]
PST - ppublish
SO  - Cell. 2017 Nov 2;171(4):950-965.e28. doi: 10.1016/j.cell.2017.10.014.

PMID- 29257951
OWN - NLM
STAT- MEDLINE
DCOM- 20180117
LR  - 20180117
IS  - 1878-1551 (Electronic)
IS  - 1534-5807 (Linking)
VI  - 43
IP  - 6
DP  - 2017 Dec 18
TI  - Atg5 Disassociates the V1V0-ATPase to Promote Exosome Production and Tumor
      Metastasis Independent of Canonical Macroautophagy.
PG  - 716-730.e7
LID - S1534-5807(17)30953-X [pii]
LID - 10.1016/j.devcel.2017.11.018 [doi]
AB  - Autophagy and autophagy-related genes (Atg) have been attributed prominent roles 
      in tumorigenesis, tumor growth, and metastasis. Extracellular vesicles called
      exosomes are also implicated in cancer metastasis. Here, we demonstrate that
      exosome production is strongly reduced in cells lacking Atg5 and Atg16L1, but
      this is independent of Atg7 and canonical autophagy. Atg5 specifically decreases 
      acidification of late endosomes where exosomes are produced, disrupting the
      acidifying V1V0-ATPase by removing a regulatory component, ATP6V1E1, into
      exosomes. The effect of Atg5 on exosome production promotes the migration and in 
      vivo metastasis of orthotopic breast cancer cells. These findings uncover
      mechanisms controlling exosome release and identify means by which
      autophagy-related genes can contribute to metastasis in autophagy-independent
      pathways.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Guo, Huishan
AU  - Guo H
AD  - Department of Cellular and Molecular Medicine, University of Ottawa, 3131 Roger
      Guindon Hall, 451 Smyth Road, Ottawa K1H 8M5, Canada.
FAU - Chitiprolu, Maneka
AU  - Chitiprolu M
AD  - Department of Cellular and Molecular Medicine, University of Ottawa, 3131 Roger
      Guindon Hall, 451 Smyth Road, Ottawa K1H 8M5, Canada.
FAU - Roncevic, Luc
AU  - Roncevic L
AD  - Department of Cellular and Molecular Medicine, University of Ottawa, 3131 Roger
      Guindon Hall, 451 Smyth Road, Ottawa K1H 8M5, Canada.
FAU - Javalet, Charlotte
AU  - Javalet C
AD  - Institut National de la Sante et de la Recherche Medicale (INSERM), U1216, 38042 
      Grenoble, France; Universite Grenoble Alpes, Institut des Neurosciences, 38042
      Grenoble, France.
FAU - Hemming, Fiona J
AU  - Hemming FJ
AD  - Institut National de la Sante et de la Recherche Medicale (INSERM), U1216, 38042 
      Grenoble, France; Universite Grenoble Alpes, Institut des Neurosciences, 38042
      Grenoble, France.
FAU - Trung, My Tran
AU  - Trung MT
AD  - Department of Cellular and Molecular Medicine, University of Ottawa, 3131 Roger
      Guindon Hall, 451 Smyth Road, Ottawa K1H 8M5, Canada.
FAU - Meng, Lingrui
AU  - Meng L
AD  - Department of Cellular and Molecular Medicine, University of Ottawa, 3131 Roger
      Guindon Hall, 451 Smyth Road, Ottawa K1H 8M5, Canada.
FAU - Latreille, Elyse
AU  - Latreille E
AD  - Department of Cellular and Molecular Medicine, University of Ottawa, 3131 Roger
      Guindon Hall, 451 Smyth Road, Ottawa K1H 8M5, Canada.
FAU - Tanese de Souza, Christiano
AU  - Tanese de Souza C
AD  - Ottawa Hospital Research Institute, Ottawa K1H 8L6, Canada.
FAU - McCulloch, Danielle
AU  - McCulloch D
AD  - Department of Cellular and Molecular Medicine, University of Ottawa, 3131 Roger
      Guindon Hall, 451 Smyth Road, Ottawa K1H 8M5, Canada.
FAU - Baldwin, R Mitchell
AU  - Baldwin RM
AD  - Department of Cellular and Molecular Medicine, University of Ottawa, 3131 Roger
      Guindon Hall, 451 Smyth Road, Ottawa K1H 8M5, Canada.
FAU - Auer, Rebecca
AU  - Auer R
AD  - Ottawa Hospital Research Institute, Ottawa K1H 8L6, Canada.
FAU - Cote, Jocelyn
AU  - Cote J
AD  - Department of Cellular and Molecular Medicine, University of Ottawa, 3131 Roger
      Guindon Hall, 451 Smyth Road, Ottawa K1H 8M5, Canada.
FAU - Russell, Ryan Charles
AU  - Russell RC
AD  - Department of Cellular and Molecular Medicine, University of Ottawa, 3131 Roger
      Guindon Hall, 451 Smyth Road, Ottawa K1H 8M5, Canada.
FAU - Sadoul, Remy
AU  - Sadoul R
AD  - Institut National de la Sante et de la Recherche Medicale (INSERM), U1216, 38042 
      Grenoble, France; Universite Grenoble Alpes, Institut des Neurosciences, 38042
      Grenoble, France.
FAU - Gibbings, Derrick
AU  - Gibbings D
AD  - Department of Cellular and Molecular Medicine, University of Ottawa, 3131 Roger
      Guindon Hall, 451 Smyth Road, Ottawa K1H 8M5, Canada; Ottawa Institute for System
      Biology, University of Ottawa, Ottawa K1H 8M5, Canada. Electronic address:
      gibbings@uottawa.ca.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Dev Cell
JT  - Developmental cell
JID - 101120028
RN  - 0 (Autophagy-Related Protein 5)
RN  - EC 3.6.1.- (Vacuolar Proton-Translocating ATPases)
RN  - EC 6.2.1.45 (Autophagy-Related Protein 7)
SB  - IM
MH  - Animals
MH  - Autophagy/physiology
MH  - Autophagy-Related Protein 5/genetics/*metabolism
MH  - Autophagy-Related Protein 7/genetics/metabolism
MH  - Breast Neoplasms/*metabolism/*pathology
MH  - Cell Line, Tumor/metabolism
MH  - Endosomes/metabolism
MH  - Exosomes/metabolism
MH  - Female
MH  - Humans
MH  - Lysosomes/metabolism
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Neoplasm Metastasis
MH  - Vacuolar Proton-Translocating ATPases/genetics/*metabolism
OTO - NOTNLM
OT  - LC3
OT  - V(1)V(0)-ATPase
OT  - acidification
OT  - autophagy
OT  - cancer
OT  - endosome
OT  - exosomes
OT  - extracellular vesicles
OT  - multivesicular body
OT  - tumor
EDAT- 2017/12/20 06:00
MHDA- 2018/01/18 06:00
CRDT- 2017/12/20 06:00
PHST- 2016/01/27 00:00 [received]
PHST- 2017/10/29 00:00 [revised]
PHST- 2017/11/20 00:00 [accepted]
PHST- 2017/12/20 06:00 [entrez]
PHST- 2017/12/20 06:00 [pubmed]
PHST- 2018/01/18 06:00 [medline]
AID - S1534-5807(17)30953-X [pii]
AID - 10.1016/j.devcel.2017.11.018 [doi]
PST - ppublish
SO  - Dev Cell. 2017 Dec 18;43(6):716-730.e7. doi: 10.1016/j.devcel.2017.11.018.

PMID- 28874546
OWN - NLM
STAT- In-Data-Review
LR  - 20171007
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Linking)
VI  - 114
IP  - 38
DP  - 2017 Sep 19
TI  - Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the 
      earlier detection of pancreatic cancers.
PG  - 10202-10207
LID - 10.1073/pnas.1704961114 [doi]
AB  - The earlier diagnosis of cancer is one of the keys to reducing cancer deaths in
      the future. Here we describe our efforts to develop a noninvasive blood test for 
      the detection of pancreatic ductal adenocarcinoma. We combined blood tests for
      KRAS gene mutations with carefully thresholded protein biomarkers to determine
      whether the combination of these markers was superior to any single marker. The
      cohort tested included 221 patients with resectable pancreatic ductal
      adenocarcinomas and 182 control patients without known cancer. KRAS mutations
      were detected in the plasma of 66 patients (30%), and every mutation found in the
      plasma was identical to that subsequently found in the patient's primary tumor
      (100% concordance). The use of KRAS in conjunction with four thresholded protein 
      biomarkers increased the sensitivity to 64%. Only one of the 182 plasma samples
      from the control cohort was positive for any of the DNA or protein biomarkers
      (99.5% specificity). This combinatorial approach may prove useful for the earlier
      detection of many cancer types.
FAU - Cohen, Joshua D
AU  - Cohen JD
AD  - The Ludwig Center, The Johns Hopkins Medical Institutions, Baltimore, MD 21287.
AD  - Howard Hughes Medical Institute, The Johns Hopkins Medical Institutions,
      Baltimore, MD 21287.
AD  - Sidney Kimmel Cancer Center at Johns Hopkins, The Johns Hopkins Medical
      Institutions, Baltimore, MD 21287.
AD  - The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins Medical
      Institutions, Baltimore, MD 21287.
AD  - Department of Biomedical Engineering, The Johns Hopkins University School of
      Medicine, Baltimore, MD 21205.
FAU - Javed, Ammar A
AU  - Javed AA
AD  - Department of Surgery, The Johns Hopkins Medical Institutions, Baltimore, MD
      21287.
FAU - Thoburn, Christopher
AU  - Thoburn C
AD  - Sidney Kimmel Cancer Center at Johns Hopkins, The Johns Hopkins Medical
      Institutions, Baltimore, MD 21287.
FAU - Wong, Fay
AU  - Wong F
AD  - The Ludwig Center, The Johns Hopkins Medical Institutions, Baltimore, MD 21287.
AD  - Howard Hughes Medical Institute, The Johns Hopkins Medical Institutions,
      Baltimore, MD 21287.
AD  - Sidney Kimmel Cancer Center at Johns Hopkins, The Johns Hopkins Medical
      Institutions, Baltimore, MD 21287.
AD  - The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins Medical
      Institutions, Baltimore, MD 21287.
FAU - Tie, Jeanne
AU  - Tie J
AD  - Division of Systems Biology and Personalized Medicine, Walter and Eliza Hall
      Institute of Medical Research, Parkville, VIC 3021, Australia.
AD  - Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, 
      Melbourne, VIC 3010, Australia.
AD  - Department of Medical Oncology, Western Health, Melbourne, VIC 3021, Australia.
FAU - Gibbs, Peter
AU  - Gibbs P
AD  - Division of Systems Biology and Personalized Medicine, Walter and Eliza Hall
      Institute of Medical Research, Parkville, VIC 3021, Australia.
AD  - Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, 
      Melbourne, VIC 3010, Australia.
AD  - Department of Medical Oncology, Western Health, Melbourne, VIC 3021, Australia.
FAU - Schmidt, C Max
AU  - Schmidt CM
AD  - Department of Surgery, Indiana University School of Medicine, Indianapolis, IN
      46202.
AD  - Department of Biochemistry and Molecular Biology, Indiana University School of
      Medicine, Indianapolis, IN 46202.
FAU - Yip-Schneider, Michele T
AU  - Yip-Schneider MT
AD  - Department of Surgery, Indiana University School of Medicine, Indianapolis, IN
      46202.
FAU - Allen, Peter J
AU  - Allen PJ
AD  - Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY
      10065.
FAU - Schattner, Mark
AU  - Schattner M
AD  - Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
      10065.
FAU - Brand, Randall E
AU  - Brand RE
AD  - Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15260.
FAU - Singhi, Aatur D
AU  - Singhi AD
AD  - Department of Pathology, University of Pittsburgh, Pittsburgh, PA 15260.
FAU - Petersen, Gloria M
AU  - Petersen GM
AD  - Department of Epidemiology, Mayo Clinic, Rochester, MN 55902.
FAU - Hong, Seung-Mo
AU  - Hong SM
AD  - Department of Pathology, Asan Medical Center, University of Ulsan College of
      Medicine, Seoul 05505, Korea.
FAU - Kim, Song Cheol
AU  - Kim SC
AD  - Department of Hepatobiliary and Pancreas Surgery, Asan Medical Center, University
      of Ulsan College of Medicine, Seoul 05505, Korea.
FAU - Falconi, Massimo
AU  - Falconi M
AD  - Division of Pancreatic Surgery, Department of Surgery, San Raffaele Scientific
      Institute Research Hospital, 20132 Milan, Italy.
FAU - Doglioni, Claudio
AU  - Doglioni C
AD  - Department of Pathology, San Raffaele Scientific Institute Research Hospital,
      20132 Milan, Italy.
FAU - Weiss, Matthew J
AU  - Weiss MJ
AD  - Department of Surgery, The Johns Hopkins Medical Institutions, Baltimore, MD
      21287.
FAU - Ahuja, Nita
AU  - Ahuja N
AD  - Department of Surgery, The Johns Hopkins Medical Institutions, Baltimore, MD
      21287.
FAU - He, Jin
AU  - He J
AD  - Department of Surgery, The Johns Hopkins Medical Institutions, Baltimore, MD
      21287.
FAU - Makary, Martin A
AU  - Makary MA
AD  - Department of Surgery, The Johns Hopkins Medical Institutions, Baltimore, MD
      21287.
FAU - Maitra, Anirban
AU  - Maitra A
AD  - The Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas
      MD Anderson Cancer Center, Houston, TX 77030.
FAU - Hanash, Samir M
AU  - Hanash SM
AD  - The Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas
      MD Anderson Cancer Center, Houston, TX 77030.
FAU - Dal Molin, Marco
AU  - Dal Molin M
AD  - The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins Medical
      Institutions, Baltimore, MD 21287.
FAU - Wang, Yuxuan
AU  - Wang Y
AD  - The Ludwig Center, The Johns Hopkins Medical Institutions, Baltimore, MD 21287.
AD  - Howard Hughes Medical Institute, The Johns Hopkins Medical Institutions,
      Baltimore, MD 21287.
AD  - Sidney Kimmel Cancer Center at Johns Hopkins, The Johns Hopkins Medical
      Institutions, Baltimore, MD 21287.
AD  - The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins Medical
      Institutions, Baltimore, MD 21287.
FAU - Li, Lu
AU  - Li L
AD  - Department of Biostatistics, The Johns Hopkins Bloomberg School of Public Health,
      Baltimore, MD 21205.
FAU - Ptak, Janine
AU  - Ptak J
AD  - The Ludwig Center, The Johns Hopkins Medical Institutions, Baltimore, MD 21287.
AD  - Howard Hughes Medical Institute, The Johns Hopkins Medical Institutions,
      Baltimore, MD 21287.
AD  - Sidney Kimmel Cancer Center at Johns Hopkins, The Johns Hopkins Medical
      Institutions, Baltimore, MD 21287.
AD  - The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins Medical
      Institutions, Baltimore, MD 21287.
FAU - Dobbyn, Lisa
AU  - Dobbyn L
AD  - The Ludwig Center, The Johns Hopkins Medical Institutions, Baltimore, MD 21287.
AD  - Howard Hughes Medical Institute, The Johns Hopkins Medical Institutions,
      Baltimore, MD 21287.
AD  - Sidney Kimmel Cancer Center at Johns Hopkins, The Johns Hopkins Medical
      Institutions, Baltimore, MD 21287.
AD  - The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins Medical
      Institutions, Baltimore, MD 21287.
FAU - Schaefer, Joy
AU  - Schaefer J
AD  - The Ludwig Center, The Johns Hopkins Medical Institutions, Baltimore, MD 21287.
AD  - Howard Hughes Medical Institute, The Johns Hopkins Medical Institutions,
      Baltimore, MD 21287.
AD  - Sidney Kimmel Cancer Center at Johns Hopkins, The Johns Hopkins Medical
      Institutions, Baltimore, MD 21287.
AD  - The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins Medical
      Institutions, Baltimore, MD 21287.
FAU - Silliman, Natalie
AU  - Silliman N
AD  - The Ludwig Center, The Johns Hopkins Medical Institutions, Baltimore, MD 21287.
AD  - Howard Hughes Medical Institute, The Johns Hopkins Medical Institutions,
      Baltimore, MD 21287.
AD  - Sidney Kimmel Cancer Center at Johns Hopkins, The Johns Hopkins Medical
      Institutions, Baltimore, MD 21287.
AD  - The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins Medical
      Institutions, Baltimore, MD 21287.
FAU - Popoli, Maria
AU  - Popoli M
AD  - The Ludwig Center, The Johns Hopkins Medical Institutions, Baltimore, MD 21287.
AD  - Howard Hughes Medical Institute, The Johns Hopkins Medical Institutions,
      Baltimore, MD 21287.
AD  - Sidney Kimmel Cancer Center at Johns Hopkins, The Johns Hopkins Medical
      Institutions, Baltimore, MD 21287.
AD  - The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins Medical
      Institutions, Baltimore, MD 21287.
FAU - Goggins, Michael G
AU  - Goggins MG
AD  - Sidney Kimmel Cancer Center at Johns Hopkins, The Johns Hopkins Medical
      Institutions, Baltimore, MD 21287.
AD  - The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins Medical
      Institutions, Baltimore, MD 21287.
AD  - Department of Medicine, The Johns Hopkins Medical Institutions, Baltimore, MD
      21287.
AD  - Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD
      21287.
FAU - Hruban, Ralph H
AU  - Hruban RH
AD  - Sidney Kimmel Cancer Center at Johns Hopkins, The Johns Hopkins Medical
      Institutions, Baltimore, MD 21287.
AD  - The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins Medical
      Institutions, Baltimore, MD 21287.
AD  - Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD
      21287.
FAU - Wolfgang, Christopher L
AU  - Wolfgang CL
AD  - Department of Surgery, The Johns Hopkins Medical Institutions, Baltimore, MD
      21287.
FAU - Klein, Alison P
AU  - Klein AP
AD  - Sidney Kimmel Cancer Center at Johns Hopkins, The Johns Hopkins Medical
      Institutions, Baltimore, MD 21287.
AD  - The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins Medical
      Institutions, Baltimore, MD 21287.
AD  - Department of Epidemiology, The Johns Hopkins Bloomberg School of Public Health, 
      Baltimore, MD 21205.
FAU - Tomasetti, Cristian
AU  - Tomasetti C
AD  - Sidney Kimmel Cancer Center at Johns Hopkins, The Johns Hopkins Medical
      Institutions, Baltimore, MD 21287.
AD  - Department of Biostatistics, The Johns Hopkins Bloomberg School of Public Health,
      Baltimore, MD 21205.
AD  - Division of Biostatistics and Bioinformatics, Department of Oncology, The Johns
      Hopkins Medical Institutions, Baltimore, MD 21287.
FAU - Papadopoulos, Nickolas
AU  - Papadopoulos N
AD  - The Ludwig Center, The Johns Hopkins Medical Institutions, Baltimore, MD 21287.
AD  - Sidney Kimmel Cancer Center at Johns Hopkins, The Johns Hopkins Medical
      Institutions, Baltimore, MD 21287.
AD  - The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins Medical
      Institutions, Baltimore, MD 21287.
FAU - Kinzler, Kenneth W
AU  - Kinzler KW
AD  - The Ludwig Center, The Johns Hopkins Medical Institutions, Baltimore, MD 21287.
AD  - Sidney Kimmel Cancer Center at Johns Hopkins, The Johns Hopkins Medical
      Institutions, Baltimore, MD 21287.
AD  - The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins Medical
      Institutions, Baltimore, MD 21287.
FAU - Vogelstein, Bert
AU  - Vogelstein B
AD  - The Ludwig Center, The Johns Hopkins Medical Institutions, Baltimore, MD 21287;
      bertvog@gmail.com amlennon@jhmi.edu.
AD  - Howard Hughes Medical Institute, The Johns Hopkins Medical Institutions,
      Baltimore, MD 21287.
AD  - Sidney Kimmel Cancer Center at Johns Hopkins, The Johns Hopkins Medical
      Institutions, Baltimore, MD 21287.
AD  - The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins Medical
      Institutions, Baltimore, MD 21287.
FAU - Lennon, Anne Marie
AU  - Lennon AM
AD  - The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins Medical
      Institutions, Baltimore, MD 21287; bertvog@gmail.com amlennon@jhmi.edu.
AD  - Department of Medicine, The Johns Hopkins Medical Institutions, Baltimore, MD
      21287.
LA  - eng
SI  - GENBANK/EGAS00001002444
GR  - U01 CA200468/CA/NCI NIH HHS/United States
GR  - T32 GM007309/GM/NIGMS NIH HHS/United States
GR  - P50 CA062924/CA/NCI NIH HHS/United States
GR  - P30 CA006973/CA/NCI NIH HHS/United States
GR  - U01 CA152753/CA/NCI NIH HHS/United States
GR  - P50 CA102701/CA/NCI NIH HHS/United States
GR  - U01 CA196403/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20170905
PL  - United States
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
PMC - PMC5617273
OTO - NOTNLM
OT  - circulating tumor DNA
OT  - early cancer detection
OT  - liquid biopsy
OT  - pancreatic cancer
OT  - protein biomarkers
COIS- Conflict of interest statement: C.M.S. and M.T.Y.-S. are founders and coowners of
      B9, Inc. and have no conflicts of interest with respect to the new technology
      described in this article. N.P., K.W.K., and B.V. are founders of Personal Genome
      Diagnostics, Inc. and PapGene, Inc. K.W.K. and B.V. are members of the Scientific
      Advisory Board of Sysmex-Inostics and Morphotek. B.V. is also a member of the
      Scientific Advisory Board of Exelixis GP. These companies and others have
      licensed technologies from Johns Hopkins, including those related to early
      diagnostics. N.P., K.W.K., and B.V. are the inventors of some of these
      technologies and receive equity or royalties from their licenses. The terms of
      these arrangements are being managed by the university in accordance with its
      conflict of interest policies. N.P., K.W.K., and B.V. have no conflicts of
      interest with respect to the new technology described in this article, as defined
      by the Johns Hopkins University policy on conflict of interest.
EDAT- 2017/09/07 06:00
MHDA- 2017/09/07 06:00
CRDT- 2017/09/07 06:00
PMCR- 2018/03/19 00:00
PHST- 2018/03/19 00:00 [pmc-release]
PHST- 2017/09/07 06:00 [pubmed]
PHST- 2017/09/07 06:00 [medline]
PHST- 2017/09/07 06:00 [entrez]
AID - 1704961114 [pii]
AID - 10.1073/pnas.1704961114 [doi]
PST - ppublish
SO  - Proc Natl Acad Sci U S A. 2017 Sep 19;114(38):10202-10207. doi:
      10.1073/pnas.1704961114. Epub 2017 Sep 5.

PMID- 29141164
OWN - NLM
STAT- MEDLINE
DCOM- 20171201
LR  - 20171201
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 377
IP  - 20
DP  - 2017 Nov 16
TI  - Lomustine and Bevacizumab in Progressive Glioblastoma.
PG  - 1954-1963
LID - 10.1056/NEJMoa1707358 [doi]
AB  - BACKGROUND: Bevacizumab is approved for the treatment of patients with
      progressive glioblastoma on the basis of uncontrolled data. Data from a phase 2
      trial suggested that the addition of bevacizumab to lomustine might improve
      overall survival as compared with monotherapies. We sought to determine whether
      the combination would result in longer overall survival than lomustine alone
      among patients at first progression of glioblastoma. METHODS: We randomly
      assigned patients with progression after chemoradiation in a 2:1 ratio to receive
      lomustine plus bevacizumab (combination group, 288 patients) or lomustine alone
      (monotherapy group, 149 patients). The methylation status of the promoter of
      O(6)-methylguanine-DNA methyltransferase (MGMT) was assessed. Health-related
      quality of life and neurocognitive function were evaluated at baseline and every 
      12 weeks. The primary end point of the trial was overall survival. RESULTS: A
      total of 437 patients underwent randomization. The median number of 6-week
      treatment cycles was three in the combination group and one in the monotherapy
      group. With 329 overall survival events (75.3%), the combination therapy did not 
      provide a survival advantage; the median overall survival was 9.1 months (95%
      confidence interval [CI], 8.1 to 10.1) in the combination group and 8.6 months
      (95% CI, 7.6 to 10.4) in the monotherapy group (hazard ratio for death, 0.95; 95%
      CI, 0.74 to 1.21; P=0.65). Locally assessed progression-free survival was 2.7
      months longer in the combination group than in the monotherapy group: 4.2 months 
      versus 1.5 months (hazard ratio for disease progression or death, 0.49; 95% CI,
      0.39 to 0.61; P<0.001). Grade 3 to 5 adverse events occurred in 63.6% of the
      patients in the combination group and 38.1% of the patients in the monotherapy
      group. The addition of bevacizumab to lomustine affected neither health-related
      quality of life nor neurocognitive function. The MGMT status was prognostic.
      CONCLUSIONS: Despite somewhat prolonged progression-free survival, treatment with
      lomustine plus bevacizumab did not confer a survival advantage over treatment
      with lomustine alone in patients with progressive glioblastoma. (Funded by an
      unrestricted educational grant from F. Hoffmann-La Roche and by the EORTC Cancer 
      Research Fund; EORTC 26101 ClinicalTrials.gov number, NCT01290939 ; Eudra-CT
      number, 2010-023218-30 .).
FAU - Wick, Wolfgang
AU  - Wick W
AD  - From the University Medical Center and German Cancer Research Center, Heidelberg,
      Germany (W.W., M.B., F.S., I.H., A.D., M.P.); the European Organization for
      Research and Treatment of Cancer, Brussels (T.G., V.G.), and Leuven Cancer
      Institute-KU Leuven, Leuven (P.M.C.) - both in Belgium; Haaglanden Medical
      Center, The Hague (M.T.), Erasmus MC Cancer Institute, Rotterdam (W.T., J.C.B.,
      M.J.B.), and VU University Medical Center, Amsterdam (M.K.) - all in the
      Netherlands; the Medical Oncology Department, Azienda Unita Sanitaria Locale di
      Bologna-IRCCS Istituto delle Scienze Neurologiche, Bologna, Italy (A.A.B.);
      Institut Gustave Roussy, Villejuif (J.D.), Assistance Publique-Hopitaux de Paris,
      Hopitaux Universitaires La Pitie Salpetriere-Charles Foix, Service de Neurologie 
      2-Mazarin, INSERM Unite 1127, Centre National de la Recherche Scientifique Unite 
      Mixte de Recherche (UMR) 7225, Sorbonne Universites, University Pierre and Marie 
      Curie 06 UMR S1127, and Institut du Cerveau et de la Moelle Epiniere, Paris
      (A.I.), Institut de Cancerologie de l'Ouest-Centre Rene Gauducheau,
      Saint-Herblain (M.C.), Institut Regional du Cancer Montpellier, Montpellier
      (M.F.), and Centre Hospitalier Regional Universitaire de Lille, Lille (E.L.R.,
      F.D.) - all in France; and the Departments of Oncology and Neurology, University 
      Hospital and University of Zurich, Zurich, Switzerland (R.S., M.W.).
FAU - Gorlia, Thierry
AU  - Gorlia T
AD  - From the University Medical Center and German Cancer Research Center, Heidelberg,
      Germany (W.W., M.B., F.S., I.H., A.D., M.P.); the European Organization for
      Research and Treatment of Cancer, Brussels (T.G., V.G.), and Leuven Cancer
      Institute-KU Leuven, Leuven (P.M.C.) - both in Belgium; Haaglanden Medical
      Center, The Hague (M.T.), Erasmus MC Cancer Institute, Rotterdam (W.T., J.C.B.,
      M.J.B.), and VU University Medical Center, Amsterdam (M.K.) - all in the
      Netherlands; the Medical Oncology Department, Azienda Unita Sanitaria Locale di
      Bologna-IRCCS Istituto delle Scienze Neurologiche, Bologna, Italy (A.A.B.);
      Institut Gustave Roussy, Villejuif (J.D.), Assistance Publique-Hopitaux de Paris,
      Hopitaux Universitaires La Pitie Salpetriere-Charles Foix, Service de Neurologie 
      2-Mazarin, INSERM Unite 1127, Centre National de la Recherche Scientifique Unite 
      Mixte de Recherche (UMR) 7225, Sorbonne Universites, University Pierre and Marie 
      Curie 06 UMR S1127, and Institut du Cerveau et de la Moelle Epiniere, Paris
      (A.I.), Institut de Cancerologie de l'Ouest-Centre Rene Gauducheau,
      Saint-Herblain (M.C.), Institut Regional du Cancer Montpellier, Montpellier
      (M.F.), and Centre Hospitalier Regional Universitaire de Lille, Lille (E.L.R.,
      F.D.) - all in France; and the Departments of Oncology and Neurology, University 
      Hospital and University of Zurich, Zurich, Switzerland (R.S., M.W.).
FAU - Bendszus, Martin
AU  - Bendszus M
AD  - From the University Medical Center and German Cancer Research Center, Heidelberg,
      Germany (W.W., M.B., F.S., I.H., A.D., M.P.); the European Organization for
      Research and Treatment of Cancer, Brussels (T.G., V.G.), and Leuven Cancer
      Institute-KU Leuven, Leuven (P.M.C.) - both in Belgium; Haaglanden Medical
      Center, The Hague (M.T.), Erasmus MC Cancer Institute, Rotterdam (W.T., J.C.B.,
      M.J.B.), and VU University Medical Center, Amsterdam (M.K.) - all in the
      Netherlands; the Medical Oncology Department, Azienda Unita Sanitaria Locale di
      Bologna-IRCCS Istituto delle Scienze Neurologiche, Bologna, Italy (A.A.B.);
      Institut Gustave Roussy, Villejuif (J.D.), Assistance Publique-Hopitaux de Paris,
      Hopitaux Universitaires La Pitie Salpetriere-Charles Foix, Service de Neurologie 
      2-Mazarin, INSERM Unite 1127, Centre National de la Recherche Scientifique Unite 
      Mixte de Recherche (UMR) 7225, Sorbonne Universites, University Pierre and Marie 
      Curie 06 UMR S1127, and Institut du Cerveau et de la Moelle Epiniere, Paris
      (A.I.), Institut de Cancerologie de l'Ouest-Centre Rene Gauducheau,
      Saint-Herblain (M.C.), Institut Regional du Cancer Montpellier, Montpellier
      (M.F.), and Centre Hospitalier Regional Universitaire de Lille, Lille (E.L.R.,
      F.D.) - all in France; and the Departments of Oncology and Neurology, University 
      Hospital and University of Zurich, Zurich, Switzerland (R.S., M.W.).
FAU - Taphoorn, Martin
AU  - Taphoorn M
AD  - From the University Medical Center and German Cancer Research Center, Heidelberg,
      Germany (W.W., M.B., F.S., I.H., A.D., M.P.); the European Organization for
      Research and Treatment of Cancer, Brussels (T.G., V.G.), and Leuven Cancer
      Institute-KU Leuven, Leuven (P.M.C.) - both in Belgium; Haaglanden Medical
      Center, The Hague (M.T.), Erasmus MC Cancer Institute, Rotterdam (W.T., J.C.B.,
      M.J.B.), and VU University Medical Center, Amsterdam (M.K.) - all in the
      Netherlands; the Medical Oncology Department, Azienda Unita Sanitaria Locale di
      Bologna-IRCCS Istituto delle Scienze Neurologiche, Bologna, Italy (A.A.B.);
      Institut Gustave Roussy, Villejuif (J.D.), Assistance Publique-Hopitaux de Paris,
      Hopitaux Universitaires La Pitie Salpetriere-Charles Foix, Service de Neurologie 
      2-Mazarin, INSERM Unite 1127, Centre National de la Recherche Scientifique Unite 
      Mixte de Recherche (UMR) 7225, Sorbonne Universites, University Pierre and Marie 
      Curie 06 UMR S1127, and Institut du Cerveau et de la Moelle Epiniere, Paris
      (A.I.), Institut de Cancerologie de l'Ouest-Centre Rene Gauducheau,
      Saint-Herblain (M.C.), Institut Regional du Cancer Montpellier, Montpellier
      (M.F.), and Centre Hospitalier Regional Universitaire de Lille, Lille (E.L.R.,
      F.D.) - all in France; and the Departments of Oncology and Neurology, University 
      Hospital and University of Zurich, Zurich, Switzerland (R.S., M.W.).
FAU - Sahm, Felix
AU  - Sahm F
AD  - From the University Medical Center and German Cancer Research Center, Heidelberg,
      Germany (W.W., M.B., F.S., I.H., A.D., M.P.); the European Organization for
      Research and Treatment of Cancer, Brussels (T.G., V.G.), and Leuven Cancer
      Institute-KU Leuven, Leuven (P.M.C.) - both in Belgium; Haaglanden Medical
      Center, The Hague (M.T.), Erasmus MC Cancer Institute, Rotterdam (W.T., J.C.B.,
      M.J.B.), and VU University Medical Center, Amsterdam (M.K.) - all in the
      Netherlands; the Medical Oncology Department, Azienda Unita Sanitaria Locale di
      Bologna-IRCCS Istituto delle Scienze Neurologiche, Bologna, Italy (A.A.B.);
      Institut Gustave Roussy, Villejuif (J.D.), Assistance Publique-Hopitaux de Paris,
      Hopitaux Universitaires La Pitie Salpetriere-Charles Foix, Service de Neurologie 
      2-Mazarin, INSERM Unite 1127, Centre National de la Recherche Scientifique Unite 
      Mixte de Recherche (UMR) 7225, Sorbonne Universites, University Pierre and Marie 
      Curie 06 UMR S1127, and Institut du Cerveau et de la Moelle Epiniere, Paris
      (A.I.), Institut de Cancerologie de l'Ouest-Centre Rene Gauducheau,
      Saint-Herblain (M.C.), Institut Regional du Cancer Montpellier, Montpellier
      (M.F.), and Centre Hospitalier Regional Universitaire de Lille, Lille (E.L.R.,
      F.D.) - all in France; and the Departments of Oncology and Neurology, University 
      Hospital and University of Zurich, Zurich, Switzerland (R.S., M.W.).
FAU - Harting, Inga
AU  - Harting I
AD  - From the University Medical Center and German Cancer Research Center, Heidelberg,
      Germany (W.W., M.B., F.S., I.H., A.D., M.P.); the European Organization for
      Research and Treatment of Cancer, Brussels (T.G., V.G.), and Leuven Cancer
      Institute-KU Leuven, Leuven (P.M.C.) - both in Belgium; Haaglanden Medical
      Center, The Hague (M.T.), Erasmus MC Cancer Institute, Rotterdam (W.T., J.C.B.,
      M.J.B.), and VU University Medical Center, Amsterdam (M.K.) - all in the
      Netherlands; the Medical Oncology Department, Azienda Unita Sanitaria Locale di
      Bologna-IRCCS Istituto delle Scienze Neurologiche, Bologna, Italy (A.A.B.);
      Institut Gustave Roussy, Villejuif (J.D.), Assistance Publique-Hopitaux de Paris,
      Hopitaux Universitaires La Pitie Salpetriere-Charles Foix, Service de Neurologie 
      2-Mazarin, INSERM Unite 1127, Centre National de la Recherche Scientifique Unite 
      Mixte de Recherche (UMR) 7225, Sorbonne Universites, University Pierre and Marie 
      Curie 06 UMR S1127, and Institut du Cerveau et de la Moelle Epiniere, Paris
      (A.I.), Institut de Cancerologie de l'Ouest-Centre Rene Gauducheau,
      Saint-Herblain (M.C.), Institut Regional du Cancer Montpellier, Montpellier
      (M.F.), and Centre Hospitalier Regional Universitaire de Lille, Lille (E.L.R.,
      F.D.) - all in France; and the Departments of Oncology and Neurology, University 
      Hospital and University of Zurich, Zurich, Switzerland (R.S., M.W.).
FAU - Brandes, Alba A
AU  - Brandes AA
AD  - From the University Medical Center and German Cancer Research Center, Heidelberg,
      Germany (W.W., M.B., F.S., I.H., A.D., M.P.); the European Organization for
      Research and Treatment of Cancer, Brussels (T.G., V.G.), and Leuven Cancer
      Institute-KU Leuven, Leuven (P.M.C.) - both in Belgium; Haaglanden Medical
      Center, The Hague (M.T.), Erasmus MC Cancer Institute, Rotterdam (W.T., J.C.B.,
      M.J.B.), and VU University Medical Center, Amsterdam (M.K.) - all in the
      Netherlands; the Medical Oncology Department, Azienda Unita Sanitaria Locale di
      Bologna-IRCCS Istituto delle Scienze Neurologiche, Bologna, Italy (A.A.B.);
      Institut Gustave Roussy, Villejuif (J.D.), Assistance Publique-Hopitaux de Paris,
      Hopitaux Universitaires La Pitie Salpetriere-Charles Foix, Service de Neurologie 
      2-Mazarin, INSERM Unite 1127, Centre National de la Recherche Scientifique Unite 
      Mixte de Recherche (UMR) 7225, Sorbonne Universites, University Pierre and Marie 
      Curie 06 UMR S1127, and Institut du Cerveau et de la Moelle Epiniere, Paris
      (A.I.), Institut de Cancerologie de l'Ouest-Centre Rene Gauducheau,
      Saint-Herblain (M.C.), Institut Regional du Cancer Montpellier, Montpellier
      (M.F.), and Centre Hospitalier Regional Universitaire de Lille, Lille (E.L.R.,
      F.D.) - all in France; and the Departments of Oncology and Neurology, University 
      Hospital and University of Zurich, Zurich, Switzerland (R.S., M.W.).
FAU - Taal, Walter
AU  - Taal W
AD  - From the University Medical Center and German Cancer Research Center, Heidelberg,
      Germany (W.W., M.B., F.S., I.H., A.D., M.P.); the European Organization for
      Research and Treatment of Cancer, Brussels (T.G., V.G.), and Leuven Cancer
      Institute-KU Leuven, Leuven (P.M.C.) - both in Belgium; Haaglanden Medical
      Center, The Hague (M.T.), Erasmus MC Cancer Institute, Rotterdam (W.T., J.C.B.,
      M.J.B.), and VU University Medical Center, Amsterdam (M.K.) - all in the
      Netherlands; the Medical Oncology Department, Azienda Unita Sanitaria Locale di
      Bologna-IRCCS Istituto delle Scienze Neurologiche, Bologna, Italy (A.A.B.);
      Institut Gustave Roussy, Villejuif (J.D.), Assistance Publique-Hopitaux de Paris,
      Hopitaux Universitaires La Pitie Salpetriere-Charles Foix, Service de Neurologie 
      2-Mazarin, INSERM Unite 1127, Centre National de la Recherche Scientifique Unite 
      Mixte de Recherche (UMR) 7225, Sorbonne Universites, University Pierre and Marie 
      Curie 06 UMR S1127, and Institut du Cerveau et de la Moelle Epiniere, Paris
      (A.I.), Institut de Cancerologie de l'Ouest-Centre Rene Gauducheau,
      Saint-Herblain (M.C.), Institut Regional du Cancer Montpellier, Montpellier
      (M.F.), and Centre Hospitalier Regional Universitaire de Lille, Lille (E.L.R.,
      F.D.) - all in France; and the Departments of Oncology and Neurology, University 
      Hospital and University of Zurich, Zurich, Switzerland (R.S., M.W.).
FAU - Domont, Julien
AU  - Domont J
AD  - From the University Medical Center and German Cancer Research Center, Heidelberg,
      Germany (W.W., M.B., F.S., I.H., A.D., M.P.); the European Organization for
      Research and Treatment of Cancer, Brussels (T.G., V.G.), and Leuven Cancer
      Institute-KU Leuven, Leuven (P.M.C.) - both in Belgium; Haaglanden Medical
      Center, The Hague (M.T.), Erasmus MC Cancer Institute, Rotterdam (W.T., J.C.B.,
      M.J.B.), and VU University Medical Center, Amsterdam (M.K.) - all in the
      Netherlands; the Medical Oncology Department, Azienda Unita Sanitaria Locale di
      Bologna-IRCCS Istituto delle Scienze Neurologiche, Bologna, Italy (A.A.B.);
      Institut Gustave Roussy, Villejuif (J.D.), Assistance Publique-Hopitaux de Paris,
      Hopitaux Universitaires La Pitie Salpetriere-Charles Foix, Service de Neurologie 
      2-Mazarin, INSERM Unite 1127, Centre National de la Recherche Scientifique Unite 
      Mixte de Recherche (UMR) 7225, Sorbonne Universites, University Pierre and Marie 
      Curie 06 UMR S1127, and Institut du Cerveau et de la Moelle Epiniere, Paris
      (A.I.), Institut de Cancerologie de l'Ouest-Centre Rene Gauducheau,
      Saint-Herblain (M.C.), Institut Regional du Cancer Montpellier, Montpellier
      (M.F.), and Centre Hospitalier Regional Universitaire de Lille, Lille (E.L.R.,
      F.D.) - all in France; and the Departments of Oncology and Neurology, University 
      Hospital and University of Zurich, Zurich, Switzerland (R.S., M.W.).
FAU - Idbaih, Ahmed
AU  - Idbaih A
AD  - From the University Medical Center and German Cancer Research Center, Heidelberg,
      Germany (W.W., M.B., F.S., I.H., A.D., M.P.); the European Organization for
      Research and Treatment of Cancer, Brussels (T.G., V.G.), and Leuven Cancer
      Institute-KU Leuven, Leuven (P.M.C.) - both in Belgium; Haaglanden Medical
      Center, The Hague (M.T.), Erasmus MC Cancer Institute, Rotterdam (W.T., J.C.B.,
      M.J.B.), and VU University Medical Center, Amsterdam (M.K.) - all in the
      Netherlands; the Medical Oncology Department, Azienda Unita Sanitaria Locale di
      Bologna-IRCCS Istituto delle Scienze Neurologiche, Bologna, Italy (A.A.B.);
      Institut Gustave Roussy, Villejuif (J.D.), Assistance Publique-Hopitaux de Paris,
      Hopitaux Universitaires La Pitie Salpetriere-Charles Foix, Service de Neurologie 
      2-Mazarin, INSERM Unite 1127, Centre National de la Recherche Scientifique Unite 
      Mixte de Recherche (UMR) 7225, Sorbonne Universites, University Pierre and Marie 
      Curie 06 UMR S1127, and Institut du Cerveau et de la Moelle Epiniere, Paris
      (A.I.), Institut de Cancerologie de l'Ouest-Centre Rene Gauducheau,
      Saint-Herblain (M.C.), Institut Regional du Cancer Montpellier, Montpellier
      (M.F.), and Centre Hospitalier Regional Universitaire de Lille, Lille (E.L.R.,
      F.D.) - all in France; and the Departments of Oncology and Neurology, University 
      Hospital and University of Zurich, Zurich, Switzerland (R.S., M.W.).
FAU - Campone, Mario
AU  - Campone M
AD  - From the University Medical Center and German Cancer Research Center, Heidelberg,
      Germany (W.W., M.B., F.S., I.H., A.D., M.P.); the European Organization for
      Research and Treatment of Cancer, Brussels (T.G., V.G.), and Leuven Cancer
      Institute-KU Leuven, Leuven (P.M.C.) - both in Belgium; Haaglanden Medical
      Center, The Hague (M.T.), Erasmus MC Cancer Institute, Rotterdam (W.T., J.C.B.,
      M.J.B.), and VU University Medical Center, Amsterdam (M.K.) - all in the
      Netherlands; the Medical Oncology Department, Azienda Unita Sanitaria Locale di
      Bologna-IRCCS Istituto delle Scienze Neurologiche, Bologna, Italy (A.A.B.);
      Institut Gustave Roussy, Villejuif (J.D.), Assistance Publique-Hopitaux de Paris,
      Hopitaux Universitaires La Pitie Salpetriere-Charles Foix, Service de Neurologie 
      2-Mazarin, INSERM Unite 1127, Centre National de la Recherche Scientifique Unite 
      Mixte de Recherche (UMR) 7225, Sorbonne Universites, University Pierre and Marie 
      Curie 06 UMR S1127, and Institut du Cerveau et de la Moelle Epiniere, Paris
      (A.I.), Institut de Cancerologie de l'Ouest-Centre Rene Gauducheau,
      Saint-Herblain (M.C.), Institut Regional du Cancer Montpellier, Montpellier
      (M.F.), and Centre Hospitalier Regional Universitaire de Lille, Lille (E.L.R.,
      F.D.) - all in France; and the Departments of Oncology and Neurology, University 
      Hospital and University of Zurich, Zurich, Switzerland (R.S., M.W.).
FAU - Clement, Paul M
AU  - Clement PM
AD  - From the University Medical Center and German Cancer Research Center, Heidelberg,
      Germany (W.W., M.B., F.S., I.H., A.D., M.P.); the European Organization for
      Research and Treatment of Cancer, Brussels (T.G., V.G.), and Leuven Cancer
      Institute-KU Leuven, Leuven (P.M.C.) - both in Belgium; Haaglanden Medical
      Center, The Hague (M.T.), Erasmus MC Cancer Institute, Rotterdam (W.T., J.C.B.,
      M.J.B.), and VU University Medical Center, Amsterdam (M.K.) - all in the
      Netherlands; the Medical Oncology Department, Azienda Unita Sanitaria Locale di
      Bologna-IRCCS Istituto delle Scienze Neurologiche, Bologna, Italy (A.A.B.);
      Institut Gustave Roussy, Villejuif (J.D.), Assistance Publique-Hopitaux de Paris,
      Hopitaux Universitaires La Pitie Salpetriere-Charles Foix, Service de Neurologie 
      2-Mazarin, INSERM Unite 1127, Centre National de la Recherche Scientifique Unite 
      Mixte de Recherche (UMR) 7225, Sorbonne Universites, University Pierre and Marie 
      Curie 06 UMR S1127, and Institut du Cerveau et de la Moelle Epiniere, Paris
      (A.I.), Institut de Cancerologie de l'Ouest-Centre Rene Gauducheau,
      Saint-Herblain (M.C.), Institut Regional du Cancer Montpellier, Montpellier
      (M.F.), and Centre Hospitalier Regional Universitaire de Lille, Lille (E.L.R.,
      F.D.) - all in France; and the Departments of Oncology and Neurology, University 
      Hospital and University of Zurich, Zurich, Switzerland (R.S., M.W.).
FAU - Stupp, Roger
AU  - Stupp R
AD  - From the University Medical Center and German Cancer Research Center, Heidelberg,
      Germany (W.W., M.B., F.S., I.H., A.D., M.P.); the European Organization for
      Research and Treatment of Cancer, Brussels (T.G., V.G.), and Leuven Cancer
      Institute-KU Leuven, Leuven (P.M.C.) - both in Belgium; Haaglanden Medical
      Center, The Hague (M.T.), Erasmus MC Cancer Institute, Rotterdam (W.T., J.C.B.,
      M.J.B.), and VU University Medical Center, Amsterdam (M.K.) - all in the
      Netherlands; the Medical Oncology Department, Azienda Unita Sanitaria Locale di
      Bologna-IRCCS Istituto delle Scienze Neurologiche, Bologna, Italy (A.A.B.);
      Institut Gustave Roussy, Villejuif (J.D.), Assistance Publique-Hopitaux de Paris,
      Hopitaux Universitaires La Pitie Salpetriere-Charles Foix, Service de Neurologie 
      2-Mazarin, INSERM Unite 1127, Centre National de la Recherche Scientifique Unite 
      Mixte de Recherche (UMR) 7225, Sorbonne Universites, University Pierre and Marie 
      Curie 06 UMR S1127, and Institut du Cerveau et de la Moelle Epiniere, Paris
      (A.I.), Institut de Cancerologie de l'Ouest-Centre Rene Gauducheau,
      Saint-Herblain (M.C.), Institut Regional du Cancer Montpellier, Montpellier
      (M.F.), and Centre Hospitalier Regional Universitaire de Lille, Lille (E.L.R.,
      F.D.) - all in France; and the Departments of Oncology and Neurology, University 
      Hospital and University of Zurich, Zurich, Switzerland (R.S., M.W.).
FAU - Fabbro, Michel
AU  - Fabbro M
AD  - From the University Medical Center and German Cancer Research Center, Heidelberg,
      Germany (W.W., M.B., F.S., I.H., A.D., M.P.); the European Organization for
      Research and Treatment of Cancer, Brussels (T.G., V.G.), and Leuven Cancer
      Institute-KU Leuven, Leuven (P.M.C.) - both in Belgium; Haaglanden Medical
      Center, The Hague (M.T.), Erasmus MC Cancer Institute, Rotterdam (W.T., J.C.B.,
      M.J.B.), and VU University Medical Center, Amsterdam (M.K.) - all in the
      Netherlands; the Medical Oncology Department, Azienda Unita Sanitaria Locale di
      Bologna-IRCCS Istituto delle Scienze Neurologiche, Bologna, Italy (A.A.B.);
      Institut Gustave Roussy, Villejuif (J.D.), Assistance Publique-Hopitaux de Paris,
      Hopitaux Universitaires La Pitie Salpetriere-Charles Foix, Service de Neurologie 
      2-Mazarin, INSERM Unite 1127, Centre National de la Recherche Scientifique Unite 
      Mixte de Recherche (UMR) 7225, Sorbonne Universites, University Pierre and Marie 
      Curie 06 UMR S1127, and Institut du Cerveau et de la Moelle Epiniere, Paris
      (A.I.), Institut de Cancerologie de l'Ouest-Centre Rene Gauducheau,
      Saint-Herblain (M.C.), Institut Regional du Cancer Montpellier, Montpellier
      (M.F.), and Centre Hospitalier Regional Universitaire de Lille, Lille (E.L.R.,
      F.D.) - all in France; and the Departments of Oncology and Neurology, University 
      Hospital and University of Zurich, Zurich, Switzerland (R.S., M.W.).
FAU - Le Rhun, Emilie
AU  - Le Rhun E
AD  - From the University Medical Center and German Cancer Research Center, Heidelberg,
      Germany (W.W., M.B., F.S., I.H., A.D., M.P.); the European Organization for
      Research and Treatment of Cancer, Brussels (T.G., V.G.), and Leuven Cancer
      Institute-KU Leuven, Leuven (P.M.C.) - both in Belgium; Haaglanden Medical
      Center, The Hague (M.T.), Erasmus MC Cancer Institute, Rotterdam (W.T., J.C.B.,
      M.J.B.), and VU University Medical Center, Amsterdam (M.K.) - all in the
      Netherlands; the Medical Oncology Department, Azienda Unita Sanitaria Locale di
      Bologna-IRCCS Istituto delle Scienze Neurologiche, Bologna, Italy (A.A.B.);
      Institut Gustave Roussy, Villejuif (J.D.), Assistance Publique-Hopitaux de Paris,
      Hopitaux Universitaires La Pitie Salpetriere-Charles Foix, Service de Neurologie 
      2-Mazarin, INSERM Unite 1127, Centre National de la Recherche Scientifique Unite 
      Mixte de Recherche (UMR) 7225, Sorbonne Universites, University Pierre and Marie 
      Curie 06 UMR S1127, and Institut du Cerveau et de la Moelle Epiniere, Paris
      (A.I.), Institut de Cancerologie de l'Ouest-Centre Rene Gauducheau,
      Saint-Herblain (M.C.), Institut Regional du Cancer Montpellier, Montpellier
      (M.F.), and Centre Hospitalier Regional Universitaire de Lille, Lille (E.L.R.,
      F.D.) - all in France; and the Departments of Oncology and Neurology, University 
      Hospital and University of Zurich, Zurich, Switzerland (R.S., M.W.).
FAU - Dubois, Francois
AU  - Dubois F
AD  - From the University Medical Center and German Cancer Research Center, Heidelberg,
      Germany (W.W., M.B., F.S., I.H., A.D., M.P.); the European Organization for
      Research and Treatment of Cancer, Brussels (T.G., V.G.), and Leuven Cancer
      Institute-KU Leuven, Leuven (P.M.C.) - both in Belgium; Haaglanden Medical
      Center, The Hague (M.T.), Erasmus MC Cancer Institute, Rotterdam (W.T., J.C.B.,
      M.J.B.), and VU University Medical Center, Amsterdam (M.K.) - all in the
      Netherlands; the Medical Oncology Department, Azienda Unita Sanitaria Locale di
      Bologna-IRCCS Istituto delle Scienze Neurologiche, Bologna, Italy (A.A.B.);
      Institut Gustave Roussy, Villejuif (J.D.), Assistance Publique-Hopitaux de Paris,
      Hopitaux Universitaires La Pitie Salpetriere-Charles Foix, Service de Neurologie 
      2-Mazarin, INSERM Unite 1127, Centre National de la Recherche Scientifique Unite 
      Mixte de Recherche (UMR) 7225, Sorbonne Universites, University Pierre and Marie 
      Curie 06 UMR S1127, and Institut du Cerveau et de la Moelle Epiniere, Paris
      (A.I.), Institut de Cancerologie de l'Ouest-Centre Rene Gauducheau,
      Saint-Herblain (M.C.), Institut Regional du Cancer Montpellier, Montpellier
      (M.F.), and Centre Hospitalier Regional Universitaire de Lille, Lille (E.L.R.,
      F.D.) - all in France; and the Departments of Oncology and Neurology, University 
      Hospital and University of Zurich, Zurich, Switzerland (R.S., M.W.).
FAU - Weller, Michael
AU  - Weller M
AD  - From the University Medical Center and German Cancer Research Center, Heidelberg,
      Germany (W.W., M.B., F.S., I.H., A.D., M.P.); the European Organization for
      Research and Treatment of Cancer, Brussels (T.G., V.G.), and Leuven Cancer
      Institute-KU Leuven, Leuven (P.M.C.) - both in Belgium; Haaglanden Medical
      Center, The Hague (M.T.), Erasmus MC Cancer Institute, Rotterdam (W.T., J.C.B.,
      M.J.B.), and VU University Medical Center, Amsterdam (M.K.) - all in the
      Netherlands; the Medical Oncology Department, Azienda Unita Sanitaria Locale di
      Bologna-IRCCS Istituto delle Scienze Neurologiche, Bologna, Italy (A.A.B.);
      Institut Gustave Roussy, Villejuif (J.D.), Assistance Publique-Hopitaux de Paris,
      Hopitaux Universitaires La Pitie Salpetriere-Charles Foix, Service de Neurologie 
      2-Mazarin, INSERM Unite 1127, Centre National de la Recherche Scientifique Unite 
      Mixte de Recherche (UMR) 7225, Sorbonne Universites, University Pierre and Marie 
      Curie 06 UMR S1127, and Institut du Cerveau et de la Moelle Epiniere, Paris
      (A.I.), Institut de Cancerologie de l'Ouest-Centre Rene Gauducheau,
      Saint-Herblain (M.C.), Institut Regional du Cancer Montpellier, Montpellier
      (M.F.), and Centre Hospitalier Regional Universitaire de Lille, Lille (E.L.R.,
      F.D.) - all in France; and the Departments of Oncology and Neurology, University 
      Hospital and University of Zurich, Zurich, Switzerland (R.S., M.W.).
FAU - von Deimling, Andreas
AU  - von Deimling A
AD  - From the University Medical Center and German Cancer Research Center, Heidelberg,
      Germany (W.W., M.B., F.S., I.H., A.D., M.P.); the European Organization for
      Research and Treatment of Cancer, Brussels (T.G., V.G.), and Leuven Cancer
      Institute-KU Leuven, Leuven (P.M.C.) - both in Belgium; Haaglanden Medical
      Center, The Hague (M.T.), Erasmus MC Cancer Institute, Rotterdam (W.T., J.C.B.,
      M.J.B.), and VU University Medical Center, Amsterdam (M.K.) - all in the
      Netherlands; the Medical Oncology Department, Azienda Unita Sanitaria Locale di
      Bologna-IRCCS Istituto delle Scienze Neurologiche, Bologna, Italy (A.A.B.);
      Institut Gustave Roussy, Villejuif (J.D.), Assistance Publique-Hopitaux de Paris,
      Hopitaux Universitaires La Pitie Salpetriere-Charles Foix, Service de Neurologie 
      2-Mazarin, INSERM Unite 1127, Centre National de la Recherche Scientifique Unite 
      Mixte de Recherche (UMR) 7225, Sorbonne Universites, University Pierre and Marie 
      Curie 06 UMR S1127, and Institut du Cerveau et de la Moelle Epiniere, Paris
      (A.I.), Institut de Cancerologie de l'Ouest-Centre Rene Gauducheau,
      Saint-Herblain (M.C.), Institut Regional du Cancer Montpellier, Montpellier
      (M.F.), and Centre Hospitalier Regional Universitaire de Lille, Lille (E.L.R.,
      F.D.) - all in France; and the Departments of Oncology and Neurology, University 
      Hospital and University of Zurich, Zurich, Switzerland (R.S., M.W.).
FAU - Golfinopoulos, Vassilis
AU  - Golfinopoulos V
AD  - From the University Medical Center and German Cancer Research Center, Heidelberg,
      Germany (W.W., M.B., F.S., I.H., A.D., M.P.); the European Organization for
      Research and Treatment of Cancer, Brussels (T.G., V.G.), and Leuven Cancer
      Institute-KU Leuven, Leuven (P.M.C.) - both in Belgium; Haaglanden Medical
      Center, The Hague (M.T.), Erasmus MC Cancer Institute, Rotterdam (W.T., J.C.B.,
      M.J.B.), and VU University Medical Center, Amsterdam (M.K.) - all in the
      Netherlands; the Medical Oncology Department, Azienda Unita Sanitaria Locale di
      Bologna-IRCCS Istituto delle Scienze Neurologiche, Bologna, Italy (A.A.B.);
      Institut Gustave Roussy, Villejuif (J.D.), Assistance Publique-Hopitaux de Paris,
      Hopitaux Universitaires La Pitie Salpetriere-Charles Foix, Service de Neurologie 
      2-Mazarin, INSERM Unite 1127, Centre National de la Recherche Scientifique Unite 
      Mixte de Recherche (UMR) 7225, Sorbonne Universites, University Pierre and Marie 
      Curie 06 UMR S1127, and Institut du Cerveau et de la Moelle Epiniere, Paris
      (A.I.), Institut de Cancerologie de l'Ouest-Centre Rene Gauducheau,
      Saint-Herblain (M.C.), Institut Regional du Cancer Montpellier, Montpellier
      (M.F.), and Centre Hospitalier Regional Universitaire de Lille, Lille (E.L.R.,
      F.D.) - all in France; and the Departments of Oncology and Neurology, University 
      Hospital and University of Zurich, Zurich, Switzerland (R.S., M.W.).
FAU - Bromberg, Jacoline C
AU  - Bromberg JC
AD  - From the University Medical Center and German Cancer Research Center, Heidelberg,
      Germany (W.W., M.B., F.S., I.H., A.D., M.P.); the European Organization for
      Research and Treatment of Cancer, Brussels (T.G., V.G.), and Leuven Cancer
      Institute-KU Leuven, Leuven (P.M.C.) - both in Belgium; Haaglanden Medical
      Center, The Hague (M.T.), Erasmus MC Cancer Institute, Rotterdam (W.T., J.C.B.,
      M.J.B.), and VU University Medical Center, Amsterdam (M.K.) - all in the
      Netherlands; the Medical Oncology Department, Azienda Unita Sanitaria Locale di
      Bologna-IRCCS Istituto delle Scienze Neurologiche, Bologna, Italy (A.A.B.);
      Institut Gustave Roussy, Villejuif (J.D.), Assistance Publique-Hopitaux de Paris,
      Hopitaux Universitaires La Pitie Salpetriere-Charles Foix, Service de Neurologie 
      2-Mazarin, INSERM Unite 1127, Centre National de la Recherche Scientifique Unite 
      Mixte de Recherche (UMR) 7225, Sorbonne Universites, University Pierre and Marie 
      Curie 06 UMR S1127, and Institut du Cerveau et de la Moelle Epiniere, Paris
      (A.I.), Institut de Cancerologie de l'Ouest-Centre Rene Gauducheau,
      Saint-Herblain (M.C.), Institut Regional du Cancer Montpellier, Montpellier
      (M.F.), and Centre Hospitalier Regional Universitaire de Lille, Lille (E.L.R.,
      F.D.) - all in France; and the Departments of Oncology and Neurology, University 
      Hospital and University of Zurich, Zurich, Switzerland (R.S., M.W.).
FAU - Platten, Michael
AU  - Platten M
AD  - From the University Medical Center and German Cancer Research Center, Heidelberg,
      Germany (W.W., M.B., F.S., I.H., A.D., M.P.); the European Organization for
      Research and Treatment of Cancer, Brussels (T.G., V.G.), and Leuven Cancer
      Institute-KU Leuven, Leuven (P.M.C.) - both in Belgium; Haaglanden Medical
      Center, The Hague (M.T.), Erasmus MC Cancer Institute, Rotterdam (W.T., J.C.B.,
      M.J.B.), and VU University Medical Center, Amsterdam (M.K.) - all in the
      Netherlands; the Medical Oncology Department, Azienda Unita Sanitaria Locale di
      Bologna-IRCCS Istituto delle Scienze Neurologiche, Bologna, Italy (A.A.B.);
      Institut Gustave Roussy, Villejuif (J.D.), Assistance Publique-Hopitaux de Paris,
      Hopitaux Universitaires La Pitie Salpetriere-Charles Foix, Service de Neurologie 
      2-Mazarin, INSERM Unite 1127, Centre National de la Recherche Scientifique Unite 
      Mixte de Recherche (UMR) 7225, Sorbonne Universites, University Pierre and Marie 
      Curie 06 UMR S1127, and Institut du Cerveau et de la Moelle Epiniere, Paris
      (A.I.), Institut de Cancerologie de l'Ouest-Centre Rene Gauducheau,
      Saint-Herblain (M.C.), Institut Regional du Cancer Montpellier, Montpellier
      (M.F.), and Centre Hospitalier Regional Universitaire de Lille, Lille (E.L.R.,
      F.D.) - all in France; and the Departments of Oncology and Neurology, University 
      Hospital and University of Zurich, Zurich, Switzerland (R.S., M.W.).
FAU - Klein, Martin
AU  - Klein M
AD  - From the University Medical Center and German Cancer Research Center, Heidelberg,
      Germany (W.W., M.B., F.S., I.H., A.D., M.P.); the European Organization for
      Research and Treatment of Cancer, Brussels (T.G., V.G.), and Leuven Cancer
      Institute-KU Leuven, Leuven (P.M.C.) - both in Belgium; Haaglanden Medical
      Center, The Hague (M.T.), Erasmus MC Cancer Institute, Rotterdam (W.T., J.C.B.,
      M.J.B.), and VU University Medical Center, Amsterdam (M.K.) - all in the
      Netherlands; the Medical Oncology Department, Azienda Unita Sanitaria Locale di
      Bologna-IRCCS Istituto delle Scienze Neurologiche, Bologna, Italy (A.A.B.);
      Institut Gustave Roussy, Villejuif (J.D.), Assistance Publique-Hopitaux de Paris,
      Hopitaux Universitaires La Pitie Salpetriere-Charles Foix, Service de Neurologie 
      2-Mazarin, INSERM Unite 1127, Centre National de la Recherche Scientifique Unite 
      Mixte de Recherche (UMR) 7225, Sorbonne Universites, University Pierre and Marie 
      Curie 06 UMR S1127, and Institut du Cerveau et de la Moelle Epiniere, Paris
      (A.I.), Institut de Cancerologie de l'Ouest-Centre Rene Gauducheau,
      Saint-Herblain (M.C.), Institut Regional du Cancer Montpellier, Montpellier
      (M.F.), and Centre Hospitalier Regional Universitaire de Lille, Lille (E.L.R.,
      F.D.) - all in France; and the Departments of Oncology and Neurology, University 
      Hospital and University of Zurich, Zurich, Switzerland (R.S., M.W.).
FAU - van den Bent, Martin J
AU  - van den Bent MJ
AD  - From the University Medical Center and German Cancer Research Center, Heidelberg,
      Germany (W.W., M.B., F.S., I.H., A.D., M.P.); the European Organization for
      Research and Treatment of Cancer, Brussels (T.G., V.G.), and Leuven Cancer
      Institute-KU Leuven, Leuven (P.M.C.) - both in Belgium; Haaglanden Medical
      Center, The Hague (M.T.), Erasmus MC Cancer Institute, Rotterdam (W.T., J.C.B.,
      M.J.B.), and VU University Medical Center, Amsterdam (M.K.) - all in the
      Netherlands; the Medical Oncology Department, Azienda Unita Sanitaria Locale di
      Bologna-IRCCS Istituto delle Scienze Neurologiche, Bologna, Italy (A.A.B.);
      Institut Gustave Roussy, Villejuif (J.D.), Assistance Publique-Hopitaux de Paris,
      Hopitaux Universitaires La Pitie Salpetriere-Charles Foix, Service de Neurologie 
      2-Mazarin, INSERM Unite 1127, Centre National de la Recherche Scientifique Unite 
      Mixte de Recherche (UMR) 7225, Sorbonne Universites, University Pierre and Marie 
      Curie 06 UMR S1127, and Institut du Cerveau et de la Moelle Epiniere, Paris
      (A.I.), Institut de Cancerologie de l'Ouest-Centre Rene Gauducheau,
      Saint-Herblain (M.C.), Institut Regional du Cancer Montpellier, Montpellier
      (M.F.), and Centre Hospitalier Regional Universitaire de Lille, Lille (E.L.R.,
      F.D.) - all in France; and the Departments of Oncology and Neurology, University 
      Hospital and University of Zurich, Zurich, Switzerland (R.S., M.W.).
LA  - eng
SI  - ClinicalTrials.gov/NCT01290939
SI  - EudraCT/2010-023218-30
PT  - Clinical Trial, Phase III
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Antineoplastic Agents, Alkylating)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - 7BRF0Z81KG (Lomustine)
SB  - AIM
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents, Alkylating/*administration & dosage/adverse effects
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Bevacizumab/*administration & dosage/adverse effects
MH  - Brain Neoplasms/*drug therapy/mortality/radiotherapy
MH  - Chemoradiotherapy
MH  - Disease-Free Survival
MH  - Female
MH  - Glioblastoma/*drug therapy/mortality/radiotherapy
MH  - Humans
MH  - Intention to Treat Analysis
MH  - Kaplan-Meier Estimate
MH  - Lomustine/*administration & dosage/adverse effects
MH  - Male
MH  - Middle Aged
EDAT- 2017/11/16 06:00
MHDA- 2017/12/02 06:00
CRDT- 2017/11/16 06:00
PHST- 2017/11/16 06:00 [entrez]
PHST- 2017/11/16 06:00 [pubmed]
PHST- 2017/12/02 06:00 [medline]
AID - 10.1056/NEJMoa1707358 [doi]
PST - ppublish
SO  - N Engl J Med. 2017 Nov 16;377(20):1954-1963. doi: 10.1056/NEJMoa1707358.

PMID- 29136505
OWN - NLM
STAT- MEDLINE
DCOM- 20171127
LR  - 20171128
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 5
DP  - 2017 Nov 13
TI  - Inhibition of TRF1 Telomere Protein Impairs Tumor Initiation and Progression in
      Glioblastoma Mouse Models and Patient-Derived Xenografts.
PG  - 590-607.e4
LID - S1535-6108(17)30459-2 [pii]
LID - 10.1016/j.ccell.2017.10.006 [doi]
AB  - Glioblastoma multiforme (GBM) is a deadly and common brain tumor. Poor prognosis 
      is linked to high proliferation and cell heterogeneity, including glioma stem
      cells (GSCs). Telomere genes are frequently mutated. The telomere binding protein
      TRF1 is essential for telomere protection, and for adult and pluripotent stem
      cells. Here, we find TRF1 upregulation in mouse and human GBM. Brain-specific
      Trf1 genetic deletion in GBM mouse models inhibited GBM initiation and
      progression, increasing survival. Trf1 deletion increased telomeric DNA damage
      and reduced proliferation and stemness. TRF1 chemical inhibitors mimicked these
      effects in human GBM cells and also blocked tumor sphere formation and tumor
      growth in xenografts from patient-derived primary GSCs. Thus, targeting telomeres
      throughout TRF1 inhibition is an effective therapeutic strategy for GBM.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Bejarano, Leire
AU  - Bejarano L
AD  - Telomeres and Telomerase Group, Molecular Oncology Program, Spanish National
      Cancer Research Centre (CNIO), Melchor Fernandez Almagro 3, Madrid, 28029, Spain.
FAU - Schuhmacher, Alberto J
AU  - Schuhmacher AJ
AD  - Seve-Ballesteros Foundation Brain Tumor Group, Cancer Cell Biology Program,
      Spanish National Cancer Centre (CNIO), Melchor Fernandez Almagro 3, Madrid,
      28029, Spain.
FAU - Mendez, Marinela
AU  - Mendez M
AD  - Telomeres and Telomerase Group, Molecular Oncology Program, Spanish National
      Cancer Research Centre (CNIO), Melchor Fernandez Almagro 3, Madrid, 28029, Spain.
FAU - Megias, Diego
AU  - Megias D
AD  - Confocal Microscopy Unit, Biotechnology Program, Spanish National Cancer Research
      Centre (CNIO), Madrid, 28029 Spain.
FAU - Blanco-Aparicio, Carmen
AU  - Blanco-Aparicio C
AD  - Experimental Therapeutics Program, Spanish National Cancer Centre (CNIO), Melchor
      Fernandez Almagro 3, Madrid, 28029, Spain.
FAU - Martinez, Sonia
AU  - Martinez S
AD  - Experimental Therapeutics Program, Spanish National Cancer Centre (CNIO), Melchor
      Fernandez Almagro 3, Madrid, 28029, Spain.
FAU - Pastor, Joaquin
AU  - Pastor J
AD  - Experimental Therapeutics Program, Spanish National Cancer Centre (CNIO), Melchor
      Fernandez Almagro 3, Madrid, 28029, Spain.
FAU - Squatrito, Massimo
AU  - Squatrito M
AD  - Seve-Ballesteros Foundation Brain Tumor Group, Cancer Cell Biology Program,
      Spanish National Cancer Centre (CNIO), Melchor Fernandez Almagro 3, Madrid,
      28029, Spain.
FAU - Blasco, Maria A
AU  - Blasco MA
AD  - Telomeres and Telomerase Group, Molecular Oncology Program, Spanish National
      Cancer Research Centre (CNIO), Melchor Fernandez Almagro 3, Madrid, 28029, Spain.
      Electronic address: mblasco@cnio.es.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Telomeric Repeat Binding Protein 1)
SB  - IM
MH  - Animals
MH  - Brain Neoplasms/*genetics/metabolism/pathology
MH  - Cell Line, Tumor
MH  - *Disease Models, Animal
MH  - Disease Progression
MH  - Gene Expression Regulation, Neoplastic
MH  - Glioblastoma/*genetics/metabolism/pathology
MH  - Humans
MH  - Mice, Knockout
MH  - Mice, Nude
MH  - Neoplastic Stem Cells/metabolism
MH  - RNA Interference
MH  - Telomere/genetics/metabolism
MH  - Telomeric Repeat Binding Protein 1/antagonists & inhibitors/*genetics/metabolism
MH  - Transplantation, Heterologous
OTO - NOTNLM
OT  - TRF1
OT  - glioblastoma
OT  - glioma stem cells
OT  - shelterin
OT  - stemness
OT  - telomeres
OT  - therapy
EDAT- 2017/11/15 06:00
MHDA- 2017/11/29 06:00
CRDT- 2017/11/15 06:00
PHST- 2017/04/19 00:00 [received]
PHST- 2017/07/28 00:00 [revised]
PHST- 2017/10/07 00:00 [accepted]
PHST- 2017/11/15 06:00 [entrez]
PHST- 2017/11/15 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
AID - S1535-6108(17)30459-2 [pii]
AID - 10.1016/j.ccell.2017.10.006 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Nov 13;32(5):590-607.e4. doi: 10.1016/j.ccell.2017.10.006.

PMID- 29064744
OWN - NLM
STAT- MEDLINE
DCOM- 20171219
LR  - 20171219
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Linking)
VI  - 35
IP  - 36
DP  - 2017 Dec 20
TI  - Radiation Therapy for Oropharyngeal Squamous Cell Carcinoma: American Society of 
      Clinical Oncology Endorsement of the American Society for Radiation Oncology
      Evidence-Based Clinical Practice Guideline.
PG  - 4078-4090
LID - 10.1200/JCO.2017.73.8633 [doi]
AB  - Purpose The American Society for Radiation Oncology (ASTRO) produced an
      evidence-based guideline on radiation therapy in oropharyngeal squamous cell
      carcinoma (OPSCC) that was determined to be relevant to the American Society of
      Clinical Oncology (ASCO) membership. After applying standard critical appraisal
      policy and endorsement procedures, ASCO chose to endorse the ASTRO guideline.
      Methods The ASTRO guideline was reviewed by ASCO content experts for clinical
      accuracy and by ASCO methodologists for developmental rigor. On favorable review,
      an ASCO Expert Panel was convened to review the guideline contents and
      recommendations. The ASCO guideline approval body, the Clinical Practice
      Guidelines Committee, approved the final endorsement. Results The ASCO Expert
      Panel determined that the ASTRO guideline recommendations, published in July
      2017, are clear, thorough, and based upon the most relevant scientific evidence. 
      ASCO endorsed the ASTRO guideline and added minor qualifying statements.
      Recommendations Recommendations for the addition of systemic therapy to
      definitive radiotherapy in the treatment of OPSCC, postoperative radiotherapy
      with and without systemic therapy following primary surgery of OPSCC, induction
      chemotherapy in the treatment of OPSCC, and the appropriate dose, fractionation, 
      and volume regimens with and without systemic therapy in the treatment of OPSCC
      are outlined for a variety of disease stages and clinical scenarios. ASCO
      Endorsement Panel qualifying statements and minor modifications were made to the 
      ASTRO recommendations. The staging system that is referenced in these guidelines 
      is the American Joint Committee on Cancer Staging Manual, 7th edition. Additional
      information is available at: www.asco.org/head-neck-cancer-guidelines and
      www.asco.org/guidelineswiki .
FAU - Quon, Harry
AU  - Quon H
AD  - Harry Quon and Arlene Forastiere, Johns Hopkins University School of Medicine,
      Baltimore, MD; Neha Vapiwala, Perelman School of Medicine, University of
      Pennsylvania, Philadelphia, PA; Erin B. Kennedy, American Society of Clinical
      Oncology, Alexandria, VA; David J. Adelstein, Taussig Cancer Institute,
      Cleveland, OH; Holly Boykin, Head and Neck Cancer Alliance, Charleston, SC;
      Joseph A. Califano, University of California San Diego Medical Center, San Diego;
      F. Chris Holsinger, Stanford University Medical Center, Palo Alto, CA; Brian
      Nussenbaum, Washington University School of Medicine, St. Louis, MO; David I.
      Rosenthal, The University of Texas MD Anderson Cancer Center, Houston TX; and
      Lillian L. Siu and John N. Waldron, Princess Margaret Cancer Centre, Toronto,
      Canada.
FAU - Vapiwala, Neha
AU  - Vapiwala N
AD  - Harry Quon and Arlene Forastiere, Johns Hopkins University School of Medicine,
      Baltimore, MD; Neha Vapiwala, Perelman School of Medicine, University of
      Pennsylvania, Philadelphia, PA; Erin B. Kennedy, American Society of Clinical
      Oncology, Alexandria, VA; David J. Adelstein, Taussig Cancer Institute,
      Cleveland, OH; Holly Boykin, Head and Neck Cancer Alliance, Charleston, SC;
      Joseph A. Califano, University of California San Diego Medical Center, San Diego;
      F. Chris Holsinger, Stanford University Medical Center, Palo Alto, CA; Brian
      Nussenbaum, Washington University School of Medicine, St. Louis, MO; David I.
      Rosenthal, The University of Texas MD Anderson Cancer Center, Houston TX; and
      Lillian L. Siu and John N. Waldron, Princess Margaret Cancer Centre, Toronto,
      Canada.
FAU - Forastiere, Arlene
AU  - Forastiere A
AD  - Harry Quon and Arlene Forastiere, Johns Hopkins University School of Medicine,
      Baltimore, MD; Neha Vapiwala, Perelman School of Medicine, University of
      Pennsylvania, Philadelphia, PA; Erin B. Kennedy, American Society of Clinical
      Oncology, Alexandria, VA; David J. Adelstein, Taussig Cancer Institute,
      Cleveland, OH; Holly Boykin, Head and Neck Cancer Alliance, Charleston, SC;
      Joseph A. Califano, University of California San Diego Medical Center, San Diego;
      F. Chris Holsinger, Stanford University Medical Center, Palo Alto, CA; Brian
      Nussenbaum, Washington University School of Medicine, St. Louis, MO; David I.
      Rosenthal, The University of Texas MD Anderson Cancer Center, Houston TX; and
      Lillian L. Siu and John N. Waldron, Princess Margaret Cancer Centre, Toronto,
      Canada.
FAU - Kennedy, Erin B
AU  - Kennedy EB
AD  - Harry Quon and Arlene Forastiere, Johns Hopkins University School of Medicine,
      Baltimore, MD; Neha Vapiwala, Perelman School of Medicine, University of
      Pennsylvania, Philadelphia, PA; Erin B. Kennedy, American Society of Clinical
      Oncology, Alexandria, VA; David J. Adelstein, Taussig Cancer Institute,
      Cleveland, OH; Holly Boykin, Head and Neck Cancer Alliance, Charleston, SC;
      Joseph A. Califano, University of California San Diego Medical Center, San Diego;
      F. Chris Holsinger, Stanford University Medical Center, Palo Alto, CA; Brian
      Nussenbaum, Washington University School of Medicine, St. Louis, MO; David I.
      Rosenthal, The University of Texas MD Anderson Cancer Center, Houston TX; and
      Lillian L. Siu and John N. Waldron, Princess Margaret Cancer Centre, Toronto,
      Canada.
FAU - Adelstein, David J
AU  - Adelstein DJ
AD  - Harry Quon and Arlene Forastiere, Johns Hopkins University School of Medicine,
      Baltimore, MD; Neha Vapiwala, Perelman School of Medicine, University of
      Pennsylvania, Philadelphia, PA; Erin B. Kennedy, American Society of Clinical
      Oncology, Alexandria, VA; David J. Adelstein, Taussig Cancer Institute,
      Cleveland, OH; Holly Boykin, Head and Neck Cancer Alliance, Charleston, SC;
      Joseph A. Califano, University of California San Diego Medical Center, San Diego;
      F. Chris Holsinger, Stanford University Medical Center, Palo Alto, CA; Brian
      Nussenbaum, Washington University School of Medicine, St. Louis, MO; David I.
      Rosenthal, The University of Texas MD Anderson Cancer Center, Houston TX; and
      Lillian L. Siu and John N. Waldron, Princess Margaret Cancer Centre, Toronto,
      Canada.
FAU - Boykin, Holly
AU  - Boykin H
AD  - Harry Quon and Arlene Forastiere, Johns Hopkins University School of Medicine,
      Baltimore, MD; Neha Vapiwala, Perelman School of Medicine, University of
      Pennsylvania, Philadelphia, PA; Erin B. Kennedy, American Society of Clinical
      Oncology, Alexandria, VA; David J. Adelstein, Taussig Cancer Institute,
      Cleveland, OH; Holly Boykin, Head and Neck Cancer Alliance, Charleston, SC;
      Joseph A. Califano, University of California San Diego Medical Center, San Diego;
      F. Chris Holsinger, Stanford University Medical Center, Palo Alto, CA; Brian
      Nussenbaum, Washington University School of Medicine, St. Louis, MO; David I.
      Rosenthal, The University of Texas MD Anderson Cancer Center, Houston TX; and
      Lillian L. Siu and John N. Waldron, Princess Margaret Cancer Centre, Toronto,
      Canada.
FAU - Califano, Joseph A
AU  - Califano JA
AD  - Harry Quon and Arlene Forastiere, Johns Hopkins University School of Medicine,
      Baltimore, MD; Neha Vapiwala, Perelman School of Medicine, University of
      Pennsylvania, Philadelphia, PA; Erin B. Kennedy, American Society of Clinical
      Oncology, Alexandria, VA; David J. Adelstein, Taussig Cancer Institute,
      Cleveland, OH; Holly Boykin, Head and Neck Cancer Alliance, Charleston, SC;
      Joseph A. Califano, University of California San Diego Medical Center, San Diego;
      F. Chris Holsinger, Stanford University Medical Center, Palo Alto, CA; Brian
      Nussenbaum, Washington University School of Medicine, St. Louis, MO; David I.
      Rosenthal, The University of Texas MD Anderson Cancer Center, Houston TX; and
      Lillian L. Siu and John N. Waldron, Princess Margaret Cancer Centre, Toronto,
      Canada.
FAU - Holsinger, F Chris
AU  - Holsinger FC
AD  - Harry Quon and Arlene Forastiere, Johns Hopkins University School of Medicine,
      Baltimore, MD; Neha Vapiwala, Perelman School of Medicine, University of
      Pennsylvania, Philadelphia, PA; Erin B. Kennedy, American Society of Clinical
      Oncology, Alexandria, VA; David J. Adelstein, Taussig Cancer Institute,
      Cleveland, OH; Holly Boykin, Head and Neck Cancer Alliance, Charleston, SC;
      Joseph A. Califano, University of California San Diego Medical Center, San Diego;
      F. Chris Holsinger, Stanford University Medical Center, Palo Alto, CA; Brian
      Nussenbaum, Washington University School of Medicine, St. Louis, MO; David I.
      Rosenthal, The University of Texas MD Anderson Cancer Center, Houston TX; and
      Lillian L. Siu and John N. Waldron, Princess Margaret Cancer Centre, Toronto,
      Canada.
FAU - Nussenbaum, Brian
AU  - Nussenbaum B
AD  - Harry Quon and Arlene Forastiere, Johns Hopkins University School of Medicine,
      Baltimore, MD; Neha Vapiwala, Perelman School of Medicine, University of
      Pennsylvania, Philadelphia, PA; Erin B. Kennedy, American Society of Clinical
      Oncology, Alexandria, VA; David J. Adelstein, Taussig Cancer Institute,
      Cleveland, OH; Holly Boykin, Head and Neck Cancer Alliance, Charleston, SC;
      Joseph A. Califano, University of California San Diego Medical Center, San Diego;
      F. Chris Holsinger, Stanford University Medical Center, Palo Alto, CA; Brian
      Nussenbaum, Washington University School of Medicine, St. Louis, MO; David I.
      Rosenthal, The University of Texas MD Anderson Cancer Center, Houston TX; and
      Lillian L. Siu and John N. Waldron, Princess Margaret Cancer Centre, Toronto,
      Canada.
FAU - Rosenthal, David I
AU  - Rosenthal DI
AD  - Harry Quon and Arlene Forastiere, Johns Hopkins University School of Medicine,
      Baltimore, MD; Neha Vapiwala, Perelman School of Medicine, University of
      Pennsylvania, Philadelphia, PA; Erin B. Kennedy, American Society of Clinical
      Oncology, Alexandria, VA; David J. Adelstein, Taussig Cancer Institute,
      Cleveland, OH; Holly Boykin, Head and Neck Cancer Alliance, Charleston, SC;
      Joseph A. Califano, University of California San Diego Medical Center, San Diego;
      F. Chris Holsinger, Stanford University Medical Center, Palo Alto, CA; Brian
      Nussenbaum, Washington University School of Medicine, St. Louis, MO; David I.
      Rosenthal, The University of Texas MD Anderson Cancer Center, Houston TX; and
      Lillian L. Siu and John N. Waldron, Princess Margaret Cancer Centre, Toronto,
      Canada.
FAU - Siu, Lillian L
AU  - Siu LL
AD  - Harry Quon and Arlene Forastiere, Johns Hopkins University School of Medicine,
      Baltimore, MD; Neha Vapiwala, Perelman School of Medicine, University of
      Pennsylvania, Philadelphia, PA; Erin B. Kennedy, American Society of Clinical
      Oncology, Alexandria, VA; David J. Adelstein, Taussig Cancer Institute,
      Cleveland, OH; Holly Boykin, Head and Neck Cancer Alliance, Charleston, SC;
      Joseph A. Califano, University of California San Diego Medical Center, San Diego;
      F. Chris Holsinger, Stanford University Medical Center, Palo Alto, CA; Brian
      Nussenbaum, Washington University School of Medicine, St. Louis, MO; David I.
      Rosenthal, The University of Texas MD Anderson Cancer Center, Houston TX; and
      Lillian L. Siu and John N. Waldron, Princess Margaret Cancer Centre, Toronto,
      Canada.
FAU - Waldron, John N
AU  - Waldron JN
AD  - Harry Quon and Arlene Forastiere, Johns Hopkins University School of Medicine,
      Baltimore, MD; Neha Vapiwala, Perelman School of Medicine, University of
      Pennsylvania, Philadelphia, PA; Erin B. Kennedy, American Society of Clinical
      Oncology, Alexandria, VA; David J. Adelstein, Taussig Cancer Institute,
      Cleveland, OH; Holly Boykin, Head and Neck Cancer Alliance, Charleston, SC;
      Joseph A. Califano, University of California San Diego Medical Center, San Diego;
      F. Chris Holsinger, Stanford University Medical Center, Palo Alto, CA; Brian
      Nussenbaum, Washington University School of Medicine, St. Louis, MO; David I.
      Rosenthal, The University of Texas MD Anderson Cancer Center, Houston TX; and
      Lillian L. Siu and John N. Waldron, Princess Margaret Cancer Centre, Toronto,
      Canada.
LA  - eng
PT  - Journal Article
PT  - Practice Guideline
DEP - 20171024
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of
      Clinical Oncology
JID - 8309333
RN  - Carcinoma, squamous cell of head and neck
SB  - IM
MH  - Carcinoma, Squamous Cell/*radiotherapy
MH  - Head and Neck Neoplasms/*radiotherapy
MH  - Humans
MH  - Oropharyngeal Neoplasms/*radiotherapy
MH  - Radiation Oncology/methods/*standards
EDAT- 2017/10/25 06:00
MHDA- 2017/12/20 06:00
CRDT- 2017/10/25 06:00
PHST- 2017/10/25 06:00 [pubmed]
PHST- 2017/12/20 06:00 [medline]
PHST- 2017/10/25 06:00 [entrez]
AID - 10.1200/JCO.2017.73.8633 [doi]
PST - ppublish
SO  - J Clin Oncol. 2017 Dec 20;35(36):4078-4090. doi: 10.1200/JCO.2017.73.8633. Epub
      2017 Oct 24.

PMID- 29035366
OWN - NLM
STAT- MEDLINE
DCOM- 20171226
LR  - 20171226
IS  - 1546-170X (Electronic)
IS  - 1078-8956 (Linking)
VI  - 23
IP  - 11
DP  - 2017 Nov
TI  - Cytoplasmic p53 couples oncogene-driven glucose metabolism to apoptosis and is a 
      therapeutic target in glioblastoma.
PG  - 1342-1351
LID - 10.1038/nm.4418 [doi]
AB  - Cross-talk among oncogenic signaling and metabolic pathways may create
      opportunities for new therapeutic strategies in cancer. Here we show that
      although acute inhibition of EGFR-driven glucose metabolism induces only minimal 
      cell death, it lowers the apoptotic threshold in a subset of patient-derived
      glioblastoma (GBM) cells. Mechanistic studies revealed that after attenuated
      glucose consumption, Bcl-xL blocks cytoplasmic p53 from triggering intrinsic
      apoptosis. Consequently, targeting of EGFR-driven glucose metabolism in
      combination with pharmacological stabilization of p53 with the brain-penetrant
      small molecule idasanutlin resulted in synthetic lethality in orthotopic
      glioblastoma xenograft models. Notably, neither the degree of EGFR-signaling
      inhibition nor genetic analysis of EGFR was sufficient to predict sensitivity to 
      this therapeutic combination. However, detection of rapid inhibitory effects on
      [(18)F]fluorodeoxyglucose uptake, assessed through noninvasive positron emission 
      tomography, was an effective predictive biomarker of response in vivo. Together, 
      these studies identify a crucial link among oncogene signaling, glucose
      metabolism, and cytoplasmic p53, which may potentially be exploited for
      combination therapy in GBM and possibly other malignancies.
FAU - Mai, Wilson X
AU  - Mai WX
AD  - Department of Molecular and Medical Pharmacology, David Geffen UCLA School of
      Medicine, Los Angeles, California, USA.
FAU - Gosa, Laura
AU  - Gosa L
AD  - Department of Molecular and Medical Pharmacology, David Geffen UCLA School of
      Medicine, Los Angeles, California, USA.
FAU - Daniels, Veerle W
AU  - Daniels VW
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts, USA.
FAU - Ta, Lisa
AU  - Ta L
AD  - Department of Molecular and Medical Pharmacology, David Geffen UCLA School of
      Medicine, Los Angeles, California, USA.
FAU - Tsang, Jonathan E
AU  - Tsang JE
AD  - Department of Molecular and Medical Pharmacology, David Geffen UCLA School of
      Medicine, Los Angeles, California, USA.
FAU - Higgins, Brian
AU  - Higgins B
AD  - Pharma Research and Early Development, Roche Innovation Center, New York, New
      York, USA.
FAU - Gilmore, W Blake
AU  - Gilmore WB
AD  - Department of Molecular and Medical Pharmacology, David Geffen UCLA School of
      Medicine, Los Angeles, California, USA.
FAU - Bayley, Nicholas A
AU  - Bayley NA
AD  - Department of Molecular and Medical Pharmacology, David Geffen UCLA School of
      Medicine, Los Angeles, California, USA.
FAU - Harati, Mitra Dehghan
AU  - Harati MD
AUID- ORCID: http://orcid.org/0000-0001-7611-1653
AD  - Department of Pathology, David Geffen UCLA School of Medicine, Los Angeles,
      California, USA.
FAU - Lee, Jason T
AU  - Lee JT
AD  - Department of Molecular and Medical Pharmacology, David Geffen UCLA School of
      Medicine, Los Angeles, California, USA.
AD  - Jonsson Comprehensive Cancer Center, David Geffen UCLA School of Medicine, Los
      Angeles, California, USA.
FAU - Yong, William H
AU  - Yong WH
AD  - Department of Pathology, David Geffen UCLA School of Medicine, Los Angeles,
      California, USA.
AD  - Jonsson Comprehensive Cancer Center, David Geffen UCLA School of Medicine, Los
      Angeles, California, USA.
FAU - Kornblum, Harley I
AU  - Kornblum HI
AD  - Department of Molecular and Medical Pharmacology, David Geffen UCLA School of
      Medicine, Los Angeles, California, USA.
AD  - Jonsson Comprehensive Cancer Center, David Geffen UCLA School of Medicine, Los
      Angeles, California, USA.
FAU - Bensinger, Steven J
AU  - Bensinger SJ
AD  - Jonsson Comprehensive Cancer Center, David Geffen UCLA School of Medicine, Los
      Angeles, California, USA.
AD  - Department of Microbiology, Immunology, and Molecular Genetics, David Geffen UCLA
      School of Medicine, Los Angeles, California, USA.
FAU - Mischel, Paul S
AU  - Mischel PS
AD  - Ludwig Institute for Cancer Research, University of California San Diego, San
      Diego, California, USA.
FAU - Rao, P Nagesh
AU  - Rao PN
AUID- ORCID: http://orcid.org/0000-0003-0920-7027
AD  - Department of Pathology, David Geffen UCLA School of Medicine, Los Angeles,
      California, USA.
FAU - Clark, Peter M
AU  - Clark PM
AD  - Department of Molecular and Medical Pharmacology, David Geffen UCLA School of
      Medicine, Los Angeles, California, USA.
AD  - Jonsson Comprehensive Cancer Center, David Geffen UCLA School of Medicine, Los
      Angeles, California, USA.
FAU - Cloughesy, Timothy F
AU  - Cloughesy TF
AD  - Jonsson Comprehensive Cancer Center, David Geffen UCLA School of Medicine, Los
      Angeles, California, USA.
AD  - Department of Neurology, David Geffen UCLA School of Medicine, Los Angeles,
      California, USA.
FAU - Letai, Anthony
AU  - Letai A
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts, USA.
FAU - Nathanson, David A
AU  - Nathanson DA
AD  - Department of Molecular and Medical Pharmacology, David Geffen UCLA School of
      Medicine, Los Angeles, California, USA.
AD  - Jonsson Comprehensive Cancer Center, David Geffen UCLA School of Medicine, Los
      Angeles, California, USA.
AD  - Ahmanson Translational Imaging Division, David Geffen UCLA School of Medicine,
      Los Angeles, California, USA.
LA  - eng
GR  - R56 NS052563/NS/NINDS NIH HHS/United States
GR  - R01 CA213133/CA/NCI NIH HHS/United States
GR  - R01 CA205967/CA/NCI NIH HHS/United States
GR  - R01 NS052563/NS/NINDS NIH HHS/United States
GR  - U54 CA199090/CA/NCI NIH HHS/United States
GR  - P50 CA211015/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20171009
PL  - United States
TA  - Nat Med
JT  - Nature medicine
JID - 9502015
RN  - 0 (TP53 protein, human)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - EC 2.7.10.1 (Receptor, Epidermal Growth Factor)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Animals
MH  - *Apoptosis
MH  - Brain Neoplasms/*metabolism/pathology
MH  - Cytoplasm/*metabolism
MH  - Female
MH  - Glioblastoma/*metabolism/pathology
MH  - Glucose/*metabolism
MH  - Humans
MH  - Mice
MH  - Mice, Inbred NOD
MH  - Receptor, Epidermal Growth Factor/metabolism
MH  - Tumor Cells, Cultured
MH  - Tumor Suppressor Protein p53/*metabolism
MH  - Xenograft Model Antitumor Assays
PMC - PMC5683421
MID - NIHMS905238
EDAT- 2017/10/17 06:00
MHDA- 2017/12/27 06:00
CRDT- 2017/10/17 06:00
PMCR- 2018/04/09 00:00
PHST- 2017/01/11 00:00 [received]
PHST- 2017/09/08 00:00 [accepted]
PHST- 2018/04/09 00:00 [pmc-release]
PHST- 2017/10/17 06:00 [pubmed]
PHST- 2017/12/27 06:00 [medline]
PHST- 2017/10/17 06:00 [entrez]
AID - nm.4418 [pii]
AID - 10.1038/nm.4418 [doi]
PST - ppublish
SO  - Nat Med. 2017 Nov;23(11):1342-1351. doi: 10.1038/nm.4418. Epub 2017 Oct 9.

PMID- 29206104
OWN - NLM
STAT- In-Data-Review
LR  - 20180112
IS  - 2050-084X (Electronic)
IS  - 2050-084X (Linking)
VI  - 6
DP  - 2017 Dec 5
TI  - The Human Cell Atlas.
LID - 10.7554/eLife.27041 [doi]
LID - e27041 [pii]
AB  - The recent advent of methods for high-throughput single-cell molecular profiling 
      has catalyzed a growing sense in the scientific community that the time is ripe
      to complete the 150-year-old effort to identify all cell types in the human body.
      The Human Cell Atlas Project is an international collaborative effort that aims
      to define all human cell types in terms of distinctive molecular profiles (such
      as gene expression profiles) and to connect this information with classical
      cellular descriptions (such as location and morphology). An open comprehensive
      reference map of the molecular state of cells in healthy human tissues would
      propel the systematic study of physiological states, developmental trajectories, 
      regulatory circuitry and interactions of cells, and also provide a framework for 
      understanding cellular dysregulation in human disease. Here we describe the idea,
      its potential utility, early proofs-of-concept, and some design considerations
      for the Human Cell Atlas, including a commitment to open data, code, and
      community.
FAU - Regev, Aviv
AU  - Regev A
AUID- ORCID: http://orcid.org/0000-0003-3293-3158
AD  - Broad Institute of MIT and Harvard, Cambridge, United States.
AD  - Department of Biology, Massachusetts Institute of Technology, Cambridge, United
      States.
AD  - Howard Hughes Medical Institute, Chevy Chase, United States.
FAU - Teichmann, Sarah A
AU  - Teichmann SA
AD  - Wellcome Trust Sanger Institute, Wellcome Genome Campus, Hinxton, United Kingdom.
AD  - EMBL-European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, United
      Kingdom.
AD  - Cavendish Laboratory, Department of Physics, University of Cambridge, Cambridge, 
      United Kingdom.
FAU - Lander, Eric S
AU  - Lander ES
AD  - Broad Institute of MIT and Harvard, Cambridge, United States.
AD  - Department of Biology, Massachusetts Institute of Technology, Cambridge, United
      States.
AD  - Department of Systems Biology, Harvard Medical School, Boston, United States.
FAU - Amit, Ido
AU  - Amit I
AD  - Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.
FAU - Benoist, Christophe
AU  - Benoist C
AD  - Division of Immunology, Department of Microbiology and Immunobiology, Harvard
      Medical School, Boston, United States.
FAU - Birney, Ewan
AU  - Birney E
AD  - EMBL-European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, United
      Kingdom.
FAU - Bodenmiller, Bernd
AU  - Bodenmiller B
AD  - EMBL-European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, United
      Kingdom.
AD  - Institute of Molecular Life Sciences, University of Zurich, Zurich, Switzerland.
FAU - Campbell, Peter
AU  - Campbell P
AD  - Wellcome Trust Sanger Institute, Wellcome Genome Campus, Hinxton, United Kingdom.
AD  - Department of Haematology, University of Cambridge, Cambridge, United Kingdom.
FAU - Carninci, Piero
AU  - Carninci P
AUID- ORCID: https://orcid.org/0000-0001-7202-7243
AD  - Cavendish Laboratory, Department of Physics, University of Cambridge, Cambridge, 
      United Kingdom.
AD  - Division of Genomic Technologies, RIKEN Center for Life Science Technologies,
      Yokohama, Japan.
FAU - Clatworthy, Menna
AU  - Clatworthy M
AD  - Molecular Immunity Unit, Department of Medicine, MRC Laboratory of Molecular
      Biology, University of Cambridge, Cambridge, United Kingdom.
FAU - Clevers, Hans
AU  - Clevers H
AD  - Hubrecht Institute, Princess Maxima Center for Pediatric Oncology and University 
      Medical Center Utrecht, Utrecht, The Netherlands.
FAU - Deplancke, Bart
AU  - Deplancke B
AUID- ORCID: https://orcid.org/0000-0001-9935-843X
AD  - Institute of Bioengineering, School of Life Sciences, Swiss Federal Institute of 
      Technology (EPFL), Lausanne, Switzerland.
FAU - Dunham, Ian
AU  - Dunham I
AD  - EMBL-European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, United
      Kingdom.
FAU - Eberwine, James
AU  - Eberwine J
AD  - Department of Systems Pharmacology and Translational Therapeutics, Perelman
      School of Medicine, University of Pennsylvania, Philadelphia, United States.
FAU - Eils, Roland
AU  - Eils R
AD  - Division of Theoretical Bioinformatics (B080), German Cancer Research Center
      (DKFZ), Heidelberg, Germany.
AD  - Department for Bioinformatics and Functional Genomics, Institute for Pharmacy and
      Molecular Biotechnology (IPMB) and BioQuant, Heidelberg University, Heidelberg,
      Germany.
FAU - Enard, Wolfgang
AU  - Enard W
AUID- ORCID: https://orcid.org/0000-0002-4056-0550
AD  - Department of Biology II, Ludwig Maximilian University Munich, Martinsried,
      Germany.
FAU - Farmer, Andrew
AU  - Farmer A
AD  - Takara Bio United States, Inc., Mountain View, United States.
FAU - Fugger, Lars
AU  - Fugger L
AD  - Oxford Centre for Neuroinflammation, Nuffield Department of Clinical
      Neurosciences, and MRC Human Immunology Unit, Weatherall Institute of Molecular
      Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom.
FAU - Gottgens, Berthold
AU  - Gottgens B
AUID- ORCID: https://orcid.org/0000-0001-6302-5705
AD  - Department of Haematology, University of Cambridge, Cambridge, United Kingdom.
AD  - Wellcome Trust-MRC Cambridge Stem Cell Institute, University of Cambridge,
      Cambridge, United Kingdom.
FAU - Hacohen, Nir
AU  - Hacohen N
AD  - Broad Institute of MIT and Harvard, Cambridge, United States.
AD  - Massachusetts General Hospital Cancer Center, Boston, United States.
FAU - Haniffa, Muzlifah
AU  - Haniffa M
AUID- ORCID: https://orcid.org/0000-0002-3927-2084
AD  - Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United
      Kingdom.
FAU - Hemberg, Martin
AU  - Hemberg M
AD  - Wellcome Trust Sanger Institute, Wellcome Genome Campus, Hinxton, United Kingdom.
FAU - Kim, Seung
AU  - Kim S
AD  - Departments of Developmental Biology and of Medicine, Stanford University School 
      of Medicine, Stanford, United States.
FAU - Klenerman, Paul
AU  - Klenerman P
AD  - Peter Medawar Building for Pathogen Research and the Translational
      Gastroenterology Unit, Nuffield Department of Clinical Medicine, University of
      Oxford, Oxford, United Kingdom.
AD  - Oxford NIHR Biomedical Research Centre, John Radcliffe Hospital, Oxford, United
      Kingdom.
FAU - Kriegstein, Arnold
AU  - Kriegstein A
AD  - Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research,
      University of California, San Francisco, San Francisco, United States.
FAU - Lein, Ed
AU  - Lein E
AUID- ORCID: https://orcid.org/0000-0001-9012-6552
AD  - Allen Institute for Brain Science, Seattle, United States.
FAU - Linnarsson, Sten
AU  - Linnarsson S
AD  - Laboratory for Molecular Neurobiology, Department of Medical Biochemistry and
      Biophysics, Karolinska Institutet, Stockholm, Sweden.
FAU - Lundberg, Emma
AU  - Lundberg E
AD  - Science for Life Laboratory, School of Biotechnology, KTH Royal Institute of
      Technology, Stockholm, Sweden.
AD  - Department of Genetics, Stanford University, Stanford, United States.
FAU - Lundeberg, Joakim
AU  - Lundeberg J
AD  - Science for Life Laboratory, Department of Gene Technology, KTH Royal Institute
      of Technology, Stockholm, Sweden.
FAU - Majumder, Partha
AU  - Majumder P
AD  - National Institute of Biomedical Genomics, Kalyani, India.
FAU - Marioni, John C
AU  - Marioni JC
AD  - Wellcome Trust Sanger Institute, Wellcome Genome Campus, Hinxton, United Kingdom.
AD  - EMBL-European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, United
      Kingdom.
AD  - Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge,
      United Kingdom.
FAU - Merad, Miriam
AU  - Merad M
AD  - Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New
      York, United States.
FAU - Mhlanga, Musa
AU  - Mhlanga M
AD  - Division of Chemical, Systems & Synthetic Biology, Institute for Infectious
      Disease & Molecular Medicine (IDM), Department of Integrative Biomedical
      Sciences, Faculty of Health Sciences, University of Cape Town, Cape Town, South
      Africa.
FAU - Nawijn, Martijn
AU  - Nawijn M
AD  - Department of Pathology and Medical Biology, GRIAC Research Institute, University
      of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
FAU - Netea, Mihai
AU  - Netea M
AD  - Department of Internal Medicine and Radboud Center for Infectious Diseases,
      Radboud University Medical Center, Nijmegen, The Netherlands.
FAU - Nolan, Garry
AU  - Nolan G
AD  - Department of Microbiology and Immunology, Stanford University, Stanford, United 
      States.
FAU - Pe'er, Dana
AU  - Pe'er D
AD  - Computational and Systems Biology Program, Sloan Kettering Institute, New York,
      United States.
FAU - Phillipakis, Anthony
AU  - Phillipakis A
AD  - Broad Institute of MIT and Harvard, Cambridge, United States.
FAU - Ponting, Chris P
AU  - Ponting CP
AUID- ORCID: https://orcid.org/0000-0003-0202-7816
AD  - MRC Human Genetics Unit, MRC Institute of Genetics & Molecular Medicine,
      University of Edinburgh, Edinburgh, United Kingdom.
FAU - Quake, Stephen
AU  - Quake S
AD  - Department of Applied Physics and Department of Bioengineering, Stanford
      University, Stanford, United States.
AD  - Chan Zuckerberg Biohub, San Francisco, United States.
FAU - Reik, Wolf
AU  - Reik W
AD  - Wellcome Trust Sanger Institute, Wellcome Genome Campus, Hinxton, United Kingdom.
AD  - Epigenetics Programme, The Babraham Institute, Cambridge, United Kingdom.
AD  - Centre for Trophoblast Research, University of Cambridge, Cambridge, United
      Kingdom.
FAU - Rozenblatt-Rosen, Orit
AU  - Rozenblatt-Rosen O
AD  - Broad Institute of MIT and Harvard, Cambridge, United States.
FAU - Sanes, Joshua
AU  - Sanes J
AUID- ORCID: https://orcid.org/0000-0001-8926-8836
AD  - Center for Brain Science and Department of Molecular and Cellular Biology,
      Harvard University, Cambridge, United States.
FAU - Satija, Rahul
AU  - Satija R
AUID- ORCID: https://orcid.org/0000-0001-9448-8833
AD  - Department of Biology, New York University, New York, United States.
AD  - New York Genome Center, New York University, New York, United States.
FAU - Schumacher, Ton N
AU  - Schumacher TN
AD  - Division of Immunology, The Netherlands Cancer Institute, Amsterdam, The
      Netherlands.
FAU - Shalek, Alex
AU  - Shalek A
AD  - Broad Institute of MIT and Harvard, Cambridge, United States.
AD  - Institute for Medical Engineering & Science (IMES) and Department of Chemistry,
      Massachusetts Institute of Technology, Cambridge, United States.
AD  - Ragon Institute of MGH, MIT and Harvard, Cambridge, United States.
FAU - Shapiro, Ehud
AU  - Shapiro E
AD  - Department of Computer Science and Department of Biomolecular Sciences, Weizmann 
      Institute of Science, Rehovot, Israel.
FAU - Sharma, Padmanee
AU  - Sharma P
AD  - Department of Genitourinary Medical Oncology, Department of Immunology, MD
      Anderson Cancer Center, University of Texas, Houston, United States.
FAU - Shin, Jay W
AU  - Shin JW
AD  - Division of Genomic Technologies, RIKEN Center for Life Science Technologies,
      Yokohama, Japan.
FAU - Stegle, Oliver
AU  - Stegle O
AD  - EMBL-European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, United
      Kingdom.
FAU - Stratton, Michael
AU  - Stratton M
AD  - Wellcome Trust Sanger Institute, Wellcome Genome Campus, Hinxton, United Kingdom.
FAU - Stubbington, Michael J T
AU  - Stubbington MJT
AD  - Wellcome Trust Sanger Institute, Wellcome Genome Campus, Hinxton, United Kingdom.
FAU - Theis, Fabian J
AU  - Theis FJ
AD  - Institute of Computational Biology, German Research Center for Environmental
      Health, Helmholtz Center Munich, Neuherberg, Germany.
AD  - Department of Mathematics, Technical University of Munich, Garching, Germany.
FAU - Uhlen, Matthias
AU  - Uhlen M
AD  - Science for Life Laboratory and Department of Proteomics, KTH Royal Institute of 
      Technology, Stockholm, Sweden.
AD  - Novo Nordisk Foundation Center for Biosustainability, Danish Technical
      University, Lyngby, Denmark.
FAU - van Oudenaarden, Alexander
AU  - van Oudenaarden A
AD  - Hubrecht Institute and University Medical Center Utrecht, Utrecht, The
      Netherlands.
FAU - Wagner, Allon
AU  - Wagner A
AD  - Department of Electrical Engineering and Computer Science and the Center for
      Computational Biology, University of California, Berkeley, Berkeley, United
      States.
FAU - Watt, Fiona
AU  - Watt F
AUID- ORCID: https://orcid.org/0000-0001-9151-5154
AD  - Centre for Stem Cells and Regenerative Medicine, King's College London, London,
      United Kingdom.
FAU - Weissman, Jonathan
AU  - Weissman J
AUID- ORCID: https://orcid.org/0000-0003-2445-670X
AD  - Howard Hughes Medical Institute, Chevy Chase, United States.
AD  - Department of Cellular & Molecular Pharmacology, University of California, San
      Francisco, San Francisco, United States.
AD  - California Institute for Quantitative Biomedical Research, University of
      California, San Francisco, San Francisco, United States.
AD  - Center for RNA Systems Biology, University of California, San Francisco, San
      Francisco, United States.
FAU - Wold, Barbara
AU  - Wold B
AD  - Division of Biology and Biological Engineering, California Institute of
      Technology, Pasadena, United States.
FAU - Xavier, Ramnik
AU  - Xavier R
AD  - Broad Institute of MIT and Harvard, Cambridge, United States.
AD  - Center for Computational and Integrative Biology, Massachusetts General Hospital,
      Boston, United States.
AD  - Gastrointestinal Unit and Center for the Study of Inflammatory Bowel Disease,
      Massachusetts General Hospital, Boston, United States.
AD  - Center for Microbiome Informatics and Therapeutics, Massachusetts Institute of
      Technology, Cambridge, United States.
FAU - Yosef, Nir
AU  - Yosef N
AUID- ORCID: https://orcid.org/0000-0001-9004-1225
AD  - Ragon Institute of MGH, MIT and Harvard, Cambridge, United States.
AD  - Department of Electrical Engineering and Computer Science and the Center for
      Computational Biology, University of California, Berkeley, Berkeley, United
      States.
CN  - Human Cell Atlas Meeting Participants
LA  - eng
PT  - Journal Article
DEP - 20171205
PL  - England
TA  - Elife
JT  - eLife
JID - 101579614
PMC - PMC5762154
OTO - NOTNLM
OT  - cell atlas
OT  - cell biology
OT  - computational biology
OT  - human
OT  - lineage
OT  - mouse
OT  - science forum
OT  - single-cell genomics
OT  - systems biology
EDAT- 2017/12/06 06:00
MHDA- 2017/12/06 06:00
CRDT- 2017/12/06 06:00
PHST- 2017/03/28 00:00 [received]
PHST- 2017/11/30 00:00 [accepted]
PHST- 2017/12/06 06:00 [pubmed]
PHST- 2017/12/06 06:00 [medline]
PHST- 2017/12/06 06:00 [entrez]
AID - 10.7554/eLife.27041 [doi]
PST - epublish
SO  - Elife. 2017 Dec 5;6. doi: 10.7554/eLife.27041.

PMID- 29078414
OWN - NLM
STAT- In-Data-Review
LR  - 20171219
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Linking)
VI  - 114
IP  - 45
DP  - 2017 Nov 7
TI  - Twenty-five years of mTOR: Uncovering the link from nutrients to growth.
PG  - 11818-11825
LID - 10.1073/pnas.1716173114 [doi]
AB  - In my PNAS Inaugural Article, I describe the development of the mTOR field,
      starting with efforts to understand the mechanism of action of the drug
      rapamycin, which approximately 25 y ago led to the discovery of the mTOR protein 
      kinase. I focus on insights that we have contributed and on work that has been
      particularly influential to me, as well as provide some personal reflections and 
      stories. We now appreciate that, as part of two distinct complexes, mTORC1 and
      mTORC2, mTOR is the major regulator of growth (mass accumulation) in animals and 
      is the key link between the availability of nutrients in the environment and the 
      control of most anabolic and catabolic processes. Nutrients signal to mTORC1
      through the lysosome-associated Rag GTPases and their many regulators and
      associated cytosolic and lysosomal nutrient sensors. mTOR signaling is
      deregulated in common diseases, like cancer and epilepsy, and mTORC1 is a
      well-validated modulator of aging in multiple model organisms. There is
      significant excitement around using mTORC1 inhibitors to treat cancer and
      neurological disease and, potentially, to improve healthspan and lifespan.
CI  - Copyright (c) 2017 the Author(s). Published by PNAS.
FAU - Sabatini, David M
AU  - Sabatini DM
AUID- ORCID: http://orcid.org/0000-0002-1446-7256
AD  - Whitehead Institute for Biomedical Research, Cambridge, MA 02142;
      sabatini@wi.mit.edu.
AD  - Howard Hughes Medical Institute, Massachusetts Institute of Technology,
      Cambridge, MA 02139.
AD  - Department of Biology, Massachusetts Institute of Technology, Cambridge, MA
      02142.
AD  - Koch Institute for Integrative Cancer Research, Massachusetts Institute of
      Technology, Cambridge, MA 02142.
AD  - Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, 
      MA 02142.
LA  - eng
PT  - Journal Article
DEP - 20171025
PL  - United States
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
PMC - PMC5692607
OTO - NOTNLM
OT  - Rag GTPase
OT  - growth
OT  - mTOR
OT  - nutrients
OT  - rapamycin
COIS- The author declares no conflict of interest.
EDAT- 2017/10/29 06:00
MHDA- 2017/10/29 06:00
CRDT- 2017/10/29 06:00
PHST- 2017/10/29 06:00 [pubmed]
PHST- 2017/10/29 06:00 [medline]
PHST- 2017/10/29 06:00 [entrez]
AID - 1716173114 [pii]
AID - 10.1073/pnas.1716173114 [doi]
PST - ppublish
SO  - Proc Natl Acad Sci U S A. 2017 Nov 7;114(45):11818-11825. doi:
      10.1073/pnas.1716173114. Epub 2017 Oct 25.

PMID- 29122757
OWN - NLM
STAT- In-Data-Review
LR  - 20180119
IS  - 1528-0020 (Electronic)
IS  - 0006-4971 (Linking)
VI  - 131
IP  - 3
DP  - 2018 Jan 18
TI  - CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells.
PG  - 311-322
LID - 10.1182/blood-2017-05-787598 [doi]
AB  - Adoptive transfer of T cells genetically modified to express a cancer-specific
      T-cell receptor (TCR) has shown significant therapeutic potential for both
      hematological and solid tumors. However, a major issue of transducing T cells
      with a transgenic TCR is the preexisting expression of TCRs in the recipient
      cells. These endogenous TCRs compete with the transgenic TCR for surface
      expression and allow mixed dimer formation. Mixed dimers, formed by mispairing
      between the endogenous and transgenic TCRs, may harbor autoreactive
      specificities. To circumvent these problems, we designed a system where the
      endogenous TCR-beta is knocked out from the recipient cells using clustered
      regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated
      protein-9 (Cas9) technology, simultaneously with transduction with a
      cancer-reactive receptor of choice. This TCR replacement strategy resulted in
      markedly increased surface expression of transgenic alphabeta and gammadelta
      TCRs, which in turn translated to a stronger, and more polyfunctional, response
      of engineered T cells to their target cancer cell lines. Additionally, the
      TCR-plus-CRISPR-modified T cells were up to a thousandfold more sensitive to
      antigen than standard TCR-transduced T cells or conventional model proxy systems 
      used for studying TCR activity. Finally, transduction with a pan-cancer-reactive 
      gammadelta TCR used in conjunction with CRISPR/Cas9 knockout of the endogenous
      alphabeta TCR resulted in more efficient redirection of CD4(+) and CD8(+) T cells
      against a panel of established blood cancers and primary, patient-derived B-cell 
      acute lymphoblastic leukemia blasts compared with standard TCR transfer. Our
      results suggest that TCR transfer combined with genome editing could lead to new,
      improved generations of cancer immunotherapies.
CI  - (c) 2018 by The American Society of Hematology.
FAU - Legut, Mateusz
AU  - Legut M
AD  - Division of Infection and Immunity, School of Medicine.
AD  - Systems Immunity Research Institute, and.
FAU - Dolton, Garry
AU  - Dolton G
AD  - Division of Infection and Immunity, School of Medicine.
AD  - Systems Immunity Research Institute, and.
FAU - Mian, Afsar Ali
AU  - Mian AA
AD  - Haematology, Division of Cancer and Genetics, School of Medicine, Cardiff
      University, Cardiff, United Kingdom.
FAU - Ottmann, Oliver G
AU  - Ottmann OG
AUID- ORCID: http://orcid.org/0000-0001-9559-1330
AD  - Haematology, Division of Cancer and Genetics, School of Medicine, Cardiff
      University, Cardiff, United Kingdom.
FAU - Sewell, Andrew K
AU  - Sewell AK
AUID- ORCID: http://orcid.org/0000-0003-3194-3135
AD  - Division of Infection and Immunity, School of Medicine.
AD  - Systems Immunity Research Institute, and.
LA  - eng
PT  - Journal Article
DEP - 20171109
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
EDAT- 2017/11/11 06:00
MHDA- 2017/11/11 06:00
CRDT- 2017/11/11 06:00
PHST- 2017/05/30 00:00 [received]
PHST- 2017/11/04 00:00 [accepted]
PHST- 2017/11/11 06:00 [pubmed]
PHST- 2017/11/11 06:00 [medline]
PHST- 2017/11/11 06:00 [entrez]
AID - blood-2017-05-787598 [pii]
AID - 10.1182/blood-2017-05-787598 [doi]
PST - ppublish
SO  - Blood. 2018 Jan 18;131(3):311-322. doi: 10.1182/blood-2017-05-787598. Epub 2017
      Nov 9.

PMID- 29100056
OWN - NLM
STAT- MEDLINE
DCOM- 20171121
LR  - 20171128
IS  - 1097-4164 (Electronic)
IS  - 1097-2765 (Linking)
VI  - 68
IP  - 3
DP  - 2017 Nov 2
TI  - Regulation of the Hippo-YAP Pathway by Glucose Sensor O-GlcNAcylation.
PG  - 591-604.e5
LID - S1097-2765(17)30759-1 [pii]
LID - 10.1016/j.molcel.2017.10.010 [doi]
AB  - The Hippo pathway is crucial in organ size control and tissue homeostasis, with
      deregulation leading to cancer. An extracellular nutrition signal, such as
      glucose, regulates the Hippo pathway activation. However, the mechanisms are
      still not clear. Here, we found that the Hippo pathway is directly regulated by
      the hexosamine biosynthesis pathway (HBP) in response to metabolic nutrients.
      Mechanistically, the core component of Hippo pathway (YAP) is O-GlcNAcylated by
      O-GlcNAc transferase (OGT) at serine 109. YAP O-GlcNAcylation disrupts its
      interaction with upstream kinase LATS1, prevents its phosphorylation, and
      activates its transcriptional activity. And this activation is not dependent on
      AMPK. We also identified OGT as a YAP-regulated gene that forms a feedback loop. 
      Finally, we confirmed that glucose-induced YAP O-GlcNAcylation and activation
      promoted tumorigenesis. Together, our data establish a molecular mechanism and
      functional significance of the HBP in directly linking extracellular glucose
      signal to the Hippo-YAP pathway and tumorigenesis.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Peng, Changmin
AU  - Peng C
AD  - Key Laboratory of Industrial Fermentation Microbiology, Ministry of Education,
      Tianjin Industrial Microbiology Key Lab, College of Biotechnology, Tianjin
      University of Science and Technology, No 29, 13ST. TEDA, Tianjin 300457, China;
      State Key Laboratory of Proteomics, Beijing Proteome Research Center, National
      Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing
      102206, China.
FAU - Zhu, Yue
AU  - Zhu Y
AD  - State Key Laboratory of Proteomics, Beijing Proteome Research Center, National
      Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing
      102206, China; Anhui Medical University, Hefei 230032, China; Beijing Institute
      of Radiation Medicine, Beijing 102206, China.
FAU - Zhang, Wanjun
AU  - Zhang W
AD  - State Key Laboratory of Proteomics, Beijing Proteome Research Center, National
      Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing
      102206, China.
FAU - Liao, Qinchao
AU  - Liao Q
AD  - Key Laboratory of Industrial Fermentation Microbiology, Ministry of Education,
      Tianjin Industrial Microbiology Key Lab, College of Biotechnology, Tianjin
      University of Science and Technology, No 29, 13ST. TEDA, Tianjin 300457, China.
FAU - Chen, Yali
AU  - Chen Y
AD  - State Key Laboratory of Proteomics, Beijing Proteome Research Center, National
      Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing
      102206, China.
FAU - Zhao, Xinyuan
AU  - Zhao X
AD  - State Key Laboratory of Proteomics, Beijing Proteome Research Center, National
      Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing
      102206, China.
FAU - Guo, Qiang
AU  - Guo Q
AD  - Cell Signaling and Epigenetics Laboratory, School of Pharmaceutical Sciences,
      Wenzhou Medical University, Wenzhou 325035, Zhejiang, China.
FAU - Shen, Pan
AU  - Shen P
AD  - State Key Laboratory of Proteomics, Beijing Proteome Research Center, National
      Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing
      102206, China.
FAU - Zhen, Bei
AU  - Zhen B
AD  - State Key Laboratory of Proteomics, Beijing Proteome Research Center, National
      Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing
      102206, China.
FAU - Qian, Xiaohong
AU  - Qian X
AD  - State Key Laboratory of Proteomics, Beijing Proteome Research Center, National
      Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing
      102206, China.
FAU - Yang, Dong
AU  - Yang D
AD  - State Key Laboratory of Proteomics, Beijing Proteome Research Center, National
      Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing
      102206, China.
FAU - Zhang, Jin-San
AU  - Zhang JS
AD  - Cell Signaling and Epigenetics Laboratory, School of Pharmaceutical Sciences,
      Wenzhou Medical University, Wenzhou 325035, Zhejiang, China.
FAU - Xiao, Dongguang
AU  - Xiao D
AD  - Key Laboratory of Industrial Fermentation Microbiology, Ministry of Education,
      Tianjin Industrial Microbiology Key Lab, College of Biotechnology, Tianjin
      University of Science and Technology, No 29, 13ST. TEDA, Tianjin 300457, China.
FAU - Qin, Weijie
AU  - Qin W
AD  - State Key Laboratory of Proteomics, Beijing Proteome Research Center, National
      Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing
      102206, China. Electronic address: aunp_dna@126.com.
FAU - Pei, Huadong
AU  - Pei H
AD  - State Key Laboratory of Proteomics, Beijing Proteome Research Center, National
      Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing
      102206, China; Department of Biochemistry and Molecular Medicine, George
      Washington University School of Medicine and Health Science, 2300 Eye Street,
      N.W., Washington, DC 20037, USA. Electronic address: peihuadong@hotmail.com.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Mol Cell
JT  - Molecular cell
JID - 9802571
RN  - 0 (Adaptor Proteins, Signal Transducing)
RN  - 0 (Phosphoproteins)
RN  - 0 (YAP1 (Yes-associated) protein, human)
RN  - 452VLY9402 (Serine)
RN  - EC 2.4.1.- (N-Acetylglucosaminyltransferases)
RN  - EC 2.4.1.- (O-GlcNAc transferase)
RN  - EC 2.7.1.- (LATS1 protein, human)
RN  - EC 2.7.11.1 (Protein-Serine-Threonine Kinases)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Adaptor Proteins, Signal Transducing/genetics/*metabolism
MH  - Animals
MH  - Cell Proliferation
MH  - Cell Transformation, Neoplastic/genetics/*metabolism/pathology
MH  - Gene Expression Regulation, Neoplastic
MH  - Glucose/*metabolism
MH  - Glycosylation
MH  - HEK293 Cells
MH  - HeLa Cells
MH  - Humans
MH  - Mice, Nude
MH  - N-Acetylglucosaminyltransferases/*metabolism
MH  - Neoplasms/*enzymology/genetics/pathology
MH  - Phosphoproteins/genetics/*metabolism
MH  - Phosphorylation
MH  - *Protein Processing, Post-Translational
MH  - Protein-Serine-Threonine Kinases/genetics/metabolism
MH  - Serine
MH  - Signal Transduction
MH  - Time Factors
MH  - Transcription, Genetic
MH  - Transcriptional Activation
OTO - NOTNLM
OT  - Hippo
OT  - O-GlcNAcylation
OT  - OGT
OT  - YAP
OT  - pancreatic cancer
EDAT- 2017/11/04 06:00
MHDA- 2017/11/29 06:00
CRDT- 2017/11/04 06:00
PHST- 2017/02/19 00:00 [received]
PHST- 2017/06/07 00:00 [revised]
PHST- 2017/10/06 00:00 [accepted]
PHST- 2017/11/04 06:00 [entrez]
PHST- 2017/11/04 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
AID - S1097-2765(17)30759-1 [pii]
AID - 10.1016/j.molcel.2017.10.010 [doi]
PST - ppublish
SO  - Mol Cell. 2017 Nov 2;68(3):591-604.e5. doi: 10.1016/j.molcel.2017.10.010.

PMID- 29089311
OWN - NLM
STAT- MEDLINE
DCOM- 20180124
LR  - 20180124
IS  - 1528-0020 (Electronic)
IS  - 0006-4971 (Linking)
VI  - 130
IP  - 26
DP  - 2017 Dec 28
TI  - SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7(+)
      normal lymphocytes.
PG  - 2838-2847
LID - 10.1182/blood-2017-04-778423 [doi]
AB  - SLAMF7 is under intense investigation as a target for immunotherapy in multiple
      myeloma. In this study, we redirected the specificity of T cells to SLAMF7
      through expression of a chimeric antigen receptor (CAR) derived from the huLuc63 
      antibody (elotuzumab) and demonstrate that SLAMF7-CAR T cells prepared from
      patients and healthy donors confer potent antimyeloma reactivity. We confirmed
      uniform, high-level expression of SLAMF7 on malignant plasma cells in previously 
      untreated and in relapsed/refractory (R/R) myeloma patients who had received
      previous treatment with proteasome inhibitors and immunomodulatory drugs.
      Consequently, SLAMF7-CAR T cells conferred rapid cytolysis of previously
      untreated and R/R primary myeloma cells in vitro. In addition, a single
      administration of SLAMF7-CAR T cells led to resolution of medullary and
      extramedullary myeloma manifestations in a murine xenograft model in vivo. SLAMF7
      is expressed on a fraction of normal lymphocytes, including subsets of natural
      killer (NK) cells, T cells, and B cells. After modification with the SLAMF7-CAR, 
      both CD8(+) and CD4(+) T cells rapidly acquired and maintained a SLAMF7(-)
      phenotype and could be readily expanded to therapeutically relevant cell doses.
      We analyzed the recognition of normal lymphocytes by SLAMF7-CAR T cells and show 
      that they induce selective fratricide of SLAMF7(+/high) NK cells, CD4(+) and
      CD8(+) T cells, and B cells. Importantly, however, the fratricide conferred by
      SLAMF7-CAR T cells spares the SLAMF7(-/low) fraction in each cell subset and
      preserves functional lymphocytes, including virus-specific T cells. In aggregate,
      our data illustrate the potential use of SLAMF7-CAR T-cell therapy as an
      effective treatment against multiple myeloma and provide novel insights into the 
      consequences of targeting SLAMF7 for the normal lymphocyte compartment.
CI  - (c) 2017 by The American Society of Hematology.
FAU - Gogishvili, Tea
AU  - Gogishvili T
AD  - Medizinische Klinik und Poliklinik II, Universitatsklinikum Wurzburg, Wurzburg,
      Germany.
FAU - Danhof, Sophia
AU  - Danhof S
AD  - Medizinische Klinik und Poliklinik II, Universitatsklinikum Wurzburg, Wurzburg,
      Germany.
FAU - Prommersberger, Sabrina
AU  - Prommersberger S
AD  - Medizinische Klinik und Poliklinik II, Universitatsklinikum Wurzburg, Wurzburg,
      Germany.
FAU - Rydzek, Julian
AU  - Rydzek J
AD  - Medizinische Klinik und Poliklinik II, Universitatsklinikum Wurzburg, Wurzburg,
      Germany.
FAU - Schreder, Martin
AU  - Schreder M
AD  - Medizinische Klinik und Poliklinik II, Universitatsklinikum Wurzburg, Wurzburg,
      Germany.
FAU - Brede, Christian
AU  - Brede C
AD  - Medizinische Klinik und Poliklinik II, Universitatsklinikum Wurzburg, Wurzburg,
      Germany.
FAU - Einsele, Hermann
AU  - Einsele H
AD  - Medizinische Klinik und Poliklinik II, Universitatsklinikum Wurzburg, Wurzburg,
      Germany.
FAU - Hudecek, Michael
AU  - Hudecek M
AUID- ORCID: 0000-0002-2280-2202
AD  - Medizinische Klinik und Poliklinik II, Universitatsklinikum Wurzburg, Wurzburg,
      Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20171031
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Receptors, Antigen, T-Cell)
RN  - 0 (SLAMF7 protein, human)
RN  - 0 (Signaling Lymphocytic Activation Molecule Family)
RN  - 1351PE5UGS (elotuzumab)
SB  - AIM
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal, Humanized
MH  - Heterografts
MH  - Humans
MH  - Immunotherapy, Adoptive/*methods
MH  - Lymphocytes/immunology
MH  - Mice
MH  - Multiple Myeloma/pathology/*therapy
MH  - Receptors, Antigen, T-Cell/genetics/immunology
MH  - Signaling Lymphocytic Activation Molecule Family/analysis/*immunology
MH  - T-Lymphocytes/immunology/transplantation
EDAT- 2017/11/02 06:00
MHDA- 2018/01/25 06:00
CRDT- 2017/11/02 06:00
PHST- 2017/04/06 00:00 [received]
PHST- 2017/10/24 00:00 [accepted]
PHST- 2017/11/02 06:00 [pubmed]
PHST- 2018/01/25 06:00 [medline]
PHST- 2017/11/02 06:00 [entrez]
AID - blood-2017-04-778423 [pii]
AID - 10.1182/blood-2017-04-778423 [doi]
PST - ppublish
SO  - Blood. 2017 Dec 28;130(26):2838-2847. doi: 10.1182/blood-2017-04-778423. Epub
      2017 Oct 31.

PMID- 29049395
OWN - NLM
STAT- MEDLINE
DCOM- 20171222
LR  - 20171222
IS  - 1553-7404 (Electronic)
IS  - 1553-7390 (Linking)
VI  - 13
IP  - 10
DP  - 2017 Oct
TI  - Guidelines for morpholino use in zebrafish.
PG  - e1007000
LID - 10.1371/journal.pgen.1007000 [doi]
FAU - Stainier, Didier Y R
AU  - Stainier DYR
AUID- ORCID: 0000-0002-0382-0026
AD  - Department of Developmental Genetics, Max Planck Institute for Heart and Lung
      Research, Bad Nauheim, Germany.
FAU - Raz, Erez
AU  - Raz E
AUID- ORCID: 0000-0002-6347-3302
AD  - Institute of Cell Biology, ZBME, University of Munster, Munster, Germany.
FAU - Lawson, Nathan D
AU  - Lawson ND
AD  - Department of Molecular, Cell, and Cancer Biology, University of Massachusetts
      Medical School, Worcester, Massachusetts, United States of America.
FAU - Ekker, Stephen C
AU  - Ekker SC
AD  - Mayo Clinic, Rochester, Minnesota, United States of America.
FAU - Burdine, Rebecca D
AU  - Burdine RD
AD  - Department of Molecular Biology, Princeton University, Princeton, New Jersey,
      United States of America.
FAU - Eisen, Judith S
AU  - Eisen JS
AUID- ORCID: 0000-0003-1229-1696
AD  - Institute of Neuroscience, University of Oregon, Eugene, Oregon, United States of
      America.
FAU - Ingham, Philip W
AU  - Ingham PW
AD  - Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.
AD  - The Living Systems Institute, University of Exeter, Exeter, United Kingdom.
FAU - Schulte-Merker, Stefan
AU  - Schulte-Merker S
AD  - Institute of Cardiovascular Organogenesis and Regeneration, WWU Munster, Faculty 
      of Medicine, Munster, Germany.
FAU - Yelon, Deborah
AU  - Yelon D
AD  - Division of Biological Sciences, University of California, San Diego, La Jolla,
      California, United States of America.
FAU - Weinstein, Brant M
AU  - Weinstein BM
AD  - Division of Developmental Biology, NICHD, NIH, Bethesda, Maryland, United States 
      of America.
FAU - Mullins, Mary C
AU  - Mullins MC
AUID- ORCID: 0000-0002-9979-1564
AD  - Department of Cell and Developmental Biology, University of Pennsylvania Perelman
      School of Medicine, Philadelphia, Pennsylvania, United States of America.
FAU - Wilson, Stephen W
AU  - Wilson SW
AUID- ORCID: 0000-0002-8557-5940
AD  - Department of Cell and Developmental Biology, University College London, London, 
      United Kingdom.
FAU - Ramakrishnan, Lalita
AU  - Ramakrishnan L
AD  - Molecular Immunity Unit, Department of Medicine, University of Cambridge, MRC
      Laboratory of Molecular Biology, Cambridge, United Kingdom.
FAU - Amacher, Sharon L
AU  - Amacher SL
AD  - Departments of Molecular Genetics and Biological Chemistry and Pharmacology, Ohio
      State University, Columbus, Ohio, United States of America.
FAU - Neuhauss, Stephan C F
AU  - Neuhauss SCF
AUID- ORCID: 0000-0002-9615-480X
AD  - Institute of Molecular Life Sciences, University of Zurich, Zurich, Switzerland.
FAU - Meng, Anming
AU  - Meng A
AD  - School of Life Sciences, Tsinghua University, Beijing, China.
FAU - Mochizuki, Naoki
AU  - Mochizuki N
AUID- ORCID: 0000-0002-3938-9602
AD  - National Cerebral and Cardiovascular Center Research Institute, Osaka, Japan.
FAU - Panula, Pertti
AU  - Panula P
AD  - Department of Anatomy and Neuroscience Center, University of Helsinki, Helsinki, 
      Finland.
FAU - Moens, Cecilia B
AU  - Moens CB
AD  - Division of Basic Sciences, Fred Hutchinson Cancer Research Center, Seattle,
      Washington, United States of America.
LA  - eng
GR  - R13 HD075578/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20171019
PL  - United States
TA  - PLoS Genet
JT  - PLoS genetics
JID - 101239074
RN  - 0 (Morpholinos)
SB  - IM
MH  - Animals
MH  - Female
MH  - Genetic Techniques/*standards
MH  - Male
MH  - Morpholinos/adverse effects/*genetics
MH  - Zebrafish/*genetics
PMC - PMC5648102
EDAT- 2017/10/20 06:00
MHDA- 2017/12/23 06:00
CRDT- 2017/10/20 06:00
PHST- 2017/10/20 06:00 [entrez]
PHST- 2017/10/20 06:00 [pubmed]
PHST- 2017/12/23 06:00 [medline]
AID - 10.1371/journal.pgen.1007000 [doi]
AID - PGENETICS-D-17-01294 [pii]
PST - epublish
SO  - PLoS Genet. 2017 Oct 19;13(10):e1007000. doi: 10.1371/journal.pgen.1007000.
      eCollection 2017 Oct.

PMID- 29136509
OWN - NLM
STAT- MEDLINE
DCOM- 20171127
LR  - 20171219
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 5
DP  - 2017 Nov 13
TI  - An HIF-1alpha/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression.
PG  - 669-683.e5
LID - S1535-6108(17)30456-7 [pii]
LID - 10.1016/j.ccell.2017.10.003 [doi]
AB  - Cytotoxic T cells infiltrating tumors are thought to utilize HIF transcription
      factors during adaptation to the hypoxic tumor microenvironment. Deletion
      analyses of the two key HIF isoforms found that HIF-1alpha, but not HIF-2alpha,
      was essential for the effector state in CD8(+) T cells. Furthermore, loss of
      HIF-1alpha in CD8(+) T cells reduced tumor infiltration and tumor cell killing,
      and altered tumor vascularization. Deletion of VEGF-A, an HIF target gene, in
      CD8(+) T cells accelerated tumorigenesis while also altering vascularization.
      Analyses of human breast cancer showed inverse correlations between VEGF-A
      expression and CD8(+) T cell infiltration, and a link between T cell infiltration
      and vascularization. These data demonstrate that the HIF-1alpha/VEGF-A axis is an
      essential aspect of tumor immunity.
CI  - Copyright (c) 2017 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Palazon, Asis
AU  - Palazon A
AD  - Department of Physiology, Development and Neuroscience, University of Cambridge, 
      Cambridge CB2 3EG, UK.
FAU - Tyrakis, Petros A
AU  - Tyrakis PA
AD  - Department of Physiology, Development and Neuroscience, University of Cambridge, 
      Cambridge CB2 3EG, UK; Cancer Research UK, Cambridge Institute, Cambridge CB2
      0RE, UK.
FAU - Macias, David
AU  - Macias D
AD  - Cancer Research UK, Cambridge Institute, Cambridge CB2 0RE, UK.
FAU - Velica, Pedro
AU  - Velica P
AD  - Department of Cell and Molecular Biology, Karolinska Institute, 171 77 Stockholm,
      Sweden.
FAU - Rundqvist, Helene
AU  - Rundqvist H
AD  - Department of Cell and Molecular Biology, Karolinska Institute, 171 77 Stockholm,
      Sweden.
FAU - Fitzpatrick, Susan
AU  - Fitzpatrick S
AD  - Cancer Research UK, Cambridge Institute, Cambridge CB2 0RE, UK.
FAU - Vojnovic, Nikola
AU  - Vojnovic N
AD  - Department of Cell and Molecular Biology, Karolinska Institute, 171 77 Stockholm,
      Sweden.
FAU - Phan, Anthony T
AU  - Phan AT
AD  - Molecular Biology Section, Division of Biological Sciences, University of
      California San Diego, La Jolla, CA 92161, USA.
FAU - Loman, Niklas
AU  - Loman N
AD  - Department of Clinical Sciences, Division of Oncology and Pathology, Lund
      University, 223 81 Lund, Sweden.
FAU - Hedenfalk, Ingrid
AU  - Hedenfalk I
AD  - Department of Clinical Sciences, Division of Oncology and Pathology, Lund
      University, 223 81 Lund, Sweden.
FAU - Hatschek, Thomas
AU  - Hatschek T
AD  - Karolinska Oncology, Karolinska Institute and University Hospital, 171 76
      Stockholm, Sweden.
FAU - Lovrot, John
AU  - Lovrot J
AD  - Karolinska Oncology, Karolinska Institute and University Hospital, 171 76
      Stockholm, Sweden.
FAU - Foukakis, Theodoros
AU  - Foukakis T
AD  - Karolinska Oncology, Karolinska Institute and University Hospital, 171 76
      Stockholm, Sweden.
FAU - Goldrath, Ananda W
AU  - Goldrath AW
AD  - Molecular Biology Section, Division of Biological Sciences, University of
      California San Diego, La Jolla, CA 92161, USA.
FAU - Bergh, Jonas
AU  - Bergh J
AD  - Karolinska Oncology, Karolinska Institute and University Hospital, 171 76
      Stockholm, Sweden.
FAU - Johnson, Randall S
AU  - Johnson RS
AD  - Department of Physiology, Development and Neuroscience, University of Cambridge, 
      Cambridge CB2 3EG, UK; Department of Cell and Molecular Biology, Karolinska
      Institute, 171 77 Stockholm, Sweden. Electronic address: rsj33@cam.ac.uk.
LA  - eng
GR  - Wellcome Trust/United Kingdom
GR  - R01 AI096852/AI/NIAID NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Hypoxia-Inducible Factor 1, alpha Subunit)
RN  - 0 (Vascular Endothelial Growth Factor A)
SB  - IM
MH  - Animals
MH  - Breast Neoplasms/genetics/metabolism
MH  - CD8-Positive T-Lymphocytes/metabolism
MH  - Cell Line, Tumor
MH  - Cells, Cultured
MH  - Disease Progression
MH  - Female
MH  - Gene Expression Profiling/methods
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Hypoxia-Inducible Factor 1, alpha Subunit/*genetics/metabolism
MH  - Mice, Inbred C57BL
MH  - Mice, Knockout
MH  - Neoplasms, Experimental/blood supply/*genetics/metabolism
MH  - Neovascularization, Pathologic/genetics/metabolism
MH  - T-Lymphocytes, Cytotoxic/*metabolism
MH  - Vascular Endothelial Growth Factor A/*genetics/metabolism
PMC - PMC5691891
OTO - NOTNLM
OT  - HIF transcription factors
OT  - VEGF
OT  - angiogenesis
OT  - cytotoxic T cells
OT  - hypoxia
OT  - immunotherapy
EDAT- 2017/11/15 06:00
MHDA- 2017/11/29 06:00
CRDT- 2017/11/15 06:00
PHST- 2016/09/03 00:00 [received]
PHST- 2017/05/18 00:00 [revised]
PHST- 2017/10/04 00:00 [accepted]
PHST- 2017/11/15 06:00 [entrez]
PHST- 2017/11/15 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
AID - S1535-6108(17)30456-7 [pii]
AID - 10.1016/j.ccell.2017.10.003 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Nov 13;32(5):669-683.e5. doi: 10.1016/j.ccell.2017.10.003.

PMID- 29167102
OWN - NLM
STAT- MEDLINE
DCOM- 20180101
LR  - 20180113
IS  - 1756-1833 (Electronic)
IS  - 0959-535X (Linking)
VI  - 359
DP  - 2017 Nov 22
TI  - Coffee consumption and health: umbrella review of meta-analyses of multiple
      health outcomes.
PG  - j5024
LID - 10.1136/bmj.j5024 [doi]
AB  - Objectives To evaluate the existing evidence for associations between coffee
      consumption and multiple health outcomes.Design Umbrella review of the evidence
      across meta-analyses of observational and interventional studies of coffee
      consumption and any health outcome.Data sources PubMed, Embase, CINAHL, Cochrane 
      Database of Systematic Reviews, and screening of references.Eligibility criteria 
      for selecting studies Meta-analyses of both observational and interventional
      studies that examined the associations between coffee consumption and any health 
      outcome in any adult population in all countries and all settings. Studies of
      genetic polymorphisms for coffee metabolism were excluded.Results The umbrella
      review identified 201 meta-analyses of observational research with 67 unique
      health outcomes and 17 meta-analyses of interventional research with nine unique 
      outcomes. Coffee consumption was more often associated with benefit than harm for
      a range of health outcomes across exposures including high versus low, any versus
      none, and one extra cup a day. There was evidence of a non-linear association
      between consumption and some outcomes, with summary estimates indicating largest 
      relative risk reduction at intakes of three to four cups a day versus none,
      including all cause mortality (relative risk 0.83, 95% confidence interval 0.83
      to 0.88), cardiovascular mortality (0.81, 0.72 to 0.90), and cardiovascular
      disease (0.85, 0.80 to 0.90). High versus low consumption was associated with an 
      18% lower risk of incident cancer (0.82, 0.74 to 0.89). Consumption was also
      associated with a lower risk of several specific cancers and neurological,
      metabolic, and liver conditions. Harmful associations were largely nullified by
      adequate adjustment for smoking, except in pregnancy, where high versus low/no
      consumption was associated with low birth weight (odds ratio 1.31, 95% confidence
      interval 1.03 to 1.67), preterm birth in the first (1.22, 1.00 to 1.49) and
      second (1.12, 1.02 to 1.22) trimester, and pregnancy loss (1.46, 1.06 to 1.99).
      There was also an association between coffee drinking and risk of fracture in
      women but not in men.Conclusion Coffee consumption seems generally safe within
      usual levels of intake, with summary estimates indicating largest risk reduction 
      for various health outcomes at three to four cups a day, and more likely to
      benefit health than harm. Robust randomised controlled trials are needed to
      understand whether the observed associations are causal. Importantly, outside of 
      pregnancy, existing evidence suggests that coffee could be tested as an
      intervention without significant risk of causing harm. Women at increased risk of
      fracture should possibly be excluded.
CI  - Published by the BMJ Publishing Group Limited. For permission to use (where not
      already granted under a licence) please go to
      http://group.bmj.com/group/rights-licensing/permissions.
FAU - Poole, Robin
AU  - Poole R
AD  - Academic Unit of Primary Care and Population Sciences, Faculty of Medicine,
      University of Southampton, South Academic Block, Southampton General Hospital,
      Southampton, Hampshire SO16 6YD, UK.
FAU - Kennedy, Oliver J
AU  - Kennedy OJ
AD  - Academic Unit of Primary Care and Population Sciences, Faculty of Medicine,
      University of Southampton, South Academic Block, Southampton General Hospital,
      Southampton, Hampshire SO16 6YD, UK.
FAU - Roderick, Paul
AU  - Roderick P
AD  - Academic Unit of Primary Care and Population Sciences, Faculty of Medicine,
      University of Southampton, South Academic Block, Southampton General Hospital,
      Southampton, Hampshire SO16 6YD, UK.
FAU - Fallowfield, Jonathan A
AU  - Fallowfield JA
AD  - Medical Research Council/University of Edinburgh Centre for Inflammation
      Research, Queen's Medical Research Institute, Edinburgh, EH16 4TJ, UK.
FAU - Hayes, Peter C
AU  - Hayes PC
AD  - Medical Research Council/University of Edinburgh Centre for Inflammation
      Research, Queen's Medical Research Institute, Edinburgh, EH16 4TJ, UK.
FAU - Parkes, Julie
AU  - Parkes J
AD  - Academic Unit of Primary Care and Population Sciences, Faculty of Medicine,
      University of Southampton, South Academic Block, Southampton General Hospital,
      Southampton, Hampshire SO16 6YD, UK.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20171122
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
RN  - 0 (Coffee)
RN  - 3G6A5W338E (Caffeine)
SB  - AIM
SB  - IM
EIN - BMJ. 2018 Jan 12;360:k194. PMID: 29330262
MH  - Adult
MH  - Caffeine/*adverse effects
MH  - Cardiovascular Diseases/*epidemiology/prevention & control
MH  - Coffee/*adverse effects
MH  - Female
MH  - Fractures, Bone/*epidemiology/prevention & control
MH  - Humans
MH  - Infant, Low Birth Weight
MH  - Observational Studies as Topic
MH  - Pregnancy
MH  - Premature Birth/*epidemiology/prevention & control
PMC - PMC5696634
COIS- Competing interests: All authors have completed the ICMJE uniform disclosure form
      at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation
      for the submitted work; JAF reports research grants from GlaxoSmithKline and from
      Intercept Pharmaceuticals, and personal fees from Novartis and from Merck,
      outside the submitted work; PCH reports personal fees from MSD, personal fees
      from Gilead, personal fees from Abbvie, personal fees from Jannsen, personal fees
      from BMS, personal fees from Pfizer, grants and personal fees from Roche,
      personal fees from Novartis, outside the submitted work; no other relationships
      or activities that could appear to have influenced the submitted work.
EDAT- 2017/11/24 06:00
MHDA- 2018/01/02 06:00
CRDT- 2017/11/24 06:00
PHST- 2017/11/24 06:00 [entrez]
PHST- 2017/11/24 06:00 [pubmed]
PHST- 2018/01/02 06:00 [medline]
PST - epublish
SO  - BMJ. 2017 Nov 22;359:j5024.

PMID- 29153842
OWN - NLM
STAT- MEDLINE
DCOM- 20171220
LR  - 20171220
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 32
IP  - 6
DP  - 2017 Dec 11
TI  - Stress-Activated NRF2-MDM2 Cascade Controls Neoplastic Progression in Pancreas.
PG  - 824-839.e8
LID - S1535-6108(17)30464-6 [pii]
LID - 10.1016/j.ccell.2017.10.011 [doi]
AB  - Despite expression of oncogenic KRAS, premalignant pancreatic intraepithelial
      neoplasia 1 (PanIN1) lesions rarely become fully malignant pancreatic ductal
      adenocarcinoma (PDAC). The molecular mechanisms through which established risk
      factors, such as chronic pancreatitis, acinar cell damage, and/or defective
      autophagy increase the likelihood of PDAC development are poorly understood. We
      show that accumulation of the autophagy substrate p62/SQSTM1 in stressed
      Kras(G12D) acinar cells is associated with PDAC development and maintenance of
      malignancy in human cells and mice. p62 accumulation promotes neoplastic
      progression by controlling the NRF2-mediated induction of MDM2, which acts
      through p53-dependent and -independent mechanisms to abrogate checkpoints that
      prevent conversion of differentiated acinar cells to proliferative ductal
      progenitors. MDM2 targeting may be useful for preventing PDAC development in
      high-risk individuals.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Todoric, Jelena
AU  - Todoric J
AD  - Laboratory of Gene Regulation and Signal Transduction, Department of
      Pharmacology, School of Medicine, University of California San Diego, La Jolla,
      CA 92093, USA; Department of Laboratory Medicine, Medical University of Vienna,
      1090 Vienna, Austria.
FAU - Antonucci, Laura
AU  - Antonucci L
AD  - Laboratory of Gene Regulation and Signal Transduction, Department of
      Pharmacology, School of Medicine, University of California San Diego, La Jolla,
      CA 92093, USA.
FAU - Di Caro, Giuseppe
AU  - Di Caro G
AD  - Laboratory of Gene Regulation and Signal Transduction, Department of
      Pharmacology, School of Medicine, University of California San Diego, La Jolla,
      CA 92093, USA.
FAU - Li, Ning
AU  - Li N
AD  - Laboratory of Gene Regulation and Signal Transduction, Department of
      Pharmacology, School of Medicine, University of California San Diego, La Jolla,
      CA 92093, USA.
FAU - Wu, Xuefeng
AU  - Wu X
AD  - Laboratory of Gene Regulation and Signal Transduction, Department of
      Pharmacology, School of Medicine, University of California San Diego, La Jolla,
      CA 92093, USA.
FAU - Lytle, Nikki K
AU  - Lytle NK
AD  - Departments of Pharmacology and Medicine, Moores Cancer Center, University of
      California San Diego School of Medicine, La Jolla, CA 92093, USA; Sanford
      Consortium for Regenerative Medicine, La Jolla, CA 92037, USA.
FAU - Dhar, Debanjan
AU  - Dhar D
AD  - Laboratory of Gene Regulation and Signal Transduction, Department of
      Pharmacology, School of Medicine, University of California San Diego, La Jolla,
      CA 92093, USA.
FAU - Banerjee, Sourav
AU  - Banerjee S
AD  - Department of Pharmacology, School of Medicine, University of California San
      Diego, La Jolla, CA 92093, USA.
FAU - Fagman, Johan B
AU  - Fagman JB
AD  - Laboratory of Gene Regulation and Signal Transduction, Department of
      Pharmacology, School of Medicine, University of California San Diego, La Jolla,
      CA 92093, USA.
FAU - Browne, Cecille D
AU  - Browne CD
AD  - Laboratory of Gene Regulation and Signal Transduction, Department of
      Pharmacology, School of Medicine, University of California San Diego, La Jolla,
      CA 92093, USA.
FAU - Umemura, Atsushi
AU  - Umemura A
AD  - Laboratory of Gene Regulation and Signal Transduction, Department of
      Pharmacology, School of Medicine, University of California San Diego, La Jolla,
      CA 92093, USA; Department of Molecular Gastroenterology and Hepatology, Graduate 
      School of Medical Science, Kyoto Prefectural University of Medicine, 602-8566
      Kyoto, Japan.
FAU - Valasek, Mark A
AU  - Valasek MA
AD  - Department of Pathology, School of Medicine, University of California San Diego, 
      La Jolla, CA 92093, USA.
FAU - Kessler, Hannes
AU  - Kessler H
AD  - Laboratory of Gene Regulation and Signal Transduction, Department of
      Pharmacology, School of Medicine, University of California San Diego, La Jolla,
      CA 92093, USA.
FAU - Tarin, David
AU  - Tarin D
AD  - Department of Pathology, School of Medicine, University of California San Diego, 
      La Jolla, CA 92093, USA.
FAU - Goggins, Michael
AU  - Goggins M
AD  - Departments of Medicine (Gastroenterology) and Radiology, The Sol Goldman
      Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore,
      MD 21287, USA.
FAU - Reya, Tannishtha
AU  - Reya T
AD  - Departments of Pharmacology and Medicine, Moores Cancer Center, University of
      California San Diego School of Medicine, La Jolla, CA 92093, USA; Sanford
      Consortium for Regenerative Medicine, La Jolla, CA 92037, USA.
FAU - Diaz-Meco, Maria
AU  - Diaz-Meco M
AD  - Cancer Metabolism and Signaling Networks Program, Sanford Burnham Prebys Medical 
      Discovery Institute, La Jolla, CA 92037, USA.
FAU - Moscat, Jorge
AU  - Moscat J
AD  - Cancer Metabolism and Signaling Networks Program, Sanford Burnham Prebys Medical 
      Discovery Institute, La Jolla, CA 92037, USA.
FAU - Karin, Michael
AU  - Karin M
AD  - Laboratory of Gene Regulation and Signal Transduction, Department of
      Pharmacology, School of Medicine, University of California San Diego, La Jolla,
      CA 92093, USA; Department of Pathology, School of Medicine, University of
      California San Diego, La Jolla, CA 92093, USA. Electronic address:
      karinoffice@ucsd.edu.
LA  - eng
GR  - R01 CA192642/CA/NCI NIH HHS/United States
GR  - R01 CA218254/CA/NCI NIH HHS/United States
GR  - P50 CA062924/CA/NCI NIH HHS/United States
GR  - R01 CA172025/CA/NCI NIH HHS/United States
GR  - R01 CA211794/CA/NCI NIH HHS/United States
GR  - P30 CA030199/CA/NCI NIH HHS/United States
GR  - R01 CA186043/CA/NCI NIH HHS/United States
GR  - T32 GM007752/GM/NIGMS NIH HHS/United States
GR  - R01 CA132847/CA/NCI NIH HHS/United States
GR  - R01 CA163798/CA/NCI NIH HHS/United States
GR  - R03 CA167120/CA/NCI NIH HHS/United States
GR  - F31 CA206416/CA/NCI NIH HHS/United States
GR  - R01 AI043477/AI/NIAID NIH HHS/United States
GR  - R01 CA134530/CA/NCI NIH HHS/United States
GR  - R35 CA197699/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20171116
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (NF-E2-Related Factor 2)
RN  - 0 (NFE2L2 protein, human)
RN  - EC 2.3.2.27 (MDM2 protein, human)
RN  - EC 2.3.2.27 (Proto-Oncogene Proteins c-mdm2)
SB  - IM
MH  - Acinar Cells/metabolism/pathology
MH  - Adenocarcinoma in Situ/metabolism/*pathology
MH  - Animals
MH  - Carcinoma, Pancreatic Ductal/metabolism/*pathology
MH  - Disease Progression
MH  - Heterografts
MH  - Humans
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Inbred NOD
MH  - Mice, SCID
MH  - NF-E2-Related Factor 2/*metabolism
MH  - Pancreatic Neoplasms/metabolism/*pathology
MH  - Proto-Oncogene Proteins c-mdm2/*metabolism
MH  - Signal Transduction/physiology
PMC - PMC5730340
MID - NIHMS919646
OTO - NOTNLM
OT  - IKKalpha
OT  - MDM2
OT  - NRF2
OT  - acinar cell reprogramming
OT  - impaired autophagy
OT  - p62
OT  - pancreatic ductal adenocarcinoma
EDAT- 2017/11/21 06:00
MHDA- 2017/12/21 06:00
CRDT- 2017/11/21 06:00
PMCR- 2018/12/11 00:00
PHST- 2017/01/31 00:00 [received]
PHST- 2017/08/21 00:00 [revised]
PHST- 2017/10/20 00:00 [accepted]
PHST- 2018/12/11 00:00 [pmc-release]
PHST- 2017/11/21 06:00 [pubmed]
PHST- 2017/12/21 06:00 [medline]
PHST- 2017/11/21 06:00 [entrez]
AID - S1535-6108(17)30464-6 [pii]
AID - 10.1016/j.ccell.2017.10.011 [doi]
PST - ppublish
SO  - Cancer Cell. 2017 Dec 11;32(6):824-839.e8. doi: 10.1016/j.ccell.2017.10.011. Epub
      2017 Nov 16.

PMID- 29144448
OWN - NLM
STAT- In-Data-Review
LR  - 20171219
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 551
IP  - 7680
DP  - 2017 Nov 16
TI  - Regeneration of the entire human epidermis using transgenic stem cells.
PG  - 327-332
LID - 10.1038/nature24487 [doi]
AB  - Junctional epidermolysis bullosa (JEB) is a severe and often lethal genetic
      disease caused by mutations in genes encoding the basement membrane component
      laminin-332. Surviving patients with JEB develop chronic wounds to the skin and
      mucosa, which impair their quality of life and lead to skin cancer. Here we show 
      that autologous transgenic keratinocyte cultures regenerated an entire, fully
      functional epidermis on a seven-year-old child suffering from a devastating,
      life-threatening form of JEB. The proviral integration pattern was maintained in 
      vivo and epidermal renewal did not cause any clonal selection. Clonal tracing
      showed that the human epidermis is sustained not by equipotent progenitors, but
      by a limited number of long-lived stem cells, detected as holoclones, that can
      extensively self-renew in vitro and in vivo and produce progenitors that
      replenish terminally differentiated keratinocytes. This study provides a
      blueprint that can be applied to other stem cell-mediated combined ex vivo cell
      and gene therapies.
FAU - Hirsch, Tobias
AU  - Hirsch T
AD  - Department of Plastic Surgery, Burn Centre, BG University Hospital Bergmannsheil,
      Ruhr University Bochum, 44789 Bochum, Germany.
FAU - Rothoeft, Tobias
AU  - Rothoeft T
AD  - Department of Neonatology and Pediatric Intensive Care, University Children's
      Hospital, Ruhr University Bochum, 44791 Bochum, Germany.
FAU - Teig, Norbert
AU  - Teig N
AD  - Department of Neonatology and Pediatric Intensive Care, University Children's
      Hospital, Ruhr University Bochum, 44791 Bochum, Germany.
FAU - Bauer, Johann W
AU  - Bauer JW
AD  - EB House Austria and Department of Dermatology, University Hospital of the
      Paracelsus Medical University, 5020 Salzburg, Austria.
FAU - Pellegrini, Graziella
AU  - Pellegrini G
AD  - Department of Surgery, Medicine, Dentistry and Morphological Sciences, University
      of Modena and Reggio Emilia, 41124 Modena, Italy.
AD  - Center for Regenerative Medicine "Stefano Ferrari", Department of Life Sciences, 
      University of Modena and Reggio Emilia, 41125 Modena, Italy.
FAU - De Rosa, Laura
AU  - De Rosa L
AD  - Center for Regenerative Medicine "Stefano Ferrari", Department of Life Sciences, 
      University of Modena and Reggio Emilia, 41125 Modena, Italy.
FAU - Scaglione, Davide
AU  - Scaglione D
AD  - IGA Technology Services s.r.l., 33100 Udine, Italy.
FAU - Reichelt, Julia
AU  - Reichelt J
AD  - EB House Austria and Department of Dermatology, University Hospital of the
      Paracelsus Medical University, 5020 Salzburg, Austria.
FAU - Klausegger, Alfred
AU  - Klausegger A
AD  - EB House Austria and Department of Dermatology, University Hospital of the
      Paracelsus Medical University, 5020 Salzburg, Austria.
FAU - Kneisz, Daniela
AU  - Kneisz D
AD  - EB House Austria and Department of Dermatology, University Hospital of the
      Paracelsus Medical University, 5020 Salzburg, Austria.
FAU - Romano, Oriana
AU  - Romano O
AD  - Department of Life Sciences, University of Modena and Reggio Emilia, 41125
      Modena, Italy.
FAU - Secone Seconetti, Alessia
AU  - Secone Seconetti A
AD  - Center for Regenerative Medicine "Stefano Ferrari", Department of Life Sciences, 
      University of Modena and Reggio Emilia, 41125 Modena, Italy.
FAU - Contin, Roberta
AU  - Contin R
AD  - Center for Regenerative Medicine "Stefano Ferrari", Department of Life Sciences, 
      University of Modena and Reggio Emilia, 41125 Modena, Italy.
FAU - Enzo, Elena
AU  - Enzo E
AD  - Center for Regenerative Medicine "Stefano Ferrari", Department of Life Sciences, 
      University of Modena and Reggio Emilia, 41125 Modena, Italy.
FAU - Jurman, Irena
AU  - Jurman I
AD  - Istituto di Genomica Applicata and Dipartimento di Scienze Agroalimentari,
      Ambientali e Animali, University of Udine, 33100 Udine, Italy.
FAU - Carulli, Sonia
AU  - Carulli S
AD  - Holostem Terapie Avanzate s.r.l., 41125 Modena, Italy.
FAU - Jacobsen, Frank
AU  - Jacobsen F
AD  - Department of Plastic Surgery, Burn Centre, BG University Hospital Bergmannsheil,
      Ruhr University Bochum, 44789 Bochum, Germany.
FAU - Luecke, Thomas
AU  - Luecke T
AD  - Department of Neuropaediatrics, University Children's Hospital, Ruhr University
      Bochum, 44791 Bochum, Germany.
FAU - Lehnhardt, Marcus
AU  - Lehnhardt M
AD  - Department of Plastic Surgery, Burn Centre, BG University Hospital Bergmannsheil,
      Ruhr University Bochum, 44789 Bochum, Germany.
FAU - Fischer, Meike
AU  - Fischer M
AD  - Department of Neonatology and Pediatric Intensive Care, University Children's
      Hospital, Ruhr University Bochum, 44791 Bochum, Germany.
FAU - Kueckelhaus, Maximilian
AU  - Kueckelhaus M
AD  - Department of Plastic Surgery, Burn Centre, BG University Hospital Bergmannsheil,
      Ruhr University Bochum, 44789 Bochum, Germany.
FAU - Quaglino, Daniela
AU  - Quaglino D
AD  - Department of Life Sciences, University of Modena and Reggio Emilia, 41125
      Modena, Italy.
FAU - Morgante, Michele
AU  - Morgante M
AD  - Istituto di Genomica Applicata and Dipartimento di Scienze Agroalimentari,
      Ambientali e Animali, University of Udine, 33100 Udine, Italy.
FAU - Bicciato, Silvio
AU  - Bicciato S
AD  - Department of Life Sciences, University of Modena and Reggio Emilia, 41125
      Modena, Italy.
FAU - Bondanza, Sergio
AU  - Bondanza S
AD  - Holostem Terapie Avanzate s.r.l., 41125 Modena, Italy.
FAU - De Luca, Michele
AU  - De Luca M
AD  - Center for Regenerative Medicine "Stefano Ferrari", Department of Life Sciences, 
      University of Modena and Reggio Emilia, 41125 Modena, Italy.
LA  - eng
PT  - Journal Article
DEP - 20171108
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
EDAT- 2017/11/17 06:00
MHDA- 2017/11/17 06:00
CRDT- 2017/11/17 06:00
PHST- 2017/06/19 00:00 [received]
PHST- 2017/10/10 00:00 [accepted]
PHST- 2017/11/17 06:00 [entrez]
PHST- 2017/11/17 06:00 [pubmed]
PHST- 2017/11/17 06:00 [medline]
AID - nature24487 [pii]
AID - 10.1038/nature24487 [doi]
PST - ppublish
SO  - Nature. 2017 Nov 16;551(7680):327-332. doi: 10.1038/nature24487. Epub 2017 Nov 8.

PMID- 29224777
OWN - NLM
STAT- MEDLINE
DCOM- 20171228
LR  - 20180127
IS  - 1097-4172 (Electronic)
IS  - 0092-8674 (Linking)
VI  - 171
IP  - 7
DP  - 2017 Dec 14
TI  - YY1 Is a Structural Regulator of Enhancer-Promoter Loops.
PG  - 1573-1588.e28
LID - S0092-8674(17)31317-X [pii]
LID - 10.1016/j.cell.2017.11.008 [doi]
AB  - There is considerable evidence that chromosome structure plays important roles in
      gene control, but we have limited understanding of the proteins that contribute
      to structural interactions between gene promoters and their enhancer elements.
      Large DNA loops that encompass genes and their regulatory elements depend on
      CTCF-CTCF interactions, but most enhancer-promoter interactions do not employ
      this structural protein. Here, we show that the ubiquitously expressed
      transcription factor Yin Yang 1 (YY1) contributes to enhancer-promoter structural
      interactions in a manner analogous to DNA interactions mediated by CTCF. YY1
      binds to active enhancers and promoter-proximal elements and forms dimers that
      facilitate the interaction of these DNA elements. Deletion of YY1 binding sites
      or depletion of YY1 protein disrupts enhancer-promoter looping and gene
      expression. We propose that YY1-mediated enhancer-promoter interactions are a
      general feature of mammalian gene control.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Weintraub, Abraham S
AU  - Weintraub AS
AD  - Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA; Department
      of Biology, Massachusetts Institute of Technology, Cambridge, MA 02142, USA.
FAU - Li, Charles H
AU  - Li CH
AD  - Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA; Department
      of Biology, Massachusetts Institute of Technology, Cambridge, MA 02142, USA.
FAU - Zamudio, Alicia V
AU  - Zamudio AV
AD  - Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA; Department
      of Biology, Massachusetts Institute of Technology, Cambridge, MA 02142, USA.
FAU - Sigova, Alla A
AU  - Sigova AA
AD  - Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.
FAU - Hannett, Nancy M
AU  - Hannett NM
AD  - Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.
FAU - Day, Daniel S
AU  - Day DS
AD  - Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.
FAU - Abraham, Brian J
AU  - Abraham BJ
AD  - Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.
FAU - Cohen, Malkiel A
AU  - Cohen MA
AD  - Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.
FAU - Nabet, Behnam
AU  - Nabet B
AD  - Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical
      School, Boston, MA 02115, USA; Department of Cancer Biology, Dana-Farber Cancer
      Institute, Boston, MA 02115, USA.
FAU - Buckley, Dennis L
AU  - Buckley DL
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115,
      USA.
FAU - Guo, Yang Eric
AU  - Guo YE
AD  - Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.
FAU - Hnisz, Denes
AU  - Hnisz D
AD  - Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.
FAU - Jaenisch, Rudolf
AU  - Jaenisch R
AD  - Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA; Department
      of Biology, Massachusetts Institute of Technology, Cambridge, MA 02142, USA.
FAU - Bradner, James E
AU  - Bradner JE
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115,
      USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
FAU - Gray, Nathanael S
AU  - Gray NS
AD  - Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical
      School, Boston, MA 02115, USA; Department of Cancer Biology, Dana-Farber Cancer
      Institute, Boston, MA 02115, USA.
FAU - Young, Richard A
AU  - Young RA
AD  - Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA; Department
      of Biology, Massachusetts Institute of Technology, Cambridge, MA 02142, USA.
      Electronic address: young@wi.mit.edu.
LA  - eng
GR  - R01 GM123511/GM/NIGMS NIH HHS/United States
GR  - R01 HG002668/HG/NHGRI NIH HHS/United States
GR  - R01 MH104610/MH/NIMH NIH HHS/United States
PT  - Journal Article
DEP - 20171207
PL  - United States
TA  - Cell
JT  - Cell
JID - 0413066
RN  - 0 (CCCTC-Binding Factor)
RN  - 0 (YY1 Transcription Factor)
RN  - 0 (YY1 protein, human)
RN  - 0 (Yy1 protein, mouse)
SB  - IM
MH  - Animals
MH  - CCCTC-Binding Factor/metabolism
MH  - Embryonic Stem Cells/metabolism
MH  - *Enhancer Elements, Genetic
MH  - Humans
MH  - Mice
MH  - *Promoter Regions, Genetic
MH  - YY1 Transcription Factor/*metabolism
PMC - PMC5785279
MID - NIHMS933446
OTO - NOTNLM
OT  - chromosome structure
OT  - enhancers
OT  - gene regulation
OT  - promoters
EDAT- 2017/12/12 06:00
MHDA- 2017/12/29 06:00
CRDT- 2017/12/12 06:00
PMCR- 2018/06/14 00:00
PHST- 2017/06/01 00:00 [received]
PHST- 2017/09/08 00:00 [revised]
PHST- 2017/10/31 00:00 [accepted]
PHST- 2018/06/14 00:00 [pmc-release]
PHST- 2017/12/12 06:00 [pubmed]
PHST- 2017/12/29 06:00 [medline]
PHST- 2017/12/12 06:00 [entrez]
AID - S0092-8674(17)31317-X [pii]
AID - 10.1016/j.cell.2017.11.008 [doi]
PST - ppublish
SO  - Cell. 2017 Dec 14;171(7):1573-1588.e28. doi: 10.1016/j.cell.2017.11.008. Epub
      2017 Dec 7.

PMID- 29097494
OWN - NLM
STAT- In-Process
LR  - 20180108
IS  - 1095-9203 (Electronic)
IS  - 0036-8075 (Linking)
VI  - 359
IP  - 6371
DP  - 2018 Jan 5
TI  - Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial
      tumors.
PG  - 91-97
LID - 10.1126/science.aan3706 [doi]
AB  - Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis induce
      sustained clinical responses in a sizable minority of cancer patients. We found
      that primary resistance to ICIs can be attributed to abnormal gut microbiome
      composition. Antibiotics inhibited the clinical benefit of ICIs in patients with 
      advanced cancer. Fecal microbiota transplantation (FMT) from cancer patients who 
      responded to ICIs into germ-free or antibiotic-treated mice ameliorated the
      antitumor effects of PD-1 blockade, whereas FMT from nonresponding patients
      failed to do so. Metagenomics of patient stool samples at diagnosis revealed
      correlations between clinical responses to ICIs and the relative abundance of
      Akkermansia muciniphila Oral supplementation with A. muciniphila after FMT with
      nonresponder feces restored the efficacy of PD-1 blockade in an
      interleukin-12-dependent manner by increasing the recruitment of
      CCR9(+)CXCR3(+)CD4(+) T lymphocytes into mouse tumor beds.
CI  - Copyright (c) 2018, American Association for the Advancement of Science.
FAU - Routy, Bertrand
AU  - Routy B
AUID- ORCID: http://orcid.org/0000-0002-0756-6571
AD  - Gustave Roussy Cancer Campus (GRCC), Villejuif, France.
AD  - Institut National de la Sante et de la Recherche Medicale (INSERM) U1015 and
      Equipe Labellisee-Ligue Nationale contre le Cancer, Villejuif, France.
AD  - Univ. Paris-Sud, Universite Paris-Saclay, Gustave Roussy, Villejuif, France.
FAU - Le Chatelier, Emmanuelle
AU  - Le Chatelier E
AUID- ORCID: http://orcid.org/0000-0002-2724-0536
AD  - MGP MetaGenoPolis, INRA, Universite Paris-Saclay, Jouy-en-Josas, France.
FAU - Derosa, Lisa
AU  - Derosa L
AD  - Gustave Roussy Cancer Campus (GRCC), Villejuif, France.
AD  - Institut National de la Sante et de la Recherche Medicale (INSERM) U1015 and
      Equipe Labellisee-Ligue Nationale contre le Cancer, Villejuif, France.
AD  - Univ. Paris-Sud, Universite Paris-Saclay, Gustave Roussy, Villejuif, France.
FAU - Duong, Connie P M
AU  - Duong CPM
AUID- ORCID: http://orcid.org/0000-0002-9067-8557
AD  - Gustave Roussy Cancer Campus (GRCC), Villejuif, France.
AD  - Institut National de la Sante et de la Recherche Medicale (INSERM) U1015 and
      Equipe Labellisee-Ligue Nationale contre le Cancer, Villejuif, France.
AD  - Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428,
      Villejuif, France.
FAU - Alou, Maryam Tidjani
AU  - Alou MT
AD  - Gustave Roussy Cancer Campus (GRCC), Villejuif, France.
AD  - Institut National de la Sante et de la Recherche Medicale (INSERM) U1015 and
      Equipe Labellisee-Ligue Nationale contre le Cancer, Villejuif, France.
AD  - Univ. Paris-Sud, Universite Paris-Saclay, Gustave Roussy, Villejuif, France.
FAU - Daillere, Romain
AU  - Daillere R
AUID- ORCID: http://orcid.org/0000-0003-3617-6377
AD  - Gustave Roussy Cancer Campus (GRCC), Villejuif, France.
AD  - Institut National de la Sante et de la Recherche Medicale (INSERM) U1015 and
      Equipe Labellisee-Ligue Nationale contre le Cancer, Villejuif, France.
AD  - Univ. Paris-Sud, Universite Paris-Saclay, Gustave Roussy, Villejuif, France.
FAU - Fluckiger, Aurelie
AU  - Fluckiger A
AUID- ORCID: http://orcid.org/0000-0001-7135-0049
AD  - Gustave Roussy Cancer Campus (GRCC), Villejuif, France.
AD  - Institut National de la Sante et de la Recherche Medicale (INSERM) U1015 and
      Equipe Labellisee-Ligue Nationale contre le Cancer, Villejuif, France.
AD  - Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428,
      Villejuif, France.
FAU - Messaoudene, Meriem
AU  - Messaoudene M
AD  - Gustave Roussy Cancer Campus (GRCC), Villejuif, France.
AD  - Institut National de la Sante et de la Recherche Medicale (INSERM) U1015 and
      Equipe Labellisee-Ligue Nationale contre le Cancer, Villejuif, France.
FAU - Rauber, Conrad
AU  - Rauber C
AD  - Gustave Roussy Cancer Campus (GRCC), Villejuif, France.
AD  - Institut National de la Sante et de la Recherche Medicale (INSERM) U1015 and
      Equipe Labellisee-Ligue Nationale contre le Cancer, Villejuif, France.
AD  - Univ. Paris-Sud, Universite Paris-Saclay, Gustave Roussy, Villejuif, France.
FAU - Roberti, Maria P
AU  - Roberti MP
AD  - Gustave Roussy Cancer Campus (GRCC), Villejuif, France.
AD  - Institut National de la Sante et de la Recherche Medicale (INSERM) U1015 and
      Equipe Labellisee-Ligue Nationale contre le Cancer, Villejuif, France.
AD  - Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428,
      Villejuif, France.
FAU - Fidelle, Marine
AU  - Fidelle M
AD  - Gustave Roussy Cancer Campus (GRCC), Villejuif, France.
AD  - Univ. Paris-Sud, Universite Paris-Saclay, Gustave Roussy, Villejuif, France.
AD  - Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428,
      Villejuif, France.
FAU - Flament, Caroline
AU  - Flament C
AD  - Gustave Roussy Cancer Campus (GRCC), Villejuif, France.
AD  - Institut National de la Sante et de la Recherche Medicale (INSERM) U1015 and
      Equipe Labellisee-Ligue Nationale contre le Cancer, Villejuif, France.
AD  - Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428,
      Villejuif, France.
FAU - Poirier-Colame, Vichnou
AU  - Poirier-Colame V
AD  - Gustave Roussy Cancer Campus (GRCC), Villejuif, France.
AD  - Institut National de la Sante et de la Recherche Medicale (INSERM) U1015 and
      Equipe Labellisee-Ligue Nationale contre le Cancer, Villejuif, France.
AD  - Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428,
      Villejuif, France.
FAU - Opolon, Paule
AU  - Opolon P
AD  - Gustave Roussy, Laboratoire de Pathologie Experimentale, 94800 Villejuif, France.
FAU - Klein, Christophe
AU  - Klein C
AD  - Centre de Recherche des Cordeliers, INSERM, Universite Paris Descartes, Sorbonne 
      Paris Cite, UMRS 1138, Universite Pierre et Marie Curie Universite Paris 06,
      Sorbonne Universites, Paris, France.
FAU - Iribarren, Kristina
AU  - Iribarren K
AUID- ORCID: http://orcid.org/0000-0002-2930-8573
AD  - Metabolomics and Cell Biology Platforms, GRCC, Villejuif, France.
AD  - Paris Descartes University, Sorbonne Paris Cite, Paris, France.
AD  - Equipe 11 Labellisee-Ligue Nationale contre le Cancer, Centre de Recherche des
      Cordeliers, Paris, France.
AD  - INSERM U1138, Paris, France.
AD  - Universite Pierre et Marie Curie, Paris, France.
FAU - Mondragon, Laura
AU  - Mondragon L
AUID- ORCID: http://orcid.org/0000-0002-3257-045X
AD  - Metabolomics and Cell Biology Platforms, GRCC, Villejuif, France.
AD  - Paris Descartes University, Sorbonne Paris Cite, Paris, France.
AD  - Equipe 11 Labellisee-Ligue Nationale contre le Cancer, Centre de Recherche des
      Cordeliers, Paris, France.
AD  - INSERM U1138, Paris, France.
AD  - Universite Pierre et Marie Curie, Paris, France.
FAU - Jacquelot, Nicolas
AU  - Jacquelot N
AUID- ORCID: http://orcid.org/0000-0003-0282-1892
AD  - Gustave Roussy Cancer Campus (GRCC), Villejuif, France.
AD  - Institut National de la Sante et de la Recherche Medicale (INSERM) U1015 and
      Equipe Labellisee-Ligue Nationale contre le Cancer, Villejuif, France.
AD  - Univ. Paris-Sud, Universite Paris-Saclay, Gustave Roussy, Villejuif, France.
FAU - Qu, Bo
AU  - Qu B
AUID- ORCID: http://orcid.org/0000-0001-7947-3350
AD  - Gustave Roussy Cancer Campus (GRCC), Villejuif, France.
AD  - Institut National de la Sante et de la Recherche Medicale (INSERM) U1015 and
      Equipe Labellisee-Ligue Nationale contre le Cancer, Villejuif, France.
AD  - Univ. Paris-Sud, Universite Paris-Saclay, Gustave Roussy, Villejuif, France.
FAU - Ferrere, Gladys
AU  - Ferrere G
AD  - Gustave Roussy Cancer Campus (GRCC), Villejuif, France.
AD  - Institut National de la Sante et de la Recherche Medicale (INSERM) U1015 and
      Equipe Labellisee-Ligue Nationale contre le Cancer, Villejuif, France.
AD  - Univ. Paris-Sud, Universite Paris-Saclay, Gustave Roussy, Villejuif, France.
FAU - Clemenson, Celine
AU  - Clemenson C
AD  - Gustave Roussy Cancer Campus (GRCC), Villejuif, France.
AD  - Department of Radiation Oncology, INSERM U1030, and Molecular Radiotherapy,
      Gustave Roussy, Universite Paris-Saclay, F-94805 Villejuif, France.
FAU - Mezquita, Laura
AU  - Mezquita L
AD  - Gustave Roussy Cancer Campus (GRCC), Villejuif, France.
AD  - Department of Medical Oncology, Gustave Roussy, Villejuif, France.
FAU - Masip, Jordi Remon
AU  - Masip JR
AUID- ORCID: http://orcid.org/0000-0001-9839-149X
AD  - Gustave Roussy Cancer Campus (GRCC), Villejuif, France.
AD  - Department of Medical Oncology, Gustave Roussy, Villejuif, France.
FAU - Naltet, Charles
AU  - Naltet C
AD  - Thoracic Oncology Department-CIC1425/CLIP2 Paris-Nord, Hospital Bichat-Claude
      Bernard, AP-HP, Universite Paris-Diderot, Paris, France.
FAU - Brosseau, Solenn
AU  - Brosseau S
AD  - Thoracic Oncology Department-CIC1425/CLIP2 Paris-Nord, Hospital Bichat-Claude
      Bernard, AP-HP, Universite Paris-Diderot, Paris, France.
FAU - Kaderbhai, Coureche
AU  - Kaderbhai C
AD  - Department of Medical Oncology, Center GF Leclerc, Dijon, France.
FAU - Richard, Corentin
AU  - Richard C
AD  - Department of Medical Oncology, Center GF Leclerc, Dijon, France.
FAU - Rizvi, Hira
AU  - Rizvi H
AD  - Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer
      Center, New York, NY, USA.
FAU - Levenez, Florence
AU  - Levenez F
AD  - MGP MetaGenoPolis, INRA, Universite Paris-Saclay, Jouy-en-Josas, France.
FAU - Galleron, Nathalie
AU  - Galleron N
AD  - MGP MetaGenoPolis, INRA, Universite Paris-Saclay, Jouy-en-Josas, France.
FAU - Quinquis, Benoit
AU  - Quinquis B
AD  - MGP MetaGenoPolis, INRA, Universite Paris-Saclay, Jouy-en-Josas, France.
FAU - Pons, Nicolas
AU  - Pons N
AUID- ORCID: http://orcid.org/0000-0003-1926-8077
AD  - MGP MetaGenoPolis, INRA, Universite Paris-Saclay, Jouy-en-Josas, France.
FAU - Ryffel, Bernhard
AU  - Ryffel B
AD  - Molecular Immunology and Embryology, UMR 7355, CNRS, University of Orleans,
      Orleans, France.
FAU - Minard-Colin, Veronique
AU  - Minard-Colin V
AD  - Gustave Roussy Cancer Campus (GRCC), Villejuif, France.
AD  - Department of Pediatric Oncology, GRCC, Villejuif, France.
FAU - Gonin, Patrick
AU  - Gonin P
AUID- ORCID: http://orcid.org/0000-0001-6151-4580
AD  - Gustave Roussy Cancer Campus (GRCC), Villejuif, France.
AD  - Preclinical Research Platform, GRCC, Villejuif, France.
FAU - Soria, Jean-Charles
AU  - Soria JC
AD  - Gustave Roussy Cancer Campus (GRCC), Villejuif, France.
AD  - Department of Medical Oncology, Gustave Roussy, Villejuif, France.
FAU - Deutsch, Eric
AU  - Deutsch E
AUID- ORCID: http://orcid.org/0000-0002-8223-3697
AD  - Gustave Roussy Cancer Campus (GRCC), Villejuif, France.
AD  - Department of Radiation Oncology, INSERM U1030, and Molecular Radiotherapy,
      Gustave Roussy, Universite Paris-Saclay, F-94805 Villejuif, France.
FAU - Loriot, Yohann
AU  - Loriot Y
AD  - Gustave Roussy Cancer Campus (GRCC), Villejuif, France.
AD  - Univ. Paris-Sud, Universite Paris-Saclay, Gustave Roussy, Villejuif, France.
AD  - Department of Medical Oncology, Gustave Roussy, Villejuif, France.
FAU - Ghiringhelli, Francois
AU  - Ghiringhelli F
AD  - Department of Medical Oncology, Center GF Leclerc, Dijon, France.
FAU - Zalcman, Gerard
AU  - Zalcman G
AUID- ORCID: http://orcid.org/0000-0002-0343-9575
AD  - Thoracic Oncology Department-CIC1425/CLIP2 Paris-Nord, Hospital Bichat-Claude
      Bernard, AP-HP, Universite Paris-Diderot, Paris, France.
FAU - Goldwasser, Francois
AU  - Goldwasser F
AD  - Paris Descartes University, Sorbonne Paris Cite, Paris, France.
AD  - Department of Medical Oncology, Cochin Hospital, Assistance Publique-Hopitaux de 
      Paris, Paris, France.
AD  - Immunomodulatory Therapies Multidisciplinary Study Group (CERTIM), Paris, France.
FAU - Escudier, Bernard
AU  - Escudier B
AUID- ORCID: http://orcid.org/0000-0002-4626-0479
AD  - Gustave Roussy Cancer Campus (GRCC), Villejuif, France.
AD  - Department of Medical Oncology, Gustave Roussy, Villejuif, France.
AD  - INSERM U981, GRCC, Villejuif, France.
FAU - Hellmann, Matthew D
AU  - Hellmann MD
AUID- ORCID: http://orcid.org/0000-0002-2670-9777
AD  - Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering
      Cancer Center, New York, NY, USA.
AD  - Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
FAU - Eggermont, Alexander
AU  - Eggermont A
AUID- ORCID: http://orcid.org/0000-0001-7458-4326
AD  - Gustave Roussy Cancer Campus (GRCC), Villejuif, France.
AD  - Institut National de la Sante et de la Recherche Medicale (INSERM) U1015 and
      Equipe Labellisee-Ligue Nationale contre le Cancer, Villejuif, France.
AD  - Department of Medical Oncology, Gustave Roussy, Villejuif, France.
FAU - Raoult, Didier
AU  - Raoult D
AD  - URMITE, Aix Marseille Universite, UM63, CNRS 7278, IRD 198, INSERM 1095,
      IHU-Mediterranee Infection, 13005 Marseille, France.
FAU - Albiges, Laurence
AU  - Albiges L
AD  - Gustave Roussy Cancer Campus (GRCC), Villejuif, France.
AD  - Univ. Paris-Sud, Universite Paris-Saclay, Gustave Roussy, Villejuif, France.
AD  - Department of Medical Oncology, Gustave Roussy, Villejuif, France.
FAU - Kroemer, Guido
AU  - Kroemer G
AUID- ORCID: http://orcid.org/0000-0002-9334-4405
AD  - Metabolomics and Cell Biology Platforms, GRCC, Villejuif, France.
      laurence.zitvogel@gustaveroussy.fr kroemer@orange.fr.
AD  - Paris Descartes University, Sorbonne Paris Cite, Paris, France.
AD  - Equipe 11 Labellisee-Ligue Nationale contre le Cancer, Centre de Recherche des
      Cordeliers, Paris, France.
AD  - INSERM U1138, Paris, France.
AD  - Universite Pierre et Marie Curie, Paris, France.
AD  - Pole de Biologie, Hopital Europeen Georges Pompidou, Assistance Publique-Hopitaux
      de Paris, Paris, France.
AD  - Department of Women's and Children's Health, Karolinska University Hospital,
      17176 Stockholm, Sweden.
FAU - Zitvogel, Laurence
AU  - Zitvogel L
AUID- ORCID: http://orcid.org/0000-0003-1596-0998
AD  - Gustave Roussy Cancer Campus (GRCC), Villejuif, France.
      laurence.zitvogel@gustaveroussy.fr kroemer@orange.fr.
AD  - Institut National de la Sante et de la Recherche Medicale (INSERM) U1015 and
      Equipe Labellisee-Ligue Nationale contre le Cancer, Villejuif, France.
AD  - Univ. Paris-Sud, Universite Paris-Saclay, Gustave Roussy, Villejuif, France.
AD  - Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428,
      Villejuif, France.
LA  - eng
PT  - Journal Article
DEP - 20171102
PL  - United States
TA  - Science
JT  - Science (New York, N.Y.)
JID - 0404511
CIN - Science. 2018 Jan 5;359(6371):32-34. PMID: 29302001
EDAT- 2017/11/04 06:00
MHDA- 2017/11/04 06:00
CRDT- 2017/11/04 06:00
PHST- 2017/04/05 00:00 [received]
PHST- 2017/09/20 00:00 [accepted]
PHST- 2017/11/04 06:00 [pubmed]
PHST- 2017/11/04 06:00 [medline]
PHST- 2017/11/04 06:00 [entrez]
AID - science.aan3706 [pii]
AID - 10.1126/science.aan3706 [doi]
PST - ppublish
SO  - Science. 2018 Jan 5;359(6371):91-97. doi: 10.1126/science.aan3706. Epub 2017 Nov 
      2.

PMID- 29028415
OWN - NLM
STAT- In-Data-Review
LR  - 20180109
IS  - 1555-8584 (Electronic)
IS  - 1547-6286 (Linking)
VI  - 15
IP  - 1
DP  - 2018 Jan 2
TI  - CRISPR/Cas9-mediated noncoding RNA editing in human cancers.
PG  - 35-43
LID - 10.1080/15476286.2017.1391443 [doi]
AB  - Cancer is characterized by multiple genetic and epigenetic alterations, including
      a higher prevalence of mutations of oncogenes and/or tumor suppressors. Mounting 
      evidences have shown that noncoding RNAs (ncRNAs) are involved in the epigenetic 
      regulation of cancer genes and their associated pathways. The clustered regularly
      interspaced short palindromic repeats (CRISPR)-associated nuclease 9
      (CRISPR/Cas9) system, a revolutionary genome-editing technology, has shed light
      on ncRNA-based cancer therapy. Here, we briefly introduce the classifications and
      mechanisms of CRISPR/Cas9 system. Importantly, we mainly focused on the
      applications of CRISPR/Cas9 system as a molecular tool for ncRNA (microRNA, long 
      noncoding RNA and circular RNA, etc.) editing in human cancers, and the novel
      techniques that are based on CRISPR/Cas9 system. Additionally, the off-target
      effects and the corresponding solutions as well as the challenges toward
      CRISPR/Cas9 were also evaluated and discussed. Long- and short-ncRNAs have been
      employed as targets in precision oncology, and CRISPR/Cas9-mediated ncRNA editing
      may provide an excellent way to cure cancer.
FAU - Yang, Jie
AU  - Yang J
AD  - a Department of Biochemistry and Molecular Biology , Medical School of Ningbo
      University , Ningbo , Zhejiang , China.
AD  - b Zhejiang Provincial Key Laboratory of Pathophysiology, Medical School of Ningbo
      University , Ningbo , Zhejiang , China.
FAU - Meng, Xiaodan
AU  - Meng X
AD  - a Department of Biochemistry and Molecular Biology , Medical School of Ningbo
      University , Ningbo , Zhejiang , China.
AD  - b Zhejiang Provincial Key Laboratory of Pathophysiology, Medical School of Ningbo
      University , Ningbo , Zhejiang , China.
FAU - Pan, Jinchang
AU  - Pan J
AD  - a Department of Biochemistry and Molecular Biology , Medical School of Ningbo
      University , Ningbo , Zhejiang , China.
AD  - b Zhejiang Provincial Key Laboratory of Pathophysiology, Medical School of Ningbo
      University , Ningbo , Zhejiang , China.
FAU - Jiang, Nan
AU  - Jiang N
AUID- ORCID: http://orcid.org/0000-0002-8423-7675
AD  - a Department of Biochemistry and Molecular Biology , Medical School of Ningbo
      University , Ningbo , Zhejiang , China.
AD  - b Zhejiang Provincial Key Laboratory of Pathophysiology, Medical School of Ningbo
      University , Ningbo , Zhejiang , China.
FAU - Zhou, Chengwei
AU  - Zhou C
AD  - c Department of Thoracic Surgery , The Affiliated Hospital of Medical School of
      Ningbo University , Ningbo , Zhejiang , China.
FAU - Wu, Zhenhua
AU  - Wu Z
AD  - d Department of Otolaryngology Head and Neck Surgery , The Affiliated Ningbo
      Medical Center Lihuili Eastern Hospital of Medical School of Ningbo University , 
      Ningbo , Zhejiang , China.
FAU - Gong, Zhaohui
AU  - Gong Z
AD  - a Department of Biochemistry and Molecular Biology , Medical School of Ningbo
      University , Ningbo , Zhejiang , China.
AD  - b Zhejiang Provincial Key Laboratory of Pathophysiology, Medical School of Ningbo
      University , Ningbo , Zhejiang , China.
LA  - eng
PT  - Journal Article
DEP - 20171109
PL  - United States
TA  - RNA Biol
JT  - RNA biology
JID - 101235328
OTO - NOTNLM
OT  - CRISPR-Cas9
OT  - RNA editing
OT  - cancer
OT  - circular RNA
OT  - genome editing
OT  - long noncoding RNA
OT  - microRNA
EDAT- 2017/10/14 06:00
MHDA- 2017/10/14 06:00
CRDT- 2017/10/14 06:00
PHST- 2017/10/14 06:00 [pubmed]
PHST- 2017/10/14 06:00 [medline]
PHST- 2017/10/14 06:00 [entrez]
AID - 10.1080/15476286.2017.1391443 [doi]
PST - ppublish
SO  - RNA Biol. 2018 Jan 2;15(1):35-43. doi: 10.1080/15476286.2017.1391443. Epub 2017
      Nov 9.

PMID- 29053970
OWN - NLM
STAT- MEDLINE
DCOM- 20171101
LR  - 20171219
IS  - 1097-4172 (Electronic)
IS  - 0092-8674 (Linking)
VI  - 171
IP  - 3
DP  - 2017 Oct 19
TI  - mTORC1 Activator SLC38A9 Is Required to Efflux Essential Amino Acids from
      Lysosomes and Use Protein as a Nutrient.
PG  - 642-654.e12
LID - S0092-8674(17)31140-6 [pii]
LID - 10.1016/j.cell.2017.09.046 [doi]
AB  - The mTORC1 kinase is a master growth regulator that senses many environmental
      cues, including amino acids. Activation of mTORC1 by arginine requires SLC38A9, a
      poorly understood lysosomal membrane protein with homology to amino acid
      transporters. Here, we validate that SLC38A9 is an arginine sensor for the mTORC1
      pathway, and we uncover an unexpectedly central role for SLC38A9 in amino acid
      homeostasis. SLC38A9 mediates the transport, in an arginine-regulated fashion, of
      many essential amino acids out of lysosomes, including leucine, which mTORC1
      senses through the cytosolic Sestrin proteins. SLC38A9 is necessary for leucine
      generated via lysosomal proteolysis to exit lysosomes and activate mTORC1.
      Pancreatic cancer cells, which use macropinocytosed protein as a nutrient source,
      require SLC38A9 to form tumors. Thus, through SLC38A9, arginine serves as a
      lysosomal messenger that couples mTORC1 activation to the release from lysosomes 
      of the essential amino acids needed to drive cell growth.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Wyant, Gregory A
AU  - Wyant GA
AD  - Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA; Department
      of Biology, Massachusetts Institute of Technology, 9 Cambridge Center, Cambridge,
      MA 02142, USA; Howard Hughes Medical Institute, Cambridge, MA 02139, USA; Koch
      Institute for Integrative Cancer Research, 77 Massachusetts Avenue, Cambridge, MA
      02139, USA; Broad Institute of MIT and Harvard, 7 Cambridge Center, Cambridge, MA
      02142, USA.
FAU - Abu-Remaileh, Monther
AU  - Abu-Remaileh M
AD  - Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA; Department
      of Biology, Massachusetts Institute of Technology, 9 Cambridge Center, Cambridge,
      MA 02142, USA; Howard Hughes Medical Institute, Cambridge, MA 02139, USA; Koch
      Institute for Integrative Cancer Research, 77 Massachusetts Avenue, Cambridge, MA
      02139, USA; Broad Institute of MIT and Harvard, 7 Cambridge Center, Cambridge, MA
      02142, USA.
FAU - Wolfson, Rachel L
AU  - Wolfson RL
AD  - Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA; Department
      of Biology, Massachusetts Institute of Technology, 9 Cambridge Center, Cambridge,
      MA 02142, USA; Howard Hughes Medical Institute, Cambridge, MA 02139, USA; Koch
      Institute for Integrative Cancer Research, 77 Massachusetts Avenue, Cambridge, MA
      02139, USA; Broad Institute of MIT and Harvard, 7 Cambridge Center, Cambridge, MA
      02142, USA; Harvard Medical School M.D.-Ph.D. Program, Daniel C. Tosteson Medical
      Education Center, 260 Longwood Avenue, Boston, MA 02115, USA.
FAU - Chen, Walter W
AU  - Chen WW
AD  - Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA; Department
      of Biology, Massachusetts Institute of Technology, 9 Cambridge Center, Cambridge,
      MA 02142, USA; Howard Hughes Medical Institute, Cambridge, MA 02139, USA; Koch
      Institute for Integrative Cancer Research, 77 Massachusetts Avenue, Cambridge, MA
      02139, USA; Broad Institute of MIT and Harvard, 7 Cambridge Center, Cambridge, MA
      02142, USA; Harvard Medical School M.D.-Ph.D. Program, Daniel C. Tosteson Medical
      Education Center, 260 Longwood Avenue, Boston, MA 02115, USA.
FAU - Freinkman, Elizaveta
AU  - Freinkman E
AD  - Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA; Department
      of Biology, Massachusetts Institute of Technology, 9 Cambridge Center, Cambridge,
      MA 02142, USA.
FAU - Danai, Laura V
AU  - Danai LV
AD  - Koch Institute for Integrative Cancer Research, 77 Massachusetts Avenue,
      Cambridge, MA 02139, USA.
FAU - Vander Heiden, Matthew G
AU  - Vander Heiden MG
AD  - Koch Institute for Integrative Cancer Research, 77 Massachusetts Avenue,
      Cambridge, MA 02139, USA; Broad Institute of MIT and Harvard, 7 Cambridge Center,
      Cambridge, MA 02142, USA; Dana-Farber Cancer Institute, Boston, MA 02115, USA.
FAU - Sabatini, David M
AU  - Sabatini DM
AD  - Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA; Department
      of Biology, Massachusetts Institute of Technology, 9 Cambridge Center, Cambridge,
      MA 02142, USA; Howard Hughes Medical Institute, Cambridge, MA 02139, USA; Koch
      Institute for Integrative Cancer Research, 77 Massachusetts Avenue, Cambridge, MA
      02139, USA; Broad Institute of MIT and Harvard, 7 Cambridge Center, Cambridge, MA
      02142, USA. Electronic address: sabatini@wi.mit.edu.
LA  - eng
GR  - R01 CA103866/CA/NCI NIH HHS/United States
GR  - R01 CA168653/CA/NCI NIH HHS/United States
GR  - F30 CA189333/CA/NCI NIH HHS/United States
GR  - T32 GM007753/GM/NIGMS NIH HHS/United States
GR  - R37 AI047389/AI/NIAID NIH HHS/United States
GR  - F32 CA210421/CA/NCI NIH HHS/United States
GR  - R01 CA129105/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cell
JT  - Cell
JID - 0413066
RN  - 0 (Amino Acid Transport Systems)
RN  - 0 (Amino Acids, Essential)
RN  - 0 (Multiprotein Complexes)
RN  - 0 (SLC38A9 protein, human)
RN  - 0 (SLC38A9 protein, mouse)
RN  - 94ZLA3W45F (Arginine)
RN  - EC 2.7.1.1 (TOR Serine-Threonine Kinases)
RN  - EC 2.7.11.1 (Mechanistic Target of Rapamycin Complex 1)
SB  - IM
MH  - Amino Acid Sequence
MH  - Amino Acid Transport Systems/chemistry/genetics/*metabolism
MH  - Amino Acids, Essential/*metabolism
MH  - Animals
MH  - Arginine/metabolism
MH  - Cell Line
MH  - Cell Line, Tumor
MH  - Humans
MH  - Lysosomes/*metabolism
MH  - Male
MH  - Mechanistic Target of Rapamycin Complex 1
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Multiprotein Complexes/*metabolism
MH  - Sequence Alignment
MH  - TOR Serine-Threonine Kinases/*metabolism
PMC - PMC5704964
MID - NIHMS915522
OTO - NOTNLM
OT  - amino acid sensing
OT  - autophagy
OT  - lysosome
OT  - mTOR
OT  - micropinocytosis
OT  - nutrient sensing
EDAT- 2017/10/21 06:00
MHDA- 2017/11/02 06:00
CRDT- 2017/10/21 06:00
PMCR- 2018/10/19 00:00
PHST- 2017/04/26 00:00 [received]
PHST- 2017/07/18 00:00 [revised]
PHST- 2017/09/25 00:00 [accepted]
PHST- 2018/10/19 00:00 [pmc-release]
PHST- 2017/10/21 06:00 [entrez]
PHST- 2017/10/21 06:00 [pubmed]
PHST- 2017/11/02 06:00 [medline]
AID - S0092-8674(17)31140-6 [pii]
AID - 10.1016/j.cell.2017.09.046 [doi]
PST - ppublish
SO  - Cell. 2017 Oct 19;171(3):642-654.e12. doi: 10.1016/j.cell.2017.09.046.

PMID- 29236685
OWN - NLM
STAT- In-Data-Review
LR  - 20180102
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 552
IP  - 7685
DP  - 2017 Dec 21
TI  - Origin and differentiation of human memory CD8 T cells after vaccination.
PG  - 362-367
LID - 10.1038/nature24633 [doi]
AB  - The differentiation of human memory CD8 T cells is not well understood. Here we
      address this issue using the live yellow fever virus (YFV) vaccine, which induces
      long-term immunity in humans. We used in vivo deuterium labelling to mark CD8 T
      cells that proliferated in response to the virus and then assessed cellular
      turnover and longevity by quantifying deuterium dilution kinetics in YFV-specific
      CD8 T cells using mass spectrometry. This longitudinal analysis showed that the
      memory pool originates from CD8 T cells that divided extensively during the first
      two weeks after infection and is maintained by quiescent cells that divide less
      than once every year (doubling time of over 450 days). Although these long-lived 
      YFV-specific memory CD8 T cells did not express effector molecules, their
      epigenetic landscape resembled that of effector CD8 T cells. This open chromatin 
      profile at effector genes was maintained in memory CD8 T cells isolated even a
      decade after vaccination, indicating that these cells retain an epigenetic
      fingerprint of their effector history and remain poised to respond rapidly upon
      re-exposure to the pathogen.
FAU - Akondy, Rama S
AU  - Akondy RS
AD  - Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia, USA.
AD  - Department of Microbiology and Immunology, Emory University School of Medicine,
      Atlanta, Georgia, USA.
FAU - Fitch, Mark
AU  - Fitch M
AD  - Department of Nutritional Sciences and Toxicology, UC Berkeley, Berkeley,
      California, USA.
FAU - Edupuganti, Srilatha
AU  - Edupuganti S
AD  - Department of Medicine, Division of Infectious Diseases, Emory University School 
      of Medicine, Atlanta, Georgia, USA.
FAU - Yang, Shu
AU  - Yang S
AD  - Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia, USA.
AD  - Department of Microbiology and Immunology, Emory University School of Medicine,
      Atlanta, Georgia, USA.
FAU - Kissick, Haydn T
AU  - Kissick HT
AD  - Department of Urology, Emory University School of Medicine, Atlanta, Georgia,
      USA.
FAU - Li, Kelvin W
AU  - Li KW
AD  - KineMed Inc., Emeryville California, USA.
FAU - Youngblood, Ben A
AU  - Youngblood BA
AD  - Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia, USA.
AD  - Department of Microbiology and Immunology, Emory University School of Medicine,
      Atlanta, Georgia, USA.
AD  - St.Jude Children's Research Hospital, Memphis, Tennessee, USA.
FAU - Abdelsamed, Hossam A
AU  - Abdelsamed HA
AD  - St.Jude Children's Research Hospital, Memphis, Tennessee, USA.
FAU - McGuire, Donald J
AU  - McGuire DJ
AD  - Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia, USA.
FAU - Cohen, Kristen W
AU  - Cohen KW
AD  - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, 
      Seattle, Washington, USA.
FAU - Alexe, Gabriela
AU  - Alexe G
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical
      School, Boston, Massachusetts 02115, USA.
AD  - Broad Institute of MIT and Harvard, Cambridge, Masschusetts 02142, USA.
FAU - Nagar, Shashi
AU  - Nagar S
AD  - Department of Medicine, Division of Infectious Diseases, Emory University School 
      of Medicine, Atlanta, Georgia, USA.
FAU - McCausland, Megan M
AU  - McCausland MM
AD  - Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia, USA.
AD  - Department of Microbiology and Immunology, Emory University School of Medicine,
      Atlanta, Georgia, USA.
FAU - Gupta, Satish
AU  - Gupta S
AD  - Strand Lifesciences, Bangalore, India.
FAU - Tata, Pramila
AU  - Tata P
AD  - Strand Lifesciences, Bangalore, India.
FAU - Haining, W Nicholas
AU  - Haining WN
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical
      School, Boston, Massachusetts 02115, USA.
AD  - Broad Institute of MIT and Harvard, Cambridge, Masschusetts 02142, USA.
FAU - McElrath, M Juliana
AU  - McElrath MJ
AD  - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, 
      Seattle, Washington, USA.
FAU - Zhang, David
AU  - Zhang D
AD  - Department of Medicine, Division of Immunology and Rheumatology, Stanford
      University School of Medicine, Stanford, California, USA.
FAU - Hu, Bin
AU  - Hu B
AD  - Department of Medicine, Division of Immunology and Rheumatology, Stanford
      University School of Medicine, Stanford, California, USA.
FAU - Greenleaf, William J
AU  - Greenleaf WJ
AD  - Department of Genetics, Stanford University School of Medicine, Stanford,
      California, USA.
FAU - Goronzy, Jorg J
AU  - Goronzy JJ
AD  - Department of Medicine, Division of Immunology and Rheumatology, Stanford
      University School of Medicine, Stanford, California, USA.
FAU - Mulligan, Mark J
AU  - Mulligan MJ
AD  - Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia, USA.
AD  - Department of Medicine, Division of Infectious Diseases, Emory University School 
      of Medicine, Atlanta, Georgia, USA.
FAU - Hellerstein, Marc
AU  - Hellerstein M
AD  - Department of Nutritional Sciences and Toxicology, UC Berkeley, Berkeley,
      California, USA.
AD  - KineMed Inc., Emeryville California, USA.
FAU - Ahmed, Rafi
AU  - Ahmed R
AD  - Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia, USA.
AD  - Department of Microbiology and Immunology, Emory University School of Medicine,
      Atlanta, Georgia, USA.
LA  - eng
PT  - Journal Article
DEP - 20171213
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
EDAT- 2017/12/14 06:00
MHDA- 2017/12/14 06:00
CRDT- 2017/12/14 06:00
PHST- 2015/11/03 00:00 [received]
PHST- 2017/10/13 00:00 [accepted]
PHST- 2017/12/14 06:00 [pubmed]
PHST- 2017/12/14 06:00 [medline]
PHST- 2017/12/14 06:00 [entrez]
AID - nature24633 [pii]
AID - 10.1038/nature24633 [doi]
PST - ppublish
SO  - Nature. 2017 Dec 21;552(7685):362-367. doi: 10.1038/nature24633. Epub 2017 Dec
      13.

PMID- 29097398
OWN - NLM
STAT- In-Process
LR  - 20171219
IS  - 1943-2631 (Electronic)
IS  - 0016-6731 (Linking)
VI  - 207
IP  - 3
DP  - 2017 Nov
TI  - Cell Biology of the Mitochondrion.
PG  - 843-871
LID - 10.1534/genetics.117.300262 [doi]
AB  - Mitochondria are best known for harboring pathways involved in ATP synthesis
      through the tricarboxylic acid cycle and oxidative phosphorylation. Major
      advances in understanding these roles were made with Caenorhabditiselegans
      mutants affecting key components of the metabolic pathways. These mutants have
      not only helped elucidate some of the intricacies of metabolism pathways, but
      they have also served as jumping off points for pharmacology, toxicology, and
      aging studies. The field of mitochondria research has also undergone a
      renaissance, with the increased appreciation of the role of mitochondria in cell 
      processes other than energy production. Here, we focus on discoveries that were
      made using C. elegans, with a few excursions into areas that were studied more
      thoroughly in other organisms, like mitochondrial protein import in yeast.
      Advances in mitochondrial biogenesis and membrane dynamics were made through the 
      discoveries of novel functions in mitochondrial fission and fusion proteins. Some
      of these functions were only apparent through the use of diverse model systems,
      such as C. elegans Studies of stress responses, exemplified by mitophagy and the 
      mitochondrial unfolded protein response, have also benefitted greatly from the
      use of model organisms. Recent developments include the discoveries in C. elegans
      of cell autonomous and nonautonomous pathways controlling the mitochondrial
      unfolded protein response, as well as mechanisms for degradation of paternal
      mitochondria after fertilization. The evolutionary conservation of many, if not
      all, of these pathways ensures that results obtained with C. elegans are equally 
      applicable to studies of human mitochondria in health and disease.
CI  - Copyright (c) 2017 by the Genetics Society of America.
FAU - van der Bliek, Alexander M
AU  - van der Bliek AM
AUID- ORCID: http://orcid.org/0000-0002-6211-5765
AD  - Department of Biological Chemistry, Jonsson Comprehensive Cancer Center and
      Molecular Biology Institute, David Geffen School of Medicine at UCLA, Los
      Angeles, California 90024 avan@mednet.ucla.edu.
FAU - Sedensky, Margaret M
AU  - Sedensky MM
AUID- ORCID: http://orcid.org/0000-0001-9822-6558
AD  - Department of Anesthesiology and Pain Medicine, University of Washington and
      Center for Developmental Therapeutics, Seattle Children's Research Institute,
      Washington 98101.
FAU - Morgan, Phil G
AU  - Morgan PG
AUID- ORCID: http://orcid.org/0000-0003-4857-2756
AD  - Department of Anesthesiology and Pain Medicine, University of Washington and
      Center for Developmental Therapeutics, Seattle Children's Research Institute,
      Washington 98101.
LA  - eng
GR  - R01 GM105696/GM/NIGMS NIH HHS/United States
GR  - R01 GM118514/GM/NIGMS NIH HHS/United States
GR  - U01 GM109764/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Genetics
JT  - Genetics
JID - 0374636
PMC - PMC5676242
OTO - NOTNLM
OT  - WormBook
OT  - biogenesis
OT  - electron transport chain
OT  - mitochondrial morphology
OT  - quality control
OT  - respiration, free radicals
EDAT- 2017/11/04 06:00
MHDA- 2017/11/04 06:00
CRDT- 2017/11/04 06:00
PMCR- 2018/11/01 00:00
PHST- 2017/07/07 00:00 [received]
PHST- 2017/09/05 00:00 [accepted]
PHST- 2018/11/01 00:00 [pmc-release]
PHST- 2017/11/04 06:00 [entrez]
PHST- 2017/11/04 06:00 [pubmed]
PHST- 2017/11/04 06:00 [medline]
AID - genetics.117.300262 [pii]
AID - 10.1534/genetics.117.300262 [doi]
PST - ppublish
SO  - Genetics. 2017 Nov;207(3):843-871. doi: 10.1534/genetics.117.300262.

PMID- 29195074
OWN - NLM
STAT- MEDLINE
DCOM- 20171222
LR  - 20171222
IS  - 1097-4172 (Electronic)
IS  - 0092-8674 (Linking)
VI  - 171
IP  - 6
DP  - 2017 Nov 30
TI  - Myc Cooperates with Ras by Programming Inflammation and Immune Suppression.
PG  - 1301-1315.e14
LID - S0092-8674(17)31322-3 [pii]
LID - 10.1016/j.cell.2017.11.013 [doi]
AB  - The two oncogenes KRas and Myc cooperate to drive tumorigenesis, but the
      mechanism underlying this remains unclear. In a mouse lung model of
      KRas(G12D)-driven adenomas, we find that co-activation of Myc drives the
      immediate transition to highly proliferative and invasive adenocarcinomas marked 
      by highly inflammatory, angiogenic, and immune-suppressed stroma. We identify
      epithelial-derived signaling molecules CCL9 and IL-23 as the principal
      instructing signals for stromal reprogramming. CCL9 mediates recruitment of
      macrophages, angiogenesis, and PD-L1-dependent expulsion of T and B cells. IL-23 
      orchestrates exclusion of adaptive T and B cells and innate immune NK cells.
      Co-blockade of both CCL9 and IL-23 abrogates Myc-induced tumor progression.
      Subsequent deactivation of Myc in established adenocarcinomas triggers immediate 
      reversal of all stromal changes and tumor regression, which are independent of
      CD4(+)CD8(+) T cells but substantially dependent on returning NK cells. We show
      that Myc extensively programs an immune suppressive stroma that is obligatory for
      tumor progression.
CI  - Copyright (c) 2017 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Kortlever, Roderik M
AU  - Kortlever RM
AD  - Department of Biochemistry, University of Cambridge, 80 Tennis Court Road,
      Cambridge CB2 1GA, UK; Department of Pathology and Helen Diller Family
      Comprehensive Cancer Center, University of California, San Francisco, San
      Francisco, CA 94143, USA.
FAU - Sodir, Nicole M
AU  - Sodir NM
AD  - Department of Biochemistry, University of Cambridge, 80 Tennis Court Road,
      Cambridge CB2 1GA, UK; Department of Pathology and Helen Diller Family
      Comprehensive Cancer Center, University of California, San Francisco, San
      Francisco, CA 94143, USA.
FAU - Wilson, Catherine H
AU  - Wilson CH
AD  - Department of Biochemistry, University of Cambridge, 80 Tennis Court Road,
      Cambridge CB2 1GA, UK.
FAU - Burkhart, Deborah L
AU  - Burkhart DL
AD  - Department of Biochemistry, University of Cambridge, 80 Tennis Court Road,
      Cambridge CB2 1GA, UK.
FAU - Pellegrinet, Luca
AU  - Pellegrinet L
AD  - Department of Biochemistry, University of Cambridge, 80 Tennis Court Road,
      Cambridge CB2 1GA, UK.
FAU - Brown Swigart, Lamorna
AU  - Brown Swigart L
AD  - Department of Pathology and Helen Diller Family Comprehensive Cancer Center,
      University of California, San Francisco, San Francisco, CA 94143, USA.
FAU - Littlewood, Trevor D
AU  - Littlewood TD
AD  - Department of Biochemistry, University of Cambridge, 80 Tennis Court Road,
      Cambridge CB2 1GA, UK.
FAU - Evan, Gerard I
AU  - Evan GI
AD  - Department of Biochemistry, University of Cambridge, 80 Tennis Court Road,
      Cambridge CB2 1GA, UK; Department of Pathology and Helen Diller Family
      Comprehensive Cancer Center, University of California, San Francisco, San
      Francisco, CA 94143, USA. Electronic address: gie20@cam.ac.uk.
LA  - eng
GR  - R01 CA098018/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cell
JT  - Cell
JID - 0413066
RN  - 0 (Ccl9 protein, mouse)
RN  - 0 (Chemokines, CC)
RN  - 0 (Interleukin-23)
RN  - 0 (Macrophage Inflammatory Proteins)
RN  - 0 (Myc protein, mouse)
RN  - 0 (Proto-Oncogene Proteins c-myc)
RN  - EC 3.6.5.2 (Kras2 protein, mouse)
RN  - EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras))
SB  - IM
MH  - Adenocarcinoma/*immunology/metabolism/pathology
MH  - Adenoma/genetics/*immunology/pathology
MH  - Animals
MH  - Carcinogenesis
MH  - Chemokines, CC/immunology
MH  - Disease Models, Animal
MH  - Female
MH  - Inflammation/immunology/metabolism
MH  - Interleukin-23/immunology
MH  - Lung Neoplasms/*genetics/*immunology/pathology
MH  - Macrophage Inflammatory Proteins/immunology
MH  - Macrophages/immunology
MH  - Male
MH  - Mice
MH  - Proto-Oncogene Proteins c-myc/*metabolism
MH  - Proto-Oncogene Proteins p21(ras)/*metabolism
MH  - Tumor Microenvironment
PMC - PMC5720393
OTO - NOTNLM
OT  - CCL9
OT  - IL-23
OT  - Myc
OT  - NK cells
OT  - Ras
OT  - immune suppression
OT  - inflammation
OT  - lung cancer
OT  - oncogene cooperation
OT  - tumor microenvironment
EDAT- 2017/12/02 06:00
MHDA- 2017/12/23 06:00
CRDT- 2017/12/02 06:00
PHST- 2017/02/24 00:00 [received]
PHST- 2017/09/19 00:00 [revised]
PHST- 2017/11/07 00:00 [accepted]
PHST- 2017/12/02 06:00 [entrez]
PHST- 2017/12/02 06:00 [pubmed]
PHST- 2017/12/23 06:00 [medline]
AID - S0092-8674(17)31322-3 [pii]
AID - 10.1016/j.cell.2017.11.013 [doi]
PST - ppublish
SO  - Cell. 2017 Nov 30;171(6):1301-1315.e14. doi: 10.1016/j.cell.2017.11.013.

PMID- 29128965
OWN - NLM
STAT- In-Process
LR  - 20171219
IS  - 1179-1950 (Electronic)
IS  - 0012-6667 (Linking)
VI  - 77
IP  - 18
DP  - 2017 Dec
TI  - Abemaciclib: First Global Approval.
PG  - 2063-2070
LID - 10.1007/s40265-017-0840-z [doi]
AB  - Abemaciclib (Verzenio) is an orally administered inhibitor of cyclin-dependent
      kinases 4 and 6 that is being developed by Eli Lilly and Company. Abemaciclib has
      been approved in the USA for the treatment of hormone receptor (HR)-positive,
      human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic
      breast cancer, in combination with fulvestrant in women with disease progression 
      following endocrine therapy, and as monotherapy in adult patients with disease
      progression following endocrine therapy and prior chemotherapy in the metastatic 
      setting. In addition, abemaciclib is in various stages of development
      internationally for a variety of cancers. This article summarizes the milestones 
      in the development of abemaciclib leading to its first approval for the treatment
      of patients with HR-positive, HER2-negative advanced or metastatic breast cancer.
FAU - Kim, Esther S
AU  - Kim ES
AD  - Springer, Private Bag 65901, Mairangi Bay 0754, Auckland, New Zealand.
      dru@adis.com.
LA  - eng
PT  - Journal Article
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
EDAT- 2017/11/13 06:00
MHDA- 2017/11/13 06:00
CRDT- 2017/11/13 06:00
PHST- 2017/11/13 06:00 [pubmed]
PHST- 2017/11/13 06:00 [medline]
PHST- 2017/11/13 06:00 [entrez]
AID - 10.1007/s40265-017-0840-z [doi]
AID - 10.1007/s40265-017-0840-z [pii]
PST - ppublish
SO  - Drugs. 2017 Dec;77(18):2063-2070. doi: 10.1007/s40265-017-0840-z.

PMID- 29035360
OWN - NLM
STAT- MEDLINE
DCOM- 20171107
LR  - 20171229
IS  - 1476-4679 (Electronic)
IS  - 1465-7392 (Linking)
VI  - 19
IP  - 11
DP  - 2017 Nov
TI  - EZH2 promotes degradation of stalled replication forks by recruiting MUS81
      through histone H3 trimethylation.
PG  - 1371-1378
LID - 10.1038/ncb3626 [doi]
AB  - The emergence of resistance to poly-ADP-ribose polymerase inhibitors (PARPi)
      poses a threat to the treatment of BRCA1 and BRCA2 (BRCA1/2)-deficient tumours.
      Stabilization of stalled DNA replication forks is a recently identified
      PARPi-resistance mechanism that promotes genomic stability in BRCA1/2-deficient
      cancers. Dissecting the molecular pathways controlling genomic stability at
      stalled forks is critical. Here we show that EZH2 localizes at stalled forks
      where it methylates Lys27 on histone 3 (H3K27me3), mediating recruitment of the
      MUS81 nuclease. Low EZH2 levels reduce H3K27 methylation, prevent MUS81
      recruitment at stalled forks and cause fork stabilization. As a consequence, loss
      of function of the EZH2/MUS81 axis promotes PARPi resistance in BRCA2-deficient
      cells. Accordingly, low EZH2 or MUS81 expression levels predict chemoresistance
      and poor outcome in patients with BRCA2-mutated tumours. Moreover, inhibition of 
      Ezh2 in a murine Brca2(-/-) breast tumour model is associated with acquired PARPi
      resistance. Our findings identify EZH2 as a critical regulator of genomic
      stability at stalled forks that couples histone modifications to nuclease
      recruitment. Our data identify EZH2 expression as a biomarker of BRCA2-deficient 
      tumour response to chemotherapy.
FAU - Rondinelli, Beatrice
AU  - Rondinelli B
AD  - Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical
      School, Boston, Massachusetts 02215, USA.
AD  - Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Harvard Medical
      School, Boston, Massachusetts 02215, USA.
FAU - Gogola, Ewa
AU  - Gogola E
AD  - Division of Molecular Pathology and Cancer Genomics Netherlands, The Netherlands 
      Cancer Institute, Amsterdam 1066 CX, the Netherlands.
FAU - Yucel, Hatice
AU  - Yucel H
AD  - Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical
      School, Boston, Massachusetts 02215, USA.
FAU - Duarte, Alexandra A
AU  - Duarte AA
AD  - Division of Molecular Pathology and Cancer Genomics Netherlands, The Netherlands 
      Cancer Institute, Amsterdam 1066 CX, the Netherlands.
FAU - van de Ven, Marieke
AU  - van de Ven M
AD  - Mouse Clinic for Cancer and Aging (MCCA), Preclinical Intervention Unit, The
      Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands.
FAU - van der Sluijs, Roxanne
AU  - van der Sluijs R
AD  - Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical
      School, Boston, Massachusetts 02215, USA.
AD  - University of Amsterdam, Amsterdam 1012 WX, the Netherlands.
FAU - Konstantinopoulos, Panagiotis A
AU  - Konstantinopoulos PA
AD  - Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Harvard Medical
      School, Boston, Massachusetts 02215, USA.
AD  - Department of Medical Oncology, Medical Gynecologic Oncology Program, Dana-Farber
      Cancer Institute, Harvard Medical School, Boston, Massachusetts 02215, USA.
FAU - Jonkers, Jos
AU  - Jonkers J
AD  - Division of Molecular Pathology and Cancer Genomics Netherlands, The Netherlands 
      Cancer Institute, Amsterdam 1066 CX, the Netherlands.
FAU - Ceccaldi, Raphael
AU  - Ceccaldi R
AD  - Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical
      School, Boston, Massachusetts 02215, USA.
AD  - Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Harvard Medical
      School, Boston, Massachusetts 02215, USA.
FAU - Rottenberg, Sven
AU  - Rottenberg S
AD  - Division of Molecular Pathology and Cancer Genomics Netherlands, The Netherlands 
      Cancer Institute, Amsterdam 1066 CX, the Netherlands.
AD  - Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, Bern 3012, 
      Switzerland.
FAU - D'Andrea, Alan D
AU  - D'Andrea AD
AUID- ORCID: http://orcid.org/0000-0001-6168-6294
AD  - Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical
      School, Boston, Massachusetts 02215, USA.
AD  - Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Harvard Medical
      School, Boston, Massachusetts 02215, USA.
LA  - eng
GR  - R01 HL052725/HL/NHLBI NIH HHS/United States
GR  - P50 CA168504/CA/NCI NIH HHS/United States
GR  - R56 DK043889/DK/NIDDK NIH HHS/United States
GR  - P01 HL048546/HL/NHLBI NIH HHS/United States
GR  - R01 DK043889/DK/NIDDK NIH HHS/United States
PT  - Journal Article
DEP - 20171016
PL  - England
TA  - Nat Cell Biol
JT  - Nature cell biology
JID - 100890575
RN  - 0 (BRCA1 Protein)
RN  - 0 (BRCA1 protein, human)
RN  - 0 (BRCA2 Protein)
RN  - 0 (BRCA2 protein, human)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Histones)
RN  - 0 (Poly(ADP-ribose) Polymerase Inhibitors)
RN  - EC 2.1.1.43 (EZH2 protein, human)
RN  - EC 2.1.1.43 (Enhancer of Zeste Homolog 2 Protein)
RN  - EC 3.1.- (Endonucleases)
RN  - EC 3.1.- (MUS81 protein, human)
SB  - IM
MH  - Animals
MH  - BRCA1 Protein/metabolism
MH  - BRCA2 Protein/metabolism
MH  - Biomarkers, Tumor/metabolism
MH  - Breast Neoplasms/genetics/metabolism
MH  - Cell Line
MH  - Cell Line, Tumor
MH  - DNA Replication/drug effects/*genetics
MH  - DNA-Binding Proteins/*metabolism
MH  - Drug Resistance, Neoplasm/genetics
MH  - Endonucleases/*metabolism
MH  - Enhancer of Zeste Homolog 2 Protein/*metabolism
MH  - Female
MH  - Genomic Instability/drug effects/genetics
MH  - HEK293 Cells
MH  - HeLa Cells
MH  - Histones/*metabolism
MH  - Humans
MH  - Methylation/drug effects
MH  - Mice
MH  - Mice, Nude
MH  - Poly(ADP-ribose) Polymerase Inhibitors/pharmacology
EDAT- 2017/10/17 06:00
MHDA- 2017/11/08 06:00
CRDT- 2017/10/17 06:00
PHST- 2017/08/01 00:00 [received]
PHST- 2017/09/13 00:00 [accepted]
PHST- 2017/10/17 06:00 [pubmed]
PHST- 2017/11/08 06:00 [medline]
PHST- 2017/10/17 06:00 [entrez]
AID - ncb3626 [pii]
AID - 10.1038/ncb3626 [doi]
PST - ppublish
SO  - Nat Cell Biol. 2017 Nov;19(11):1371-1378. doi: 10.1038/ncb3626. Epub 2017 Oct 16.

PMID- 29045389
OWN - NLM
STAT- In-Data-Review
LR  - 20171219
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 550
IP  - 7677
DP  - 2017 Oct 26
TI  - Molecular basis of USP7 inhibition by selective small-molecule inhibitors.
PG  - 481-486
LID - 10.1038/nature24451 [doi]
AB  - Ubiquitination controls the stability of most cellular proteins, and its
      deregulation contributes to human diseases including cancer. Deubiquitinases
      remove ubiquitin from proteins, and their inhibition can induce the degradation
      of selected proteins, potentially including otherwise 'undruggable' targets. For 
      example, the inhibition of ubiquitin-specific protease 7 (USP7) results in the
      degradation of the oncogenic E3 ligase MDM2, and leads to re-activation of the
      tumour suppressor p53 in various cancers. Here we report that two compounds,
      FT671 and FT827, inhibit USP7 with high affinity and specificity in vitro and
      within human cells. Co-crystal structures reveal that both compounds target a
      dynamic pocket near the catalytic centre of the auto-inhibited apo form of USP7, 
      which differs from other USP deubiquitinases. Consistent with USP7 target
      engagement in cells, FT671 destabilizes USP7 substrates including MDM2, increases
      levels of p53, and results in the transcription of p53 target genes, induction of
      the tumour suppressor p21, and inhibition of tumour growth in mice.
FAU - Turnbull, Andrew P
AU  - Turnbull AP
AD  - CRUK Therapeutic Discovery Laboratories, London Bioscience Innovation Centre,
      London NW1 0NH, UK.
FAU - Ioannidis, Stephanos
AU  - Ioannidis S
AD  - FORMA Therapeutics, Arsenal Street, Watertown, Massachusetts 02472, USA.
FAU - Krajewski, Wojciech W
AU  - Krajewski WW
AD  - CRUK Therapeutic Discovery Laboratories, London Bioscience Innovation Centre,
      London NW1 0NH, UK.
FAU - Pinto-Fernandez, Adan
AU  - Pinto-Fernandez A
AD  - Target Discovery Institute, Nuffield Department of Medicine, University of
      Oxford, Roosevelt Drive, Oxford OX3 7FZ, UK.
FAU - Heride, Claire
AU  - Heride C
AD  - Cellular and Molecular Physiology, Institute of Translational Medicine,
      University of Liverpool, Crown Street, Liverpool L69 3BX, UK.
FAU - Martin, Agnes C L
AU  - Martin ACL
AD  - CRUK Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research
      Campus, Cambridge CB22 3AT, UK.
FAU - Tonkin, Louise M
AU  - Tonkin LM
AD  - CRUK Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research
      Campus, Cambridge CB22 3AT, UK.
FAU - Townsend, Elizabeth C
AU  - Townsend EC
AD  - FORMA Therapeutics, Arsenal Street, Watertown, Massachusetts 02472, USA.
FAU - Buker, Shane M
AU  - Buker SM
AD  - FORMA Therapeutics, Arsenal Street, Watertown, Massachusetts 02472, USA.
FAU - Lancia, David R
AU  - Lancia DR
AD  - FORMA Therapeutics, Arsenal Street, Watertown, Massachusetts 02472, USA.
FAU - Caravella, Justin A
AU  - Caravella JA
AD  - FORMA Therapeutics, Arsenal Street, Watertown, Massachusetts 02472, USA.
FAU - Toms, Angela V
AU  - Toms AV
AD  - FORMA Therapeutics, Arsenal Street, Watertown, Massachusetts 02472, USA.
FAU - Charlton, Thomas M
AU  - Charlton TM
AD  - Target Discovery Institute, Nuffield Department of Medicine, University of
      Oxford, Roosevelt Drive, Oxford OX3 7FZ, UK.
FAU - Lahdenranta, Johanna
AU  - Lahdenranta J
AD  - FORMA Therapeutics, Arsenal Street, Watertown, Massachusetts 02472, USA.
FAU - Wilker, Erik
AU  - Wilker E
AD  - FORMA Therapeutics, Arsenal Street, Watertown, Massachusetts 02472, USA.
FAU - Follows, Bruce C
AU  - Follows BC
AD  - FORMA Therapeutics, Arsenal Street, Watertown, Massachusetts 02472, USA.
FAU - Evans, Nicola J
AU  - Evans NJ
AD  - CRUK Therapeutic Discovery Laboratories, London Bioscience Innovation Centre,
      London NW1 0NH, UK.
FAU - Stead, Lucy
AU  - Stead L
AD  - Cellular and Molecular Physiology, Institute of Translational Medicine,
      University of Liverpool, Crown Street, Liverpool L69 3BX, UK.
FAU - Alli, Cristina
AU  - Alli C
AD  - CRUK Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research
      Campus, Cambridge CB22 3AT, UK.
FAU - Zarayskiy, Vladislav V
AU  - Zarayskiy VV
AD  - FORMA Therapeutics, Arsenal Street, Watertown, Massachusetts 02472, USA.
FAU - Talbot, Adam C
AU  - Talbot AC
AD  - FORMA Therapeutics, Arsenal Street, Watertown, Massachusetts 02472, USA.
FAU - Buckmelter, Alexandre J
AU  - Buckmelter AJ
AD  - FORMA Therapeutics, Arsenal Street, Watertown, Massachusetts 02472, USA.
FAU - Wang, Minghua
AU  - Wang M
AD  - FORMA Therapeutics, Arsenal Street, Watertown, Massachusetts 02472, USA.
FAU - McKinnon, Crystal L
AU  - McKinnon CL
AD  - FORMA Therapeutics, Arsenal Street, Watertown, Massachusetts 02472, USA.
FAU - Saab, Fabienne
AU  - Saab F
AD  - CRUK Therapeutic Discovery Laboratories, London Bioscience Innovation Centre,
      London NW1 0NH, UK.
FAU - McGouran, Joanna F
AU  - McGouran JF
AD  - Target Discovery Institute, Nuffield Department of Medicine, University of
      Oxford, Roosevelt Drive, Oxford OX3 7FZ, UK.
FAU - Century, Hannah
AU  - Century H
AD  - Target Discovery Institute, Nuffield Department of Medicine, University of
      Oxford, Roosevelt Drive, Oxford OX3 7FZ, UK.
FAU - Gersch, Malte
AU  - Gersch M
AD  - Medical Research Council Laboratory of Molecular Biology, Francis Crick Avenue,
      Cambridge CB2 0QH, UK.
FAU - Pittman, Marc S
AU  - Pittman MS
AD  - CRUK Therapeutic Discovery Laboratories, London Bioscience Innovation Centre,
      London NW1 0NH, UK.
FAU - Marshall, C Gary
AU  - Marshall CG
AD  - FORMA Therapeutics, Arsenal Street, Watertown, Massachusetts 02472, USA.
FAU - Raynham, Tony M
AU  - Raynham TM
AD  - CRUK Therapeutic Discovery Laboratories, London Bioscience Innovation Centre,
      London NW1 0NH, UK.
FAU - Simcox, Mary
AU  - Simcox M
AD  - FORMA Therapeutics, Arsenal Street, Watertown, Massachusetts 02472, USA.
FAU - Stewart, Lorna M D
AU  - Stewart LMD
AD  - CRUK Therapeutic Discovery Laboratories, London Bioscience Innovation Centre,
      London NW1 0NH, UK.
FAU - McLoughlin, Sheila B
AU  - McLoughlin SB
AD  - CRUK Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research
      Campus, Cambridge CB22 3AT, UK.
FAU - Escobedo, Jaime A
AU  - Escobedo JA
AD  - FORMA Therapeutics, Arsenal Street, Watertown, Massachusetts 02472, USA.
FAU - Bair, Kenneth W
AU  - Bair KW
AD  - FORMA Therapeutics, Arsenal Street, Watertown, Massachusetts 02472, USA.
FAU - Dinsmore, Christopher J
AU  - Dinsmore CJ
AD  - FORMA Therapeutics, Arsenal Street, Watertown, Massachusetts 02472, USA.
FAU - Hammonds, Tim R
AU  - Hammonds TR
AD  - CRUK Therapeutic Discovery Laboratories, London Bioscience Innovation Centre,
      London NW1 0NH, UK.
FAU - Kim, Sunkyu
AU  - Kim S
AD  - FORMA Therapeutics, Arsenal Street, Watertown, Massachusetts 02472, USA.
FAU - Urbe, Sylvie
AU  - Urbe S
AD  - Cellular and Molecular Physiology, Institute of Translational Medicine,
      University of Liverpool, Crown Street, Liverpool L69 3BX, UK.
FAU - Clague, Michael J
AU  - Clague MJ
AD  - Cellular and Molecular Physiology, Institute of Translational Medicine,
      University of Liverpool, Crown Street, Liverpool L69 3BX, UK.
FAU - Kessler, Benedikt M
AU  - Kessler BM
AD  - Target Discovery Institute, Nuffield Department of Medicine, University of
      Oxford, Roosevelt Drive, Oxford OX3 7FZ, UK.
FAU - Komander, David
AU  - Komander D
AD  - Medical Research Council Laboratory of Molecular Biology, Francis Crick Avenue,
      Cambridge CB2 0QH, UK.
LA  - eng
PT  - Journal Article
DEP - 20171018
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
EDAT- 2017/10/19 06:00
MHDA- 2017/10/19 06:00
CRDT- 2017/10/19 06:00
PHST- 2017/03/23 00:00 [received]
PHST- 2017/09/25 00:00 [accepted]
PHST- 2017/10/19 06:00 [pubmed]
PHST- 2017/10/19 06:00 [medline]
PHST- 2017/10/19 06:00 [entrez]
AID - nature24451 [pii]
AID - 10.1038/nature24451 [doi]
PST - ppublish
SO  - Nature. 2017 Oct 26;550(7677):481-486. doi: 10.1038/nature24451. Epub 2017 Oct
      18.

PMID- 29144463
OWN - NLM
STAT- In-Data-Review
LR  - 20171219
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 551
IP  - 7680
DP  - 2017 Nov 16
TI  - A single-cell survey of the small intestinal epithelium.
PG  - 333-339
LID - 10.1038/nature24489 [doi]
AB  - Intestinal epithelial cells absorb nutrients, respond to microbes, function as a 
      barrier and help to coordinate immune responses. Here we report profiling of
      53,193 individual epithelial cells from the small intestine and organoids of
      mice, which enabled the identification and characterization of previously unknown
      subtypes of intestinal epithelial cell and their gene signatures. We found
      unexpected diversity in hormone-secreting enteroendocrine cells and constructed
      the taxonomy of newly identified subtypes, and distinguished between two subtypes
      of tuft cell, one of which expresses the epithelial cytokine Tslp and the
      pan-immune marker CD45, which was not previously associated with
      non-haematopoietic cells. We also characterized the ways in which cell-intrinsic 
      states and the proportions of different cell types respond to bacterial and
      helminth infections: Salmonella infection caused an increase in the abundance of 
      Paneth cells and enterocytes, and broad activation of an antimicrobial program;
      Heligmosomoides polygyrus caused an increase in the abundance of goblet and tuft 
      cells. Our survey highlights previously unidentified markers and programs,
      associates sensory molecules with cell types, and uncovers principles of gut
      homeostasis and response to pathogens.
FAU - Haber, Adam L
AU  - Haber AL
AD  - Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, 
      Massachusetts 02142, USA.
FAU - Biton, Moshe
AU  - Biton M
AD  - Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, 
      Massachusetts 02142, USA.
AD  - Center for Computational and Integrative Biology, Massachusetts General Hospital,
      Boston, Massachusetts 02114, USA.
FAU - Rogel, Noga
AU  - Rogel N
AD  - Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, 
      Massachusetts 02142, USA.
FAU - Herbst, Rebecca H
AU  - Herbst RH
AD  - Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, 
      Massachusetts 02142, USA.
AD  - Department of Systems Biology, Harvard Medical School, Boston, Massachusetts
      02114, USA.
FAU - Shekhar, Karthik
AU  - Shekhar K
AD  - Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, 
      Massachusetts 02142, USA.
FAU - Smillie, Christopher
AU  - Smillie C
AD  - Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, 
      Massachusetts 02142, USA.
FAU - Burgin, Grace
AU  - Burgin G
AD  - Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, 
      Massachusetts 02142, USA.
FAU - Delorey, Toni M
AU  - Delorey TM
AD  - Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, 
      Massachusetts 02142, USA.
AD  - Department of Biology and Biotechnology, Worcester Polytechnic Institute,
      Worcester, Massachusetts 01609, USA.
FAU - Howitt, Michael R
AU  - Howitt MR
AD  - Departments of Immunology and Infectious Diseases and Genetics and Complex
      Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts
      02115, USA.
FAU - Katz, Yarden
AU  - Katz Y
AD  - Department of Systems Biology, Harvard Medical School, Boston, Massachusetts
      02114, USA.
FAU - Tirosh, Itay
AU  - Tirosh I
AD  - Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, 
      Massachusetts 02142, USA.
FAU - Beyaz, Semir
AU  - Beyaz S
AD  - The David H. Koch Institute for Integrative Cancer Research at Massachusetts
      Institute of Technology, Department of Biology, Massachusetts Institute of
      Technology, Cambridge, Massachusetts 02139, USA.
AD  - Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical
      School, Boston, Massachusetts 02115, USA.
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute, Howard Hughes
      Medical Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston,
      Massachusetts 02115, USA.
FAU - Dionne, Danielle
AU  - Dionne D
AD  - Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, 
      Massachusetts 02142, USA.
FAU - Zhang, Mei
AU  - Zhang M
AD  - Mucosal Immunology and Biology Research Center, Massachusetts General Hospital
      and Harvard Medical School, Charlestown, Massachusetts 02129, USA.
FAU - Raychowdhury, Raktima
AU  - Raychowdhury R
AD  - Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, 
      Massachusetts 02142, USA.
FAU - Garrett, Wendy S
AU  - Garrett WS
AD  - Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, 
      Massachusetts 02142, USA.
AD  - Departments of Immunology and Infectious Diseases and Genetics and Complex
      Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts
      02115, USA.
FAU - Rozenblatt-Rosen, Orit
AU  - Rozenblatt-Rosen O
AD  - Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, 
      Massachusetts 02142, USA.
FAU - Shi, Hai Ning
AU  - Shi HN
AD  - Mucosal Immunology and Biology Research Center, Massachusetts General Hospital
      and Harvard Medical School, Charlestown, Massachusetts 02129, USA.
FAU - Yilmaz, Omer
AU  - Yilmaz O
AD  - Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, 
      Massachusetts 02142, USA.
AD  - The David H. Koch Institute for Integrative Cancer Research at Massachusetts
      Institute of Technology, Department of Biology, Massachusetts Institute of
      Technology, Cambridge, Massachusetts 02139, USA.
AD  - Departments of Pathology, Gastroenterology, and Surgery, Massachusetts General
      Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA.
FAU - Xavier, Ramnik J
AU  - Xavier RJ
AD  - Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, 
      Massachusetts 02142, USA.
AD  - Center for Computational and Integrative Biology, Massachusetts General Hospital,
      Boston, Massachusetts 02114, USA.
AD  - Gastrointestinal Unit and Center for the Study of Inflammatory Bowel Disease,
      Massachusetts General Hospital, Boston, Massachusetts 02114, USA.
FAU - Regev, Aviv
AU  - Regev A
AD  - Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, 
      Massachusetts 02142, USA.
AD  - Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute
      of Technology, Cambridge, Massachusetts 02140, USA.
LA  - eng
PT  - Journal Article
DEP - 20171108
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
EDAT- 2017/11/17 06:00
MHDA- 2017/11/17 06:00
CRDT- 2017/11/17 06:00
PHST- 2016/11/10 00:00 [received]
PHST- 2017/10/03 00:00 [accepted]
PHST- 2017/11/17 06:00 [entrez]
PHST- 2017/11/17 06:00 [pubmed]
PHST- 2017/11/17 06:00 [medline]
AID - nature24489 [pii]
AID - 10.1038/nature24489 [doi]
PST - ppublish
SO  - Nature. 2017 Nov 16;551(7680):333-339. doi: 10.1038/nature24489. Epub 2017 Nov 8.

PMID- 29222508
OWN - NLM
STAT- In-Data-Review
LR  - 20171220
IS  - 2041-1723 (Electronic)
IS  - 2041-1723 (Linking)
VI  - 8
IP  - 1
DP  - 2017 Dec 8
TI  - CRISPR-Cpf1 mediates efficient homology-directed repair and
      temperature-controlled genome editing.
PG  - 2024
LID - 10.1038/s41467-017-01836-2 [doi]
AB  - Cpf1 is a novel class of CRISPR-Cas DNA endonucleases, with a wide range of
      activity across different eukaryotic systems. Yet, the underlying determinants of
      this variability are poorly understood. Here, we demonstrate that LbCpf1, but not
      AsCpf1, ribonucleoprotein complexes allow efficient mutagenesis in zebrafish and 
      Xenopus. We show that temperature modulates Cpf1 activity by controlling its
      ability to access genomic DNA. This effect is stronger on AsCpf1, explaining its 
      lower efficiency in ectothermic organisms. We capitalize on this property to show
      that temporal control of the temperature allows post-translational modulation of 
      Cpf1-mediated genome editing. Finally, we determine that LbCpf1 significantly
      increases homology-directed repair in zebrafish, improving current approaches for
      targeted DNA integration in the genome. Together, we provide a molecular
      understanding of Cpf1 activity in vivo and establish Cpf1 as an efficient and
      inducible genome engineering tool across ectothermic species.
FAU - Moreno-Mateos, Miguel A
AU  - Moreno-Mateos MA
AD  - Department of Genetics, Yale University School of Medicine, New Haven, CT, 06510,
      USA. moreno.mateos.ma@gmail.com.
FAU - Fernandez, Juan P
AU  - Fernandez JP
AD  - Department of Genetics, Yale University School of Medicine, New Haven, CT, 06510,
      USA.
FAU - Rouet, Romain
AU  - Rouet R
AD  - Department of Molecular and Cell Biology, University of California, Berkeley, CA,
      94720, USA.
AD  - California Institute for Quantitative Biosciences, University of California,
      Berkeley, CA, 94720, USA.
FAU - Vejnar, Charles E
AU  - Vejnar CE
AD  - Department of Genetics, Yale University School of Medicine, New Haven, CT, 06510,
      USA.
FAU - Lane, Maura A
AU  - Lane MA
AD  - Department of Genetics, Yale University School of Medicine, New Haven, CT, 06510,
      USA.
AD  - Department of Pediatrics, Yale University School of Medicine, New Haven, CT,
      06520, USA.
FAU - Mis, Emily
AU  - Mis E
AD  - Department of Genetics, Yale University School of Medicine, New Haven, CT, 06510,
      USA.
AD  - Department of Pediatrics, Yale University School of Medicine, New Haven, CT,
      06520, USA.
FAU - Khokha, Mustafa K
AU  - Khokha MK
AD  - Department of Genetics, Yale University School of Medicine, New Haven, CT, 06510,
      USA.
AD  - Department of Pediatrics, Yale University School of Medicine, New Haven, CT,
      06520, USA.
FAU - Doudna, Jennifer A
AU  - Doudna JA
AUID- ORCID: http://orcid.org/0000-0001-9161-999X
AD  - Department of Molecular and Cell Biology, University of California, Berkeley, CA,
      94720, USA.
AD  - California Institute for Quantitative Biosciences, University of California,
      Berkeley, CA, 94720, USA.
AD  - Department of Chemistry, University of California, Berkeley, CA, 94720, USA.
AD  - Innovative Genomics Initiative, University of California, Berkeley, CA, 94720,
      USA.
AD  - MBIB Division, Lawrence Berkeley National Laboratory, Berkeley, CA, 94720, USA.
AD  - Howard Hughes Medical Institute, University of California, Berkeley, CA, 94720,
      USA.
FAU - Giraldez, Antonio J
AU  - Giraldez AJ
AD  - Department of Genetics, Yale University School of Medicine, New Haven, CT, 06510,
      USA. antonio.giraldez@yale.edu.
AD  - Yale Stem Cell Center, Yale University School of Medicine, New Haven, CT, 06510, 
      USA. antonio.giraldez@yale.edu.
AD  - Yale Cancer Center, Yale University School of Medicine, New Haven, CT, 06510,
      USA. antonio.giraldez@yale.edu.
LA  - eng
GR  - R21 HD073768/HD/NICHD NIH HHS/United States
GR  - R01 GM103789/GM/NIGMS NIH HHS/United States
GR  - R01 HD081379/HD/NICHD NIH HHS/United States
GR  - R01 GM101108/GM/NIGMS NIH HHS/United States
GR  - R33 HL120783/HL/NHLBI NIH HHS/United States
GR  - R01 GM081602/GM/NIGMS NIH HHS/United States
GR  - R35 GM122580/GM/NIGMS NIH HHS/United States
GR  - R01 GM102251/GM/NIGMS NIH HHS/United States
GR  - R01 HD074078/HD/NICHD NIH HHS/United States
PT  - Journal Article
DEP - 20171208
PL  - England
TA  - Nat Commun
JT  - Nature communications
JID - 101528555
PMC - PMC5722943
EDAT- 2017/12/10 06:00
MHDA- 2017/12/10 06:00
CRDT- 2017/12/10 06:00
PHST- 2017/05/12 00:00 [received]
PHST- 2017/10/18 00:00 [accepted]
PHST- 2017/12/10 06:00 [entrez]
PHST- 2017/12/10 06:00 [pubmed]
PHST- 2017/12/10 06:00 [medline]
AID - 10.1038/s41467-017-01836-2 [doi]
AID - 10.1038/s41467-017-01836-2 [pii]
PST - epublish
SO  - Nat Commun. 2017 Dec 8;8(1):2024. doi: 10.1038/s41467-017-01836-2.

PMID- 29168506
OWN - NLM
STAT- In-Data-Review
LR  - 20180126
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 551
IP  - 7682
DP  - 2017 Nov 30
TI  - NFS1 undergoes positive selection in lung tumours and protects cells from
      ferroptosis.
PG  - 639-643
LID - 10.1038/nature24637 [doi]
AB  - Environmental nutrient levels impact cancer cell metabolism, resulting in
      context-dependent gene essentiality. Here, using loss-of-function screening based
      on RNA interference, we show that environmental oxygen levels are a major driver 
      of differential essentiality between in vitro model systems and in vivo tumours. 
      Above the 3-8% oxygen concentration typical of most tissues, we find that cancer 
      cells depend on high levels of the iron-sulfur cluster biosynthetic enzyme NFS1. 
      Mammary or subcutaneous tumours grow despite suppression of NFS1, whereas
      metastatic or primary lung tumours do not. Consistent with a role in surviving
      the high oxygen environment of incipient lung tumours, NFS1 lies in a region of
      genomic amplification present in lung adenocarcinoma and is most highly expressed
      in well-differentiated adenocarcinomas. NFS1 activity is particularly important
      for maintaining the iron-sulfur co-factors present in multiple cell-essential
      proteins upon exposure to oxygen compared to other forms of oxidative damage.
      Furthermore, insufficient iron-sulfur cluster maintenance robustly activates the 
      iron-starvation response and, in combination with inhibition of glutathione
      biosynthesis, triggers ferroptosis, a non-apoptotic form of cell death.
      Suppression of NFS1 cooperates with inhibition of cysteine transport to trigger
      ferroptosis in vitro and slow tumour growth. Therefore, lung adenocarcinomas
      select for expression of a pathway that confers resistance to high oxygen tension
      and protects cells from undergoing ferroptosis in response to oxidative damage.
FAU - Alvarez, Samantha W
AU  - Alvarez SW
AD  - Department of Pathology, New York University School of Medicine, New York, New
      York 10016, USA.
AD  - Laura & Isaac Perlmutter Cancer Center, New York University School of Medicine,
      New York, New York 10016, USA.
FAU - Sviderskiy, Vladislav O
AU  - Sviderskiy VO
AD  - Department of Pathology, New York University School of Medicine, New York, New
      York 10016, USA.
AD  - Laura & Isaac Perlmutter Cancer Center, New York University School of Medicine,
      New York, New York 10016, USA.
FAU - Terzi, Erdem M
AU  - Terzi EM
AD  - Department of Pathology, New York University School of Medicine, New York, New
      York 10016, USA.
AD  - Laura & Isaac Perlmutter Cancer Center, New York University School of Medicine,
      New York, New York 10016, USA.
FAU - Papagiannakopoulos, Thales
AU  - Papagiannakopoulos T
AD  - Department of Pathology, New York University School of Medicine, New York, New
      York 10016, USA.
AD  - Laura & Isaac Perlmutter Cancer Center, New York University School of Medicine,
      New York, New York 10016, USA.
FAU - Moreira, Andre L
AU  - Moreira AL
AD  - Department of Pathology, New York University School of Medicine, New York, New
      York 10016, USA.
AD  - Laura & Isaac Perlmutter Cancer Center, New York University School of Medicine,
      New York, New York 10016, USA.
FAU - Adams, Sylvia
AU  - Adams S
AD  - Department of Pathology, New York University School of Medicine, New York, New
      York 10016, USA.
AD  - Laura & Isaac Perlmutter Cancer Center, New York University School of Medicine,
      New York, New York 10016, USA.
FAU - Sabatini, David M
AU  - Sabatini DM
AD  - Whitehead Institute for Biomedical Research, Nine Cambridge Center, Cambridge,
      Massachusetts 02142, USA.
AD  - Howard Hughes Medical Institute, Department of Biology, Massachusetts Institute
      of Technology, Cambridge, Massachusetts 02139, USA.
AD  - The David H. Koch Institute for Integrative Cancer Research, 77 Massachusetts
      Avenue, Cambridge, Massachusetts 02139, USA.
AD  - Department of Biology, Massachusetts Institute of Technology, Cambridge,
      Massachusetts 02139, USA.
AD  - Broad Institute of Harvard and Massachusetts Institute of Technology, Seven
      Cambridge Center, Cambridge, Massachusetts 02142, USA.
FAU - Birsoy, Kivanc
AU  - Birsoy K
AD  - Whitehead Institute for Biomedical Research, Nine Cambridge Center, Cambridge,
      Massachusetts 02142, USA.
AD  - Howard Hughes Medical Institute, Department of Biology, Massachusetts Institute
      of Technology, Cambridge, Massachusetts 02139, USA.
AD  - The David H. Koch Institute for Integrative Cancer Research, 77 Massachusetts
      Avenue, Cambridge, Massachusetts 02139, USA.
AD  - Department of Biology, Massachusetts Institute of Technology, Cambridge,
      Massachusetts 02139, USA.
AD  - Broad Institute of Harvard and Massachusetts Institute of Technology, Seven
      Cambridge Center, Cambridge, Massachusetts 02142, USA.
AD  - Laboratory of Metabolic Regulation and Genetics, The Rockefeller University, 1230
      York Avenue, New York 10065, USA.
FAU - Possemato, Richard
AU  - Possemato R
AD  - Department of Pathology, New York University School of Medicine, New York, New
      York 10016, USA.
AD  - Laura & Isaac Perlmutter Cancer Center, New York University School of Medicine,
      New York, New York 10016, USA.
AD  - Whitehead Institute for Biomedical Research, Nine Cambridge Center, Cambridge,
      Massachusetts 02142, USA.
AD  - Howard Hughes Medical Institute, Department of Biology, Massachusetts Institute
      of Technology, Cambridge, Massachusetts 02139, USA.
AD  - The David H. Koch Institute for Integrative Cancer Research, 77 Massachusetts
      Avenue, Cambridge, Massachusetts 02139, USA.
AD  - Department of Biology, Massachusetts Institute of Technology, Cambridge,
      Massachusetts 02139, USA.
AD  - Broad Institute of Harvard and Massachusetts Institute of Technology, Seven
      Cambridge Center, Cambridge, Massachusetts 02142, USA.
LA  - eng
GR  - R01 CA103866/CA/NCI NIH HHS/United States
GR  - K22 CA193660/CA/NCI NIH HHS/United States
GR  - T32 GM007308/GM/NIGMS NIH HHS/United States
GR  - R37 AI047389/AI/NIAID NIH HHS/United States
GR  - R01 CA129105/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20171122
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
EDAT- 2017/11/24 06:00
MHDA- 2017/11/24 06:00
CRDT- 2017/11/24 06:00
PHST- 2016/05/12 00:00 [received]
PHST- 2017/10/10 00:00 [accepted]
PHST- 2017/11/24 06:00 [pubmed]
PHST- 2017/11/24 06:00 [medline]
PHST- 2017/11/24 06:00 [entrez]
AID - nature24637 [pii]
AID - 10.1038/nature24637 [doi]
PST - ppublish
SO  - Nature. 2017 Nov 30;551(7682):639-643. doi: 10.1038/nature24637. Epub 2017 Nov
      22.

PMID- 29025771
OWN - NLM
STAT- In-Process
LR  - 20171219
IS  - 2159-8290 (Electronic)
IS  - 2159-8274 (Linking)
VI  - 7
IP  - 12
DP  - 2017 Dec
TI  - Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after 
      Adoptive Immunotherapy with CD19 CAR-T Cells.
PG  - 1404-1419
LID - 10.1158/2159-8290.CD-17-0698 [doi]
AB  - Lymphodepletion chemotherapy followed by infusion of CD19-targeted chimeric
      antigen receptor-modified T (CAR-T) cells can be complicated by neurologic
      adverse events (AE) in patients with refractory B-cell malignancies. In 133
      adults treated with CD19 CAR-T cells, we found that acute lymphoblastic leukemia,
      high CD19(+) cells in bone marrow, high CAR-T cell dose, cytokine release
      syndrome, and preexisting neurologic comorbidities were associated with increased
      risk of neurologic AEs. Patients with severe neurotoxicity demonstrated evidence 
      of endothelial activation, including disseminated intravascular coagulation,
      capillary leak, and increased blood-brain barrier (BBB) permeability. The
      permeable BBB failed to protect the cerebrospinal fluid from high concentrations 
      of systemic cytokines, including IFNgamma, which induced brain vascular pericyte 
      stress and their secretion of endothelium-activating cytokines. Endothelial
      activation and multifocal vascular disruption were found in the brain of a
      patient with fatal neurotoxicity. Biomarkers of endothelial activation were
      higher before treatment in patients who subsequently developed grade >/=4
      neurotoxicity.Significance: We provide a detailed clinical, radiologic, and
      pathologic characterization of neurotoxicity after CD19 CAR-T cells, and identify
      risk factors for neurotoxicity. We show endothelial dysfunction and increased BBB
      permeability in neurotoxicity and find that patients with evidence of endothelial
      activation before lymphodepletion may be at increased risk of neurotoxicity.
      Cancer Discov; 7(12); 1404-19. (c)2017 AACR.See related commentary by Mackall and
      Miklos, p. 1371This article is highlighted in the In This Issue feature, p. 1355.
CI  - (c)2017 American Association for Cancer Research.
FAU - Gust, Juliane
AU  - Gust J
AD  - Department of Neurology, University of Washington, Seattle, Washington.
FAU - Hay, Kevin A
AU  - Hay KA
AD  - Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle,
      Washington.
AD  - Department of Medicine, University of British Columbia, Vancouver, British
      Columbia, Canada.
FAU - Hanafi, Laila-Aicha
AU  - Hanafi LA
AD  - Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle,
      Washington.
FAU - Li, Daniel
AU  - Li D
AD  - Juno Therapeutics, Seattle, Washington.
FAU - Myerson, David
AU  - Myerson D
AD  - Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle,
      Washington.
AD  - Department of Pathology, University of Washington, Seattle, Washington.
FAU - Gonzalez-Cuyar, Luis F
AU  - Gonzalez-Cuyar LF
AD  - Department of Pathology, University of Washington, Seattle, Washington.
FAU - Yeung, Cecilia
AU  - Yeung C
AD  - Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle,
      Washington.
AD  - Department of Pathology, University of Washington, Seattle, Washington.
FAU - Liles, W Conrad
AU  - Liles WC
AD  - Department of Medicine, University of Washington, Seattle, Washington.
FAU - Wurfel, Mark
AU  - Wurfel M
AD  - Department of Medicine, University of Washington, Seattle, Washington.
FAU - Lopez, Jose A
AU  - Lopez JA
AD  - Department of Medicine, University of Washington, Seattle, Washington.
AD  - Bloodworks Northwest Research Institute, Seattle, Washington.
FAU - Chen, Junmei
AU  - Chen J
AD  - Bloodworks Northwest Research Institute, Seattle, Washington.
FAU - Chung, Dominic
AU  - Chung D
AD  - Bloodworks Northwest Research Institute, Seattle, Washington.
FAU - Harju-Baker, Susanna
AU  - Harju-Baker S
AD  - Department of Medicine, University of Washington, Seattle, Washington.
FAU - Ozpolat, Tahsin
AU  - Ozpolat T
AD  - Bloodworks Northwest Research Institute, Seattle, Washington.
FAU - Fink, Kathleen R
AU  - Fink KR
AD  - Department of Radiology, University of Washington, Seattle, Washington.
FAU - Riddell, Stanley R
AU  - Riddell SR
AD  - Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle,
      Washington.
AD  - Department of Medicine, University of Washington, Seattle, Washington.
FAU - Maloney, David G
AU  - Maloney DG
AD  - Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle,
      Washington.
AD  - Department of Medicine, University of Washington, Seattle, Washington.
FAU - Turtle, Cameron J
AU  - Turtle CJ
AD  - Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle,
      Washington. cturtle@fhcrc.org.
AD  - Department of Medicine, University of Washington, Seattle, Washington.
LA  - eng
GR  - R56 HL131946/HL/NHLBI NIH HHS/United States
GR  - R21 HL129526/HL/NHLBI NIH HHS/United States
GR  - P30 CA015704/CA/NCI NIH HHS/United States
GR  - P30 DK056465/DK/NIDDK NIH HHS/United States
GR  - R01 HL117639/HL/NHLBI NIH HHS/United States
GR  - R01 CA136551/CA/NCI NIH HHS/United States
GR  - R01 HL112633/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20171012
PL  - United States
TA  - Cancer Discov
JT  - Cancer discovery
JID - 101561693
CIN - Cancer Discov. 2017 Dec;7(12 ):1371-1373. PMID: 29208775
PMC - PMC5718945
MID - NIHMS906838
EDAT- 2017/10/14 06:00
MHDA- 2017/10/14 06:00
CRDT- 2017/10/14 06:00
PMCR- 2018/12/01 00:00
PHST- 2017/06/19 00:00 [received]
PHST- 2017/08/07 00:00 [revised]
PHST- 2017/09/11 00:00 [accepted]
PHST- 2018/12/01 00:00 [pmc-release]
PHST- 2017/10/14 06:00 [pubmed]
PHST- 2017/10/14 06:00 [medline]
PHST- 2017/10/14 06:00 [entrez]
AID - 2159-8290.CD-17-0698 [pii]
AID - 10.1158/2159-8290.CD-17-0698 [doi]
PST - ppublish
SO  - Cancer Discov. 2017 Dec;7(12):1404-1419. doi: 10.1158/2159-8290.CD-17-0698. Epub 
      2017 Oct 12.

PMID- 29079252
OWN - NLM
STAT- In-Process
LR  - 20171127
IS  - 2213-8595 (Electronic)
IS  - 2213-8587 (Linking)
VI  - 5
IP  - 12
DP  - 2017 Dec
TI  - Effect of an intensified multifactorial intervention on cardiovascular outcomes
      and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled 
      trial.
PG  - 951-964
LID - S2213-8587(17)30327-3 [pii]
LID - 10.1016/S2213-8587(17)30327-3 [doi]
AB  - BACKGROUND: Limited evidence suggests that multifactorial interventions for
      control of glucose, blood pressure, and lipids reduce macrovascular complications
      and mortality in patients with type 2 diabetes. However, safe and effective
      treatment targets for these risk factors have not been determined for such
      interventions. METHODS: In this multicentre, open-label, randomised,
      parallel-group trial, undertaken at 81 clinical sites in Japan, we randomly
      assigned (1:1) patients with type 2 diabetes aged 45-69 years with hypertension, 
      dyslipidaemia, or both, and an HbA1c of 6.9% (52.0 mmol/mol) or higher, to
      receive conventional therapy for glucose, blood pressure, and lipid control
      (targets: HbA1c <6.9% [52.0 mmol/mol], blood pressure <130/80 mm Hg, LDL
      cholesterol <120 mg/dL [or 100 mg/dL in patients with a history of coronary
      artery disease]) or intensive therapy (HbA1c <6.2% [44.3 mmol/mol], blood
      pressure <120/75 mm Hg, LDL cholesterol <80 mg/dL [or 70 mg/dL in patients with a
      history of coronary artery disease]). Randomisation was done using a
      computer-generated, dynamic balancing method, stratified by sex, age, HbA1c, and 
      history of cardiovascular disease. Neither patients nor investigators were masked
      to group assignment. The primary outcome was occurrence of any of a composite of 
      myocardial infarction, stroke, revascularisation (coronary artery bypass surgery,
      percutaneous transluminal coronary angioplasty, carotid endarterectomy,
      percutaneous transluminal cerebral angioplasty, and carotid artery stenting), and
      all-cause mortality. The primary analysis was done in the intention-to-treat
      population. This study is registered with ClinicalTrials.gov, number NCT00300976.
      FINDINGS: Between June 16, 2006, and March 31, 2009, 2542 eligible patients were 
      randomly assigned to intensive therapy or conventional therapy (1271 in each
      group) and followed up for a median of 8.5 years (IQR 7.3-9.0). Two patients in
      the intensive therapy group were found to be ineligible after randomisation and
      were excluded from the analyses. During the intervention period, mean HbA1c,
      systolic blood pressure, diastolic blood pressure, and LDL cholesterol
      concentrations were significantly lower in the intensive therapy group than in
      the conventional therapy group (6.8% [51.0 mmol/mol] vs 7.2% [55.2 mmol/mol]; 123
      mm Hg vs 129 mm Hg; 71 mm Hg vs 74 mm Hg; and 85 mg/dL vs 104 mg/dL,
      respectively; all p<0.0001). The primary outcome occurred in 109 patients in the 
      intensive therapy group and in 133 patients in the conventional therapy group
      (hazard ratio [HR] 0.81, 95% CI 0.63-1.04; p=0.094). In a post-hoc breakdown of
      the composite outcome, frequencies of all-cause mortality (HR 1.01, 95% CI
      0.68-1.51; p=0.95) and coronary events (myocardial infarction, coronary artery
      bypass surgery, and percutaneous transluminal coronary angioplasty; HR 0.86,
      0.58-1.27; p=0.44) did not differ between groups, but cerebrovascular events
      (stroke, carotid endarterectomy, percutaneous transluminal cerebral angioplasty, 
      and carotid artery stenting) were significantly less frequent in the intensive
      therapy group (HR 0.42, 0.24-0.74; p=0.002). Apart from non-severe hypoglycaemia 
      (521 [41%] patients in the intensive therapy group vs 283 [22%] in the
      conventional therapy group, p<0.0001) and oedema (193 [15%] vs 129 [10%],
      p=0.0001), the frequencies of major adverse events did not differ between groups.
      INTERPRETATION: Our results do not fully support the efficacy of further
      intensified multifactorial intervention compared with current standard care for
      the prevention of a composite of coronary events, cerebrovascular events, and
      all-cause mortality. Nevertheless, our findings suggest a potential benefit of an
      intensified intervention for the prevention of cerebrovascular events in patients
      with type 2 diabetes. FUNDING: Ministry of Health, Labour and Welfare of Japan,
      Asahi Kasei Pharma, Astellas Pharma, AstraZeneca, Bayer, Boehringer Ingelheim,
      Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, GlaxoSmithKline, Kissei
      Pharmaceutical, Kowa Pharmaceutical, Mitsubishi Tanabe Pharma, Mochida
      Pharmaceutical, MSD, Novartis Pharma, Novo Nordisk, Ono Pharmaceutical, Pfizer,
      Sanwa Kagaku Kenkyusho, Shionogi, Sumitomo Dainippon Pharma, Taisho Toyama
      Pharmaceutical, and Takeda.
CI  - Copyright (c) 2017 Elsevier Ltd. All rights reserved.
FAU - Ueki, Kohjiro
AU  - Ueki K
AD  - Department of Molecular Diabetic Medicine, Diabetes Research Center, National
      Center for Global Health and Medicine, Tokyo, Japan; Department of Diabetes and
      Metabolic Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, 
      Japan.
FAU - Sasako, Takayoshi
AU  - Sasako T
AD  - Department of Diabetes and Metabolic Diseases, Graduate School of Medicine, The
      University of Tokyo, Tokyo, Japan; Translational Systems Biology and Medicine
      Initiative, The University of Tokyo, Tokyo, Japan.
FAU - Okazaki, Yukiko
AU  - Okazaki Y
AD  - Department of Diabetes and Metabolic Diseases, Graduate School of Medicine, The
      University of Tokyo, Tokyo, Japan.
FAU - Kato, Masayuki
AU  - Kato M
AD  - Health Management Center and Diagnostic Imaging Center, Toranomon Hospital,
      Tokyo, Japan.
FAU - Okahata, Sumie
AU  - Okahata S
AD  - Division of Diabetes and Metabolism, Toho University Ohashi Medical Center,
      Tokyo, Japan.
FAU - Katsuyama, Hisayuki
AU  - Katsuyama H
AD  - Department of Internal Medicine, National Center for Global Health and Medicine, 
      Kohnodai Hospital, Chiba, Japan.
FAU - Haraguchi, Mikiko
AU  - Haraguchi M
AD  - Department of Diabetes and Metabolic Diseases, Graduate School of Medicine, The
      University of Tokyo, Tokyo, Japan.
FAU - Morita, Ai
AU  - Morita A
AD  - Department of Diabetes and Metabolic Diseases, Graduate School of Medicine, The
      University of Tokyo, Tokyo, Japan.
FAU - Ohashi, Ken
AU  - Ohashi K
AD  - Department of General Internal Medicine, National Cancer Center Hospital, Tokyo, 
      Japan.
FAU - Hara, Kazuo
AU  - Hara K
AD  - Department of Endocrinology and Metabolism, Saitama Medical Center, Jichi Medical
      University, Saitama, Japan.
FAU - Morise, Atsushi
AU  - Morise A
AD  - Department of Internal Medicine, Tokyo Takanawa Hospital, Tokyo, Japan.
FAU - Izumi, Kazuo
AU  - Izumi K
AD  - Department of Clinical Research Strategic Planning, Center for Clinical Sciences,
      National Center for Global Health and Medicine, Tokyo, Japan.
FAU - Ishizuka, Naoki
AU  - Ishizuka N
AD  - Clinical Research Center, The Cancer Institute Hospital, Japanese Foundation for 
      Cancer Research, Tokyo, Japan.
FAU - Ohashi, Yasuo
AU  - Ohashi Y
AD  - Department of Integrated Science and Engineering for Sustainable Society, Chuo
      University, Tokyo, Japan.
FAU - Noda, Mitsuhiko
AU  - Noda M
AD  - Department of Endocrinology and Diabetes, Saitama Medical University, Saitama,
      Japan.
FAU - Kadowaki, Takashi
AU  - Kadowaki T
AD  - Department of Diabetes and Metabolic Diseases, Graduate School of Medicine, The
      University of Tokyo, Tokyo, Japan; Translational Systems Biology and Medicine
      Initiative, The University of Tokyo, Tokyo, Japan. Electronic address:
      kadowaki-3im@h.u-tokyo.ac.jp.
CN  - J-DOIT3 Study Group
LA  - eng
PT  - Journal Article
DEP - 20171024
PL  - England
TA  - Lancet Diabetes Endocrinol
JT  - The lancet. Diabetes & endocrinology
JID - 101618821
IR  - Haneda M
FIR - Haneda, Masakazu
IR  - Iwashima Y
FIR - Iwashima, Yasunori
IR  - Suda T
FIR - Suda, Toshihiro
IR  - Tamasawa N
FIR - Tamasawa, Naoki
IR  - Daimon M
FIR - Daimon, Makoto
IR  - Satoh J
FIR - Satoh, Jo
IR  - Takebe N
FIR - Takebe, Noriko
IR  - Ishigaki Y
FIR - Ishigaki, Yasushi
IR  - Watanabe T
FIR - Watanabe, Tsuyoshi
IR  - Satoh H
FIR - Satoh, Hiroaki
IR  - Kasai K
FIR - Kasai, Kikuo
IR  - Aso Y
FIR - Aso, Yoshimasa
IR  - Ishibashi S
FIR - Ishibashi, Shun
IR  - Katayama S
FIR - Katayama, Shigehiro
IR  - Ishikawa SE
FIR - Ishikawa, San-E
IR  - Kakei M
FIR - Kakei, Masafumi
IR  - Namai K
FIR - Namai, Kazuyuki
IR  - Hashimoto N
FIR - Hashimoto, Naotake
IR  - Suzuki Y
FIR - Suzuki, Yoshifumi
IR  - Onishi S
FIR - Onishi, Shunichiro
IR  - Yokote K
FIR - Yokote, Koutaro
IR  - Matsuda M
FIR - Matsuda, Masafumi
IR  - Masuzawa M
FIR - Masuzawa, Masahiro
IR  - Hayashi Y
FIR - Hayashi, Yoichi
IR  - Saito S
FIR - Saito, Satoshi
IR  - Ogihara N
FIR - Ogihara, Norikazu
IR  - Ishihara H
FIR - Ishihara, Hisamitsu
IR  - Tajima N
FIR - Tajima, Naoko
IR  - Utsunomiya K
FIR - Utsunomiya, Kazunori
IR  - Shimada A
FIR - Shimada, Akira
IR  - Itoh H
FIR - Itoh, Hiroshi
IR  - Kawamori R
FIR - Kawamori, Ryuzo
IR  - Watada H
FIR - Watada, Hirotaka
IR  - Hayashi M
FIR - Hayashi, Michio
IR  - Mori Y
FIR - Mori, Yasumichi
IR  - Shiba T
FIR - Shiba, Teruo
IR  - Isogawa A
FIR - Isogawa, Akihiro
IR  - Sakura H
FIR - Sakura, Hiroshi
IR  - Odawara M
FIR - Odawara, Masato
IR  - Tobe K
FIR - Tobe, Kazuyuki
IR  - Tsukamoto K
FIR - Tsukamoto, Kazuhisa
IR  - Yamauchi T
FIR - Yamauchi, Toshimasa
IR  - Teramoto T
FIR - Teramoto, Tamio
IR  - Hirata Y
FIR - Hirata, Yukio
IR  - Uchimura I
FIR - Uchimura, Isao
IR  - Ogawa Y
FIR - Ogawa, Yoshihiro
IR  - Yoshino G
FIR - Yoshino, Gen
IR  - Hirose T
FIR - Hirose, Takahisa
IR  - Kajio H
FIR - Kajio, Hiroshi
IR  - Atsumi Y
FIR - Atsumi, Yoshihito
IR  - Shimada A
FIR - Shimada, Akira
IR  - Oikawa Y
FIR - Oikawa, Yoichi
IR  - Araki A
FIR - Araki, Atsushi
IR  - Ueki A
FIR - Ueki, Akio
IR  - Ohno A
FIR - Ohno, Atsushi
IR  - Kitaoka M
FIR - Kitaoka, Masafumi
IR  - Fujita Y
FIR - Fujita, Yoshikuni
IR  - Moriya T
FIR - Moriya, Tatsumi
IR  - Tojo T
FIR - Tojo, Taiki
IR  - Shichiri M
FIR - Shichiri, Masayoshi
IR  - Suzuki D
FIR - Suzuki, Daisuke
IR  - Toyoda M
FIR - Toyoda, Masao
IR  - Hamano K
FIR - Hamano, Kumiko
IR  - Komi R
FIR - Komi, Rieko
IR  - Terauchi Y
FIR - Terauchi, Yasuo
IR  - Kuzuya N
FIR - Kuzuya, Nobuaki
IR  - Yamada M
FIR - Yamada, Masayo
IR  - Takamura T
FIR - Takamura, Toshinari
IR  - Imura M
FIR - Imura, Mitsuo
IR  - Tanaka H
FIR - Tanaka, Hiroshi
IR  - Hayashi M
FIR - Hayashi, Masayuki
IR  - Kato Y
FIR - Kato, Yasuhisa
IR  - Itoh M
FIR - Itoh, Mitsuyasu
IR  - Suzuki A
FIR - Suzuki, Atsushi
IR  - Nakayama M
FIR - Nakayama, Mikihiro
IR  - Sano T
FIR - Sano, Takahisa
IR  - Nakashima E
FIR - Nakashima, Eitaro
IR  - Sumida Y
FIR - Sumida, Yasuhiro
IR  - Yano Y
FIR - Yano, Yutaka
IR  - Tanaka T
FIR - Tanaka, Tsuyoshi
IR  - Murata K
FIR - Murata, Kazuya
IR  - Kashiwagi A
FIR - Kashiwagi, Atsunori
IR  - Maegawa H
FIR - Maegawa, Hiroshi
IR  - Kono S
FIR - Kono, Shigeo
IR  - Inagaki N
FIR - Inagaki, Nobuya
IR  - Kosugi K
FIR - Kosugi, Keisuke
IR  - Yasuda T
FIR - Yasuda, Tetsuyuki
IR  - Yoshimasa Y
FIR - Yoshimasa, Yasunao
IR  - Kishimoto I
FIR - Kishimoto, Ichiro
IR  - Sato T
FIR - Sato, Toshihiko
IR  - Hosoi M
FIR - Hosoi, Masayuki
IR  - Yamasaki T
FIR - Yamasaki, Tomoyuki
IR  - Matsuhisa M
FIR - Matsuhisa, Munehide
IR  - Shimomura I
FIR - Shimomura, Iichiro
IR  - Taniguchi A
FIR - Taniguchi, Ataru
IR  - Kuroe A
FIR - Kuroe, Akira
IR  - Kurose T
FIR - Kurose, Takeshi
IR  - Ohara T
FIR - Ohara, Takeshi
IR  - Sakaguchi K
FIR - Sakaguchi, Kazuhiko
IR  - Namba M
FIR - Namba, Mitsuyoshi
IR  - Kaku K
FIR - Kaku, Kohei
IR  - Fujiwara M
FIR - Fujiwara, Masazumi
IR  - Shimizu I
FIR - Shimizu, Ikki
IR  - Ono K
FIR - Ono, Keizo
IR  - Ebisui O
FIR - Ebisui, Osamu
IR  - Tanizawa Y
FIR - Tanizawa, Yukio
IR  - Okada Y
FIR - Okada, Yosuke
IR  - Natori S
FIR - Natori, Shoichi
IR  - Kodera T
FIR - Kodera, Takehiko
IR  - Sato N
FIR - Sato, Naoichi
IR  - Ide M
FIR - Ide, Makoto
IR  - Yamada K
FIR - Yamada, Kentaro
IR  - Umeda F
FIR - Umeda, Fumio
IR  - Natori S
FIR - Natori, Shoichi
IR  - Eto T
FIR - Eto, Tomoaki
IR  - Mimura K
FIR - Mimura, Kazuo
IR  - Hiramatsu S
FIR - Hiramatsu, Shinsuke
IR  - Inoue T
FIR - Inoue, Tomoaki
IR  - Takei R
FIR - Takei, Ryoko
IR  - Ogo A
FIR - Ogo, Atsushi
IR  - Eguchi K
FIR - Eguchi, Katsumi
IR  - Kawasaki E
FIR - Kawasaki, Eiji
IR  - Koide Y
FIR - Koide, Yuji
IR  - Araki E
FIR - Araki, Eiichi
IR  - Jinnouchi H
FIR - Jinnouchi, Hideaki
IR  - Yamamoto H
FIR - Yamamoto, Hiroaki
IR  - Motoyoshi M
FIR - Motoyoshi, Mitsutaka
IR  - Hiyoshi T
FIR - Hiyoshi, Toru
IR  - Tanaka Y
FIR - Tanaka, Yasushi
IR  - Momoki T
FIR - Momoki, Tadahisa
IR  - Sato K
FIR - Sato, Koichiro
IR  - Yoneyama A
FIR - Yoneyama, Akihiko
IR  - Ito K
FIR - Ito, Kenichi
IR  - Sobajima H
FIR - Sobajima, Hiroshi
IR  - Ikegami H
FIR - Ikegami, Hiroshi
IR  - Ikeda M
FIR - Ikeda, Masaki
IR  - Ikeda H
FIR - Ikeda, Hiroki
IR  - Takahashi K
FIR - Takahashi, Kenji
IR  - Makino H
FIR - Makino, Hirofumi
IR  - Ueda Y
FIR - Ueda, Yasuo
IR  - Nakazato M
FIR - Nakazato, Masamitsu
EDAT- 2017/10/29 06:00
MHDA- 2017/10/29 06:00
CRDT- 2017/10/29 06:00
PHST- 2017/08/11 00:00 [received]
PHST- 2017/09/11 00:00 [revised]
PHST- 2017/09/11 00:00 [accepted]
PHST- 2017/10/29 06:00 [pubmed]
PHST- 2017/10/29 06:00 [medline]
PHST- 2017/10/29 06:00 [entrez]
AID - S2213-8587(17)30327-3 [pii]
AID - 10.1016/S2213-8587(17)30327-3 [doi]
PST - ppublish
SO  - Lancet Diabetes Endocrinol. 2017 Dec;5(12):951-964. doi:
      10.1016/S2213-8587(17)30327-3. Epub 2017 Oct 24.

PMID- 29153836
OWN - NLM
STAT- MEDLINE
DCOM- 20171228
LR  - 20180123
IS  - 1097-4172 (Electronic)
IS  - 0092-8674 (Linking)
VI  - 171
IP  - 7
DP  - 2017 Dec 14
TI  - Post-transcriptional Regulation of De Novo Lipogenesis by mTORC1-S6K1-SRPK2
      Signaling.
PG  - 1545-1558.e18
LID - S0092-8674(17)31263-1 [pii]
LID - 10.1016/j.cell.2017.10.037 [doi]
AB  - mTORC1 is a signal integrator and master regulator of cellular anabolic processes
      linked to cell growth and survival. Here, we demonstrate that mTORC1 promotes
      lipid biogenesis via SRPK2, a key regulator of RNA-binding SR proteins.
      mTORC1-activated S6K1 phosphorylates SRPK2 at Ser494, which primes Ser497
      phosphorylation by CK1. These phosphorylation events promote SRPK2 nuclear
      translocation and phosphorylation of SR proteins. Genome-wide transcriptome
      analysis reveals that lipid biosynthetic enzymes are among the downstream targets
      of mTORC1-SRPK2 signaling. Mechanistically, SRPK2 promotes SR protein binding to 
      U1-70K to induce splicing of lipogenic pre-mRNAs. Inhibition of this signaling
      pathway leads to intron retention of lipogenic genes, which triggers
      nonsense-mediated mRNA decay. Genetic or pharmacological inhibition of SRPK2
      blunts de novo lipid synthesis, thereby suppressing cell growth. These results
      thus reveal a novel role of mTORC1-SRPK2 signaling in post-transcriptional
      regulation of lipid metabolism and demonstrate that SRPK2 is a potential
      therapeutic target for mTORC1-driven metabolic disorders.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Lee, Gina
AU  - Lee G
AD  - Meyer Cancer Center, Weill Cornell Medicine, New York, NY 10065, USA; Department 
      of Pharmacology, Weill Cornell Medicine, New York, NY 10065, USA.
FAU - Zheng, Yuxiang
AU  - Zheng Y
AD  - Meyer Cancer Center, Weill Cornell Medicine, New York, NY 10065, USA; Department 
      of Medicine, Weill Cornell Medicine, New York, NY 10065, USA.
FAU - Cho, Sungyun
AU  - Cho S
AD  - Meyer Cancer Center, Weill Cornell Medicine, New York, NY 10065, USA.
FAU - Jang, Cholsoon
AU  - Jang C
AD  - Lewis-Sigler Institute for Integrative Genomics and Department of Chemistry,
      Princeton University, Princeton, NJ 08544, USA.
FAU - England, Christina
AU  - England C
AD  - Meyer Cancer Center, Weill Cornell Medicine, New York, NY 10065, USA.
FAU - Dempsey, Jamie M
AU  - Dempsey JM
AD  - Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA.
FAU - Yu, Yonghao
AU  - Yu Y
AD  - Department of Biochemistry, University of Texas Southwestern Medical Center,
      Dallas, TX 75390, USA.
FAU - Liu, Xiaolei
AU  - Liu X
AD  - Department of Internal Medicine, University of Cincinnati College of Medicine,
      Cincinnati, OH 45267, USA.
FAU - He, Long
AU  - He L
AD  - Meyer Cancer Center, Weill Cornell Medicine, New York, NY 10065, USA; Department 
      of Pharmacology, Weill Cornell Medicine, New York, NY 10065, USA.
FAU - Cavaliere, Paola M
AU  - Cavaliere PM
AD  - Meyer Cancer Center, Weill Cornell Medicine, New York, NY 10065, USA.
FAU - Chavez, Andre
AU  - Chavez A
AD  - Meyer Cancer Center, Weill Cornell Medicine, New York, NY 10065, USA.
FAU - Zhang, Erik
AU  - Zhang E
AD  - Department of Internal Medicine, University of Cincinnati College of Medicine,
      Cincinnati, OH 45267, USA.
FAU - Isik, Meltem
AU  - Isik M
AD  - Joslin Diabetes Center and Department of Genetics, Harvard Medical School,
      Boston, MA 02215, USA.
FAU - Couvillon, Anthony
AU  - Couvillon A
AD  - Cell Signaling Technology, Danvers, MA 01923, USA.
FAU - Dephoure, Noah E
AU  - Dephoure NE
AD  - Meyer Cancer Center, Weill Cornell Medicine, New York, NY 10065, USA.
FAU - Blackwell, T Keith
AU  - Blackwell TK
AD  - Joslin Diabetes Center and Department of Genetics, Harvard Medical School,
      Boston, MA 02215, USA.
FAU - Yu, Jane J
AU  - Yu JJ
AD  - Department of Internal Medicine, University of Cincinnati College of Medicine,
      Cincinnati, OH 45267, USA.
FAU - Rabinowitz, Joshua D
AU  - Rabinowitz JD
AD  - Lewis-Sigler Institute for Integrative Genomics and Department of Chemistry,
      Princeton University, Princeton, NJ 08544, USA.
FAU - Cantley, Lewis C
AU  - Cantley LC
AD  - Meyer Cancer Center, Weill Cornell Medicine, New York, NY 10065, USA; Department 
      of Medicine, Weill Cornell Medicine, New York, NY 10065, USA.
FAU - Blenis, John
AU  - Blenis J
AD  - Meyer Cancer Center, Weill Cornell Medicine, New York, NY 10065, USA; Department 
      of Pharmacology, Weill Cornell Medicine, New York, NY 10065, USA. Electronic
      address: job2064@med.cornell.edu.
LA  - eng
GR  - R01 AG054215/AG/NIA NIH HHS/United States
GR  - P01 CA120964/CA/NCI NIH HHS/United States
GR  - R01 GM114160/GM/NIGMS NIH HHS/United States
GR  - P30 DK036836/DK/NIDDK NIH HHS/United States
GR  - R01 GM041890/GM/NIGMS NIH HHS/United States
GR  - R35 CA197588/CA/NCI NIH HHS/United States
GR  - R35 GM122610/GM/NIGMS NIH HHS/United States
PT  - Journal Article
DEP - 20171116
PL  - United States
TA  - Cell
JT  - Cell
JID - 0413066
RN  - 0 (Fatty Acids)
RN  - 97C5T2UQ7J (Cholesterol)
RN  - EC 2.7.11.1 (Mechanistic Target of Rapamycin Complex 1)
RN  - EC 2.7.11.1 (Protein-Serine-Threonine Kinases)
RN  - EC 2.7.11.1 (Ribosomal Protein S6 Kinases, 70-kDa)
RN  - EC 2.7.11.1 (SRPK2 protein, human)
RN  - EC 2.7.11.1 (ribosomal protein S6 kinase, 70kD, polypeptide 1)
SB  - IM
MH  - Animals
MH  - Cell Nucleus/metabolism
MH  - Cholesterol/metabolism
MH  - Fatty Acids/metabolism
MH  - Female
MH  - *Gene Expression Regulation
MH  - Heterografts
MH  - Humans
MH  - *Lipogenesis
MH  - Mechanistic Target of Rapamycin Complex 1/metabolism
MH  - Mice
MH  - Mice, Nude
MH  - Neoplasm Transplantation
MH  - Protein-Serine-Threonine Kinases/metabolism
MH  - *RNA Processing, Post-Transcriptional
MH  - Ribosomal Protein S6 Kinases, 70-kDa/metabolism
MH  - *Signal Transduction
OTO - NOTNLM
OT  - CK1
OT  - RNA splicing
OT  - RNA stability
OT  - S6K1
OT  - SR proteins
OT  - SRPK2
OT  - cancer metabolism
OT  - de novo lipid synthesis
OT  - mTOR
OT  - nonsense-mediated decay
EDAT- 2017/11/21 06:00
MHDA- 2017/12/29 06:00
CRDT- 2017/11/21 06:00
PHST- 2017/08/29 00:00 [received]
PHST- 2017/10/03 00:00 [revised]
PHST- 2017/10/23 00:00 [accepted]
PHST- 2017/11/21 06:00 [pubmed]
PHST- 2017/12/29 06:00 [medline]
PHST- 2017/11/21 06:00 [entrez]
AID - S0092-8674(17)31263-1 [pii]
AID - 10.1016/j.cell.2017.10.037 [doi]
PST - ppublish
SO  - Cell. 2017 Dec 14;171(7):1545-1558.e18. doi: 10.1016/j.cell.2017.10.037. Epub
      2017 Nov 16.

PMID- 29249359
OWN - NLM
STAT- In-Data-Review
LR  - 20180116
IS  - 1097-4172 (Electronic)
IS  - 0092-8674 (Linking)
VI  - 172
IP  - 1-2
DP  - 2018 Jan 11
TI  - R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m(6)A/MYC/CEBPA Signaling.
PG  - 90-105.e23
LID - S0092-8674(17)31382-X [pii]
LID - 10.1016/j.cell.2017.11.031 [doi]
AB  - R-2-hydroxyglutarate (R-2HG), produced at high levels by mutant isocitrate
      dehydrogenase 1/2 (IDH1/2) enzymes, was reported as an oncometabolite. We show
      here that R-2HG also exerts a broad anti-leukemic activity in vitro and in vivo
      by inhibiting leukemia cell proliferation/viability and by promoting cell-cycle
      arrest and apoptosis. Mechanistically, R-2HG inhibits fat mass and
      obesity-associated protein (FTO) activity, thereby increasing global
      N(6)-methyladenosine (m(6)A) RNA modification in R-2HG-sensitive leukemia cells, 
      which in turn decreases the stability of MYC/CEBPA transcripts, leading to the
      suppression of relevant pathways. Ectopically expressed mutant IDH1 and S-2HG
      recapitulate the effects of R-2HG. High levels of FTO sensitize leukemic cells to
      R-2HG, whereas hyperactivation of MYC signaling confers resistance that can be
      reversed by the inhibition of MYC signaling. R-2HG also displays anti-tumor
      activity in glioma. Collectively, while R-2HG accumulated in IDH1/2 mutant
      cancers contributes to cancer initiation, our work demonstrates anti-tumor
      effects of 2HG in inhibiting proliferation/survival of FTO-high cancer cells via 
      targeting FTO/m(6)A/MYC/CEBPA signaling.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Su, Rui
AU  - Su R
AD  - Department of Cancer Biology, University of Cincinnati, Cincinnati, OH 45219,
      USA.
FAU - Dong, Lei
AU  - Dong L
AD  - Department of Cancer Biology, University of Cincinnati, Cincinnati, OH 45219,
      USA.
FAU - Li, Chenying
AU  - Li C
AD  - Department of Cancer Biology, University of Cincinnati, Cincinnati, OH 45219,
      USA; Key Laboratory of Hematopoietic Malignancies, The First Affiliated Hospital 
      of Zhejiang University, Hangzhou, Zhejiang 310003, China.
FAU - Nachtergaele, Sigrid
AU  - Nachtergaele S
AD  - Department of Chemistry, Department of Biochemistry and Molecular Biology,
      Institute for Biophysical Dynamics, Howard Hughes Medical Institute, University
      of Chicago, Chicago, IL 60637, USA.
FAU - Wunderlich, Mark
AU  - Wunderlich M
AD  - Division of Experimental Hematology and Cancer Biology, Cincinnati Children's
      Hospital Medical Center, Cincinnati, OH 45229, USA.
FAU - Qing, Ying
AU  - Qing Y
AD  - Department of Cancer Biology, University of Cincinnati, Cincinnati, OH 45219,
      USA.
FAU - Deng, Xiaolan
AU  - Deng X
AD  - Department of Cancer Biology, University of Cincinnati, Cincinnati, OH 45219,
      USA; School of Pharmacy, China Medical University, Shenyang, Liaoning 110001,
      China.
FAU - Wang, Yungui
AU  - Wang Y
AD  - Department of Cancer Biology, University of Cincinnati, Cincinnati, OH 45219,
      USA; Key Laboratory of Hematopoietic Malignancies, The First Affiliated Hospital 
      of Zhejiang University, Hangzhou, Zhejiang 310003, China.
FAU - Weng, Xiaocheng
AU  - Weng X
AD  - Department of Chemistry, Department of Biochemistry and Molecular Biology,
      Institute for Biophysical Dynamics, Howard Hughes Medical Institute, University
      of Chicago, Chicago, IL 60637, USA; College of Chemistry and Molecular Sciences, 
      Key Laboratory of Biomedical Polymers of Ministry of Education, Wuhan University,
      Hubei, Wuhan 430072, China.
FAU - Hu, Chao
AU  - Hu C
AD  - Department of Cancer Biology, University of Cincinnati, Cincinnati, OH 45219,
      USA; Key Laboratory of Hematopoietic Malignancies, The First Affiliated Hospital 
      of Zhejiang University, Hangzhou, Zhejiang 310003, China.
FAU - Yu, Mengxia
AU  - Yu M
AD  - Key Laboratory of Hematopoietic Malignancies, The First Affiliated Hospital of
      Zhejiang University, Hangzhou, Zhejiang 310003, China.
FAU - Skibbe, Jennifer
AU  - Skibbe J
AD  - Department of Cancer Biology, University of Cincinnati, Cincinnati, OH 45219,
      USA.
FAU - Dai, Qing
AU  - Dai Q
AD  - Department of Chemistry, Department of Biochemistry and Molecular Biology,
      Institute for Biophysical Dynamics, Howard Hughes Medical Institute, University
      of Chicago, Chicago, IL 60637, USA.
FAU - Zou, Dongling
AU  - Zou D
AD  - Department of Cancer Biology, University of Cincinnati, Cincinnati, OH 45219,
      USA; Depart of Gynecologic Oncology, Chongqing Cancer Institute and Hospital and 
      Cancer Center, Chongqing 400030, China.
FAU - Wu, Tong
AU  - Wu T
AD  - Department of Chemistry, Department of Biochemistry and Molecular Biology,
      Institute for Biophysical Dynamics, Howard Hughes Medical Institute, University
      of Chicago, Chicago, IL 60637, USA.
FAU - Yu, Kangkang
AU  - Yu K
AD  - Department of Chemistry, Department of Biochemistry and Molecular Biology,
      Institute for Biophysical Dynamics, Howard Hughes Medical Institute, University
      of Chicago, Chicago, IL 60637, USA.
FAU - Weng, Hengyou
AU  - Weng H
AD  - Department of Cancer Biology, University of Cincinnati, Cincinnati, OH 45219,
      USA.
FAU - Huang, Huilin
AU  - Huang H
AD  - Department of Cancer Biology, University of Cincinnati, Cincinnati, OH 45219,
      USA.
FAU - Ferchen, Kyle
AU  - Ferchen K
AD  - Department of Cancer Biology, University of Cincinnati, Cincinnati, OH 45219,
      USA.
FAU - Qin, Xi
AU  - Qin X
AD  - Department of Cancer Biology, University of Cincinnati, Cincinnati, OH 45219,
      USA.
FAU - Zhang, Bin
AU  - Zhang B
AD  - Gehr Family Center for Leukemia Research, City of Hope, 1500 E. Duarte Rd.,
      Duarte, CA 91010, USA.
FAU - Qi, Jun
AU  - Qi J
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical
      School, Boston, MA 02215, USA.
FAU - Sasaki, Atsuo T
AU  - Sasaki AT
AD  - Division of Hematology and Oncology, Department of Internal Medicine, University 
      of Cincinnati, Cincinnati, OH 45267, USA.
FAU - Plas, David R
AU  - Plas DR
AD  - Department of Cancer Biology, University of Cincinnati, Cincinnati, OH 45219,
      USA.
FAU - Bradner, James E
AU  - Bradner JE
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical
      School, Boston, MA 02215, USA.
FAU - Wei, Minjie
AU  - Wei M
AD  - School of Pharmacy, China Medical University, Shenyang, Liaoning 110001, China.
FAU - Marcucci, Guido
AU  - Marcucci G
AD  - Gehr Family Center for Leukemia Research, City of Hope, 1500 E. Duarte Rd.,
      Duarte, CA 91010, USA.
FAU - Jiang, Xi
AU  - Jiang X
AD  - Department of Cancer Biology, University of Cincinnati, Cincinnati, OH 45219,
      USA.
FAU - Mulloy, James C
AU  - Mulloy JC
AD  - Division of Experimental Hematology and Cancer Biology, Cincinnati Children's
      Hospital Medical Center, Cincinnati, OH 45229, USA.
FAU - Jin, Jie
AU  - Jin J
AD  - Key Laboratory of Hematopoietic Malignancies, The First Affiliated Hospital of
      Zhejiang University, Hangzhou, Zhejiang 310003, China. Electronic address:
      jiej0503@163.com.
FAU - He, Chuan
AU  - He C
AD  - Department of Chemistry, Department of Biochemistry and Molecular Biology,
      Institute for Biophysical Dynamics, Howard Hughes Medical Institute, University
      of Chicago, Chicago, IL 60637, USA. Electronic address: chuanhe@uchicago.edu.
FAU - Chen, Jianjun
AU  - Chen J
AD  - Department of Cancer Biology, University of Cincinnati, Cincinnati, OH 45219,
      USA; Gehr Family Center for Leukemia Research, City of Hope, 1500 E. Duarte Rd., 
      Duarte, CA 91010, USA. Electronic address: jianchen@coh.org.
LA  - eng
GR  - RM1 HG008935/HG/NHGRI NIH HHS/United States
GR  - R50 CA211404/CA/NCI NIH HHS/United States
GR  - R01 CA182528/CA/NCI NIH HHS/United States
GR  - R01 GM071440/GM/NIGMS NIH HHS/United States
GR  - R01 CA214965/CA/NCI NIH HHS/United States
GR  - R01 NS089815/NS/NINDS NIH HHS/United States
GR  - R01 CA178454/CA/NCI NIH HHS/United States
GR  - R01 CA211614/CA/NCI NIH HHS/United States
GR  - R21 NS100077/NS/NINDS NIH HHS/United States
PT  - Journal Article
DEP - 20171214
PL  - United States
TA  - Cell
JT  - Cell
JID - 0413066
PMC - PMC5766423
MID - NIHMS922030
OTO - NOTNLM
OT  - CEBPA
OT  - FTO
OT  - IDH mutation
OT  - MYC
OT  - N(6)-methyladenosine (m(6)A)
OT  - R-2HG
OT  - S-2HG
OT  - glioma
OT  - leukemia
EDAT- 2017/12/19 06:00
MHDA- 2017/12/19 06:00
CRDT- 2017/12/19 06:00
PMCR- 2019/01/11 00:00
PHST- 2017/04/06 00:00 [received]
PHST- 2017/08/30 00:00 [revised]
PHST- 2017/11/16 00:00 [accepted]
PHST- 2019/01/11 00:00 [pmc-release]
PHST- 2017/12/19 06:00 [pubmed]
PHST- 2017/12/19 06:00 [medline]
PHST- 2017/12/19 06:00 [entrez]
AID - S0092-8674(17)31382-X [pii]
AID - 10.1016/j.cell.2017.11.031 [doi]
PST - ppublish
SO  - Cell. 2018 Jan 11;172(1-2):90-105.e23. doi: 10.1016/j.cell.2017.11.031. Epub 2017
      Dec 14.

PMID- 29123071
OWN - NLM
STAT- In-Process
LR  - 20180103
IS  - 1095-9203 (Electronic)
IS  - 0036-8075 (Linking)
VI  - 358
IP  - 6364
DP  - 2017 Nov 10
TI  - SAMTOR is an S-adenosylmethionine sensor for the mTORC1 pathway.
PG  - 813-818
LID - 10.1126/science.aao3265 [doi]
AB  - mTOR complex 1 (mTORC1) regulates cell growth and metabolism in response to
      multiple environmental cues. Nutrients signal via the Rag guanosine
      triphosphatases (GTPases) to promote the localization of mTORC1 to the lysosomal 
      surface, its site of activation. We identified SAMTOR, a previously
      uncharacterized protein, which inhibits mTORC1 signaling by interacting with
      GATOR1, the GTPase activating protein (GAP) for RagA/B. We found that the methyl 
      donor S-adenosylmethionine (SAM) disrupts the SAMTOR-GATOR1 complex by binding
      directly to SAMTOR with a dissociation constant of approximately 7 muM. In cells,
      methionine starvation reduces SAM levels below this dissociation constant and
      promotes the association of SAMTOR with GATOR1, thereby inhibiting mTORC1
      signaling in a SAMTOR-dependent fashion. Methionine-induced activation of mTORC1 
      requires the SAM binding capacity of SAMTOR. Thus, SAMTOR is a SAM sensor that
      links methionine and one-carbon metabolism to mTORC1 signaling.
CI  - Copyright (c) 2017 The Authors, some rights reserved; exclusive licensee American
      Association for the Advancement of Science. No claim to original U.S. Government 
      Works.
FAU - Gu, Xin
AU  - Gu X
AUID- ORCID: 0000-0002-3393-6927
AD  - Whitehead Institute for Biomedical Research and Department of Biology,
      Massachusetts Institute of Technology, Cambridge, MA 02142, USA.
AD  - Howard Hughes Medical Institute, Department of Biology, Massachusetts Institute
      of Technology, Cambridge, MA 02139, USA.
AD  - Koch Institute for Integrative Cancer Research and Department of Biology,
      Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
AD  - Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
FAU - Orozco, Jose M
AU  - Orozco JM
AUID- ORCID: 0000-0002-4587-0777
AD  - Whitehead Institute for Biomedical Research and Department of Biology,
      Massachusetts Institute of Technology, Cambridge, MA 02142, USA.
AD  - Howard Hughes Medical Institute, Department of Biology, Massachusetts Institute
      of Technology, Cambridge, MA 02139, USA.
AD  - Koch Institute for Integrative Cancer Research and Department of Biology,
      Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
AD  - Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
FAU - Saxton, Robert A
AU  - Saxton RA
AUID- ORCID: 0000-0002-9376-3984
AD  - Whitehead Institute for Biomedical Research and Department of Biology,
      Massachusetts Institute of Technology, Cambridge, MA 02142, USA.
AD  - Howard Hughes Medical Institute, Department of Biology, Massachusetts Institute
      of Technology, Cambridge, MA 02139, USA.
AD  - Koch Institute for Integrative Cancer Research and Department of Biology,
      Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
AD  - Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
FAU - Condon, Kendall J
AU  - Condon KJ
AUID- ORCID: 0000-0002-9515-8892
AD  - Whitehead Institute for Biomedical Research and Department of Biology,
      Massachusetts Institute of Technology, Cambridge, MA 02142, USA.
AD  - Howard Hughes Medical Institute, Department of Biology, Massachusetts Institute
      of Technology, Cambridge, MA 02139, USA.
AD  - Koch Institute for Integrative Cancer Research and Department of Biology,
      Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
AD  - Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
FAU - Liu, Grace Y
AU  - Liu GY
AUID- ORCID: 0000-0001-5463-3055
AD  - Whitehead Institute for Biomedical Research and Department of Biology,
      Massachusetts Institute of Technology, Cambridge, MA 02142, USA.
AD  - Howard Hughes Medical Institute, Department of Biology, Massachusetts Institute
      of Technology, Cambridge, MA 02139, USA.
AD  - Koch Institute for Integrative Cancer Research and Department of Biology,
      Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
AD  - Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
FAU - Krawczyk, Patrycja A
AU  - Krawczyk PA
AUID- ORCID: 0000-0003-0653-1817
AD  - Whitehead Institute for Biomedical Research and Department of Biology,
      Massachusetts Institute of Technology, Cambridge, MA 02142, USA.
AD  - Howard Hughes Medical Institute, Department of Biology, Massachusetts Institute
      of Technology, Cambridge, MA 02139, USA.
AD  - Koch Institute for Integrative Cancer Research and Department of Biology,
      Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
AD  - Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
FAU - Scaria, Sonia M
AU  - Scaria SM
AD  - Whitehead Institute for Biomedical Research and Department of Biology,
      Massachusetts Institute of Technology, Cambridge, MA 02142, USA.
AD  - Howard Hughes Medical Institute, Department of Biology, Massachusetts Institute
      of Technology, Cambridge, MA 02139, USA.
AD  - Koch Institute for Integrative Cancer Research and Department of Biology,
      Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
AD  - Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
FAU - Harper, J Wade
AU  - Harper JW
AUID- ORCID: 0000-0002-6944-7236
AD  - Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA.
FAU - Gygi, Steven P
AU  - Gygi SP
AUID- ORCID: 0000-0001-7626-0034
AD  - Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA.
FAU - Sabatini, David M
AU  - Sabatini DM
AUID- ORCID: 0000-0002-1446-7256
AD  - Whitehead Institute for Biomedical Research and Department of Biology,
      Massachusetts Institute of Technology, Cambridge, MA 02142, USA.
      sabatini@wi.mit.edu.
AD  - Howard Hughes Medical Institute, Department of Biology, Massachusetts Institute
      of Technology, Cambridge, MA 02139, USA.
AD  - Koch Institute for Integrative Cancer Research and Department of Biology,
      Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
AD  - Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
LA  - eng
GR  - R01 CA103866/CA/NCI NIH HHS/United States
GR  - R37 NS083524/NS/NINDS NIH HHS/United States
GR  - T32 GM007753/GM/NIGMS NIH HHS/United States
GR  - F30 CA210373/CA/NCI NIH HHS/United States
GR  - R37 AI047389/AI/NIAID NIH HHS/United States
GR  - U41 HG006673/HG/NHGRI NIH HHS/United States
GR  - R01 AG011085/AG/NIA NIH HHS/United States
GR  - F31 GM121093/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Science
JT  - Science (New York, N.Y.)
JID - 0404511
PMC - PMC5747364
MID - NIHMS925589
EDAT- 2017/11/11 06:00
MHDA- 2017/11/11 06:00
CRDT- 2017/11/11 06:00
PMCR- 2018/11/10 00:00
PHST- 2017/07/09 00:00 [received]
PHST- 2017/09/29 00:00 [accepted]
PHST- 2018/11/10 00:00 [pmc-release]
PHST- 2017/11/11 06:00 [entrez]
PHST- 2017/11/11 06:00 [pubmed]
PHST- 2017/11/11 06:00 [medline]
AID - 358/6364/813 [pii]
AID - 10.1126/science.aao3265 [doi]
PST - ppublish
SO  - Science. 2017 Nov 10;358(6364):813-818. doi: 10.1126/science.aao3265.

PMID- 29083402
OWN - NLM
STAT- MEDLINE
DCOM- 20171215
LR  - 20171219
IS  - 1548-7105 (Electronic)
IS  - 1548-7091 (Linking)
VI  - 14
IP  - 12
DP  - 2017 Dec
TI  - Inducible and multiplex gene regulation using CRISPR-Cpf1-based transcription
      factors.
PG  - 1163-1166
LID - 10.1038/nmeth.4483 [doi]
AB  - Targeted and inducible regulation of mammalian gene expression is a broadly
      important capability. We engineered drug-inducible catalytically inactive Cpf1
      nuclease fused to transcriptional activation domains to tune the expression of
      endogenous genes in human cells. Leveraging the multiplex capability of the Cpf1 
      platform, we demonstrate both synergistic and combinatorial gene expression in
      human cells. Our work should enable the development of multiplex gene
      perturbation library screens for understanding complex cellular phenotypes.
FAU - Tak, Y Esther
AU  - Tak YE
AD  - Molecular Pathology Unit, Center for Cancer Research, and Center for
      Computational and Integrative Biology, Massachusetts General Hospital,
      Charlestown, Massachusetts, USA.
AD  - Department of Pathology, Harvard Medical School, Boston, Massachusetts, USA.
FAU - Kleinstiver, Benjamin P
AU  - Kleinstiver BP
AD  - Molecular Pathology Unit, Center for Cancer Research, and Center for
      Computational and Integrative Biology, Massachusetts General Hospital,
      Charlestown, Massachusetts, USA.
AD  - Department of Pathology, Harvard Medical School, Boston, Massachusetts, USA.
FAU - Nunez, James K
AU  - Nunez JK
AD  - Department of Cellular & Molecular Pharmacology University of California, San
      Francisco, San Francisco, California, USA.
FAU - Hsu, Jonathan Y
AU  - Hsu JY
AD  - Molecular Pathology Unit, Center for Cancer Research, and Center for
      Computational and Integrative Biology, Massachusetts General Hospital,
      Charlestown, Massachusetts, USA.
AD  - Department of Biological Engineering, Massachusetts Institute of Technology,
      Cambridge, Massachusetts, USA.
FAU - Horng, Joy E
AU  - Horng JE
AD  - Molecular Pathology Unit, Center for Cancer Research, and Center for
      Computational and Integrative Biology, Massachusetts General Hospital,
      Charlestown, Massachusetts, USA.
FAU - Gong, Jingyi
AU  - Gong J
AD  - Molecular Pathology Unit, Center for Cancer Research, and Center for
      Computational and Integrative Biology, Massachusetts General Hospital,
      Charlestown, Massachusetts, USA.
FAU - Weissman, Jonathan S
AU  - Weissman JS
AD  - Department of Cellular & Molecular Pharmacology University of California, San
      Francisco, San Francisco, California, USA.
AD  - Howard Hughes Medical Institute, San Francisco, California, USA.
FAU - Joung, J Keith
AU  - Joung JK
AUID- ORCID: http://orcid.org/0000-0001-5630-5645
AD  - Molecular Pathology Unit, Center for Cancer Research, and Center for
      Computational and Integrative Biology, Massachusetts General Hospital,
      Charlestown, Massachusetts, USA.
AD  - Department of Pathology, Harvard Medical School, Boston, Massachusetts, USA.
LA  - eng
PT  - Journal Article
DEP - 20171030
PL  - United States
TA  - Nat Methods
JT  - Nature methods
JID - 101215604
RN  - 0 (BRLF1 protein, Human herpesvirus 4)
RN  - 0 (Bacterial Proteins)
RN  - 0 (Herpes Simplex Virus Protein Vmw65)
RN  - 0 (Immediate-Early Proteins)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 0 (Trans-Activators)
RN  - 0 (Transcription Factor RelA)
RN  - 147336-22-9 (Green Fluorescent Proteins)
RN  - EC 3.1.- (Endonucleases)
SB  - IM
MH  - Bacterial Proteins/*genetics
MH  - CRISPR-Cas Systems/*genetics
MH  - Cell Culture Techniques
MH  - Clustered Regularly Interspaced Short Palindromic Repeats/*genetics
MH  - Endonucleases/*genetics
MH  - Green Fluorescent Proteins/genetics
MH  - HEK293 Cells
MH  - Herpes Simplex Virus Protein Vmw65/genetics
MH  - Humans
MH  - Immediate-Early Proteins/genetics
MH  - Plasmids
MH  - Recombinant Fusion Proteins/genetics
MH  - Trans-Activators/genetics
MH  - Transcription Factor RelA/genetics
MH  - *Transcriptional Activation
MH  - Transfection
EDAT- 2017/10/31 06:00
MHDA- 2017/12/16 06:00
CRDT- 2017/10/31 06:00
PHST- 2017/06/14 00:00 [received]
PHST- 2017/09/24 00:00 [accepted]
PHST- 2017/10/31 06:00 [pubmed]
PHST- 2017/12/16 06:00 [medline]
PHST- 2017/10/31 06:00 [entrez]
AID - nmeth.4483 [pii]
AID - 10.1038/nmeth.4483 [doi]
PST - ppublish
SO  - Nat Methods. 2017 Dec;14(12):1163-1166. doi: 10.1038/nmeth.4483. Epub 2017 Oct
      30.

PMID- 29143823
OWN - NLM
STAT- In-Data-Review
LR  - 20171219
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 551
IP  - 7682
DP  - 2017 Nov 30
TI  - Salt-responsive gut commensal modulates TH17 axis and disease.
PG  - 585-589
LID - 10.1038/nature24628 [doi]
AB  - A Western lifestyle with high salt consumption can lead to hypertension and
      cardiovascular disease. High salt may additionally drive autoimmunity by inducing
      T helper 17 (TH17) cells, which can also contribute to hypertension. Induction of
      TH17 cells depends on gut microbiota; however, the effect of salt on the gut
      microbiome is unknown. Here we show that high salt intake affects the gut
      microbiome in mice, particularly by depleting Lactobacillus murinus.
      Consequently, treatment of mice with L. murinus prevented salt-induced
      aggravation of actively induced experimental autoimmune encephalomyelitis and
      salt-sensitive hypertension by modulating TH17 cells. In line with these
      findings, a moderate high-salt challenge in a pilot study in humans reduced
      intestinal survival of Lactobacillus spp., increased TH17 cells and increased
      blood pressure. Our results connect high salt intake to the gut-immune axis and
      highlight the gut microbiome as a potential therapeutic target to counteract
      salt-sensitive conditions.
FAU - Wilck, Nicola
AU  - Wilck N
AD  - Experimental and Clinical Research Center, a joint cooperation of Max-Delbruck
      Center for Molecular Medicine and Charite-Universitatsmedizin Berlin, 13125
      Berlin, Germany.
AD  - Charite-Universitatsmedizin Berlin, 10117 Berlin, Germany.
AD  - Max-Delbruck Center for Molecular Medicine in the Helmholtz Association, 13125
      Berlin, Germany.
AD  - DZHK (German Centre for Cardiovascular Research), partner site Berlin, Germany.
AD  - Berlin Institute of Health (BIH), Berlin, Germany.
FAU - Matus, Mariana G
AU  - Matus MG
AD  - Center for Microbiome Informatics and Therapeutics, and Department of Biological 
      Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts
      02139, USA.
AD  - Computational and Systems Biology Program, Massachusetts Institute of Technology,
      Cambridge, Massachusetts 02139, USA.
FAU - Kearney, Sean M
AU  - Kearney SM
AD  - Center for Microbiome Informatics and Therapeutics, and Department of Biological 
      Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts
      02139, USA.
FAU - Olesen, Scott W
AU  - Olesen SW
AD  - Center for Microbiome Informatics and Therapeutics, and Department of Biological 
      Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts
      02139, USA.
FAU - Forslund, Kristoffer
AU  - Forslund K
AD  - European Molecular Biology Laboratory, Structural and Computational Biology Unit,
      69117 Heidelberg, Germany.
FAU - Bartolomaeus, Hendrik
AU  - Bartolomaeus H
AD  - Experimental and Clinical Research Center, a joint cooperation of Max-Delbruck
      Center for Molecular Medicine and Charite-Universitatsmedizin Berlin, 13125
      Berlin, Germany.
AD  - Charite-Universitatsmedizin Berlin, 10117 Berlin, Germany.
AD  - Max-Delbruck Center for Molecular Medicine in the Helmholtz Association, 13125
      Berlin, Germany.
AD  - DZHK (German Centre for Cardiovascular Research), partner site Berlin, Germany.
FAU - Haase, Stefanie
AU  - Haase S
AD  - Department of Neurology, Friedrich-Alexander-University Erlangen-Nuremberg, 91054
      Erlangen, Germany.
FAU - Mahler, Anja
AU  - Mahler A
AD  - Experimental and Clinical Research Center, a joint cooperation of Max-Delbruck
      Center for Molecular Medicine and Charite-Universitatsmedizin Berlin, 13125
      Berlin, Germany.
AD  - Berlin Institute of Health (BIH), Berlin, Germany.
FAU - Balogh, Andras
AU  - Balogh A
AD  - Experimental and Clinical Research Center, a joint cooperation of Max-Delbruck
      Center for Molecular Medicine and Charite-Universitatsmedizin Berlin, 13125
      Berlin, Germany.
AD  - Charite-Universitatsmedizin Berlin, 10117 Berlin, Germany.
AD  - Max-Delbruck Center for Molecular Medicine in the Helmholtz Association, 13125
      Berlin, Germany.
AD  - DZHK (German Centre for Cardiovascular Research), partner site Berlin, Germany.
AD  - Berlin Institute of Health (BIH), Berlin, Germany.
FAU - Marko, Lajos
AU  - Marko L
AD  - Experimental and Clinical Research Center, a joint cooperation of Max-Delbruck
      Center for Molecular Medicine and Charite-Universitatsmedizin Berlin, 13125
      Berlin, Germany.
AD  - Charite-Universitatsmedizin Berlin, 10117 Berlin, Germany.
AD  - Max-Delbruck Center for Molecular Medicine in the Helmholtz Association, 13125
      Berlin, Germany.
AD  - DZHK (German Centre for Cardiovascular Research), partner site Berlin, Germany.
AD  - Berlin Institute of Health (BIH), Berlin, Germany.
FAU - Vvedenskaya, Olga
AU  - Vvedenskaya O
AD  - Max-Delbruck Center for Molecular Medicine in the Helmholtz Association, 13125
      Berlin, Germany.
AD  - Integrative Proteomics and Metabolomics Platform, Berlin Institute for Medical
      Systems Biology BIMSB, 13125 Berlin, Germany.
AD  - Berlin School of Integrative Oncology, Charite University Medicine Berlin,
      Berlin, Germany.
FAU - Kleiner, Friedrich H
AU  - Kleiner FH
AD  - Experimental and Clinical Research Center, a joint cooperation of Max-Delbruck
      Center for Molecular Medicine and Charite-Universitatsmedizin Berlin, 13125
      Berlin, Germany.
FAU - Tsvetkov, Dmitry
AU  - Tsvetkov D
AD  - Experimental and Clinical Research Center, a joint cooperation of Max-Delbruck
      Center for Molecular Medicine and Charite-Universitatsmedizin Berlin, 13125
      Berlin, Germany.
AD  - Charite-Universitatsmedizin Berlin, 10117 Berlin, Germany.
FAU - Klug, Lars
AU  - Klug L
AD  - Experimental and Clinical Research Center, a joint cooperation of Max-Delbruck
      Center for Molecular Medicine and Charite-Universitatsmedizin Berlin, 13125
      Berlin, Germany.
AD  - Berlin Institute of Health (BIH), Berlin, Germany.
FAU - Costea, Paul I
AU  - Costea PI
AD  - European Molecular Biology Laboratory, Structural and Computational Biology Unit,
      69117 Heidelberg, Germany.
FAU - Sunagawa, Shinichi
AU  - Sunagawa S
AD  - European Molecular Biology Laboratory, Structural and Computational Biology Unit,
      69117 Heidelberg, Germany.
AD  - Institute of Microbiology, ETH Zurich, 8092 Zurich, Switzerland.
FAU - Maier, Lisa
AU  - Maier L
AD  - European Molecular Biology Laboratory, Genome Biology Unit, 69117 Heidelberg,
      Germany.
FAU - Rakova, Natalia
AU  - Rakova N
AD  - Experimental and Clinical Research Center, a joint cooperation of Max-Delbruck
      Center for Molecular Medicine and Charite-Universitatsmedizin Berlin, 13125
      Berlin, Germany.
AD  - Department of Neurology, Friedrich-Alexander-University Erlangen-Nuremberg, 91054
      Erlangen, Germany.
FAU - Schatz, Valentin
AU  - Schatz V
AD  - Institute of Clinical Microbiology and Hygiene, University Hospital of
      Regensburg, University of Regensburg, 93053 Regensburg, Germany.
FAU - Neubert, Patrick
AU  - Neubert P
AD  - Institute of Clinical Microbiology and Hygiene, University Hospital of
      Regensburg, University of Regensburg, 93053 Regensburg, Germany.
FAU - Fratzer, Christian
AU  - Fratzer C
AD  - Lipidomix GmbH, 13125 Berlin, Germany.
FAU - Krannich, Alexander
AU  - Krannich A
AD  - Berlin Institute of Health (BIH), Berlin, Germany.
FAU - Gollasch, Maik
AU  - Gollasch M
AD  - Experimental and Clinical Research Center, a joint cooperation of Max-Delbruck
      Center for Molecular Medicine and Charite-Universitatsmedizin Berlin, 13125
      Berlin, Germany.
AD  - Charite-Universitatsmedizin Berlin, 10117 Berlin, Germany.
AD  - Max-Delbruck Center for Molecular Medicine in the Helmholtz Association, 13125
      Berlin, Germany.
FAU - Grohme, Diana A
AU  - Grohme DA
AD  - Translational Immunology, Department of Clinical Pathobiochemistry, Medical
      Faculty Carl Gustav Carus, Technical University of Dresden, 01307 Dresden,
      Germany.
FAU - Corte-Real, Beatriz F
AU  - Corte-Real BF
AD  - VIB Laboratory of Translational Immunomodulation, VIB Center for Inflammation
      Research (IRC), Hasselt University, Campus Diepenbeek, 3590 Diepenbeek, Belgium.
FAU - Gerlach, Roman G
AU  - Gerlach RG
AD  - Project Group 5, Robert Koch Institute, 38855 Wernigerode, Germany.
FAU - Basic, Marijana
AU  - Basic M
AD  - Hannover Medical School, Institute for Laboratory Animal Science and Central
      Animal Facility, 30625 Hannover, Germany.
FAU - Typas, Athanasios
AU  - Typas A
AD  - European Molecular Biology Laboratory, Genome Biology Unit, 69117 Heidelberg,
      Germany.
FAU - Wu, Chuan
AU  - Wu C
AD  - Experimental Immunology Branch, National Cancer Institute, US National Institutes
      of Health, Bethesda, Maryland, USA.
FAU - Titze, Jens M
AU  - Titze JM
AD  - Division of Clinical Pharmacology, Vanderbilt University School of Medicine,
      Nashville, Tennessee, USA.
FAU - Jantsch, Jonathan
AU  - Jantsch J
AD  - Institute of Clinical Microbiology and Hygiene, University Hospital of
      Regensburg, University of Regensburg, 93053 Regensburg, Germany.
FAU - Boschmann, Michael
AU  - Boschmann M
AD  - Experimental and Clinical Research Center, a joint cooperation of Max-Delbruck
      Center for Molecular Medicine and Charite-Universitatsmedizin Berlin, 13125
      Berlin, Germany.
AD  - Berlin Institute of Health (BIH), Berlin, Germany.
FAU - Dechend, Ralf
AU  - Dechend R
AD  - Experimental and Clinical Research Center, a joint cooperation of Max-Delbruck
      Center for Molecular Medicine and Charite-Universitatsmedizin Berlin, 13125
      Berlin, Germany.
AD  - Charite-Universitatsmedizin Berlin, 10117 Berlin, Germany.
AD  - Berlin Institute of Health (BIH), Berlin, Germany.
FAU - Kleinewietfeld, Markus
AU  - Kleinewietfeld M
AD  - Translational Immunology, Department of Clinical Pathobiochemistry, Medical
      Faculty Carl Gustav Carus, Technical University of Dresden, 01307 Dresden,
      Germany.
AD  - VIB Laboratory of Translational Immunomodulation, VIB Center for Inflammation
      Research (IRC), Hasselt University, Campus Diepenbeek, 3590 Diepenbeek, Belgium.
AD  - Center for Regenerative Therapies Dresden (CRTD), 01307 Dresden, Germany.
FAU - Kempa, Stefan
AU  - Kempa S
AD  - Max-Delbruck Center for Molecular Medicine in the Helmholtz Association, 13125
      Berlin, Germany.
AD  - Berlin Institute of Health (BIH), Berlin, Germany.
AD  - Integrative Proteomics and Metabolomics Platform, Berlin Institute for Medical
      Systems Biology BIMSB, 13125 Berlin, Germany.
FAU - Bork, Peer
AU  - Bork P
AD  - Max-Delbruck Center for Molecular Medicine in the Helmholtz Association, 13125
      Berlin, Germany.
AD  - European Molecular Biology Laboratory, Structural and Computational Biology Unit,
      69117 Heidelberg, Germany.
AD  - Molecular Medicine Partnership Unit, University of Heidelberg and European
      Molecular Biology Laboratory, 69120 Heidelberg, Germany.
AD  - Department of Bioinformatics, Biocenter, University of Wurzburg, 97074 Wurzburg, 
      Germany.
FAU - Linker, Ralf A
AU  - Linker RA
AD  - Department of Neurology, Friedrich-Alexander-University Erlangen-Nuremberg, 91054
      Erlangen, Germany.
FAU - Alm, Eric J
AU  - Alm EJ
AD  - Center for Microbiome Informatics and Therapeutics, and Department of Biological 
      Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts
      02139, USA.
FAU - Muller, Dominik N
AU  - Muller DN
AD  - Experimental and Clinical Research Center, a joint cooperation of Max-Delbruck
      Center for Molecular Medicine and Charite-Universitatsmedizin Berlin, 13125
      Berlin, Germany.
AD  - Charite-Universitatsmedizin Berlin, 10117 Berlin, Germany.
AD  - Max-Delbruck Center for Molecular Medicine in the Helmholtz Association, 13125
      Berlin, Germany.
AD  - DZHK (German Centre for Cardiovascular Research), partner site Berlin, Germany.
AD  - Berlin Institute of Health (BIH), Berlin, Germany.
LA  - eng
PT  - Journal Article
DEP - 20171115
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
EDAT- 2017/11/17 06:00
MHDA- 2017/11/17 06:00
CRDT- 2017/11/17 06:00
PHST- 2016/07/26 00:00 [received]
PHST- 2017/10/10 00:00 [accepted]
PHST- 2017/11/17 06:00 [pubmed]
PHST- 2017/11/17 06:00 [medline]
PHST- 2017/11/17 06:00 [entrez]
AID - nature24628 [pii]
AID - 10.1038/nature24628 [doi]
PST - ppublish
SO  - Nature. 2017 Nov 30;551(7682):585-589. doi: 10.1038/nature24628. Epub 2017 Nov
      15.

PMID- 29033128
OWN - NLM
STAT- MEDLINE
DCOM- 20171215
LR  - 20171215
IS  - 1097-4172 (Electronic)
IS  - 0092-8674 (Linking)
VI  - 171
IP  - 5
DP  - 2017 Nov 16
TI  - The DNA Inflammasome in Human Myeloid Cells Is Initiated by a STING-Cell Death
      Program Upstream of NLRP3.
PG  - 1110-1124.e18
LID - S0092-8674(17)31133-9 [pii]
LID - 10.1016/j.cell.2017.09.039 [doi]
AB  - Detection of cytosolic DNA constitutes a central event in the context of numerous
      infectious and sterile inflammatory conditions. Recent studies have uncovered a
      bipartite mode of cytosolic DNA recognition, in which the cGAS-STING axis
      triggers antiviral immunity, whereas AIM2 triggers inflammasome activation. Here,
      we show that AIM2 is dispensable for DNA-mediated inflammasome activation in
      human myeloid cells. Instead, detection of cytosolic DNA by the cGAS-STING axis
      induces a cell death program initiating potassium efflux upstream of NLRP3.
      Forward genetics identified regulators of lysosomal trafficking to modulate this 
      cell death program, and subsequent studies revealed that activated STING traffics
      to the lysosome, where it triggers membrane permeabilization and thus lysosomal
      cell death (LCD). Importantly, the cGAS-STING-NLRP3 pathway constitutes the
      default inflammasome response during viral and bacterial infections in human
      myeloid cells. We conclude that targeting the cGAS-STING-LCD-NLRP3 pathway will
      ameliorate pathology in inflammatory conditions that are associated with
      cytosolic DNA sensing.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Gaidt, Moritz M
AU  - Gaidt MM
AD  - Gene Center and Department of Biochemistry, Ludwig-Maximilians-Universitat
      Munchen, 81377 Munich, Germany.
FAU - Ebert, Thomas S
AU  - Ebert TS
AD  - Gene Center and Department of Biochemistry, Ludwig-Maximilians-Universitat
      Munchen, 81377 Munich, Germany.
FAU - Chauhan, Dhruv
AU  - Chauhan D
AD  - Gene Center and Department of Biochemistry, Ludwig-Maximilians-Universitat
      Munchen, 81377 Munich, Germany.
FAU - Ramshorn, Katharina
AU  - Ramshorn K
AD  - Gene Center and Department of Biochemistry, Ludwig-Maximilians-Universitat
      Munchen, 81377 Munich, Germany.
FAU - Pinci, Francesca
AU  - Pinci F
AD  - Gene Center and Department of Biochemistry, Ludwig-Maximilians-Universitat
      Munchen, 81377 Munich, Germany.
FAU - Zuber, Sarah
AU  - Zuber S
AD  - Gene Center and Department of Biochemistry, Ludwig-Maximilians-Universitat
      Munchen, 81377 Munich, Germany.
FAU - O'Duill, Fionan
AU  - O'Duill F
AD  - Gene Center and Department of Biochemistry, Ludwig-Maximilians-Universitat
      Munchen, 81377 Munich, Germany.
FAU - Schmid-Burgk, Jonathan L
AU  - Schmid-Burgk JL
AD  - Gene Center and Department of Biochemistry, Ludwig-Maximilians-Universitat
      Munchen, 81377 Munich, Germany.
FAU - Hoss, Florian
AU  - Hoss F
AD  - Institute of Innate Immunity, University Hospital, University of Bonn, 53127
      Bonn, Germany.
FAU - Buhmann, Raymund
AU  - Buhmann R
AD  - Department of Transfusion Medicine, University Hospital,
      Ludwig-Maximilians-Universitat Munchen, 81377 Munich, Germany.
FAU - Wittmann, Georg
AU  - Wittmann G
AD  - Department of Transfusion Medicine, University Hospital,
      Ludwig-Maximilians-Universitat Munchen, 81377 Munich, Germany.
FAU - Latz, Eicke
AU  - Latz E
AD  - Institute of Innate Immunity, University Hospital, University of Bonn, 53127
      Bonn, Germany; Department of Infectious Diseases and Immunology, University of
      Massachusetts Medical School, Worcester, MA 01655, USA.
FAU - Subklewe, Marion
AU  - Subklewe M
AD  - Laboratory for Translational Cancer Immunology, Gene Center,
      Ludwig-Maximilians-Universitat Munchen, 81377 Munich, Germany; Department of
      Medicine III, University Hospital, Ludwig-Maximilians-Universitat Munchen, 81377 
      Munich, Germany.
FAU - Hornung, Veit
AU  - Hornung V
AD  - Gene Center and Department of Biochemistry, Ludwig-Maximilians-Universitat
      Munchen, 81377 Munich, Germany; Center for Integrated Protein Science (CIPSM),
      Ludwig-Maximilians-Universitat Munchen, 81377 Munich, Germany. Electronic
      address: hornung@genzentrum.lmu.de.
LA  - eng
PT  - Journal Article
DEP - 20171012
PL  - United States
TA  - Cell
JT  - Cell
JID - 0413066
RN  - 0 (Inflammasomes)
RN  - 0 (MPYS protein, human)
RN  - 0 (Membrane Proteins)
RN  - 0 (NLR Family, Pyrin Domain-Containing 3 Protein)
RN  - 0 (NLRP3 protein, human)
RN  - 9007-49-2 (DNA)
SB  - IM
MH  - *Cell Death
MH  - DNA/metabolism
MH  - Humans
MH  - Inflammasomes/*metabolism
MH  - Membrane Proteins/metabolism
MH  - Monocytes/*cytology/metabolism
MH  - NLR Family, Pyrin Domain-Containing 3 Protein/*metabolism
MH  - Signal Transduction
OTO - NOTNLM
OT  - AIM2
OT  - Caspase-1
OT  - DNA
OT  - IL-1beta
OT  - NLRP3
OT  - STING
OT  - cGAS
OT  - inflammasome
OT  - lysosomal cell death
EDAT- 2017/10/17 06:00
MHDA- 2017/12/16 06:00
CRDT- 2017/10/17 06:00
PHST- 2017/05/18 00:00 [received]
PHST- 2017/08/11 00:00 [revised]
PHST- 2017/09/20 00:00 [accepted]
PHST- 2017/10/17 06:00 [pubmed]
PHST- 2017/12/16 06:00 [medline]
PHST- 2017/10/17 06:00 [entrez]
AID - S0092-8674(17)31133-9 [pii]
AID - 10.1016/j.cell.2017.09.039 [doi]
PST - ppublish
SO  - Cell. 2017 Nov 16;171(5):1110-1124.e18. doi: 10.1016/j.cell.2017.09.039. Epub
      2017 Oct 12.

PMID- 29168843
OWN - NLM
STAT- In-Data-Review
LR  - 20171211
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 551
IP  - 7681
DP  - 2017 Nov 23
TI  - How T cells spot tumour cells.
PG  - 444-446
LID - 10.1038/d41586-017-07267-9 [doi]
FAU - Sarkizova, Siranush
AU  - Sarkizova S
AD  - Siranush Sarkizova is at the Center for Cancer Research, Massachusetts General
      Hospital, Boston, Massachusetts 02114, USA; the Broad Institute of MIT and
      Harvard, Cambridge, Massachusetts; and the Department of Biomedical Informatics, 
      Harvard Medical School, Boston.
FAU - Hacohen, Nir
AU  - Hacohen N
AD  - Nir Hacohen is at the Center for Cancer Research, Massachusetts General Hospital,
      Boston, Massachusetts 02114, USA, and at the Broad Institute of MIT and Harvard, 
      Cambridge, Massachusetts.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
EDAT- 2017/11/24 06:00
MHDA- 2017/11/24 06:00
CRDT- 2017/11/24 06:00
PHST- 2017/11/24 06:00 [entrez]
PHST- 2017/11/24 06:00 [pubmed]
PHST- 2017/11/24 06:00 [medline]
AID - d41586-017-07267-9 [pii]
AID - 10.1038/d41586-017-07267-9 [doi]
PST - ppublish
SO  - Nature. 2017 Nov 23;551(7681):444-446. doi: 10.1038/d41586-017-07267-9.

PMID- 29143824
OWN - NLM
STAT- In-Data-Review
LR  - 20171219
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 552
IP  - 7683
DP  - 2017 Dec 7
TI  - PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis.
PG  - 121-125
LID - 10.1038/nature24649 [doi]
AB  - T cell non-Hodgkin lymphomas are a heterogeneous group of highly aggressive
      malignancies with poor clinical outcomes. T cell lymphomas originate from
      peripheral T cells and are frequently characterized by genetic gain-of-function
      variants in T cell receptor (TCR) signalling molecules. Although these oncogenic 
      alterations are thought to drive TCR pathways to induce chronic proliferation and
      cell survival programmes, it remains unclear whether T cells contain tumour
      suppressors that can counteract these events. Here we show that the acute
      enforcement of oncogenic TCR signalling in lymphocytes in a mouse model of human 
      T cell lymphoma drives the strong expansion of these cells in vivo. However, this
      response is short-lived and robustly counteracted by cell-intrinsic mechanisms. A
      subsequent genome-wide in vivo screen using T cell-specific transposon
      mutagenesis identified PDCD1, which encodes the inhibitory receptor programmed
      death-1 (PD-1), as a master gene that suppresses oncogenic T cell signalling.
      Mono- and bi-allelic deletions of PDCD1 are also recurrently observed in human T 
      cell lymphomas with frequencies that can exceed 30%, indicating high clinical
      relevance. Mechanistically, the activity of PD-1 enhances levels of the tumour
      suppressor PTEN and attenuates signalling by the kinases AKT and PKC in
      pre-malignant cells. By contrast, a homo- or heterozygous deletion of PD-1 allows
      unrestricted T cell growth after an oncogenic insult and leads to the rapid
      development of highly aggressive lymphomas in vivo that are readily
      transplantable to recipients. Thus, the inhibitory PD-1 receptor is a potent
      haploinsufficient tumour suppressor in T cell lymphomas that is frequently
      altered in human disease. These findings extend the known physiological functions
      of PD-1 beyond the prevention of immunopathology after antigen-induced T cell
      activation, and have implications for T cell lymphoma therapies and for current
      strategies that target PD-1 in the broader context of immuno-oncology.
FAU - Wartewig, Tim
AU  - Wartewig T
AD  - Institut fur Klinische Chemie und Pathobiochemie, Klinikum rechts der Isar,
      Technische Universitat Munchen, 81675 Munchen, Germany.
AD  - TranslaTUM, Center for Translational Cancer Research, Technische Universitat
      Munchen, 81675 Munchen, Germany.
FAU - Kurgyis, Zsuzsanna
AU  - Kurgyis Z
AD  - Institut fur Klinische Chemie und Pathobiochemie, Klinikum rechts der Isar,
      Technische Universitat Munchen, 81675 Munchen, Germany.
AD  - TranslaTUM, Center for Translational Cancer Research, Technische Universitat
      Munchen, 81675 Munchen, Germany.
FAU - Keppler, Selina
AU  - Keppler S
AD  - Institut fur Klinische Chemie und Pathobiochemie, Klinikum rechts der Isar,
      Technische Universitat Munchen, 81675 Munchen, Germany.
AD  - TranslaTUM, Center for Translational Cancer Research, Technische Universitat
      Munchen, 81675 Munchen, Germany.
FAU - Pechloff, Konstanze
AU  - Pechloff K
AD  - Institut fur Klinische Chemie und Pathobiochemie, Klinikum rechts der Isar,
      Technische Universitat Munchen, 81675 Munchen, Germany.
AD  - TranslaTUM, Center for Translational Cancer Research, Technische Universitat
      Munchen, 81675 Munchen, Germany.
AD  - German Cancer Consortium (DKTK), 69120 Heidelberg, Germany.
FAU - Hameister, Erik
AU  - Hameister E
AD  - Institut fur Klinische Chemie und Pathobiochemie, Klinikum rechts der Isar,
      Technische Universitat Munchen, 81675 Munchen, Germany.
AD  - TranslaTUM, Center for Translational Cancer Research, Technische Universitat
      Munchen, 81675 Munchen, Germany.
FAU - Ollinger, Rupert
AU  - Ollinger R
AD  - TranslaTUM, Center for Translational Cancer Research, Technische Universitat
      Munchen, 81675 Munchen, Germany.
AD  - Department of Medicine II, Klinikum Rechts der Isar, Technische Universitat
      Munchen, 81675 Munchen, Germany.
FAU - Maresch, Roman
AU  - Maresch R
AD  - TranslaTUM, Center for Translational Cancer Research, Technische Universitat
      Munchen, 81675 Munchen, Germany.
AD  - Department of Medicine II, Klinikum Rechts der Isar, Technische Universitat
      Munchen, 81675 Munchen, Germany.
FAU - Buch, Thorsten
AU  - Buch T
AD  - Institute of Laboratory Animal Science, University of Zurich, Zurich,
      Switzerland.
FAU - Steiger, Katja
AU  - Steiger K
AD  - Institute of Pathology, Technische Universitat Munchen, 81675 Munchen, Germany.
FAU - Winter, Christof
AU  - Winter C
AD  - Institut fur Klinische Chemie und Pathobiochemie, Klinikum rechts der Isar,
      Technische Universitat Munchen, 81675 Munchen, Germany.
AD  - TranslaTUM, Center for Translational Cancer Research, Technische Universitat
      Munchen, 81675 Munchen, Germany.
AD  - German Cancer Consortium (DKTK), 69120 Heidelberg, Germany.
FAU - Rad, Roland
AU  - Rad R
AD  - TranslaTUM, Center for Translational Cancer Research, Technische Universitat
      Munchen, 81675 Munchen, Germany.
AD  - German Cancer Consortium (DKTK), 69120 Heidelberg, Germany.
AD  - Department of Medicine II, Klinikum Rechts der Isar, Technische Universitat
      Munchen, 81675 Munchen, Germany.
FAU - Ruland, Jurgen
AU  - Ruland J
AD  - Institut fur Klinische Chemie und Pathobiochemie, Klinikum rechts der Isar,
      Technische Universitat Munchen, 81675 Munchen, Germany.
AD  - TranslaTUM, Center for Translational Cancer Research, Technische Universitat
      Munchen, 81675 Munchen, Germany.
AD  - German Cancer Consortium (DKTK), 69120 Heidelberg, Germany.
AD  - German Center for Infection Research (DZIF), partner site Munich, Germany.
LA  - eng
PT  - Journal Article
DEP - 20171115
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
EIN - Nature. 2017 Nov 29;:. PMID: 29186126
EDAT- 2017/11/17 06:00
MHDA- 2017/11/17 06:00
CRDT- 2017/11/17 06:00
PHST- 2017/02/16 00:00 [received]
PHST- 2017/10/26 00:00 [accepted]
PHST- 2017/11/17 06:00 [pubmed]
PHST- 2017/11/17 06:00 [medline]
PHST- 2017/11/17 06:00 [entrez]
AID - nature24649 [pii]
AID - 10.1038/nature24649 [doi]
PST - ppublish
SO  - Nature. 2017 Dec 7;552(7683):121-125. doi: 10.1038/nature24649. Epub 2017 Nov 15.

PMID- 29191878
OWN - NLM
STAT- In-Process
LR  - 20171204
IS  - 1095-9203 (Electronic)
IS  - 0036-8075 (Linking)
VI  - 358
IP  - 6367
DP  - 2017 Dec 1
TI  - The target landscape of clinical kinase drugs.
LID - eaan4368 [pii]
LID - 10.1126/science.aan4368 [doi]
AB  - Kinase inhibitors are important cancer therapeutics. Polypharmacology is commonly
      observed, requiring thorough target deconvolution to understand drug mechanism of
      action. Using chemical proteomics, we analyzed the target spectrum of 243
      clinically evaluated kinase drugs. The data revealed previously unknown targets
      for established drugs, offered a perspective on the "druggable" kinome,
      highlighted (non)kinase off-targets, and suggested potential therapeutic
      applications. Integration of phosphoproteomic data refined drug-affected
      pathways, identified response markers, and strengthened rationale for combination
      treatments. We exemplify translational value by discovering SIK2 (salt-inducible 
      kinase 2) inhibitors that modulate cytokine production in primary cells, by
      identifying drugs against the lung cancer survival marker MELK (maternal
      embryonic leucine zipper kinase), and by repurposing cabozantinib to treat
      FLT3-ITD-positive acute myeloid leukemia. This resource, available via the
      ProteomicsDB database, should facilitate basic, clinical, and drug discovery
      research and aid clinical decision-making.
CI  - Copyright (c) 2017 The Authors, some rights reserved; exclusive licensee American
      Association for the Advancement of Science. No claim to original U.S. Government 
      Works.
FAU - Klaeger, Susan
AU  - Klaeger S
AUID- ORCID: 0000-0002-0074-5163
AD  - Chair of Proteomics and Bioanalytics, Technical University of Munich (TUM),
      Freising, Germany.
AD  - German Cancer Consortium (DKTK), Heidelberg, Germany.
AD  - German Cancer Research Center (DKFZ), Heidelberg, Germany.
FAU - Heinzlmeir, Stephanie
AU  - Heinzlmeir S
AUID- ORCID: 0000-0002-1066-6565
AD  - Chair of Proteomics and Bioanalytics, Technical University of Munich (TUM),
      Freising, Germany.
AD  - German Cancer Consortium (DKTK), Heidelberg, Germany.
AD  - German Cancer Research Center (DKFZ), Heidelberg, Germany.
FAU - Wilhelm, Mathias
AU  - Wilhelm M
AUID- ORCID: 0000-0002-9224-3258
AD  - Chair of Proteomics and Bioanalytics, Technical University of Munich (TUM),
      Freising, Germany.
FAU - Polzer, Harald
AU  - Polzer H
AD  - German Cancer Consortium (DKTK), Heidelberg, Germany.
AD  - German Cancer Research Center (DKFZ), Heidelberg, Germany.
AD  - Department of Internal Medicine III, University Hospital,
      Ludwig-Maximilians-Universitat (LMU) Munchen, Munich, Germany.
FAU - Vick, Binje
AU  - Vick B
AUID- ORCID: 0000-0003-1956-2778
AD  - German Cancer Consortium (DKTK), Heidelberg, Germany.
AD  - German Cancer Research Center (DKFZ), Heidelberg, Germany.
AD  - Department of Apoptosis in Hematopoietic Stem Cells, Helmholtz Center Munich,
      German Center for Environmental Health (HMGU), Munich, Germany.
FAU - Koenig, Paul-Albert
AU  - Koenig PA
AUID- ORCID: 0000-0001-5995-2557
AD  - Institut fur Klinische Chemie und Pathobiochemie, TUM, Munich, Germany.
FAU - Reinecke, Maria
AU  - Reinecke M
AD  - Chair of Proteomics and Bioanalytics, Technical University of Munich (TUM),
      Freising, Germany.
AD  - German Cancer Consortium (DKTK), Heidelberg, Germany.
AD  - German Cancer Research Center (DKFZ), Heidelberg, Germany.
FAU - Ruprecht, Benjamin
AU  - Ruprecht B
AD  - Chair of Proteomics and Bioanalytics, Technical University of Munich (TUM),
      Freising, Germany.
FAU - Petzoldt, Svenja
AU  - Petzoldt S
AD  - Chair of Proteomics and Bioanalytics, Technical University of Munich (TUM),
      Freising, Germany.
AD  - German Cancer Consortium (DKTK), Heidelberg, Germany.
AD  - German Cancer Research Center (DKFZ), Heidelberg, Germany.
FAU - Meng, Chen
AU  - Meng C
AD  - Chair of Proteomics and Bioanalytics, Technical University of Munich (TUM),
      Freising, Germany.
FAU - Zecha, Jana
AU  - Zecha J
AD  - Chair of Proteomics and Bioanalytics, Technical University of Munich (TUM),
      Freising, Germany.
AD  - German Cancer Consortium (DKTK), Heidelberg, Germany.
AD  - German Cancer Research Center (DKFZ), Heidelberg, Germany.
FAU - Reiter, Katrin
AU  - Reiter K
AUID- ORCID: 0000-0001-5793-7097
AD  - German Cancer Consortium (DKTK), Heidelberg, Germany.
AD  - German Cancer Research Center (DKFZ), Heidelberg, Germany.
AD  - Department of Internal Medicine III, University Hospital,
      Ludwig-Maximilians-Universitat (LMU) Munchen, Munich, Germany.
FAU - Qiao, Huichao
AU  - Qiao H
AD  - Chair of Proteomics and Bioanalytics, Technical University of Munich (TUM),
      Freising, Germany.
FAU - Helm, Dominic
AU  - Helm D
AUID- ORCID: 0000-0001-9321-2069
AD  - Chair of Proteomics and Bioanalytics, Technical University of Munich (TUM),
      Freising, Germany.
FAU - Koch, Heiner
AU  - Koch H
AD  - Chair of Proteomics and Bioanalytics, Technical University of Munich (TUM),
      Freising, Germany.
AD  - German Cancer Consortium (DKTK), Heidelberg, Germany.
AD  - German Cancer Research Center (DKFZ), Heidelberg, Germany.
FAU - Schoof, Melanie
AU  - Schoof M
AD  - Chair of Proteomics and Bioanalytics, Technical University of Munich (TUM),
      Freising, Germany.
FAU - Canevari, Giulia
AU  - Canevari G
AD  - Oncology, Nerviano Medical Sciences Srl, Milan, Italy.
FAU - Casale, Elena
AU  - Casale E
AD  - Oncology, Nerviano Medical Sciences Srl, Milan, Italy.
FAU - Depaolini, Stefania Re
AU  - Depaolini SR
AD  - Oncology, Nerviano Medical Sciences Srl, Milan, Italy.
FAU - Feuchtinger, Annette
AU  - Feuchtinger A
AD  - Research Unit Analytical Pathology, Helmholtz Zentrum Munchen, Neuherberg,
      Germany.
FAU - Wu, Zhixiang
AU  - Wu Z
AUID- ORCID: 0000-0002-3526-7966
AD  - Chair of Proteomics and Bioanalytics, Technical University of Munich (TUM),
      Freising, Germany.
FAU - Schmidt, Tobias
AU  - Schmidt T
AUID- ORCID: 0000-0002-1883-6514
AD  - Chair of Proteomics and Bioanalytics, Technical University of Munich (TUM),
      Freising, Germany.
FAU - Rueckert, Lars
AU  - Rueckert L
AD  - SAP SE, Potsdam, Germany.
FAU - Becker, Wilhelm
AU  - Becker W
AUID- ORCID: 0000-0001-6989-1137
AD  - SAP SE, Potsdam, Germany.
FAU - Huenges, Jan
AU  - Huenges J
AD  - SAP SE, Potsdam, Germany.
FAU - Garz, Anne-Kathrin
AU  - Garz AK
AD  - German Cancer Consortium (DKTK), Heidelberg, Germany.
AD  - German Cancer Research Center (DKFZ), Heidelberg, Germany.
AD  - Department of Medicine III, Klinikum rechts der Isar, TUM, Munich, Germany.
FAU - Gohlke, Bjoern-Oliver
AU  - Gohlke BO
AUID- ORCID: 0000-0003-3094-1031
AD  - German Cancer Consortium (DKTK), Heidelberg, Germany.
AD  - German Cancer Research Center (DKFZ), Heidelberg, Germany.
AD  - Structural Bioinformatics Group, Charite-Universitatsmedizin, Berlin, Germany.
FAU - Zolg, Daniel Paul
AU  - Zolg DP
AD  - Chair of Proteomics and Bioanalytics, Technical University of Munich (TUM),
      Freising, Germany.
FAU - Kayser, Gian
AU  - Kayser G
AUID- ORCID: 0000-0002-0587-9742
AD  - Institute of Surgical Pathology, University Medical Center Freiburg, Faculty of
      Medicine, University of Freiburg, Freiburg, Germany.
FAU - Vooder, Tonu
AU  - Vooder T
AUID- ORCID: 0000-0003-2683-8744
AD  - Center of Thoracic Surgery, Krefeld, Germany.
AD  - Estonian Genome Center, University of Tartu, Tartu, Estonia.
AD  - Tartu University Hospital, Tartu, Estonia.
FAU - Preissner, Robert
AU  - Preissner R
AD  - German Cancer Consortium (DKTK), Heidelberg, Germany.
AD  - German Cancer Research Center (DKFZ), Heidelberg, Germany.
AD  - Structural Bioinformatics Group, Charite-Universitatsmedizin, Berlin, Germany.
FAU - Hahne, Hannes
AU  - Hahne H
AD  - Chair of Proteomics and Bioanalytics, Technical University of Munich (TUM),
      Freising, Germany.
FAU - Tonisson, Neeme
AU  - Tonisson N
AUID- ORCID: 0000-0002-1715-3164
AD  - Estonian Genome Center, University of Tartu, Tartu, Estonia.
AD  - Tartu University Hospital, Tartu, Estonia.
FAU - Kramer, Karl
AU  - Kramer K
AD  - Chair of Proteomics and Bioanalytics, Technical University of Munich (TUM),
      Freising, Germany.
FAU - Gotze, Katharina
AU  - Gotze K
AD  - German Cancer Consortium (DKTK), Heidelberg, Germany.
AD  - German Cancer Research Center (DKFZ), Heidelberg, Germany.
AD  - Department of Medicine III, Klinikum rechts der Isar, TUM, Munich, Germany.
FAU - Bassermann, Florian
AU  - Bassermann F
AUID- ORCID: 0000-0003-4435-2609
AD  - German Cancer Consortium (DKTK), Heidelberg, Germany.
AD  - German Cancer Research Center (DKFZ), Heidelberg, Germany.
AD  - Department of Medicine III, Klinikum rechts der Isar, TUM, Munich, Germany.
FAU - Schlegl, Judith
AU  - Schlegl J
AUID- ORCID: 0000-0002-3640-1901
AD  - SAP SE, Walldorf, Germany.
FAU - Ehrlich, Hans-Christian
AU  - Ehrlich HC
AUID- ORCID: 0000-0001-5866-5433
AD  - SAP SE, Potsdam, Germany.
FAU - Aiche, Stephan
AU  - Aiche S
AUID- ORCID: 0000-0001-9601-8229
AD  - SAP SE, Potsdam, Germany.
FAU - Walch, Axel
AU  - Walch A
AD  - Research Unit Analytical Pathology, Helmholtz Zentrum Munchen, Neuherberg,
      Germany.
FAU - Greif, Philipp A
AU  - Greif PA
AD  - German Cancer Consortium (DKTK), Heidelberg, Germany.
AD  - German Cancer Research Center (DKFZ), Heidelberg, Germany.
AD  - Department of Internal Medicine III, University Hospital,
      Ludwig-Maximilians-Universitat (LMU) Munchen, Munich, Germany.
FAU - Schneider, Sabine
AU  - Schneider S
AUID- ORCID: 0000-0003-1054-8689
AD  - Department of Chemistry, TUM, Garching, Germany.
AD  - Center For Integrated Protein Science Munich (CIPSM), Munich, Germany.
FAU - Felder, Eduard Rudolf
AU  - Felder ER
AUID- ORCID: 0000-0002-1428-4222
AD  - Oncology, Nerviano Medical Sciences Srl, Milan, Italy.
FAU - Ruland, Juergen
AU  - Ruland J
AUID- ORCID: 0000-0002-8381-3597
AD  - German Cancer Consortium (DKTK), Heidelberg, Germany.
AD  - German Cancer Research Center (DKFZ), Heidelberg, Germany.
AD  - Institut fur Klinische Chemie und Pathobiochemie, TUM, Munich, Germany.
FAU - Medard, Guillaume
AU  - Medard G
AUID- ORCID: 0000-0002-4782-4029
AD  - Chair of Proteomics and Bioanalytics, Technical University of Munich (TUM),
      Freising, Germany.
FAU - Jeremias, Irmela
AU  - Jeremias I
AD  - German Cancer Consortium (DKTK), Heidelberg, Germany.
AD  - Department of Apoptosis in Hematopoietic Stem Cells, Helmholtz Center Munich,
      German Center for Environmental Health (HMGU), Munich, Germany.
AD  - Department of Pediatrics, Dr von Hauner Children's Hospital, LMU, Munich,
      Germany.
FAU - Spiekermann, Karsten
AU  - Spiekermann K
AUID- ORCID: 0000-0002-5139-4957
AD  - German Cancer Consortium (DKTK), Heidelberg, Germany.
AD  - German Cancer Research Center (DKFZ), Heidelberg, Germany.
AD  - Department of Internal Medicine III, University Hospital,
      Ludwig-Maximilians-Universitat (LMU) Munchen, Munich, Germany.
FAU - Kuster, Bernhard
AU  - Kuster B
AUID- ORCID: 0000-0002-9094-1677
AD  - Chair of Proteomics and Bioanalytics, Technical University of Munich (TUM),
      Freising, Germany. kuster@tum.de.
AD  - German Cancer Consortium (DKTK), Heidelberg, Germany.
AD  - German Cancer Research Center (DKFZ), Heidelberg, Germany.
AD  - Center For Integrated Protein Science Munich (CIPSM), Munich, Germany.
AD  - Bavarian Biomolecular Mass Spectrometry Center (BayBioMS), TUM, Freising,
      Germany.
LA  - eng
GR  - European Research Council/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Science
JT  - Science (New York, N.Y.)
JID - 0404511
EDAT- 2017/12/02 06:00
MHDA- 2017/12/02 06:00
CRDT- 2017/12/02 06:00
PHST- 2017/04/13 00:00 [received]
PHST- 2017/09/20 00:00 [accepted]
PHST- 2017/12/02 06:00 [entrez]
PHST- 2017/12/02 06:00 [pubmed]
PHST- 2017/12/02 06:00 [medline]
AID - 358/6367/eaan4368 [pii]
AID - 10.1126/science.aan4368 [doi]
PST - ppublish
SO  - Science. 2017 Dec 1;358(6367). pii: 358/6367/eaan4368. doi:
      10.1126/science.aan4368.

PMID- 29231133
OWN - NLM
STAT- Publisher
LR  - 20180111
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
DP  - 2017 Dec 12
TI  - Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
LID - 10.1056/NEJMoa1714678 [doi]
AB  - Background The combination of bortezomib, melphalan, and prednisone is a standard
      treatment for patients with newly diagnosed multiple myeloma who are ineligible
      for autologous stem-cell transplantation. Daratumumab has shown efficacy in
      combination with standard-of-care regimens in patients with relapsed or
      refractory multiple myeloma. Methods In this phase 3 trial, we randomly assigned 
      706 patients with newly diagnosed multiple myeloma who were ineligible for
      stem-cell transplantation to receive nine cycles of bortezomib, melphalan, and
      prednisone either alone (control group) or with daratumumab (daratumumab group)
      until disease progression. The primary end point was progression-free survival.
      Results At a median follow-up of 16.5 months in a prespecified interim analysis, 
      the 18-month progression-free survival rate was 71.6% (95% confidence interval
      [CI], 65.5 to 76.8) in the daratumumab group and 50.2% (95% CI, 43.2 to 56.7) in 
      the control group (hazard ratio for disease progression or death, 0.50; 95% CI,
      0.38 to 0.65; P<0.001). The overall response rate was 90.9% in the daratumumab
      group, as compared with 73.9% in the control group (P<0.001), and the rate of
      complete response or better (including stringent complete response) was 42.6%,
      versus 24.4% (P<0.001). In the daratumumab group, 22.3% of the patients were
      negative for minimal residual disease (at a threshold of 1 tumor cell per 10(5)
      white cells), as compared with 6.2% of those in the control group (P<0.001). The 
      most common adverse events of grade 3 or 4 were hematologic: neutropenia (in
      39.9% of the patients in the daratumumab group and in 38.7% of those in the
      control group), thrombocytopenia (in 34.4% and 37.6%, respectively), and anemia
      (in 15.9% and 19.8%, respectively). The rate of grade 3 or 4 infections was 23.1%
      in the daratumumab group and 14.7% in the control group; the rate of treatment
      discontinuation due to infections was 0.9% and 1.4%, respectively.
      Daratumumab-associated infusion-related reactions occurred in 27.7% of the
      patients. Conclusions Among patients with newly diagnosed multiple myeloma who
      were ineligible for stem-cell transplantation, daratumumab combined with
      bortezomib, melphalan, and prednisone resulted in a lower risk of disease
      progression or death than the same regimen without daratumumab. The
      daratumumab-containing regimen was associated with more grade 3 or 4 infections. 
      (Funded by Janssen Research and Development; ALCYONE ClinicalTrials.gov number,
      NCT02195479 .).
FAU - Mateos, Maria-Victoria
AU  - Mateos MV
AD  - From University Hospital of Salamanca-Instituto de Investigacion Biomedica de
      Salamanca, Salamanca (M.-V.M.), and Clinica Universidad de Navarra-Centro de
      Investigacion Medica Aplicada, Instituto de Investigacion Sanitaria de Navarra,
      Centro de Investigacion Biomedica en Red de Cancer, Pamplona (J.S.-M.) - both in 
      Spain; National and Kapodistrian University of Athens, Athens (M.A.D.); the
      Institute of Hematology, Department of Experimental, Diagnostic, and Specialty
      Medicine, University of Bologna, Bologna (M. Cavo), and Azienda Ospedaliera
      "Santa Maria," Terni (A.M.L.) - both in Italy; Japanese Red Cross Medical Center,
      Department of Hematology, Tokyo (K.S.); University of Chicago Medical Center,
      Chicago (A.J.); Wurzburg University Medical Center, Wurzburg, Germany (S.K.);
      Universite Catholique de Louvain (UCL), Centre Hospitalier Universitaire UCL
      Namur, Yvoir (C.D.), and Janssen Research and Development, Beerse (W.D.) - both
      in Belgium; Champalimaud Center for the Unknown, Lisbon, Portugal (P.L.);
      Semmelweis Egyetem, Budapest, Hungary (Z.N.); Dnepropetrovsk City Clinical
      Hospital #4, Dnepropetrovsk, Ukraine (P.K.); University Hospital Brno, Brno,
      Czech Republic (L.P.); University Hospitals Birmingham NHS Foundation Trust,
      Birmingham (M. Cook), and Leicester Royal Infirmary-Haematology, Leicester (M.G.)
      - both in the United Kingdom; the Department of Cancer Prevention, School of
      Public Health, Silesian Medical University, Katowice, Poland (S.G.); Clinica de
      Tratamento E, Cuiaba, Brazil (A.C.); Andrew Love Cancer Centre, Geelong, VIC,
      Australia (P.C.); Clinic of Professional Pathology, Saratov, Russia (T.S.); the
      Department of Internal Medicine, Seoul National University College of Medicine,
      Seoul, South Korea (S.-S.Y.); LTD "Medinvent" Institute of Health, Tbilisi,
      Georgia (G.I.); Matsuyama Red Cross Hospital, Matsuyama, Japan (T.F.); Janssen
      Research and Development, Spring House, PA (C.C., R.C., W.C., M.Q.); and Janssen 
      Research and Development, Raritan, NJ (J.W., H.N.).
FAU - Dimopoulos, Meletios A
AU  - Dimopoulos MA
AD  - From University Hospital of Salamanca-Instituto de Investigacion Biomedica de
      Salamanca, Salamanca (M.-V.M.), and Clinica Universidad de Navarra-Centro de
      Investigacion Medica Aplicada, Instituto de Investigacion Sanitaria de Navarra,
      Centro de Investigacion Biomedica en Red de Cancer, Pamplona (J.S.-M.) - both in 
      Spain; National and Kapodistrian University of Athens, Athens (M.A.D.); the
      Institute of Hematology, Department of Experimental, Diagnostic, and Specialty
      Medicine, University of Bologna, Bologna (M. Cavo), and Azienda Ospedaliera
      "Santa Maria," Terni (A.M.L.) - both in Italy; Japanese Red Cross Medical Center,
      Department of Hematology, Tokyo (K.S.); University of Chicago Medical Center,
      Chicago (A.J.); Wurzburg University Medical Center, Wurzburg, Germany (S.K.);
      Universite Catholique de Louvain (UCL), Centre Hospitalier Universitaire UCL
      Namur, Yvoir (C.D.), and Janssen Research and Development, Beerse (W.D.) - both
      in Belgium; Champalimaud Center for the Unknown, Lisbon, Portugal (P.L.);
      Semmelweis Egyetem, Budapest, Hungary (Z.N.); Dnepropetrovsk City Clinical
      Hospital #4, Dnepropetrovsk, Ukraine (P.K.); University Hospital Brno, Brno,
      Czech Republic (L.P.); University Hospitals Birmingham NHS Foundation Trust,
      Birmingham (M. Cook), and Leicester Royal Infirmary-Haematology, Leicester (M.G.)
      - both in the United Kingdom; the Department of Cancer Prevention, School of
      Public Health, Silesian Medical University, Katowice, Poland (S.G.); Clinica de
      Tratamento E, Cuiaba, Brazil (A.C.); Andrew Love Cancer Centre, Geelong, VIC,
      Australia (P.C.); Clinic of Professional Pathology, Saratov, Russia (T.S.); the
      Department of Internal Medicine, Seoul National University College of Medicine,
      Seoul, South Korea (S.-S.Y.); LTD "Medinvent" Institute of Health, Tbilisi,
      Georgia (G.I.); Matsuyama Red Cross Hospital, Matsuyama, Japan (T.F.); Janssen
      Research and Development, Spring House, PA (C.C., R.C., W.C., M.Q.); and Janssen 
      Research and Development, Raritan, NJ (J.W., H.N.).
FAU - Cavo, Michele
AU  - Cavo M
AD  - From University Hospital of Salamanca-Instituto de Investigacion Biomedica de
      Salamanca, Salamanca (M.-V.M.), and Clinica Universidad de Navarra-Centro de
      Investigacion Medica Aplicada, Instituto de Investigacion Sanitaria de Navarra,
      Centro de Investigacion Biomedica en Red de Cancer, Pamplona (J.S.-M.) - both in 
      Spain; National and Kapodistrian University of Athens, Athens (M.A.D.); the
      Institute of Hematology, Department of Experimental, Diagnostic, and Specialty
      Medicine, University of Bologna, Bologna (M. Cavo), and Azienda Ospedaliera
      "Santa Maria," Terni (A.M.L.) - both in Italy; Japanese Red Cross Medical Center,
      Department of Hematology, Tokyo (K.S.); University of Chicago Medical Center,
      Chicago (A.J.); Wurzburg University Medical Center, Wurzburg, Germany (S.K.);
      Universite Catholique de Louvain (UCL), Centre Hospitalier Universitaire UCL
      Namur, Yvoir (C.D.), and Janssen Research and Development, Beerse (W.D.) - both
      in Belgium; Champalimaud Center for the Unknown, Lisbon, Portugal (P.L.);
      Semmelweis Egyetem, Budapest, Hungary (Z.N.); Dnepropetrovsk City Clinical
      Hospital #4, Dnepropetrovsk, Ukraine (P.K.); University Hospital Brno, Brno,
      Czech Republic (L.P.); University Hospitals Birmingham NHS Foundation Trust,
      Birmingham (M. Cook), and Leicester Royal Infirmary-Haematology, Leicester (M.G.)
      - both in the United Kingdom; the Department of Cancer Prevention, School of
      Public Health, Silesian Medical University, Katowice, Poland (S.G.); Clinica de
      Tratamento E, Cuiaba, Brazil (A.C.); Andrew Love Cancer Centre, Geelong, VIC,
      Australia (P.C.); Clinic of Professional Pathology, Saratov, Russia (T.S.); the
      Department of Internal Medicine, Seoul National University College of Medicine,
      Seoul, South Korea (S.-S.Y.); LTD "Medinvent" Institute of Health, Tbilisi,
      Georgia (G.I.); Matsuyama Red Cross Hospital, Matsuyama, Japan (T.F.); Janssen
      Research and Development, Spring House, PA (C.C., R.C., W.C., M.Q.); and Janssen 
      Research and Development, Raritan, NJ (J.W., H.N.).
FAU - Suzuki, Kenshi
AU  - Suzuki K
AD  - From University Hospital of Salamanca-Instituto de Investigacion Biomedica de
      Salamanca, Salamanca (M.-V.M.), and Clinica Universidad de Navarra-Centro de
      Investigacion Medica Aplicada, Instituto de Investigacion Sanitaria de Navarra,
      Centro de Investigacion Biomedica en Red de Cancer, Pamplona (J.S.-M.) - both in 
      Spain; National and Kapodistrian University of Athens, Athens (M.A.D.); the
      Institute of Hematology, Department of Experimental, Diagnostic, and Specialty
      Medicine, University of Bologna, Bologna (M. Cavo), and Azienda Ospedaliera
      "Santa Maria," Terni (A.M.L.) - both in Italy; Japanese Red Cross Medical Center,
      Department of Hematology, Tokyo (K.S.); University of Chicago Medical Center,
      Chicago (A.J.); Wurzburg University Medical Center, Wurzburg, Germany (S.K.);
      Universite Catholique de Louvain (UCL), Centre Hospitalier Universitaire UCL
      Namur, Yvoir (C.D.), and Janssen Research and Development, Beerse (W.D.) - both
      in Belgium; Champalimaud Center for the Unknown, Lisbon, Portugal (P.L.);
      Semmelweis Egyetem, Budapest, Hungary (Z.N.); Dnepropetrovsk City Clinical
      Hospital #4, Dnepropetrovsk, Ukraine (P.K.); University Hospital Brno, Brno,
      Czech Republic (L.P.); University Hospitals Birmingham NHS Foundation Trust,
      Birmingham (M. Cook), and Leicester Royal Infirmary-Haematology, Leicester (M.G.)
      - both in the United Kingdom; the Department of Cancer Prevention, School of
      Public Health, Silesian Medical University, Katowice, Poland (S.G.); Clinica de
      Tratamento E, Cuiaba, Brazil (A.C.); Andrew Love Cancer Centre, Geelong, VIC,
      Australia (P.C.); Clinic of Professional Pathology, Saratov, Russia (T.S.); the
      Department of Internal Medicine, Seoul National University College of Medicine,
      Seoul, South Korea (S.-S.Y.); LTD "Medinvent" Institute of Health, Tbilisi,
      Georgia (G.I.); Matsuyama Red Cross Hospital, Matsuyama, Japan (T.F.); Janssen
      Research and Development, Spring House, PA (C.C., R.C., W.C., M.Q.); and Janssen 
      Research and Development, Raritan, NJ (J.W., H.N.).
FAU - Jakubowiak, Andrzej
AU  - Jakubowiak A
AD  - From University Hospital of Salamanca-Instituto de Investigacion Biomedica de
      Salamanca, Salamanca (M.-V.M.), and Clinica Universidad de Navarra-Centro de
      Investigacion Medica Aplicada, Instituto de Investigacion Sanitaria de Navarra,
      Centro de Investigacion Biomedica en Red de Cancer, Pamplona (J.S.-M.) - both in 
      Spain; National and Kapodistrian University of Athens, Athens (M.A.D.); the
      Institute of Hematology, Department of Experimental, Diagnostic, and Specialty
      Medicine, University of Bologna, Bologna (M. Cavo), and Azienda Ospedaliera
      "Santa Maria," Terni (A.M.L.) - both in Italy; Japanese Red Cross Medical Center,
      Department of Hematology, Tokyo (K.S.); University of Chicago Medical Center,
      Chicago (A.J.); Wurzburg University Medical Center, Wurzburg, Germany (S.K.);
      Universite Catholique de Louvain (UCL), Centre Hospitalier Universitaire UCL
      Namur, Yvoir (C.D.), and Janssen Research and Development, Beerse (W.D.) - both
      in Belgium; Champalimaud Center for the Unknown, Lisbon, Portugal (P.L.);
      Semmelweis Egyetem, Budapest, Hungary (Z.N.); Dnepropetrovsk City Clinical
      Hospital #4, Dnepropetrovsk, Ukraine (P.K.); University Hospital Brno, Brno,
      Czech Republic (L.P.); University Hospitals Birmingham NHS Foundation Trust,
      Birmingham (M. Cook), and Leicester Royal Infirmary-Haematology, Leicester (M.G.)
      - both in the United Kingdom; the Department of Cancer Prevention, School of
      Public Health, Silesian Medical University, Katowice, Poland (S.G.); Clinica de
      Tratamento E, Cuiaba, Brazil (A.C.); Andrew Love Cancer Centre, Geelong, VIC,
      Australia (P.C.); Clinic of Professional Pathology, Saratov, Russia (T.S.); the
      Department of Internal Medicine, Seoul National University College of Medicine,
      Seoul, South Korea (S.-S.Y.); LTD "Medinvent" Institute of Health, Tbilisi,
      Georgia (G.I.); Matsuyama Red Cross Hospital, Matsuyama, Japan (T.F.); Janssen
      Research and Development, Spring House, PA (C.C., R.C., W.C., M.Q.); and Janssen 
      Research and Development, Raritan, NJ (J.W., H.N.).
FAU - Knop, Stefan
AU  - Knop S
AD  - From University Hospital of Salamanca-Instituto de Investigacion Biomedica de
      Salamanca, Salamanca (M.-V.M.), and Clinica Universidad de Navarra-Centro de
      Investigacion Medica Aplicada, Instituto de Investigacion Sanitaria de Navarra,
      Centro de Investigacion Biomedica en Red de Cancer, Pamplona (J.S.-M.) - both in 
      Spain; National and Kapodistrian University of Athens, Athens (M.A.D.); the
      Institute of Hematology, Department of Experimental, Diagnostic, and Specialty
      Medicine, University of Bologna, Bologna (M. Cavo), and Azienda Ospedaliera
      "Santa Maria," Terni (A.M.L.) - both in Italy; Japanese Red Cross Medical Center,
      Department of Hematology, Tokyo (K.S.); University of Chicago Medical Center,
      Chicago (A.J.); Wurzburg University Medical Center, Wurzburg, Germany (S.K.);
      Universite Catholique de Louvain (UCL), Centre Hospitalier Universitaire UCL
      Namur, Yvoir (C.D.), and Janssen Research and Development, Beerse (W.D.) - both
      in Belgium; Champalimaud Center for the Unknown, Lisbon, Portugal (P.L.);
      Semmelweis Egyetem, Budapest, Hungary (Z.N.); Dnepropetrovsk City Clinical
      Hospital #4, Dnepropetrovsk, Ukraine (P.K.); University Hospital Brno, Brno,
      Czech Republic (L.P.); University Hospitals Birmingham NHS Foundation Trust,
      Birmingham (M. Cook), and Leicester Royal Infirmary-Haematology, Leicester (M.G.)
      - both in the United Kingdom; the Department of Cancer Prevention, School of
      Public Health, Silesian Medical University, Katowice, Poland (S.G.); Clinica de
      Tratamento E, Cuiaba, Brazil (A.C.); Andrew Love Cancer Centre, Geelong, VIC,
      Australia (P.C.); Clinic of Professional Pathology, Saratov, Russia (T.S.); the
      Department of Internal Medicine, Seoul National University College of Medicine,
      Seoul, South Korea (S.-S.Y.); LTD "Medinvent" Institute of Health, Tbilisi,
      Georgia (G.I.); Matsuyama Red Cross Hospital, Matsuyama, Japan (T.F.); Janssen
      Research and Development, Spring House, PA (C.C., R.C., W.C., M.Q.); and Janssen 
      Research and Development, Raritan, NJ (J.W., H.N.).
FAU - Doyen, Chantal
AU  - Doyen C
AD  - From University Hospital of Salamanca-Instituto de Investigacion Biomedica de
      Salamanca, Salamanca (M.-V.M.), and Clinica Universidad de Navarra-Centro de
      Investigacion Medica Aplicada, Instituto de Investigacion Sanitaria de Navarra,
      Centro de Investigacion Biomedica en Red de Cancer, Pamplona (J.S.-M.) - both in 
      Spain; National and Kapodistrian University of Athens, Athens (M.A.D.); the
      Institute of Hematology, Department of Experimental, Diagnostic, and Specialty
      Medicine, University of Bologna, Bologna (M. Cavo), and Azienda Ospedaliera
      "Santa Maria," Terni (A.M.L.) - both in Italy; Japanese Red Cross Medical Center,
      Department of Hematology, Tokyo (K.S.); University of Chicago Medical Center,
      Chicago (A.J.); Wurzburg University Medical Center, Wurzburg, Germany (S.K.);
      Universite Catholique de Louvain (UCL), Centre Hospitalier Universitaire UCL
      Namur, Yvoir (C.D.), and Janssen Research and Development, Beerse (W.D.) - both
      in Belgium; Champalimaud Center for the Unknown, Lisbon, Portugal (P.L.);
      Semmelweis Egyetem, Budapest, Hungary (Z.N.); Dnepropetrovsk City Clinical
      Hospital #4, Dnepropetrovsk, Ukraine (P.K.); University Hospital Brno, Brno,
      Czech Republic (L.P.); University Hospitals Birmingham NHS Foundation Trust,
      Birmingham (M. Cook), and Leicester Royal Infirmary-Haematology, Leicester (M.G.)
      - both in the United Kingdom; the Department of Cancer Prevention, School of
      Public Health, Silesian Medical University, Katowice, Poland (S.G.); Clinica de
      Tratamento E, Cuiaba, Brazil (A.C.); Andrew Love Cancer Centre, Geelong, VIC,
      Australia (P.C.); Clinic of Professional Pathology, Saratov, Russia (T.S.); the
      Department of Internal Medicine, Seoul National University College of Medicine,
      Seoul, South Korea (S.-S.Y.); LTD "Medinvent" Institute of Health, Tbilisi,
      Georgia (G.I.); Matsuyama Red Cross Hospital, Matsuyama, Japan (T.F.); Janssen
      Research and Development, Spring House, PA (C.C., R.C., W.C., M.Q.); and Janssen 
      Research and Development, Raritan, NJ (J.W., H.N.).
FAU - Lucio, Paulo
AU  - Lucio P
AD  - From University Hospital of Salamanca-Instituto de Investigacion Biomedica de
      Salamanca, Salamanca (M.-V.M.), and Clinica Universidad de Navarra-Centro de
      Investigacion Medica Aplicada, Instituto de Investigacion Sanitaria de Navarra,
      Centro de Investigacion Biomedica en Red de Cancer, Pamplona (J.S.-M.) - both in 
      Spain; National and Kapodistrian University of Athens, Athens (M.A.D.); the
      Institute of Hematology, Department of Experimental, Diagnostic, and Specialty
      Medicine, University of Bologna, Bologna (M. Cavo), and Azienda Ospedaliera
      "Santa Maria," Terni (A.M.L.) - both in Italy; Japanese Red Cross Medical Center,
      Department of Hematology, Tokyo (K.S.); University of Chicago Medical Center,
      Chicago (A.J.); Wurzburg University Medical Center, Wurzburg, Germany (S.K.);
      Universite Catholique de Louvain (UCL), Centre Hospitalier Universitaire UCL
      Namur, Yvoir (C.D.), and Janssen Research and Development, Beerse (W.D.) - both
      in Belgium; Champalimaud Center for the Unknown, Lisbon, Portugal (P.L.);
      Semmelweis Egyetem, Budapest, Hungary (Z.N.); Dnepropetrovsk City Clinical
      Hospital #4, Dnepropetrovsk, Ukraine (P.K.); University Hospital Brno, Brno,
      Czech Republic (L.P.); University Hospitals Birmingham NHS Foundation Trust,
      Birmingham (M. Cook), and Leicester Royal Infirmary-Haematology, Leicester (M.G.)
      - both in the United Kingdom; the Department of Cancer Prevention, School of
      Public Health, Silesian Medical University, Katowice, Poland (S.G.); Clinica de
      Tratamento E, Cuiaba, Brazil (A.C.); Andrew Love Cancer Centre, Geelong, VIC,
      Australia (P.C.); Clinic of Professional Pathology, Saratov, Russia (T.S.); the
      Department of Internal Medicine, Seoul National University College of Medicine,
      Seoul, South Korea (S.-S.Y.); LTD "Medinvent" Institute of Health, Tbilisi,
      Georgia (G.I.); Matsuyama Red Cross Hospital, Matsuyama, Japan (T.F.); Janssen
      Research and Development, Spring House, PA (C.C., R.C., W.C., M.Q.); and Janssen 
      Research and Development, Raritan, NJ (J.W., H.N.).
FAU - Nagy, Zsolt
AU  - Nagy Z
AD  - From University Hospital of Salamanca-Instituto de Investigacion Biomedica de
      Salamanca, Salamanca (M.-V.M.), and Clinica Universidad de Navarra-Centro de
      Investigacion Medica Aplicada, Instituto de Investigacion Sanitaria de Navarra,
      Centro de Investigacion Biomedica en Red de Cancer, Pamplona (J.S.-M.) - both in 
      Spain; National and Kapodistrian University of Athens, Athens (M.A.D.); the
      Institute of Hematology, Department of Experimental, Diagnostic, and Specialty
      Medicine, University of Bologna, Bologna (M. Cavo), and Azienda Ospedaliera
      "Santa Maria," Terni (A.M.L.) - both in Italy; Japanese Red Cross Medical Center,
      Department of Hematology, Tokyo (K.S.); University of Chicago Medical Center,
      Chicago (A.J.); Wurzburg University Medical Center, Wurzburg, Germany (S.K.);
      Universite Catholique de Louvain (UCL), Centre Hospitalier Universitaire UCL
      Namur, Yvoir (C.D.), and Janssen Research and Development, Beerse (W.D.) - both
      in Belgium; Champalimaud Center for the Unknown, Lisbon, Portugal (P.L.);
      Semmelweis Egyetem, Budapest, Hungary (Z.N.); Dnepropetrovsk City Clinical
      Hospital #4, Dnepropetrovsk, Ukraine (P.K.); University Hospital Brno, Brno,
      Czech Republic (L.P.); University Hospitals Birmingham NHS Foundation Trust,
      Birmingham (M. Cook), and Leicester Royal Infirmary-Haematology, Leicester (M.G.)
      - both in the United Kingdom; the Department of Cancer Prevention, School of
      Public Health, Silesian Medical University, Katowice, Poland (S.G.); Clinica de
      Tratamento E, Cuiaba, Brazil (A.C.); Andrew Love Cancer Centre, Geelong, VIC,
      Australia (P.C.); Clinic of Professional Pathology, Saratov, Russia (T.S.); the
      Department of Internal Medicine, Seoul National University College of Medicine,
      Seoul, South Korea (S.-S.Y.); LTD "Medinvent" Institute of Health, Tbilisi,
      Georgia (G.I.); Matsuyama Red Cross Hospital, Matsuyama, Japan (T.F.); Janssen
      Research and Development, Spring House, PA (C.C., R.C., W.C., M.Q.); and Janssen 
      Research and Development, Raritan, NJ (J.W., H.N.).
FAU - Kaplan, Polina
AU  - Kaplan P
AD  - From University Hospital of Salamanca-Instituto de Investigacion Biomedica de
      Salamanca, Salamanca (M.-V.M.), and Clinica Universidad de Navarra-Centro de
      Investigacion Medica Aplicada, Instituto de Investigacion Sanitaria de Navarra,
      Centro de Investigacion Biomedica en Red de Cancer, Pamplona (J.S.-M.) - both in 
      Spain; National and Kapodistrian University of Athens, Athens (M.A.D.); the
      Institute of Hematology, Department of Experimental, Diagnostic, and Specialty
      Medicine, University of Bologna, Bologna (M. Cavo), and Azienda Ospedaliera
      "Santa Maria," Terni (A.M.L.) - both in Italy; Japanese Red Cross Medical Center,
      Department of Hematology, Tokyo (K.S.); University of Chicago Medical Center,
      Chicago (A.J.); Wurzburg University Medical Center, Wurzburg, Germany (S.K.);
      Universite Catholique de Louvain (UCL), Centre Hospitalier Universitaire UCL
      Namur, Yvoir (C.D.), and Janssen Research and Development, Beerse (W.D.) - both
      in Belgium; Champalimaud Center for the Unknown, Lisbon, Portugal (P.L.);
      Semmelweis Egyetem, Budapest, Hungary (Z.N.); Dnepropetrovsk City Clinical
      Hospital #4, Dnepropetrovsk, Ukraine (P.K.); University Hospital Brno, Brno,
      Czech Republic (L.P.); University Hospitals Birmingham NHS Foundation Trust,
      Birmingham (M. Cook), and Leicester Royal Infirmary-Haematology, Leicester (M.G.)
      - both in the United Kingdom; the Department of Cancer Prevention, School of
      Public Health, Silesian Medical University, Katowice, Poland (S.G.); Clinica de
      Tratamento E, Cuiaba, Brazil (A.C.); Andrew Love Cancer Centre, Geelong, VIC,
      Australia (P.C.); Clinic of Professional Pathology, Saratov, Russia (T.S.); the
      Department of Internal Medicine, Seoul National University College of Medicine,
      Seoul, South Korea (S.-S.Y.); LTD "Medinvent" Institute of Health, Tbilisi,
      Georgia (G.I.); Matsuyama Red Cross Hospital, Matsuyama, Japan (T.F.); Janssen
      Research and Development, Spring House, PA (C.C., R.C., W.C., M.Q.); and Janssen 
      Research and Development, Raritan, NJ (J.W., H.N.).
FAU - Pour, Ludek
AU  - Pour L
AD  - From University Hospital of Salamanca-Instituto de Investigacion Biomedica de
      Salamanca, Salamanca (M.-V.M.), and Clinica Universidad de Navarra-Centro de
      Investigacion Medica Aplicada, Instituto de Investigacion Sanitaria de Navarra,
      Centro de Investigacion Biomedica en Red de Cancer, Pamplona (J.S.-M.) - both in 
      Spain; National and Kapodistrian University of Athens, Athens (M.A.D.); the
      Institute of Hematology, Department of Experimental, Diagnostic, and Specialty
      Medicine, University of Bologna, Bologna (M. Cavo), and Azienda Ospedaliera
      "Santa Maria," Terni (A.M.L.) - both in Italy; Japanese Red Cross Medical Center,
      Department of Hematology, Tokyo (K.S.); University of Chicago Medical Center,
      Chicago (A.J.); Wurzburg University Medical Center, Wurzburg, Germany (S.K.);
      Universite Catholique de Louvain (UCL), Centre Hospitalier Universitaire UCL
      Namur, Yvoir (C.D.), and Janssen Research and Development, Beerse (W.D.) - both
      in Belgium; Champalimaud Center for the Unknown, Lisbon, Portugal (P.L.);
      Semmelweis Egyetem, Budapest, Hungary (Z.N.); Dnepropetrovsk City Clinical
      Hospital #4, Dnepropetrovsk, Ukraine (P.K.); University Hospital Brno, Brno,
      Czech Republic (L.P.); University Hospitals Birmingham NHS Foundation Trust,
      Birmingham (M. Cook), and Leicester Royal Infirmary-Haematology, Leicester (M.G.)
      - both in the United Kingdom; the Department of Cancer Prevention, School of
      Public Health, Silesian Medical University, Katowice, Poland (S.G.); Clinica de
      Tratamento E, Cuiaba, Brazil (A.C.); Andrew Love Cancer Centre, Geelong, VIC,
      Australia (P.C.); Clinic of Professional Pathology, Saratov, Russia (T.S.); the
      Department of Internal Medicine, Seoul National University College of Medicine,
      Seoul, South Korea (S.-S.Y.); LTD "Medinvent" Institute of Health, Tbilisi,
      Georgia (G.I.); Matsuyama Red Cross Hospital, Matsuyama, Japan (T.F.); Janssen
      Research and Development, Spring House, PA (C.C., R.C., W.C., M.Q.); and Janssen 
      Research and Development, Raritan, NJ (J.W., H.N.).
FAU - Cook, Mark
AU  - Cook M
AD  - From University Hospital of Salamanca-Instituto de Investigacion Biomedica de
      Salamanca, Salamanca (M.-V.M.), and Clinica Universidad de Navarra-Centro de
      Investigacion Medica Aplicada, Instituto de Investigacion Sanitaria de Navarra,
      Centro de Investigacion Biomedica en Red de Cancer, Pamplona (J.S.-M.) - both in 
      Spain; National and Kapodistrian University of Athens, Athens (M.A.D.); the
      Institute of Hematology, Department of Experimental, Diagnostic, and Specialty
      Medicine, University of Bologna, Bologna (M. Cavo), and Azienda Ospedaliera
      "Santa Maria," Terni (A.M.L.) - both in Italy; Japanese Red Cross Medical Center,
      Department of Hematology, Tokyo (K.S.); University of Chicago Medical Center,
      Chicago (A.J.); Wurzburg University Medical Center, Wurzburg, Germany (S.K.);
      Universite Catholique de Louvain (UCL), Centre Hospitalier Universitaire UCL
      Namur, Yvoir (C.D.), and Janssen Research and Development, Beerse (W.D.) - both
      in Belgium; Champalimaud Center for the Unknown, Lisbon, Portugal (P.L.);
      Semmelweis Egyetem, Budapest, Hungary (Z.N.); Dnepropetrovsk City Clinical
      Hospital #4, Dnepropetrovsk, Ukraine (P.K.); University Hospital Brno, Brno,
      Czech Republic (L.P.); University Hospitals Birmingham NHS Foundation Trust,
      Birmingham (M. Cook), and Leicester Royal Infirmary-Haematology, Leicester (M.G.)
      - both in the United Kingdom; the Department of Cancer Prevention, School of
      Public Health, Silesian Medical University, Katowice, Poland (S.G.); Clinica de
      Tratamento E, Cuiaba, Brazil (A.C.); Andrew Love Cancer Centre, Geelong, VIC,
      Australia (P.C.); Clinic of Professional Pathology, Saratov, Russia (T.S.); the
      Department of Internal Medicine, Seoul National University College of Medicine,
      Seoul, South Korea (S.-S.Y.); LTD "Medinvent" Institute of Health, Tbilisi,
      Georgia (G.I.); Matsuyama Red Cross Hospital, Matsuyama, Japan (T.F.); Janssen
      Research and Development, Spring House, PA (C.C., R.C., W.C., M.Q.); and Janssen 
      Research and Development, Raritan, NJ (J.W., H.N.).
FAU - Grosicki, Sebastian
AU  - Grosicki S
AD  - From University Hospital of Salamanca-Instituto de Investigacion Biomedica de
      Salamanca, Salamanca (M.-V.M.), and Clinica Universidad de Navarra-Centro de
      Investigacion Medica Aplicada, Instituto de Investigacion Sanitaria de Navarra,
      Centro de Investigacion Biomedica en Red de Cancer, Pamplona (J.S.-M.) - both in 
      Spain; National and Kapodistrian University of Athens, Athens (M.A.D.); the
      Institute of Hematology, Department of Experimental, Diagnostic, and Specialty
      Medicine, University of Bologna, Bologna (M. Cavo), and Azienda Ospedaliera
      "Santa Maria," Terni (A.M.L.) - both in Italy; Japanese Red Cross Medical Center,
      Department of Hematology, Tokyo (K.S.); University of Chicago Medical Center,
      Chicago (A.J.); Wurzburg University Medical Center, Wurzburg, Germany (S.K.);
      Universite Catholique de Louvain (UCL), Centre Hospitalier Universitaire UCL
      Namur, Yvoir (C.D.), and Janssen Research and Development, Beerse (W.D.) - both
      in Belgium; Champalimaud Center for the Unknown, Lisbon, Portugal (P.L.);
      Semmelweis Egyetem, Budapest, Hungary (Z.N.); Dnepropetrovsk City Clinical
      Hospital #4, Dnepropetrovsk, Ukraine (P.K.); University Hospital Brno, Brno,
      Czech Republic (L.P.); University Hospitals Birmingham NHS Foundation Trust,
      Birmingham (M. Cook), and Leicester Royal Infirmary-Haematology, Leicester (M.G.)
      - both in the United Kingdom; the Department of Cancer Prevention, School of
      Public Health, Silesian Medical University, Katowice, Poland (S.G.); Clinica de
      Tratamento E, Cuiaba, Brazil (A.C.); Andrew Love Cancer Centre, Geelong, VIC,
      Australia (P.C.); Clinic of Professional Pathology, Saratov, Russia (T.S.); the
      Department of Internal Medicine, Seoul National University College of Medicine,
      Seoul, South Korea (S.-S.Y.); LTD "Medinvent" Institute of Health, Tbilisi,
      Georgia (G.I.); Matsuyama Red Cross Hospital, Matsuyama, Japan (T.F.); Janssen
      Research and Development, Spring House, PA (C.C., R.C., W.C., M.Q.); and Janssen 
      Research and Development, Raritan, NJ (J.W., H.N.).
FAU - Crepaldi, Andre
AU  - Crepaldi A
AD  - From University Hospital of Salamanca-Instituto de Investigacion Biomedica de
      Salamanca, Salamanca (M.-V.M.), and Clinica Universidad de Navarra-Centro de
      Investigacion Medica Aplicada, Instituto de Investigacion Sanitaria de Navarra,
      Centro de Investigacion Biomedica en Red de Cancer, Pamplona (J.S.-M.) - both in 
      Spain; National and Kapodistrian University of Athens, Athens (M.A.D.); the
      Institute of Hematology, Department of Experimental, Diagnostic, and Specialty
      Medicine, University of Bologna, Bologna (M. Cavo), and Azienda Ospedaliera
      "Santa Maria," Terni (A.M.L.) - both in Italy; Japanese Red Cross Medical Center,
      Department of Hematology, Tokyo (K.S.); University of Chicago Medical Center,
      Chicago (A.J.); Wurzburg University Medical Center, Wurzburg, Germany (S.K.);
      Universite Catholique de Louvain (UCL), Centre Hospitalier Universitaire UCL
      Namur, Yvoir (C.D.), and Janssen Research and Development, Beerse (W.D.) - both
      in Belgium; Champalimaud Center for the Unknown, Lisbon, Portugal (P.L.);
      Semmelweis Egyetem, Budapest, Hungary (Z.N.); Dnepropetrovsk City Clinical
      Hospital #4, Dnepropetrovsk, Ukraine (P.K.); University Hospital Brno, Brno,
      Czech Republic (L.P.); University Hospitals Birmingham NHS Foundation Trust,
      Birmingham (M. Cook), and Leicester Royal Infirmary-Haematology, Leicester (M.G.)
      - both in the United Kingdom; the Department of Cancer Prevention, School of
      Public Health, Silesian Medical University, Katowice, Poland (S.G.); Clinica de
      Tratamento E, Cuiaba, Brazil (A.C.); Andrew Love Cancer Centre, Geelong, VIC,
      Australia (P.C.); Clinic of Professional Pathology, Saratov, Russia (T.S.); the
      Department of Internal Medicine, Seoul National University College of Medicine,
      Seoul, South Korea (S.-S.Y.); LTD "Medinvent" Institute of Health, Tbilisi,
      Georgia (G.I.); Matsuyama Red Cross Hospital, Matsuyama, Japan (T.F.); Janssen
      Research and Development, Spring House, PA (C.C., R.C., W.C., M.Q.); and Janssen 
      Research and Development, Raritan, NJ (J.W., H.N.).
FAU - Liberati, Anna M
AU  - Liberati AM
AD  - From University Hospital of Salamanca-Instituto de Investigacion Biomedica de
      Salamanca, Salamanca (M.-V.M.), and Clinica Universidad de Navarra-Centro de
      Investigacion Medica Aplicada, Instituto de Investigacion Sanitaria de Navarra,
      Centro de Investigacion Biomedica en Red de Cancer, Pamplona (J.S.-M.) - both in 
      Spain; National and Kapodistrian University of Athens, Athens (M.A.D.); the
      Institute of Hematology, Department of Experimental, Diagnostic, and Specialty
      Medicine, University of Bologna, Bologna (M. Cavo), and Azienda Ospedaliera
      "Santa Maria," Terni (A.M.L.) - both in Italy; Japanese Red Cross Medical Center,
      Department of Hematology, Tokyo (K.S.); University of Chicago Medical Center,
      Chicago (A.J.); Wurzburg University Medical Center, Wurzburg, Germany (S.K.);
      Universite Catholique de Louvain (UCL), Centre Hospitalier Universitaire UCL
      Namur, Yvoir (C.D.), and Janssen Research and Development, Beerse (W.D.) - both
      in Belgium; Champalimaud Center for the Unknown, Lisbon, Portugal (P.L.);
      Semmelweis Egyetem, Budapest, Hungary (Z.N.); Dnepropetrovsk City Clinical
      Hospital #4, Dnepropetrovsk, Ukraine (P.K.); University Hospital Brno, Brno,
      Czech Republic (L.P.); University Hospitals Birmingham NHS Foundation Trust,
      Birmingham (M. Cook), and Leicester Royal Infirmary-Haematology, Leicester (M.G.)
      - both in the United Kingdom; the Department of Cancer Prevention, School of
      Public Health, Silesian Medical University, Katowice, Poland (S.G.); Clinica de
      Tratamento E, Cuiaba, Brazil (A.C.); Andrew Love Cancer Centre, Geelong, VIC,
      Australia (P.C.); Clinic of Professional Pathology, Saratov, Russia (T.S.); the
      Department of Internal Medicine, Seoul National University College of Medicine,
      Seoul, South Korea (S.-S.Y.); LTD "Medinvent" Institute of Health, Tbilisi,
      Georgia (G.I.); Matsuyama Red Cross Hospital, Matsuyama, Japan (T.F.); Janssen
      Research and Development, Spring House, PA (C.C., R.C., W.C., M.Q.); and Janssen 
      Research and Development, Raritan, NJ (J.W., H.N.).
FAU - Campbell, Philip
AU  - Campbell P
AD  - From University Hospital of Salamanca-Instituto de Investigacion Biomedica de
      Salamanca, Salamanca (M.-V.M.), and Clinica Universidad de Navarra-Centro de
      Investigacion Medica Aplicada, Instituto de Investigacion Sanitaria de Navarra,
      Centro de Investigacion Biomedica en Red de Cancer, Pamplona (J.S.-M.) - both in 
      Spain; National and Kapodistrian University of Athens, Athens (M.A.D.); the
      Institute of Hematology, Department of Experimental, Diagnostic, and Specialty
      Medicine, University of Bologna, Bologna (M. Cavo), and Azienda Ospedaliera
      "Santa Maria," Terni (A.M.L.) - both in Italy; Japanese Red Cross Medical Center,
      Department of Hematology, Tokyo (K.S.); University of Chicago Medical Center,
      Chicago (A.J.); Wurzburg University Medical Center, Wurzburg, Germany (S.K.);
      Universite Catholique de Louvain (UCL), Centre Hospitalier Universitaire UCL
      Namur, Yvoir (C.D.), and Janssen Research and Development, Beerse (W.D.) - both
      in Belgium; Champalimaud Center for the Unknown, Lisbon, Portugal (P.L.);
      Semmelweis Egyetem, Budapest, Hungary (Z.N.); Dnepropetrovsk City Clinical
      Hospital #4, Dnepropetrovsk, Ukraine (P.K.); University Hospital Brno, Brno,
      Czech Republic (L.P.); University Hospitals Birmingham NHS Foundation Trust,
      Birmingham (M. Cook), and Leicester Royal Infirmary-Haematology, Leicester (M.G.)
      - both in the United Kingdom; the Department of Cancer Prevention, School of
      Public Health, Silesian Medical University, Katowice, Poland (S.G.); Clinica de
      Tratamento E, Cuiaba, Brazil (A.C.); Andrew Love Cancer Centre, Geelong, VIC,
      Australia (P.C.); Clinic of Professional Pathology, Saratov, Russia (T.S.); the
      Department of Internal Medicine, Seoul National University College of Medicine,
      Seoul, South Korea (S.-S.Y.); LTD "Medinvent" Institute of Health, Tbilisi,
      Georgia (G.I.); Matsuyama Red Cross Hospital, Matsuyama, Japan (T.F.); Janssen
      Research and Development, Spring House, PA (C.C., R.C., W.C., M.Q.); and Janssen 
      Research and Development, Raritan, NJ (J.W., H.N.).
FAU - Shelekhova, Tatiana
AU  - Shelekhova T
AD  - From University Hospital of Salamanca-Instituto de Investigacion Biomedica de
      Salamanca, Salamanca (M.-V.M.), and Clinica Universidad de Navarra-Centro de
      Investigacion Medica Aplicada, Instituto de Investigacion Sanitaria de Navarra,
      Centro de Investigacion Biomedica en Red de Cancer, Pamplona (J.S.-M.) - both in 
      Spain; National and Kapodistrian University of Athens, Athens (M.A.D.); the
      Institute of Hematology, Department of Experimental, Diagnostic, and Specialty
      Medicine, University of Bologna, Bologna (M. Cavo), and Azienda Ospedaliera
      "Santa Maria," Terni (A.M.L.) - both in Italy; Japanese Red Cross Medical Center,
      Department of Hematology, Tokyo (K.S.); University of Chicago Medical Center,
      Chicago (A.J.); Wurzburg University Medical Center, Wurzburg, Germany (S.K.);
      Universite Catholique de Louvain (UCL), Centre Hospitalier Universitaire UCL
      Namur, Yvoir (C.D.), and Janssen Research and Development, Beerse (W.D.) - both
      in Belgium; Champalimaud Center for the Unknown, Lisbon, Portugal (P.L.);
      Semmelweis Egyetem, Budapest, Hungary (Z.N.); Dnepropetrovsk City Clinical
      Hospital #4, Dnepropetrovsk, Ukraine (P.K.); University Hospital Brno, Brno,
      Czech Republic (L.P.); University Hospitals Birmingham NHS Foundation Trust,
      Birmingham (M. Cook), and Leicester Royal Infirmary-Haematology, Leicester (M.G.)
      - both in the United Kingdom; the Department of Cancer Prevention, School of
      Public Health, Silesian Medical University, Katowice, Poland (S.G.); Clinica de
      Tratamento E, Cuiaba, Brazil (A.C.); Andrew Love Cancer Centre, Geelong, VIC,
      Australia (P.C.); Clinic of Professional Pathology, Saratov, Russia (T.S.); the
      Department of Internal Medicine, Seoul National University College of Medicine,
      Seoul, South Korea (S.-S.Y.); LTD "Medinvent" Institute of Health, Tbilisi,
      Georgia (G.I.); Matsuyama Red Cross Hospital, Matsuyama, Japan (T.F.); Janssen
      Research and Development, Spring House, PA (C.C., R.C., W.C., M.Q.); and Janssen 
      Research and Development, Raritan, NJ (J.W., H.N.).
FAU - Yoon, Sung-Soo
AU  - Yoon SS
AD  - From University Hospital of Salamanca-Instituto de Investigacion Biomedica de
      Salamanca, Salamanca (M.-V.M.), and Clinica Universidad de Navarra-Centro de
      Investigacion Medica Aplicada, Instituto de Investigacion Sanitaria de Navarra,
      Centro de Investigacion Biomedica en Red de Cancer, Pamplona (J.S.-M.) - both in 
      Spain; National and Kapodistrian University of Athens, Athens (M.A.D.); the
      Institute of Hematology, Department of Experimental, Diagnostic, and Specialty
      Medicine, University of Bologna, Bologna (M. Cavo), and Azienda Ospedaliera
      "Santa Maria," Terni (A.M.L.) - both in Italy; Japanese Red Cross Medical Center,
      Department of Hematology, Tokyo (K.S.); University of Chicago Medical Center,
      Chicago (A.J.); Wurzburg University Medical Center, Wurzburg, Germany (S.K.);
      Universite Catholique de Louvain (UCL), Centre Hospitalier Universitaire UCL
      Namur, Yvoir (C.D.), and Janssen Research and Development, Beerse (W.D.) - both
      in Belgium; Champalimaud Center for the Unknown, Lisbon, Portugal (P.L.);
      Semmelweis Egyetem, Budapest, Hungary (Z.N.); Dnepropetrovsk City Clinical
      Hospital #4, Dnepropetrovsk, Ukraine (P.K.); University Hospital Brno, Brno,
      Czech Republic (L.P.); University Hospitals Birmingham NHS Foundation Trust,
      Birmingham (M. Cook), and Leicester Royal Infirmary-Haematology, Leicester (M.G.)
      - both in the United Kingdom; the Department of Cancer Prevention, School of
      Public Health, Silesian Medical University, Katowice, Poland (S.G.); Clinica de
      Tratamento E, Cuiaba, Brazil (A.C.); Andrew Love Cancer Centre, Geelong, VIC,
      Australia (P.C.); Clinic of Professional Pathology, Saratov, Russia (T.S.); the
      Department of Internal Medicine, Seoul National University College of Medicine,
      Seoul, South Korea (S.-S.Y.); LTD "Medinvent" Institute of Health, Tbilisi,
      Georgia (G.I.); Matsuyama Red Cross Hospital, Matsuyama, Japan (T.F.); Janssen
      Research and Development, Spring House, PA (C.C., R.C., W.C., M.Q.); and Janssen 
      Research and Development, Raritan, NJ (J.W., H.N.).
FAU - Iosava, Genadi
AU  - Iosava G
AD  - From University Hospital of Salamanca-Instituto de Investigacion Biomedica de
      Salamanca, Salamanca (M.-V.M.), and Clinica Universidad de Navarra-Centro de
      Investigacion Medica Aplicada, Instituto de Investigacion Sanitaria de Navarra,
      Centro de Investigacion Biomedica en Red de Cancer, Pamplona (J.S.-M.) - both in 
      Spain; National and Kapodistrian University of Athens, Athens (M.A.D.); the
      Institute of Hematology, Department of Experimental, Diagnostic, and Specialty
      Medicine, University of Bologna, Bologna (M. Cavo), and Azienda Ospedaliera
      "Santa Maria," Terni (A.M.L.) - both in Italy; Japanese Red Cross Medical Center,
      Department of Hematology, Tokyo (K.S.); University of Chicago Medical Center,
      Chicago (A.J.); Wurzburg University Medical Center, Wurzburg, Germany (S.K.);
      Universite Catholique de Louvain (UCL), Centre Hospitalier Universitaire UCL
      Namur, Yvoir (C.D.), and Janssen Research and Development, Beerse (W.D.) - both
      in Belgium; Champalimaud Center for the Unknown, Lisbon, Portugal (P.L.);
      Semmelweis Egyetem, Budapest, Hungary (Z.N.); Dnepropetrovsk City Clinical
      Hospital #4, Dnepropetrovsk, Ukraine (P.K.); University Hospital Brno, Brno,
      Czech Republic (L.P.); University Hospitals Birmingham NHS Foundation Trust,
      Birmingham (M. Cook), and Leicester Royal Infirmary-Haematology, Leicester (M.G.)
      - both in the United Kingdom; the Department of Cancer Prevention, School of
      Public Health, Silesian Medical University, Katowice, Poland (S.G.); Clinica de
      Tratamento E, Cuiaba, Brazil (A.C.); Andrew Love Cancer Centre, Geelong, VIC,
      Australia (P.C.); Clinic of Professional Pathology, Saratov, Russia (T.S.); the
      Department of Internal Medicine, Seoul National University College of Medicine,
      Seoul, South Korea (S.-S.Y.); LTD "Medinvent" Institute of Health, Tbilisi,
      Georgia (G.I.); Matsuyama Red Cross Hospital, Matsuyama, Japan (T.F.); Janssen
      Research and Development, Spring House, PA (C.C., R.C., W.C., M.Q.); and Janssen 
      Research and Development, Raritan, NJ (J.W., H.N.).
FAU - Fujisaki, Tomoaki
AU  - Fujisaki T
AD  - From University Hospital of Salamanca-Instituto de Investigacion Biomedica de
      Salamanca, Salamanca (M.-V.M.), and Clinica Universidad de Navarra-Centro de
      Investigacion Medica Aplicada, Instituto de Investigacion Sanitaria de Navarra,
      Centro de Investigacion Biomedica en Red de Cancer, Pamplona (J.S.-M.) - both in 
      Spain; National and Kapodistrian University of Athens, Athens (M.A.D.); the
      Institute of Hematology, Department of Experimental, Diagnostic, and Specialty
      Medicine, University of Bologna, Bologna (M. Cavo), and Azienda Ospedaliera
      "Santa Maria," Terni (A.M.L.) - both in Italy; Japanese Red Cross Medical Center,
      Department of Hematology, Tokyo (K.S.); University of Chicago Medical Center,
      Chicago (A.J.); Wurzburg University Medical Center, Wurzburg, Germany (S.K.);
      Universite Catholique de Louvain (UCL), Centre Hospitalier Universitaire UCL
      Namur, Yvoir (C.D.), and Janssen Research and Development, Beerse (W.D.) - both
      in Belgium; Champalimaud Center for the Unknown, Lisbon, Portugal (P.L.);
      Semmelweis Egyetem, Budapest, Hungary (Z.N.); Dnepropetrovsk City Clinical
      Hospital #4, Dnepropetrovsk, Ukraine (P.K.); University Hospital Brno, Brno,
      Czech Republic (L.P.); University Hospitals Birmingham NHS Foundation Trust,
      Birmingham (M. Cook), and Leicester Royal Infirmary-Haematology, Leicester (M.G.)
      - both in the United Kingdom; the Department of Cancer Prevention, School of
      Public Health, Silesian Medical University, Katowice, Poland (S.G.); Clinica de
      Tratamento E, Cuiaba, Brazil (A.C.); Andrew Love Cancer Centre, Geelong, VIC,
      Australia (P.C.); Clinic of Professional Pathology, Saratov, Russia (T.S.); the
      Department of Internal Medicine, Seoul National University College of Medicine,
      Seoul, South Korea (S.-S.Y.); LTD "Medinvent" Institute of Health, Tbilisi,
      Georgia (G.I.); Matsuyama Red Cross Hospital, Matsuyama, Japan (T.F.); Janssen
      Research and Development, Spring House, PA (C.C., R.C., W.C., M.Q.); and Janssen 
      Research and Development, Raritan, NJ (J.W., H.N.).
FAU - Garg, Mamta
AU  - Garg M
AD  - From University Hospital of Salamanca-Instituto de Investigacion Biomedica de
      Salamanca, Salamanca (M.-V.M.), and Clinica Universidad de Navarra-Centro de
      Investigacion Medica Aplicada, Instituto de Investigacion Sanitaria de Navarra,
      Centro de Investigacion Biomedica en Red de Cancer, Pamplona (J.S.-M.) - both in 
      Spain; National and Kapodistrian University of Athens, Athens (M.A.D.); the
      Institute of Hematology, Department of Experimental, Diagnostic, and Specialty
      Medicine, University of Bologna, Bologna (M. Cavo), and Azienda Ospedaliera
      "Santa Maria," Terni (A.M.L.) - both in Italy; Japanese Red Cross Medical Center,
      Department of Hematology, Tokyo (K.S.); University of Chicago Medical Center,
      Chicago (A.J.); Wurzburg University Medical Center, Wurzburg, Germany (S.K.);
      Universite Catholique de Louvain (UCL), Centre Hospitalier Universitaire UCL
      Namur, Yvoir (C.D.), and Janssen Research and Development, Beerse (W.D.) - both
      in Belgium; Champalimaud Center for the Unknown, Lisbon, Portugal (P.L.);
      Semmelweis Egyetem, Budapest, Hungary (Z.N.); Dnepropetrovsk City Clinical
      Hospital #4, Dnepropetrovsk, Ukraine (P.K.); University Hospital Brno, Brno,
      Czech Republic (L.P.); University Hospitals Birmingham NHS Foundation Trust,
      Birmingham (M. Cook), and Leicester Royal Infirmary-Haematology, Leicester (M.G.)
      - both in the United Kingdom; the Department of Cancer Prevention, School of
      Public Health, Silesian Medical University, Katowice, Poland (S.G.); Clinica de
      Tratamento E, Cuiaba, Brazil (A.C.); Andrew Love Cancer Centre, Geelong, VIC,
      Australia (P.C.); Clinic of Professional Pathology, Saratov, Russia (T.S.); the
      Department of Internal Medicine, Seoul National University College of Medicine,
      Seoul, South Korea (S.-S.Y.); LTD "Medinvent" Institute of Health, Tbilisi,
      Georgia (G.I.); Matsuyama Red Cross Hospital, Matsuyama, Japan (T.F.); Janssen
      Research and Development, Spring House, PA (C.C., R.C., W.C., M.Q.); and Janssen 
      Research and Development, Raritan, NJ (J.W., H.N.).
FAU - Chiu, Christopher
AU  - Chiu C
AD  - From University Hospital of Salamanca-Instituto de Investigacion Biomedica de
      Salamanca, Salamanca (M.-V.M.), and Clinica Universidad de Navarra-Centro de
      Investigacion Medica Aplicada, Instituto de Investigacion Sanitaria de Navarra,
      Centro de Investigacion Biomedica en Red de Cancer, Pamplona (J.S.-M.) - both in 
      Spain; National and Kapodistrian University of Athens, Athens (M.A.D.); the
      Institute of Hematology, Department of Experimental, Diagnostic, and Specialty
      Medicine, University of Bologna, Bologna (M. Cavo), and Azienda Ospedaliera
      "Santa Maria," Terni (A.M.L.) - both in Italy; Japanese Red Cross Medical Center,
      Department of Hematology, Tokyo (K.S.); University of Chicago Medical Center,
      Chicago (A.J.); Wurzburg University Medical Center, Wurzburg, Germany (S.K.);
      Universite Catholique de Louvain (UCL), Centre Hospitalier Universitaire UCL
      Namur, Yvoir (C.D.), and Janssen Research and Development, Beerse (W.D.) - both
      in Belgium; Champalimaud Center for the Unknown, Lisbon, Portugal (P.L.);
      Semmelweis Egyetem, Budapest, Hungary (Z.N.); Dnepropetrovsk City Clinical
      Hospital #4, Dnepropetrovsk, Ukraine (P.K.); University Hospital Brno, Brno,
      Czech Republic (L.P.); University Hospitals Birmingham NHS Foundation Trust,
      Birmingham (M. Cook), and Leicester Royal Infirmary-Haematology, Leicester (M.G.)
      - both in the United Kingdom; the Department of Cancer Prevention, School of
      Public Health, Silesian Medical University, Katowice, Poland (S.G.); Clinica de
      Tratamento E, Cuiaba, Brazil (A.C.); Andrew Love Cancer Centre, Geelong, VIC,
      Australia (P.C.); Clinic of Professional Pathology, Saratov, Russia (T.S.); the
      Department of Internal Medicine, Seoul National University College of Medicine,
      Seoul, South Korea (S.-S.Y.); LTD "Medinvent" Institute of Health, Tbilisi,
      Georgia (G.I.); Matsuyama Red Cross Hospital, Matsuyama, Japan (T.F.); Janssen
      Research and Development, Spring House, PA (C.C., R.C., W.C., M.Q.); and Janssen 
      Research and Development, Raritan, NJ (J.W., H.N.).
FAU - Wang, Jianping
AU  - Wang J
AD  - From University Hospital of Salamanca-Instituto de Investigacion Biomedica de
      Salamanca, Salamanca (M.-V.M.), and Clinica Universidad de Navarra-Centro de
      Investigacion Medica Aplicada, Instituto de Investigacion Sanitaria de Navarra,
      Centro de Investigacion Biomedica en Red de Cancer, Pamplona (J.S.-M.) - both in 
      Spain; National and Kapodistrian University of Athens, Athens (M.A.D.); the
      Institute of Hematology, Department of Experimental, Diagnostic, and Specialty
      Medicine, University of Bologna, Bologna (M. Cavo), and Azienda Ospedaliera
      "Santa Maria," Terni (A.M.L.) - both in Italy; Japanese Red Cross Medical Center,
      Department of Hematology, Tokyo (K.S.); University of Chicago Medical Center,
      Chicago (A.J.); Wurzburg University Medical Center, Wurzburg, Germany (S.K.);
      Universite Catholique de Louvain (UCL), Centre Hospitalier Universitaire UCL
      Namur, Yvoir (C.D.), and Janssen Research and Development, Beerse (W.D.) - both
      in Belgium; Champalimaud Center for the Unknown, Lisbon, Portugal (P.L.);
      Semmelweis Egyetem, Budapest, Hungary (Z.N.); Dnepropetrovsk City Clinical
      Hospital #4, Dnepropetrovsk, Ukraine (P.K.); University Hospital Brno, Brno,
      Czech Republic (L.P.); University Hospitals Birmingham NHS Foundation Trust,
      Birmingham (M. Cook), and Leicester Royal Infirmary-Haematology, Leicester (M.G.)
      - both in the United Kingdom; the Department of Cancer Prevention, School of
      Public Health, Silesian Medical University, Katowice, Poland (S.G.); Clinica de
      Tratamento E, Cuiaba, Brazil (A.C.); Andrew Love Cancer Centre, Geelong, VIC,
      Australia (P.C.); Clinic of Professional Pathology, Saratov, Russia (T.S.); the
      Department of Internal Medicine, Seoul National University College of Medicine,
      Seoul, South Korea (S.-S.Y.); LTD "Medinvent" Institute of Health, Tbilisi,
      Georgia (G.I.); Matsuyama Red Cross Hospital, Matsuyama, Japan (T.F.); Janssen
      Research and Development, Spring House, PA (C.C., R.C., W.C., M.Q.); and Janssen 
      Research and Development, Raritan, NJ (J.W., H.N.).
FAU - Carson, Robin
AU  - Carson R
AD  - From University Hospital of Salamanca-Instituto de Investigacion Biomedica de
      Salamanca, Salamanca (M.-V.M.), and Clinica Universidad de Navarra-Centro de
      Investigacion Medica Aplicada, Instituto de Investigacion Sanitaria de Navarra,
      Centro de Investigacion Biomedica en Red de Cancer, Pamplona (J.S.-M.) - both in 
      Spain; National and Kapodistrian University of Athens, Athens (M.A.D.); the
      Institute of Hematology, Department of Experimental, Diagnostic, and Specialty
      Medicine, University of Bologna, Bologna (M. Cavo), and Azienda Ospedaliera
      "Santa Maria," Terni (A.M.L.) - both in Italy; Japanese Red Cross Medical Center,
      Department of Hematology, Tokyo (K.S.); University of Chicago Medical Center,
      Chicago (A.J.); Wurzburg University Medical Center, Wurzburg, Germany (S.K.);
      Universite Catholique de Louvain (UCL), Centre Hospitalier Universitaire UCL
      Namur, Yvoir (C.D.), and Janssen Research and Development, Beerse (W.D.) - both
      in Belgium; Champalimaud Center for the Unknown, Lisbon, Portugal (P.L.);
      Semmelweis Egyetem, Budapest, Hungary (Z.N.); Dnepropetrovsk City Clinical
      Hospital #4, Dnepropetrovsk, Ukraine (P.K.); University Hospital Brno, Brno,
      Czech Republic (L.P.); University Hospitals Birmingham NHS Foundation Trust,
      Birmingham (M. Cook), and Leicester Royal Infirmary-Haematology, Leicester (M.G.)
      - both in the United Kingdom; the Department of Cancer Prevention, School of
      Public Health, Silesian Medical University, Katowice, Poland (S.G.); Clinica de
      Tratamento E, Cuiaba, Brazil (A.C.); Andrew Love Cancer Centre, Geelong, VIC,
      Australia (P.C.); Clinic of Professional Pathology, Saratov, Russia (T.S.); the
      Department of Internal Medicine, Seoul National University College of Medicine,
      Seoul, South Korea (S.-S.Y.); LTD "Medinvent" Institute of Health, Tbilisi,
      Georgia (G.I.); Matsuyama Red Cross Hospital, Matsuyama, Japan (T.F.); Janssen
      Research and Development, Spring House, PA (C.C., R.C., W.C., M.Q.); and Janssen 
      Research and Development, Raritan, NJ (J.W., H.N.).
FAU - Crist, Wendy
AU  - Crist W
AD  - From University Hospital of Salamanca-Instituto de Investigacion Biomedica de
      Salamanca, Salamanca (M.-V.M.), and Clinica Universidad de Navarra-Centro de
      Investigacion Medica Aplicada, Instituto de Investigacion Sanitaria de Navarra,
      Centro de Investigacion Biomedica en Red de Cancer, Pamplona (J.S.-M.) - both in 
      Spain; National and Kapodistrian University of Athens, Athens (M.A.D.); the
      Institute of Hematology, Department of Experimental, Diagnostic, and Specialty
      Medicine, University of Bologna, Bologna (M. Cavo), and Azienda Ospedaliera
      "Santa Maria," Terni (A.M.L.) - both in Italy; Japanese Red Cross Medical Center,
      Department of Hematology, Tokyo (K.S.); University of Chicago Medical Center,
      Chicago (A.J.); Wurzburg University Medical Center, Wurzburg, Germany (S.K.);
      Universite Catholique de Louvain (UCL), Centre Hospitalier Universitaire UCL
      Namur, Yvoir (C.D.), and Janssen Research and Development, Beerse (W.D.) - both
      in Belgium; Champalimaud Center for the Unknown, Lisbon, Portugal (P.L.);
      Semmelweis Egyetem, Budapest, Hungary (Z.N.); Dnepropetrovsk City Clinical
      Hospital #4, Dnepropetrovsk, Ukraine (P.K.); University Hospital Brno, Brno,
      Czech Republic (L.P.); University Hospitals Birmingham NHS Foundation Trust,
      Birmingham (M. Cook), and Leicester Royal Infirmary-Haematology, Leicester (M.G.)
      - both in the United Kingdom; the Department of Cancer Prevention, School of
      Public Health, Silesian Medical University, Katowice, Poland (S.G.); Clinica de
      Tratamento E, Cuiaba, Brazil (A.C.); Andrew Love Cancer Centre, Geelong, VIC,
      Australia (P.C.); Clinic of Professional Pathology, Saratov, Russia (T.S.); the
      Department of Internal Medicine, Seoul National University College of Medicine,
      Seoul, South Korea (S.-S.Y.); LTD "Medinvent" Institute of Health, Tbilisi,
      Georgia (G.I.); Matsuyama Red Cross Hospital, Matsuyama, Japan (T.F.); Janssen
      Research and Development, Spring House, PA (C.C., R.C., W.C., M.Q.); and Janssen 
      Research and Development, Raritan, NJ (J.W., H.N.).
FAU - Deraedt, William
AU  - Deraedt W
AD  - From University Hospital of Salamanca-Instituto de Investigacion Biomedica de
      Salamanca, Salamanca (M.-V.M.), and Clinica Universidad de Navarra-Centro de
      Investigacion Medica Aplicada, Instituto de Investigacion Sanitaria de Navarra,
      Centro de Investigacion Biomedica en Red de Cancer, Pamplona (J.S.-M.) - both in 
      Spain; National and Kapodistrian University of Athens, Athens (M.A.D.); the
      Institute of Hematology, Department of Experimental, Diagnostic, and Specialty
      Medicine, University of Bologna, Bologna (M. Cavo), and Azienda Ospedaliera
      "Santa Maria," Terni (A.M.L.) - both in Italy; Japanese Red Cross Medical Center,
      Department of Hematology, Tokyo (K.S.); University of Chicago Medical Center,
      Chicago (A.J.); Wurzburg University Medical Center, Wurzburg, Germany (S.K.);
      Universite Catholique de Louvain (UCL), Centre Hospitalier Universitaire UCL
      Namur, Yvoir (C.D.), and Janssen Research and Development, Beerse (W.D.) - both
      in Belgium; Champalimaud Center for the Unknown, Lisbon, Portugal (P.L.);
      Semmelweis Egyetem, Budapest, Hungary (Z.N.); Dnepropetrovsk City Clinical
      Hospital #4, Dnepropetrovsk, Ukraine (P.K.); University Hospital Brno, Brno,
      Czech Republic (L.P.); University Hospitals Birmingham NHS Foundation Trust,
      Birmingham (M. Cook), and Leicester Royal Infirmary-Haematology, Leicester (M.G.)
      - both in the United Kingdom; the Department of Cancer Prevention, School of
      Public Health, Silesian Medical University, Katowice, Poland (S.G.); Clinica de
      Tratamento E, Cuiaba, Brazil (A.C.); Andrew Love Cancer Centre, Geelong, VIC,
      Australia (P.C.); Clinic of Professional Pathology, Saratov, Russia (T.S.); the
      Department of Internal Medicine, Seoul National University College of Medicine,
      Seoul, South Korea (S.-S.Y.); LTD "Medinvent" Institute of Health, Tbilisi,
      Georgia (G.I.); Matsuyama Red Cross Hospital, Matsuyama, Japan (T.F.); Janssen
      Research and Development, Spring House, PA (C.C., R.C., W.C., M.Q.); and Janssen 
      Research and Development, Raritan, NJ (J.W., H.N.).
FAU - Nguyen, Huong
AU  - Nguyen H
AD  - From University Hospital of Salamanca-Instituto de Investigacion Biomedica de
      Salamanca, Salamanca (M.-V.M.), and Clinica Universidad de Navarra-Centro de
      Investigacion Medica Aplicada, Instituto de Investigacion Sanitaria de Navarra,
      Centro de Investigacion Biomedica en Red de Cancer, Pamplona (J.S.-M.) - both in 
      Spain; National and Kapodistrian University of Athens, Athens (M.A.D.); the
      Institute of Hematology, Department of Experimental, Diagnostic, and Specialty
      Medicine, University of Bologna, Bologna (M. Cavo), and Azienda Ospedaliera
      "Santa Maria," Terni (A.M.L.) - both in Italy; Japanese Red Cross Medical Center,
      Department of Hematology, Tokyo (K.S.); University of Chicago Medical Center,
      Chicago (A.J.); Wurzburg University Medical Center, Wurzburg, Germany (S.K.);
      Universite Catholique de Louvain (UCL), Centre Hospitalier Universitaire UCL
      Namur, Yvoir (C.D.), and Janssen Research and Development, Beerse (W.D.) - both
      in Belgium; Champalimaud Center for the Unknown, Lisbon, Portugal (P.L.);
      Semmelweis Egyetem, Budapest, Hungary (Z.N.); Dnepropetrovsk City Clinical
      Hospital #4, Dnepropetrovsk, Ukraine (P.K.); University Hospital Brno, Brno,
      Czech Republic (L.P.); University Hospitals Birmingham NHS Foundation Trust,
      Birmingham (M. Cook), and Leicester Royal Infirmary-Haematology, Leicester (M.G.)
      - both in the United Kingdom; the Department of Cancer Prevention, School of
      Public Health, Silesian Medical University, Katowice, Poland (S.G.); Clinica de
      Tratamento E, Cuiaba, Brazil (A.C.); Andrew Love Cancer Centre, Geelong, VIC,
      Australia (P.C.); Clinic of Professional Pathology, Saratov, Russia (T.S.); the
      Department of Internal Medicine, Seoul National University College of Medicine,
      Seoul, South Korea (S.-S.Y.); LTD "Medinvent" Institute of Health, Tbilisi,
      Georgia (G.I.); Matsuyama Red Cross Hospital, Matsuyama, Japan (T.F.); Janssen
      Research and Development, Spring House, PA (C.C., R.C., W.C., M.Q.); and Janssen 
      Research and Development, Raritan, NJ (J.W., H.N.).
FAU - Qi, Ming
AU  - Qi M
AD  - From University Hospital of Salamanca-Instituto de Investigacion Biomedica de
      Salamanca, Salamanca (M.-V.M.), and Clinica Universidad de Navarra-Centro de
      Investigacion Medica Aplicada, Instituto de Investigacion Sanitaria de Navarra,
      Centro de Investigacion Biomedica en Red de Cancer, Pamplona (J.S.-M.) - both in 
      Spain; National and Kapodistrian University of Athens, Athens (M.A.D.); the
      Institute of Hematology, Department of Experimental, Diagnostic, and Specialty
      Medicine, University of Bologna, Bologna (M. Cavo), and Azienda Ospedaliera
      "Santa Maria," Terni (A.M.L.) - both in Italy; Japanese Red Cross Medical Center,
      Department of Hematology, Tokyo (K.S.); University of Chicago Medical Center,
      Chicago (A.J.); Wurzburg University Medical Center, Wurzburg, Germany (S.K.);
      Universite Catholique de Louvain (UCL), Centre Hospitalier Universitaire UCL
      Namur, Yvoir (C.D.), and Janssen Research and Development, Beerse (W.D.) - both
      in Belgium; Champalimaud Center for the Unknown, Lisbon, Portugal (P.L.);
      Semmelweis Egyetem, Budapest, Hungary (Z.N.); Dnepropetrovsk City Clinical
      Hospital #4, Dnepropetrovsk, Ukraine (P.K.); University Hospital Brno, Brno,
      Czech Republic (L.P.); University Hospitals Birmingham NHS Foundation Trust,
      Birmingham (M. Cook), and Leicester Royal Infirmary-Haematology, Leicester (M.G.)
      - both in the United Kingdom; the Department of Cancer Prevention, School of
      Public Health, Silesian Medical University, Katowice, Poland (S.G.); Clinica de
      Tratamento E, Cuiaba, Brazil (A.C.); Andrew Love Cancer Centre, Geelong, VIC,
      Australia (P.C.); Clinic of Professional Pathology, Saratov, Russia (T.S.); the
      Department of Internal Medicine, Seoul National University College of Medicine,
      Seoul, South Korea (S.-S.Y.); LTD "Medinvent" Institute of Health, Tbilisi,
      Georgia (G.I.); Matsuyama Red Cross Hospital, Matsuyama, Japan (T.F.); Janssen
      Research and Development, Spring House, PA (C.C., R.C., W.C., M.Q.); and Janssen 
      Research and Development, Raritan, NJ (J.W., H.N.).
FAU - San-Miguel, Jesus
AU  - San-Miguel J
AD  - From University Hospital of Salamanca-Instituto de Investigacion Biomedica de
      Salamanca, Salamanca (M.-V.M.), and Clinica Universidad de Navarra-Centro de
      Investigacion Medica Aplicada, Instituto de Investigacion Sanitaria de Navarra,
      Centro de Investigacion Biomedica en Red de Cancer, Pamplona (J.S.-M.) - both in 
      Spain; National and Kapodistrian University of Athens, Athens (M.A.D.); the
      Institute of Hematology, Department of Experimental, Diagnostic, and Specialty
      Medicine, University of Bologna, Bologna (M. Cavo), and Azienda Ospedaliera
      "Santa Maria," Terni (A.M.L.) - both in Italy; Japanese Red Cross Medical Center,
      Department of Hematology, Tokyo (K.S.); University of Chicago Medical Center,
      Chicago (A.J.); Wurzburg University Medical Center, Wurzburg, Germany (S.K.);
      Universite Catholique de Louvain (UCL), Centre Hospitalier Universitaire UCL
      Namur, Yvoir (C.D.), and Janssen Research and Development, Beerse (W.D.) - both
      in Belgium; Champalimaud Center for the Unknown, Lisbon, Portugal (P.L.);
      Semmelweis Egyetem, Budapest, Hungary (Z.N.); Dnepropetrovsk City Clinical
      Hospital #4, Dnepropetrovsk, Ukraine (P.K.); University Hospital Brno, Brno,
      Czech Republic (L.P.); University Hospitals Birmingham NHS Foundation Trust,
      Birmingham (M. Cook), and Leicester Royal Infirmary-Haematology, Leicester (M.G.)
      - both in the United Kingdom; the Department of Cancer Prevention, School of
      Public Health, Silesian Medical University, Katowice, Poland (S.G.); Clinica de
      Tratamento E, Cuiaba, Brazil (A.C.); Andrew Love Cancer Centre, Geelong, VIC,
      Australia (P.C.); Clinic of Professional Pathology, Saratov, Russia (T.S.); the
      Department of Internal Medicine, Seoul National University College of Medicine,
      Seoul, South Korea (S.-S.Y.); LTD "Medinvent" Institute of Health, Tbilisi,
      Georgia (G.I.); Matsuyama Red Cross Hospital, Matsuyama, Japan (T.F.); Janssen
      Research and Development, Spring House, PA (C.C., R.C., W.C., M.Q.); and Janssen 
      Research and Development, Raritan, NJ (J.W., H.N.).
CN  - ALCYONE Trial Investigators
LA  - eng
PT  - Journal Article
DEP - 20171212
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
EDAT- 2017/12/13 06:00
MHDA- 2017/12/13 06:00
CRDT- 2017/12/13 06:00
PHST- 2017/12/13 06:00 [pubmed]
PHST- 2017/12/13 06:00 [medline]
PHST- 2017/12/13 06:00 [entrez]
AID - 10.1056/NEJMoa1714678 [doi]
PST - aheadofprint
SO  - N Engl J Med. 2017 Dec 12. doi: 10.1056/NEJMoa1714678.

PMID- 29151534
OWN - NLM
STAT- Publisher
LR  - 20171120
IS  - 1349-7235 (Electronic)
IS  - 0918-2918 (Linking)
DP  - 2017 Nov 20
TI  - A Case of Colobronchial Fistula Causing Foul-smelling Sputum with a Fecal Odor.
LID - 10.2169/internalmedicine.9489-17 [doi]
FAU - Kosugi, Kazuhiro
AU  - Kosugi K
AD  - Department of Palliative Care, Kawasaki Municipal Ida Hospital, Japan.
FAU - Nishi, Tomohiro
AU  - Nishi T
AD  - Department of Medical Oncology, Kawasaki Municipal Ida Hospital, Japan.
FAU - Iijima, Tatsuyuki
AU  - Iijima T
AD  - Department of Internal Medicine, Kawasaki Municipal Ida Hospital, Japan.
FAU - Tanimoto, Tetsuya
AU  - Tanimoto T
AD  - Department of Internal Medicine, Navitas Clinic, Japan.
LA  - eng
PT  - Journal Article
DEP - 20171120
PL  - Japan
TA  - Intern Med
JT  - Internal medicine (Tokyo, Japan)
JID - 9204241
OTO - NOTNLM
OT  - colobrochial fistula
OT  - foul-smelling sputum
OT  - stomach neoplasms
EDAT- 2017/11/21 06:00
MHDA- 2017/11/21 06:00
CRDT- 2017/11/21 06:00
PHST- 2017/11/21 06:00 [entrez]
PHST- 2017/11/21 06:00 [pubmed]
PHST- 2017/11/21 06:00 [medline]
AID - 10.2169/internalmedicine.9489-17 [doi]
PST - aheadofprint
SO  - Intern Med. 2017 Nov 20. doi: 10.2169/internalmedicine.9489-17.

PMID- 29131148
OWN - NLM
STAT- MEDLINE
DCOM- 20171219
LR  - 20171219
IS  - 1546-1696 (Electronic)
IS  - 1087-0156 (Linking)
VI  - 35
IP  - 12
DP  - 2017 Dec
TI  - Structure-guided chemical modification of guide RNA enables potent non-viral in
      vivo genome editing.
PG  - 1179-1187
LID - 10.1038/nbt.4005 [doi]
AB  - Efficient genome editing with Cas9-sgRNA in vivo has required the use of viral
      delivery systems, which have limitations for clinical applications. Translational
      efforts to develop other RNA therapeutics have shown that judicious chemical
      modification of RNAs can improve therapeutic efficacy by reducing susceptibility 
      to nuclease degradation. Guided by the structure of the Cas9-sgRNA complex, we
      identify regions of sgRNA that can be modified while maintaining or enhancing
      genome-editing activity, and we develop an optimal set of chemical modifications 
      for in vivo applications. Using lipid nanoparticle formulations of these enhanced
      sgRNAs (e-sgRNA) and mRNA encoding Cas9, we show that a single intravenous
      injection into mice induces >80% editing of Pcsk9 in the liver. Serum Pcsk9 is
      reduced to undetectable levels, and cholesterol levels are significantly lowered 
      about 35% to 40% in animals. This strategy may enable non-viral, Cas9-based
      genome editing in the liver in clinical settings.
FAU - Yin, Hao
AU  - Yin H
AD  - David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute 
      of Technology, Cambridge, Massachusetts, USA.
FAU - Song, Chun-Qing
AU  - Song CQ
AD  - RNA Therapeutics Institute, University of Massachusetts Medical School,
      Worcester, Massachusetts, USA.
FAU - Suresh, Sneha
AU  - Suresh S
AD  - David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute 
      of Technology, Cambridge, Massachusetts, USA.
FAU - Wu, Qiongqiong
AU  - Wu Q
AD  - David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute 
      of Technology, Cambridge, Massachusetts, USA.
FAU - Walsh, Stephen
AU  - Walsh S
AD  - David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute 
      of Technology, Cambridge, Massachusetts, USA.
FAU - Rhym, Luke Hyunsik
AU  - Rhym LH
AD  - David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute 
      of Technology, Cambridge, Massachusetts, USA.
AD  - Department of Chemical Engineering, Massachusetts Institute of Technology,
      Cambridge, Massachusetts, USA.
FAU - Mintzer, Esther
AU  - Mintzer E
AD  - Department of Molecular, Cell and Cancer Biology, University of Massachusetts
      Medical School, Worcester, Massachusetts, USA.
FAU - Bolukbasi, Mehmet Fatih
AU  - Bolukbasi MF
AUID- ORCID: http://orcid.org/0000-0002-5612-3881
AD  - Department of Molecular, Cell and Cancer Biology, University of Massachusetts
      Medical School, Worcester, Massachusetts, USA.
AD  - Department of Biochemistry and Molecular Pharmacology, University of
      Massachusetts Medical School, Worcester, Massachusetts, USA.
FAU - Zhu, Lihua Julie
AU  - Zhu LJ
AUID- ORCID: http://orcid.org/0000-0001-7416-0590
AD  - Department of Molecular, Cell and Cancer Biology, University of Massachusetts
      Medical School, Worcester, Massachusetts, USA.
AD  - Program in Bioinformatics and Integrative Biology, University of Massachusetts
      Medical School, Worcester, Massachusetts, USA.
AD  - Department of Molecular Medicine, University of Massachusetts Medical School,
      Worcester, Massachusetts, USA.
FAU - Kauffman, Kevin
AU  - Kauffman K
AD  - David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute 
      of Technology, Cambridge, Massachusetts, USA.
AD  - Department of Chemical Engineering, Massachusetts Institute of Technology,
      Cambridge, Massachusetts, USA.
FAU - Mou, Haiwei
AU  - Mou H
AD  - RNA Therapeutics Institute, University of Massachusetts Medical School,
      Worcester, Massachusetts, USA.
FAU - Oberholzer, Alicia
AU  - Oberholzer A
AD  - David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute 
      of Technology, Cambridge, Massachusetts, USA.
FAU - Ding, Junmei
AU  - Ding J
AD  - David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute 
      of Technology, Cambridge, Massachusetts, USA.
FAU - Kwan, Suet-Yan
AU  - Kwan SY
AD  - RNA Therapeutics Institute, University of Massachusetts Medical School,
      Worcester, Massachusetts, USA.
FAU - Bogorad, Roman L
AU  - Bogorad RL
AD  - David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute 
      of Technology, Cambridge, Massachusetts, USA.
FAU - Zatsepin, Timofei
AU  - Zatsepin T
AUID- ORCID: http://orcid.org/0000-0003-0030-9174
AD  - Center of Translational Biomedicine, Skolkovo Institute of Science and
      Technology, Skolkovo, Moscow, Russia.
AD  - Department of Chemistry, Lomonosov Moscow State University, Moscow, Russia.
FAU - Koteliansky, Victor
AU  - Koteliansky V
AD  - Center of Translational Biomedicine, Skolkovo Institute of Science and
      Technology, Skolkovo, Moscow, Russia.
FAU - Wolfe, Scot A
AU  - Wolfe SA
AD  - Department of Molecular, Cell and Cancer Biology, University of Massachusetts
      Medical School, Worcester, Massachusetts, USA.
AD  - Department of Biochemistry and Molecular Pharmacology, University of
      Massachusetts Medical School, Worcester, Massachusetts, USA.
FAU - Xue, Wen
AU  - Xue W
AUID- ORCID: http://orcid.org/0000-0002-9797-8042
AD  - RNA Therapeutics Institute, University of Massachusetts Medical School,
      Worcester, Massachusetts, USA.
AD  - Department of Molecular, Cell and Cancer Biology, University of Massachusetts
      Medical School, Worcester, Massachusetts, USA.
AD  - Department of Molecular Medicine, University of Massachusetts Medical School,
      Worcester, Massachusetts, USA.
FAU - Langer, Robert
AU  - Langer R
AD  - David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute 
      of Technology, Cambridge, Massachusetts, USA.
AD  - Department of Chemical Engineering, Massachusetts Institute of Technology,
      Cambridge, Massachusetts, USA.
AD  - Harvard-MIT Division of Health Sciences & Technology, Cambridge, Massachusetts,
      USA.
AD  - Institute of Medical Engineering and Science, Massachusetts Institute of
      Technology, Cambridge, Massachusetts, USA.
FAU - Anderson, Daniel G
AU  - Anderson DG
AD  - David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute 
      of Technology, Cambridge, Massachusetts, USA.
AD  - Department of Chemical Engineering, Massachusetts Institute of Technology,
      Cambridge, Massachusetts, USA.
AD  - Harvard-MIT Division of Health Sciences & Technology, Cambridge, Massachusetts,
      USA.
AD  - Institute of Medical Engineering and Science, Massachusetts Institute of
      Technology, Cambridge, Massachusetts, USA.
LA  - eng
GR  - DP2 HL137167/HL/NHLBI NIH HHS/United States
GR  - P01 HL131471/HL/NHLBI NIH HHS/United States
GR  - R00 CA169512/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20171113
PL  - United States
TA  - Nat Biotechnol
JT  - Nature biotechnology
JID - 9604648
RN  - 0 (RNA, Guide)
RN  - EC 3.4.21.- (Pcsk9 protein, mouse)
RN  - EC 3.4.21.- (Proprotein Convertase 9)
SB  - IM
MH  - Animals
MH  - CRISPR-Cas Systems/genetics
MH  - Gene Editing/*methods
MH  - *Gene Transfer Techniques
MH  - Liver/*metabolism
MH  - Mice
MH  - Nanoparticles/chemistry
MH  - Nucleic Acid Conformation
MH  - Proprotein Convertase 9/genetics
MH  - RNA, Guide/*genetics
EDAT- 2017/11/14 06:00
MHDA- 2017/12/20 06:00
CRDT- 2017/11/14 06:00
PHST- 2016/11/29 00:00 [received]
PHST- 2017/10/09 00:00 [accepted]
PHST- 2017/11/14 06:00 [pubmed]
PHST- 2017/12/20 06:00 [medline]
PHST- 2017/11/14 06:00 [entrez]
AID - nbt.4005 [pii]
AID - 10.1038/nbt.4005 [doi]
PST - ppublish
SO  - Nat Biotechnol. 2017 Dec;35(12):1179-1187. doi: 10.1038/nbt.4005. Epub 2017 Nov
      13.

PMID- 29186125
OWN - NLM
STAT- In-Data-Review
LR  - 20171219
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 552
IP  - 7683
DP  - 2017 Dec 7
TI  - Promoter-bound METTL3 maintains myeloid leukaemia by m(6)A-dependent translation 
      control.
PG  - 126-131
LID - 10.1038/nature24678 [doi]
AB  - N(6)-methyladenosine (m(6)A) is an abundant internal RNA modification in both
      coding and non-coding RNAs that is catalysed by the METTL3-METTL14
      methyltransferase complex. However, the specific role of these enzymes in cancer 
      is still largely unknown. Here we define a pathway that is specific for METTL3
      and is implicated in the maintenance of a leukaemic state. We identify METTL3 as 
      an essential gene for growth of acute myeloid leukaemia cells in two distinct
      genetic screens. Downregulation of METTL3 results in cell cycle arrest,
      differentiation of leukaemic cells and failure to establish leukaemia in
      immunodeficient mice. We show that METTL3, independently of METTL14, associates
      with chromatin and localizes to the transcriptional start sites of active genes. 
      The vast majority of these genes have the CAATT-box binding protein CEBPZ present
      at the transcriptional start site, and this is required for recruitment of METTL3
      to chromatin. Promoter-bound METTL3 induces m(6)A modification within the coding 
      region of the associated mRNA transcript, and enhances its translation by
      relieving ribosome stalling. We show that genes regulated by METTL3 in this way
      are necessary for acute myeloid leukaemia. Together, these data define METTL3 as 
      a regulator of a chromatin-based pathway that is necessary for maintenance of the
      leukaemic state and identify this enzyme as a potential therapeutic target for
      acute myeloid leukaemia.
FAU - Barbieri, Isaia
AU  - Barbieri I
AD  - The Gurdon Institute and Department of Pathology, University of Cambridge, Tennis
      Court Road, Cambridge CB2 1QN, UK.
FAU - Tzelepis, Konstantinos
AU  - Tzelepis K
AD  - Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Cambridge CB10
      1SA, UK.
FAU - Pandolfini, Luca
AU  - Pandolfini L
AD  - The Gurdon Institute and Department of Pathology, University of Cambridge, Tennis
      Court Road, Cambridge CB2 1QN, UK.
FAU - Shi, Junwei
AU  - Shi J
AD  - Cold Spring Harbor Laboratory, 1 Bungtown Road, Cold Spring Harbor, New York
      11724, USA.
FAU - Millan-Zambrano, Gonzalo
AU  - Millan-Zambrano G
AD  - The Gurdon Institute and Department of Pathology, University of Cambridge, Tennis
      Court Road, Cambridge CB2 1QN, UK.
FAU - Robson, Samuel C
AU  - Robson SC
AD  - The Gurdon Institute and Department of Pathology, University of Cambridge, Tennis
      Court Road, Cambridge CB2 1QN, UK.
FAU - Aspris, Demetrios
AU  - Aspris D
AD  - Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Cambridge CB10
      1SA, UK.
FAU - Migliori, Valentina
AU  - Migliori V
AD  - The Gurdon Institute and Department of Pathology, University of Cambridge, Tennis
      Court Road, Cambridge CB2 1QN, UK.
FAU - Bannister, Andrew J
AU  - Bannister AJ
AD  - The Gurdon Institute and Department of Pathology, University of Cambridge, Tennis
      Court Road, Cambridge CB2 1QN, UK.
FAU - Han, Namshik
AU  - Han N
AD  - The Gurdon Institute and Department of Pathology, University of Cambridge, Tennis
      Court Road, Cambridge CB2 1QN, UK.
FAU - De Braekeleer, Etienne
AU  - De Braekeleer E
AD  - Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Cambridge CB10
      1SA, UK.
FAU - Ponstingl, Hannes
AU  - Ponstingl H
AD  - Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Cambridge CB10
      1SA, UK.
FAU - Hendrick, Alan
AU  - Hendrick A
AD  - Storm Therapeutics Ltd, Moneta Building (B280), Babraham Research Campus,
      Cambridge CB22 3AT, UK.
FAU - Vakoc, Christopher R
AU  - Vakoc CR
AD  - Cold Spring Harbor Laboratory, 1 Bungtown Road, Cold Spring Harbor, New York
      11724, USA.
FAU - Vassiliou, George S
AU  - Vassiliou GS
AD  - Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Cambridge CB10
      1SA, UK.
AD  - Wellcome Trust-MRC Cambridge Stem Cell Institute, University of Cambridge,
      Cambridge CB2 0XY, UK.
AD  - Department of Haematology, Cambridge University Hospitals NHS Trust, Cambridge
      CB2 0QQ, UK.
FAU - Kouzarides, Tony
AU  - Kouzarides T
AD  - The Gurdon Institute and Department of Pathology, University of Cambridge, Tennis
      Court Road, Cambridge CB2 1QN, UK.
LA  - eng
PT  - Journal Article
DEP - 20171127
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
EDAT- 2017/12/01 06:00
MHDA- 2017/12/01 06:00
CRDT- 2017/11/30 06:00
PHST- 2017/02/07 00:00 [received]
PHST- 2017/10/25 00:00 [accepted]
PHST- 2017/12/01 06:00 [pubmed]
PHST- 2017/12/01 06:00 [medline]
PHST- 2017/11/30 06:00 [entrez]
AID - nature24678 [pii]
AID - 10.1038/nature24678 [doi]
PST - ppublish
SO  - Nature. 2017 Dec 7;552(7683):126-131. doi: 10.1038/nature24678. Epub 2017 Nov 27.

PMID- 29132145
OWN - NLM
STAT- In-Data-Review
LR  - 20171219
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 551
IP  - 7680
DP  - 2017 Nov 16
TI  - Gene therapy: Transgenic stem cells replace skin.
PG  - 306-307
LID - 10.1038/nature24753 [doi]
FAU - Aragona, Mariaceleste
AU  - Aragona M
AD  - the Laboratory of Stem Cells and Cancer, Universite Libre de Bruxelles, 1070
      Brussels, Belgium.
FAU - Blanpain, Cedric
AU  - Blanpain C
AD  - the Laboratory of Stem Cells and Cancer, Universite Libre de Bruxelles, 1070
      Brussels, Belgium.
LA  - eng
PT  - Journal Article
DEP - 20171108
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
EDAT- 2017/11/14 06:00
MHDA- 2017/11/14 06:00
CRDT- 2017/11/14 06:00
PHST- 2017/11/14 06:00 [pubmed]
PHST- 2017/11/14 06:00 [medline]
PHST- 2017/11/14 06:00 [entrez]
AID - nature24753 [pii]
AID - 10.1038/nature24753 [doi]
PST - ppublish
SO  - Nature. 2017 Nov 16;551(7680):306-307. doi: 10.1038/nature24753. Epub 2017 Nov 8.

PMID- 29255264
OWN - NLM
STAT- In-Data-Review
LR  - 20171223
IS  - 1546-1718 (Electronic)
IS  - 1061-4036 (Linking)
VI  - 50
IP  - 1
DP  - 2018 Jan
TI  - Identification of H3K4me1-associated proteins at mammalian enhancers.
PG  - 73-82
LID - 10.1038/s41588-017-0015-6 [doi]
AB  - Enhancers act to regulate cell-type-specific gene expression by facilitating the 
      transcription of target genes. In mammalian cells, active or primed enhancers are
      commonly marked by monomethylation of histone H3 at lysine 4 (H3K4me1) in a
      cell-type-specific manner. Whether and how this histone modification regulates
      enhancer-dependent transcription programs in mammals is unclear. In this study,
      we conducted SILAC mass spectrometry experiments with mononucleosomes and
      identified multiple H3K4me1-associated proteins, including many involved in
      chromatin remodeling. We demonstrate that H3K4me1 augments association of the
      chromatin-remodeling complex BAF to enhancers in vivo and that, in vitro,
      H3K4me1-marked nucleosomes are more efficiently remodeled by the BAF complex.
      Crystal structures of the BAF component BAF45C indicate that monomethylation, but
      not trimethylation, is accommodated by BAF45C's H3K4-binding site. Our results
      suggest that H3K4me1 has an active role at enhancers by facilitating binding of
      the BAF complex and possibly other chromatin regulators.
FAU - Local, Andrea
AU  - Local A
AD  - Ludwig Institute for Cancer Research, La Jolla, CA, USA.
AD  - Aptose Biosciences, Inc., San Diego, CA, USA.
FAU - Huang, Hui
AU  - Huang H
AD  - Ludwig Institute for Cancer Research, La Jolla, CA, USA.
AD  - Biomedical Sciences Graduate Program, University of California, San Diego, La
      Jolla, CA, USA.
FAU - Albuquerque, Claudio P
AU  - Albuquerque CP
AD  - Ludwig Institute for Cancer Research, La Jolla, CA, USA.
FAU - Singh, Namit
AU  - Singh N
AD  - Ludwig Institute for Cancer Research, La Jolla, CA, USA.
FAU - Lee, Ah Young
AU  - Lee AY
AD  - Ludwig Institute for Cancer Research, La Jolla, CA, USA.
FAU - Wang, Wei
AU  - Wang W
AD  - Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, 
      San Diego, La Jolla, CA, USA.
FAU - Wang, Chaochen
AU  - Wang C
AD  - Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, 
      San Diego, La Jolla, CA, USA.
FAU - Hsia, Judy E
AU  - Hsia JE
AD  - Ludwig Institute for Cancer Research, La Jolla, CA, USA.
FAU - Shiau, Andrew K
AU  - Shiau AK
AD  - Ludwig Institute for Cancer Research, La Jolla, CA, USA.
FAU - Ge, Kai
AU  - Ge K
AD  - National Institute of Diabetes and Digestive and Kidney Diseases, US National
      Institutes of Health, Bethesda, MD, USA.
FAU - Corbett, Kevin D
AU  - Corbett KD
AUID- ORCID: http://orcid.org/0000-0001-5854-2388
AD  - Ludwig Institute for Cancer Research, La Jolla, CA, USA.
AD  - Department of Cellular and Molecular Medicine, University of California San Diego
      School of Medicine, La Jolla, CA, USA.
FAU - Wang, Dong
AU  - Wang D
AUID- ORCID: http://orcid.org/0000-0002-2829-1546
AD  - Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, 
      San Diego, La Jolla, CA, USA.
FAU - Zhou, Huilin
AU  - Zhou H
AD  - Ludwig Institute for Cancer Research, La Jolla, CA, USA.
AD  - Department of Cellular and Molecular Medicine, University of California San Diego
      School of Medicine, La Jolla, CA, USA.
FAU - Ren, Bing
AU  - Ren B
AUID- ORCID: http://orcid.org/0000-0002-5435-1127
AD  - Ludwig Institute for Cancer Research, La Jolla, CA, USA. biren@ucsd.edu.
AD  - Department of Cellular and Molecular Medicine, University of California San Diego
      School of Medicine, La Jolla, CA, USA. biren@ucsd.edu.
AD  - Center for Epigenomics, Institute of Genomic Medicine, La Jolla, CA, USA.
      biren@ucsd.edu.
LA  - eng
PT  - Journal Article
DEP - 20171218
PL  - United States
TA  - Nat Genet
JT  - Nature genetics
JID - 9216904
EDAT- 2017/12/20 06:00
MHDA- 2017/12/20 06:00
CRDT- 2017/12/20 06:00
PHST- 2016/02/26 00:00 [received]
PHST- 2017/11/21 00:00 [accepted]
PHST- 2017/12/20 06:00 [pubmed]
PHST- 2017/12/20 06:00 [medline]
PHST- 2017/12/20 06:00 [entrez]
AID - 10.1038/s41588-017-0015-6 [doi]
AID - 10.1038/s41588-017-0015-6 [pii]
PST - ppublish
SO  - Nat Genet. 2018 Jan;50(1):73-82. doi: 10.1038/s41588-017-0015-6. Epub 2017 Dec
      18.

PMID- 29102613
OWN - NLM
STAT- Publisher
LR  - 20180109
IS  - 1528-0012 (Electronic)
IS  - 0016-5085 (Linking)
DP  - 2017 Nov 2
TI  - Fructan, Rather Than Gluten, Induces Symptoms in Patients With Self-reported
      Non-celiac Gluten Sensitivity.
LID - S0016-5085(17)36302-3 [pii]
LID - 10.1053/j.gastro.2017.10.040 [doi]
AB  - BACKGROUND & AIMS: Non-celiac gluten sensitivity is characterized by symptom
      improvement after gluten withdrawal in absence of celiac disease. The mechanisms 
      of non-celiac gluten sensitivity are unclear, and there are no biomarkers for
      this disorder. Foods with gluten often contain fructans, a type of fermentable
      oligo-, di-, monosaccharides and polyols. We aimed to investigate the effect of
      gluten and fructans separately in individuals with self-reported gluten
      sensitivity. METHODS: We performed a double-blind crossover challenge of 59
      individuals on a self-instituted gluten-free diet, for whom celiac disease had
      been excluded. The study was performed at Oslo University Hospital in Norway from
      October 2014 through May 2016. Participants were randomly assigned to groups
      placed on diets containing gluten (5.7 g), fructans (2.1 g), or placebo,
      concealed in muesli bars, for 7 days. Following a minimum 7-day washout period
      (until the symptoms induced by the previous challenge were resolved),
      participants crossed over into a different group, until they completed all 3
      challenges (gluten, fructan, and placebo). Symptoms were measured by
      gastrointestinal symptom rating scale irritable bowel syndrome (GSRS-IBS)
      version. A linear mixed model for analysis was used. RESULTS: Overall GSRS-IBS
      scores differed significantly during gluten, fructan, and placebo challenges;
      mean values were 33.1 +/- 13.3, 38.6 +/- 12.3, and 34.3 +/- 13.9, respectively (P
      = .04). Mean scores for GSRS bloating were 9.3 +/- 3.5, 11.6 +/- 3.5, and 10.1
      +/- 3.7, respectively, during the gluten, fructan, and placebo challenges (P =
      .004). The overall GSRS-IBS score for participants consuming fructans was
      significantly higher than for participants consuming gluten (P = .049), as was
      the GSRS bloating score (P = .003). Thirteen participants had the highest overall
      GSRS-IBS score after consuming gluten, 24 had the highest score after consuming
      fructan, and 22 had the highest score after consuming placebo. There was no
      difference in GSRS-IBS scores between gluten and placebo groups. CONCLUSIONS: In 
      a randomized, double-blind, placebo-controlled crossover study of individuals
      with self-reported non-celiac gluten sensitivity, we found fructans to induce
      symptoms, measured by the GSRS-IBS. Clinicaltrials.gov no: NCT02464150.
CI  - Copyright (c) 2018 AGA Institute. Published by Elsevier Inc. All rights reserved.
FAU - Skodje, Gry I
AU  - Skodje GI
AD  - Division of Cancer Medicine, Oslo University Hospital, Rikshospitalet, Oslo,
      Norway; K. G. Jebsen Celiac Disease Research Centre, University of Oslo, Norway; 
      Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo,
      Norway. Electronic address: g.i.skodje@medisin.uio.no.
FAU - Sarna, Vikas K
AU  - Sarna VK
AD  - K. G. Jebsen Celiac Disease Research Centre, University of Oslo, Norway;
      Department of Immunology and Transfusion Medicine, Oslo University Hospital,
      Oslo, Norway.
FAU - Minelle, Ingunn H
AU  - Minelle IH
AD  - Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo,
      Norway.
FAU - Rolfsen, Kjersti L
AU  - Rolfsen KL
AD  - Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo,
      Norway.
FAU - Muir, Jane G
AU  - Muir JG
AD  - Department of Gastroenterology, Monash University and Alfred Hospital, Melbourne,
      Victoria, Australia.
FAU - Gibson, Peter R
AU  - Gibson PR
AD  - Department of Gastroenterology, Monash University and Alfred Hospital, Melbourne,
      Victoria, Australia.
FAU - Veierod, Marit B
AU  - Veierod MB
AD  - Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo,
      Norway; Oslo Centre for Biostatistics and Epidemiology, Department of
      Biostatistics, Institute of Basic Medical Sciences, University of Oslo, Oslo,
      Norway.
FAU - Henriksen, Christine
AU  - Henriksen C
AD  - K. G. Jebsen Celiac Disease Research Centre, University of Oslo, Norway;
      Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo,
      Norway.
FAU - Lundin, Knut E A
AU  - Lundin KEA
AD  - K. G. Jebsen Celiac Disease Research Centre, University of Oslo, Norway;
      Department of Immunology and Transfusion Medicine, Oslo University Hospital,
      Oslo, Norway; Department of Gastroenterology, Oslo University Hospital
      Rikshospitalet, 0424 Oslo, Norway; Centre for Immune Regulation, University of
      Oslo, Oslo, Norway.
LA  - eng
PT  - Journal Article
DEP - 20171102
PL  - United States
TA  - Gastroenterology
JT  - Gastroenterology
JID - 0374630
OTO - NOTNLM
OT  - Challenge
OT  - FODMAP
OT  - Intestine
OT  - NCGS
OT  - Wheat
EDAT- 2017/11/06 06:00
MHDA- 2017/11/06 06:00
CRDT- 2017/11/06 06:00
PHST- 2017/05/16 00:00 [received]
PHST- 2017/10/18 00:00 [revised]
PHST- 2017/10/19 00:00 [accepted]
PHST- 2017/11/06 06:00 [pubmed]
PHST- 2017/11/06 06:00 [medline]
PHST- 2017/11/06 06:00 [entrez]
AID - S0016-5085(17)36302-3 [pii]
AID - 10.1053/j.gastro.2017.10.040 [doi]
PST - aheadofprint
SO  - Gastroenterology. 2017 Nov 2. pii: S0016-5085(17)36302-3. doi:
      10.1053/j.gastro.2017.10.040.

PMID- 29097493
OWN - NLM
STAT- In-Process
LR  - 20180124
IS  - 1095-9203 (Electronic)
IS  - 0036-8075 (Linking)
VI  - 359
IP  - 6371
DP  - 2018 Jan 5
TI  - Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma
      patients.
PG  - 97-103
LID - 10.1126/science.aan4236 [doi]
AB  - Preclinical mouse models suggest that the gut microbiome modulates tumor response
      to checkpoint blockade immunotherapy; however, this has not been
      well-characterized in human cancer patients. Here we examined the oral and gut
      microbiome of melanoma patients undergoing anti-programmed cell death 1 protein
      (PD-1) immunotherapy (n = 112). Significant differences were observed in the
      diversity and composition of the patient gut microbiome of responders versus
      nonresponders. Analysis of patient fecal microbiome samples (n = 43, 30
      responders, 13 nonresponders) showed significantly higher alpha diversity (P <
      0.01) and relative abundance of bacteria of the Ruminococcaceae family (P < 0.01)
      in responding patients. Metagenomic studies revealed functional differences in
      gut bacteria in responders, including enrichment of anabolic pathways. Immune
      profiling suggested enhanced systemic and antitumor immunity in responding
      patients with a favorable gut microbiome as well as in germ-free mice receiving
      fecal transplants from responding patients. Together, these data have important
      implications for the treatment of melanoma patients with immune checkpoint
      inhibitors.
CI  - Copyright (c) 2018, American Association for the Advancement of Science.
FAU - Gopalakrishnan, V
AU  - Gopalakrishnan V
AUID- ORCID: 0000-0002-8704-035X
AD  - Department of Surgical Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
AD  - Department of Epidemiology, Human Genetics and Environmental Sciences, University
      of Texas School of Public Health, Houston, TX 77030, USA.
FAU - Spencer, C N
AU  - Spencer CN
AUID- ORCID: 0000-0002-3287-0292
AD  - Department of Epidemiology, Human Genetics and Environmental Sciences, University
      of Texas School of Public Health, Houston, TX 77030, USA.
AD  - Department of Genomic Medicine, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Nezi, L
AU  - Nezi L
AUID- ORCID: 0000-0002-4670-7656
AD  - Department of Genomic Medicine, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Reuben, A
AU  - Reuben A
AUID- ORCID: 0000-0003-4510-0382
AD  - Department of Surgical Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Andrews, M C
AU  - Andrews MC
AUID- ORCID: 0000-0003-1231-8641
AD  - Department of Surgical Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Karpinets, T V
AU  - Karpinets TV
AUID- ORCID: 0000-0002-3668-8148
AD  - Department of Genomic Medicine, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Prieto, P A
AU  - Prieto PA
AD  - Department of Surgical Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Vicente, D
AU  - Vicente D
AUID- ORCID: 0000-0001-8613-9027
AD  - Department of Surgical Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Hoffman, K
AU  - Hoffman K
AUID- ORCID: 0000-0002-4497-120X
AD  - Department of Epidemiology, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Wei, S C
AU  - Wei SC
AUID- ORCID: 0000-0001-9673-9683
AD  - Department of Immunology, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Cogdill, A P
AU  - Cogdill AP
AUID- ORCID: 0000-0001-8917-9462
AD  - Department of Surgical Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
AD  - Department of Immunology, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Zhao, L
AU  - Zhao L
AUID- ORCID: 0000-0001-7010-9966
AD  - Department of Genomic Medicine, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Hudgens, C W
AU  - Hudgens CW
AUID- ORCID: 0000-0001-8312-7485
AD  - Department of Translational Molecular Pathology, The University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Hutchinson, D S
AU  - Hutchinson DS
AUID- ORCID: 0000-0002-9035-8705
AD  - Department of Molecular Virology and Microbiology, Baylor College of Medicine,
      Houston, TX 77030, USA.
FAU - Manzo, T
AU  - Manzo T
AD  - Department of Genomic Medicine, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Petaccia de Macedo, M
AU  - Petaccia de Macedo M
AD  - Department of Translational Molecular Pathology, The University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Cotechini, T
AU  - Cotechini T
AD  - Department of Cell, Developmental and Cell Biology, Oregon Health and Sciences
      University, Portland, OR 97239, USA.
FAU - Kumar, T
AU  - Kumar T
AUID- ORCID: 0000-0003-2825-3387
AD  - Department of Genomic Medicine, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Chen, W S
AU  - Chen WS
AUID- ORCID: 0000-0002-3637-7948
AD  - Department of Pathology, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Reddy, S M
AU  - Reddy SM
AD  - Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Szczepaniak Sloane, R
AU  - Szczepaniak Sloane R
AUID- ORCID: 0000-0002-4106-8330
AD  - Department of Surgical Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Galloway-Pena, J
AU  - Galloway-Pena J
AD  - Department of Infectious Diseases, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Jiang, H
AU  - Jiang H
AD  - Department of Surgical Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Chen, P L
AU  - Chen PL
AD  - Department of Pathology, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Shpall, E J
AU  - Shpall EJ
AD  - Department of Stem Cell Transplantation, The University of Texas MD Anderson
      Cancer Center, Houston, TX 77030, USA.
FAU - Rezvani, K
AU  - Rezvani K
AUID- ORCID: 0000-0002-9599-2246
AD  - Department of Stem Cell Transplantation, The University of Texas MD Anderson
      Cancer Center, Houston, TX 77030, USA.
FAU - Alousi, A M
AU  - Alousi AM
AD  - Department of Stem Cell Transplantation, The University of Texas MD Anderson
      Cancer Center, Houston, TX 77030, USA.
FAU - Chemaly, R F
AU  - Chemaly RF
AD  - Department of Infectious Diseases, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Shelburne, S
AU  - Shelburne S
AUID- ORCID: 0000-0001-9721-263X
AD  - Department of Genomic Medicine, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
AD  - Department of Infectious Diseases, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Vence, L M
AU  - Vence LM
AD  - Department of Immunology, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Okhuysen, P C
AU  - Okhuysen PC
AUID- ORCID: 0000-0002-1596-3411
AD  - Department of Infectious Diseases, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Jensen, V B
AU  - Jensen VB
AD  - Department of Veterinary Medicine and Surgery, The University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Swennes, A G
AU  - Swennes AG
AUID- ORCID: 0000-0002-2507-6103
AD  - Department of Molecular Virology and Microbiology, Baylor College of Medicine,
      Houston, TX 77030, USA.
FAU - McAllister, F
AU  - McAllister F
AUID- ORCID: 0000-0002-9915-0943
AD  - Department of Clinical Cancer Prevention, The University of Texas MD Anderson
      Cancer Center, Houston, TX 77030, USA.
FAU - Marcelo Riquelme Sanchez, E
AU  - Marcelo Riquelme Sanchez E
AUID- ORCID: 0000-0002-2696-7995
AD  - Department of Clinical Cancer Prevention, The University of Texas MD Anderson
      Cancer Center, Houston, TX 77030, USA.
FAU - Zhang, Y
AU  - Zhang Y
AUID- ORCID: 0000-0001-7986-7704
AD  - Department of Clinical Cancer Prevention, The University of Texas MD Anderson
      Cancer Center, Houston, TX 77030, USA.
FAU - Le Chatelier, E
AU  - Le Chatelier E
AUID- ORCID: 0000-0002-2724-0536
AD  - Centre de Recherche de Jouy-en-Josas, Institut National de la Recherche
      Agronomique, 78352 Jouy-en-Josas, France.
FAU - Zitvogel, L
AU  - Zitvogel L
AD  - Centre d'Investigation Clinique Biotherapie, Institut Gustave-Roussy, 94805
      Villejuif Cedex, France.
FAU - Pons, N
AU  - Pons N
AUID- ORCID: 0000-0003-1926-8077
AD  - Centre de Recherche de Jouy-en-Josas, Institut National de la Recherche
      Agronomique, 78352 Jouy-en-Josas, France.
FAU - Austin-Breneman, J L
AU  - Austin-Breneman JL
AUID- ORCID: 0000-0002-4841-6588
AD  - Department of Surgical Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Haydu, L E
AU  - Haydu LE
AD  - Department of Surgical Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Burton, E M
AU  - Burton EM
AD  - Department of Surgical Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Gardner, J M
AU  - Gardner JM
AUID- ORCID: 0000-0001-5484-6691
AD  - Department of Surgical Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Sirmans, E
AU  - Sirmans E
AD  - Department of Melanoma Medical Oncology, The University of Texas MD Anderson
      Cancer Center, Houston, TX 77030, USA.
FAU - Hu, J
AU  - Hu J
AD  - Department of Biostatistics, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Lazar, A J
AU  - Lazar AJ
AUID- ORCID: 0000-0002-6395-4499
AD  - Department of Translational Molecular Pathology, The University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA.
AD  - Department of Pathology, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Tsujikawa, T
AU  - Tsujikawa T
AUID- ORCID: 0000-0003-1647-342X
AD  - Department of Cell, Developmental and Cell Biology, Oregon Health and Sciences
      University, Portland, OR 97239, USA.
FAU - Diab, A
AU  - Diab A
AUID- ORCID: 0000-0002-0153-0244
AD  - Department of Melanoma Medical Oncology, The University of Texas MD Anderson
      Cancer Center, Houston, TX 77030, USA.
FAU - Tawbi, H
AU  - Tawbi H
AUID- ORCID: 0000-0003-1942-851X
AD  - Department of Melanoma Medical Oncology, The University of Texas MD Anderson
      Cancer Center, Houston, TX 77030, USA.
FAU - Glitza, I C
AU  - Glitza IC
AUID- ORCID: 0000-0002-4530-7765
AD  - Department of Melanoma Medical Oncology, The University of Texas MD Anderson
      Cancer Center, Houston, TX 77030, USA.
FAU - Hwu, W J
AU  - Hwu WJ
AUID- ORCID: 0000-0003-1674-0751
AD  - Department of Melanoma Medical Oncology, The University of Texas MD Anderson
      Cancer Center, Houston, TX 77030, USA.
FAU - Patel, S P
AU  - Patel SP
AUID- ORCID: 0000-0003-1339-1517
AD  - Department of Melanoma Medical Oncology, The University of Texas MD Anderson
      Cancer Center, Houston, TX 77030, USA.
FAU - Woodman, S E
AU  - Woodman SE
AD  - Department of Melanoma Medical Oncology, The University of Texas MD Anderson
      Cancer Center, Houston, TX 77030, USA.
FAU - Amaria, R N
AU  - Amaria RN
AD  - Department of Melanoma Medical Oncology, The University of Texas MD Anderson
      Cancer Center, Houston, TX 77030, USA.
FAU - Davies, M A
AU  - Davies MA
AUID- ORCID: 0000-0002-0977-0912
AD  - Department of Melanoma Medical Oncology, The University of Texas MD Anderson
      Cancer Center, Houston, TX 77030, USA.
FAU - Gershenwald, J E
AU  - Gershenwald JE
AUID- ORCID: 0000-0003-4519-5369
AD  - Department of Surgical Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Hwu, P
AU  - Hwu P
AUID- ORCID: 0000-0003-0554-2856
AD  - Department of Melanoma Medical Oncology, The University of Texas MD Anderson
      Cancer Center, Houston, TX 77030, USA.
FAU - Lee, J E
AU  - Lee JE
AUID- ORCID: 0000-0001-6010-5590
AD  - Department of Surgical Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Zhang, J
AU  - Zhang J
AD  - Department of Genomic Medicine, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Coussens, L M
AU  - Coussens LM
AUID- ORCID: 0000-0003-2389-1865
AD  - Department of Cell, Developmental and Cell Biology, Oregon Health and Sciences
      University, Portland, OR 97239, USA.
FAU - Cooper, Z A
AU  - Cooper ZA
AUID- ORCID: 0000-0003-1059-0940
AD  - Department of Surgical Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
AD  - Department of Genomic Medicine, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Futreal, P A
AU  - Futreal PA
AUID- ORCID: 0000-0001-8663-2671
AD  - Department of Genomic Medicine, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Daniel, C R
AU  - Daniel CR
AD  - Department of Epidemiology, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
AD  - Department of Epidemiology, Human Genetics and Environmental Sciences, University
      of Texas School of Public Health, Houston, TX 77030, USA.
FAU - Ajami, N J
AU  - Ajami NJ
AUID- ORCID: 0000-0002-3808-8576
AD  - Department of Molecular Virology and Microbiology, Baylor College of Medicine,
      Houston, TX 77030, USA.
FAU - Petrosino, J F
AU  - Petrosino JF
AUID- ORCID: 0000-0002-4046-6898
AD  - Department of Molecular Virology and Microbiology, Baylor College of Medicine,
      Houston, TX 77030, USA.
FAU - Tetzlaff, M T
AU  - Tetzlaff MT
AUID- ORCID: 0000-0001-7899-4138
AD  - Department of Translational Molecular Pathology, The University of Texas MD
      Anderson Cancer Center, Houston, TX 77030, USA.
AD  - Department of Pathology, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Sharma, P
AU  - Sharma P
AUID- ORCID: 0000-0003-4658-055X
AD  - Department of Immunology, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
AD  - Department of Genitourinary Medical Oncology, The University of Texas MD Anderson
      Cancer Center, Houston, TX 77030, USA.
FAU - Allison, J P
AU  - Allison JP
AUID- ORCID: 0000-0001-8980-5697
AD  - Department of Immunology, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Jenq, R R
AU  - Jenq RR
AUID- ORCID: 0000-0002-5434-439X
AD  - Department of Genomic Medicine, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Wargo, J A
AU  - Wargo JA
AUID- ORCID: 0000-0003-3438-7576
AD  - Department of Surgical Oncology, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA. jwargo@mdanderson.org.
AD  - Department of Genomic Medicine, The University of Texas MD Anderson Cancer
      Center, Houston, TX 77030, USA.
LA  - eng
GR  - P30 CA016672/CA/NCI NIH HHS/United States
GR  - R25 CA056452/CA/NCI NIH HHS/United States
GR  - UL1 TR000128/TR/NCATS NIH HHS/United States
GR  - R25 CA057730/CA/NCI NIH HHS/United States
GR  - K08 CA160692/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, Non-U.S. Gov't
DEP - 20171102
PL  - United States
TA  - Science
JT  - Science (New York, N.Y.)
JID - 0404511
CIN - Science. 2018 Jan 5;359(6371):32-34. PMID: 29302001
EDAT- 2017/11/04 06:00
MHDA- 2017/11/04 06:00
CRDT- 2017/11/04 06:00
PHST- 2017/04/12 00:00 [received]
PHST- 2017/10/17 00:00 [accepted]
PHST- 2017/11/04 06:00 [pubmed]
PHST- 2017/11/04 06:00 [medline]
PHST- 2017/11/04 06:00 [entrez]
AID - science.aan4236 [pii]
AID - 10.1126/science.aan4236 [doi]
PST - ppublish
SO  - Science. 2018 Jan 5;359(6371):97-103. doi: 10.1126/science.aan4236. Epub 2017 Nov
      2.

PMID- 29147628
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20171219
IS  - 2162-4011 (Print)
IS  - 2162-4011 (Linking)
VI  - 6
IP  - 11
DP  - 2017
TI  - Trial Watch: Adoptively transferred cells for anticancer immunotherapy.
PG  - e1363139
LID - 10.1080/2162402X.2017.1363139 [doi]
AB  - Immunotherapies aimed at strengthening immune effector responses against
      malignant cells are growing at exponential rates. Alongside, the impressive
      benefits obtained by patients with advanced melanoma who received adoptively
      transferred tumor-infiltrating lymphocytes (TILs) have encouraged the scientific 
      community to pursue adoptive cell transfer (ACT)-based immunotherapy. ACT
      involves autologous or allogenic effector lymphocytes that are generally obtained
      from the peripheral blood or resected tumors, expanded and activated ex vivo, and
      administered to lymphodepleted patients. ACT may be optionally associated with
      chemo- and/or immunotherapeutics, with the overall aim of enhancing the
      proliferation, persistence and functionality of infused cells, as well as to
      ensure their evolution in an immunological permissive local and systemic
      microenvironment. In addition, isolated lymphocytes can be genetically engineered
      to endow them with the ability to target a specific tumor-associated antigen
      (TAA), to increase their lifespan, and/or to reduce their potential toxicity. The
      infusion of chimeric antigen receptor (CAR)-expressing cytotoxic T lymphocytes
      redirected against CD19 has shown promising clinical efficacy in patients with
      B-cell malignancies. Accordingly, the US Food and Drug Administration (FDA) has
      recently granted 'breakthrough therapy' designation to a CAR-based T-cell therapy
      (CTL019) for patients with B-cell malignancies. Considerable efforts are now
      being devoted to the development of efficient ACT-based immunotherapies for
      non-hematological neoplasms. In this Trial Watch, we summarize recent clinical
      advances on the use of ACT for oncological indications.
FAU - Fournier, Carole
AU  - Fournier C
AD  - INSERM, U1231, Dijon, France.
AD  - Faculte de Medecine, Universite de Bourgogne Franche Comte, Dijon, France.
FAU - Martin, Francois
AU  - Martin F
AD  - INSERM, U1231, Dijon, France.
AD  - Faculte de Medecine, Universite de Bourgogne Franche Comte, Dijon, France.
FAU - Zitvogel, Laurence
AU  - Zitvogel L
AD  - Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.
AD  - INSERM, U1015, Villejuif, France.
AD  - Center of Clinical Investigations in Biotherapies of Cancer (CICBT), Villejuif,
      France.
AD  - Universite Paris Sud/Paris XI, Le Kremlin-Bicetre, France.
FAU - Kroemer, Guido
AU  - Kroemer G
AD  - Universite Paris Descartes/Paris V, France.
AD  - Universite Pierre et Marie Curie/Paris VI, Paris.
AD  - Equipe 11 labellisee Ligue contre le Cancer, Centre de Recherche des Cordeliers, 
      Paris, France.
AD  - INSERM, U1138, Paris, France.
AD  - Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer
      Institute, Villejuif, France.
AD  - Karolinska Institute, Department of Women's and Children's Health, Karolinska
      University Hospital, Stockholm, Sweden.
AD  - Pole de Biologie, Hopital Europeen George Pompidou, AP-HP; Paris, France.
FAU - Galluzzi, Lorenzo
AU  - Galluzzi L
AD  - Universite Paris Descartes/Paris V, France.
AD  - Department of Radiation Oncology, Weill Cornell Medical College, New York, NY,
      USA.
AD  - Sandra and Edward Meyer Cancer Center, New York, NY, USA.
FAU - Apetoh, Lionel
AU  - Apetoh L
AD  - INSERM, U1231, Dijon, France.
AD  - Faculte de Medecine, Universite de Bourgogne Franche Comte, Dijon, France.
AD  - Centre Georges Francois Leclerc, Dijon, France.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170811
PL  - United States
TA  - Oncoimmunology
JT  - Oncoimmunology
JID - 101570526
PMC - PMC5674950
OTO - NOTNLM
OT  - NK cell
OT  - PD-1
OT  - PD-L1
OT  - chimeric antigen receptor
OT  - cytotoxic T lymphocyte
OT  - immune checkpoint blockers
EDAT- 2017/11/18 06:00
MHDA- 2017/11/18 06:01
CRDT- 2017/11/18 06:00
PMCR- 2018/08/11 00:00
PHST- 2017/07/19 00:00 [received]
PHST- 2017/07/29 00:00 [revised]
PHST- 2017/07/30 00:00 [accepted]
PHST- 2018/08/11 00:00 [pmc-release]
PHST- 2017/11/18 06:00 [entrez]
PHST- 2017/11/18 06:00 [pubmed]
PHST- 2017/11/18 06:01 [medline]
AID - 10.1080/2162402X.2017.1363139 [doi]
AID - 1363139 [pii]
PST - epublish
SO  - Oncoimmunology. 2017 Aug 11;6(11):e1363139. doi: 10.1080/2162402X.2017.1363139.
      eCollection 2017.

PMID- 29055087
OWN - NLM
STAT- Publisher
LR  - 20171108
IS  - 1742-4658 (Electronic)
IS  - 1742-464X (Linking)
DP  - 2017 Oct 21
TI  - Metabolism and TAM functions-it takes two to tango.
LID - 10.1111/febs.14295 [doi]
AB  - From the evidence on clinical studies and experimental mouse models we now know
      that tumor-associated macrophages (TAMs) sustain tumor development in many
      different ways. They play a role in angiogenesis, tumor cell invasion, and
      metastasis formation. Additionally, TAMs interfere with natural killer and T-cell
      antitumoral activities, producing an immune-suppressive environment that protects
      tumor cell growth. This indicates that the tumoricidal activity of macrophages
      within the tumor microenviroment is lost due to an imbalance of the regulatory
      mechanisms underpinning these cells' function. Since metabolism is emerging as a 
      major modulator of macrophage function, metabolic changes in response to signals 
      coming from cancer or other immune cells might promote this imbalance, enhancing 
      the tumorigenic activities of TAMs. In this review we describe the novel, most
      recent findings on how metabolism shapes TAM functions or conversely, how TAMs
      influence the activity of other cells through metabolic mechanisms. The complete 
      elucidation of the metabolic switches between pro- and antitumoral properties of 
      macrophages, now still in its infancy, is destined to provide scientists with new
      instruments not only to understand but also to combat cancer.
CI  - (c) 2017 Federation of European Biochemical Societies.
FAU - Mazzone, Massimiliano
AU  - Mazzone M
AD  - Laboratory of Tumor Inflammation and Angiogenesis, Center for Cancer Biology
      (CCB), VIB, Leuven, Belgium.
AD  - Laboratory of Tumor Inflammation and Angiogenesis, Department of Oncology, KU
      Leuven, Belgium.
FAU - Menga, Alessio
AU  - Menga A
AD  - Hematology Unit, National Cancer Research Center, Istituto Tumori 'Giovanni Paolo
      II', Bari, Italy.
FAU - Castegna, Alessandra
AU  - Castegna A
AD  - Hematology Unit, National Cancer Research Center, Istituto Tumori 'Giovanni Paolo
      II', Bari, Italy.
AD  - Department of Biosciences, Biotechnologies and Biopharmaceutics, University of
      Bari, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20171021
PL  - England
TA  - FEBS J
JT  - The FEBS journal
JID - 101229646
OTO - NOTNLM
OT  - mTOR
OT  - IL-10
OT  - arginine
OT  - cancer
OT  - glutamine synthetase
OT  - lactate
OT  - macrophage polarization
OT  - metabolic rewiring
OT  - tryptophan
OT  - tumor-associated macrophages
EDAT- 2017/10/22 06:00
MHDA- 2017/10/22 06:00
CRDT- 2017/10/22 06:00
PHST- 2017/08/09 00:00 [received]
PHST- 2017/09/25 00:00 [revised]
PHST- 2017/10/17 00:00 [accepted]
PHST- 2017/10/22 06:00 [pubmed]
PHST- 2017/10/22 06:00 [medline]
PHST- 2017/10/22 06:00 [entrez]
AID - 10.1111/febs.14295 [doi]
PST - aheadofprint
SO  - FEBS J. 2017 Oct 21. doi: 10.1111/febs.14295.

PMID- 29150936
OWN - NLM
STAT- Publisher
LR  - 20171118
IS  - 1097-4652 (Electronic)
IS  - 0021-9541 (Linking)
DP  - 2017 Nov 18
TI  - The roles of Wnt/beta-catenin pathway in tissue development and regenerative
      medicine.
LID - 10.1002/jcp.26265 [doi]
AB  - Regenerative medicine is a translational field which combines tissue engineering 
      and molecular biology to construct spare organs or help injured or defective
      tissues to regenerate or restore their normal functions. This is particularly
      important with specific organs such as heart, central nervous system, retina or
      limbs which possess very limited regenerative capacity. As such, regenerative
      medicine has received peculiar attention in the last decade. In this regard,
      Wnt/beta-catenin signaling pathway has been subject to intensive research, since 
      it plays many essential roles in the regulation of the progenitor cell fate,
      developmental decisions, proliferation during embryonic development, and adult
      tissue homeostasis. In this paper, we will briefly introduce Wnt/beta-catenin
      signaling pathway and discuss how it integrally contributes to both stem and
      cancer stem cell maintenance. Finally, we summarize the current understanding of 
      the role of Wnt/beta-catenin signaling in the development and regeneration of
      heart, lung, liver, bone, and cartilage. This article is protected by copyright. 
      All rights reserved.
CI  - This article is protected by copyright. All rights reserved.
FAU - Majidinia, Maryam
AU  - Majidinia M
AD  - Solid Tumor Research Center, Urmia University of Medical Sciences, Urmia, Iran.
FAU - Aghazadeh, Javad
AU  - Aghazadeh J
AD  - Department of Neurosurgery, Urmia University of Medical Sciences, Urmia, Iran.
FAU - Jahanban-Esfahlani, Rana
AU  - Jahanban-Esfahlani R
AD  - Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
AD  - Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz,
      Iran.
FAU - Yousefi, Bahman
AU  - Yousefi B
AD  - Institute for Stem Cell and Regenerative Medicine, Tabriz University of Medical
      Sciences, Tabriz, Iran.
AD  - Molecular Targeting Therapy Research Group, Faculty of Medicine, Tabriz
      University of Medical Sciences, Tabriz, Iran.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20171118
PL  - United States
TA  - J Cell Physiol
JT  - Journal of cellular physiology
JID - 0050222
OTO - NOTNLM
OT  - Wnt signaling pathway
OT  - development
OT  - regeneration
OT  - stem cell
OT  - tissue engineering
EDAT- 2017/11/19 06:00
MHDA- 2017/11/19 06:00
CRDT- 2017/11/19 06:00
PHST- 2017/06/02 00:00 [received]
PHST- 2017/09/17 00:00 [revised]
PHST- 2017/11/14 00:00 [accepted]
PHST- 2017/11/19 06:00 [entrez]
PHST- 2017/11/19 06:00 [pubmed]
PHST- 2017/11/19 06:00 [medline]
AID - 10.1002/jcp.26265 [doi]
PST - aheadofprint
SO  - J Cell Physiol. 2017 Nov 18. doi: 10.1002/jcp.26265.

PMID- 29251726
OWN - NLM
STAT- Publisher
LR  - 20180124
IS  - 1546-1696 (Electronic)
IS  - 1087-0156 (Linking)
DP  - 2017 Dec 18
TI  - Orthologous CRISPR-Cas9 enzymes for combinatorial genetic screens.
LID - 10.1038/nbt.4048 [doi]
AB  - Combinatorial genetic screening using CRISPR-Cas9 is a useful approach to uncover
      redundant genes and to explore complex gene networks. However, current methods
      suffer from interference between the single-guide RNAs (sgRNAs) and from limited 
      gene targeting activity. To increase the efficiency of combinatorial screening,
      we employ orthogonal Cas9 enzymes from Staphylococcus aureus and Streptococcus
      pyogenes. We used machine learning to establish S. aureus Cas9 sgRNA design rules
      and paired S. aureus Cas9 with S. pyogenes Cas9 to achieve dual targeting in a
      high fraction of cells. We also developed a lentiviral vector and cloning
      strategy to generate high-complexity pooled dual-knockout libraries to identify
      synthetic lethal and buffering gene pairs across multiple cell types, including
      MAPK pathway genes and apoptotic genes. Our orthologous approach also enabled a
      screen combining gene knockouts with transcriptional activation, which revealed
      genetic interactions with TP53. The "Big Papi" (paired aureus and pyogenes for
      interactions) approach described here will be widely applicable for the study of 
      combinatorial phenotypes.
FAU - Najm, Fadi J
AU  - Najm FJ
AD  - Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA.
AD  - Department of Pathology, Massachusetts General Hospital and Harvard Medical
      School, Boston, Massachusetts, USA.
AD  - Center for Cancer Research, Massachusetts General Hospital and Harvard Medical
      School, Boston, Massachusetts, USA.
FAU - Strand, Christine
AU  - Strand C
AUID- ORCID: http://orcid.org/0000-0001-5783-6667
AD  - Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA.
FAU - Donovan, Katherine F
AU  - Donovan KF
AD  - Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA.
FAU - Hegde, Mudra
AU  - Hegde M
AD  - Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA.
FAU - Sanson, Kendall R
AU  - Sanson KR
AD  - Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA.
FAU - Vaimberg, Emma W
AU  - Vaimberg EW
AD  - Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA.
FAU - Sullender, Meagan E
AU  - Sullender ME
AUID- ORCID: http://orcid.org/0000-0001-6666-8650
AD  - Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA.
FAU - Hartenian, Ella
AU  - Hartenian E
AD  - Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA.
FAU - Kalani, Zohra
AU  - Kalani Z
AD  - Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA.
FAU - Fusi, Nicolo
AU  - Fusi N
AUID- ORCID: http://orcid.org/0000-0002-4102-0169
AD  - Microsoft Research New England, Cambridge, Massachusetts, USA.
FAU - Listgarten, Jennifer
AU  - Listgarten J
AUID- ORCID: http://orcid.org/0000-0002-6600-1431
AD  - Microsoft Research New England, Cambridge, Massachusetts, USA.
FAU - Younger, Scott T
AU  - Younger ST
AD  - Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA.
FAU - Bernstein, Bradley E
AU  - Bernstein BE
AD  - Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA.
AD  - Department of Pathology, Massachusetts General Hospital and Harvard Medical
      School, Boston, Massachusetts, USA.
AD  - Center for Cancer Research, Massachusetts General Hospital and Harvard Medical
      School, Boston, Massachusetts, USA.
FAU - Root, David E
AU  - Root DE
AD  - Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA.
FAU - Doench, John G
AU  - Doench JG
AUID- ORCID: http://orcid.org/0000-0002-3707-9889
AD  - Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA.
LA  - eng
GR  - DP1 CA216873/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20171218
PL  - United States
TA  - Nat Biotechnol
JT  - Nature biotechnology
JID - 9604648
EDAT- 2017/12/19 06:00
MHDA- 2017/12/19 06:00
CRDT- 2017/12/19 06:00
PHST- 2017/03/13 00:00 [received]
PHST- 2017/11/04 00:00 [accepted]
PHST- 2017/12/19 06:00 [pubmed]
PHST- 2017/12/19 06:00 [medline]
PHST- 2017/12/19 06:00 [entrez]
AID - nbt.4048 [pii]
AID - 10.1038/nbt.4048 [doi]
PST - aheadofprint
SO  - Nat Biotechnol. 2017 Dec 18. pii: nbt.4048. doi: 10.1038/nbt.4048.

PMID- 29211711
OWN - NLM
STAT- In-Data-Review
LR  - 20171222
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 552
IP  - 7684
DP  - 2017 Dec 14
TI  - KAT2A coupled with the alpha-KGDH complex acts as a histone H3
      succinyltransferase.
PG  - 273-277
LID - 10.1038/nature25003 [doi]
AB  - Histone modifications, such as the frequently occurring lysine succinylation, are
      central to the regulation of chromatin-based processes. However, the mechanism
      and functional consequences of histone succinylation are unknown. Here we show
      that the alpha-ketoglutarate dehydrogenase (alpha-KGDH) complex is localized in
      the nucleus in human cell lines and binds to lysine acetyltransferase 2A (KAT2A, 
      also known as GCN5) in the promoter regions of genes. We show that
      succinyl-coenzyme A (succinyl-CoA) binds to KAT2A. The crystal structure of the
      catalytic domain of KAT2A in complex with succinyl-CoA at 2.3 A resolution shows 
      that succinyl-CoA binds to a deep cleft of KAT2A with the succinyl moiety
      pointing towards the end of a flexible loop 3, which adopts different structural 
      conformations in succinyl-CoA-bound and acetyl-CoA-bound forms. Site-directed
      mutagenesis indicates that tyrosine 645 in this loop has an important role in the
      selective binding of succinyl-CoA over acetyl-CoA. KAT2A acts as a
      succinyltransferase and succinylates histone H3 on lysine 79, with a maximum
      frequency around the transcription start sites of genes. Preventing the
      alpha-KGDH complex from entering the nucleus, or expression of KAT2A(Tyr645Ala), 
      reduces gene expression and inhibits tumour cell proliferation and tumour growth.
      These findings reveal an important mechanism of histone modification and
      demonstrate that local generation of succinyl-CoA by the nuclear alpha-KGDH
      complex coupled with the succinyltransferase activity of KAT2A is instrumental in
      histone succinylation, tumour cell proliferation, and tumour development.
FAU - Wang, Yugang
AU  - Wang Y
AD  - Brain Tumor Center, Department of Neuro-Oncology, The University of Texas MD
      Anderson Cancer Center, Houston, Texas 77030, USA.
FAU - Guo, Yusong R
AU  - Guo YR
AD  - Department of BioSciences, Rice University, Houston, Texas 77005, USA.
FAU - Liu, Ke
AU  - Liu K
AD  - Department of Statistics, University of California, Berkeley, California 94720,
      USA.
FAU - Yin, Zheng
AU  - Yin Z
AD  - Department of Systems Medicine and Bioengineering, Houston Methodist Research
      Institute, Houston, Texas 77030, USA.
FAU - Liu, Rui
AU  - Liu R
AD  - Brain Tumor Center, Department of Neuro-Oncology, The University of Texas MD
      Anderson Cancer Center, Houston, Texas 77030, USA.
FAU - Xia, Yan
AU  - Xia Y
AD  - Brain Tumor Center, Department of Neuro-Oncology, The University of Texas MD
      Anderson Cancer Center, Houston, Texas 77030, USA.
FAU - Tan, Lin
AU  - Tan L
AD  - Department of General Oncology, Division of Cancer Medicine, The University of
      Texas MD Anderson Cancer Center, Houston, Texas 77054, USA.
FAU - Yang, Peiying
AU  - Yang P
AD  - Department of General Oncology, Division of Cancer Medicine, The University of
      Texas MD Anderson Cancer Center, Houston, Texas 77054, USA.
FAU - Lee, Jong-Ho
AU  - Lee JH
AD  - Brain Tumor Center, Department of Neuro-Oncology, The University of Texas MD
      Anderson Cancer Center, Houston, Texas 77030, USA.
FAU - Li, Xin-Jian
AU  - Li XJ
AD  - Brain Tumor Center, Department of Neuro-Oncology, The University of Texas MD
      Anderson Cancer Center, Houston, Texas 77030, USA.
FAU - Hawke, David
AU  - Hawke D
AD  - Department of Molecular Pathology, The University of Texas MD Anderson Cancer
      Center, Houston, Texas 77030, USA.
FAU - Zheng, Yanhua
AU  - Zheng Y
AD  - Brain Tumor Center, Department of Neuro-Oncology, The University of Texas MD
      Anderson Cancer Center, Houston, Texas 77030, USA.
FAU - Qian, Xu
AU  - Qian X
AD  - People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang 310014, China.
FAU - Lyu, Jianxin
AU  - Lyu J
AD  - People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang 310014, China.
AD  - Key Laboratory of Laboratory Medicine, Ministry of Education of China, School of 
      Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou,
      Zhejiang 325035, China.
FAU - He, Jie
AU  - He J
AD  - Laboratory of Thoracic Surgery, Cancer Institute and Hospital, Chinese Academy of
      Medical Sciences, Peking Union Medical College, Beijing 100021, China.
FAU - Xing, Dongming
AU  - Xing D
AD  - Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao,
      Shandong 266061, China.
AD  - Qingdao Cancer Institute, Qingdao, Shandong 266061, China.
AD  - School of Life Sciences, Tsinghua University, Beijing, 100084, China.
FAU - Tao, Yizhi Jane
AU  - Tao YJ
AD  - Department of BioSciences, Rice University, Houston, Texas 77005, USA.
FAU - Lu, Zhimin
AU  - Lu Z
AD  - Brain Tumor Center, Department of Neuro-Oncology, The University of Texas MD
      Anderson Cancer Center, Houston, Texas 77030, USA.
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD
      Anderson Cancer Center, Houston, Texas 77030, USA.
AD  - MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, The
      University of Texas, Houston, Texas 77030, USA.
LA  - eng
PT  - Journal Article
DEP - 20171206
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
EDAT- 2017/12/07 06:00
MHDA- 2017/12/07 06:00
CRDT- 2017/12/07 06:00
PHST- 2016/10/05 00:00 [received]
PHST- 2017/11/02 00:00 [accepted]
PHST- 2017/12/07 06:00 [pubmed]
PHST- 2017/12/07 06:00 [medline]
PHST- 2017/12/07 06:00 [entrez]
AID - nature25003 [pii]
AID - 10.1038/nature25003 [doi]
PST - ppublish
SO  - Nature. 2017 Dec 14;552(7684):273-277. doi: 10.1038/nature25003. Epub 2017 Dec 6.

PMID- 29244059
OWN - NLM
STAT- Publisher
LR  - 20171215
IS  - 1758-535X (Electronic)
IS  - 1079-5006 (Linking)
DP  - 2017 Dec 13
TI  - The Mediterranean diet: metabolic and molecular mechanisms.
LID - 10.1093/gerona/glx227 [doi]
AB  - Consuming a Mediterranean diet rich in minimally processed plant foods has been
      associated with a reduced risk of developing multiple chronic diseases and
      increased life expectancy. Data from several randomized clinic trials have
      demonstrated a beneficial effect in the primary and secondary prevention of
      cardiovascular disease, type 2 diabetes, atrial fibrillation and breast cancer.
      The exact mechanism by which an increased adherence to the traditional
      Mediterranean diet exerts its favorable effects is not known. However,
      accumulating evidence indicates that the five most important adaptations induced 
      by the Mediterranean dietary pattern are: (1) lipid lowering effect, (2)
      protection against oxidative stress, inflammation and platelet aggregation, (3)
      modification of hormones and growth factors involved in the pathogenesis of
      cancer, (4) inhibition of nutrient sensing pathways by specific amino acid
      restriction, and (4) gut microbiota-mediated production of metabolites
      influencing metabolic health. More studies are needed to understand how single
      modifications of nutrients typical of the Mediterranean diet interact with energy
      intake, energy expenditure, and the microbiome in modulating the key mechanisms
      that promote cellular, tissue, and organ health during aging.
CI  - (c) The Author(s) 2017. Published by Oxford University Press on behalf of The
      Gerontological Society of America. All rights reserved. For permissions, please
      e-mail: journals.permissions@oup.com.
FAU - Tosti, Valeria
AU  - Tosti V
AD  - Division of Geriatrics and Nutritional Science, Washington University, St. Louis,
      MO, USA.
FAU - Bertozzi, Beatrice
AU  - Bertozzi B
AD  - Division of Geriatrics and Nutritional Science, Washington University, St. Louis,
      MO, USA.
FAU - Fontana, Luigi
AU  - Fontana L
AD  - Division of Geriatrics and Nutritional Science, Washington University, St. Louis,
      MO, USA.
AD  - Department of Clinical and Experimental Sciences, Brescia University Medical
      School, Brescia, Italy.
LA  - eng
PT  - Journal Article
DEP - 20171213
PL  - United States
TA  - J Gerontol A Biol Sci Med Sci
JT  - The journals of gerontology. Series A, Biological sciences and medical sciences
JID - 9502837
OTO - NOTNLM
OT  - Mediterranean diet
OT  - cancer
OT  - cardiovascular disease
EDAT- 2017/12/16 06:00
MHDA- 2017/12/16 06:00
CRDT- 2017/12/16 06:00
PHST- 2017/11/01 00:00 [received]
PHST- 2017/12/16 06:00 [entrez]
PHST- 2017/12/16 06:00 [pubmed]
PHST- 2017/12/16 06:00 [medline]
AID - 4736301 [pii]
AID - 10.1093/gerona/glx227 [doi]
PST - aheadofprint
SO  - J Gerontol A Biol Sci Med Sci. 2017 Dec 13. pii: 4736301. doi:
      10.1093/gerona/glx227.

PMID- 29194581
OWN - NLM
STAT- Publisher
LR  - 20171201
IS  - 1542-4863 (Electronic)
IS  - 0007-9235 (Linking)
DP  - 2017 Dec 1
TI  - Hodgkin lymphoma: A review and update on recent progress.
LID - 10.3322/caac.21438 [doi]
AB  - Hodgkin lymphoma (HL) is a unique hematopoietic neoplasm characterized by
      cancerous Reed-Sternberg cells in an inflammatory background. Patients are
      commonly diagnosed with HL in their 20s and 30s, and they present with
      supradiaphragmatic lymphadenopathy, often with systemic B symptoms. Even in
      advanced-stage disease, HL is highly curable with combination chemotherapy,
      radiation, or combined-modality treatment. Although the same doxorubicin,
      bleomycin, vinblastine, and dacarbazine chemotherapeutic regimen has been the
      mainstay of therapy over the last 30 years, risk-adapted approaches have helped
      de-escalate therapy in low-risk patients while intensifying treatment for higher 
      risk patients. Even patients who are not cured with initial therapy can often be 
      salvaged with alternate chemotherapy combinations, the novel antibody-drug
      conjugate brentuximab, or high-dose autologous or allogeneic hematopoietic stem
      cell transplantation. The programmed death-1 inhibitors nivolumab and
      pembrolizumab have both demonstrated high response rates and durable remissions
      in patients with relapsed/refractory HL. Alternate donor sources and
      reduced-intensity conditioning have made allogeneic hematopoietic stem cell
      transplantation a viable option for more patients. Future research will look to
      integrate novel strategies into earlier lines of therapy to improve the HL cure
      rate and minimize long-term treatment toxicities. CA Cancer J Clin 2017. (c) 2017
      American Cancer Society.
CI  - (c) 2017 American Cancer Society.
FAU - Shanbhag, Satish
AU  - Shanbhag S
AUID- ORCID: http://orcid.org/0000-0003-0663-6221
AD  - Assistant Professor of Medicine, Departments of Medicine and Oncology, Johns
      Hopkins University School of Medicine, Baltimore, MD.
FAU - Ambinder, Richard F
AU  - Ambinder RF
AD  - Director, Division of Hematologic Malignancies and Professor of Oncology,
      Departments of Medicine and Oncology, Johns Hopkins University School of
      Medicine, Baltimore, MD.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20171201
PL  - United States
TA  - CA Cancer J Clin
JT  - CA: a cancer journal for clinicians
JID - 0370647
OTO - NOTNLM
OT  - Hodgkin lymphoma
OT  - allogeneic stem cell transplantation
OT  - antibody-drug conjugate
OT  - brentuximab
OT  - immunotherapy
OT  - positron emission tomography (PET)-adapted therapy
OT  - programmed death 1 (PD-1) inhibitor
EDAT- 2017/12/02 06:00
MHDA- 2017/12/02 06:00
CRDT- 2017/12/02 06:00
PHST- 2017/08/10 00:00 [received]
PHST- 2017/09/18 00:00 [revised]
PHST- 2017/09/18 00:00 [accepted]
PHST- 2017/12/02 06:00 [entrez]
PHST- 2017/12/02 06:00 [pubmed]
PHST- 2017/12/02 06:00 [medline]
AID - 10.3322/caac.21438 [doi]
PST - aheadofprint
SO  - CA Cancer J Clin. 2017 Dec 1. doi: 10.3322/caac.21438.

PMID- 29144972
OWN - NLM
STAT- MEDLINE
DCOM- 20171222
LR  - 20171222
IS  - 1097-4199 (Electronic)
IS  - 0896-6273 (Linking)
VI  - 96
IP  - 4
DP  - 2017 Nov 15
TI  - Building Bridges through Science.
PG  - 730-735
LID - S0896-6273(17)30872-3 [pii]
LID - 10.1016/j.neuron.2017.09.028 [doi]
AB  - Science is ideally suited to connect people from different cultures and thereby
      foster mutual understanding. To promote international life science collaboration,
      we have launched "The Science Bridge" initiative. Our current project focuses on 
      partnership between Western and Middle Eastern neuroscience communities.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Lissek, Thomas
AU  - Lissek T
AD  - Heidelberg University, 69120 Heidelberg, Germany.
FAU - Adams, Michelle
AU  - Adams M
AD  - Bilkent University, 06800 Bilkent, Ankara, Turkey.
FAU - Adelman, John
AU  - Adelman J
AD  - Vollum Institute, Oregon Health & Science University, Portland, OR 97239, USA.
FAU - Ahissar, Ehud
AU  - Ahissar E
AD  - Weizmann Institute of Science, Rehovot 76100, Israel.
FAU - Akaaboune, Mohammed
AU  - Akaaboune M
AD  - University of Michigan, Ann Arbor, MI 48109-1048, USA.
FAU - Akil, Huda
AU  - Akil H
AD  - University of Michigan, Ann Arbor, MI 48109-1048, USA.
FAU - al'Absi, Mustafa
AU  - al'Absi M
AD  - University of Minnesota Medical School, Duluth, MN 55812, USA.
FAU - Arain, Fazal
AU  - Arain F
AD  - Aga Khan University, Karachi 74800, Pakistan.
FAU - Arango-Lasprilla, Juan Carlos
AU  - Arango-Lasprilla JC
AD  - BioCruces Health Research Institute, 48903 Barakaldo, Spain.
FAU - Atasoy, Deniz
AU  - Atasoy D
AD  - Istanbul Medipol University, 34810 Beykoz/Istanbul, Turkey.
FAU - Avila, Jesus
AU  - Avila J
AD  - Centro de Investigacion en Red de Enfermedades Neurodegenerativas (CIBERNED),
      ISCIII, 28031 Madrid, Spain.
FAU - Badawi, Ashraf
AU  - Badawi A
AD  - University of Science and Technology, Zewail City, 12578 Giza, Egypt.
FAU - Bading, Hilmar
AU  - Bading H
AD  - Heidelberg University, 69120 Heidelberg, Germany.
FAU - Baig, Abdul Mannan
AU  - Baig AM
AD  - Aga Khan University, Karachi 74800, Pakistan.
FAU - Baleriola, Jimena
AU  - Baleriola J
AD  - Achucarro Basque Center for Neuroscience, 48940 Leioa, Spain.
FAU - Belmonte, Carlos
AU  - Belmonte C
AD  - Instituto de Neurociencias, UMH-CSIC, 03550 San Juan De Alicante, Spain.
FAU - Bertocchi, Ilaria
AU  - Bertocchi I
AD  - Neuroscience Institute Cavalieri Ottolenghi, 10043 Torino, Italy.
FAU - Betz, Heinrich
AU  - Betz H
AD  - Max Planck Institute for Medical Research, 69120 Heidelberg, Germany.
FAU - Blakemore, Colin
AU  - Blakemore C
AD  - School of Advanced Study, University of London, London WC1E 7HU, UK.
FAU - Blanke, Olaf
AU  - Blanke O
AD  - Center for Neuroprosthetics, Swiss Federal Institute of Technology, 1002 Geneva, 
      Switzerland.
FAU - Boehm-Sturm, Philipp
AU  - Boehm-Sturm P
AD  - Charite - Universitatsmedizin Berlin, 10117 Berlin, Germany.
FAU - Bonhoeffer, Tobias
AU  - Bonhoeffer T
AD  - Max Planck Institute for Neurobiology, 82152 Martinsried, Germany.
FAU - Bonifazi, Paolo
AU  - Bonifazi P
AD  - BioCruces Health Research Institute, 48903 Barakaldo, Spain.
FAU - Brose, Nils
AU  - Brose N
AD  - Max-Planck Institute of Experimental Medicine, 37075 Gottingen, Germany.
FAU - Campolongo, Patrizia
AU  - Campolongo P
AD  - Sapienza University of Rome, 00185 Rome, Italy.
FAU - Celikel, Tansu
AU  - Celikel T
AD  - Radboud University, 6525 HP Nijmegen, Netherlands.
FAU - Chang, Cathy C
AU  - Chang CC
AD  - Dartmouth College, Hanover, NH 03755, USA.
FAU - Chang, Ta-Yuan
AU  - Chang TY
AD  - Dartmouth College, Hanover, NH 03755, USA.
FAU - Citri, Ami
AU  - Citri A
AD  - The Hebrew University, Jerusalem 9190401, Israel.
FAU - Cline, Hollis T
AU  - Cline HT
AD  - The Scripps Research Institute, La Jolla, CA 92037, USA.
FAU - Cortes, Jesus M
AU  - Cortes JM
AD  - BioCruces Health Research Institute, 48903 Barakaldo, Spain.
FAU - Cullen, Kathleen
AU  - Cullen K
AD  - Johns Hopkins University, Baltimore, MD 21218, USA.
FAU - Dean, Kellie
AU  - Dean K
AD  - University College Cork, Cork T12 YN60, Ireland.
FAU - Delgado-Garcia, Jose M
AU  - Delgado-Garcia JM
AD  - Universidad Pablo de Olivide, 41013 Seville, Spain.
FAU - Desroches, Mathieu
AU  - Desroches M
AD  - Inria, Sophia Antipolis Research Centre, 06902 Sophia Antipolis Cedex, France.
FAU - Disterhoft, John F
AU  - Disterhoft JF
AD  - Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA.
FAU - Dowling, John E
AU  - Dowling JE
AD  - Harvard University, Cambridge, MA 02138, USA.
FAU - Draguhn, Andreas
AU  - Draguhn A
AD  - Heidelberg University, 69120 Heidelberg, Germany.
FAU - El-Khamisy, Sherif F
AU  - El-Khamisy SF
AD  - University of Science and Technology, Zewail City, 12578 Giza, Egypt.
FAU - El Manira, Abdeljabbar
AU  - El Manira A
AD  - Karolinska Institute, 171 77 Stockholm, Sweden.
FAU - Enam, S Ather
AU  - Enam SA
AD  - Aga Khan University, Karachi 74800, Pakistan.
FAU - Encinas, Juan M
AU  - Encinas JM
AD  - Achucarro Basque Center for Neuroscience, 48940 Leioa, Spain.
FAU - Erramuzpe, Asier
AU  - Erramuzpe A
AD  - BioCruces Health Research Institute, 48903 Barakaldo, Spain.
FAU - Esteban, Jose A
AU  - Esteban JA
AD  - Centro de Biologia Molecular Severo Ochoa (CSIC/UAM), 28049 Madrid, Spain.
FAU - Farinas, Isabel
AU  - Farinas I
AD  - Universidad de Valencia, 46100 Burjassot, Spain.
FAU - Fischer, Edmond
AU  - Fischer E
AD  - University of Washington, Seattle, WA 98195, USA.
FAU - Fukunaga, Izumi
AU  - Fukunaga I
AD  - Okinawa Institute of Science and Technology Graduate University Okinawa 904-0495,
      Japan.
FAU - Gabilondo, Inigo
AU  - Gabilondo I
AD  - Hospital Universitario Cruces, 48903 Barakaldo, Spain.
FAU - Ganten, Detlev
AU  - Ganten D
AD  - Charite-Universitatsmedizin Berlin, 10117 Berlin, Germany.
FAU - Gidon, Albert
AU  - Gidon A
AD  - Charite-Universitatsmedizin Berlin, 10117 Berlin, Germany.
FAU - Gomez-Esteban, Juan Carlos
AU  - Gomez-Esteban JC
AD  - Hospital Universitario Cruces, 48903 Barakaldo, Spain.
FAU - Greengard, Paul
AU  - Greengard P
AD  - Rockefeller University, New York, NY 10065, USA.
FAU - Grinevich, Valery
AU  - Grinevich V
AD  - German Cancer Research Center, 69120 Heidelberg, Germany.
FAU - Gruart, Agnes
AU  - Gruart A
AD  - Universidad Pablo de Olivide, 41013 Seville, Spain.
FAU - Guillemin, Roger
AU  - Guillemin R
AD  - Salk Institute, La Jolla, CA 92037, USA.
FAU - Hariri, Ahmad R
AU  - Hariri AR
AD  - Duke University, Durham, NC 27708, USA.
FAU - Hassan, Bassem
AU  - Hassan B
AD  - Institut du Cerveau et de la Moelle Epiniere (ICM) - Hopital Pitie-Salpetriere,
      UPMC, Sorbonne Universites, Inserm, CNRS, 75013 Paris, France.
FAU - Hausser, Michael
AU  - Hausser M
AD  - University College London, London WC1E 6BT, UK.
FAU - Hayashi, Yasunori
AU  - Hayashi Y
AD  - Kyoto University Graduate School of Medicine, Kyoto 606-8501, Japan.
FAU - Hussain, Natasha K
AU  - Hussain NK
AD  - Johns Hopkins University, Baltimore, MD 21218, USA.
FAU - Jabbar, Adnan Abdul
AU  - Jabbar AA
AD  - Aga Khan University, Karachi 74800, Pakistan.
FAU - Jaber, Mohamed
AU  - Jaber M
AD  - INSERM U-1084, Universite de Poitiers, 86073 Poitiers, France.
FAU - Jahn, Reinhardt
AU  - Jahn R
AD  - Max Planck Institute for Biophysical Chemistry, 37077 Gottingen, Germany.
FAU - Janahi, Essam Mohammed
AU  - Janahi EM
AD  - Department of Biology, College of Science, University of Bahrain, Sakhir, P.O.
      Box 32038, Bahrain.
FAU - Kabbaj, Mohamed
AU  - Kabbaj M
AD  - Florida State University, Tallahassee, FL 32306, USA.
FAU - Kettenmann, Helmut
AU  - Kettenmann H
AD  - Max Delbruck Center for Molecular Medicine, 13125 Berlin, Germany.
FAU - Kindt, Merel
AU  - Kindt M
AD  - University of Amsterdam, 1012 WX Amsterdam, Netherlands.
FAU - Knafo, Shira
AU  - Knafo S
AD  - Universidad del Pais Vasco, 48940 Leioa, Spain.
FAU - Kohr, Georg
AU  - Kohr G
AD  - Central Institute of Mental Health, 68159 Mannheim, Germany.
FAU - Komai, Shoji
AU  - Komai S
AD  - NARA Institute of Science and Technology, Ikoma, Nara 630-0192, Japan.
FAU - Krugers, Harm
AU  - Krugers H
AD  - University of Amsterdam, 1012 WX Amsterdam, Netherlands.
FAU - Kuhn, Bernd
AU  - Kuhn B
AD  - Okinawa Institute of Science and Technology Graduate University Okinawa 904-0495,
      Japan.
FAU - Ghazal, Nouria Lakhdar
AU  - Ghazal NL
AD  - Mohammed V University of Rabat, 10500 Rabat, Morocco.
FAU - Larkum, Matthew E
AU  - Larkum ME
AD  - Humboldt University, 10117 Berlin, Germany.
FAU - London, Mickey
AU  - London M
AD  - The Hebrew University, Jerusalem 9190401, Israel.
FAU - Lutz, Beat
AU  - Lutz B
AD  - University Medical Center, 55131 Mainz, Germany.
FAU - Matute, Carlos
AU  - Matute C
AD  - Achucarro Basque Center for Neuroscience, 48940 Leioa, Spain.
FAU - Martinez-Millan, Luis
AU  - Martinez-Millan L
AD  - Achucarro Basque Center for Neuroscience, 48940 Leioa, Spain.
FAU - Maroun, Mouna
AU  - Maroun M
AD  - University of Haifa, 3498838 Haifa, Israel.
FAU - McGaugh, James
AU  - McGaugh J
AD  - University of California Irvine, CA 92697, USA.
FAU - Moustafa, Ahmed A
AU  - Moustafa AA
AD  - Western Sydney University, Penrith NSW 2751, Australia.
FAU - Nasim, Anwar
AU  - Nasim A
AD  - Pakistan Academy of Sciences, Islamabad 44000, Pakistan.
FAU - Nave, Klaus-Armin
AU  - Nave KA
AD  - Max-Planck Institute of Experimental Medicine, 37075 Gottingen, Germany.
FAU - Neher, Erwin
AU  - Neher E
AD  - Max Planck Institute for Biophysical Chemistry, 37077 Gottingen, Germany.
FAU - Nikolich, Karoly
AU  - Nikolich K
AD  - Stanford University, Stanford, CA 94305, USA.
FAU - Outeiro, Tiago
AU  - Outeiro T
AD  - University Medical Center Gottingen, 37075 Gottingen, Germany.
FAU - Palmer, Lucy M
AU  - Palmer LM
AD  - Florey institute of Neuroscience and Mental Health, University of Melbourne, 3010
      Australia.
FAU - Penagarikano, Olga
AU  - Penagarikano O
AD  - University of the Basque Country, 48940 Leioa, Spain.
FAU - Perez-Otano, Isabel
AU  - Perez-Otano I
AD  - Instituto de Neurociencias, UMH-CSIC, 03550 San Juan De Alicante, Spain.
FAU - Pfaff, Donald W
AU  - Pfaff DW
AD  - Rockefeller University, New York, NY 10065, USA.
FAU - Poucet, Bruno
AU  - Poucet B
AD  - Aix-Marseille Universite - Centre National de la Recherche Scientifique, 13331
      Marseille, France.
FAU - Rahman, Atta-Ur
AU  - Rahman AU
AD  - University of Karachi, 75270 Karachi, Pakistan.
FAU - Ramos-Cabrer, Pedro
AU  - Ramos-Cabrer P
AD  - CIC biomaGUNE, 20014 Donostia-San Sebastian, Spain.
FAU - Rashidy-Pour, Ali
AU  - Rashidy-Pour A
AD  - Semnan University of Medical Sciences, Semnan, P.O.Box 35131-19111, Iran.
FAU - Roberts, Richard J
AU  - Roberts RJ
AD  - New England Biolabs Inc., Ipswich, MA 01938, USA.
FAU - Rodrigues, Serafim
AU  - Rodrigues S
AD  - Basque Center for Applied Mathematics, 48009 Bilbao, Spain.
FAU - Sanes, Joshua R
AU  - Sanes JR
AD  - Harvard University, Cambridge, MA 02138, USA.
FAU - Schaefer, Andreas T
AU  - Schaefer AT
AD  - The Francis Crick Institute, London NW1 1AT, UK.
FAU - Segal, Menahem
AU  - Segal M
AD  - Weizmann Institute of Science, Rehovot 76100, Israel.
FAU - Segev, Idan
AU  - Segev I
AD  - The Hebrew University, Jerusalem 9190401, Israel.
FAU - Shafqat, Saad
AU  - Shafqat S
AD  - Aga Khan University, Karachi 74800, Pakistan.
FAU - Siddiqui, Nikhat Ahmed
AU  - Siddiqui NA
AD  - Barrett Hodgson University, Karachi 74900, Pakistan.
FAU - Soreq, Hermona
AU  - Soreq H
AD  - The Hebrew University, Jerusalem 9190401, Israel.
FAU - Soriano-Garcia, Eduardo
AU  - Soriano-Garcia E
AD  - University of Barcelona, 08007 Barcelona, Spain.
FAU - Spanagel, Rainer
AU  - Spanagel R
AD  - Central Institute of Mental Health, 68159 Mannheim, Germany.
FAU - Sprengel, Rolf
AU  - Sprengel R
AD  - Max Planck Institute for Medical Research, 69120 Heidelberg, Germany.
FAU - Stuart, Greg
AU  - Stuart G
AD  - Australian National University, Acton ACT 2601, Australia.
FAU - Sudhof, Thomas C
AU  - Sudhof TC
AD  - Stanford University, Stanford, CA 94305, USA.
FAU - Tonnesen, Jan
AU  - Tonnesen J
AD  - Achucarro Basque Center for Neuroscience, 48940 Leioa, Spain.
FAU - Trevino, Mario
AU  - Trevino M
AD  - Universidad de Guadalajara, 44100 Guadalajara, Mexico.
FAU - Uthman, Basim M
AU  - Uthman BM
AD  - Weill Cornell Medicine in Qatar, P.O. Box 24144, Doha, Qatar.
FAU - Venter, J Craig
AU  - Venter JC
AD  - J. Craig Venter Institute, La Jolla, CA 92037, USA.
FAU - Verkhratsky, Alexei
AU  - Verkhratsky A
AD  - The University of Manchester, Manchester M13 9PL, UK.
FAU - Weiss, Craig
AU  - Weiss C
AD  - Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA.
FAU - Wiesel, Torsten N
AU  - Wiesel TN
AD  - Rockefeller University, New York, NY 10065, USA.
FAU - Yaksi, Emre
AU  - Yaksi E
AD  - Kavli Institute for Systems Neuroscience, 7030 Trondheim, Norway.
FAU - Yizhar, Ofer
AU  - Yizhar O
AD  - Weizmann Institute of Science, Rehovot 76100, Israel.
FAU - Young, Larry J
AU  - Young LJ
AD  - Emory University, Atlanta, GA 30322, USA.
FAU - Young, Paul
AU  - Young P
AD  - University College Cork, Cork T12 YN60, Ireland.
FAU - Zawia, Nasser H
AU  - Zawia NH
AD  - University of Rhode Island, Kingston, RI 02881, USA.
FAU - Zugaza, Jose L
AU  - Zugaza JL
AD  - Achucarro Basque Center for Neuroscience, 48940 Leioa, Spain.
FAU - Hasan, Mazahir T
AU  - Hasan MT
AD  - Achucarro Basque Center for Neuroscience, 48940 Leioa, Spain. Electronic address:
      mazahir.hasan@achucarro.org.
LA  - eng
PT  - Historical Article
PT  - Journal Article
PL  - United States
TA  - Neuron
JT  - Neuron
JID - 8809320
SB  - IM
MH  - Europe
MH  - History, 15th Century
MH  - History, 21st Century
MH  - History, Ancient
MH  - History, Medieval
MH  - Humans
MH  - *International Cooperation
MH  - Middle East
MH  - Neurosciences/*history
EDAT- 2017/11/18 06:00
MHDA- 2017/12/23 06:00
CRDT- 2017/11/18 06:00
PHST- 2017/08/25 00:00 [received]
PHST- 2017/09/16 00:00 [revised]
PHST- 2017/09/19 00:00 [accepted]
PHST- 2017/11/18 06:00 [entrez]
PHST- 2017/11/18 06:00 [pubmed]
PHST- 2017/12/23 06:00 [medline]
AID - S0896-6273(17)30872-3 [pii]
AID - 10.1016/j.neuron.2017.09.028 [doi]
PST - ppublish
SO  - Neuron. 2017 Nov 15;96(4):730-735. doi: 10.1016/j.neuron.2017.09.028.

PMID- 29186115
OWN - NLM
STAT- In-Data-Review
LR  - 20180119
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 552
IP  - 7683
DP  - 2017 Dec 7
TI  - A transfer-RNA-derived small RNA regulates ribosome biogenesis.
PG  - 57-62
LID - 10.1038/nature25005 [doi]
AB  - Transfer-RNA-derived small RNAs (tsRNAs; also called tRNA-derived fragments) are 
      an abundant class of small non-coding RNAs whose biological roles are not well
      understood. Here we show that inhibition of a specific tsRNA, LeuCAG3'tsRNA,
      induces apoptosis in rapidly dividing cells in vitro and in a patient-derived
      orthotopic hepatocellular carcinoma model in mice. This tsRNA binds at least two 
      ribosomal protein mRNAs (RPS28 and RPS15) to enhance their translation. A
      decrease in translation of RPS28 mRNA blocks pre-18S ribosomal RNA processing,
      resulting in a reduction in the number of 40S ribosomal subunits. These data
      establish a post-transcriptional mechanism that can fine-tune gene expression
      during different physiological states and provide a potential new target for
      treating cancer.
FAU - Kim, Hak Kyun
AU  - Kim HK
AD  - Department of Pediatrics, Stanford University, Stanford, California 94305, USA.
AD  - Department of Genetics, Stanford University, Stanford, California 94305, USA.
FAU - Fuchs, Gabriele
AU  - Fuchs G
AD  - Department of Microbiology and Immunology, Stanford University, Stanford,
      California 94305, USA.
FAU - Wang, Shengchun
AU  - Wang S
AD  - Department of Pediatrics, Stanford University, Stanford, California 94305, USA.
AD  - Department of Genetics, Stanford University, Stanford, California 94305, USA.
FAU - Wei, Wei
AU  - Wei W
AD  - Asian Liver Center, Department of Surgery, Stanford University School of
      Medicine, Stanford, California 94305, USA.
FAU - Zhang, Yue
AU  - Zhang Y
AD  - Department of Pediatrics, Stanford University, Stanford, California 94305, USA.
AD  - Department of Genetics, Stanford University, Stanford, California 94305, USA.
FAU - Park, Hyesuk
AU  - Park H
AD  - Department of Pediatrics, Stanford University, Stanford, California 94305, USA.
AD  - Department of Genetics, Stanford University, Stanford, California 94305, USA.
FAU - Roy-Chaudhuri, Biswajoy
AU  - Roy-Chaudhuri B
AD  - Department of Pediatrics, Stanford University, Stanford, California 94305, USA.
AD  - Department of Genetics, Stanford University, Stanford, California 94305, USA.
FAU - Li, Pan
AU  - Li P
AD  - MOE Key Laboratory of Bioinformatics, Beijing Advanced Innovation Center for
      Structural Biology, Center for Synthetic and Systems Biology, Tsinghua-Peking
      Joint Center for Life Sciences, School of Life Sciences, Tsinghua University,
      Beijing 100084, China.
FAU - Xu, Jianpeng
AU  - Xu J
AD  - Department of Pediatrics, Stanford University, Stanford, California 94305, USA.
AD  - Department of Genetics, Stanford University, Stanford, California 94305, USA.
FAU - Chu, Kirk
AU  - Chu K
AD  - Department of Pediatrics, Stanford University, Stanford, California 94305, USA.
AD  - Department of Genetics, Stanford University, Stanford, California 94305, USA.
FAU - Zhang, Feijie
AU  - Zhang F
AD  - Department of Pediatrics, Stanford University, Stanford, California 94305, USA.
AD  - Department of Genetics, Stanford University, Stanford, California 94305, USA.
FAU - Chua, Mei-Sze
AU  - Chua MS
AD  - Asian Liver Center, Department of Surgery, Stanford University School of
      Medicine, Stanford, California 94305, USA.
FAU - So, Samuel
AU  - So S
AD  - Asian Liver Center, Department of Surgery, Stanford University School of
      Medicine, Stanford, California 94305, USA.
FAU - Zhang, Qiangfeng Cliff
AU  - Zhang QC
AD  - MOE Key Laboratory of Bioinformatics, Beijing Advanced Innovation Center for
      Structural Biology, Center for Synthetic and Systems Biology, Tsinghua-Peking
      Joint Center for Life Sciences, School of Life Sciences, Tsinghua University,
      Beijing 100084, China.
FAU - Sarnow, Peter
AU  - Sarnow P
AD  - Department of Microbiology and Immunology, Stanford University, Stanford,
      California 94305, USA.
FAU - Kay, Mark A
AU  - Kay MA
AD  - Department of Pediatrics, Stanford University, Stanford, California 94305, USA.
AD  - Department of Genetics, Stanford University, Stanford, California 94305, USA.
LA  - eng
GR  - R01 DK114483/DK/NIDDK NIH HHS/United States
PT  - Journal Article
DEP - 20171129
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
EDAT- 2017/12/01 06:00
MHDA- 2017/12/01 06:00
CRDT- 2017/11/30 06:00
PHST- 2017/04/19 00:00 [received]
PHST- 2017/11/07 00:00 [accepted]
PHST- 2017/12/01 06:00 [pubmed]
PHST- 2017/12/01 06:00 [medline]
PHST- 2017/11/30 06:00 [entrez]
AID - nature25005 [pii]
AID - 10.1038/nature25005 [doi]
PST - ppublish
SO  - Nature. 2017 Dec 7;552(7683):57-62. doi: 10.1038/nature25005. Epub 2017 Nov 29.

PMID- 29125603
OWN - NLM
STAT- In-Process
LR  - 20180101
IS  - 1476-5403 (Electronic)
IS  - 1350-9047 (Linking)
VI  - 25
IP  - 1
DP  - 2018 Jan
TI  - Cell cycle arrest through indirect transcriptional repression by p53: I have a
      DREAM.
PG  - 114-132
LID - 10.1038/cdd.2017.172 [doi]
AB  - Activation of the p53 tumor suppressor can lead to cell cycle arrest. The key
      mechanism of p53-mediated arrest is transcriptional downregulation of many cell
      cycle genes. In recent years it has become evident that p53-dependent repression 
      is controlled by the p53-p21-DREAM-E2F/CHR pathway (p53-DREAM pathway). DREAM is 
      a transcriptional repressor that binds to E2F or CHR promoter sites. Gene
      regulation and deregulation by DREAM shares many mechanistic characteristics with
      the retinoblastoma pRB tumor suppressor that acts through E2F elements. However, 
      because of its binding to E2F and CHR elements, DREAM regulates a larger set of
      target genes leading to regulatory functions distinct from pRB/E2F. The p53-DREAM
      pathway controls more than 250 mostly cell cycle-associated genes. The functional
      spectrum of these pathway targets spans from the G1 phase to the end of mitosis. 
      Consequently, through downregulating the expression of gene products which are
      essential for progression through the cell cycle, the p53-DREAM pathway
      participates in the control of all checkpoints from DNA synthesis to cytokinesis 
      including G1/S, G2/M and spindle assembly checkpoints. Therefore, defects in the 
      p53-DREAM pathway contribute to a general loss of checkpoint control.
      Furthermore, deregulation of DREAM target genes promotes chromosomal instability 
      and aneuploidy of cancer cells. Also, DREAM regulation is abrogated by the human 
      papilloma virus HPV E7 protein linking the p53-DREAM pathway to carcinogenesis by
      HPV. Another feature of the pathway is that it downregulates many genes involved 
      in DNA repair and telomere maintenance as well as Fanconi anemia. Importantly,
      when DREAM function is lost, CDK inhibitor drugs employed in cancer treatment
      such as Palbociclib, Abemaciclib and Ribociclib can compensate for defects in
      early steps in the pathway upstream from cyclin/CDK complexes. In summary, the
      p53-p21-DREAM-E2F/CHR pathway controls a plethora of cell cycle genes, can
      contribute to cell cycle arrest and is a target for cancer therapy.
FAU - Engeland, Kurt
AU  - Engeland K
AD  - Molecular Oncology, Medical School, University of Leipzig, Leipzig, Germany.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20171110
PL  - England
TA  - Cell Death Differ
JT  - Cell death and differentiation
JID - 9437445
PMC - PMC5729532
EDAT- 2017/11/11 06:00
MHDA- 2017/11/11 06:00
CRDT- 2017/11/11 06:00
PHST- 2017/07/21 00:00 [received]
PHST- 2017/09/10 00:00 [revised]
PHST- 2017/09/13 00:00 [accepted]
PHST- 2017/11/11 06:00 [pubmed]
PHST- 2017/11/11 06:00 [medline]
PHST- 2017/11/11 06:00 [entrez]
AID - cdd2017172 [pii]
AID - 10.1038/cdd.2017.172 [doi]
PST - ppublish
SO  - Cell Death Differ. 2018 Jan;25(1):114-132. doi: 10.1038/cdd.2017.172. Epub 2017
      Nov 10.

PMID- 29168504
OWN - NLM
STAT- In-Data-Review
LR  - 20171219
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 551
IP  - 7682
DP  - 2017 Nov 30
TI  - Mechanism of tandem duplication formation in BRCA1-mutant cells.
PG  - 590-595
LID - 10.1038/nature24477 [doi]
AB  - Small, approximately 10-kilobase microhomology-mediated tandem duplications are
      abundant in the genomes of BRCA1-linked but not BRCA2-linked breast cancer. Here 
      we define the mechanism underlying this rearrangement signature. We show that, in
      primary mammalian cells, BRCA1, but not BRCA2, suppresses the formation of tandem
      duplications at a site-specific chromosomal replication fork barrier imposed by
      the binding of Tus proteins to an array of Ter sites. BRCA1 has no equivalent
      role at chromosomal double-stranded DNA breaks, indicating that tandem
      duplications form specifically at stalled forks. Tandem duplications in BRCA1
      mutant cells arise by a replication restart-bypass mechanism terminated by end
      joining or by microhomology-mediated template switching, the latter forming
      complex tandem duplication breakpoints. Solitary DNA ends form directly at
      Tus-Ter, implicating misrepair of these lesions in tandem duplication formation. 
      Furthermore, BRCA1 inactivation is strongly associated with ~10 kilobase tandem
      duplications in ovarian cancer. This tandem duplicator phenotype may be a general
      signature of BRCA1-deficient cancer.
FAU - Willis, Nicholas A
AU  - Willis NA
AD  - Department of Medicine, Division of Hematology-Oncology and Cancer Research
      Institute, Beth Israel Deaconess Medical Center and Harvard Medical School,
      Boston, Massachusetts, USA.
FAU - Frock, Richard L
AU  - Frock RL
AD  - Boston Children's Hospital, Howard Hughes Medical Institute and Department of
      Genetics, Harvard Medical School, Boston, Massachusetts, USA.
FAU - Menghi, Francesca
AU  - Menghi F
AD  - The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut, USA.
FAU - Duffey, Erin E
AU  - Duffey EE
AD  - Department of Medicine, Division of Hematology-Oncology and Cancer Research
      Institute, Beth Israel Deaconess Medical Center and Harvard Medical School,
      Boston, Massachusetts, USA.
FAU - Panday, Arvind
AU  - Panday A
AD  - Department of Medicine, Division of Hematology-Oncology and Cancer Research
      Institute, Beth Israel Deaconess Medical Center and Harvard Medical School,
      Boston, Massachusetts, USA.
FAU - Camacho, Virginia
AU  - Camacho V
AD  - Department of Medicine, Flow Cytometry Core, Beth Israel Deaconess Medical
      Center, Boston, Massachusetts, USA.
FAU - Hasty, E Paul
AU  - Hasty EP
AD  - The University of Texas Health Science Center at San Antonio, San Antonio, Texas,
      USA.
FAU - Liu, Edison T
AU  - Liu ET
AD  - The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut, USA.
AD  - The Jackson Laboratory, Bar Harbor, Maine, USA.
FAU - Alt, Frederick W
AU  - Alt FW
AD  - Boston Children's Hospital, Howard Hughes Medical Institute and Department of
      Genetics, Harvard Medical School, Boston, Massachusetts, USA.
FAU - Scully, Ralph
AU  - Scully R
AD  - Department of Medicine, Division of Hematology-Oncology and Cancer Research
      Institute, Beth Israel Deaconess Medical Center and Harvard Medical School,
      Boston, Massachusetts, USA.
LA  - eng
GR  - R01 ES022054/ES/NIEHS NIH HHS/United States
GR  - R01 CA095175/CA/NCI NIH HHS/United States
GR  - P30 CA034196/CA/NCI NIH HHS/United States
GR  - P50 CA168504/CA/NCI NIH HHS/United States
GR  - R01 CA188032/CA/NCI NIH HHS/United States
GR  - R21 AG042848/AG/NIA NIH HHS/United States
GR  - R01 CA217991/CA/NCI NIH HHS/United States
GR  - R21 ES027776/ES/NIEHS NIH HHS/United States
PT  - Journal Article
DEP - 20171122
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
PMC - PMC5728692
MID - NIHMS911888
EDAT- 2017/11/24 06:00
MHDA- 2017/11/24 06:00
CRDT- 2017/11/24 06:00
PMCR- 2018/05/22 00:00
PHST- 2016/08/01 00:00 [received]
PHST- 2017/10/09 00:00 [accepted]
PHST- 2018/05/22 00:00 [pmc-release]
PHST- 2017/11/24 06:00 [pubmed]
PHST- 2017/11/24 06:00 [medline]
PHST- 2017/11/24 06:00 [entrez]
AID - nature24477 [pii]
AID - 10.1038/nature24477 [doi]
PST - ppublish
SO  - Nature. 2017 Nov 30;551(7682):590-595. doi: 10.1038/nature24477. Epub 2017 Nov
      22.

PMID- 29072292
OWN - NLM
STAT- In-Data-Review
LR  - 20180117
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 551
IP  - 7678
DP  - 2017 Nov 2
TI  - IL-1R8 is a checkpoint in NK cells regulating anti-tumour and anti-viral
      activity.
PG  - 110-114
LID - 10.1038/nature24293 [doi]
AB  - Interleukin-1 receptor 8 (IL-1R8, also known as single immunoglobulin
      IL-1R-related receptor, SIGIRR, or TIR8) is a member of the IL-1 receptor (ILR)
      family with distinct structural and functional characteristics, acting as a
      negative regulator of ILR and Toll-like receptor (TLR) downstream signalling
      pathways and inflammation. Natural killer (NK) cells are innate lymphoid cells
      which mediate resistance against pathogens and contribute to the activation and
      orientation of adaptive immune responses. NK cells mediate resistance against
      haematopoietic neoplasms but are generally considered to play a minor role in
      solid tumour carcinogenesis. Here we report that IL-1R8 serves as a checkpoint
      for NK cell maturation and effector function. Its genetic blockade unleashes
      NK-cell-mediated resistance to hepatic carcinogenesis, haematogenous liver and
      lung metastasis, and cytomegalovirus infection.
FAU - Molgora, Martina
AU  - Molgora M
AD  - Humanitas Clinical and Research Center, 20089 Rozzano, Italy.
FAU - Bonavita, Eduardo
AU  - Bonavita E
AD  - Humanitas Clinical and Research Center, 20089 Rozzano, Italy.
FAU - Ponzetta, Andrea
AU  - Ponzetta A
AD  - Humanitas Clinical and Research Center, 20089 Rozzano, Italy.
FAU - Riva, Federica
AU  - Riva F
AD  - Department of Animal Pathology, Faculty of Veterinary Medicine, University of
      Milan, 20133 Milan, Italy.
FAU - Barbagallo, Marialuisa
AU  - Barbagallo M
AD  - Humanitas Clinical and Research Center, 20089 Rozzano, Italy.
FAU - Jaillon, Sebastien
AU  - Jaillon S
AD  - Humanitas Clinical and Research Center, 20089 Rozzano, Italy.
AD  - Department of Biomedical Sciences, Humanitas University, 20090 Pieve Emanuele
      Milan, Italy.
FAU - Popovic, Branka
AU  - Popovic B
AD  - Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia.
FAU - Bernardini, Giovanni
AU  - Bernardini G
AD  - Dipartimento di Medicina Molecolare Istituto Pasteur-Fondazione Cenci Bolognetti,
      Universita di Roma "La Sapienza", 00161 Rome, Italy.
AD  - IRCCS Neuromed, 86077 Pozzilli (IS), Italy.
FAU - Magrini, Elena
AU  - Magrini E
AD  - Humanitas Clinical and Research Center, 20089 Rozzano, Italy.
FAU - Gianni, Francesca
AU  - Gianni F
AD  - Humanitas Clinical and Research Center, 20089 Rozzano, Italy.
FAU - Zelenay, Santiago
AU  - Zelenay S
AD  - Cancer Research UK Manchester Institute, The University of Manchester, Manchester
      M20 4QL, UK.
FAU - Jonjic, Stipan
AU  - Jonjic S
AD  - Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia.
FAU - Santoni, Angela
AU  - Santoni A
AD  - Dipartimento di Medicina Molecolare Istituto Pasteur-Fondazione Cenci Bolognetti,
      Universita di Roma "La Sapienza", 00161 Rome, Italy.
AD  - IRCCS Neuromed, 86077 Pozzilli (IS), Italy.
FAU - Garlanda, Cecilia
AU  - Garlanda C
AD  - Humanitas Clinical and Research Center, 20089 Rozzano, Italy.
AD  - Department of Biomedical Sciences, Humanitas University, 20090 Pieve Emanuele
      Milan, Italy.
FAU - Mantovani, Alberto
AU  - Mantovani A
AD  - Humanitas Clinical and Research Center, 20089 Rozzano, Italy.
AD  - Department of Biomedical Sciences, Humanitas University, 20090 Pieve Emanuele
      Milan, Italy.
AD  - The William Harvey Research Institute, Queen Mary University of London, London
      EC1M 6BQ, UK.
LA  - eng
PT  - Journal Article
DEP - 20171025
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
PMC - PMC5768243
MID - EMS74230
EDAT- 2017/10/27 06:00
MHDA- 2017/10/27 06:00
CRDT- 2017/10/27 06:00
PMCR- 2018/04/25 00:00
PHST- 2016/09/22 00:00 [received]
PHST- 2017/09/19 00:00 [accepted]
PHST- 2018/04/25 00:00 [pmc-release]
PHST- 2017/10/27 06:00 [pubmed]
PHST- 2017/10/27 06:00 [medline]
PHST- 2017/10/27 06:00 [entrez]
AID - nature24293 [pii]
AID - 10.1038/nature24293 [doi]
PST - ppublish
SO  - Nature. 2017 Nov 2;551(7678):110-114. doi: 10.1038/nature24293. Epub 2017 Oct 25.

PMID- 29170278
OWN - NLM
STAT- In-Process
LR  - 20180108
IS  - 1095-9203 (Electronic)
IS  - 0036-8075 (Linking)
VI  - 359
IP  - 6371
DP  - 2018 Jan 5
TI  - A mitosis-specific and R loop-driven ATR pathway promotes faithful chromosome
      segregation.
PG  - 108-114
LID - 10.1126/science.aan6490 [doi]
AB  - The ataxia telangiectasia mutated and Rad3-related (ATR) kinase is crucial for
      DNA damage and replication stress responses. Here, we describe an unexpected role
      of ATR in mitosis. Acute inhibition or degradation of ATR in mitosis induces
      whole-chromosome missegregation. The effect of ATR ablation is not due to altered
      cyclin-dependent kinase 1 (CDK1) activity, DNA damage responses, or unscheduled
      DNA synthesis but to loss of an ATR function at centromeres. In mitosis, ATR
      localizes to centromeres through Aurora A-regulated association with centromere
      protein F (CENP-F), allowing ATR to engage replication protein A (RPA)-coated
      centromeric R loops. As ATR is activated at centromeres, it stimulates Aurora B
      through Chk1, preventing formation of lagging chromosomes. Thus, a
      mitosis-specific and R loop-driven ATR pathway acts at centromeres to promote
      faithful chromosome segregation, revealing functions of R loops and ATR in
      suppressing chromosome instability.
CI  - Copyright (c) 2018, American Association for the Advancement of Science.
FAU - Kabeche, Lilian
AU  - Kabeche L
AUID- ORCID: 0000-0001-9917-856X
AD  - Massachusetts General Hospital Cancer Center, Harvard Medical School,
      Charlestown, MA 02129, USA.
FAU - Nguyen, Hai Dang
AU  - Nguyen HD
AUID- ORCID: 0000-0002-4200-8778
AD  - Massachusetts General Hospital Cancer Center, Harvard Medical School,
      Charlestown, MA 02129, USA.
FAU - Buisson, Remi
AU  - Buisson R
AUID- ORCID: 0000-0002-7196-8209
AD  - Massachusetts General Hospital Cancer Center, Harvard Medical School,
      Charlestown, MA 02129, USA.
FAU - Zou, Lee
AU  - Zou L
AUID- ORCID: 0000-0003-3094-1058
AD  - Massachusetts General Hospital Cancer Center, Harvard Medical School,
      Charlestown, MA 02129, USA.
AD  - Department of Pathology, Massachusetts General Hospital, Harvard Medical School, 
      Boston, MA 02114, USA.
LA  - eng
GR  - T32 CA009216/CA/NCI NIH HHS/United States
GR  - T32 DK007540/DK/NIDDK NIH HHS/United States
GR  - K99 CA212154/CA/NCI NIH HHS/United States
GR  - R01 GM076388/GM/NIGMS NIH HHS/United States
GR  - R01 CA197779/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20171123
PL  - United States
TA  - Science
JT  - Science (New York, N.Y.)
JID - 0404511
CIN - Science. 2018 Jan 5;359(6371):30-31. PMID: 29302000
EDAT- 2017/11/25 06:00
MHDA- 2017/11/25 06:00
CRDT- 2017/11/25 06:00
PHST- 2017/05/12 00:00 [received]
PHST- 2017/09/22 00:00 [revised]
PHST- 2017/11/09 00:00 [accepted]
PHST- 2017/11/25 06:00 [pubmed]
PHST- 2017/11/25 06:00 [medline]
PHST- 2017/11/25 06:00 [entrez]
AID - science.aan6490 [pii]
AID - 10.1126/science.aan6490 [doi]
PST - ppublish
SO  - Science. 2018 Jan 5;359(6371):108-114. doi: 10.1126/science.aan6490. Epub 2017
      Nov 23.

PMID- 29133799
OWN - NLM
STAT- In-Data-Review
LR  - 20171219
IS  - 2041-1723 (Electronic)
IS  - 2041-1723 (Linking)
VI  - 8
IP  - 1
DP  - 2017 Nov 13
TI  - Hit-and-run epigenetic editing prevents senescence entry in primary breast cells 
      from healthy donors.
PG  - 1450
LID - 10.1038/s41467-017-01078-2 [doi]
AB  - Aberrant promoter DNA hypermethylation is a hallmark of cancer; however, whether 
      this is sufficient to drive cellular transformation is not clear. To investigate 
      this question, we use a CRISPR-dCas9 epigenetic editing tool, where an inactive
      form of Cas9 is fused to DNA methyltransferase effectors. Using this system, here
      we show simultaneous de novo DNA methylation of genes commonly methylated in
      cancer, CDKN2A, RASSF1, HIC1 and PTEN in primary breast cells isolated from
      healthy human breast tissue. We find that promoter methylation is maintained in
      this system, even in the absence of the fusion construct, and this prevents cells
      from engaging senescence arrest. Our data show that the key driver of this
      phenotype is repression of CDKN2A transcript p16 where myoepithelial cells
      harbour cancer-like gene expression but do not exhibit anchorage-independent
      growth. This work demonstrates that hit-and-run epigenetic events can prevent
      senescence entry, which may facilitate tumour initiation.
FAU - Saunderson, Emily A
AU  - Saunderson EA
AUID- ORCID: http://orcid.org/0000-0003-2132-7785
AD  - Barts Cancer Institute, John Vane Science Centre, Charterhouse Square, Queen Mary
      University of London, London, EC1M 6BQ, UK.
FAU - Stepper, Peter
AU  - Stepper P
AD  - Institute for Biochemistry and Technical Biochemistry, Department of
      Biochemistry, Faculty of Chemistry, University of Stuttgart, D-70569, Stuttgart, 
      Germany.
FAU - Gomm, Jennifer J
AU  - Gomm JJ
AD  - Barts Cancer Institute, John Vane Science Centre, Charterhouse Square, Queen Mary
      University of London, London, EC1M 6BQ, UK.
FAU - Hoa, Lily
AU  - Hoa L
AUID- ORCID: http://orcid.org/0000-0002-6336-2063
AD  - Barts Cancer Institute, John Vane Science Centre, Charterhouse Square, Queen Mary
      University of London, London, EC1M 6BQ, UK.
FAU - Morgan, Adrienne
AU  - Morgan A
AD  - Barts Cancer Institute, John Vane Science Centre, Charterhouse Square, Queen Mary
      University of London, London, EC1M 6BQ, UK.
FAU - Allen, Michael D
AU  - Allen MD
AUID- ORCID: http://orcid.org/0000-0003-2121-8087
AD  - Barts Cancer Institute, John Vane Science Centre, Charterhouse Square, Queen Mary
      University of London, London, EC1M 6BQ, UK.
FAU - Jones, J Louise
AU  - Jones JL
AD  - Barts Cancer Institute, John Vane Science Centre, Charterhouse Square, Queen Mary
      University of London, London, EC1M 6BQ, UK.
FAU - Gribben, John G
AU  - Gribben JG
AD  - Barts Cancer Institute, John Vane Science Centre, Charterhouse Square, Queen Mary
      University of London, London, EC1M 6BQ, UK.
FAU - Jurkowski, Tomasz P
AU  - Jurkowski TP
AUID- ORCID: http://orcid.org/0000-0002-2012-0240
AD  - Institute for Biochemistry and Technical Biochemistry, Department of
      Biochemistry, Faculty of Chemistry, University of Stuttgart, D-70569, Stuttgart, 
      Germany. tomasz.jurkowski@ibc.uni-stuttgart.de.
FAU - Ficz, Gabriella
AU  - Ficz G
AUID- ORCID: http://orcid.org/0000-0001-9313-9578
AD  - Barts Cancer Institute, John Vane Science Centre, Charterhouse Square, Queen Mary
      University of London, London, EC1M 6BQ, UK. g.ficz@qmul.ac.uk.
LA  - eng
PT  - Journal Article
DEP - 20171113
PL  - England
TA  - Nat Commun
JT  - Nature communications
JID - 101528555
PMC - PMC5684409
EDAT- 2017/11/15 06:00
MHDA- 2017/11/15 06:00
CRDT- 2017/11/15 06:00
PHST- 2016/12/23 00:00 [received]
PHST- 2017/08/16 00:00 [accepted]
PHST- 2017/11/15 06:00 [entrez]
PHST- 2017/11/15 06:00 [pubmed]
PHST- 2017/11/15 06:00 [medline]
AID - 10.1038/s41467-017-01078-2 [doi]
AID - 10.1038/s41467-017-01078-2 [pii]
PST - epublish
SO  - Nat Commun. 2017 Nov 13;8(1):1450. doi: 10.1038/s41467-017-01078-2.

PMID- 29036671
OWN - NLM
STAT- MEDLINE
DCOM- 20171212
LR  - 20171219
IS  - 1362-4962 (Electronic)
IS  - 0305-1048 (Linking)
VI  - 45
IP  - 20
DP  - 2017 Nov 16
TI  - CRISPR/Cas9-mediated gene knockout is insensitive to target copy number but is
      dependent on guide RNA potency and Cas9/sgRNA threshold expression level.
PG  - 12039-12053
LID - 10.1093/nar/gkx843 [doi]
AB  - CRISPR/Cas9 is a powerful gene editing tool for gene knockout studies and
      functional genomic screens. Successful implementation of CRISPR often requires
      Cas9 to elicit efficient target knockout in a population of cells. In this study,
      we investigated the role of several key factors, including variation in target
      copy number, inherent potency of sgRNA guides, and expression level of Cas9 and
      sgRNA, in determining CRISPR knockout efficiency. Using isogenic, clonal cell
      lines with variable copy numbers of an EGFP transgene, we discovered that CRISPR 
      knockout is relatively insensitive to target copy number, but is highly dependent
      on the potency of the sgRNA guide sequence. Kinetic analysis revealed that most
      target mutation occurs between 5 and 10 days following Cas9/sgRNA transduction,
      while sgRNAs with different potencies differ by their knockout time course and by
      their terminal-phase knockout efficiency. We showed that prolonged, low level
      expression of Cas9 and sgRNA often fails to elicit target mutation, particularly 
      if the potency of the sgRNA is also low. Our findings provide new insights into
      the behavior of CRISPR/Cas9 in mammalian cells that could be used for future
      improvement of this platform.
CI  - Published by Oxford University Press on behalf of Nucleic Acids Research 2017.
FAU - Yuen, Garmen
AU  - Yuen G
AD  - Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National
      Cancer Institute, Bethesda, MD, USA.
FAU - Khan, Fehad J
AU  - Khan FJ
AD  - Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National
      Cancer Institute, Bethesda, MD, USA.
AD  - Undergraduate Scholarship Program, National Institutes of Health, Bethesda, MD,
      USA.
FAU - Gao, Shaojian
AU  - Gao S
AD  - Thoracic and Gastrointestinal Oncology Branch, Center for Cancer Research,
      National Cancer Institute, Bethesda, MD, USA.
FAU - Stommel, Jayne M
AU  - Stommel JM
AD  - Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute,
      Bethesda, MD, USA.
FAU - Batchelor, Eric
AU  - Batchelor E
AD  - Laboratory of Pathology, Center for Cancer Research, National Cancer Institute,
      Bethesda, MD, USA.
FAU - Wu, Xiaolin
AU  - Wu X
AD  - Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick
      National Laboratory for Cancer Research, Frederick, MD, USA.
FAU - Luo, Ji
AU  - Luo J
AD  - Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National
      Cancer Institute, Bethesda, MD, USA.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Nucleic Acids Res
JT  - Nucleic acids research
JID - 0411011
RN  - 0 (Bacterial Proteins)
RN  - 0 (RNA, Guide)
RN  - 147336-22-9 (Green Fluorescent Proteins)
RN  - EC 3.1.- (Cas9 endonuclease Streptococcus pyogenes)
RN  - EC 3.1.- (Endonucleases)
SB  - IM
MH  - Bacterial Proteins/genetics/metabolism
MH  - *CRISPR-Cas Systems
MH  - Cell Line, Tumor
MH  - Endonucleases/genetics/metabolism
MH  - Flow Cytometry
MH  - *Gene Dosage
MH  - Gene Knockout Techniques/*methods
MH  - Green Fluorescent Proteins/*genetics/metabolism
MH  - HEK293 Cells
MH  - Humans
MH  - Kinetics
MH  - Mutation
MH  - Polymerase Chain Reaction
MH  - RNA, Guide/genetics/metabolism
MH  - Reproducibility of Results
MH  - Transgenes/genetics
PMC - PMC5714203
EDAT- 2017/10/17 06:00
MHDA- 2017/12/13 06:00
CRDT- 2017/10/17 06:00
PHST- 2017/04/12 00:00 [received]
PHST- 2017/09/13 00:00 [accepted]
PHST- 2017/10/17 06:00 [pubmed]
PHST- 2017/12/13 06:00 [medline]
PHST- 2017/10/17 06:00 [entrez]
AID - 4210936 [pii]
AID - 10.1093/nar/gkx843 [doi]
PST - ppublish
SO  - Nucleic Acids Res. 2017 Nov 16;45(20):12039-12053. doi: 10.1093/nar/gkx843.

PMID- 29176737
OWN - NLM
STAT- In-Data-Review
LR  - 20180112
IS  - 1546-170X (Electronic)
IS  - 1078-8956 (Linking)
VI  - 24
IP  - 1
DP  - 2018 Jan
TI  - cGAS drives noncanonical-inflammasome activation in age-related macular
      degeneration.
PG  - 50-61
LID - 10.1038/nm.4450 [doi]
AB  - Geographic atrophy is a blinding form of age-related macular degeneration
      characterized by retinal pigmented epithelium (RPE) death; the RPE also exhibits 
      DICER1 deficiency, resultant accumulation of endogenous Alu-retroelement RNA, and
      NLRP3-inflammasome activation. How the inflammasome is activated in this
      untreatable disease is largely unknown. Here we demonstrate that RPE degeneration
      in human-cell-culture and mouse models is driven by a noncanonical-inflammasome
      pathway that activates caspase-4 (caspase-11 in mice) and caspase-1, and requires
      cyclic GMP-AMP synthase (cGAS)-dependent interferon-beta production and gasdermin
      D-dependent interleukin-18 secretion. Decreased DICER1 levels or Alu-RNA
      accumulation triggers cytosolic escape of mitochondrial DNA, which engages cGAS. 
      Moreover, caspase-4, gasdermin D, interferon-beta, and cGAS levels were elevated 
      in the RPE in human eyes with geographic atrophy. Collectively, these data
      highlight an unexpected role of cGAS in responding to mobile-element transcripts,
      reveal cGAS-driven interferon signaling as a conduit for
      mitochondrial-damage-induced inflammasome activation, expand the immune-sensing
      repertoire of cGAS and caspase-4 to noninfectious human disease, and identify new
      potential targets for treatment of a major cause of blindness.
FAU - Kerur, Nagaraj
AU  - Kerur N
AUID- ORCID: http://orcid.org/0000-0001-5040-2129
AD  - Center for Advanced Vision Science, University of Virginia School of Medicine,
      Charlottesville, Virginia, USA.
AD  - Department of Ophthalmology, University of Virginia School of Medicine,
      Charlottesville, Virginia, USA.
AD  - Department of Ophthalmology and Visual Sciences, University of Kentucky,
      Lexington, Kentucky, USA.
FAU - Fukuda, Shinichi
AU  - Fukuda S
AUID- ORCID: http://orcid.org/0000-0002-4160-8229
AD  - Center for Advanced Vision Science, University of Virginia School of Medicine,
      Charlottesville, Virginia, USA.
AD  - Department of Ophthalmology, University of Virginia School of Medicine,
      Charlottesville, Virginia, USA.
AD  - Department of Ophthalmology, University of Tsukuba, Ibaraki, Japan.
FAU - Banerjee, Daipayan
AU  - Banerjee D
AD  - Center for Advanced Vision Science, University of Virginia School of Medicine,
      Charlottesville, Virginia, USA.
AD  - Department of Ophthalmology, University of Virginia School of Medicine,
      Charlottesville, Virginia, USA.
AD  - Department of Ophthalmology and Visual Sciences, University of Kentucky,
      Lexington, Kentucky, USA.
FAU - Kim, Younghee
AU  - Kim Y
AD  - Center for Advanced Vision Science, University of Virginia School of Medicine,
      Charlottesville, Virginia, USA.
AD  - Department of Ophthalmology, University of Virginia School of Medicine,
      Charlottesville, Virginia, USA.
AD  - Department of Ophthalmology and Visual Sciences, University of Kentucky,
      Lexington, Kentucky, USA.
FAU - Fu, Dongxu
AU  - Fu D
AD  - Center for Advanced Vision Science, University of Virginia School of Medicine,
      Charlottesville, Virginia, USA.
AD  - Department of Ophthalmology, University of Virginia School of Medicine,
      Charlottesville, Virginia, USA.
FAU - Apicella, Ivana
AU  - Apicella I
AD  - Center for Advanced Vision Science, University of Virginia School of Medicine,
      Charlottesville, Virginia, USA.
AD  - Department of Ophthalmology, University of Virginia School of Medicine,
      Charlottesville, Virginia, USA.
FAU - Varshney, Akhil
AU  - Varshney A
AD  - Center for Advanced Vision Science, University of Virginia School of Medicine,
      Charlottesville, Virginia, USA.
AD  - Department of Ophthalmology, University of Virginia School of Medicine,
      Charlottesville, Virginia, USA.
FAU - Yasuma, Reo
AU  - Yasuma R
AD  - Center for Advanced Vision Science, University of Virginia School of Medicine,
      Charlottesville, Virginia, USA.
AD  - Department of Ophthalmology, University of Virginia School of Medicine,
      Charlottesville, Virginia, USA.
AD  - Department of Ophthalmology and Visual Sciences, University of Kentucky,
      Lexington, Kentucky, USA.
FAU - Fowler, Benjamin J
AU  - Fowler BJ
AD  - Department of Ophthalmology and Visual Sciences, University of Kentucky,
      Lexington, Kentucky, USA.
FAU - Baghdasaryan, Elmira
AU  - Baghdasaryan E
AD  - Doheny Eye Institute, Los Angeles, Los Angeles, California, USA.
AD  - Department of Ophthalmology, David Geffen School of Medicine, University of
      California-Los Angeles, Los Angeles, California, USA.
FAU - Marion, Kenneth M
AU  - Marion KM
AUID- ORCID: http://orcid.org/0000-0003-1275-5729
AD  - Doheny Eye Institute, Los Angeles, Los Angeles, California, USA.
FAU - Huang, Xiwen
AU  - Huang X
AUID- ORCID: http://orcid.org/0000-0003-2174-1767
AD  - Doheny Eye Institute, Los Angeles, Los Angeles, California, USA.
FAU - Yasuma, Tetsuhiro
AU  - Yasuma T
AD  - Department of Ophthalmology, University of Tsukuba, Ibaraki, Japan.
AD  - Department of Ophthalmology, Nagoya University Graduate School of Medicine,
      Nagoya, Japan.
FAU - Hirano, Yoshio
AU  - Hirano Y
AUID- ORCID: http://orcid.org/0000-0002-9173-0839
AD  - Department of Ophthalmology, University of Tsukuba, Ibaraki, Japan.
AD  - Department of Ophthalmology, Nagoya City University Graduate School of Medical
      Sciences, Nagoya, Japan.
FAU - Serbulea, Vlad
AU  - Serbulea V
AD  - Department of Pharmacology, University of Virginia School of Medicine,
      Charlottesville, Virginia, USA.
FAU - Ambati, Meenakshi
AU  - Ambati M
AD  - Center for Digital Image Evaluation, Charlottesville, Virginia, USA.
FAU - Ambati, Vidya L
AU  - Ambati VL
AD  - Center for Digital Image Evaluation, Charlottesville, Virginia, USA.
FAU - Kajiwara, Yuji
AU  - Kajiwara Y
AUID- ORCID: http://orcid.org/0000-0002-9307-8215
AD  - Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New 
      York, USA.
FAU - Ambati, Kameshwari
AU  - Ambati K
AD  - Center for Advanced Vision Science, University of Virginia School of Medicine,
      Charlottesville, Virginia, USA.
AD  - Department of Ophthalmology, University of Virginia School of Medicine,
      Charlottesville, Virginia, USA.
AD  - Department of Ophthalmology and Visual Sciences, University of Kentucky,
      Lexington, Kentucky, USA.
FAU - Hirahara, Shuichiro
AU  - Hirahara S
AD  - Center for Advanced Vision Science, University of Virginia School of Medicine,
      Charlottesville, Virginia, USA.
AD  - Department of Ophthalmology, University of Virginia School of Medicine,
      Charlottesville, Virginia, USA.
FAU - Bastos-Carvalho, Ana
AU  - Bastos-Carvalho A
AD  - Department of Ophthalmology and Visual Sciences, University of Kentucky,
      Lexington, Kentucky, USA.
FAU - Ogura, Yuichiro
AU  - Ogura Y
AD  - Department of Ophthalmology, Nagoya City University Graduate School of Medical
      Sciences, Nagoya, Japan.
FAU - Terasaki, Hiroko
AU  - Terasaki H
AD  - Department of Ophthalmology, Nagoya University Graduate School of Medicine,
      Nagoya, Japan.
FAU - Oshika, Tetsuro
AU  - Oshika T
AD  - Department of Ophthalmology, University of Tsukuba, Ibaraki, Japan.
FAU - Kim, Kyung Bo
AU  - Kim KB
AD  - Department of Pharmaceutical Sciences, University of Kentucky, Lexington,
      Kentucky, USA.
FAU - Hinton, David R
AU  - Hinton DR
AD  - Departments of Pathology and Ophthalmology, USC Roski Eye Institute, Keck School 
      of Medicine of the University of Southern California, Los Angeles, California,
      USA.
FAU - Leitinger, Norbert
AU  - Leitinger N
AD  - Department of Pharmacology, University of Virginia School of Medicine,
      Charlottesville, Virginia, USA.
FAU - Cambier, John C
AU  - Cambier JC
AD  - Department of Immunology and Microbiology, University of Colorado School of
      Medicine, Aurora, Colorado, USA.
FAU - Buxbaum, Joseph D
AU  - Buxbaum JD
AD  - Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New 
      York, USA.
FAU - Kenney, M Cristina
AU  - Kenney MC
AD  - Gavin Herbert Eye Institute, University of California Irvine, Irvine, California,
      USA.
FAU - Jazwinski, S Michal
AU  - Jazwinski SM
AD  - Tulane Center for Aging and Department of Medicine, Tulane University Health
      Sciences Center, New Orleans, Louisiana, USA.
FAU - Nagai, Hiroshi
AU  - Nagai H
AUID- ORCID: http://orcid.org/0000-0002-3779-9085
AD  - Division of Dermatology, Department of Internal Related, Kobe University Graduate
      School of Medicine, Kobe, Japan.
FAU - Hara, Isao
AU  - Hara I
AD  - Department of Urology, Wakayama Medical University, Wakayama, Japan.
FAU - West, A Phillip
AU  - West AP
AD  - Department of Microbial Pathogenesis and Immunology, Texas A&M University,
      College Station, Texas, USA.
FAU - Fitzgerald, Katherine A
AU  - Fitzgerald KA
AD  - Division of Infectious Diseases and Immunology, Department of Medicine,
      University of Massachusetts Medical School, Worcester, Massachusetts, USA.
FAU - Sadda, SriniVas R
AU  - Sadda SR
AD  - Doheny Eye Institute, Los Angeles, Los Angeles, California, USA.
AD  - Department of Ophthalmology, David Geffen School of Medicine, University of
      California-Los Angeles, Los Angeles, California, USA.
FAU - Gelfand, Bradley D
AU  - Gelfand BD
AD  - Center for Advanced Vision Science, University of Virginia School of Medicine,
      Charlottesville, Virginia, USA.
AD  - Department of Ophthalmology, University of Virginia School of Medicine,
      Charlottesville, Virginia, USA.
AD  - Department of Ophthalmology and Visual Sciences, University of Kentucky,
      Lexington, Kentucky, USA.
AD  - Department of Biomedical Engineering, University of Virginia School of Medicine, 
      Charlottesville, Virginia, USA.
FAU - Ambati, Jayakrishna
AU  - Ambati J
AUID- ORCID: http://orcid.org/0000-0003-1622-6365
AD  - Center for Advanced Vision Science, University of Virginia School of Medicine,
      Charlottesville, Virginia, USA.
AD  - Department of Ophthalmology, University of Virginia School of Medicine,
      Charlottesville, Virginia, USA.
AD  - Department of Ophthalmology and Visual Sciences, University of Kentucky,
      Lexington, Kentucky, USA.
AD  - Department of Pathology, University of Virginia School of Medicine,
      Charlottesville, Virginia, USA.
AD  - Department of Microbiology, Immunology, and Cancer Biology, University of
      Virginia School of Medicine, Charlottesville, Virginia, USA.
LA  - eng
GR  - UL1 TR000117/TR/NCATS NIH HHS/United States
GR  - R01 DK096076/DK/NIDDK NIH HHS/United States
GR  - P01 HL120840/HL/NHLBI NIH HHS/United States
GR  - R00 EY024336/EY/NEI NIH HHS/United States
GR  - R01 EY018350/EY/NEI NIH HHS/United States
GR  - K99 EY024336/EY/NEI NIH HHS/United States
GR  - UL1 RR033173/RR/NCRR NIH HHS/United States
GR  - R21 AI099346/AI/NIAID NIH HHS/United States
GR  - R01 EY018836/EY/NEI NIH HHS/United States
GR  - R01 AI124487/AI/NIAID NIH HHS/United States
GR  - R01 EY001545/EY/NEI NIH HHS/United States
GR  - F31 DK108553/DK/NIDDK NIH HHS/United States
GR  - R01 EY020672/EY/NEI NIH HHS/United States
GR  - T32 HL091812/HL/NHLBI NIH HHS/United States
GR  - R01 EY024068/EY/NEI NIH HHS/United States
GR  - DP1 GM114862/GM/NIGMS NIH HHS/United States
GR  - T32 GM007055/GM/NIGMS NIH HHS/United States
GR  - R37 AG006168/AG/NIA NIH HHS/United States
GR  - R01 EY022238/EY/NEI NIH HHS/United States
PT  - Journal Article
DEP - 20171127
PL  - United States
TA  - Nat Med
JT  - Nature medicine
JID - 9502015
PMC - PMC5760363
MID - NIHMS917058
EDAT- 2017/11/28 06:00
MHDA- 2017/11/28 06:00
CRDT- 2017/11/28 06:00
PMCR- 2018/05/27 00:00
PHST- 2016/05/12 00:00 [received]
PHST- 2017/10/31 00:00 [accepted]
PHST- 2018/05/27 00:00 [pmc-release]
PHST- 2017/11/28 06:00 [pubmed]
PHST- 2017/11/28 06:00 [medline]
PHST- 2017/11/28 06:00 [entrez]
AID - nm.4450 [pii]
AID - 10.1038/nm.4450 [doi]
PST - ppublish
SO  - Nat Med. 2018 Jan;24(1):50-61. doi: 10.1038/nm.4450. Epub 2017 Nov 27.

PMID- 29030335
OWN - NLM
STAT- MEDLINE
DCOM- 20180126
LR  - 20180126
IS  - 1528-0020 (Electronic)
IS  - 0006-4971 (Linking)
VI  - 130
IP  - 25
DP  - 2017 Dec 21
TI  - Single-cell RNA-seq reveals a distinct transcriptome signature of aneuploid
      hematopoietic cells.
PG  - 2762-2773
LID - 10.1182/blood-2017-08-803353 [doi]
AB  - Cancer cells frequently exhibit chromosomal abnormalities. Specific cytogenetic
      aberrations often are predictors of outcome, especially in hematologic neoplasms,
      such as monosomy 7 in myeloid malignancies. The functional consequences of
      aneuploidy at the cellular level are difficult to assess because of a lack of
      convenient markers to distinguish abnormal from diploid cells. We performed
      single-cell RNA sequencing (scRNA-seq) to study hematopoietic stem and progenitor
      cells from the bone marrow of 4 healthy donors and 5 patients with bone marrow
      failure and chromosome gain or loss. In total, transcriptome sequences were
      obtained from 391 control cells and 588 cells from patients. We characterized
      normal hematopoiesis as binary differentiation from stem cells to erythroid and
      myeloid-lymphoid pathways. Aneuploid cells were distinguished from diploid cells 
      in patient samples by computational analyses of read fractions and gene
      expression of individual chromosomes. We confirmed assignment of aneuploidy to
      individual cells quantitatively, by copy-number variation, and qualitatively, by 
      loss of heterozygosity. When we projected patients' single cells onto the map of 
      normal hematopoiesis, diverse patterns were observed, broadly reflecting clinical
      phenotypes. Patients' monosomy 7 cells showed downregulation of genes involved in
      immune response and DNA damage checkpoint and apoptosis pathways, which may
      contribute to the clonal expansion of monosomy 7 cells with accumulated gene
      mutations. scRNA-seq is a powerful technique through which to infer the
      functional consequences of chromosome gain and loss and explore gene targets for 
      directed therapy.
FAU - Zhao, Xin
AU  - Zhao X
AUID- ORCID: 0000-0003-2874-3300
AD  - Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes
      of Health, Bethesda, MD.
AD  - Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical
      Sciences & Peking Union Medical College, Tianjin, People's Republic of China.
FAU - Gao, Shouguo
AU  - Gao S
AD  - Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes
      of Health, Bethesda, MD.
FAU - Wu, Zhijie
AU  - Wu Z
AD  - Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes
      of Health, Bethesda, MD.
AD  - Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical
      Sciences & Peking Union Medical College, Tianjin, People's Republic of China.
FAU - Kajigaya, Sachiko
AU  - Kajigaya S
AD  - Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes
      of Health, Bethesda, MD.
FAU - Feng, Xingmin
AU  - Feng X
AD  - Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes
      of Health, Bethesda, MD.
FAU - Liu, Qingguo
AU  - Liu Q
AD  - Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes
      of Health, Bethesda, MD.
AD  - Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical
      Sciences & Peking Union Medical College, Tianjin, People's Republic of China.
FAU - Townsley, Danielle M
AU  - Townsley DM
AD  - Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes
      of Health, Bethesda, MD.
FAU - Cooper, James
AU  - Cooper J
AD  - Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes
      of Health, Bethesda, MD.
FAU - Chen, Jinguo
AU  - Chen J
AD  - Center for Human Immunology, Autoimmunity and Inflammation, National Institutes
      of Health, Bethesda, MD; and.
FAU - Keyvanfar, Keyvan
AU  - Keyvanfar K
AD  - Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes
      of Health, Bethesda, MD.
FAU - Fernandez Ibanez, Maria Del Pilar
AU  - Fernandez Ibanez MDP
AD  - Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes
      of Health, Bethesda, MD.
FAU - Wang, Xujing
AU  - Wang X
AD  - Systems Biology Center, National Heart, Lung, and Blood Institute, National
      Institutes of Health, Bethesda, MD.
FAU - Young, Neal S
AU  - Young NS
AD  - Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes
      of Health, Bethesda, MD.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, N.I.H., Intramural
DEP - 20171013
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - Chromosome 7, monosomy
SB  - AIM
SB  - IM
CIN - Blood. 2017 Dec 21;130(25):2693-2695. PMID: 29269530
MH  - Adult
MH  - *Aneuploidy
MH  - Bone Marrow Cells
MH  - Bone Marrow Diseases/genetics/pathology
MH  - Case-Control Studies
MH  - Chromosome Deletion
MH  - Chromosome Disorders/genetics
MH  - Chromosomes, Human, Pair 7
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - *Hematopoietic Stem Cells
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Sequence Analysis, RNA
MH  - Single-Cell Analysis/*methods
MH  - Transcriptome/*genetics
PMC - PMC5746166
EDAT- 2017/10/17 06:00
MHDA- 2018/01/27 06:00
CRDT- 2017/10/15 06:00
PHST- 2017/08/29 00:00 [received]
PHST- 2017/10/03 00:00 [accepted]
PHST- 2017/10/17 06:00 [pubmed]
PHST- 2018/01/27 06:00 [medline]
PHST- 2017/10/15 06:00 [entrez]
AID - blood-2017-08-803353 [pii]
AID - 10.1182/blood-2017-08-803353 [doi]
PST - ppublish
SO  - Blood. 2017 Dec 21;130(25):2762-2773. doi: 10.1182/blood-2017-08-803353. Epub
      2017 Oct 13.

PMID- 29032264
OWN - NLM
STAT- In-Data-Review
LR  - 20171226
IS  - 1523-6536 (Electronic)
IS  - 1083-8791 (Linking)
VI  - 24
IP  - 1
DP  - 2018 Jan
TI  - Building a Safer and Faster CAR: Seatbelts, Airbags, and CRISPR.
PG  - 27-31
LID - S1083-8791(17)30776-0 [pii]
LID - 10.1016/j.bbmt.2017.10.017 [doi]
AB  - Therapeutic T cell engineering has recently garnered widespread interest because 
      of the success of CD19 chimeric antigen receptor (CAR) therapy. CARs are
      synthetic receptors for antigen that redirect the specificity and reprogram the
      function of the T cells in which they are genetically introduced. CARs targeting 
      CD19, a cell surface molecule found in most leukemias and lymphomas, have yielded
      high remission rates in patients with chemorefractory, relapsed disease,
      including acute lymphoblastic leukemia, chronic lymphocytic leukemia, and
      non-Hodgkin lymphoma. The toxicities of this treatment include B cell aplasia,
      cytokine release syndrome (CRS), and neurotoxicity. Although reversible in most
      instances, these toxicities may require specific medical interventions, including
      transfer to intensive care to treat severe CRS. Guidelines for managing these
      toxicities are emerging. The recent report of a nonhuman primate model for CRS is
      poised to help advance the management of this syndrome. Finally, new engineering 
      modalities, based on the use of targeted nucleases like CRISPR, may further
      enhance the efficacy and safety of CAR T cells.
CI  - Copyright (c) 2017 The American Society for Blood and Marrow Transplantation.
      Published by Elsevier Inc. All rights reserved.
FAU - Perales, Miguel-Angel
AU  - Perales MA
AD  - Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan
      Kettering Cancer Center, New York, New York; Department of Medicine, Weill
      Cornell Medical College, New York, New York. Electronic address:
      peralesm@mskcc.org.
FAU - Kebriaei, Partow
AU  - Kebriaei P
AD  - Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer 
      Center, Houston, Texas.
FAU - Kean, Leslie S
AU  - Kean LS
AD  - The Ben Towne Center for Childhood Cancer Research, Seattle Children's Research
      Center, Seattle, Washington; The Fred Hutchinson Cancer Research Center, Seattle,
      Washington; Department of Pediatrics, University of Washington, Seattle,
      Washington.
FAU - Sadelain, Michel
AU  - Sadelain M
AD  - Center for Cell Engineering and Immunology Program, Memorial Sloan Kettering
      Cancer Center, New York, New York.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20171013
PL  - United States
TA  - Biol Blood Marrow Transplant
JT  - Biology of blood and marrow transplantation : journal of the American Society for
      Blood and Marrow Transplantation
JID - 9600628
OTO - NOTNLM
OT  - Adoptive T cell therapy
OT  - Adoptive immunotherapy
OT  - CART
OT  - Chimeric antigen receptor T cells
OT  - Cytokine release syndrome
OT  - Hematopoietic stem cell transplantation
OT  - Immunotherapy
OT  - Neurologic Toxicity
EDAT- 2017/10/17 06:00
MHDA- 2017/10/17 06:00
CRDT- 2017/10/17 06:00
PHST- 2017/10/09 00:00 [received]
PHST- 2017/10/09 00:00 [accepted]
PHST- 2017/10/17 06:00 [pubmed]
PHST- 2017/10/17 06:00 [medline]
PHST- 2017/10/17 06:00 [entrez]
AID - S1083-8791(17)30776-0 [pii]
AID - 10.1016/j.bbmt.2017.10.017 [doi]
PST - ppublish
SO  - Biol Blood Marrow Transplant. 2018 Jan;24(1):27-31. doi:
      10.1016/j.bbmt.2017.10.017. Epub 2017 Oct 13.

PMID- 29133350
OWN - NLM
STAT- MEDLINE
DCOM- 20180124
LR  - 20180124
IS  - 1528-0020 (Electronic)
IS  - 0006-4971 (Linking)
VI  - 130
IP  - 26
DP  - 2017 Dec 28
TI  - Extracellular histones induce erythrocyte fragility and anemia.
PG  - 2884-2888
LID - 10.1182/blood-2017-06-790519 [doi]
AB  - Extracellular histones have been shown to play an important pathogenic role in
      many diseases, primarily through their cytotoxicity toward nucleated cells and
      their ability to promote platelet activation with resultant thrombosis and
      thrombocytopenia. In contrast, little is known about the effect of extracellular 
      histones on erythrocyte function. We demonstrate in this study that histones
      promote erythrocyte aggregation, sedimentation, and using a novel in vitro shear 
      stress model, we show that histones induce erythrocyte fragility and lysis in a
      concentration-dependent manner. Furthermore, histones impair erythrocyte
      deformability based on reduced passage of erythrocytes through an artificial
      spleen. These in vitro results were mirrored in vivo with the injection of
      histones inducing anemia within minutes of administration, with a concomitant
      increase in splenic hemoglobin content. Thrombocytopenia and leukopenia were also
      observed. These findings suggest that histones binding to erythrocytes may
      contribute to the elevated erythrocyte sedimentation rates observed in
      inflammatory conditions. Furthermore, histone-induced increases in red blood cell
      lysis and splenic clearance may be a significant factor in the unexplained
      anemias seen in critically ill patients.
CI  - (c) 2017 by The American Society of Hematology.
FAU - Kordbacheh, Farzaneh
AU  - Kordbacheh F
AD  - Australian Cancer Research Foundation Department of Cancer Biology and
      Therapeutics and.
FAU - O'Meara, Connor H
AU  - O'Meara CH
AD  - Australian Cancer Research Foundation Department of Cancer Biology and
      Therapeutics and.
FAU - Coupland, Lucy A
AU  - Coupland LA
AD  - Australian Cancer Research Foundation Department of Cancer Biology and
      Therapeutics and.
FAU - Lelliott, Patrick M
AU  - Lelliott PM
AD  - Department of Immunology and Infectious Disease, John Curtin School of Medical
      Research, Australian National University, Canberra, ACT, Australia.
FAU - Parish, Christopher R
AU  - Parish CR
AD  - Australian Cancer Research Foundation Department of Cancer Biology and
      Therapeutics and.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20171113
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (Hemoglobins)
RN  - 0 (Histones)
SB  - AIM
SB  - IM
MH  - Anemia/*chemically induced
MH  - Animals
MH  - Blood Sedimentation/drug effects
MH  - Erythrocyte Aggregation/drug effects
MH  - Erythrocyte Deformability/drug effects
MH  - Erythrocytes/*drug effects
MH  - Hemoglobins/analysis
MH  - Histones/administration & dosage/*pharmacology
MH  - Humans
MH  - Mice
MH  - Spleen/chemistry
MH  - Stress, Mechanical
EDAT- 2017/11/15 06:00
MHDA- 2018/01/25 06:00
CRDT- 2017/11/15 06:00
PHST- 2017/06/12 00:00 [received]
PHST- 2017/11/05 00:00 [accepted]
PHST- 2017/11/15 06:00 [pubmed]
PHST- 2018/01/25 06:00 [medline]
PHST- 2017/11/15 06:00 [entrez]
AID - blood-2017-06-790519 [pii]
AID - 10.1182/blood-2017-06-790519 [doi]
PST - ppublish
SO  - Blood. 2017 Dec 28;130(26):2884-2888. doi: 10.1182/blood-2017-06-790519. Epub
      2017 Nov 13.

PMID- 29170450
OWN - NLM
STAT- In-Data-Review
LR  - 20171219
IS  - 2041-1723 (Electronic)
IS  - 2041-1723 (Linking)
VI  - 8
IP  - 1
DP  - 2017 Nov 24
TI  - Interplay between Notch1 and Notch3 promotes EMT and tumor initiation in squamous
      cell carcinoma.
PG  - 1758
LID - 10.1038/s41467-017-01500-9 [doi]
AB  - Notch1 transactivates Notch3 to drive terminal differentiation in stratified
      squamous epithelia. Notch1 and other Notch receptor paralogs cooperate to act as 
      a tumor suppressor in squamous cell carcinomas (SCCs). However, Notch1 can be
      stochastically activated to promote carcinogenesis in murine models of SCC.
      Activated form of Notch1 promotes xenograft tumor growth when expressed
      ectopically. Here, we demonstrate that Notch1 activation and
      epithelial-mesenchymal transition (EMT) are coupled to promote SCC tumor
      initiation in concert with transforming growth factor (TGF)-beta present in the
      tumor microenvironment. We find that TGFbeta activates the transcription factor
      ZEB1 to repress Notch3, thereby limiting terminal differentiation. Concurrently, 
      TGFbeta drives Notch1-mediated EMT to generate tumor initiating cells
      characterized by high CD44 expression. Moreover, Notch1 is activated in a small
      subset of SCC cells at the invasive tumor front and predicts for poor prognosis
      of esophageal SCC, shedding light upon the tumor promoting oncogenic aspect of
      Notch1 in SCC.
FAU - Natsuizaka, Mitsuteru
AU  - Natsuizaka M
AD  - Gastroenterology Division, Department of Medicine, University of Pennsylvania,
      Philadelphia, PA, 19104, USA.
AD  - Abramson Cancer Center, Philadelphia, PA, 19104, USA.
AD  - University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 19104, 
      USA.
AD  - Department of Gastroenterology and Hepatology, Hokkaido University Graduate
      School of Medicine, Sapporo, Hokkaido, 060-8638, Japan.
FAU - Whelan, Kelly A
AU  - Whelan KA
AD  - Gastroenterology Division, Department of Medicine, University of Pennsylvania,
      Philadelphia, PA, 19104, USA.
AD  - Abramson Cancer Center, Philadelphia, PA, 19104, USA.
AD  - University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 19104, 
      USA.
FAU - Kagawa, Shingo
AU  - Kagawa S
AD  - Gastroenterology Division, Department of Medicine, University of Pennsylvania,
      Philadelphia, PA, 19104, USA.
AD  - Abramson Cancer Center, Philadelphia, PA, 19104, USA.
AD  - University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 19104, 
      USA.
AD  - Department of General Surgery, Chiba University Graduate School of Medicine,
      Chiba, Chiba, 260-0856, Japan.
FAU - Tanaka, Koji
AU  - Tanaka K
AD  - Gastroenterology Division, Department of Medicine, University of Pennsylvania,
      Philadelphia, PA, 19104, USA.
AD  - Abramson Cancer Center, Philadelphia, PA, 19104, USA.
AD  - University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 19104, 
      USA.
AD  - Department of Surgery, Gastroenterological Surgery, Osaka University Graduate
      School of Medicine, Suita, Osaka, 565-0871, Japan.
FAU - Giroux, Veronique
AU  - Giroux V
AD  - Gastroenterology Division, Department of Medicine, University of Pennsylvania,
      Philadelphia, PA, 19104, USA.
AD  - Abramson Cancer Center, Philadelphia, PA, 19104, USA.
AD  - University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 19104, 
      USA.
FAU - Chandramouleeswaran, Prasanna M
AU  - Chandramouleeswaran PM
AD  - Gastroenterology Division, Department of Medicine, University of Pennsylvania,
      Philadelphia, PA, 19104, USA.
AD  - Abramson Cancer Center, Philadelphia, PA, 19104, USA.
AD  - University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 19104, 
      USA.
FAU - Long, Apple
AU  - Long A
AD  - Gastroenterology Division, Department of Medicine, University of Pennsylvania,
      Philadelphia, PA, 19104, USA.
AD  - Abramson Cancer Center, Philadelphia, PA, 19104, USA.
AD  - University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 19104, 
      USA.
FAU - Sahu, Varun
AU  - Sahu V
AD  - Abramson Cancer Center, Philadelphia, PA, 19104, USA.
AD  - University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 19104, 
      USA.
AD  - Department of Otorhinolaryngology, University of Pennsylvania, Philadelphia, PA, 
      19104, USA.
FAU - Darling, Douglas S
AU  - Darling DS
AD  - Department of Oral Immunology and Infectious Diseases, and Center for Genetics
      and Molecular Medicine, University of Louisville, Louisville, KY, 40202, USA.
FAU - Que, Jianwen
AU  - Que J
AD  - Department of Medicine, Division of Digestive and Liver Diseases, Columbia
      University, New York, NY, 10032, USA.
FAU - Yang, Yizeng
AU  - Yang Y
AD  - Gastroenterology Division, Department of Medicine, University of Pennsylvania,
      Philadelphia, PA, 19104, USA.
AD  - Abramson Cancer Center, Philadelphia, PA, 19104, USA.
AD  - University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 19104, 
      USA.
FAU - Katz, Jonathan P
AU  - Katz JP
AD  - Gastroenterology Division, Department of Medicine, University of Pennsylvania,
      Philadelphia, PA, 19104, USA.
AD  - Abramson Cancer Center, Philadelphia, PA, 19104, USA.
AD  - University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 19104, 
      USA.
FAU - Wileyto, E Paul
AU  - Wileyto EP
AD  - Abramson Cancer Center, Philadelphia, PA, 19104, USA.
AD  - University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 19104, 
      USA.
AD  - Department of Biostatistics and Epidemiology, University of Pennsylvania,
      Philadelphia, PA, 19104, USA.
FAU - Basu, Devraj
AU  - Basu D
AD  - Abramson Cancer Center, Philadelphia, PA, 19104, USA.
AD  - University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 19104, 
      USA.
AD  - Department of Otorhinolaryngology, University of Pennsylvania, Philadelphia, PA, 
      19104, USA.
FAU - Kita, Yoshiaki
AU  - Kita Y
AD  - Department of Digestive Surgery, Breast and Thyroid Surgery, Kagoshima University
      Graduate School of Medical and Dental Sciences, Kagoshima, 890-8520, Japan.
FAU - Natsugoe, Shoji
AU  - Natsugoe S
AD  - Department of Digestive Surgery, Breast and Thyroid Surgery, Kagoshima University
      Graduate School of Medical and Dental Sciences, Kagoshima, 890-8520, Japan.
FAU - Naganuma, Seiji
AU  - Naganuma S
AD  - Department of Pathology, Kochi Medical School, Nankoku-shi, Kochi, 783-8505,
      Japan.
FAU - Klein-Szanto, Andres J
AU  - Klein-Szanto AJ
AD  - Histopathology Facility and Cancer Biology Program, Fox Chase Cancer Center,
      Philadelphia, PA, 19111, USA.
FAU - Diehl, J Alan
AU  - Diehl JA
AD  - Department of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical
      University of South Carolina, Charleston, SC, 29425, USA.
FAU - Bass, Adam J
AU  - Bass AJ
AD  - Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School,
      Boston, MA, 02215, USA.
FAU - Wong, Kwok-Kin
AU  - Wong KK
AD  - Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School,
      Boston, MA, 02215, USA. kwok-kin.wong@nyumc.org.
AD  - Division of Hematology and Medical Oncology, New York University, New York, NY,
      10016, USA. kwok-kin.wong@nyumc.org.
FAU - Rustgi, Anil K
AU  - Rustgi AK
AD  - University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 19104, 
      USA.
FAU - Nakagawa, Hiroshi
AU  - Nakagawa H
AD  - University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 19104, 
      USA. nakagawh@mail.med.upenn.edu.
LA  - eng
GR  - K01 DK103953/DK/NIDDK NIH HHS/United States
GR  - R01 DK101294/DK/NIDDK NIH HHS/United States
GR  - R01 DK100342/DK/NIDDK NIH HHS/United States
GR  - P30 DK050306/DK/NIDDK NIH HHS/United States
GR  - R01 DK114436/DK/NIDDK NIH HHS/United States
GR  - R21 DE024396/DE/NIDCR NIH HHS/United States
GR  - P30 ES013508/ES/NIEHS NIH HHS/United States
GR  - P01 CA098101/CA/NCI NIH HHS/United States
GR  - R01 DK069984/DK/NIDDK NIH HHS/United States
GR  - T32 DK007066/DK/NIDDK NIH HHS/United States
GR  - T32 CA115299/CA/NCI NIH HHS/United States
GR  - F31 CA174176/CA/NCI NIH HHS/United States
GR  - K26 RR032714/RR/NCRR NIH HHS/United States
PT  - Journal Article
DEP - 20171124
PL  - England
TA  - Nat Commun
JT  - Nature communications
JID - 101528555
PMC - PMC5700926
EDAT- 2017/11/25 06:00
MHDA- 2017/11/25 06:00
CRDT- 2017/11/25 06:00
PHST- 2016/07/28 00:00 [received]
PHST- 2017/09/21 00:00 [accepted]
PHST- 2017/11/25 06:00 [entrez]
PHST- 2017/11/25 06:00 [pubmed]
PHST- 2017/11/25 06:00 [medline]
AID - 10.1038/s41467-017-01500-9 [doi]
AID - 10.1038/s41467-017-01500-9 [pii]
PST - epublish
SO  - Nat Commun. 2017 Nov 24;8(1):1758. doi: 10.1038/s41467-017-01500-9.

PMID- 29178945
OWN - NLM
STAT- In-Process
LR  - 20171219
IS  - 1474-760X (Electronic)
IS  - 1474-7596 (Linking)
VI  - 18
IP  - 1
DP  - 2017 Nov 24
TI  - CRISPR/Cas9-mediated targeted chromosome elimination.
PG  - 224
LID - 10.1186/s13059-017-1354-4 [doi]
AB  - BACKGROUND: The CRISPR/Cas9 system has become an efficient gene editing method
      for generating cells carrying precise gene mutations, including the rearrangement
      and deletion of chromosomal segments. However, whether an entire chromosome could
      be eliminated by this technology is still unknown. RESULTS: Here we demonstrate
      the use of the CRISPR/Cas9 system to eliminate targeted chromosomes. Using either
      multiple cleavages induced by a single-guide RNA (sgRNA) that targets multiple
      chromosome-specific sites or a cocktail of multiple sgRNAs, each targeting one
      specific site, we found that a sex chromosome could be selectively eliminated in 
      cultured cells, embryos, and tissues in vivo. Furthermore, this approach was able
      to produce a targeted autosome loss in aneuploid mouse embryonic stem cells with 
      an extra human chromosome and human induced pluripotent stem cells with trisomy
      21, as well as cancer cells. CONCLUSIONS: CRISPR/Cas9-mediated targeted
      chromosome elimination offers a new approach to develop animal models with
      chromosome deletions, and a potential therapeutic strategy for human aneuploidy
      diseases involving additional chromosomes.
FAU - Zuo, Erwei
AU  - Zuo E
AD  - Institute of Neuroscience, State Key Laboratory of Neuroscience, Key Laboratory
      of Primate Neurobiology, CAS Center for Excellence in Brain Science and
      Intelligence Technology, Shanghai Institutes for Biological Sciences, Chinese
      Academy of Sciences, Shanghai, 200031, China.
FAU - Huo, Xiaona
AU  - Huo X
AD  - Institute of Neuroscience, State Key Laboratory of Neuroscience, Key Laboratory
      of Primate Neurobiology, CAS Center for Excellence in Brain Science and
      Intelligence Technology, Shanghai Institutes for Biological Sciences, Chinese
      Academy of Sciences, Shanghai, 200031, China.
FAU - Yao, Xuan
AU  - Yao X
AD  - Institute of Neuroscience, State Key Laboratory of Neuroscience, Key Laboratory
      of Primate Neurobiology, CAS Center for Excellence in Brain Science and
      Intelligence Technology, Shanghai Institutes for Biological Sciences, Chinese
      Academy of Sciences, Shanghai, 200031, China.
FAU - Hu, Xinde
AU  - Hu X
AD  - Institute of Neuroscience, State Key Laboratory of Neuroscience, Key Laboratory
      of Primate Neurobiology, CAS Center for Excellence in Brain Science and
      Intelligence Technology, Shanghai Institutes for Biological Sciences, Chinese
      Academy of Sciences, Shanghai, 200031, China.
FAU - Sun, Yidi
AU  - Sun Y
AD  - Key Lab of Computational Biology, CAS-MPG Partner Institute for Computational
      Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of
      Sciences, Shanghai, 200031, China.
FAU - Yin, Jianhang
AU  - Yin J
AD  - State Key Laboratory of Membrane Biology and Minstry of Education Key Laboratory 
      of Cell Proliferation and Differentiation, School of Life Sciences,
      Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, 100871,
      China.
FAU - He, Bingbing
AU  - He B
AD  - Institute of Neuroscience, State Key Laboratory of Neuroscience, Key Laboratory
      of Primate Neurobiology, CAS Center for Excellence in Brain Science and
      Intelligence Technology, Shanghai Institutes for Biological Sciences, Chinese
      Academy of Sciences, Shanghai, 200031, China.
AD  - University of Chinese Academy of Sciences, Shanghai, 200031, China.
FAU - Wang, Xing
AU  - Wang X
AD  - Institute of Neuroscience, State Key Laboratory of Neuroscience, Key Laboratory
      of Primate Neurobiology, CAS Center for Excellence in Brain Science and
      Intelligence Technology, Shanghai Institutes for Biological Sciences, Chinese
      Academy of Sciences, Shanghai, 200031, China.
AD  - University of Chinese Academy of Sciences, Shanghai, 200031, China.
FAU - Shi, Linyu
AU  - Shi L
AD  - Institute of Neuroscience, State Key Laboratory of Neuroscience, Key Laboratory
      of Primate Neurobiology, CAS Center for Excellence in Brain Science and
      Intelligence Technology, Shanghai Institutes for Biological Sciences, Chinese
      Academy of Sciences, Shanghai, 200031, China.
FAU - Ping, Jie
AU  - Ping J
AD  - Center for Quantitative Sciences, Vanderbilt University School of Medicine,
      Nashville, Tennessee, 37232, USA.
FAU - Wei, Yu
AU  - Wei Y
AD  - Institute of Neuroscience, State Key Laboratory of Neuroscience, Key Laboratory
      of Primate Neurobiology, CAS Center for Excellence in Brain Science and
      Intelligence Technology, Shanghai Institutes for Biological Sciences, Chinese
      Academy of Sciences, Shanghai, 200031, China.
AD  - Shanghai University, Shanghai, 200444, China.
FAU - Ying, Wenqin
AU  - Ying W
AD  - Institute of Neuroscience, State Key Laboratory of Neuroscience, Key Laboratory
      of Primate Neurobiology, CAS Center for Excellence in Brain Science and
      Intelligence Technology, Shanghai Institutes for Biological Sciences, Chinese
      Academy of Sciences, Shanghai, 200031, China.
FAU - Wei, Wei
AU  - Wei W
AD  - Institute of Neuroscience, State Key Laboratory of Neuroscience, Key Laboratory
      of Primate Neurobiology, CAS Center for Excellence in Brain Science and
      Intelligence Technology, Shanghai Institutes for Biological Sciences, Chinese
      Academy of Sciences, Shanghai, 200031, China.
AD  - College of Animal Science and Technology, Guangxi University, Nanning, Guangxi,
      530004, China.
FAU - Liu, Wenjia
AU  - Liu W
AD  - Institute of Neuroscience, State Key Laboratory of Neuroscience, Key Laboratory
      of Primate Neurobiology, CAS Center for Excellence in Brain Science and
      Intelligence Technology, Shanghai Institutes for Biological Sciences, Chinese
      Academy of Sciences, Shanghai, 200031, China.
FAU - Tang, Cheng
AU  - Tang C
AD  - Institute of Neuroscience, State Key Laboratory of Neuroscience, Key Laboratory
      of Primate Neurobiology, CAS Center for Excellence in Brain Science and
      Intelligence Technology, Shanghai Institutes for Biological Sciences, Chinese
      Academy of Sciences, Shanghai, 200031, China.
FAU - Li, Yixue
AU  - Li Y
AD  - Key Lab of Computational Biology, CAS-MPG Partner Institute for Computational
      Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of
      Sciences, Shanghai, 200031, China.
FAU - Hu, Jiazhi
AU  - Hu J
AD  - State Key Laboratory of Membrane Biology and Minstry of Education Key Laboratory 
      of Cell Proliferation and Differentiation, School of Life Sciences,
      Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, 100871,
      China. hujz@pku.edu.cn.
FAU - Yang, Hui
AU  - Yang H
AD  - Institute of Neuroscience, State Key Laboratory of Neuroscience, Key Laboratory
      of Primate Neurobiology, CAS Center for Excellence in Brain Science and
      Intelligence Technology, Shanghai Institutes for Biological Sciences, Chinese
      Academy of Sciences, Shanghai, 200031, China. huiyang@ion.ac.cn.
LA  - eng
PT  - Journal Article
DEP - 20171124
PL  - England
TA  - Genome Biol
JT  - Genome biology
JID - 100960660
PMC - PMC5701507
EDAT- 2017/11/28 06:00
MHDA- 2017/11/28 06:00
CRDT- 2017/11/28 06:00
PHST- 2017/07/05 00:00 [received]
PHST- 2017/10/26 00:00 [accepted]
PHST- 2017/11/28 06:00 [entrez]
PHST- 2017/11/28 06:00 [pubmed]
PHST- 2017/11/28 06:00 [medline]
AID - 10.1186/s13059-017-1354-4 [doi]
AID - 10.1186/s13059-017-1354-4 [pii]
PST - epublish
SO  - Genome Biol. 2017 Nov 24;18(1):224. doi: 10.1186/s13059-017-1354-4.

PMID- 29236692
OWN - NLM
STAT- In-Data-Review
LR  - 20180120
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 552
IP  - 7685
DP  - 2017 Dec 21
TI  - Mechanisms of mTORC1 activation by RHEB and inhibition by PRAS40.
PG  - 368-373
LID - 10.1038/nature25023 [doi]
AB  - The mechanistic target of rapamycin complex 1 (mTORC1) controls cell growth and
      metabolism in response to nutrients, energy levels, and growth factors. It
      contains the atypical kinase mTOR and the RAPTOR subunit that binds to the Tor
      signalling sequence (TOS) motif of substrates and regulators. mTORC1 is activated
      by the small GTPase RHEB (Ras homologue enriched in brain) and inhibited by
      PRAS40. Here we present the 3.0 angstrom cryo-electron microscopy structure of
      mTORC1 and the 3.4 angstrom structure of activated RHEB-mTORC1. RHEB binds to
      mTOR distally from the kinase active site, yet causes a global conformational
      change that allosterically realigns active-site residues, accelerating catalysis.
      Cancer-associated hyperactivating mutations map to structural elements that
      maintain the inactive state, and we provide biochemical evidence that they mimic 
      RHEB relieving auto-inhibition. We also present crystal structures of RAPTOR-TOS 
      motif complexes that define the determinants of TOS recognition, of an mTOR
      FKBP12-rapamycin-binding (FRB) domain-substrate complex that establishes a second
      substrate-recruitment mechanism, and of a truncated mTOR-PRAS40 complex that
      reveals PRAS40 inhibits both substrate-recruitment sites. These findings help
      explain how mTORC1 selects its substrates, how its kinase activity is controlled,
      and how it is activated by cancer-associated mutations.
FAU - Yang, Haijuan
AU  - Yang H
AD  - Structural Biology Program, Memorial Sloan Kettering Cancer Center, New York, New
      York 10065, USA.
FAU - Jiang, Xiaolu
AU  - Jiang X
AD  - Structural Biology Program, Memorial Sloan Kettering Cancer Center, New York, New
      York 10065, USA.
AD  - Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New
      York, New York 10065, USA.
FAU - Li, Buren
AU  - Li B
AD  - Structural Biology Program, Memorial Sloan Kettering Cancer Center, New York, New
      York 10065, USA.
FAU - Yang, Hyo J
AU  - Yang HJ
AD  - Structural Biology Program, Memorial Sloan Kettering Cancer Center, New York, New
      York 10065, USA.
AD  - Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New
      York, New York 10065, USA.
FAU - Miller, Meredith
AU  - Miller M
AD  - Structural Biology Program, Memorial Sloan Kettering Cancer Center, New York, New
      York 10065, USA.
AD  - Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New
      York, New York 10065, USA.
FAU - Yang, Angela
AU  - Yang A
AD  - Structural Biology Program, Memorial Sloan Kettering Cancer Center, New York, New
      York 10065, USA.
AD  - Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New
      York, New York 10065, USA.
FAU - Dhar, Ankita
AU  - Dhar A
AD  - Structural Biology Program, Memorial Sloan Kettering Cancer Center, New York, New
      York 10065, USA.
FAU - Pavletich, Nikola P
AU  - Pavletich NP
AD  - Structural Biology Program, Memorial Sloan Kettering Cancer Center, New York, New
      York 10065, USA.
AD  - Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New
      York, New York 10065, USA.
LA  - eng
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - P41 GM103310/GM/NIGMS NIH HHS/United States
GR  - R01 GM064644/GM/NIGMS NIH HHS/United States
PT  - Journal Article
DEP - 20171213
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
PMC - PMC5750076
MID - NIHMS919073
EDAT- 2017/12/14 06:00
MHDA- 2017/12/14 06:00
CRDT- 2017/12/14 06:00
PMCR- 2018/06/13 00:00
PHST- 2017/06/09 00:00 [received]
PHST- 2017/11/08 00:00 [accepted]
PHST- 2018/06/13 00:00 [pmc-release]
PHST- 2017/12/14 06:00 [pubmed]
PHST- 2017/12/14 06:00 [medline]
PHST- 2017/12/14 06:00 [entrez]
AID - nature25023 [pii]
AID - 10.1038/nature25023 [doi]
PST - ppublish
SO  - Nature. 2017 Dec 21;552(7685):368-373. doi: 10.1038/nature25023. Epub 2017 Dec
      13.

PMID- 29170511
OWN - NLM
STAT- In-Data-Review
LR  - 20171219
IS  - 2041-1723 (Electronic)
IS  - 2041-1723 (Linking)
VI  - 8
IP  - 1
DP  - 2017 Nov 23
TI  - T cell-targeting nanoparticles focus delivery of immunotherapy to improve
      antitumor immunity.
PG  - 1747
LID - 10.1038/s41467-017-01830-8 [doi]
AB  - Targeted delivery of compounds to particular cell subsets can enhance therapeutic
      index by concentrating their action on the cells of interest. Because attempts to
      target tumors directly have yielded limited benefit, we instead target endogenous
      immune cell subsets in the circulation that can migrate actively into tumors. We 
      describe antibody-targeted nanoparticles that bind to CD8(+) T cells in the
      blood, lymphoid tissues, and tumors of mice. PD-1(+) T cells are successfully
      targeted in the circulation and tumor. The delivery of an inhibitor of TGFbeta
      signaling to PD-1-expressing cells extends the survival of tumor-bearing mice,
      whereas free drugs have no effect at such doses. This modular platform also
      enables PD-1-targeted delivery of a TLR7/8 agonist to the tumor microenvironment,
      increasing the proportion of tumor-infiltrating CD8(+) T cells and sensitizing
      tumors to subsequent anti-PD-1. Targeted delivery of immunotherapy to defined
      subsets of endogenous leukocytes may be superior to administration of free drugs.
FAU - Schmid, Daniela
AU  - Schmid D
AD  - Department of Cancer Immunology & Virology, Dana-Farber Cancer Institute, Boston,
      MA, 02215, USA.
AD  - Department of Microbiology & Immunobiology, Harvard Medical School, Boston, MA,
      02215, USA.
FAU - Park, Chun Gwon
AU  - Park CG
AD  - Department of Cancer Immunology & Virology, Dana-Farber Cancer Institute, Boston,
      MA, 02215, USA.
AD  - Department of Microbiology & Immunobiology, Harvard Medical School, Boston, MA,
      02215, USA.
FAU - Hartl, Christina A
AU  - Hartl CA
AD  - Department of Cancer Immunology & Virology, Dana-Farber Cancer Institute, Boston,
      MA, 02215, USA.
FAU - Subedi, Nikita
AU  - Subedi N
AD  - Department of Cancer Immunology & Virology, Dana-Farber Cancer Institute, Boston,
      MA, 02215, USA.
FAU - Cartwright, Adam N
AU  - Cartwright AN
AUID- ORCID: http://orcid.org/0000-0002-5579-2944
AD  - Department of Cancer Immunology & Virology, Dana-Farber Cancer Institute, Boston,
      MA, 02215, USA.
FAU - Puerto, Regina Bou
AU  - Puerto RB
AD  - Department of Cancer Immunology & Virology, Dana-Farber Cancer Institute, Boston,
      MA, 02215, USA.
FAU - Zheng, Yiran
AU  - Zheng Y
AD  - Department of Biological Engineering, MIT, Cambridge, MA, 02139, USA.
AD  - Koch Institute for Integrative Cancer Research, Cambridge, MA, 02139, USA.
FAU - Maiarana, James
AU  - Maiarana J
AD  - Department of Cancer Immunology & Virology, Dana-Farber Cancer Institute, Boston,
      MA, 02215, USA.
FAU - Freeman, Gordon J
AU  - Freeman GJ
AD  - Department of Cancer Immunology & Virology, Dana-Farber Cancer Institute, Boston,
      MA, 02215, USA.
FAU - Wucherpfennig, Kai W
AU  - Wucherpfennig KW
AD  - Department of Cancer Immunology & Virology, Dana-Farber Cancer Institute, Boston,
      MA, 02215, USA.
FAU - Irvine, Darrell J
AU  - Irvine DJ
AD  - Department of Biological Engineering, MIT, Cambridge, MA, 02139, USA.
AD  - Koch Institute for Integrative Cancer Research, Cambridge, MA, 02139, USA.
AD  - Howard Hughes Medical Institute, Chevy Chase, MD, 20815, USA.
FAU - Goldberg, Michael S
AU  - Goldberg MS
AD  - Department of Cancer Immunology & Virology, Dana-Farber Cancer Institute, Boston,
      MA, 02215, USA. michael_goldberg1@dfci.harvard.edu.
AD  - Department of Microbiology & Immunobiology, Harvard Medical School, Boston, MA,
      02215, USA. michael_goldberg1@dfci.harvard.edu.
LA  - eng
PT  - Journal Article
DEP - 20171123
PL  - England
TA  - Nat Commun
JT  - Nature communications
JID - 101528555
PMC - PMC5700944
EDAT- 2017/11/25 06:00
MHDA- 2017/11/25 06:00
CRDT- 2017/11/25 06:00
PHST- 2017/02/21 00:00 [received]
PHST- 2017/10/19 00:00 [accepted]
PHST- 2017/11/25 06:00 [entrez]
PHST- 2017/11/25 06:00 [pubmed]
PHST- 2017/11/25 06:00 [medline]
AID - 10.1038/s41467-017-01830-8 [doi]
AID - 10.1038/s41467-017-01830-8 [pii]
PST - epublish
SO  - Nat Commun. 2017 Nov 23;8(1):1747. doi: 10.1038/s41467-017-01830-8.

PMID- 29174843
OWN - NLM
STAT- Publisher
LR  - 20171127
IS  - 1525-0024 (Electronic)
IS  - 1525-0016 (Linking)
DP  - 2017 Oct 28
TI  - An Efficient Single-Cell RNA-Seq Approach to Identify Neoantigen-Specific T Cell 
      Receptors.
LID - S1525-0016(17)30555-5 [pii]
LID - 10.1016/j.ymthe.2017.10.018 [doi]
AB  - The adoptive transfer of neoantigen-reactive tumor-infiltrating lymphocytes
      (TILs) can result in tumor regression in patients with metastatic cancer. To
      improve the efficacy of adoptive T cell therapy targeting these tumor-specific
      mutations, we have proposed a new therapeutic strategy, which involves the
      genetic modification of autologous T cells with neoantigen-specific T cell
      receptors (TCRs) and the transfer of these modified T cells back to cancer
      patients. However, the current techniques to isolate neoantigen-specific TCRs are
      labor intensive, time consuming, and technically challenging, not suitable for
      clinical applications. To facilitate this process, a new approach was developed, 
      which included the co-culture of TILs with tandem minigene (TMG)-transfected or
      peptide-pulsed autologous antigen-presenting cells (APCs) and the single-cell RNA
      sequencing (RNA-seq) analysis of T cells to identify paired TCR sequences
      associated with cells expressing high levels of interferon-gamma (IFN-gamma) and 
      interleukin-2 (IL-2). Following this new approach, multiple TCRs were identified,
      synthesized, cloned into a retroviral vector, and then transduced into donor T
      cells. These transduced T cells were shown to specifically recognize the
      neoantigens presented by autologous APCs. In conclusion, this approach provides
      an efficient procedure to isolate neoantigen-specific TCRs for clinical
      applications, as well as for basic and translational research.
CI  - Published by Elsevier Inc.
FAU - Lu, Yong-Chen
AU  - Lu YC
AD  - Surgery Branch, National Cancer Institute, National Institutes of Health,
      Bethesda, MD 20892, USA. Electronic address: yong-chen.lu@nih.gov.
FAU - Zheng, Zhili
AU  - Zheng Z
AD  - Surgery Branch, National Cancer Institute, National Institutes of Health,
      Bethesda, MD 20892, USA.
FAU - Robbins, Paul F
AU  - Robbins PF
AD  - Surgery Branch, National Cancer Institute, National Institutes of Health,
      Bethesda, MD 20892, USA.
FAU - Tran, Eric
AU  - Tran E
AD  - Surgery Branch, National Cancer Institute, National Institutes of Health,
      Bethesda, MD 20892, USA.
FAU - Prickett, Todd D
AU  - Prickett TD
AD  - Surgery Branch, National Cancer Institute, National Institutes of Health,
      Bethesda, MD 20892, USA.
FAU - Gartner, Jared J
AU  - Gartner JJ
AD  - Surgery Branch, National Cancer Institute, National Institutes of Health,
      Bethesda, MD 20892, USA.
FAU - Li, Yong F
AU  - Li YF
AD  - Surgery Branch, National Cancer Institute, National Institutes of Health,
      Bethesda, MD 20892, USA.
FAU - Ray, Satyajit
AU  - Ray S
AD  - Surgery Branch, National Cancer Institute, National Institutes of Health,
      Bethesda, MD 20892, USA.
FAU - Franco, Zulmarie
AU  - Franco Z
AD  - Surgery Branch, National Cancer Institute, National Institutes of Health,
      Bethesda, MD 20892, USA.
FAU - Bliskovsky, Valery
AU  - Bliskovsky V
AD  - Genetics Branch, National Cancer Institute, National Institutes of Health,
      Bethesda, MD 20892, USA.
FAU - Fitzgerald, Peter C
AU  - Fitzgerald PC
AD  - Genome Analysis Unit, National Cancer Institute, National Institutes of Health,
      Bethesda, MD 20892, USA.
FAU - Rosenberg, Steven A
AU  - Rosenberg SA
AD  - Surgery Branch, National Cancer Institute, National Institutes of Health,
      Bethesda, MD 20892, USA. Electronic address: sar@nih.gov.
LA  - eng
PT  - Journal Article
DEP - 20171028
PL  - United States
TA  - Mol Ther
JT  - Molecular therapy : the journal of the American Society of Gene Therapy
JID - 100890581
OTO - NOTNLM
OT  - cancer immunotherapy
OT  - gene therapy
OT  - single cell
EDAT- 2017/11/28 06:00
MHDA- 2017/11/28 06:00
CRDT- 2017/11/28 06:00
PHST- 2017/08/18 00:00 [received]
PHST- 2017/10/24 00:00 [revised]
PHST- 2017/10/24 00:00 [accepted]
PHST- 2017/11/28 06:00 [entrez]
PHST- 2017/11/28 06:00 [pubmed]
PHST- 2017/11/28 06:00 [medline]
AID - S1525-0016(17)30555-5 [pii]
AID - 10.1016/j.ymthe.2017.10.018 [doi]
PST - aheadofprint
SO  - Mol Ther. 2017 Oct 28. pii: S1525-0016(17)30555-5. doi:
      10.1016/j.ymthe.2017.10.018.

PMID- 29257139
OWN - NLM
STAT- Publisher
LR  - 20171219
IS  - 1476-5551 (Electronic)
IS  - 0887-6924 (Linking)
DP  - 2017 Jan 16
TI  - Management of relapsed and refractory multiple myeloma: novel agents, antibodies,
      immunotherapies and beyond.
LID - 10.1038/leu.2017.329 [doi]
AB  - Despite enormous advances, management of multiple myeloma (MM) remains
      challenging. Multiple factors impact the decision to treat or which regimen to
      use at MM relapse/progression. Recent major randomized controlled trials (RCTs)
      showed widely varying progression-free survivals (PFS), ranging from a median of 
      4 months (MM-003) to 23.6 months (ASPIRE). Based on these RCTs, next-generation
      proteasome inhibitors (carfilzomib and ixazomib), next-generation
      immunomodulatory agent (pomalidomide), and monoclonal antibodies (elotuzumab and 
      daratumumab) were approved for relapsed and refractory MM. Daratumumab, targeting
      CD38, has multiple mechanisms of action including modulation of the
      immunosuppressive bone marrow micro-environment. In addition to the remarkable
      single agent activity in refractory MM, daratumumab produced deep responses and
      superior PFS in MM when combined with lenalidomide/dexamethasone, or
      bortezomib/dexamethasone. Other anti-CD38 antibodies, such as isatuximab and
      MOR202, are undergoing assessment. Elotuzumab, targeting SLAMF7, yielded superior
      response rates and PFS when combined with lenalidomide/dexamethasone. New
      combinations of these next generation novel agents and/or antibodies are
      undergoing clinical trials. Venetoclax, an oral BH3 mimetic inhibiting BCL2,
      showed single agent activity in MM with t(11;14), and is being studied in
      combination with bortezomib/dexamethasone. Selinexor, an Exportin-1 inhibitor,
      yielded promising results in quad- or penta-refractory MM including patients
      resistant to daratumumab. Pembrolizumab, an anti-PD1 check-point inhibitor, is
      being tested in combination with lenalidomide/dexamethasone or
      pomalidomide/dexamethasone. Chimeric antigen receptor-T cells targeting B-cell
      maturation antigen have yielded deep responses in RRMM. Finally, salvage
      autologous stem cell transplantation (ASCT) remains an important treatment in MM 
      relapsing/progressing after a first ASCT. Herein, the clinical trial data of
      these agents are summarized, cautious interpretation of RCTs highlighted, and
      algorithm for salvage treatment of relapse/refractory MM proposed.Leukemia
      advance online publication, 19 December 2017; doi:10.1038/leu.2017.329.
FAU - Chim, C S
AU  - Chim CS
AD  - Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong
      Kong, Hong Kong.
FAU - Kumar, S K
AU  - Kumar SK
AUID- ORCID: http://orcid.org/0000-0001-5392-9284
AD  - Department of Medicine, Mayo Clinic at Rochester, Rochester, MN, USA.
FAU - Orlowski, R Z
AU  - Orlowski RZ
AD  - Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of
      Texas MD Anderson Cancer Center, Houston, TX, USA.
FAU - Cook, G
AU  - Cook G
AD  - Haematology & Myeloma Studies, Section of Experimental Haematology, Leeds
      Institute of Cancer and Pathology, University of Leeds, Leeds, UK.
FAU - Richardson, P G
AU  - Richardson PG
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical
      School, Boston, MA, USA.
FAU - Gertz, M A
AU  - Gertz MA
AD  - Department of Medicine, Mayo Clinic at Rochester, Rochester, MN, USA.
FAU - Giralt, S
AU  - Giralt S
AD  - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.
FAU - Mateos, M V
AU  - Mateos MV
AD  - Department of Haematology, University Hospital of Salamanca, Salamanca, Spain.
FAU - Leleu, X
AU  - Leleu X
AD  - Hopital La Mileterie, part of the Academic Hospital of Poitiers (CHU), France.
FAU - Anderson, K C
AU  - Anderson KC
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical
      School, Boston, MA, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170116
PL  - England
TA  - Leukemia
JT  - Leukemia
JID - 8704895
EDAT- 2017/12/20 06:00
MHDA- 2017/12/20 06:00
CRDT- 2017/12/20 06:00
PHST- 2017/08/02 00:00 [received]
PHST- 2017/10/09 00:00 [revised]
PHST- 2017/11/06 00:00 [accepted]
PHST- 2017/12/20 06:00 [entrez]
PHST- 2017/12/20 06:00 [pubmed]
PHST- 2017/12/20 06:00 [medline]
AID - leu2017329 [pii]
AID - 10.1038/leu.2017.329 [doi]
PST - aheadofprint
SO  - Leukemia. 2017 Jan 16. pii: leu2017329. doi: 10.1038/leu.2017.329.

PMID- 29225342
OWN - NLM
STAT- In-Data-Review
LR  - 20171220
IS  - 2041-1723 (Electronic)
IS  - 2041-1723 (Linking)
VI  - 8
IP  - 1
DP  - 2017 Dec 11
TI  - Differentiation dynamics of mammary epithelial cells revealed by single-cell RNA 
      sequencing.
PG  - 2128
LID - 10.1038/s41467-017-02001-5 [doi]
AB  - Characterising the hierarchy of mammary epithelial cells (MECs) and how they are 
      regulated during adult development is important for understanding how breast
      cancer arises. Here we report the use of single-cell RNA sequencing to determine 
      the gene expression profile of MECs across four developmental stages;
      nulliparous, mid gestation, lactation and post involution. Our analysis of 23,184
      cells identifies 15 clusters, few of which could be fully characterised by a
      single marker gene. We argue instead that the epithelial cells-especially in the 
      luminal compartment-should rather be conceptualised as being part of a continuous
      spectrum of differentiation. Furthermore, our data support the existence of a
      common luminal progenitor cell giving rise to intermediate, restricted alveolar
      and hormone-sensing progenitors. This luminal progenitor compartment undergoes
      transcriptional changes in response to a full pregnancy, lactation and
      involution. In summary, our results provide a global, unbiased view of adult
      mammary gland development.
FAU - Bach, Karsten
AU  - Bach K
AD  - Department of Pharmacology, University of Cambridge, Cambridge, CB2 1PD, UK.
AD  - Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, CB2
      0RE, UK.
AD  - Cancer Research UK Cambridge Cancer Centre, Cambridge, CB2 0RE, UK.
FAU - Pensa, Sara
AU  - Pensa S
AD  - Department of Pharmacology, University of Cambridge, Cambridge, CB2 1PD, UK.
AD  - Cancer Research UK Cambridge Cancer Centre, Cambridge, CB2 0RE, UK.
FAU - Grzelak, Marta
AU  - Grzelak M
AD  - Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, CB2
      0RE, UK.
AD  - Cancer Research UK Cambridge Cancer Centre, Cambridge, CB2 0RE, UK.
FAU - Hadfield, James
AU  - Hadfield J
AUID- ORCID: http://orcid.org/0000-0001-9868-4989
AD  - Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, CB2
      0RE, UK.
AD  - Cancer Research UK Cambridge Cancer Centre, Cambridge, CB2 0RE, UK.
FAU - Adams, David J
AU  - Adams DJ
AD  - Cancer Research UK Cambridge Cancer Centre, Cambridge, CB2 0RE, UK.
AD  - Wellcome Trust Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, CB10
      1HH, UK.
FAU - Marioni, John C
AU  - Marioni JC
AD  - Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, CB2
      0RE, UK. marioni@ebi.ac.uk.
AD  - Cancer Research UK Cambridge Cancer Centre, Cambridge, CB2 0RE, UK.
      marioni@ebi.ac.uk.
AD  - Wellcome Trust Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, CB10
      1HH, UK. marioni@ebi.ac.uk.
AD  - European Bioinformatics Institute, European Molecular Biology Laboratory,
      Hinxton, CB10 1 SD, UK. marioni@ebi.ac.uk.
FAU - Khaled, Walid T
AU  - Khaled WT
AD  - Department of Pharmacology, University of Cambridge, Cambridge, CB2 1PD, UK.
      wtk22@cam.ac.uk.
AD  - Cancer Research UK Cambridge Cancer Centre, Cambridge, CB2 0RE, UK.
      wtk22@cam.ac.uk.
LA  - eng
GR  - Wellcome Trust/United Kingdom
PT  - Journal Article
DEP - 20171211
PL  - England
TA  - Nat Commun
JT  - Nature communications
JID - 101528555
PMC - PMC5723634
EDAT- 2017/12/12 06:00
MHDA- 2017/12/12 06:00
CRDT- 2017/12/12 06:00
PHST- 2017/04/13 00:00 [received]
PHST- 2017/11/01 00:00 [accepted]
PHST- 2017/12/12 06:00 [entrez]
PHST- 2017/12/12 06:00 [pubmed]
PHST- 2017/12/12 06:00 [medline]
AID - 10.1038/s41467-017-02001-5 [doi]
AID - 10.1038/s41467-017-02001-5 [pii]
PST - epublish
SO  - Nat Commun. 2017 Dec 11;8(1):2128. doi: 10.1038/s41467-017-02001-5.

PMID- 29227474
OWN - NLM
STAT- In-Data-Review
LR  - 20180111
IS  - 1546-170X (Electronic)
IS  - 1078-8956 (Linking)
VI  - 24
IP  - 1
DP  - 2018 Jan
TI  - A proteolytic fragment of histone deacetylase 4 protects the heart from failure
      by regulating the hexosamine biosynthetic pathway.
PG  - 62-72
LID - 10.1038/nm.4452 [doi]
AB  - The stress-responsive epigenetic repressor histone deacetylase 4 (HDAC4)
      regulates cardiac gene expression. Here we show that the levels of an N-terminal 
      proteolytically derived fragment of HDAC4, termed HDAC4-NT, are lower in failing 
      mouse hearts than in healthy control hearts. Virus-mediated transfer of the
      portion of the Hdac4 gene encoding HDAC4-NT into the mouse myocardium protected
      the heart from remodeling and failure; this was associated with decreased
      expression of Nr4a1, which encodes a nuclear orphan receptor, and decreased
      NR4A1-dependent activation of the hexosamine biosynthetic pathway (HBP).
      Conversely, exercise enhanced HDAC4-NT levels, and mice with a
      cardiomyocyte-specific deletion of Hdac4 show reduced exercise capacity, which
      was characterized by cardiac fatigue and increased expression of Nr4a1.
      Mechanistically, we found that NR4A1 negatively regulated contractile function in
      a manner that depended on the HBP and the calcium sensor STIM1. Our work
      describes a new regulatory axis in which epigenetic regulation of a metabolic
      pathway affects calcium handling. Activation of this axis during intermittent
      physiological stress promotes cardiac function, whereas its impairment in
      sustained pathological cardiac stress leads to heart failure.
FAU - Lehmann, Lorenz H
AU  - Lehmann LH
AD  - Department of Molecular Cardiology and Epigenetics, Heidelberg University,
      Heidelberg, Germany.
AD  - German Centre for Cardiovascular Research (DZHK), partner site
      Heidelberg/Mannheim, Heidelberg, Germany.
AD  - Department of Cardiology, Heidelberg University, Heidelberg, Germany.
FAU - Jebessa, Zegeye H
AU  - Jebessa ZH
AD  - Department of Molecular Cardiology and Epigenetics, Heidelberg University,
      Heidelberg, Germany.
AD  - German Centre for Cardiovascular Research (DZHK), partner site
      Heidelberg/Mannheim, Heidelberg, Germany.
FAU - Kreusser, Michael M
AU  - Kreusser MM
AD  - Department of Molecular Cardiology and Epigenetics, Heidelberg University,
      Heidelberg, Germany.
AD  - German Centre for Cardiovascular Research (DZHK), partner site
      Heidelberg/Mannheim, Heidelberg, Germany.
AD  - Department of Cardiology, Heidelberg University, Heidelberg, Germany.
FAU - Horsch, Axel
AU  - Horsch A
AD  - Department of Molecular Cardiology and Epigenetics, Heidelberg University,
      Heidelberg, Germany.
AD  - German Centre for Cardiovascular Research (DZHK), partner site
      Heidelberg/Mannheim, Heidelberg, Germany.
FAU - He, Tao
AU  - He T
AD  - Department of Molecular Cardiology and Epigenetics, Heidelberg University,
      Heidelberg, Germany.
AD  - German Centre for Cardiovascular Research (DZHK), partner site
      Heidelberg/Mannheim, Heidelberg, Germany.
FAU - Kronlage, Mariya
AU  - Kronlage M
AD  - Department of Molecular Cardiology and Epigenetics, Heidelberg University,
      Heidelberg, Germany.
AD  - German Centre for Cardiovascular Research (DZHK), partner site
      Heidelberg/Mannheim, Heidelberg, Germany.
AD  - Department of Cardiology, Heidelberg University, Heidelberg, Germany.
FAU - Dewenter, Matthias
AU  - Dewenter M
AD  - Department of Molecular Cardiology and Epigenetics, Heidelberg University,
      Heidelberg, Germany.
AD  - German Centre for Cardiovascular Research (DZHK), partner site
      Heidelberg/Mannheim, Heidelberg, Germany.
FAU - Sramek, Viviana
AU  - Sramek V
AD  - Department of Molecular Cardiology and Epigenetics, Heidelberg University,
      Heidelberg, Germany.
AD  - German Centre for Cardiovascular Research (DZHK), partner site
      Heidelberg/Mannheim, Heidelberg, Germany.
FAU - Oehl, Ulrike
AU  - Oehl U
AD  - Department of Molecular Cardiology and Epigenetics, Heidelberg University,
      Heidelberg, Germany.
AD  - German Centre for Cardiovascular Research (DZHK), partner site
      Heidelberg/Mannheim, Heidelberg, Germany.
FAU - Krebs-Haupenthal, Jutta
AU  - Krebs-Haupenthal J
AD  - Department of Molecular Cardiology and Epigenetics, Heidelberg University,
      Heidelberg, Germany.
AD  - German Centre for Cardiovascular Research (DZHK), partner site
      Heidelberg/Mannheim, Heidelberg, Germany.
FAU - von der Lieth, Albert H
AU  - von der Lieth AH
AD  - Department of Molecular Cardiology and Epigenetics, Heidelberg University,
      Heidelberg, Germany.
AD  - German Centre for Cardiovascular Research (DZHK), partner site
      Heidelberg/Mannheim, Heidelberg, Germany.
FAU - Schmidt, Andrea
AU  - Schmidt A
AD  - Department of Molecular Cardiology and Epigenetics, Heidelberg University,
      Heidelberg, Germany.
AD  - German Centre for Cardiovascular Research (DZHK), partner site
      Heidelberg/Mannheim, Heidelberg, Germany.
FAU - Sun, Qiang
AU  - Sun Q
AD  - Department of Molecular Cardiology and Epigenetics, Heidelberg University,
      Heidelberg, Germany.
AD  - German Centre for Cardiovascular Research (DZHK), partner site
      Heidelberg/Mannheim, Heidelberg, Germany.
FAU - Ritterhoff, Julia
AU  - Ritterhoff J
AD  - German Centre for Cardiovascular Research (DZHK), partner site
      Heidelberg/Mannheim, Heidelberg, Germany.
AD  - Department of Cardiology, Heidelberg University, Heidelberg, Germany.
FAU - Finke, Daniel
AU  - Finke D
AD  - Department of Molecular Cardiology and Epigenetics, Heidelberg University,
      Heidelberg, Germany.
AD  - German Centre for Cardiovascular Research (DZHK), partner site
      Heidelberg/Mannheim, Heidelberg, Germany.
AD  - Department of Cardiology, Heidelberg University, Heidelberg, Germany.
FAU - Volkers, Mirko
AU  - Volkers M
AD  - German Centre for Cardiovascular Research (DZHK), partner site
      Heidelberg/Mannheim, Heidelberg, Germany.
AD  - Department of Cardiology, Heidelberg University, Heidelberg, Germany.
FAU - Jungmann, Andreas
AU  - Jungmann A
AD  - German Centre for Cardiovascular Research (DZHK), partner site
      Heidelberg/Mannheim, Heidelberg, Germany.
AD  - Department of Cardiology, Heidelberg University, Heidelberg, Germany.
FAU - Sauer, Sven W
AU  - Sauer SW
AD  - Center for Child and Adolescent Medicine, Department I, Heidelberg University,
      Heidelberg, Germany.
FAU - Thiel, Christian
AU  - Thiel C
AD  - Center for Child and Adolescent Medicine, Department I, Heidelberg University,
      Heidelberg, Germany.
FAU - Nickel, Alexander
AU  - Nickel A
AD  - Department of Internal Medicine, Saarland University Hospital, Homburg Saar,
      Germany.
FAU - Kohlhaas, Michael
AU  - Kohlhaas M
AD  - Department of Internal Medicine, Saarland University Hospital, Homburg Saar,
      Germany.
FAU - Schafer, Michaela
AU  - Schafer M
AD  - German Centre for Cardiovascular Research (DZHK), partner site
      Heidelberg/Mannheim, Heidelberg, Germany.
AD  - Institute for Diabetes and Cancer (IDC), Helmholtz Center Munich and Joint
      Heidelberg-IDC Translational Diabetes Program, Heidelberg University, Neuherberg,
      Germany.
FAU - Sticht, Carsten
AU  - Sticht C
AD  - Medical Research Center, Medical Faculty Mannheim, Heidelberg University,
      Mannheim, Germany.
FAU - Maack, Christoph
AU  - Maack C
AD  - Department of Internal Medicine, Saarland University Hospital, Homburg Saar,
      Germany.
FAU - Gretz, Norbert
AU  - Gretz N
AD  - Medical Research Center, Medical Faculty Mannheim, Heidelberg University,
      Mannheim, Germany.
FAU - Wagner, Michael
AU  - Wagner M
AD  - Department of Pharmacology and Toxicology, Faculty of Medicine Carl Gustav Carus,
      Technische Universitat Dresden, Dresden, Germany.
FAU - El-Armouche, Ali
AU  - El-Armouche A
AD  - Department of Pharmacology and Toxicology, Faculty of Medicine Carl Gustav Carus,
      Technische Universitat Dresden, Dresden, Germany.
FAU - Maier, Lars S
AU  - Maier LS
AD  - Department of Internal Medicine II, University Hospital Regensburg, Regensburg,
      Germany.
FAU - Londono, Juan E Camacho
AU  - Londono JEC
AD  - German Centre for Cardiovascular Research (DZHK), partner site
      Heidelberg/Mannheim, Heidelberg, Germany.
AD  - Institute of Pharmacology, Heidelberg University, Heidelberg, Germany.
FAU - Meder, Benjamin
AU  - Meder B
AD  - German Centre for Cardiovascular Research (DZHK), partner site
      Heidelberg/Mannheim, Heidelberg, Germany.
AD  - Department of Cardiology, Heidelberg University, Heidelberg, Germany.
FAU - Freichel, Marc
AU  - Freichel M
AD  - German Centre for Cardiovascular Research (DZHK), partner site
      Heidelberg/Mannheim, Heidelberg, Germany.
AD  - Institute of Pharmacology, Heidelberg University, Heidelberg, Germany.
FAU - Grone, Hermann-Josef
AU  - Grone HJ
AD  - Department of Cellular and Molecular Pathology, German Cancer Research Center,
      Heidelberg, Germany.
FAU - Most, Patrick
AU  - Most P
AD  - German Centre for Cardiovascular Research (DZHK), partner site
      Heidelberg/Mannheim, Heidelberg, Germany.
AD  - Department of Cardiology, Heidelberg University, Heidelberg, Germany.
FAU - Muller, Oliver J
AU  - Muller OJ
AUID- ORCID: http://orcid.org/0000-0001-8223-2638
AD  - German Centre for Cardiovascular Research (DZHK), partner site
      Heidelberg/Mannheim, Heidelberg, Germany.
AD  - Department of Cardiology, Heidelberg University, Heidelberg, Germany.
FAU - Herzig, Stephan
AU  - Herzig S
AD  - German Centre for Cardiovascular Research (DZHK), partner site
      Heidelberg/Mannheim, Heidelberg, Germany.
AD  - Institute for Diabetes and Cancer (IDC), Helmholtz Center Munich and Joint
      Heidelberg-IDC Translational Diabetes Program, Heidelberg University, Neuherberg,
      Germany.
FAU - Furlong, Eileen E M
AU  - Furlong EEM
AUID- ORCID: http://orcid.org/0000-0002-9544-8339
AD  - German Centre for Cardiovascular Research (DZHK), partner site
      Heidelberg/Mannheim, Heidelberg, Germany.
AD  - European Molecular Biology Laboratory, Genome Biology Unit, Heidelberg, Germany.
FAU - Katus, Hugo A
AU  - Katus HA
AD  - German Centre for Cardiovascular Research (DZHK), partner site
      Heidelberg/Mannheim, Heidelberg, Germany.
AD  - Department of Cardiology, Heidelberg University, Heidelberg, Germany.
FAU - Backs, Johannes
AU  - Backs J
AUID- ORCID: http://orcid.org/0000-0002-2322-2699
AD  - Department of Molecular Cardiology and Epigenetics, Heidelberg University,
      Heidelberg, Germany.
AD  - German Centre for Cardiovascular Research (DZHK), partner site
      Heidelberg/Mannheim, Heidelberg, Germany.
LA  - eng
PT  - Journal Article
DEP - 20171211
PL  - United States
TA  - Nat Med
JT  - Nature medicine
JID - 9502015
EDAT- 2017/12/12 06:00
MHDA- 2017/12/12 06:00
CRDT- 2017/12/12 06:00
PHST- 2015/08/09 00:00 [received]
PHST- 2017/11/06 00:00 [accepted]
PHST- 2017/12/12 06:00 [pubmed]
PHST- 2017/12/12 06:00 [medline]
PHST- 2017/12/12 06:00 [entrez]
AID - nm.4452 [pii]
AID - 10.1038/nm.4452 [doi]
PST - ppublish
SO  - Nat Med. 2018 Jan;24(1):62-72. doi: 10.1038/nm.4452. Epub 2017 Dec 11.

PMID- 29224076
OWN - NLM
STAT- In-Process
LR  - 20171210
IS  - 1940-6029 (Electronic)
IS  - 1064-3745 (Linking)
VI  - 1712
DP  - 2018
TI  - Next-Generation Sequencing of Genome-Wide CRISPR Screens.
PG  - 203-216
LID - 10.1007/978-1-4939-7514-3_13 [doi]
AB  - Genome-wide functional genomic screens utilizing the clustered regularly
      interspaced short palindromic repeats (CRISPR)-Cas9 system have proven to be a
      powerful tool for systematic genomic perturbation in mammalian cells and provide 
      an alternative to previous screens utilizing RNA interference technology. The
      wide availability of these libraries through public plasmid repositories as well 
      as the decreasing cost and speed in quantifying these screens using
      high-throughput next-generation sequencing (NGS) allows for the adoption of the
      technology in a variety of laboratories interested in diverse biologic questions.
      Here, we describe the protocol to generate next-generation sequencing libraries
      from genome-wide CRISPR genomic screens.
FAU - Yau, Edwin H
AU  - Yau EH
AD  - Division of Hematology-Oncology, Department of Internal Medicine, University of
      California, San Diego, La Jolla, CA, 92037, USA.
AD  - Solid Tumor Therapeutics Program, Moores Cancer Center, University of California,
      San Diego, 3855 Health Sciences Drive, La Jolla, CA, 92093, USA.
FAU - Rana, Tariq M
AU  - Rana TM
AD  - Solid Tumor Therapeutics Program, Moores Cancer Center, University of California,
      San Diego, 3855 Health Sciences Drive, La Jolla, CA, 92093, USA. trana@ucsd.edu.
AD  - Department of Pediatrics, University of California, San Diego, 9500 Gilman Drive,
      MC 0762, La Jolla, CA, 92093, USA. trana@ucsd.edu.
AD  - Institute for Genomic Medicine, University of California, San Diego, 9500 Gilman 
      Drive, La Jolla, CA, 92093, USA. trana@ucsd.edu.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Methods Mol Biol
JT  - Methods in molecular biology (Clifton, N.J.)
JID - 9214969
OTO - NOTNLM
OT  - CRISPR
OT  - Cas9
OT  - GeCKO
OT  - Genome engineering
OT  - Genome-wide screen
EDAT- 2017/12/11 06:00
MHDA- 2017/12/11 06:00
CRDT- 2017/12/11 06:00
PHST- 2017/12/11 06:00 [entrez]
PHST- 2017/12/11 06:00 [pubmed]
PHST- 2017/12/11 06:00 [medline]
AID - 10.1007/978-1-4939-7514-3_13 [doi]
PST - ppublish
SO  - Methods Mol Biol. 2018;1712:203-216. doi: 10.1007/978-1-4939-7514-3_13.

PMID- 29155426
OWN - NLM
STAT- In-Data-Review
LR  - 20180123
IS  - 1546-170X (Electronic)
IS  - 1078-8956 (Linking)
VI  - 24
IP  - 1
DP  - 2018 Jan
TI  - CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to
      CD19-targeted CAR immunotherapy.
PG  - 20-28
LID - 10.1038/nm.4441 [doi]
AB  - Chimeric antigen receptor (CAR) T cells targeting CD19 mediate potent effects in 
      relapsed and/or refractory pre-B cell acute lymphoblastic leukemia (B-ALL), but
      antigen loss is a frequent cause of resistance to CD19-targeted immunotherapy.
      CD22 is also expressed in most cases of B-ALL and is usually retained following
      CD19 loss. We report results from a phase 1 trial testing a new CD22-targeted CAR
      (CD22-CAR) in 21 children and adults, including 17 who were previously treated
      with CD19-directed immunotherapy. Dose-dependent antileukemic activity was
      observed, with complete remission obtained in 73% (11/15) of patients receiving
      >/=1 x 10(6) CD22-CAR T cells per kg body weight, including 5 of 5 patients with 
      CD19(dim) or CD19(-) B-ALL. Median remission duration was 6 months. Relapses were
      associated with diminished CD22 site density that likely permitted CD22(+) cell
      escape from killing by CD22-CAR T cells. These results are the first to establish
      the clinical activity of a CD22-CAR in B-ALL, including leukemia resistant to
      anti-CD19 immunotherapy, demonstrating potency against B-ALL comparable to that
      of CD19-CAR at biologically active doses. Our results also highlight the critical
      role played by antigen density in regulating CAR function.
FAU - Fry, Terry J
AU  - Fry TJ
AUID- ORCID: http://orcid.org/0000-0001-8044-5226
AD  - Pediatric Oncology Branch, Center for Cancer Research, National Institutes of
      Health (NIH), Bethesda, Maryland, USA.
FAU - Shah, Nirali N
AU  - Shah NN
AD  - Pediatric Oncology Branch, Center for Cancer Research, National Institutes of
      Health (NIH), Bethesda, Maryland, USA.
FAU - Orentas, Rimas J
AU  - Orentas RJ
AD  - Pediatric Oncology Branch, Center for Cancer Research, National Institutes of
      Health (NIH), Bethesda, Maryland, USA.
FAU - Stetler-Stevenson, Maryalice
AU  - Stetler-Stevenson M
AD  - Laboratory of Pathology, Center for Cancer Research, NIH, Bethesda, Maryland,
      USA.
FAU - Yuan, Constance M
AU  - Yuan CM
AD  - Laboratory of Pathology, Center for Cancer Research, NIH, Bethesda, Maryland,
      USA.
FAU - Ramakrishna, Sneha
AU  - Ramakrishna S
AD  - Pediatric Oncology Branch, Center for Cancer Research, National Institutes of
      Health (NIH), Bethesda, Maryland, USA.
FAU - Wolters, Pamela
AU  - Wolters P
AD  - Pediatric Oncology Branch, Center for Cancer Research, National Institutes of
      Health (NIH), Bethesda, Maryland, USA.
FAU - Martin, Staci
AU  - Martin S
AD  - Pediatric Oncology Branch, Center for Cancer Research, National Institutes of
      Health (NIH), Bethesda, Maryland, USA.
FAU - Delbrook, Cindy
AU  - Delbrook C
AD  - Pediatric Oncology Branch, Center for Cancer Research, National Institutes of
      Health (NIH), Bethesda, Maryland, USA.
FAU - Yates, Bonnie
AU  - Yates B
AD  - Pediatric Oncology Branch, Center for Cancer Research, National Institutes of
      Health (NIH), Bethesda, Maryland, USA.
FAU - Shalabi, Haneen
AU  - Shalabi H
AD  - Pediatric Oncology Branch, Center for Cancer Research, National Institutes of
      Health (NIH), Bethesda, Maryland, USA.
FAU - Fountaine, Thomas J
AU  - Fountaine TJ
AD  - Pediatric Oncology Branch, Center for Cancer Research, National Institutes of
      Health (NIH), Bethesda, Maryland, USA.
FAU - Shern, Jack F
AU  - Shern JF
AD  - Pediatric Oncology Branch, Center for Cancer Research, National Institutes of
      Health (NIH), Bethesda, Maryland, USA.
FAU - Majzner, Robbie G
AU  - Majzner RG
AD  - Department of Pediatrics, Stanford University, Stanford, California, USA.
FAU - Stroncek, David F
AU  - Stroncek DF
AD  - Department of Transfusion Medicine, NIH Clinical Center, NIH, Bethesda, Maryland,
      USA.
FAU - Sabatino, Marianna
AU  - Sabatino M
AD  - Department of Transfusion Medicine, NIH Clinical Center, NIH, Bethesda, Maryland,
      USA.
FAU - Feng, Yang
AU  - Feng Y
AD  - Cancer and Inflammation Program, National Cancer Institute, NIH, Bethesda,
      Maryland, USA.
FAU - Dimitrov, Dimiter S
AU  - Dimitrov DS
AD  - Cancer and Inflammation Program, National Cancer Institute, NIH, Bethesda,
      Maryland, USA.
FAU - Zhang, Ling
AU  - Zhang L
AD  - Pediatric Oncology Branch, Center for Cancer Research, National Institutes of
      Health (NIH), Bethesda, Maryland, USA.
FAU - Nguyen, Sang
AU  - Nguyen S
AD  - Pediatric Oncology Branch, Center for Cancer Research, National Institutes of
      Health (NIH), Bethesda, Maryland, USA.
FAU - Qin, Haiying
AU  - Qin H
AD  - Pediatric Oncology Branch, Center for Cancer Research, National Institutes of
      Health (NIH), Bethesda, Maryland, USA.
FAU - Dropulic, Boro
AU  - Dropulic B
AD  - Lentigen Corporation, Gaithersburg, Maryland, USA.
FAU - Lee, Daniel W
AU  - Lee DW
AD  - Pediatric Oncology Branch, Center for Cancer Research, National Institutes of
      Health (NIH), Bethesda, Maryland, USA.
FAU - Mackall, Crystal L
AU  - Mackall CL
AUID- ORCID: http://orcid.org/0000-0003-0359-9023
AD  - Department of Pediatrics and Standford Cancer Center, Stanford University,
      Stanford, California, USA.
LA  - eng
GR  - Z99 CA999999/Intramural NIH HHS/United States
GR  - ZIA BC011295-01/Intramural NIH HHS/United States
PT  - Journal Article
DEP - 20171120
PL  - United States
TA  - Nat Med
JT  - Nature medicine
JID - 9502015
PMC - PMC5774642
MID - NIHMS913214
EDAT- 2017/11/21 06:00
MHDA- 2017/11/21 06:00
CRDT- 2017/11/21 06:00
PMCR- 2018/05/20 00:00
PHST- 2017/02/08 00:00 [received]
PHST- 2017/10/13 00:00 [accepted]
PHST- 2018/05/20 00:00 [pmc-release]
PHST- 2017/11/21 06:00 [pubmed]
PHST- 2017/11/21 06:00 [medline]
PHST- 2017/11/21 06:00 [entrez]
AID - nm.4441 [pii]
AID - 10.1038/nm.4441 [doi]
PST - ppublish
SO  - Nat Med. 2018 Jan;24(1):20-28. doi: 10.1038/nm.4441. Epub 2017 Nov 20.

PMID- 29211713
OWN - NLM
STAT- In-Data-Review
LR  - 20180110
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 552
IP  - 7684
DP  - 2017 Dec 14
TI  - Runx3 programs CD8(+) T cell residency in non-lymphoid tissues and tumours.
PG  - 253-257
LID - 10.1038/nature24993 [doi]
AB  - Tissue-resident memory CD8(+) T (TRM) cells are found at common sites of pathogen
      exposure, where they elicit rapid and robust protective immune responses.
      However, the molecular signals that control TRM cell differentiation and
      homeostasis are not fully understood. Here we show that mouse TRM precursor cells
      represent a unique CD8(+) T cell subset that is distinct from the precursors of
      circulating memory cell populations at the levels of gene expression and
      chromatin accessibility. Using computational and pooled in vivo RNA interference 
      screens, we identify the transcription factor Runx3 as a key regulator of TRM
      cell differentiation and homeostasis. Runx3 was required to establish TRM cell
      populations in diverse tissue environments, and supported the expression of
      crucial tissue-residency genes while suppressing genes associated with tissue
      egress and recirculation. Furthermore, we show that human and mouse
      tumour-infiltrating lymphocytes share a core tissue-residency gene-expression
      signature with TRM cells that is associated with Runx3 activity. In a mouse model
      of adoptive T cell therapy for melanoma, Runx3-deficient CD8(+)
      tumour-infiltrating lymphocytes failed to accumulate in tumours, resulting in
      greater rates of tumour growth and mortality. Conversely, overexpression of Runx3
      enhanced tumour-specific CD8(+) T cell abundance, delayed tumour growth, and
      prolonged survival. In addition to establishing Runx3 as a central regulator of
      TRM cell differentiation, these results provide insight into the signals that
      promote T cell residency in non-lymphoid sites, which could be used to enhance
      vaccine efficacy or adoptive cell therapy treatments that target cancer.
FAU - Milner, J Justin
AU  - Milner JJ
AD  - Division of Biological Sciences, University of California, San Diego, La Jolla,
      California, USA.
FAU - Toma, Clara
AU  - Toma C
AD  - Division of Biological Sciences, University of California, San Diego, La Jolla,
      California, USA.
FAU - Yu, Bingfei
AU  - Yu B
AD  - Division of Biological Sciences, University of California, San Diego, La Jolla,
      California, USA.
FAU - Zhang, Kai
AU  - Zhang K
AD  - Bioinformatics and Systems Biology Graduate Program, University of California,
      San Diego, La Jolla, California, USA.
FAU - Omilusik, Kyla
AU  - Omilusik K
AD  - Division of Biological Sciences, University of California, San Diego, La Jolla,
      California, USA.
FAU - Phan, Anthony T
AU  - Phan AT
AD  - Division of Biological Sciences, University of California, San Diego, La Jolla,
      California, USA.
FAU - Wang, Dapeng
AU  - Wang D
AD  - Department of Immunology and Microbiology, The Scripps Research Institute,
      Jupiter, Florida, USA.
FAU - Getzler, Adam J
AU  - Getzler AJ
AD  - Department of Immunology and Microbiology, The Scripps Research Institute,
      Jupiter, Florida, USA.
FAU - Nguyen, Toan
AU  - Nguyen T
AD  - Division of Biological Sciences, University of California, San Diego, La Jolla,
      California, USA.
FAU - Crotty, Shane
AU  - Crotty S
AD  - Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La 
      Jolla, California, USA.
AD  - Division of Infectious Diseases, Department of Medicine, University of
      California, San Diego, La Jolla, California, USA.
FAU - Wang, Wei
AU  - Wang W
AD  - Bioinformatics and Systems Biology Graduate Program, University of California,
      San Diego, La Jolla, California, USA.
AD  - Department of Chemistry and Biochemistry, University of California, San Diego, La
      Jolla, California, USA.
AD  - Department of Cellular and Molecular Medicine, University of California, San
      Diego, La Jolla, California, USA.
FAU - Pipkin, Matthew E
AU  - Pipkin ME
AD  - Department of Immunology and Microbiology, The Scripps Research Institute,
      Jupiter, Florida, USA.
FAU - Goldrath, Ananda W
AU  - Goldrath AW
AD  - Division of Biological Sciences, University of California, San Diego, La Jolla,
      California, USA.
LA  - eng
GR  - U19 AI109976/AI/NIAID NIH HHS/United States
PT  - Journal Article
DEP - 20171206
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
EIN - Nature. 2018 Jan 10;:. PMID: 29320476
PMC - PMC5747964
MID - NIHMS917057
EDAT- 2017/12/07 06:00
MHDA- 2017/12/07 06:00
CRDT- 2017/12/07 06:00
PMCR- 2018/06/06 00:00
PHST- 2017/05/26 00:00 [received]
PHST- 2017/10/31 00:00 [accepted]
PHST- 2018/06/06 00:00 [pmc-release]
PHST- 2017/12/07 06:00 [pubmed]
PHST- 2017/12/07 06:00 [medline]
PHST- 2017/12/07 06:00 [entrez]
AID - nature24993 [pii]
AID - 10.1038/nature24993 [doi]
PST - ppublish
SO  - Nature. 2017 Dec 14;552(7684):253-257. doi: 10.1038/nature24993. Epub 2017 Dec 6.

PMID- 29221731
OWN - NLM
STAT- MEDLINE
DCOM- 20171226
LR  - 20180119
IS  - 1097-4180 (Electronic)
IS  - 1074-7613 (Linking)
VI  - 47
IP  - 6
DP  - 2017 Dec 19
TI  - White Adipose Tissue Is a Reservoir for Memory T Cells and Promotes Protective
      Memory Responses to Infection.
PG  - 1154-1168.e6
LID - S1074-7613(17)30486-7 [pii]
LID - 10.1016/j.immuni.2017.11.009 [doi]
AB  - White adipose tissue bridges body organs and plays a fundamental role in host
      metabolism. To what extent adipose tissue also contributes to immune surveillance
      and long-term protective defense remains largely unknown. Here, we have shown
      that at steady state, white adipose tissue contained abundant memory lymphocyte
      populations. After infection, white adipose tissue accumulated large numbers of
      pathogen-specific memory T cells, including tissue-resident cells. Memory T cells
      in white adipose tissue expressed a distinct metabolic profile, and white adipose
      tissue from previously infected mice was sufficient to protect uninfected mice
      from lethal pathogen challenge. Induction of recall responses within white
      adipose tissue was associated with the collapse of lipid metabolism in favor of
      antimicrobial responses. Our results suggest that white adipose tissue represents
      a memory T cell reservoir that provides potent and rapid effector memory
      responses, positioning this compartment as a potential major contributor to
      immunological memory.
CI  - Published by Elsevier Inc.
FAU - Han, Seong-Ji
AU  - Han SJ
AD  - Mucosal Immunology Section, Laboratory of Parasitic Diseases, National Institute 
      of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA.
FAU - Glatman Zaretsky, Arielle
AU  - Glatman Zaretsky A
AD  - Mucosal Immunology Section, Laboratory of Parasitic Diseases, National Institute 
      of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA.
FAU - Andrade-Oliveira, Vinicius
AU  - Andrade-Oliveira V
AD  - Mucosal Immunology Section, Laboratory of Parasitic Diseases, National Institute 
      of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA.
FAU - Collins, Nicholas
AU  - Collins N
AD  - Mucosal Immunology Section, Laboratory of Parasitic Diseases, National Institute 
      of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA.
FAU - Dzutsev, Amiran
AU  - Dzutsev A
AD  - Cancer and Inflammation Program, Center for Cancer Research, National Cancer
      Institute, NIH, Bethesda, MD 20892, USA.
FAU - Shaik, Jahangheer
AU  - Shaik J
AD  - Mucosal Immunology Section, Laboratory of Parasitic Diseases, National Institute 
      of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA.
FAU - Morais da Fonseca, Denise
AU  - Morais da Fonseca D
AD  - Mucosal Immunology Section, Laboratory of Parasitic Diseases, National Institute 
      of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA.
FAU - Harrison, Oliver J
AU  - Harrison OJ
AD  - Mucosal Immunology Section, Laboratory of Parasitic Diseases, National Institute 
      of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA.
FAU - Tamoutounour, Samira
AU  - Tamoutounour S
AD  - Mucosal Immunology Section, Laboratory of Parasitic Diseases, National Institute 
      of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA.
FAU - Byrd, Allyson L
AU  - Byrd AL
AD  - Mucosal Immunology Section, Laboratory of Parasitic Diseases, National Institute 
      of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA; Translational
      and Functional Genomics Branch, National Human Genome Research Institute, NIH,
      Bethesda, MD 20892, USA; Department of Bioinformatics, Boston University, Boston,
      MA 02215, USA.
FAU - Smelkinson, Margery
AU  - Smelkinson M
AD  - Biological Imaging, Research Technology Branch, National Institute of Allergy and
      Infectious Diseases, NIH, Bethesda, MD 20892, USA.
FAU - Bouladoux, Nicolas
AU  - Bouladoux N
AD  - Mucosal Immunology Section, Laboratory of Parasitic Diseases, National Institute 
      of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA; NIAID
      Microbiome Program, NIH, Bethesda, MD 20892, USA.
FAU - Bliska, James B
AU  - Bliska JB
AD  - Department of Molecular Genetics and Microbiology, 238 Centers for Molecular
      Medicine, Stony Brook University, Stonybrook, NY 11794, USA.
FAU - Brenchley, Jason M
AU  - Brenchley JM
AD  - Barrier Immunity Section, Laboratory of Parasitic Diseases, National Institute of
      Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA.
FAU - Brodsky, Igor E
AU  - Brodsky IE
AD  - Department of Pathobiology, School of Veterinary Medicine, University of
      Pennsylvania, Philadelphia, PA 19104, USA.
FAU - Belkaid, Yasmine
AU  - Belkaid Y
AD  - Mucosal Immunology Section, Laboratory of Parasitic Diseases, National Institute 
      of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA; NIAID
      Microbiome Program, NIH, Bethesda, MD 20892, USA. Electronic address:
      ybelkaid@niaid.nih.gov.
LA  - eng
GR  - R01 AI099222/AI/NIAID NIH HHS/United States
GR  - ZIA AI001132-06/Intramural NIH HHS/United States
PT  - Journal Article
DEP - 20171205
PL  - United States
TA  - Immunity
JT  - Immunity
JID - 9432918
RN  - 0 (Bacterial Proteins)
RN  - 0 (Interleukin-17)
RN  - 0 (Interleukin-5)
RN  - 0 (Luminescent Proteins)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (yellow fluorescent protein, Bacteria)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Adipose Tissue, White/immunology/*transplantation
MH  - Animals
MH  - Bacterial Proteins/genetics/metabolism
MH  - CD4-Positive T-Lymphocytes/*immunology/microbiology/parasitology
MH  - CD8-Positive T-Lymphocytes/*immunology/microbiology/parasitology
MH  - Gene Expression
MH  - Genes, Reporter
MH  - *Immunologic Memory
MH  - Interferon-gamma/genetics/immunology
MH  - Interleukin-17/genetics/immunology
MH  - Interleukin-5/genetics/immunology
MH  - Lipid Metabolism
MH  - Luminescent Proteins/genetics/metabolism
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Transgenic
MH  - Survival Analysis
MH  - Tissue Transplantation
MH  - Toxoplasma/immunology
MH  - Toxoplasmosis/genetics/*immunology/mortality/parasitology
MH  - Tumor Necrosis Factor-alpha/genetics/immunology
MH  - Yersinia pseudotuberculosis/immunology
MH  - Yersinia pseudotuberculosis
      Infections/genetics/*immunology/microbiology/mortality
PMC - PMC5773068
MID - NIHMS925857
OTO - NOTNLM
OT  - T cells
OT  - adipocytes
OT  - adipose tissue
OT  - central memory T cells
OT  - effector memory T cells
OT  - infection
OT  - lipids
OT  - memory
OT  - metabolism
OT  - resident memory T cells
EDAT- 2017/12/10 06:00
MHDA- 2017/12/27 06:00
CRDT- 2017/12/10 06:00
PMCR- 2018/12/19 00:00
PHST- 2017/02/07 00:00 [received]
PHST- 2017/09/13 00:00 [revised]
PHST- 2017/11/06 00:00 [accepted]
PHST- 2018/12/19 00:00 [pmc-release]
PHST- 2017/12/10 06:00 [pubmed]
PHST- 2017/12/27 06:00 [medline]
PHST- 2017/12/10 06:00 [entrez]
AID - S1074-7613(17)30486-7 [pii]
AID - 10.1016/j.immuni.2017.11.009 [doi]
PST - ppublish
SO  - Immunity. 2017 Dec 19;47(6):1154-1168.e6. doi: 10.1016/j.immuni.2017.11.009. Epub
      2017 Dec 5.

PMID- 29180699
OWN - NLM
STAT- In-Data-Review
LR  - 20180117
IS  - 1546-1718 (Electronic)
IS  - 1061-4036 (Linking)
VI  - 50
IP  - 1
DP  - 2018 Jan
TI  - Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and
      persistence.
PG  - 62-72
LID - 10.1038/s41588-017-0001-z [doi]
AB  - Mutations in IDH1 and IDH2 (encoding isocitrate dehydrogenase 1 and 2) drive the 
      development of gliomas and other human malignancies. Mutant IDH1 induces
      epigenetic changes that promote tumorigenesis, but the scale and reversibility of
      these changes are unknown. Here, using human astrocyte and glioma tumorsphere
      systems, we generate a large-scale atlas of mutant-IDH1-induced epigenomic
      reprogramming. We characterize the reversibility of the alterations in DNA
      methylation, the histone landscape, and transcriptional reprogramming that occur 
      following IDH1 mutation. We discover genome-wide coordinate changes in the
      localization and intensity of multiple histone marks and chromatin states. Mutant
      IDH1 establishes a CD24(+) population with a proliferative advantage and
      stem-like transcriptional features. Strikingly, prolonged exposure to mutant IDH1
      results in irreversible genomic and epigenetic alterations. Together, these
      observations provide unprecedented high-resolution molecular portraits of
      mutant-IDH1-dependent epigenomic reprogramming. These findings have substantial
      implications for understanding of mutant IDH function and for optimizing
      therapeutic approaches to targeting IDH-mutant tumors.
FAU - Turcan, Sevin
AU  - Turcan S
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY, USA. sevin.turcan@med.uni-heidelberg.de.
AD  - Department of Neurology, University Hospital Heidelberg, Heidelberg, Germany.
      sevin.turcan@med.uni-heidelberg.de.
FAU - Makarov, Vladimir
AU  - Makarov V
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY, USA.
FAU - Taranda, Julian
AU  - Taranda J
AD  - Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA.
FAU - Wang, Yuxiang
AU  - Wang Y
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY, USA.
FAU - Fabius, Armida W M
AU  - Fabius AWM
AUID- ORCID: http://orcid.org/0000-0002-1220-1868
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY, USA.
AD  - Department of Ophthalmology, VU Medical Center, Amsterdam, The Netherlands.
FAU - Wu, Wei
AU  - Wu W
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY, USA.
FAU - Zheng, Yupeng
AU  - Zheng Y
AD  - Sanofi Genzyme, Waltham, MA, USA.
FAU - El-Amine, Nour
AU  - El-Amine N
AD  - Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA.
FAU - Haddock, Sara
AU  - Haddock S
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY, USA.
AD  - Weill Cornell School of Medicine, New York, NY, USA.
FAU - Nanjangud, Gouri
AU  - Nanjangud G
AUID- ORCID: http://orcid.org/0000-0002-8547-1957
AD  - Molecular Cytogenetics Core Facility, Memorial Sloan Kettering Cancer Center, New
      York, NY, USA.
FAU - LeKaye, H Carl
AU  - LeKaye HC
AD  - Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, 
      NY, USA.
FAU - Brennan, Cameron
AU  - Brennan C
AD  - Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, NY,
      USA.
FAU - Cross, Justin
AU  - Cross J
AD  - Donald B. and Catherine C. Marron Cancer Metabolism Center, Memorial Sloan
      Kettering Cancer Center, New York, NY, USA.
FAU - Huse, Jason T
AU  - Huse JT
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY, USA.
FAU - Kelleher, Neil L
AU  - Kelleher NL
AUID- ORCID: http://orcid.org/0000-0002-8815-3372
AD  - Department of Chemistry, Northwestern University, Evanston, IL, USA.
FAU - Osten, Pavel
AU  - Osten P
AD  - Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA.
FAU - Thompson, Craig B
AU  - Thompson CB
AD  - Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New 
      York, NY, USA.
FAU - Chan, Timothy A
AU  - Chan TA
AUID- ORCID: http://orcid.org/0000-0002-9265-0283
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY, USA. chant@mskcc.org.
AD  - Weill Cornell School of Medicine, New York, NY, USA. chant@mskcc.org.
AD  - Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer
      Center, New York, NY, USA. chant@mskcc.org.
LA  - eng
GR  - T32 CA160001/CA/NCI NIH HHS/United States
GR  - R01 MH096946/MH/NIMH NIH HHS/United States
GR  - R01 CA177828/CA/NCI NIH HHS/United States
GR  - P41 GM108569/GM/NIGMS NIH HHS/United States
GR  - P30 CA008748/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20171127
PL  - United States
TA  - Nat Genet
JT  - Nature genetics
JID - 9216904
PMC - PMC5769471
MID - NIHMS926768
EDAT- 2017/11/29 06:00
MHDA- 2017/11/29 06:00
CRDT- 2017/11/29 06:00
PMCR- 2019/01/01 00:00
PHST- 2016/11/11 00:00 [received]
PHST- 2017/10/25 00:00 [accepted]
PHST- 2019/01/01 00:00 [pmc-release]
PHST- 2017/11/29 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
PHST- 2017/11/29 06:00 [entrez]
AID - 10.1038/s41588-017-0001-z [doi]
AID - 10.1038/s41588-017-0001-z [pii]
PST - ppublish
SO  - Nat Genet. 2018 Jan;50(1):62-72. doi: 10.1038/s41588-017-0001-z. Epub 2017 Nov
      27.

PMID- 29224095
OWN - NLM
STAT- In-Data-Review
LR  - 20171210
IS  - 0065-2598 (Print)
IS  - 0065-2598 (Linking)
VI  - 1043
DP  - 2017
TI  - Sex Differences in Muscle Wasting.
PG  - 153-197
LID - 10.1007/978-3-319-70178-3_9 [doi]
AB  - With aging and other muscle wasting diseases, men and women undergo similar
      pathological changes in skeletal muscle: increased inflammation, enhanced
      oxidative stress, mitochondrial dysfunction, satellite cell senescence, elevated 
      apoptosis and proteasome activity, and suppressed protein synthesis and myocyte
      regeneration. Decreased food intake and physical activity also indirectly
      contribute to muscle wasting. Sex hormones also play important roles in
      maintaining skeletal muscle homeostasis. Testosterone is a potent anabolic factor
      promoting muscle protein synthesis and muscular regeneration. Estrogens have a
      protective effect on skeletal muscle by attenuating inflammation; however, the
      mechanisms of estrogen action in skeletal muscle are less well characterized than
      those of testosterone. Age- and/or disease-induced alterations in sex hormones
      are major contributors to muscle wasting. Hence, men and women may respond
      differently to catabolic conditions because of their hormonal profiles. Here we
      review the similarities and differences between men and women with common wasting
      conditions including sarcopenia and cachexia due to cancer, end-stage renal
      disease/chronic kidney disease, liver disease, chronic heart failure, and chronic
      obstructive pulmonary disease based on the literature in clinical studies. In
      addition, the responses in men and women to the commonly used therapeutic agents 
      and their efficacy to improve muscle mass and function are also reviewed.
FAU - Anderson, Lindsey J
AU  - Anderson LJ
AD  - Geriatric Research, Education and Clinical Center (GRECC), VA Puget Sound Health 
      Care System, and Department of Medicine, Division of Gerontology & Geriatric
      Medicine, University of Washington School of Medicine, Seattle, WA, USA.
FAU - Liu, Haiming
AU  - Liu H
AD  - Geriatric Research, Education and Clinical Center (GRECC), VA Puget Sound Health 
      Care System, and Department of Medicine, Division of Gerontology & Geriatric
      Medicine, University of Washington School of Medicine, Seattle, WA, USA.
FAU - Garcia, Jose M
AU  - Garcia JM
AD  - Geriatric Research, Education and Clinical Center (GRECC), VA Puget Sound Health 
      Care System, and Department of Medicine, Division of Gerontology & Geriatric
      Medicine, University of Washington School of Medicine, Seattle, WA, USA.
      jose.garcia@va.gov.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Adv Exp Med Biol
JT  - Advances in experimental medicine and biology
JID - 0121103
EDAT- 2017/12/11 06:00
MHDA- 2017/12/11 06:00
CRDT- 2017/12/11 06:00
PHST- 2017/12/11 06:00 [entrez]
PHST- 2017/12/11 06:00 [pubmed]
PHST- 2017/12/11 06:00 [medline]
AID - 10.1007/978-3-319-70178-3_9 [doi]
PST - ppublish
SO  - Adv Exp Med Biol. 2017;1043:153-197. doi: 10.1007/978-3-319-70178-3_9.

PMID- 29113963
OWN - NLM
STAT- In-Data-Review
LR  - 20180119
IS  - 1528-0020 (Electronic)
IS  - 0006-4971 (Linking)
VI  - 131
IP  - 3
DP  - 2018 Jan 18
TI  - Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid
      malignancies.
PG  - 328-341
LID - 10.1182/blood-2017-06-789669 [doi]
AB  - Additional Sex Combs-Like 1 (ASXL1) is mutated at a high frequency in all forms
      of myeloid malignancies associated with poor prognosis. We generated a Vav1
      promoter-driven Flag-Asxl1(Y588X) transgenic mouse model, Asxl1(Y588X) Tg, to
      express a truncated FLAG-ASXL1(aa1-587) protein in the hematopoietic system. The 
      Asxl1(Y588X) Tg mice had an enlarged hematopoietic stem cell (HSC) pool,
      shortened survival, and predisposition to a spectrum of myeloid malignancies,
      thereby recapitulating the characteristics of myeloid malignancy patients with
      ASXL1 mutations. ATAC- and RNA-sequencing analyses revealed that the
      ASXL1(aa1-587) truncating protein expression results in more open chromatin in
      cKit(+) cells compared with wild-type cells, accompanied by dysregulated
      expression of genes critical for HSC self-renewal and differentiation. Liquid
      chromatography-tandem mass spectrometry and coimmunoprecipitation experiments
      showed that ASXL1(aa1-587) acquired an interaction with BRD4. An epigenetic drug 
      screening demonstrated a hypersensitivity of Asxl1(Y588X) Tg bone marrow cells to
      BET bromodomain inhibitors. This study demonstrates that ASXL1(aa1-587) plays a
      gain-of-function role in promoting myeloid malignancies. Our model provides a
      powerful platform to test therapeutic approaches of targeting the ASXL1
      truncation mutations in myeloid malignancies.
CI  - (c) 2018 by The American Society of Hematology.
FAU - Yang, Hui
AU  - Yang H
AD  - Sylvester Comprehensive Cancer Center.
AD  - Department of Biochemistry and Molecular Biology.
FAU - Kurtenbach, Stefan
AU  - Kurtenbach S
AD  - Sylvester Comprehensive Cancer Center.
AD  - Bascom Palmer Eye Institute.
FAU - Guo, Ying
AU  - Guo Y
AD  - Sylvester Comprehensive Cancer Center.
AD  - Department of Biochemistry and Molecular Biology.
FAU - Lohse, Ines
AU  - Lohse I
AD  - Sylvester Comprehensive Cancer Center.
AD  - Center for Therapeutic Innovation and Department of Psychiatry and Behavioral
      Sciences.
FAU - Durante, Michael A
AU  - Durante MA
AD  - Sylvester Comprehensive Cancer Center.
AD  - Bascom Palmer Eye Institute.
FAU - Li, Jianping
AU  - Li J
AD  - Sylvester Comprehensive Cancer Center.
AD  - Department of Biochemistry and Molecular Biology.
FAU - Li, Zhaomin
AU  - Li Z
AD  - Sylvester Comprehensive Cancer Center.
AD  - Department of Biochemistry and Molecular Biology.
FAU - Al-Ali, Hassan
AU  - Al-Ali H
AD  - Sylvester Comprehensive Cancer Center.
AD  - Department of Neurological Surgery, The Miami Project to Cure Paralysis, Peggy
      and Harold Katz Family Drug Discovery Center, and.
FAU - Li, Lingxiao
AU  - Li L
AD  - Sylvester Comprehensive Cancer Center.
AD  - Department of Internal Medicine, University of Miami Miller School of Medicine,
      Miami, FL; and.
FAU - Chen, Zizhen
AU  - Chen Z
AD  - State Key Laboratory of Experimental Hematology, Institute of Hematology and
      Blood Diseases Hospital and Center for Stem Cell Medicine, Chinese Academy of
      Medical Sciences and Peking Union Medical College, Tianjin, China.
FAU - Field, Matthew G
AU  - Field MG
AD  - Sylvester Comprehensive Cancer Center.
AD  - Bascom Palmer Eye Institute.
FAU - Zhang, Peng
AU  - Zhang P
AUID- ORCID: http://orcid.org/0000-0002-3394-6922
AD  - Sylvester Comprehensive Cancer Center.
AD  - Department of Biochemistry and Molecular Biology.
FAU - Chen, Shi
AU  - Chen S
AD  - Sylvester Comprehensive Cancer Center.
AD  - Department of Biochemistry and Molecular Biology.
FAU - Yamamoto, Shohei
AU  - Yamamoto S
AD  - Sylvester Comprehensive Cancer Center.
AD  - Department of Biochemistry and Molecular Biology.
FAU - Li, Zhuo
AU  - Li Z
AD  - Sylvester Comprehensive Cancer Center.
AD  - Department of Biochemistry and Molecular Biology.
FAU - Zhou, Yuan
AU  - Zhou Y
AD  - State Key Laboratory of Experimental Hematology, Institute of Hematology and
      Blood Diseases Hospital and Center for Stem Cell Medicine, Chinese Academy of
      Medical Sciences and Peking Union Medical College, Tianjin, China.
FAU - Nimer, Stephen D
AU  - Nimer SD
AD  - Sylvester Comprehensive Cancer Center.
AD  - Department of Biochemistry and Molecular Biology.
AD  - Department of Internal Medicine, University of Miami Miller School of Medicine,
      Miami, FL; and.
FAU - Harbour, J William
AU  - Harbour JW
AD  - Sylvester Comprehensive Cancer Center.
AD  - Department of Biochemistry and Molecular Biology.
AD  - Bascom Palmer Eye Institute.
FAU - Wahlestedt, Claes
AU  - Wahlestedt C
AD  - Sylvester Comprehensive Cancer Center.
AD  - Center for Therapeutic Innovation and Department of Psychiatry and Behavioral
      Sciences.
FAU - Xu, Mingjiang
AU  - Xu M
AD  - Sylvester Comprehensive Cancer Center.
AD  - Department of Biochemistry and Molecular Biology.
FAU - Yang, Feng-Chun
AU  - Yang FC
AD  - Sylvester Comprehensive Cancer Center.
AD  - Department of Biochemistry and Molecular Biology.
LA  - eng
PT  - Journal Article
DEP - 20171107
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
EDAT- 2017/11/09 06:00
MHDA- 2017/11/09 06:00
CRDT- 2017/11/09 06:00
PHST- 2017/06/08 00:00 [received]
PHST- 2017/10/28 00:00 [accepted]
PHST- 2017/11/09 06:00 [pubmed]
PHST- 2017/11/09 06:00 [medline]
PHST- 2017/11/09 06:00 [entrez]
AID - blood-2017-06-789669 [pii]
AID - 10.1182/blood-2017-06-789669 [doi]
PST - ppublish
SO  - Blood. 2018 Jan 18;131(3):328-341. doi: 10.1182/blood-2017-06-789669. Epub 2017
      Nov 7.

PMID- 29212954
OWN - NLM
STAT- Publisher
LR  - 20180113
IS  - 2379-3708 (Electronic)
IS  - 2379-3708 (Linking)
VI  - 2
IP  - 23
DP  - 2017 Dec 7
TI  - Inhibition of AKT signaling uncouples T cell differentiation from expansion for
      receptor-engineered adoptive immunotherapy.
LID - 10.1172/jci.insight.95103 [doi]
LID - 95103 [pii]
AB  - Adoptive immunotherapies using T cells genetically redirected with a chimeric
      antigen receptor (CAR) or T cell receptor (TCR) are entering mainstream clinical 
      practice. Despite encouraging results, some patients do not respond to current
      therapies. In part, this phenomenon has been associated with infusion of reduced 
      numbers of early memory T cells. Herein, we report that AKT signaling inhibition 
      is compatible with CAR and TCR retroviral transduction of human T cells while
      promoting a CD62L-expressing central memory phenotype. Critically, this
      intervention did not compromise cell yield. Mechanistically, disruption of AKT
      signaling preserved MAPK activation and promoted the intranuclear localization of
      FOXO1, a transcriptional regulator of T cell memory. Consequently, AKT signaling 
      inhibition synchronized the transcriptional profile for FOXO1-dependent target
      genes across multiple donors. Expression of an AKT-resistant FOXO1 mutant
      phenocopied the influence of AKT signaling inhibition, while addition of AKT
      signaling inhibition to T cells expressing mutant FOXO1 failed to further augment
      the frequency of CD62L-expressing cells. Finally, treatment of established B cell
      acute lymphoblastic leukemia was superior using anti-CD19 CAR-modified T cells
      transduced and expanded in the presence of an AKT inhibitor compared with
      conventionally grown T cells. Thus, inhibition of signaling along the PI3K/AKT
      axis represents a generalizable strategy to generate large numbers of
      receptor-modified T cells with an early memory phenotype and superior antitumor
      efficacy.
FAU - Klebanoff, Christopher A
AU  - Klebanoff CA
AD  - Center for Cell Engineering and Department of Medicine, Memorial Sloan Kettering 
      Cancer Center (MSKCC), New York, New York, USA.
AD  - Parker Institute for Cancer Immunotherapy, New York, New York, USA.
AD  - Center for Cancer Research (CCR), National Cancer Institute (NCI), NIH, Bethesda,
      Maryland, USA.
FAU - Crompton, Joseph G
AU  - Crompton JG
AD  - Center for Cancer Research (CCR), National Cancer Institute (NCI), NIH, Bethesda,
      Maryland, USA.
AD  - Department of Surgery, University of California Los Angeles, Los Angeles,
      California, USA.
FAU - Leonardi, Anthony J
AU  - Leonardi AJ
AD  - Center for Cancer Research (CCR), National Cancer Institute (NCI), NIH, Bethesda,
      Maryland, USA.
FAU - Yamamoto, Tori N
AU  - Yamamoto TN
AD  - Center for Cancer Research (CCR), National Cancer Institute (NCI), NIH, Bethesda,
      Maryland, USA.
AD  - Immunology Graduate Group, University of Pennsylvania, Philadelphia,
      Pennsylvania, USA.
FAU - Chandran, Smita S
AU  - Chandran SS
AD  - Center for Cell Engineering and Department of Medicine, Memorial Sloan Kettering 
      Cancer Center (MSKCC), New York, New York, USA.
AD  - Parker Institute for Cancer Immunotherapy, New York, New York, USA.
FAU - Eil, Robert L
AU  - Eil RL
AD  - Center for Cancer Research (CCR), National Cancer Institute (NCI), NIH, Bethesda,
      Maryland, USA.
FAU - Sukumar, Madhusudhanan
AU  - Sukumar M
AD  - Center for Cancer Research (CCR), National Cancer Institute (NCI), NIH, Bethesda,
      Maryland, USA.
FAU - Vodnala, Suman K
AU  - Vodnala SK
AD  - Center for Cancer Research (CCR), National Cancer Institute (NCI), NIH, Bethesda,
      Maryland, USA.
FAU - Hu, Jinhui
AU  - Hu J
AD  - Center for Cancer Research (CCR), National Cancer Institute (NCI), NIH, Bethesda,
      Maryland, USA.
AD  - Experimental Transplantation and Immunology Branch and.
FAU - Ji, Yun
AU  - Ji Y
AD  - Center for Cancer Research (CCR), National Cancer Institute (NCI), NIH, Bethesda,
      Maryland, USA.
AD  - Experimental Transplantation and Immunology Branch and.
FAU - Clever, David
AU  - Clever D
AD  - Center for Cancer Research (CCR), National Cancer Institute (NCI), NIH, Bethesda,
      Maryland, USA.
FAU - Black, Mary A
AU  - Black MA
AD  - Center for Cancer Research (CCR), National Cancer Institute (NCI), NIH, Bethesda,
      Maryland, USA.
FAU - Gurusamy, Devikala
AU  - Gurusamy D
AD  - Center for Cancer Research (CCR), National Cancer Institute (NCI), NIH, Bethesda,
      Maryland, USA.
FAU - Kruhlak, Michael J
AU  - Kruhlak MJ
AD  - Experimental Immunology Branch, CCR, NCI, NIH, Bethesda, Maryland, USA.
FAU - Jin, Ping
AU  - Jin P
AD  - Cell Processing Section, Department of Transfusion Medicine, Clinical Center,
      NIH, Bethesda, Maryland, USA.
FAU - Stroncek, David F
AU  - Stroncek DF
AD  - Cell Processing Section, Department of Transfusion Medicine, Clinical Center,
      NIH, Bethesda, Maryland, USA.
FAU - Gattinoni, Luca
AU  - Gattinoni L
AD  - Center for Cancer Research (CCR), National Cancer Institute (NCI), NIH, Bethesda,
      Maryland, USA.
AD  - Experimental Transplantation and Immunology Branch and.
FAU - Feldman, Steven A
AU  - Feldman SA
AD  - Center for Cancer Research (CCR), National Cancer Institute (NCI), NIH, Bethesda,
      Maryland, USA.
FAU - Restifo, Nicholas P
AU  - Restifo NP
AD  - Center for Cancer Research (CCR), National Cancer Institute (NCI), NIH, Bethesda,
      Maryland, USA.
AD  - Center for Cell-based Therapy, CCR, NCI, NIH, Bethesda, Maryland, USA.
LA  - eng
GR  - P30 CA008748/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20171207
PL  - United States
TA  - JCI Insight
JT  - JCI insight
JID - 101676073
PMC - PMC5752304
OTO - NOTNLM
OT  - Cancer gene therapy
OT  - Cancer immunotherapy
OT  - Cellular immune response
OT  - Immunology
OT  - Oncology
EDAT- 2017/12/08 06:00
MHDA- 2017/12/08 06:00
CRDT- 2017/12/08 06:00
PHST- 2017/05/11 00:00 [received]
PHST- 2017/10/19 00:00 [accepted]
PHST- 2017/12/08 06:00 [entrez]
PHST- 2017/12/08 06:00 [pubmed]
PHST- 2017/12/08 06:00 [medline]
AID - 95103 [pii]
AID - 10.1172/jci.insight.95103 [doi]
PST - aheadofprint
SO  - JCI Insight. 2017 Dec 7;2(23). pii: 95103. doi: 10.1172/jci.insight.95103.

PMID- 29091775
OWN - NLM
STAT- In-Process
LR  - 20180105
IS  - 2211-1247 (Electronic)
VI  - 21
IP  - 5
DP  - 2017 Oct 31
TI  - Single-Cell RNA-Seq Analysis of Infiltrating Neoplastic Cells at the Migrating
      Front of Human Glioblastoma.
PG  - 1399-1410
LID - S2211-1247(17)31462-6 [pii]
LID - 10.1016/j.celrep.2017.10.030 [doi]
AB  - Glioblastoma (GBM) is the most common primary brain cancer in adults and is
      notoriously difficult to treat because of its diffuse nature. We performed
      single-cell RNA sequencing (RNA-seq) on 3,589 cells in a cohort of four patients.
      We obtained cells from the tumor core as well as surrounding peripheral tissue.
      Our analysis revealed cellular variation in the tumor's genome and transcriptome.
      We were also able to identify infiltrating neoplastic cells in regions peripheral
      to the core lesions. Despite the existence of significant heterogeneity among
      neoplastic cells, we found that infiltrating GBM cells share a consistent gene
      signature between patients, suggesting a common mechanism of infiltration.
      Additionally, in investigating the immunological response to the tumors, we found
      transcriptionally distinct myeloid cell populations residing in the tumor core
      and the surrounding peritumoral space. Our data provide a detailed dissection of 
      GBM cell types, revealing an abundance of information about tumor formation and
      migration.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved
FAU - Darmanis, Spyros
AU  - Darmanis S
AD  - Departments of Bioengineering and Applied Physics, Stanford University and Chan
      Zuckerberg Biohub, 318 Campus Drive, Stanford, CA 94305, USA.
FAU - Sloan, Steven A
AU  - Sloan SA
AD  - Department of Neurobiology, Stanford University, 291 Campus Drive, Stanford, CA
      94305, USA.
FAU - Croote, Derek
AU  - Croote D
AD  - Departments of Bioengineering and Applied Physics, Stanford University and Chan
      Zuckerberg Biohub, 318 Campus Drive, Stanford, CA 94305, USA.
FAU - Mignardi, Marco
AU  - Mignardi M
AD  - Departments of Bioengineering and Applied Physics, Stanford University and Chan
      Zuckerberg Biohub, 318 Campus Drive, Stanford, CA 94305, USA.
FAU - Chernikova, Sophia
AU  - Chernikova S
AD  - Department of Neurosurgery, Stanford University, 300 Pasteur Drive, Stanford, CA 
      94304, USA.
FAU - Samghababi, Peyman
AU  - Samghababi P
AD  - Department of Pathology, Stanford University, 300 Pasteur Drive, Stanford, CA
      94304, USA.
FAU - Zhang, Ye
AU  - Zhang Y
AD  - Department of Neurobiology, Stanford University, 291 Campus Drive, Stanford, CA
      94305, USA.
FAU - Neff, Norma
AU  - Neff N
AD  - Departments of Bioengineering and Applied Physics, Stanford University and Chan
      Zuckerberg Biohub, 318 Campus Drive, Stanford, CA 94305, USA.
FAU - Kowarsky, Mark
AU  - Kowarsky M
AD  - Departments of Bioengineering and Applied Physics, Stanford University and Chan
      Zuckerberg Biohub, 318 Campus Drive, Stanford, CA 94305, USA.
FAU - Caneda, Christine
AU  - Caneda C
AD  - Department of Neurobiology, Stanford University, 291 Campus Drive, Stanford, CA
      94305, USA.
FAU - Li, Gordon
AU  - Li G
AD  - Department of Neurosurgery, Stanford University, 300 Pasteur Drive, Stanford, CA 
      94304, USA.
FAU - Chang, Steven D
AU  - Chang SD
AD  - Department of Neurosurgery, Stanford University, 300 Pasteur Drive, Stanford, CA 
      94304, USA.
FAU - Connolly, Ian David
AU  - Connolly ID
AD  - Department of Neurosurgery, Stanford University, 300 Pasteur Drive, Stanford, CA 
      94304, USA.
FAU - Li, Yingmei
AU  - Li Y
AD  - Department of Neurosurgery, Stanford University, 300 Pasteur Drive, Stanford, CA 
      94304, USA.
FAU - Barres, Ben A
AU  - Barres BA
AD  - Department of Neurobiology, Stanford University, 291 Campus Drive, Stanford, CA
      94305, USA.
FAU - Gephart, Melanie Hayden
AU  - Gephart MH
AD  - Department of Neurosurgery, Stanford University, 300 Pasteur Drive, Stanford, CA 
      94304, USA.
FAU - Quake, Stephen R
AU  - Quake SR
AD  - Departments of Bioengineering and Applied Physics, Stanford University and Chan
      Zuckerberg Biohub, 318 Campus Drive, Stanford, CA 94305, USA. Electronic address:
      quake@stanford.edu.
LA  - eng
GR  - R01 CA216054/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cell Rep
JT  - Cell reports
JID - 101573691
OTO - NOTNLM
OT  - *GBM
OT  - *RNA-seq
OT  - *brain
OT  - *checkpoint
OT  - *diffuse
OT  - *glioblastoma
OT  - *glioma
OT  - *heterogeneity
OT  - *infiltrating
OT  - *single cell
EDAT- 2017/11/02 06:00
MHDA- 2017/11/02 06:00
CRDT- 2017/11/02 06:00
PHST- 2017/02/23 00:00 [received]
PHST- 2017/07/19 00:00 [revised]
PHST- 2017/10/08 00:00 [accepted]
PHST- 2017/11/02 06:00 [entrez]
PHST- 2017/11/02 06:00 [pubmed]
PHST- 2017/11/02 06:00 [medline]
AID - S2211-1247(17)31462-6 [pii]
AID - 10.1016/j.celrep.2017.10.030 [doi]
PST - ppublish
SO  - Cell Rep. 2017 Oct 31;21(5):1399-1410. doi: 10.1016/j.celrep.2017.10.030.

PMID- 29255258
OWN - NLM
STAT- In-Data-Review
LR  - 20171223
IS  - 1546-1718 (Electronic)
IS  - 1061-4036 (Linking)
VI  - 50
IP  - 1
DP  - 2018 Jan
TI  - Single-cell DNA methylome sequencing of human preimplantation embryos.
PG  - 12-19
LID - 10.1038/s41588-017-0007-6 [doi]
AB  - DNA methylation is a crucial layer of epigenetic regulation during mammalian
      embryonic development (1-3) . Although the DNA methylome of early human embryos
      has been analyzed (4-6) , some of the key features have not been addressed thus
      far. Here we performed single-cell DNA methylome sequencing for human
      preimplantation embryos and found that tens of thousands of genomic loci
      exhibited de novo DNA methylation. This finding indicates that genome-wide DNA
      methylation reprogramming during preimplantation development is a dynamic balance
      between strong global demethylation and drastic focused remethylation.
      Furthermore, demethylation of the paternal genome is much faster and thorough
      than that of the maternal genome. From the two-cell to the postimplantation
      stage, methylation of the paternal genome is consistently lower than that of the 
      maternal genome. We also show that the genetic lineage of early blastomeres can
      be traced by DNA methylation analysis. Our work paves the way for deciphering the
      secrets of DNA methylation reprogramming in early human embryos.
FAU - Zhu, Ping
AU  - Zhu P
AUID- ORCID: http://orcid.org/0000-0002-4521-7524
AD  - Beijing Advanced Innovation Center for Genomics, College of Life Sciences,
      Department of Obstetrics and Gynecology, Third Hospital, Peking University,
      Beijing, China.
AD  - Biomedical Institute for Pioneering Investigation via Convergence and Center for 
      Reproductive Medicine, College of Life Sciences, Department of Obstetrics and
      Gynecology, Third Hospital, Peking University, Beijing, China.
AD  - Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, China.
AD  - State Key Laboratory of Experimental Hematology, Institute of Hematology and
      Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union
      Medical College, Tianjin, China.
FAU - Guo, Hongshan
AU  - Guo H
AD  - Beijing Advanced Innovation Center for Genomics, College of Life Sciences,
      Department of Obstetrics and Gynecology, Third Hospital, Peking University,
      Beijing, China.
AD  - Biomedical Institute for Pioneering Investigation via Convergence and Center for 
      Reproductive Medicine, College of Life Sciences, Department of Obstetrics and
      Gynecology, Third Hospital, Peking University, Beijing, China.
AD  - Massachusetts General Hospital Cancer Center, Harvard Medical School,
      Charlestown, MA, USA.
FAU - Ren, Yixin
AU  - Ren Y
AD  - Beijing Advanced Innovation Center for Genomics, College of Life Sciences,
      Department of Obstetrics and Gynecology, Third Hospital, Peking University,
      Beijing, China.
AD  - Key Laboratory of Assisted Reproduction and Key Laboratory of Cell Proliferation 
      and Differentiation, Ministry of Education, Beijing, China.
FAU - Hou, Yu
AU  - Hou Y
AUID- ORCID: http://orcid.org/0000-0001-7875-7087
AD  - Beijing Advanced Innovation Center for Genomics, College of Life Sciences,
      Department of Obstetrics and Gynecology, Third Hospital, Peking University,
      Beijing, China.
AD  - Biomedical Institute for Pioneering Investigation via Convergence and Center for 
      Reproductive Medicine, College of Life Sciences, Department of Obstetrics and
      Gynecology, Third Hospital, Peking University, Beijing, China.
FAU - Dong, Ji
AU  - Dong J
AD  - Beijing Advanced Innovation Center for Genomics, College of Life Sciences,
      Department of Obstetrics and Gynecology, Third Hospital, Peking University,
      Beijing, China.
AD  - Biomedical Institute for Pioneering Investigation via Convergence and Center for 
      Reproductive Medicine, College of Life Sciences, Department of Obstetrics and
      Gynecology, Third Hospital, Peking University, Beijing, China.
FAU - Li, Rong
AU  - Li R
AD  - Beijing Advanced Innovation Center for Genomics, College of Life Sciences,
      Department of Obstetrics and Gynecology, Third Hospital, Peking University,
      Beijing, China.
AD  - Key Laboratory of Assisted Reproduction and Key Laboratory of Cell Proliferation 
      and Differentiation, Ministry of Education, Beijing, China.
FAU - Lian, Ying
AU  - Lian Y
AD  - Beijing Advanced Innovation Center for Genomics, College of Life Sciences,
      Department of Obstetrics and Gynecology, Third Hospital, Peking University,
      Beijing, China.
AD  - Key Laboratory of Assisted Reproduction and Key Laboratory of Cell Proliferation 
      and Differentiation, Ministry of Education, Beijing, China.
FAU - Fan, Xiaoying
AU  - Fan X
AD  - Beijing Advanced Innovation Center for Genomics, College of Life Sciences,
      Department of Obstetrics and Gynecology, Third Hospital, Peking University,
      Beijing, China.
AD  - Biomedical Institute for Pioneering Investigation via Convergence and Center for 
      Reproductive Medicine, College of Life Sciences, Department of Obstetrics and
      Gynecology, Third Hospital, Peking University, Beijing, China.
FAU - Hu, Boqiang
AU  - Hu B
AD  - Beijing Advanced Innovation Center for Genomics, College of Life Sciences,
      Department of Obstetrics and Gynecology, Third Hospital, Peking University,
      Beijing, China.
AD  - Biomedical Institute for Pioneering Investigation via Convergence and Center for 
      Reproductive Medicine, College of Life Sciences, Department of Obstetrics and
      Gynecology, Third Hospital, Peking University, Beijing, China.
FAU - Gao, Yun
AU  - Gao Y
AD  - Beijing Advanced Innovation Center for Genomics, College of Life Sciences,
      Department of Obstetrics and Gynecology, Third Hospital, Peking University,
      Beijing, China.
AD  - Biomedical Institute for Pioneering Investigation via Convergence and Center for 
      Reproductive Medicine, College of Life Sciences, Department of Obstetrics and
      Gynecology, Third Hospital, Peking University, Beijing, China.
FAU - Wang, Xiaoye
AU  - Wang X
AD  - Beijing Advanced Innovation Center for Genomics, College of Life Sciences,
      Department of Obstetrics and Gynecology, Third Hospital, Peking University,
      Beijing, China.
AD  - Key Laboratory of Assisted Reproduction and Key Laboratory of Cell Proliferation 
      and Differentiation, Ministry of Education, Beijing, China.
FAU - Wei, Yuan
AU  - Wei Y
AD  - Beijing Advanced Innovation Center for Genomics, College of Life Sciences,
      Department of Obstetrics and Gynecology, Third Hospital, Peking University,
      Beijing, China.
AD  - Key Laboratory of Assisted Reproduction and Key Laboratory of Cell Proliferation 
      and Differentiation, Ministry of Education, Beijing, China.
FAU - Liu, Ping
AU  - Liu P
AD  - Beijing Advanced Innovation Center for Genomics, College of Life Sciences,
      Department of Obstetrics and Gynecology, Third Hospital, Peking University,
      Beijing, China.
AD  - Key Laboratory of Assisted Reproduction and Key Laboratory of Cell Proliferation 
      and Differentiation, Ministry of Education, Beijing, China.
FAU - Yan, Jie
AU  - Yan J
AD  - Beijing Advanced Innovation Center for Genomics, College of Life Sciences,
      Department of Obstetrics and Gynecology, Third Hospital, Peking University,
      Beijing, China.
AD  - Key Laboratory of Assisted Reproduction and Key Laboratory of Cell Proliferation 
      and Differentiation, Ministry of Education, Beijing, China.
FAU - Ren, Xiulian
AU  - Ren X
AD  - Beijing Advanced Innovation Center for Genomics, College of Life Sciences,
      Department of Obstetrics and Gynecology, Third Hospital, Peking University,
      Beijing, China.
AD  - Key Laboratory of Assisted Reproduction and Key Laboratory of Cell Proliferation 
      and Differentiation, Ministry of Education, Beijing, China.
FAU - Yuan, Peng
AU  - Yuan P
AD  - Beijing Advanced Innovation Center for Genomics, College of Life Sciences,
      Department of Obstetrics and Gynecology, Third Hospital, Peking University,
      Beijing, China.
AD  - Key Laboratory of Assisted Reproduction and Key Laboratory of Cell Proliferation 
      and Differentiation, Ministry of Education, Beijing, China.
FAU - Yuan, Yifeng
AU  - Yuan Y
AD  - Beijing Advanced Innovation Center for Genomics, College of Life Sciences,
      Department of Obstetrics and Gynecology, Third Hospital, Peking University,
      Beijing, China.
AD  - Key Laboratory of Assisted Reproduction and Key Laboratory of Cell Proliferation 
      and Differentiation, Ministry of Education, Beijing, China.
FAU - Yan, Zhiqiang
AU  - Yan Z
AD  - Beijing Advanced Innovation Center for Genomics, College of Life Sciences,
      Department of Obstetrics and Gynecology, Third Hospital, Peking University,
      Beijing, China.
AD  - Key Laboratory of Assisted Reproduction and Key Laboratory of Cell Proliferation 
      and Differentiation, Ministry of Education, Beijing, China.
FAU - Wen, Lu
AU  - Wen L
AD  - Beijing Advanced Innovation Center for Genomics, College of Life Sciences,
      Department of Obstetrics and Gynecology, Third Hospital, Peking University,
      Beijing, China.
AD  - Biomedical Institute for Pioneering Investigation via Convergence and Center for 
      Reproductive Medicine, College of Life Sciences, Department of Obstetrics and
      Gynecology, Third Hospital, Peking University, Beijing, China.
FAU - Yan, Liying
AU  - Yan L
AUID- ORCID: http://orcid.org/0000-0001-9572-9440
AD  - Beijing Advanced Innovation Center for Genomics, College of Life Sciences,
      Department of Obstetrics and Gynecology, Third Hospital, Peking University,
      Beijing, China. yanliyingkind@aliyun.com.
AD  - Biomedical Institute for Pioneering Investigation via Convergence and Center for 
      Reproductive Medicine, College of Life Sciences, Department of Obstetrics and
      Gynecology, Third Hospital, Peking University, Beijing, China.
      yanliyingkind@aliyun.com.
AD  - Key Laboratory of Assisted Reproduction and Key Laboratory of Cell Proliferation 
      and Differentiation, Ministry of Education, Beijing, China.
      yanliyingkind@aliyun.com.
AD  - Beijing Key Laboratory of Reproductive Endocrinology and Assisted Reproductive
      Technology, Beijing, China. yanliyingkind@aliyun.com.
FAU - Qiao, Jie
AU  - Qiao J
AUID- ORCID: http://orcid.org/0000-0003-2126-1376
AD  - Beijing Advanced Innovation Center for Genomics, College of Life Sciences,
      Department of Obstetrics and Gynecology, Third Hospital, Peking University,
      Beijing, China. jie.qiao@263.net.
AD  - Biomedical Institute for Pioneering Investigation via Convergence and Center for 
      Reproductive Medicine, College of Life Sciences, Department of Obstetrics and
      Gynecology, Third Hospital, Peking University, Beijing, China. jie.qiao@263.net.
AD  - Key Laboratory of Assisted Reproduction and Key Laboratory of Cell Proliferation 
      and Differentiation, Ministry of Education, Beijing, China. jie.qiao@263.net.
AD  - Beijing Key Laboratory of Reproductive Endocrinology and Assisted Reproductive
      Technology, Beijing, China. jie.qiao@263.net.
AD  - Academy for Advanced Interdisciplinary Studies, Peking University, Beijing,
      China. jie.qiao@263.net.
AD  - Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, China.
      jie.qiao@263.net.
FAU - Tang, Fuchou
AU  - Tang F
AUID- ORCID: http://orcid.org/0000-0002-8625-7717
AD  - Beijing Advanced Innovation Center for Genomics, College of Life Sciences,
      Department of Obstetrics and Gynecology, Third Hospital, Peking University,
      Beijing, China. tangfuchou@pku.edu.cn.
AD  - Biomedical Institute for Pioneering Investigation via Convergence and Center for 
      Reproductive Medicine, College of Life Sciences, Department of Obstetrics and
      Gynecology, Third Hospital, Peking University, Beijing, China.
      tangfuchou@pku.edu.cn.
AD  - Key Laboratory of Assisted Reproduction and Key Laboratory of Cell Proliferation 
      and Differentiation, Ministry of Education, Beijing, China.
      tangfuchou@pku.edu.cn.
AD  - Academy for Advanced Interdisciplinary Studies, Peking University, Beijing,
      China. tangfuchou@pku.edu.cn.
AD  - Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, China.
      tangfuchou@pku.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20171218
PL  - United States
TA  - Nat Genet
JT  - Nature genetics
JID - 9216904
EDAT- 2017/12/20 06:00
MHDA- 2017/12/20 06:00
CRDT- 2017/12/20 06:00
PHST- 2016/10/23 00:00 [received]
PHST- 2017/11/01 00:00 [accepted]
PHST- 2017/12/20 06:00 [pubmed]
PHST- 2017/12/20 06:00 [medline]
PHST- 2017/12/20 06:00 [entrez]
AID - 10.1038/s41588-017-0007-6 [doi]
AID - 10.1038/s41588-017-0007-6 [pii]
PST - ppublish
SO  - Nat Genet. 2018 Jan;50(1):12-19. doi: 10.1038/s41588-017-0007-6. Epub 2017 Dec
      18.

PMID- 29190685
OWN - NLM
STAT- MEDLINE
DCOM- 20171226
LR  - 20171228
IS  - 1545-7885 (Electronic)
IS  - 1544-9173 (Linking)
VI  - 15
IP  - 11
DP  - 2017 Nov
TI  - Evaluation of RNAi and CRISPR technologies by large-scale gene expression
      profiling in the Connectivity Map.
PG  - e2003213
LID - 10.1371/journal.pbio.2003213 [doi]
AB  - The application of RNA interference (RNAi) to mammalian cells has provided the
      means to perform phenotypic screens to determine the functions of genes. Although
      RNAi has revolutionized loss-of-function genetic experiments, it has been
      difficult to systematically assess the prevalence and consequences of off-target 
      effects. The Connectivity Map (CMAP) represents an unprecedented resource to
      study the gene expression consequences of expressing short hairpin RNAs (shRNAs).
      Analysis of signatures for over 13,000 shRNAs applied in 9 cell lines revealed
      that microRNA (miRNA)-like off-target effects of RNAi are far stronger and more
      pervasive than generally appreciated. We show that mitigating off-target effects 
      is feasible in these datasets via computational methodologies to produce a
      consensus gene signature (CGS). In addition, we compared RNAi technology to
      clustered regularly interspaced short palindromic repeat (CRISPR)-based knockout 
      by analysis of 373 single guide RNAs (sgRNAs) in 6 cells lines and show that the 
      on-target efficacies are comparable, but CRISPR technology is far less
      susceptible to systematic off-target effects. These results will help guide the
      proper use and analysis of loss-of-function reagents for the determination of
      gene function.
FAU - Smith, Ian
AU  - Smith I
AD  - Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of
      America.
FAU - Greenside, Peyton G
AU  - Greenside PG
AD  - Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of
      America.
FAU - Natoli, Ted
AU  - Natoli T
AD  - Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of
      America.
FAU - Lahr, David L
AU  - Lahr DL
AD  - Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of
      America.
FAU - Wadden, David
AU  - Wadden D
AD  - Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of
      America.
FAU - Tirosh, Itay
AU  - Tirosh I
AD  - Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of
      America.
FAU - Narayan, Rajiv
AU  - Narayan R
AD  - Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of
      America.
FAU - Root, David E
AU  - Root DE
AD  - Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of
      America.
FAU - Golub, Todd R
AU  - Golub TR
AD  - Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of
      America.
AD  - Harvard Medical School, Boston, Massachusetts, United States of America.
AD  - Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston,
      Massachusetts, United States of America.
AD  - Howard Hughes Medical Institute, Chevy Chase, Maryland, United States of America.
FAU - Subramanian, Aravind
AU  - Subramanian A
AD  - Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of
      America.
FAU - Doench, John G
AU  - Doench JG
AUID- ORCID: http://orcid.org/0000-0002-3707-9889
AD  - Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of
      America.
LA  - eng
PT  - Evaluation Studies
PT  - Journal Article
DEP - 20171130
PL  - United States
TA  - PLoS Biol
JT  - PLoS biology
JID - 101183755
RN  - 0 (RNA, Small Interfering)
SB  - IM
MH  - Cells, Cultured
MH  - *Clustered Regularly Interspaced Short Palindromic Repeats
MH  - *Gene Expression Profiling
MH  - Gene Expression Regulation, Neoplastic
MH  - Gene Regulatory Networks/*genetics
MH  - Genomics/*methods/standards
MH  - HT29 Cells
MH  - Hep G2 Cells
MH  - Humans
MH  - MCF-7 Cells
MH  - RNA Interference/*physiology
MH  - RNA, Small Interfering/genetics
MH  - Transcriptome
PMC - PMC5726721
EDAT- 2017/12/01 06:00
MHDA- 2017/12/27 06:00
CRDT- 2017/12/01 06:00
PHST- 2017/06/05 00:00 [received]
PHST- 2017/11/09 00:00 [accepted]
PHST- 2017/12/12 00:00 [revised]
PHST- 2017/12/01 06:00 [pubmed]
PHST- 2017/12/27 06:00 [medline]
PHST- 2017/12/01 06:00 [entrez]
AID - 10.1371/journal.pbio.2003213 [doi]
AID - pbio.2003213 [pii]
PST - epublish
SO  - PLoS Biol. 2017 Nov 30;15(11):e2003213. doi: 10.1371/journal.pbio.2003213.
      eCollection 2017 Nov.

PMID- 29300693
OWN - NLM
STAT- Publisher
LR  - 20180116
IS  - 1942-0870 (Electronic)
IS  - 1942-0862 (Linking)
DP  - 2018 Jan 4
TI  - Antibodies to watch in 2018.
PG  - 1-21
LID - 10.1080/19420862.2018.1415671 [doi]
AB  - The pace of antibody therapeutics development accelerated in 2017, and this
      faster pace is projected to continue through 2018. Notably, the annual number of 
      antibody therapeutics granted a first approval in either the European Union (EU) 
      or United States (US) reached double-digits (total of 10) for the first time in
      2017. The 10 antibodies granted approvals are: brodalumab, dupilumab, sarilumab, 
      guselkumab, benralizumab, ocrelizumab, inotuzumab ozogamicin, avelumab,
      duvalumab, and emicizumab. Brodalumab, however, had already been approved in
      Japan in 2016. As of December 1, 2017, nine antibody therapeutics (ibalizumab,
      burosumab, tildrakizumab, caplacizumab, erenumab, fremanezumab, galcanezumab,
      romosozumab, mogamulizumab) were in regulatory review in the EU or US, and
      regulatory actions on their marketing applications are expected by the end of
      2018. Based on company announcements and estimated clinical study primary
      completion dates, and assuming the study results are positive, marketing
      applications for at least 12 antibody therapeutics that are now being evaluated
      in late-stage clinical studies may be submitted by the end of 2018. Of the 12
      candidates, 8 are for non-cancer indications (lanadelumab, crizanlizumab,
      ravulizumab, eptinezumab, risankizumab, satralizumab, brolucizumab, PRO140) and 4
      are for cancer (sacituzumab govitecan, moxetumomab pasudotox, cemiplimab,
      ublituximab). Additional antibody therapeutics to watch in 2018 include 19 mAbs
      undergoing evaluation in late-stage studies with primary completion dates in late
      2017 or during 2018. Of these mAbs, 9 are for non-cancer indications
      (lampalizumab, roledumab, emapalumab, fasinumab, tanezumab, etrolizumab, NEOD001,
      gantenerumab, anifrolumab) and 10 are for cancer indications (tremelimumab,
      isatuximab, BCD-100, carotuximab, camrelizumab, IBI308, glembatumumab vedotin,
      mirvetuximab soravtansine, oportuzumab monatox, L19IL2/L19TNF). Positive clinical
      study results may enable marketing application submissions in 2018. Brief
      summaries of these antibody therapeutics are provided in this installment of the 
      'Antibodies to watch' article series.
FAU - Kaplon, Helene
AU  - Kaplon H
AD  - a Laboratory UMRS 1138 "Cancer, Immune Control and Escape" , Cordeliers Research 
      Centre , Paris , France.
FAU - Reichert, Janice M
AU  - Reichert JM
AD  - b The Antibody Society , Framingham , MA , USA.
LA  - eng
PT  - Journal Article
DEP - 20180104
PL  - United States
TA  - MAbs
JT  - mAbs
JID - 101479829
OTO - NOTNLM
OT  - European Medicines Agency
OT  - Food and Drug Administration
OT  - antibody therapeutics
OT  - cancer
OT  - immune-mediated disorders
EDAT- 2018/01/05 06:00
MHDA- 2018/01/05 06:00
CRDT- 2018/01/05 06:00
PHST- 2018/01/05 06:00 [pubmed]
PHST- 2018/01/05 06:00 [medline]
PHST- 2018/01/05 06:00 [entrez]
AID - 10.1080/19420862.2018.1415671 [doi]
PST - aheadofprint
SO  - MAbs. 2018 Jan 4:1-21. doi: 10.1080/19420862.2018.1415671.

PMID- 29149615
OWN - NLM
STAT- MEDLINE
DCOM- 20171215
LR  - 20171219
IS  - 1097-4172 (Electronic)
IS  - 0092-8674 (Linking)
VI  - 171
IP  - 5
DP  - 2017 Nov 16
TI  - Rethinking Unconventional Translation in Neurodegeneration.
PG  - 994-1000
LID - S0092-8674(17)31268-0 [pii]
LID - 10.1016/j.cell.2017.10.042 [doi]
AB  - Eukaryotic translation is tightly regulated to ensure that protein production
      occurs at the right time and place. Recent studies on abnormal repeat proteins,
      especially in age-dependent neurodegenerative diseases caused by nucleotide
      repeat expansion, have highlighted or identified two forms of unconventional
      translation initiation: usage of AUG-like sites (near cognates) or
      repeat-associated non-AUG (RAN) translation. We discuss how repeat proteins may
      differ due to not just unconventional initiation, but also ribosomal
      frameshifting and/or imperfect repeat DNA replication, expansion, and repair, and
      we highlight how research on translation of repeats may uncover insights into the
      biology of translation and its contribution to disease.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Gao, Fen-Biao
AU  - Gao FB
AD  - Department of Neurology, University of Massachusetts Medical School, Worcester,
      MA 01605, USA. Electronic address: fen-biao.gao@umassmed.edu.
FAU - Richter, Joel D
AU  - Richter JD
AD  - Program in Molecular Medicine, University of Massachusetts Medical School,
      Worcester, MA, 01605 USA. Electronic address: joel.richter@umassmed.edu.
FAU - Cleveland, Don W
AU  - Cleveland DW
AD  - Ludwig Institute for Cancer Research, University of California at San Diego, La
      Jolla, CA 92093, USA; Department of Neurosciences, University of California at
      San Diego, La Jolla, CA 92093, USA; Department of Cellular and Molecular
      Medicine, University of California at San Diego, La Jolla, CA 92093, USA.
      Electronic address: dcleveland@ucsd.edu.
LA  - eng
GR  - R01 NS027036/NS/NINDS NIH HHS/United States
GR  - R01 NS093097/NS/NINDS NIH HHS/United States
GR  - U54 HD082013/HD/NICHD NIH HHS/United States
GR  - R01 NS101986/NS/NINDS NIH HHS/United States
GR  - R01 NS079415/NS/NINDS NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cell
JT  - Cell
JID - 0413066
RN  - 0 (Codon, Initiator)
RN  - 0 (Regulatory Sequences, Ribonucleic Acid)
SB  - IM
MH  - Animals
MH  - Codon, Initiator
MH  - Frameshifting, Ribosomal
MH  - Humans
MH  - Neurodegenerative Diseases/*genetics/metabolism
MH  - Open Reading Frames
MH  - *Protein Biosynthesis
MH  - Regulatory Sequences, Ribonucleic Acid
MH  - Trinucleotide Repeat Expansion
PMC - PMC5728172
MID - NIHMS917221
OTO - NOTNLM
OT  - ALS
OT  - C9ORF72
OT  - dipeptide repeat proteins
OT  - frontotemporal dementia
OT  - near-cognate start codon
OT  - repeat expansion
OT  - translation
OT  - upstream open reading frame
EDAT- 2017/11/18 06:00
MHDA- 2017/12/16 06:00
CRDT- 2017/11/18 06:00
PMCR- 2018/11/16 00:00
PHST- 2017/09/11 00:00 [received]
PHST- 2017/10/16 00:00 [revised]
PHST- 2017/10/25 00:00 [accepted]
PHST- 2018/11/16 00:00 [pmc-release]
PHST- 2017/11/18 06:00 [entrez]
PHST- 2017/11/18 06:00 [pubmed]
PHST- 2017/12/16 06:00 [medline]
AID - S0092-8674(17)31268-0 [pii]
AID - 10.1016/j.cell.2017.10.042 [doi]
PST - ppublish
SO  - Cell. 2017 Nov 16;171(5):994-1000. doi: 10.1016/j.cell.2017.10.042.

PMID- 29079582
OWN - NLM
STAT- MEDLINE
DCOM- 20180126
LR  - 20180126
IS  - 1528-0020 (Electronic)
IS  - 0006-4971 (Linking)
VI  - 130
IP  - 25
DP  - 2017 Dec 21
TI  - c-MPL provides tumor-targeted T-cell receptor-transgenic T cells with
      costimulation and cytokine signals.
PG  - 2739-2749
LID - 10.1182/blood-2017-02-769463 [doi]
AB  - Adoptively transferred T-cell receptor (TCR)-engineered T cells depend on
      host-derived costimulation and cytokine signals for their full and sustained
      activation. However, in patients with cancer, both signals are frequently
      impaired. Hence, we developed a novel strategy that combines both essential
      signals in 1 transgene by expressing the nonlymphoid hematopoietic growth factor 
      receptor c-MPL (myeloproliferative leukemia), the receptor for thrombopoietin
      (TPO), in T cells. c-MPL signaling activates pathways shared with conventional
      costimulatory and cytokine receptor signaling. Thus, we hypothesized that
      host-derived TPO, present in the tumor microenvironment, or pharmacological c-MPL
      agonists approved by the US Food and Drug Administration could deliver both
      signals to c-MPL-engineered TCR-transgenic T cells. We found that c-MPL(+)
      polyclonal T cells expand and proliferate in response to TPO, and persist longer 
      after adoptive transfer in immunodeficient human TPO-transgenic mice. In
      TCR-transgenic T cells, c-MPL activation enhances antitumor function, T-cell
      expansion, and cytokine production and preserves a central memory phenotype.
      c-MPL signaling also enables sequential tumor cell killing, enhances the
      formation of effective immune synapses, and improves antileukemic activity in
      vivo in a leukemia xenograft model. We identify the type 1 interferon pathway as 
      a molecular mechanism by which c-MPL mediates immune stimulation in T cells. In
      conclusion, we present a novel immunotherapeutic strategy using c-MPL-enhanced
      transgenic T cells responding to either endogenously produced TPO (a
      microenvironment factor in hematologic malignancies) or c-MPL-targeted
      pharmacological agents.
CI  - (c) 2017 by The American Society of Hematology.
FAU - Nishimura, Christopher D
AU  - Nishimura CD
AD  - Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist
      Hospital and Texas Children's Hospital, Houston, TX; and.
FAU - Brenner, Daniel A
AU  - Brenner DA
AD  - Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist
      Hospital and Texas Children's Hospital, Houston, TX; and.
AD  - Center for Human Immunobiology.
FAU - Mukherjee, Malini
AU  - Mukherjee M
AD  - Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist
      Hospital and Texas Children's Hospital, Houston, TX; and.
AD  - Center for Human Immunobiology.
FAU - Hirsch, Rachel A
AU  - Hirsch RA
AD  - Department of Molecular and Human Genetics.
FAU - Ott, Leah
AU  - Ott L
AD  - Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist
      Hospital and Texas Children's Hospital, Houston, TX; and.
FAU - Wu, Meng-Fen
AU  - Wu MF
AD  - Department of Biostatistics, Dan L. Duncan Comprehensive Cancer Center.
FAU - Liu, Hao
AU  - Liu H
AD  - Department of Biostatistics, Dan L. Duncan Comprehensive Cancer Center.
FAU - Dakhova, Olga
AU  - Dakhova O
AD  - Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist
      Hospital and Texas Children's Hospital, Houston, TX; and.
FAU - Orange, Jordan S
AU  - Orange JS
AD  - Center for Human Immunobiology.
AD  - Department of Pediatrics, and.
FAU - Brenner, Malcolm K
AU  - Brenner MK
AD  - Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist
      Hospital and Texas Children's Hospital, Houston, TX; and.
AD  - Department of Molecular and Human Genetics.
AD  - Department of Pediatrics, and.
AD  - Department of Medicine, Baylor College of Medicine, Houston, TX.
FAU - Lin, Charles Y
AU  - Lin CY
AD  - Department of Molecular and Human Genetics.
FAU - Arber, Caroline
AU  - Arber C
AD  - Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist
      Hospital and Texas Children's Hospital, Houston, TX; and.
AD  - Department of Medicine, Baylor College of Medicine, Houston, TX.
LA  - eng
GR  - P30 CA125123/CA/NCI NIH HHS/United States
GR  - P50 CA126752/CA/NCI NIH HHS/United States
GR  - R01 CA215452/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20171027
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (Cytokines)
RN  - 0 (Interferon Type I)
RN  - 0 (Receptors, Thrombopoietin)
RN  - 143641-95-6 (MPL protein, human)
SB  - AIM
SB  - IM
MH  - Animals
MH  - Cell Proliferation/drug effects
MH  - Cytokines/metabolism
MH  - Heterografts
MH  - Humans
MH  - Immunotherapy, Adoptive/*methods
MH  - Interferon Type I/metabolism
MH  - Mice
MH  - Receptors, Thrombopoietin/agonists/metabolism/*physiology
MH  - Signal Transduction/drug effects
PMC - PMC5746163
EDAT- 2017/10/29 06:00
MHDA- 2018/01/27 06:00
CRDT- 2017/10/29 06:00
PMCR- 2018/12/21 00:00
PHST- 2017/02/17 00:00 [received]
PHST- 2017/10/20 00:00 [accepted]
PHST- 2018/12/21 00:00 [pmc-release]
PHST- 2017/10/29 06:00 [pubmed]
PHST- 2018/01/27 06:00 [medline]
PHST- 2017/10/29 06:00 [entrez]
AID - blood-2017-02-769463 [pii]
AID - 10.1182/blood-2017-02-769463 [doi]
PST - ppublish
SO  - Blood. 2017 Dec 21;130(25):2739-2749. doi: 10.1182/blood-2017-02-769463. Epub
      2017 Oct 27.

PMID- 29045391
OWN - NLM
STAT- In-Data-Review
LR  - 20180125
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 550
IP  - 7677
DP  - 2017 Oct 26
TI  - Network control principles predict neuron function in the Caenorhabditis elegans 
      connectome.
PG  - 519-523
LID - 10.1038/nature24056 [doi]
AB  - Recent studies on the controllability of complex systems offer a powerful
      mathematical framework to systematically explore the structure-function
      relationship in biological, social, and technological networks. Despite
      theoretical advances, we lack direct experimental proof of the validity of these 
      widely used control principles. Here we fill this gap by applying a control
      framework to the connectome of the nematode Caenorhabditis elegans, allowing us
      to predict the involvement of each C. elegans neuron in locomotor behaviours. We 
      predict that control of the muscles or motor neurons requires 12 neuronal
      classes, which include neuronal groups previously implicated in locomotion by
      laser ablation, as well as one previously uncharacterized neuron, PDB. We
      validate this prediction experimentally, finding that the ablation of PDB leads
      to a significant loss of dorsoventral polarity in large body bends. Importantly, 
      control principles also allow us to investigate the involvement of individual
      neurons within each neuronal class. For example, we predict that, within the
      class of DD motor neurons, only three (DD04, DD05, or DD06) should affect
      locomotion when ablated individually. This prediction is also confirmed; single
      cell ablations of DD04 or DD05 specifically affect posterior body movements,
      whereas ablations of DD02 or DD03 do not. Our predictions are robust to deletions
      of weak connections, missing connections, and rewired connections in the current 
      connectome, indicating the potential applicability of this analytical framework
      to larger and less well-characterized connectomes.
FAU - Yan, Gang
AU  - Yan G
AD  - Center for Complex Network Research and Department of Physics, Northeastern
      University, Boston, Massachusetts 02115, USA.
AD  - School of Physics Science and Engineering, Tongji University, Shanghai 200092,
      China.
FAU - Vertes, Petra E
AU  - Vertes PE
AD  - Department of Psychiatry, Behavioural and Clinical Neuroscience Institute,
      University of Cambridge, Cambridge CB2 0SZ, UK.
FAU - Towlson, Emma K
AU  - Towlson EK
AD  - Center for Complex Network Research and Department of Physics, Northeastern
      University, Boston, Massachusetts 02115, USA.
FAU - Chew, Yee Lian
AU  - Chew YL
AD  - Division of Neurobiology, MRC Laboratory of Molecular Biology, Cambridge
      Biomedical Campus, Francis Crick Avenue, Cambridge CB2 0QH, UK.
FAU - Walker, Denise S
AU  - Walker DS
AD  - Division of Neurobiology, MRC Laboratory of Molecular Biology, Cambridge
      Biomedical Campus, Francis Crick Avenue, Cambridge CB2 0QH, UK.
FAU - Schafer, William R
AU  - Schafer WR
AD  - Division of Neurobiology, MRC Laboratory of Molecular Biology, Cambridge
      Biomedical Campus, Francis Crick Avenue, Cambridge CB2 0QH, UK.
FAU - Barabasi, Albert-Laszlo
AU  - Barabasi AL
AD  - Center for Complex Network Research and Department of Physics, Northeastern
      University, Boston, Massachusetts 02115, USA.
AD  - Center for Cancer Systems Biology, Dana Farber Cancer Institute, Boston,
      Massachusetts 02115, USA.
AD  - Department of Medicine, Brigham and Women's Hospital, Harvard Medical School,
      Boston, Massachusetts 02115, USA.
AD  - Center for Network Science, Central European University, H-1051 Budapest,
      Hungary.
LA  - eng
GR  - Wellcome Trust/United Kingdom
GR  - MR/K020706/1/Medical Research Council/United Kingdom
GR  - P40 OD010440/OD/NIH HHS/United States
PT  - Journal Article
DEP - 20171018
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
PMC - PMC5710776
MID - EMS74036
EDAT- 2017/10/19 06:00
MHDA- 2017/10/19 06:00
CRDT- 2017/10/19 06:00
PMCR- 2018/04/18 00:00
PHST- 2016/12/08 00:00 [received]
PHST- 2017/09/04 00:00 [accepted]
PHST- 2018/04/18 00:00 [pmc-release]
PHST- 2017/10/19 06:00 [pubmed]
PHST- 2017/10/19 06:00 [medline]
PHST- 2017/10/19 06:00 [entrez]
AID - nature24056 [pii]
AID - 10.1038/nature24056 [doi]
PST - ppublish
SO  - Nature. 2017 Oct 26;550(7677):519-523. doi: 10.1038/nature24056. Epub 2017 Oct
      18.

PMID- 29186120
OWN - NLM
STAT- In-Data-Review
LR  - 20180117
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 552
IP  - 7684
DP  - 2017 Dec 14
TI  - Pluripotent state transitions coordinate morphogenesis in mouse and human
      embryos.
PG  - 239-243
LID - 10.1038/nature24675 [doi]
AB  - The foundations of mammalian development lie in a cluster of embryonic epiblast
      stem cells. In response to extracellular matrix signalling, these cells undergo
      epithelialization and create an apical surface in contact with a cavity, a
      fundamental event for all subsequent development. Concomitantly, epiblast cells
      transit through distinct pluripotent states, before lineage commitment at
      gastrulation. These pluripotent states have been characterized at the molecular
      level, but their biological importance remains unclear. Here we show that exit
      from an unrestricted naive pluripotent state is required for epiblast
      epithelialization and generation of the pro-amniotic cavity in mouse embryos.
      Embryonic stem cells locked in the naive state are able to initiate polarization 
      but fail to undergo lumenogenesis. Mechanistically, exit from naive pluripotency 
      activates an Oct4-governed transcriptional program that results in expression of 
      glycosylated sialomucin proteins and the vesicle tethering and fusion events of
      lumenogenesis. Similarly, exit of epiblasts from naive pluripotency in cultured
      human post-implantation embryos triggers amniotic cavity formation and
      developmental progression. Our results add tissue-level architecture as a new
      criterion for the characterization of different pluripotent states, and show the 
      relevance of transitions between these states during development of the mammalian
      embryo.
FAU - Shahbazi, Marta N
AU  - Shahbazi MN
AD  - Mammalian Embryo and Stem Cell Group, University of Cambridge, Department of
      Physiology, Development and Neuroscience, Downing Street, Cambridge CB2 3EG, UK.
FAU - Scialdone, Antonio
AU  - Scialdone A
AD  - EMBL-European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus,
      Cambridge CB10 1SD, UK.
FAU - Skorupska, Natalia
AU  - Skorupska N
AD  - Mammalian Embryo and Stem Cell Group, University of Cambridge, Department of
      Physiology, Development and Neuroscience, Downing Street, Cambridge CB2 3EG, UK.
FAU - Weberling, Antonia
AU  - Weberling A
AD  - Mammalian Embryo and Stem Cell Group, University of Cambridge, Department of
      Physiology, Development and Neuroscience, Downing Street, Cambridge CB2 3EG, UK.
FAU - Recher, Gaelle
AU  - Recher G
AD  - Mammalian Embryo and Stem Cell Group, University of Cambridge, Department of
      Physiology, Development and Neuroscience, Downing Street, Cambridge CB2 3EG, UK.
FAU - Zhu, Meng
AU  - Zhu M
AD  - Mammalian Embryo and Stem Cell Group, University of Cambridge, Department of
      Physiology, Development and Neuroscience, Downing Street, Cambridge CB2 3EG, UK.
FAU - Jedrusik, Agnieszka
AU  - Jedrusik A
AD  - Mammalian Embryo and Stem Cell Group, University of Cambridge, Department of
      Physiology, Development and Neuroscience, Downing Street, Cambridge CB2 3EG, UK.
FAU - Devito, Liani G
AU  - Devito LG
AD  - Faculty of Life Sciences and Medicine, King's College London, Women's Health
      Academic Centre, Assisted Conception Unit, Guy's Hospital, Great Maze Pond,
      London SE1 9RT, UK.
FAU - Noli, Laila
AU  - Noli L
AD  - Faculty of Life Sciences and Medicine, King's College London, Women's Health
      Academic Centre, Assisted Conception Unit, Guy's Hospital, Great Maze Pond,
      London SE1 9RT, UK.
FAU - Macaulay, Iain C
AU  - Macaulay IC
AD  - Wellcome Trust Sanger Institute, Wellcome Genome Campus, Cambridge CB10 1SA, UK.
FAU - Buecker, Christa
AU  - Buecker C
AD  - Department of Chemical and Systems Biology, Stanford University School of
      Medicine, Stanford, California 94305, USA.
FAU - Khalaf, Yakoub
AU  - Khalaf Y
AD  - Faculty of Life Sciences and Medicine, King's College London, Women's Health
      Academic Centre, Assisted Conception Unit, Guy's Hospital, Great Maze Pond,
      London SE1 9RT, UK.
FAU - Ilic, Dusko
AU  - Ilic D
AD  - Faculty of Life Sciences and Medicine, King's College London, Women's Health
      Academic Centre, Assisted Conception Unit, Guy's Hospital, Great Maze Pond,
      London SE1 9RT, UK.
FAU - Voet, Thierry
AU  - Voet T
AD  - Wellcome Trust Sanger Institute, Wellcome Genome Campus, Cambridge CB10 1SA, UK.
AD  - Laboratory of Reproductive Genomics, Department of Human Genetics, KU Leuven,
      Herestraat 49, Leuven 3000, Belgium.
FAU - Marioni, John C
AU  - Marioni JC
AD  - EMBL-European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus,
      Cambridge CB10 1SD, UK.
AD  - Wellcome Trust Sanger Institute, Wellcome Genome Campus, Cambridge CB10 1SA, UK.
AD  - Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2
      0RE, UK.
FAU - Zernicka-Goetz, Magdalena
AU  - Zernicka-Goetz M
AD  - Mammalian Embryo and Stem Cell Group, University of Cambridge, Department of
      Physiology, Development and Neuroscience, Downing Street, Cambridge CB2 3EG, UK.
LA  - eng
GR  - Wellcome Trust/United Kingdom
PT  - Journal Article
DEP - 20171129
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
PMC - PMC5768241
MID - EMS74765
EDAT- 2017/12/01 06:00
MHDA- 2017/12/01 06:00
CRDT- 2017/11/30 06:00
PMCR- 2018/05/29 00:00
PHST- 2017/04/19 00:00 [received]
PHST- 2017/11/02 00:00 [accepted]
PHST- 2018/05/29 00:00 [pmc-release]
PHST- 2017/12/01 06:00 [pubmed]
PHST- 2017/12/01 06:00 [medline]
PHST- 2017/11/30 06:00 [entrez]
AID - nature24675 [pii]
AID - 10.1038/nature24675 [doi]
PST - ppublish
SO  - Nature. 2017 Dec 14;552(7684):239-243. doi: 10.1038/nature24675. Epub 2017 Nov
      29.

PMID- 29227476
OWN - NLM
STAT- In-Data-Review
LR  - 20180111
IS  - 1546-170X (Electronic)
IS  - 1078-8956 (Linking)
VI  - 24
IP  - 1
DP  - 2018 Jan
TI  - The molecular landscape of pediatric acute myeloid leukemia reveals recurrent
      structural alterations and age-specific mutational interactions.
PG  - 103-112
LID - 10.1038/nm.4439 [doi]
AB  - We present the molecular landscape of pediatric acute myeloid leukemia (AML) and 
      characterize nearly 1,000 participants in Children's Oncology Group (COG) AML
      trials. The COG-National Cancer Institute (NCI) TARGET AML initiative assessed
      cases by whole-genome, targeted DNA, mRNA and microRNA sequencing and CpG
      methylation profiling. Validated DNA variants corresponded to diverse, infrequent
      mutations, with fewer than 40 genes mutated in >2% of cases. In contrast, somatic
      structural variants, including new gene fusions and focal deletions of MBNL1,
      ZEB2 and ELF1, were disproportionately prevalent in young individuals as compared
      to adults. Conversely, mutations in DNMT3A and TP53, which were common in adults,
      were conspicuously absent from virtually all pediatric cases. New mutations in
      GATA2, FLT3 and CBL and recurrent mutations in MYC-ITD, NRAS, KRAS and WT1 were
      frequent in pediatric AML. Deletions, mutations and promoter DNA hypermethylation
      convergently impacted Wnt signaling, Polycomb repression, innate immune cell
      interactions and a cluster of zinc finger-encoding genes associated with KMT2A
      rearrangements. These results highlight the need for and facilitate the
      development of age-tailored targeted therapies for the treatment of pediatric
      AML.
FAU - Bolouri, Hamid
AU  - Bolouri H
AD  - Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle,
      Washington, USA.
FAU - Farrar, Jason E
AU  - Farrar JE
AUID- ORCID: http://orcid.org/0000-0003-2148-5839
AD  - Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical
      Sciences and Arkansas Children's Research Institute, Little Rock, Arkansas, USA.
FAU - Triche, Timothy Jr
AU  - Triche T Jr
AD  - Jane Anne Nohl Division of Hematology, University of Southern California Norris
      Comprehensive Cancer Center, Los Angeles, California, USA.
FAU - Ries, Rhonda E
AU  - Ries RE
AD  - Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle,
      Washington, USA.
FAU - Lim, Emilia L
AU  - Lim EL
AD  - Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency,
      Vancouver, British Columbia, Canada.
FAU - Alonzo, Todd A
AU  - Alonzo TA
AD  - Keck School of Medicine, University of Southern California, Los Angeles,
      California, USA.
AD  - Children's Oncology Group, Monrovia, California, USA.
FAU - Ma, Yussanne
AU  - Ma Y
AD  - Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency,
      Vancouver, British Columbia, Canada.
FAU - Moore, Richard
AU  - Moore R
AD  - Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency,
      Vancouver, British Columbia, Canada.
FAU - Mungall, Andrew J
AU  - Mungall AJ
AUID- ORCID: http://orcid.org/0000-0002-0905-2742
AD  - Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency,
      Vancouver, British Columbia, Canada.
FAU - Marra, Marco A
AU  - Marra MA
AD  - Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency,
      Vancouver, British Columbia, Canada.
FAU - Zhang, Jinghui
AU  - Zhang J
AD  - Division of Computational Biology, St. Jude Children's Research Hospital,
      Memphis, Tennessee, USA.
FAU - Ma, Xiaotu
AU  - Ma X
AD  - Division of Computational Biology, St. Jude Children's Research Hospital,
      Memphis, Tennessee, USA.
FAU - Liu, Yu
AU  - Liu Y
AD  - Division of Computational Biology, St. Jude Children's Research Hospital,
      Memphis, Tennessee, USA.
FAU - Liu, Yanling
AU  - Liu Y
AD  - Division of Computational Biology, St. Jude Children's Research Hospital,
      Memphis, Tennessee, USA.
FAU - Auvil, Jaime M Guidry
AU  - Auvil JMG
AD  - Office of Cancer Genomics, National Cancer Institute, Bethesda, Maryland, USA.
FAU - Davidsen, Tanja M
AU  - Davidsen TM
AD  - Office of Cancer Genomics, National Cancer Institute, Bethesda, Maryland, USA.
FAU - Gesuwan, Patee
AU  - Gesuwan P
AD  - Office of Cancer Genomics, National Cancer Institute, Bethesda, Maryland, USA.
FAU - Hermida, Leandro C
AU  - Hermida LC
AD  - Office of Cancer Genomics, National Cancer Institute, Bethesda, Maryland, USA.
FAU - Salhia, Bodour
AU  - Salhia B
AD  - Department of Translational Genomics, Keck School of Medicine, University of
      Southern California, Los Angeles, California, USA.
FAU - Capone, Stephen
AU  - Capone S
AD  - Jane Anne Nohl Division of Hematology, University of Southern California Norris
      Comprehensive Cancer Center, Los Angeles, California, USA.
FAU - Ramsingh, Giridharan
AU  - Ramsingh G
AD  - Jane Anne Nohl Division of Hematology, University of Southern California Norris
      Comprehensive Cancer Center, Los Angeles, California, USA.
FAU - Zwaan, Christian Michel
AU  - Zwaan CM
AD  - Department of Pediatric Oncology, Erasmus MC-Sophia Children's Hospital,
      Rotterdam, the Netherlands.
FAU - Noort, Sanne
AU  - Noort S
AD  - Department of Pediatric Oncology, Erasmus MC-Sophia Children's Hospital,
      Rotterdam, the Netherlands.
FAU - Piccolo, Stephen R
AU  - Piccolo SR
AUID- ORCID: http://orcid.org/0000-0003-2001-5640
AD  - Department of Biology, Brigham Young University, Provo, Utah, USA.
AD  - Department of Biomedical Informatics, University of Utah, Salt Lake City, Utah,
      USA.
FAU - Kolb, E Anders
AU  - Kolb EA
AD  - Nemours Center for Cancer and Blood Disorders, Alfred I. DuPont Hospital for
      Children, Wilmington, Delaware, USA.
FAU - Gamis, Alan S
AU  - Gamis AS
AD  - Division of Hematology, Oncology and Bone Marrow Transplantation, Children's
      Mercy Hospitals and Clinics, Kansas City, Missouri, USA.
FAU - Smith, Malcolm A
AU  - Smith MA
AD  - Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland,
      USA.
FAU - Gerhard, Daniela S
AU  - Gerhard DS
AD  - Office of Cancer Genomics, National Cancer Institute, Bethesda, Maryland, USA.
FAU - Meshinchi, Soheil
AU  - Meshinchi S
AD  - Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle,
      Washington, USA.
LA  - eng
PT  - Journal Article
DEP - 20171211
PL  - United States
TA  - Nat Med
JT  - Nature medicine
JID - 9502015
EDAT- 2017/12/12 06:00
MHDA- 2017/12/12 06:00
CRDT- 2017/12/12 06:00
PHST- 2017/02/06 00:00 [received]
PHST- 2017/10/12 00:00 [accepted]
PHST- 2017/12/12 06:00 [pubmed]
PHST- 2017/12/12 06:00 [medline]
PHST- 2017/12/12 06:00 [entrez]
AID - nm.4439 [pii]
AID - 10.1038/nm.4439 [doi]
PST - ppublish
SO  - Nat Med. 2018 Jan;24(1):103-112. doi: 10.1038/nm.4439. Epub 2017 Dec 11.

PMID- 29150421
OWN - NLM
STAT- In-Data-Review
LR  - 20180119
IS  - 1528-0020 (Electronic)
IS  - 0006-4971 (Linking)
VI  - 131
IP  - 3
DP  - 2018 Jan 18
TI  - Final analysis of survival outcomes in the phase 3 FIRST trial of up-front
      treatment for multiple myeloma.
PG  - 301-310
LID - 10.1182/blood-2017-07-795047 [doi]
AB  - This FIRST trial final analysis examined survival outcomes in patients with
      transplant-ineligible newly diagnosed multiple myeloma (NDMM) treated with
      lenalidomide and low-dose dexamethasone until disease progression (Rd
      continuous), Rd for 72 weeks (18 cycles; Rd18), or melphalan, prednisone, and
      thalidomide (MPT; 72 weeks). The primary endpoint was progression-free survival
      (PFS; primary comparison: Rd continuous vs MPT). Overall survival (OS) was a key 
      secondary endpoint (final analysis prespecified >/=60 months' follow-up).
      Patients were randomized to Rd continuous (n = 535), Rd18 (n = 541), or MPT (n = 
      547). At a median follow-up of 67 months, PFS was significantly longer with Rd
      continuous vs MPT (hazard ratio [HR], 0.69; 95% confidence interval [CI],
      0.59-0.79; P < .00001) and was similarly extended vs Rd18. Median OS was 10
      months longer with Rd continuous vs MPT (59.1 vs 49.1 months; HR, 0.78; 95% CI,
      0.67-0.92; P = .0023), and similar with Rd18 (62.3 months). In patients achieving
      complete or very good partial responses, Rd continuous had an approximately
      30-month longer median time to next treatment vs Rd18 (69.5 vs 39.9 months). Over
      half of all patients who received second-line treatment were given a
      bortezomib-based therapy. Second-line outcomes were improved in patients
      receiving bortezomib after Rd continuous and Rd18 vs after MPT. No new safety
      concerns, including risk for secondary malignancies, were observed. Treatment
      with Rd continuous significantly improved survival outcomes vs MPT, supporting Rd
      continuous as a standard of care for patients with transplant-ineligible NDMM.
      This trial was registered at www.clinicaltrials.gov as #NCT00689936 and EudraCT
      as 2007-004823-39.
CI  - (c) 2018 by The American Society of Hematology.
FAU - Facon, Thierry
AU  - Facon T
AD  - Service des Maladies du Sang, Hopital Claude Huriez, Lille, France.
FAU - Dimopoulos, Meletios A
AU  - Dimopoulos MA
AD  - Department of Clinical Therapeutics, National and Kapodistrian University of
      Athens School of Medicine, Athens, Greece.
FAU - Dispenzieri, Angela
AU  - Dispenzieri A
AD  - Mayo Clinic, Rochester, MN.
FAU - Catalano, John V
AU  - Catalano JV
AD  - Frankston Hospital and Monash University, Frankston, Australia.
FAU - Belch, Andrew
AU  - Belch A
AD  - Cross Cancer Institute, Edmonton, Canada.
FAU - Cavo, Michele
AU  - Cavo M
AD  - Seragnoli Institute of Hematology, Bologna University School of Medicine,
      Bologna, Italy.
FAU - Pinto, Antonello
AU  - Pinto A
AD  - Department of Hematology and Developmental Therapeutics, Hematology/Oncology and 
      Stem Cells Transplantation Unit, National Cancer Institute, Fondazione "Pascale,"
      Naples, Italy.
FAU - Weisel, Katja
AU  - Weisel K
AD  - Department of Hematology, University of Tuebingen, Tuebingen, Germany.
FAU - Ludwig, Heinz
AU  - Ludwig H
AD  - Wilhelminenspital, Center for Oncology, Vienna, Austria.
FAU - Bahlis, Nizar J
AU  - Bahlis NJ
AD  - Southern Alberta Cancer Research Institute, University of Calgary, Calgary,
      Canada.
FAU - Banos, Anne
AU  - Banos A
AD  - Centre Hospitalier de la Cote Basque, Bayonne, France.
FAU - Tiab, Mourad
AU  - Tiab M
AD  - Department of Hematology, University Hospital, La Roche Sur Yon, France.
FAU - Delforge, Michel
AU  - Delforge M
AD  - University Hospital Leuven, Leuven, Belgium.
FAU - Cavenagh, Jamie D
AU  - Cavenagh JD
AD  - Barts Health National Health Service Trust, London, United Kingdom.
FAU - Geraldes, Catarina
AU  - Geraldes C
AD  - Hospitais da Universidade de Coimbra, Coimbra, Portugal.
FAU - Lee, Je-Jung
AU  - Lee JJ
AD  - Chonnam National University Hwasun Hospital, Jeollanamdo, South Korea.
FAU - Chen, Christine
AU  - Chen C
AD  - Princess Margaret Hospital, Toronto, Canada.
FAU - Oriol, Albert
AU  - Oriol A
AD  - Institut Catala d'Oncologia and Institut Josep Carreras, Hospital Germans Trias i
      Pujol, Badalona, Spain.
FAU - De La Rubia, Javier
AU  - De La Rubia J
AD  - Hospital Dr. Peset, Valencia, Spain.
FAU - White, Darrell
AU  - White D
AD  - Queen Elizabeth II Health Sciences Centre, Halifax, Canada.
FAU - Binder, Daniel
AU  - Binder D
AD  - Kantonsspital Winterthur, Winterthur, Switzerland.
FAU - Lu, Jin
AU  - Lu J
AD  - Peking University People's Hospital, Beijing, China.
FAU - Anderson, Kenneth C
AU  - Anderson KC
AD  - Dana-Farber Cancer Institute, Boston, MA.
FAU - Moreau, Philippe
AU  - Moreau P
AD  - Department of Hematology, University of Nantes, Nantes, France.
FAU - Attal, Michel
AU  - Attal M
AD  - Institut Universitaire du Cancer, Toulouse-Oncopole, France.
FAU - Perrot, Aurore
AU  - Perrot A
AD  - Centre Hospitalier Regional Universitaire de Nancy, Universite de Lorraine,
      Nancy, France.
FAU - Arnulf, Bertrand
AU  - Arnulf B
AD  - Hopital Saint Louis, Paris, France.
FAU - Qiu, Lugui
AU  - Qiu L
AD  - Blood Disease Hospital, Chinese Academy of Medical Science and Peking Union
      Medical College, Tianjin, China.
FAU - Roussel, Murielle
AU  - Roussel M
AD  - Centre Hospitalier Universitaire Purpan/Institut Universitaire du Cancer de
      Toulouse Oncopole, Toulouse, France.
FAU - Boyle, Eileen
AU  - Boyle E
AD  - Service des Maladies du Sang, Hopital Claude Huriez, Lille, France.
FAU - Manier, Salomon
AU  - Manier S
AD  - Service des Maladies du Sang, Hopital Claude Huriez, Lille, France.
FAU - Mohty, Mohamad
AU  - Mohty M
AD  - Hopital Saint-Antoine, Paris, France.
FAU - Avet-Loiseau, Herve
AU  - Avet-Loiseau H
AD  - Unite de Genomique du Myelome, Centre Hospitalier Universitaire Rangueil,
      Toulouse, France.
FAU - Leleu, Xavier
AU  - Leleu X
AD  - Hopital de la Miletrie, Centre Hospitalier Universitaire INSERM, Poitiers,
      France.
FAU - Ervin-Haynes, Annette
AU  - Ervin-Haynes A
AD  - Celgene Corporation, Summit, NJ.
FAU - Chen, Guang
AU  - Chen G
AD  - Celgene Corporation, Summit, NJ.
FAU - Houck, Vanessa
AU  - Houck V
AD  - Celgene Corporation, Summit, NJ.
FAU - Benboubker, Lotfi
AU  - Benboubker L
AD  - Centre Hospitalier Universitaire Hopital Bretonneau, Tours Cedex, France; and.
FAU - Hulin, Cyrille
AU  - Hulin C
AD  - Bordeaux Hospital University Center (Centre Hospitalier Universitaire), Bordeaux,
      France.
LA  - eng
PT  - Journal Article
DEP - 20171117
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
EDAT- 2017/11/19 06:00
MHDA- 2017/11/19 06:00
CRDT- 2017/11/19 06:00
PHST- 2017/07/07 00:00 [received]
PHST- 2017/10/31 00:00 [accepted]
PHST- 2017/11/19 06:00 [pubmed]
PHST- 2017/11/19 06:00 [medline]
PHST- 2017/11/19 06:00 [entrez]
AID - blood-2017-07-795047 [pii]
AID - 10.1182/blood-2017-07-795047 [doi]
PST - ppublish
SO  - Blood. 2018 Jan 18;131(3):301-310. doi: 10.1182/blood-2017-07-795047. Epub 2017
      Nov 17.

PMID- 29202477
OWN - NLM
STAT- In-Data-Review
LR  - 20180102
IS  - 1558-8238 (Electronic)
IS  - 0021-9738 (Linking)
VI  - 128
IP  - 1
DP  - 2018 Jan 2
TI  - CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2.
PG  - 446-462
LID - 10.1172/JCI90793 [doi]
LID - 90793 [pii]
AB  - Pharmacologically difficult targets, such as MYC transcription factors, represent
      a major challenge in cancer therapy. For the childhood cancer neuroblastoma,
      amplification of the oncogene MYCN is associated with high-risk disease and poor 
      prognosis. Here, we deployed genome-scale CRISPR-Cas9 screening of MYCN-amplified
      neuroblastoma and found a preferential dependency on genes encoding the polycomb 
      repressive complex 2 (PRC2) components EZH2, EED, and SUZ12. Genetic and
      pharmacological suppression of EZH2 inhibited neuroblastoma growth in vitro and
      in vivo. Moreover, compared with neuroblastomas without MYCN amplification,
      MYCN-amplified neuroblastomas expressed higher levels of EZH2. ChIP analysis
      showed that MYCN binds at the EZH2 promoter, thereby directly driving expression.
      Transcriptomic and epigenetic analysis, as well as genetic rescue experiments,
      revealed that EZH2 represses neuronal differentiation in neuroblastoma in a
      PRC2-dependent manner. Moreover, MYCN-amplified and high-risk primary tumors from
      patients with neuroblastoma exhibited strong repression of EZH2-regulated genes. 
      Additionally, overexpression of IGFBP3, a direct EZH2 target, suppressed
      neuroblastoma growth in vitro and in vivo. We further observed strong synergy
      between histone deacetylase inhibitors and EZH2 inhibitors. Together, these
      observations demonstrate that MYCN upregulates EZH2, leading to inactivation of a
      tumor suppressor program in neuroblastoma, and support testing EZH2 inhibitors in
      patients with MYCN-amplified neuroblastoma.
FAU - Chen, Liying
AU  - Chen L
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston
      Children's Hospital, Boston, Massachusetts, USA.
AD  - Broad Institute, Cambridge, Massachusetts, USA.
FAU - Alexe, Gabriela
AU  - Alexe G
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston
      Children's Hospital, Boston, Massachusetts, USA.
AD  - Broad Institute, Cambridge, Massachusetts, USA.
AD  - Harvard Medical School, Boston, Massachusetts, USA.
AD  - Bioinformatics Graduate Program, Boston University, Boston, Massachusetts, USA.
FAU - Dharia, Neekesh V
AU  - Dharia NV
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston
      Children's Hospital, Boston, Massachusetts, USA.
AD  - Broad Institute, Cambridge, Massachusetts, USA.
AD  - Harvard Medical School, Boston, Massachusetts, USA.
FAU - Ross, Linda
AU  - Ross L
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston
      Children's Hospital, Boston, Massachusetts, USA.
FAU - Iniguez, Amanda Balboni
AU  - Iniguez AB
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston
      Children's Hospital, Boston, Massachusetts, USA.
AD  - Broad Institute, Cambridge, Massachusetts, USA.
FAU - Conway, Amy Saur
AU  - Conway AS
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston
      Children's Hospital, Boston, Massachusetts, USA.
FAU - Wang, Emily Jue
AU  - Wang EJ
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston
      Children's Hospital, Boston, Massachusetts, USA.
FAU - Veschi, Veronica
AU  - Veschi V
AD  - Cell and Molecular Biology Section, Pediatric Oncology Branch, Center for Cancer 
      Research, National Cancer Institute, NIH, Bethesda, Maryland, USA.
FAU - Lam, Norris
AU  - Lam N
AD  - Cell and Molecular Biology Section, Pediatric Oncology Branch, Center for Cancer 
      Research, National Cancer Institute, NIH, Bethesda, Maryland, USA.
FAU - Qi, Jun
AU  - Qi J
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts, USA.
FAU - Gustafson, W Clay
AU  - Gustafson WC
AD  - Department of Pediatrics, Helen Diller Family Comprehensive Cancer Center, UCSF, 
      San Francisco, California, USA.
FAU - Nasholm, Nicole
AU  - Nasholm N
AD  - Department of Pediatrics, Helen Diller Family Comprehensive Cancer Center, UCSF, 
      San Francisco, California, USA.
FAU - Vazquez, Francisca
AU  - Vazquez F
AD  - Broad Institute, Cambridge, Massachusetts, USA.
FAU - Weir, Barbara A
AU  - Weir BA
AD  - Broad Institute, Cambridge, Massachusetts, USA.
FAU - Cowley, Glenn S
AU  - Cowley GS
AD  - Broad Institute, Cambridge, Massachusetts, USA.
FAU - Ali, Levi D
AU  - Ali LD
AD  - Broad Institute, Cambridge, Massachusetts, USA.
FAU - Pantel, Sasha
AU  - Pantel S
AD  - Broad Institute, Cambridge, Massachusetts, USA.
FAU - Jiang, Guozhi
AU  - Jiang G
AD  - Broad Institute, Cambridge, Massachusetts, USA.
FAU - Harrington, William F
AU  - Harrington WF
AD  - Broad Institute, Cambridge, Massachusetts, USA.
FAU - Lee, Yenarae
AU  - Lee Y
AD  - Broad Institute, Cambridge, Massachusetts, USA.
FAU - Goodale, Amy
AU  - Goodale A
AD  - Broad Institute, Cambridge, Massachusetts, USA.
FAU - Lubonja, Rakela
AU  - Lubonja R
AD  - Broad Institute, Cambridge, Massachusetts, USA.
FAU - Krill-Burger, John M
AU  - Krill-Burger JM
AD  - Broad Institute, Cambridge, Massachusetts, USA.
FAU - Meyers, Robin M
AU  - Meyers RM
AD  - Broad Institute, Cambridge, Massachusetts, USA.
FAU - Tsherniak, Aviad
AU  - Tsherniak A
AD  - Broad Institute, Cambridge, Massachusetts, USA.
FAU - Root, David E
AU  - Root DE
AD  - Broad Institute, Cambridge, Massachusetts, USA.
FAU - Bradner, James E
AU  - Bradner JE
AD  - Harvard Medical School, Boston, Massachusetts, USA.
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts, USA.
AD  - Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, USA.
FAU - Golub, Todd R
AU  - Golub TR
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston
      Children's Hospital, Boston, Massachusetts, USA.
AD  - Broad Institute, Cambridge, Massachusetts, USA.
AD  - Harvard Medical School, Boston, Massachusetts, USA.
FAU - Roberts, Charles Wm
AU  - Roberts CW
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston
      Children's Hospital, Boston, Massachusetts, USA.
AD  - Comprehensive Cancer Center and Department of Oncology, St. Jude Children's
      Research Hospital, Memphis, Tennessee, USA.
FAU - Hahn, William C
AU  - Hahn WC
AD  - Broad Institute, Cambridge, Massachusetts, USA.
AD  - Harvard Medical School, Boston, Massachusetts, USA.
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts, USA.
FAU - Weiss, William A
AU  - Weiss WA
AD  - Department of Pediatrics, Helen Diller Family Comprehensive Cancer Center, UCSF, 
      San Francisco, California, USA.
AD  - Department of Neurology, Neurological Surgery, Brain Tumor Research Center, UCSF,
      San Francisco, California, USA.
FAU - Thiele, Carol J
AU  - Thiele CJ
AD  - Cell and Molecular Biology Section, Pediatric Oncology Branch, Center for Cancer 
      Research, National Cancer Institute, NIH, Bethesda, Maryland, USA.
FAU - Stegmaier, Kimberly
AU  - Stegmaier K
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston
      Children's Hospital, Boston, Massachusetts, USA.
AD  - Broad Institute, Cambridge, Massachusetts, USA.
AD  - Harvard Medical School, Boston, Massachusetts, USA.
LA  - eng
PT  - Journal Article
DEP - 20171204
PL  - United States
TA  - J Clin Invest
JT  - The Journal of clinical investigation
JID - 7802877
OTO - NOTNLM
OT  - Epigenetics
OT  - Oncology
EDAT- 2017/12/05 06:00
MHDA- 2017/12/05 06:00
CRDT- 2017/12/05 06:00
PHST- 2016/09/19 00:00 [received]
PHST- 2017/10/24 00:00 [accepted]
PHST- 2017/12/05 06:00 [pubmed]
PHST- 2017/12/05 06:00 [medline]
PHST- 2017/12/05 06:00 [entrez]
AID - 90793 [pii]
AID - 10.1172/JCI90793 [doi]
PST - ppublish
SO  - J Clin Invest. 2018 Jan 2;128(1):446-462. doi: 10.1172/JCI90793. Epub 2017 Dec 4.

PMID- 28744288
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20170728
IS  - 1664-3224 (Print)
IS  - 1664-3224 (Linking)
VI  - 8
DP  - 2017
TI  - Naltrexone Inhibits IL-6 and TNFalpha Production in Human Immune Cell Subsets
      following Stimulation with Ligands for Intracellular Toll-Like Receptors.
PG  - 809
LID - 10.3389/fimmu.2017.00809 [doi]
AB  - The opioid antagonist naltrexone hydrochloride has been suggested to be a
      potential therapy at low dosage for multiple inflammatory conditions and cancers.
      Little is known about the immune-modulating effects of naltrexone, but an effect 
      on the activity of toll-like receptor 4 (TLR4) has been reported. We analyzed the
      effects of naltrexone hydrochloride on IL-6 secretion by peripheral blood
      mononuclear cells (PBMC) in vitro following stimulation with ligands for TLR4 and
      for the intracellular receptors TLR7, TLR8, and TLR9. Naltrexone did not affect
      cell viability or induce apoptosis of PBMC. Intracellular staining demonstrated
      that naltrexone inhibited production of IL-6 and TNFalpha by monocyte and
      plasmacytoid dendritic cell subsets within the PBMC population following
      treatment with ligands for TLR7/8 and TLR9, respectively. No effect of cytokine
      production by PBMC following stimulation of TLR4 was observed. Additionally,
      naltrexone inhibited IL-6 production in isolated monocytes and B cells after
      TLR7/8 and TLR9 stimulation, respectively, but no effect on IL-6 production in
      isolated monocytes after TLR4 stimulation was observed. These findings indicate
      that naltrexone has the potential to modulate the secretion of inflammatory
      cytokines in response to intracellular TLR activity, supporting the hypothesis
      that it may have potential for use as an immunomodulator.
FAU - Cant, Rachel
AU  - Cant R
AD  - Institute for Infection and Immunity, St George's University of London, London,
      United Kingdom.
FAU - Dalgleish, Angus G
AU  - Dalgleish AG
AD  - Institute for Infection and Immunity, St George's University of London, London,
      United Kingdom.
FAU - Allen, Rachel L
AU  - Allen RL
AD  - Institute for Infection and Immunity, St George's University of London, London,
      United Kingdom.
LA  - eng
PT  - Journal Article
DEP - 20170711
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
PMC - PMC5504148
OTO - NOTNLM
OT  - B cells
OT  - interleukin-6
OT  - monocytes
OT  - naltrexone
OT  - plasmacytoid dendritic cells
OT  - toll-like receptor
OT  - tumor necrosis factor alpha
EDAT- 2017/07/27 06:00
MHDA- 2017/07/27 06:01
CRDT- 2017/07/27 06:00
PHST- 2016/12/16 00:00 [received]
PHST- 2017/06/26 00:00 [accepted]
PHST- 2017/07/27 06:00 [entrez]
PHST- 2017/07/27 06:00 [pubmed]
PHST- 2017/07/27 06:01 [medline]
AID - 10.3389/fimmu.2017.00809 [doi]
PST - epublish
SO  - Front Immunol. 2017 Jul 11;8:809. doi: 10.3389/fimmu.2017.00809. eCollection
      2017.

PMID- 29102433
OWN - NLM
STAT- In-Process
LR  - 20171127
IS  - 2213-8595 (Electronic)
IS  - 2213-8587 (Linking)
VI  - 5
IP  - 12
DP  - 2017 Dec
TI  - Effect of vitamin D supplementation on non-skeletal disorders: a systematic
      review of meta-analyses and randomised trials.
PG  - 986-1004
LID - S2213-8587(17)30357-1 [pii]
LID - 10.1016/S2213-8587(17)30357-1 [doi]
AB  - Randomised trials reported up to Dec 31, 2012, did not confirm that vitamin D
      supplementation could protect from non-skeletal health conditions affecting
      adults, as was expected on the basis of data from observational studies. To
      examine whether the more recently published meta-analyses and trials would change
      past conclusions, we systematically reviewed meta-analyses of vitamin D
      supplementation and non-skeletal disorders published between Jan 1, 2013, and May
      31, 2017, that included study participants of all ages, including pregnant women.
      We also searched for randomised trials not included in meta-analyses. We
      identified 87 meta-analyses, of which 52 were excluded because they contained
      less recent literature or were of suboptimal quality. We retrieved 202 articles
      on trials that were not included in meta-analyses. Recent meta-analyses reinforce
      the finding that 10-20 mug per day of vitamin D can reduce all-cause mortality
      and cancer mortality in middle-aged and older people. Although vitamin D doses
      were greater than those assessed in the past, we found no new evidence that
      supplementation could have an effect on most non-skeletal conditions, including
      cardiovascular disease, adiposity, glucose metabolism, mood disorders, muscular
      function, tuberculosis, and colorectal adenomas, or on maternal and perinatal
      conditions. New data on cancer outcomes were scarce. The compilation of results
      from 83 trials showed that vitamin D supplementation had no significant effect on
      biomarkers of systemic inflammation. The main new finding highlighted by this
      systematic review is that vitamin D supplementation might help to prevent common 
      upper respiratory tract infections and asthma exacerbations. There remains little
      evidence to suggest that vitamin D supplementation has an effect on most
      conditions, including chronic inflammation, despite use of increased doses of
      vitamin D, strengthening the hypothesis that low vitamin D status is a
      consequence of ill health, rather than its cause. We further hypothesise that
      vitamin D supplementation could exert immunomodulatory effects that strengthen
      resistance to acute infections, which would reduce the risk of death in
      debilitated individuals. We identified many meta-analyses of suboptimal quality, 
      which is of concern. Future systematic reviews on vitamin D should be based on
      data sharing so that data for participants with the same outcomes measured in the
      same way can be pooled to generate stronger evidence.
CI  - Copyright (c) 2017 Elsevier Ltd. All rights reserved.
FAU - Autier, Philippe
AU  - Autier P
AD  - International Prevention Research Institute, Lyon, France; University of
      Strathclyde Institute of Global Public Health at the International Prevention
      Research Institute, Lyon, France. Electronic address: philippe.autier@i-pri.org.
FAU - Mullie, Patrick
AU  - Mullie P
AD  - Faculty of Physical Education and Physiotherapy, Vrije Universiteit Brussel,
      Brussels, Belgium.
FAU - Macacu, Alina
AU  - Macacu A
AD  - International Prevention Research Institute, Lyon, France.
FAU - Dragomir, Miruna
AU  - Dragomir M
AD  - International Prevention Research Institute, Lyon, France.
FAU - Boniol, Magali
AU  - Boniol M
AD  - International Prevention Research Institute, Lyon, France.
FAU - Coppens, Kim
AU  - Coppens K
AD  - International Prevention Research Institute, Lyon, France.
FAU - Pizot, Cecile
AU  - Pizot C
AD  - International Prevention Research Institute, Lyon, France.
FAU - Boniol, Mathieu
AU  - Boniol M
AD  - International Prevention Research Institute, Lyon, France; University of
      Strathclyde Institute of Global Public Health at the International Prevention
      Research Institute, Lyon, France.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20171105
PL  - England
TA  - Lancet Diabetes Endocrinol
JT  - The lancet. Diabetes & endocrinology
JID - 101618821
EDAT- 2017/11/06 06:00
MHDA- 2017/11/06 06:00
CRDT- 2017/11/06 06:00
PHST- 2017/04/07 00:00 [received]
PHST- 2017/07/13 00:00 [revised]
PHST- 2017/07/18 00:00 [accepted]
PHST- 2017/11/06 06:00 [pubmed]
PHST- 2017/11/06 06:00 [medline]
PHST- 2017/11/06 06:00 [entrez]
AID - S2213-8587(17)30357-1 [pii]
AID - 10.1016/S2213-8587(17)30357-1 [doi]
PST - ppublish
SO  - Lancet Diabetes Endocrinol. 2017 Dec;5(12):986-1004. doi:
      10.1016/S2213-8587(17)30357-1. Epub 2017 Nov 5.

PMID- 29241552
OWN - NLM
STAT- In-Process
LR  - 20171215
IS  - 2211-1247 (Electronic)
VI  - 21
IP  - 11
DP  - 2017 Dec 12
TI  - A Single-Cell RNA Sequencing Study Reveals Cellular and Molecular Dynamics of the
      Hippocampal Neurogenic Niche.
PG  - 3271-3284
LID - S2211-1247(17)31702-3 [pii]
LID - 10.1016/j.celrep.2017.11.050 [doi]
AB  - Adult neurogenesis in the murine dentate gyrus occurs in a specialized
      microenvironment that sustains the generation of neurons during life. To fully
      understand adult neurogenesis, it is essential to determine the neural stem cell 
      (NSC) and progenitor developmental stages, their molecular determinants, and the 
      niche cellular and molecular composition. We report on a single-cell RNA
      sequencing study of the hippocampal niche, performed by isolating all the
      non-neuronal cell populations. Our analysis provides a comprehensive description 
      of the dentate gyrus cells, and it allows the identification of exclusive
      cell-type-specific markers. We define the developmental stages and
      transcriptional dynamics of NSCs and progenitors, and we find that, while NSCs
      represent a heterogeneous cellular continuum, progenitors can be grouped into
      distinct subtypes. We determine the oligodendrocyte lineage and transcriptional
      dynamics, and we describe the microglia transcriptional profile and activation
      state. The combined data constitute a valuable resource to understand regulatory 
      mechanisms of adult neurogenesis.
CI  - Copyright (c) 2017 The Author(s). Published by Elsevier Inc. All rights reserved.
FAU - Artegiani, Benedetta
AU  - Artegiani B
AD  - Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences and University
      Medical Center Utrecht, Cancer Genomics Netherlands, Utrecht, the Netherlands.
FAU - Lyubimova, Anna
AU  - Lyubimova A
AD  - Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences and University
      Medical Center Utrecht, Cancer Genomics Netherlands, Utrecht, the Netherlands.
FAU - Muraro, Mauro
AU  - Muraro M
AD  - Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences and University
      Medical Center Utrecht, Cancer Genomics Netherlands, Utrecht, the Netherlands.
FAU - van Es, Johan H
AU  - van Es JH
AD  - Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences and University
      Medical Center Utrecht, Cancer Genomics Netherlands, Utrecht, the Netherlands.
FAU - van Oudenaarden, Alexander
AU  - van Oudenaarden A
AD  - Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences and University
      Medical Center Utrecht, Cancer Genomics Netherlands, Utrecht, the Netherlands.
FAU - Clevers, Hans
AU  - Clevers H
AD  - Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences and University
      Medical Center Utrecht, Cancer Genomics Netherlands, Utrecht, the Netherlands.
      Electronic address: h.clevers@hubrecht.eu.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cell Rep
JT  - Cell reports
JID - 101573691
OTO - NOTNLM
OT  - adult neurogenesis
OT  - aging
OT  - dentate gyrus
OT  - hippocampal niche
OT  - microglia
OT  - neural progenitors
OT  - neural stem cells
OT  - single cell RNA sequencing
EDAT- 2017/12/16 06:00
MHDA- 2017/12/16 06:00
CRDT- 2017/12/16 06:00
PHST- 2017/06/10 00:00 [received]
PHST- 2017/10/09 00:00 [revised]
PHST- 2017/11/14 00:00 [accepted]
PHST- 2017/12/16 06:00 [entrez]
PHST- 2017/12/16 06:00 [pubmed]
PHST- 2017/12/16 06:00 [medline]
AID - S2211-1247(17)31702-3 [pii]
AID - 10.1016/j.celrep.2017.11.050 [doi]
PST - ppublish
SO  - Cell Rep. 2017 Dec 12;21(11):3271-3284. doi: 10.1016/j.celrep.2017.11.050.

PMID- 29167392
OWN - NLM
STAT- In-Process
LR  - 20171123
IS  - 1946-6242 (Electronic)
IS  - 1946-6234 (Linking)
VI  - 9
IP  - 417
DP  - 2017 Nov 22
TI  - TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and
      leukemic clearance.
LID - eaag1209 [pii]
LID - 10.1126/scitranslmed.aag1209 [doi]
AB  - Chimeric antigen receptor (CAR)-expressing T cells induce durable remissions in
      patients with relapsed/refractory B cell malignancies. CARs are synthetic
      constructs that, when introduced into mature T cells, confer a second, non-major 
      histocompatibility complex-restricted specificity in addition to the endogenous T
      cell receptor (TCR). The implications of TCR activation on CAR T cell efficacy
      has not been well defined. Using an immunocompetent, syngeneic murine model of
      CD19-targeted CAR T cell therapy for pre-B cell acute lymphoblastic leukemia in
      which the CAR is introduced into T cells with known TCR specificity, we
      demonstrate loss of CD8 CAR T cell efficacy associated with T cell exhaustion and
      apoptosis when TCR antigen is present. CD4 CAR T cells demonstrate equivalent
      cytotoxicity to CD8 CAR T cells and, in contrast, retain in vivo efficacy despite
      TCR stimulation. Gene expression profiles confirm increased exhaustion and
      apoptosis of CD8 CAR T cells upon dual receptor stimulation compared to CD4 CAR T
      cells and indicate inherent differences between CD4 and CD8 CAR T cells in the
      use of T cell-associated signaling pathways. These results provide insights into 
      important aspects of CAR T cell immune biology and indicate opportunities to
      rationally design CAR constructs to optimize clinical efficacy.
CI  - Copyright (c) 2017 The Authors, some rights reserved; exclusive licensee American
      Association for the Advancement of Science. No claim to original U.S. Government 
      Works.
FAU - Yang, Yinmeng
AU  - Yang Y
AUID- ORCID: http://orcid.org/0000-0002-5985-4241
AD  - Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute,
      National Institutes of Health, Bethesda, MD 20892, USA.
AD  - Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown
      University, Washington, DC 20057, USA.
FAU - Kohler, M Eric
AU  - Kohler ME
AD  - Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute,
      National Institutes of Health, Bethesda, MD 20892, USA.
AD  - Departments of Pediatric Oncology and Pediatric Hematology, Johns Hopkins
      University, Baltimore, MD 21287, USA.
FAU - Chien, Christopher D
AU  - Chien CD
AUID- ORCID: http://orcid.org/0000-0002-4871-5262
AD  - Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute,
      National Institutes of Health, Bethesda, MD 20892, USA.
FAU - Sauter, Christopher T
AU  - Sauter CT
AUID- ORCID: http://orcid.org/0000-0003-3725-2423
AD  - Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute,
      National Institutes of Health, Bethesda, MD 20892, USA.
FAU - Jacoby, Elad
AU  - Jacoby E
AUID- ORCID: http://orcid.org/0000-0003-1411-8942
AD  - Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute,
      National Institutes of Health, Bethesda, MD 20892, USA.
FAU - Yan, Chunhua
AU  - Yan C
AD  - Center for Biomedical Informatics and Information Technology, National Cancer
      Institute, National Institutes of Health, Bethesda, MD 20892, USA.
FAU - Hu, Ying
AU  - Hu Y
AD  - Center for Biomedical Informatics and Information Technology, National Cancer
      Institute, National Institutes of Health, Bethesda, MD 20892, USA.
FAU - Wanhainen, Kelsey
AU  - Wanhainen K
AD  - Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute,
      National Institutes of Health, Bethesda, MD 20892, USA.
FAU - Qin, Haiying
AU  - Qin H
AUID- ORCID: http://orcid.org/0000-0001-5966-8812
AD  - Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute,
      National Institutes of Health, Bethesda, MD 20892, USA.
FAU - Fry, Terry J
AU  - Fry TJ
AUID- ORCID: http://orcid.org/0000-0001-8044-5226
AD  - Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute,
      National Institutes of Health, Bethesda, MD 20892, USA. fryt@mail.nih.gov.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Sci Transl Med
JT  - Science translational medicine
JID - 101505086
EDAT- 2017/11/24 06:00
MHDA- 2017/11/24 06:00
CRDT- 2017/11/24 06:00
PHST- 2016/05/20 00:00 [received]
PHST- 2017/06/06 00:00 [revised]
PHST- 2017/10/29 00:00 [accepted]
PHST- 2017/11/24 06:00 [entrez]
PHST- 2017/11/24 06:00 [pubmed]
PHST- 2017/11/24 06:00 [medline]
AID - 9/417/eaag1209 [pii]
AID - 10.1126/scitranslmed.aag1209 [doi]
PST - ppublish
SO  - Sci Transl Med. 2017 Nov 22;9(417). pii: 9/417/eaag1209. doi:
      10.1126/scitranslmed.aag1209.

PMID- 29224781
OWN - NLM
STAT- MEDLINE
DCOM- 20171228
LR  - 20180120
IS  - 1097-4172 (Electronic)
IS  - 0092-8674 (Linking)
VI  - 171
IP  - 7
DP  - 2017 Dec 14
TI  - Structural Basis for Regulated Proteolysis by the alpha-Secretase ADAM10.
PG  - 1638-1648.e7
LID - S0092-8674(17)31323-5 [pii]
LID - 10.1016/j.cell.2017.11.014 [doi]
AB  - Cleavage of membrane-anchored proteins by ADAM (a disintegrin and
      metalloproteinase) endopeptidases plays a key role in a wide variety of
      biological signal transduction and protein turnover processes. Among ADAM family 
      members, ADAM10 stands out as particularly important because it is both
      responsible for regulated proteolysis of Notch receptors and catalyzes the
      non-amyloidogenic alpha-secretase cleavage of the Alzheimer's precursor protein
      (APP). We present here the X-ray crystal structure of the ADAM10 ectodomain,
      which, together with biochemical and cellular studies, reveals how access to the 
      enzyme active site is regulated. The enzyme adopts an unanticipated architecture 
      in which the C-terminal cysteine-rich domain partially occludes the enzyme active
      site, preventing unfettered substrate access. Binding of a modulatory antibody to
      the cysteine-rich domain liberates the catalytic domain from autoinhibition,
      enhancing enzymatic activity toward a peptide substrate. Together, these studies 
      reveal a mechanism for regulation of ADAM activity and offer a roadmap for its
      modulation.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Seegar, Tom C M
AU  - Seegar TCM
AD  - Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical
      School, Boston, MA 02115, USA.
FAU - Killingsworth, Lauren B
AU  - Killingsworth LB
AD  - Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical
      School, Boston, MA 02115, USA.
FAU - Saha, Nayanendu
AU  - Saha N
AD  - Structural Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 
      10065, USA.
FAU - Meyer, Peter A
AU  - Meyer PA
AD  - SBGrid Initiative, Harvard Medical School, Boston, MA 02115, USA.
FAU - Patra, Dhabaleswar
AU  - Patra D
AD  - Life Sciences Institute and Department of Biological Chemistry, University of
      Michigan, Ann Arbor, MI 48109, USA.
FAU - Zimmerman, Brandon
AU  - Zimmerman B
AD  - Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical
      School, Boston, MA 02115, USA.
FAU - Janes, Peter W
AU  - Janes PW
AD  - Department of Biochemistry and Molecular Biology, Monash University, VIC 3800,
      Australia.
FAU - Rubinstein, Eric
AU  - Rubinstein E
AD  - Inserm and Universite Paris-Sud, Institut Andre Lwoff, Villejuif, France.
FAU - Nikolov, Dimitar B
AU  - Nikolov DB
AD  - Structural Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 
      10065, USA.
FAU - Skiniotis, Georgios
AU  - Skiniotis G
AD  - Department of Molecular and Cellular Physiology, and Department of Structural
      Biology, Stanford University School of Medicine, Stanford, CA 94305, USA.
FAU - Kruse, Andrew C
AU  - Kruse AC
AD  - Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical
      School, Boston, MA 02115, USA.
FAU - Blacklow, Stephen C
AU  - Blacklow SC
AD  - Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical
      School, Boston, MA 02115, USA. Electronic address:
      stephen_blacklow@hms.harvard.edu.
LA  - eng
GR  - P41 GM103403/GM/NIGMS NIH HHS/United States
GR  - T32 HL007627/HL/NHLBI NIH HHS/United States
GR  - R01 CA092433/CA/NCI NIH HHS/United States
GR  - R01 NS038486/NS/NINDS NIH HHS/United States
GR  - R35 CA220340/CA/NCI NIH HHS/United States
GR  - P01 CA119070/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20171207
PL  - United States
TA  - Cell
JT  - Cell
JID - 0413066
RN  - 0 (Membrane Proteins)
RN  - 0 (Receptors, Notch)
RN  - EC 3.4.- (Amyloid Precursor Protein Secretases)
RN  - EC 3.4.24.81 (ADAM10 Protein)
RN  - EC 3.4.24.81 (ADAM10 protein, human)
SB  - IM
MH  - ADAM10 Protein/*chemistry/metabolism
MH  - Amyloid Precursor Protein Secretases/*chemistry/metabolism
MH  - Crystallography, X-Ray
MH  - Humans
MH  - Membrane Proteins/*chemistry/metabolism
MH  - Models, Molecular
MH  - *Proteolysis
MH  - Receptors, Notch/metabolism
MH  - Signal Transduction
PMC - PMC5773094
MID - NIHMS919617
OTO - NOTNLM
OT  - ADAM10
OT  - Notch signaling
OT  - X-ray crystallography
OT  - amyloid precursor protein
EDAT- 2017/12/12 06:00
MHDA- 2017/12/29 06:00
CRDT- 2017/12/12 06:00
PMCR- 2018/12/14 00:00
PHST- 2017/07/12 00:00 [received]
PHST- 2017/10/10 00:00 [revised]
PHST- 2017/11/08 00:00 [accepted]
PHST- 2018/12/14 00:00 [pmc-release]
PHST- 2017/12/12 06:00 [pubmed]
PHST- 2017/12/29 06:00 [medline]
PHST- 2017/12/12 06:00 [entrez]
AID - S0092-8674(17)31323-5 [pii]
AID - 10.1016/j.cell.2017.11.014 [doi]
PST - ppublish
SO  - Cell. 2017 Dec 14;171(7):1638-1648.e7. doi: 10.1016/j.cell.2017.11.014. Epub 2017
      Dec 7.

PMID- 29348365
OWN - NLM
STAT- Publisher
LR  - 20180119
IS  - 1095-9203 (Electronic)
IS  - 0036-8075 (Linking)
DP  - 2018 Jan 18
TI  - Detection and localization of surgically resectable cancers with a multi-analyte 
      blood test.
LID - eaar3247 [pii]
LID - 10.1126/science.aar3247 [doi]
AB  - Earlier detection is key to reducing cancer deaths. Here we describe a blood test
      that can detect eight common cancer types through assessment of the levels of
      circulating proteins and mutations in cell-free DNA. We applied this test, called
      CancerSEEK, to 1,005 patients with non-metastatic, clinically detected cancers of
      the ovary, liver, stomach, pancreas, esophagus, colorectum, lung, or breast.
      CancerSEEK tests were positive in a median of 70% of the eight cancer types. The 
      sensitivities ranged from 69% to 98% for the detection of five cancer types
      (ovary, liver, stomach, pancreas, and esophagus) for which there are no screening
      tests available for average-risk individuals. The specificity of CancerSEEK was >
      99%: only 7 of 812 healthy controls scored positive. In addition, CancerSEEK
      localized the cancer to a small number of anatomic sites in a median of 83% of
      the patients.
CI  - Copyright (c) 2018, American Association for the Advancement of Science.
FAU - Cohen, Joshua D
AU  - Cohen JD
AUID- ORCID: http://orcid.org/0000-0003-1158-5668
AD  - Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University
      School of Medicine, Baltimore, MD 21205, USA.
AD  - Howard Hughes Medical Institute, Johns Hopkins University School of Medicine,
      Baltimore, MD 21205, USA.
AD  - Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine,
      Baltimore, MD 21205, USA.
AD  - Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of
      Medicine, Baltimore, MD 21205, USA.
AD  - Department of Biomedical Engineering, Johns Hopkins University School of
      Medicine, Baltimore, MD 21205, USA.
FAU - Li, Lu
AU  - Li L
AUID- ORCID: http://orcid.org/0000-0002-1920-4965
AD  - Department of Biostatistics, Johns Hopkins University Bloomberg School of Public 
      Health, Baltimore, MD 21205, USA.
FAU - Wang, Yuxuan
AU  - Wang Y
AUID- ORCID: http://orcid.org/0000-0002-2932-6042
AD  - Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University
      School of Medicine, Baltimore, MD 21205, USA.
AD  - Howard Hughes Medical Institute, Johns Hopkins University School of Medicine,
      Baltimore, MD 21205, USA.
AD  - Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine,
      Baltimore, MD 21205, USA.
AD  - Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of
      Medicine, Baltimore, MD 21205, USA.
FAU - Thoburn, Christopher
AU  - Thoburn C
AUID- ORCID: http://orcid.org/0000-0001-7743-9183
AD  - Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine,
      Baltimore, MD 21205, USA.
FAU - Afsari, Bahman
AU  - Afsari B
AD  - Division of Biostatistics and Bioinformatics, Department of Oncology, Johns
      Hopkins Medical Institutions, Baltimore, MD 21287, USA.
FAU - Danilova, Ludmila
AU  - Danilova L
AUID- ORCID: http://orcid.org/0000-0003-2813-3094
AD  - Division of Biostatistics and Bioinformatics, Department of Oncology, Johns
      Hopkins Medical Institutions, Baltimore, MD 21287, USA.
FAU - Douville, Christopher
AU  - Douville C
AUID- ORCID: http://orcid.org/0000-0002-2510-4151
AD  - Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University
      School of Medicine, Baltimore, MD 21205, USA.
AD  - Howard Hughes Medical Institute, Johns Hopkins University School of Medicine,
      Baltimore, MD 21205, USA.
AD  - Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine,
      Baltimore, MD 21205, USA.
AD  - Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of
      Medicine, Baltimore, MD 21205, USA.
FAU - Javed, Ammar A
AU  - Javed AA
AUID- ORCID: http://orcid.org/0000-0002-5463-5250
AD  - Department of Surgery, Johns Hopkins Medical Institutions, Baltimore, MD 21287,
      USA.
FAU - Wong, Fay
AU  - Wong F
AUID- ORCID: http://orcid.org/0000-0001-9759-3778
AD  - Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University
      School of Medicine, Baltimore, MD 21205, USA.
AD  - Howard Hughes Medical Institute, Johns Hopkins University School of Medicine,
      Baltimore, MD 21205, USA.
AD  - Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine,
      Baltimore, MD 21205, USA.
AD  - Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of
      Medicine, Baltimore, MD 21205, USA.
FAU - Mattox, Austin
AU  - Mattox A
AUID- ORCID: http://orcid.org/0000-0002-7567-5542
AD  - Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University
      School of Medicine, Baltimore, MD 21205, USA.
AD  - Howard Hughes Medical Institute, Johns Hopkins University School of Medicine,
      Baltimore, MD 21205, USA.
AD  - Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine,
      Baltimore, MD 21205, USA.
AD  - Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of
      Medicine, Baltimore, MD 21205, USA.
FAU - Hruban, Ralph H
AU  - Hruban RH
AD  - Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine,
      Baltimore, MD 21205, USA.
AD  - Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of
      Medicine, Baltimore, MD 21205, USA.
AD  - Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21287,
      USA.
FAU - Wolfgang, Christopher L
AU  - Wolfgang CL
AUID- ORCID: http://orcid.org/0000-0002-8717-0373
AD  - Department of Surgery, Johns Hopkins Medical Institutions, Baltimore, MD 21287,
      USA.
FAU - Goggins, Michael G
AU  - Goggins MG
AD  - Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine,
      Baltimore, MD 21205, USA.
AD  - Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of
      Medicine, Baltimore, MD 21205, USA.
AD  - Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21287,
      USA.
AD  - Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, MD 21287, 
      USA.
AD  - Department of Oncology, Johns Hopkins Medical Institutions, Baltimore, MD 21287, 
      USA.
FAU - Dal Molin, Marco
AU  - Dal Molin M
AD  - Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of
      Medicine, Baltimore, MD 21205, USA.
FAU - Wang, Tian-Li
AU  - Wang TL
AD  - Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine,
      Baltimore, MD 21205, USA.
AD  - Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21287,
      USA.
FAU - Roden, Richard
AU  - Roden R
AUID- ORCID: http://orcid.org/0000-0002-2506-0195
AD  - Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine,
      Baltimore, MD 21205, USA.
AD  - Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21287,
      USA.
FAU - Klein, Alison P
AU  - Klein AP
AUID- ORCID: http://orcid.org/0000-0003-2737-8399
AD  - Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine,
      Baltimore, MD 21205, USA.
AD  - Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of
      Medicine, Baltimore, MD 21205, USA.
AD  - Department of Epidemiology, Johns Hopkins University Bloomberg School of Public
      Health, Baltimore, MD 21205, USA.
FAU - Ptak, Janine
AU  - Ptak J
AUID- ORCID: http://orcid.org/0000-0003-1934-8739
AD  - Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University
      School of Medicine, Baltimore, MD 21205, USA.
AD  - Howard Hughes Medical Institute, Johns Hopkins University School of Medicine,
      Baltimore, MD 21205, USA.
AD  - Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine,
      Baltimore, MD 21205, USA.
AD  - Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of
      Medicine, Baltimore, MD 21205, USA.
FAU - Dobbyn, Lisa
AU  - Dobbyn L
AUID- ORCID: http://orcid.org/0000-0002-3159-189X
AD  - Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University
      School of Medicine, Baltimore, MD 21205, USA.
AD  - Howard Hughes Medical Institute, Johns Hopkins University School of Medicine,
      Baltimore, MD 21205, USA.
AD  - Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine,
      Baltimore, MD 21205, USA.
AD  - Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of
      Medicine, Baltimore, MD 21205, USA.
FAU - Schaefer, Joy
AU  - Schaefer J
AUID- ORCID: http://orcid.org/0000-0001-6788-8989
AD  - Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University
      School of Medicine, Baltimore, MD 21205, USA.
AD  - Howard Hughes Medical Institute, Johns Hopkins University School of Medicine,
      Baltimore, MD 21205, USA.
AD  - Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine,
      Baltimore, MD 21205, USA.
AD  - Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of
      Medicine, Baltimore, MD 21205, USA.
FAU - Silliman, Natalie
AU  - Silliman N
AUID- ORCID: http://orcid.org/0000-0002-5198-9037
AD  - Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University
      School of Medicine, Baltimore, MD 21205, USA.
AD  - Howard Hughes Medical Institute, Johns Hopkins University School of Medicine,
      Baltimore, MD 21205, USA.
AD  - Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine,
      Baltimore, MD 21205, USA.
AD  - Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of
      Medicine, Baltimore, MD 21205, USA.
FAU - Popoli, Maria
AU  - Popoli M
AD  - Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University
      School of Medicine, Baltimore, MD 21205, USA.
AD  - Howard Hughes Medical Institute, Johns Hopkins University School of Medicine,
      Baltimore, MD 21205, USA.
AD  - Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine,
      Baltimore, MD 21205, USA.
AD  - Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of
      Medicine, Baltimore, MD 21205, USA.
FAU - Vogelstein, Joshua T
AU  - Vogelstein JT
AD  - Institute for Computational Medicine, Johns Hopkins University School of
      Medicine, Baltimore, MD 21205, USA.
FAU - Browne, James D
AU  - Browne JD
AD  - Department of Computer Science, Johns Hopkins University Whiting School of
      Engineering, Baltimore, MD 21218 USA.
FAU - Schoen, Robert E
AU  - Schoen RE
AUID- ORCID: http://orcid.org/0000-0001-7153-2766
AD  - Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15260 USA.
AD  - Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA 15260 USA.
FAU - Brand, Randall E
AU  - Brand RE
AUID- ORCID: http://orcid.org/0000-0002-4136-3313
AD  - Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15260 USA.
FAU - Tie, Jeanne
AU  - Tie J
AUID- ORCID: http://orcid.org/0000-0001-9244-2057
AD  - Division of Systems Biology and Personalized Medicine, Walter and Eliza Hall
      Institute of Medical Research, Parkville, VIC 3021, Australia.
AD  - Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne,
      Melbourne, VIC 3010, Australia.
AD  - Department of Medical Oncology, Western Health, Melbourne, VIC 3021, Australia.
AD  - Department of Medical Oncology, Peter MacCallum Cancer Center, Melbourne, VIC
      3000, Australia.
FAU - Gibbs, Peter
AU  - Gibbs P
AD  - Division of Systems Biology and Personalized Medicine, Walter and Eliza Hall
      Institute of Medical Research, Parkville, VIC 3021, Australia.
AD  - Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne,
      Melbourne, VIC 3010, Australia.
AD  - Department of Medical Oncology, Western Health, Melbourne, VIC 3021, Australia.
AD  - Department of Medical Oncology, Peter MacCallum Cancer Center, Melbourne, VIC
      3000, Australia.
FAU - Wong, Hui-Li
AU  - Wong HL
AUID- ORCID: http://orcid.org/0000-0003-3803-2107
AD  - Division of Systems Biology and Personalized Medicine, Walter and Eliza Hall
      Institute of Medical Research, Parkville, VIC 3021, Australia.
FAU - Mansfield, Aaron S
AU  - Mansfield AS
AUID- ORCID: http://orcid.org/0000-0002-9483-6903
AD  - Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, MN 
      55902 USA.
FAU - Jen, Jin
AU  - Jen J
AUID- ORCID: http://orcid.org/0000-0002-8790-9836
AD  - Division of Experimental Pathology, Department of Laboratory Medicine and
      Pathology, Mayo Clinic, Rochester, MN 55902 USA.
FAU - Hanash, Samir M
AU  - Hanash SM
AD  - Sheikh Ahmed Center for Pancreatic Cancer Research, University of Texas MD
      Anderson Cancer Center, Houston, TX 77030 USA.
FAU - Falconi, Massimo
AU  - Falconi M
AD  - Division of Pancreatic Surgery, Department of Surgery, San Raffaele Scientific
      Institute Research Hospital, 20132 Milan, Italy.
FAU - Allen, Peter J
AU  - Allen PJ
AD  - Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10065
      USA.
FAU - Zhou, Shibin
AU  - Zhou S
AUID- ORCID: http://orcid.org/0000-0003-1941-4425
AD  - Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University
      School of Medicine, Baltimore, MD 21205, USA.
AD  - Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine,
      Baltimore, MD 21205, USA.
AD  - Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of
      Medicine, Baltimore, MD 21205, USA.
FAU - Bettegowda, Chetan
AU  - Bettegowda C
AD  - Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University
      School of Medicine, Baltimore, MD 21205, USA.
AD  - Howard Hughes Medical Institute, Johns Hopkins University School of Medicine,
      Baltimore, MD 21205, USA.
AD  - Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine,
      Baltimore, MD 21205, USA.
AD  - Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of
      Medicine, Baltimore, MD 21205, USA.
FAU - Diaz, Luis
AU  - Diaz L
AUID- ORCID: http://orcid.org/0000-0002-7079-8914
AD  - Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University
      School of Medicine, Baltimore, MD 21205, USA.
AD  - Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine,
      Baltimore, MD 21205, USA.
AD  - Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of
      Medicine, Baltimore, MD 21205, USA.
FAU - Tomasetti, Cristian
AU  - Tomasetti C
AUID- ORCID: http://orcid.org/0000-0003-3277-4804
AD  - Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine,
      Baltimore, MD 21205, USA. ctomasetti@jhu.edu amlennon@jhmi.edu kinzlke@jhmi.edu
      bertvog@gmail.com npapado1@jhmi.edu.
AD  - Department of Biostatistics, Johns Hopkins University Bloomberg School of Public 
      Health, Baltimore, MD 21205, USA.
AD  - Division of Biostatistics and Bioinformatics, Department of Oncology, Johns
      Hopkins Medical Institutions, Baltimore, MD 21287, USA.
FAU - Kinzler, Kenneth W
AU  - Kinzler KW
AUID- ORCID: http://orcid.org/0000-0001-5591-1176
AD  - Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University
      School of Medicine, Baltimore, MD 21205, USA. ctomasetti@jhu.edu
      amlennon@jhmi.edu kinzlke@jhmi.edu bertvog@gmail.com npapado1@jhmi.edu.
AD  - Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine,
      Baltimore, MD 21205, USA.
AD  - Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of
      Medicine, Baltimore, MD 21205, USA.
FAU - Vogelstein, Bert
AU  - Vogelstein B
AUID- ORCID: http://orcid.org/0000-0003-0766-3854
AD  - Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University
      School of Medicine, Baltimore, MD 21205, USA. ctomasetti@jhu.edu
      amlennon@jhmi.edu kinzlke@jhmi.edu bertvog@gmail.com npapado1@jhmi.edu.
AD  - Howard Hughes Medical Institute, Johns Hopkins University School of Medicine,
      Baltimore, MD 21205, USA.
AD  - Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine,
      Baltimore, MD 21205, USA.
AD  - Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of
      Medicine, Baltimore, MD 21205, USA.
FAU - Lennon, Anne Marie
AU  - Lennon AM
AUID- ORCID: http://orcid.org/0000-0001-8957-3945
AD  - Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine,
      Baltimore, MD 21205, USA. ctomasetti@jhu.edu amlennon@jhmi.edu kinzlke@jhmi.edu
      bertvog@gmail.com npapado1@jhmi.edu.
AD  - Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of
      Medicine, Baltimore, MD 21205, USA.
AD  - Department of Surgery, Johns Hopkins Medical Institutions, Baltimore, MD 21287,
      USA.
AD  - Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, MD 21287, 
      USA.
AD  - Department of Oncology, Johns Hopkins Medical Institutions, Baltimore, MD 21287, 
      USA.
FAU - Papadopoulos, Nickolas
AU  - Papadopoulos N
AUID- ORCID: http://orcid.org/0000-0001-7135-7451
AD  - Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University
      School of Medicine, Baltimore, MD 21205, USA. ctomasetti@jhu.edu
      amlennon@jhmi.edu kinzlke@jhmi.edu bertvog@gmail.com npapado1@jhmi.edu.
AD  - Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine,
      Baltimore, MD 21205, USA.
AD  - Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of
      Medicine, Baltimore, MD 21205, USA.
LA  - eng
PT  - Journal Article
DEP - 20180118
PL  - United States
TA  - Science
JT  - Science (New York, N.Y.)
JID - 0404511
EDAT- 2018/01/20 06:00
MHDA- 2018/01/20 06:00
CRDT- 2018/01/20 06:00
PHST- 2017/10/31 00:00 [received]
PHST- 2018/01/08 00:00 [accepted]
PHST- 2018/01/20 06:00 [entrez]
PHST- 2018/01/20 06:00 [pubmed]
PHST- 2018/01/20 06:00 [medline]
AID - science.aar3247 [pii]
AID - 10.1126/science.aar3247 [doi]
PST - aheadofprint
SO  - Science. 2018 Jan 18. pii: science.aar3247. doi: 10.1126/science.aar3247.

PMID- 29158380
OWN - NLM
STAT- In-Data-Review
LR  - 20171219
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Linking)
VI  - 114
IP  - 49
DP  - 2017 Dec 5
TI  - Anti-SIRPalpha antibody immunotherapy enhances neutrophil and macrophage
      antitumor activity.
PG  - E10578-E10585
LID - 10.1073/pnas.1710877114 [doi]
AB  - Cancer immunotherapy has emerged as a promising therapeutic intervention.
      However, complete and durable responses are only seen in a fraction of patients
      who have cancer. A key factor that limits therapeutic success is the infiltration
      of tumors by cells of the myeloid lineage. The inhibitory receptor signal
      regulatory protein-alpha (SIRPalpha) is a myeloid-specific immune checkpoint that
      engages the "don't eat me" signal CD47 expressed on tumors and normal tissues. We
      therefore developed the monoclonal antibody KWAR23, which binds human SIRPalpha
      with high affinity and disrupts its binding to CD47. Administered by itself,
      KWAR23 is inert, but given in combination with tumor-opsonizing monoclonal
      antibodies, KWAR23 greatly augments myeloid cell-dependent killing of a
      collection of hematopoietic and nonhematopoietic human tumor-derived cell lines. 
      Following KWAR23 antibody treatment in a human SIRPA knockin mouse model, both
      neutrophils and macrophages infiltrate a human Burkitt's lymphoma xenograft and
      inhibit tumor growth, generating complete responses in the majority of treated
      animals. We further demonstrate that a bispecific anti-CD70/SIRPalpha antibody
      outperforms individually delivered antibodies in specific types of cancers. These
      studies demonstrate that SIRPalpha blockade induces potent antitumor activity by 
      targeting multiple myeloid cell subsets that frequently infiltrate tumors. Thus, 
      KWAR23 represents a promising candidate for combination therapy.
FAU - Ring, Nan Guo
AU  - Ring NG
AD  - Institute for Stem Cell Biology and Regenerative Medicine, and Ludwig Center for 
      Cancer Stem Cell Research, Stanford University School of Medicine, Stanford, CA
      94305.
AD  - Department of Immunobiology, Yale University School of Medicine, New Haven, CT
      06520.
FAU - Herndler-Brandstetter, Dietmar
AU  - Herndler-Brandstetter D
AD  - Department of Immunobiology, Yale University School of Medicine, New Haven, CT
      06520.
FAU - Weiskopf, Kipp
AU  - Weiskopf K
AD  - Institute for Stem Cell Biology and Regenerative Medicine, and Ludwig Center for 
      Cancer Stem Cell Research, Stanford University School of Medicine, Stanford, CA
      94305.
FAU - Shan, Liang
AU  - Shan L
AD  - Department of Immunobiology, Yale University School of Medicine, New Haven, CT
      06520.
FAU - Volkmer, Jens-Peter
AU  - Volkmer JP
AD  - Institute for Stem Cell Biology and Regenerative Medicine, and Ludwig Center for 
      Cancer Stem Cell Research, Stanford University School of Medicine, Stanford, CA
      94305.
FAU - George, Benson M
AU  - George BM
AD  - Institute for Stem Cell Biology and Regenerative Medicine, and Ludwig Center for 
      Cancer Stem Cell Research, Stanford University School of Medicine, Stanford, CA
      94305.
FAU - Lietzenmayer, Melanie
AU  - Lietzenmayer M
AD  - Department of Immunobiology, Yale University School of Medicine, New Haven, CT
      06520.
FAU - McKenna, Kelly M
AU  - McKenna KM
AD  - Institute for Stem Cell Biology and Regenerative Medicine, and Ludwig Center for 
      Cancer Stem Cell Research, Stanford University School of Medicine, Stanford, CA
      94305.
FAU - Naik, Tejaswitha J
AU  - Naik TJ
AD  - Institute for Stem Cell Biology and Regenerative Medicine, and Ludwig Center for 
      Cancer Stem Cell Research, Stanford University School of Medicine, Stanford, CA
      94305.
FAU - McCarty, Aaron
AU  - McCarty A
AD  - Institute for Stem Cell Biology and Regenerative Medicine, and Ludwig Center for 
      Cancer Stem Cell Research, Stanford University School of Medicine, Stanford, CA
      94305.
FAU - Zheng, Yunjiang
AU  - Zheng Y
AD  - Department of Immunobiology, Yale University School of Medicine, New Haven, CT
      06520.
FAU - Ring, Aaron M
AU  - Ring AM
AD  - Department of Immunobiology, Yale University School of Medicine, New Haven, CT
      06520.
FAU - Flavell, Richard A
AU  - Flavell RA
AD  - Department of Immunobiology, Yale University School of Medicine, New Haven, CT
      06520; richard.flavell@yale.edu irv@stanford.edu.
AD  - Howard Hughes Medical Institute, New Haven, CT 06520.
FAU - Weissman, Irving L
AU  - Weissman IL
AD  - Institute for Stem Cell Biology and Regenerative Medicine, and Ludwig Center for 
      Cancer Stem Cell Research, Stanford University School of Medicine, Stanford, CA
      94305; richard.flavell@yale.edu irv@stanford.edu.
LA  - eng
GR  - K99 AI125065/AI/NIAID NIH HHS/United States
GR  - T32 AI007019/AI/NIAID NIH HHS/United States
GR  - T32 GM007365/GM/NIGMS NIH HHS/United States
PT  - Journal Article
DEP - 20171120
PL  - United States
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
PMC - PMC5724266
OTO - NOTNLM
OT  - SIRPA
OT  - bispecific antibody
OT  - cancer immunotherapy
OT  - humanized mouse
OT  - myeloid cells
COIS- Conflict of interest statement: K.W., A.M.R., and I.L.W. are shareholders of
      Forty Seven, Inc., and have filed a patent application that describes the human
      anti-SIRPalpha antibody KWAR23. I.L.W. is co-inventor of the patent, and
      co-founder and director of the company that has licensed the antibody.
EDAT- 2017/11/22 06:00
MHDA- 2017/11/22 06:00
CRDT- 2017/11/22 06:00
PMCR- 2018/06/05 00:00
PHST- 2018/06/05 00:00 [pmc-release]
PHST- 2017/11/22 06:00 [pubmed]
PHST- 2017/11/22 06:00 [medline]
PHST- 2017/11/22 06:00 [entrez]
AID - 1710877114 [pii]
AID - 10.1073/pnas.1710877114 [doi]
PST - ppublish
SO  - Proc Natl Acad Sci U S A. 2017 Dec 5;114(49):E10578-E10585. doi:
      10.1073/pnas.1710877114. Epub 2017 Nov 20.

PMID- 29144447
OWN - NLM
STAT- In-Data-Review
LR  - 20171219
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 551
IP  - 7680
DP  - 2017 Nov 16
TI  - BCAT1 restricts alphaKG levels in AML stem cells leading to IDHmut-like DNA
      hypermethylation.
PG  - 384-388
LID - 10.1038/nature24294 [doi]
AB  - The branched-chain amino acid (BCAA) pathway and high levels of BCAA transaminase
      1 (BCAT1) have recently been associated with aggressiveness in several cancer
      entities. However, the mechanistic role of BCAT1 in this process remains largely 
      uncertain. Here, by performing high-resolution proteomic analysis of human acute 
      myeloid leukaemia (AML) stem-cell and non-stem-cell populations, we find the BCAA
      pathway enriched and BCAT1 protein and transcripts overexpressed in leukaemia
      stem cells. We show that BCAT1, which transfers alpha-amino groups from BCAAs to 
      alpha-ketoglutarate (alphaKG), is a critical regulator of intracellular alphaKG
      homeostasis. Further to its role in the tricarboxylic acid cycle, alphaKG is an
      essential cofactor for alphaKG-dependent dioxygenases such as Egl-9 family
      hypoxia inducible factor 1 (EGLN1) and the ten-eleven translocation (TET) family 
      of DNA demethylases. Knockdown of BCAT1 in leukaemia cells caused accumulation of
      alphaKG, leading to EGLN1-mediated HIF1alpha protein degradation. This resulted
      in a growth and survival defect and abrogated leukaemia-initiating potential. By 
      contrast, overexpression of BCAT1 in leukaemia cells decreased intracellular
      alphaKG levels and caused DNA hypermethylation through altered TET activity. AML 
      with high levels of BCAT1 (BCAT1(high)) displayed a DNA hypermethylation
      phenotype similar to cases carrying a mutant isocitrate dehydrogenase (IDH(mut)),
      in which TET2 is inhibited by the oncometabolite 2-hydroxyglutarate. High levels 
      of BCAT1 strongly correlate with shorter overall survival in IDH(WT)TET2(WT), but
      not IDH(mut) or TET2(mut) AML. Gene sets characteristic for IDH(mut) AML were
      enriched in samples from patients with an IDH(WT)TET2(WT)BCAT1(high) status.
      BCAT1(high) AML showed robust enrichment for leukaemia stem-cell signatures, and 
      paired sample analysis showed a significant increase in BCAT1 levels upon disease
      relapse. In summary, by limiting intracellular alphaKG, BCAT1 links BCAA
      catabolism to HIF1alpha stability and regulation of the epigenomic landscape,
      mimicking the effects of IDH mutations. Our results suggest the
      BCAA-BCAT1-alphaKG pathway as a therapeutic target to compromise leukaemia
      stem-cell function in patients with IDH(WT)TET2(WT) AML.
FAU - Raffel, Simon
AU  - Raffel S
AD  - Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM 
      gGmbH), 69120 Heidelberg, Germany.
AD  - Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ) and
      DKFZ-ZMBH Alliance, 69120 Heidelberg, Germany.
AD  - Department of Internal Medicine V, Heidelberg University Hospital, 69120
      Heidelberg, Germany.
FAU - Falcone, Mattia
AU  - Falcone M
AD  - Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM 
      gGmbH), 69120 Heidelberg, Germany.
AD  - Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ) and
      DKFZ-ZMBH Alliance, 69120 Heidelberg, Germany.
FAU - Kneisel, Niclas
AU  - Kneisel N
AD  - Division of Molecular Genetics, German Cancer Research Center (DKFZ), 69120
      Heidelberg, Germany.
FAU - Hansson, Jenny
AU  - Hansson J
AD  - Genome Biology Unit, European Molecular Biology Laboratory (EMBL), 69117
      Heidelberg, Germany.
FAU - Wang, Wei
AU  - Wang W
AD  - Division of Molecular Genetics, German Cancer Research Center (DKFZ), 69120
      Heidelberg, Germany.
FAU - Lutz, Christoph
AU  - Lutz C
AD  - Department of Internal Medicine V, Heidelberg University Hospital, 69120
      Heidelberg, Germany.
FAU - Bullinger, Lars
AU  - Bullinger L
AD  - Department of Internal Medicine III, University Hospital Ulm, 89081 Ulm, Germany.
FAU - Poschet, Gernot
AU  - Poschet G
AD  - Centre for Organismal Studies (COS), University of Heidelberg, 69120 Heidelberg, 
      Germany.
FAU - Nonnenmacher, Yannic
AU  - Nonnenmacher Y
AD  - Department of Bioinfomatics and Biochemistry and Braunschweig Integrated Center
      of Systems Biology (BRICS), Technical University Braunschweig, 38106
      Braunschweig, Germany.
AD  - Luxemburg Centre for Systems Biomedicine, University of Luxemburg, L-4367
      Belvaux, Luxemburg.
FAU - Barnert, Andrea
AU  - Barnert A
AD  - Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM 
      gGmbH), 69120 Heidelberg, Germany.
AD  - Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ) and
      DKFZ-ZMBH Alliance, 69120 Heidelberg, Germany.
FAU - Bahr, Carsten
AU  - Bahr C
AD  - Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM 
      gGmbH), 69120 Heidelberg, Germany.
AD  - Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ) and
      DKFZ-ZMBH Alliance, 69120 Heidelberg, Germany.
FAU - Zeisberger, Petra
AU  - Zeisberger P
AD  - Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM 
      gGmbH), 69120 Heidelberg, Germany.
AD  - Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ) and
      DKFZ-ZMBH Alliance, 69120 Heidelberg, Germany.
FAU - Przybylla, Adriana
AU  - Przybylla A
AD  - Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM 
      gGmbH), 69120 Heidelberg, Germany.
AD  - Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ) and
      DKFZ-ZMBH Alliance, 69120 Heidelberg, Germany.
FAU - Sohn, Markus
AU  - Sohn M
AD  - Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM 
      gGmbH), 69120 Heidelberg, Germany.
AD  - Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ) and
      DKFZ-ZMBH Alliance, 69120 Heidelberg, Germany.
FAU - Tonjes, Martje
AU  - Tonjes M
AD  - Division of Molecular Genetics, German Cancer Research Center (DKFZ), 69120
      Heidelberg, Germany.
FAU - Erez, Ayelet
AU  - Erez A
AD  - Department of Biological Regulation, Weizmann Institute of Science, Rehovot,
      Israel.
FAU - Adler, Lital
AU  - Adler L
AD  - Department of Biological Regulation, Weizmann Institute of Science, Rehovot,
      Israel.
FAU - Jensen, Patrizia
AU  - Jensen P
AD  - Department of Translational Oncology, National Center for Tumor Diseases (NCT)
      Heidelberg and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
FAU - Scholl, Claudia
AU  - Scholl C
AD  - Division of Applied Functional Genomics, German Cancer Research Center (DKFZ),
      69120 Heidelberg, Germany.
AD  - German Cancer Consortium (DKTK), DKFZ, 69120 Heidelberg, Germany.
FAU - Frohling, Stefan
AU  - Frohling S
AD  - Department of Translational Oncology, National Center for Tumor Diseases (NCT)
      Heidelberg and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
AD  - Section for Personalized Oncology, Heidelberg University Hospital, 69120
      Heidelberg, Germany.
AD  - German Cancer Consortium (DKTK), DKFZ, 69120 Heidelberg, Germany.
FAU - Cocciardi, Sibylle
AU  - Cocciardi S
AD  - Department of Internal Medicine III, University Hospital Ulm, 89081 Ulm, Germany.
FAU - Wuchter, Patrick
AU  - Wuchter P
AD  - Department of Internal Medicine V, Heidelberg University Hospital, 69120
      Heidelberg, Germany.
AD  - Institute of Transfusion Medicine and Immunology Mannheim, Medical Faculty
      Mannheim, Heidelberg University, German Red Cross Blood Service
      Baden-Wurttemberg-Hessen, 68167 Mannheim, Germany.
FAU - Thiede, Christian
AU  - Thiede C
AD  - Medical Department 1, University Hospital Carl Gustav Carus, 01307 Dresden,
      Germany.
FAU - Florcken, Anne
AU  - Florcken A
AD  - Department of Hematology, Oncology and Tumor Immunology; Charite-University
      Medicine Berlin, Campus Virchow Klinikum, 13353 Berlin, Germany.
FAU - Westermann, Jorg
AU  - Westermann J
AD  - Department of Hematology, Oncology and Tumor Immunology; Charite-University
      Medicine Berlin, Campus Virchow Klinikum, 13353 Berlin, Germany.
FAU - Ehninger, Gerhard
AU  - Ehninger G
AD  - Department of Hematology, Oncology and Tumor Immunology; Charite-University
      Medicine Berlin, Campus Virchow Klinikum, 13353 Berlin, Germany.
FAU - Lichter, Peter
AU  - Lichter P
AD  - Division of Molecular Genetics, German Cancer Research Center (DKFZ), 69120
      Heidelberg, Germany.
AD  - German Cancer Consortium (DKTK), DKFZ, 69120 Heidelberg, Germany.
FAU - Hiller, Karsten
AU  - Hiller K
AD  - Department of Bioinfomatics and Biochemistry and Braunschweig Integrated Center
      of Systems Biology (BRICS), Technical University Braunschweig, 38106
      Braunschweig, Germany.
AD  - Luxemburg Centre for Systems Biomedicine, University of Luxemburg, L-4367
      Belvaux, Luxemburg.
FAU - Hell, Rudiger
AU  - Hell R
AD  - Centre for Organismal Studies (COS), University of Heidelberg, 69120 Heidelberg, 
      Germany.
FAU - Herrmann, Carl
AU  - Herrmann C
AD  - Division of Theoretical Bioinformatics, German Cancer Research Center (DKFZ),
      69120 Heidelberg, Germany.
AD  - Institute of Pharmacy and Molecular Biotechnology, and Bioquant Center,
      University of Heidelberg, 69120 Heidelberg, Germany.
FAU - Ho, Anthony D
AU  - Ho AD
AD  - Department of Internal Medicine V, Heidelberg University Hospital, 69120
      Heidelberg, Germany.
FAU - Krijgsveld, Jeroen
AU  - Krijgsveld J
AD  - Genome Biology Unit, European Molecular Biology Laboratory (EMBL), 69117
      Heidelberg, Germany.
FAU - Radlwimmer, Bernhard
AU  - Radlwimmer B
AD  - Division of Molecular Genetics, German Cancer Research Center (DKFZ), 69120
      Heidelberg, Germany.
AD  - German Cancer Consortium (DKTK), DKFZ, 69120 Heidelberg, Germany.
FAU - Trumpp, Andreas
AU  - Trumpp A
AD  - Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM 
      gGmbH), 69120 Heidelberg, Germany.
AD  - Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ) and
      DKFZ-ZMBH Alliance, 69120 Heidelberg, Germany.
AD  - German Cancer Consortium (DKTK), DKFZ, 69120 Heidelberg, Germany.
LA  - eng
PT  - Journal Article
DEP - 20171108
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
EDAT- 2017/11/17 06:00
MHDA- 2017/11/17 06:00
CRDT- 2017/11/17 06:00
PHST- 2017/03/06 00:00 [received]
PHST- 2017/09/19 00:00 [accepted]
PHST- 2017/11/17 06:00 [entrez]
PHST- 2017/11/17 06:00 [pubmed]
PHST- 2017/11/17 06:00 [medline]
AID - nature24294 [pii]
AID - 10.1038/nature24294 [doi]
PST - ppublish
SO  - Nature. 2017 Nov 16;551(7680):384-388. doi: 10.1038/nature24294. Epub 2017 Nov 8.

PMID- 29224778
OWN - NLM
STAT- In-Data-Review
LR  - 20180112
IS  - 1097-4172 (Electronic)
IS  - 0092-8674 (Linking)
VI  - 172
IP  - 1-2
DP  - 2018 Jan 11
TI  - Rapid Mobilization Reveals a Highly Engraftable Hematopoietic Stem Cell.
PG  - 191-204.e10
LID - S0092-8674(17)31312-0 [pii]
LID - 10.1016/j.cell.2017.11.003 [doi]
AB  - Hematopoietic stem cell transplantation is a potential curative therapy for
      malignant and nonmalignant diseases. Improving the efficiency of stem cell
      collection and the quality of the cells acquired can broaden the donor pool and
      improve patient outcomes. We developed a rapid stem cell mobilization regimen
      utilizing a unique CXCR2 agonist, GRObeta, and the CXCR4 antagonist AMD3100. A
      single injection of both agents resulted in stem cell mobilization peaking within
      15 min that was equivalent in magnitude to a standard multi-day regimen of
      granulocyte colony-stimulating factor (G-CSF). Mechanistic studies determined
      that rapid mobilization results from synergistic signaling on neutrophils,
      resulting in enhanced MMP-9 release, and unexpectedly revealed genetic
      polymorphisms in MMP-9 that alter activity. This mobilization regimen results in 
      preferential trafficking of stem cells that demonstrate a higher engraftment
      efficiency than those mobilized by G-CSF. Our studies suggest a potential new
      strategy for the rapid collection of an improved hematopoietic graft.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Hoggatt, Jonathan
AU  - Hoggatt J
AD  - Harvard Medical School, Cancer Center and Center for Transplantation Sciences,
      Massachusetts General Hospital, Boston, MA 02129, USA; Harvard Stem Cell
      Institute, Cambridge, MA 02138, USA; Department of Stem Cell and Regenerative
      Biology, Harvard University, Cambridge, MA 02138, USA. Electronic address:
      hoggatt.jonathan@mgh.harvard.edu.
FAU - Singh, Pratibha
AU  - Singh P
AD  - Department of Microbiology and Immunology, Indiana University School of Medicine,
      Indianapolis, IN 46202, USA.
FAU - Tate, Tiffany A
AU  - Tate TA
AD  - Harvard Stem Cell Institute, Cambridge, MA 02138, USA; Department of Stem Cell
      and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA.
FAU - Chou, Bin-Kuan
AU  - Chou BK
AD  - Harvard Medical School, Cancer Center and Center for Transplantation Sciences,
      Massachusetts General Hospital, Boston, MA 02129, USA; Harvard Stem Cell
      Institute, Cambridge, MA 02138, USA.
FAU - Datari, Shruti R
AU  - Datari SR
AD  - Harvard Medical School, Cancer Center and Center for Transplantation Sciences,
      Massachusetts General Hospital, Boston, MA 02129, USA; Harvard Stem Cell
      Institute, Cambridge, MA 02138, USA.
FAU - Fukuda, Seiji
AU  - Fukuda S
AD  - Department of Microbiology and Immunology, Indiana University School of Medicine,
      Indianapolis, IN 46202, USA.
FAU - Liu, Liqiong
AU  - Liu L
AD  - Department of Microbiology and Immunology, Indiana University School of Medicine,
      Indianapolis, IN 46202, USA.
FAU - Kharchenko, Peter V
AU  - Kharchenko PV
AD  - Harvard Stem Cell Institute, Cambridge, MA 02138, USA; Department of Biomedical
      Informatics, Harvard Medical School, Boston, MA 02115, USA.
FAU - Schajnovitz, Amir
AU  - Schajnovitz A
AD  - Harvard Stem Cell Institute, Cambridge, MA 02138, USA; Department of Stem Cell
      and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA; Center
      for Regenerative Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.
FAU - Baryawno, Ninib
AU  - Baryawno N
AD  - Harvard Stem Cell Institute, Cambridge, MA 02138, USA; Department of Stem Cell
      and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA; Center
      for Regenerative Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.
FAU - Mercier, Francois E
AU  - Mercier FE
AD  - Harvard Stem Cell Institute, Cambridge, MA 02138, USA; Department of Stem Cell
      and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA; Center
      for Regenerative Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.
FAU - Boyer, Joseph
AU  - Boyer J
AD  - Department of Statistical Sciences, GlaxoSmithKline, Collegeville, PA 19426, USA;
      GlaxoSmithKline, Collegeville, PA 19426, USA.
FAU - Gardner, Jason
AU  - Gardner J
AD  - GlaxoSmithKline, Collegeville, PA 19426, USA.
FAU - Morrow, Dwight M
AU  - Morrow DM
AD  - GlaxoSmithKline, Collegeville, PA 19426, USA.
FAU - Scadden, David T
AU  - Scadden DT
AD  - Harvard Stem Cell Institute, Cambridge, MA 02138, USA; Department of Stem Cell
      and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA; Center
      for Regenerative Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.
      Electronic address: david_scadden@harvard.edu.
FAU - Pelus, Louis M
AU  - Pelus LM
AD  - Department of Microbiology and Immunology, Indiana University School of Medicine,
      Indianapolis, IN 46202, USA. Electronic address: lpelus@iupui.edu.
LA  - eng
PT  - Journal Article
DEP - 20171207
PL  - United States
TA  - Cell
JT  - Cell
JID - 0413066
OTO - NOTNLM
OT  - AMD3100
OT  - CXCR2
OT  - CXCR4
OT  - MMP-9
OT  - bone marrow transplantation
OT  - granulocyte colony-stimulating factor
OT  - hematopoiesis
OT  - hematopoietic stem cell mobilization
OT  - neutrophils
OT  - stem cell trafficking
EDAT- 2017/12/12 06:00
MHDA- 2017/12/12 06:00
CRDT- 2017/12/12 06:00
PHST- 2017/08/24 00:00 [received]
PHST- 2017/10/02 00:00 [revised]
PHST- 2017/10/31 00:00 [accepted]
PHST- 2017/12/12 06:00 [pubmed]
PHST- 2017/12/12 06:00 [medline]
PHST- 2017/12/12 06:00 [entrez]
AID - S0092-8674(17)31312-0 [pii]
AID - 10.1016/j.cell.2017.11.003 [doi]
PST - ppublish
SO  - Cell. 2018 Jan 11;172(1-2):191-204.e10. doi: 10.1016/j.cell.2017.11.003. Epub
      2017 Dec 7.

PMID- 29141229
OWN - NLM
STAT- In-Process
LR  - 20180111
IS  - 2211-1247 (Electronic)
VI  - 21
IP  - 7
DP  - 2017 Nov 14
TI  - Widespread Translational Remodeling during Human Neuronal Differentiation.
PG  - 2005-2016
LID - S2211-1247(17)31575-9 [pii]
LID - 10.1016/j.celrep.2017.10.095 [doi]
AB  - Faithful cellular differentiation requires temporally precise activation of gene 
      expression programs, which are coordinated at the transcriptional and
      translational levels. Neurons express the most complex set of mRNAs of any human 
      tissue, but translational changes during neuronal differentiation remain
      incompletely understood. Here, we induced forebrain neuronal differentiation of
      human embryonic stem cells (hESCs) and measured genome-wide RNA and translation
      levels with transcript-isoform resolution. We found that thousands of genes
      change translation status during differentiation without a corresponding change
      in RNA level. Specifically, we identified mTOR signaling as a key driver for
      elevated translation of translation-related genes in hESCs. In contrast,
      translational repression in active neurons is mediated by regulatory sequences in
      3' UTRs. Together, our findings identify extensive translational control changes 
      during human neuronal differentiation and a crucial role of 3' UTRs in driving
      cell-type-specific translation.
CI  - Copyright (c) 2017 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Blair, John D
AU  - Blair JD
AD  - Department of Molecular and Cell Biology, University of California, Berkeley,
      Berkeley, CA 94720, USA.
FAU - Hockemeyer, Dirk
AU  - Hockemeyer D
AD  - Department of Molecular and Cell Biology, University of California, Berkeley,
      Berkeley, CA 94720, USA.
FAU - Doudna, Jennifer A
AU  - Doudna JA
AD  - Department of Molecular and Cell Biology, University of California, Berkeley,
      Berkeley, CA 94720, USA; Howard Hughes Medical Institute, University of
      California, Berkeley, Berkeley, CA 94720, USA; Department of Chemistry,
      University of California, Berkeley, Berkeley, CA 94720, USA; Innovative Genomics 
      Institute, University of California, Berkeley, Berkeley, CA 94720, USA; Molecular
      Biophysics and Imaging Biosciences Division, Lawrence Berkeley National
      Laboratory, Berkeley, CA 94720, USA.
FAU - Bateup, Helen S
AU  - Bateup HS
AD  - Department of Molecular and Cell Biology, University of California, Berkeley,
      Berkeley, CA 94720, USA; Helen Wills Neuroscience Institute, University of
      California, Berkeley, Berkeley, CA 94720, USA. Electronic address:
      bateup@berkeley.edu.
FAU - Floor, Stephen N
AU  - Floor SN
AD  - Department of Molecular and Cell Biology, University of California, Berkeley,
      Berkeley, CA 94720, USA; Howard Hughes Medical Institute, University of
      California, Berkeley, Berkeley, CA 94720, USA; Department of Cell and Tissue
      Biology, University of California, San Francisco, San Francisco, CA 94143, USA;
      Helen Diller Family Comprehensive Cancer Center, University of California, San
      Francisco, San Francisco, CA 94143, USA. Electronic address:
      stephen.floor@ucsf.edu.
LA  - eng
GR  - R01 CA196884/CA/NCI NIH HHS/United States
GR  - R01 NS097823/NS/NINDS NIH HHS/United States
GR  - S10 OD018174/OD/NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cell Rep
JT  - Cell reports
JID - 101573691
PMC - PMC5759054
MID - NIHMS919657
OTO - NOTNLM
OT  - RNA
OT  - TrIP-seq
OT  - cellular differentiation
OT  - human stem cell
OT  - neural progenitor cell
OT  - neurogenesis
OT  - neuron
OT  - polysome profiling
OT  - ribosome profiling
OT  - translational control
EDAT- 2017/11/16 06:00
MHDA- 2017/11/16 06:00
CRDT- 2017/11/16 06:00
PHST- 2017/08/21 00:00 [received]
PHST- 2017/10/13 00:00 [revised]
PHST- 2017/10/24 00:00 [accepted]
PHST- 2017/11/16 06:00 [entrez]
PHST- 2017/11/16 06:00 [pubmed]
PHST- 2017/11/16 06:00 [medline]
AID - S2211-1247(17)31575-9 [pii]
AID - 10.1016/j.celrep.2017.10.095 [doi]
PST - ppublish
SO  - Cell Rep. 2017 Nov 14;21(7):2005-2016. doi: 10.1016/j.celrep.2017.10.095.

PMID- 29144457
OWN - NLM
STAT- In-Data-Review
LR  - 20171219
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 551
IP  - 7680
DP  - 2017 Nov 16
TI  - A ubiquitin-dependent signalling axis specific for ALKBH-mediated DNA
      dealkylation repair.
PG  - 389-393
LID - 10.1038/nature24484 [doi]
AB  - DNA repair is essential to prevent the cytotoxic or mutagenic effects of various 
      types of DNA lesions, which are sensed by distinct pathways to recruit repair
      factors specific to the damage type. Although biochemical mechanisms for
      repairing several forms of genomic insults are well understood, the upstream
      signalling pathways that trigger repair are established for only certain types of
      damage, such as double-stranded breaks and interstrand crosslinks. Understanding 
      the upstream signalling events that mediate recognition and repair of DNA
      alkylation damage is particularly important, since alkylation chemotherapy is one
      of the most widely used systemic modalities for cancer treatment and because
      environmental chemicals may trigger DNA alkylation. Here we demonstrate that
      human cells have a previously unrecognized signalling mechanism for sensing
      damage induced by alkylation. We find that the alkylation repair complex ASCC
      (activating signal cointegrator complex) relocalizes to distinct nuclear foci
      specifically upon exposure of cells to alkylating agents. These foci associate
      with alkylated nucleotides, and coincide spatially with elongating RNA polymerase
      II and splicing components. Proper recruitment of the repair complex requires
      recognition of K63-linked polyubiquitin by the CUE (coupling of ubiquitin
      conjugation to ER degradation) domain of the subunit ASCC2. Loss of this subunit 
      impedes alkylation adduct repair kinetics and increases sensitivity to alkylating
      agents, but not other forms of DNA damage. We identify RING finger protein 113A
      (RNF113A) as the E3 ligase responsible for upstream ubiquitin signalling in the
      ASCC pathway. Cells from patients with X-linked trichothiodystrophy, which
      harbour a mutation in RNF113A, are defective in ASCC foci formation and are
      hypersensitive to alkylating agents. Together, our work reveals a previously
      unrecognized ubiquitin-dependent pathway induced specifically to repair
      alkylation damage, shedding light on the molecular mechanism of X-linked
      trichothiodystrophy.
FAU - Brickner, Joshua R
AU  - Brickner JR
AD  - Department of Pathology and Immunology, Division of Laboratory and Genomic
      Medicine, Washington University School of Medicine, St. Louis, Missouri 63110,
      USA.
FAU - Soll, Jennifer M
AU  - Soll JM
AD  - Department of Pathology and Immunology, Division of Laboratory and Genomic
      Medicine, Washington University School of Medicine, St. Louis, Missouri 63110,
      USA.
FAU - Lombardi, Patrick M
AU  - Lombardi PM
AD  - Department of Biophysics and Biophysical Chemistry, Johns Hopkins University
      School of Medicine, Baltimore, Maryland 21205, USA.
FAU - Vagbo, Cathrine B
AU  - Vagbo CB
AD  - Department of Clinical and Molecular Medicine, Norwegian University of Science
      and Technology, NTNU, NO-7491 Trondheim, Norway.
AD  - PROMEC Core Facility for Proteomics and Metabolomics, NTNU and the Central Norway
      Regional Health Authority, NO-7491 Trondheim, Norway.
FAU - Mudge, Miranda C
AU  - Mudge MC
AD  - Department of Pathology and Immunology, Division of Laboratory and Genomic
      Medicine, Washington University School of Medicine, St. Louis, Missouri 63110,
      USA.
FAU - Oyeniran, Clement
AU  - Oyeniran C
AD  - Department of Pathology and Immunology, Division of Laboratory and Genomic
      Medicine, Washington University School of Medicine, St. Louis, Missouri 63110,
      USA.
FAU - Rabe, Renana
AU  - Rabe R
AD  - Department of Clinical and Molecular Medicine, Norwegian University of Science
      and Technology, NTNU, NO-7491 Trondheim, Norway.
FAU - Jackson, Jessica
AU  - Jackson J
AD  - Edward A. Doisy Department of Biochemistry and Molecular Biology, St. Louis
      University School of Medicine, St. Louis, Missouri 63104, USA.
FAU - Sullender, Meagan E
AU  - Sullender ME
AD  - Department of Pathology and Immunology, Division of Laboratory and Genomic
      Medicine, Washington University School of Medicine, St. Louis, Missouri 63110,
      USA.
FAU - Blazosky, Elyse
AU  - Blazosky E
AD  - Department of Biophysics and Biophysical Chemistry, Johns Hopkins University
      School of Medicine, Baltimore, Maryland 21205, USA.
FAU - Byrum, Andrea K
AU  - Byrum AK
AD  - Department of Pathology and Immunology, Division of Laboratory and Genomic
      Medicine, Washington University School of Medicine, St. Louis, Missouri 63110,
      USA.
FAU - Zhao, Yu
AU  - Zhao Y
AD  - Department of Pathology and Immunology, Division of Laboratory and Genomic
      Medicine, Washington University School of Medicine, St. Louis, Missouri 63110,
      USA.
FAU - Corbett, Mark A
AU  - Corbett MA
AD  - Adelaide Medical School and Robinson Research Institute, The University of
      Adelaide, Adelaide, South Australia 5000, Australia.
FAU - Gecz, Jozef
AU  - Gecz J
AD  - Adelaide Medical School and Robinson Research Institute, The University of
      Adelaide, Adelaide, South Australia 5000, Australia.
AD  - Healthy Mothers and Babies, South Australian Medical Research Institute,
      Adelaide, South Australia 5000, Australia.
FAU - Field, Michael
AU  - Field M
AD  - Genetics of Learning Disability Service, Hunter Genetics, Waratah, New South
      Wales 2298, Australia.
FAU - Vindigni, Alessandro
AU  - Vindigni A
AD  - Edward A. Doisy Department of Biochemistry and Molecular Biology, St. Louis
      University School of Medicine, St. Louis, Missouri 63104, USA.
FAU - Slupphaug, Geir
AU  - Slupphaug G
AD  - Department of Clinical and Molecular Medicine, Norwegian University of Science
      and Technology, NTNU, NO-7491 Trondheim, Norway.
AD  - PROMEC Core Facility for Proteomics and Metabolomics, NTNU and the Central Norway
      Regional Health Authority, NO-7491 Trondheim, Norway.
FAU - Wolberger, Cynthia
AU  - Wolberger C
AD  - Department of Biophysics and Biophysical Chemistry, Johns Hopkins University
      School of Medicine, Baltimore, Maryland 21205, USA.
FAU - Mosammaparast, Nima
AU  - Mosammaparast N
AD  - Department of Pathology and Immunology, Division of Laboratory and Genomic
      Medicine, Washington University School of Medicine, St. Louis, Missouri 63110,
      USA.
LA  - eng
PT  - Journal Article
DEP - 20171108
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
EDAT- 2017/11/17 06:00
MHDA- 2017/11/17 06:00
CRDT- 2017/11/17 06:00
PHST- 2016/07/31 00:00 [received]
PHST- 2017/10/04 00:00 [accepted]
PHST- 2017/11/17 06:00 [entrez]
PHST- 2017/11/17 06:00 [pubmed]
PHST- 2017/11/17 06:00 [medline]
AID - nature24484 [pii]
AID - 10.1038/nature24484 [doi]
PST - ppublish
SO  - Nature. 2017 Nov 16;551(7680):389-393. doi: 10.1038/nature24484. Epub 2017 Nov 8.

PMID- 29053959
OWN - NLM
STAT- MEDLINE
DCOM- 20171027
LR  - 20171219
IS  - 1097-4164 (Electronic)
IS  - 1097-2765 (Linking)
VI  - 68
IP  - 2
DP  - 2017 Oct 19
TI  - Restoration of Replication Fork Stability in BRCA1- and BRCA2-Deficient Cells by 
      Inactivation of SNF2-Family Fork Remodelers.
PG  - 414-430.e8
LID - S1097-2765(17)30714-1 [pii]
LID - 10.1016/j.molcel.2017.09.036 [doi]
AB  - To ensure the completion of DNA replication and maintenance of genome integrity, 
      DNA repair factors protect stalled replication forks upon replication stress.
      Previous studies have identified a critical role for the tumor suppressors BRCA1 
      and BRCA2 in preventing the degradation of nascent DNA by the MRE11 nuclease
      after replication stress. Here we show that depletion of SMARCAL1, a SNF2-family 
      DNA translocase that remodels stalled forks, restores replication fork stability 
      and reduces the formation of replication stress-induced DNA breaks and
      chromosomal aberrations in BRCA1/2-deficient cells. In addition to SMARCAL1,
      other SNF2-family fork remodelers, including ZRANB3 and HLTF, cause nascent DNA
      degradation and genomic instability in BRCA1/2-deficient cells upon replication
      stress. Our observations indicate that nascent DNA degradation in
      BRCA1/2-deficient cells occurs as a consequence of MRE11-dependent nucleolytic
      processing of reversed forks generated by fork remodelers. These studies provide 
      mechanistic insights into the processes that cause genome instability in
      BRCA1/2-deficient cells.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Taglialatela, Angelo
AU  - Taglialatela A
AD  - Department of Genetics and Development, Columbia University Medical Center, New
      York, NY 10032, USA; Herbert Irving Comprehensive Cancer Center, Columbia
      University Medical Center, New York, NY 10032, USA.
FAU - Alvarez, Silvia
AU  - Alvarez S
AD  - Department of Genetics and Development, Columbia University Medical Center, New
      York, NY 10032, USA; Herbert Irving Comprehensive Cancer Center, Columbia
      University Medical Center, New York, NY 10032, USA.
FAU - Leuzzi, Giuseppe
AU  - Leuzzi G
AD  - Department of Genetics and Development, Columbia University Medical Center, New
      York, NY 10032, USA; Herbert Irving Comprehensive Cancer Center, Columbia
      University Medical Center, New York, NY 10032, USA.
FAU - Sannino, Vincenzo
AU  - Sannino V
AD  - DNA Metabolism Laboratory, IFOM, FIRC Institute for Molecular Oncology, 20139
      Milan, Italy.
FAU - Ranjha, Lepakshi
AU  - Ranjha L
AD  - Institute for Research in Biomedicine, Universita della Svizzera Italiana, 6500
      Bellinzona, Switzerland.
FAU - Huang, Jen-Wei
AU  - Huang JW
AD  - Department of Genetics and Development, Columbia University Medical Center, New
      York, NY 10032, USA; Herbert Irving Comprehensive Cancer Center, Columbia
      University Medical Center, New York, NY 10032, USA.
FAU - Madubata, Chioma
AU  - Madubata C
AD  - Department of Systems Biology, Columbia University Medical Center, New York, NY
      10032, USA; Department of Biomedical Informatics, Columbia University Medical
      Center, New York, NY 10032, USA.
FAU - Anand, Roopesh
AU  - Anand R
AD  - Institute for Research in Biomedicine, Universita della Svizzera Italiana, 6500
      Bellinzona, Switzerland.
FAU - Levy, Brynn
AU  - Levy B
AD  - Department of Pathology and Cell Biology, Columbia University Medical Center, New
      York, NY 10032, USA.
FAU - Rabadan, Raul
AU  - Rabadan R
AD  - Department of Systems Biology, Columbia University Medical Center, New York, NY
      10032, USA; Department of Biomedical Informatics, Columbia University Medical
      Center, New York, NY 10032, USA.
FAU - Cejka, Petr
AU  - Cejka P
AD  - Institute for Research in Biomedicine, Universita della Svizzera Italiana, 6500
      Bellinzona, Switzerland; Department of Biology, Institute of Biochemistry, Swiss 
      Federal Institute of Technology, 8093 Zurich, Switzerland.
FAU - Costanzo, Vincenzo
AU  - Costanzo V
AD  - DNA Metabolism Laboratory, IFOM, FIRC Institute for Molecular Oncology, 20139
      Milan, Italy.
FAU - Ciccia, Alberto
AU  - Ciccia A
AD  - Department of Genetics and Development, Columbia University Medical Center, New
      York, NY 10032, USA; Herbert Irving Comprehensive Cancer Center, Columbia
      University Medical Center, New York, NY 10032, USA. Electronic address:
      ac3685@cumc.columbia.edu.
LA  - eng
GR  - F31 CA210607/CA/NCI NIH HHS/United States
GR  - R01 CA197774/CA/NCI NIH HHS/United States
GR  - T32 CA009503/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Mol Cell
JT  - Molecular cell
JID - 9802571
RN  - 0 (BRCA2 Protein)
RN  - 0 (BRCA2 protein, human)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (HLTF protein, human)
RN  - 0 (MRE11A protein, human)
RN  - 0 (Transcription Factors)
RN  - EC 2.3.2.27 (BRAP protein, human)
RN  - EC 2.3.2.27 (Ubiquitin-Protein Ligases)
RN  - EC 2.7.7.- (SMARCAL1 protein, human)
RN  - EC 3.1.- (MRE11 Homologue Protein)
RN  - EC 3.6.4.- (DNA Helicases)
RN  - EC 3.6.4.- (ZRANB3 protein, human)
SB  - IM
MH  - BRCA2 Protein/*deficiency
MH  - Cell Line, Tumor
MH  - *DNA Breaks
MH  - DNA Helicases/genetics/*metabolism
MH  - DNA-Binding Proteins/genetics/*metabolism
MH  - Genomic Instability
MH  - Humans
MH  - MRE11 Homologue Protein
MH  - Transcription Factors/genetics/*metabolism
MH  - Ubiquitin-Protein Ligases/*deficiency
PMC - PMC5720682
MID - NIHMS910091
OTO - NOTNLM
OT  - BRCA1 and BRCA2
OT  - DNA replication stress
OT  - HLTF
OT  - MRE11
OT  - RAD51
OT  - SMARCAL1
OT  - ZRANB3
OT  - breast and ovarian cancer
OT  - replication fork instability
OT  - replication fork reversal
EDAT- 2017/10/21 06:00
MHDA- 2017/10/28 06:00
CRDT- 2017/10/21 06:00
PMCR- 2018/10/19 00:00
PHST- 2017/02/10 00:00 [received]
PHST- 2017/07/17 00:00 [revised]
PHST- 2017/09/25 00:00 [accepted]
PHST- 2018/10/19 00:00 [pmc-release]
PHST- 2017/10/21 06:00 [entrez]
PHST- 2017/10/21 06:00 [pubmed]
PHST- 2017/10/28 06:00 [medline]
AID - S1097-2765(17)30714-1 [pii]
AID - 10.1016/j.molcel.2017.09.036 [doi]
PST - ppublish
SO  - Mol Cell. 2017 Oct 19;68(2):414-430.e8. doi: 10.1016/j.molcel.2017.09.036.

PMID- 29257710
OWN - NLM
STAT- Publisher
LR  - 20180114
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Linking)
DP  - 2017 Dec 19
TI  - Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible
      Factor-2alpha Antagonist in Patients With Previously Treated Advanced Clear Cell 
      Renal Cell Carcinoma.
PG  - JCO2017742627
LID - 10.1200/JCO.2017.74.2627 [doi]
AB  - Purpose The von Hippel-Lindau tumor suppressor is inactivated in the majority of 
      clear cell renal cell carcinomas (ccRCCs), leading to inappropriate stabilization
      of hypoxia-inducible factor-2alpha (HIF-2alpha). PT2385 is a first-in-class
      HIF-2alpha antagonist. Objectives of this first-in-human study were to
      characterize the safety, pharmacokinetics, pharmacodynamics, and efficacy, and to
      identify the recommended phase II dose (RP2D) of PT2385. Patients and Methods
      Eligible patients had locally advanced or metastatic ccRCC that had progressed
      during one or more prior regimens that included a vascular endothelial growth
      factor inhibitor. PT2385 was administered orally at twice-per-day doses of 100 to
      1,800 mg, according to a 3 + 3 dose-escalation design, followed by an expansion
      phase at the RP2D. Results The dose-escalation and expansion phases enrolled 26
      and 25 patients, respectively. Patients were heavily pretreated, with a median of
      four (range, one to seven) prior therapies. No dose-limiting toxicity was
      observed at any dose. On the basis of safety, pharmacokinetic, and
      pharmacodynamic profiling, the RP2D was defined as 800 mg twice per day. PT2385
      was well tolerated, with anemia (grade 1 to 2, 35%; grade 3, 10%), peripheral
      edema (grade 1 to 2, 37%; grade 3, 2%), and fatigue (grade 1 to 2, 37%; no grade 
      3 or 4) being the most common treatment-emergent adverse events. No patients
      discontinued treatment because of adverse events. Complete response, partial
      response, and stable disease as best response were achieved by 2%, 12%, and 52%
      of patients, respectively. At data cutoff, eight patients remained in the study, 
      with 13 patients in the study for >/= 1 year. Conclusion PT2385 has a favorable
      safety profile and is active in patients with heavily pretreated ccRCC,
      validating direct HIF-2alpha antagonism for the treatment of patients with ccRCC.
FAU - Courtney, Kevin D
AU  - Courtney KD
AD  - Kevin D. Courtney and James Brugarolas, University of Texas Southwestern Medical 
      Center; Naseem J. Zojwalla, Ann M. Lowe, Keshi Wang, Eli M. Wallace, and John A. 
      Josey, Peloton Therapeutics, Dallas, TX; Jeffrey R. Infante, TN Oncology and
      Sarah Cannon Research Institute, Nashville, TN; Elaine T. Lam, University of
      Colorado Cancer Center, Aurora, CO; Robert A. Figlin, Cedars-Sinai Medical
      Center, Los Angeles, CA; Brian I. Rini, Cleveland Clinic Taussig Cancer
      Institute, Cleveland, OH; Toni K. Choueiri, Dana-Farber Cancer Institute, Brigham
      and Women's Hospital, and Harvard Medical School, Boston, MA.
FAU - Infante, Jeffrey R
AU  - Infante JR
AD  - Kevin D. Courtney and James Brugarolas, University of Texas Southwestern Medical 
      Center; Naseem J. Zojwalla, Ann M. Lowe, Keshi Wang, Eli M. Wallace, and John A. 
      Josey, Peloton Therapeutics, Dallas, TX; Jeffrey R. Infante, TN Oncology and
      Sarah Cannon Research Institute, Nashville, TN; Elaine T. Lam, University of
      Colorado Cancer Center, Aurora, CO; Robert A. Figlin, Cedars-Sinai Medical
      Center, Los Angeles, CA; Brian I. Rini, Cleveland Clinic Taussig Cancer
      Institute, Cleveland, OH; Toni K. Choueiri, Dana-Farber Cancer Institute, Brigham
      and Women's Hospital, and Harvard Medical School, Boston, MA.
FAU - Lam, Elaine T
AU  - Lam ET
AD  - Kevin D. Courtney and James Brugarolas, University of Texas Southwestern Medical 
      Center; Naseem J. Zojwalla, Ann M. Lowe, Keshi Wang, Eli M. Wallace, and John A. 
      Josey, Peloton Therapeutics, Dallas, TX; Jeffrey R. Infante, TN Oncology and
      Sarah Cannon Research Institute, Nashville, TN; Elaine T. Lam, University of
      Colorado Cancer Center, Aurora, CO; Robert A. Figlin, Cedars-Sinai Medical
      Center, Los Angeles, CA; Brian I. Rini, Cleveland Clinic Taussig Cancer
      Institute, Cleveland, OH; Toni K. Choueiri, Dana-Farber Cancer Institute, Brigham
      and Women's Hospital, and Harvard Medical School, Boston, MA.
FAU - Figlin, Robert A
AU  - Figlin RA
AD  - Kevin D. Courtney and James Brugarolas, University of Texas Southwestern Medical 
      Center; Naseem J. Zojwalla, Ann M. Lowe, Keshi Wang, Eli M. Wallace, and John A. 
      Josey, Peloton Therapeutics, Dallas, TX; Jeffrey R. Infante, TN Oncology and
      Sarah Cannon Research Institute, Nashville, TN; Elaine T. Lam, University of
      Colorado Cancer Center, Aurora, CO; Robert A. Figlin, Cedars-Sinai Medical
      Center, Los Angeles, CA; Brian I. Rini, Cleveland Clinic Taussig Cancer
      Institute, Cleveland, OH; Toni K. Choueiri, Dana-Farber Cancer Institute, Brigham
      and Women's Hospital, and Harvard Medical School, Boston, MA.
FAU - Rini, Brian I
AU  - Rini BI
AD  - Kevin D. Courtney and James Brugarolas, University of Texas Southwestern Medical 
      Center; Naseem J. Zojwalla, Ann M. Lowe, Keshi Wang, Eli M. Wallace, and John A. 
      Josey, Peloton Therapeutics, Dallas, TX; Jeffrey R. Infante, TN Oncology and
      Sarah Cannon Research Institute, Nashville, TN; Elaine T. Lam, University of
      Colorado Cancer Center, Aurora, CO; Robert A. Figlin, Cedars-Sinai Medical
      Center, Los Angeles, CA; Brian I. Rini, Cleveland Clinic Taussig Cancer
      Institute, Cleveland, OH; Toni K. Choueiri, Dana-Farber Cancer Institute, Brigham
      and Women's Hospital, and Harvard Medical School, Boston, MA.
FAU - Brugarolas, James
AU  - Brugarolas J
AD  - Kevin D. Courtney and James Brugarolas, University of Texas Southwestern Medical 
      Center; Naseem J. Zojwalla, Ann M. Lowe, Keshi Wang, Eli M. Wallace, and John A. 
      Josey, Peloton Therapeutics, Dallas, TX; Jeffrey R. Infante, TN Oncology and
      Sarah Cannon Research Institute, Nashville, TN; Elaine T. Lam, University of
      Colorado Cancer Center, Aurora, CO; Robert A. Figlin, Cedars-Sinai Medical
      Center, Los Angeles, CA; Brian I. Rini, Cleveland Clinic Taussig Cancer
      Institute, Cleveland, OH; Toni K. Choueiri, Dana-Farber Cancer Institute, Brigham
      and Women's Hospital, and Harvard Medical School, Boston, MA.
FAU - Zojwalla, Naseem J
AU  - Zojwalla NJ
AD  - Kevin D. Courtney and James Brugarolas, University of Texas Southwestern Medical 
      Center; Naseem J. Zojwalla, Ann M. Lowe, Keshi Wang, Eli M. Wallace, and John A. 
      Josey, Peloton Therapeutics, Dallas, TX; Jeffrey R. Infante, TN Oncology and
      Sarah Cannon Research Institute, Nashville, TN; Elaine T. Lam, University of
      Colorado Cancer Center, Aurora, CO; Robert A. Figlin, Cedars-Sinai Medical
      Center, Los Angeles, CA; Brian I. Rini, Cleveland Clinic Taussig Cancer
      Institute, Cleveland, OH; Toni K. Choueiri, Dana-Farber Cancer Institute, Brigham
      and Women's Hospital, and Harvard Medical School, Boston, MA.
FAU - Lowe, Ann M
AU  - Lowe AM
AD  - Kevin D. Courtney and James Brugarolas, University of Texas Southwestern Medical 
      Center; Naseem J. Zojwalla, Ann M. Lowe, Keshi Wang, Eli M. Wallace, and John A. 
      Josey, Peloton Therapeutics, Dallas, TX; Jeffrey R. Infante, TN Oncology and
      Sarah Cannon Research Institute, Nashville, TN; Elaine T. Lam, University of
      Colorado Cancer Center, Aurora, CO; Robert A. Figlin, Cedars-Sinai Medical
      Center, Los Angeles, CA; Brian I. Rini, Cleveland Clinic Taussig Cancer
      Institute, Cleveland, OH; Toni K. Choueiri, Dana-Farber Cancer Institute, Brigham
      and Women's Hospital, and Harvard Medical School, Boston, MA.
FAU - Wang, Keshi
AU  - Wang K
AD  - Kevin D. Courtney and James Brugarolas, University of Texas Southwestern Medical 
      Center; Naseem J. Zojwalla, Ann M. Lowe, Keshi Wang, Eli M. Wallace, and John A. 
      Josey, Peloton Therapeutics, Dallas, TX; Jeffrey R. Infante, TN Oncology and
      Sarah Cannon Research Institute, Nashville, TN; Elaine T. Lam, University of
      Colorado Cancer Center, Aurora, CO; Robert A. Figlin, Cedars-Sinai Medical
      Center, Los Angeles, CA; Brian I. Rini, Cleveland Clinic Taussig Cancer
      Institute, Cleveland, OH; Toni K. Choueiri, Dana-Farber Cancer Institute, Brigham
      and Women's Hospital, and Harvard Medical School, Boston, MA.
FAU - Wallace, Eli M
AU  - Wallace EM
AD  - Kevin D. Courtney and James Brugarolas, University of Texas Southwestern Medical 
      Center; Naseem J. Zojwalla, Ann M. Lowe, Keshi Wang, Eli M. Wallace, and John A. 
      Josey, Peloton Therapeutics, Dallas, TX; Jeffrey R. Infante, TN Oncology and
      Sarah Cannon Research Institute, Nashville, TN; Elaine T. Lam, University of
      Colorado Cancer Center, Aurora, CO; Robert A. Figlin, Cedars-Sinai Medical
      Center, Los Angeles, CA; Brian I. Rini, Cleveland Clinic Taussig Cancer
      Institute, Cleveland, OH; Toni K. Choueiri, Dana-Farber Cancer Institute, Brigham
      and Women's Hospital, and Harvard Medical School, Boston, MA.
FAU - Josey, John A
AU  - Josey JA
AD  - Kevin D. Courtney and James Brugarolas, University of Texas Southwestern Medical 
      Center; Naseem J. Zojwalla, Ann M. Lowe, Keshi Wang, Eli M. Wallace, and John A. 
      Josey, Peloton Therapeutics, Dallas, TX; Jeffrey R. Infante, TN Oncology and
      Sarah Cannon Research Institute, Nashville, TN; Elaine T. Lam, University of
      Colorado Cancer Center, Aurora, CO; Robert A. Figlin, Cedars-Sinai Medical
      Center, Los Angeles, CA; Brian I. Rini, Cleveland Clinic Taussig Cancer
      Institute, Cleveland, OH; Toni K. Choueiri, Dana-Farber Cancer Institute, Brigham
      and Women's Hospital, and Harvard Medical School, Boston, MA.
FAU - Choueiri, Toni K
AU  - Choueiri TK
AD  - Kevin D. Courtney and James Brugarolas, University of Texas Southwestern Medical 
      Center; Naseem J. Zojwalla, Ann M. Lowe, Keshi Wang, Eli M. Wallace, and John A. 
      Josey, Peloton Therapeutics, Dallas, TX; Jeffrey R. Infante, TN Oncology and
      Sarah Cannon Research Institute, Nashville, TN; Elaine T. Lam, University of
      Colorado Cancer Center, Aurora, CO; Robert A. Figlin, Cedars-Sinai Medical
      Center, Los Angeles, CA; Brian I. Rini, Cleveland Clinic Taussig Cancer
      Institute, Cleveland, OH; Toni K. Choueiri, Dana-Farber Cancer Institute, Brigham
      and Women's Hospital, and Harvard Medical School, Boston, MA.
LA  - eng
GR  - K12 CA086913/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20171219
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of
      Clinical Oncology
JID - 8309333
EDAT- 2017/12/20 06:00
MHDA- 2017/12/20 06:00
CRDT- 2017/12/20 06:00
PHST- 2017/12/20 06:00 [entrez]
PHST- 2017/12/20 06:00 [pubmed]
PHST- 2017/12/20 06:00 [medline]
AID - 10.1200/JCO.2017.74.2627 [doi]
PST - aheadofprint
SO  - J Clin Oncol. 2017 Dec 19:JCO2017742627. doi: 10.1200/JCO.2017.74.2627.

PMID- 29058709
OWN - NLM
STAT- MEDLINE
DCOM- 20171229
LR  - 20180119
IS  - 1545-9985 (Electronic)
IS  - 1545-9985 (Linking)
VI  - 24
IP  - 12
DP  - 2017 Dec
TI  - Molecular analysis of PRC2 recruitment to DNA in chromatin and its inhibition by 
      RNA.
PG  - 1028-1038
LID - 10.1038/nsmb.3487 [doi]
AB  - Many studies have revealed pathways of epigenetic gene silencing by Polycomb
      repressive complex 2 (PRC2) in vivo, but understanding the underlying molecular
      mechanisms requires biochemistry. Here we analyze interactions of reconstituted
      human PRC2 with nucleosome complexes. Histone modifications, the H3K27M cancer
      mutation, and inclusion of JARID2 or EZH1 in the PRC2 complex have unexpectedly
      minor effects on PRC2-nucleosome binding. Instead, protein-free linker DNA
      dominates the PRC2-nucleosome interaction. Specificity for CG-rich sequences is
      consistent with PRC2 occupying CG-rich DNA in vivo. PRC2 preferentially binds
      methylated DNA regulated by its AEBP2 subunit, suggesting how DNA and histone
      methylation collaborate to repress chromatin. We find that RNA, known to inhibit 
      PRC2 activity, is not a methyltransferase inhibitor per se. Instead, RNA
      sequesters PRC2 from nucleosome substrates, because PRC2 binding requires linker 
      DNA, and RNA and DNA binding are mutually exclusive. Together, we provide a model
      for PRC2 recruitment and an explanation for how actively transcribed genomic
      regions bind PRC2 but escape silencing.
FAU - Wang, Xueyin
AU  - Wang X
AD  - Department of Chemistry & Biochemistry, BioFrontiers Institute, University of
      Colorado Boulder, Boulder, Colorado, USA.
AD  - Howard Hughes Medical Institute, University of Colorado Boulder, Boulder,
      Colorado, USA.
FAU - Paucek, Richard D
AU  - Paucek RD
AUID- ORCID: http://orcid.org/0000-0002-4105-2443
AD  - Department of Chemistry & Biochemistry, BioFrontiers Institute, University of
      Colorado Boulder, Boulder, Colorado, USA.
AD  - Howard Hughes Medical Institute, University of Colorado Boulder, Boulder,
      Colorado, USA.
FAU - Gooding, Anne R
AU  - Gooding AR
AD  - Department of Chemistry & Biochemistry, BioFrontiers Institute, University of
      Colorado Boulder, Boulder, Colorado, USA.
AD  - Howard Hughes Medical Institute, University of Colorado Boulder, Boulder,
      Colorado, USA.
FAU - Brown, Zachary Z
AU  - Brown ZZ
AD  - Department of Chemistry, Princeton University, Princeton, New Jersey, USA.
FAU - Ge, Eva J
AU  - Ge EJ
AD  - Department of Chemistry, Princeton University, Princeton, New Jersey, USA.
FAU - Muir, Tom W
AU  - Muir TW
AD  - Department of Chemistry, Princeton University, Princeton, New Jersey, USA.
FAU - Cech, Thomas R
AU  - Cech TR
AUID- ORCID: http://orcid.org/0000-0001-7338-3389
AD  - Department of Chemistry & Biochemistry, BioFrontiers Institute, University of
      Colorado Boulder, Boulder, Colorado, USA.
AD  - Howard Hughes Medical Institute, University of Colorado Boulder, Boulder,
      Colorado, USA.
LA  - eng
GR  - Howard Hughes Medical Institute/United States
GR  - P01 CA196539/CA/NCI NIH HHS/United States
GR  - R01 GM086868/GM/NIGMS NIH HHS/United States
GR  - R37 GM086868/GM/NIGMS NIH HHS/United States
PT  - Journal Article
DEP - 20171023
PL  - United States
TA  - Nat Struct Mol Biol
JT  - Nature structural & molecular biology
JID - 101186374
RN  - 0 (AEBP2 protein, human)
RN  - 0 (Chromatin)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Histones)
RN  - 0 (JARID2 protein, human)
RN  - 0 (MTF2 protein, human)
RN  - 0 (Nucleosomes)
RN  - 0 (Repressor Proteins)
RN  - 63231-63-0 (RNA)
RN  - 9007-49-2 (DNA)
RN  - EC 2.1.1.43 (EZH1 protein, human)
RN  - EC 2.1.1.43 (Polycomb Repressive Complex 2)
SB  - IM
MH  - Base Composition/genetics
MH  - Cell Line
MH  - Chromatin/*genetics
MH  - DNA/metabolism
MH  - DNA Methylation/genetics
MH  - DNA-Binding Proteins/*genetics
MH  - Epigenesis, Genetic/genetics
MH  - Gene Silencing/*physiology
MH  - Histones/genetics/metabolism
MH  - Humans
MH  - Nucleosomes/metabolism
MH  - Polycomb Repressive Complex 2/*genetics
MH  - Protein Binding/genetics
MH  - RNA/*metabolism
MH  - Repressor Proteins/metabolism
PMC - PMC5771497
MID - NIHMS928189
EDAT- 2017/10/24 06:00
MHDA- 2017/12/30 06:00
CRDT- 2017/10/24 06:00
PMCR- 2018/04/23 00:00
PHST- 2017/06/14 00:00 [received]
PHST- 2017/09/20 00:00 [accepted]
PHST- 2018/04/23 00:00 [pmc-release]
PHST- 2017/10/24 06:00 [pubmed]
PHST- 2017/12/30 06:00 [medline]
PHST- 2017/10/24 06:00 [entrez]
AID - nsmb.3487 [pii]
AID - 10.1038/nsmb.3487 [doi]
PST - ppublish
SO  - Nat Struct Mol Biol. 2017 Dec;24(12):1028-1038. doi: 10.1038/nsmb.3487. Epub 2017
      Oct 23.

PMID- 29078283
OWN - NLM
STAT- In-Data-Review
LR  - 20171219
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Linking)
VI  - 114
IP  - 45
DP  - 2017 Nov 7
TI  - Humanized mouse model supports development, function, and tissue residency of
      human natural killer cells.
PG  - E9626-E9634
LID - 10.1073/pnas.1705301114 [doi]
AB  - Immunodeficient mice reconstituted with a human immune system represent a
      promising tool for translational research as they may allow modeling and therapy 
      of human diseases in vivo. However, insufficient development and function of
      human natural killer (NK) cells and T cell subsets limit the applicability of
      humanized mice for studying cancer biology and therapy. Here, we describe a human
      interleukin 15 (IL15) and human signal regulatory protein alpha (SIRPA) knock-in 
      mouse on a Rag2(-/-) Il2rg(-/-) background (SRG-15). Transplantation of human
      hematopoietic stem and progenitor cells into SRG-15 mice dramatically improved
      the development and functional maturation of circulating and tissue-resident
      human NK and CD8(+) T cells and promoted the development of tissue-resident
      innate lymphoid cell (ILC) subsets. Profiling of human NK cell subsets by mass
      cytometry revealed a highly similar expression pattern of killer inhibitory
      receptors and other candidate molecules in NK cell subpopulations between SRG-15 
      mice and humans. In contrast to nonobese diabetic severe combined immunodeficient
      Il2rg(-/-) (NSG) mice, human NK cells in SRG-15 mice did not require
      preactivation but infiltrated a Burkitt's lymphoma xenograft and efficiently
      inhibited tumor growth following treatment with the therapeutic antibody
      rituximab. Our humanized mouse model may thus be useful for preclinical testing
      of novel human NK cell-targeted and combinatory cancer immunotherapies and for
      studying how they elicit human antitumor immune responses in vivo.
CI  - Published under the PNAS license.
FAU - Herndler-Brandstetter, Dietmar
AU  - Herndler-Brandstetter D
AD  - Department of Immunobiology, Yale University School of Medicine, New Haven, CT
      06519.
FAU - Shan, Liang
AU  - Shan L
AD  - Department of Immunobiology, Yale University School of Medicine, New Haven, CT
      06519.
FAU - Yao, Yi
AU  - Yao Y
AD  - Department of Internal Medicine, Yale University School of Medicine, New Haven,
      CT 06519.
FAU - Stecher, Carmen
AU  - Stecher C
AD  - Department of Immunobiology, Yale University School of Medicine, New Haven, CT
      06519.
FAU - Plajer, Valerie
AU  - Plajer V
AD  - Department of Immunobiology, Yale University School of Medicine, New Haven, CT
      06519.
FAU - Lietzenmayer, Melanie
AU  - Lietzenmayer M
AD  - Department of Immunobiology, Yale University School of Medicine, New Haven, CT
      06519.
FAU - Strowig, Till
AU  - Strowig T
AD  - Department of Immunobiology, Yale University School of Medicine, New Haven, CT
      06519.
FAU - de Zoete, Marcel R
AU  - de Zoete MR
AD  - Department of Immunobiology, Yale University School of Medicine, New Haven, CT
      06519.
FAU - Palm, Noah W
AU  - Palm NW
AD  - Department of Immunobiology, Yale University School of Medicine, New Haven, CT
      06519.
FAU - Chen, Jie
AU  - Chen J
AD  - Department of Immunobiology, Yale University School of Medicine, New Haven, CT
      06519.
FAU - Blish, Catherine A
AU  - Blish CA
AD  - Department of Medicine, Stanford University School of Medicine, Stanford, CA
      94305.
FAU - Frleta, Davor
AU  - Frleta D
AD  - Regeneron Pharmaceuticals Inc., Tarrytown, NY 10591.
FAU - Gurer, Cagan
AU  - Gurer C
AD  - Regeneron Pharmaceuticals Inc., Tarrytown, NY 10591.
FAU - Macdonald, Lynn E
AU  - Macdonald LE
AD  - Regeneron Pharmaceuticals Inc., Tarrytown, NY 10591.
FAU - Murphy, Andrew J
AU  - Murphy AJ
AD  - Regeneron Pharmaceuticals Inc., Tarrytown, NY 10591.
FAU - Yancopoulos, George D
AU  - Yancopoulos GD
AD  - Regeneron Pharmaceuticals Inc., Tarrytown, NY 10591.
FAU - Montgomery, Ruth R
AU  - Montgomery RR
AD  - Department of Internal Medicine, Yale University School of Medicine, New Haven,
      CT 06519.
FAU - Flavell, Richard A
AU  - Flavell RA
AD  - Department of Immunobiology, Yale University School of Medicine, New Haven, CT
      06519; richard.flavell@yale.edu.
AD  - Howard Hughes Medical Institute, New Haven, CT 06519.
LA  - eng
GR  - K99 AI125065/AI/NIAID NIH HHS/United States
GR  - T32 AI007019/AI/NIAID NIH HHS/United States
GR  - T32 AR007107/AR/NIAMS NIH HHS/United States
GR  - U19 AI089992/AI/NIAID NIH HHS/United States
PT  - Journal Article
DEP - 20171025
PL  - United States
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
PMC - PMC5692533
OTO - NOTNLM
OT  - IL-15
OT  - ILC
OT  - NK cells
OT  - cancer immunotherapy
OT  - humanized mice
COIS- Conflict of interest statement: D.F., C.G., L.E.M., A.J.M., and G.D.Y. are
      employees and shareholders of Regeneron Pharmaceuticals. Regeneron
      Pharmaceuticals, D.H.-B., L.S., T.S., M.R.d.Z., N.W.P., and R.A.F. have filed a
      patent application related to this work.
EDAT- 2017/10/29 06:00
MHDA- 2017/10/29 06:00
CRDT- 2017/10/29 06:00
PMCR- 2018/05/07 00:00
PHST- 2018/05/07 00:00 [pmc-release]
PHST- 2017/10/29 06:00 [pubmed]
PHST- 2017/10/29 06:00 [medline]
PHST- 2017/10/29 06:00 [entrez]
AID - 1705301114 [pii]
AID - 10.1073/pnas.1705301114 [doi]
PST - ppublish
SO  - Proc Natl Acad Sci U S A. 2017 Nov 7;114(45):E9626-E9634. doi:
      10.1073/pnas.1705301114. Epub 2017 Oct 25.

PMID- 29101163
OWN - NLM
STAT- Publisher
LR  - 20180127
IS  - 2159-8290 (Electronic)
IS  - 2159-8274 (Linking)
DP  - 2017 Nov 3
TI  - CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation.
LID - 10.1158/2159-8290.CD-17-0915 [doi]
AB  - Immune checkpoint blockade, exemplified by antibodies targeting the PD-1
      receptor, can induce durable tumor regressions in some patients. To enhance the
      efficacy of existing immunotherapies, we screened for small molecules capable of 
      increasing the activity of T cells suppressed by PD-1. Here, we show that
      short-term exposure to small-molecule inhibitors of cyclin-dependent kinases 4
      and 6 (CDK4/6) significantly enhances T-cell activation, contributing to
      antitumor effects in vivo, due in part to the derepression of NFAT family
      proteins and their target genes, critical regulators of T-cell function. Although
      CDK4/6 inhibitors decrease T-cell proliferation, they increase tumor infiltration
      and activation of effector T cells. Moreover, CDK4/6 inhibition augments the
      response to PD-1 blockade in a novel ex vivo organotypic tumor spheroid culture
      system and in multiple in vivo murine syngeneic models, thereby providing a
      rationale for combining CDK4/6 inhibitors and immunotherapies.SIGNIFICANCE: Our
      results define previously unrecognized immunomodulatory functions of CDK4/6 and
      suggest that combining CDK4/6 inhibitors with immune checkpoint blockade may
      increase treatment efficacy in patients. Furthermore, our study highlights the
      critical importance of identifying complementary strategies to improve the
      efficacy of immunotherapy for patients with cancer. Cancer Discov; 8(2); 1-18.
      (c)2017 AACR.See related commentary by Balko and Sosman, p. 143.
CI  - (c)2017 American Association for Cancer Research.
FAU - Deng, Jiehui
AU  - Deng J
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
AD  - Division of Hematology & Medical Oncology, Laura and Isaac Perlmutter Cancer
      Center, New York University Langone Medical Center, New York, New York.
FAU - Wang, Eric S
AU  - Wang ES
AD  - Department of Cancer Biology, Dana-Farber Cancer Institute, Department of
      Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, 
      Massachusetts.
FAU - Jenkins, Russell W
AU  - Jenkins RW
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
AD  - Division of Medical Oncology, Massachusetts General Hospital Cancer Center,
      Harvard Medical School, Boston, Massachusetts.
FAU - Li, Shuai
AU  - Li S
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Dries, Ruben
AU  - Dries R
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
AD  - Department of Biostatistics and Computational Biology, Dana-Farber Cancer
      Institute, Boston, Massachusetts.
FAU - Yates, Kathleen
AU  - Yates K
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Chhabra, Sandeep
AU  - Chhabra S
AD  - Department of Cancer Biology, Dana-Farber Cancer Institute, Department of
      Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, 
      Massachusetts.
FAU - Huang, Wei
AU  - Huang W
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Liu, Hongye
AU  - Liu H
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
AD  - Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Aref, Amir R
AU  - Aref AR
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
AD  - Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Ivanova, Elena
AU  - Ivanova E
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
AD  - Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Paweletz, Cloud P
AU  - Paweletz CP
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
AD  - Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Bowden, Michaela
AU  - Bowden M
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
AD  - Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Zhou, Chensheng W
AU  - Zhou CW
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
AD  - Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Herter-Sprie, Grit S
AU  - Herter-Sprie GS
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Sorrentino, Jessica A
AU  - Sorrentino JA
AD  - G1 Therapeutics, Research Triangle Park, North Carolina.
FAU - Bisi, John E
AU  - Bisi JE
AD  - G1 Therapeutics, Research Triangle Park, North Carolina.
FAU - Lizotte, Patrick H
AU  - Lizotte PH
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
AD  - Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Merlino, Ashley A
AU  - Merlino AA
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Quinn, Max M
AU  - Quinn MM
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Bufe, Lauren E
AU  - Bufe LE
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Yang, Annan
AU  - Yang A
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Zhang, Yanxi
AU  - Zhang Y
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Zhang, Hua
AU  - Zhang H
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Gao, Peng
AU  - Gao P
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Chen, Ting
AU  - Chen T
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Cavanaugh, Megan E
AU  - Cavanaugh ME
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
AD  - Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Rode, Amanda J
AU  - Rode AJ
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
AD  - Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Haines, Eric
AU  - Haines E
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Roberts, Patrick J
AU  - Roberts PJ
AD  - G1 Therapeutics, Research Triangle Park, North Carolina.
FAU - Strum, Jay C
AU  - Strum JC
AD  - G1 Therapeutics, Research Triangle Park, North Carolina.
FAU - Richards, William G
AU  - Richards WG
AD  - Division of Thoracic Surgery, Brigham and Women's Hospital, Boston,
      Massachusetts.
FAU - Lorch, Jochen H
AU  - Lorch JH
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Parangi, Sareh
AU  - Parangi S
AD  - Department of Surgery, Massachusetts General Hospital, Harvard Medical School,
      Boston, Massachusetts.
FAU - Gunda, Viswanath
AU  - Gunda V
AD  - Department of Surgery, Massachusetts General Hospital, Harvard Medical School,
      Boston, Massachusetts.
FAU - Boland, Genevieve M
AU  - Boland GM
AD  - Department of Surgery, Massachusetts General Hospital, Harvard Medical School,
      Boston, Massachusetts.
FAU - Bueno, Raphael
AU  - Bueno R
AD  - Division of Thoracic Surgery, Brigham and Women's Hospital, Boston,
      Massachusetts.
FAU - Palakurthi, Sangeetha
AU  - Palakurthi S
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
AD  - Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Freeman, Gordon J
AU  - Freeman GJ
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
AD  - Department of Medicine, Brigham and Women's Hospital, Harvard Medical School,
      Boston, Massachusetts.
FAU - Ritz, Jerome
AU  - Ritz J
AD  - Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Haining, W Nicholas
AU  - Haining WN
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Sharpless, Norman E
AU  - Sharpless NE
AD  - The Lineberger Comprehensive Cancer Center, University of North Carolina School
      of Medicine, Chapel Hill, North Carolina.
FAU - Arthanari, Haribabu
AU  - Arthanari H
AD  - Department of Cancer Biology, Dana-Farber Cancer Institute, Department of
      Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, 
      Massachusetts.
FAU - Shapiro, Geoffrey I
AU  - Shapiro GI
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
AD  - Department of Medicine, Brigham and Women's Hospital, Harvard Medical School,
      Boston, Massachusetts.
FAU - Barbie, David A
AU  - Barbie DA
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts. kwok-kin.wong@nyumc.org Nathanael_Gray@dfci.harvard.edu
      dbarbie@partners.org.
AD  - Department of Medicine, Brigham and Women's Hospital, Harvard Medical School,
      Boston, Massachusetts.
FAU - Gray, Nathanael S
AU  - Gray NS
AD  - Department of Cancer Biology, Dana-Farber Cancer Institute, Department of
      Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, 
      Massachusetts. kwok-kin.wong@nyumc.org Nathanael_Gray@dfci.harvard.edu
      dbarbie@partners.org.
FAU - Wong, Kwok-Kin
AU  - Wong KK
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts. kwok-kin.wong@nyumc.org Nathanael_Gray@dfci.harvard.edu
      dbarbie@partners.org.
AD  - Division of Hematology & Medical Oncology, Laura and Isaac Perlmutter Cancer
      Center, New York University Langone Medical Center, New York, New York.
AD  - Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
AD  - Department of Medicine, Brigham and Women's Hospital, Harvard Medical School,
      Boston, Massachusetts.
LA  - eng
GR  - R01 CA122794/CA/NCI NIH HHS/United States
GR  - P01 CA120964/CA/NCI NIH HHS/United States
GR  - R01 CA179483/CA/NCI NIH HHS/United States
GR  - P01 CA154303/CA/NCI NIH HHS/United States
GR  - R01 CA163896/CA/NCI NIH HHS/United States
GR  - R01 CA166480/CA/NCI NIH HHS/United States
GR  - R01 CA140594/CA/NCI NIH HHS/United States
GR  - R01 AG024379/AG/NIA NIH HHS/United States
PT  - Journal Article
DEP - 20171103
PL  - United States
TA  - Cancer Discov
JT  - Cancer discovery
JID - 101561693
EDAT- 2017/11/05 06:00
MHDA- 2017/11/05 06:00
CRDT- 2017/11/05 06:00
PHST- 2017/08/11 00:00 [received]
PHST- 2017/10/24 00:00 [revised]
PHST- 2017/10/31 00:00 [accepted]
PHST- 2017/11/05 06:00 [pubmed]
PHST- 2017/11/05 06:00 [medline]
PHST- 2017/11/05 06:00 [entrez]
AID - 2159-8290.CD-17-0915 [pii]
AID - 10.1158/2159-8290.CD-17-0915 [doi]
PST - aheadofprint
SO  - Cancer Discov. 2017 Nov 3. pii: 2159-8290.CD-17-0915. doi:
      10.1158/2159-8290.CD-17-0915.

PMID- 29257133
OWN - NLM
STAT- In-Process
LR  - 20180125
IS  - 2052-4463 (Electronic)
IS  - 2052-4463 (Linking)
VI  - 4
DP  - 2017 Dec 19
TI  - Sequence data and association statistics from 12,940 type 2 diabetes cases and
      controls.
PG  - 170179
LID - 10.1038/sdata.2017.179 [doi]
AB  - To investigate the genetic basis of type 2 diabetes (T2D) to high resolution, the
      GoT2D and T2D-GENES consortia catalogued variation from whole-genome sequencing
      of 2,657 European individuals and exome sequencing of 12,940 individuals of
      multiple ancestries. Over 27M SNPs, indels, and structural variants were
      identified, including 99% of low-frequency (minor allele frequency [MAF] 0.1-5%) 
      non-coding variants in the whole-genome sequenced individuals and 99.7% of
      low-frequency coding variants in the whole-exome sequenced individuals. Each
      variant was tested for association with T2D in the sequenced individuals, and, to
      increase power, most were tested in larger numbers of individuals (>80% of
      low-frequency coding variants in ~82 K Europeans via the exome chip, and ~90% of 
      low-frequency non-coding variants in ~44 K Europeans via genotype imputation).
      The variants, genotypes, and association statistics from these analyses provide
      the largest reference to date of human genetic information relevant to T2D, for
      use in activities such as T2D-focused genotype imputation, functional
      characterization of variants or genes, and other novel analyses to detect
      associations between sequence variation and T2D.
FAU - Jason, Flannick
AU  - Jason F
AD  - Department of Molecular Biology, Massachusetts General Hospital, Boston,
      Massachusetts, USA.
AD  - Program in Medical and Population Genetics, Broad Institute, Cambridge,
      Massachusetts, USA.
FAU - Fuchsberger, Christian
AU  - Fuchsberger C
AD  - Department of Biostatistics and Center for Statistical Genetics, University of
      Michigan, Ann Arbor, Michigan, USA.
FAU - Mahajan, Anubha
AU  - Mahajan A
AD  - Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine,
      University of Oxford, Oxford, UK.
FAU - Teslovich, Tanya M
AU  - Teslovich TM
AD  - Department of Biostatistics and Center for Statistical Genetics, University of
      Michigan, Ann Arbor, Michigan, USA.
FAU - Agarwala, Vineeta
AU  - Agarwala V
AD  - Program in Medical and Population Genetics, Broad Institute, Cambridge,
      Massachusetts, USA.
AD  - Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute
      of Technology, Cambridge, Massachusetts, USA.
FAU - Gaulton, Kyle J
AU  - Gaulton KJ
AUID- ORCID: 0000-0003-1318-7161
AD  - Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine,
      University of Oxford, Oxford, UK.
FAU - Caulkins, Lizz
AU  - Caulkins L
AD  - Program in Medical and Population Genetics, Broad Institute, Cambridge,
      Massachusetts, USA.
FAU - Koesterer, Ryan
AU  - Koesterer R
AD  - Program in Medical and Population Genetics, Broad Institute, Cambridge,
      Massachusetts, USA.
FAU - Ma, Clement
AU  - Ma C
AD  - Department of Biostatistics and Center for Statistical Genetics, University of
      Michigan, Ann Arbor, Michigan, USA.
FAU - Moutsianas, Loukas
AU  - Moutsianas L
AD  - Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine,
      University of Oxford, Oxford, UK.
FAU - McCarthy, Davis J
AU  - McCarthy DJ
AD  - Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine,
      University of Oxford, Oxford, UK.
AD  - Department of Statistics, University of Oxford, Oxford, UK.
FAU - Rivas, Manuel A
AU  - Rivas MA
AD  - Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine,
      University of Oxford, Oxford, UK.
FAU - Perry, John R B
AU  - Perry JRB
AD  - Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine,
      University of Oxford, Oxford, UK.
AD  - Genetics of Complex Traits, University of Exeter Medical School, University of
      Exeter, Exeter, UK.
AD  - MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge,
      Cambridge, UK.
AD  - Department of Twin Research and Genetic Epidemiology, King's College London,
      London, UK.
FAU - Sim, Xueling
AU  - Sim X
AD  - Department of Biostatistics and Center for Statistical Genetics, University of
      Michigan, Ann Arbor, Michigan, USA.
FAU - Blackwell, Thomas W
AU  - Blackwell TW
AD  - Department of Biostatistics and Center for Statistical Genetics, University of
      Michigan, Ann Arbor, Michigan, USA.
FAU - Robertson, Neil R
AU  - Robertson NR
AD  - Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine,
      University of Oxford, Oxford, UK.
AD  - Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of
      Medicine, University of Oxford, Oxford, UK.
FAU - Rayner, N William
AU  - Rayner NW
AD  - Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine,
      University of Oxford, Oxford, UK.
AD  - Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of
      Medicine, University of Oxford, Oxford, UK.
AD  - Department of Human Genetics, Wellcome Trust Sanger Institute, Hinxton,
      Cambridgeshire, UK.
FAU - Cingolani, Pablo
AU  - Cingolani P
AD  - School of Computer Science, McGill University, Montreal, Quebec, Canada.
AD  - McGill University and Genome Quebec Innovation Centre, Montreal, Quebec, Canada.
FAU - Locke, Adam E
AU  - Locke AE
AUID- ORCID: 0000-0001-6227-198X
AD  - Department of Biostatistics and Center for Statistical Genetics, University of
      Michigan, Ann Arbor, Michigan, USA.
FAU - Tajes, Juan Fernandez
AU  - Tajes JF
AD  - Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine,
      University of Oxford, Oxford, UK.
FAU - Highland, Heather M
AU  - Highland HM
AD  - Human Genetics Center, The University of Texas Graduate School of Biomedical
      Sciences at Houston, The University of Texas Health Science Center at Houston,
      Houston, Texas, USA.
FAU - Dupuis, Josee
AU  - Dupuis J
AD  - Department of Biostatistics, Boston University School of Public Health, Boston,
      Massachusetts, USA.
AD  - National Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham,
      Massachusetts, USA.
FAU - Chines, Peter S
AU  - Chines PS
AD  - Medical Genomics and Metabolic Genetics Branch, National Human Genome Research
      Institute, National Institutes of Health, Bethesda, Maryland, USA.
FAU - Lindgren, Cecilia M
AU  - Lindgren CM
AD  - Program in Medical and Population Genetics, Broad Institute, Cambridge,
      Massachusetts, USA.
AD  - Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine,
      University of Oxford, Oxford, UK.
FAU - Hartl, Christopher
AU  - Hartl C
AD  - Program in Medical and Population Genetics, Broad Institute, Cambridge,
      Massachusetts, USA.
FAU - Jackson, Anne U
AU  - Jackson AU
AD  - Department of Biostatistics and Center for Statistical Genetics, University of
      Michigan, Ann Arbor, Michigan, USA.
FAU - Chen, Han
AU  - Chen H
AD  - Department of Biostatistics, Boston University School of Public Health, Boston,
      Massachusetts, USA.
AD  - Department of Biostatistics, Harvard School of Public Health, Boston,
      Massachusetts, USA.
FAU - Huyghe, Jeroen R
AU  - Huyghe JR
AD  - Department of Biostatistics and Center for Statistical Genetics, University of
      Michigan, Ann Arbor, Michigan, USA.
FAU - van de Bunt, Martijn
AU  - van de Bunt M
AUID- ORCID: 0000-0002-6744-6125
AD  - Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine,
      University of Oxford, Oxford, UK.
AD  - Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of
      Medicine, University of Oxford, Oxford, UK.
FAU - Pearson, Richard D
AU  - Pearson RD
AD  - Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine,
      University of Oxford, Oxford, UK.
FAU - Kumar, Ashish
AU  - Kumar A
AD  - Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine,
      University of Oxford, Oxford, UK.
AD  - Chronic Disease Epidemiology, Swiss Tropical and Public Health Institute,
      University of Basel, Basel, Switzerland.
FAU - Muller-Nurasyid, Martina
AU  - Muller-Nurasyid M
AUID- ORCID: 0000-0002-7898-2353
AD  - Institute of Genetic Epidemiology, Helmholtz Zentrum Munchen, German Research
      Center for Environmental Health, Neuherberg, Germany.
AD  - Department of Medicine I, University Hospital Grosshadern,
      Ludwig-Maximilians-Universitat, Munich, Germany.
AD  - Chair of Genetic Epidemiology, IBE, Faculty of Medicine, LMU Munich, Germany.
AD  - DZHK (German Centre for Cardiovascular Research), partner site Munich Heart
      Alliance, Munich, Germany.
FAU - Grarup, Niels
AU  - Grarup N
AUID- ORCID: 0000-0001-5526-1070
AD  - The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of
      Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
FAU - Stringham, Heather M
AU  - Stringham HM
AUID- ORCID: 0000-0002-2991-6392
AD  - Department of Biostatistics and Center for Statistical Genetics, University of
      Michigan, Ann Arbor, Michigan, USA.
FAU - Gamazon, Eric R
AU  - Gamazon ER
AUID- ORCID: 0000-0003-4204-8734
AD  - Department of Medicine, Section of Genetic Medicine, The University of Chicago,
      Chicago, Illinois, USA.
FAU - Lee, Jaehoon
AU  - Lee J
AD  - Department of Statistics, Seoul National University, Seoul, Republic of Korea.
FAU - Chen, Yuhui
AU  - Chen Y
AD  - Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine,
      University of Oxford, Oxford, UK.
FAU - Scott, Robert A
AU  - Scott RA
AD  - MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge,
      Cambridge, UK.
FAU - Below, Jennifer E
AU  - Below JE
AD  - Human Genetics Center, School of Public Health, The University of Texas Health
      Science Center at Houston, Houston, Texas, USA.
FAU - Chen, Peng
AU  - Chen P
AD  - Saw Swee Hock School of Public Health, National University of Singapore, National
      University Health System, Singapore, Singapore.
FAU - Huang, Jinyan
AU  - Huang J
AD  - Department of Epidemiology, Harvard School of Public Health, Boston,
      Massachusetts, USA.
FAU - Go, Min Jin
AU  - Go MJ
AD  - Center for Genome Science, Korea National Institute of Health, Chungcheongbuk-do,
      Republic of Korea.
FAU - Stitzel, Michael L
AU  - Stitzel ML
AD  - The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut, USA.
FAU - Pasko, Dorota
AU  - Pasko D
AD  - Genetics of Complex Traits, University of Exeter Medical School, University of
      Exeter, Exeter, UK.
FAU - Parker, Stephen C J
AU  - Parker SCJ
AD  - Departments of Computational Medicine & Bioinformatics and Human Genetics,
      University of Michigan, Ann Arbor, Michigan, USA.
FAU - Varga, Tibor V
AU  - Varga TV
AUID- ORCID: 0000-0002-2383-699X
AD  - Department of Clinical Sciences, Lund University Diabetes Centre, Genetic and
      Molecular Epidemiology Unit, Lund University, Malmo, Sweden.
FAU - Green, Todd
AU  - Green T
AD  - Program in Medical and Population Genetics, Broad Institute, Cambridge,
      Massachusetts, USA.
FAU - Beer, Nicola L
AU  - Beer NL
AUID- ORCID: 0000-0002-4964-7150
AD  - Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of
      Medicine, University of Oxford, Oxford, UK.
FAU - Day-Williams, Aaron G
AU  - Day-Williams AG
AD  - Department of Human Genetics, Wellcome Trust Sanger Institute, Hinxton,
      Cambridgeshire, UK.
FAU - Ferreira, Teresa
AU  - Ferreira T
AD  - Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine,
      University of Oxford, Oxford, UK.
FAU - Fingerlin, Tasha
AU  - Fingerlin T
AD  - Department of Epidemiology, Colorado School of Public Health, University of
      Colorado, Aurora, Colorado, USA.
FAU - Horikoshi, Momoko
AU  - Horikoshi M
AD  - Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine,
      University of Oxford, Oxford, UK.
AD  - Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of
      Medicine, University of Oxford, Oxford, UK.
FAU - Hu, Cheng
AU  - Hu C
AD  - Department of Endocrinology and Metabolism, Shanghai Diabetes Institute, Shanghai
      Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.
FAU - Huh, Iksoo
AU  - Huh I
AD  - Department of Statistics, Seoul National University, Seoul, Republic of Korea.
FAU - Ikram, Mohammad Kamran
AU  - Ikram MK
AD  - Singapore Eye Research Institute, Singapore National Eye Centre, Singapore,
      Singapore.
AD  - Department of Ophthalmology, Yong Loo Lin School of Medicine, National University
      of Singapore, National University Health System, Singapore, Singapore.
AD  - The Eye Academic Clinical Programme, Duke-NUS Graduate Medical School, Singapore,
      Singapore.
FAU - Kim, Bong-Jo
AU  - Kim BJ
AD  - Center for Genome Science, Korea National Institute of Health, Chungcheongbuk-do,
      Republic of Korea.
FAU - Kim, Yongkang
AU  - Kim Y
AD  - Department of Statistics, Seoul National University, Seoul, Republic of Korea.
FAU - Kim, Young Jin
AU  - Kim YJ
AD  - Center for Genome Science, Korea National Institute of Health, Chungcheongbuk-do,
      Republic of Korea.
FAU - Kwon, Min-Seok
AU  - Kwon MS
AD  - Interdisciplinary Program in Bioinformatics, Seoul National University, Seoul,
      Republic of Korea.
FAU - Lee, Juyoung
AU  - Lee J
AD  - Center for Genome Science, Korea National Institute of Health, Chungcheongbuk-do,
      Republic of Korea.
FAU - Lee, Selyeong
AU  - Lee S
AD  - Department of Statistics, Seoul National University, Seoul, Republic of Korea.
FAU - Lin, Keng-Han
AU  - Lin KH
AD  - Department of Biostatistics and Center for Statistical Genetics, University of
      Michigan, Ann Arbor, Michigan, USA.
FAU - Maxwell, Taylor J
AU  - Maxwell TJ
AD  - Human Genetics Center, School of Public Health, The University of Texas Health
      Science Center at Houston, Houston, Texas, USA.
FAU - Nagai, Yoshihiko
AU  - Nagai Y
AD  - McGill University and Genome Quebec Innovation Centre, Montreal, Quebec, Canada.
AD  - Department of Human Genetics, McGill University, Montreal, Quebec, Canada.
AD  - Research Institute of the McGill University Health Centre, Montreal, Quebec,
      Canada.
FAU - Wang, Xu
AU  - Wang X
AD  - Saw Swee Hock School of Public Health, National University of Singapore, National
      University Health System, Singapore, Singapore.
FAU - Welch, Ryan P
AU  - Welch RP
AUID- ORCID: 0000-0001-6378-1295
AD  - Department of Biostatistics and Center for Statistical Genetics, University of
      Michigan, Ann Arbor, Michigan, USA.
FAU - Yoon, Joon
AU  - Yoon J
AUID- ORCID: 0000-0002-9509-119X
AD  - Interdisciplinary Program in Bioinformatics, Seoul National University, Seoul,
      Republic of Korea.
FAU - Zhang, Weihua
AU  - Zhang W
AD  - Department of Epidemiology and Biostatistics, Imperial College London, London,
      UK.
AD  - Department of Cardiology, Ealing Hospital NHS Trust, Southall, Middlesex, UK.
FAU - Barzilai, Nir
AU  - Barzilai N
AD  - Departments of Medicine and Genetics, Albert Einstein College of Medicine, New
      York, USA.
FAU - Voight, Benjamin F
AU  - Voight BF
AUID- ORCID: 0000-0002-6205-9994
AD  - Department of Systems Pharmacology and Translational Therapeutics, University of 
      Pennsylvania-Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
AD  - Department of Genetics, University of Pennsylvania-Perelman School of Medicine,
      Philadelphia, Pennsylvania, USA.
FAU - Han, Bok-Ghee
AU  - Han BG
AD  - Center for Genome Science, Korea National Institute of Health, Chungcheongbuk-do,
      Republic of Korea.
FAU - Jenkinson, Christopher P
AU  - Jenkinson CP
AD  - Department of Medicine, University of Texas Health Science Center, San Antonio,
      Texas, USA.
AD  - Research, South Texas Veterans Health Care System, San Antonio, Texas, USA.
FAU - Kuulasmaa, Teemu
AU  - Kuulasmaa T
AD  - Faculty of Health Sciences, Institute of Clinical Medicine, Internal Medicine,
      University of Eastern Finland, Kuopio, Finland.
FAU - Kuusisto, Johanna
AU  - Kuusisto J
AD  - Faculty of Health Sciences, Institute of Clinical Medicine, Internal Medicine,
      University of Eastern Finland, Kuopio, Finland.
AD  - Kuopio University Hospital, Kuopio, Finland.
FAU - Manning, Alisa
AU  - Manning A
AD  - Program in Medical and Population Genetics, Broad Institute, Cambridge,
      Massachusetts, USA.
FAU - Ng, Maggie C Y
AU  - Ng MCY
AD  - Center for Genomics and Personalized Medicine Research, Wake Forest School of
      Medicine, Winston-Salem, North Carolina, USA.
AD  - Center for Diabetes Research, Wake Forest School of Medicine, Winston-Salem,
      North Carolina, USA.
FAU - Palmer, Nicholette D
AU  - Palmer ND
AD  - Center for Genomics and Personalized Medicine Research, Wake Forest School of
      Medicine, Winston-Salem, North Carolina, USA.
AD  - Center for Diabetes Research, Wake Forest School of Medicine, Winston-Salem,
      North Carolina, USA.
AD  - Department of Biochemistry, Wake Forest School of Medicine, Winston-Salem, North 
      Carolina, USA.
FAU - Balkau, Beverley
AU  - Balkau B
AD  - Centre for Research in Epidemiology and Population Health, Inserm U1018,
      Villejuif, France.
FAU - Stancakova, Alena
AU  - Stancakova A
AD  - Faculty of Health Sciences, Institute of Clinical Medicine, Internal Medicine,
      University of Eastern Finland, Kuopio, Finland.
FAU - Abboud, Hanna E
AU  - Abboud HE
AD  - Department of Medicine, University of Texas Health Science Center, San Antonio,
      Texas, USA.
FAU - Boeing, Heiner
AU  - Boeing H
AD  - German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.
FAU - Giedraitis, Vilmantas
AU  - Giedraitis V
AUID- ORCID: 0000-0003-3423-2021
AD  - Department of Public Health and Caring Sciences, Geriatrics, Uppsala University, 
      Uppsala, Sweden.
FAU - Prabhakaran, Dorairaj
AU  - Prabhakaran D
AD  - Centre for Chronic Disease Control, New Delhi, India.
FAU - Gottesman, Omri
AU  - Gottesman O
AD  - The Charles Bronfman Institute for Personalized Medicine, The Icahn School of
      Medicine at Mount Sinai, New York, USA.
FAU - Scott, James
AU  - Scott J
AD  - National Heart and Lung Institute, Cardiovascular Sciences, Hammersmith Campus,
      Imperial College London, London, UK.
FAU - Carey, Jason
AU  - Carey J
AD  - Program in Medical and Population Genetics, Broad Institute, Cambridge,
      Massachusetts, USA.
FAU - Kwan, Phoenix
AU  - Kwan P
AD  - Department of Biostatistics and Center for Statistical Genetics, University of
      Michigan, Ann Arbor, Michigan, USA.
FAU - Grant, George
AU  - Grant G
AD  - Program in Medical and Population Genetics, Broad Institute, Cambridge,
      Massachusetts, USA.
FAU - Smith, Joshua D
AU  - Smith JD
AD  - Department of Genome Sciences, University of Washington School of Medicine,
      Seattle, Washington, USA.
FAU - Neale, Benjamin M
AU  - Neale BM
AUID- ORCID: 0000-0003-1513-6077
AD  - Program in Medical and Population Genetics, Broad Institute, Cambridge,
      Massachusetts, USA.
AD  - Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts
      General Hospital, Boston, Massachusetts, USA.
FAU - Purcell, Shaun
AU  - Purcell S
AD  - Program in Medical and Population Genetics, Broad Institute, Cambridge,
      Massachusetts, USA.
AD  - Center for Genomic Medicine, Department of Medicine, Massachusetts General
      Hospital, Boston, Massachusetts, USA.
AD  - Department of Psychiatry, Icahn Institute for Genomics and Multiscale Biology,
      Icahn School of Medicine at Mount Sinai, New York, USA.
FAU - Butterworth, Adam S
AU  - Butterworth AS
AD  - Department of Public Health and Primary Care, University of Cambridge, Cambridge,
      UK.
FAU - Howson, Joanna M M
AU  - Howson JMM
AD  - Department of Public Health and Primary Care, University of Cambridge, Cambridge,
      UK.
FAU - Lee, Heung Man
AU  - Lee HM
AD  - Department of Medicine and Therapeutics, The Chinese University of Hong Kong,
      Hong Kong, China.
FAU - Lu, Yingchang
AU  - Lu Y
AD  - The Charles Bronfman Institute for Personalized Medicine, The Icahn School of
      Medicine at Mount Sinai, New York, USA.
FAU - Kwak, Soo-Heon
AU  - Kwak SH
AD  - Department of Internal Medicine, Seoul National University College of Medicine,
      Seoul, Republic of Korea.
FAU - Zhao, Wei
AU  - Zhao W
AD  - Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania,
      USA.
FAU - Danesh, John
AU  - Danesh J
AD  - Department of Human Genetics, Wellcome Trust Sanger Institute, Hinxton,
      Cambridgeshire, UK.
AD  - Department of Public Health and Primary Care, University of Cambridge, Cambridge,
      UK.
AD  - NIHR Blood and Transplant Research Unit in Donor Health and Genomics, Department 
      of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
FAU - Lam, Vincent K L
AU  - Lam VKL
AD  - Department of Medicine and Therapeutics, The Chinese University of Hong Kong,
      Hong Kong, China.
FAU - Park, Kyong Soo
AU  - Park KS
AUID- ORCID: 0000-0003-3597-342X
AD  - Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School 
      of Convergence Science and Technology, and College of Medicine, Seoul National
      University, Seoul, Republic of Korea.
FAU - Saleheen, Danish
AU  - Saleheen D
AD  - Department of Biostatistics and Epidemiology, University of Pennsylvania,
      Philadelphia, Pennsylvania, USA.
AD  - Center for Non-Communicable Diseases, Karachi, Pakistan.
FAU - So, Wing Yee
AU  - So WY
AD  - Department of Medicine and Therapeutics, The Chinese University of Hong Kong,
      Hong Kong, China.
FAU - Tam, Claudia H T
AU  - Tam CHT
AD  - Department of Medicine and Therapeutics, The Chinese University of Hong Kong,
      Hong Kong, China.
FAU - Afzal, Uzma
AU  - Afzal U
AD  - Department of Epidemiology and Biostatistics, Imperial College London, London,
      UK.
FAU - Aguilar, David
AU  - Aguilar D
AD  - Cardiovascular Division, Baylor College of Medicine, Houston, Texas, USA.
FAU - Arya, Rector
AU  - Arya R
AD  - Department of Pediatrics, University of Texas Health Science Center, San Antonio,
      Texas, USA.
FAU - Aung, Tin
AU  - Aung T
AD  - Singapore Eye Research Institute, Singapore National Eye Centre, Singapore,
      Singapore.
AD  - Department of Ophthalmology, Yong Loo Lin School of Medicine, National University
      of Singapore, National University Health System, Singapore, Singapore.
AD  - The Eye Academic Clinical Programme, Duke-NUS Graduate Medical School, Singapore,
      Singapore.
FAU - Chan, Edmund
AU  - Chan E
AD  - Department of Medicine, Yong Loo Lin School of Medicine, National University of
      Singapore, National University Health System, Singapore, Singapore.
FAU - Navarro, Carmen
AU  - Navarro C
AD  - Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca,
      Murcia, Spain.
AD  - CIBER Epidemiologia y Salud Publica (CIBERESP), Spain.
AD  - Unit of Preventive Medicine and Public Health, School of Medicine, University of 
      Murcia, Spain.
FAU - Cheng, Ching-Yu
AU  - Cheng CY
AD  - Saw Swee Hock School of Public Health, National University of Singapore, National
      University Health System, Singapore, Singapore.
AD  - Singapore Eye Research Institute, Singapore National Eye Centre, Singapore,
      Singapore.
AD  - Department of Ophthalmology, Yong Loo Lin School of Medicine, National University
      of Singapore, National University Health System, Singapore, Singapore.
AD  - The Eye Academic Clinical Programme, Duke-NUS Graduate Medical School, Singapore,
      Singapore.
FAU - Palli, Domenico
AU  - Palli D
AUID- ORCID: 0000-0002-5558-2437
AD  - Cancer Research and Prevention Institute (ISPO), Florence, Italy.
FAU - Correa, Adolfo
AU  - Correa A
AD  - Department of Medicine, University of Mississippi Medical Center, Jackson,
      Mississippi, USA.
FAU - Curran, Joanne E
AU  - Curran JE
AD  - South Texas Diabetes and Obesity Institute, Regional Academic Health Center,
      University of Texas Health Science Center at San Antonio/University of Texas Rio 
      Grande Valley, Brownsville, Texas, USA.
FAU - Rybin, Dennis
AU  - Rybin D
AD  - Department of Biostatistics, Boston University School of Public Health, Boston,
      Massachusetts, USA.
FAU - Farook, Vidya S
AU  - Farook VS
AD  - Department of Genetics, Texas Biomedical Research Institute, San Antonio, Texas, 
      USA.
FAU - Fowler, Sharon P
AU  - Fowler SP
AD  - Department of Medicine, University of Texas Health Science Center, San Antonio,
      Texas, USA.
FAU - Freedman, Barry I
AU  - Freedman BI
AD  - Department of Internal Medicine, Section on Nephrology, Wake Forest School of
      Medicine, Winston-Salem, North Carolina, USA.
FAU - Griswold, Michael
AU  - Griswold M
AD  - Center of Biostatistics and Bioinformatics, University of Mississippi Medical
      Center, Jackson, Mississippi, USA.
FAU - Hale, Daniel Esten
AU  - Hale DE
AD  - Department of Pediatrics, University of Texas Health Science Center, San Antonio,
      Texas, USA.
FAU - Hicks, Pamela J
AU  - Hicks PJ
AD  - Center for Genomics and Personalized Medicine Research, Wake Forest School of
      Medicine, Winston-Salem, North Carolina, USA.
AD  - Center for Diabetes Research, Wake Forest School of Medicine, Winston-Salem,
      North Carolina, USA.
AD  - Department of Biochemistry, Wake Forest School of Medicine, Winston-Salem, North 
      Carolina, USA.
FAU - Khor, Chiea-Chuen
AU  - Khor CC
AUID- ORCID: 0000-0002-1128-4729
AD  - Saw Swee Hock School of Public Health, National University of Singapore, National
      University Health System, Singapore, Singapore.
AD  - Singapore Eye Research Institute, Singapore National Eye Centre, Singapore,
      Singapore.
AD  - Department of Ophthalmology, Yong Loo Lin School of Medicine, National University
      of Singapore, National University Health System, Singapore, Singapore.
AD  - Department of Paediatrics, Yong Loo Lin School of Medicine, National University
      of Singapore, National University Health System, Singapore, Singapore.
AD  - Division of Human Genetics, Genome Institute of Singapore, A*STAR, Singapore,
      Singapore.
FAU - Kumar, Satish
AU  - Kumar S
AUID- ORCID: 0000-0002-1969-4431
AD  - South Texas Diabetes and Obesity Institute, Regional Academic Health Center,
      University of Texas Health Science Center at San Antonio/University of Texas Rio 
      Grande Valley, Brownsville, Texas, USA.
FAU - Lehne, Benjamin
AU  - Lehne B
AD  - Department of Epidemiology and Biostatistics, Imperial College London, London,
      UK.
FAU - Thuillier, Dorothee
AU  - Thuillier D
AD  - CNRS-UMR8199, Lille University, Lille Pasteur Institute, Lille, France.
FAU - Lim, Wei Yen
AU  - Lim WY
AD  - Saw Swee Hock School of Public Health, National University of Singapore, National
      University Health System, Singapore, Singapore.
FAU - Liu, Jianjun
AU  - Liu J
AD  - Saw Swee Hock School of Public Health, National University of Singapore, National
      University Health System, Singapore, Singapore.
AD  - Division of Human Genetics, Genome Institute of Singapore, A*STAR, Singapore,
      Singapore.
FAU - Loh, Marie
AU  - Loh M
AD  - Department of Epidemiology and Biostatistics, Imperial College London, London,
      UK.
AD  - Institute of Health Sciences, University of Oulu, Oulu, Finland.
AD  - Translational Laboratory in Genetic Medicine (TLGM), Agency for Science,
      Technology and Research (A*STAR), Singapore, Singapore.
FAU - Musani, Solomon K
AU  - Musani SK
AD  - Jackson Heart Study, University of Mississippi Medical Center, Jackson,
      Mississippi, USA.
FAU - Puppala, Sobha
AU  - Puppala S
AD  - Department of Genetics, Texas Biomedical Research Institute, San Antonio, Texas, 
      USA.
FAU - Scott, William R
AU  - Scott WR
AD  - Department of Epidemiology and Biostatistics, Imperial College London, London,
      UK.
FAU - Yengo, Loic
AU  - Yengo L
AD  - CNRS-UMR8199, Lille University, Lille Pasteur Institute, Lille, France.
FAU - Tan, Sian-Tsung
AU  - Tan ST
AD  - Department of Cardiology, Ealing Hospital NHS Trust, Southall, Middlesex, UK.
AD  - National Heart and Lung Institute, Cardiovascular Sciences, Hammersmith Campus,
      Imperial College London, London, UK.
FAU - Taylor, Herman A
AU  - Taylor HA
AD  - Department of Medicine, University of Mississippi Medical Center, Jackson,
      Mississippi, USA.
FAU - Thameem, Farook
AU  - Thameem F
AD  - Department of Medicine, University of Texas Health Science Center, San Antonio,
      Texas, USA.
FAU - Wilson, Gregory
AU  - Wilson G
AD  - College of Public Services, Jackson State University, Jackson, Mississippi, USA.
FAU - Wong, Tien Yin
AU  - Wong TY
AD  - Singapore Eye Research Institute, Singapore National Eye Centre, Singapore,
      Singapore.
AD  - Department of Ophthalmology, Yong Loo Lin School of Medicine, National University
      of Singapore, National University Health System, Singapore, Singapore.
AD  - The Eye Academic Clinical Programme, Duke-NUS Graduate Medical School, Singapore,
      Singapore.
FAU - Njolstad, Pal Rasmus
AU  - Njolstad PR
AD  - KG Jebsen Center for Diabetes Research, Department of Clinical Science,
      University of Bergen, Bergen, Norway.
AD  - Department of Pediatrics, Haukeland University Hospital, Bergen, Norway.
FAU - Levy, Jonathan C
AU  - Levy JC
AD  - Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of
      Medicine, University of Oxford, Oxford, UK.
FAU - Mangino, Massimo
AU  - Mangino M
AUID- ORCID: 0000-0002-2167-7470
AD  - Department of Twin Research and Genetic Epidemiology, King's College London,
      London, UK.
AD  - NIHR Biomedical Research Centre at Guy's and St Thomas' Foundation Trust, London,
      UK.
FAU - Bonnycastle, Lori L
AU  - Bonnycastle LL
AD  - Medical Genomics and Metabolic Genetics Branch, National Human Genome Research
      Institute, National Institutes of Health, Bethesda, Maryland, USA.
FAU - Schwarzmayr, Thomas
AU  - Schwarzmayr T
AD  - Institute of Human Genetics, Helmholtz Zentrum Munchen, German Research Center
      for Environmental Health, Neuherberg, Germany.
FAU - Fadista, Joao
AU  - Fadista J
AD  - Department of Clinical Sciences, Diabetes and Endocrinology, Lund University
      Diabetes Centre, Malmo, Sweden.
FAU - Surdulescu, Gabriela L
AU  - Surdulescu GL
AD  - Department of Twin Research and Genetic Epidemiology, King's College London,
      London, UK.
FAU - Herder, Christian
AU  - Herder C
AUID- ORCID: 0000-0002-2050-093X
AD  - Institute of Clinical Diabetology, German Diabetes Center, Leibniz Center for
      Diabetes Research at Heinrich Heine University, Dusseldorf, Germany.
AD  - German Center for Diabetes Research (DZD), Munchen-Neuherberg, Germany.
FAU - Groves, Christopher J
AU  - Groves CJ
AD  - Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of
      Medicine, University of Oxford, Oxford, UK.
FAU - Wieland, Thomas
AU  - Wieland T
AD  - Institute of Human Genetics, Helmholtz Zentrum Munchen, German Research Center
      for Environmental Health, Neuherberg, Germany.
FAU - Bork-Jensen, Jette
AU  - Bork-Jensen J
AD  - The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of
      Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
FAU - Brandslund, Ivan
AU  - Brandslund I
AD  - Institute of Regional Health Research, University of Southern Denmark, Odense,
      Denmark.
AD  - Department of Clinical Biochemistry, Vejle Hospital, Vejle, Denmark.
FAU - Christensen, Cramer
AU  - Christensen C
AD  - Department of Internal Medicine and Endocrinology, Vejle Hospital, Vejle,
      Denmark.
FAU - Koistinen, Heikki A
AU  - Koistinen HA
AUID- ORCID: 0000-0001-7870-070X
AD  - Department of Health, National Institute for Health and Welfare, Helsinki,
      Finland.
AD  - Abdominal Center: Endocrinology, University of Helsinki and Helsinki University
      Central Hospital, Helsinki, Finland.
AD  - Minerva Foundation Institute for Medical Research, Helsinki, Finland.
AD  - Department of Medicine, University of Helsinki and Helsinki University Central
      Hospital, Helsinki, Finland.
FAU - Doney, Alex S F
AU  - Doney ASF
AD  - Division of Cardiovascular and Diabetes Medicine, Medical Research Institute,
      Ninewells Hospital and Medical School, Dundee, UK.
FAU - Kinnunen, Leena
AU  - Kinnunen L
AD  - Department of Health, National Institute for Health and Welfare, Helsinki,
      Finland.
FAU - Esko, Tonu
AU  - Esko T
AD  - Program in Medical and Population Genetics, Broad Institute, Cambridge,
      Massachusetts, USA.
AD  - Estonian Genome Center, University of Tartu, Tartu, Estonia.
AD  - Department of Genetics, Harvard Medical School, Boston, Massachusetts, USA.
AD  - Division of Endocrinology, Boston Children's Hospital, Boston, Massachusetts,
      USA.
FAU - Farmer, Andrew J
AU  - Farmer AJ
AD  - Nuffield Department of Primary Care Health Sciences, University of Oxford,
      Oxford, UK.
FAU - Hakaste, Liisa
AU  - Hakaste L
AD  - Abdominal Center: Endocrinology, University of Helsinki and Helsinki University
      Central Hospital, Helsinki, Finland.
AD  - Folkhalsan Research Centre, Helsinki, Finland.
AD  - Research Programs Unit, Diabetes and Obesity, University of Helsinki, Helsinki,
      Finland.
FAU - Hodgkiss, Dylan
AU  - Hodgkiss D
AD  - Department of Twin Research and Genetic Epidemiology, King's College London,
      London, UK.
FAU - Kravic, Jasmina
AU  - Kravic J
AD  - Department of Clinical Sciences, Diabetes and Endocrinology, Lund University
      Diabetes Centre, Malmo, Sweden.
FAU - Lyssenko, Valeri
AU  - Lyssenko V
AD  - Department of Clinical Sciences, Diabetes and Endocrinology, Lund University
      Diabetes Centre, Malmo, Sweden.
FAU - Hollensted, Mette
AU  - Hollensted M
AD  - The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of
      Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
FAU - Jorgensen, Marit E
AU  - Jorgensen ME
AD  - Steno Diabetes Center, Gentofte, Denmark.
FAU - Jorgensen, Torben
AU  - Jorgensen T
AD  - Research Centre for Prevention and Health, Capital Region of Denmark, Glostrup,
      Denmark.
AD  - Department of Public Health, Institute of Health Sciences, University of
      Copenhagen, Copenhagen, Denmark.
AD  - Faculty of Medicine, Aalborg University, Aalborg, Denmark.
FAU - Ladenvall, Claes
AU  - Ladenvall C
AD  - Department of Clinical Sciences, Diabetes and Endocrinology, Lund University
      Diabetes Centre, Malmo, Sweden.
FAU - Justesen, Johanne Marie
AU  - Justesen JM
AUID- ORCID: 0000-0002-0484-8522
AD  - The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of
      Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
FAU - Karajamaki, Annemari
AU  - Karajamaki A
AD  - Department of Primary Health Care, Vaasa Central Hospital, Vaasa, Finland.
AD  - Diabetes Center, Vaasa Health Care Center, Vaasa, Finland.
FAU - Kriebel, Jennifer
AU  - Kriebel J
AUID- ORCID: 0000-0003-4270-018X
AD  - German Center for Diabetes Research (DZD), Munchen-Neuherberg, Germany.
AD  - Institute of Epidemiology II, Helmholtz Zentrum Munchen, German Research Center
      for Environmental Health, Neuherberg, Germany.
AD  - Research Unit of Molecular Epidemiology, Helmholtz Zentrum Munchen, German
      Research Center for Environmental Health, Neuherberg, Germany.
FAU - Rathmann, Wolfgang
AU  - Rathmann W
AD  - German Center for Diabetes Research (DZD), Munchen-Neuherberg, Germany.
AD  - Institute for Biometrics and Epidemiology, German Diabetes Center, Leibniz Center
      for Diabetes Research at Heinrich Heine University, Dusseldorf, Germany.
FAU - Lannfelt, Lars
AU  - Lannfelt L
AD  - Department of Public Health and Caring Sciences, Geriatrics, Uppsala University, 
      Uppsala, Sweden.
FAU - Lauritzen, Torsten
AU  - Lauritzen T
AD  - Department of Public Health, Section of General Practice, Aarhus University,
      Aarhus, Denmark.
FAU - Narisu, Narisu
AU  - Narisu N
AD  - Medical Genomics and Metabolic Genetics Branch, National Human Genome Research
      Institute, National Institutes of Health, Bethesda, Maryland, USA.
FAU - Linneberg, Allan
AU  - Linneberg A
AD  - Research Centre for Prevention and Health, Capital Region of Denmark, Glostrup,
      Denmark.
AD  - Department of Clinical Experimental Research, Rigshospitalet, Glostrup, Denmark.
AD  - Department of Clinical Medicine, Faculty of Health and Medical Sciences,
      University of Copenhagen, Copenhagen, Denmark.
FAU - Melander, Olle
AU  - Melander O
AD  - Department of Clinical Sciences, Hypertension and Cardiovascular Disease, Lund
      University, Malmo, Sweden.
FAU - Milani, Lili
AU  - Milani L
AUID- ORCID: 0000-0002-5323-3102
AD  - Estonian Genome Center, University of Tartu, Tartu, Estonia.
FAU - Neville, Matt
AU  - Neville M
AD  - Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of
      Medicine, University of Oxford, Oxford, UK.
AD  - Oxford NIHR Biomedical Research Centre, Oxford University Hospitals Trust,
      Oxford, UK.
FAU - Orho-Melander, Marju
AU  - Orho-Melander M
AD  - Department of Clinical Sciences, Diabetes and Cardiovascular Disease, Genetic
      Epidemiology, Lund University, Malmo, Sweden.
FAU - Qi, Lu
AU  - Qi L
AD  - Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts, 
      USA.
AD  - Channing Division of Network Medicine, Department of Medicine, Brigham and
      Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
FAU - Qi, Qibin
AU  - Qi Q
AD  - Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts, 
      USA.
AD  - Department of Epidemiology and Population Health, Albert Einstein College of
      Medicine, New York, USA.
FAU - Roden, Michael
AU  - Roden M
AD  - Institute of Clinical Diabetology, German Diabetes Center, Leibniz Center for
      Diabetes Research at Heinrich Heine University, Dusseldorf, Germany.
AD  - German Center for Diabetes Research (DZD), Munchen-Neuherberg, Germany.
AD  - Division of Endocrinology and Diabetology, Medical Faculty, Heinrich-Heine
      University, Dusseldorf, Germany.
FAU - Rolandsson, Olov
AU  - Rolandsson O
AD  - Department of Public Health and Clinical Medicine, Umea University, Umea, Sweden.
FAU - Swift, Amy
AU  - Swift A
AD  - Medical Genomics and Metabolic Genetics Branch, National Human Genome Research
      Institute, National Institutes of Health, Bethesda, Maryland, USA.
FAU - Rosengren, Anders H
AU  - Rosengren AH
AD  - Department of Clinical Sciences, Diabetes and Endocrinology, Lund University
      Diabetes Centre, Malmo, Sweden.
FAU - Stirrups, Kathleen
AU  - Stirrups K
AD  - Department of Human Genetics, Wellcome Trust Sanger Institute, Hinxton,
      Cambridgeshire, UK.
FAU - Wood, Andrew R
AU  - Wood AR
AD  - Genetics of Complex Traits, University of Exeter Medical School, University of
      Exeter, Exeter, UK.
FAU - Mihailov, Evelin
AU  - Mihailov E
AD  - Estonian Genome Center, University of Tartu, Tartu, Estonia.
FAU - Blancher, Christine
AU  - Blancher C
AD  - High Throughput Genomics, Oxford Genomics Centre, Wellcome Trust Centre for Human
      Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
FAU - Carneiro, Mauricio O
AU  - Carneiro MO
AD  - Program in Medical and Population Genetics, Broad Institute, Cambridge,
      Massachusetts, USA.
FAU - Maguire, Jared
AU  - Maguire J
AD  - Program in Medical and Population Genetics, Broad Institute, Cambridge,
      Massachusetts, USA.
FAU - Poplin, Ryan
AU  - Poplin R
AD  - Program in Medical and Population Genetics, Broad Institute, Cambridge,
      Massachusetts, USA.
FAU - Shakir, Khalid
AU  - Shakir K
AD  - Program in Medical and Population Genetics, Broad Institute, Cambridge,
      Massachusetts, USA.
FAU - Fennell, Timothy
AU  - Fennell T
AD  - Program in Medical and Population Genetics, Broad Institute, Cambridge,
      Massachusetts, USA.
FAU - DePristo, Mark
AU  - DePristo M
AD  - Program in Medical and Population Genetics, Broad Institute, Cambridge,
      Massachusetts, USA.
FAU - de Angelis, Martin Hrabe
AU  - de Angelis MH
AD  - German Center for Diabetes Research (DZD), Munchen-Neuherberg, Germany.
AD  - Institute of Experimental Genetics, Helmholtz Zentrum Munchen, German Research
      Center for Environmental Health, Neuherberg, Germany.
AD  - Center of Life and Food Sciences Weihenstephan, Technische Universitat Munchen,
      Freising-Weihenstephan, Germany.
FAU - Deloukas, Panos
AU  - Deloukas P
AUID- ORCID: 0000-0001-9251-070X
AD  - Department of Human Genetics, Wellcome Trust Sanger Institute, Hinxton,
      Cambridgeshire, UK.
AD  - William Harvey Research Institute, Barts and The London School of Medicine and
      Dentistry, Queen Mary University of London, London, UK.
AD  - Princess Al-Jawhara Al-Brahim Centre of Excellence in Research of Hereditary
      Disorders (PACER-HD), King Abdulaziz University, Jeddah, Saudi Arabia.
FAU - Gjesing, Anette P
AU  - Gjesing AP
AD  - The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of
      Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
FAU - Jun, Goo
AU  - Jun G
AD  - Department of Biostatistics and Center for Statistical Genetics, University of
      Michigan, Ann Arbor, Michigan, USA.
AD  - Human Genetics Center, School of Public Health, The University of Texas Health
      Science Center at Houston, Houston, Texas, USA.
FAU - Nilsson, Peter
AU  - Nilsson P
AD  - Department of Clinical Sciences, Medicine, Lund University, Malmo, Sweden.
FAU - Murphy, Jacquelyn
AU  - Murphy J
AD  - Program in Medical and Population Genetics, Broad Institute, Cambridge,
      Massachusetts, USA.
FAU - Onofrio, Robert
AU  - Onofrio R
AD  - Program in Medical and Population Genetics, Broad Institute, Cambridge,
      Massachusetts, USA.
FAU - Thorand, Barbara
AU  - Thorand B
AD  - German Center for Diabetes Research (DZD), Munchen-Neuherberg, Germany.
AD  - Institute of Epidemiology II, Helmholtz Zentrum Munchen, German Research Center
      for Environmental Health, Neuherberg, Germany.
FAU - Hansen, Torben
AU  - Hansen T
AD  - The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of
      Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
AD  - Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.
FAU - Meisinger, Christa
AU  - Meisinger C
AD  - German Center for Diabetes Research (DZD), Munchen-Neuherberg, Germany.
AD  - Institute of Epidemiology II, Helmholtz Zentrum Munchen, German Research Center
      for Environmental Health, Neuherberg, Germany.
FAU - Hu, Frank B
AU  - Hu FB
AD  - Department of Epidemiology, Harvard School of Public Health, Boston,
      Massachusetts, USA.
AD  - Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts, 
      USA.
FAU - Isomaa, Bo
AU  - Isomaa B
AD  - Folkhalsan Research Centre, Helsinki, Finland.
AD  - Department of Social Services and Health Care, Jakobstad, Finland.
FAU - Karpe, Fredrik
AU  - Karpe F
AD  - Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of
      Medicine, University of Oxford, Oxford, UK.
AD  - Oxford NIHR Biomedical Research Centre, Oxford University Hospitals Trust,
      Oxford, UK.
FAU - Liang, Liming
AU  - Liang L
AD  - Department of Biostatistics, Harvard School of Public Health, Boston,
      Massachusetts, USA.
AD  - Department of Epidemiology, Harvard School of Public Health, Boston,
      Massachusetts, USA.
FAU - Peters, Annette
AU  - Peters A
AD  - DZHK (German Centre for Cardiovascular Research), partner site Munich Heart
      Alliance, Munich, Germany.
AD  - German Center for Diabetes Research (DZD), Munchen-Neuherberg, Germany.
AD  - Institute of Epidemiology II, Helmholtz Zentrum Munchen, German Research Center
      for Environmental Health, Neuherberg, Germany.
FAU - Huth, Cornelia
AU  - Huth C
AD  - German Center for Diabetes Research (DZD), Munchen-Neuherberg, Germany.
AD  - Institute of Epidemiology II, Helmholtz Zentrum Munchen, German Research Center
      for Environmental Health, Neuherberg, Germany.
FAU - O'Rahilly, Stephen P
AU  - O'Rahilly SP
AD  - Metabolic Research Laboratories, Institute of Metabolic Science, University of
      Cambridge, Cambridge, UK.
FAU - Palmer, Colin N A
AU  - Palmer CNA
AD  - Pat Macpherson Centre for Pharmacogenetics and Pharmacogenomics, Medical Research
      Institute, Ninewells Hospital and Medical School, Dundee, UK.
FAU - Pedersen, Oluf
AU  - Pedersen O
AD  - The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of
      Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
FAU - Rauramaa, Rainer
AU  - Rauramaa R
AD  - Foundation for Research in Health, Exercise and Nutrition, Kuopio Research
      Institute of Exercise Medicine, Kuopio, Finland.
FAU - Tuomilehto, Jaakko
AU  - Tuomilehto J
AUID- ORCID: 0000-0002-8306-6202
AD  - Center for Vascular Prevention, Danube University Krems, Krems, Austria.
AD  - Diabetes Research Group, King Abdulaziz University, Jeddah, Saudi Arabia.
AD  - Dasman Diabetes Institute, Dasman, Kuwait.
AD  - National Institute for Health and Welfare, Helsinki, Finland.
FAU - Salomaa, Veikko
AU  - Salomaa V
AD  - National Institute for Health and Welfare, Helsinki, Finland.
FAU - Watanabe, Richard M
AU  - Watanabe RM
AD  - Department of Preventive Medicine, Keck School of Medicine, University of
      Southern California, Los Angeles, California, USA.
AD  - Department of Physiology & Biophysics, Keck School of Medicine, University of
      Southern California, Los Angeles, California, USA.
AD  - Diabetes and Obesity Research Institute, Keck School of Medicine, University of
      Southern California, Los Angeles, California, USA.
FAU - Syvanen, Ann-Christine
AU  - Syvanen AC
AD  - Department of Medical Sciences, Molecular Medicine and Science for Life
      Laboratory, Uppsala University, Uppsala, Sweden.
FAU - Bergman, Richard N
AU  - Bergman RN
AD  - Cedars-Sinai Diabetes and Obesity Research Institute, Los Angeles, California,
      USA.
FAU - Bharadwaj, Dwaipayan
AU  - Bharadwaj D
AD  - Functional Genomics Unit, CSIR-Institute of Genomics & Integrative Biology
      (CSIR-IGIB), New Delhi, India.
FAU - Bottinger, Erwin P
AU  - Bottinger EP
AD  - The Charles Bronfman Institute for Personalized Medicine, The Icahn School of
      Medicine at Mount Sinai, New York, USA.
FAU - Cho, Yoon Shin
AU  - Cho YS
AD  - Department of Biomedical Science, Hallym University, Chuncheon, Republic of
      Korea.
FAU - Chandak, Giriraj R
AU  - Chandak GR
AD  - CSIR-Centre for Cellular and Molecular Biology, Hyderabad, Telangana, India.
FAU - Chan, Juliana Cn
AU  - Chan JC
AD  - Department of Medicine and Therapeutics, The Chinese University of Hong Kong,
      Hong Kong, China.
AD  - Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong,
      Hong Kong, China.
AD  - Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong,
      Hong Kong, China.
FAU - Chia, Kee Seng
AU  - Chia KS
AD  - Saw Swee Hock School of Public Health, National University of Singapore, National
      University Health System, Singapore, Singapore.
FAU - Daly, Mark J
AU  - Daly MJ
AD  - Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts
      General Hospital, Boston, Massachusetts, USA.
FAU - Ebrahim, Shah B
AU  - Ebrahim SB
AD  - Centre for Chronic Disease Control, New Delhi, India.
FAU - Langenberg, Claudia
AU  - Langenberg C
AD  - MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge,
      Cambridge, UK.
FAU - Elliott, Paul
AU  - Elliott P
AUID- ORCID: 0000-0002-7511-5684
AD  - Department of Epidemiology and Biostatistics, Imperial College London, London,
      UK.
AD  - MRC-PHE Centre for Environment and Health, Imperial College London, London, UK.
FAU - Jablonski, Kathleen A
AU  - Jablonski KA
AD  - The Biostatistics Center, The George Washington University, Rockville, Maryland, 
      USA.
FAU - Lehman, Donna M
AU  - Lehman DM
AD  - Department of Medicine, University of Texas Health Science Center, San Antonio,
      Texas, USA.
FAU - Jia, Weiping
AU  - Jia W
AD  - Department of Endocrinology and Metabolism, Shanghai Diabetes Institute, Shanghai
      Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.
FAU - Ma, Ronald C W
AU  - Ma RCW
AUID- ORCID: 0000-0002-1227-803X
AD  - Department of Medicine and Therapeutics, The Chinese University of Hong Kong,
      Hong Kong, China.
AD  - Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong,
      Hong Kong, China.
AD  - Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong,
      Hong Kong, China.
FAU - Pollin, Toni I
AU  - Pollin TI
AD  - Department of Medicine, Division of Endocrinology, Diabetes and Nutrition, and
      Program in Personalized and Genomic Medicine, University of Maryland School of
      Medicine, Baltimore, Maryland, USA.
FAU - Sandhu, Manjinder
AU  - Sandhu M
AD  - Department of Human Genetics, Wellcome Trust Sanger Institute, Hinxton,
      Cambridgeshire, UK.
AD  - Department of Public Health and Primary Care, University of Cambridge, Cambridge,
      UK.
FAU - Tandon, Nikhil
AU  - Tandon N
AD  - Department of Endocrinology and Metabolism, All India Institute of Medical
      Sciences, New Delhi, India.
FAU - Froguel, Philippe
AU  - Froguel P
AUID- ORCID: 0000-0003-2972-0784
AD  - CNRS-UMR8199, Lille University, Lille Pasteur Institute, Lille, France.
AD  - Department of Genomics of Common Disease, School of Public Health, Imperial
      College London, London, UK.
FAU - Barroso, Ines
AU  - Barroso I
AUID- ORCID: 0000-0001-5800-4520
AD  - Department of Human Genetics, Wellcome Trust Sanger Institute, Hinxton,
      Cambridgeshire, UK.
AD  - Metabolic Research Laboratories, Institute of Metabolic Science, University of
      Cambridge, Cambridge, UK.
FAU - Teo, Yik Ying
AU  - Teo YY
AD  - Saw Swee Hock School of Public Health, National University of Singapore, National
      University Health System, Singapore, Singapore.
AD  - Life Sciences Institute, National University of Singapore, Singapore, Singapore.
AD  - Department of Statistics and Applied Probability, National University of
      Singapore, Singapore, Singapore.
FAU - Zeggini, Eleftheria
AU  - Zeggini E
AUID- ORCID: 0000-0003-4238-659X
AD  - Department of Human Genetics, Wellcome Trust Sanger Institute, Hinxton,
      Cambridgeshire, UK.
FAU - Loos, Ruth J F
AU  - Loos RJF
AUID- ORCID: 0000-0002-8532-5087
AD  - The Charles Bronfman Institute for Personalized Medicine, The Icahn School of
      Medicine at Mount Sinai, New York, USA.
FAU - Small, Kerrin S
AU  - Small KS
AUID- ORCID: 0000-0003-4566-0005
AD  - Department of Twin Research and Genetic Epidemiology, King's College London,
      London, UK.
FAU - Ried, Janina S
AU  - Ried JS
AD  - Institute of Genetic Epidemiology, Helmholtz Zentrum Munchen, German Research
      Center for Environmental Health, Neuherberg, Germany.
FAU - DeFronzo, Ralph A
AU  - DeFronzo RA
AD  - Department of Medicine, University of Texas Health Science Center, San Antonio,
      Texas, USA.
FAU - Grallert, Harald
AU  - Grallert H
AD  - German Center for Diabetes Research (DZD), Munchen-Neuherberg, Germany.
AD  - Institute of Epidemiology II, Helmholtz Zentrum Munchen, German Research Center
      for Environmental Health, Neuherberg, Germany.
AD  - Research Unit of Molecular Epidemiology, Helmholtz Zentrum Munchen, German
      Research Center for Environmental Health, Neuherberg, Germany.
FAU - Glaser, Benjamin
AU  - Glaser B
AD  - Endocrinology and Metabolism Service, Hadassah-Hebrew University Medical Center, 
      Jerusalem, Israel.
FAU - Metspalu, Andres
AU  - Metspalu A
AD  - Estonian Genome Center, University of Tartu, Tartu, Estonia.
FAU - Wareham, Nicholas J
AU  - Wareham NJ
AD  - MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge,
      Cambridge, UK.
FAU - Walker, Mark
AU  - Walker M
AD  - The Medical School, Institute of Cellular Medicine, Newcastle University,
      Newcastle, UK.
FAU - Banks, Eric
AU  - Banks E
AD  - Program in Medical and Population Genetics, Broad Institute, Cambridge,
      Massachusetts, USA.
FAU - Gieger, Christian
AU  - Gieger C
AD  - Institute of Genetic Epidemiology, Helmholtz Zentrum Munchen, German Research
      Center for Environmental Health, Neuherberg, Germany.
AD  - Institute of Epidemiology II, Helmholtz Zentrum Munchen, German Research Center
      for Environmental Health, Neuherberg, Germany.
AD  - Research Unit of Molecular Epidemiology, Helmholtz Zentrum Munchen, German
      Research Center for Environmental Health, Neuherberg, Germany.
FAU - Ingelsson, Erik
AU  - Ingelsson E
AD  - Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine,
      University of Oxford, Oxford, UK.
AD  - Department of Medical Sciences, Molecular Epidemiology and Science for Life
      Laboratory, Uppsala University, Uppsala, Sweden.
FAU - Im, Hae Kyung
AU  - Im HK
AUID- ORCID: 0000-0003-0333-5685
AD  - Department of Medicine, Section of Genetic Medicine, The University of Chicago,
      Chicago, Illinois, USA.
FAU - Illig, Thomas
AU  - Illig T
AD  - Research Unit of Molecular Epidemiology, Helmholtz Zentrum Munchen, German
      Research Center for Environmental Health, Neuherberg, Germany.
AD  - Hannover Unified Biobank, Hannover Medical School, Hanover, Germany.
AD  - Department of Human Genetics, Hannover Medical School, Hanover, Germany.
FAU - Franks, Paul W
AU  - Franks PW
AD  - Department of Clinical Sciences, Lund University Diabetes Centre, Genetic and
      Molecular Epidemiology Unit, Lund University, Malmo, Sweden.
AD  - Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts, 
      USA.
AD  - Department of Public Health and Clinical Medicine, Umea University, Umea, Sweden.
FAU - Buck, Gemma
AU  - Buck G
AD  - High Throughput Genomics, Oxford Genomics Centre, Wellcome Trust Centre for Human
      Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
FAU - Trakalo, Joseph
AU  - Trakalo J
AD  - High Throughput Genomics, Oxford Genomics Centre, Wellcome Trust Centre for Human
      Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
FAU - Buck, David
AU  - Buck D
AD  - High Throughput Genomics, Oxford Genomics Centre, Wellcome Trust Centre for Human
      Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
FAU - Prokopenko, Inga
AU  - Prokopenko I
AUID- ORCID: 0000-0003-1624-7457
AD  - Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine,
      University of Oxford, Oxford, UK.
AD  - Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of
      Medicine, University of Oxford, Oxford, UK.
AD  - Department of Genomics of Common Disease, School of Public Health, Imperial
      College London, London, UK.
FAU - Magi, Reedik
AU  - Magi R
AD  - Estonian Genome Center, University of Tartu, Tartu, Estonia.
FAU - Lind, Lars
AU  - Lind L
AD  - Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
FAU - Farjoun, Yossi
AU  - Farjoun Y
AD  - Data Sciences and Data Engineering, Broad Institute, Cambridge, Massachusetts,
      USA.
FAU - Owen, Katharine R
AU  - Owen KR
AD  - Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of
      Medicine, University of Oxford, Oxford, UK.
AD  - Oxford NIHR Biomedical Research Centre, Oxford University Hospitals Trust,
      Oxford, UK.
FAU - Gloyn, Anna L
AU  - Gloyn AL
AUID- ORCID: 0000-0003-1205-1844
AD  - Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine,
      University of Oxford, Oxford, UK.
AD  - Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of
      Medicine, University of Oxford, Oxford, UK.
AD  - Oxford NIHR Biomedical Research Centre, Oxford University Hospitals Trust,
      Oxford, UK.
FAU - Strauch, Konstantin
AU  - Strauch K
AD  - Institute of Genetic Epidemiology, Helmholtz Zentrum Munchen, German Research
      Center for Environmental Health, Neuherberg, Germany.
AD  - Chair of Genetic Epidemiology, IBE, Faculty of Medicine, LMU Munich, Germany.
FAU - Tuomi, Tiinamaija
AU  - Tuomi T
AD  - Abdominal Center: Endocrinology, University of Helsinki and Helsinki University
      Central Hospital, Helsinki, Finland.
AD  - Folkhalsan Research Centre, Helsinki, Finland.
AD  - Research Programs Unit, Diabetes and Obesity, University of Helsinki, Helsinki,
      Finland.
AD  - Finnish Institute for Molecular Medicine, University of Helsinki, Helsinki,
      Finland.
FAU - Kooner, Jaspal Singh
AU  - Kooner JS
AD  - Department of Cardiology, Ealing Hospital NHS Trust, Southall, Middlesex, UK.
AD  - National Heart and Lung Institute, Cardiovascular Sciences, Hammersmith Campus,
      Imperial College London, London, UK.
AD  - Imperial College Healthcare NHS Trust, Imperial College London, London, UK.
FAU - Lee, Jong-Young
AU  - Lee JY
AUID- ORCID: 0000-0002-0092-9958
AD  - Center for Genome Science, Korea National Institute of Health, Chungcheongbuk-do,
      Republic of Korea.
FAU - Park, Taesung
AU  - Park T
AD  - Department of Statistics, Seoul National University, Seoul, Republic of Korea.
AD  - Interdisciplinary Program in Bioinformatics, Seoul National University, Seoul,
      Republic of Korea.
FAU - Donnelly, Peter
AU  - Donnelly P
AD  - Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine,
      University of Oxford, Oxford, UK.
AD  - Department of Statistics, University of Oxford, Oxford, UK.
FAU - Morris, Andrew D
AU  - Morris AD
AD  - Clinical Research Centre, Centre for Molecular Medicine, Ninewells Hospital and
      Medical School, Dundee, UK.
AD  - The Usher Institute to the Population Health Sciences and Informatics, University
      of Edinburgh, Edinburgh, UK.
FAU - Hattersley, Andrew T
AU  - Hattersley AT
AD  - University of Exeter Medical School, University of Exeter, Exeter, UK.
FAU - Bowden, Donald W
AU  - Bowden DW
AD  - Center for Genomics and Personalized Medicine Research, Wake Forest School of
      Medicine, Winston-Salem, North Carolina, USA.
AD  - Center for Diabetes Research, Wake Forest School of Medicine, Winston-Salem,
      North Carolina, USA.
AD  - Department of Biochemistry, Wake Forest School of Medicine, Winston-Salem, North 
      Carolina, USA.
FAU - Collins, Francis S
AU  - Collins FS
AD  - Medical Genomics and Metabolic Genetics Branch, National Human Genome Research
      Institute, National Institutes of Health, Bethesda, Maryland, USA.
FAU - Atzmon, Gil
AU  - Atzmon G
AD  - Departments of Medicine and Genetics, Albert Einstein College of Medicine, New
      York, USA.
AD  - Department of Natural Science, University of Haifa, Haifa, Israel.
FAU - Chambers, John C
AU  - Chambers JC
AD  - Department of Epidemiology and Biostatistics, Imperial College London, London,
      UK.
AD  - Department of Cardiology, Ealing Hospital NHS Trust, Southall, Middlesex, UK.
AD  - Imperial College Healthcare NHS Trust, Imperial College London, London, UK.
FAU - Spector, Timothy D
AU  - Spector TD
AD  - Department of Twin Research and Genetic Epidemiology, King's College London,
      London, UK.
FAU - Laakso, Markku
AU  - Laakso M
AD  - Faculty of Health Sciences, Institute of Clinical Medicine, Internal Medicine,
      University of Eastern Finland, Kuopio, Finland.
AD  - Kuopio University Hospital, Kuopio, Finland.
FAU - Strom, Tim M
AU  - Strom TM
AD  - Institute of Human Genetics, Helmholtz Zentrum Munchen, German Research Center
      for Environmental Health, Neuherberg, Germany.
AD  - Institute of Human Genetics, Technische Universitat Munchen, Munich, Germany.
FAU - Bell, Graeme I
AU  - Bell GI
AD  - Departments of Medicine and Human Genetics, The University of Chicago, Chicago,
      Illinois, USA.
FAU - Blangero, John
AU  - Blangero J
AD  - South Texas Diabetes and Obesity Institute, Regional Academic Health Center,
      University of Texas Health Science Center at San Antonio/University of Texas Rio 
      Grande Valley, Brownsville, Texas, USA.
FAU - Duggirala, Ravindranath
AU  - Duggirala R
AD  - Department of Genetics, Texas Biomedical Research Institute, San Antonio, Texas, 
      USA.
FAU - Tai, E Shyong
AU  - Tai ES
AD  - Saw Swee Hock School of Public Health, National University of Singapore, National
      University Health System, Singapore, Singapore.
AD  - Department of Medicine, Yong Loo Lin School of Medicine, National University of
      Singapore, National University Health System, Singapore, Singapore.
AD  - Cardiovascular & Metabolic Disorders Program, Duke-NUS Medical School Singapore, 
      Singapore, Singapore.
FAU - McVean, Gilean
AU  - McVean G
AD  - Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine,
      University of Oxford, Oxford, UK.
AD  - Li Ka Shing Centre for Health Information and Discovery, University of Oxford,
      Oxford, UK.
FAU - Hanis, Craig L
AU  - Hanis CL
AD  - Human Genetics Center, School of Public Health, The University of Texas Health
      Science Center at Houston, Houston, Texas, USA.
FAU - Wilson, James G
AU  - Wilson JG
AD  - Department of Physiology and Biophysics, University of Mississippi Medical
      Center, Jackson, Mississippi, USA.
FAU - Seielstad, Mark
AU  - Seielstad M
AUID- ORCID: 0000-0001-5783-1401
AD  - Department of Laboratory Medicine & Institute for Human Genetics, University of
      California, San Francisco, San Francisco, California, USA.
AD  - Blood Systems Research Institute, San Francisco, California, USA.
FAU - Frayling, Timothy M
AU  - Frayling TM
AD  - Genetics of Complex Traits, University of Exeter Medical School, University of
      Exeter, Exeter, UK.
FAU - Meigs, James B
AU  - Meigs JB
AD  - General Medicine Division, Massachusetts General Hospital and Department of
      Medicine, Harvard Medical School, Boston, Massachusetts, USA.
FAU - Cox, Nancy J
AU  - Cox NJ
AD  - Department of Medicine, Section of Genetic Medicine, The University of Chicago,
      Chicago, Illinois, USA.
FAU - Sladek, Rob
AU  - Sladek R
AD  - McGill University and Genome Quebec Innovation Centre, Montreal, Quebec, Canada.
AD  - Department of Human Genetics, McGill University, Montreal, Quebec, Canada.
AD  - Division of Endocrinology and Metabolism, Department of Medicine, McGill
      University, Montreal, Quebec, Canada.
FAU - Lander, Eric S
AU  - Lander ES
AD  - Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
FAU - Gabriel, Stacey
AU  - Gabriel S
AD  - Program in Medical and Population Genetics, Broad Institute, Cambridge,
      Massachusetts, USA.
FAU - Mohlke, Karen L
AU  - Mohlke KL
AUID- ORCID: 0000-0001-6721-153X
AD  - Department of Genetics, University of North Carolina, Chapel Hill, North
      Carolina, USA.
FAU - Meitinger, Thomas
AU  - Meitinger T
AD  - Institute of Human Genetics, Helmholtz Zentrum Munchen, German Research Center
      for Environmental Health, Neuherberg, Germany.
AD  - Institute of Human Genetics, Technische Universitat Munchen, Munich, Germany.
FAU - Groop, Leif
AU  - Groop L
AUID- ORCID: 0000-0002-0187-3263
AD  - Department of Clinical Sciences, Diabetes and Endocrinology, Lund University
      Diabetes Centre, Malmo, Sweden.
AD  - Finnish Institute for Molecular Medicine, University of Helsinki, Helsinki,
      Finland.
FAU - Abecasis, Goncalo
AU  - Abecasis G
AD  - Department of Biostatistics and Center for Statistical Genetics, University of
      Michigan, Ann Arbor, Michigan, USA.
FAU - Scott, Laura J
AU  - Scott LJ
AD  - Department of Biostatistics and Center for Statistical Genetics, University of
      Michigan, Ann Arbor, Michigan, USA.
FAU - Morris, Andrew P
AU  - Morris AP
AD  - Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine,
      University of Oxford, Oxford, UK.
AD  - Estonian Genome Center, University of Tartu, Tartu, Estonia.
AD  - Department of Biostatistics, University of Liverpool, Liverpool, UK.
FAU - Kang, Hyun Min
AU  - Kang HM
AD  - Department of Molecular Biology, Massachusetts General Hospital, Boston,
      Massachusetts, USA.
FAU - Altshuler, David
AU  - Altshuler D
AD  - Department of Molecular Biology, Massachusetts General Hospital, Boston,
      Massachusetts, USA.
AD  - Program in Medical and Population Genetics, Broad Institute, Cambridge,
      Massachusetts, USA.
AD  - Department of Genetics, Harvard Medical School, Boston, Massachusetts, USA.
AD  - Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
AD  - Diabetes Research Center (Diabetes Unit), Department of Medicine, Massachusetts
      General Hospital, Boston, Massachusetts, USA.
AD  - Department of Biology, Massachusetts Institute of Technology, Cambridge,
      Massachusetts, USA.
FAU - Burtt, Noel P
AU  - Burtt NP
AD  - Program in Medical and Population Genetics, Broad Institute, Cambridge,
      Massachusetts, USA.
FAU - Florez, Jose C
AU  - Florez JC
AD  - Program in Medical and Population Genetics, Broad Institute, Cambridge,
      Massachusetts, USA.
AD  - Center for Genomic Medicine, Department of Medicine, Massachusetts General
      Hospital, Boston, Massachusetts, USA.
AD  - Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
AD  - Diabetes Research Center (Diabetes Unit), Department of Medicine, Massachusetts
      General Hospital, Boston, Massachusetts, USA.
FAU - Boehnke, Michael
AU  - Boehnke M
AD  - Department of Biostatistics and Center for Statistical Genetics, University of
      Michigan, Ann Arbor, Michigan, USA.
FAU - McCarthy, Mark I
AU  - McCarthy MI
AD  - Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine,
      University of Oxford, Oxford, UK.
AD  - Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of
      Medicine, University of Oxford, Oxford, UK.
AD  - Oxford NIHR Biomedical Research Centre, Oxford University Hospitals Trust,
      Oxford, UK.
LA  - eng
GR  - G0700931/Medical Research Council/United Kingdom
GR  - MR/L01632X/1/Medical Research Council/United Kingdom
GR  - F32 DK079466/DK/NIDDK NIH HHS/United States
GR  - MR/L01341X/1/Medical Research Council/United Kingdom
GR  - G0601966/Medical Research Council/United Kingdom
GR  - R01 DK101478/DK/NIDDK NIH HHS/United States
GR  - K24 DK080140/DK/NIDDK NIH HHS/United States
GR  - U01 DK078616/DK/NIDDK NIH HHS/United States
PT  - Journal Article
DEP - 20171219
PL  - England
TA  - Sci Data
JT  - Scientific data
JID - 101640192
EIN - Sci Data. 2018 Jan 23;5:180002. PMID: 29360107
PMC - PMC5735917
EDAT- 2017/12/20 06:00
MHDA- 2017/12/20 06:00
CRDT- 2017/12/20 06:00
PHST- 2017/05/31 00:00 [received]
PHST- 2017/11/02 00:00 [accepted]
PHST- 2017/12/20 06:00 [entrez]
PHST- 2017/12/20 06:00 [pubmed]
PHST- 2017/12/20 06:00 [medline]
AID - sdata2017179 [pii]
AID - 10.1038/sdata.2017.179 [doi]
PST - epublish
SO  - Sci Data. 2017 Dec 19;4:170179. doi: 10.1038/sdata.2017.179.

PMID- 29123070
OWN - NLM
STAT- In-Process
LR  - 20171116
IS  - 1095-9203 (Electronic)
IS  - 0036-8075 (Linking)
VI  - 358
IP  - 6364
DP  - 2017 Nov 10
TI  - Redox-sensitive alteration of replisome architecture safeguards genome integrity.
PG  - 797-802
LID - 10.1126/science.aao3172 [doi]
AB  - DNA replication requires coordination between replication fork progression and
      deoxynucleotide triphosphate (dNTP)-generating metabolic pathways. We find that
      perturbation of ribonucleotide reductase (RNR) in humans elevates reactive oxygen
      species (ROS) that are detected by peroxiredoxin 2 (PRDX2). In the oligomeric
      state, PRDX2 forms a replisome-associated ROS sensor, which binds the fork
      accelerator TIMELESS when exposed to low levels of ROS. Elevated ROS levels
      generated by RNR attenuation disrupt oligomerized PRDX2 to smaller subunits,
      whose dissociation from chromatin enforces the displacement of TIMELESS from the 
      replisome. This process instantly slows replication fork progression, which
      mitigates pathological consequences of replication stress. Thus, redox signaling 
      couples fluctuations of dNTP biogenesis with replisome activity to reduce stress 
      during genome duplication. We propose that cancer cells exploit this pathway to
      increase their adaptability to adverse metabolic conditions.
CI  - Copyright (c) 2017 The Authors, some rights reserved; exclusive licensee American
      Association for the Advancement of Science. No claim to original U.S. Government 
      Works.
FAU - Somyajit, Kumar
AU  - Somyajit K
AUID- ORCID: 0000-0003-2496-7155
AD  - Protein Signaling Program, Novo Nordisk Foundation Center for Protein Research,
      Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3b,
      DK-2200 Copenhagen, Denmark.
FAU - Gupta, Rajat
AU  - Gupta R
AD  - Proteomics Program, Novo Nordisk Foundation Center for Protein Research, Faculty 
      of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3b, DK-2200
      Copenhagen, Denmark.
FAU - Sedlackova, Hana
AU  - Sedlackova H
AD  - Protein Signaling Program, Novo Nordisk Foundation Center for Protein Research,
      Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3b,
      DK-2200 Copenhagen, Denmark.
FAU - Neelsen, Kai John
AU  - Neelsen KJ
AD  - Protein Signaling Program, Novo Nordisk Foundation Center for Protein Research,
      Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3b,
      DK-2200 Copenhagen, Denmark.
FAU - Ochs, Fena
AU  - Ochs F
AD  - Protein Signaling Program, Novo Nordisk Foundation Center for Protein Research,
      Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3b,
      DK-2200 Copenhagen, Denmark.
FAU - Rask, Maj-Britt
AU  - Rask MB
AD  - Protein Signaling Program, Novo Nordisk Foundation Center for Protein Research,
      Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3b,
      DK-2200 Copenhagen, Denmark.
FAU - Choudhary, Chunaram
AU  - Choudhary C
AD  - Proteomics Program, Novo Nordisk Foundation Center for Protein Research, Faculty 
      of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3b, DK-2200
      Copenhagen, Denmark.
FAU - Lukas, Jiri
AU  - Lukas J
AUID- ORCID: 0000-0001-9087-506X
AD  - Protein Signaling Program, Novo Nordisk Foundation Center for Protein Research,
      Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3b,
      DK-2200 Copenhagen, Denmark. jiri.lukas@cpr.ku.dk.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Science
JT  - Science (New York, N.Y.)
JID - 0404511
CIN - Science. 2017 Nov 10;358(6364):722-723. PMID: 29123052
EDAT- 2017/11/11 06:00
MHDA- 2017/11/11 06:00
CRDT- 2017/11/11 06:00
PHST- 2017/07/07 00:00 [received]
PHST- 2017/09/26 00:00 [accepted]
PHST- 2017/11/11 06:00 [entrez]
PHST- 2017/11/11 06:00 [pubmed]
PHST- 2017/11/11 06:00 [medline]
AID - 358/6364/797 [pii]
AID - 10.1126/science.aao3172 [doi]
PST - ppublish
SO  - Science. 2017 Nov 10;358(6364):797-802. doi: 10.1126/science.aao3172.

PMID- 29118007
OWN - NLM
STAT- In-Data-Review
LR  - 20180125
IS  - 1528-0020 (Electronic)
IS  - 0006-4971 (Linking)
VI  - 131
IP  - 1
DP  - 2018 Jan 4
TI  - PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.
PG  - 68-83
LID - 10.1182/blood-2017-07-740993 [doi]
AB  - Programmed cell death protein 1 (PD-1) blockade targeting the PD-1 immune
      checkpoint has demonstrated unprecedented clinical efficacy in the treatment of
      advanced cancers including hematologic malignancies. This article reviews the
      landscape of PD-1/programmed death-ligand 1 (PD-L1) expression and current PD-1
      blockade immunotherapy trials in B-cell lymphomas. Most notably, in
      relapsed/refractory classical Hodgkin lymphoma, which frequently has increased
      PD-1(+) tumor-infiltrating T cells, 9p24.1 genetic alteration, and high PD-L1
      expression, anti-PD-1 monotherapy has demonstrated remarkable objective response 
      rates (ORRs) of 65% to 87% and durable disease control in phase 1/2 clinical
      trials. The median duration of response was 16 months in a phase 2 trial. PD-1
      blockade has also shown promise in a phase 1 trial of nivolumab in
      relapsed/refractory B-cell non-Hodgkin lymphomas, including follicular lymphoma, 
      which often displays abundant PD-1 expression on intratumoral T cells, and
      diffuse large B-cell lymphoma, which variably expresses PD-1 and PD-L1. In
      primary mediastinal large B-cell lymphoma, which frequently has 9p24.1
      alterations, the ORR was 35% in a phase 2 trial of pembrolizumab. In contrast,
      the ORR with pembrolizumab was 0% in relapsed chronic lymphocytic leukemia (CLL) 
      and 44% in CLL with Richter transformation in a phase 2 trial. T cells from CLL
      patients have elevated PD-1 expression; CLL PD-1(+) T cells can exhibit a
      pseudo-exhaustion or a replicative senescence phenotype. PD-1 expression was also
      found in marginal zone lymphoma but not in mantle cell lymphoma, although
      currently anti-PD-1 clinical trial data are not available. Mechanisms and
      predictive biomarkers for PD-1 blockade immunotherapy, treatment-related adverse 
      events, hyperprogression, and combination therapies are discussed in the context 
      of B-cell lymphomas.
CI  - (c) 2018 by The American Society of Hematology.
FAU - Xu-Monette, Zijun Y
AU  - Xu-Monette ZY
AD  - Department of Hematopathology, The University of Texas MD Anderson Cancer Center,
      Houston, TX.
FAU - Zhou, Jianfeng
AU  - Zhou J
AD  - Department of Hematology and Cancer Biology Research Center, Tongji Hospital,
      Tongji Medical College, Huazhong University of Science and Technology, Wuhan,
      Hubei, China; and.
FAU - Young, Ken H
AU  - Young KH
AD  - Department of Hematopathology, The University of Texas MD Anderson Cancer Center,
      Houston, TX.
AD  - Graduate School of Biomedical Science, The University of Texas Health Science
      Center at Houston, Houston, TX.
LA  - eng
GR  - P30 CA016672/CA/NCI NIH HHS/United States
GR  - P50 CA142509/CA/NCI NIH HHS/United States
GR  - RC1 CA146299/CA/NCI NIH HHS/United States
GR  - R01 CA187415/CA/NCI NIH HHS/United States
GR  - P50 CA136411/CA/NCI NIH HHS/United States
GR  - R01 CA138688/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20171108
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
PMC - PMC5755041
EDAT- 2017/11/10 06:00
MHDA- 2017/11/10 06:00
CRDT- 2017/11/10 06:00
PMCR- 2019/01/04 00:00
PHST- 2017/07/05 00:00 [received]
PHST- 2017/10/28 00:00 [accepted]
PHST- 2019/01/04 00:00 [pmc-release]
PHST- 2017/11/10 06:00 [pubmed]
PHST- 2017/11/10 06:00 [medline]
PHST- 2017/11/10 06:00 [entrez]
AID - blood-2017-07-740993 [pii]
AID - 10.1182/blood-2017-07-740993 [doi]
PST - ppublish
SO  - Blood. 2018 Jan 4;131(1):68-83. doi: 10.1182/blood-2017-07-740993. Epub 2017 Nov 
      8.

PMID- 29056340
OWN - NLM
STAT- MEDLINE
DCOM- 20171121
LR  - 20171224
IS  - 1097-4172 (Electronic)
IS  - 0092-8674 (Linking)
VI  - 171
IP  - 4
DP  - 2017 Nov 2
TI  - STING Senses Microbial Viability to Orchestrate Stress-Mediated Autophagy of the 
      Endoplasmic Reticulum.
PG  - 809-823.e13
LID - S0092-8674(17)31128-5 [pii]
LID - 10.1016/j.cell.2017.09.034 [doi]
AB  - Constitutive cell-autonomous immunity in metazoans predates interferon-inducible 
      immunity and comprises primordial innate defense. Phagocytes mobilize
      interferon-inducible responses upon engagement of well-characterized signaling
      pathways by pathogen-associated molecular patterns (PAMPs). The signals
      controlling deployment of constitutive cell-autonomous responses during infection
      have remained elusive. Vita-PAMPs denote microbial viability, signaling the
      danger of cellular exploitation by intracellular pathogens. We show that
      cyclic-di-adenosine monophosphate in live Gram-positive bacteria is a vita-PAMP, 
      engaging the innate sensor stimulator of interferon genes (STING) to mediate
      endoplasmic reticulum (ER) stress. Subsequent inactivation of the mechanistic
      target of rapamycin mobilizes autophagy, which sequesters stressed ER membranes, 
      resolves ER stress, and curtails phagocyte death. This vita-PAMP-induced ER-phagy
      additionally orchestrates an interferon response by localizing ER-resident STING 
      to autophagosomes. Our findings identify stress-mediated ER-phagy as a
      cell-autonomous response mobilized by STING-dependent sensing of a specific
      vita-PAMP and elucidate how innate receptors engage multilayered homeostatic
      mechanisms to promote immunity and survival after infection.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Moretti, Julien
AU  - Moretti J
AD  - The Jill Roberts Institute for Research in Inflammatory Bowel Disease, Weill
      Cornell Medicine, Cornell University, New York, NY 10021, USA; Joan and Sanford
      I. Weill Department of Medicine, Weill Cornell Medicine, Cornell University, New 
      York, NY 10021, USA.
FAU - Roy, Soumit
AU  - Roy S
AD  - Department of Medicine, Immunology Institute, Icahn School of Medicine at Mount
      Sinai, New York, NY 10029, USA.
FAU - Bozec, Dominique
AU  - Bozec D
AD  - Brain Tumor Nanotechnology Laboratory, Department of Neurosurgery, Tisch Cancer
      Institute, The Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
FAU - Martinez, Jennifer
AU  - Martinez J
AD  - Immunity, Inflammation, and Disease Laboratory, Inflammation and Autoimmunity
      Group, National Institute of Environmental Health Sciences, Research Triangle
      Park, NC 27709, USA.
FAU - Chapman, Jessica R
AU  - Chapman JR
AD  - Office of Collaborative Science, Department of Biochemistry and Molecular
      Pharmacology, New York University School of Medicine, New York, NY 10016, USA.
FAU - Ueberheide, Beatrix
AU  - Ueberheide B
AD  - Office of Collaborative Science, Department of Biochemistry and Molecular
      Pharmacology, New York University School of Medicine, New York, NY 10016, USA.
FAU - Lamming, Dudley W
AU  - Lamming DW
AD  - Department of Medicine, University of Wisconsin-Madison, Madison, WI 53705, USA.
FAU - Chen, Zhijian J
AU  - Chen ZJ
AD  - Department of Molecular Biology and Howard Hughes Medical Institute, University
      of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
FAU - Horng, Tiffany
AU  - Horng T
AD  - Department of Genetics and Complex Diseases, Harvard T.H. Chan School of Public
      Health, Boston, MA 02115, USA.
FAU - Yeretssian, Garabet
AU  - Yeretssian G
AD  - The Leona M. and Harry B. Helmsley Charitable Trust, New York, NY 10169, USA.
FAU - Green, Douglas R
AU  - Green DR
AD  - Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN
      38105, USA.
FAU - Blander, J Magarian
AU  - Blander JM
AD  - The Jill Roberts Institute for Research in Inflammatory Bowel Disease, Weill
      Cornell Medicine, Cornell University, New York, NY 10021, USA; Joan and Sanford
      I. Weill Department of Medicine, Weill Cornell Medicine, Cornell University, New 
      York, NY 10021, USA; Department of Microbiology and Immunology, Weill Cornell
      Medicine, Cornell University, New York, NY 10021, USA; Sandra and Edward Meyer
      Cancer Center, Weill Cornell Medicine, Cornell University, New York, NY 10021,
      USA; Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School
      of Medical Sciences, Weill Cornell Medicine, Cornell University, New York, NY
      10021, USA. Electronic address: jmblander@med.cornell.edu.
LA  - eng
GR  - R01 DK111862/DK/NIDDK NIH HHS/United States
GR  - R00 AG041765/AG/NIA NIH HHS/United States
GR  - R01 AI127658/AI/NIAID NIH HHS/United States
GR  - P01 DK072201/DK/NIDDK NIH HHS/United States
GR  - R01 AI073899/AI/NIAID NIH HHS/United States
GR  - R01 AI095245/AI/NIAID NIH HHS/United States
GR  - R21 AI080959/AI/NIAID NIH HHS/United States
GR  - R01 AI040646/AI/NIAID NIH HHS/United States
GR  - R56 AI073899/AI/NIAID NIH HHS/United States
GR  - R01 AI123284/AI/NIAID NIH HHS/United States
PT  - Journal Article
DEP - 20171019
PL  - United States
TA  - Cell
JT  - Cell
JID - 0413066
RN  - 0 (MPYS protein, mouse)
RN  - 0 (Membrane Proteins)
RN  - 0 (Pathogen-Associated Molecular Pattern Molecules)
RN  - EC 2.7.1.1 (TOR Serine-Threonine Kinases)
RN  - EC 2.7.1.1 (mTOR protein, mouse)
SB  - IM
MH  - Animals
MH  - Autophagy
MH  - Endoplasmic Reticulum/metabolism
MH  - Endoplasmic Reticulum Stress
MH  - Female
MH  - Gram-Positive Bacteria/*physiology
MH  - Gram-Positive Bacterial Infections/*immunology
MH  - Male
MH  - Membrane Proteins/*metabolism
MH  - Mice
MH  - Pathogen-Associated Molecular Pattern Molecules/metabolism
MH  - Phagocytes/*immunology
MH  - TOR Serine-Threonine Kinases/metabolism
OTO - NOTNLM
OT  - ER stress
OT  - ER-phagy
OT  - Gram-positive bacteria
OT  - STING
OT  - autophagy
OT  - c-di-AMP
OT  - cell-autonomous innate immunity
OT  - mTOR
OT  - type-I interferon
OT  - vita-PAMP
EDAT- 2017/10/24 06:00
MHDA- 2017/11/29 06:00
CRDT- 2017/10/24 06:00
PHST- 2016/02/16 00:00 [received]
PHST- 2017/05/10 00:00 [revised]
PHST- 2017/09/18 00:00 [accepted]
PHST- 2017/10/24 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
PHST- 2017/10/24 06:00 [entrez]
AID - S0092-8674(17)31128-5 [pii]
AID - 10.1016/j.cell.2017.09.034 [doi]
PST - ppublish
SO  - Cell. 2017 Nov 2;171(4):809-823.e13. doi: 10.1016/j.cell.2017.09.034. Epub 2017
      Oct 19.

PMID- 29202481
OWN - NLM
STAT- In-Data-Review
LR  - 20180102
IS  - 1558-8238 (Electronic)
IS  - 0021-9738 (Linking)
VI  - 128
IP  - 1
DP  - 2018 Jan 2
TI  - Bone marrow drives central nervous system regeneration after radiation injury.
PG  - 281-293
LID - 10.1172/JCI90647 [doi]
LID - 90647 [pii]
AB  - Nervous system injury is a frequent result of cancer therapy involving cranial
      irradiation, leaving patients with marked memory and other neurobehavioral
      disabilities. Here, we report an unanticipated link between bone marrow and brain
      in the setting of radiation injury. Specifically, we demonstrate that bone
      marrow-derived monocytes and macrophages are essential for structural and
      functional repair mechanisms, including regeneration of cerebral white matter and
      improvement in neurocognitive function. Using a granulocyte-colony stimulating
      factor (G-CSF) receptor knockout mouse model in combination with bone marrow cell
      transplantation, MRI, and neurocognitive functional assessments, we demonstrate
      that bone marrow-derived G-CSF-responsive cells home to the injured brain and are
      critical for altering neural progenitor cells and brain repair. Additionally,
      compared with untreated animals, animals that received G-CSF following radiation 
      injury exhibited enhanced functional brain repair. Together, these results
      demonstrate that, in addition to its known role in defense and debris removal,
      the hematopoietic system provides critical regenerative drive to the brain that
      can be modulated by clinically available agents.
FAU - Dietrich, Jorg
AU  - Dietrich J
AD  - Center for Regenerative Medicine, Massachusetts General Hospital (MGH), Boston,
      Massachusetts, USA.
AD  - Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, 
      Massachusetts, USA.
AD  - Harvard Stem Cell Institute, Cambridge, Massachusetts, USA.
AD  - Department of Neurology and Division of Neuro-Oncology, MGH, and.
FAU - Baryawno, Ninib
AU  - Baryawno N
AD  - Center for Regenerative Medicine, Massachusetts General Hospital (MGH), Boston,
      Massachusetts, USA.
AD  - Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, 
      Massachusetts, USA.
AD  - Harvard Stem Cell Institute, Cambridge, Massachusetts, USA.
FAU - Nayyar, Naema
AU  - Nayyar N
AD  - Center for Regenerative Medicine, Massachusetts General Hospital (MGH), Boston,
      Massachusetts, USA.
AD  - Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, 
      Massachusetts, USA.
AD  - Harvard Stem Cell Institute, Cambridge, Massachusetts, USA.
FAU - Valtis, Yannis K
AU  - Valtis YK
AD  - Center for Regenerative Medicine, Massachusetts General Hospital (MGH), Boston,
      Massachusetts, USA.
AD  - Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, 
      Massachusetts, USA.
AD  - Harvard Stem Cell Institute, Cambridge, Massachusetts, USA.
FAU - Yang, Betty
AU  - Yang B
AD  - Center for Regenerative Medicine, Massachusetts General Hospital (MGH), Boston,
      Massachusetts, USA.
AD  - Harvard Stem Cell Institute, Cambridge, Massachusetts, USA.
FAU - Ly, Ina
AU  - Ly I
AD  - Department of Neurology and Division of Neuro-Oncology, MGH, and.
FAU - Besnard, Antoine
AU  - Besnard A
AD  - Center for Regenerative Medicine, Massachusetts General Hospital (MGH), Boston,
      Massachusetts, USA.
AD  - Harvard Stem Cell Institute, Cambridge, Massachusetts, USA.
FAU - Severe, Nicolas
AU  - Severe N
AD  - Center for Regenerative Medicine, Massachusetts General Hospital (MGH), Boston,
      Massachusetts, USA.
AD  - Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, 
      Massachusetts, USA.
AD  - Harvard Stem Cell Institute, Cambridge, Massachusetts, USA.
FAU - Gustafsson, Karin U
AU  - Gustafsson KU
AD  - Center for Regenerative Medicine, Massachusetts General Hospital (MGH), Boston,
      Massachusetts, USA.
AD  - Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, 
      Massachusetts, USA.
AD  - Harvard Stem Cell Institute, Cambridge, Massachusetts, USA.
FAU - Andronesi, Ovidiu C
AU  - Andronesi OC
AD  - Department of Radiology, Athinoula A. Martinos Biomedical Imaging Center, MGH,
      Harvard Medical School, Boston, Massachusetts, USA.
FAU - Batchelor, Tracy T
AU  - Batchelor TT
AD  - Department of Neurology and Division of Neuro-Oncology, MGH, and.
FAU - Sahay, Amar
AU  - Sahay A
AD  - Center for Regenerative Medicine, Massachusetts General Hospital (MGH), Boston,
      Massachusetts, USA.
AD  - Harvard Stem Cell Institute, Cambridge, Massachusetts, USA.
FAU - Scadden, David T
AU  - Scadden DT
AD  - Center for Regenerative Medicine, Massachusetts General Hospital (MGH), Boston,
      Massachusetts, USA.
AD  - Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, 
      Massachusetts, USA.
AD  - Harvard Stem Cell Institute, Cambridge, Massachusetts, USA.
LA  - eng
PT  - Journal Article
DEP - 20171204
PL  - United States
TA  - J Clin Invest
JT  - The Journal of clinical investigation
JID - 7802877
OTO - NOTNLM
OT  - Bone marrow
OT  - Hematology
OT  - Neuroscience
EDAT- 2017/12/05 06:00
MHDA- 2017/12/05 06:00
CRDT- 2017/12/05 06:00
PHST- 2016/09/14 00:00 [received]
PHST- 2017/10/24 00:00 [accepted]
PHST- 2017/12/05 06:00 [pubmed]
PHST- 2017/12/05 06:00 [medline]
PHST- 2017/12/05 06:00 [entrez]
AID - 90647 [pii]
AID - 10.1172/JCI90647 [doi]
PST - ppublish
SO  - J Clin Invest. 2018 Jan 2;128(1):281-293. doi: 10.1172/JCI90647. Epub 2017 Dec 4.

PMID- 29203910
OWN - NLM
STAT- In-Data-Review
LR  - 20171226
IS  - 1546-1718 (Electronic)
IS  - 1061-4036 (Linking)
VI  - 50
IP  - 1
DP  - 2018 Jan
TI  - TET proteins safeguard bivalent promoters from de novo methylation in human
      embryonic stem cells.
PG  - 83-95
LID - 10.1038/s41588-017-0002-y [doi]
AB  - TET enzymes oxidize 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC),
      which can lead to DNA demethylation. However, direct connections between
      TET-mediated DNA demethylation and transcriptional output are difficult to
      establish owing to challenges in distinguishing global versus locus-specific
      effects. Here we show that TET1, TET2 and TET3 triple-knockout (TKO) human
      embryonic stem cells (hESCs) exhibit prominent bivalent promoter hypermethylation
      without an overall corresponding decrease in gene expression in the
      undifferentiated state. Focusing on the bivalent PAX6 locus, we find that
      increased DNMT3B binding is associated with promoter hypermethylation, which
      precipitates a neural differentiation defect and failure of PAX6 induction during
      differentiation. dCas9-mediated locus-specific demethylation and global
      inactivation of DNMT3B in TKO hESCs partially reverses the hypermethylation at
      the PAX6 promoter and improves differentiation to neuroectoderm. Taking these
      findings together with further genome-wide methylation and TET1 and DNMT3B
      ChIP-seq analyses, we conclude that TET proteins safeguard bivalent promoters
      from de novo methylation to ensure robust lineage-specific transcription upon
      differentiation.
FAU - Verma, Nipun
AU  - Verma N
AUID- ORCID: http://orcid.org/0000-0002-9522-6699
AD  - Developmental Biology Program, Sloan Kettering Institute, New York, NY, USA.
AD  - Weill Graduate School of Medical Sciences at Cornell University/The Rockefeller
      University/Sloan Kettering Institute Tri-Institutional MD-PhD Program, New York, 
      NY, USA.
FAU - Pan, Heng
AU  - Pan H
AD  - Department of Physiology and Biophysics, Englander Institute for Precision
      Medicine, Institute for Computational Biomedicine, Weill Cornell Medical College,
      New York, NY, USA.
AD  - Weill Cornell Graduate School of Medical Sciences, Weill Cornell Medical College,
      New York, NY, USA.
FAU - Dore, Louis C
AU  - Dore LC
AD  - Department of Chemistry, Department of Biochemistry and Molecular Biology,
      Institute for Biophysical Dynamics, Howard Hughes Medical Institute, University
      of Chicago, Chicago, IL, USA.
FAU - Shukla, Abhijit
AU  - Shukla A
AD  - Developmental Biology Program, Sloan Kettering Institute, New York, NY, USA.
FAU - Li, Qing V
AU  - Li QV
AD  - Developmental Biology Program, Sloan Kettering Institute, New York, NY, USA.
AD  - Louis V. Gerstner Jr. Graduate School of Biomedical Sciences, Memorial Sloan
      Kettering Cancer Center, New York, NY, USA.
FAU - Pelham-Webb, Bobbie
AU  - Pelham-Webb B
AD  - Weill Graduate School of Medical Sciences at Cornell University/The Rockefeller
      University/Sloan Kettering Institute Tri-Institutional MD-PhD Program, New York, 
      NY, USA.
FAU - Teijeiro, Virginia
AU  - Teijeiro V
AD  - Developmental Biology Program, Sloan Kettering Institute, New York, NY, USA.
AD  - Weill Cornell Graduate School of Medical Sciences, Weill Cornell Medical College,
      New York, NY, USA.
FAU - Gonzalez, Federico
AU  - Gonzalez F
AD  - Developmental Biology Program, Sloan Kettering Institute, New York, NY, USA.
AD  - Institute for Bioengineering of Catalonia (IBEC), Barcelona, Spain.
FAU - Krivtsov, Andrei
AU  - Krivtsov A
AD  - Cancer Biology and Genetics Program, Sloan Kettering Institute, New York, NY,
      USA.
FAU - Chang, Chan-Jung
AU  - Chang CJ
AD  - Department of Oncological Sciences and Black Family Stem Cell Institute, Icahn
      School of Medicine at Mount Sinai, New York, NY, USA.
FAU - Papapetrou, Eirini P
AU  - Papapetrou EP
AD  - Department of Oncological Sciences and Black Family Stem Cell Institute, Icahn
      School of Medicine at Mount Sinai, New York, NY, USA.
FAU - He, Chuan
AU  - He C
AD  - Department of Chemistry, Department of Biochemistry and Molecular Biology,
      Institute for Biophysical Dynamics, Howard Hughes Medical Institute, University
      of Chicago, Chicago, IL, USA.
FAU - Elemento, Olivier
AU  - Elemento O
AD  - Department of Physiology and Biophysics, Englander Institute for Precision
      Medicine, Institute for Computational Biomedicine, Weill Cornell Medical College,
      New York, NY, USA. ole2001@med.cornell.edu.
FAU - Huangfu, Danwei
AU  - Huangfu D
AUID- ORCID: http://orcid.org/0000-0002-1145-6199
AD  - Developmental Biology Program, Sloan Kettering Institute, New York, NY, USA.
      huangfud@mskcc.org.
LA  - eng
GR  - P30 CA008748/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20171204
PL  - United States
TA  - Nat Genet
JT  - Nature genetics
JID - 9216904
EIN - Nat Genet. 2017 Dec 18;:. PMID: 29255265
EIN - Nat Genet. 2017 Dec 18;:. PMID: 29255266
PMC - PMC5742051
MID - NIHMS915929
EDAT- 2017/12/06 06:00
MHDA- 2017/12/06 06:00
CRDT- 2017/12/06 06:00
PMCR- 2018/06/04 00:00
PHST- 2016/10/31 00:00 [received]
PHST- 2017/10/25 00:00 [accepted]
PHST- 2018/06/04 00:00 [pmc-release]
PHST- 2017/12/06 06:00 [pubmed]
PHST- 2017/12/06 06:00 [medline]
PHST- 2017/12/06 06:00 [entrez]
AID - 10.1038/s41588-017-0002-y [doi]
AID - 10.1038/s41588-017-0002-y [pii]
PST - ppublish
SO  - Nat Genet. 2018 Jan;50(1):83-95. doi: 10.1038/s41588-017-0002-y. Epub 2017 Dec 4.

PMID- 29155425
OWN - NLM
STAT- In-Data-Review
LR  - 20180112
IS  - 1546-170X (Electronic)
IS  - 1078-8956 (Linking)
VI  - 24
IP  - 1
DP  - 2018 Jan
TI  - Granulocyte-derived TNFalpha promotes vascular and hematopoietic regeneration in 
      the bone marrow.
PG  - 95-102
LID - 10.1038/nm.4448 [doi]
AB  - Endothelial cells are a critical component of the bone marrow (BM) stromal
      network, which maintains and regulates hematopoietic cells. Vascular regeneration
      precedes, and is necessary for, successful hematopoietic stem cell (HSC)
      transplantation, the only cure for most hematopoietic diseases. Recent data
      suggest that mature hematopoietic cells regulate BM stromal-cell function.
      Whether a similar cross-talk regulates the BM vasculature is not known. Here we
      found that donor hematopoietic cells act on sinusoidal endothelial cells and
      induce host blood vessel and hematopoietic regeneration after BM transplantation 
      in mice. Adoptive transfer of BM, but not peripheral, granulocytes prevented the 
      death of mice transplanted with limited numbers of HSCs and accelerated recovery 
      of host vessels and hematopoietic cells. Moreover, selective granulocyte ablation
      in vivo impaired vascular and hematopoietic regeneration after BM
      transplantation. Gene expression analyses indicated that granulocytes are the
      main source of the cytokine TNFalpha, whereas its receptor TNFR1 is selectively
      upregulated in regenerating blood vessels. In adoptive transfer experiments, wild
      type, but not Tnfa(-/-), granulocytes induced vascular recovery, and wild-type
      granulocyte transfer did not prevent death or promote vascular regeneration in
      Tnfr1(-/-); Tnfr2(-/-) mice. Thus, by delivering TNFalpha to endothelial cells,
      granulocytes promote blood vessel growth and hematopoietic regeneration.
      Manipulation of the cross-talk between granulocytes and endothelial cells may
      lead to new therapeutic approaches to improve blood vessel regeneration and
      increase survival and hematopoietic recovery after HSC transplantation.
FAU - Bowers, Emily
AU  - Bowers E
AD  - Department of Cell and Developmental Biology, University of Michigan School of
      Medicine, Ann Arbor, Michigan, USA.
AD  - Center for Organogenesis, University of Michigan School of Medicine, Ann Arbor,
      Michigan, USA.
FAU - Slaughter, Anastasiya
AU  - Slaughter A
AD  - Department of Cell and Developmental Biology, University of Michigan School of
      Medicine, Ann Arbor, Michigan, USA.
FAU - Frenette, Paul S
AU  - Frenette PS
AD  - Ruth L. and David S. Gottesman Institute for Stem Cell and Regenerative Medicine 
      Research, Albert Einstein College of Medicine, Bronx, New York, USA.
AD  - Departments of Medicine and of Cell Biology, Albert Einstein College of Medicine,
      Bronx, New York, USA.
FAU - Kuick, Rork
AU  - Kuick R
AUID- ORCID: http://orcid.org/0000-0002-8817-5192
AD  - Department of Biostatistics, University of Michigan School of Public Health, Ann 
      Arbor, Michigan, USA.
FAU - Pello, Oscar M
AU  - Pello OM
AD  - The John Goldman Center for Cellular Therapy, Hammersmith Hospital, Imperial
      College Healthcare NHS Trust, London, UK.
FAU - Lucas, Daniel
AU  - Lucas D
AD  - Department of Cell and Developmental Biology, University of Michigan School of
      Medicine, Ann Arbor, Michigan, USA.
AD  - Center for Organogenesis, University of Michigan School of Medicine, Ann Arbor,
      Michigan, USA.
AD  - The University of Michigan Comprehensive Cancer Center, University of Michigan,
      Ann Arbor, USA.
LA  - eng
GR  - P30 CA046592/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20171120
PL  - United States
TA  - Nat Med
JT  - Nature medicine
JID - 9502015
PMC - PMC5760474
MID - NIHMS915652
EDAT- 2017/11/21 06:00
MHDA- 2017/11/21 06:00
CRDT- 2017/11/21 06:00
PMCR- 2018/05/20 00:00
PHST- 2016/09/12 00:00 [received]
PHST- 2017/10/23 00:00 [accepted]
PHST- 2018/05/20 00:00 [pmc-release]
PHST- 2017/11/21 06:00 [pubmed]
PHST- 2017/11/21 06:00 [medline]
PHST- 2017/11/21 06:00 [entrez]
AID - nm.4448 [pii]
AID - 10.1038/nm.4448 [doi]
PST - ppublish
SO  - Nat Med. 2018 Jan;24(1):95-102. doi: 10.1038/nm.4448. Epub 2017 Nov 20.

PMID- 29192133
OWN - NLM
STAT- In-Process
LR  - 20171226
IS  - 1095-9203 (Electronic)
IS  - 0036-8075 (Linking)
VI  - 358
IP  - 6370
DP  - 2017 Dec 22
TI  - Synthetic transcription elongation factors license transcription across
      repressive chromatin.
PG  - 1617-1622
LID - 10.1126/science.aan6414 [doi]
AB  - The release of paused RNA polymerase II into productive elongation is highly
      regulated, especially at genes that affect human development and disease. To
      exert control over this rate-limiting step, we designed sequence-specific
      synthetic transcription elongation factors (Syn-TEFs). These molecules are
      composed of programmable DNA-binding ligands flexibly tethered to a small
      molecule that engages the transcription elongation machinery. By limiting
      activity to targeted loci, Syn-TEFs convert constituent modules from
      broad-spectrum inhibitors of transcription into gene-specific stimulators. Here
      we present Syn-TEF1, a molecule that actively enables transcription across
      repressive GAA repeats that silence frataxin expression in Friedreich's ataxia, a
      terminal neurodegenerative disease with no effective therapy. The modular design 
      of Syn-TEF1 defines a general framework for developing a class of molecules that 
      license transcription elongation at targeted genomic loci.
CI  - Copyright (c) 2017 The Authors, some rights reserved; exclusive licensee American
      Association for the Advancement of Science. No claim to original U.S. Government 
      Works.
FAU - Erwin, Graham S
AU  - Erwin GS
AD  - Department of Biochemistry, University of Wisconsin-Madison, Madison, WI 53706,
      USA.
FAU - Grieshop, Matthew P
AU  - Grieshop MP
AUID- ORCID: 0000-0002-0075-8597
AD  - Department of Biochemistry, University of Wisconsin-Madison, Madison, WI 53706,
      USA.
FAU - Ali, Asfa
AU  - Ali A
AD  - Department of Biochemistry, University of Wisconsin-Madison, Madison, WI 53706,
      USA.
FAU - Qi, Jun
AU  - Qi J
AUID- ORCID: 0000-0002-1461-3356
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Lawlor, Matthew
AU  - Lawlor M
AUID- ORCID: 0000-0003-0700-5763
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Kumar, Deepak
AU  - Kumar D
AD  - Department of Neurology, All India Institute of Medical Sciences, New Delhi,
      India.
AD  - Genomics and Molecular Medicine, Council of Scientific and Industrial Research
      (CSIR)-Institute of Genomics and Integrative Biology (IGIB), New Delhi, India.
FAU - Ahmad, Istaq
AU  - Ahmad I
AUID- ORCID: 0000-0001-8201-0381
AD  - Department of Neurology, All India Institute of Medical Sciences, New Delhi,
      India.
AD  - Genomics and Molecular Medicine, Council of Scientific and Industrial Research
      (CSIR)-Institute of Genomics and Integrative Biology (IGIB), New Delhi, India.
FAU - McNally, Anna
AU  - McNally A
AUID- ORCID: 0000-0002-7069-4920
AD  - Novartis Institutes for BioMedical Research (NIBR), Cambridge, MA 02139, USA.
FAU - Teider, Natalia
AU  - Teider N
AD  - Novartis Institutes for BioMedical Research (NIBR), Cambridge, MA 02139, USA.
FAU - Worringer, Katie
AU  - Worringer K
AUID- ORCID: 0000-0001-7807-2344
AD  - Novartis Institutes for BioMedical Research (NIBR), Cambridge, MA 02139, USA.
FAU - Sivasankaran, Rajeev
AU  - Sivasankaran R
AD  - Novartis Institutes for BioMedical Research (NIBR), Cambridge, MA 02139, USA.
FAU - Syed, Deeba N
AU  - Syed DN
AUID- ORCID: 0000-0001-6948-5817
AD  - Department of Dermatology, University of Wisconsin-Madison, Madison, WI 53706,
      USA.
FAU - Eguchi, Asuka
AU  - Eguchi A
AUID- ORCID: 0000-0003-3010-0275
AD  - Department of Biochemistry, University of Wisconsin-Madison, Madison, WI 53706,
      USA.
FAU - Ashraf, Md
AU  - Ashraf M
AD  - Department of Biochemistry, University of Wisconsin-Madison, Madison, WI 53706,
      USA.
FAU - Jeffery, Justin
AU  - Jeffery J
AD  - Small Animal Imaging Facility, University of Wisconsin Carbone Cancer Center,
      Madison, WI 53792, USA.
FAU - Xu, Mousheng
AU  - Xu M
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Park, Paul M C
AU  - Park PMC
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Mukhtar, Hasan
AU  - Mukhtar H
AD  - Department of Dermatology, University of Wisconsin-Madison, Madison, WI 53706,
      USA.
FAU - Srivastava, Achal K
AU  - Srivastava AK
AD  - Department of Neurology, All India Institute of Medical Sciences, New Delhi,
      India.
FAU - Faruq, Mohammed
AU  - Faruq M
AD  - Genomics and Molecular Medicine, Council of Scientific and Industrial Research
      (CSIR)-Institute of Genomics and Integrative Biology (IGIB), New Delhi, India.
FAU - Bradner, James E
AU  - Bradner JE
AUID- ORCID: 0000-0003-1422-5318
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
AD  - Novartis Institutes for BioMedical Research (NIBR), Cambridge, MA 02139, USA.
FAU - Ansari, Aseem Z
AU  - Ansari AZ
AUID- ORCID: 0000-0003-1432-4498
AD  - Department of Biochemistry, University of Wisconsin-Madison, Madison, WI 53706,
      USA. azansari@wisc.edu.
AD  - The Genome Center of Wisconsin, University of Wisconsin-Madison, Madison, WI
      53706, USA.
LA  - eng
GR  - R01 CA133508/CA/NCI NIH HHS/United States
GR  - R01 GM117362/GM/NIGMS NIH HHS/United States
GR  - U01 HL099773/HL/NHLBI NIH HHS/United States
GR  - P30 AR066524/AR/NIAMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, N.I.H., Extramural
DEP - 20171130
PL  - United States
TA  - Science
JT  - Science (New York, N.Y.)
JID - 0404511
EDAT- 2017/12/02 06:00
MHDA- 2017/12/02 06:00
CRDT- 2017/12/02 06:00
PHST- 2017/05/12 00:00 [received]
PHST- 2017/11/15 00:00 [accepted]
PHST- 2017/12/02 06:00 [pubmed]
PHST- 2017/12/02 06:00 [medline]
PHST- 2017/12/02 06:00 [entrez]
AID - science.aan6414 [pii]
AID - 10.1126/science.aan6414 [doi]
PST - ppublish
SO  - Science. 2017 Dec 22;358(6370):1617-1622. doi: 10.1126/science.aan6414. Epub 2017
      Nov 30.

PMID- 29101162
OWN - NLM
STAT- Publisher
LR  - 20180124
IS  - 2159-8290 (Electronic)
IS  - 2159-8274 (Linking)
DP  - 2017 Nov 3
TI  - Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids.
LID - 10.1158/2159-8290.CD-17-0833 [doi]
AB  - Ex vivo systems that incorporate features of the tumor microenvironment and model
      the dynamic response to immune checkpoint blockade (ICB) may facilitate efforts
      in precision immuno-oncology and the development of effective combination
      therapies. Here, we demonstrate the ability to interrogate ex vivo response to
      ICB using murine- and patient-derived organotypic tumor spheroids (MDOTS/PDOTS). 
      MDOTS/PDOTS isolated from mouse and human tumors retain autologous lymphoid and
      myeloid cell populations and respond to ICB in short-term three-dimensional
      microfluidic culture. Response and resistance to ICB was recapitulated using
      MDOTS derived from established immunocompetent mouse tumor models. MDOTS
      profiling demonstrated that TBK1/IKKepsilon inhibition enhanced response to PD-1 
      blockade, which effectively predicted tumor response in vivo Systematic profiling
      of secreted cytokines in PDOTS captured key features associated with response and
      resistance to PD-1 blockade. Thus, MDOTS/PDOTS profiling represents a novel
      platform to evaluate ICB using established murine models as well as clinically
      relevant patient specimens.SIGNIFICANCE: Resistance to PD-1 blockade remains a
      challenge for many patients, and biomarkers to guide treatment are lacking. Here,
      we demonstrate feasibility of ex vivo profiling of PD-1 blockade to interrogate
      the tumor immune microenvironment, develop therapeutic combinations, and
      facilitate precision immuno-oncology efforts. Cancer Discov; 8(2); 1-20. (c)2017 
      AACR.See related commentary by Balko and Sosman, p. 143.
CI  - (c)2017 American Association for Cancer Research.
FAU - Jenkins, Russell W
AU  - Jenkins RW
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
AD  - Division of Medical Oncology, Massachusetts General Hospital Cancer Center,
      Harvard Medical School, Boston, Massachusetts.
FAU - Aref, Amir R
AU  - Aref AR
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
AD  - Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Lizotte, Patrick H
AU  - Lizotte PH
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
AD  - Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Ivanova, Elena
AU  - Ivanova E
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
AD  - Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Stinson, Susanna
AU  - Stinson S
AD  - Gilead Sciences, Foster City, California.
FAU - Zhou, Chensheng W
AU  - Zhou CW
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
AD  - Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Bowden, Michaela
AU  - Bowden M
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
AD  - Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Deng, Jiehui
AU  - Deng J
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Liu, Hongye
AU  - Liu H
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
AD  - Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
AD  - Laboratory of Systems Pharmacology, Harvard Medical School, Boston,
      Massachusetts.
FAU - Miao, Diana
AU  - Miao D
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
AD  - Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
FAU - He, Meng Xiao
AU  - He MX
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
AD  - Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
AD  - Harvard Graduate Program in Biophysics, Boston, Massachusetts.
FAU - Walker, William
AU  - Walker W
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
AD  - Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Zhang, Gao
AU  - Zhang G
AD  - Melanoma Research Center and Molecular and Cellular Oncogenesis Program, The
      Wistar Institute, Philadelphia, Pennsylvania.
FAU - Tian, Tian
AU  - Tian T
AD  - Department of Computer Science, New Jersey Institute of Technology, Newark, New
      Jersey.
FAU - Cheng, Chaoran
AU  - Cheng C
AD  - Department of Computer Science, New Jersey Institute of Technology, Newark, New
      Jersey.
FAU - Wei, Zhi
AU  - Wei Z
AD  - Department of Computer Science, New Jersey Institute of Technology, Newark, New
      Jersey.
FAU - Palakurthi, Sangeetha
AU  - Palakurthi S
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
AD  - Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Bittinger, Mark
AU  - Bittinger M
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
AD  - Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Vitzthum, Hans
AU  - Vitzthum H
AD  - Division of Medical Oncology, Massachusetts General Hospital Cancer Center,
      Harvard Medical School, Boston, Massachusetts.
FAU - Kim, Jong Wook
AU  - Kim JW
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
AD  - Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
FAU - Merlino, Ashley
AU  - Merlino A
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Quinn, Max
AU  - Quinn M
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Venkataramani, Chandrasekar
AU  - Venkataramani C
AD  - Gilead Sciences, Foster City, California.
FAU - Kaplan, Joshua A
AU  - Kaplan JA
AD  - Gilead Sciences, Foster City, California.
FAU - Portell, Andrew
AU  - Portell A
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
AD  - Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Gokhale, Prafulla C
AU  - Gokhale PC
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
AD  - Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Phillips, Bart
AU  - Phillips B
AD  - Gilead Sciences, Foster City, California.
FAU - Smart, Alicia
AU  - Smart A
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
AD  - Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
FAU - Rotem, Asaf
AU  - Rotem A
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Jones, Robert E
AU  - Jones RE
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
AD  - Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Keogh, Lauren
AU  - Keogh L
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
AD  - Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Anguiano, Maria
AU  - Anguiano M
AD  - Center for Applied Medical Research, University of Navarra, Pamplona, Spain.
FAU - Stapleton, Lance
AU  - Stapleton L
AD  - Gilead Sciences, Foster City, California.
FAU - Jia, Zhiheng
AU  - Jia Z
AD  - Gilead Sciences, Foster City, California.
FAU - Barzily-Rokni, Michal
AU  - Barzily-Rokni M
AD  - Division of Medical Oncology, Massachusetts General Hospital Cancer Center,
      Harvard Medical School, Boston, Massachusetts.
FAU - Canadas, Israel
AU  - Canadas I
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Thai, Tran C
AU  - Thai TC
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Hammond, Marc R
AU  - Hammond MR
AD  - Division of Medical Oncology, Massachusetts General Hospital Cancer Center,
      Harvard Medical School, Boston, Massachusetts.
FAU - Vlahos, Raven
AU  - Vlahos R
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
AD  - Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Wang, Eric S
AU  - Wang ES
AD  - Department of Cancer Biology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Zhang, Hua
AU  - Zhang H
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Li, Shuai
AU  - Li S
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Hanna, Glenn J
AU  - Hanna GJ
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Huang, Wei
AU  - Huang W
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
AD  - Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Hoang, Mai P
AU  - Hoang MP
AD  - Department of Pathology, Massachusetts General Hospital, Harvard Medical School, 
      Boston, Massachusetts.
FAU - Piris, Adriano
AU  - Piris A
AD  - Department of Pathology, Brigham and Women's Hospital, and Harvard Medical
      School, Boston, Massachusetts.
FAU - Eliane, Jean-Pierre
AU  - Eliane JP
AD  - Department of Pathology, Massachusetts General Hospital, Harvard Medical School, 
      Boston, Massachusetts.
FAU - Stemmer-Rachamimov, Anat O
AU  - Stemmer-Rachamimov AO
AD  - Department of Pathology, Massachusetts General Hospital, Harvard Medical School, 
      Boston, Massachusetts.
FAU - Cameron, Lisa
AU  - Cameron L
AD  - Confocal and Light Microscopy Core Facility, Dana-Farber Cancer Institute,
      Boston, Massachusetts.
FAU - Su, Mei-Ju
AU  - Su MJ
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Shah, Parin
AU  - Shah P
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Izar, Benjamin
AU  - Izar B
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
AD  - Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
FAU - Thakuria, Manisha
AU  - Thakuria M
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
AD  - Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, 
      Boston, Massachusetts.
FAU - LeBoeuf, Nicole R
AU  - LeBoeuf NR
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
AD  - Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, 
      Boston, Massachusetts.
FAU - Rabinowits, Guilherme
AU  - Rabinowits G
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Gunda, Viswanath
AU  - Gunda V
AD  - Department of Surgery, Massachusetts General Hospital, Harvard Medical School,
      Boston, Massachusetts.
FAU - Parangi, Sareh
AU  - Parangi S
AD  - Department of Surgery, Massachusetts General Hospital, Harvard Medical School,
      Boston, Massachusetts.
FAU - Cleary, James M
AU  - Cleary JM
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Miller, Brian C
AU  - Miller BC
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Kitajima, Shunsuke
AU  - Kitajima S
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Thummalapalli, Rohit
AU  - Thummalapalli R
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Miao, Benchun
AU  - Miao B
AD  - Division of Medical Oncology, Massachusetts General Hospital Cancer Center,
      Harvard Medical School, Boston, Massachusetts.
FAU - Barbie, Thanh U
AU  - Barbie TU
AD  - Department of Surgical Oncology, Brigham and Women's Hospital, Harvard Medical
      School, Boston, Massachusetts.
FAU - Sivathanu, Vivek
AU  - Sivathanu V
AD  - Department of Mechanical Engineering, Massachusetts Institute of Technology,
      Cambridge, Massachusetts.
FAU - Wong, Joshua
AU  - Wong J
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Richards, William G
AU  - Richards WG
AD  - Division of Thoracic Surgery, Brigham and Women's Hospital, Harvard Medical
      School, Boston, Massachusetts.
FAU - Bueno, Raphael
AU  - Bueno R
AD  - Division of Thoracic Surgery, Brigham and Women's Hospital, Harvard Medical
      School, Boston, Massachusetts.
FAU - Yoon, Charles H
AU  - Yoon CH
AD  - Department of Surgical Oncology, Brigham and Women's Hospital, Harvard Medical
      School, Boston, Massachusetts.
FAU - Miret, Juan
AU  - Miret J
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
AD  - Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Herlyn, Meenhard
AU  - Herlyn M
AD  - Melanoma Research Center and Molecular and Cellular Oncogenesis Program, The
      Wistar Institute, Philadelphia, Pennsylvania.
FAU - Garraway, Levi A
AU  - Garraway LA
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Van Allen, Eliezer M
AU  - Van Allen EM
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
AD  - Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
FAU - Freeman, Gordon J
AU  - Freeman GJ
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Kirschmeier, Paul T
AU  - Kirschmeier PT
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
AD  - Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Lorch, Jochen H
AU  - Lorch JH
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Ott, Patrick A
AU  - Ott PA
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Hodi, F Stephen
AU  - Hodi FS
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Flaherty, Keith T
AU  - Flaherty KT
AD  - Division of Medical Oncology, Massachusetts General Hospital Cancer Center,
      Harvard Medical School, Boston, Massachusetts.
FAU - Kamm, Roger D
AU  - Kamm RD
AD  - Department of Mechanical Engineering, Massachusetts Institute of Technology,
      Cambridge, Massachusetts.
AD  - Department of Biological Engineering, Massachusetts Institute of Technology,
      Cambridge, Massachusetts.
FAU - Boland, Genevieve M
AU  - Boland GM
AD  - Department of Surgery, Massachusetts General Hospital, Harvard Medical School,
      Boston, Massachusetts.
FAU - Wong, Kwok-Kin
AU  - Wong KK
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
AD  - Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Dornan, David
AU  - Dornan D
AD  - Gilead Sciences, Foster City, California. dbarbie@partners.org
      CloudP_Paweletz@dfci.harvard.edu David.Dornan@gilead.com.
FAU - Paweletz, Cloud Peter
AU  - Paweletz CP
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts. dbarbie@partners.org CloudP_Paweletz@dfci.harvard.edu
      David.Dornan@gilead.com.
AD  - Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston,
      Massachusetts.
FAU - Barbie, David A
AU  - Barbie DA
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts. dbarbie@partners.org CloudP_Paweletz@dfci.harvard.edu
      David.Dornan@gilead.com.
LA  - eng
GR  - P30 CA010815/CA/NCI NIH HHS/United States
GR  - R01 CA190394/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20171103
PL  - United States
TA  - Cancer Discov
JT  - Cancer discovery
JID - 101561693
EDAT- 2017/11/05 06:00
MHDA- 2017/11/05 06:00
CRDT- 2017/11/05 06:00
PHST- 2017/07/24 00:00 [received]
PHST- 2017/10/23 00:00 [revised]
PHST- 2017/10/31 00:00 [accepted]
PHST- 2017/11/05 06:00 [pubmed]
PHST- 2017/11/05 06:00 [medline]
PHST- 2017/11/05 06:00 [entrez]
AID - 2159-8290.CD-17-0833 [pii]
AID - 10.1158/2159-8290.CD-17-0833 [doi]
PST - aheadofprint
SO  - Cancer Discov. 2017 Nov 3. pii: 2159-8290.CD-17-0833. doi:
      10.1158/2159-8290.CD-17-0833.

PMID- 29235467
OWN - NLM
STAT- In-Data-Review
LR  - 20171220
IS  - 2041-1723 (Electronic)
IS  - 2041-1723 (Linking)
VI  - 8
IP  - 1
DP  - 2017 Dec 13
TI  - In situ functional dissection of RNA cis-regulatory elements by multiplex
      CRISPR-Cas9 genome engineering.
PG  - 2109
LID - 10.1038/s41467-017-00686-2 [doi]
AB  - RNA regulatory elements (RREs) are an important yet relatively under-explored
      facet of gene regulation. Deciphering the prevalence and functional impact of
      this post-transcriptional control layer requires technologies for disrupting RREs
      without perturbing cellular homeostasis. Here we describe genome-engineering
      based evaluation of RNA regulatory element activity (GenERA), a clustered
      regularly interspaced short palindromic repeats (CRISPR)-Cas9 platform for in
      situ high-content functional analysis of RREs. We use GenERA to survey the entire
      regulatory landscape of a 3'UTR, and apply it in a multiplex fashion to analyse
      combinatorial interactions between sets of miRNA response elements (MREs),
      providing strong evidence for cooperative activity. We also employ this
      technology to probe the functionality of an entire MRE network under cellular
      homeostasis, and show that high-resolution analysis of the GenERA dataset can be 
      used to extract functional features of MREs. This study provides a genome
      editing-based multiplex strategy for direct functional interrogation of RNA
      cis-regulatory elements in a native cellular environment.
FAU - Wu, Qianxin
AU  - Wu Q
AD  - Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine,
      University of Oxford, Oxford, OX3 9DS, UK.
AD  - Wellcome Trust Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, CB10
      1SA, UK.
FAU - Ferry, Quentin R V
AU  - Ferry QRV
AD  - Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine,
      University of Oxford, Oxford, OX3 9DS, UK.
FAU - Baeumler, Toni A
AU  - Baeumler TA
AD  - Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine,
      University of Oxford, Oxford, OX3 9DS, UK.
FAU - Michaels, Yale S
AU  - Michaels YS
AD  - Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine,
      University of Oxford, Oxford, OX3 9DS, UK.
FAU - Vitsios, Dimitrios M
AU  - Vitsios DM
AUID- ORCID: http://orcid.org/0000-0002-8939-5445
AD  - European Molecular Biology Laboratory-European Bioinformatics Institute, Wellcome
      Trust Genome Campus, Hinxton, Cambridge, CB10 1SD, UK.
FAU - Habib, Omer
AU  - Habib O
AD  - Center for Genome Engineering, Institute for Basic Science (IBS), Seoul, 08826,
      Republic of Korea.
FAU - Arnold, Roland
AU  - Arnold R
AD  - Molecular and Population Genetics Laboratory, Oxford Centre for Cancer Gene
      Research, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford,
      OX3 7BN, UK.
FAU - Jiang, Xiaowei
AU  - Jiang X
AUID- ORCID: http://orcid.org/0000-0002-6030-1249
AD  - Molecular and Population Genetics Laboratory, Oxford Centre for Cancer Gene
      Research, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford,
      OX3 7BN, UK.
FAU - Maio, Stefano
AU  - Maio S
AD  - Weatherall Institute of Molecular Medicine, Developmental Immunology, University 
      of Oxford, Oxford, OX3 9DS, UK.
FAU - Steinkraus, Bruno R
AU  - Steinkraus BR
AD  - Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine,
      University of Oxford, Oxford, OX3 9DS, UK.
FAU - Tapia, Marta
AU  - Tapia M
AD  - Weatherall Institute of Molecular Medicine, MRC Molecular Haematology Unit, NIHR 
      Oxford Biomedical Research Centre Programme, University of Oxford, Oxford, OX3
      9DS, UK.
FAU - Piazza, Paolo
AU  - Piazza P
AD  - Wellcome Trust Centre for Human Genetics, Oxford, OX3 7BN, UK.
FAU - Xu, Ni
AU  - Xu N
AD  - Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine,
      University of Oxford, Oxford, OX3 9DS, UK.
FAU - Hollander, Georg A
AU  - Hollander GA
AD  - Weatherall Institute of Molecular Medicine, Developmental Immunology, University 
      of Oxford, Oxford, OX3 9DS, UK.
AD  - Department of Biomedicine, Laboratory of Paediatric Immunology, University of
      Basel, CH-4058, Basel, Switzerland.
FAU - Milne, Thomas A
AU  - Milne TA
AUID- ORCID: http://orcid.org/0000-0002-0413-4271
AD  - Weatherall Institute of Molecular Medicine, MRC Molecular Haematology Unit, NIHR 
      Oxford Biomedical Research Centre Programme, University of Oxford, Oxford, OX3
      9DS, UK.
FAU - Kim, Jin-Soo
AU  - Kim JS
AD  - Center for Genome Engineering, Institute for Basic Science (IBS), Seoul, 08826,
      Republic of Korea.
AD  - Department of Chemistry, Seoul National University, Seoul, 151-747, Republic of
      Korea.
FAU - Enright, Anton J
AU  - Enright AJ
AUID- ORCID: http://orcid.org/0000-0002-6090-3100
AD  - European Molecular Biology Laboratory-European Bioinformatics Institute, Wellcome
      Trust Genome Campus, Hinxton, Cambridge, CB10 1SD, UK.
FAU - Bassett, Andrew R
AU  - Bassett AR
AUID- ORCID: http://orcid.org/0000-0003-1632-9137
AD  - Sir William Dunn School of Pathology, University of Oxford, South Parks Road,
      Oxford, OX1 3RF, UK.
AD  - Wellcome Trust Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, CB10
      1SA, UK.
FAU - Fulga, Tudor A
AU  - Fulga TA
AD  - Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine,
      University of Oxford, Oxford, OX3 9DS, UK. tudor.fulga@imm.ox.ac.uk.
LA  - eng
GR  - Wellcome Trust/United Kingdom
GR  - 340560/European Research Council/International
PT  - Journal Article
DEP - 20171213
PL  - England
TA  - Nat Commun
JT  - Nature communications
JID - 101528555
PMC - PMC5727397
EDAT- 2017/12/14 06:00
MHDA- 2017/12/14 06:00
CRDT- 2017/12/14 06:00
PHST- 2017/05/02 00:00 [received]
PHST- 2017/07/19 00:00 [accepted]
PHST- 2017/12/14 06:00 [entrez]
PHST- 2017/12/14 06:00 [pubmed]
PHST- 2017/12/14 06:00 [medline]
AID - 10.1038/s41467-017-00686-2 [doi]
AID - 10.1038/s41467-017-00686-2 [pii]
PST - epublish
SO  - Nat Commun. 2017 Dec 13;8(1):2109. doi: 10.1038/s41467-017-00686-2.

PMID- 29249356
OWN - NLM
STAT- In-Data-Review
LR  - 20180126
IS  - 1097-4172 (Electronic)
IS  - 0092-8674 (Linking)
VI  - 172
IP  - 1-2
DP  - 2018 Jan 11
TI  - Nudt21 Controls Cell Fate by Connecting Alternative Polyadenylation to Chromatin 
      Signaling.
PG  - 106-120.e21
LID - S0092-8674(17)31370-3 [pii]
LID - 10.1016/j.cell.2017.11.023 [doi]
AB  - Cell fate transitions involve rapid gene expression changes and global chromatin 
      remodeling, yet the underlying regulatory pathways remain incompletely
      understood. Here, we identified the RNA-processing factor Nudt21 as a novel
      regulator of cell fate change using transcription-factor-induced reprogramming as
      a screening assay. Suppression of Nudt21 enhanced the generation of induced
      pluripotent stem cells, facilitated transdifferentiation into trophoblast stem
      cells, and impaired differentiation of myeloid precursors and embryonic stem
      cells, suggesting a broader role for Nudt21 in cell fate change. We show that
      Nudt21 directs differential polyadenylation of over 1,500 transcripts in cells
      acquiring pluripotency, although only a fraction changed protein levels.
      Remarkably, these proteins were strongly enriched for chromatin regulators, and
      their suppression neutralized the effect of Nudt21 during reprogramming.
      Collectively, our data uncover Nudt21 as a novel post-transcriptional regulator
      of cell fate and establish a direct, previously unappreciated link between
      alternative polyadenylation and chromatin signaling.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Brumbaugh, Justin
AU  - Brumbaugh J
AD  - Department of Molecular Biology, Massachusetts General Hospital, Boston, MA
      02114, USA; Center for Regenerative Medicine, Massachusetts General Hospital,
      Boston, MA 02114, USA; Cancer Center, Massachusetts General Hospital, Boston, MA 
      02114, USA; Department of Stem Cell and Regenerative Biology, Harvard University,
      Cambridge, MA 02138, USA; Harvard Stem Cell Institute, Cambridge, MA 02138, USA.
FAU - Di Stefano, Bruno
AU  - Di Stefano B
AD  - Department of Molecular Biology, Massachusetts General Hospital, Boston, MA
      02114, USA; Center for Regenerative Medicine, Massachusetts General Hospital,
      Boston, MA 02114, USA; Cancer Center, Massachusetts General Hospital, Boston, MA 
      02114, USA; Department of Stem Cell and Regenerative Biology, Harvard University,
      Cambridge, MA 02138, USA; Harvard Stem Cell Institute, Cambridge, MA 02138, USA.
FAU - Wang, Xiuye
AU  - Wang X
AD  - Department of Microbiology and Molecular Genetics, School of Medicine, University
      of California, Irvine, Irvine, CA 92697, USA.
FAU - Borkent, Marti
AU  - Borkent M
AD  - Department of Molecular Biology, Massachusetts General Hospital, Boston, MA
      02114, USA; Center for Regenerative Medicine, Massachusetts General Hospital,
      Boston, MA 02114, USA; Cancer Center, Massachusetts General Hospital, Boston, MA 
      02114, USA; Department of Stem Cell and Regenerative Biology, Harvard University,
      Cambridge, MA 02138, USA; Harvard Stem Cell Institute, Cambridge, MA 02138, USA.
FAU - Forouzmand, Elmira
AU  - Forouzmand E
AD  - Department of Microbiology and Molecular Genetics, School of Medicine, University
      of California, Irvine, Irvine, CA 92697, USA.
FAU - Clowers, Katie J
AU  - Clowers KJ
AD  - Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA.
FAU - Ji, Fei
AU  - Ji F
AD  - Department of Molecular Biology, Massachusetts General Hospital, Boston, MA
      02114, USA.
FAU - Schwarz, Benjamin A
AU  - Schwarz BA
AD  - Department of Molecular Biology, Massachusetts General Hospital, Boston, MA
      02114, USA; Center for Regenerative Medicine, Massachusetts General Hospital,
      Boston, MA 02114, USA; Cancer Center, Massachusetts General Hospital, Boston, MA 
      02114, USA; Department of Stem Cell and Regenerative Biology, Harvard University,
      Cambridge, MA 02138, USA; Harvard Stem Cell Institute, Cambridge, MA 02138, USA.
FAU - Kalocsay, Marian
AU  - Kalocsay M
AD  - Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA.
FAU - Elledge, Stephen J
AU  - Elledge SJ
AD  - Howard Hughes Medical Institute, Brigham and Women's Hospital and Department of
      Genetics, Harvard Medical School, Boston, MA 02115, USA.
FAU - Chen, Yue
AU  - Chen Y
AD  - Department of Biochemistry, Molecular Biology, and Biophysics, College of
      Biological Sciences, University of Minnesota, Saint Paul, MN 55018, USA.
FAU - Sadreyev, Ruslan I
AU  - Sadreyev RI
AD  - Department of Molecular Biology, Massachusetts General Hospital, Boston, MA
      02114, USA; Cancer Center, Massachusetts General Hospital, Boston, MA 02114, USA.
FAU - Gygi, Steven P
AU  - Gygi SP
AD  - Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA.
FAU - Hu, Guang
AU  - Hu G
AD  - Epigenetics and Stem Cell Biology Laboratory, National Institute of Environmental
      Health Sciences, Research Triangle Park, NC 27709, USA.
FAU - Shi, Yongsheng
AU  - Shi Y
AD  - Department of Microbiology and Molecular Genetics, School of Medicine, University
      of California, Irvine, Irvine, CA 92697, USA. Electronic address:
      yongshes@uci.edu.
FAU - Hochedlinger, Konrad
AU  - Hochedlinger K
AD  - Department of Molecular Biology, Massachusetts General Hospital, Boston, MA
      02114, USA; Center for Regenerative Medicine, Massachusetts General Hospital,
      Boston, MA 02114, USA; Cancer Center, Massachusetts General Hospital, Boston, MA 
      02114, USA; Department of Stem Cell and Regenerative Biology, Harvard University,
      Cambridge, MA 02138, USA; Harvard Stem Cell Institute, Cambridge, MA 02138, USA. 
      Electronic address: khochedlinger@mgh.harvard.edu.
LA  - eng
GR  - R01 GM090056/GM/NIGMS NIH HHS/United States
GR  - R01 AG011085/AG/NIA NIH HHS/United States
GR  - R01 HD058013/HD/NICHD NIH HHS/United States
GR  - R01 CA177651/CA/NCI NIH HHS/United States
GR  - F32 HD078029/HD/NICHD NIH HHS/United States
PT  - Journal Article
DEP - 20171214
PL  - United States
TA  - Cell
JT  - Cell
JID - 0413066
EIN - Cell. 2018 Jan 25;172(3):629-631. PMID: 29373832
PMC - PMC5766360
MID - NIHMS921736
OTO - NOTNLM
OT  - Alternative polyadenylation
OT  - chromatin
OT  - embryonic stem cells
OT  - epigenetic regulation
OT  - induced pluripotent stem cells
OT  - induced trophoblast stem cells
OT  - microRNA
OT  - pluripotency
OT  - reprogramming
OT  - transdifferentiation
EDAT- 2017/12/19 06:00
MHDA- 2017/12/19 06:00
CRDT- 2017/12/19 06:00
PMCR- 2019/01/11 00:00
PHST- 2017/06/14 00:00 [received]
PHST- 2017/10/08 00:00 [revised]
PHST- 2017/11/10 00:00 [accepted]
PHST- 2019/01/11 00:00 [pmc-release]
PHST- 2017/12/19 06:00 [pubmed]
PHST- 2017/12/19 06:00 [medline]
PHST- 2017/12/19 06:00 [entrez]
AID - S0092-8674(17)31370-3 [pii]
AID - 10.1016/j.cell.2017.11.023 [doi]
PST - ppublish
SO  - Cell. 2018 Jan 11;172(1-2):106-120.e21. doi: 10.1016/j.cell.2017.11.023. Epub
      2017 Dec 14.

PMID- 29227473
OWN - NLM
STAT- In-Data-Review
LR  - 20180120
IS  - 1552-4469 (Electronic)
IS  - 1552-4450 (Linking)
VI  - 14
IP  - 2
DP  - 2018 Feb
TI  - Structure-inspired design of beta-arrestin-biased ligands for aminergic GPCRs.
PG  - 126-134
LID - 10.1038/nchembio.2527 [doi]
AB  - Development of biased ligands targeting G protein-coupled receptors (GPCRs) is a 
      promising approach for current drug discovery. Although structure-based drug
      design of biased agonists remains challenging even with an abundance of GPCR
      crystal structures, we present an approach for translating GPCR structural data
      into beta-arrestin-biased ligands for aminergic GPCRs. We identified specific
      amino acid-ligand contacts at transmembrane helix 5 (TM5) and extracellular loop 
      2 (EL2) responsible for Gi/o and beta-arrestin signaling, respectively, and
      targeted those residues to develop biased ligands. For these ligands, we found
      that bias is conserved at other aminergic GPCRs that retain similar residues at
      TM5 and EL2. Our approach provides a template for generating arrestin-biased
      ligands by modifying predicted ligand interactions that block TM5 interactions
      and promote EL2 interactions. This strategy may facilitate the structure-guided
      design of arrestin-biased ligands at other GPCRs, including polypharmacological
      biased ligands.
FAU - McCorvy, John D
AU  - McCorvy JD
AD  - National Institute of Mental Health Psychoactive Drug Screening Program,
      Department of Pharmacology and Division of Chemical Biology and Medicinal
      Chemistry, University of North Carolina Chapel Hill Medical School, Chapel Hill, 
      North Carolina, USA.
FAU - Butler, Kyle V
AU  - Butler KV
AD  - Center for Chemical Biology and Drug Discovery, Departments of Pharmacological
      Sciences and Oncological Sciences, Tisch Cancer Institute, Icahn School of
      Medicine at Mount Sinai, New York, New York, USA.
FAU - Kelly, Brendan
AU  - Kelly B
AD  - Departments of Computer Science and Molecular and Cellular Physiology, Institute 
      for Computational and Mathematical Engineering, and Biophysics Program, Stanford 
      University, Stanford, California, USA.
FAU - Rechsteiner, Katie
AU  - Rechsteiner K
AD  - National Institute of Mental Health Psychoactive Drug Screening Program,
      Department of Pharmacology and Division of Chemical Biology and Medicinal
      Chemistry, University of North Carolina Chapel Hill Medical School, Chapel Hill, 
      North Carolina, USA.
FAU - Karpiak, Joel
AU  - Karpiak J
AD  - Department of Pharmaceutical Chemistry, University of California at San
      Francisco, Byers Hall, San Francisco, California, USA.
FAU - Betz, Robin M
AU  - Betz RM
AD  - Departments of Computer Science and Molecular and Cellular Physiology, Institute 
      for Computational and Mathematical Engineering, and Biophysics Program, Stanford 
      University, Stanford, California, USA.
FAU - Kormos, Bethany L
AU  - Kormos BL
AD  - Neuroscience and Pain Medicinal Chemistry, Pfizer Worldwide R&D, Cambridge,
      Massachusetts, USA.
FAU - Shoichet, Brian K
AU  - Shoichet BK
AD  - Department of Pharmaceutical Chemistry, University of California at San
      Francisco, Byers Hall, San Francisco, California, USA.
FAU - Dror, Ron O
AU  - Dror RO
AD  - Departments of Computer Science and Molecular and Cellular Physiology, Institute 
      for Computational and Mathematical Engineering, and Biophysics Program, Stanford 
      University, Stanford, California, USA.
FAU - Jin, Jian
AU  - Jin J
AUID- ORCID: http://orcid.org/0000-0002-2387-3862
AD  - Center for Chemical Biology and Drug Discovery, Departments of Pharmacological
      Sciences and Oncological Sciences, Tisch Cancer Institute, Icahn School of
      Medicine at Mount Sinai, New York, New York, USA.
FAU - Roth, Bryan L
AU  - Roth BL
AD  - National Institute of Mental Health Psychoactive Drug Screening Program,
      Department of Pharmacology and Division of Chemical Biology and Medicinal
      Chemistry, University of North Carolina Chapel Hill Medical School, Chapel Hill, 
      North Carolina, USA.
LA  - eng
SI  - PubChem-Substance/348353604
SI  - PubChem-Substance/348353607
SI  - PubChem-Substance/348353608
SI  - PubChem-Substance/348353609
SI  - PubChem-Substance/348353610
SI  - PubChem-Substance/348353611
SI  - PubChem-Substance/348353612
SI  - PubChem-Substance/348353613
SI  - PubChem-Substance/348353614
SI  - PubChem-Substance/348353605
SI  - PubChem-Substance/348353606
GR  - U01 MH105892/MH/NIMH NIH HHS/United States
GR  - U19 MH082441/MH/NIMH NIH HHS/United States
GR  - R01 NS100930/NS/NINDS NIH HHS/United States
GR  - R01 MH112205/MH/NIMH NIH HHS/United States
GR  - U24 DK116195/DK/NIDDK NIH HHS/United States
GR  - R01 GM059957/GM/NIGMS NIH HHS/United States
PT  - Journal Article
DEP - 20171211
PL  - United States
TA  - Nat Chem Biol
JT  - Nature chemical biology
JID - 101231976
PMC - PMC5771956
MID - NIHMS914736
EDAT- 2017/12/12 06:00
MHDA- 2017/12/12 06:00
CRDT- 2017/12/12 06:00
PMCR- 2018/06/11 00:00
PHST- 2017/01/20 00:00 [received]
PHST- 2017/10/20 00:00 [accepted]
PHST- 2018/06/11 00:00 [pmc-release]
PHST- 2017/12/12 06:00 [pubmed]
PHST- 2017/12/12 06:00 [medline]
PHST- 2017/12/12 06:00 [entrez]
AID - nchembio.2527 [pii]
AID - 10.1038/nchembio.2527 [doi]
PST - ppublish
SO  - Nat Chem Biol. 2018 Feb;14(2):126-134. doi: 10.1038/nchembio.2527. Epub 2017 Dec 
      11.

PMID- 29056343
OWN - NLM
STAT- MEDLINE
DCOM- 20171121
LR  - 20171219
IS  - 1097-4172 (Electronic)
IS  - 0092-8674 (Linking)
VI  - 171
IP  - 4
DP  - 2017 Nov 2
TI  - ILC1 Confer Early Host Protection at Initial Sites of Viral Infection.
PG  - 795-808.e12
LID - S0092-8674(17)31183-2 [pii]
LID - 10.1016/j.cell.2017.09.052 [doi]
AB  - Infection is restrained by the concerted activation of tissue-resident and
      circulating immune cells. Whether tissue-resident lymphocytes confer early
      antiviral immunity at local sites of primary infection prior to the initiation of
      circulating responses is not well understood. Furthermore, the kinetics of
      initial antiviral responses at sites of infection remain unclear. Here, we show
      that tissue-resident type 1 innate lymphoid cells (ILC1) serve an essential early
      role in host immunity through rapid production of interferon (IFN)-gamma
      following viral infection. Ablation of Zfp683-dependent liver ILC1 lead to
      increased viral load in the presence of intact adaptive and innate immune cells
      critical for mouse cytomegalovirus (MCMV) clearance. Swift production of
      interleukin (IL)-12 by tissue-resident XCR1(+) conventional dendritic cells
      (cDC1) promoted ILC1 production of IFN-gamma in a STAT4-dependent manner to limit
      early viral burden. Thus, ILC1 contribute an essential role in viral
      immunosurveillance at sites of initial infection in response to local
      cDC1-derived proinflammatory cytokines.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Weizman, Orr-El
AU  - Weizman OE
AD  - Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065,
      USA.
FAU - Adams, Nicholas M
AU  - Adams NM
AD  - Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065,
      USA.
FAU - Schuster, Iona S
AU  - Schuster IS
AD  - Immunology and Virology Program, Centre for Ophthalmology and Visual Science, The
      University of Western Australia, Crawley, WA, Australia; Centre for Experimental 
      Immunology, Lions Eye Institute, Nedlands, WA, Australia.
FAU - Krishna, Chirag
AU  - Krishna C
AD  - Computational and Systems Biology Program, Memorial Sloan Kettering Cancer
      Center, New York, NY 10065, USA.
FAU - Pritykin, Yuri
AU  - Pritykin Y
AD  - Computational and Systems Biology Program, Memorial Sloan Kettering Cancer
      Center, New York, NY 10065, USA.
FAU - Lau, Colleen
AU  - Lau C
AD  - Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065,
      USA.
FAU - Degli-Esposti, Mariapia A
AU  - Degli-Esposti MA
AD  - Immunology and Virology Program, Centre for Ophthalmology and Visual Science, The
      University of Western Australia, Crawley, WA, Australia; Centre for Experimental 
      Immunology, Lions Eye Institute, Nedlands, WA, Australia.
FAU - Leslie, Christina S
AU  - Leslie CS
AD  - Computational and Systems Biology Program, Memorial Sloan Kettering Cancer
      Center, New York, NY 10065, USA.
FAU - Sun, Joseph C
AU  - Sun JC
AD  - Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065,
      USA; Department of Immunology and Microbial Pathogenesis, Weill Cornell Medical
      College, New York, NY 10065, USA. Electronic address: sunj@mskcc.org.
FAU - O'Sullivan, Timothy E
AU  - O'Sullivan TE
AD  - Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065,
      USA. Electronic address: tosullivan@mednet.ucla.edu.
LA  - eng
GR  - R01 AI100874/AI/NIAID NIH HHS/United States
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - T32 GM083937/GM/NIGMS NIH HHS/United States
GR  - T32 GM007739/GM/NIGMS NIH HHS/United States
GR  - R01 AI130043/AI/NIAID NIH HHS/United States
PT  - Journal Article
DEP - 20171019
PL  - United States
TA  - Cell
JT  - Cell
JID - 0413066
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Animals
MH  - Herpesviridae Infections/*immunology/pathology
MH  - Immunity, Innate
MH  - Immunologic Surveillance
MH  - Inflammation/immunology
MH  - Interferon-gamma/immunology
MH  - Killer Cells, Natural/immunology
MH  - Liver/cytology/immunology
MH  - Lymphocytes/*immunology
MH  - Mice, Inbred C57BL
MH  - Muromegalovirus/*physiology
MH  - Peritoneal Cavity/cytology
MH  - Virus Replication
PMC - PMC5687850
MID - NIHMS909950
OTO - NOTNLM
OT  - ILC1
OT  - MCMV
OT  - cDC1
OT  - infection
OT  - influenza
OT  - innate immunity
OT  - sendai virus
OT  - tissue-resident
EDAT- 2017/10/24 06:00
MHDA- 2017/11/29 06:00
CRDT- 2017/10/24 06:00
PMCR- 2018/11/02 00:00
PHST- 2017/05/17 00:00 [received]
PHST- 2017/08/11 00:00 [revised]
PHST- 2017/08/16 00:00 [accepted]
PHST- 2018/11/02 00:00 [pmc-release]
PHST- 2017/10/24 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
PHST- 2017/10/24 06:00 [entrez]
AID - S0092-8674(17)31183-2 [pii]
AID - 10.1016/j.cell.2017.09.052 [doi]
PST - ppublish
SO  - Cell. 2017 Nov 2;171(4):795-808.e12. doi: 10.1016/j.cell.2017.09.052. Epub 2017
      Oct 19.

PMID- 29227470
OWN - NLM
STAT- In-Data-Review
LR  - 20180127
IS  - 1546-1696 (Electronic)
IS  - 1087-0156 (Linking)
VI  - 36
IP  - 1
DP  - 2018 Jan
TI  - Multiplexed droplet single-cell RNA-sequencing using natural genetic variation.
PG  - 89-94
LID - 10.1038/nbt.4042 [doi]
AB  - Droplet single-cell RNA-sequencing (dscRNA-seq) has enabled rapid, massively
      parallel profiling of transcriptomes. However, assessing differential expression 
      across multiple individuals has been hampered by inefficient sample processing
      and technical batch effects. Here we describe a computational tool, demuxlet,
      that harnesses natural genetic variation to determine the sample identity of each
      droplet containing a single cell (singlet) and detect droplets containing two
      cells (doublets). These capabilities enable multiplexed dscRNA-seq experiments in
      which cells from unrelated individuals are pooled and captured at higher
      throughput than in standard workflows. Using simulated data, we show that 50
      single-nucleotide polymorphisms (SNPs) per cell are sufficient to assign 97% of
      singlets and identify 92% of doublets in pools of up to 64 individuals. Given
      genotyping data for each of eight pooled samples, demuxlet correctly recovers the
      sample identity of >99% of singlets and identifies doublets at rates consistent
      with previous estimates. We apply demuxlet to assess cell-type-specific changes
      in gene expression in 8 pooled lupus patient samples treated with interferon
      (IFN)-beta and perform eQTL analysis on 23 pooled samples.
FAU - Kang, Hyun Min
AU  - Kang HM
AD  - Department of Biostatistics and Center for Statistical Genetics, University of
      Michigan School of Public Health, Ann Arbor, Michigan, USA.
FAU - Subramaniam, Meena
AU  - Subramaniam M
AD  - Biological and Medical Informatics Graduate Program, University of California,
      San Francisco, San Francisco, California, USA.
AD  - Institute for Human Genetics (IHG), University of California, San Francisco, San 
      Francisco, California, USA.
AD  - Institute for Computational Health Sciences, University of California, San
      Francisco, San Francisco, California, USA.
AD  - Department of Epidemiology and Biostatistics, University of California, San
      Francisco, San Francisco, California, USA.
AD  - Department of Bioengineering and Therapeutic Sciences, University of California, 
      San Francisco, San Francisco, California, USA.
FAU - Targ, Sasha
AU  - Targ S
AD  - Biological and Medical Informatics Graduate Program, University of California,
      San Francisco, San Francisco, California, USA.
AD  - Institute for Human Genetics (IHG), University of California, San Francisco, San 
      Francisco, California, USA.
AD  - Institute for Computational Health Sciences, University of California, San
      Francisco, San Francisco, California, USA.
AD  - Department of Epidemiology and Biostatistics, University of California, San
      Francisco, San Francisco, California, USA.
AD  - Department of Bioengineering and Therapeutic Sciences, University of California, 
      San Francisco, San Francisco, California, USA.
AD  - Medical Scientist Training Program (MSTP), University of California, San
      Francisco, San Francisco, California, USA.
FAU - Nguyen, Michelle
AU  - Nguyen M
AD  - Department of Microbiology and Immunology, University of California, San
      Francisco, San Francisco, California, USA.
AD  - Diabetes Center, University of California, San Francisco, San Francisco,
      California, USA.
AD  - Innovative Genomics Institute, University of California, Berkeley, Berkeley,
      California, USA.
FAU - Maliskova, Lenka
AU  - Maliskova L
AD  - Institute for Human Genetics (IHG), University of California, San Francisco, San 
      Francisco, California, USA.
AD  - Department of Neurology, University of California, San Francisco, San Francisco, 
      California, USA.
FAU - McCarthy, Elizabeth
AU  - McCarthy E
AD  - Medical Scientist Training Program (MSTP), University of California, San
      Francisco, San Francisco, California, USA.
FAU - Wan, Eunice
AU  - Wan E
AD  - Institute for Human Genetics (IHG), University of California, San Francisco, San 
      Francisco, California, USA.
FAU - Wong, Simon
AU  - Wong S
AD  - Institute for Human Genetics (IHG), University of California, San Francisco, San 
      Francisco, California, USA.
FAU - Byrnes, Lauren
AU  - Byrnes L
AD  - Developmental and Stem Cell Biology Graduate Program, University of California,
      San Francisco, San Francisco, California, USA.
FAU - Lanata, Cristina M
AU  - Lanata CM
AD  - Department of Medicine, University of California, San Francisco, San Francisco,
      California, USA.
AD  - Rosalind Russell/Ephraim P Engleman Rheumatology Research Center, University of
      California, San Francisco, San Francisco, California, USA.
FAU - Gate, Rachel E
AU  - Gate RE
AD  - Biological and Medical Informatics Graduate Program, University of California,
      San Francisco, San Francisco, California, USA.
AD  - Institute for Human Genetics (IHG), University of California, San Francisco, San 
      Francisco, California, USA.
AD  - Institute for Computational Health Sciences, University of California, San
      Francisco, San Francisco, California, USA.
AD  - Department of Epidemiology and Biostatistics, University of California, San
      Francisco, San Francisco, California, USA.
AD  - Department of Bioengineering and Therapeutic Sciences, University of California, 
      San Francisco, San Francisco, California, USA.
FAU - Mostafavi, Sara
AU  - Mostafavi S
AD  - Department of Statistics, University of British Columbia, Vancouver, British
      Columbia, Canada.
FAU - Marson, Alexander
AU  - Marson A
AD  - Department of Microbiology and Immunology, University of California, San
      Francisco, San Francisco, California, USA.
AD  - Diabetes Center, University of California, San Francisco, San Francisco,
      California, USA.
AD  - Innovative Genomics Institute, University of California, Berkeley, Berkeley,
      California, USA.
AD  - Department of Medicine, University of California, San Francisco, San Francisco,
      California, USA.
AD  - UCSF Helen Diller Family Comprehensive Cancer Center, University of California,
      San Francisco, San Francisco, California, USA.
AD  - Chan Zuckerberg Biohub, San Francisco, California, USA.
FAU - Zaitlen, Noah
AU  - Zaitlen N
AD  - Institute for Human Genetics (IHG), University of California, San Francisco, San 
      Francisco, California, USA.
AD  - Department of Medicine, University of California, San Francisco, San Francisco,
      California, USA.
AD  - Lung Biology Center, University of California, San Francisco, San Francisco,
      California, USA.
FAU - Criswell, Lindsey A
AU  - Criswell LA
AD  - Institute for Human Genetics (IHG), University of California, San Francisco, San 
      Francisco, California, USA.
AD  - Department of Medicine, University of California, San Francisco, San Francisco,
      California, USA.
AD  - Rosalind Russell/Ephraim P Engleman Rheumatology Research Center, University of
      California, San Francisco, San Francisco, California, USA.
AD  - Department of Orofacial Sciences, University of California, San Francisco, San
      Francisco, USA.
FAU - Ye, Chun Jimmie
AU  - Ye CJ
AD  - Institute for Human Genetics (IHG), University of California, San Francisco, San 
      Francisco, California, USA.
AD  - Institute for Computational Health Sciences, University of California, San
      Francisco, San Francisco, California, USA.
AD  - Department of Epidemiology and Biostatistics, University of California, San
      Francisco, San Francisco, California, USA.
AD  - Department of Bioengineering and Therapeutic Sciences, University of California, 
      San Francisco, San Francisco, California, USA.
LA  - eng
GR  - F30 DK115167/DK/NIDDK NIH HHS/United States
GR  - R03 DE025665/DE/NIDCR NIH HHS/United States
GR  - R21 AI133337/AI/NIAID NIH HHS/United States
GR  - R01 AR071522/AR/NIAMS NIH HHS/United States
GR  - K25 HL121295/HL/NHLBI NIH HHS/United States
PT  - Journal Article
DEP - 20171211
PL  - United States
TA  - Nat Biotechnol
JT  - Nature biotechnology
JID - 9604648
PMC - PMC5784859
MID - NIHMS921103
EDAT- 2017/12/12 06:00
MHDA- 2017/12/12 06:00
CRDT- 2017/12/12 06:00
PMCR- 2018/06/11 00:00
PHST- 2017/03/20 00:00 [received]
PHST- 2017/11/16 00:00 [accepted]
PHST- 2018/06/11 00:00 [pmc-release]
PHST- 2017/12/12 06:00 [pubmed]
PHST- 2017/12/12 06:00 [medline]
PHST- 2017/12/12 06:00 [entrez]
AID - nbt.4042 [pii]
AID - 10.1038/nbt.4042 [doi]
PST - ppublish
SO  - Nat Biotechnol. 2018 Jan;36(1):89-94. doi: 10.1038/nbt.4042. Epub 2017 Dec 11.

PMID- 29202482
OWN - NLM
STAT- In-Data-Review
LR  - 20180102
IS  - 1558-8238 (Electronic)
IS  - 0021-9738 (Linking)
VI  - 128
IP  - 1
DP  - 2018 Jan 2
TI  - Ligand-activated BMP signaling inhibits cell differentiation and death to promote
      melanoma.
PG  - 294-308
LID - 10.1172/JCI92513 [doi]
LID - 92513 [pii]
AB  - Oncogenomic studies indicate that copy number variation (CNV) alters genes
      involved in tumor progression; however, identification of specific driver genes
      affected by CNV has been difficult, as these rearrangements are often contained
      in large chromosomal intervals among several bystander genes. Here, we addressed 
      this problem and identified a CNV-targeted oncogene by performing comparative
      oncogenomics of human and zebrafish melanomas. We determined that the gene
      encoding growth differentiation factor 6 (GDF6), which is the ligand for the BMP 
      family, is recurrently amplified and transcriptionally upregulated in melanoma.
      GDF6-induced BMP signaling maintained a trunk neural crest gene signature in
      melanomas. Additionally, GDF6 repressed the melanocyte differentiation gene MITF 
      and the proapoptotic factor SOX9, thereby preventing differentiation, inhibiting 
      cell death, and promoting tumor growth. GDF6 was specifically expressed in
      melanomas but not melanocytes. Moreover, GDF6 expression levels in melanomas were
      inversely correlated with patient survival. Our study has identified a
      fundamental role for GDF6 and BMP signaling in governing an embryonic cell gene
      signature to promote melanoma progression, thus providing potential opportunities
      for targeted therapy to treat GDF6-positive cancers.
FAU - Venkatesan, Arvind M
AU  - Venkatesan AM
AD  - Program in Molecular Medicine.
AD  - Department of Molecular, Cell and Cancer Biology.
FAU - Vyas, Rajesh
AU  - Vyas R
AD  - Program in Molecular Medicine.
AD  - Department of Molecular, Cell and Cancer Biology.
FAU - Gramann, Alec K
AU  - Gramann AK
AD  - Program in Molecular Medicine.
AD  - Department of Molecular, Cell and Cancer Biology.
FAU - Dresser, Karen
AU  - Dresser K
AD  - Department of Pathology, and.
FAU - Gujja, Sharvari
AU  - Gujja S
AD  - Program in Molecular Medicine.
FAU - Bhatnagar, Sanchita
AU  - Bhatnagar S
AD  - Program in Molecular Medicine.
AD  - Department of Molecular, Cell and Cancer Biology.
AD  - Howard Hughes Medical Institute, University of Massachusetts Medical School
      (UMMS), Worcester, Massachusetts, USA.
FAU - Chhangawala, Sagar
AU  - Chhangawala S
AD  - Departments of Surgery and Medicine, Weill Cornell Medical College, New York, New
      York, USA.
FAU - Gomes, Camilla Borges Ferreira
AU  - Gomes CBF
AD  - Program in Dermatopathology, Department of Pathology, Brigham and Women's
      Hospital, Harvard Medical School, Boston, Massachusetts, USA.
FAU - Xi, Hualin Simon
AU  - Xi HS
AD  - Program in Molecular Medicine.
FAU - Lian, Christine G
AU  - Lian CG
AD  - Program in Dermatopathology, Department of Pathology, Brigham and Women's
      Hospital, Harvard Medical School, Boston, Massachusetts, USA.
FAU - Houvras, Yariv
AU  - Houvras Y
AD  - Departments of Surgery and Medicine, Weill Cornell Medical College, New York, New
      York, USA.
FAU - Edwards, Yvonne J K
AU  - Edwards YJK
AD  - Program in Molecular Medicine.
FAU - Deng, April
AU  - Deng A
AD  - Department of Pathology, and.
FAU - Green, Michael
AU  - Green M
AD  - Program in Molecular Medicine.
AD  - Department of Molecular, Cell and Cancer Biology.
AD  - Howard Hughes Medical Institute, University of Massachusetts Medical School
      (UMMS), Worcester, Massachusetts, USA.
FAU - Ceol, Craig J
AU  - Ceol CJ
AD  - Program in Molecular Medicine.
AD  - Department of Molecular, Cell and Cancer Biology.
LA  - eng
PT  - Journal Article
DEP - 20171204
PL  - United States
TA  - J Clin Invest
JT  - The Journal of clinical investigation
JID - 7802877
OTO - NOTNLM
OT  - Cancer
OT  - Development
OT  - Oncology
EDAT- 2017/12/05 06:00
MHDA- 2017/12/05 06:00
CRDT- 2017/12/05 06:00
PHST- 2016/12/27 00:00 [received]
PHST- 2017/10/19 00:00 [accepted]
PHST- 2017/12/05 06:00 [pubmed]
PHST- 2017/12/05 06:00 [medline]
PHST- 2017/12/05 06:00 [entrez]
AID - 92513 [pii]
AID - 10.1172/JCI92513 [doi]
PST - ppublish
SO  - J Clin Invest. 2018 Jan 2;128(1):294-308. doi: 10.1172/JCI92513. Epub 2017 Dec 4.

PMID- 29251875
STAT- Publisher
DA  - 20171219
ISBN- 9780994438126
PB  - Codon Publications
DP  - 2017 Sep 27
TI  - Noncoding RNAs in Glioblastoma
BTI - Glioblastoma
LID - 10.15586/codon.glioblastoma.2017 [doi]
CP  - Chapter 6
AB  - The vast majority of the human genome is transcribed into noncoding RNAs. Among
      these, microRNAs (miRNA) and long noncoding RNAs (lncRNA) are frequently
      deregulated in cancer, where they regulate a wide variety of functions.
      Glioblastoma (GBM) is the most common and the most deadly primary human brain
      tumor. This chapter reviews the deregulation, functions, mechanisms of action,
      and clinical applications of miRNAs and lncRNAs in GBM. miRNAs are short
      noncoding RNAs that broadly and profoundly regulate gene expression. Numerous
      miRNAs are deregulated in GBM, where their expression levels can serve as
      diagnostic and prognostic biomarkers. miRNAs can act as oncogenes or tumor
      suppressors in GBM by regulating the expression of numerous tumor-suppressive or 
      oncogenic proteins. miRNAs regulate all GBM malignancy parameters including tumor
      cell proliferation, cell survival, invasion, angiogenesis, cancer stem cells,
      immune escape, and therapy resistance. miRNAs are also secreted in body fluids,
      where they can be used as biomarkers. Because of their deep involvement in GBM
      malignancy, efforts are under way to also exploit miRNAs as therapeutic agents or
      targets. lncRNAs are a diverse group of noncoding RNAs that are >200 nucleotides 
      long. Several lncRNAs are deregulated in GBM, where their expressions can
      associate with clinical parameters. lncRNAs regulate GBM functions including
      tumor cell proliferation, survival, invasion, cancer stem cell differentiation,
      and therapy resistance. lncRNAs exert their actions via transcriptional,
      post-transcriptional, and epigenetic mechanisms that are only partly understood. 
      Studying noncoding RNAs is important for the understanding, management, and
      development of future therapies for GBM.
CI  - Copyright: The Authors.
FED - De Vleeschouwer, Steven
ED  - De Vleeschouwer S
FAU - Zhang, Ying
AU  - Zhang Y
FAU - Cruickshanks, Nichola
AU  - Cruickshanks N
FAU - Pahuski, Mary
AU  - Pahuski M
FAU - Yuan, Fang
AU  - Yuan F
FAU - Dutta, Anindya
AU  - Dutta A
FAU - Schiff, David
AU  - Schiff D
FAU - Purow, Benjamin
AU  - Purow B
FAU - Abounader, Roger
AU  - Abounader R
LA  - eng
PT  - Review
PT  - Book Chapter
PL  - Brisbane (AU)
EDAT- 2017/12/19 06:01
MHDA- 2017/12/19 06:01
CDAT- 2017/12/19 06:01
AID - NBK469994 [bookaccession]
AID - 10.15586/codon.glioblastoma.2017.ch6 [doi]

PMID- 29083408
OWN - NLM
STAT- MEDLINE
DCOM- 20171211
LR  - 20180125
IS  - 1546-1718 (Electronic)
IS  - 1061-4036 (Linking)
VI  - 49
IP  - 12
DP  - 2017 Dec
TI  - Exome-wide association study of plasma lipids in >300,000 individuals.
PG  - 1758-1766
LID - 10.1038/ng.3977 [doi]
AB  - We screened variants on an exome-focused genotyping array in >300,000
      participants (replication in >280,000 participants) and identified 444
      independent variants in 250 loci significantly associated with total cholesterol 
      (TC), high-density-lipoprotein cholesterol (HDL-C), low-density-lipoprotein
      cholesterol (LDL-C), and/or triglycerides (TG). At two loci (JAK2 and A1CF),
      experimental analysis in mice showed lipid changes consistent with the human
      data. We also found that: (i) beta-thalassemia trait carriers displayed lower TC 
      and were protected from coronary artery disease (CAD); (ii) excluding the CETP
      locus, there was not a predictable relationship between plasma HDL-C and risk for
      age-related macular degeneration; (iii) only some mechanisms of lowering LDL-C
      appeared to increase risk for type 2 diabetes (T2D); and (iv) TG-lowering alleles
      involved in hepatic production of TG-rich lipoproteins (TM6SF2 and PNPLA3)
      tracked with higher liver fat, higher risk for T2D, and lower risk for CAD,
      whereas TG-lowering alleles involved in peripheral lipolysis (LPL and ANGPTL4)
      had no effect on liver fat but decreased risks for both T2D and CAD.
FAU - Liu, Dajiang J
AU  - Liu DJ
AD  - Department of Public Health Sciences, Institute of Personalized Medicine, Penn
      State College of Medicine, Hershey, Pennsylvania, USA.
FAU - Peloso, Gina M
AU  - Peloso GM
AD  - Department of Biostatistics, Boston University School of Public Health, Boston,
      Massachusetts, USA.
AD  - Program in Medical and Population Genetics, Broad Institute, Cambridge,
      Massachusetts, USA.
FAU - Yu, Haojie
AU  - Yu H
AD  - Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute,
      Harvard University, Cambridge, Massachusetts, USA.
FAU - Butterworth, Adam S
AU  - Butterworth AS
AD  - MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary
      Care, University of Cambridge, Cambridge, UK.
AD  - The National Institute for Health Research Blood and Transplant Research Unit
      (NIHR BTRU) in Donor Health and Genomics at the University of Cambridge,
      Cambridge, UK.
FAU - Wang, Xiao
AU  - Wang X
AD  - Cardiovascular Institute, Perelman School of Medicine, University of
      Pennsylvania, Philadelphia, Pennsylvania, USA.
FAU - Mahajan, Anubha
AU  - Mahajan A
AD  - Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
FAU - Saleheen, Danish
AU  - Saleheen D
AD  - MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary
      Care, University of Cambridge, Cambridge, UK.
AD  - Department of Biostatistics and Epidemiology, Perelman School of Medicine,
      University of Pennsylvania, Philadelphia, Pennsylvania, USA.
AD  - Center for Non-Communicable Diseases, Karachi, Pakistan.
FAU - Emdin, Connor
AU  - Emdin C
AD  - Program in Medical and Population Genetics, Broad Institute, Cambridge,
      Massachusetts, USA.
AD  - Center for Genomic Medicine, Massachusetts General Hospital, Boston,
      Massachusetts, USA.
FAU - Alam, Dewan
AU  - Alam D
AD  - ICDDR, B, Dhaka, Bangladesh.
FAU - Alves, Alexessander Couto
AU  - Alves AC
AD  - Imperial College London, London, UK.
FAU - Amouyel, Philippe
AU  - Amouyel P
AD  - Universite Lille, INSERM, CHU Lille, Institut Pasteur de Lille,
      U1167-RID-AGE-Risk Factors and Molecular Determinants of Aging-related Diseases, 
      Lille, France.
FAU - Di Angelantonio, Emanuele
AU  - Di Angelantonio E
AD  - MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary
      Care, University of Cambridge, Cambridge, UK.
AD  - The National Institute for Health Research Blood and Transplant Research Unit
      (NIHR BTRU) in Donor Health and Genomics at the University of Cambridge,
      Cambridge, UK.
FAU - Arveiler, Dominique
AU  - Arveiler D
AD  - Department of Epidemiology and Public Health, EA 3430, University of Strasbourg, 
      Strasbourg, France.
FAU - Assimes, Themistocles L
AU  - Assimes TL
AD  - VA Palo Alto Health Care System, Palo Alto, California, USA.
AD  - Department of Medicine, Stanford University School of Medicine, Stanford,
      California, USA.
FAU - Auer, Paul L
AU  - Auer PL
AD  - Zilber School of Public Health, University of Wisconsin-Milwaukee, Milwaukee,
      Wisconsin, USA.
FAU - Baber, Usman
AU  - Baber U
AD  - Cardiovascular Institute, Mount Sinai Medical Center, Icahn School of Medicine at
      Mount Sinai, New York, New York, USA.
FAU - Ballantyne, Christie M
AU  - Ballantyne CM
AD  - Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
FAU - Bang, Lia E
AU  - Bang LE
AD  - Department of Cardiology, Rigshospitalet, Copenhagen University Hospital,
      Copenhagen, Denmark.
FAU - Benn, Marianne
AU  - Benn M
AD  - Department of Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark.
AD  - Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen,
      Denmark.
FAU - Bis, Joshua C
AU  - Bis JC
AD  - Cardiovascular Health Research Unit, Department of Medicine, University of
      Washington, Seattle, Washington, USA.
FAU - Boehnke, Michael
AU  - Boehnke M
AD  - Center for Statistical Genetics, Department of Biostatistics, University of
      Michigan School of Public Health, Ann Arbor, Michigan, USA.
FAU - Boerwinkle, Eric
AU  - Boerwinkle E
AD  - Human Genetics Center, Department of Epidemiology, Human Genetics, and
      Environmental Sciences, School of Public Health, The University of Texas Health
      Science Center at Houston, Houston, Texas, USA.
AD  - Human Genome Sequencing Center, Baylor College of Medicine, Houston, Texas, USA.
FAU - Bork-Jensen, Jette
AU  - Bork-Jensen J
AD  - The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of
      Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
FAU - Bottinger, Erwin P
AU  - Bottinger EP
AD  - The Charles Bronfman Institute for Personalized Medicine, Ichan School of
      Medicine at Mount Sinai, New York, New York, USA.
FAU - Brandslund, Ivan
AU  - Brandslund I
AD  - Department of Clinical Biochemistry, Lillebaelt Hospital, Vejle, Denmark.
AD  - Institute of Regional Health Research, University of Southern Denmark, Odense,
      Denmark.
FAU - Brown, Morris
AU  - Brown M
AD  - Clinical Pharmacology, William Harvey Research Institute, Barts and The London
      School of Medicine and Dentistry, Queen Mary University of London, London, UK.
FAU - Busonero, Fabio
AU  - Busonero F
AD  - Istituto di Ricerca Genetica e Biomedica, Consiglio Nazionale delle Ricerche
      (CNR), Monserrato, Cagliari, Italy.
FAU - Caulfield, Mark J
AU  - Caulfield MJ
AD  - Clinical Pharmacology, William Harvey Research Institute, Barts and The London
      School of Medicine and Dentistry, Queen Mary University of London, London, UK.
AD  - The Barts Heart Centre, William Harvey Research Institute, Queen Mary University 
      of London, London, UK.
AD  - NIHR Barts Cardiovascular Biomedical Research Unit, Queen Mary University of
      London, London, UK.
FAU - Chambers, John C
AU  - Chambers JC
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Imperial
      College London, London, UK.
AD  - Department of Cardiology, Ealing Hospital NHS Trust, Southall, UK.
AD  - Imperial College Healthcare NHS Trust, London, UK.
FAU - Chasman, Daniel I
AU  - Chasman DI
AD  - Division of Preventive Medicine, Brigham and Women's Hospital, Boston,
      Massachusetts, USA.
AD  - Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
FAU - Chen, Y Eugene
AU  - Chen YE
AD  - Department of Internal Medicine, Division of Cardiovascular Medicine, University 
      of Michigan, Ann Arbor, Michigan, USA.
FAU - Chen, Yii-Der Ida
AU  - Chen YI
AD  - The Institute for Translational Genomics and Population Sciences, LABioMed at
      Harbor-UCLA Medical Center, Departments of Pediatrics and Medicine, Los Angeles, 
      California, USA.
FAU - Chowdhury, Rajiv
AU  - Chowdhury R
AD  - MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary
      Care, University of Cambridge, Cambridge, UK.
FAU - Christensen, Cramer
AU  - Christensen C
AD  - Medical Department, Lillebaelt Hospital, Vejle, Denmark.
FAU - Chu, Audrey Y
AU  - Chu AY
AD  - Division of Preventive Medicine, Brigham and Women's Hospital, Boston,
      Massachusetts, USA.
AD  - NHLBI Framingham Heart Study, Framingham, Massachusetts, USA.
FAU - Connell, John M
AU  - Connell JM
AD  - Medical Research Institute, Ninewells Hospital and Medical School, University of 
      Dundee, Dundee, UK.
FAU - Cucca, Francesco
AU  - Cucca F
AD  - Istituto di Ricerca Genetica e Biomedica, Consiglio Nazionale delle Ricerche
      (CNR), Monserrato, Cagliari, Italy.
AD  - Dipartimento di Scienze Biomediche, Universita degli Studi di Sassari, Sassari,
      Italy.
FAU - Cupples, L Adrienne
AU  - Cupples LA
AD  - Department of Biostatistics, Boston University School of Public Health, Boston,
      Massachusetts, USA.
AD  - NHLBI Framingham Heart Study, Framingham, Massachusetts, USA.
FAU - Damrauer, Scott M
AU  - Damrauer SM
AD  - Corporal Michael Crescenz VA Medical Center, Philadelphia, Pennsylvania, USA.
AD  - Department of Surgery, Perelman School of Medicine, University of Pennsylvania,
      Philadelphia, Pennsylvania, USA.
FAU - Davies, Gail
AU  - Davies G
AD  - Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, 
      Edinburgh, UK.
AD  - Department of Psychology, University of Edinburgh, Edinburgh, UK.
FAU - Deary, Ian J
AU  - Deary IJ
AD  - Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, 
      Edinburgh, UK.
AD  - Department of Psychology, University of Edinburgh, Edinburgh, UK.
FAU - Dedoussis, George
AU  - Dedoussis G
AD  - Department of Nutrition and Dietetics, School of Health Science and Education,
      Harokopio University, Athens, Greece.
FAU - Denny, Joshua C
AU  - Denny JC
AD  - Department of Biomedical Informatics, Vanderbilt University Medical Center,
      Nashville, Tennessee, USA.
AD  - Department of Medicine, Vanderbilt University Medical Center, Nashville,
      Tennessee, USA.
FAU - Dominiczak, Anna
AU  - Dominiczak A
AD  - British Heart Foundation Glasgow Cardiovascular Research Centre, Institute of
      Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life
      Sciences, University of Glasgow, Glasgow, UK.
FAU - Dube, Marie-Pierre
AU  - Dube MP
AD  - Montreal Heart Institute, Montreal, Quebec, Canada.
AD  - Universite de Montreal Beaulieu-Saucier Pharmacogenomics Center, Montreal,
      Quebec, Canada.
AD  - Universite de Montreal, Montreal, Quebec, Canada.
FAU - Ebeling, Tapani
AU  - Ebeling T
AD  - Department of Medicine, Oulu University Hospital and University of Oulu, Oulu,
      Finland.
FAU - Eiriksdottir, Gudny
AU  - Eiriksdottir G
AD  - The Icelandic Heart Association, Kopavogur, Iceland.
FAU - Esko, Tonu
AU  - Esko T
AD  - Program in Medical and Population Genetics, Broad Institute, Cambridge,
      Massachusetts, USA.
AD  - Estonian Genome Center, University of Tartu, Tartu, Estonia.
FAU - Farmaki, Aliki-Eleni
AU  - Farmaki AE
AD  - Department of Nutrition and Dietetics, School of Health Science and Education,
      Harokopio University, Athens, Greece.
FAU - Feitosa, Mary F
AU  - Feitosa MF
AD  - Division of Statistical Genomics, Department of Genetics, Washington University
      School of Medicine, St. Louis, Missouri, USA.
FAU - Ferrario, Marco
AU  - Ferrario M
AD  - Research Centre in Epidemiology and Preventive Medicine-EPIMED, Department of
      Medicine and Surgery, University of Insubria, Varese, Italy.
FAU - Ferrieres, Jean
AU  - Ferrieres J
AD  - Department of Epidemiology, UMR 1027-INSERM, Toulouse University-CHU Toulouse,
      Toulouse, France.
FAU - Ford, Ian
AU  - Ford I
AD  - Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK.
FAU - Fornage, Myriam
AU  - Fornage M
AD  - Institute of Molecular Medicine, The University of Texas Health Science Center at
      Houston, Houston, Texas, USA.
FAU - Franks, Paul W
AU  - Franks PW
AD  - Department of Clinical Sciences, Genetic and Molecular Epidemiology Unit, Lund
      University, Malmo, Sweden.
AD  - Department of Public Health & Clinical Medicine, Umea University, Umea, Sweden.
AD  - Department of Nutrition, Harvard T. H. Chan School of Public Health, Boston,
      Massachusetts, USA.
FAU - Frayling, Timothy M
AU  - Frayling TM
AD  - Genetics of Complex Traits, University of Exeter Medical School, University of
      Exeter, Exeter, UK.
FAU - Frikke-Schmidt, Ruth
AU  - Frikke-Schmidt R
AD  - Department of Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark.
AD  - Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen,
      Denmark.
FAU - Fritsche, Lars G
AU  - Fritsche LG
AD  - Center for Statistical Genetics, Department of Biostatistics, University of
      Michigan School of Public Health, Ann Arbor, Michigan, USA.
FAU - Frossard, Philippe
AU  - Frossard P
AD  - Center for Non-Communicable Diseases, Karachi, Pakistan.
FAU - Fuster, Valentin
AU  - Fuster V
AD  - Cardiovascular Institute, Mount Sinai Medical Center, Icahn School of Medicine at
      Mount Sinai, New York, New York, USA.
AD  - Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid,
      Spain.
FAU - Ganesh, Santhi K
AU  - Ganesh SK
AD  - Department of Internal Medicine, Division of Cardiovascular Medicine, University 
      of Michigan, Ann Arbor, Michigan, USA.
AD  - Department of Human Genetics, University of Michigan, Ann Arbor, Michigan, USA.
FAU - Gao, Wei
AU  - Gao W
AD  - Department of Cardiology, Peking University Third Hospital, Key Laboratory of
      Cardiovascular Molecular Biology and Regulatory Peptides, Ministry of Health,
      Beijing, China.
FAU - Garcia, Melissa E
AU  - Garcia ME
AD  - National Heart, Lung, and Blood Institute, Bethesda, Maryland, USA.
FAU - Gieger, Christian
AU  - Gieger C
AD  - German Center for Diabetes Research (DZD e.V.), Neuherberg, Germany.
AD  - Research Unit of Molecular Epidemiology, Helmholtz Zentrum Munchen, German
      Research Center for Environmental Health, Neuherberg, Germany.
AD  - Institute of Epidemiology II, Helmholtz Zentrum Munchen-German Research Center
      for Environmental Health, Neuherberg, Germany.
FAU - Giulianini, Franco
AU  - Giulianini F
AD  - Division of Preventive Medicine, Brigham and Women's Hospital, Boston,
      Massachusetts, USA.
FAU - Goodarzi, Mark O
AU  - Goodarzi MO
AD  - Departments of Medicine and of Biomedical Sciences, Cedars-Sinai Medical Center, 
      Los Angeles, California, USA.
AD  - Division of Endocrinology, Diabetes and Metabolism, Cedars-Sinai Medical Center, 
      Los Angeles, California, USA.
FAU - Grallert, Harald
AU  - Grallert H
AD  - German Center for Diabetes Research (DZD e.V.), Neuherberg, Germany.
AD  - Research Unit of Molecular Epidemiology, Helmholtz Zentrum Munchen, German
      Research Center for Environmental Health, Neuherberg, Germany.
AD  - Institute of Epidemiology II, Helmholtz Zentrum Munchen-German Research Center
      for Environmental Health, Neuherberg, Germany.
FAU - Grarup, Niels
AU  - Grarup N
AD  - The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of
      Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
FAU - Groop, Leif
AU  - Groop L
AD  - Department of Clinical Sciences, Diabetes and Endocrinology, Clinical Research
      Centre, Lund University, Malmo, Sweden.
FAU - Grove, Megan L
AU  - Grove ML
AD  - Human Genetics Center, Department of Epidemiology, Human Genetics, and
      Environmental Sciences, School of Public Health, The University of Texas Health
      Science Center at Houston, Houston, Texas, USA.
FAU - Gudnason, Vilmundur
AU  - Gudnason V
AD  - The Icelandic Heart Association, Kopavogur, Iceland.
AD  - Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
FAU - Hansen, Torben
AU  - Hansen T
AD  - The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of
      Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
AD  - Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.
FAU - Harris, Tamara B
AU  - Harris TB
AD  - Laboratory of Epidemiology and Population Sciences, National Institute on Aging, 
      Bethesda, Maryland, USA.
FAU - Hayward, Caroline
AU  - Hayward C
AD  - Medical Research Council Human Genetics Unit, Institute of Genetics and Molecular
      Medicine, University of Edinburgh, Edinburgh, UK.
FAU - Hirschhorn, Joel N
AU  - Hirschhorn JN
AD  - Program in Medical and Population Genetics, Broad Institute, Cambridge,
      Massachusetts, USA.
AD  - Division of Endocrinology and Center for Basic and Translational Obesity
      Research, Boston Children's Hospital, Boston, Massachusetts, USA.
FAU - Holmen, Oddgeir L
AU  - Holmen OL
AD  - Department of Public Health and General Practice, HUNT Research Centre, Norwegian
      University of Science and Technology, Levanger, Norway.
AD  - St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.
FAU - Huffman, Jennifer
AU  - Huffman J
AD  - Medical Research Council Human Genetics Unit, Institute of Genetics and Molecular
      Medicine, University of Edinburgh, Edinburgh, UK.
FAU - Huo, Yong
AU  - Huo Y
AD  - Department of Cardiology, Peking University First Hospital, Beijing, China.
FAU - Hveem, Kristian
AU  - Hveem K
AD  - K. G. Jebsen Center for Genetic Epidemiology, Department of Public Health and
      Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science
      and Technology (NTNU), Trondheim, Norway.
FAU - Jabeen, Sehrish
AU  - Jabeen S
AD  - Center for Non-Communicable Diseases, Karachi, Pakistan.
FAU - Jackson, Anne U
AU  - Jackson AU
AD  - Center for Statistical Genetics, Department of Biostatistics, University of
      Michigan School of Public Health, Ann Arbor, Michigan, USA.
FAU - Jakobsdottir, Johanna
AU  - Jakobsdottir J
AD  - The Icelandic Heart Association, Kopavogur, Iceland.
AD  - Department of Health Sciences, University of Iceland, Reykjavik, Iceland.
FAU - Jarvelin, Marjo-Riitta
AU  - Jarvelin MR
AD  - Imperial College London, London, UK.
FAU - Jensen, Gorm B
AU  - Jensen GB
AD  - The Copenhagen City Heart Study, Frederiksberg Hospital, Copenhagen, Denmark.
FAU - Jorgensen, Marit E
AU  - Jorgensen ME
AD  - Steno Diabetes Center, Gentofte, Denmark.
AD  - National Institute of Public Health, Southern Denmark University, Copenhagen,
      Denmark.
FAU - Jukema, J Wouter
AU  - Jukema JW
AD  - Department of Cardiology, Leiden University Medical Center, Leiden, the
      Netherlands.
AD  - The Interuniversity Cardiology Institute of the Netherlands, Utrecht, the
      Netherlands.
FAU - Justesen, Johanne M
AU  - Justesen JM
AD  - The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of
      Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
FAU - Kamstrup, Pia R
AU  - Kamstrup PR
AD  - Department of Clinical Biochemistry and the Copenhagen General Population Study, 
      Herlev and Gentofte Hospital, Copenhagen University Hospital, Copenhagen,
      Denmark.
FAU - Kanoni, Stavroula
AU  - Kanoni S
AD  - William Harvey Research Institute, Barts and The London School of Medicine and
      Dentistry, Queen Mary University of London, London, UK.
FAU - Karpe, Fredrik
AU  - Karpe F
AD  - Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of
      Medicine, University of Oxford, Oxford, UK.
AD  - Oxford NIHR Biomedical Research Centre, Oxford University Hospitals Trust,
      Oxford, UK.
FAU - Kee, Frank
AU  - Kee F
AD  - UKCRC Centre of Excellence for Public Health, Queens University, Belfast, UK.
FAU - Khera, Amit V
AU  - Khera AV
AD  - Program in Medical and Population Genetics, Broad Institute, Cambridge,
      Massachusetts, USA.
AD  - Center for Genomic Medicine, Massachusetts General Hospital, Boston,
      Massachusetts, USA.
FAU - Klarin, Derek
AU  - Klarin D
AD  - Program in Medical and Population Genetics, Broad Institute, Cambridge,
      Massachusetts, USA.
AD  - Center for Genomic Medicine, Massachusetts General Hospital, Boston,
      Massachusetts, USA.
AD  - Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA
      Boston Healthcare System, Boston, Massachusetts, USA.
FAU - Koistinen, Heikki A
AU  - Koistinen HA
AD  - Department of Health, National Institute for Health and Welfare, Helsinki,
      Finland.
AD  - Department of Medicine and Abdominal Center: Endocrinology, University of
      Helsinki and Helsinki University Central Hospital, Helsinki, Finland.
AD  - Minerva Foundation Institute for Medical Research, Helsinki, Finland.
FAU - Kooner, Jaspal S
AU  - Kooner JS
AD  - Department of Cardiology, Ealing Hospital NHS Trust, Southall, UK.
AD  - Imperial College Healthcare NHS Trust, London, UK.
AD  - National Heart and Lung Institute, Imperial College London, Hammersmith Hospital,
      London, UK.
FAU - Kooperberg, Charles
AU  - Kooperberg C
AD  - Division of Public Health Sciences, Fred Hutchinson Cancer Research Center,
      Seattle, Washington, USA.
FAU - Kuulasmaa, Kari
AU  - Kuulasmaa K
AD  - Department of Health, National Institute for Health and Welfare, Helsinki,
      Finland.
FAU - Kuusisto, Johanna
AU  - Kuusisto J
AD  - Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland 
      and Kuopio University Hospital, Kuopio, Finland.
FAU - Laakso, Markku
AU  - Laakso M
AD  - Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland 
      and Kuopio University Hospital, Kuopio, Finland.
FAU - Lakka, Timo
AU  - Lakka T
AD  - Department of Physiology, Institute of Biomedicine, University of Eastern
      Finland, Kuopio Campus, Kuopio, Finland.
AD  - Kuopio Research Institute of Exercise Medicine, Kuopio, Finland.
AD  - Department of Clinical Physiology and Nuclear Medicine, Kuopio University
      Hospital, Kuopio, Finland.
FAU - Langenberg, Claudia
AU  - Langenberg C
AD  - MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge
      School of Clinical Medicine, Cambridge, UK.
FAU - Langsted, Anne
AU  - Langsted A
AD  - Department of Clinical Biochemistry and the Copenhagen General Population Study, 
      Herlev and Gentofte Hospital, Copenhagen University Hospital, Copenhagen,
      Denmark.
AD  - Faculty of Health and Medical Sciences, University of Denmark, Copenhagen,
      Denmark.
FAU - Launer, Lenore J
AU  - Launer LJ
AD  - Laboratory of Epidemiology and Population Sciences, National Institute on Aging, 
      Bethesda, Maryland, USA.
FAU - Lauritzen, Torsten
AU  - Lauritzen T
AD  - Department of Public Health, Section of General Practice, University of Aarhus,
      Aarhus, Denmark.
FAU - Liewald, David C M
AU  - Liewald DCM
AD  - Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, 
      Edinburgh, UK.
AD  - Department of Psychology, University of Edinburgh, Edinburgh, UK.
FAU - Lin, Li An
AU  - Lin LA
AD  - Institute of Molecular Medicine, The University of Texas Health Science Center at
      Houston, Houston, Texas, USA.
FAU - Linneberg, Allan
AU  - Linneberg A
AD  - Department of Clinical Experimental Research, Rigshospitalet, Glostrup, Denmark.
AD  - Department of Clinical Medicine, Faculty of Health and Medical Sciences,
      University of Copenhagen, Copenhagen, Denmark.
AD  - Research Center for Prevention and Health, Copenhagen, Denmark.
FAU - Loos, Ruth J F
AU  - Loos RJF
AD  - The Charles Bronfman Institute for Personalized Medicine, Ichan School of
      Medicine at Mount Sinai, New York, New York, USA.
AD  - The Mindich Child Health and Development Institute, Ichan School of Medicine at
      Mount Sinai, New York, New York, USA.
FAU - Lu, Yingchang
AU  - Lu Y
AD  - The Charles Bronfman Institute for Personalized Medicine, Ichan School of
      Medicine at Mount Sinai, New York, New York, USA.
FAU - Lu, Xiangfeng
AU  - Lu X
AD  - Department of Internal Medicine, Division of Cardiovascular Medicine, University 
      of Michigan, Ann Arbor, Michigan, USA.
AD  - State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center
      for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union
      Medical College, Beijing, China.
FAU - Magi, Reedik
AU  - Magi R
AD  - Estonian Genome Center, University of Tartu, Tartu, Estonia.
FAU - Malarstig, Anders
AU  - Malarstig A
AD  - Cardiovascular Genetics and Genomics Group, Cardiovascular Medicine Unit,
      Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden.
AD  - Pharmatherapeutics Clinical Research, Pfizer Worldwide R&D, Sollentuna, Sweden.
FAU - Manichaikul, Ani
AU  - Manichaikul A
AD  - Center for Public Health Genomics, University of Virginia, Charlottesville,
      Virginia, USA.
FAU - Manning, Alisa K
AU  - Manning AK
AD  - Program in Medical and Population Genetics, Broad Institute, Cambridge,
      Massachusetts, USA.
AD  - Center for Genomic Medicine, Massachusetts General Hospital, Boston,
      Massachusetts, USA.
AD  - Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts,
      USA.
FAU - Mantyselka, Pekka
AU  - Mantyselka P
AD  - Unit of Primary Health Care, University of Eastern Finland and Kuopio University 
      Hospital, Kuopio, Finland.
FAU - Marouli, Eirini
AU  - Marouli E
AD  - William Harvey Research Institute, Barts and The London School of Medicine and
      Dentistry, Queen Mary University of London, London, UK.
FAU - Masca, Nicholas G D
AU  - Masca NGD
AD  - Department of Cardiovascular Sciences, University of Leicester, Leicester, UK.
AD  - NIHR Leicester Biomedical Research Centre, Glenfield Hospital, Leicester, UK.
FAU - Maschio, Andrea
AU  - Maschio A
AD  - Istituto di Ricerca Genetica e Biomedica, Consiglio Nazionale delle Ricerche
      (CNR), Monserrato, Cagliari, Italy.
FAU - Meigs, James B
AU  - Meigs JB
AD  - Program in Medical and Population Genetics, Broad Institute, Cambridge,
      Massachusetts, USA.
AD  - Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts,
      USA.
AD  - Division of General Internal Medicine, Massachusetts General Hospital, Boston,
      Massachusetts, USA.
FAU - Melander, Olle
AU  - Melander O
AD  - Department of Clinical Sciences, University Hospital Malmo Clinical Research
      Center, Lund University, Malmo, Sweden.
FAU - Metspalu, Andres
AU  - Metspalu A
AD  - Estonian Genome Center, University of Tartu, Tartu, Estonia.
FAU - Morris, Andrew P
AU  - Morris AP
AD  - Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
AD  - Department of Biostatistics, University of Liverpool, Liverpool, UK.
FAU - Morrison, Alanna C
AU  - Morrison AC
AD  - Human Genetics Center, Department of Epidemiology, Human Genetics, and
      Environmental Sciences, School of Public Health, The University of Texas Health
      Science Center at Houston, Houston, Texas, USA.
FAU - Mulas, Antonella
AU  - Mulas A
AD  - Istituto di Ricerca Genetica e Biomedica, Consiglio Nazionale delle Ricerche
      (CNR), Monserrato, Cagliari, Italy.
FAU - Muller-Nurasyid, Martina
AU  - Muller-Nurasyid M
AD  - Institute of Epidemiology II, Helmholtz Zentrum Munchen-German Research Center
      for Environmental Health, Neuherberg, Germany.
AD  - Department of Medicine I, Ludwig-Maximilians-University, Munich, Germany.
AD  - DZHK German Centre for Cardiovascular Research, Munich Heart Alliance, Munich,
      Germany.
FAU - Munroe, Patricia B
AU  - Munroe PB
AD  - Clinical Pharmacology, William Harvey Research Institute, Barts and The London
      School of Medicine and Dentistry, Queen Mary University of London, London, UK.
AD  - NIHR Barts Cardiovascular Biomedical Research Unit, Queen Mary University of
      London, London, UK.
FAU - Neville, Matt J
AU  - Neville MJ
AD  - Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of
      Medicine, University of Oxford, Oxford, UK.
FAU - Nielsen, Jonas B
AU  - Nielsen JB
AUID- ORCID: http://orcid.org/0000-0002-6654-2852
AD  - Department of Internal Medicine, Division of Cardiovascular Medicine, University 
      of Michigan, Ann Arbor, Michigan, USA.
FAU - Nielsen, Sune F
AU  - Nielsen SF
AD  - Department of Clinical Biochemistry and the Copenhagen General Population Study, 
      Herlev and Gentofte Hospital, Copenhagen University Hospital, Copenhagen,
      Denmark.
AD  - Faculty of Health and Medical Sciences, University of Denmark, Copenhagen,
      Denmark.
FAU - Nordestgaard, Borge G
AU  - Nordestgaard BG
AD  - Department of Clinical Biochemistry and the Copenhagen General Population Study, 
      Herlev and Gentofte Hospital, Copenhagen University Hospital, Copenhagen,
      Denmark.
AD  - Faculty of Health and Medical Sciences, University of Denmark, Copenhagen,
      Denmark.
FAU - Ordovas, Jose M
AU  - Ordovas JM
AD  - Department of Cardiovascular Epidemiology and Population Genetics, National
      Center for Cardiovascular Investigation, Madrid, Spain.
AD  - IMDEA-Alimentacion, Madrid, Spain.
AD  - Nutrition and Genomics Laboratory, Jean Mayer-USDA Human Nutrition Research
      Center on Aging at Tufts University, Boston, Massachusetts, USA.
FAU - Mehran, Roxana
AU  - Mehran R
AD  - Cardiovascular Institute, Mount Sinai Medical Center, Icahn School of Medicine at
      Mount Sinai, New York, New York, USA.
FAU - O'Donnell, Christoper J
AU  - O'Donnell CJ
AD  - Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA
      Boston Healthcare System, Boston, Massachusetts, USA.
AD  - Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
FAU - Orho-Melander, Marju
AU  - Orho-Melander M
AD  - Department of Clinical Sciences, University Hospital Malmo Clinical Research
      Center, Lund University, Malmo, Sweden.
FAU - Molony, Cliona M
AU  - Molony CM
AD  - Genetics, Merck Sharp & Dohme Corporation, Kenilworth, New Jersey, USA.
FAU - Muntendam, Pieter
AU  - Muntendam P
AD  - G3 Pharmaceuticals, Lexington, Massachusetts, USA.
FAU - Padmanabhan, Sandosh
AU  - Padmanabhan S
AD  - British Heart Foundation Glasgow Cardiovascular Research Centre, Institute of
      Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life
      Sciences, University of Glasgow, Glasgow, UK.
FAU - Palmer, Colin N A
AU  - Palmer CNA
AD  - Medical Research Institute, Ninewells Hospital and Medical School, University of 
      Dundee, Dundee, UK.
FAU - Pasko, Dorota
AU  - Pasko D
AD  - Genetics of Complex Traits, University of Exeter Medical School, University of
      Exeter, Exeter, UK.
FAU - Patel, Aniruddh P
AU  - Patel AP
AD  - Program in Medical and Population Genetics, Broad Institute, Cambridge,
      Massachusetts, USA.
AD  - Center for Genomic Medicine, Massachusetts General Hospital, Boston,
      Massachusetts, USA.
AD  - Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
AD  - Cardiovascular Research Center, Massachusetts General Hospital, Boston,
      Massachusetts, USA.
FAU - Pedersen, Oluf
AU  - Pedersen O
AD  - The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of
      Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
FAU - Perola, Markus
AU  - Perola M
AD  - Department of Health, National Institute for Health and Welfare, Helsinki,
      Finland.
AD  - Institute of Molecular Medicine FIMM, University of Helsinki, Finland.
FAU - Peters, Annette
AU  - Peters A
AD  - German Center for Diabetes Research (DZD e.V.), Neuherberg, Germany.
AD  - Institute of Epidemiology II, Helmholtz Zentrum Munchen-German Research Center
      for Environmental Health, Neuherberg, Germany.
AD  - DZHK German Centre for Cardiovascular Research, Munich Heart Alliance, Munich,
      Germany.
FAU - Pisinger, Charlotta
AU  - Pisinger C
AD  - Research Center for Prevention and Health, Copenhagen, Denmark.
FAU - Pistis, Giorgio
AU  - Pistis G
AD  - Istituto di Ricerca Genetica e Biomedica, Consiglio Nazionale delle Ricerche
      (CNR), Monserrato, Cagliari, Italy.
FAU - Polasek, Ozren
AU  - Polasek O
AD  - Faculty of Medicine, University of Split, Split, Croatia.
AD  - Usher Institute of Population Health Sciences and Informatics, University of
      Edinburgh, Edinburgh, UK.
FAU - Poulter, Neil
AU  - Poulter N
AD  - International Centre for Circulatory Health, Imperial College London, London, UK.
FAU - Psaty, Bruce M
AU  - Psaty BM
AD  - Cardiovascular Health Research Unit, Department of Medicine, University of
      Washington, Seattle, Washington, USA.
AD  - Kaiser Permanente Washington Health Research Institute, Seattle, Washington, USA.
AD  - Departments of Epidemiology and Health Services, University of Washington,
      Seattle, Washington, USA.
FAU - Rader, Daniel J
AU  - Rader DJ
AD  - Departments of Genetics, Medicine, and Pediatrics, Perelman School of Medicine,
      University of Pennsylvania, Philadelphia, Pennsylvania, USA.
FAU - Rasheed, Asif
AU  - Rasheed A
AD  - Center for Non-Communicable Diseases, Karachi, Pakistan.
FAU - Rauramaa, Rainer
AU  - Rauramaa R
AD  - Kuopio Research Institute of Exercise Medicine, Kuopio, Finland.
AD  - Department of Clinical Physiology and Nuclear Medicine, Kuopio University
      Hospital, Kuopio, Finland.
FAU - Reilly, Dermot F
AU  - Reilly DF
AD  - Genetics, Merck Sharp & Dohme Corporation, Kenilworth, New Jersey, USA.
FAU - Reiner, Alex P
AU  - Reiner AP
AD  - Division of Public Health Sciences, Fred Hutchinson Cancer Research Center,
      Seattle, Washington, USA.
AD  - Department of Epidemiology, University of Washington, Seattle, Washington, USA.
FAU - Renstrom, Frida
AU  - Renstrom F
AD  - Department of Clinical Sciences, Genetic and Molecular Epidemiology Unit, Lund
      University, Malmo, Sweden.
AD  - Department of Biobank Research, Umea University, Umea, Sweden.
FAU - Rich, Stephen S
AU  - Rich SS
AD  - Center for Public Health Genomics, University of Virginia, Charlottesville,
      Virginia, USA.
FAU - Ridker, Paul M
AU  - Ridker PM
AD  - Division of Preventive Medicine, Brigham and Women's Hospital, Boston,
      Massachusetts, USA.
FAU - Rioux, John D
AU  - Rioux JD
AD  - Montreal Heart Institute, Montreal, Quebec, Canada.
FAU - Robertson, Neil R
AU  - Robertson NR
AD  - Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
AD  - Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of
      Medicine, University of Oxford, Oxford, UK.
FAU - Roden, Dan M
AU  - Roden DM
AD  - Department of Biomedical Informatics, Vanderbilt University Medical Center,
      Nashville, Tennessee, USA.
AD  - Department of Medicine, Vanderbilt University Medical Center, Nashville,
      Tennessee, USA.
FAU - Rotter, Jerome I
AU  - Rotter JI
AD  - The Institute for Translational Genomics and Population Sciences, LABioMed at
      Harbor-UCLA Medical Center, Departments of Pediatrics and Medicine, Los Angeles, 
      California, USA.
FAU - Rudan, Igor
AU  - Rudan I
AD  - Usher Institute of Population Health Sciences and Informatics, University of
      Edinburgh, Edinburgh, UK.
FAU - Salomaa, Veikko
AU  - Salomaa V
AD  - Department of Health, National Institute for Health and Welfare, Helsinki,
      Finland.
FAU - Samani, Nilesh J
AU  - Samani NJ
AD  - Department of Cardiovascular Sciences, University of Leicester, Leicester, UK.
AD  - NIHR Leicester Biomedical Research Centre, Glenfield Hospital, Leicester, UK.
FAU - Sanna, Serena
AU  - Sanna S
AD  - Istituto di Ricerca Genetica e Biomedica, Consiglio Nazionale delle Ricerche
      (CNR), Monserrato, Cagliari, Italy.
FAU - Sattar, Naveed
AU  - Sattar N
AD  - British Heart Foundation Glasgow Cardiovascular Research Centre, Institute of
      Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life
      Sciences, University of Glasgow, Glasgow, UK.
AD  - Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of
      Medicine, University of Oxford, Oxford, UK.
FAU - Schmidt, Ellen M
AU  - Schmidt EM
AD  - Department of Computational Medicine and Bioinformatics, University of Michigan, 
      Ann Arbor, Michigan, USA.
FAU - Scott, Robert A
AU  - Scott RA
AD  - MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge
      School of Clinical Medicine, Cambridge, UK.
FAU - Sever, Peter
AU  - Sever P
AD  - International Centre for Circulatory Health, Imperial College London, London, UK.
FAU - Sevilla, Raquel S
AU  - Sevilla RS
AD  - Imaging, Merck Sharp & Dohme Corporation, Kenilworth, New Jersey, USA.
FAU - Shaffer, Christian M
AU  - Shaffer CM
AD  - Department of Medicine, Vanderbilt University Medical Center, Nashville,
      Tennessee, USA.
FAU - Sim, Xueling
AU  - Sim X
AD  - Center for Statistical Genetics, Department of Biostatistics, University of
      Michigan School of Public Health, Ann Arbor, Michigan, USA.
AD  - Saw Swee Hock School of Public Health, National University of Singapore,
      Singapore.
FAU - Sivapalaratnam, Suthesh
AU  - Sivapalaratnam S
AD  - Department of Vascular Medicine, Academic Medical Center, University of
      Amsterdam, Amsterdam, the Netherlands.
FAU - Small, Kerrin S
AU  - Small KS
AD  - Department of Twin Research and Genetic Epidemiology, King's College London,
      London, UK.
FAU - Smith, Albert V
AU  - Smith AV
AD  - The Icelandic Heart Association, Kopavogur, Iceland.
AD  - Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
FAU - Smith, Blair H
AU  - Smith BH
AD  - Division of Population Health Sciences, Ninewells Hospital and Medical School,
      University of Dundee, Dundee, UK.
AD  - Generation Scotland, Centre for Genomic and Experimental Medicine, University of 
      Edinburgh, Edinburgh, UK.
FAU - Somayajula, Sangeetha
AU  - Somayajula S
AD  - Scientific Informatics, Merck Sharp & Dohme Corporation, Kenilworth, New Jersey, 
      USA.
FAU - Southam, Lorraine
AU  - Southam L
AD  - Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
AD  - Wellcome Trust Sanger Institute, Genome Campus, Hinxton, UK.
FAU - Spector, Timothy D
AU  - Spector TD
AD  - Department of Twin Research and Genetic Epidemiology, King's College London,
      London, UK.
FAU - Speliotes, Elizabeth K
AU  - Speliotes EK
AD  - Department of Computational Medicine and Bioinformatics, University of Michigan, 
      Ann Arbor, Michigan, USA.
AD  - Department of Internal Medicine, Division of Gastroenterology, University of
      Michigan, Ann Arbor, Michigan, USA.
FAU - Starr, John M
AU  - Starr JM
AD  - Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, 
      Edinburgh, UK.
AD  - Alzheimer Scotland Dementia Research Centre, University of Edinburgh, Edinburgh, 
      UK.
FAU - Stirrups, Kathleen E
AU  - Stirrups KE
AD  - William Harvey Research Institute, Barts and The London School of Medicine and
      Dentistry, Queen Mary University of London, London, UK.
AD  - Department of Haematology, University of Cambridge, Cambridge, UK.
FAU - Stitziel, Nathan
AU  - Stitziel N
AD  - Cardiovascular Division, Departments of Medicine and Genetics, Washington
      University School of Medicine, St. Louis, Missouri, USA.
AD  - The McDonnell Genome Institute, Washington University School of Medicine, St.
      Louis, Missouri, USA.
FAU - Strauch, Konstantin
AU  - Strauch K
AD  - IBE, Faculty of Medicine, Ludwig-Maximilians-Universitat Munich, Germany.
AD  - Institute of Genetic Epidemiology, Helmholtz Zentrum Munchen, German Research
      Center for Environmental Health, Neuherberg, Germany.
FAU - Stringham, Heather M
AU  - Stringham HM
AD  - Center for Statistical Genetics, Department of Biostatistics, University of
      Michigan School of Public Health, Ann Arbor, Michigan, USA.
FAU - Surendran, Praveen
AU  - Surendran P
AD  - MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary
      Care, University of Cambridge, Cambridge, UK.
FAU - Tada, Hayato
AU  - Tada H
AD  - Division of Cardiovascular Medicine, Kanazawa University Graduate School of
      Medicine, Kanazawa, Japan.
FAU - Tall, Alan R
AU  - Tall AR
AD  - Department of Medicine, Division of Molecular Medicine, Columbia University, New 
      York, New York, USA.
FAU - Tang, Hua
AU  - Tang H
AD  - Department of Genetics, Stanford University School of Medicine, Stanford,
      California, USA.
FAU - Tardif, Jean-Claude
AU  - Tardif JC
AD  - Montreal Heart Institute, Montreal, Quebec, Canada.
AD  - Universite de Montreal, Montreal, Quebec, Canada.
FAU - Taylor, Kent D
AU  - Taylor KD
AD  - The Institute for Translational Genomics and Population Sciences, LABioMed at
      Harbor-UCLA Medical Center, Departments of Pediatrics and Medicine, Los Angeles, 
      California, USA.
FAU - Trompet, Stella
AU  - Trompet S
AD  - Department of Cardiology, Leiden University Medical Center, Leiden, the
      Netherlands.
AD  - Department of Gerontology and Geriatrics, Leiden University Medical Center,
      Leiden, the Netherlands.
FAU - Tsao, Philip S
AU  - Tsao PS
AD  - VA Palo Alto Health Care System, Palo Alto, California, USA.
AD  - Department of Medicine, Stanford University School of Medicine, Stanford,
      California, USA.
FAU - Tuomilehto, Jaakko
AU  - Tuomilehto J
AD  - Chronic Disease Prevention Unit, National Institute for Health and Welfare,
      Helsinki, Finland.
AD  - Dasman Diabetes Institute, Dasman, Kuwait.
AD  - Centre for Vascular Prevention, Danube-University Krems, Krems, Austria.
AD  - Saudi Diabetes Research Group, King Abdulaziz University, Fahd Medical Research
      Center, Jeddah, Saudi Arabia.
FAU - Tybjaerg-Hansen, Anne
AU  - Tybjaerg-Hansen A
AD  - Department of Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark.
AD  - Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen,
      Denmark.
FAU - van Zuydam, Natalie R
AU  - van Zuydam NR
AD  - Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
AD  - Medical Research Institute, Ninewells Hospital and Medical School, University of 
      Dundee, Dundee, UK.
FAU - Varbo, Anette
AU  - Varbo A
AD  - Department of Clinical Biochemistry and the Copenhagen General Population Study, 
      Herlev and Gentofte Hospital, Copenhagen University Hospital, Copenhagen,
      Denmark.
AD  - Faculty of Health and Medical Sciences, University of Denmark, Copenhagen,
      Denmark.
FAU - Varga, Tibor V
AU  - Varga TV
AD  - Department of Clinical Sciences, Genetic and Molecular Epidemiology Unit, Lund
      University, Malmo, Sweden.
FAU - Virtamo, Jarmo
AU  - Virtamo J
AD  - Department of Health, National Institute for Health and Welfare, Helsinki,
      Finland.
FAU - Waldenberger, Melanie
AU  - Waldenberger M
AD  - Research Unit of Molecular Epidemiology, Helmholtz Zentrum Munchen, German
      Research Center for Environmental Health, Neuherberg, Germany.
AD  - Institute of Epidemiology II, Helmholtz Zentrum Munchen-German Research Center
      for Environmental Health, Neuherberg, Germany.
AD  - DZHK German Centre for Cardiovascular Research, Munich Heart Alliance, Munich,
      Germany.
FAU - Wang, Nan
AU  - Wang N
AD  - Department of Medicine, Division of Molecular Medicine, Columbia University, New 
      York, New York, USA.
FAU - Wareham, Nick J
AU  - Wareham NJ
AD  - MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge
      School of Clinical Medicine, Cambridge, UK.
FAU - Warren, Helen R
AU  - Warren HR
AD  - Clinical Pharmacology, William Harvey Research Institute, Barts and The London
      School of Medicine and Dentistry, Queen Mary University of London, London, UK.
AD  - NIHR Barts Cardiovascular Biomedical Research Unit, Queen Mary University of
      London, London, UK.
FAU - Weeke, Peter E
AU  - Weeke PE
AD  - Department of Medicine, Vanderbilt University Medical Center, Nashville,
      Tennessee, USA.
AD  - The Heart Centre, Department of Cardiology, Copenhagen University Hospital,
      Rigshospitalet, Copenhagen, Denmark.
FAU - Weinstock, Joshua
AU  - Weinstock J
AD  - Center for Statistical Genetics, Department of Biostatistics, University of
      Michigan School of Public Health, Ann Arbor, Michigan, USA.
FAU - Wessel, Jennifer
AU  - Wessel J
AD  - Department of Epidemiology, Indiana University Fairbanks School of Public Health,
      Indianapolis, Indiana, USA.
AD  - Department of Medicine, Indiana University School of Medicine, Indianapolis,
      Indiana, USA.
FAU - Wilson, James G
AU  - Wilson JG
AD  - Department of Physiology and Biophysics, University of Mississippi Medical
      Center, Jackson, Mississippi, USA.
FAU - Wilson, Peter W F
AU  - Wilson PWF
AD  - Atlanta VA Medical Center, Decatur, Georgia, USA.
AD  - Emory Clinical Cardiovascular Research Institute, Atlanta, Georgia, USA.
FAU - Xu, Ming
AU  - Xu M
AD  - Department of Cardiology, Institute of Vascular Medicine, Peking University Third
      Hospital, Key Laboratory of Molecular Cardiovascular Sciences, Ministry of
      Education, Beijing, China.
FAU - Yaghootkar, Hanieh
AU  - Yaghootkar H
AD  - Genetics of Complex Traits, University of Exeter Medical School, University of
      Exeter, Exeter, UK.
FAU - Young, Robin
AU  - Young R
AD  - MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary
      Care, University of Cambridge, Cambridge, UK.
FAU - Zeggini, Eleftheria
AU  - Zeggini E
AD  - Wellcome Trust Sanger Institute, Genome Campus, Hinxton, UK.
FAU - Zhang, He
AU  - Zhang H
AD  - Department of Internal Medicine, Division of Cardiovascular Medicine, University 
      of Michigan, Ann Arbor, Michigan, USA.
FAU - Zheng, Neil S
AU  - Zheng NS
AD  - Yale College, Yale University, New Haven, Connecticut, USA.
FAU - Zhang, Weihua
AU  - Zhang W
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Imperial
      College London, London, UK.
FAU - Zhang, Yan
AU  - Zhang Y
AD  - Department of Cardiology, Peking University First Hospital, Beijing, China.
FAU - Zhou, Wei
AU  - Zhou W
AD  - Department of Computational Medicine and Bioinformatics, University of Michigan, 
      Ann Arbor, Michigan, USA.
FAU - Zhou, Yanhua
AU  - Zhou Y
AD  - Department of Biostatistics, Boston University School of Public Health, Boston,
      Massachusetts, USA.
FAU - Zoledziewska, Magdalena
AU  - Zoledziewska M
AD  - Istituto di Ricerca Genetica e Biomedica, Consiglio Nazionale delle Ricerche
      (CNR), Monserrato, Cagliari, Italy.
CN  - Charge Diabetes Working Group
CN  - EPIC-InterAct Consortium
CN  - EPIC-CVD Consortium
CN  - GOLD Consortium
CN  - VA Million Veteran Program
FAU - Howson, Joanna M M
AU  - Howson JMM
AD  - MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary
      Care, University of Cambridge, Cambridge, UK.
FAU - Danesh, John
AU  - Danesh J
AD  - MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary
      Care, University of Cambridge, Cambridge, UK.
AD  - The National Institute for Health Research Blood and Transplant Research Unit
      (NIHR BTRU) in Donor Health and Genomics at the University of Cambridge,
      Cambridge, UK.
AD  - Wellcome Trust Sanger Institute, Genome Campus, Hinxton, UK.
FAU - McCarthy, Mark I
AU  - McCarthy MI
AD  - Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
AD  - Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of
      Medicine, University of Oxford, Oxford, UK.
AD  - Oxford NIHR Biomedical Research Centre, Oxford University Hospitals Trust,
      Oxford, UK.
FAU - Cowan, Chad A
AU  - Cowan CA
AD  - Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute,
      Harvard University, Cambridge, Massachusetts, USA.
AD  - Center for Regenerative Medicine, Massachusetts General Hospital, Boston,
      Massachusetts, USA.
FAU - Abecasis, Goncalo
AU  - Abecasis G
AD  - Center for Statistical Genetics, Department of Biostatistics, University of
      Michigan School of Public Health, Ann Arbor, Michigan, USA.
FAU - Deloukas, Panos
AU  - Deloukas P
AD  - William Harvey Research Institute, Barts and The London School of Medicine and
      Dentistry, Queen Mary University of London, London, UK.
AD  - Princess Al-Jawhara Al-Brahim Centre of Excellence in Research of Hereditary
      Disorders (PACER-HD), King Abdulaziz University, Jeddah, Saudi Arabia.
FAU - Musunuru, Kiran
AU  - Musunuru K
AD  - Cardiovascular Institute, Perelman School of Medicine, University of
      Pennsylvania, Philadelphia, Pennsylvania, USA.
FAU - Willer, Cristen J
AU  - Willer CJ
AD  - Department of Internal Medicine, Division of Cardiovascular Medicine, University 
      of Michigan, Ann Arbor, Michigan, USA.
AD  - Department of Human Genetics, University of Michigan, Ann Arbor, Michigan, USA.
AD  - Department of Computational Medicine and Bioinformatics, University of Michigan, 
      Ann Arbor, Michigan, USA.
FAU - Kathiresan, Sekar
AU  - Kathiresan S
AUID- ORCID: http://orcid.org/0000-0002-6724-032X
AD  - Program in Medical and Population Genetics, Broad Institute, Cambridge,
      Massachusetts, USA.
AD  - Center for Genomic Medicine, Massachusetts General Hospital, Boston,
      Massachusetts, USA.
AD  - Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
AD  - Cardiovascular Research Center, Massachusetts General Hospital, Boston,
      Massachusetts, USA.
LA  - eng
GR  - R01 DK106621/DK/NIDDK NIH HHS/United States
GR  - R01 HL109946/HL/NHLBI NIH HHS/United States
GR  - R01 HL122684/HL/NHLBI NIH HHS/United States
GR  - R21 DA040177/DA/NIDA NIH HHS/United States
GR  - R01 HL127564/HL/NHLBI NIH HHS/United States
GR  - R01 HL117491/HL/NHLBI NIH HHS/United States
GR  - MC_UU_12015/1/Medical Research Council/United Kingdom
GR  - R01 HL105756/HL/NHLBI NIH HHS/United States
GR  - R01 HL129778/HL/NHLBI NIH HHS/United States
GR  - K99 HL094535/HL/NHLBI NIH HHS/United States
GR  - K01 HL125751/HL/NHLBI NIH HHS/United States
GR  - R01 HG008983/HG/NHGRI NIH HHS/United States
GR  - K24 DK080140/DK/NIDDK NIH HHS/United States
GR  - R00 HL094535/HL/NHLBI NIH HHS/United States
GR  - U01 DK078616/DK/NIDDK NIH HHS/United States
GR  - R01 DA037904/DA/NIDA NIH HHS/United States
GR  - R01 DK107904/DK/NIDDK NIH HHS/United States
GR  - Wellcome Trust/United Kingdom
GR  - R21 HL121422/HL/NHLBI NIH HHS/United States
PT  - Journal Article
DEP - 20171030
PL  - United States
TA  - Nat Genet
JT  - Nature genetics
JID - 9216904
RN  - 0 (Lipids)
SB  - IM
MH  - Coronary Artery Disease/blood/genetics
MH  - Diabetes Mellitus, Type 2/blood/genetics
MH  - Exome/*genetics
MH  - Genetic Association Studies/*methods
MH  - Genetic Predisposition to Disease/genetics
MH  - *Genetic Variation
MH  - Genotype
MH  - Humans
MH  - Lipids/*blood
MH  - Macular Degeneration/blood/genetics
MH  - Phenotype
MH  - Risk Factors
PMC - PMC5709146
MID - NIHMS909134
EDAT- 2017/10/31 06:00
MHDA- 2017/12/12 06:00
CRDT- 2017/10/31 06:00
PMCR- 2018/04/30 00:00
PHST- 2017/01/25 00:00 [received]
PHST- 2017/09/26 00:00 [accepted]
PHST- 2018/04/30 00:00 [pmc-release]
PHST- 2017/10/31 06:00 [pubmed]
PHST- 2017/12/12 06:00 [medline]
PHST- 2017/10/31 06:00 [entrez]
AID - ng.3977 [pii]
AID - 10.1038/ng.3977 [doi]
PST - ppublish
SO  - Nat Genet. 2017 Dec;49(12):1758-1766. doi: 10.1038/ng.3977. Epub 2017 Oct 30.

PMID- 29107331
OWN - NLM
STAT- MEDLINE
DCOM- 20171222
LR  - 20171222
IS  - 1097-4172 (Electronic)
IS  - 0092-8674 (Linking)
VI  - 171
IP  - 6
DP  - 2017 Nov 30
TI  - Force Triggers YAP Nuclear Entry by Regulating Transport across Nuclear Pores.
PG  - 1397-1410.e14
LID - S0092-8674(17)31192-3 [pii]
LID - 10.1016/j.cell.2017.10.008 [doi]
AB  - YAP is a mechanosensitive transcriptional activator with a critical role in
      cancer, regeneration, and organ size control. Here, we show that force applied to
      the nucleus directly drives YAP nuclear translocation by decreasing the
      mechanical restriction of nuclear pores to molecular transport. Exposure to a
      stiff environment leads cells to establish a mechanical connection between the
      nucleus and the cytoskeleton, allowing forces exerted through focal adhesions to 
      reach the nucleus. Force transmission then leads to nuclear flattening, which
      stretches nuclear pores, reduces their mechanical resistance to molecular
      transport, and increases YAP nuclear import. The restriction to transport is
      further regulated by the mechanical stability of the transported protein, which
      determines both active nuclear transport of YAP and passive transport of small
      proteins. Our results unveil a mechanosensing mechanism mediated directly by
      nuclear pores, demonstrated for YAP but with potential general applicability in
      transcriptional regulation.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Elosegui-Artola, Alberto
AU  - Elosegui-Artola A
AD  - Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of
      Science and Technology (BIST), 08028 Barcelona, Spain. Electronic address:
      aelosegui@ibecbarcelona.eu.
FAU - Andreu, Ion
AU  - Andreu I
AD  - Mondragon University, 20500 Arrasate, Spain; CEIT and TECNUN (University of
      Navarra), 20018 Donostia-San Sebastian, Spain.
FAU - Beedle, Amy E M
AU  - Beedle AEM
AD  - Randall Division of Cell and Molecular Biophysics, King's College London, London 
      SE1 1UL, UK; Department of Physics, King's College London, London WC2R 2LS, UK.
FAU - Lezamiz, Ainhoa
AU  - Lezamiz A
AD  - Randall Division of Cell and Molecular Biophysics, King's College London, London 
      SE1 1UL, UK; Department of Physics, King's College London, London WC2R 2LS, UK.
FAU - Uroz, Marina
AU  - Uroz M
AD  - Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of
      Science and Technology (BIST), 08028 Barcelona, Spain.
FAU - Kosmalska, Anita J
AU  - Kosmalska AJ
AD  - Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of
      Science and Technology (BIST), 08028 Barcelona, Spain; University of Barcelona,
      08028 Barcelona, Spain.
FAU - Oria, Roger
AU  - Oria R
AD  - Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of
      Science and Technology (BIST), 08028 Barcelona, Spain; University of Barcelona,
      08028 Barcelona, Spain.
FAU - Kechagia, Jenny Z
AU  - Kechagia JZ
AD  - Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of
      Science and Technology (BIST), 08028 Barcelona, Spain.
FAU - Rico-Lastres, Palma
AU  - Rico-Lastres P
AD  - Randall Division of Cell and Molecular Biophysics, King's College London, London 
      SE1 1UL, UK; Department of Physics, King's College London, London WC2R 2LS, UK.
FAU - Le Roux, Anabel-Lise
AU  - Le Roux AL
AD  - Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of
      Science and Technology (BIST), 08028 Barcelona, Spain.
FAU - Shanahan, Catherine M
AU  - Shanahan CM
AD  - Cardiovascular Division, James Black Centre, King's College London, London SE5
      9NU, UK.
FAU - Trepat, Xavier
AU  - Trepat X
AD  - Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of
      Science and Technology (BIST), 08028 Barcelona, Spain; University of Barcelona,
      08028 Barcelona, Spain; Institucio Catalana de Recerca i Estudis Avancats
      (ICREA), 08010 Barcelona, Spain; Centro de Investigacion Biomedica en Red en
      Bioingenieria, Biomateriales y Nanomedicina, 28029 Madrid, Spain.
FAU - Navajas, Daniel
AU  - Navajas D
AD  - Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of
      Science and Technology (BIST), 08028 Barcelona, Spain; University of Barcelona,
      08028 Barcelona, Spain; Centro de Investigacion Biomedica en Red en Enfermedades 
      Respiratorias, 28029 Madrid, Spain.
FAU - Garcia-Manyes, Sergi
AU  - Garcia-Manyes S
AD  - Randall Division of Cell and Molecular Biophysics, King's College London, London 
      SE1 1UL, UK; Department of Physics, King's College London, London WC2R 2LS, UK.
FAU - Roca-Cusachs, Pere
AU  - Roca-Cusachs P
AD  - Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of
      Science and Technology (BIST), 08028 Barcelona, Spain; University of Barcelona,
      08028 Barcelona, Spain. Electronic address: rocacusachs@ub.edu.
LA  - eng
PT  - Journal Article
DEP - 20171026
PL  - United States
TA  - Cell
JT  - Cell
JID - 0413066
RN  - 0 (Adaptor Proteins, Signal Transducing)
RN  - 0 (Phosphoproteins)
RN  - 0 (YAP1 (Yes-associated) protein, human)
RN  - 0 (Yap protein, mouse)
SB  - IM
MH  - *Active Transport, Cell Nucleus
MH  - Adaptor Proteins, Signal Transducing/*metabolism
MH  - Animals
MH  - Biomechanical Phenomena
MH  - Cell Line, Tumor
MH  - Cell Nucleus/metabolism
MH  - Humans
MH  - Mice
MH  - Nuclear Pore/*metabolism
MH  - Phosphoproteins/*metabolism
MH  - Transcription, Genetic
OTO - NOTNLM
OT  - Hippo pathway
OT  - atomic force microscopy
OT  - mechanosensing
OT  - mechanotransduction
OT  - molecular mechanical stability
OT  - nuclear mechanics
OT  - nuclear pores
OT  - nuclear transport
OT  - rigidity sensing
OT  - transcription regulation
EDAT- 2017/11/07 06:00
MHDA- 2017/12/23 06:00
CRDT- 2017/11/07 06:00
PHST- 2017/05/02 00:00 [received]
PHST- 2017/08/14 00:00 [revised]
PHST- 2017/10/04 00:00 [accepted]
PHST- 2017/11/07 06:00 [pubmed]
PHST- 2017/12/23 06:00 [medline]
PHST- 2017/11/07 06:00 [entrez]
AID - S0092-8674(17)31192-3 [pii]
AID - 10.1016/j.cell.2017.10.008 [doi]
PST - ppublish
SO  - Cell. 2017 Nov 30;171(6):1397-1410.e14. doi: 10.1016/j.cell.2017.10.008. Epub
      2017 Oct 26.

PMID- 29334372
OWN - NLM
STAT- Publisher
LR  - 20180129
IS  - 1546-170X (Electronic)
IS  - 1078-8956 (Linking)
DP  - 2018 Jan 15
TI  - Pharmacological blockade of ASCT2-dependent glutamine transport leads to
      antitumor efficacy in preclinical models.
LID - 10.1038/nm.4464 [doi]
AB  - The unique metabolic demands of cancer cells underscore potentially fruitful
      opportunities for drug discovery in the era of precision medicine. However,
      therapeutic targeting of cancer metabolism has led to surprisingly few new drugs 
      to date. The neutral amino acid glutamine serves as a key intermediate in
      numerous metabolic processes leveraged by cancer cells, including biosynthesis,
      cell signaling, and oxidative protection. Herein we report the preclinical
      development of V-9302, a competitive small molecule antagonist of transmembrane
      glutamine flux that selectively and potently targets the amino acid transporter
      ASCT2. Pharmacological blockade of ASCT2 with V-9302 resulted in attenuated
      cancer cell growth and proliferation, increased cell death, and increased
      oxidative stress, which collectively contributed to antitumor responses in vitro 
      and in vivo. This is the first study, to our knowledge, to demonstrate the
      utility of a pharmacological inhibitor of glutamine transport in oncology,
      representing a new class of targeted therapy and laying a framework for
      paradigm-shifting therapies targeting cancer cell metabolism.
FAU - Schulte, Michael L
AU  - Schulte ML
AD  - Vanderbilt Center for Molecular Probes, Vanderbilt University Medical Center,
      Nashville, Tennessee, USA.
AD  - Vanderbilt University Institute of Imaging Science, Vanderbilt University Medical
      Center, Nashville, Tennessee, USA.
AD  - Department of Radiology and Radiological Sciences, Vanderbilt University Medical 
      Center, Nashville, Tennessee, USA.
FAU - Fu, Allie
AU  - Fu A
AD  - Vanderbilt Center for Molecular Probes, Vanderbilt University Medical Center,
      Nashville, Tennessee, USA.
FAU - Zhao, Ping
AU  - Zhao P
AD  - Vanderbilt Center for Molecular Probes, Vanderbilt University Medical Center,
      Nashville, Tennessee, USA.
FAU - Li, Jun
AU  - Li J
AD  - Vanderbilt Center for Molecular Probes, Vanderbilt University Medical Center,
      Nashville, Tennessee, USA.
FAU - Geng, Ling
AU  - Geng L
AD  - Vanderbilt Center for Molecular Probes, Vanderbilt University Medical Center,
      Nashville, Tennessee, USA.
FAU - Smith, Shannon T
AU  - Smith ST
AD  - Vanderbilt Center for Molecular Probes, Vanderbilt University Medical Center,
      Nashville, Tennessee, USA.
FAU - Kondo, Jumpei
AU  - Kondo J
AD  - Department of Medicine, Vanderbilt University Medical Center, Nashville,
      Tennessee, USA.
FAU - Coffey, Robert J
AU  - Coffey RJ
AUID- ORCID: http://orcid.org/0000-0002-2180-3844
AD  - Department of Medicine, Vanderbilt University Medical Center, Nashville,
      Tennessee, USA.
AD  - Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville,
      Tennessee, USA.
AD  - Veterans Health Administration, Tennessee Valley Healthcare System, Nashville,
      Tennessee, USA.
FAU - Johnson, Marc O
AU  - Johnson MO
AD  - Department of Pathology, Microbiology, and Immunology, Vanderbilt University
      Medical Center, Nashville, Tennessee, USA.
FAU - Rathmell, Jeffrey C
AU  - Rathmell JC
AD  - Department of Pathology, Microbiology, and Immunology, Vanderbilt University
      Medical Center, Nashville, Tennessee, USA.
FAU - Sharick, Joe T
AU  - Sharick JT
AD  - Department of Biomedical Engineering, Vanderbilt University, Nashville,
      Tennessee, USA.
FAU - Skala, Melissa C
AU  - Skala MC
AD  - Department of Biomedical Engineering, Vanderbilt University, Nashville,
      Tennessee, USA.
FAU - Smith, Jarrod A
AU  - Smith JA
AD  - Vanderbilt Center for Structural Biology, Vanderbilt University, Nashville,
      Tennessee, USA.
AD  - Department of Biochemistry, Vanderbilt University, Nashville, Tennessee, USA.
FAU - Berlin, Jordan
AU  - Berlin J
AD  - Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville,
      Tennessee, USA.
FAU - Washington, M Kay
AU  - Washington MK
AD  - Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville,
      Tennessee, USA.
AD  - Department of Pathology, Microbiology, and Immunology, Vanderbilt University
      Medical Center, Nashville, Tennessee, USA.
FAU - Nickels, Michael L
AU  - Nickels ML
AD  - Vanderbilt Center for Molecular Probes, Vanderbilt University Medical Center,
      Nashville, Tennessee, USA.
AD  - Vanderbilt University Institute of Imaging Science, Vanderbilt University Medical
      Center, Nashville, Tennessee, USA.
AD  - Department of Radiology and Radiological Sciences, Vanderbilt University Medical 
      Center, Nashville, Tennessee, USA.
FAU - Manning, H Charles
AU  - Manning HC
AD  - Vanderbilt Center for Molecular Probes, Vanderbilt University Medical Center,
      Nashville, Tennessee, USA.
AD  - Vanderbilt University Institute of Imaging Science, Vanderbilt University Medical
      Center, Nashville, Tennessee, USA.
AD  - Department of Radiology and Radiological Sciences, Vanderbilt University Medical 
      Center, Nashville, Tennessee, USA.
AD  - Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville,
      Tennessee, USA.
AD  - Department of Biomedical Engineering, Vanderbilt University, Nashville,
      Tennessee, USA.
AD  - Department of Neurosurgery, Vanderbilt University Medical Center, Nashville,
      Tennessee, USA.
AD  - Department of Chemistry, Vanderbilt University, Nashville, Tennessee, USA.
LA  - eng
GR  - P50 CA095103/CA/NCI NIH HHS/United States
GR  - R01 DK105550/DK/NIDDK NIH HHS/United States
GR  - R01 CA185747/CA/NCI NIH HHS/United States
GR  - P30 CA068485/CA/NCI NIH HHS/United States
GR  - R01 HL136664/HL/NHLBI NIH HHS/United States
PT  - Journal Article
DEP - 20180115
PL  - United States
TA  - Nat Med
JT  - Nature medicine
JID - 9502015
EDAT- 2018/01/16 06:00
MHDA- 2018/01/16 06:00
CRDT- 2018/01/16 06:00
PHST- 2017/01/12 00:00 [received]
PHST- 2017/11/29 00:00 [accepted]
PHST- 2018/01/16 06:00 [pubmed]
PHST- 2018/01/16 06:00 [medline]
PHST- 2018/01/16 06:00 [entrez]
AID - nm.4464 [pii]
AID - 10.1038/nm.4464 [doi]
PST - aheadofprint
SO  - Nat Med. 2018 Jan 15. pii: nm.4464. doi: 10.1038/nm.4464.

PMID- 29158268
OWN - NLM
STAT- Publisher
LR  - 20180106
IS  - 1078-0432 (Print)
IS  - 1078-0432 (Linking)
DP  - 2017 Nov 20
TI  - CAR T-Cell Therapies in Glioblastoma: A First Look.
LID - 10.1158/1078-0432.CCR-17-2871 [doi]
AB  - Glioblastoma is an aggressive malignancy with a poor prognosis. The current
      standard of care for newly diagnosed glioblastoma patients includes surgery to
      the extent, temozolomide combined with radiotherapy, and alternating electric
      fields therapy. After recurrence, there is no standard therapy and survival is
      less than 9 months. Recurrent glioblastoma offers a unique opportunity to
      investigate new treatment approaches in a malignancy known for remarkable genetic
      heterogeneity, an immunosuppressive microenvironment, and a partially permissive 
      anatomic blood-brain barrier. Results from three first-in-man chimeric antigen
      receptor (CAR) T-cell trials targeting IL13Ralpha2, Her2/CMV, and EGFRvIII have
      recently been reported. Each one of these trials addresses important questions,
      such as T-cell trafficking to CNS, engraftment and persistence, tumor
      microenvironment remodeling, and monitoring of glioma response to CAR T cells.
      Objective radiologic responses have been reported. Here, we discuss and summarize
      the results of these trials and suggest opportunities for the field. Clin Cancer 
      Res; 24(3); 1-6. (c)2017 AACR.
CI  - (c)2017 American Association for Cancer Research.
FAU - Migliorini, Denis
AU  - Migliorini D
AD  - Center for Cellular Immunotherapies and Parker Institute for Cancer
      Immunotherapy, Perelman School of Medicine, University of Pennsylvania,
      Philadelphia, Pennsylvania.
FAU - Dietrich, Pierre-Yves
AU  - Dietrich PY
AD  - Department of Oncology, Geneva University Hospital, Geneva, Switzerland.
FAU - Stupp, Roger
AU  - Stupp R
AD  - Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg
      School of Medicine, Chicago, Illinois.
FAU - Linette, Gerald P
AU  - Linette GP
AD  - Center for Cellular Immunotherapies and Parker Institute for Cancer
      Immunotherapy, Perelman School of Medicine, University of Pennsylvania,
      Philadelphia, Pennsylvania. glinette@upenn.edu.
FAU - Posey, Avery D Jr
AU  - Posey AD Jr
AD  - Center for Cellular Immunotherapies and Parker Institute for Cancer
      Immunotherapy, Perelman School of Medicine, University of Pennsylvania,
      Philadelphia, Pennsylvania.
FAU - June, Carl H
AU  - June CH
AD  - Center for Cellular Immunotherapies and Parker Institute for Cancer
      Immunotherapy, Perelman School of Medicine, University of Pennsylvania,
      Philadelphia, Pennsylvania.
LA  - eng
PT  - Journal Article
DEP - 20171120
PL  - United States
TA  - Clin Cancer Res
JT  - Clinical cancer research : an official journal of the American Association for
      Cancer Research
JID - 9502500
EDAT- 2017/11/22 06:00
MHDA- 2017/11/22 06:00
CRDT- 2017/11/22 06:00
PHST- 2017/09/29 00:00 [received]
PHST- 2017/11/08 00:00 [revised]
PHST- 2017/11/16 00:00 [accepted]
PHST- 2017/11/22 06:00 [pubmed]
PHST- 2017/11/22 06:00 [medline]
PHST- 2017/11/22 06:00 [entrez]
AID - 1078-0432.CCR-17-2871 [pii]
AID - 10.1158/1078-0432.CCR-17-2871 [doi]
PST - aheadofprint
SO  - Clin Cancer Res. 2017 Nov 20. pii: 1078-0432.CCR-17-2871. doi:
      10.1158/1078-0432.CCR-17-2871.

PMID- 29091516
OWN - NLM
STAT- In-Data-Review
LR  - 20180117
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Linking)
VI  - 36
IP  - 3
DP  - 2018 Jan 20
TI  - Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results
      From the Randomized BFORE Trial.
PG  - 231-237
LID - 10.1200/JCO.2017.74.7162 [doi]
AB  - Purpose Bosutinib is a potent dual SRC/ABL kinase inhibitor approved for adults
      with Philadelphia chromosome-positive chronic myeloid leukemia (CML) resistant
      and /or intolerant to prior therapy. We assessed the efficacy and safety of
      bosutinib versus imatinib for first-line treatment of chronic-phase CML. Methods 
      In this ongoing, multinational, phase III study, 536 patients with newly
      diagnosed chronic-phase CML were randomly assigned 1:1 to receive 400 mg of
      bosutinib once daily (n = 268) or imatinib (n = 268). Per protocol, efficacy was 
      assessed in patients who were Philadelphia chromosome-positive with typical
      (e13a2/e14a2) transcripts (bosutinib, n = 246; imatinib, n = 241). Patients with 
      Philadelphia chromosome-negative-/ BCR-ABL1-positive status and those with
      unknown Philadelphia chromosome status and/or atypical BCR-ABL1 transcript type
      were excluded from this population. Results The major molecular response (MMR)
      rate at 12 months (primary end point) was significantly higher with bosutinib
      versus imatinib (47.2% v 36.9%, respectively; P = .02), as was complete
      cytogenetic response (CCyR) rate by 12 months (77.2% v 66.4%, respectively; P =
      .0075). Cumulative incidence was favorable with bosutinib (MMR: hazard ratio,
      1.34; P = .0173; CCyR: hazard ratio, 1.38; P < .001), with earlier response
      times. Four patients (1.6%) receiving bosutinib and six patients (2.5%) receiving
      imatinib experienced disease progression to accelerated/blast phase. Among
      treated patients, 22.0% of patients receiving bosutinib and 26.8% of patients
      receiving imatinib discontinued treatment, most commonly for drug-related
      toxicity (12.7% and 8.7%, respectively). Grade >/= 3 diarrhea (7.8% v 0.8%) and
      increased ALT (19.0% v 1.5%) and AST (9.7% v 1.9%) levels were more common with
      bosutinib. Cardiac and vascular toxicities were uncommon. Conclusion Patients who
      received bosutinib had significantly higher rates of MMR and CCyR and achieved
      responses faster than those who received imatinib. Consistent with the known
      safety profile, GI events and transaminase elevations were more common with
      bosutinib. Results indicate bosutinib may be an effective first-line treatment
      for chronic-phase CML.
FAU - Cortes, Jorge E
AU  - Cortes JE
AD  - Jorge E. Cortes, University of Texas MD Anderson Cancer Center, Houston, TX;
      Carlo Gambacorti-Passerini, University of Milano-Bicocca, Monza, Italy; Michael
      W. Deininger, University of Utah, Salt Lake City, UT; Michael J. Mauro, Memorial 
      Sloan Kettering Cancer Center, New York, NY; Charles Chuah, Singapore General
      Hospital, Duke-National University of Singapore Medical School, Singapore,
      Singapore; Dong-Wook Kim, Seoul St Mary's Hospital, The Catholic University of
      Korea, Seoul, South Korea; Irina Dyagil, National Research Center for Radiation
      Medicine, Kiev; Nataliia Glushko, Ivano-Frankivsk Regional Clinical Hospital,
      Ivano-Frankivsk, Ukraine; Dragana Milojkovic, Imperial College London at
      Hammersmith Hospital London; Laurence Reilly and Allison Jeynes-Ellis, Avillion, 
      London, United Kingdom; Philipp le Coutre, Charite-Universitatsmedizin Berlin,
      Berlin; Andreas Hochhaus, Klinik fur Innere Medizin II, Universitatsklinikum
      Jena, Jena; Tim H. Brummendorf, Universitatsklinikum RWTH Aachen, Aachen,
      Germany; Valentin Garcia-Gutierrez, Hospital Universitario Ramon y Cajal,
      Instituto Ramon y Cajal de Investigacion Sanitaria, Madrid, Spain; Eric Leip,
      Pfizer, Cambridge, MA; Nathalie Bardy-Bouxin, Pfizer International Operation,
      Paris, France.
FAU - Gambacorti-Passerini, Carlo
AU  - Gambacorti-Passerini C
AD  - Jorge E. Cortes, University of Texas MD Anderson Cancer Center, Houston, TX;
      Carlo Gambacorti-Passerini, University of Milano-Bicocca, Monza, Italy; Michael
      W. Deininger, University of Utah, Salt Lake City, UT; Michael J. Mauro, Memorial 
      Sloan Kettering Cancer Center, New York, NY; Charles Chuah, Singapore General
      Hospital, Duke-National University of Singapore Medical School, Singapore,
      Singapore; Dong-Wook Kim, Seoul St Mary's Hospital, The Catholic University of
      Korea, Seoul, South Korea; Irina Dyagil, National Research Center for Radiation
      Medicine, Kiev; Nataliia Glushko, Ivano-Frankivsk Regional Clinical Hospital,
      Ivano-Frankivsk, Ukraine; Dragana Milojkovic, Imperial College London at
      Hammersmith Hospital London; Laurence Reilly and Allison Jeynes-Ellis, Avillion, 
      London, United Kingdom; Philipp le Coutre, Charite-Universitatsmedizin Berlin,
      Berlin; Andreas Hochhaus, Klinik fur Innere Medizin II, Universitatsklinikum
      Jena, Jena; Tim H. Brummendorf, Universitatsklinikum RWTH Aachen, Aachen,
      Germany; Valentin Garcia-Gutierrez, Hospital Universitario Ramon y Cajal,
      Instituto Ramon y Cajal de Investigacion Sanitaria, Madrid, Spain; Eric Leip,
      Pfizer, Cambridge, MA; Nathalie Bardy-Bouxin, Pfizer International Operation,
      Paris, France.
FAU - Deininger, Michael W
AU  - Deininger MW
AD  - Jorge E. Cortes, University of Texas MD Anderson Cancer Center, Houston, TX;
      Carlo Gambacorti-Passerini, University of Milano-Bicocca, Monza, Italy; Michael
      W. Deininger, University of Utah, Salt Lake City, UT; Michael J. Mauro, Memorial 
      Sloan Kettering Cancer Center, New York, NY; Charles Chuah, Singapore General
      Hospital, Duke-National University of Singapore Medical School, Singapore,
      Singapore; Dong-Wook Kim, Seoul St Mary's Hospital, The Catholic University of
      Korea, Seoul, South Korea; Irina Dyagil, National Research Center for Radiation
      Medicine, Kiev; Nataliia Glushko, Ivano-Frankivsk Regional Clinical Hospital,
      Ivano-Frankivsk, Ukraine; Dragana Milojkovic, Imperial College London at
      Hammersmith Hospital London; Laurence Reilly and Allison Jeynes-Ellis, Avillion, 
      London, United Kingdom; Philipp le Coutre, Charite-Universitatsmedizin Berlin,
      Berlin; Andreas Hochhaus, Klinik fur Innere Medizin II, Universitatsklinikum
      Jena, Jena; Tim H. Brummendorf, Universitatsklinikum RWTH Aachen, Aachen,
      Germany; Valentin Garcia-Gutierrez, Hospital Universitario Ramon y Cajal,
      Instituto Ramon y Cajal de Investigacion Sanitaria, Madrid, Spain; Eric Leip,
      Pfizer, Cambridge, MA; Nathalie Bardy-Bouxin, Pfizer International Operation,
      Paris, France.
FAU - Mauro, Michael J
AU  - Mauro MJ
AD  - Jorge E. Cortes, University of Texas MD Anderson Cancer Center, Houston, TX;
      Carlo Gambacorti-Passerini, University of Milano-Bicocca, Monza, Italy; Michael
      W. Deininger, University of Utah, Salt Lake City, UT; Michael J. Mauro, Memorial 
      Sloan Kettering Cancer Center, New York, NY; Charles Chuah, Singapore General
      Hospital, Duke-National University of Singapore Medical School, Singapore,
      Singapore; Dong-Wook Kim, Seoul St Mary's Hospital, The Catholic University of
      Korea, Seoul, South Korea; Irina Dyagil, National Research Center for Radiation
      Medicine, Kiev; Nataliia Glushko, Ivano-Frankivsk Regional Clinical Hospital,
      Ivano-Frankivsk, Ukraine; Dragana Milojkovic, Imperial College London at
      Hammersmith Hospital London; Laurence Reilly and Allison Jeynes-Ellis, Avillion, 
      London, United Kingdom; Philipp le Coutre, Charite-Universitatsmedizin Berlin,
      Berlin; Andreas Hochhaus, Klinik fur Innere Medizin II, Universitatsklinikum
      Jena, Jena; Tim H. Brummendorf, Universitatsklinikum RWTH Aachen, Aachen,
      Germany; Valentin Garcia-Gutierrez, Hospital Universitario Ramon y Cajal,
      Instituto Ramon y Cajal de Investigacion Sanitaria, Madrid, Spain; Eric Leip,
      Pfizer, Cambridge, MA; Nathalie Bardy-Bouxin, Pfizer International Operation,
      Paris, France.
FAU - Chuah, Charles
AU  - Chuah C
AD  - Jorge E. Cortes, University of Texas MD Anderson Cancer Center, Houston, TX;
      Carlo Gambacorti-Passerini, University of Milano-Bicocca, Monza, Italy; Michael
      W. Deininger, University of Utah, Salt Lake City, UT; Michael J. Mauro, Memorial 
      Sloan Kettering Cancer Center, New York, NY; Charles Chuah, Singapore General
      Hospital, Duke-National University of Singapore Medical School, Singapore,
      Singapore; Dong-Wook Kim, Seoul St Mary's Hospital, The Catholic University of
      Korea, Seoul, South Korea; Irina Dyagil, National Research Center for Radiation
      Medicine, Kiev; Nataliia Glushko, Ivano-Frankivsk Regional Clinical Hospital,
      Ivano-Frankivsk, Ukraine; Dragana Milojkovic, Imperial College London at
      Hammersmith Hospital London; Laurence Reilly and Allison Jeynes-Ellis, Avillion, 
      London, United Kingdom; Philipp le Coutre, Charite-Universitatsmedizin Berlin,
      Berlin; Andreas Hochhaus, Klinik fur Innere Medizin II, Universitatsklinikum
      Jena, Jena; Tim H. Brummendorf, Universitatsklinikum RWTH Aachen, Aachen,
      Germany; Valentin Garcia-Gutierrez, Hospital Universitario Ramon y Cajal,
      Instituto Ramon y Cajal de Investigacion Sanitaria, Madrid, Spain; Eric Leip,
      Pfizer, Cambridge, MA; Nathalie Bardy-Bouxin, Pfizer International Operation,
      Paris, France.
FAU - Kim, Dong-Wook
AU  - Kim DW
AD  - Jorge E. Cortes, University of Texas MD Anderson Cancer Center, Houston, TX;
      Carlo Gambacorti-Passerini, University of Milano-Bicocca, Monza, Italy; Michael
      W. Deininger, University of Utah, Salt Lake City, UT; Michael J. Mauro, Memorial 
      Sloan Kettering Cancer Center, New York, NY; Charles Chuah, Singapore General
      Hospital, Duke-National University of Singapore Medical School, Singapore,
      Singapore; Dong-Wook Kim, Seoul St Mary's Hospital, The Catholic University of
      Korea, Seoul, South Korea; Irina Dyagil, National Research Center for Radiation
      Medicine, Kiev; Nataliia Glushko, Ivano-Frankivsk Regional Clinical Hospital,
      Ivano-Frankivsk, Ukraine; Dragana Milojkovic, Imperial College London at
      Hammersmith Hospital London; Laurence Reilly and Allison Jeynes-Ellis, Avillion, 
      London, United Kingdom; Philipp le Coutre, Charite-Universitatsmedizin Berlin,
      Berlin; Andreas Hochhaus, Klinik fur Innere Medizin II, Universitatsklinikum
      Jena, Jena; Tim H. Brummendorf, Universitatsklinikum RWTH Aachen, Aachen,
      Germany; Valentin Garcia-Gutierrez, Hospital Universitario Ramon y Cajal,
      Instituto Ramon y Cajal de Investigacion Sanitaria, Madrid, Spain; Eric Leip,
      Pfizer, Cambridge, MA; Nathalie Bardy-Bouxin, Pfizer International Operation,
      Paris, France.
FAU - Dyagil, Irina
AU  - Dyagil I
AD  - Jorge E. Cortes, University of Texas MD Anderson Cancer Center, Houston, TX;
      Carlo Gambacorti-Passerini, University of Milano-Bicocca, Monza, Italy; Michael
      W. Deininger, University of Utah, Salt Lake City, UT; Michael J. Mauro, Memorial 
      Sloan Kettering Cancer Center, New York, NY; Charles Chuah, Singapore General
      Hospital, Duke-National University of Singapore Medical School, Singapore,
      Singapore; Dong-Wook Kim, Seoul St Mary's Hospital, The Catholic University of
      Korea, Seoul, South Korea; Irina Dyagil, National Research Center for Radiation
      Medicine, Kiev; Nataliia Glushko, Ivano-Frankivsk Regional Clinical Hospital,
      Ivano-Frankivsk, Ukraine; Dragana Milojkovic, Imperial College London at
      Hammersmith Hospital London; Laurence Reilly and Allison Jeynes-Ellis, Avillion, 
      London, United Kingdom; Philipp le Coutre, Charite-Universitatsmedizin Berlin,
      Berlin; Andreas Hochhaus, Klinik fur Innere Medizin II, Universitatsklinikum
      Jena, Jena; Tim H. Brummendorf, Universitatsklinikum RWTH Aachen, Aachen,
      Germany; Valentin Garcia-Gutierrez, Hospital Universitario Ramon y Cajal,
      Instituto Ramon y Cajal de Investigacion Sanitaria, Madrid, Spain; Eric Leip,
      Pfizer, Cambridge, MA; Nathalie Bardy-Bouxin, Pfizer International Operation,
      Paris, France.
FAU - Glushko, Nataliia
AU  - Glushko N
AD  - Jorge E. Cortes, University of Texas MD Anderson Cancer Center, Houston, TX;
      Carlo Gambacorti-Passerini, University of Milano-Bicocca, Monza, Italy; Michael
      W. Deininger, University of Utah, Salt Lake City, UT; Michael J. Mauro, Memorial 
      Sloan Kettering Cancer Center, New York, NY; Charles Chuah, Singapore General
      Hospital, Duke-National University of Singapore Medical School, Singapore,
      Singapore; Dong-Wook Kim, Seoul St Mary's Hospital, The Catholic University of
      Korea, Seoul, South Korea; Irina Dyagil, National Research Center for Radiation
      Medicine, Kiev; Nataliia Glushko, Ivano-Frankivsk Regional Clinical Hospital,
      Ivano-Frankivsk, Ukraine; Dragana Milojkovic, Imperial College London at
      Hammersmith Hospital London; Laurence Reilly and Allison Jeynes-Ellis, Avillion, 
      London, United Kingdom; Philipp le Coutre, Charite-Universitatsmedizin Berlin,
      Berlin; Andreas Hochhaus, Klinik fur Innere Medizin II, Universitatsklinikum
      Jena, Jena; Tim H. Brummendorf, Universitatsklinikum RWTH Aachen, Aachen,
      Germany; Valentin Garcia-Gutierrez, Hospital Universitario Ramon y Cajal,
      Instituto Ramon y Cajal de Investigacion Sanitaria, Madrid, Spain; Eric Leip,
      Pfizer, Cambridge, MA; Nathalie Bardy-Bouxin, Pfizer International Operation,
      Paris, France.
FAU - Milojkovic, Dragana
AU  - Milojkovic D
AD  - Jorge E. Cortes, University of Texas MD Anderson Cancer Center, Houston, TX;
      Carlo Gambacorti-Passerini, University of Milano-Bicocca, Monza, Italy; Michael
      W. Deininger, University of Utah, Salt Lake City, UT; Michael J. Mauro, Memorial 
      Sloan Kettering Cancer Center, New York, NY; Charles Chuah, Singapore General
      Hospital, Duke-National University of Singapore Medical School, Singapore,
      Singapore; Dong-Wook Kim, Seoul St Mary's Hospital, The Catholic University of
      Korea, Seoul, South Korea; Irina Dyagil, National Research Center for Radiation
      Medicine, Kiev; Nataliia Glushko, Ivano-Frankivsk Regional Clinical Hospital,
      Ivano-Frankivsk, Ukraine; Dragana Milojkovic, Imperial College London at
      Hammersmith Hospital London; Laurence Reilly and Allison Jeynes-Ellis, Avillion, 
      London, United Kingdom; Philipp le Coutre, Charite-Universitatsmedizin Berlin,
      Berlin; Andreas Hochhaus, Klinik fur Innere Medizin II, Universitatsklinikum
      Jena, Jena; Tim H. Brummendorf, Universitatsklinikum RWTH Aachen, Aachen,
      Germany; Valentin Garcia-Gutierrez, Hospital Universitario Ramon y Cajal,
      Instituto Ramon y Cajal de Investigacion Sanitaria, Madrid, Spain; Eric Leip,
      Pfizer, Cambridge, MA; Nathalie Bardy-Bouxin, Pfizer International Operation,
      Paris, France.
FAU - le Coutre, Philipp
AU  - le Coutre P
AD  - Jorge E. Cortes, University of Texas MD Anderson Cancer Center, Houston, TX;
      Carlo Gambacorti-Passerini, University of Milano-Bicocca, Monza, Italy; Michael
      W. Deininger, University of Utah, Salt Lake City, UT; Michael J. Mauro, Memorial 
      Sloan Kettering Cancer Center, New York, NY; Charles Chuah, Singapore General
      Hospital, Duke-National University of Singapore Medical School, Singapore,
      Singapore; Dong-Wook Kim, Seoul St Mary's Hospital, The Catholic University of
      Korea, Seoul, South Korea; Irina Dyagil, National Research Center for Radiation
      Medicine, Kiev; Nataliia Glushko, Ivano-Frankivsk Regional Clinical Hospital,
      Ivano-Frankivsk, Ukraine; Dragana Milojkovic, Imperial College London at
      Hammersmith Hospital London; Laurence Reilly and Allison Jeynes-Ellis, Avillion, 
      London, United Kingdom; Philipp le Coutre, Charite-Universitatsmedizin Berlin,
      Berlin; Andreas Hochhaus, Klinik fur Innere Medizin II, Universitatsklinikum
      Jena, Jena; Tim H. Brummendorf, Universitatsklinikum RWTH Aachen, Aachen,
      Germany; Valentin Garcia-Gutierrez, Hospital Universitario Ramon y Cajal,
      Instituto Ramon y Cajal de Investigacion Sanitaria, Madrid, Spain; Eric Leip,
      Pfizer, Cambridge, MA; Nathalie Bardy-Bouxin, Pfizer International Operation,
      Paris, France.
FAU - Garcia-Gutierrez, Valentin
AU  - Garcia-Gutierrez V
AD  - Jorge E. Cortes, University of Texas MD Anderson Cancer Center, Houston, TX;
      Carlo Gambacorti-Passerini, University of Milano-Bicocca, Monza, Italy; Michael
      W. Deininger, University of Utah, Salt Lake City, UT; Michael J. Mauro, Memorial 
      Sloan Kettering Cancer Center, New York, NY; Charles Chuah, Singapore General
      Hospital, Duke-National University of Singapore Medical School, Singapore,
      Singapore; Dong-Wook Kim, Seoul St Mary's Hospital, The Catholic University of
      Korea, Seoul, South Korea; Irina Dyagil, National Research Center for Radiation
      Medicine, Kiev; Nataliia Glushko, Ivano-Frankivsk Regional Clinical Hospital,
      Ivano-Frankivsk, Ukraine; Dragana Milojkovic, Imperial College London at
      Hammersmith Hospital London; Laurence Reilly and Allison Jeynes-Ellis, Avillion, 
      London, United Kingdom; Philipp le Coutre, Charite-Universitatsmedizin Berlin,
      Berlin; Andreas Hochhaus, Klinik fur Innere Medizin II, Universitatsklinikum
      Jena, Jena; Tim H. Brummendorf, Universitatsklinikum RWTH Aachen, Aachen,
      Germany; Valentin Garcia-Gutierrez, Hospital Universitario Ramon y Cajal,
      Instituto Ramon y Cajal de Investigacion Sanitaria, Madrid, Spain; Eric Leip,
      Pfizer, Cambridge, MA; Nathalie Bardy-Bouxin, Pfizer International Operation,
      Paris, France.
FAU - Reilly, Laurence
AU  - Reilly L
AD  - Jorge E. Cortes, University of Texas MD Anderson Cancer Center, Houston, TX;
      Carlo Gambacorti-Passerini, University of Milano-Bicocca, Monza, Italy; Michael
      W. Deininger, University of Utah, Salt Lake City, UT; Michael J. Mauro, Memorial 
      Sloan Kettering Cancer Center, New York, NY; Charles Chuah, Singapore General
      Hospital, Duke-National University of Singapore Medical School, Singapore,
      Singapore; Dong-Wook Kim, Seoul St Mary's Hospital, The Catholic University of
      Korea, Seoul, South Korea; Irina Dyagil, National Research Center for Radiation
      Medicine, Kiev; Nataliia Glushko, Ivano-Frankivsk Regional Clinical Hospital,
      Ivano-Frankivsk, Ukraine; Dragana Milojkovic, Imperial College London at
      Hammersmith Hospital London; Laurence Reilly and Allison Jeynes-Ellis, Avillion, 
      London, United Kingdom; Philipp le Coutre, Charite-Universitatsmedizin Berlin,
      Berlin; Andreas Hochhaus, Klinik fur Innere Medizin II, Universitatsklinikum
      Jena, Jena; Tim H. Brummendorf, Universitatsklinikum RWTH Aachen, Aachen,
      Germany; Valentin Garcia-Gutierrez, Hospital Universitario Ramon y Cajal,
      Instituto Ramon y Cajal de Investigacion Sanitaria, Madrid, Spain; Eric Leip,
      Pfizer, Cambridge, MA; Nathalie Bardy-Bouxin, Pfizer International Operation,
      Paris, France.
FAU - Jeynes-Ellis, Allison
AU  - Jeynes-Ellis A
AD  - Jorge E. Cortes, University of Texas MD Anderson Cancer Center, Houston, TX;
      Carlo Gambacorti-Passerini, University of Milano-Bicocca, Monza, Italy; Michael
      W. Deininger, University of Utah, Salt Lake City, UT; Michael J. Mauro, Memorial 
      Sloan Kettering Cancer Center, New York, NY; Charles Chuah, Singapore General
      Hospital, Duke-National University of Singapore Medical School, Singapore,
      Singapore; Dong-Wook Kim, Seoul St Mary's Hospital, The Catholic University of
      Korea, Seoul, South Korea; Irina Dyagil, National Research Center for Radiation
      Medicine, Kiev; Nataliia Glushko, Ivano-Frankivsk Regional Clinical Hospital,
      Ivano-Frankivsk, Ukraine; Dragana Milojkovic, Imperial College London at
      Hammersmith Hospital London; Laurence Reilly and Allison Jeynes-Ellis, Avillion, 
      London, United Kingdom; Philipp le Coutre, Charite-Universitatsmedizin Berlin,
      Berlin; Andreas Hochhaus, Klinik fur Innere Medizin II, Universitatsklinikum
      Jena, Jena; Tim H. Brummendorf, Universitatsklinikum RWTH Aachen, Aachen,
      Germany; Valentin Garcia-Gutierrez, Hospital Universitario Ramon y Cajal,
      Instituto Ramon y Cajal de Investigacion Sanitaria, Madrid, Spain; Eric Leip,
      Pfizer, Cambridge, MA; Nathalie Bardy-Bouxin, Pfizer International Operation,
      Paris, France.
FAU - Leip, Eric
AU  - Leip E
AD  - Jorge E. Cortes, University of Texas MD Anderson Cancer Center, Houston, TX;
      Carlo Gambacorti-Passerini, University of Milano-Bicocca, Monza, Italy; Michael
      W. Deininger, University of Utah, Salt Lake City, UT; Michael J. Mauro, Memorial 
      Sloan Kettering Cancer Center, New York, NY; Charles Chuah, Singapore General
      Hospital, Duke-National University of Singapore Medical School, Singapore,
      Singapore; Dong-Wook Kim, Seoul St Mary's Hospital, The Catholic University of
      Korea, Seoul, South Korea; Irina Dyagil, National Research Center for Radiation
      Medicine, Kiev; Nataliia Glushko, Ivano-Frankivsk Regional Clinical Hospital,
      Ivano-Frankivsk, Ukraine; Dragana Milojkovic, Imperial College London at
      Hammersmith Hospital London; Laurence Reilly and Allison Jeynes-Ellis, Avillion, 
      London, United Kingdom; Philipp le Coutre, Charite-Universitatsmedizin Berlin,
      Berlin; Andreas Hochhaus, Klinik fur Innere Medizin II, Universitatsklinikum
      Jena, Jena; Tim H. Brummendorf, Universitatsklinikum RWTH Aachen, Aachen,
      Germany; Valentin Garcia-Gutierrez, Hospital Universitario Ramon y Cajal,
      Instituto Ramon y Cajal de Investigacion Sanitaria, Madrid, Spain; Eric Leip,
      Pfizer, Cambridge, MA; Nathalie Bardy-Bouxin, Pfizer International Operation,
      Paris, France.
FAU - Bardy-Bouxin, Nathalie
AU  - Bardy-Bouxin N
AD  - Jorge E. Cortes, University of Texas MD Anderson Cancer Center, Houston, TX;
      Carlo Gambacorti-Passerini, University of Milano-Bicocca, Monza, Italy; Michael
      W. Deininger, University of Utah, Salt Lake City, UT; Michael J. Mauro, Memorial 
      Sloan Kettering Cancer Center, New York, NY; Charles Chuah, Singapore General
      Hospital, Duke-National University of Singapore Medical School, Singapore,
      Singapore; Dong-Wook Kim, Seoul St Mary's Hospital, The Catholic University of
      Korea, Seoul, South Korea; Irina Dyagil, National Research Center for Radiation
      Medicine, Kiev; Nataliia Glushko, Ivano-Frankivsk Regional Clinical Hospital,
      Ivano-Frankivsk, Ukraine; Dragana Milojkovic, Imperial College London at
      Hammersmith Hospital London; Laurence Reilly and Allison Jeynes-Ellis, Avillion, 
      London, United Kingdom; Philipp le Coutre, Charite-Universitatsmedizin Berlin,
      Berlin; Andreas Hochhaus, Klinik fur Innere Medizin II, Universitatsklinikum
      Jena, Jena; Tim H. Brummendorf, Universitatsklinikum RWTH Aachen, Aachen,
      Germany; Valentin Garcia-Gutierrez, Hospital Universitario Ramon y Cajal,
      Instituto Ramon y Cajal de Investigacion Sanitaria, Madrid, Spain; Eric Leip,
      Pfizer, Cambridge, MA; Nathalie Bardy-Bouxin, Pfizer International Operation,
      Paris, France.
FAU - Hochhaus, Andreas
AU  - Hochhaus A
AD  - Jorge E. Cortes, University of Texas MD Anderson Cancer Center, Houston, TX;
      Carlo Gambacorti-Passerini, University of Milano-Bicocca, Monza, Italy; Michael
      W. Deininger, University of Utah, Salt Lake City, UT; Michael J. Mauro, Memorial 
      Sloan Kettering Cancer Center, New York, NY; Charles Chuah, Singapore General
      Hospital, Duke-National University of Singapore Medical School, Singapore,
      Singapore; Dong-Wook Kim, Seoul St Mary's Hospital, The Catholic University of
      Korea, Seoul, South Korea; Irina Dyagil, National Research Center for Radiation
      Medicine, Kiev; Nataliia Glushko, Ivano-Frankivsk Regional Clinical Hospital,
      Ivano-Frankivsk, Ukraine; Dragana Milojkovic, Imperial College London at
      Hammersmith Hospital London; Laurence Reilly and Allison Jeynes-Ellis, Avillion, 
      London, United Kingdom; Philipp le Coutre, Charite-Universitatsmedizin Berlin,
      Berlin; Andreas Hochhaus, Klinik fur Innere Medizin II, Universitatsklinikum
      Jena, Jena; Tim H. Brummendorf, Universitatsklinikum RWTH Aachen, Aachen,
      Germany; Valentin Garcia-Gutierrez, Hospital Universitario Ramon y Cajal,
      Instituto Ramon y Cajal de Investigacion Sanitaria, Madrid, Spain; Eric Leip,
      Pfizer, Cambridge, MA; Nathalie Bardy-Bouxin, Pfizer International Operation,
      Paris, France.
FAU - Brummendorf, Tim H
AU  - Brummendorf TH
AD  - Jorge E. Cortes, University of Texas MD Anderson Cancer Center, Houston, TX;
      Carlo Gambacorti-Passerini, University of Milano-Bicocca, Monza, Italy; Michael
      W. Deininger, University of Utah, Salt Lake City, UT; Michael J. Mauro, Memorial 
      Sloan Kettering Cancer Center, New York, NY; Charles Chuah, Singapore General
      Hospital, Duke-National University of Singapore Medical School, Singapore,
      Singapore; Dong-Wook Kim, Seoul St Mary's Hospital, The Catholic University of
      Korea, Seoul, South Korea; Irina Dyagil, National Research Center for Radiation
      Medicine, Kiev; Nataliia Glushko, Ivano-Frankivsk Regional Clinical Hospital,
      Ivano-Frankivsk, Ukraine; Dragana Milojkovic, Imperial College London at
      Hammersmith Hospital London; Laurence Reilly and Allison Jeynes-Ellis, Avillion, 
      London, United Kingdom; Philipp le Coutre, Charite-Universitatsmedizin Berlin,
      Berlin; Andreas Hochhaus, Klinik fur Innere Medizin II, Universitatsklinikum
      Jena, Jena; Tim H. Brummendorf, Universitatsklinikum RWTH Aachen, Aachen,
      Germany; Valentin Garcia-Gutierrez, Hospital Universitario Ramon y Cajal,
      Instituto Ramon y Cajal de Investigacion Sanitaria, Madrid, Spain; Eric Leip,
      Pfizer, Cambridge, MA; Nathalie Bardy-Bouxin, Pfizer International Operation,
      Paris, France.
LA  - eng
PT  - Journal Article
DEP - 20171101
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of
      Clinical Oncology
JID - 8309333
EDAT- 2017/11/02 06:00
MHDA- 2017/11/02 06:00
CRDT- 2017/11/02 06:00
PHST- 2017/11/02 06:00 [pubmed]
PHST- 2017/11/02 06:00 [medline]
PHST- 2017/11/02 06:00 [entrez]
AID - 10.1200/JCO.2017.74.7162 [doi]
PST - ppublish
SO  - J Clin Oncol. 2018 Jan 20;36(3):231-237. doi: 10.1200/JCO.2017.74.7162. Epub 2017
      Nov 1.

PMID- 29058724
OWN - NLM
STAT- MEDLINE
DCOM- 20171218
LR  - 20171219
IS  - 1552-4469 (Electronic)
IS  - 1552-4450 (Linking)
VI  - 13
IP  - 12
DP  - 2017 Dec
TI  - A CRISPR screen identifies a pathway required for paraquat-induced cell death.
PG  - 1274-1279
LID - 10.1038/nchembio.2499 [doi]
AB  - Paraquat, a herbicide linked to Parkinson's disease, generates reactive oxygen
      species (ROS), which causes cell death. Because the source of paraquat-induced
      ROS production remains unknown, we conducted a CRISPR-based positive-selection
      screen to identify metabolic genes essential for paraquat-induced cell death. Our
      screen uncovered three genes, POR (cytochrome P450 oxidoreductase), ATP7A (copper
      transporter), and SLC45A4 (sucrose transporter), required for paraquat-induced
      cell death. Furthermore, our results revealed POR as the source of
      paraquat-induced ROS production. Thus, our study highlights the use of functional
      genomic screens for uncovering redox biology.
FAU - Reczek, Colleen R
AU  - Reczek CR
AD  - Department of Medicine, Northwestern University Feinberg School of Medicine,
      Chicago, Illinois, USA.
FAU - Birsoy, Kivanc
AU  - Birsoy K
AD  - Laboratory of Metabolic Regulation and Genetics, The Rockefeller University, New 
      York, New York, USA.
FAU - Kong, Hyewon
AU  - Kong H
AD  - Department of Medicine, Northwestern University Feinberg School of Medicine,
      Chicago, Illinois, USA.
FAU - Martinez-Reyes, Inmaculada
AU  - Martinez-Reyes I
AD  - Department of Medicine, Northwestern University Feinberg School of Medicine,
      Chicago, Illinois, USA.
FAU - Wang, Tim
AU  - Wang T
AD  - Whitehead Institute for Biomedical Research, Department of Biology, Massachusetts
      Institute of Technology, Cambridge, Massachusetts, USA.
AD  - Howard Hughes Medical Institute, Department of Biology, Massachusetts Institute
      of Technology, Cambridge, Massachusetts, USA.
AD  - Koch Institute for Integrative Cancer Research, Massachusetts Institute of
      Technology, Cambridge, Massachusetts, USA.
AD  - Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, 
      Massachusetts, USA.
FAU - Gao, Peng
AU  - Gao P
AD  - Metabolomics Core Facility, Northwestern University Robert H. Lurie Comprehensive
      Cancer Center, Chicago, Illinois, USA.
FAU - Sabatini, David M
AU  - Sabatini DM
AD  - Whitehead Institute for Biomedical Research, Department of Biology, Massachusetts
      Institute of Technology, Cambridge, Massachusetts, USA.
AD  - Howard Hughes Medical Institute, Department of Biology, Massachusetts Institute
      of Technology, Cambridge, Massachusetts, USA.
AD  - Koch Institute for Integrative Cancer Research, Massachusetts Institute of
      Technology, Cambridge, Massachusetts, USA.
AD  - Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, 
      Massachusetts, USA.
FAU - Chandel, Navdeep S
AU  - Chandel NS
AD  - Department of Medicine, Northwestern University Feinberg School of Medicine,
      Chicago, Illinois, USA.
LA  - eng
SI  - PubChem-Substance/342613938
SI  - PubChem-Substance/342613939
SI  - PubChem-Substance/342613940
SI  - PubChem-Substance/342613941
SI  - PubChem-Substance/342613942
GR  - K22 CA193660/CA/NCI NIH HHS/United States
GR  - T32 CA009560/CA/NCI NIH HHS/United States
GR  - P01 AG049665/AG/NIA NIH HHS/United States
GR  - R35 CA197532/CA/NCI NIH HHS/United States
GR  - T32 HL076139/HL/NHLBI NIH HHS/United States
PT  - Journal Article
DEP - 20171023
PL  - United States
TA  - Nat Chem Biol
JT  - Nature chemical biology
JID - 101231976
RN  - 0 (Reactive Oxygen Species)
RN  - PLG39H7695 (Paraquat)
SB  - IM
MH  - Cell Death/drug effects
MH  - Clustered Regularly Interspaced Short Palindromic Repeats/*drug effects/genetics
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Jurkat Cells
MH  - Molecular Structure
MH  - Oxidation-Reduction
MH  - Paraquat/chemistry/*pharmacology
MH  - Reactive Oxygen Species/metabolism
MH  - Structure-Activity Relationship
PMC - PMC5698099
MID - NIHMS907097
EDAT- 2017/10/24 06:00
MHDA- 2017/12/19 06:00
CRDT- 2017/10/24 06:00
PMCR- 2018/04/23 00:00
PHST- 2016/12/12 00:00 [received]
PHST- 2017/09/18 00:00 [accepted]
PHST- 2018/04/23 00:00 [pmc-release]
PHST- 2017/10/24 06:00 [pubmed]
PHST- 2017/12/19 06:00 [medline]
PHST- 2017/10/24 06:00 [entrez]
AID - nchembio.2499 [pii]
AID - 10.1038/nchembio.2499 [doi]
PST - ppublish
SO  - Nat Chem Biol. 2017 Dec;13(12):1274-1279. doi: 10.1038/nchembio.2499. Epub 2017
      Oct 23.

PMID- 29229813
OWN - NLM
STAT- In-Data-Review
LR  - 20180111
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Linking)
VI  - 114
IP  - 52
DP  - 2017 Dec 26
TI  - Human genetic variation alters CRISPR-Cas9 on- and off-targeting specificity at
      therapeutically implicated loci.
PG  - E11257-E11266
LID - 10.1073/pnas.1714640114 [doi]
AB  - The CRISPR-Cas9 nuclease system holds enormous potential for therapeutic genome
      editing of a wide spectrum of diseases. Large efforts have been made to further
      understanding of on- and off-target activity to assist the design of CRISPR-based
      therapies with optimized efficacy and safety. However, current efforts have
      largely focused on the reference genome or the genome of cell lines to evaluate
      guide RNA (gRNA) efficiency, safety, and toxicity. Here, we examine the effect of
      human genetic variation on both on- and off-target specificity. Specifically, we 
      utilize 7,444 whole-genome sequences to examine the effect of variants on the
      targeting specificity of approximately 3,000 gRNAs across 30 therapeutically
      implicated loci. We demonstrate that human genetic variation can alter the
      off-target landscape genome-wide including creating and destroying protospacer
      adjacent motifs (PAMs). Furthermore, single-nucleotide polymorphisms (SNPs) and
      insertions/deletions (indels) can result in altered on-target sites and novel
      potent off-target sites, which can predispose patients to treatment failure and
      adverse effects, respectively; however, these events are rare. Taken together,
      these data highlight the importance of considering individual genomes for
      therapeutic genome-editing applications for the design and evaluation of
      CRISPR-based therapies to minimize risk of treatment failure and/or adverse
      outcomes.
CI  - Copyright (c) 2017 the Author(s). Published by PNAS.
FAU - Lessard, Samuel
AU  - Lessard S
AD  - Research Center, Montreal Heart Institute, Montreal, QC H1T 1C8, Canada.
AD  - Department of Medicine, Faculty of Medicine, Universite de Montreal, Montreal, QC
      H3T 1J4, Canada.
FAU - Francioli, Laurent
AU  - Francioli L
AD  - Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston,
      MA 02114.
AD  - Program in Medical and Population Genetics, Broad Institute of Massachusetts
      Institute of Technology and Harvard, Cambridge, MA 02142.
FAU - Alfoldi, Jessica
AU  - Alfoldi J
AD  - Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston,
      MA 02114.
AD  - Program in Medical and Population Genetics, Broad Institute of Massachusetts
      Institute of Technology and Harvard, Cambridge, MA 02142.
FAU - Tardif, Jean-Claude
AU  - Tardif JC
AD  - Research Center, Montreal Heart Institute, Montreal, QC H1T 1C8, Canada.
AD  - Department of Medicine, Faculty of Medicine, Universite de Montreal, Montreal, QC
      H3T 1J4, Canada.
FAU - Ellinor, Patrick T
AU  - Ellinor PT
AD  - Program in Medical and Population Genetics, Broad Institute of Massachusetts
      Institute of Technology and Harvard, Cambridge, MA 02142.
AD  - Cardiovascular Research Center, Massachusetts General Hospital, Charlestown, MA
      02129.
FAU - MacArthur, Daniel G
AU  - MacArthur DG
AD  - Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston,
      MA 02114.
AD  - Program in Medical and Population Genetics, Broad Institute of Massachusetts
      Institute of Technology and Harvard, Cambridge, MA 02142.
FAU - Lettre, Guillaume
AU  - Lettre G
AD  - Research Center, Montreal Heart Institute, Montreal, QC H1T 1C8, Canada.
AD  - Department of Medicine, Faculty of Medicine, Universite de Montreal, Montreal, QC
      H3T 1J4, Canada.
FAU - Orkin, Stuart H
AU  - Orkin SH
AD  - Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115;
      stuart_orkin@dfci.harvard.edu matthew_canver@hms.harvard.edu.
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02115.
AD  - Harvard Stem Cell Institute, Harvard University, Cambridge, MA 02138.
AD  - Department of Pediatrics, Harvard Medical School, Boston, MA 02115.
AD  - Howard Hughes Medical Institute, Boston, MA 02115.
FAU - Canver, Matthew C
AU  - Canver MC
AD  - Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115;
      stuart_orkin@dfci.harvard.edu matthew_canver@hms.harvard.edu.
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02115.
AD  - Harvard Stem Cell Institute, Harvard University, Cambridge, MA 02138.
AD  - Department of Pediatrics, Harvard Medical School, Boston, MA 02115.
LA  - eng
GR  - F30 DK103359/DK/NIDDK NIH HHS/United States
GR  - P01 HL032262/HL/NHLBI NIH HHS/United States
GR  - P30 DK049216/DK/NIDDK NIH HHS/United States
PT  - Journal Article
DEP - 20171211
PL  - United States
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
PMC - PMC5748207
OTO - NOTNLM
OT  - CRISPR-Cas9
OT  - human genetic variation
OT  - off-target specificity
OT  - on-target specificity
OT  - therapeutic genome editing
COIS- The authors declare no conflict of interest.
EDAT- 2017/12/13 06:00
MHDA- 2017/12/13 06:00
CRDT- 2017/12/13 06:00
PHST- 2017/12/13 06:00 [pubmed]
PHST- 2017/12/13 06:00 [medline]
PHST- 2017/12/13 06:00 [entrez]
AID - 1714640114 [pii]
AID - 10.1073/pnas.1714640114 [doi]
PST - ppublish
SO  - Proc Natl Acad Sci U S A. 2017 Dec 26;114(52):E11257-E11266. doi:
      10.1073/pnas.1714640114. Epub 2017 Dec 11.

PMID- 29030545
OWN - NLM
STAT- In-Process
LR  - 20180108
IS  - 2041-1723 (Electronic)
IS  - 2041-1723 (Linking)
VI  - 8
IP  - 1
DP  - 2017 Oct 13
TI  - Fructose-1,6-bisphosphate couples glycolytic flux to activation of Ras.
PG  - 922
LID - 10.1038/s41467-017-01019-z [doi]
AB  - Yeast and cancer cells share the unusual characteristic of favoring fermentation 
      of sugar over respiration. We now reveal an evolutionary conserved mechanism
      linking fermentation to activation of Ras, a major regulator of cell
      proliferation in yeast and mammalian cells, and prime proto-oncogene product. A
      yeast mutant (tps1) with overactive influx of glucose into glycolysis and
      hyperaccumulation of Fru1,6bisP, shows hyperactivation of Ras, which causes its
      glucose growth defect by triggering apoptosis. Fru1,6bisP is a potent activator
      of Ras in permeabilized yeast cells, likely acting through Cdc25. As in yeast,
      glucose triggers activation of Ras and its downstream targets MEK and ERK in
      mammalian cells. Biolayer interferometry measurements show that physiological
      concentrations of Fru1,6bisP stimulate dissociation of the pure Sos1/H-Ras
      complex. Thermal shift assay confirms direct binding to Sos1, the mammalian
      ortholog of Cdc25. Our results suggest that the Warburg effect creates a vicious 
      cycle through Fru1,6bisP activation of Ras, by which enhanced fermentation
      stimulates oncogenic potency.Yeast and cancer cells both favor sugar fermentation
      in aerobic conditions. Here the authors describe a conserved mechanism from yeast
      to mammals where the glycolysis intermediate fructose-1,6-bisphosphate binds
      Cdc25/Sos1 and couples increased glycolytic flux to increased Ras
      proto-oncoprotein activity.
FAU - Peeters, Ken
AU  - Peeters K
AD  - Laboratory of Molecular Cell Biology, Institute of Botany and Microbiology, KU
      Leuven, Kasteelpark Arenberg 31, Leuven-Heverlee, Flanders, B-3001, Belgium.
AD  - Center for Microbiology, VIB, Kasteelpark Arenberg 31, Leuven-Heverlee, Flanders,
      B-3001, Belgium.
FAU - Van Leemputte, Frederik
AU  - Van Leemputte F
AD  - Laboratory of Molecular Cell Biology, Institute of Botany and Microbiology, KU
      Leuven, Kasteelpark Arenberg 31, Leuven-Heverlee, Flanders, B-3001, Belgium.
AD  - Center for Microbiology, VIB, Kasteelpark Arenberg 31, Leuven-Heverlee, Flanders,
      B-3001, Belgium.
FAU - Fischer, Baptiste
AU  - Fischer B
AUID- ORCID: 0000-0001-9620-921X
AD  - VIB-VUB Center for Structural Biology, Pleinlaan 2, Brussels, 1050, Belgium.
AD  - Structural Biology Brussels (SBB), Vrije Universiteit Brussel, Pleinlaan 2,
      Brussels, 1050, Belgium.
FAU - Bonini, Beatriz M
AU  - Bonini BM
AD  - Laboratory of Molecular Cell Biology, Institute of Botany and Microbiology, KU
      Leuven, Kasteelpark Arenberg 31, Leuven-Heverlee, Flanders, B-3001, Belgium.
AD  - Center for Microbiology, VIB, Kasteelpark Arenberg 31, Leuven-Heverlee, Flanders,
      B-3001, Belgium.
FAU - Quezada, Hector
AU  - Quezada H
AUID- ORCID: 0000-0003-2663-4696
AD  - Laboratory of Molecular Cell Biology, Institute of Botany and Microbiology, KU
      Leuven, Kasteelpark Arenberg 31, Leuven-Heverlee, Flanders, B-3001, Belgium.
AD  - Center for Microbiology, VIB, Kasteelpark Arenberg 31, Leuven-Heverlee, Flanders,
      B-3001, Belgium.
FAU - Tsytlonok, Maksym
AU  - Tsytlonok M
AD  - VIB-VUB Center for Structural Biology, Pleinlaan 2, Brussels, 1050, Belgium.
AD  - Structural Biology Brussels (SBB), Vrije Universiteit Brussel, Pleinlaan 2,
      Brussels, 1050, Belgium.
FAU - Haesen, Dorien
AU  - Haesen D
AD  - Laboratory of Protein Phosphorylation and Proteomics, Department of Cellular and 
      Molecular Medicine, KU Leuven, Gasthuisberg O&N1, Herestraat 49, Leuven, 3000,
      Belgium.
FAU - Vanthienen, Ward
AU  - Vanthienen W
AD  - Laboratory of Molecular Cell Biology, Institute of Botany and Microbiology, KU
      Leuven, Kasteelpark Arenberg 31, Leuven-Heverlee, Flanders, B-3001, Belgium.
AD  - Center for Microbiology, VIB, Kasteelpark Arenberg 31, Leuven-Heverlee, Flanders,
      B-3001, Belgium.
FAU - Bernardes, Nuno
AU  - Bernardes N
AUID- ORCID: 0000-0002-4495-6608
AD  - Laboratory of Molecular Cell Biology, Institute of Botany and Microbiology, KU
      Leuven, Kasteelpark Arenberg 31, Leuven-Heverlee, Flanders, B-3001, Belgium.
AD  - Center for Microbiology, VIB, Kasteelpark Arenberg 31, Leuven-Heverlee, Flanders,
      B-3001, Belgium.
FAU - Gonzalez-Blas, Carmen Bravo
AU  - Gonzalez-Blas CB
AUID- ORCID: 0000-0003-0973-9410
AD  - Laboratory of Molecular Cell Biology, Institute of Botany and Microbiology, KU
      Leuven, Kasteelpark Arenberg 31, Leuven-Heverlee, Flanders, B-3001, Belgium.
AD  - Center for Microbiology, VIB, Kasteelpark Arenberg 31, Leuven-Heverlee, Flanders,
      B-3001, Belgium.
FAU - Janssens, Veerle
AU  - Janssens V
AUID- ORCID: 0000-0002-6772-8448
AD  - Laboratory of Protein Phosphorylation and Proteomics, Department of Cellular and 
      Molecular Medicine, KU Leuven, Gasthuisberg O&N1, Herestraat 49, Leuven, 3000,
      Belgium.
FAU - Tompa, Peter
AU  - Tompa P
AD  - VIB-VUB Center for Structural Biology, Pleinlaan 2, Brussels, 1050, Belgium.
AD  - Structural Biology Brussels (SBB), Vrije Universiteit Brussel, Pleinlaan 2,
      Brussels, 1050, Belgium.
FAU - Versees, Wim
AU  - Versees W
AD  - VIB-VUB Center for Structural Biology, Pleinlaan 2, Brussels, 1050, Belgium.
AD  - Structural Biology Brussels (SBB), Vrije Universiteit Brussel, Pleinlaan 2,
      Brussels, 1050, Belgium.
FAU - Thevelein, Johan M
AU  - Thevelein JM
AUID- ORCID: 0000-0002-2626-0180
AD  - Laboratory of Molecular Cell Biology, Institute of Botany and Microbiology, KU
      Leuven, Kasteelpark Arenberg 31, Leuven-Heverlee, Flanders, B-3001, Belgium.
      johan.thevelein@kuleuven.vib.be.
AD  - Center for Microbiology, VIB, Kasteelpark Arenberg 31, Leuven-Heverlee, Flanders,
      B-3001, Belgium. johan.thevelein@kuleuven.vib.be.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20171013
PL  - England
TA  - Nat Commun
JT  - Nature communications
JID - 101528555
PMC - PMC5640605
EDAT- 2017/10/17 06:00
MHDA- 2017/10/17 06:00
CRDT- 2017/10/15 06:00
PHST- 2016/07/07 00:00 [received]
PHST- 2017/08/14 00:00 [accepted]
PHST- 2017/10/15 06:00 [entrez]
PHST- 2017/10/17 06:00 [pubmed]
PHST- 2017/10/17 06:00 [medline]
AID - 10.1038/s41467-017-01019-z [doi]
AID - 10.1038/s41467-017-01019-z [pii]
PST - epublish
SO  - Nat Commun. 2017 Oct 13;8(1):922. doi: 10.1038/s41467-017-01019-z.

PMID- 29342381
OWN - NLM
STAT- MEDLINE
DCOM- 20180124
LR  - 20180124
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 378
IP  - 3
DP  - 2018 Jan 18
TI  - Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance.
PG  - 241-249
LID - 10.1056/NEJMoa1709974 [doi]
AB  - BACKGROUND: Monoclonal gammopathy of undetermined significance (MGUS) occurs in
      approximately 3% of persons 50 years of age or older. METHODS: We studied 1384
      patients who were residing in southeastern Minnesota and in whom MGUS was
      diagnosed at the Mayo Clinic in the period from 1960 through 1994; the median
      follow-up was 34.1 years (range, 0.0 to 43.6). The primary end point was
      progression to multiple myeloma or another plasma-cell or lymphoid disorder.
      RESULTS: During 14,130 person-years of follow-up, MGUS progressed in 147 patients
      (11%), a rate that was 6.5 times (95% confidence interval [CI], 5.5 to 7.7) as
      high as the rate in the control population. The risk of progression without
      accounting for death due to competing causes was 10% at 10 years, 18% at 20
      years, 28% at 30 years, 36% at 35 years, and 36% at 40 years. Among patients with
      IgM MGUS, the presence of two adverse risk factors - namely, an abnormal serum
      free light-chain ratio (ratio of kappa to lambda free light chains) and a high
      serum monoclonal protein (M protein) level (>/=1.5 g per deciliter) - was
      associated with a risk of progression at 20 years of 55%, as compared with 41%
      among patients who had one adverse risk factor and 19% among patients who had
      neither risk factor. Among patients with non-IgM MGUS, the risk of progression at
      20 years was 30% among those who had the two risk factors, 20% among those who
      had one risk factor, and 7% among those who had neither risk factor. Patients
      with MGUS had shorter survival than was expected in the control population of
      Minnesota residents of matched age and sex (median, 8.1 vs. 12.4 years; P<0.001).
      CONCLUSIONS: Significant differences were noted in the risk of progression
      between patients with IgM MGUS and those with non-IgM MGUS. Overall survival was 
      shorter among patients with MGUS than was expected in a matched control
      population. (Funded by the National Cancer Institute.).
FAU - Kyle, Robert A
AU  - Kyle RA
AD  - From the Divisions of Hematology (R.A.K., A.D., S.K., S.V.R.), Biostatistics
      (D.R.L., T.M.T.), and Epidemiology (J.R.C.), Mayo Clinic, Rochester, MN.
FAU - Larson, Dirk R
AU  - Larson DR
AD  - From the Divisions of Hematology (R.A.K., A.D., S.K., S.V.R.), Biostatistics
      (D.R.L., T.M.T.), and Epidemiology (J.R.C.), Mayo Clinic, Rochester, MN.
FAU - Therneau, Terry M
AU  - Therneau TM
AD  - From the Divisions of Hematology (R.A.K., A.D., S.K., S.V.R.), Biostatistics
      (D.R.L., T.M.T.), and Epidemiology (J.R.C.), Mayo Clinic, Rochester, MN.
FAU - Dispenzieri, Angela
AU  - Dispenzieri A
AD  - From the Divisions of Hematology (R.A.K., A.D., S.K., S.V.R.), Biostatistics
      (D.R.L., T.M.T.), and Epidemiology (J.R.C.), Mayo Clinic, Rochester, MN.
FAU - Kumar, Shaji
AU  - Kumar S
AD  - From the Divisions of Hematology (R.A.K., A.D., S.K., S.V.R.), Biostatistics
      (D.R.L., T.M.T.), and Epidemiology (J.R.C.), Mayo Clinic, Rochester, MN.
FAU - Cerhan, James R
AU  - Cerhan JR
AD  - From the Divisions of Hematology (R.A.K., A.D., S.K., S.V.R.), Biostatistics
      (D.R.L., T.M.T.), and Epidemiology (J.R.C.), Mayo Clinic, Rochester, MN.
FAU - Rajkumar, S Vincent
AU  - Rajkumar SV
AD  - From the Divisions of Hematology (R.A.K., A.D., S.K., S.V.R.), Biostatistics
      (D.R.L., T.M.T.), and Epidemiology (J.R.C.), Mayo Clinic, Rochester, MN.
LA  - eng
GR  - R01 CA107476/CA/NCI NIH HHS/United States
GR  - R01 CA168762/CA/NCI NIH HHS/United States
GR  - P50 CA186781/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Glycoproteins)
RN  - 0 (Immunoglobulin Light Chains)
RN  - 0 (Immunoglobulin M)
RN  - 0 (protein M (glycoprotein))
SB  - AIM
SB  - IM
MH  - Adult
MH  - Aged
MH  - Bone Marrow Examination
MH  - *Disease Progression
MH  - Female
MH  - Follow-Up Studies
MH  - Glycoproteins/blood
MH  - Humans
MH  - Immunoglobulin Light Chains/blood
MH  - Immunoglobulin M/blood
MH  - Male
MH  - Middle Aged
MH  - Monoclonal Gammopathy of Undetermined
      Significance/*complications/mortality/pathology
MH  - Multiple Myeloma/etiology
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Risk Factors
EDAT- 2018/01/18 06:00
MHDA- 2018/01/25 06:00
CRDT- 2018/01/18 06:00
PHST- 2018/01/18 06:00 [entrez]
PHST- 2018/01/18 06:00 [pubmed]
PHST- 2018/01/25 06:00 [medline]
AID - 10.1056/NEJMoa1709974 [doi]
PST - ppublish
SO  - N Engl J Med. 2018 Jan 18;378(3):241-249. doi: 10.1056/NEJMoa1709974.

PMID- 29262275
OWN - NLM
STAT- MEDLINE
DCOM- 20180108
LR  - 20180108
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 377
IP  - 25
DP  - 2017 Dec 21
TI  - Tumor Mutational Burden and Response Rate to PD-1 Inhibition.
PG  - 2500-2501
LID - 10.1056/NEJMc1713444 [doi]
FAU - Yarchoan, Mark
AU  - Yarchoan M
AD  - Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
      ejaffee@jhmi.edu.
FAU - Hopkins, Alexander
AU  - Hopkins A
AD  - Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
      ejaffee@jhmi.edu.
FAU - Jaffee, Elizabeth M
AU  - Jaffee EM
AD  - Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
      ejaffee@jhmi.edu.
LA  - eng
PT  - Letter
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Antineoplastic Agents)
RN  - 0 (B7-H1 Antigen)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CD274 protein, human)
RN  - 0 (PDCD1 protein, human)
RN  - 0 (Programmed Cell Death 1 Receptor)
SB  - AIM
SB  - IM
MH  - Antineoplastic Agents/therapeutic use
MH  - B7-H1 Antigen/*antagonists & inhibitors
MH  - Biomarkers, Tumor
MH  - DNA Mutational Analysis
MH  - Humans
MH  - Models, Genetic
MH  - *Mutation
MH  - Neoplasms/drug therapy/*genetics
MH  - Programmed Cell Death 1 Receptor/*antagonists & inhibitors
EDAT- 2017/12/21 06:00
MHDA- 2018/01/09 06:00
CRDT- 2017/12/21 06:00
PHST- 2017/12/21 06:00 [entrez]
PHST- 2017/12/21 06:00 [pubmed]
PHST- 2018/01/09 06:00 [medline]
AID - 10.1056/NEJMc1713444 [doi]
PST - ppublish
SO  - N Engl J Med. 2017 Dec 21;377(25):2500-2501. doi: 10.1056/NEJMc1713444.

PMID- 29126267
OWN - NLM
STAT- In-Process
LR  - 20171211
IS  - 1574-6941 (Electronic)
IS  - 0168-6496 (Linking)
VI  - 93
IP  - 12
DP  - 2017 Dec 1
TI  - Identification of universal gut microbial biomarkers of common human intestinal
      diseases by meta-analysis.
LID - 10.1093/femsec/fix153 [doi]
AB  - Intestinal diseases, such as Crohn's disease (CD), ulcerative colitis (UC) and
      pseudomembranous colitis (CDI), are among the most common diseases in humans and 
      may lead to more serious pathologies, e.g. colorectal cancer (CRC). Next
      generation sequencing has in recent years allowed the identification of
      correlations between intestinal bacteria and diseases, although the formulation
      of universal gut microbial biomarkers for such diseases is only in its infancy.
      In the current study, we selected and reanalyzed a total of 3048 public datasets 
      obtained from 16S rRNA profiling of individuals affected by CD, UC, CDI and CRC. 
      This meta-analysis revealed possible biases in the reconstruction of the gut
      microbiota composition due to the use of different primer pairs employed for PCR 
      of 16S rRNA gene fragments. Notably, this approach also identified common
      features of individuals affected by gut diseases (DS), including lower
      biodiversity compared to control subjects. Moreover, potential universal
      intestinal disease microbial biomarkers were identified through cross-disease
      comparisons. In detail, CTRL showed high abundance of the genera Barnesiella,
      Ruminococcaceae UCG-005, Alistipes, Christensenellaceae R-7 group and
      unclassified member of Lachnospiraceae family, while DS exhibited high abundance 
      of Lactobacillus, unclassified member of Erysipelotrichaceae family and
      Streptococcus genera.
CI  - (c) FEMS 2017. All rights reserved. For permissions, please e-mail:
      journals.permissions@oup.com.
FAU - Mancabelli, Leonardo
AU  - Mancabelli L
AD  - Laboratory of Probiogenomics, Department of Chemistry, Life Sciences and
      Environmental Sustainability, University of Parma, Parma, Italy.
FAU - Milani, Christian
AU  - Milani C
AD  - Laboratory of Probiogenomics, Department of Chemistry, Life Sciences and
      Environmental Sustainability, University of Parma, Parma, Italy.
FAU - Lugli, Gabriele Andrea
AU  - Lugli GA
AD  - Laboratory of Probiogenomics, Department of Chemistry, Life Sciences and
      Environmental Sustainability, University of Parma, Parma, Italy.
FAU - Turroni, Francesca
AU  - Turroni F
AD  - Laboratory of Probiogenomics, Department of Chemistry, Life Sciences and
      Environmental Sustainability, University of Parma, Parma, Italy.
FAU - Cocconi, Deborah
AU  - Cocconi D
AD  - Laboratory of Probiogenomics, Department of Chemistry, Life Sciences and
      Environmental Sustainability, University of Parma, Parma, Italy.
FAU - van Sinderen, Douwe
AU  - van Sinderen D
AD  - Microbiome Research Hub, University of Parma, Parma, Italy.
FAU - Ventura, Marco
AU  - Ventura M
AD  - Laboratory of Probiogenomics, Department of Chemistry, Life Sciences and
      Environmental Sustainability, University of Parma, Parma, Italy.
LA  - eng
PT  - Journal Article
PL  - England
TA  - FEMS Microbiol Ecol
JT  - FEMS microbiology ecology
JID - 8901229
OTO - NOTNLM
OT  - gut diseases
OT  - metagenomics
OT  - microbial biomarkers
OT  - microbiome
OT  - microbiota
EDAT- 2017/11/11 06:00
MHDA- 2017/11/11 06:00
CRDT- 2017/11/11 06:00
PHST- 2017/08/04 00:00 [received]
PHST- 2017/11/07 00:00 [accepted]
PHST- 2017/11/11 06:00 [pubmed]
PHST- 2017/11/11 06:00 [medline]
PHST- 2017/11/11 06:00 [entrez]
AID - 4604777 [pii]
AID - 10.1093/femsec/fix153 [doi]
PST - ppublish
SO  - FEMS Microbiol Ecol. 2017 Dec 1;93(12). pii: 4604777. doi: 10.1093/femsec/fix153.

PMID- 29320654
OWN - NLM
STAT- MEDLINE
DCOM- 20180118
LR  - 20180118
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 378
IP  - 2
DP  - 2018 Jan 11
TI  - Immune-Related Adverse Events Associated with Immune Checkpoint Blockade.
PG  - 158-168
LID - 10.1056/NEJMra1703481 [doi]
FAU - Postow, Michael A
AU  - Postow MA
AD  - From Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College,
      New York.
FAU - Sidlow, Robert
AU  - Sidlow R
AD  - From Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College,
      New York.
FAU - Hellmann, Matthew D
AU  - Hellmann MD
AD  - From Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College,
      New York.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - 0 (Immunosuppressive Agents)
SB  - AIM
SB  - IM
MH  - Antibodies, Monoclonal/adverse effects
MH  - Antineoplastic Agents, Immunological/*adverse effects
MH  - Cell Cycle Checkpoints/*immunology
MH  - Humans
MH  - Immunosuppressive Agents/adverse effects
MH  - Immunotherapy/*adverse effects/methods
MH  - Neoplasms/drug therapy/immunology
MH  - T-Lymphocytes/physiology
EDAT- 2018/01/11 06:00
MHDA- 2018/01/19 06:00
CRDT- 2018/01/11 06:00
PHST- 2018/01/11 06:00 [entrez]
PHST- 2018/01/11 06:00 [pubmed]
PHST- 2018/01/19 06:00 [medline]
AID - 10.1056/NEJMra1703481 [doi]
PST - ppublish
SO  - N Engl J Med. 2018 Jan 11;378(2):158-168. doi: 10.1056/NEJMra1703481.

PMID- 29155442
OWN - NLM
STAT- Publisher
LR  - 20171228
IS  - 1749-6632 (Electronic)
IS  - 0077-8923 (Linking)
DP  - 2017 Nov 20
TI  - Safety of folic acid.
LID - 10.1111/nyas.13499 [doi]
AB  - There is a large body of literature demonstrating the efficacy of maternal folic 
      acid intake in preventing birth defects, as well as investigations into potential
      adverse consequences of consuming folic acid above the upper intake level (UL).
      Recently, two authoritative bodies convened expert panels to assess risks from
      high intakes of folic acid: the U.S. National Toxicology Program and the UK
      Scientific Advisory Committee on Nutrition. Overall, the totality of the evidence
      examined by these panels, as well as studies published since the release of their
      reports, have not established risks for adverse consequences resulting from
      existing mandatory folic acid fortification programs that have been implemented
      in many countries. Current folic acid fortification programs have been shown to
      support public health in populations, and the exposure levels are informed by and
      adherent to the precautionary principle. Additional research is needed to assess 
      the health effects of folic acid supplement use when the current upper limit for 
      folic acid is exceeded.
CI  - (c) 2017 The Authors. Annals of the New York Academy of Sciences published by
      Wiley Periodicals, Inc. on behalf of New York Academy of Sciences.
FAU - Field, Martha S
AU  - Field MS
AD  - Division of Nutritional Sciences, Cornell University, Ithaca, New York.
FAU - Stover, Patrick J
AU  - Stover PJ
AD  - Division of Nutritional Sciences, Cornell University, Ithaca, New York.
LA  - eng
GR  - R01 HD059120/HD/NICHD NIH HHS/United States
GR  - R37 DK058144/DK/NIDDK NIH HHS/United States
PT  - Journal Article
DEP - 20171120
PL  - United States
TA  - Ann N Y Acad Sci
JT  - Annals of the New York Academy of Sciences
JID - 7506858
OTO - NOTNLM
OT  - cancer
OT  - folate
OT  - folic acid
OT  - neural tube defects
OT  - safety
EDAT- 2017/11/21 06:00
MHDA- 2017/11/21 06:00
CRDT- 2017/11/21 06:00
PHST- 2017/07/13 00:00 [received]
PHST- 2017/08/24 00:00 [revised]
PHST- 2017/08/30 00:00 [accepted]
PHST- 2017/11/21 06:00 [entrez]
PHST- 2017/11/21 06:00 [pubmed]
PHST- 2017/11/21 06:00 [medline]
AID - 10.1111/nyas.13499 [doi]
PST - aheadofprint
SO  - Ann N Y Acad Sci. 2017 Nov 20. doi: 10.1111/nyas.13499.

PMID- 29045906
OWN - NLM
STAT- MEDLINE
DCOM- 20171106
LR  - 20171219
IS  - 1097-4180 (Electronic)
IS  - 1074-7613 (Linking)
VI  - 47
IP  - 4
DP  - 2017 Oct 17
TI  - CTLA-4(+)PD-1(-) Memory CD4(+) T Cells Critically Contribute to Viral Persistence
      in Antiretroviral Therapy-Suppressed, SIV-Infected Rhesus Macaques.
PG  - 776-788.e5
LID - S1074-7613(17)30429-6 [pii]
LID - 10.1016/j.immuni.2017.09.018 [doi]
AB  - Antiretroviral therapy (ART) suppresses viral replication in HIV-infected
      individuals but does not eliminate the reservoir of latently infected cells.
      Recent work identified PD-1(+) follicular helper T (Tfh) cells as an important
      cellular compartment for viral persistence. Here, using ART-treated, SIV-infected
      rhesus macaques, we show that CTLA-4(+)PD-1(-) memory CD4(+) T cells, which share
      phenotypic markers with regulatory T cells, were enriched in SIV DNA in blood,
      lymph nodes (LN), spleen, and gut, and contained replication-competent and
      infectious virus. In contrast to PD-1(+) Tfh cells, SIV-enriched CTLA-4(+)PD-1(-)
      CD4(+) T cells were found outside the B cell follicle of the LN, predicted the
      size of the persistent viral reservoir during ART, and significantly increased
      their contribution to the SIV reservoir with prolonged ART-mediated viral
      suppression. We have shown that CTLA-4(+)PD-1(-) memory CD4(+) T cells are a
      previously unrecognized component of the SIV and HIV reservoir that should be
      therapeutically targeted for a functional HIV-1 cure.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - McGary, Colleen S
AU  - McGary CS
AD  - Division of Microbiology and Immunology, Yerkes National Primate Research Center,
      Emory University, Atlanta, GA 30329, USA.
FAU - Deleage, Claire
AU  - Deleage C
AD  - AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research,
      Leidos Biomedical Research, Inc., Frederick, MD 21702, USA.
FAU - Harper, Justin
AU  - Harper J
AD  - Division of Microbiology and Immunology, Yerkes National Primate Research Center,
      Emory University, Atlanta, GA 30329, USA.
FAU - Micci, Luca
AU  - Micci L
AD  - Division of Microbiology and Immunology, Yerkes National Primate Research Center,
      Emory University, Atlanta, GA 30329, USA.
FAU - Ribeiro, Susan P
AU  - Ribeiro SP
AD  - Department of Pathology, Case Western Reserve University, Cleveland, OH 44106,
      USA.
FAU - Paganini, Sara
AU  - Paganini S
AD  - Division of Microbiology and Immunology, Yerkes National Primate Research Center,
      Emory University, Atlanta, GA 30329, USA.
FAU - Kuri-Cervantes, Leticia
AU  - Kuri-Cervantes L
AD  - Department of Pathology, Case Western Reserve University, Cleveland, OH 44106,
      USA.
FAU - Benne, Clarisse
AU  - Benne C
AD  - Department of Pathology, Case Western Reserve University, Cleveland, OH 44106,
      USA.
FAU - Ryan, Emily S
AU  - Ryan ES
AD  - Division of Microbiology and Immunology, Yerkes National Primate Research Center,
      Emory University, Atlanta, GA 30329, USA.
FAU - Balderas, Robert
AU  - Balderas R
AD  - Becton Dickinson Immunosciences, San Jose, CA 95131, USA.
FAU - Jean, Sherrie
AU  - Jean S
AD  - Division of Microbiology and Immunology, Yerkes National Primate Research Center,
      Emory University, Atlanta, GA 30329, USA.
FAU - Easley, Kirk
AU  - Easley K
AD  - Department of Biostatistics and Bioinformatics, Rollins School of Public Health, 
      Atlanta, GA 30329, USA.
FAU - Marconi, Vincent
AU  - Marconi V
AD  - Division of Microbiology and Immunology, Yerkes National Primate Research Center,
      Emory University, Atlanta, GA 30329, USA; Department of Medicine, Emory
      University School of Medicine, Atlanta, GA 30329, USA.
FAU - Silvestri, Guido
AU  - Silvestri G
AD  - Division of Microbiology and Immunology, Yerkes National Primate Research Center,
      Emory University, Atlanta, GA 30329, USA; Department of Medicine, Emory
      University School of Medicine, Atlanta, GA 30329, USA.
FAU - Estes, Jacob D
AU  - Estes JD
AD  - AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research,
      Leidos Biomedical Research, Inc., Frederick, MD 21702, USA.
FAU - Sekaly, Rafick-Pierre
AU  - Sekaly RP
AD  - Department of Pathology, Case Western Reserve University, Cleveland, OH 44106,
      USA.
FAU - Paiardini, Mirko
AU  - Paiardini M
AD  - Division of Microbiology and Immunology, Yerkes National Primate Research Center,
      Emory University, Atlanta, GA 30329, USA; Department of Medicine, Emory
      University School of Medicine, Atlanta, GA 30329, USA. Electronic address:
      mirko.paiardini@emory.edu.
LA  - eng
GR  - P30 AI050409/AI/NIAID NIH HHS/United States
GR  - R01 AI116379/AI/NIAID NIH HHS/United States
GR  - P51 OD011132/OD/NIH HHS/United States
GR  - R33 AI116171/AI/NIAID NIH HHS/United States
GR  - HHSN261200800001C/RC/CCR NIH HHS/United States
GR  - R33 AI104278/AI/NIAID NIH HHS/United States
GR  - R01 AI110334/AI/NIAID NIH HHS/United States
GR  - HHSN261200800001E/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Immunity
JT  - Immunity
JID - 9432918
RN  - 0 (Anti-Retroviral Agents)
RN  - 0 (CTLA-4 Antigen)
RN  - 0 (Programmed Cell Death 1 Receptor)
SB  - IM
MH  - Animals
MH  - Anti-Retroviral Agents/*therapeutic use
MH  - CD4-Positive T-Lymphocytes/*drug effects/immunology/virology
MH  - CTLA-4 Antigen/*immunology/metabolism
MH  - HIV Infections/drug therapy/immunology/virology
MH  - HIV-1/drug effects/immunology/physiology
MH  - Host-Pathogen Interactions/drug effects/immunology
MH  - Humans
MH  - Immunologic Memory/drug effects/immunology
MH  - In Situ Hybridization
MH  - Lymph Nodes/drug effects/immunology/virology
MH  - Macaca mulatta
MH  - Microscopy, Confocal
MH  - Programmed Cell Death 1 Receptor/*immunology/metabolism
MH  - Simian Acquired Immunodeficiency Syndrome/*drug therapy/immunology/virology
MH  - Simian Immunodeficiency Virus/*drug effects/immunology/physiology
MH  - T-Lymphocytes, Helper-Inducer/drug effects/immunology/virology
MH  - T-Lymphocytes, Regulatory/drug effects/immunology/virology
PMC - PMC5679306
MID - NIHMS909903
OTO - NOTNLM
OT  - CTLA-4
OT  - HIV
OT  - PD-1
OT  - SIV
OT  - T follicular helper cells
OT  - animal models
OT  - co-inhibitory receptors
OT  - latent viral reservoir
OT  - regulatory T cells
EDAT- 2017/10/19 06:00
MHDA- 2017/11/07 06:00
CRDT- 2017/10/19 06:00
PMCR- 2018/10/17 00:00
PHST- 2017/01/15 00:00 [received]
PHST- 2017/06/13 00:00 [revised]
PHST- 2017/09/27 00:00 [accepted]
PHST- 2018/10/17 00:00 [pmc-release]
PHST- 2017/10/19 06:00 [entrez]
PHST- 2017/10/19 06:00 [pubmed]
PHST- 2017/11/07 06:00 [medline]
AID - S1074-7613(17)30429-6 [pii]
AID - 10.1016/j.immuni.2017.09.018 [doi]
PST - ppublish
SO  - Immunity. 2017 Oct 17;47(4):776-788.e5. doi: 10.1016/j.immuni.2017.09.018.

PMID- 29334719
OWN - NLM
STAT- In-Process
LR  - 20180115
IS  - 0253-9624 (Print)
IS  - 0253-9624 (Linking)
VI  - 52
IP  - 1
DP  - 2018 Jan 6
TI  - [Human papillomavirus infection and vaccination].
PG  - 106-112
LID - 10.3760/cma.j.issn.0253-9624.2018.01.021 [doi]
AB  - Human papillomavirus (HPV) is an infection that can be sexually transmitted and
      result in health consequences. Persistent high-risk HPV infection can lead to
      various cancers and is the essential cause of cervical cancer. HPV vaccine can
      prevent the HPV infection and thus the incidence of cervical cancer. In this
      review we introduced the prevalence of HPV infection and vaccination, and the
      prevention and early detection of cervical cancer. We also introduced the present
      knowledge and awareness of HPV infection and HPV vaccine in Chinese. Propaganda
      all over China should be performed on HPV vaccination to improve the vaccination 
      rate, thus preventing the incidence of cervical cancer.
FAU - He, Z H
AU  - He ZH
AD  - Department of Obstetrics & Gynaecology, The First Affiliated Hospital of
      Guangzhou Medical University, Guangzhou, 510120, China.
FAU - Kou, Z Q
AU  - Kou ZQ
FAU - Xu, A Q
AU  - Xu AQ
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhonghua Yu Fang Yi Xue Za Zhi
JT  - Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
JID - 7904962
OTO - NOTNLM
OT  - Human papillomavirus
OT  - Immunity
OT  - Knowledge and awareness
OT  - Papillomavirus vaccines
EDAT- 2018/01/16 06:00
MHDA- 2018/01/16 06:00
CRDT- 2018/01/16 06:00
PHST- 2018/01/16 06:00 [entrez]
PHST- 2018/01/16 06:00 [pubmed]
PHST- 2018/01/16 06:00 [medline]
PST - ppublish
SO  - Zhonghua Yu Fang Yi Xue Za Zhi. 2018 Jan 6;52(1):106-112.

PMID- 29038338
OWN - NLM
STAT- In-Data-Review
LR  - 20180125
IS  - 1528-0020 (Electronic)
IS  - 0006-4971 (Linking)
VI  - 131
IP  - 1
DP  - 2018 Jan 4
TI  - Infectious complications of CD19-targeted chimeric antigen receptor-modified
      T-cell immunotherapy.
PG  - 121-130
LID - 10.1182/blood-2017-07-793760 [doi]
AB  - Lymphodepletion chemotherapy with CD19-targeted chimeric antigen
      receptor-modified T (CAR-T)-cell immunotherapy is a novel treatment for
      refractory or relapsed B-cell malignancies. Infectious complications of this
      approach have not been systematically studied. We evaluated infections occurring 
      between days 0 to 90 in 133 patients treated with CD19 CAR-T cells in a phase 1/2
      study. We used Poisson and Cox regression to evaluate pre- and posttreatment risk
      factors for infection, respectively. The cohort included patients with acute
      lymphoblastic leukemia (ALL; n = 47), chronic lymphocytic leukemia (n = 24), and 
      non-Hodgkin lymphoma (n = 62). There were 43 infections in 30 of 133 patients
      (23%) within 28 days after CAR-T-cell infusion with an infection density of 1.19 
      infections for every 100 days at risk. There was a lower infection density of
      0.67 between days 29 and 90 (P = .02). The first infection occurred a median of 6
      days after CAR-T-cell infusion. Six patients (5%) developed invasive fungal
      infections and 5 patients (4%) had life-threatening or fatal infections. Patients
      with ALL, >/=4 prior antitumor regimens, and receipt of the highest CAR-T-cell
      dose (2 x 10(7) cells per kg) had a higher infection density within 28 days in an
      adjusted model of baseline characteristics. Cytokine release syndrome (CRS)
      severity was the only factor after CAR-T-cell infusion associated with infection 
      in a multivariable analysis. The incidence of infections was comparable to
      observations from clinical trials of salvage chemoimmunotherapies in similar
      patients. This trial was registered at www.clinicaltrials.gov as #NCT01865617.
CI  - (c) 2018 by The American Society of Hematology.
FAU - Hill, Joshua A
AU  - Hill JA
AD  - Department of Medicine, University of Washington, Seattle, WA.
AD  - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, 
      Seattle, WA.
FAU - Li, Daniel
AU  - Li D
AD  - Juno Therapeutics, Seattle, WA.
FAU - Hay, Kevin A
AU  - Hay KA
AD  - Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
AD  - Department of Medicine, University of British Columbia, Vancouver, BC, Canada;
      and.
FAU - Green, Margaret L
AU  - Green ML
AD  - Department of Medicine, University of Washington, Seattle, WA.
AD  - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, 
      Seattle, WA.
FAU - Cherian, Sindhu
AU  - Cherian S
AD  - Department of Laboratory Medicine, University of Washington, Seattle, WA.
FAU - Chen, Xueyan
AU  - Chen X
AD  - Department of Laboratory Medicine, University of Washington, Seattle, WA.
FAU - Riddell, Stanley R
AU  - Riddell SR
AD  - Department of Medicine, University of Washington, Seattle, WA.
AD  - Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
FAU - Maloney, David G
AU  - Maloney DG
AD  - Department of Medicine, University of Washington, Seattle, WA.
AD  - Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
FAU - Boeckh, Michael
AU  - Boeckh M
AD  - Department of Medicine, University of Washington, Seattle, WA.
AD  - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, 
      Seattle, WA.
FAU - Turtle, Cameron J
AU  - Turtle CJ
AD  - Department of Medicine, University of Washington, Seattle, WA.
AD  - Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
LA  - eng
GR  - K23 AI119133/AI/NIAID NIH HHS/United States
GR  - R01 CA136551/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20171016
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
PMC - PMC5755046
EDAT- 2017/10/19 06:00
MHDA- 2017/10/19 06:00
CRDT- 2017/10/18 06:00
PMCR- 2019/01/04 00:00
PHST- 2017/07/13 00:00 [received]
PHST- 2017/10/08 00:00 [accepted]
PHST- 2019/01/04 00:00 [pmc-release]
PHST- 2017/10/19 06:00 [pubmed]
PHST- 2017/10/19 06:00 [medline]
PHST- 2017/10/18 06:00 [entrez]
AID - blood-2017-07-793760 [pii]
AID - 10.1182/blood-2017-07-793760 [doi]
PST - ppublish
SO  - Blood. 2018 Jan 4;131(1):121-130. doi: 10.1182/blood-2017-07-793760. Epub 2017
      Oct 16.

PMID- 29228199
OWN - NLM
STAT- Publisher
LR  - 20171211
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
DP  - 2017 Dec 7
TI  - New neoplasm during GH replacement in adults with pituitary deficiency following 
      malignancy- a KIMS analysis.
LID - 10.1210/jc.2017-01899 [doi]
AB  - Context: Data on the association between growth hormone (GH) replacement in
      patients with GH deficiency (GHD) after malignancies and new neoplasms show
      conflicting results. Objective: To clarify the incidence of new malignant
      neoplasm in childhood (CO) and adult-onset (AO) adult cancer survivors (CS).
      Design: Retrospective comparison of CO-CS and AO-CS with CO idiopathic GHD (IGHD)
      and AO non-functioning pituitary adenoma patients (NFPA) and with the general
      population (standardized incidence ratio, SIR). Setting: Data from KIMS study
      (Pfizer International Metabolic Database). Patients: CO-CS (n=349; 50.4% females,
      mean baseline (MBL) IGF-I SDS -2.4) and IGHD (n=619; 35.7% females, MBL IGF-I SDS
      -3.4) as well as AO-CS (n=174; 42.5% females, MBL IGF-I SDS -1.4) and NFPA
      (n=2449; 38.1% females, MBL IGF-I SDS -1.0). Main Outcome Measures: SIRs of
      malignant neoplasms. Results: After a median follow-up of 5.9 years (2192
      patient-years), 15 CO-CS (4.3%) had developed 16 new neoplasms. The SIR was 10.4 
      (95%CI, 5.9-16.9) and 6.5 (95%CI, 3.0-12.4) after exclusion of 7 patients with
      skin cancers. In IGHD three malignant neoplasms (0.5%) were observed after a
      median follow-up of 5.4 years (3908 patient-years, SIR 0.47, 95%CI, 0.09-1.37).
      New malignant neoplasms occurred in three AO-CS (1.7%; SIR 1.1; 95%CI, 0.2-3.2)
      and 146 NFPA patients (153 cases, 6.0%, SIR 1.1; 95%CI, 0.9-1.2) after a median
      follow-up of 4.9 (1024 patient-years) and 5.6 years (15215 patient-years).
      Conclusions: The risk of second malignant neoplasms was increased in CO-CS but
      not in AO-CS which illustrates the need to closely follow patients on GH
      replacement due to a prior malignancy.
FAU - Krzyzanowska-Mittermayer, Katarzyna
AU  - Krzyzanowska-Mittermayer K
AD  - Rudolfstiftung Hospital, 1st Medical Department, Vienna, Austria.
FAU - Mattsson, Anders F
AU  - Mattsson AF
AD  - Pfizer Endocrine Care, Sollentuna, Sweden.
FAU - Maiter, Dominique
AU  - Maiter D
AD  - UCL St Luc Hospital, Department of Endocrinology and Nutrition, Brussels,
      Belgium.
FAU - Feldt-Rasmussen, Ulla
AU  - Feldt-Rasmussen U
AD  - Copenhagen University, Rigshospitalet, Department of Endocrinology, Denmark.
FAU - Camacho-Hubner, Cecilia
AU  - Camacho-Hubner C
AD  - Endocrine Care, Pfizer Inc. New York, USA.
FAU - Luger, Anton
AU  - Luger A
AD  - Division of Endocrinology and Metabolism, Department of Medicine III, Medical
      University and General Hospital of Vienna, Vienna, Austria.
FAU - Abs, Roger
AU  - Abs R
AD  - Antwerp Centre for Endocrinology, Antwerp, Belgium.
LA  - eng
PT  - Journal Article
DEP - 20171207
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
EDAT- 2017/12/12 06:00
MHDA- 2017/12/12 06:00
CRDT- 2017/12/12 06:00
PHST- 2017/08/26 00:00 [received]
PHST- 2017/11/30 00:00 [accepted]
PHST- 2017/12/12 06:00 [entrez]
PHST- 2017/12/12 06:00 [pubmed]
PHST- 2017/12/12 06:00 [medline]
AID - 4705941 [pii]
AID - 10.1210/jc.2017-01899 [doi]
PST - aheadofprint
SO  - J Clin Endocrinol Metab. 2017 Dec 7. pii: 4705941. doi: 10.1210/jc.2017-01899.

PMID- 29223952
OWN - NLM
STAT- Publisher
LR  - 20171210
IS  - 1528-0020 (Electronic)
IS  - 0006-4971 (Linking)
DP  - 2017 Dec 9
TI  - Isolated myeloperoxidase expression in pediatric B/myeloid mixed phenotype acute 
      leukemia is linked with better survival.
LID - blood-2017-09-807602 [pii]
LID - 10.1182/blood-2017-09-807602 [doi]
FAU - Raikar, Sunil S
AU  - Raikar SS
AUID- ORCID: http://orcid.org/0000-0003-2903-9542
AD  - Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Children's
      Healthcare of Atlanta and Emory University, Atlanta, GA, United States;
      sraikar@emory.edu.
FAU - Park, Sunita I
AU  - Park SI
AD  - Department of Pathology, Children's Healthcare of Atlanta, Atlanta, GA, United
      States.
FAU - Leong, Traci
AU  - Leong T
AD  - Department of Biostatistics, Rollins School of Public Health, Emory University,
      Atlanta, GA, United States.
FAU - Jaye, David L
AU  - Jaye DL
AUID- ORCID: http://orcid.org/0000-0001-7977-6909
AD  - Department of Pathology and Laboratory Medicine, Winship Cancer Institute and
      Emory University, Atlanta, GA, United States.
FAU - Keller, Frank G
AU  - Keller FG
AD  - Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Children's
      Healthcare of Atlanta and Emory University, Atlanta, GA, United States.
FAU - Horan, John T
AU  - Horan JT
AUID- ORCID: http://orcid.org/0000-0002-1291-3339
AD  - Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Children's
      Healthcare of Atlanta and Emory University, Atlanta, GA, United States.
FAU - Woods, William G
AU  - Woods WG
AD  - Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Children's
      Healthcare of Atlanta and Emory University, Atlanta, GA, United States.
LA  - eng
PT  - Journal Article
DEP - 20171209
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
EDAT- 2017/12/11 06:00
MHDA- 2017/12/11 06:00
CRDT- 2017/12/11 06:00
PHST- 2017/09/21 00:00 [received]
PHST- 2017/12/03 00:00 [accepted]
PHST- 2017/12/11 06:00 [entrez]
PHST- 2017/12/11 06:00 [pubmed]
PHST- 2017/12/11 06:00 [medline]
AID - blood-2017-09-807602 [pii]
AID - 10.1182/blood-2017-09-807602 [doi]
PST - aheadofprint
SO  - Blood. 2017 Dec 9. pii: blood-2017-09-807602. doi: 10.1182/blood-2017-09-807602.

PMID- 29348500
OWN - NLM
STAT- In-Data-Review
LR  - 20180126
IS  - 1529-2916 (Electronic)
IS  - 1529-2908 (Linking)
VI  - 19
IP  - 2
DP  - 2018 Feb
TI  - Myeloid-derived suppressor cells coming of age.
PG  - 108-119
LID - 10.1038/s41590-017-0022-x [doi]
AB  - Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of cells 
      generated during a large array of pathologic conditions ranging from cancer to
      obesity. These cells represent a pathologic state of activation of monocytes and 
      relatively immature neutrophils. MDSCs are characterized by a distinct set of
      genomic and biochemical features, and can, on the basis of recent findings, be
      distinguished by specific surface molecules. The salient feature of these cells
      is their ability to inhibit T cell function and thus contribute to the
      pathogenesis of various diseases. In this Review, we discuss the origin and
      nature of these cells; their distinctive features; and their biological roles in 
      cancer, infectious diseases, autoimmunity, obesity and pregnancy.
FAU - Veglia, Filippo
AU  - Veglia F
AD  - The Wistar Institute, Philadelphia, PA, USA.
FAU - Perego, Michela
AU  - Perego M
AUID- ORCID: http://orcid.org/0000-0002-5671-928X
AD  - The Wistar Institute, Philadelphia, PA, USA.
FAU - Gabrilovich, Dmitry
AU  - Gabrilovich D
AD  - The Wistar Institute, Philadelphia, PA, USA. dgabrilovich@wistar.org.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180118
PL  - United States
TA  - Nat Immunol
JT  - Nature immunology
JID - 100941354
EDAT- 2018/01/20 06:00
MHDA- 2018/01/20 06:00
CRDT- 2018/01/20 06:00
PHST- 2017/09/07 00:00 [received]
PHST- 2017/11/07 00:00 [accepted]
PHST- 2018/01/20 06:00 [pubmed]
PHST- 2018/01/20 06:00 [medline]
PHST- 2018/01/20 06:00 [entrez]
AID - 10.1038/s41590-017-0022-x [doi]
AID - 10.1038/s41590-017-0022-x [pii]
PST - ppublish
SO  - Nat Immunol. 2018 Feb;19(2):108-119. doi: 10.1038/s41590-017-0022-x. Epub 2018
      Jan 18.

PMID- 29143192
OWN - NLM
STAT- In-Process
LR  - 20180124
IS  - 1179-1950 (Electronic)
IS  - 0012-6667 (Linking)
VI  - 77
IP  - 18
DP  - 2017 Dec
TI  - Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current
      Therapeutic Options and Potential Targets for Novel Therapies.
PG  - 1935-1966
LID - 10.1007/s40265-017-0830-1 [doi]
AB  - No specific antivirals are currently available for two emerging infectious
      diseases, Middle East respiratory syndrome (MERS) and severe acute respiratory
      syndrome (SARS). A literature search was performed covering pathogenesis,
      clinical features and therapeutics, clinically developed drugs for repurposing
      and novel drug targets. This review presents current knowledge on the
      epidemiology, pathogenesis and clinical features of the SARS and MERS
      coronaviruses. The rationale for and outcomes with treatments used for SARS and
      MERS is discussed. The main focus of the review is on drug development and the
      potential that drugs approved for other indications provide for repurposing. The 
      drugs we discuss belong to a wide range of different drug classes, such as cancer
      therapeutics, antipsychotics, and antimalarials. In addition to their activity
      against MERS and SARS coronaviruses, many of these approved drugs have
      broad-spectrum potential and have already been in clinical use for treating other
      viral infections. A wealth of knowledge is available for these drugs. However,
      the information in this review is not meant to guide clinical decisions, and any 
      therapeutic described here should only be used in context of a clinical trial.
      Potential targets for novel antivirals and antibodies are discussed as well as
      lessons learned from treatment development for other RNA viruses. The article
      concludes with a discussion of the gaps in our knowledge and areas for future
      research on emerging coronaviruses.
FAU - Dyall, Julie
AU  - Dyall J
AUID- ORCID: http://orcid.org/0000-0002-9856-4183
AD  - Integrated Research Facility, Division of Clinical Research, National Institute
      of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD,
      USA. dyallj@niaid.nih.gov.
FAU - Gross, Robin
AU  - Gross R
AD  - Integrated Research Facility, Division of Clinical Research, National Institute
      of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD,
      USA.
FAU - Kindrachuk, Jason
AU  - Kindrachuk J
AD  - Department of Medical Microbiology, University of Manitoba, Winnipeg, MN, Canada.
FAU - Johnson, Reed F
AU  - Johnson RF
AD  - Emerging Viral Pathogens Section, National Institute of Allergy and Infectious
      Diseases, National Institutes of Health, Frederick, MD, USA.
FAU - Olinger, Gene G Jr.
AU  - Olinger GG Jr.
AD  - University of Boston, Boston, MA, USA.
FAU - Hensley, Lisa E
AU  - Hensley LE
AD  - Integrated Research Facility, Division of Clinical Research, National Institute
      of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD,
      USA.
FAU - Frieman, Matthew B
AU  - Frieman MB
AD  - Department of Microbiology and Immunology, University of Maryland, School of
      Medicine, Baltimore, MD, USA.
FAU - Jahrling, Peter B
AU  - Jahrling PB
AD  - Integrated Research Facility, Division of Clinical Research, National Institute
      of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD,
      USA.
AD  - Emerging Viral Pathogens Section, National Institute of Allergy and Infectious
      Diseases, National Institutes of Health, Frederick, MD, USA.
LA  - eng
GR  - HHSN272200700016I/AO/NIAID NIH HHS/United States
GR  - ZID AI009006-08/Intramural NIH HHS/United States
GR  - HHSN272200700016I/National Institute of Allergy and Infectious Diseases/United
      States
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
PMC - PMC5733787
MID - NIHMS921442
EDAT- 2017/11/17 06:00
MHDA- 2017/11/17 06:00
CRDT- 2017/11/17 06:00
PMCR- 2018/12/01 00:00
PHST- 2018/12/01 00:00 [pmc-release]
PHST- 2017/11/17 06:00 [pubmed]
PHST- 2017/11/17 06:00 [medline]
PHST- 2017/11/17 06:00 [entrez]
AID - 10.1007/s40265-017-0830-1 [doi]
AID - 10.1007/s40265-017-0830-1 [pii]
PST - ppublish
SO  - Drugs. 2017 Dec;77(18):1935-1966. doi: 10.1007/s40265-017-0830-1.

PMID- 29320312
OWN - NLM
STAT- Publisher
LR  - 20180110
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Linking)
DP  - 2018 Jan 10
TI  - Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles:
      Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.
PG  - JCO2017753780
LID - 10.1200/JCO.2017.75.3780 [doi]
AB  - Purpose Detection of specific molecular alterations in tumors guides the
      selection of effective targeted treatment of patients with several types of
      cancer. These molecular alterations may occur in other tumor types for which the 
      efficacy of targeted therapy remains unclear. The MyPathway study evaluates the
      efficacy and safety of selected targeted therapies in tumor types that harbor
      relevant genetic alterations but are outside of current labeling for these
      treatments. Methods MyPathway ( ClinicalTrials.gov identifier: NCT02091141) is a 
      multicenter, nonrandomized, phase IIa multiple basket study. Patients with
      advanced refractory solid tumors harboring molecular alterations in human
      epidermal growth factor receptor-2, epidermal growth factor receptor, v-raf
      murine sarcoma viral oncogene homolog B1, or the Hedgehog pathway are treated
      with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib,
      respectively. The primary end point is investigator-assessed objective response
      rate within each tumor-pathway cohort. Results Between April 1, 2014 and November
      1, 2016, 251 patients with 35 different tumor types received study treatment. The
      efficacy population contains 230 treated patients who were evaluated for response
      or discontinued treatment before evaluation. Fifty-two patients (23%) with 14
      different tumor types had objective responses (complete, n = 4; partial, n = 48).
      Tumor-pathway cohorts with notable objective response rates included human
      epidermal growth factor receptor-2-amplified/overexpressing colorectal (38% [14
      of 37]; 95% CI, 23% to 55%) and v-raf murine sarcoma viral oncogene homolog B1
      V600-mutated non-small-cell lung cancer (43% [six of 14]; 95% CI, 18% to 71%).
      Conclusion The four currently approved targeted therapy regimens in the MyPathway
      study produced meaningful responses when administered without chemotherapy in
      several refractory solid tumor types not currently labeled for these agents.
FAU - Hainsworth, John D
AU  - Hainsworth JD
AD  - John D. Hainsworth, David R. Spigel, and Howard Burris, Sarah Cannon Research
      Institute; Tennessee Oncology, Nashville, TN; Funda Meric-Bernstam, University of
      Texas MD Anderson Cancer Center, Houston, TX; Charles Swanton, Francis Crick
      Institute, London, United Kingdom; Herbert Hurwitz, Duke University Medical
      Center, Durham, NC; Christopher Sweeney, Dana-Farber Cancer Institute, Harvard
      Medical School, Boston, MA; Ron Bose, Washington University School of Medicine,
      St Louis, MO; Bongin Yoo, Alisha Stein, and Mary Beattie, Genentech, South San
      Francisco; and Razelle Kurzrock, Moores Cancer Center, University of California
      San Diego, San Diego, CA.
FAU - Meric-Bernstam, Funda
AU  - Meric-Bernstam F
AD  - John D. Hainsworth, David R. Spigel, and Howard Burris, Sarah Cannon Research
      Institute; Tennessee Oncology, Nashville, TN; Funda Meric-Bernstam, University of
      Texas MD Anderson Cancer Center, Houston, TX; Charles Swanton, Francis Crick
      Institute, London, United Kingdom; Herbert Hurwitz, Duke University Medical
      Center, Durham, NC; Christopher Sweeney, Dana-Farber Cancer Institute, Harvard
      Medical School, Boston, MA; Ron Bose, Washington University School of Medicine,
      St Louis, MO; Bongin Yoo, Alisha Stein, and Mary Beattie, Genentech, South San
      Francisco; and Razelle Kurzrock, Moores Cancer Center, University of California
      San Diego, San Diego, CA.
FAU - Swanton, Charles
AU  - Swanton C
AD  - John D. Hainsworth, David R. Spigel, and Howard Burris, Sarah Cannon Research
      Institute; Tennessee Oncology, Nashville, TN; Funda Meric-Bernstam, University of
      Texas MD Anderson Cancer Center, Houston, TX; Charles Swanton, Francis Crick
      Institute, London, United Kingdom; Herbert Hurwitz, Duke University Medical
      Center, Durham, NC; Christopher Sweeney, Dana-Farber Cancer Institute, Harvard
      Medical School, Boston, MA; Ron Bose, Washington University School of Medicine,
      St Louis, MO; Bongin Yoo, Alisha Stein, and Mary Beattie, Genentech, South San
      Francisco; and Razelle Kurzrock, Moores Cancer Center, University of California
      San Diego, San Diego, CA.
FAU - Hurwitz, Herbert
AU  - Hurwitz H
AD  - John D. Hainsworth, David R. Spigel, and Howard Burris, Sarah Cannon Research
      Institute; Tennessee Oncology, Nashville, TN; Funda Meric-Bernstam, University of
      Texas MD Anderson Cancer Center, Houston, TX; Charles Swanton, Francis Crick
      Institute, London, United Kingdom; Herbert Hurwitz, Duke University Medical
      Center, Durham, NC; Christopher Sweeney, Dana-Farber Cancer Institute, Harvard
      Medical School, Boston, MA; Ron Bose, Washington University School of Medicine,
      St Louis, MO; Bongin Yoo, Alisha Stein, and Mary Beattie, Genentech, South San
      Francisco; and Razelle Kurzrock, Moores Cancer Center, University of California
      San Diego, San Diego, CA.
FAU - Spigel, David R
AU  - Spigel DR
AD  - John D. Hainsworth, David R. Spigel, and Howard Burris, Sarah Cannon Research
      Institute; Tennessee Oncology, Nashville, TN; Funda Meric-Bernstam, University of
      Texas MD Anderson Cancer Center, Houston, TX; Charles Swanton, Francis Crick
      Institute, London, United Kingdom; Herbert Hurwitz, Duke University Medical
      Center, Durham, NC; Christopher Sweeney, Dana-Farber Cancer Institute, Harvard
      Medical School, Boston, MA; Ron Bose, Washington University School of Medicine,
      St Louis, MO; Bongin Yoo, Alisha Stein, and Mary Beattie, Genentech, South San
      Francisco; and Razelle Kurzrock, Moores Cancer Center, University of California
      San Diego, San Diego, CA.
FAU - Sweeney, Christopher
AU  - Sweeney C
AD  - John D. Hainsworth, David R. Spigel, and Howard Burris, Sarah Cannon Research
      Institute; Tennessee Oncology, Nashville, TN; Funda Meric-Bernstam, University of
      Texas MD Anderson Cancer Center, Houston, TX; Charles Swanton, Francis Crick
      Institute, London, United Kingdom; Herbert Hurwitz, Duke University Medical
      Center, Durham, NC; Christopher Sweeney, Dana-Farber Cancer Institute, Harvard
      Medical School, Boston, MA; Ron Bose, Washington University School of Medicine,
      St Louis, MO; Bongin Yoo, Alisha Stein, and Mary Beattie, Genentech, South San
      Francisco; and Razelle Kurzrock, Moores Cancer Center, University of California
      San Diego, San Diego, CA.
FAU - Burris, Howard
AU  - Burris H
AD  - John D. Hainsworth, David R. Spigel, and Howard Burris, Sarah Cannon Research
      Institute; Tennessee Oncology, Nashville, TN; Funda Meric-Bernstam, University of
      Texas MD Anderson Cancer Center, Houston, TX; Charles Swanton, Francis Crick
      Institute, London, United Kingdom; Herbert Hurwitz, Duke University Medical
      Center, Durham, NC; Christopher Sweeney, Dana-Farber Cancer Institute, Harvard
      Medical School, Boston, MA; Ron Bose, Washington University School of Medicine,
      St Louis, MO; Bongin Yoo, Alisha Stein, and Mary Beattie, Genentech, South San
      Francisco; and Razelle Kurzrock, Moores Cancer Center, University of California
      San Diego, San Diego, CA.
FAU - Bose, Ron
AU  - Bose R
AD  - John D. Hainsworth, David R. Spigel, and Howard Burris, Sarah Cannon Research
      Institute; Tennessee Oncology, Nashville, TN; Funda Meric-Bernstam, University of
      Texas MD Anderson Cancer Center, Houston, TX; Charles Swanton, Francis Crick
      Institute, London, United Kingdom; Herbert Hurwitz, Duke University Medical
      Center, Durham, NC; Christopher Sweeney, Dana-Farber Cancer Institute, Harvard
      Medical School, Boston, MA; Ron Bose, Washington University School of Medicine,
      St Louis, MO; Bongin Yoo, Alisha Stein, and Mary Beattie, Genentech, South San
      Francisco; and Razelle Kurzrock, Moores Cancer Center, University of California
      San Diego, San Diego, CA.
FAU - Yoo, Bongin
AU  - Yoo B
AD  - John D. Hainsworth, David R. Spigel, and Howard Burris, Sarah Cannon Research
      Institute; Tennessee Oncology, Nashville, TN; Funda Meric-Bernstam, University of
      Texas MD Anderson Cancer Center, Houston, TX; Charles Swanton, Francis Crick
      Institute, London, United Kingdom; Herbert Hurwitz, Duke University Medical
      Center, Durham, NC; Christopher Sweeney, Dana-Farber Cancer Institute, Harvard
      Medical School, Boston, MA; Ron Bose, Washington University School of Medicine,
      St Louis, MO; Bongin Yoo, Alisha Stein, and Mary Beattie, Genentech, South San
      Francisco; and Razelle Kurzrock, Moores Cancer Center, University of California
      San Diego, San Diego, CA.
FAU - Stein, Alisha
AU  - Stein A
AD  - John D. Hainsworth, David R. Spigel, and Howard Burris, Sarah Cannon Research
      Institute; Tennessee Oncology, Nashville, TN; Funda Meric-Bernstam, University of
      Texas MD Anderson Cancer Center, Houston, TX; Charles Swanton, Francis Crick
      Institute, London, United Kingdom; Herbert Hurwitz, Duke University Medical
      Center, Durham, NC; Christopher Sweeney, Dana-Farber Cancer Institute, Harvard
      Medical School, Boston, MA; Ron Bose, Washington University School of Medicine,
      St Louis, MO; Bongin Yoo, Alisha Stein, and Mary Beattie, Genentech, South San
      Francisco; and Razelle Kurzrock, Moores Cancer Center, University of California
      San Diego, San Diego, CA.
FAU - Beattie, Mary
AU  - Beattie M
AD  - John D. Hainsworth, David R. Spigel, and Howard Burris, Sarah Cannon Research
      Institute; Tennessee Oncology, Nashville, TN; Funda Meric-Bernstam, University of
      Texas MD Anderson Cancer Center, Houston, TX; Charles Swanton, Francis Crick
      Institute, London, United Kingdom; Herbert Hurwitz, Duke University Medical
      Center, Durham, NC; Christopher Sweeney, Dana-Farber Cancer Institute, Harvard
      Medical School, Boston, MA; Ron Bose, Washington University School of Medicine,
      St Louis, MO; Bongin Yoo, Alisha Stein, and Mary Beattie, Genentech, South San
      Francisco; and Razelle Kurzrock, Moores Cancer Center, University of California
      San Diego, San Diego, CA.
FAU - Kurzrock, Razelle
AU  - Kurzrock R
AD  - John D. Hainsworth, David R. Spigel, and Howard Burris, Sarah Cannon Research
      Institute; Tennessee Oncology, Nashville, TN; Funda Meric-Bernstam, University of
      Texas MD Anderson Cancer Center, Houston, TX; Charles Swanton, Francis Crick
      Institute, London, United Kingdom; Herbert Hurwitz, Duke University Medical
      Center, Durham, NC; Christopher Sweeney, Dana-Farber Cancer Institute, Harvard
      Medical School, Boston, MA; Ron Bose, Washington University School of Medicine,
      St Louis, MO; Bongin Yoo, Alisha Stein, and Mary Beattie, Genentech, South San
      Francisco; and Razelle Kurzrock, Moores Cancer Center, University of California
      San Diego, San Diego, CA.
LA  - eng
PT  - Journal Article
DEP - 20180110
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of
      Clinical Oncology
JID - 8309333
EDAT- 2018/01/11 06:00
MHDA- 2018/01/11 06:00
CRDT- 2018/01/11 06:00
PHST- 2018/01/11 06:00 [entrez]
PHST- 2018/01/11 06:00 [pubmed]
PHST- 2018/01/11 06:00 [medline]
AID - 10.1200/JCO.2017.75.3780 [doi]
PST - aheadofprint
SO  - J Clin Oncol. 2018 Jan 10:JCO2017753780. doi: 10.1200/JCO.2017.75.3780.

PMID- 29294043
OWN - NLM
STAT- Publisher
LR  - 20180102
IS  - 1460-2377 (Electronic)
IS  - 0953-8178 (Linking)
DP  - 2017 Dec 23
TI  - Clinical response to PD-1 blockade correlates with a sub-fraction of peripheral
      central memory CD4+ T cells in patients with malignant melanoma.
LID - 10.1093/intimm/dxx073 [doi]
AB  - Cancer immunotherapy that blocks immune checkpoint molecules, such as PD-1/PD-L1,
      unleashes dysfunctional antitumor T-cell responses and has durable clinical
      benefits in various types of cancers. Yet its clinical efficacy is limited to a
      small proportion of patients, highlighting the need for identifying biomarkers
      that can predict the clinical response by exploring antitumor responses crucial
      for tumor regression. Here we explored T-cell responses associated with clinical 
      benefits using peripheral blood mononuclear cells (PBMCs) from patients with
      malignant melanoma treated with anti-PD-1 monoclonal antibody (mAb). Pre- and
      post-treatment samples were collected from two different cohorts (discovery set
      and validation set) and subjected to mass cytometry assays that measured the
      expression levels of 35 proteins. Screening by high dimensional clustering in the
      discovery set identified increases in three micro-clusters of CD4+ T cells, a
      subset of central memory CD4+ T cells harboring CD27+FAS-CD45RA-CCR7+ phenotype, 
      after treatment in long-term survivors, but not in non-responders. The same
      increase was also observed in clinical responders in the validation set. We
      propose that increases in this subset of central memory CD4+ T cells in
      peripheral blood can be potentially used as a predictor of clinical response to
      PD-1 blockade therapy in patients with malignant melanoma.
CI  - (c) The Japanese Society for Immunology. 2017. All rights reserved. For
      permissions, please e-mail: journals.permissions@oup.com.
FAU - Takeuchi, Yoshiko
AU  - Takeuchi Y
AD  - Division of Cancer Immunology, Research Institute, National Cancer Center,
      Tokyo/Chiba, Japan.
AD  - Division of Cancer Immunology, Exploratory Oncology Research & Clinical Trial
      Center (EPOC), National Cancer Center, Tokyo/Chiba, Japan.
AD  - Department of Respiratory Medicine and Clinical Immunology, Osaka University
      Graduate School of Medicine, Suita, Osaka, Japan.
FAU - Tanemura, Atsushi
AU  - Tanemura A
AD  - Department of Dermatology, Osaka University Graduate School of Medicine, Suita,
      Osaka, Japan.
FAU - Tada, Yasuko
AU  - Tada Y
AD  - Division of Cancer Immunology, Research Institute, National Cancer Center,
      Tokyo/Chiba, Japan.
AD  - Division of Cancer Immunology, Exploratory Oncology Research & Clinical Trial
      Center (EPOC), National Cancer Center, Tokyo/Chiba, Japan.
FAU - Katayama, Ichiro
AU  - Katayama I
AD  - Department of Dermatology, Osaka University Graduate School of Medicine, Suita,
      Osaka, Japan.
FAU - Kumanogoh, Atsushi
AU  - Kumanogoh A
AD  - Department of Respiratory Medicine and Clinical Immunology, Osaka University
      Graduate School of Medicine, Suita, Osaka, Japan.
FAU - Nishikawa, Hiroyoshi
AU  - Nishikawa H
AD  - Division of Cancer Immunology, Research Institute, National Cancer Center,
      Tokyo/Chiba, Japan.
AD  - Division of Cancer Immunology, Exploratory Oncology Research & Clinical Trial
      Center (EPOC), National Cancer Center, Tokyo/Chiba, Japan.
AD  - Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, 
      Japan.
LA  - eng
PT  - Journal Article
DEP - 20171223
PL  - England
TA  - Int Immunol
JT  - International immunology
JID - 8916182
OTO - NOTNLM
OT  - Biomarker
OT  - Cancer immunotherapy
OT  - CyTOF
OT  - Mass cytometry
OT  - PD-1 blockade
EDAT- 2018/01/03 06:00
MHDA- 2018/01/03 06:00
CRDT- 2018/01/03 06:00
PHST- 2017/11/27 00:00 [received]
PHST- 2018/01/03 06:00 [entrez]
PHST- 2018/01/03 06:00 [pubmed]
PHST- 2018/01/03 06:00 [medline]
AID - 4774075 [pii]
AID - 10.1093/intimm/dxx073 [doi]
PST - aheadofprint
SO  - Int Immunol. 2017 Dec 23. pii: 4774075. doi: 10.1093/intimm/dxx073.

PMID- 29334371
OWN - NLM
STAT- Publisher
LR  - 20180129
IS  - 1546-170X (Electronic)
IS  - 1078-8956 (Linking)
DP  - 2018 Jan 15
TI  - Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug
      conjugate and BRAF/MEK inhibitors.
LID - 10.1038/nm.4472 [doi]
AB  - Intratumor heterogeneity is a key factor contributing to therapeutic failure and,
      hence, cancer lethality. Heterogeneous tumors show partial therapy responses,
      allowing for the emergence of drug-resistant clones that often express high
      levels of the receptor tyrosine kinase AXL. In melanoma, AXL-high cells are
      resistant to MAPK pathway inhibitors, whereas AXL-low cells are sensitive to
      these inhibitors, rationalizing a differential therapeutic approach. We developed
      an antibody-drug conjugate, AXL-107-MMAE, comprising a human AXL antibody linked 
      to the microtubule-disrupting agent monomethyl auristatin E. We found that
      AXL-107-MMAE, as a single agent, displayed potent in vivo anti-tumor activity in 
      patient-derived xenografts, including melanoma, lung, pancreas and cervical
      cancer. By eliminating distinct populations in heterogeneous melanoma cell pools,
      AXL-107-MMAE and MAPK pathway inhibitors cooperatively inhibited tumor growth.
      Furthermore, by inducing AXL transcription, BRAF/MEK inhibitors potentiated the
      efficacy of AXL-107-MMAE. These findings provide proof of concept for the premise
      that rationalized combinatorial targeting of distinct populations in
      heterogeneous tumors may improve therapeutic effect, and merit clinical
      validation of AXL-107-MMAE in both treatment-naive and drug-resistant cancers in 
      mono- or combination therapy.
FAU - Boshuizen, Julia
AU  - Boshuizen J
AUID- ORCID: http://orcid.org/0000-0002-8135-0525
AD  - Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands 
      Cancer Institute, Amsterdam, the Netherlands.
FAU - Koopman, Louise A
AU  - Koopman LA
AD  - Genmab, Utrecht, the Netherlands.
FAU - Krijgsman, Oscar
AU  - Krijgsman O
AD  - Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands 
      Cancer Institute, Amsterdam, the Netherlands.
FAU - Shahrabi, Aida
AU  - Shahrabi A
AD  - Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands 
      Cancer Institute, Amsterdam, the Netherlands.
FAU - van den Heuvel, Elke Gresnigt-
AU  - van den Heuvel EG
AD  - Genmab, Utrecht, the Netherlands.
FAU - Ligtenberg, Maarten A
AU  - Ligtenberg MA
AD  - Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands 
      Cancer Institute, Amsterdam, the Netherlands.
FAU - Vredevoogd, David W
AU  - Vredevoogd DW
AUID- ORCID: http://orcid.org/0000-0001-6718-1422
AD  - Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands 
      Cancer Institute, Amsterdam, the Netherlands.
FAU - Kemper, Kristel
AU  - Kemper K
AD  - Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands 
      Cancer Institute, Amsterdam, the Netherlands.
FAU - Kuilman, Thomas
AU  - Kuilman T
AUID- ORCID: http://orcid.org/0000-0001-6724-6767
AD  - Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands 
      Cancer Institute, Amsterdam, the Netherlands.
FAU - Song, Ji-Ying
AU  - Song JY
AD  - Division of Experimental Animal Pathology, The Netherlands Cancer Institute,
      Amsterdam, the Netherlands.
FAU - Pencheva, Nora
AU  - Pencheva N
AD  - Genmab, Utrecht, the Netherlands.
FAU - Mortensen, Jens Thing
AU  - Mortensen JT
AD  - Genmab, Utrecht, the Netherlands.
FAU - Foppen, Marnix Geukes
AU  - Foppen MG
AD  - Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands 
      Cancer Institute, Amsterdam, the Netherlands.
FAU - Rozeman, Elisa A
AU  - Rozeman EA
AD  - Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands 
      Cancer Institute, Amsterdam, the Netherlands.
FAU - Blank, Christian U
AU  - Blank CU
AD  - Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands 
      Cancer Institute, Amsterdam, the Netherlands.
FAU - Janmaat, Maarten L
AU  - Janmaat ML
AD  - Genmab, Utrecht, the Netherlands.
FAU - Satijn, David
AU  - Satijn D
AD  - Genmab, Utrecht, the Netherlands.
FAU - Breij, Esther C W
AU  - Breij ECW
AD  - Genmab, Utrecht, the Netherlands.
FAU - Peeper, Daniel S
AU  - Peeper DS
AUID- ORCID: http://orcid.org/0000-0003-1293-3177
AD  - Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands 
      Cancer Institute, Amsterdam, the Netherlands.
FAU - Parren, Paul W H I
AU  - Parren PWHI
AUID- ORCID: http://orcid.org/0000-0002-4365-3859
AD  - Genmab, Utrecht, the Netherlands.
AD  - Department of Immunohematology & Blood Transfusion, Leiden University Medical
      Center, Leiden, the Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20180115
PL  - United States
TA  - Nat Med
JT  - Nature medicine
JID - 9502015
EDAT- 2018/01/16 06:00
MHDA- 2018/01/16 06:00
CRDT- 2018/01/16 06:00
PHST- 2017/03/28 00:00 [received]
PHST- 2017/12/15 00:00 [accepted]
PHST- 2018/01/16 06:00 [pubmed]
PHST- 2018/01/16 06:00 [medline]
PHST- 2018/01/16 06:00 [entrez]
AID - nm.4472 [pii]
AID - 10.1038/nm.4472 [doi]
PST - aheadofprint
SO  - Nat Med. 2018 Jan 15. pii: nm.4472. doi: 10.1038/nm.4472.

PMID- 29304718
OWN - NLM
STAT- Publisher
LR  - 20180129
IS  - 1554-8635 (Electronic)
IS  - 1554-8627 (Linking)
DP  - 2018 Jan 29
TI  - Autophagy and inflammation: A special review issue.
PG  - 1-2
LID - 10.1080/15548627.2017.1412229 [doi]
AB  - Macroautophagy/autophagy is a fundamental intracellular homeostatic process that 
      is of interest both for its basic biology and for its effect on human physiology 
      in a wide spectrum of conditions and diseases. Autophagy was first appreciated
      primarily as a metabolic and cytoplasmic quality control process, but in the past
      decade its role in immunity has been steadily growing. The connections between
      these aspects beckon explorations of the network and connections that exist
      between metabolism, quality control, and inflammation and immunity processes,
      which are so key to many human diseases including neurodegeneration, obesity and 
      diabetes, chronic inflammatory conditions, cancer, infection, and aging. The
      purpose of this issue is to stimulate further the burgeoning studies of the
      intersections between autophagy and inflammation, and the inevitable overlaps
      with metabolic and quality control functions of autophagy.
FAU - Deretic, Vojo
AU  - Deretic V
AUID- ORCID: http://orcid.org/0000-0002-3624-5208
AD  - a Department of Molecular Genetics and Microbiology , University of New Mexico
      Health Sciences Center , Albuquerque , NM USA.
AD  - b Autophagy Inflammation and Metabolism Center of Biomedical Research Excellence 
      , University of New Mexico Health Sciences Center , Albuquerque , NM USA.
FAU - Klionsky, Daniel J
AU  - Klionsky DJ
AUID- ORCID: http://orcid.org/0000-0002-7828-8118
AD  - c Life Sciences Institute, University of Michigan , Ann Arbor , MI USA.
LA  - eng
PT  - Journal Article
DEP - 20180129
PL  - United States
TA  - Autophagy
JT  - Autophagy
JID - 101265188
OTO - NOTNLM
OT  - autophagy
OT  - immune response
OT  - immunology
OT  - lysosome
OT  - xenophagy
EDAT- 2018/01/07 06:00
MHDA- 2018/01/07 06:00
CRDT- 2018/01/07 06:00
PHST- 2018/01/07 06:00 [pubmed]
PHST- 2018/01/07 06:00 [medline]
PHST- 2018/01/07 06:00 [entrez]
AID - 10.1080/15548627.2017.1412229 [doi]
PST - aheadofprint
SO  - Autophagy. 2018 Jan 29:1-2. doi: 10.1080/15548627.2017.1412229.

PMID- 29298869
OWN - NLM
STAT- In-Data-Review
LR  - 20180104
IS  - 1946-6242 (Electronic)
IS  - 1946-6234 (Linking)
VI  - 10
IP  - 422
DP  - 2018 Jan 3
TI  - Intravenous delivery of oncolytic reovirus to brain tumor patients
      immunologically primes for subsequent checkpoint blockade.
LID - eaam7577 [pii]
LID - 10.1126/scitranslmed.aam7577 [doi]
AB  - Immune checkpoint inhibitors, including those targeting programmed cell death
      protein 1 (PD-1), are reshaping cancer therapeutic strategies. Evidence suggests,
      however, that tumor response and patient survival are determined by tumor
      programmed death ligand 1 (PD-L1) expression. We hypothesized that
      preconditioning of the tumor immune microenvironment using targeted,
      virus-mediated interferon (IFN) stimulation would up-regulate tumor PD-L1 protein
      expression and increase cytotoxic T cell infiltration, improving the efficacy of 
      subsequent checkpoint blockade. Oncolytic viruses (OVs) represent a promising
      form of cancer immunotherapy. For brain tumors, almost all studies to date have
      used direct intralesional injection of OV, because of the largely untested belief
      that intravenous administration will not deliver virus to this site. We show, in 
      a window-of-opportunity clinical study, that intravenous infusion of oncolytic
      human Orthoreovirus (referred to herein as reovirus) leads to infection of tumor 
      cells subsequently resected as part of standard clinical care, both in high-grade
      glioma and in brain metastases, and increases cytotoxic T cell tumor infiltration
      relative to patients not treated with virus. We further show that reovirus
      up-regulates IFN-regulated gene expression, as well as the PD-1/PD-L1 axis in
      tumors, via an IFN-mediated mechanism. Finally, we show that addition of PD-1
      blockade to reovirus enhances systemic therapy in a preclinical glioma model.
      These results support the development of combined systemic immunovirotherapy
      strategies for the treatment of both primary and secondary tumors in the brain.
CI  - Copyright (c) 2018 The Authors, some rights reserved; exclusive licensee American
      Association for the Advancement of Science. No claim to original U.S. Government 
      Works.
FAU - Samson, Adel
AU  - Samson A
AUID- ORCID: http://orcid.org/0000-0002-3081-7850
AD  - Leeds Institute of Cancer and Pathology, Faculty of Medicine and Health,
      University of Leeds, St James's University Hospital, Beckett Street, Leeds, West 
      Yorkshire LS9 7TF, UK. a.samson@leeds.ac.uk alan.melcher@icr.ac.uk
      s.c.short@leeds.ac.uk.
FAU - Scott, Karen J
AU  - Scott KJ
AD  - Leeds Institute of Cancer and Pathology, Faculty of Medicine and Health,
      University of Leeds, St James's University Hospital, Beckett Street, Leeds, West 
      Yorkshire LS9 7TF, UK.
FAU - Taggart, David
AU  - Taggart D
AUID- ORCID: http://orcid.org/0000-0001-8781-4936
AD  - Leeds Institute of Cancer and Pathology, Faculty of Medicine and Health,
      University of Leeds, St James's University Hospital, Beckett Street, Leeds, West 
      Yorkshire LS9 7TF, UK.
FAU - West, Emma J
AU  - West EJ
AD  - Leeds Institute of Cancer and Pathology, Faculty of Medicine and Health,
      University of Leeds, St James's University Hospital, Beckett Street, Leeds, West 
      Yorkshire LS9 7TF, UK.
FAU - Wilson, Erica
AU  - Wilson E
AUID- ORCID: http://orcid.org/0000-0002-0441-728X
AD  - Leeds Institute of Cancer and Pathology, Faculty of Medicine and Health,
      University of Leeds, St James's University Hospital, Beckett Street, Leeds, West 
      Yorkshire LS9 7TF, UK.
FAU - Nuovo, Gerard J
AU  - Nuovo GJ
AUID- ORCID: http://orcid.org/0000-0002-5351-4721
AD  - Ohio State University, Comprehensive Cancer Centre, Columbus, OH 43210, USA.
FAU - Thomson, Simon
AU  - Thomson S
AUID- ORCID: http://orcid.org/0000-0003-4827-1961
AD  - Leeds Teaching Hospitals National Health Service Trust, St James's University
      Hospital, Beckett Street, Leeds, West Yorkshire LS9 7TF, UK.
FAU - Corns, Robert
AU  - Corns R
AD  - Leeds Teaching Hospitals National Health Service Trust, St James's University
      Hospital, Beckett Street, Leeds, West Yorkshire LS9 7TF, UK.
FAU - Mathew, Ryan K
AU  - Mathew RK
AUID- ORCID: http://orcid.org/0000-0002-2609-9876
AD  - Leeds Institute of Cancer and Pathology, Faculty of Medicine and Health,
      University of Leeds, St James's University Hospital, Beckett Street, Leeds, West 
      Yorkshire LS9 7TF, UK.
FAU - Fuller, Martin J
AU  - Fuller MJ
AD  - Leeds Institute of Cancer and Pathology, Faculty of Medicine and Health,
      University of Leeds, St James's University Hospital, Beckett Street, Leeds, West 
      Yorkshire LS9 7TF, UK.
FAU - Kottke, Timothy J
AU  - Kottke TJ
AD  - Department of Immunology, Mayo Clinic, Rochester, MN 55905, USA.
FAU - Thompson, Jill M
AU  - Thompson JM
AD  - Department of Immunology, Mayo Clinic, Rochester, MN 55905, USA.
FAU - Ilett, Elizabeth J
AU  - Ilett EJ
AUID- ORCID: http://orcid.org/0000-0002-9875-0322
AD  - Leeds Institute of Cancer and Pathology, Faculty of Medicine and Health,
      University of Leeds, St James's University Hospital, Beckett Street, Leeds, West 
      Yorkshire LS9 7TF, UK.
FAU - Cockle, Julia V
AU  - Cockle JV
AUID- ORCID: http://orcid.org/0000-0001-9437-4633
AD  - Leeds Institute of Cancer and Pathology, Faculty of Medicine and Health,
      University of Leeds, St James's University Hospital, Beckett Street, Leeds, West 
      Yorkshire LS9 7TF, UK.
FAU - van Hille, Philip
AU  - van Hille P
AD  - Leeds Teaching Hospitals National Health Service Trust, St James's University
      Hospital, Beckett Street, Leeds, West Yorkshire LS9 7TF, UK.
FAU - Sivakumar, Gnanamurthy
AU  - Sivakumar G
AD  - Leeds Teaching Hospitals National Health Service Trust, St James's University
      Hospital, Beckett Street, Leeds, West Yorkshire LS9 7TF, UK.
FAU - Polson, Euan S
AU  - Polson ES
AD  - Leeds Institute of Cancer and Pathology, Faculty of Medicine and Health,
      University of Leeds, St James's University Hospital, Beckett Street, Leeds, West 
      Yorkshire LS9 7TF, UK.
FAU - Turnbull, Samantha J
AU  - Turnbull SJ
AUID- ORCID: http://orcid.org/0000-0002-1664-3292
AD  - Leeds Institute of Cancer and Pathology, Faculty of Medicine and Health,
      University of Leeds, St James's University Hospital, Beckett Street, Leeds, West 
      Yorkshire LS9 7TF, UK.
FAU - Appleton, Elizabeth S
AU  - Appleton ES
AD  - Leeds Institute of Cancer and Pathology, Faculty of Medicine and Health,
      University of Leeds, St James's University Hospital, Beckett Street, Leeds, West 
      Yorkshire LS9 7TF, UK.
FAU - Migneco, Gemma
AU  - Migneco G
AD  - Leeds Institute of Cancer and Pathology, Faculty of Medicine and Health,
      University of Leeds, St James's University Hospital, Beckett Street, Leeds, West 
      Yorkshire LS9 7TF, UK.
FAU - Rose, Ailsa S
AU  - Rose AS
AUID- ORCID: http://orcid.org/0000-0002-1382-969X
AD  - Leeds Institute of Cancer and Pathology, Faculty of Medicine and Health,
      University of Leeds, St James's University Hospital, Beckett Street, Leeds, West 
      Yorkshire LS9 7TF, UK.
FAU - Coffey, Matthew C
AU  - Coffey MC
AD  - Oncolytics Biotech, Calgary, Alberta T2N 1X7, Canada.
FAU - Beirne, Deborah A
AU  - Beirne DA
AUID- ORCID: http://orcid.org/0000-0002-6791-278X
AD  - Leeds Teaching Hospitals National Health Service Trust, St James's University
      Hospital, Beckett Street, Leeds, West Yorkshire LS9 7TF, UK.
FAU - Collinson, Fiona J
AU  - Collinson FJ
AD  - Leeds Institute of Clinical Trials Research, Faculty of Medicine and Health,
      University of Leeds, Leeds, West Yorkshire LS2 9JT, UK.
FAU - Ralph, Christy
AU  - Ralph C
AUID- ORCID: http://orcid.org/0000-0001-5581-2987
AD  - Leeds Institute of Cancer and Pathology, Faculty of Medicine and Health,
      University of Leeds, St James's University Hospital, Beckett Street, Leeds, West 
      Yorkshire LS9 7TF, UK.
FAU - Alan Anthoney, D
AU  - Alan Anthoney D
AUID- ORCID: http://orcid.org/0000-0001-5695-8312
AD  - Leeds Institute of Cancer and Pathology, Faculty of Medicine and Health,
      University of Leeds, St James's University Hospital, Beckett Street, Leeds, West 
      Yorkshire LS9 7TF, UK.
FAU - Twelves, Christopher J
AU  - Twelves CJ
AD  - Leeds Institute of Cancer and Pathology, Faculty of Medicine and Health,
      University of Leeds, St James's University Hospital, Beckett Street, Leeds, West 
      Yorkshire LS9 7TF, UK.
FAU - Furness, Andrew J
AU  - Furness AJ
AD  - University College London, London WC1 6BT, UK.
FAU - Quezada, Sergio A
AU  - Quezada SA
AUID- ORCID: http://orcid.org/0000-0002-9763-1700
AD  - University College London, London WC1 6BT, UK.
FAU - Wurdak, Heiko
AU  - Wurdak H
AUID- ORCID: http://orcid.org/0000-0003-4385-4324
AD  - Leeds Institute of Cancer and Pathology, Faculty of Medicine and Health,
      University of Leeds, St James's University Hospital, Beckett Street, Leeds, West 
      Yorkshire LS9 7TF, UK.
FAU - Errington-Mais, Fiona
AU  - Errington-Mais F
AUID- ORCID: http://orcid.org/0000-0003-2155-534X
AD  - Leeds Institute of Cancer and Pathology, Faculty of Medicine and Health,
      University of Leeds, St James's University Hospital, Beckett Street, Leeds, West 
      Yorkshire LS9 7TF, UK.
FAU - Pandha, Hardev
AU  - Pandha H
AD  - University of Surrey, Guildford GU2 7XH, UK.
FAU - Harrington, Kevin J
AU  - Harrington KJ
AD  - Institute of Cancer Research, 123 Old Brompton Road, London SW7 3RP, UK.
FAU - Selby, Peter J
AU  - Selby PJ
AUID- ORCID: http://orcid.org/0000-0002-3782-069X
AD  - Leeds Institute of Cancer and Pathology, Faculty of Medicine and Health,
      University of Leeds, St James's University Hospital, Beckett Street, Leeds, West 
      Yorkshire LS9 7TF, UK.
FAU - Vile, Richard G
AU  - Vile RG
AD  - Department of Immunology, Mayo Clinic, Rochester, MN 55905, USA.
FAU - Griffin, Stephen D
AU  - Griffin SD
AUID- ORCID: http://orcid.org/0000-0002-7233-5243
AD  - Leeds Institute of Cancer and Pathology, Faculty of Medicine and Health,
      University of Leeds, St James's University Hospital, Beckett Street, Leeds, West 
      Yorkshire LS9 7TF, UK.
FAU - Stead, Lucy F
AU  - Stead LF
AUID- ORCID: http://orcid.org/0000-0002-9550-4150
AD  - Leeds Institute of Cancer and Pathology, Faculty of Medicine and Health,
      University of Leeds, St James's University Hospital, Beckett Street, Leeds, West 
      Yorkshire LS9 7TF, UK.
FAU - Short, Susan C
AU  - Short SC
AUID- ORCID: http://orcid.org/0000-0003-4423-7256
AD  - Leeds Institute of Cancer and Pathology, Faculty of Medicine and Health,
      University of Leeds, St James's University Hospital, Beckett Street, Leeds, West 
      Yorkshire LS9 7TF, UK. a.samson@leeds.ac.uk alan.melcher@icr.ac.uk
      s.c.short@leeds.ac.uk.
FAU - Melcher, Alan A
AU  - Melcher AA
AUID- ORCID: http://orcid.org/0000-0002-2042-3380
AD  - Institute of Cancer Research, 123 Old Brompton Road, London SW7 3RP, UK.
      a.samson@leeds.ac.uk alan.melcher@icr.ac.uk s.c.short@leeds.ac.uk.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Sci Transl Med
JT  - Science translational medicine
JID - 101505086
EDAT- 2018/01/05 06:00
MHDA- 2018/01/05 06:00
CRDT- 2018/01/05 06:00
PHST- 2017/01/17 00:00 [received]
PHST- 2017/09/08 00:00 [revised]
PHST- 2017/11/27 00:00 [accepted]
PHST- 2018/01/05 06:00 [entrez]
PHST- 2018/01/05 06:00 [pubmed]
PHST- 2018/01/05 06:00 [medline]
AID - 10/422/eaam7577 [pii]
AID - 10.1126/scitranslmed.aam7577 [doi]
PST - ppublish
SO  - Sci Transl Med. 2018 Jan 3;10(422). pii: 10/422/eaam7577. doi:
      10.1126/scitranslmed.aam7577.

PMID- 29300620
OWN - NLM
STAT- Publisher
LR  - 20180124
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Linking)
DP  - 2018 Jan 4
TI  - TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell
      Acute Lymphoblastic Leukemia in Children.
PG  - JCO2017755215
LID - 10.1200/JCO.2017.75.5215 [doi]
AB  - Purpose Germline TP53 variation is the genetic basis of Li-Fraumeni syndrome, a
      highly penetrant cancer predisposition condition. Recent reports of germline TP53
      variants in childhood hypodiploid acute lymphoblastic leukemia (ALL) suggest that
      this type of leukemia is another manifestation of Li-Fraumeni syndrome; however, 
      the pattern, prevalence, and clinical relevance of TP53 variants in childhood ALL
      remain unknown. Patients and Methods Targeted sequencing of TP53 coding regions
      was performed in 3,801 children from the Children's Oncology Group frontline ALL 
      clinical trials, AALL0232 and P9900. TP53 variant pathogenicity was evaluated
      according to experimentally determined transcriptional activity, in silico
      prediction of damaging effects, and prevalence in non-ALL control populations.
      TP53 variants were analyzed for their association with ALL presenting features
      and treatment outcomes. Results We identified 49 unique nonsilent rare TP53
      coding variants in 77 (2.0%) of 3,801 patients sequenced, of which 22 variants
      were classified as pathogenic. TP53 pathogenic variants were significantly
      over-represented in ALL compared with non-ALL controls (odds ratio, 5.2; P <
      .001). Children with TP53 pathogenic variants were significantly older at ALL
      diagnosis (median age, 15.5 years v 7.3 years; P < .001) and were more likely to 
      have hypodiploid ALL (65.4% v 1.2%; P < .001). Carrying germline TP53 pathogenic 
      variants was associated with inferior event-free survival and overall survival
      (hazard ratio, 4.2 and 3.9; P < .001 and .001, respectively). In particular,
      children with TP53 pathogenic variants were at a dramatically higher risk of
      second cancers than those without pathogenic variants, with 5-year cumulative
      incidence of 25.1% and 0.7% ( P < .001), respectively. Conclusion
      Loss-of-function germline TP53 variants predispose children to ALL and to adverse
      treatment outcomes with ALL therapy, particularly the risk of second malignant
      neoplasms.
FAU - Qian, Maoxiang
AU  - Qian M
AD  - Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya
      Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan,
      William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children's Research
      Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, 
      Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham,
      AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and
      Wexner Medical Center; Julie M. Gastier-Foster and Elaine R. Mardis, Nationwide
      Children's Hospital, Columbus, OH; Hui Zhang, The First Affiliated Hospital of
      Guangzhou Medical University, Guangzhou, Guangdong; Heng Xu, West China Hospital,
      Sichuan University and Collaborative Innovation Center, Chengdu, China; Elizabeth
      Raetz, University of Utah, Salt Lake City, UT; Eric Larsen, Maine Children's
      Cancer Program, Scarborough, ME; Naomi Winick, University of Texas Southwestern
      Medical Center, Dallas; W. Paul Bowman, Cook Children's Medical Center, Fort
      Worth, TX; Paul L. Martin, Duke University, Durham, NC; Robert Fulton, Washington
      University School of Medicine, St Louis, MO; Michael Borowitz, Johns Hopkins
      Medical Institute, Baltimore, MD; Brent Wood, University of Washington, Seattle, 
      WA; William L. Carroll, New York University, New York, NY; Stephen P. Hunger,
      Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia,
      PA; and Mignon L. Loh, Benioff Children's Hospital and University of California, 
      San Francisco, San Francisco, CA.
FAU - Cao, Xueyuan
AU  - Cao X
AD  - Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya
      Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan,
      William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children's Research
      Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, 
      Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham,
      AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and
      Wexner Medical Center; Julie M. Gastier-Foster and Elaine R. Mardis, Nationwide
      Children's Hospital, Columbus, OH; Hui Zhang, The First Affiliated Hospital of
      Guangzhou Medical University, Guangzhou, Guangdong; Heng Xu, West China Hospital,
      Sichuan University and Collaborative Innovation Center, Chengdu, China; Elizabeth
      Raetz, University of Utah, Salt Lake City, UT; Eric Larsen, Maine Children's
      Cancer Program, Scarborough, ME; Naomi Winick, University of Texas Southwestern
      Medical Center, Dallas; W. Paul Bowman, Cook Children's Medical Center, Fort
      Worth, TX; Paul L. Martin, Duke University, Durham, NC; Robert Fulton, Washington
      University School of Medicine, St Louis, MO; Michael Borowitz, Johns Hopkins
      Medical Institute, Baltimore, MD; Brent Wood, University of Washington, Seattle, 
      WA; William L. Carroll, New York University, New York, NY; Stephen P. Hunger,
      Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia,
      PA; and Mignon L. Loh, Benioff Children's Hospital and University of California, 
      San Francisco, San Francisco, CA.
FAU - Devidas, Meenakshi
AU  - Devidas M
AD  - Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya
      Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan,
      William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children's Research
      Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, 
      Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham,
      AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and
      Wexner Medical Center; Julie M. Gastier-Foster and Elaine R. Mardis, Nationwide
      Children's Hospital, Columbus, OH; Hui Zhang, The First Affiliated Hospital of
      Guangzhou Medical University, Guangzhou, Guangdong; Heng Xu, West China Hospital,
      Sichuan University and Collaborative Innovation Center, Chengdu, China; Elizabeth
      Raetz, University of Utah, Salt Lake City, UT; Eric Larsen, Maine Children's
      Cancer Program, Scarborough, ME; Naomi Winick, University of Texas Southwestern
      Medical Center, Dallas; W. Paul Bowman, Cook Children's Medical Center, Fort
      Worth, TX; Paul L. Martin, Duke University, Durham, NC; Robert Fulton, Washington
      University School of Medicine, St Louis, MO; Michael Borowitz, Johns Hopkins
      Medical Institute, Baltimore, MD; Brent Wood, University of Washington, Seattle, 
      WA; William L. Carroll, New York University, New York, NY; Stephen P. Hunger,
      Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia,
      PA; and Mignon L. Loh, Benioff Children's Hospital and University of California, 
      San Francisco, San Francisco, CA.
FAU - Yang, Wenjian
AU  - Yang W
AD  - Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya
      Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan,
      William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children's Research
      Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, 
      Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham,
      AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and
      Wexner Medical Center; Julie M. Gastier-Foster and Elaine R. Mardis, Nationwide
      Children's Hospital, Columbus, OH; Hui Zhang, The First Affiliated Hospital of
      Guangzhou Medical University, Guangzhou, Guangdong; Heng Xu, West China Hospital,
      Sichuan University and Collaborative Innovation Center, Chengdu, China; Elizabeth
      Raetz, University of Utah, Salt Lake City, UT; Eric Larsen, Maine Children's
      Cancer Program, Scarborough, ME; Naomi Winick, University of Texas Southwestern
      Medical Center, Dallas; W. Paul Bowman, Cook Children's Medical Center, Fort
      Worth, TX; Paul L. Martin, Duke University, Durham, NC; Robert Fulton, Washington
      University School of Medicine, St Louis, MO; Michael Borowitz, Johns Hopkins
      Medical Institute, Baltimore, MD; Brent Wood, University of Washington, Seattle, 
      WA; William L. Carroll, New York University, New York, NY; Stephen P. Hunger,
      Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia,
      PA; and Mignon L. Loh, Benioff Children's Hospital and University of California, 
      San Francisco, San Francisco, CA.
FAU - Cheng, Cheng
AU  - Cheng C
AD  - Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya
      Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan,
      William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children's Research
      Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, 
      Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham,
      AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and
      Wexner Medical Center; Julie M. Gastier-Foster and Elaine R. Mardis, Nationwide
      Children's Hospital, Columbus, OH; Hui Zhang, The First Affiliated Hospital of
      Guangzhou Medical University, Guangzhou, Guangdong; Heng Xu, West China Hospital,
      Sichuan University and Collaborative Innovation Center, Chengdu, China; Elizabeth
      Raetz, University of Utah, Salt Lake City, UT; Eric Larsen, Maine Children's
      Cancer Program, Scarborough, ME; Naomi Winick, University of Texas Southwestern
      Medical Center, Dallas; W. Paul Bowman, Cook Children's Medical Center, Fort
      Worth, TX; Paul L. Martin, Duke University, Durham, NC; Robert Fulton, Washington
      University School of Medicine, St Louis, MO; Michael Borowitz, Johns Hopkins
      Medical Institute, Baltimore, MD; Brent Wood, University of Washington, Seattle, 
      WA; William L. Carroll, New York University, New York, NY; Stephen P. Hunger,
      Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia,
      PA; and Mignon L. Loh, Benioff Children's Hospital and University of California, 
      San Francisco, San Francisco, CA.
FAU - Dai, Yunfeng
AU  - Dai Y
AD  - Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya
      Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan,
      William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children's Research
      Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, 
      Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham,
      AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and
      Wexner Medical Center; Julie M. Gastier-Foster and Elaine R. Mardis, Nationwide
      Children's Hospital, Columbus, OH; Hui Zhang, The First Affiliated Hospital of
      Guangzhou Medical University, Guangzhou, Guangdong; Heng Xu, West China Hospital,
      Sichuan University and Collaborative Innovation Center, Chengdu, China; Elizabeth
      Raetz, University of Utah, Salt Lake City, UT; Eric Larsen, Maine Children's
      Cancer Program, Scarborough, ME; Naomi Winick, University of Texas Southwestern
      Medical Center, Dallas; W. Paul Bowman, Cook Children's Medical Center, Fort
      Worth, TX; Paul L. Martin, Duke University, Durham, NC; Robert Fulton, Washington
      University School of Medicine, St Louis, MO; Michael Borowitz, Johns Hopkins
      Medical Institute, Baltimore, MD; Brent Wood, University of Washington, Seattle, 
      WA; William L. Carroll, New York University, New York, NY; Stephen P. Hunger,
      Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia,
      PA; and Mignon L. Loh, Benioff Children's Hospital and University of California, 
      San Francisco, San Francisco, CA.
FAU - Carroll, Andrew
AU  - Carroll A
AD  - Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya
      Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan,
      William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children's Research
      Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, 
      Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham,
      AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and
      Wexner Medical Center; Julie M. Gastier-Foster and Elaine R. Mardis, Nationwide
      Children's Hospital, Columbus, OH; Hui Zhang, The First Affiliated Hospital of
      Guangzhou Medical University, Guangzhou, Guangdong; Heng Xu, West China Hospital,
      Sichuan University and Collaborative Innovation Center, Chengdu, China; Elizabeth
      Raetz, University of Utah, Salt Lake City, UT; Eric Larsen, Maine Children's
      Cancer Program, Scarborough, ME; Naomi Winick, University of Texas Southwestern
      Medical Center, Dallas; W. Paul Bowman, Cook Children's Medical Center, Fort
      Worth, TX; Paul L. Martin, Duke University, Durham, NC; Robert Fulton, Washington
      University School of Medicine, St Louis, MO; Michael Borowitz, Johns Hopkins
      Medical Institute, Baltimore, MD; Brent Wood, University of Washington, Seattle, 
      WA; William L. Carroll, New York University, New York, NY; Stephen P. Hunger,
      Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia,
      PA; and Mignon L. Loh, Benioff Children's Hospital and University of California, 
      San Francisco, San Francisco, CA.
FAU - Heerema, Nyla A
AU  - Heerema NA
AD  - Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya
      Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan,
      William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children's Research
      Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, 
      Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham,
      AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and
      Wexner Medical Center; Julie M. Gastier-Foster and Elaine R. Mardis, Nationwide
      Children's Hospital, Columbus, OH; Hui Zhang, The First Affiliated Hospital of
      Guangzhou Medical University, Guangzhou, Guangdong; Heng Xu, West China Hospital,
      Sichuan University and Collaborative Innovation Center, Chengdu, China; Elizabeth
      Raetz, University of Utah, Salt Lake City, UT; Eric Larsen, Maine Children's
      Cancer Program, Scarborough, ME; Naomi Winick, University of Texas Southwestern
      Medical Center, Dallas; W. Paul Bowman, Cook Children's Medical Center, Fort
      Worth, TX; Paul L. Martin, Duke University, Durham, NC; Robert Fulton, Washington
      University School of Medicine, St Louis, MO; Michael Borowitz, Johns Hopkins
      Medical Institute, Baltimore, MD; Brent Wood, University of Washington, Seattle, 
      WA; William L. Carroll, New York University, New York, NY; Stephen P. Hunger,
      Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia,
      PA; and Mignon L. Loh, Benioff Children's Hospital and University of California, 
      San Francisco, San Francisco, CA.
FAU - Zhang, Hui
AU  - Zhang H
AD  - Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya
      Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan,
      William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children's Research
      Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, 
      Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham,
      AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and
      Wexner Medical Center; Julie M. Gastier-Foster and Elaine R. Mardis, Nationwide
      Children's Hospital, Columbus, OH; Hui Zhang, The First Affiliated Hospital of
      Guangzhou Medical University, Guangzhou, Guangdong; Heng Xu, West China Hospital,
      Sichuan University and Collaborative Innovation Center, Chengdu, China; Elizabeth
      Raetz, University of Utah, Salt Lake City, UT; Eric Larsen, Maine Children's
      Cancer Program, Scarborough, ME; Naomi Winick, University of Texas Southwestern
      Medical Center, Dallas; W. Paul Bowman, Cook Children's Medical Center, Fort
      Worth, TX; Paul L. Martin, Duke University, Durham, NC; Robert Fulton, Washington
      University School of Medicine, St Louis, MO; Michael Borowitz, Johns Hopkins
      Medical Institute, Baltimore, MD; Brent Wood, University of Washington, Seattle, 
      WA; William L. Carroll, New York University, New York, NY; Stephen P. Hunger,
      Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia,
      PA; and Mignon L. Loh, Benioff Children's Hospital and University of California, 
      San Francisco, San Francisco, CA.
FAU - Moriyama, Takaya
AU  - Moriyama T
AD  - Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya
      Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan,
      William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children's Research
      Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, 
      Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham,
      AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and
      Wexner Medical Center; Julie M. Gastier-Foster and Elaine R. Mardis, Nationwide
      Children's Hospital, Columbus, OH; Hui Zhang, The First Affiliated Hospital of
      Guangzhou Medical University, Guangzhou, Guangdong; Heng Xu, West China Hospital,
      Sichuan University and Collaborative Innovation Center, Chengdu, China; Elizabeth
      Raetz, University of Utah, Salt Lake City, UT; Eric Larsen, Maine Children's
      Cancer Program, Scarborough, ME; Naomi Winick, University of Texas Southwestern
      Medical Center, Dallas; W. Paul Bowman, Cook Children's Medical Center, Fort
      Worth, TX; Paul L. Martin, Duke University, Durham, NC; Robert Fulton, Washington
      University School of Medicine, St Louis, MO; Michael Borowitz, Johns Hopkins
      Medical Institute, Baltimore, MD; Brent Wood, University of Washington, Seattle, 
      WA; William L. Carroll, New York University, New York, NY; Stephen P. Hunger,
      Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia,
      PA; and Mignon L. Loh, Benioff Children's Hospital and University of California, 
      San Francisco, San Francisco, CA.
FAU - Gastier-Foster, Julie M
AU  - Gastier-Foster JM
AD  - Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya
      Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan,
      William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children's Research
      Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, 
      Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham,
      AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and
      Wexner Medical Center; Julie M. Gastier-Foster and Elaine R. Mardis, Nationwide
      Children's Hospital, Columbus, OH; Hui Zhang, The First Affiliated Hospital of
      Guangzhou Medical University, Guangzhou, Guangdong; Heng Xu, West China Hospital,
      Sichuan University and Collaborative Innovation Center, Chengdu, China; Elizabeth
      Raetz, University of Utah, Salt Lake City, UT; Eric Larsen, Maine Children's
      Cancer Program, Scarborough, ME; Naomi Winick, University of Texas Southwestern
      Medical Center, Dallas; W. Paul Bowman, Cook Children's Medical Center, Fort
      Worth, TX; Paul L. Martin, Duke University, Durham, NC; Robert Fulton, Washington
      University School of Medicine, St Louis, MO; Michael Borowitz, Johns Hopkins
      Medical Institute, Baltimore, MD; Brent Wood, University of Washington, Seattle, 
      WA; William L. Carroll, New York University, New York, NY; Stephen P. Hunger,
      Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia,
      PA; and Mignon L. Loh, Benioff Children's Hospital and University of California, 
      San Francisco, San Francisco, CA.
FAU - Xu, Heng
AU  - Xu H
AD  - Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya
      Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan,
      William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children's Research
      Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, 
      Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham,
      AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and
      Wexner Medical Center; Julie M. Gastier-Foster and Elaine R. Mardis, Nationwide
      Children's Hospital, Columbus, OH; Hui Zhang, The First Affiliated Hospital of
      Guangzhou Medical University, Guangzhou, Guangdong; Heng Xu, West China Hospital,
      Sichuan University and Collaborative Innovation Center, Chengdu, China; Elizabeth
      Raetz, University of Utah, Salt Lake City, UT; Eric Larsen, Maine Children's
      Cancer Program, Scarborough, ME; Naomi Winick, University of Texas Southwestern
      Medical Center, Dallas; W. Paul Bowman, Cook Children's Medical Center, Fort
      Worth, TX; Paul L. Martin, Duke University, Durham, NC; Robert Fulton, Washington
      University School of Medicine, St Louis, MO; Michael Borowitz, Johns Hopkins
      Medical Institute, Baltimore, MD; Brent Wood, University of Washington, Seattle, 
      WA; William L. Carroll, New York University, New York, NY; Stephen P. Hunger,
      Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia,
      PA; and Mignon L. Loh, Benioff Children's Hospital and University of California, 
      San Francisco, San Francisco, CA.
FAU - Raetz, Elizabeth
AU  - Raetz E
AD  - Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya
      Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan,
      William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children's Research
      Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, 
      Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham,
      AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and
      Wexner Medical Center; Julie M. Gastier-Foster and Elaine R. Mardis, Nationwide
      Children's Hospital, Columbus, OH; Hui Zhang, The First Affiliated Hospital of
      Guangzhou Medical University, Guangzhou, Guangdong; Heng Xu, West China Hospital,
      Sichuan University and Collaborative Innovation Center, Chengdu, China; Elizabeth
      Raetz, University of Utah, Salt Lake City, UT; Eric Larsen, Maine Children's
      Cancer Program, Scarborough, ME; Naomi Winick, University of Texas Southwestern
      Medical Center, Dallas; W. Paul Bowman, Cook Children's Medical Center, Fort
      Worth, TX; Paul L. Martin, Duke University, Durham, NC; Robert Fulton, Washington
      University School of Medicine, St Louis, MO; Michael Borowitz, Johns Hopkins
      Medical Institute, Baltimore, MD; Brent Wood, University of Washington, Seattle, 
      WA; William L. Carroll, New York University, New York, NY; Stephen P. Hunger,
      Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia,
      PA; and Mignon L. Loh, Benioff Children's Hospital and University of California, 
      San Francisco, San Francisco, CA.
FAU - Larsen, Eric
AU  - Larsen E
AD  - Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya
      Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan,
      William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children's Research
      Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, 
      Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham,
      AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and
      Wexner Medical Center; Julie M. Gastier-Foster and Elaine R. Mardis, Nationwide
      Children's Hospital, Columbus, OH; Hui Zhang, The First Affiliated Hospital of
      Guangzhou Medical University, Guangzhou, Guangdong; Heng Xu, West China Hospital,
      Sichuan University and Collaborative Innovation Center, Chengdu, China; Elizabeth
      Raetz, University of Utah, Salt Lake City, UT; Eric Larsen, Maine Children's
      Cancer Program, Scarborough, ME; Naomi Winick, University of Texas Southwestern
      Medical Center, Dallas; W. Paul Bowman, Cook Children's Medical Center, Fort
      Worth, TX; Paul L. Martin, Duke University, Durham, NC; Robert Fulton, Washington
      University School of Medicine, St Louis, MO; Michael Borowitz, Johns Hopkins
      Medical Institute, Baltimore, MD; Brent Wood, University of Washington, Seattle, 
      WA; William L. Carroll, New York University, New York, NY; Stephen P. Hunger,
      Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia,
      PA; and Mignon L. Loh, Benioff Children's Hospital and University of California, 
      San Francisco, San Francisco, CA.
FAU - Winick, Naomi
AU  - Winick N
AD  - Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya
      Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan,
      William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children's Research
      Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, 
      Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham,
      AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and
      Wexner Medical Center; Julie M. Gastier-Foster and Elaine R. Mardis, Nationwide
      Children's Hospital, Columbus, OH; Hui Zhang, The First Affiliated Hospital of
      Guangzhou Medical University, Guangzhou, Guangdong; Heng Xu, West China Hospital,
      Sichuan University and Collaborative Innovation Center, Chengdu, China; Elizabeth
      Raetz, University of Utah, Salt Lake City, UT; Eric Larsen, Maine Children's
      Cancer Program, Scarborough, ME; Naomi Winick, University of Texas Southwestern
      Medical Center, Dallas; W. Paul Bowman, Cook Children's Medical Center, Fort
      Worth, TX; Paul L. Martin, Duke University, Durham, NC; Robert Fulton, Washington
      University School of Medicine, St Louis, MO; Michael Borowitz, Johns Hopkins
      Medical Institute, Baltimore, MD; Brent Wood, University of Washington, Seattle, 
      WA; William L. Carroll, New York University, New York, NY; Stephen P. Hunger,
      Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia,
      PA; and Mignon L. Loh, Benioff Children's Hospital and University of California, 
      San Francisco, San Francisco, CA.
FAU - Bowman, W Paul
AU  - Bowman WP
AD  - Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya
      Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan,
      William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children's Research
      Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, 
      Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham,
      AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and
      Wexner Medical Center; Julie M. Gastier-Foster and Elaine R. Mardis, Nationwide
      Children's Hospital, Columbus, OH; Hui Zhang, The First Affiliated Hospital of
      Guangzhou Medical University, Guangzhou, Guangdong; Heng Xu, West China Hospital,
      Sichuan University and Collaborative Innovation Center, Chengdu, China; Elizabeth
      Raetz, University of Utah, Salt Lake City, UT; Eric Larsen, Maine Children's
      Cancer Program, Scarborough, ME; Naomi Winick, University of Texas Southwestern
      Medical Center, Dallas; W. Paul Bowman, Cook Children's Medical Center, Fort
      Worth, TX; Paul L. Martin, Duke University, Durham, NC; Robert Fulton, Washington
      University School of Medicine, St Louis, MO; Michael Borowitz, Johns Hopkins
      Medical Institute, Baltimore, MD; Brent Wood, University of Washington, Seattle, 
      WA; William L. Carroll, New York University, New York, NY; Stephen P. Hunger,
      Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia,
      PA; and Mignon L. Loh, Benioff Children's Hospital and University of California, 
      San Francisco, San Francisco, CA.
FAU - Martin, Paul L
AU  - Martin PL
AD  - Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya
      Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan,
      William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children's Research
      Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, 
      Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham,
      AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and
      Wexner Medical Center; Julie M. Gastier-Foster and Elaine R. Mardis, Nationwide
      Children's Hospital, Columbus, OH; Hui Zhang, The First Affiliated Hospital of
      Guangzhou Medical University, Guangzhou, Guangdong; Heng Xu, West China Hospital,
      Sichuan University and Collaborative Innovation Center, Chengdu, China; Elizabeth
      Raetz, University of Utah, Salt Lake City, UT; Eric Larsen, Maine Children's
      Cancer Program, Scarborough, ME; Naomi Winick, University of Texas Southwestern
      Medical Center, Dallas; W. Paul Bowman, Cook Children's Medical Center, Fort
      Worth, TX; Paul L. Martin, Duke University, Durham, NC; Robert Fulton, Washington
      University School of Medicine, St Louis, MO; Michael Borowitz, Johns Hopkins
      Medical Institute, Baltimore, MD; Brent Wood, University of Washington, Seattle, 
      WA; William L. Carroll, New York University, New York, NY; Stephen P. Hunger,
      Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia,
      PA; and Mignon L. Loh, Benioff Children's Hospital and University of California, 
      San Francisco, San Francisco, CA.
FAU - Mardis, Elaine R
AU  - Mardis ER
AD  - Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya
      Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan,
      William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children's Research
      Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, 
      Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham,
      AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and
      Wexner Medical Center; Julie M. Gastier-Foster and Elaine R. Mardis, Nationwide
      Children's Hospital, Columbus, OH; Hui Zhang, The First Affiliated Hospital of
      Guangzhou Medical University, Guangzhou, Guangdong; Heng Xu, West China Hospital,
      Sichuan University and Collaborative Innovation Center, Chengdu, China; Elizabeth
      Raetz, University of Utah, Salt Lake City, UT; Eric Larsen, Maine Children's
      Cancer Program, Scarborough, ME; Naomi Winick, University of Texas Southwestern
      Medical Center, Dallas; W. Paul Bowman, Cook Children's Medical Center, Fort
      Worth, TX; Paul L. Martin, Duke University, Durham, NC; Robert Fulton, Washington
      University School of Medicine, St Louis, MO; Michael Borowitz, Johns Hopkins
      Medical Institute, Baltimore, MD; Brent Wood, University of Washington, Seattle, 
      WA; William L. Carroll, New York University, New York, NY; Stephen P. Hunger,
      Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia,
      PA; and Mignon L. Loh, Benioff Children's Hospital and University of California, 
      San Francisco, San Francisco, CA.
FAU - Fulton, Robert
AU  - Fulton R
AD  - Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya
      Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan,
      William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children's Research
      Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, 
      Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham,
      AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and
      Wexner Medical Center; Julie M. Gastier-Foster and Elaine R. Mardis, Nationwide
      Children's Hospital, Columbus, OH; Hui Zhang, The First Affiliated Hospital of
      Guangzhou Medical University, Guangzhou, Guangdong; Heng Xu, West China Hospital,
      Sichuan University and Collaborative Innovation Center, Chengdu, China; Elizabeth
      Raetz, University of Utah, Salt Lake City, UT; Eric Larsen, Maine Children's
      Cancer Program, Scarborough, ME; Naomi Winick, University of Texas Southwestern
      Medical Center, Dallas; W. Paul Bowman, Cook Children's Medical Center, Fort
      Worth, TX; Paul L. Martin, Duke University, Durham, NC; Robert Fulton, Washington
      University School of Medicine, St Louis, MO; Michael Borowitz, Johns Hopkins
      Medical Institute, Baltimore, MD; Brent Wood, University of Washington, Seattle, 
      WA; William L. Carroll, New York University, New York, NY; Stephen P. Hunger,
      Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia,
      PA; and Mignon L. Loh, Benioff Children's Hospital and University of California, 
      San Francisco, San Francisco, CA.
FAU - Zambetti, Gerard
AU  - Zambetti G
AD  - Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya
      Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan,
      William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children's Research
      Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, 
      Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham,
      AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and
      Wexner Medical Center; Julie M. Gastier-Foster and Elaine R. Mardis, Nationwide
      Children's Hospital, Columbus, OH; Hui Zhang, The First Affiliated Hospital of
      Guangzhou Medical University, Guangzhou, Guangdong; Heng Xu, West China Hospital,
      Sichuan University and Collaborative Innovation Center, Chengdu, China; Elizabeth
      Raetz, University of Utah, Salt Lake City, UT; Eric Larsen, Maine Children's
      Cancer Program, Scarborough, ME; Naomi Winick, University of Texas Southwestern
      Medical Center, Dallas; W. Paul Bowman, Cook Children's Medical Center, Fort
      Worth, TX; Paul L. Martin, Duke University, Durham, NC; Robert Fulton, Washington
      University School of Medicine, St Louis, MO; Michael Borowitz, Johns Hopkins
      Medical Institute, Baltimore, MD; Brent Wood, University of Washington, Seattle, 
      WA; William L. Carroll, New York University, New York, NY; Stephen P. Hunger,
      Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia,
      PA; and Mignon L. Loh, Benioff Children's Hospital and University of California, 
      San Francisco, San Francisco, CA.
FAU - Borowitz, Michael
AU  - Borowitz M
AD  - Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya
      Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan,
      William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children's Research
      Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, 
      Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham,
      AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and
      Wexner Medical Center; Julie M. Gastier-Foster and Elaine R. Mardis, Nationwide
      Children's Hospital, Columbus, OH; Hui Zhang, The First Affiliated Hospital of
      Guangzhou Medical University, Guangzhou, Guangdong; Heng Xu, West China Hospital,
      Sichuan University and Collaborative Innovation Center, Chengdu, China; Elizabeth
      Raetz, University of Utah, Salt Lake City, UT; Eric Larsen, Maine Children's
      Cancer Program, Scarborough, ME; Naomi Winick, University of Texas Southwestern
      Medical Center, Dallas; W. Paul Bowman, Cook Children's Medical Center, Fort
      Worth, TX; Paul L. Martin, Duke University, Durham, NC; Robert Fulton, Washington
      University School of Medicine, St Louis, MO; Michael Borowitz, Johns Hopkins
      Medical Institute, Baltimore, MD; Brent Wood, University of Washington, Seattle, 
      WA; William L. Carroll, New York University, New York, NY; Stephen P. Hunger,
      Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia,
      PA; and Mignon L. Loh, Benioff Children's Hospital and University of California, 
      San Francisco, San Francisco, CA.
FAU - Wood, Brent
AU  - Wood B
AD  - Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya
      Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan,
      William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children's Research
      Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, 
      Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham,
      AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and
      Wexner Medical Center; Julie M. Gastier-Foster and Elaine R. Mardis, Nationwide
      Children's Hospital, Columbus, OH; Hui Zhang, The First Affiliated Hospital of
      Guangzhou Medical University, Guangzhou, Guangdong; Heng Xu, West China Hospital,
      Sichuan University and Collaborative Innovation Center, Chengdu, China; Elizabeth
      Raetz, University of Utah, Salt Lake City, UT; Eric Larsen, Maine Children's
      Cancer Program, Scarborough, ME; Naomi Winick, University of Texas Southwestern
      Medical Center, Dallas; W. Paul Bowman, Cook Children's Medical Center, Fort
      Worth, TX; Paul L. Martin, Duke University, Durham, NC; Robert Fulton, Washington
      University School of Medicine, St Louis, MO; Michael Borowitz, Johns Hopkins
      Medical Institute, Baltimore, MD; Brent Wood, University of Washington, Seattle, 
      WA; William L. Carroll, New York University, New York, NY; Stephen P. Hunger,
      Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia,
      PA; and Mignon L. Loh, Benioff Children's Hospital and University of California, 
      San Francisco, San Francisco, CA.
FAU - Nichols, Kim E
AU  - Nichols KE
AD  - Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya
      Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan,
      William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children's Research
      Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, 
      Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham,
      AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and
      Wexner Medical Center; Julie M. Gastier-Foster and Elaine R. Mardis, Nationwide
      Children's Hospital, Columbus, OH; Hui Zhang, The First Affiliated Hospital of
      Guangzhou Medical University, Guangzhou, Guangdong; Heng Xu, West China Hospital,
      Sichuan University and Collaborative Innovation Center, Chengdu, China; Elizabeth
      Raetz, University of Utah, Salt Lake City, UT; Eric Larsen, Maine Children's
      Cancer Program, Scarborough, ME; Naomi Winick, University of Texas Southwestern
      Medical Center, Dallas; W. Paul Bowman, Cook Children's Medical Center, Fort
      Worth, TX; Paul L. Martin, Duke University, Durham, NC; Robert Fulton, Washington
      University School of Medicine, St Louis, MO; Michael Borowitz, Johns Hopkins
      Medical Institute, Baltimore, MD; Brent Wood, University of Washington, Seattle, 
      WA; William L. Carroll, New York University, New York, NY; Stephen P. Hunger,
      Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia,
      PA; and Mignon L. Loh, Benioff Children's Hospital and University of California, 
      San Francisco, San Francisco, CA.
FAU - Carroll, William L
AU  - Carroll WL
AD  - Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya
      Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan,
      William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children's Research
      Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, 
      Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham,
      AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and
      Wexner Medical Center; Julie M. Gastier-Foster and Elaine R. Mardis, Nationwide
      Children's Hospital, Columbus, OH; Hui Zhang, The First Affiliated Hospital of
      Guangzhou Medical University, Guangzhou, Guangdong; Heng Xu, West China Hospital,
      Sichuan University and Collaborative Innovation Center, Chengdu, China; Elizabeth
      Raetz, University of Utah, Salt Lake City, UT; Eric Larsen, Maine Children's
      Cancer Program, Scarborough, ME; Naomi Winick, University of Texas Southwestern
      Medical Center, Dallas; W. Paul Bowman, Cook Children's Medical Center, Fort
      Worth, TX; Paul L. Martin, Duke University, Durham, NC; Robert Fulton, Washington
      University School of Medicine, St Louis, MO; Michael Borowitz, Johns Hopkins
      Medical Institute, Baltimore, MD; Brent Wood, University of Washington, Seattle, 
      WA; William L. Carroll, New York University, New York, NY; Stephen P. Hunger,
      Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia,
      PA; and Mignon L. Loh, Benioff Children's Hospital and University of California, 
      San Francisco, San Francisco, CA.
FAU - Pui, Ching-Hon
AU  - Pui CH
AD  - Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya
      Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan,
      William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children's Research
      Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, 
      Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham,
      AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and
      Wexner Medical Center; Julie M. Gastier-Foster and Elaine R. Mardis, Nationwide
      Children's Hospital, Columbus, OH; Hui Zhang, The First Affiliated Hospital of
      Guangzhou Medical University, Guangzhou, Guangdong; Heng Xu, West China Hospital,
      Sichuan University and Collaborative Innovation Center, Chengdu, China; Elizabeth
      Raetz, University of Utah, Salt Lake City, UT; Eric Larsen, Maine Children's
      Cancer Program, Scarborough, ME; Naomi Winick, University of Texas Southwestern
      Medical Center, Dallas; W. Paul Bowman, Cook Children's Medical Center, Fort
      Worth, TX; Paul L. Martin, Duke University, Durham, NC; Robert Fulton, Washington
      University School of Medicine, St Louis, MO; Michael Borowitz, Johns Hopkins
      Medical Institute, Baltimore, MD; Brent Wood, University of Washington, Seattle, 
      WA; William L. Carroll, New York University, New York, NY; Stephen P. Hunger,
      Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia,
      PA; and Mignon L. Loh, Benioff Children's Hospital and University of California, 
      San Francisco, San Francisco, CA.
FAU - Mullighan, Charles G
AU  - Mullighan CG
AD  - Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya
      Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan,
      William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children's Research
      Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, 
      Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham,
      AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and
      Wexner Medical Center; Julie M. Gastier-Foster and Elaine R. Mardis, Nationwide
      Children's Hospital, Columbus, OH; Hui Zhang, The First Affiliated Hospital of
      Guangzhou Medical University, Guangzhou, Guangdong; Heng Xu, West China Hospital,
      Sichuan University and Collaborative Innovation Center, Chengdu, China; Elizabeth
      Raetz, University of Utah, Salt Lake City, UT; Eric Larsen, Maine Children's
      Cancer Program, Scarborough, ME; Naomi Winick, University of Texas Southwestern
      Medical Center, Dallas; W. Paul Bowman, Cook Children's Medical Center, Fort
      Worth, TX; Paul L. Martin, Duke University, Durham, NC; Robert Fulton, Washington
      University School of Medicine, St Louis, MO; Michael Borowitz, Johns Hopkins
      Medical Institute, Baltimore, MD; Brent Wood, University of Washington, Seattle, 
      WA; William L. Carroll, New York University, New York, NY; Stephen P. Hunger,
      Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia,
      PA; and Mignon L. Loh, Benioff Children's Hospital and University of California, 
      San Francisco, San Francisco, CA.
FAU - Evans, William E
AU  - Evans WE
AD  - Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya
      Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan,
      William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children's Research
      Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, 
      Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham,
      AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and
      Wexner Medical Center; Julie M. Gastier-Foster and Elaine R. Mardis, Nationwide
      Children's Hospital, Columbus, OH; Hui Zhang, The First Affiliated Hospital of
      Guangzhou Medical University, Guangzhou, Guangdong; Heng Xu, West China Hospital,
      Sichuan University and Collaborative Innovation Center, Chengdu, China; Elizabeth
      Raetz, University of Utah, Salt Lake City, UT; Eric Larsen, Maine Children's
      Cancer Program, Scarborough, ME; Naomi Winick, University of Texas Southwestern
      Medical Center, Dallas; W. Paul Bowman, Cook Children's Medical Center, Fort
      Worth, TX; Paul L. Martin, Duke University, Durham, NC; Robert Fulton, Washington
      University School of Medicine, St Louis, MO; Michael Borowitz, Johns Hopkins
      Medical Institute, Baltimore, MD; Brent Wood, University of Washington, Seattle, 
      WA; William L. Carroll, New York University, New York, NY; Stephen P. Hunger,
      Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia,
      PA; and Mignon L. Loh, Benioff Children's Hospital and University of California, 
      San Francisco, San Francisco, CA.
FAU - Hunger, Stephen P
AU  - Hunger SP
AD  - Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya
      Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan,
      William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children's Research
      Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, 
      Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham,
      AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and
      Wexner Medical Center; Julie M. Gastier-Foster and Elaine R. Mardis, Nationwide
      Children's Hospital, Columbus, OH; Hui Zhang, The First Affiliated Hospital of
      Guangzhou Medical University, Guangzhou, Guangdong; Heng Xu, West China Hospital,
      Sichuan University and Collaborative Innovation Center, Chengdu, China; Elizabeth
      Raetz, University of Utah, Salt Lake City, UT; Eric Larsen, Maine Children's
      Cancer Program, Scarborough, ME; Naomi Winick, University of Texas Southwestern
      Medical Center, Dallas; W. Paul Bowman, Cook Children's Medical Center, Fort
      Worth, TX; Paul L. Martin, Duke University, Durham, NC; Robert Fulton, Washington
      University School of Medicine, St Louis, MO; Michael Borowitz, Johns Hopkins
      Medical Institute, Baltimore, MD; Brent Wood, University of Washington, Seattle, 
      WA; William L. Carroll, New York University, New York, NY; Stephen P. Hunger,
      Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia,
      PA; and Mignon L. Loh, Benioff Children's Hospital and University of California, 
      San Francisco, San Francisco, CA.
FAU - Relling, Mary V
AU  - Relling MV
AD  - Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya
      Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan,
      William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children's Research
      Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, 
      Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham,
      AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and
      Wexner Medical Center; Julie M. Gastier-Foster and Elaine R. Mardis, Nationwide
      Children's Hospital, Columbus, OH; Hui Zhang, The First Affiliated Hospital of
      Guangzhou Medical University, Guangzhou, Guangdong; Heng Xu, West China Hospital,
      Sichuan University and Collaborative Innovation Center, Chengdu, China; Elizabeth
      Raetz, University of Utah, Salt Lake City, UT; Eric Larsen, Maine Children's
      Cancer Program, Scarborough, ME; Naomi Winick, University of Texas Southwestern
      Medical Center, Dallas; W. Paul Bowman, Cook Children's Medical Center, Fort
      Worth, TX; Paul L. Martin, Duke University, Durham, NC; Robert Fulton, Washington
      University School of Medicine, St Louis, MO; Michael Borowitz, Johns Hopkins
      Medical Institute, Baltimore, MD; Brent Wood, University of Washington, Seattle, 
      WA; William L. Carroll, New York University, New York, NY; Stephen P. Hunger,
      Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia,
      PA; and Mignon L. Loh, Benioff Children's Hospital and University of California, 
      San Francisco, San Francisco, CA.
FAU - Loh, Mignon L
AU  - Loh ML
AD  - Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya
      Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan,
      William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children's Research
      Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, 
      Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham,
      AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and
      Wexner Medical Center; Julie M. Gastier-Foster and Elaine R. Mardis, Nationwide
      Children's Hospital, Columbus, OH; Hui Zhang, The First Affiliated Hospital of
      Guangzhou Medical University, Guangzhou, Guangdong; Heng Xu, West China Hospital,
      Sichuan University and Collaborative Innovation Center, Chengdu, China; Elizabeth
      Raetz, University of Utah, Salt Lake City, UT; Eric Larsen, Maine Children's
      Cancer Program, Scarborough, ME; Naomi Winick, University of Texas Southwestern
      Medical Center, Dallas; W. Paul Bowman, Cook Children's Medical Center, Fort
      Worth, TX; Paul L. Martin, Duke University, Durham, NC; Robert Fulton, Washington
      University School of Medicine, St Louis, MO; Michael Borowitz, Johns Hopkins
      Medical Institute, Baltimore, MD; Brent Wood, University of Washington, Seattle, 
      WA; William L. Carroll, New York University, New York, NY; Stephen P. Hunger,
      Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia,
      PA; and Mignon L. Loh, Benioff Children's Hospital and University of California, 
      San Francisco, San Francisco, CA.
FAU - Yang, Jun J
AU  - Yang JJ
AD  - Maoxiang Qian, Xueyuan Cao, Wenjian Yang, Cheng Cheng, Hui Zhang, Takaya
      Moriyama, Gerard Zambetti, Kim E. Nichols, Ching-Hon Pui, Charles G. Mullighan,
      William E. Evans, Mary V. Relling, and Jun J. Yang, St Jude Children's Research
      Hospital, Memphis, TN; Meenakshi Devidas and Yunfeng Dai, University of Florida, 
      Gainesville, FL; Andrew Carroll, University of Alabama at Birmingham, Birmingham,
      AL; Nyla A. Heerema and Julie M. Gastier-Foster, The Ohio State University and
      Wexner Medical Center; Julie M. Gastier-Foster and Elaine R. Mardis, Nationwide
      Children's Hospital, Columbus, OH; Hui Zhang, The First Affiliated Hospital of
      Guangzhou Medical University, Guangzhou, Guangdong; Heng Xu, West China Hospital,
      Sichuan University and Collaborative Innovation Center, Chengdu, China; Elizabeth
      Raetz, University of Utah, Salt Lake City, UT; Eric Larsen, Maine Children's
      Cancer Program, Scarborough, ME; Naomi Winick, University of Texas Southwestern
      Medical Center, Dallas; W. Paul Bowman, Cook Children's Medical Center, Fort
      Worth, TX; Paul L. Martin, Duke University, Durham, NC; Robert Fulton, Washington
      University School of Medicine, St Louis, MO; Michael Borowitz, Johns Hopkins
      Medical Institute, Baltimore, MD; Brent Wood, University of Washington, Seattle, 
      WA; William L. Carroll, New York University, New York, NY; Stephen P. Hunger,
      Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia,
      PA; and Mignon L. Loh, Benioff Children's Hospital and University of California, 
      San Francisco, San Francisco, CA.
LA  - eng
GR  - U10 CA180899/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20180104
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of
      Clinical Oncology
JID - 8309333
EDAT- 2018/01/05 06:00
MHDA- 2018/01/05 06:00
CRDT- 2018/01/05 06:00
PHST- 2018/01/05 06:00 [pubmed]
PHST- 2018/01/05 06:00 [medline]
PHST- 2018/01/05 06:00 [entrez]
AID - 10.1200/JCO.2017.75.5215 [doi]
PST - aheadofprint
SO  - J Clin Oncol. 2018 Jan 4:JCO2017755215. doi: 10.1200/JCO.2017.75.5215.

PMID- 29334356
OWN - NLM
STAT- Publisher
LR  - 20180115
IS  - 2050-084X (Electronic)
IS  - 2050-084X (Linking)
VI  - 7
DP  - 2018 Jan 15
TI  - p53 suppresses mutagenic RAD52 and POLtheta pathways by orchestrating DNA
      replication restart homeostasis.
LID - 10.7554/eLife.31723 [doi]
LID - e31723 [pii]
AB  - Classically, p53 tumor suppressor acts in transcription, apoptosis, and cell
      cycle arrest. Yet, replication-mediated genomic instability is integral to
      oncogenesis, and p53 mutations promote tumor progression and drug-resistance. By 
      delineating human and murine separation-of-function p53 alleles, we find that p53
      null and gain-of-function (GOF) mutations exhibit defects in restart of stalled
      or damaged DNA replication forks driving genomic instability genetically
      separable from transcription activation. By assaying protein-DNA fork
      interactions in single cells, we unveil a p53-MLL3-enabled recruitment of MRE11
      DNA replication restart nuclease. Importantly, p53 defects or depletion
      unexpectedly allow mutagenic RAD52 and POLq pathways to hijack stalled forks,
      which we find reflected in p53 defective breast-cancer patient COSMIC mutational 
      signatures. These data uncover p53 as a keystone regulator of replication
      homeostasis within a DNA restart network. Mechanistically, this has important
      implications for development of resistance in cancer therapy. Combined, these
      results define an unexpected role for p53-mediated suppression of replication
      genome instability.
FAU - Roy, Sunetra
AU  - Roy S
AD  - Department of Cancer Biology, UT MD Anderson Cancer Center, Houston, United
      States.
FAU - Tomaszowski, Karl-Heinz
AU  - Tomaszowski KH
AD  - Department of Cancer Biology, UT MD Anderson Cancer Center, Houston, United
      States.
FAU - Luzwick, Jessica W
AU  - Luzwick JW
AD  - Department of Cancer Biology, UT MD Anderson Cancer Center, Houston, United
      States.
FAU - Park, Soyoung
AU  - Park S
AD  - Department of Cancer Biology, UT MD Anderson Cancer Center, Houston, United
      States.
FAU - Li, Jun
AU  - Li J
AD  - Department of Genomic Medicine, UT MD Anderson Cancer Center, Houston, United
      States.
FAU - Murphy, Maureen
AU  - Murphy M
AUID- ORCID: http://orcid.org/0000-0001-7644-7296
AD  - Molecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia,
      United States.
FAU - Schlacher, Katharina
AU  - Schlacher K
AUID- ORCID: http://orcid.org/0000-0001-7226-6391
AD  - Department of Cancer Biology, UT MD Anderson Cancer Center, Houston, United
      States.
LA  - eng
PT  - Journal Article
DEP - 20180115
PL  - England
TA  - Elife
JT  - eLife
JID - 101579614
OTO - NOTNLM
OT  - chromosomes
OT  - genes
OT  - human
OT  - mouse
EDAT- 2018/01/16 06:00
MHDA- 2018/01/16 06:00
CRDT- 2018/01/16 06:00
PHST- 2017/09/03 00:00 [received]
PHST- 2018/01/12 00:00 [accepted]
PHST- 2018/01/16 06:00 [entrez]
PHST- 2018/01/16 06:00 [pubmed]
PHST- 2018/01/16 06:00 [medline]
AID - 10.7554/eLife.31723 [doi]
PST - aheadofprint
SO  - Elife. 2018 Jan 15;7. doi: 10.7554/eLife.31723.

PMID- 29352857
OWN - NLM
STAT- Publisher
LR  - 20180121
IS  - 1879-016X (Electronic)
IS  - 0163-7258 (Linking)
DP  - 2018 Jan 17
TI  - Combining chemotherapy with PD-1 blockade in NSCLC.
LID - S0163-7258(18)30010-X [pii]
LID - 10.1016/j.pharmthera.2018.01.003 [doi]
AB  - Antitumor immunity relies on the ability of the immune system to recognize tumor 
      cells as foreign and eliminate them. An effective immune response in this setting
      is due to surveillance of tumor-specific antigens that induce an adaptive immune 
      response resulting in T-cell mediated cytotoxicity. Immune checkpoint inhibitors,
      specifically those targeting the programmed cell death-1 (PD-1)/programmed cell
      death ligand-1 (PD-L1) axis, have demonstrated promising activity in non-small
      cell lung cancer (NSCLC). However, there remains a crucial need for better
      treatment strategies for the majority of patients with advanced NSCLC,
      particularly in the frontline setting. Chemotherapy can increase antigenicity via
      immunogenic cell death (ICD) of tumor cells as well as also reduce "off target"
      immunosuppression in the tumor microenvironment (TME). Combining chemotherapy
      with PD-1 blockade harnesses the potential synergy between these agents and has
      led to encouraging results in the up-front treatment of NSCLC. In this review, we
      summarize the preclinical rationale behind these combinations and review recent
      trial data demonstrating their efficacy.
CI  - Copyright (c) 2018. Published by Elsevier Inc.
FAU - Mathew, Matthen
AU  - Mathew M
AD  - Columbia University Medical Center, 177 Fort Washington Avenue, MHB 6GN-435, New 
      York, NY 10032, United States.
FAU - Enzler, Thomas
AU  - Enzler T
AD  - Columbia University Medical Center, 177 Fort Washington Avenue, MHB 6GN-435, New 
      York, NY 10032, United States.
FAU - Shu, Catherine A
AU  - Shu CA
AD  - Columbia University Medical Center, 177 Fort Washington Avenue, MHB 6GN-435, New 
      York, NY 10032, United States.
FAU - Rizvi, Naiyer A
AU  - Rizvi NA
AD  - Columbia University Medical Center, 177 Fort Washington Avenue, MHB 6GN-435, New 
      York, NY 10032, United States. Electronic address: nar2144@cumc.columbia.edu.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180117
PL  - England
TA  - Pharmacol Ther
JT  - Pharmacology & therapeutics
JID - 7905840
OTO - NOTNLM
OT  - Chemotherapy immunotherapy combinations
OT  - Immune checkpoint inhibitors
OT  - Immunogenic cell death
OT  - NSCLC
OT  - PD-1/L1 inhibitors
EDAT- 2018/01/22 06:00
MHDA- 2018/01/22 06:00
CRDT- 2018/01/22 06:00
PHST- 2018/01/22 06:00 [entrez]
PHST- 2018/01/22 06:00 [pubmed]
PHST- 2018/01/22 06:00 [medline]
AID - S0163-7258(18)30010-X [pii]
AID - 10.1016/j.pharmthera.2018.01.003 [doi]
PST - aheadofprint
SO  - Pharmacol Ther. 2018 Jan 17. pii: S0163-7258(18)30010-X. doi:
      10.1016/j.pharmthera.2018.01.003.

PMID- 29351847
OWN - NLM
STAT- In-Data-Review
LR  - 20180125
IS  - 1097-4164 (Electronic)
IS  - 1097-2765 (Linking)
VI  - 69
IP  - 2
DP  - 2018 Jan 18
TI  - Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and
      Oncogenic Function.
PG  - 279-291.e5
LID - S1097-2765(17)30981-4 [pii]
LID - 10.1016/j.molcel.2017.12.024 [doi]
AB  - Sustained energy starvation leads to activation of AMP-activated protein kinase
      (AMPK), which coordinates energy status with numerous cellular processes
      including metabolism, protein synthesis, and autophagy. Here, we report that AMPK
      phosphorylates the histone methyltransferase EZH2 at T311 to disrupt the
      interaction between EZH2 and SUZ12, another core component of the polycomb
      repressive complex 2 (PRC2), leading to attenuated PRC2-dependent methylation of 
      histone H3 at Lys27. As such, PRC2 target genes, many of which are known tumor
      suppressors, were upregulated upon T311-EZH2 phosphorylation, which suppressed
      tumor cell growth both in cell culture and mouse xenografts. Pathologically,
      immunohistochemical analyses uncovered a positive correlation between AMPK
      activity and pT311-EZH2, and higher pT311-EZH2 correlates with better survival in
      both ovarian and breast cancer patients. Our finding suggests that AMPK agonists 
      might be promising sensitizers for EZH2-targeting cancer therapies.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Wan, Lixin
AU  - Wan L
AD  - Department of Molecular Oncology, H. Lee Moffitt Cancer Center and Research
      Institute, Tampa, FL 33612, USA; Department of Pathology, Beth Israel Deaconess
      Medical Center, Harvard Medical School, Boston, MA 02215, USA. Electronic
      address: lixin.wan@moffitt.org.
FAU - Xu, Kexin
AU  - Xu K
AD  - Department of Molecular Medicine, University of Texas Health Science Center at
      San Antonio, San Antonio, TX 78229, USA; Department of Medical Oncology and
      Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston,
      MA 02215, USA.
FAU - Wei, Yongkun
AU  - Wei Y
AD  - Department of Molecular and Cellular Oncology, University of Texas MD Anderson
      Cancer Center, Houston, TX 77030, USA.
FAU - Zhang, Jinfang
AU  - Zhang J
AD  - Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical
      School, Boston, MA 02215, USA.
FAU - Han, Tao
AU  - Han T
AD  - Department of Molecular Oncology, H. Lee Moffitt Cancer Center and Research
      Institute, Tampa, FL 33612, USA.
FAU - Fry, Christopher
AU  - Fry C
AD  - Cell Signaling Technology, Danvers, MA 01923, USA.
FAU - Zhang, Zhao
AU  - Zhang Z
AD  - Department of Molecular Medicine, University of Texas Health Science Center at
      San Antonio, San Antonio, TX 78229, USA.
FAU - Wang, Yao Vickie
AU  - Wang YV
AD  - Department of Molecular Medicine, University of Texas Health Science Center at
      San Antonio, San Antonio, TX 78229, USA.
FAU - Huang, Liyu
AU  - Huang L
AD  - Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical
      School, Boston, MA 02215, USA; Chinese National Human Genome Center at Shanghai, 
      Shanghai 201203, PRC.
FAU - Yuan, Min
AU  - Yuan M
AD  - Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215,
      USA.
FAU - Xia, Weiya
AU  - Xia W
AD  - Department of Molecular and Cellular Oncology, University of Texas MD Anderson
      Cancer Center, Houston, TX 77030, USA.
FAU - Chang, Wei-Chao
AU  - Chang WC
AD  - Graduate Institute of Biomedical Sciences and Center for Molecular Medicine,
      China Medical University, Taichung 404, Taiwan.
FAU - Huang, Wen-Chien
AU  - Huang WC
AD  - Department of Surgery, Mackay Memorial Hospital, Taipei, Taiwan.
FAU - Liu, Chien-Liang
AU  - Liu CL
AD  - Department of Surgery, Mackay Memorial Hospital, Taipei, Taiwan.
FAU - Chang, Yuan-Ching
AU  - Chang YC
AD  - Department of Surgery, Mackay Memorial Hospital, Taipei, Taiwan.
FAU - Liu, Jinsong
AU  - Liu J
AD  - Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, 
      TX, USA.
FAU - Wu, Yun
AU  - Wu Y
AD  - Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, 
      TX, USA.
FAU - Jin, Victor X
AU  - Jin VX
AD  - Department of Molecular Medicine, University of Texas Health Science Center at
      San Antonio, San Antonio, TX 78229, USA.
FAU - Dai, Xiangpeng
AU  - Dai X
AD  - Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical
      School, Boston, MA 02215, USA.
FAU - Guo, Jianfeng
AU  - Guo J
AD  - Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical
      School, Boston, MA 02215, USA; Department of Obstetrics and Gynecology, Union
      Hospital, Tongji Medical College, Huazhong University of Science and Technology, 
      Wuhan 430022, PRC.
FAU - Liu, Jia
AU  - Liu J
AD  - Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical
      School, Boston, MA 02215, USA; Cardiovascular Research Center, Xi'an Jiaotong
      University School of Medicine, Xi'an 710061, PRC.
FAU - Jiang, Shulong
AU  - Jiang S
AD  - Department of Molecular Oncology, H. Lee Moffitt Cancer Center and Research
      Institute, Tampa, FL 33612, USA; Department of Oncology, Jining First People's
      Hospital, Jining, Shandong 272111, PRC; Department of Oncology, Guang'anmen
      Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, PRC.
FAU - Li, Jin
AU  - Li J
AD  - Department of Molecular Oncology, H. Lee Moffitt Cancer Center and Research
      Institute, Tampa, FL 33612, USA; Department of Urology, 254th Hospital of PLA,
      Tianjin 300142, PRC.
FAU - Asara, John M
AU  - Asara JM
AD  - Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215,
      USA.
FAU - Brown, Myles
AU  - Brown M
AD  - Department of Medical Oncology and Center for Functional Cancer Epigenetics,
      Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine,
      Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
      Electronic address: myles_brown@dfci.harvard.edu.
FAU - Hung, Mien-Chie
AU  - Hung MC
AD  - Department of Molecular and Cellular Oncology, University of Texas MD Anderson
      Cancer Center, Houston, TX 77030, USA; Graduate Institute of Biomedical Sciences 
      and Center for Molecular Medicine, China Medical University, Taichung 404,
      Taiwan. Electronic address: mhung@mdanderson.org.
FAU - Wei, Wenyi
AU  - Wei W
AD  - Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical
      School, Boston, MA 02215, USA. Electronic address: wwei2@bidmc.harvard.edu.
LA  - eng
GR  - R00 CA178199/CA/NCI NIH HHS/United States
GR  - R00 CA183914/CA/NCI NIH HHS/United States
GR  - R01 GM114142/GM/NIGMS NIH HHS/United States
GR  - R01 GM094777/GM/NIGMS NIH HHS/United States
GR  - K99 CA183914/CA/NCI NIH HHS/United States
GR  - K99 CA212292/CA/NCI NIH HHS/United States
GR  - R01 CA211615/CA/NCI NIH HHS/United States
GR  - R01 CA177910/CA/NCI NIH HHS/United States
GR  - R01 GM089763/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Mol Cell
JT  - Molecular cell
JID - 9802571
PMC - PMC5777296
MID - NIHMS930815
OTO - NOTNLM
OT  - AMPK
OT  - EZH2
OT  - metformin
OT  - ovarian cancer
OT  - phosphorylation
OT  - polycomb repressive complex 2
EDAT- 2018/01/21 06:00
MHDA- 2018/01/21 06:00
CRDT- 2018/01/21 06:00
PMCR- 2019/01/18 00:00
PHST- 2017/07/24 00:00 [received]
PHST- 2017/11/11 00:00 [revised]
PHST- 2017/12/22 00:00 [accepted]
PHST- 2019/01/18 00:00 [pmc-release]
PHST- 2018/01/21 06:00 [entrez]
PHST- 2018/01/21 06:00 [pubmed]
PHST- 2018/01/21 06:00 [medline]
AID - S1097-2765(17)30981-4 [pii]
AID - 10.1016/j.molcel.2017.12.024 [doi]
PST - ppublish
SO  - Mol Cell. 2018 Jan 18;69(2):279-291.e5. doi: 10.1016/j.molcel.2017.12.024.

PMID- 29316436
OWN - NLM
STAT- In-Data-Review
LR  - 20180112
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 33
IP  - 1
DP  - 2018 Jan 8
TI  - Oncogenic KRAS Regulates Amino Acid Homeostasis and Asparagine Biosynthesis via
      ATF4 and Alters Sensitivity to L-Asparaginase.
PG  - 91-107.e6
LID - S1535-6108(17)30555-X [pii]
LID - 10.1016/j.ccell.2017.12.003 [doi]
AB  - KRAS is a regulator of the nutrient stress response in non-small-cell lung cancer
      (NSCLC). Induction of the ATF4 pathway during nutrient depletion requires AKT and
      NRF2 downstream of KRAS. The tumor suppressor KEAP1 strongly influences the
      outcome of activation of this pathway during nutrient stress; loss of KEAP1 in
      KRAS mutant cells leads to apoptosis. Through ATF4 regulation, KRAS alters amino 
      acid uptake and asparagine biosynthesis. The ATF4 target asparagine synthetase
      (ASNS) contributes to apoptotic suppression, protein biosynthesis, and mTORC1
      activation. Inhibition of AKT suppressed ASNS expression and, combined with
      depletion of extracellular asparagine, decreased tumor growth. Therefore, KRAS is
      important for the cellular response to nutrient stress, and ASNS represents a
      promising therapeutic target in KRAS mutant NSCLC.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Gwinn, Dana M
AU  - Gwinn DM
AD  - Division of Hematology and Oncology, Department of Pediatrics, Stanford
      University School of Medicine, Stanford, CA 94305, USA; Division of Hematology
      and Oncology, Department of Pediatrics, University of California San Francisco,
      San Francisco, CA 94158, USA.
FAU - Lee, Alex G
AU  - Lee AG
AD  - Division of Hematology and Oncology, Department of Pediatrics, Stanford
      University School of Medicine, Stanford, CA 94305, USA; Division of Hematology
      and Oncology, Department of Pediatrics, University of California San Francisco,
      San Francisco, CA 94158, USA.
FAU - Briones-Martin-Del-Campo, Marcela
AU  - Briones-Martin-Del-Campo M
AD  - Division of Hematology and Oncology, Department of Pediatrics, University of
      California San Francisco, San Francisco, CA 94158, USA.
FAU - Conn, Crystal S
AU  - Conn CS
AD  - School of Medicine and Department of Urology, Helen Diller Family Comprehensive
      Cancer Center, University of California, San Francisco, San Francisco, CA 94158, 
      USA.
FAU - Simpson, David R
AU  - Simpson DR
AD  - Division of Hematology and Oncology, Department of Pediatrics, Stanford
      University School of Medicine, Stanford, CA 94305, USA; Division of Hematology
      and Oncology, Department of Pediatrics, University of California San Francisco,
      San Francisco, CA 94158, USA.
FAU - Scott, Anna I
AU  - Scott AI
AD  - Stanford University, Department of Pathology, Stanford, CA 94305, USA.
FAU - Le, Anthony
AU  - Le A
AD  - Stanford University, Department of Pathology, Stanford, CA 94305, USA.
FAU - Cowan, Tina M
AU  - Cowan TM
AD  - Stanford University, Department of Pathology, Stanford, CA 94305, USA.
FAU - Ruggero, Davide
AU  - Ruggero D
AD  - School of Medicine and Department of Urology, Helen Diller Family Comprehensive
      Cancer Center, University of California, San Francisco, San Francisco, CA 94158, 
      USA.
FAU - Sweet-Cordero, E Alejandro
AU  - Sweet-Cordero EA
AD  - Division of Hematology and Oncology, Department of Pediatrics, Stanford
      University School of Medicine, Stanford, CA 94305, USA; Division of Hematology
      and Oncology, Department of Pediatrics, University of California San Francisco,
      San Francisco, CA 94158, USA. Electronic address:
      alejandro.sweet-cordero@ucsf.edu.
LA  - eng
GR  - R01 CA129562/CA/NCI NIH HHS/United States
GR  - T32 CA009302/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
PMC - PMC5761662
MID - NIHMS927863
OTO - NOTNLM
OT  - ASNS
OT  - ATF4
OT  - KEAP1
OT  - KRAS
OT  - L-asparaginase
OT  - NRF2
OT  - PI3K
OT  - asparagine
OT  - glutamine
OT  - synthetic vulnerability
EDAT- 2018/01/10 06:00
MHDA- 2018/01/10 06:00
CRDT- 2018/01/10 06:00
PMCR- 2019/01/08 00:00
PHST- 2016/06/13 00:00 [received]
PHST- 2017/05/25 00:00 [revised]
PHST- 2017/12/07 00:00 [accepted]
PHST- 2019/01/08 00:00 [pmc-release]
PHST- 2018/01/10 06:00 [entrez]
PHST- 2018/01/10 06:00 [pubmed]
PHST- 2018/01/10 06:00 [medline]
AID - S1535-6108(17)30555-X [pii]
AID - 10.1016/j.ccell.2017.12.003 [doi]
PST - ppublish
SO  - Cancer Cell. 2018 Jan 8;33(1):91-107.e6. doi: 10.1016/j.ccell.2017.12.003.

PMID- 29332945
OWN - NLM
STAT- Publisher
LR  - 20180122
IS  - 1740-1534 (Electronic)
IS  - 1740-1526 (Linking)
DP  - 2018 Jan 15
TI  - The human skin microbiome.
LID - 10.1038/nrmicro.2017.157 [doi]
AB  - Functioning as the exterior interface of the human body with the environment,
      skin acts as a physical barrier to prevent the invasion of foreign pathogens
      while providing a home to the commensal microbiota. The harsh physical landscape 
      of skin, particularly the desiccated, nutrient-poor, acidic environment, also
      contributes to the adversity that pathogens face when colonizing human skin.
      Despite this, the skin is colonized by a diverse microbiota. In this Review, we
      describe amplicon and shotgun metagenomic DNA sequencing studies that have been
      used to assess the taxonomic diversity of microorganisms that are associated with
      skin from the kingdom to the strain level. We discuss recent insights into skin
      microbial communities, including their composition in health and disease, the
      dynamics between species and interactions with the immune system, with a focus on
      Propionibacterium acnes, Staphylococcus epidermidis and Staphylococcus aureus.
FAU - Byrd, Allyson L
AU  - Byrd AL
AD  - Microbial Genomics Section, National Human Genome Research Institute, National
      Institutes of Health, Bethesda, Maryland 20892, USA.
AD  - Department of Bioinformatics, Boston University, Boston, Massachusetts 02215,
      USA.
AD  - Mucosal Immunology Section, Laboratory of Parasitic Diseases, National Institute 
      of Allergy and Infectious Diseases, National Institutes of Health, Bethesda,
      Maryland 20892, USA.
AD  - Department of Cancer Immunology, Genentech, South San Francisco, California
      94080, USA.
FAU - Belkaid, Yasmine
AU  - Belkaid Y
AD  - Mucosal Immunology Section, Laboratory of Parasitic Diseases, National Institute 
      of Allergy and Infectious Diseases, National Institutes of Health, Bethesda,
      Maryland 20892, USA.
AD  - National Institute of Allergy and Infectious Diseases Microbiome Program,
      Department of Intramural Research, National Institute of Allergy and Infectious
      Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.
FAU - Segre, Julia A
AU  - Segre JA
AD  - Microbial Genomics Section, National Human Genome Research Institute, National
      Institutes of Health, Bethesda, Maryland 20892, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180115
PL  - England
TA  - Nat Rev Microbiol
JT  - Nature reviews. Microbiology
JID - 101190261
EDAT- 2018/01/16 06:00
MHDA- 2018/01/16 06:00
CRDT- 2018/01/16 06:00
PHST- 2018/01/16 06:00 [pubmed]
PHST- 2018/01/16 06:00 [medline]
PHST- 2018/01/16 06:00 [entrez]
AID - nrmicro.2017.157 [pii]
AID - 10.1038/nrmicro.2017.157 [doi]
PST - aheadofprint
SO  - Nat Rev Microbiol. 2018 Jan 15. pii: nrmicro.2017.157. doi:
      10.1038/nrmicro.2017.157.

PMID- 29337182
OWN - NLM
STAT- Publisher
LR  - 20180116
IS  - 1875-9777 (Electronic)
IS  - 1875-9777 (Linking)
DP  - 2018 Jan 10
TI  - Human Pancreatic Tumor Organoids Reveal Loss of Stem Cell Niche Factor Dependence
      during Disease Progression.
LID - S1934-5909(17)30510-6 [pii]
LID - 10.1016/j.stem.2017.12.009 [doi]
AB  - Despite recent efforts to dissect the inter-tumor heterogeneity of pancreatic
      ductal adenocarcinoma (PDAC) by determining prognosis-predictive gene expression 
      signatures for specific subtypes, their functional differences remain elusive.
      Here, we established a pancreatic tumor organoid library encompassing 39
      patient-derived PDACs and identified 3 functional subtypes based on their stem
      cell niche factor dependencies on Wnt and R-spondin. A Wnt-non-producing subtype 
      required Wnt from cancer-associated fibroblasts, whereas a Wnt-producing subtype 
      autonomously secreted Wnt ligands and an R-spondin-independent subtype grew in
      the absence of Wnt and R-spondin. Transcriptome analysis of PDAC organoids
      revealed gene-expression signatures that associated Wnt niche subtypes with
      GATA6-dependent gene expression subtypes, which were functionally supported by
      genetic perturbation of GATA6. Furthermore, CRISPR-Cas9-based genome editing of
      PDAC driver genes (KRAS, CDKN2A, SMAD4, and TP53) demonstrated non-genetic
      acquisition of Wnt niche independence during pancreas tumorigenesis.
      Collectively, our results reveal functional heterogeneity of Wnt niche
      independency in PDAC that is non-genetically formed through tumor progression.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Seino, Takashi
AU  - Seino T
AD  - Department of Gastroenterology, Keio University School of Medicine, Tokyo
      160-8582, Japan.
FAU - Kawasaki, Shintaro
AU  - Kawasaki S
AD  - Department of Gastroenterology, Keio University School of Medicine, Tokyo
      160-8582, Japan.
FAU - Shimokawa, Mariko
AU  - Shimokawa M
AD  - Department of Gastroenterology, Keio University School of Medicine, Tokyo
      160-8582, Japan.
FAU - Tamagawa, Hiroki
AU  - Tamagawa H
AD  - Department of Gastroenterology, Keio University School of Medicine, Tokyo
      160-8582, Japan.
FAU - Toshimitsu, Kohta
AU  - Toshimitsu K
AD  - Department of Gastroenterology, Keio University School of Medicine, Tokyo
      160-8582, Japan.
FAU - Fujii, Masayuki
AU  - Fujii M
AD  - Department of Gastroenterology, Keio University School of Medicine, Tokyo
      160-8582, Japan.
FAU - Ohta, Yuki
AU  - Ohta Y
AD  - Department of Gastroenterology, Keio University School of Medicine, Tokyo
      160-8582, Japan.
FAU - Matano, Mami
AU  - Matano M
AD  - Department of Gastroenterology, Keio University School of Medicine, Tokyo
      160-8582, Japan.
FAU - Nanki, Kosaku
AU  - Nanki K
AD  - Department of Gastroenterology, Keio University School of Medicine, Tokyo
      160-8582, Japan.
FAU - Kawasaki, Kenta
AU  - Kawasaki K
AD  - Department of Gastroenterology, Keio University School of Medicine, Tokyo
      160-8582, Japan.
FAU - Takahashi, Sirirat
AU  - Takahashi S
AD  - Department of Gastroenterology, Keio University School of Medicine, Tokyo
      160-8582, Japan.
FAU - Sugimoto, Shinya
AU  - Sugimoto S
AD  - Department of Gastroenterology, Keio University School of Medicine, Tokyo
      160-8582, Japan.
FAU - Iwasaki, Eisuke
AU  - Iwasaki E
AD  - Department of Gastroenterology, Keio University School of Medicine, Tokyo
      160-8582, Japan.
FAU - Takagi, Junichi
AU  - Takagi J
AD  - Laboratory of Protein Synthesis and Expression, Institute for Protein Research,
      Osaka University, Suita 565-0871, Japan.
FAU - Itoi, Takao
AU  - Itoi T
AD  - Department of Gastroenterology, Tokyo Medical University, Tokyo 160-0023, Japan.
FAU - Kitago, Minoru
AU  - Kitago M
AD  - Department of Surgery, Keio University School of Medicine, Tokyo 160-8582, Japan.
FAU - Kitagawa, Yuko
AU  - Kitagawa Y
AD  - Department of Surgery, Keio University School of Medicine, Tokyo 160-8582, Japan.
FAU - Kanai, Takanori
AU  - Kanai T
AD  - Department of Gastroenterology, Keio University School of Medicine, Tokyo
      160-8582, Japan.
FAU - Sato, Toshiro
AU  - Sato T
AD  - Department of Gastroenterology, Keio University School of Medicine, Tokyo
      160-8582, Japan. Electronic address: t.sato@keio.jp.
LA  - eng
PT  - Journal Article
DEP - 20180110
PL  - United States
TA  - Cell Stem Cell
JT  - Cell stem cell
JID - 101311472
OTO - NOTNLM
OT  - CRISPR-Cas9
OT  - GATA6
OT  - Wnt
OT  - organoids
OT  - pancreatic cancer
OT  - stem cell niche
EDAT- 2018/01/18 06:00
MHDA- 2018/01/18 06:00
CRDT- 2018/01/17 06:00
PHST- 2017/05/18 00:00 [received]
PHST- 2017/10/30 00:00 [revised]
PHST- 2017/12/14 00:00 [accepted]
PHST- 2018/01/17 06:00 [entrez]
PHST- 2018/01/18 06:00 [pubmed]
PHST- 2018/01/18 06:00 [medline]
AID - S1934-5909(17)30510-6 [pii]
AID - 10.1016/j.stem.2017.12.009 [doi]
PST - aheadofprint
SO  - Cell Stem Cell. 2018 Jan 10. pii: S1934-5909(17)30510-6. doi:
      10.1016/j.stem.2017.12.009.

PMID- 29291351
OWN - NLM
STAT- Publisher
LR  - 20180129
IS  - 1546-170X (Electronic)
IS  - 1078-8956 (Linking)
DP  - 2018 Jan 1
TI  - The deubiquitinating enzyme cylindromatosis mitigates nonalcoholic
      steatohepatitis.
LID - 10.1038/nm.4461 [doi]
AB  - Nonalcoholic steatohepatitis (NASH) is a common clinical condition that can lead 
      to advanced liver diseases. Lack of effective pharmacotherapies for NASH is
      largely attributable to an incomplete understanding of its pathogenesis. The
      deubiquitinase cylindromatosis (CYLD) plays key roles in inflammation and cancer.
      Here we identified CYLD as a suppressor of NASH in mice and in monkeys. CYLD is
      progressively degraded upon interaction with the E3 ligase TRIM47 in proportion
      to NASH severity. We observed that overexpression of Cyld in hepatocytes
      concomitantly inhibits lipid accumulation, insulin resistance, inflammation and
      fibrosis in mice with NASH induced in an experimental setting. Mechanistically,
      CYLD interacts directly with the kinase TAK1 and removes its K63-linked
      polyubiquitin chain, which blocks downstream activation of the JNK-p38 cascades. 
      Notably, reconstitution of hepatic CYLD expression effectively reverses disease
      progression in mice with dietary or genetically induced NASH and in high-fat
      diet-fed monkeys predisposed to metabolic syndrome. Collectively, our findings
      demonstrate that CYLD mitigates NASH severity and identify the CYLD-TAK1 axis as 
      a promising therapeutic target for management of the disease.
FAU - Ji, Yan-Xiao
AU  - Ji YX
AUID- ORCID: http://orcid.org/0000-0002-3401-2427
AD  - Medical Science Research Center, Zhongnan Hospital of Wuhan University, Wuhan,
      China.
AD  - Institute of Model Animal of Wuhan University, Wuhan, China.
AD  - Basic Medical School, Wuhan University, Wuhan, China.
AD  - Medical Research Institute, School of Medicine, Wuhan University, Wuhan, China.
FAU - Huang, Zan
AU  - Huang Z
AUID- ORCID: http://orcid.org/0000-0001-5623-6950
AD  - College of Life Sciences, Wuhan University, Wuhan, China.
FAU - Yang, Xia
AU  - Yang X
AD  - Institute of Model Animal of Wuhan University, Wuhan, China.
AD  - Basic Medical School, Wuhan University, Wuhan, China.
AD  - Medical Research Institute, School of Medicine, Wuhan University, Wuhan, China.
FAU - Wang, Xiaozhan
AU  - Wang X
AD  - Institute of Model Animal of Wuhan University, Wuhan, China.
AD  - Basic Medical School, Wuhan University, Wuhan, China.
AD  - Medical Research Institute, School of Medicine, Wuhan University, Wuhan, China.
AD  - Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China.
FAU - Zhao, Ling-Ping
AU  - Zhao LP
AD  - Institute of Model Animal of Wuhan University, Wuhan, China.
AD  - Basic Medical School, Wuhan University, Wuhan, China.
AD  - Medical Research Institute, School of Medicine, Wuhan University, Wuhan, China.
FAU - Wang, Pi-Xiao
AU  - Wang PX
AD  - Institute of Model Animal of Wuhan University, Wuhan, China.
AD  - Basic Medical School, Wuhan University, Wuhan, China.
AD  - Medical Research Institute, School of Medicine, Wuhan University, Wuhan, China.
AD  - Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China.
FAU - Zhang, Xiao-Jing
AU  - Zhang XJ
AD  - Institute of Model Animal of Wuhan University, Wuhan, China.
AD  - Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China.
FAU - Alves-Bezerra, Michele
AU  - Alves-Bezerra M
AUID- ORCID: http://orcid.org/0000-0003-4430-6434
AD  - Division of Gastroenterology and Hepatology, Weill Cornell Medical College, New
      York, New York, USA.
FAU - Cai, Lin
AU  - Cai L
AD  - Medical Science Research Center, Zhongnan Hospital of Wuhan University, Wuhan,
      China.
AD  - Institute of Model Animal of Wuhan University, Wuhan, China.
AD  - Basic Medical School, Wuhan University, Wuhan, China.
FAU - Zhang, Peng
AU  - Zhang P
AD  - Medical Science Research Center, Zhongnan Hospital of Wuhan University, Wuhan,
      China.
AD  - Institute of Model Animal of Wuhan University, Wuhan, China.
AD  - Basic Medical School, Wuhan University, Wuhan, China.
AD  - Medical Research Institute, School of Medicine, Wuhan University, Wuhan, China.
FAU - Lu, Yue-Xin
AU  - Lu YX
AD  - Institute of Model Animal of Wuhan University, Wuhan, China.
AD  - Basic Medical School, Wuhan University, Wuhan, China.
AD  - Medical Research Institute, School of Medicine, Wuhan University, Wuhan, China.
FAU - Bai, Lan
AU  - Bai L
AD  - Institute of Model Animal of Wuhan University, Wuhan, China.
AD  - Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China.
FAU - Gao, Mao-Mao
AU  - Gao MM
AD  - Institute of Model Animal of Wuhan University, Wuhan, China.
AD  - Basic Medical School, Wuhan University, Wuhan, China.
AD  - Medical Research Institute, School of Medicine, Wuhan University, Wuhan, China.
FAU - Zhao, Huan
AU  - Zhao H
AD  - College of Life Sciences, Wuhan University, Wuhan, China.
FAU - Tian, Song
AU  - Tian S
AD  - Institute of Model Animal of Wuhan University, Wuhan, China.
AD  - Basic Medical School, Wuhan University, Wuhan, China.
AD  - Medical Research Institute, School of Medicine, Wuhan University, Wuhan, China.
FAU - Wang, Yong
AU  - Wang Y
AD  - Institute of Model Animal of Wuhan University, Wuhan, China.
FAU - Huang, Zhi-Xiang
AU  - Huang ZX
AD  - Institute of Model Animal of Wuhan University, Wuhan, China.
FAU - Zhu, Xue-Yong
AU  - Zhu XY
AD  - Institute of Model Animal of Wuhan University, Wuhan, China.
AD  - Basic Medical School, Wuhan University, Wuhan, China.
AD  - Medical Research Institute, School of Medicine, Wuhan University, Wuhan, China.
FAU - Zhang, Yan
AU  - Zhang Y
AD  - Institute of Model Animal of Wuhan University, Wuhan, China.
AD  - Basic Medical School, Wuhan University, Wuhan, China.
AD  - Medical Research Institute, School of Medicine, Wuhan University, Wuhan, China.
FAU - Gong, Jun
AU  - Gong J
AD  - Institute of Model Animal of Wuhan University, Wuhan, China.
AD  - Basic Medical School, Wuhan University, Wuhan, China.
AD  - Medical Research Institute, School of Medicine, Wuhan University, Wuhan, China.
AD  - College of Life Sciences, Wuhan University, Wuhan, China.
FAU - She, Zhi-Gang
AU  - She ZG
AD  - Institute of Model Animal of Wuhan University, Wuhan, China.
AD  - Basic Medical School, Wuhan University, Wuhan, China.
AD  - Medical Research Institute, School of Medicine, Wuhan University, Wuhan, China.
AD  - Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China.
FAU - Li, Feng
AU  - Li F
AD  - Basic Medical School, Wuhan University, Wuhan, China.
FAU - Cohen, David E
AU  - Cohen DE
AD  - Division of Gastroenterology and Hepatology, Weill Cornell Medical College, New
      York, New York, USA.
FAU - Li, Hongliang
AU  - Li H
AD  - Medical Science Research Center, Zhongnan Hospital of Wuhan University, Wuhan,
      China.
AD  - Institute of Model Animal of Wuhan University, Wuhan, China.
AD  - Basic Medical School, Wuhan University, Wuhan, China.
AD  - Medical Research Institute, School of Medicine, Wuhan University, Wuhan, China.
AD  - Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China.
LA  - eng
GR  - R01 DK056626/DK/NIDDK NIH HHS/United States
GR  - R01 DK103046/DK/NIDDK NIH HHS/United States
GR  - R37 DK048873/DK/NIDDK NIH HHS/United States
PT  - Journal Article
DEP - 20180101
PL  - United States
TA  - Nat Med
JT  - Nature medicine
JID - 9502015
EDAT- 2018/01/02 06:00
MHDA- 2018/01/02 06:00
CRDT- 2018/01/02 06:00
PHST- 2017/09/26 00:00 [received]
PHST- 2017/11/15 00:00 [accepted]
PHST- 2018/01/02 06:00 [pubmed]
PHST- 2018/01/02 06:00 [medline]
PHST- 2018/01/02 06:00 [entrez]
AID - nm.4461 [pii]
AID - 10.1038/nm.4461 [doi]
PST - aheadofprint
SO  - Nat Med. 2018 Jan 1. pii: nm.4461. doi: 10.1038/nm.4461.

PMID- 29275861
OWN - NLM
STAT- In-Data-Review
LR  - 20180126
IS  - 1097-4172 (Electronic)
IS  - 0092-8674 (Linking)
VI  - 172
IP  - 3
DP  - 2018 Jan 25
TI  - Natural Killer Cells Control Tumor Growth by Sensing a Growth Factor.
PG  - 534-548.e19
LID - S0092-8674(17)31388-0 [pii]
LID - 10.1016/j.cell.2017.11.037 [doi]
AB  - Many tumors produce platelet-derived growth factor (PDGF)-DD, which promotes
      cellular proliferation, epithelial-mesenchymal transition, stromal reaction, and 
      angiogenesis through autocrine and paracrine PDGFRbeta signaling. By screening a 
      secretome library, we found that the human immunoreceptor NKp44, encoded by NCR2 
      and expressed on natural killer (NK) cells and innate lymphoid cells, recognizes 
      PDGF-DD. PDGF-DD engagement of NKp44 triggered NK cell secretion of interferon
      gamma (IFN)-gamma and tumor necrosis factor alpha (TNF-alpha) that induced tumor 
      cell growth arrest. A distinctive transcriptional signature of PDGF-DD-induced
      cytokines and the downregulation of tumor cell-cycle genes correlated with NCR2
      expression and greater survival in glioblastoma. NKp44 expression in mouse NK
      cells controlled the dissemination of tumors expressing PDGF-DD more effectively 
      than control mice, an effect enhanced by blockade of the inhibitory receptor CD96
      or CpG-oligonucleotide treatment. Thus, while cancer cell production of PDGF-DD
      supports tumor growth and stromal reaction, it concomitantly activates innate
      immune responses to tumor expansion.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Barrow, Alexander D
AU  - Barrow AD
AD  - Department of Pathology and Immunology, Washington University School of Medicine,
      St. Louis, MO 63110, USA.
FAU - Edeling, Melissa A
AU  - Edeling MA
AD  - Department of Pathology and Immunology, Washington University School of Medicine,
      St. Louis, MO 63110, USA.
FAU - Trifonov, Vladimir
AU  - Trifonov V
AD  - Genomics Institute of the Novartis Research Foundation, San Diego, CA 92121, USA.
FAU - Luo, Jingqin
AU  - Luo J
AD  - Division of Public Health Sciences, Siteman Cancer Center Biostatistics Core,
      Washington University School of Medicine, St. Louis, MO 63110, USA.
FAU - Goyal, Piyush
AU  - Goyal P
AD  - Genomics Institute of the Novartis Research Foundation, San Diego, CA 92121, USA.
FAU - Bohl, Benjamin
AU  - Bohl B
AD  - Genomics Institute of the Novartis Research Foundation, San Diego, CA 92121, USA.
FAU - Bando, Jennifer K
AU  - Bando JK
AD  - Department of Pathology and Immunology, Washington University School of Medicine,
      St. Louis, MO 63110, USA.
FAU - Kim, Albert H
AU  - Kim AH
AD  - Department of Neurological Surgery, Washington University School of Medicine, St.
      Louis, MO 63110, USA.
FAU - Walker, John
AU  - Walker J
AD  - Genomics Institute of the Novartis Research Foundation, San Diego, CA 92121, USA.
FAU - Andahazy, Mary
AU  - Andahazy M
AD  - Genomics Institute of the Novartis Research Foundation, San Diego, CA 92121, USA.
FAU - Bugatti, Mattia
AU  - Bugatti M
AD  - Department of Pathology, University of Brescia, Brescia 25123, Italy.
FAU - Melocchi, Laura
AU  - Melocchi L
AD  - Department of Pathology, University of Brescia, Brescia 25123, Italy.
FAU - Vermi, William
AU  - Vermi W
AD  - Department of Pathology and Immunology, Washington University School of Medicine,
      St. Louis, MO 63110, USA; Department of Pathology, University of Brescia, Brescia
      25123, Italy.
FAU - Fremont, Daved H
AU  - Fremont DH
AD  - Department of Pathology and Immunology, Washington University School of Medicine,
      St. Louis, MO 63110, USA.
FAU - Cox, Sarah
AU  - Cox S
AD  - Genomics Institute of the Novartis Research Foundation, San Diego, CA 92121, USA.
FAU - Cella, Marina
AU  - Cella M
AD  - Department of Pathology and Immunology, Washington University School of Medicine,
      St. Louis, MO 63110, USA.
FAU - Schmedt, Christian
AU  - Schmedt C
AD  - Genomics Institute of the Novartis Research Foundation, San Diego, CA 92121, USA.
FAU - Colonna, Marco
AU  - Colonna M
AD  - Department of Pathology and Immunology, Washington University School of Medicine,
      St. Louis, MO 63110, USA. Electronic address: mcolonna@wustl.edu.
LA  - eng
PT  - Journal Article
DEP - 20171221
PL  - United States
TA  - Cell
JT  - Cell
JID - 0413066
OTO - NOTNLM
OT  - NK cell
OT  - NKp44
OT  - PDGF-D
OT  - cancer
OT  - cell cycle
OT  - cytokines
OT  - growth factor
OT  - immunosurveillance
OT  - innate lymphoid cells
EDAT- 2017/12/26 06:00
MHDA- 2017/12/26 06:00
CRDT- 2017/12/26 06:00
PHST- 2017/03/08 00:00 [received]
PHST- 2017/10/23 00:00 [revised]
PHST- 2017/11/20 00:00 [accepted]
PHST- 2017/12/26 06:00 [pubmed]
PHST- 2017/12/26 06:00 [medline]
PHST- 2017/12/26 06:00 [entrez]
AID - S0092-8674(17)31388-0 [pii]
AID - 10.1016/j.cell.2017.11.037 [doi]
PST - ppublish
SO  - Cell. 2018 Jan 25;172(3):534-548.e19. doi: 10.1016/j.cell.2017.11.037. Epub 2017 
      Dec 21.

PMID- 29302014
OWN - NLM
STAT- In-Process
LR  - 20180108
IS  - 1095-9203 (Electronic)
IS  - 0036-8075 (Linking)
VI  - 359
IP  - 6371
DP  - 2018 Jan 5
TI  - The commensal microbiome is associated with anti-PD-1 efficacy in metastatic
      melanoma patients.
PG  - 104-108
LID - 10.1126/science.aao3290 [doi]
AB  - Anti-PD-1-based immunotherapy has had a major impact on cancer treatment but has 
      only benefited a subset of patients. Among the variables that could contribute to
      interpatient heterogeneity is differential composition of the patients'
      microbiome, which has been shown to affect antitumor immunity and immunotherapy
      efficacy in preclinical mouse models. We analyzed baseline stool samples from
      metastatic melanoma patients before immunotherapy treatment, through an
      integration of 16S ribosomal RNA gene sequencing, metagenomic shotgun sequencing,
      and quantitative polymerase chain reaction for selected bacteria. A significant
      association was observed between commensal microbial composition and clinical
      response. Bacterial species more abundant in responders included Bifidobacterium 
      longum, Collinsella aerofaciens, and Enterococcus faecium. Reconstitution of
      germ-free mice with fecal material from responding patients could lead to
      improved tumor control, augmented T cell responses, and greater efficacy of
      anti-PD-L1 therapy. Our results suggest that the commensal microbiome may have a 
      mechanistic impact on antitumor immunity in human cancer patients.
CI  - Copyright (c) 2018, American Association for the Advancement of Science.
FAU - Matson, Vyara
AU  - Matson V
AUID- ORCID: 0000-0002-1937-8164
AD  - Department of Pathology, University of Chicago, Chicago, IL 60637, USA.
FAU - Fessler, Jessica
AU  - Fessler J
AD  - Department of Pathology, University of Chicago, Chicago, IL 60637, USA.
FAU - Bao, Riyue
AU  - Bao R
AUID- ORCID: 0000-0002-6105-1704
AD  - Center for Research Informatics, University of Chicago, IL 60637, USA.
AD  - Department of Pediatrics, University of Chicago, IL 60637, USA.
FAU - Chongsuwat, Tara
AU  - Chongsuwat T
AD  - Department of Medicine, University of Chicago, Chicago, IL 60637, USA.
FAU - Zha, Yuanyuan
AU  - Zha Y
AUID- ORCID: 0000-0002-0574-7352
AD  - Department of Medicine, University of Chicago, Chicago, IL 60637, USA.
FAU - Alegre, Maria-Luisa
AU  - Alegre ML
AD  - Department of Medicine, University of Chicago, Chicago, IL 60637, USA.
FAU - Luke, Jason J
AU  - Luke JJ
AUID- ORCID: 0000-0002-1182-4908
AD  - Department of Medicine, University of Chicago, Chicago, IL 60637, USA.
FAU - Gajewski, Thomas F
AU  - Gajewski TF
AUID- ORCID: 0000-0001-5727-3972
AD  - Department of Pathology, University of Chicago, Chicago, IL 60637, USA.
AD  - Department of Medicine, University of Chicago, Chicago, IL 60637, USA.
LA  - eng
GR  - R35 CA210098/CA/NCI NIH HHS/United States
GR  - T32 CA009594/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Science
JT  - Science (New York, N.Y.)
JID - 0404511
CIN - Science. 2018 Jan 5;359(6371):32-34. PMID: 29302001
EDAT- 2018/01/06 06:00
MHDA- 2018/01/06 06:00
CRDT- 2018/01/06 06:00
PHST- 2017/07/09 00:00 [received]
PHST- 2017/11/13 00:00 [accepted]
PHST- 2018/01/06 06:00 [entrez]
PHST- 2018/01/06 06:00 [pubmed]
PHST- 2018/01/06 06:00 [medline]
AID - 359/6371/104 [pii]
AID - 10.1126/science.aao3290 [doi]
PST - ppublish
SO  - Science. 2018 Jan 5;359(6371):104-108. doi: 10.1126/science.aao3290.

PMID- 29326244
OWN - NLM
STAT- In-Process
LR  - 20180117
IS  - 1095-9203 (Electronic)
IS  - 0036-8075 (Linking)
VI  - 359
IP  - 6372
DP  - 2018 Jan 12
TI  - Gene therapy comes of age.
LID - eaan4672 [pii]
LID - 10.1126/science.aan4672 [doi]
AB  - After almost 30 years of promise tempered by setbacks, gene therapies are rapidly
      becoming a critical component of the therapeutic armamentarium for a variety of
      inherited and acquired human diseases. Gene therapies for inherited immune
      disorders, hemophilia, eye and neurodegenerative disorders, and lymphoid cancers 
      recently progressed to approved drug status in the United States and Europe, or
      are anticipated to receive approval in the near future. In this Review, we
      discuss milestones in the development of gene therapies, focusing on direct in
      vivo administration of viral vectors and adoptive transfer of genetically
      engineered T cells or hematopoietic stem cells. We also discuss emerging genome
      editing technologies that should further advance the scope and efficacy of gene
      therapy approaches.
CI  - Copyright (c) 2018 The Authors, some rights reserved; exclusive licensee American
      Association for the Advancement of Science. No claim to original U.S. Government 
      Works.
FAU - Dunbar, Cynthia E
AU  - Dunbar CE
AUID- ORCID: 0000-0002-7645-838X
AD  - Hematology Branch, National Heart, Lung and Blood Institute, Bethesda, MD, USA.
      dunbarc@nhlbi.nih.gov m-sadelain@ski.mskcc.org.
FAU - High, Katherine A
AU  - High KA
AD  - Spark Therapeutics, Philadelphia, PA, USA.
FAU - Joung, J Keith
AU  - Joung JK
AD  - Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
FAU - Kohn, Donald B
AU  - Kohn DB
AUID- ORCID: 0000-0003-1840-6087
AD  - David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
FAU - Ozawa, Keiya
AU  - Ozawa K
AD  - The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
FAU - Sadelain, Michel
AU  - Sadelain M
AUID- ORCID: 0000-0002-9031-8025
AD  - Memorial Sloan Kettering Cancer Center, New York, NY, USA. dunbarc@nhlbi.nih.gov 
      m-sadelain@ski.mskcc.org.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Science
JT  - Science (New York, N.Y.)
JID - 0404511
EDAT- 2018/01/13 06:00
MHDA- 2018/01/13 06:00
CRDT- 2018/01/13 06:00
PHST- 2018/01/13 06:00 [entrez]
PHST- 2018/01/13 06:00 [pubmed]
PHST- 2018/01/13 06:00 [medline]
AID - 359/6372/eaan4672 [pii]
AID - 10.1126/science.aan4672 [doi]
PST - ppublish
SO  - Science. 2018 Jan 12;359(6372). pii: 359/6372/eaan4672. doi:
      10.1126/science.aan4672.

PMID- 29353050
OWN - NLM
STAT- Publisher
LR  - 20180121
IS  - 1555-7162 (Electronic)
IS  - 0002-9343 (Linking)
DP  - 2018 Jan 15
TI  - Helicobacter Pylori Infection: an Update for the Internist in the Age of
      Increasing Global Antibiotic Resistance.
LID - S0002-9343(18)30013-5 [pii]
LID - 10.1016/j.amjmed.2017.12.024 [doi]
AB  - Helicobacter pylori (H. pylori) infects approximately half the world's population
      and is especially prevalent in the developing world. H. pylori is as an important
      cause of global ill health due to its known etiological role in peptic ulcer
      disease, dyspepsia, gastric cancer, lymphoma and, more recently recognised in
      iron deficiency anemia and idiopathic thrombocytopenic purpura. Increased
      antibiotic usage worldwide has led to antibiotic resistance among many bacteria, 
      including H. pylori, resulting in falling success rates of first-line anti-H.
      pylori therapies. Eradication failures are principally due to resistance to
      clarithromycin, levofloxacin and metronidazole. Several new treatment options or 
      modifications of established regimens are now recommended by updated practice
      guidelines for primary or secondary therapy. Because these updated
      recommendations were published in the gastroenterological literature, internists 
      and primary care physicians, who commonly manage H. pylori, may be unaware of
      these advances. In this review, we outline the changing epidemiology of H.
      pylori, advise on diagnostic test selection for patients not undergoing
      endoscopy, and highlight current management options in this era of growing
      antibacterial resistance.
CI  - Copyright (c) 2018. Published by Elsevier Inc.
FAU - Siddique, Osama
AU  - Siddique O
AD  - Department of Medicine, Alpert Medical School of Brown University, Providence,
      RI, United States.
FAU - Ovalle, Anais
AU  - Ovalle A
AD  - Department of Medicine, Alpert Medical School of Brown University, Providence,
      RI, United States.
FAU - Siddique, Ayesha S
AU  - Siddique AS
AD  - Department of Pathology, Hartford Hospital, Hartford, CT, United States.
FAU - Moss, Steven F
AU  - Moss SF
AD  - Department of Medicine, Alpert Medical School of Brown University, Providence,
      RI, United States; Division of Gastroenterology and Hepatology, Alpert Medical
      School of Brown University, Providence, RI, United States. Electronic address:
      steven_moss@brown.edu.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180115
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
OTO - NOTNLM
OT  - Antibiotic resistance,
OT  - First-line therapy,
OT  - Guidelines,
OT  - Helicobacter pylori,
OT  - Internist.
OT  - Management,
OT  - Therapy,
EDAT- 2018/01/22 06:00
MHDA- 2018/01/22 06:00
CRDT- 2018/01/22 06:00
PHST- 2017/11/30 00:00 [received]
PHST- 2017/12/14 00:00 [revised]
PHST- 2017/12/15 00:00 [accepted]
PHST- 2018/01/22 06:00 [entrez]
PHST- 2018/01/22 06:00 [pubmed]
PHST- 2018/01/22 06:00 [medline]
AID - S0002-9343(18)30013-5 [pii]
AID - 10.1016/j.amjmed.2017.12.024 [doi]
PST - aheadofprint
SO  - Am J Med. 2018 Jan 15. pii: S0002-9343(18)30013-5. doi:
      10.1016/j.amjmed.2017.12.024.

PMID- 29307488
OWN - NLM
STAT- In-Data-Review
LR  - 20180116
IS  - 1097-4172 (Electronic)
IS  - 0092-8674 (Linking)
VI  - 172
IP  - 1-2
DP  - 2018 Jan 11
TI  - Multiclonal Invasion in Breast Tumors Identified by Topographic Single Cell
      Sequencing.
PG  - 205-217.e12
LID - S0092-8674(17)31449-6 [pii]
LID - 10.1016/j.cell.2017.12.007 [doi]
AB  - Ductal carcinoma in situ (DCIS) is an early-stage breast cancer that infrequently
      progresses to invasive ductal carcinoma (IDC). Genomic evolution has been
      difficult to delineate during invasion due to intratumor heterogeneity and the
      low number of tumor cells in the ducts. To overcome these challenges, we
      developed Topographic Single Cell Sequencing (TSCS) to measure genomic copy
      number profiles of single tumor cells while preserving their spatial context in
      tissue sections. We applied TSCS to 1,293 single cells from 10 synchronous
      patients with both DCIS and IDC regions in addition to exome sequencing. Our data
      reveal a direct genomic lineage between in situ and invasive tumor subpopulations
      and further show that most mutations and copy number aberrations evolved within
      the ducts prior to invasion. These results support a multiclonal invasion model, 
      in which one or more clones escape the ducts and migrate into the adjacent
      tissues to establish the invasive carcinomas.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Casasent, Anna K
AU  - Casasent AK
AD  - Department of Genetics, The University of Texas MD Anderson Cancer Center,
      Houston, TX, USA; Graduate School of Biomedical Sciences, The University of Texas
      MD Anderson Cancer Center, Houston, TX, USA.
FAU - Schalck, Aislyn
AU  - Schalck A
AD  - Department of Genetics, The University of Texas MD Anderson Cancer Center,
      Houston, TX, USA; Graduate School of Biomedical Sciences, The University of Texas
      MD Anderson Cancer Center, Houston, TX, USA.
FAU - Gao, Ruli
AU  - Gao R
AD  - Department of Genetics, The University of Texas MD Anderson Cancer Center,
      Houston, TX, USA.
FAU - Sei, Emi
AU  - Sei E
AD  - Department of Genetics, The University of Texas MD Anderson Cancer Center,
      Houston, TX, USA.
FAU - Long, Annalyssa
AU  - Long A
AD  - Department of Genetics, The University of Texas MD Anderson Cancer Center,
      Houston, TX, USA.
FAU - Pangburn, William
AU  - Pangburn W
AD  - Department of Genetics, The University of Texas MD Anderson Cancer Center,
      Houston, TX, USA.
FAU - Casasent, Tod
AU  - Casasent T
AD  - Department of Bioinformatics and Computational Biology, The University of Texas
      MD Anderson Cancer Center, Houston, TX, USA.
FAU - Meric-Bernstam, Funda
AU  - Meric-Bernstam F
AD  - Department of Investigational Cancer Therapeutics, The University of Texas MD
      Anderson Cancer Center, Houston, TX, USA.
FAU - Edgerton, Mary E
AU  - Edgerton ME
AD  - Department of Pathology, The University of Texas MD Anderson Cancer Center,
      Houston, TX, USA. Electronic address: medgerton@mdanderson.org.
FAU - Navin, Nicholas E
AU  - Navin NE
AD  - Department of Genetics, The University of Texas MD Anderson Cancer Center,
      Houston, TX, USA; Graduate School of Biomedical Sciences, The University of Texas
      MD Anderson Cancer Center, Houston, TX, USA; Department of Bioinformatics and
      Computational Biology, The University of Texas MD Anderson Cancer Center,
      Houston, TX, USA. Electronic address: nnavin@mdanderson.org.
LA  - eng
GR  - P30 CA016672/CA/NCI NIH HHS/United States
GR  - R01 CA169244/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20180104
PL  - United States
TA  - Cell
JT  - Cell
JID - 0413066
PMC - PMC5766405
MID - NIHMS926248
OTO - NOTNLM
OT  - breast cancer
OT  - breast cancer progression
OT  - cancer genomics
OT  - clonal evolution
OT  - copy number evolution
OT  - ductal carcinoma in situ
OT  - genome evolution
OT  - intratumor heterogeneity
OT  - invasion
OT  - single-cell sequencing
EDAT- 2018/01/09 06:00
MHDA- 2018/01/09 06:00
CRDT- 2018/01/09 06:00
PMCR- 2019/01/11 00:00
PHST- 2017/08/14 00:00 [received]
PHST- 2017/10/15 00:00 [revised]
PHST- 2017/12/01 00:00 [accepted]
PHST- 2019/01/11 00:00 [pmc-release]
PHST- 2018/01/09 06:00 [pubmed]
PHST- 2018/01/09 06:00 [medline]
PHST- 2018/01/09 06:00 [entrez]
AID - S0092-8674(17)31449-6 [pii]
AID - 10.1016/j.cell.2017.12.007 [doi]
PST - ppublish
SO  - Cell. 2018 Jan 11;172(1-2):205-217.e12. doi: 10.1016/j.cell.2017.12.007. Epub
      2018 Jan 4.

PMID- 29352444
OWN - NLM
STAT- Publisher
LR  - 20180120
IS  - 1559-1166 (Electronic)
IS  - 0895-8696 (Linking)
DP  - 2018 Jan 19
TI  - Activation of the Anti-Aging and Cognition-Enhancing Gene Klotho by CRISPR-dCas9 
      Transcriptional Effector Complex.
LID - 10.1007/s12031-017-1011-0 [doi]
AB  - Multiple lines of evidence show that the anti-aging and cognition-enhancing
      protein Klotho fosters neuronal survival, increases the anti-oxidative stress
      defense, and promotes remyelination of demyelinated axons. Thus, upregulation of 
      the Klotho gene can potentially alleviate the symptoms and/or prevent the
      progression of age-associated neurodegenerative diseases such as Alzheimer's
      disease and demyelinating diseases such as multiple sclerosis. Here we used a
      CRISPR-dCas9 complex to investigate single-guide RNA (sgRNA) targeting the Klotho
      promoter region for efficient transcriptional activation of the Klotho gene. We
      tested the sgRNAs within the - 1 to - 300 bp of the Klotho promoter region and
      identified two sgRNAs that can effectively enhance Klotho gene transcription. We 
      examined the transcriptional activation of the Klotho gene using three different 
      systems: a Firefly luciferase (FLuc) and NanoLuc luciferase (NLuc) coincidence
      reporter system, a NLuc knock-in in Klotho 3'-UTR using CRISPR genomic editing,
      and two human cell lines: neuronal SY5Y cells and kidney HK-2 cells that express 
      Klotho endogenously. The two sgRNAs enhanced Klotho expression at both the gene
      and protein levels. Our results show the feasibility of gene therapy for
      targeting Klotho using CRISPR technology. Enhancing Klotho levels has a
      therapeutic potential for increasing cognition and treating age-associated
      neurodegenerative, demyelinating and other diseases, such as chronic kidney
      disease and cancer.
FAU - Chen, Ci-Di
AU  - Chen CD
AD  - Department of Biochemistry, Boston University School of Medicine, Boston, MA,
      USA.
AD  - Klogene Therapeutics, Inc., Boston, MA, USA.
FAU - Zeldich, Ella
AU  - Zeldich E
AD  - Klogene Therapeutics, Inc., Boston, MA, USA.
FAU - Li, Yuexuan
AU  - Li Y
AD  - Department of Biochemistry, Boston University School of Medicine, Boston, MA,
      USA.
FAU - Yuste, Andrea
AU  - Yuste A
AD  - Department of Pharmacology and Experimental Therapeutics, Boston University
      School of Medicine, Boston, MA, USA.
FAU - Abraham, Carmela R
AU  - Abraham CR
AD  - Department of Biochemistry, Boston University School of Medicine, Boston, MA,
      USA. cabraham@bu.edu.
AD  - Klogene Therapeutics, Inc., Boston, MA, USA. cabraham@bu.edu.
AD  - Department of Pharmacology and Experimental Therapeutics, Boston University
      School of Medicine, Boston, MA, USA. cabraham@bu.edu.
LA  - eng
GR  - AG051638/National Institute on Aging/United States
GR  - 291202/Alzheimer's Drug Discovery Foundation/United States
PT  - Journal Article
DEP - 20180119
PL  - United States
TA  - J Mol Neurosci
JT  - Journal of molecular neuroscience : MN
JID - 9002991
OTO - NOTNLM
OT  - Alzheimer's disease
OT  - Cancer
OT  - Chronic kidney disease
OT  - Multiple sclerosis
OT  - Myelin
OT  - Neuroprotection
EDAT- 2018/01/21 06:00
MHDA- 2018/01/21 06:00
CRDT- 2018/01/21 06:00
PHST- 2017/11/13 00:00 [received]
PHST- 2017/11/28 00:00 [accepted]
PHST- 2018/01/21 06:00 [entrez]
PHST- 2018/01/21 06:00 [pubmed]
PHST- 2018/01/21 06:00 [medline]
AID - 10.1007/s12031-017-1011-0 [doi]
AID - 10.1007/s12031-017-1011-0 [pii]
PST - aheadofprint
SO  - J Mol Neurosci. 2018 Jan 19. pii: 10.1007/s12031-017-1011-0. doi:
      10.1007/s12031-017-1011-0.

PMID- 29342134
OWN - NLM
STAT- In-Data-Review
LR  - 20180128
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 553
IP  - 7689
DP  - 2018 Jan 25
TI  - Chromosomal instability drives metastasis through a cytosolic DNA response.
PG  - 467-472
LID - 10.1038/nature25432 [doi]
AB  - Chromosomal instability is a hallmark of cancer that results from ongoing errors 
      in chromosome segregation during mitosis. Although chromosomal instability is a
      major driver of tumour evolution, its role in metastasis has not been
      established. Here we show that chromosomal instability promotes metastasis by
      sustaining a tumour cell-autonomous response to cytosolic DNA. Errors in
      chromosome segregation create a preponderance of micronuclei whose rupture spills
      genomic DNA into the cytosol. This leads to the activation of the cGAS-STING
      (cyclic GMP-AMP synthase-stimulator of interferon genes) cytosolic DNA-sensing
      pathway and downstream noncanonical NF-kappaB signalling. Genetic suppression of 
      chromosomal instability markedly delays metastasis even in highly aneuploid
      tumour models, whereas continuous chromosome segregation errors promote cellular 
      invasion and metastasis in a STING-dependent manner. By subverting lethal
      epithelial responses to cytosolic DNA, chromosomally unstable tumour cells co-opt
      chronic activation of innate immune pathways to spread to distant organs.
FAU - Bakhoum, Samuel F
AU  - Bakhoum SF
AD  - Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New
      York, New York 10065, USA.
AD  - Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, New York
      10065, USA.
FAU - Ngo, Bryan
AU  - Ngo B
AD  - Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, New York
      10065, USA.
FAU - Laughney, Ashley M
AU  - Laughney AM
AD  - Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New 
      York, New York 10065, USA.
FAU - Cavallo, Julie-Ann
AU  - Cavallo JA
AD  - Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New
      York, New York 10065, USA.
AD  - Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, New York
      10065, USA.
FAU - Murphy, Charles J
AU  - Murphy CJ
AD  - Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, New York
      10065, USA.
FAU - Ly, Peter
AU  - Ly P
AD  - Ludwig Institute for Cancer Research, University of California San Diego, La
      Jolla, California 92093, USA.
FAU - Shah, Pragya
AU  - Shah P
AD  - Nancy E. and Peter C. Meinig School of Biomedical Engineering & Weill Institute
      for Cell and Molecular Biology, Cornell University, Ithaca, New York 14850, USA.
FAU - Sriram, Roshan K
AU  - Sriram RK
AD  - Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, New York
      10065, USA.
FAU - Watkins, Thomas B K
AU  - Watkins TBK
AD  - The Francis Crick Institute, London NW1 1AT, UK.
FAU - Taunk, Neil K
AU  - Taunk NK
AD  - Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New
      York, New York 10065, USA.
FAU - Duran, Mercedes
AU  - Duran M
AD  - Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New
      York, New York 10065, USA.
AD  - Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, New York
      10065, USA.
FAU - Pauli, Chantal
AU  - Pauli C
AD  - Institute for Pathology and Molecular Pathology, University Hospital Zurich,
      Zurich 8091, Switzerland.
FAU - Shaw, Christine
AU  - Shaw C
AD  - Molecular Cytogenetics Core, Memorial Sloan Kettering Cancer Center, New York,
      New York 10065, USA.
FAU - Chadalavada, Kalyani
AU  - Chadalavada K
AD  - Molecular Cytogenetics Core, Memorial Sloan Kettering Cancer Center, New York,
      New York 10065, USA.
FAU - Rajasekhar, Vinagolu K
AU  - Rajasekhar VK
AD  - Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
      10065, USA.
FAU - Genovese, Giulio
AU  - Genovese G
AD  - The Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02142, USA.
FAU - Venkatesan, Subramanian
AU  - Venkatesan S
AD  - UCL Cancer Institute, London WC1E 6BT, UK.
FAU - Birkbak, Nicolai J
AU  - Birkbak NJ
AD  - The Francis Crick Institute, London NW1 1AT, UK.
AD  - UCL Cancer Institute, London WC1E 6BT, UK.
FAU - McGranahan, Nicholas
AU  - McGranahan N
AD  - The Francis Crick Institute, London NW1 1AT, UK.
AD  - UCL Cancer Institute, London WC1E 6BT, UK.
FAU - Lundquist, Mark
AU  - Lundquist M
AD  - Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, New York
      10065, USA.
FAU - LaPlant, Quincey
AU  - LaPlant Q
AD  - Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New
      York, New York 10065, USA.
FAU - Healey, John H
AU  - Healey JH
AD  - Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
      10065, USA.
FAU - Elemento, Olivier
AU  - Elemento O
AD  - Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, New York
      10065, USA.
FAU - Chung, Christine H
AU  - Chung CH
AD  - Moffitt Cancer Center, Tampa, Florida 33612, USA.
FAU - Lee, Nancy Y
AU  - Lee NY
AD  - Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New
      York, New York 10065, USA.
FAU - Imielenski, Marcin
AU  - Imielenski M
AD  - Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, New York
      10065, USA.
FAU - Nanjangud, Gouri
AU  - Nanjangud G
AD  - Molecular Cytogenetics Core, Memorial Sloan Kettering Cancer Center, New York,
      New York 10065, USA.
FAU - Pe'er, Dana
AU  - Pe'er D
AD  - Computational Biology Program, Memorial Sloan Kettering Cancer Center, New York, 
      New York 10065, USA.
FAU - Cleveland, Don W
AU  - Cleveland DW
AD  - Ludwig Institute for Cancer Research, University of California San Diego, La
      Jolla, California 92093, USA.
FAU - Powell, Simon N
AU  - Powell SN
AD  - Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New
      York, New York 10065, USA.
FAU - Lammerding, Jan
AU  - Lammerding J
AD  - Nancy E. and Peter C. Meinig School of Biomedical Engineering & Weill Institute
      for Cell and Molecular Biology, Cornell University, Ithaca, New York 14850, USA.
FAU - Swanton, Charles
AU  - Swanton C
AD  - The Francis Crick Institute, London NW1 1AT, UK.
AD  - UCL Cancer Institute, London WC1E 6BT, UK.
FAU - Cantley, Lewis C
AU  - Cantley LC
AD  - Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, New York
      10065, USA.
LA  - eng
GR  - K99 CA218871/CA/NCI NIH HHS/United States
GR  - R35 CA197588/CA/NCI NIH HHS/United States
GR  - U54 CA210184/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20180117
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
PMC - PMC5785464
MID - NIHMS925648
EDAT- 2018/01/18 06:00
MHDA- 2018/01/18 06:00
CRDT- 2018/01/18 06:00
PMCR- 2018/07/17 00:00
PHST- 2017/04/24 00:00 [received]
PHST- 2017/12/06 00:00 [accepted]
PHST- 2018/07/17 00:00 [pmc-release]
PHST- 2018/01/18 06:00 [pubmed]
PHST- 2018/01/18 06:00 [medline]
PHST- 2018/01/18 06:00 [entrez]
AID - nature25432 [pii]
AID - 10.1038/nature25432 [doi]
PST - ppublish
SO  - Nature. 2018 Jan 25;553(7689):467-472. doi: 10.1038/nature25432. Epub 2018 Jan
      17.

PMID- 29337372
OWN - NLM
STAT- In-Data-Review
LR  - 20180116
IS  - 1934-3647 (Electronic)
IS  - 1934-3647 (Linking)
VI  - 121
DP  - 2018 Jan 16
TI  - CRISPR-Cas9-Edited Site Sequencing (CRES-Seq): An Efficient and High-Throughput
      Method for the Selection of CRISPR-Cas9-Edited Clones.
PG  - 31.14.1-31.14.11
LID - 10.1002/cpmb.53 [doi]
AB  - The emergence of clustered regularly interspaced short palindromic repeats-Cas9
      (CRISPR-Cas9) gene editing systems has enabled the creation of specific mutants
      at low cost, in a short time and with high efficiency, in eukaryotic cells. Since
      a CRISPR-Cas9 system typically creates an array of mutations in targeted sites, a
      successful gene editing project requires careful selection of edited clones. This
      process can be very challenging, especially when working with multiallelic genes 
      and/or polyploid cells (such as cancer and plants cells). Here we described a
      next-generation sequencing method called CRISPR-Cas9 Edited Site Sequencing
      (CRES-Seq) for the efficient and high-throughput screening of CRISPR-Cas9-edited 
      clones. CRES-Seq facilitates the precise genotyping up to 96 CRISPR-Cas9-edited
      sites (CRES) in a single MiniSeq (Illumina) run with an approximate sequencing
      cost of $6/clone. CRES-Seq is particularly useful when multiple genes are
      simultaneously targeted by CRISPR-Cas9, and also for screening of clones
      generated from multiallelic genes/polyploid cells. (c) 2018 by John Wiley & Sons,
      Inc.
CI  - Copyright (c) 2018 John Wiley & Sons, Inc.
FAU - Veeranagouda, Yaligara
AU  - Veeranagouda Y
AD  - Molecular Biology and Genomics, Translational Sciences, Sanofi R&D,
      Chilly-Mazarin, France.
FAU - Debono-Lagneaux, Delphine
AU  - Debono-Lagneaux D
AD  - Molecular Biology and Genomics, Translational Sciences, Sanofi R&D,
      Chilly-Mazarin, France.
FAU - Fournet, Hamida
AU  - Fournet H
AD  - Molecular Biology and Genomics, Translational Sciences, Sanofi R&D,
      Chilly-Mazarin, France.
FAU - Thill, Gilbert
AU  - Thill G
AD  - Molecular Biology and Genomics, Translational Sciences, Sanofi R&D,
      Chilly-Mazarin, France.
FAU - Didier, Michel
AU  - Didier M
AD  - Molecular Biology and Genomics, Translational Sciences, Sanofi R&D,
      Chilly-Mazarin, France.
LA  - eng
PT  - Journal Article
DEP - 20180116
PL  - United States
TA  - Curr Protoc Mol Biol
JT  - Current protocols in molecular biology
JID - 8908160
OTO - NOTNLM
OT  - CRISPR
OT  - CRISPR clone
OT  - CRISPR-Cas9
OT  - Cas9
OT  - NGS
OT  - gene editing
OT  - multiallelic genes
OT  - polyploidy
EDAT- 2018/01/18 06:00
MHDA- 2018/01/18 06:00
CRDT- 2018/01/17 06:00
PHST- 2018/01/17 06:00 [entrez]
PHST- 2018/01/18 06:00 [pubmed]
PHST- 2018/01/18 06:00 [medline]
AID - 10.1002/cpmb.53 [doi]
PST - epublish
SO  - Curr Protoc Mol Biol. 2018 Jan 16;121:31.14.1-31.14.11. doi: 10.1002/cpmb.53.

PMID- 29353241
OWN - NLM
STAT- Publisher
LR  - 20180121
IS  - 1524-4539 (Electronic)
IS  - 0009-7322 (Linking)
DP  - 2018 Jan 20
TI  - Inhibition of Endothelial Notch Signaling Impairs Fatty Acid Transport and Leads 
      to Metabolic and Vascular Remodeling of the Adult Heart.
LID - CIRCULATIONAHA.117.029733 [pii]
LID - 10.1161/CIRCULATIONAHA.117.029733 [doi]
AB  - Background -Nutrients are transported through endothelial cells before being
      metabolized in muscle cells. However, little is known about the regulation of
      endothelial transport processes. Notch signaling is a critical regulator of
      metabolism and angiogenesis during development. Here, we studied how genetic and 
      pharmacological manipulation of endothelial Notch signaling in adult mice affects
      endothelial fatty acid transport, cardiac angiogenesis, and heart function.
      Methods -Endothelial-specific Notch inhibition was achieved by conditional
      genetic inactivation of Rbp-jkappa in adult mice to analyze fatty acid metabolism
      and heart function. Wild-type mice were treated with neutralizing antibodies
      against the Notch ligand Dll4. Fatty acid transport was studied in cultured
      endothelial cells and transgenic mice. Results -Treatment of wild-type mice with 
      Dll4 neutralizing antibodies for eight weeks impaired fractional shortening and
      ejection fraction in the majority of mice. Inhibition of Notch signaling
      specifically in the endothelium of adult mice by genetic ablation of Rbp-jkappa
      caused heart hypertrophy and failure. Impaired heart function was preceded by
      alterations in fatty acid metabolism and an increase in cardiac blood vessel
      density. Endothelial Notch signaling controlled the expression of endothelial
      lipase, Angptl4, CD36 and Fabp4, which are all needed for fatty acid transport
      across the vessel wall. In endothelial-specific Rbp-jkappa-mutant mice lipase
      activity and transendothelial transport of long-chain fatty acids to muscle cells
      was impaired. In turn, there was accumulation of lipids in plasma and liver. The 
      attenuated supply of cardiomyocytes with long-chain fatty acids was accompanied
      by higher glucose uptake, increased concentration of glycolysis intermediates and
      mTOR-S6K signaling. Treatment with the mTOR inhibitor rapamycin or displacing
      glucose as cardiac substrate by feeding a ketogenic diet prolonged survival of
      endothelial-specific Rbp-jkappa-deficient mice. Conclusions -This study
      identifies Notch signaling as a novel regulator of fatty acid transport across
      the endothelium and as an essential repressor of angiogenesis in the adult heart.
      The data imply that the endothelium controls cardiomyocyte metabolism and
      function.
FAU - Jabs, Markus
AU  - Jabs M
AD  - Vascular Signaling and Cancer, DKFZ-ZMBH Alliance and German Cancer Research
      Center (DKFZ), Heidelberg, Germany.
FAU - Rose, Adam J
AU  - Rose AJ
AD  - Joint Division Molecular Metabolic Control, DKFZ-ZMBH Alliance and Network Aging 
      Research, German Cancer Research Center (DKFZ) Heidelberg, Center for Molecular
      Biology (ZMBH) and University Hospital Heidelberg University, Heidelberg, Germany
      & Nutrient Metabolism and Signalling Lab, Dept. Biochemistry & Molecular Biology,
      Monash Biomedicine Discovery Institute, Monash University, Clayton, VIC,
      Australia.
FAU - Lehmann, Lorenz H
AU  - Lehmann LH
AD  - Department of Molecular Cardiology and Epigenetics, University Hospital of
      Heidelberg, Heidelberg, Germany; German Centre for Cardiovascular Research
      (DZHK), Partner Site Heidelberg/Mannheim, Heidelberg, Germany; Department of
      Cardiology, University Hospital of Heidelberg, Heidelberg, Germany.
FAU - Taylor, Jacqueline
AU  - Taylor J
AD  - Vascular Signaling and Cancer, DKFZ-ZMBH Alliance and German Cancer Research
      Center (DKFZ), Heidelberg, Germany.
FAU - Moll, Iris
AU  - Moll I
AD  - Vascular Signaling and Cancer, DKFZ-ZMBH Alliance and German Cancer Research
      Center (DKFZ), Heidelberg, Germany.
FAU - Sijmonsma, Tjeerd P
AU  - Sijmonsma TP
AD  - Joint Division Molecular Metabolic Control, DKFZ-ZMBH Alliance and Network Aging 
      Research, German Cancer Research Center (DKFZ) Heidelberg, Center for Molecular
      Biology (ZMBH) and University Hospital Heidelberg University, Heidelberg, Germany
      & Nutrient Metabolism and Signalling Lab, Dept. Biochemistry & Molecular Biology,
      Monash Biomedicine Discovery Institute, Monash University, Clayton, VIC,
      Australia.
FAU - Herberich, Stefanie E
AU  - Herberich SE
AD  - Vascular Signaling and Cancer, DKFZ-ZMBH Alliance and German Cancer Research
      Center (DKFZ), Heidelberg, Germany.
FAU - Sauer, Sven W
AU  - Sauer SW
AD  - Department of General Pediatrics, Division of Inherited Metabolic Diseases,
      University Children's Hospital Heidelberg, Heidelberg, Germany.
FAU - Poschet, Gernot
AU  - Poschet G
AD  - Centre for Organismal Studies (COS), Heidelberg University, Heidelberg, Germany.
FAU - Federico, Giuseppina
AU  - Federico G
AD  - Division of Cellular and Molecular Pathology, German Cancer Research Center
      (DKFZ), Heidelberg, Germany.
FAU - Mogler, Carolin
AU  - Mogler C
AD  - Institute for Pathology, Technical University of Munich, Munich, Germany.
FAU - Weis, Eva-Maria
AU  - Weis EM
AD  - Vascular Signaling and Cancer, DKFZ-ZMBH Alliance and German Cancer Research
      Center (DKFZ), Heidelberg, Germany.
FAU - Augustin, Hellmut G
AU  - Augustin HG
AD  - Vascular Oncology and Metastasis, DKFZ-ZMBH Alliance and German Cancer Research
      Center (DKFZ), Heidelberg, Germany & Vascular Biology (CBTM), Medical Faculty
      Mannheim, Heidelberg University, Mannheim, Germany.
FAU - Yan, Minhong
AU  - Yan M
AD  - Molecular Oncology, Genentech, Inc., 1 DNA Way, South San Francisco, CA.
FAU - Gretz, Norbert
AU  - Gretz N
AD  - Medical Research Center, University of Heidelberg, Mannheim, Germany.
FAU - Schmid, Roland M
AU  - Schmid RM
AD  - Department of Medicine II, Klinikum rechts der Isar, Technische Universitat
      Munchen, Munich, Germany.
FAU - Adams, Ralf H
AU  - Adams RH
AD  - Max Planck Institute for Molecular Biomedicine, Department of Tissue
      Morphogenesis and University of Munster, Faculty of Medicine, Munster, Germany.
FAU - Grone, Hermann-Joseph
AU  - Grone HJ
AD  - Division of Cellular and Molecular Pathology, German Cancer Research Center
      (DKFZ), Heidelberg, Germany.
FAU - Hell, Rudiger
AU  - Hell R
AD  - Centre for Organismal Studies (COS), Heidelberg University, Heidelberg, Germany.
FAU - Okun, Jurgen G
AU  - Okun JG
AD  - Department of General Pediatrics, Division of Inherited Metabolic Diseases,
      University Children's Hospital Heidelberg, Heidelberg, Germany.
FAU - Backs, Johannes
AU  - Backs J
AD  - Department of Molecular Cardiology and Epigenetics, University Hospital of
      Heidelberg, Heidelberg, Germany & German Centre for Cardiovascular Research
      (DZHK), Partner Site Heidelberg/Mannheim, Heidelberg, Germany.
FAU - Nawroth, Peter P
AU  - Nawroth PP
AD  - Department of Medicine I and Clinical Chemistry, University Hospital of
      Heidelberg, Heidelberg, Germany.
FAU - Herzig, Stephan
AU  - Herzig S
AD  - Institute for Diabetes and Cancer (IDC) and Joint Heidelberg-IDC Translational
      Diabetes Program, Helmholtz Center Munich, Neuherberg, Germany.
FAU - Fischer, Andreas
AU  - Fischer A
AD  - Vascular Signaling and Cancer, DKFZ-ZMBH Alliance and German Cancer Research
      Center (DKFZ), Heidelberg, Germany; Vascular Biology (CBTM), Medical Faculty
      Mannheim, Heidelberg University, Mannheim, Germany; Department of Medicine I and 
      Clinical Chemistry, University Hospital of Heidelberg, Heidelberg, Germany
      a.fischer@dkfz.de.
LA  - eng
PT  - Journal Article
DEP - 20180120
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
OTO - NOTNLM
OT  - Angptl4
OT  - DLL4
OT  - Fatty acids
OT  - Notch signaling
OT  - angiogenesis
OT  - animal model cardiovascular disease
OT  - endothelial cell
OT  - mTOR
OT  - metabolism
EDAT- 2018/01/22 06:00
MHDA- 2018/01/22 06:00
CRDT- 2018/01/22 06:00
PHST- 2018/01/08 00:00 [accepted]
PHST- 2017/05/30 00:00 [received]
PHST- 2017/12/05 00:00 [revised]
PHST- 2018/01/22 06:00 [entrez]
PHST- 2018/01/22 06:00 [pubmed]
PHST- 2018/01/22 06:00 [medline]
AID - CIRCULATIONAHA.117.029733 [pii]
AID - 10.1161/CIRCULATIONAHA.117.029733 [doi]
PST - aheadofprint
SO  - Circulation. 2018 Jan 20. pii: CIRCULATIONAHA.117.029733. doi:
      10.1161/CIRCULATIONAHA.117.029733.

PMID- 29141230
OWN - NLM
STAT- In-Process
LR  - 20171219
IS  - 2211-1247 (Electronic)
VI  - 21
IP  - 7
DP  - 2017 Nov 14
TI  - Sub-minute Phosphoregulation of Cell Cycle Systems during Plasmodium Gamete
      Formation.
PG  - 2017-2029
LID - S2211-1247(17)31534-6 [pii]
LID - 10.1016/j.celrep.2017.10.071 [doi]
AB  - The transmission of malaria parasites to mosquitoes relies on the rapid induction
      of sexual reproduction upon their ingestion into a blood meal. Haploid female and
      male gametocytes become activated and emerge from their host cells, and the males
      enter the cell cycle to produce eight microgametes. The synchronized nature of
      gametogenesis allowed us to investigate phosphorylation signaling during its
      first minute in Plasmodium berghei via a high-resolution time course of the
      phosphoproteome. This revealed an unexpectedly broad response, with proteins
      related to distinct cell cycle events undergoing simultaneous phosphoregulation. 
      We implicate several protein kinases in the process, and we validate our analyses
      on the plant-like calcium-dependent protein kinase 4 (CDPK4) and a homolog of
      serine/arginine-rich protein kinases (SRPK1). Mutants in these kinases displayed 
      distinct phosphoproteomic disruptions, consistent with differences in their
      phenotypes. The results reveal the central role of protein phosphorylation in the
      atypical cell cycle regulation of a divergent eukaryote.
CI  - Copyright (c) 2017 The Author(s). Published by Elsevier Inc. All rights reserved.
FAU - Invergo, Brandon M
AU  - Invergo BM
AD  - European Molecular Biology Laboratory, European Bioinformatics Institute
      (EMBL-EBI), Hinxton, Cambridgeshire CB10 1SD, UK; Malaria Programme, Wellcome
      Trust Sanger Institute, Hinxton, Cambridgeshire CB10 1SA, UK.
FAU - Brochet, Mathieu
AU  - Brochet M
AD  - Malaria Programme, Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire CB10 
      1SA, UK; Department of Microbiology & Molecular Medicine, CMU, University of
      Geneva, 1211 Geneva 4, Geneva, Switzerland.
FAU - Yu, Lu
AU  - Yu L
AD  - Proteomics Mass Spectrometry, Wellcome Trust Sanger Institute, Hinxton,
      Cambridgeshire CB10 1SA, UK; The Institute of Cancer Research, Chester Betty
      Laboratory, London, Greater London SW7 3RP, UK.
FAU - Choudhary, Jyoti
AU  - Choudhary J
AD  - Proteomics Mass Spectrometry, Wellcome Trust Sanger Institute, Hinxton,
      Cambridgeshire CB10 1SA, UK; The Institute of Cancer Research, Chester Betty
      Laboratory, London, Greater London SW7 3RP, UK. Electronic address:
      jyoti.choudhary@icr.ac.uk.
FAU - Beltrao, Pedro
AU  - Beltrao P
AD  - European Molecular Biology Laboratory, European Bioinformatics Institute
      (EMBL-EBI), Hinxton, Cambridgeshire CB10 1SD, UK. Electronic address:
      pbeltrao@ebi.ac.uk.
FAU - Billker, Oliver
AU  - Billker O
AD  - Malaria Programme, Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire CB10 
      1SA, UK. Electronic address: ob4@sanger.ac.uk.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cell Rep
JT  - Cell reports
JID - 101573691
PMC - PMC5700370
OTO - NOTNLM
OT  - ARK2
OT  - CRK5
OT  - gametogenesis
OT  - proteomics
OT  - signal transduction
EDAT- 2017/11/16 06:00
MHDA- 2017/11/16 06:00
CRDT- 2017/11/16 06:00
PHST- 2017/07/19 00:00 [received]
PHST- 2017/09/02 00:00 [revised]
PHST- 2017/10/18 00:00 [accepted]
PHST- 2017/11/16 06:00 [entrez]
PHST- 2017/11/16 06:00 [pubmed]
PHST- 2017/11/16 06:00 [medline]
AID - S2211-1247(17)31534-6 [pii]
AID - 10.1016/j.celrep.2017.10.071 [doi]
PST - ppublish
SO  - Cell Rep. 2017 Nov 14;21(7):2017-2029. doi: 10.1016/j.celrep.2017.10.071.

PMID- 29202515
OWN - NLM
STAT- Publisher
LR  - 20171204
IS  - 2194-9387 (Electronic)
IS  - 2194-9379 (Linking)
DP  - 2017 Dec 4
TI  - Recent Progresses in Breast Reconstruction: Stem Cells, Biomaterials, and Growth 
      Factors.
LID - 10.1055/s-0043-122490 [doi]
AB  - Breast cancer is one of the most deadly tumors in women, and new procedures for
      post- surgical breast reconstruction have been developed which includes
      autologous stromal vascular fraction (SVF), platelet-derived growth factors,
      biomaterials and various stem cells. Adipose derived-stem cells (ASCs) has been
      reported to be one of the most widely used stem cell for breast reconstruction
      because of their ability to form new functional adipose tissue and vessels and in
      combination with stromal vascular fraction has been also reported efficient for
      breast reconstruction. Biomaterials include acellular dermal matrix, bone
      substitutes, and injectable have also been reported to be applicable for several 
      clinical applications, including breast reconstruction surgery. Nevertheless,
      further studies are needed to explicitly define methodological procedures and to 
      confirm the safety of all theses procedures during post-surgical breast
      reconstruction. The purpose of this mini-review is to summarize various recent
      and old applications of stem cells, biomaterials as well as growth factors in
      breast reconstruction.
CI  - (c) Georg Thieme Verlag KG Stuttgart . New York.
FAU - Zarei, Farshad
AU  - Zarei F
AD  - Department of Surgery, Lorestan University of Medical Sciences, Khorramabad,
      Iran.
FAU - Daraee, Hadis
AU  - Daraee H
AD  - Department of Medical Biotechnology, School of Advanced Technologies in Medicine,
      Tehran University of Medical sciences, Tehran, Iran.
LA  - eng
PT  - Journal Article
DEP - 20171204
PL  - Germany
TA  - Drug Res (Stuttg)
JT  - Drug research
JID - 101602406
COIS- Conflict of Interest: The authors have no conflict of interest in any terms or by
      any means during the study. All the funds were provided by research center and
      disbursed accordingly.
EDAT- 2017/12/05 06:00
MHDA- 2017/12/05 06:00
CRDT- 2017/12/05 06:00
PHST- 2017/12/05 06:00 [entrez]
PHST- 2017/12/05 06:00 [pubmed]
PHST- 2017/12/05 06:00 [medline]
AID - 10.1055/s-0043-122490 [doi]
PST - aheadofprint
SO  - Drug Res (Stuttg). 2017 Dec 4. doi: 10.1055/s-0043-122490.

PMID- 29298160
OWN - NLM
STAT- MEDLINE
DCOM- 20180118
LR  - 20180118
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 378
IP  - 1
DP  - 2018 Jan 4
TI  - Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma.
PG  - 35-47
AB  - BACKGROUND: Despite current therapies, diffuse cutaneous systemic sclerosis
      (scleroderma) often has a devastating outcome. We compared myeloablative CD34+
      selected autologous hematopoietic stem-cell transplantation with
      immunosuppression by means of 12 monthly infusions of cyclophosphamide in
      patients with scleroderma. METHODS: We randomly assigned adults (18 to 69 years
      of age) with severe scleroderma to undergo myeloablative autologous stem-cell
      transplantation (36 participants) or to receive cyclophosphamide (39
      participants). The primary end point was a global rank composite score comparing 
      participants with each other on the basis of a hierarchy of disease features
      assessed at 54 months: death, event-free survival (survival without respiratory, 
      renal, or cardiac failure), forced vital capacity, the score on the Disability
      Index of the Health Assessment Questionnaire, and the modified Rodnan skin score.
      RESULTS: In the intention-to-treat population, global rank composite scores at 54
      months showed the superiority of transplantation (67% of 1404 pairwise
      comparisons favored transplantation and 33% favored cyclophosphamide, P=0.01). In
      the per-protocol population (participants who received a transplant or completed 
      >/=9 doses of cyclophosphamide), the rate of event-free survival at 54 months was
      79% in the transplantation group and 50% in the cyclophosphamide group (P=0.02). 
      At 72 months, Kaplan-Meier estimates of event-free survival (74% vs. 47%) and
      overall survival (86% vs. 51%) also favored transplantation (P=0.03 and 0.02,
      respectively). A total of 9% of the participants in the transplantation group had
      initiated disease-modifying antirheumatic drugs (DMARDs) by 54 months, as
      compared with 44% of those in the cyclophosphamide group (P=0.001).
      Treatment-related mortality in the transplantation group was 3% at 54 months and 
      6% at 72 months, as compared with 0% in the cyclophosphamide group. CONCLUSIONS: 
      Myeloablative autologous hematopoietic stem-cell transplantation achieved
      long-term benefits in patients with scleroderma, including improved event-free
      and overall survival, at a cost of increased expected toxicity. Rates of
      treatment-related death and post-transplantation use of DMARDs were lower than
      those in previous reports of nonmyeloablative transplantation. (Funded by the
      National Institute of Allergy and Infectious Diseases and the National Institutes
      of Health; ClinicalTrials.gov number, NCT00114530 .).
FAU - Sullivan, Keith M
AU  - Sullivan KM
AD  - From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI
      International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill
      (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of
      Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.);
      Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas
      McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in
      Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan,
      Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University
      Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston
      University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.);
      University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research
      Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles,
      Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte,
      CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo
      Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., 
      S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin,
      Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.);
      University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo
      Medical Center, Toledo, OH (M.B.K.).
FAU - Goldmuntz, Ellen A
AU  - Goldmuntz EA
AD  - From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI
      International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill
      (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of
      Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.);
      Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas
      McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in
      Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan,
      Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University
      Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston
      University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.);
      University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research
      Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles,
      Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte,
      CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo
      Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., 
      S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin,
      Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.);
      University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo
      Medical Center, Toledo, OH (M.B.K.).
FAU - Keyes-Elstein, Lynette
AU  - Keyes-Elstein L
AD  - From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI
      International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill
      (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of
      Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.);
      Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas
      McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in
      Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan,
      Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University
      Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston
      University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.);
      University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research
      Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles,
      Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte,
      CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo
      Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., 
      S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin,
      Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.);
      University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo
      Medical Center, Toledo, OH (M.B.K.).
FAU - McSweeney, Peter A
AU  - McSweeney PA
AD  - From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI
      International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill
      (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of
      Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.);
      Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas
      McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in
      Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan,
      Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University
      Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston
      University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.);
      University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research
      Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles,
      Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte,
      CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo
      Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., 
      S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin,
      Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.);
      University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo
      Medical Center, Toledo, OH (M.B.K.).
FAU - Pinckney, Ashley
AU  - Pinckney A
AD  - From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI
      International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill
      (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of
      Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.);
      Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas
      McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in
      Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan,
      Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University
      Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston
      University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.);
      University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research
      Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles,
      Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte,
      CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo
      Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., 
      S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin,
      Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.);
      University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo
      Medical Center, Toledo, OH (M.B.K.).
FAU - Welch, Beverly
AU  - Welch B
AD  - From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI
      International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill
      (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of
      Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.);
      Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas
      McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in
      Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan,
      Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University
      Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston
      University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.);
      University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research
      Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles,
      Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte,
      CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo
      Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., 
      S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin,
      Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.);
      University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo
      Medical Center, Toledo, OH (M.B.K.).
FAU - Mayes, Maureen D
AU  - Mayes MD
AD  - From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI
      International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill
      (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of
      Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.);
      Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas
      McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in
      Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan,
      Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University
      Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston
      University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.);
      University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research
      Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles,
      Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte,
      CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo
      Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., 
      S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin,
      Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.);
      University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo
      Medical Center, Toledo, OH (M.B.K.).
FAU - Nash, Richard A
AU  - Nash RA
AD  - From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI
      International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill
      (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of
      Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.);
      Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas
      McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in
      Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan,
      Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University
      Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston
      University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.);
      University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research
      Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles,
      Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte,
      CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo
      Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., 
      S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin,
      Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.);
      University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo
      Medical Center, Toledo, OH (M.B.K.).
FAU - Crofford, Leslie J
AU  - Crofford LJ
AD  - From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI
      International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill
      (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of
      Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.);
      Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas
      McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in
      Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan,
      Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University
      Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston
      University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.);
      University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research
      Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles,
      Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte,
      CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo
      Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., 
      S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin,
      Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.);
      University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo
      Medical Center, Toledo, OH (M.B.K.).
FAU - Eggleston, Barry
AU  - Eggleston B
AD  - From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI
      International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill
      (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of
      Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.);
      Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas
      McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in
      Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan,
      Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University
      Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston
      University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.);
      University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research
      Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles,
      Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte,
      CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo
      Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., 
      S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin,
      Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.);
      University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo
      Medical Center, Toledo, OH (M.B.K.).
FAU - Castina, Sharon
AU  - Castina S
AD  - From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI
      International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill
      (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of
      Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.);
      Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas
      McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in
      Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan,
      Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University
      Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston
      University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.);
      University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research
      Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles,
      Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte,
      CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo
      Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., 
      S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin,
      Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.);
      University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo
      Medical Center, Toledo, OH (M.B.K.).
FAU - Griffith, Linda M
AU  - Griffith LM
AD  - From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI
      International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill
      (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of
      Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.);
      Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas
      McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in
      Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan,
      Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University
      Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston
      University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.);
      University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research
      Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles,
      Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte,
      CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo
      Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., 
      S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin,
      Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.);
      University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo
      Medical Center, Toledo, OH (M.B.K.).
FAU - Goldstein, Julia S
AU  - Goldstein JS
AD  - From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI
      International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill
      (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of
      Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.);
      Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas
      McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in
      Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan,
      Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University
      Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston
      University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.);
      University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research
      Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles,
      Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte,
      CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo
      Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., 
      S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin,
      Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.);
      University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo
      Medical Center, Toledo, OH (M.B.K.).
FAU - Wallace, Dennis
AU  - Wallace D
AD  - From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI
      International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill
      (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of
      Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.);
      Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas
      McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in
      Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan,
      Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University
      Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston
      University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.);
      University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research
      Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles,
      Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte,
      CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo
      Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., 
      S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin,
      Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.);
      University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo
      Medical Center, Toledo, OH (M.B.K.).
FAU - Craciunescu, Oana
AU  - Craciunescu O
AD  - From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI
      International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill
      (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of
      Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.);
      Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas
      McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in
      Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan,
      Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University
      Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston
      University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.);
      University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research
      Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles,
      Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte,
      CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo
      Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., 
      S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin,
      Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.);
      University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo
      Medical Center, Toledo, OH (M.B.K.).
FAU - Khanna, Dinesh
AU  - Khanna D
AD  - From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI
      International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill
      (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of
      Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.);
      Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas
      McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in
      Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan,
      Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University
      Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston
      University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.);
      University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research
      Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles,
      Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte,
      CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo
      Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., 
      S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin,
      Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.);
      University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo
      Medical Center, Toledo, OH (M.B.K.).
FAU - Folz, Rodney J
AU  - Folz RJ
AD  - From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI
      International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill
      (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of
      Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.);
      Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas
      McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in
      Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan,
      Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University
      Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston
      University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.);
      University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research
      Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles,
      Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte,
      CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo
      Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., 
      S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin,
      Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.);
      University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo
      Medical Center, Toledo, OH (M.B.K.).
FAU - Goldin, Jonathan
AU  - Goldin J
AD  - From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI
      International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill
      (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of
      Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.);
      Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas
      McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in
      Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan,
      Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University
      Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston
      University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.);
      University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research
      Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles,
      Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte,
      CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo
      Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., 
      S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin,
      Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.);
      University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo
      Medical Center, Toledo, OH (M.B.K.).
FAU - St Clair, E William
AU  - St Clair EW
AD  - From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI
      International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill
      (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of
      Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.);
      Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas
      McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in
      Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan,
      Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University
      Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston
      University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.);
      University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research
      Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles,
      Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte,
      CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo
      Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., 
      S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin,
      Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.);
      University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo
      Medical Center, Toledo, OH (M.B.K.).
FAU - Seibold, James R
AU  - Seibold JR
AD  - From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI
      International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill
      (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of
      Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.);
      Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas
      McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in
      Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan,
      Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University
      Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston
      University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.);
      University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research
      Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles,
      Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte,
      CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo
      Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., 
      S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin,
      Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.);
      University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo
      Medical Center, Toledo, OH (M.B.K.).
FAU - Phillips, Kristine
AU  - Phillips K
AD  - From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI
      International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill
      (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of
      Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.);
      Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas
      McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in
      Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan,
      Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University
      Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston
      University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.);
      University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research
      Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles,
      Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte,
      CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo
      Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., 
      S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin,
      Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.);
      University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo
      Medical Center, Toledo, OH (M.B.K.).
FAU - Mineishi, Shin
AU  - Mineishi S
AD  - From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI
      International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill
      (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of
      Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.);
      Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas
      McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in
      Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan,
      Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University
      Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston
      University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.);
      University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research
      Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles,
      Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte,
      CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo
      Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., 
      S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin,
      Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.);
      University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo
      Medical Center, Toledo, OH (M.B.K.).
FAU - Simms, Robert W
AU  - Simms RW
AD  - From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI
      International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill
      (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of
      Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.);
      Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas
      McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in
      Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan,
      Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University
      Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston
      University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.);
      University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research
      Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles,
      Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte,
      CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo
      Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., 
      S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin,
      Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.);
      University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo
      Medical Center, Toledo, OH (M.B.K.).
FAU - Ballen, Karen
AU  - Ballen K
AD  - From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI
      International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill
      (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of
      Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.);
      Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas
      McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in
      Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan,
      Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University
      Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston
      University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.);
      University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research
      Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles,
      Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte,
      CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo
      Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., 
      S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin,
      Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.);
      University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo
      Medical Center, Toledo, OH (M.B.K.).
FAU - Wener, Mark H
AU  - Wener MH
AD  - From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI
      International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill
      (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of
      Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.);
      Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas
      McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in
      Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan,
      Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University
      Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston
      University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.);
      University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research
      Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles,
      Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte,
      CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo
      Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., 
      S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin,
      Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.);
      University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo
      Medical Center, Toledo, OH (M.B.K.).
FAU - Georges, George E
AU  - Georges GE
AD  - From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI
      International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill
      (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of
      Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.);
      Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas
      McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in
      Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan,
      Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University
      Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston
      University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.);
      University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research
      Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles,
      Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte,
      CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo
      Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., 
      S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin,
      Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.);
      University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo
      Medical Center, Toledo, OH (M.B.K.).
FAU - Heimfeld, Shelly
AU  - Heimfeld S
AD  - From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI
      International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill
      (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of
      Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.);
      Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas
      McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in
      Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan,
      Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University
      Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston
      University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.);
      University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research
      Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles,
      Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte,
      CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo
      Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., 
      S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin,
      Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.);
      University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo
      Medical Center, Toledo, OH (M.B.K.).
FAU - Hosing, Chitra
AU  - Hosing C
AD  - From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI
      International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill
      (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of
      Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.);
      Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas
      McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in
      Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan,
      Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University
      Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston
      University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.);
      University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research
      Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles,
      Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte,
      CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo
      Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., 
      S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin,
      Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.);
      University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo
      Medical Center, Toledo, OH (M.B.K.).
FAU - Forman, Stephen
AU  - Forman S
AD  - From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI
      International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill
      (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of
      Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.);
      Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas
      McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in
      Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan,
      Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University
      Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston
      University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.);
      University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research
      Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles,
      Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte,
      CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo
      Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., 
      S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin,
      Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.);
      University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo
      Medical Center, Toledo, OH (M.B.K.).
FAU - Kafaja, Suzanne
AU  - Kafaja S
AD  - From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI
      International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill
      (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of
      Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.);
      Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas
      McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in
      Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan,
      Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University
      Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston
      University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.);
      University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research
      Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles,
      Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte,
      CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo
      Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., 
      S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin,
      Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.);
      University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo
      Medical Center, Toledo, OH (M.B.K.).
FAU - Silver, Richard M
AU  - Silver RM
AD  - From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI
      International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill
      (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of
      Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.);
      Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas
      McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in
      Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan,
      Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University
      Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston
      University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.);
      University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research
      Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles,
      Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte,
      CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo
      Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., 
      S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin,
      Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.);
      University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo
      Medical Center, Toledo, OH (M.B.K.).
FAU - Griffing, Leroy
AU  - Griffing L
AD  - From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI
      International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill
      (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of
      Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.);
      Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas
      McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in
      Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan,
      Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University
      Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston
      University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.);
      University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research
      Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles,
      Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte,
      CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo
      Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., 
      S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin,
      Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.);
      University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo
      Medical Center, Toledo, OH (M.B.K.).
FAU - Storek, Jan
AU  - Storek J
AD  - From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI
      International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill
      (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of
      Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.);
      Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas
      McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in
      Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan,
      Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University
      Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston
      University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.);
      University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research
      Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles,
      Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte,
      CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo
      Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., 
      S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin,
      Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.);
      University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo
      Medical Center, Toledo, OH (M.B.K.).
FAU - LeClercq, Sharon
AU  - LeClercq S
AD  - From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI
      International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill
      (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of
      Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.);
      Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas
      McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in
      Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan,
      Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University
      Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston
      University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.);
      University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research
      Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles,
      Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte,
      CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo
      Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., 
      S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin,
      Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.);
      University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo
      Medical Center, Toledo, OH (M.B.K.).
FAU - Brasington, Richard
AU  - Brasington R
AD  - From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI
      International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill
      (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of
      Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.);
      Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas
      McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in
      Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan,
      Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University
      Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston
      University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.);
      University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research
      Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles,
      Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte,
      CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo
      Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., 
      S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin,
      Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.);
      University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo
      Medical Center, Toledo, OH (M.B.K.).
FAU - Csuka, Mary E
AU  - Csuka ME
AD  - From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI
      International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill
      (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of
      Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.);
      Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas
      McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in
      Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan,
      Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University
      Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston
      University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.);
      University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research
      Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles,
      Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte,
      CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo
      Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., 
      S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin,
      Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.);
      University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo
      Medical Center, Toledo, OH (M.B.K.).
FAU - Bredeson, Christopher
AU  - Bredeson C
AD  - From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI
      International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill
      (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of
      Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.);
      Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas
      McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in
      Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan,
      Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University
      Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston
      University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.);
      University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research
      Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles,
      Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte,
      CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo
      Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., 
      S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin,
      Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.);
      University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo
      Medical Center, Toledo, OH (M.B.K.).
FAU - Keever-Taylor, Carolyn
AU  - Keever-Taylor C
AD  - From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI
      International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill
      (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of
      Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.);
      Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas
      McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in
      Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan,
      Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University
      Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston
      University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.);
      University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research
      Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles,
      Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte,
      CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo
      Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., 
      S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin,
      Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.);
      University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo
      Medical Center, Toledo, OH (M.B.K.).
FAU - Domsic, Robyn T
AU  - Domsic RT
AD  - From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI
      International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill
      (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of
      Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.);
      Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas
      McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in
      Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan,
      Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University
      Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston
      University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.);
      University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research
      Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles,
      Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte,
      CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo
      Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., 
      S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin,
      Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.);
      University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo
      Medical Center, Toledo, OH (M.B.K.).
FAU - Kahaleh, M Bashar
AU  - Kahaleh MB
AD  - From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI
      International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill
      (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of
      Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.);
      Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas
      McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in
      Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan,
      Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University
      Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston
      University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.);
      University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research
      Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles,
      Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte,
      CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo
      Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., 
      S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin,
      Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.);
      University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo
      Medical Center, Toledo, OH (M.B.K.).
FAU - Medsger, Thomas
AU  - Medsger T
AD  - From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI
      International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill
      (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of
      Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.);
      Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas
      McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in
      Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan,
      Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University
      Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston
      University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.);
      University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research
      Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles,
      Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte,
      CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo
      Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., 
      S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin,
      Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.);
      University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo
      Medical Center, Toledo, OH (M.B.K.).
FAU - Furst, Daniel E
AU  - Furst DE
AD  - From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI
      International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill
      (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of
      Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.);
      Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas
      McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in
      Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan,
      Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University
      Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston
      University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.);
      University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research
      Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles,
      Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte,
      CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo
      Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., 
      S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin,
      Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.);
      University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo
      Medical Center, Toledo, OH (M.B.K.).
CN  - SCOT Study Investigators
LA  - eng
SI  - ClinicalTrials.gov/NCT00114530
PT  - Clinical Trial, Phase II
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Immunosuppressive Agents)
RN  - 8N3DW7272P (Cyclophosphamide)
SB  - AIM
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Cyclophosphamide/adverse effects/*therapeutic use
MH  - Disease-Free Survival
MH  - Female
MH  - Follow-Up Studies
MH  - *Hematopoietic Stem Cell Transplantation/adverse effects/mortality
MH  - Humans
MH  - Immunosuppressive Agents/adverse effects/*therapeutic use
MH  - Infection/etiology
MH  - Intention to Treat Analysis
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Scleroderma, Systemic/drug therapy/mortality/*therapy
MH  - Transplantation Conditioning
MH  - Transplantation, Autologous
MH  - Young Adult
IR  - Amrani D
FIR - Amrani, David
IR  - Bianchine P
FIR - Bianchine, Peter
IR  - Braun A
FIR - Braun, Alan
IR  - Brittain EH
FIR - Brittain, Erica H
IR  - Brown A
FIR - Brown, Alan
IR  - Castina S
FIR - Castina, Sharon
IR  - Czarniecki C
FIR - Czarniecki, Christine
IR  - Eren M
FIR - Eren, Margaret
IR  - Fessler B
FIR - Fessler, Barri
IR  - Goldberg A
FIR - Goldberg, Avram
IR  - Hari P
FIR - Hari, Parameswaran
IR  - Hummers L
FIR - Hummers, Laura
IR  - Jimenez S
FIR - Jimenez, Sergio
IR  - Korn J
FIR - Korn, Joseph
IR  - Lohr K
FIR - Lohr, Kristine
IR  - MacNeil M
FIR - MacNeil, Megan
IR  - Markland J
FIR - Markland, Janet
IR  - McKown K
FIR - McKown, Kevin
IR  - McNamara J
FIR - McNamara, James
IR  - Molitor J
FIR - Molitor, Jerry
IR  - Paarz-Largay C
FIR - Paarz-Largay, Catherine
IR  - Pasquini M
FIR - Pasquini, Marcelo
IR  - Rodriquez R
FIR - Rodriquez, Roberto
IR  - Rowley S
FIR - Rowley, Scott
IR  - Shanahan J
FIR - Shanahan, Joseph
IR  - Shapiro L
FIR - Shapiro, Lee
IR  - Shearin J
FIR - Shearin, Jean
IR  - Spiera R
FIR - Spiera, Robert
IR  - Steen V
FIR - Steen, Virginia
IR  - Turkiewicz A
FIR - Turkiewicz, Anthony
IR  - Varga J
FIR - Varga, John
IR  - Zain J
FIR - Zain, Jasmine
EDAT- 2018/01/04 06:00
MHDA- 2018/01/19 06:00
CRDT- 2018/01/04 06:00
PHST- 2018/01/04 06:00 [entrez]
PHST- 2018/01/04 06:00 [pubmed]
PHST- 2018/01/19 06:00 [medline]
AID - 10.1056/NEJMoa1703327 [pii]
PST - ppublish
SO  - N Engl J Med. 2018 Jan 4;378(1):35-47.

PMID- 29322250
OWN - NLM
STAT- Publisher
LR  - 20180111
IS  - 1439-6327 (Electronic)
IS  - 1439-6319 (Linking)
DP  - 2018 Jan 10
TI  - Lactate metabolism: historical context, prior misinterpretations, and current
      understanding.
LID - 10.1007/s00421-017-3795-6 [doi]
AB  - Lactate (La(-)) has long been at the center of controversy in research, clinical,
      and athletic settings. Since its discovery in 1780, La(-) has often been
      erroneously viewed as simply a hypoxic waste product with multiple deleterious
      effects. Not until the 1980s, with the introduction of the cell-to-cell lactate
      shuttle did a paradigm shift in our understanding of the role of La(-) in
      metabolism begin. The evidence for La(-) as a major player in the coordination of
      whole-body metabolism has since grown rapidly. La(-) is a readily combusted fuel 
      that is shuttled throughout the body, and it is a potent signal for angiogenesis 
      irrespective of oxygen tension. Despite this, many fundamental discoveries about 
      La(-) are still working their way into mainstream research, clinical care, and
      practice. The purpose of this review is to synthesize current understanding of
      La(-) metabolism via an appraisal of its robust experimental history,
      particularly in exercise physiology. That La(-) production increases during
      dysoxia is beyond debate, but this condition is the exception rather than the
      rule. Fluctuations in blood [La(-)] in health and disease are not typically due
      to low oxygen tension, a principle first demonstrated with exercise and now
      understood to varying degrees across disciplines. From its role in coordinating
      whole-body metabolism as a fuel to its role as a signaling molecule in tumors,
      the study of La(-) metabolism continues to expand and holds potential for
      multiple clinical applications. This review highlights La(-)'s central role in
      metabolism and amplifies our understanding of past research.
FAU - Ferguson, Brian S
AU  - Ferguson BS
AD  - College of Applied Health Sciences, University of Illinois at Chicago, Chicago,
      IL, USA.
FAU - Rogatzki, Matthew J
AU  - Rogatzki MJ
AD  - Department of Health and Exercise Science, Appalachian State University, Boone,
      NC, USA.
FAU - Goodwin, Matthew L
AU  - Goodwin ML
AD  - Department of Orthopaedics, University of Utah, Salt Lake City, UT, USA.
AD  - Huntsman Cancer Institute, Salt Lake City, UT, USA.
FAU - Kane, Daniel A
AU  - Kane DA
AD  - Department of Human Kinetics, St. Francis Xavier University, Antigonish, Canada.
FAU - Rightmire, Zachary
AU  - Rightmire Z
AD  - School of Kinesiology, Auburn University, 301 Wire Road, Auburn, AL, 36849, USA.
FAU - Gladden, L Bruce
AU  - Gladden LB
AUID- ORCID: http://orcid.org/0000-0001-5193-7440
AD  - School of Kinesiology, Auburn University, 301 Wire Road, Auburn, AL, 36849, USA. 
      gladdlb@auburn.edu.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180110
PL  - Germany
TA  - Eur J Appl Physiol
JT  - European journal of applied physiology
JID - 100954790
OTO - NOTNLM
OT  - Astrocyte-neuron lactate shuttle
OT  - Cancer metabolism
OT  - Cytosolic redox
OT  - Fatigue and lactic acidosis
OT  - Glycolysis
OT  - Hypoxia
OT  - Lactate metabolism
OT  - Lactate shuttle
OT  - Lactate threshold
OT  - Mitochondria
EDAT- 2018/01/13 06:00
MHDA- 2018/01/13 06:00
CRDT- 2018/01/12 06:00
PHST- 2017/08/04 00:00 [received]
PHST- 2017/12/22 00:00 [accepted]
PHST- 2018/01/12 06:00 [entrez]
PHST- 2018/01/13 06:00 [pubmed]
PHST- 2018/01/13 06:00 [medline]
AID - 10.1007/s00421-017-3795-6 [doi]
AID - 10.1007/s00421-017-3795-6 [pii]
PST - aheadofprint
SO  - Eur J Appl Physiol. 2018 Jan 10. pii: 10.1007/s00421-017-3795-6. doi:
      10.1007/s00421-017-3795-6.

PMID- 29309058
OWN - NLM
STAT- Publisher
LR  - 20180129
IS  - 1546-170X (Electronic)
IS  - 1078-8956 (Linking)
DP  - 2018 Jan 8
TI  - Diverse genetic-driven immune landscapes dictate tumor progression through
      distinct mechanisms.
LID - 10.1038/nm.4463 [doi]
AB  - Multiple immune-cell types can infiltrate tumors and promote progression and
      metastasis through different mechanisms, including immunosuppression. How
      distinct genetic alterations in tumors affect the composition of the immune
      landscape is currently unclear. Here, we characterized the immune-cell
      composition of prostate cancers driven by the loss of the critical tumor
      suppressor gene Pten, either alone or in combination with the loss of Trp53,
      Zbtb7a or Pml. We observed a striking quantitative and qualitative heterogeneity 
      that was directly dependent on the specific genetic events in the tumor and
      ranged from 'cold', noninflamed tumors to massively infiltrated
      landscapes-results with important therapeutic implications. Further, we showed
      these qualitative differences in transcriptomic analysis of human prostate cancer
      samples. These data suggest that patient stratification on the basis of
      integrated genotypic-immunophenotypic analyses may be necessary for successful
      clinical trials and tailored precision immunological therapies.
FAU - Bezzi, Marco
AU  - Bezzi M
AD  - Cancer Research Institute, Beth Israel Deaconess Cancer Center, Department of
      Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston,
      Massachusetts, USA.
FAU - Seitzer, Nina
AU  - Seitzer N
AD  - Cancer Research Institute, Beth Israel Deaconess Cancer Center, Department of
      Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston,
      Massachusetts, USA.
FAU - Ishikawa, Tomoki
AU  - Ishikawa T
AD  - Cancer Research Institute, Beth Israel Deaconess Cancer Center, Department of
      Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston,
      Massachusetts, USA.
FAU - Reschke, Markus
AU  - Reschke M
AD  - Cancer Research Institute, Beth Israel Deaconess Cancer Center, Department of
      Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston,
      Massachusetts, USA.
FAU - Chen, Ming
AU  - Chen M
AD  - Cancer Research Institute, Beth Israel Deaconess Cancer Center, Department of
      Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston,
      Massachusetts, USA.
FAU - Wang, Guocan
AU  - Wang G
AD  - Cancer Research Institute, Beth Israel Deaconess Cancer Center, Department of
      Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston,
      Massachusetts, USA.
FAU - Mitchell, Caitlin
AU  - Mitchell C
AD  - Cancer Research Institute, Beth Israel Deaconess Cancer Center, Department of
      Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston,
      Massachusetts, USA.
FAU - Ng, Christopher
AU  - Ng C
AD  - Cancer Research Institute, Beth Israel Deaconess Cancer Center, Department of
      Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston,
      Massachusetts, USA.
FAU - Katon, Jesse
AU  - Katon J
AD  - Cancer Research Institute, Beth Israel Deaconess Cancer Center, Department of
      Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston,
      Massachusetts, USA.
FAU - Lunardi, Andrea
AU  - Lunardi A
AD  - Cancer Research Institute, Beth Israel Deaconess Cancer Center, Department of
      Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston,
      Massachusetts, USA.
FAU - Signoretti, Sabina
AU  - Signoretti S
AD  - Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts,
      USA.
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
      Massachusetts, USA.
FAU - Clohessy, John G
AU  - Clohessy JG
AD  - Cancer Research Institute, Beth Israel Deaconess Cancer Center, Department of
      Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston,
      Massachusetts, USA.
AD  - Preclinical Murine Pharmacogenetics Facility, Beth Israel Deaconess Medical
      Center, Harvard Medical School, Boston, Massachusetts, USA.
FAU - Zhang, Jiangwen
AU  - Zhang J
AD  - School of Biological Sciences, University of Hong Kong, Hong Kong SAR, China.
FAU - Pandolfi, Pier Paolo
AU  - Pandolfi PP
AUID- ORCID: http://orcid.org/0000-0002-5352-5295
AD  - Cancer Research Institute, Beth Israel Deaconess Cancer Center, Department of
      Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston,
      Massachusetts, USA.
LA  - eng
PT  - Journal Article
DEP - 20180108
PL  - United States
TA  - Nat Med
JT  - Nature medicine
JID - 9502015
EDAT- 2018/01/09 06:00
MHDA- 2018/01/09 06:00
CRDT- 2018/01/09 06:00
PHST- 2015/12/10 00:00 [received]
PHST- 2017/11/29 00:00 [accepted]
PHST- 2018/01/09 06:00 [pubmed]
PHST- 2018/01/09 06:00 [medline]
PHST- 2018/01/09 06:00 [entrez]
AID - nm.4463 [pii]
AID - 10.1038/nm.4463 [doi]
PST - aheadofprint
SO  - Nat Med. 2018 Jan 8. pii: nm.4463. doi: 10.1038/nm.4463.

PMID- 29342143
OWN - NLM
STAT- In-Data-Review
LR  - 20180128
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 553
IP  - 7689
DP  - 2018 Jan 25
TI  - Regulation of embryonic haematopoietic multipotency by EZH1.
PG  - 506-510
LID - 10.1038/nature25435 [doi]
AB  - All haematopoietic cell lineages that circulate in the blood of adult mammals
      derive from multipotent haematopoietic stem cells (HSCs). By contrast, in the
      blood of mammalian embryos, lineage-restricted progenitors arise first,
      independently of HSCs, which only emerge later in gestation. As best defined in
      the mouse, 'primitive' progenitors first appear in the yolk sac at 7.5 days
      post-coitum. Subsequently, erythroid-myeloid progenitors that express fetal
      haemoglobin, as well as fetal lymphoid progenitors, develop in the yolk sac and
      the embryo proper, but these cells lack HSC potential. Ultimately, 'definitive'
      HSCs with long-term, multilineage potential and the ability to engraft irradiated
      adults emerge at 10.5 days post-coitum from arterial endothelium in the
      aorta-gonad-mesonephros and other haemogenic vasculature. The molecular
      mechanisms of this reverse progression of haematopoietic ontogeny remain
      unexplained. We hypothesized that the definitive haematopoietic program might be 
      actively repressed in early embryogenesis through epigenetic silencing, and that 
      alleviating this repression would elicit multipotency in otherwise
      lineage-restricted haematopoietic progenitors. Here we show that reduced
      expression of the Polycomb group protein EZH1 enhances multi-lymphoid output from
      human pluripotent stem cells. In addition, Ezh1 deficiency in mouse embryos
      results in precocious emergence of functional definitive HSCs in vivo. Thus, we
      identify EZH1 as a repressor of haematopoietic multipotency in the early
      mammalian embryo.
FAU - Vo, Linda T
AU  - Vo LT
AD  - Stem Cell Program, Boston Children's Hospital, Boston, Massachusetts, USA.
AD  - Division of Hematology/Oncology, Boston Children's Hospital and Dana Farber
      Cancer Institute, Boston, Massachusetts, USA.
AD  - Harvard Medical School, Boston, Massachusetts, USA.
FAU - Kinney, Melissa A
AU  - Kinney MA
AD  - Stem Cell Program, Boston Children's Hospital, Boston, Massachusetts, USA.
AD  - Division of Hematology/Oncology, Boston Children's Hospital and Dana Farber
      Cancer Institute, Boston, Massachusetts, USA.
FAU - Liu, Xin
AU  - Liu X
AD  - Children's Medical Center Research Institute, Department of Pediatrics,
      University of Texas Southwestern Medical Center, Dallas, Texas, USA.
FAU - Zhang, Yuannyu
AU  - Zhang Y
AD  - Children's Medical Center Research Institute, Department of Pediatrics,
      University of Texas Southwestern Medical Center, Dallas, Texas, USA.
AD  - Key Laboratory of Computational Biology, CAS-MPG Partner Institute for
      Computational Biology, Shanghai Institutes for Biological Sciences, Chinese
      Academy of Sciences, Shanghai, China.
FAU - Barragan, Jessica
AU  - Barragan J
AD  - Stem Cell Program, Boston Children's Hospital, Boston, Massachusetts, USA.
AD  - Division of Hematology/Oncology, Boston Children's Hospital and Dana Farber
      Cancer Institute, Boston, Massachusetts, USA.
FAU - Sousa, Patricia M
AU  - Sousa PM
AD  - Stem Cell Program, Boston Children's Hospital, Boston, Massachusetts, USA.
AD  - Division of Hematology/Oncology, Boston Children's Hospital and Dana Farber
      Cancer Institute, Boston, Massachusetts, USA.
FAU - Jha, Deepak K
AU  - Jha DK
AD  - Stem Cell Program, Boston Children's Hospital, Boston, Massachusetts, USA.
AD  - Division of Hematology/Oncology, Boston Children's Hospital and Dana Farber
      Cancer Institute, Boston, Massachusetts, USA.
FAU - Han, Areum
AU  - Han A
AD  - Stem Cell Program, Boston Children's Hospital, Boston, Massachusetts, USA.
AD  - Division of Hematology/Oncology, Boston Children's Hospital and Dana Farber
      Cancer Institute, Boston, Massachusetts, USA.
FAU - Cesana, Marcella
AU  - Cesana M
AD  - Stem Cell Program, Boston Children's Hospital, Boston, Massachusetts, USA.
AD  - Division of Hematology/Oncology, Boston Children's Hospital and Dana Farber
      Cancer Institute, Boston, Massachusetts, USA.
FAU - Shao, Zhen
AU  - Shao Z
AD  - Key Laboratory of Computational Biology, CAS-MPG Partner Institute for
      Computational Biology, Shanghai Institutes for Biological Sciences, Chinese
      Academy of Sciences, Shanghai, China.
FAU - North, Trista E
AU  - North TE
AD  - Department of Pathology, Beth Israel-Deaconess Medical Center, Boston,
      Massachusetts, USA.
FAU - Orkin, Stuart H
AU  - Orkin SH
AD  - Division of Hematology/Oncology, Boston Children's Hospital and Dana Farber
      Cancer Institute, Boston, Massachusetts, USA.
AD  - Harvard Medical School, Boston, Massachusetts, USA.
AD  - Howard Hughes Medical Institute, Boston, Massachusetts, USA.
FAU - Doulatov, Sergei
AU  - Doulatov S
AD  - Division of Hematology, Department of Medicine, University of Washington,
      Seattle, Washington, USA.
FAU - Xu, Jian
AU  - Xu J
AD  - Children's Medical Center Research Institute, Department of Pediatrics,
      University of Texas Southwestern Medical Center, Dallas, Texas, USA.
FAU - Daley, George Q
AU  - Daley GQ
AD  - Stem Cell Program, Boston Children's Hospital, Boston, Massachusetts, USA.
AD  - Division of Hematology/Oncology, Boston Children's Hospital and Dana Farber
      Cancer Institute, Boston, Massachusetts, USA.
AD  - Harvard Medical School, Boston, Massachusetts, USA.
LA  - eng
GR  - R24 DK092760/DK/NIDDK NIH HHS/United States
GR  - U01 HL134812/HL/NHLBI NIH HHS/United States
PT  - Journal Article
DEP - 20180117
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
PMC - PMC5785461
MID - NIHMS925171
EDAT- 2018/01/18 06:00
MHDA- 2018/01/18 06:00
CRDT- 2018/01/18 06:00
PMCR- 2018/07/17 00:00
PHST- 2016/10/15 00:00 [received]
PHST- 2017/12/05 00:00 [accepted]
PHST- 2018/07/17 00:00 [pmc-release]
PHST- 2018/01/18 06:00 [pubmed]
PHST- 2018/01/18 06:00 [medline]
PHST- 2018/01/18 06:00 [entrez]
AID - nature25435 [pii]
AID - 10.1038/nature25435 [doi]
PST - ppublish
SO  - Nature. 2018 Jan 25;553(7689):506-510. doi: 10.1038/nature25435. Epub 2018 Jan
      17.

PMID- 29275866
OWN - NLM
STAT- In-Data-Review
LR  - 20180112
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 33
IP  - 1
DP  - 2018 Jan 8
TI  - Cooperative Epigenetic Remodeling by TET2 Loss and NRAS Mutation Drives Myeloid
      Transformation and MEK Inhibitor Sensitivity.
PG  - 44-59.e8
LID - S1535-6108(17)30515-9 [pii]
LID - 10.1016/j.ccell.2017.11.012 [doi]
AB  - Mutations in epigenetic modifiers and signaling factors often co-occur in myeloid
      malignancies, including TET2 and NRAS mutations. Concurrent Tet2 loss and
      Nras(G12D) expression in hematopoietic cells induced myeloid transformation, with
      a fully penetrant, lethal chronic myelomonocytic leukemia (CMML), which was
      serially transplantable. Tet2 loss and Nras mutation cooperatively led to
      decrease in negative regulators of mitogen-activated protein kinase (MAPK)
      activation, including Spry2, thereby causing synergistic activation of MAPK
      signaling by epigenetic silencing. Tet2/Nras double-mutant leukemia showed
      preferential sensitivity to MAPK kinase (MEK) inhibition in both mouse model and 
      patient samples. These data provide insights into how epigenetic and signaling
      mutations cooperate in myeloid transformation and provide a rationale for
      mechanism-based therapy in CMML patients with these high-risk genetic lesions.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Kunimoto, Hiroyoshi
AU  - Kunimoto H
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA; Center for Epigenetics Research, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA; Center for Hematologic
      Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
FAU - Meydan, Cem
AU  - Meydan C
AD  - Institute for Computational Biomedicine and Department of Physiology and
      Biophysics, Weill Cornell Medical College, New York, NY 10065, USA.
FAU - Nazir, Abbas
AU  - Nazir A
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA; Center for Epigenetics Research, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA; Center for Hematologic
      Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
FAU - Whitfield, Justin
AU  - Whitfield J
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA; Center for Epigenetics Research, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA; Center for Hematologic
      Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
FAU - Shank, Kaitlyn
AU  - Shank K
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA; Center for Epigenetics Research, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA; Center for Hematologic
      Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
FAU - Rapaport, Franck
AU  - Rapaport F
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA; Center for Hematologic Malignancies, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA.
FAU - Maher, Rebecca
AU  - Maher R
AD  - University of Connecticut School of Medicine, Farmington, CT 06032, USA.
FAU - Pronier, Elodie
AU  - Pronier E
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA; Center for Epigenetics Research, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA; Center for Hematologic
      Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
FAU - Meyer, Sara C
AU  - Meyer SC
AD  - Division of Hematology, University Hospital Basel, 4031 Basel, Switzerland;
      Department of Biomedicine, University Hospital Basel, 4031 Basel, Switzerland.
FAU - Garrett-Bakelman, Francine E
AU  - Garrett-Bakelman FE
AD  - Department of Medicine, Division of Hematology-Oncology, Weill Cornell Medical
      College, New York, NY 10065, USA; Department of Medicine, University of Virginia,
      Charlottesville, VA 22908, USA; Department of Biochemistry and Molecular
      Genetics, University of Virginia, Charlottesville, VA 22908, USA.
FAU - Tallman, Martin
AU  - Tallman M
AD  - Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065,
      USA.
FAU - Melnick, Ari
AU  - Melnick A
AD  - Department of Medicine, Division of Hematology-Oncology, Weill Cornell Medical
      College, New York, NY 10065, USA; Department of Pharmacology, Weill Cornell
      Medical College, New York, NY 10065, USA.
FAU - Levine, Ross L
AU  - Levine RL
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA; Center for Epigenetics Research, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA; Center for Hematologic
      Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA;
      Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065,
      USA. Electronic address: leviner@mskcc.org.
FAU - Shih, Alan H
AU  - Shih AH
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY 10065, USA; Center for Epigenetics Research, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA; Center for Hematologic
      Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA;
      Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065,
      USA. Electronic address: shiha@mskcc.org.
LA  - eng
GR  - R01 CA198089/CA/NCI NIH HHS/United States
GR  - U54 OD020355/OD/NIH HHS/United States
GR  - R01 CA173636/CA/NCI NIH HHS/United States
GR  - K08 CA169055/CA/NCI NIH HHS/United States
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - R35 CA197594/CA/NCI NIH HHS/United States
GR  - K08 CA181507/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20171221
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
PMC - PMC5760367
MID - NIHMS922552
OTO - NOTNLM
OT  - cancer epigenetics
OT  - leukemia biology
OT  - targeted therapeutics
EDAT- 2017/12/26 06:00
MHDA- 2017/12/26 06:00
CRDT- 2017/12/26 06:00
PMCR- 2019/01/08 00:00
PHST- 2017/03/09 00:00 [received]
PHST- 2017/10/02 00:00 [revised]
PHST- 2017/11/17 00:00 [accepted]
PHST- 2019/01/08 00:00 [pmc-release]
PHST- 2017/12/26 06:00 [pubmed]
PHST- 2017/12/26 06:00 [medline]
PHST- 2017/12/26 06:00 [entrez]
AID - S1535-6108(17)30515-9 [pii]
AID - 10.1016/j.ccell.2017.11.012 [doi]
PST - ppublish
SO  - Cancer Cell. 2018 Jan 8;33(1):44-59.e8. doi: 10.1016/j.ccell.2017.11.012. Epub
      2017 Dec 21.

PMID- 29320735
OWN - NLM
STAT- In-Data-Review
LR  - 20180110
IS  - 2211-1247 (Electronic)
VI  - 22
IP  - 2
DP  - 2018 Jan 9
TI  - RYBP Is a K63-Ubiquitin-Chain-Binding Protein that Inhibits Homologous
      Recombination Repair.
PG  - 383-395
LID - S2211-1247(17)31871-5 [pii]
LID - 10.1016/j.celrep.2017.12.047 [doi]
AB  - Ring1-YY1-binding protein (RYBP) is a member of the non-canonical polycomb
      repressive complex 1 (PRC1), and like other PRC1 members, it is best described as
      a transcriptional regulator. However, several PRC1 members were recently shown to
      function in DNA repair. Here, we report that RYBP preferentially binds
      K63-ubiquitin chains via its Npl4 zinc finger (NZF) domain. Since K63-linked
      ubiquitin chains are assembled at DNA double-strand breaks (DSBs), we examined
      the contribution of RYBP to DSB repair. Surprisingly, we find that RYBP is K48
      polyubiquitylated by RNF8 and rapidly removed from chromatin upon DNA damage by
      the VCP/p97 segregase. High expression of RYBP competitively inhibits recruitment
      of BRCA1 repair complex to DSBs, reducing DNA end resection and homologous
      recombination (HR) repair. Moreover, breast cancer cell lines expressing high
      endogenous RYBP levels show increased sensitivity to DNA-damaging agents and poly
      ADP-ribose polymerase (PARP) inhibition. These data suggest that RYBP negatively 
      regulates HR repair by competing for K63-ubiquitin chain binding.
CI  - Copyright (c) 2017 The Author(s). Published by Elsevier Inc. All rights reserved.
FAU - Ali, Mohammad A M
AU  - Ali MAM
AD  - Department of Oncology, Faculty of Medicine and Dentistry, University of Alberta,
      11560 University Avenue, Edmonton, AB T6G 2H7, Canada.
FAU - Strickfaden, Hilmar
AU  - Strickfaden H
AD  - Department of Oncology, Faculty of Medicine and Dentistry, University of Alberta,
      11560 University Avenue, Edmonton, AB T6G 2H7, Canada.
FAU - Lee, Brian L
AU  - Lee BL
AD  - Department of Biochemistry, Faculty of Medicine and Dentistry, University of
      Alberta, 11560 University Avenue, Edmonton, AB T6G 2H7, Canada.
FAU - Spyracopoulos, Leo
AU  - Spyracopoulos L
AD  - Department of Biochemistry, Faculty of Medicine and Dentistry, University of
      Alberta, 11560 University Avenue, Edmonton, AB T6G 2H7, Canada.
FAU - Hendzel, Michael J
AU  - Hendzel MJ
AD  - Department of Oncology, Faculty of Medicine and Dentistry, University of Alberta,
      11560 University Avenue, Edmonton, AB T6G 2H7, Canada. Electronic address:
      mhendzel@ualberta.ca.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cell Rep
JT  - Cell reports
JID - 101573691
OTO - NOTNLM
OT  - DNA damage response
OT  - RYBP
OT  - chromatin
OT  - double-strand break repair
OT  - histone modification
OT  - homologous recombination
OT  - polycomb proteins
OT  - ubiquitylation
EDAT- 2018/01/11 06:00
MHDA- 2018/01/11 06:00
CRDT- 2018/01/11 06:00
PHST- 2017/08/11 00:00 [received]
PHST- 2017/11/07 00:00 [revised]
PHST- 2017/12/13 00:00 [accepted]
PHST- 2018/01/11 06:00 [entrez]
PHST- 2018/01/11 06:00 [pubmed]
PHST- 2018/01/11 06:00 [medline]
AID - S2211-1247(17)31871-5 [pii]
AID - 10.1016/j.celrep.2017.12.047 [doi]
PST - ppublish
SO  - Cell Rep. 2018 Jan 9;22(2):383-395. doi: 10.1016/j.celrep.2017.12.047.

PMID- 29362479
OWN - NLM
STAT- Publisher
LR  - 20180124
IS  - 1476-5403 (Electronic)
IS  - 1350-9047 (Linking)
DP  - 2018 Jan 23
TI  - Molecular mechanisms of cell death: recommendations of the Nomenclature Committee
      on Cell Death 2018.
LID - 10.1038/s41418-017-0012-4 [doi]
AB  - Over the past decade, the Nomenclature Committee on Cell Death (NCCD) has
      formulated guidelines for the definition and interpretation of cell death from
      morphological, biochemical, and functional perspectives. Since the field
      continues to expand and novel mechanisms that orchestrate multiple cell death
      pathways are unveiled, we propose an updated classification of cell death
      subroutines focusing on mechanistic and essential (as opposed to correlative and 
      dispensable) aspects of the process. As we provide molecularly oriented
      definitions of terms including intrinsic apoptosis, extrinsic apoptosis,
      mitochondrial permeability transition (MPT)-driven necrosis, necroptosis,
      ferroptosis, pyroptosis, parthanatos, entotic cell death, NETotic cell death,
      lysosome-dependent cell death, autophagy-dependent cell death, immunogenic cell
      death, cellular senescence, and mitotic catastrophe, we discuss the utility of
      neologisms that refer to highly specialized instances of these processes. The
      mission of the NCCD is to provide a widely accepted nomenclature on cell death in
      support of the continued development of the field.
FAU - Galluzzi, Lorenzo
AU  - Galluzzi L
AD  - Department of Radiation Oncology, Weill Cornell Medical College, New York, NY,
      USA. deadoc@vodafone.it.
AD  - Sandra and Edward Meyer Cancer Center, New York, NY, USA. deadoc@vodafone.it.
AD  - Paris Descartes/Paris V University, Paris, France. deadoc@vodafone.it.
FAU - Vitale, Ilio
AU  - Vitale I
AD  - Department of Biology, University of Rome "Tor Vergata", Rome, Italy.
AD  - Unit of Cellular Networks and Molecular Therapeutic Targets, Department of
      Research, Advanced Diagnostics and Technological Innovation, Regina Elena
      National Cancer Institute, Rome, Italy.
FAU - Aaronson, Stuart A
AU  - Aaronson SA
AD  - Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New 
      York, NY, USA.
FAU - Abrams, John M
AU  - Abrams JM
AD  - Department of Cell Biology, University of Texas Southwestern Medical Center,
      Dallas, TX, USA.
FAU - Adam, Dieter
AU  - Adam D
AD  - Institute of Immunology, Kiel University, Kiel, Germany.
FAU - Agostinis, Patrizia
AU  - Agostinis P
AD  - Cell Death Research & Therapy (CDRT) Lab, Department of Cellular & Molecular
      Medicine, KU Leuven, Leuven, Belgium.
FAU - Alnemri, Emad S
AU  - Alnemri ES
AD  - Department of Biochemistry and Molecular Biology, Kimmel Cancer Center, Thomas
      Jefferson University, Philadelphia, PA, USA.
FAU - Altucci, Lucia
AU  - Altucci L
AD  - Department of Biochemistry, Biophysics and General Pathology, University of
      Campania "Luigi Vanvitelli", Napoli, Italy.
FAU - Amelio, Ivano
AU  - Amelio I
AD  - Medical Research Council (MRC) Toxicology Unit, Leicester University, Leicester, 
      UK.
FAU - Andrews, David W
AU  - Andrews DW
AD  - Biological Sciences, Sunnybrook Research Institute, Toronto, Canada.
AD  - Department of Biochemistry, University of Toronto, Toronto, Canada.
AD  - Department of Medical Biophysics, University of Toronto, Toronto, Canada.
FAU - Annicchiarico-Petruzzelli, Margherita
AU  - Annicchiarico-Petruzzelli M
AD  - Biochemistry Laboratory, Dermopatic Institute of Immaculate (IDI) IRCCS, Rome,
      Italy.
FAU - Antonov, Alexey V
AU  - Antonov AV
AD  - Medical Research Council (MRC) Toxicology Unit, Leicester University, Leicester, 
      UK.
FAU - Arama, Eli
AU  - Arama E
AD  - Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel.
FAU - Baehrecke, Eric H
AU  - Baehrecke EH
AD  - Department of Molecular, Cell and Cancer Biology, University of Massachusetts
      Medical School, Worcester, MA, USA.
FAU - Barlev, Nickolai A
AU  - Barlev NA
AD  - Institute of Cytology, Russian Academy of Sciences, Saint-Petersburg, Russia.
FAU - Bazan, Nicolas G
AU  - Bazan NG
AD  - Neuroscience Center of Excellence, Louisiana State University School of Medicine,
      New Orleans, LA, USA.
FAU - Bernassola, Francesca
AU  - Bernassola F
AD  - Department of Experimental Medicine and Surgery, University of Rome "Tor
      Vergata", Rome, Italy.
FAU - Bertrand, Mathieu J M
AU  - Bertrand MJM
AD  - VIB Center for Inflammation Research (IRC), Ghent, Belgium.
AD  - Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium.
FAU - Bianchi, Katiuscia
AU  - Bianchi K
AD  - Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of
      London, London, UK.
FAU - Blagosklonny, Mikhail V
AU  - Blagosklonny MV
AD  - Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, NY, USA.
FAU - Blomgren, Klas
AU  - Blomgren K
AD  - Department of Women's and Children's Health, Karolinska Institute, Stockholm,
      Sweden.
AD  - Department of Pediatric Oncology, Karolinska University Hospital, Stockholm,
      Sweden.
FAU - Borner, Christoph
AU  - Borner C
AD  - Institute of Molecular Medicine and Cell Research, Albert Ludwigs University,
      Freiburg, Germany.
AD  - Spemann Graduate School of Biology and Medicine (SGBM), Faculty of Medicine,
      Albert Ludwigs University, Freiburg, Germany.
FAU - Boya, Patricia
AU  - Boya P
AD  - Department of Cellular and Molecular Biology, Center for Biological Investigation
      (CIB), Spanish National Research Council (CSIC), Madrid, Spain.
FAU - Brenner, Catherine
AU  - Brenner C
AD  - INSERM U1180, Chatenay Malabry, France.
AD  - University of Paris Sud/Paris Saclay, Orsay, France.
FAU - Campanella, Michelangelo
AU  - Campanella M
AD  - Department of Biology, University of Rome "Tor Vergata", Rome, Italy.
AD  - Unit of Cellular Networks and Molecular Therapeutic Targets, Department of
      Research, Advanced Diagnostics and Technological Innovation, Regina Elena
      National Cancer Institute, Rome, Italy.
AD  - Department of Comparative Biomedical Sciences, The Royal Veterinary College,
      University of London, London, UK.
AD  - University College London Consortium for Mitochondrial Research, London, UK.
FAU - Candi, Eleonora
AU  - Candi E
AD  - Biochemistry Laboratory, Dermopatic Institute of Immaculate (IDI) IRCCS, Rome,
      Italy.
AD  - Department of Experimental Medicine and Surgery, University of Rome "Tor
      Vergata", Rome, Italy.
FAU - Carmona-Gutierrez, Didac
AU  - Carmona-Gutierrez D
AD  - Department Institute of Molecular Biosciences, NAWI Graz, University of Graz,
      Graz, Austria.
FAU - Cecconi, Francesco
AU  - Cecconi F
AD  - Department of Biology, University of Rome "Tor Vergata", Rome, Italy.
AD  - Unit of Cell Stress and Survival, Danish Cancer Society Research Center,
      Copenhagen, Denmark.
AD  - Department of Pediatric Hematology and Oncology, Bambino Gesu Children's Hospital
      IRCCS, Rome, Italy.
FAU - Chan, Francis K-M
AU  - Chan FK
AD  - Department of Pathology, University of Massachusetts Medical School, Worcester,
      MA, USA.
FAU - Chandel, Navdeep S
AU  - Chandel NS
AD  - Department of Medicine, Division of Pulmonary and Critical Care Medicine,
      Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
FAU - Cheng, Emily H
AU  - Cheng EH
AD  - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 
      New York, NY, USA.
FAU - Chipuk, Jerry E
AU  - Chipuk JE
AD  - Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New 
      York, NY, USA.
FAU - Cidlowski, John A
AU  - Cidlowski JA
AD  - Signal Transduction Laboratory, National Institutes of Environmental Health
      Sciences, NIH, Research Triangle Park, NC, USA.
FAU - Ciechanover, Aaron
AU  - Ciechanover A
AD  - Technion Integrated Cancer Center (TICC), The Ruth and Bruce Rappaport Faculty of
      Medicine and Research Institute, Technion-Israel Institute of Technology, Haifa, 
      Israel.
FAU - Cohen, Gerald M
AU  - Cohen GM
AD  - Department of Molecular and Clinical Cancer Medicine, Institute of Translational 
      Medicine, University of Liverpool, Liverpool, UK.
FAU - Conrad, Marcus
AU  - Conrad M
AD  - Institute of Developmental Genetics, Helmholtz Center Munich, German Research
      Center for Environmental Health (GmbH), Munich, Germany.
FAU - Cubillos-Ruiz, Juan R
AU  - Cubillos-Ruiz JR
AD  - Sandra and Edward Meyer Cancer Center, New York, NY, USA.
AD  - Department of Obstetrics and Gynecology, Weill Cornell Medical College, New York,
      NY, USA.
FAU - Czabotar, Peter E
AU  - Czabotar PE
AD  - The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria,
      Australia.
AD  - Department of Medical Biology, The University of Melbourne, Melbourne, Victoria, 
      Australia.
FAU - D'Angiolella, Vincenzo
AU  - D'Angiolella V
AD  - Cancer Research UK and Medical Research Council Institute for Radiation Oncology,
      Department of Oncology, University of Oxford, Old Road Campus Research Building, 
      Oxford, UK.
FAU - Dawson, Ted M
AU  - Dawson TM
AD  - Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns
      Hopkins University School of Medicine, Baltimore, MD, USA.
AD  - Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, 
      MD, USA.
AD  - Department of Pharmacology and Molecular Sciences, Johns Hopkins University
      School of Medicine, Baltimore, MD, USA.
AD  - Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of 
      Medicine, Baltimore, MD, USA.
FAU - Dawson, Valina L
AU  - Dawson VL
AD  - Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns
      Hopkins University School of Medicine, Baltimore, MD, USA.
AD  - Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, 
      MD, USA.
AD  - Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of 
      Medicine, Baltimore, MD, USA.
AD  - Department of Physiology, Johns Hopkins University School of Medicine, Baltimore,
      MD, USA.
FAU - De Laurenzi, Vincenzo
AU  - De Laurenzi V
AD  - Department of Medical, Oral and Biotechnological Sciences, CeSI-MetUniversity of 
      Chieti-Pescara "G. d'Annunzio", Chieti, Italy.
FAU - De Maria, Ruggero
AU  - De Maria R
AD  - Institute of General Pathology, Catholic University "Sacro Cuore", Rome, Italy.
FAU - Debatin, Klaus-Michael
AU  - Debatin KM
AD  - Department of Pediatrics and Adolescent Medicine, Ulm University Medical Center, 
      Ulm, Germany.
FAU - DeBerardinis, Ralph J
AU  - DeBerardinis RJ
AD  - Children's Medical Center Research Institute, University of Texas Southwestern
      Medical Center, Dallas, TX, USA.
FAU - Deshmukh, Mohanish
AU  - Deshmukh M
AD  - Department of Cell Biology and Physiology, Neuroscience Center, University of
      North Carolina, Chapel Hill, NC, USA.
FAU - Di Daniele, Nicola
AU  - Di Daniele N
AD  - Hypertension and Nephrology Unit, Department of Systems Medicine, University of
      Rome "Tor Vergata", Rome, Italy.
FAU - Di Virgilio, Francesco
AU  - Di Virgilio F
AD  - Department of Morphology, Surgery and Experimental Medicine, University of
      Ferrara, Ferrara, Italy.
FAU - Dixit, Vishva M
AU  - Dixit VM
AD  - Department of Physiological Chemistry, Genentech, South San Francisco, CA, USA.
FAU - Dixon, Scott J
AU  - Dixon SJ
AD  - Department of Biology, Stanford University, Stanford, CA, USA.
FAU - Duckett, Colin S
AU  - Duckett CS
AD  - Baylor Scott & White Research Institute, Baylor College of Medicine, Dallas, TX, 
      USA.
FAU - Dynlacht, Brian D
AU  - Dynlacht BD
AD  - Department of Pathology, New York University School of Medicine, New York, NY,
      USA.
AD  - Laura and Isaac Perlmutter Cancer Center, New York University School of Medicine,
      New York, NY, USA.
FAU - El-Deiry, Wafik S
AU  - El-Deiry WS
AD  - Laboratory of Translational Oncology and Experimental Cancer Therapeutics,
      Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA,
      USA.
AD  - Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA, USA.
FAU - Elrod, John W
AU  - Elrod JW
AD  - Center for Translational Medicine, Department of Pharmacology, Lewis Katz School 
      of Medicine at Temple University School of Medicine, Philadelphia, PA, USA.
FAU - Fimia, Gian Maria
AU  - Fimia GM
AD  - National Institute for Infectious Diseases IRCCS "Lazzaro Spallanzani", Rome,
      Italy.
AD  - Department of Biological and Environmental Sciences and Technologies (DiSTeBA),
      University of Salento, Lecce, Italy.
FAU - Fulda, Simone
AU  - Fulda S
AD  - Institute for Experimental Cancer Research in Pediatrics, Goethe-University
      Frankfurt, Frankfurt, Germany.
AD  - German Cancer Consortium (DKTK), Partner Site, Frankfurt, Germany.
AD  - German Cancer Research Center (DKFZ), Heidelberg, Germany.
FAU - Garcia-Saez, Ana J
AU  - Garcia-Saez AJ
AD  - Interfaculty Institute of Biochemistry, Tubingen University, Tubingen, Germany.
FAU - Garg, Abhishek D
AU  - Garg AD
AD  - Cell Death Research & Therapy (CDRT) Lab, Department of Cellular & Molecular
      Medicine, KU Leuven, Leuven, Belgium.
FAU - Garrido, Carmen
AU  - Garrido C
AD  - INSERM U1231 "Lipides Nutrition Cancer", Dijon, France.
AD  - Faculty of Medicine, University of Burgundy France Comte, Dijon, France.
AD  - Cancer Centre Georges Francois Leclerc, Dijon, France.
FAU - Gavathiotis, Evripidis
AU  - Gavathiotis E
AD  - Department of Biochemistry, Albert Einstein College of Medicine, Bronx, NY, USA.
AD  - Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA.
AD  - Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, NY,
      USA.
AD  - Wilf Family Cardiovascular Research Institute, Albert Einstein College of
      Medicine, Bronx, NY, USA.
FAU - Golstein, Pierre
AU  - Golstein P
AD  - Immunology Center of Marseille-Luminy, Aix Marseille University, Marseille,
      France.
FAU - Gottlieb, Eyal
AU  - Gottlieb E
AD  - Technion Integrated Cancer Center (TICC), The Ruth and Bruce Rappaport Faculty of
      Medicine and Research Institute, Technion-Israel Institute of Technology, Haifa, 
      Israel.
AD  - Cancer Research UK Beatson Institute, Glasgow, UK.
FAU - Green, Douglas R
AU  - Green DR
AD  - Department of Immunology, St Jude Children's Research Hospital, Memphis, TN, USA.
FAU - Greene, Lloyd A
AU  - Greene LA
AD  - Department of Pathology and Cell Biology, Columbia University College of
      Physicians and Surgeons, New York, NY, USA.
FAU - Gronemeyer, Hinrich
AU  - Gronemeyer H
AD  - Team labeled "Ligue Contre le Cancer", Department of Functional Genomics and
      Cancer, Institute of Genetics and Molecular and Cellular Biology (IGBMC),
      Illkirch, France.
AD  - CNRS UMR 7104, Illkirch, France.
AD  - INSERM U964, Illkirch, France.
AD  - University of Strasbourg, Illkirch, France.
FAU - Gross, Atan
AU  - Gross A
AD  - Department of Biological Regulation, Weizmann Institute of Science, Rehovot,
      Israel.
FAU - Hajnoczky, Gyorgy
AU  - Hajnoczky G
AD  - MitoCare Center, Department of Pathology, Anatomy and Cell Biology, Thomas
      Jefferson University, Philadelphia, PA, USA.
FAU - Hardwick, J Marie
AU  - Hardwick JM
AD  - Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.
FAU - Harris, Isaac S
AU  - Harris IS
AD  - Department of Cell Biology, Harvard Medical School, Boston, MA, USA.
FAU - Hengartner, Michael O
AU  - Hengartner MO
AD  - Institute of Molecular Life Sciences, University of Zurich, Zurich, Switzerland.
FAU - Hetz, Claudio
AU  - Hetz C
AD  - Biomedical Neuroscience Institute, Faculty of Medicine, University of Chile,
      Santiago, Chile.
AD  - Center for Geroscience, Brain Health and Metabolism, Santiago, Chile.
AD  - Cellular and Molecular Biology Program, Institute of Biomedical Sciences,
      University of Chile, Santiago, Chile.
FAU - Ichijo, Hidenori
AU  - Ichijo H
AD  - Laboratory of Cell Signaling, Graduate School of Pharmaceutical Sciences, The
      University of Tokyo, Tokyo, Japan.
FAU - Jaattela, Marja
AU  - Jaattela M
AD  - Cell Death and Metabolism Unit, Center for Autophagy, Recycling and Disease,
      Danish Cancer Society Research Center, Copenhagen, Denmark.
FAU - Joseph, Bertrand
AU  - Joseph B
AD  - Toxicology Unit, Institute of Environmental Medicine, Karolinska Institute,
      Stockholm, Sweden.
FAU - Jost, Philipp J
AU  - Jost PJ
AD  - III Medical Department for Hematology and Oncology, Technical University Munich, 
      Munich, Germany.
FAU - Juin, Philippe P
AU  - Juin PP
AD  - Team 8 "Stress adaptation and tumor escape", CRCINA-INSERM U1232, Nantes, France.
AD  - University of Nantes, Nantes, France.
AD  - University of Angers, Angers, France.
AD  - Institute of Cancer Research in Western France, Saint-Herblain, France.
FAU - Kaiser, William J
AU  - Kaiser WJ
AD  - Department of Microbiology, Immunology and Molecular Genetics, University of
      Texas Health Science Center, San Antonio, TX, USA.
FAU - Karin, Michael
AU  - Karin M
AD  - Laboratory of Gene Regulation and Signal Transduction, University of California
      San Diego, La Jolla, CA, USA.
AD  - Department of Pathology, University of California San Diego, La Jolla, CA, USA.
AD  - Department of Pharmacology, University of California San Diego, La Jolla, CA,
      USA.
AD  - Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.
FAU - Kaufmann, Thomas
AU  - Kaufmann T
AD  - Institute of Pharmacology, University of Bern, Bern, Switzerland.
FAU - Kepp, Oliver
AU  - Kepp O
AD  - Paris Descartes/Paris V University, Paris, France.
AD  - Faculty of Medicine, Paris Sud/Paris XI University, Kremlin-Bicetre, France.
AD  - Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer
      Campus, Villejuif, France.
AD  - Team 11 labeled "Ligue Nationale contre le Cancer", Cordeliers Research Center,
      Paris, France.
AD  - INSERM U1138, Paris, France.
AD  - Pierre et Marie Curie/Paris VI University, Paris, France.
FAU - Kimchi, Adi
AU  - Kimchi A
AD  - Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel.
FAU - Kitsis, Richard N
AU  - Kitsis RN
AD  - Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA.
AD  - Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, NY,
      USA.
AD  - Wilf Family Cardiovascular Research Institute, Albert Einstein College of
      Medicine, Bronx, NY, USA.
AD  - Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY, USA.
AD  - Einstein-Mount Sinai Diabetes Research Center, Albert Einstein College of
      Medicine, Bronx, NY, USA.
FAU - Klionsky, Daniel J
AU  - Klionsky DJ
AD  - Department of Molecular, Cellular, and Developmental Biology, University of
      Michigan, Ann Arbor, MI, USA.
AD  - Life Sciences Institute, University of Michigan, Ann Arbor, MI, USA.
FAU - Knight, Richard A
AU  - Knight RA
AD  - Medical Research Council (MRC) Toxicology Unit, Leicester University, Leicester, 
      UK.
FAU - Kumar, Sharad
AU  - Kumar S
AD  - Centre for Cancer Biology, University of South Australia and SA Pathology,
      Adelaide, South Australia, Australia.
FAU - Lee, Sam W
AU  - Lee SW
AD  - Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard
      Medical School, Charlestown, MA, USA.
FAU - Lemasters, John J
AU  - Lemasters JJ
AD  - Center for Cell Death, Injury and Regeneration, Department of Drug Discovery &
      Biomedical Sciences, Medical University of South Carolina, Charleston, SC, USA.
AD  - Center for Cell Death, Injury and Regeneration, Department of Biochemistry &
      Molecular Biology, Medical University of South Carolina, Charleston, SC, USA.
FAU - Levine, Beth
AU  - Levine B
AD  - Center for Autophagy Research, University of Texas Southwestern Medical Center,
      Dallas, TX, USA.
AD  - Department of Internal Medicine, University of Texas Southwestern Medical Center,
      Dallas, TX, USA.
AD  - Howard Hughes Medical Institute, University of Texas Southwestern Medical Center,
      Dallas, TX, USA.
FAU - Linkermann, Andreas
AU  - Linkermann A
AD  - Division of Nephrology, University Hospital Carl Gustav Carus Dresden, Dresden,
      Germany.
FAU - Lipton, Stuart A
AU  - Lipton SA
AD  - Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA,
      USA.
AD  - Department of Neuroscience, The Scripps Research Institute, La Jolla, CA, USA.
AD  - Neuroscience Translational Center, The Scripps Research Institute, La Jolla, CA, 
      USA.
FAU - Lockshin, Richard A
AU  - Lockshin RA
AD  - Department of Biology, St. John's University, Queens, NY, USA.
AD  - Queens College of the City University of New York, Queens, NY, USA.
FAU - Lopez-Otin, Carlos
AU  - Lopez-Otin C
AD  - Departament of Biochemistry and Molecular Biology, Faculty of Medicine,
      University Institute of Oncology of Asturias (IUOPA), University of Oviedo,
      Oviedo, Spain.
FAU - Lowe, Scott W
AU  - Lowe SW
AD  - Howard Hughes Medical Institute, The Rockefeller University, New York, NY, USA.
AD  - Memorial Sloan Kettering Cancer Center, New York, NY, USA.
FAU - Luedde, Tom
AU  - Luedde T
AD  - Division of Gastroenterology, Hepatology and Hepatobiliary Oncology, University
      Hospital RWTH Aachen, Aachen, Germany.
FAU - Lugli, Enrico
AU  - Lugli E
AD  - Laboratory of Translational Immunology, Humanitas Clinical and Research Center,
      Rozzano, Milan, Italy.
AD  - Humanitas Flow Cytometry Core, Humanitas Clinical and Research Center, Rozzano,
      Milan, Italy.
FAU - MacFarlane, Marion
AU  - MacFarlane M
AD  - Medical Research Council (MRC) Toxicology Unit, Leicester University, Leicester, 
      UK.
FAU - Madeo, Frank
AU  - Madeo F
AD  - Department Institute of Molecular Biosciences, NAWI Graz, University of Graz,
      Graz, Austria.
AD  - BioTechMed Graz, Graz, Austria.
FAU - Malewicz, Michal
AU  - Malewicz M
AD  - Medical Research Council (MRC) Toxicology Unit, Leicester University, Leicester, 
      UK.
FAU - Malorni, Walter
AU  - Malorni W
AD  - National Centre for Gender Medicine, Italian National Institute of Health (ISS), 
      Rome, Italy.
FAU - Manic, Gwenola
AU  - Manic G
AD  - Department of Biology, University of Rome "Tor Vergata", Rome, Italy.
AD  - Unit of Cellular Networks and Molecular Therapeutic Targets, Department of
      Research, Advanced Diagnostics and Technological Innovation, Regina Elena
      National Cancer Institute, Rome, Italy.
FAU - Marine, Jean-Christophe
AU  - Marine JC
AD  - Laboratory for Molecular Cancer Biology, VIB Center for Cancer Biology, Leuven,
      Belgium.
AD  - Laboratory for Molecular Cancer Biology, Department of Oncology, KU Leuven,
      Leuven, Belgium.
FAU - Martin, Seamus J
AU  - Martin SJ
AD  - Departments of Genetics, Trinity College, University of Dublin, Dublin 2,
      Ireland.
FAU - Martinou, Jean-Claude
AU  - Martinou JC
AD  - Department of Cell Biology, Faculty of Sciences, University of Geneva, Geneva,
      Switzerland.
FAU - Medema, Jan Paul
AU  - Medema JP
AD  - Laboratory for Experimental Oncology and Radiobiology (LEXOR), Center for
      Experimental Molecular Medicine (CEMM), Academic Medical Center (AMC), University
      of Amsterdam, Amsterdam, The Netherlands.
AD  - Cancer Genomics Center, Amsterdam, The Netherlands.
FAU - Mehlen, Patrick
AU  - Mehlen P
AD  - Apoptosis, Cancer and Development laboratory, CRCL, Lyon, France.
AD  - Team labeled "La Ligue contre le Cancer", Lyon, France.
AD  - LabEx DEVweCAN, Lyon, France.
AD  - INSERM U1052, Lyon, France.
AD  - CNRS UMR5286, Lyon, France.
AD  - Department of Translational Research and Innovation, Leon Berard Cancer Center,
      Lyon, France.
FAU - Meier, Pascal
AU  - Meier P
AD  - The Breast Cancer Now Toby Robins Research Centre, Institute of Cancer Research, 
      Mary-Jean Mitchell Green Building, Chester Beatty Laboratories, London, UK.
FAU - Melino, Sonia
AU  - Melino S
AD  - Department of Chemical Sciences and Technologies, University of Rome, Tor
      Vergata, Rome, Italy.
FAU - Miao, Edward A
AU  - Miao EA
AD  - Department of Microbiology and Immunology, University of North Carolina, Chapel
      Hill, NC, USA.
AD  - Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel
      Hill, NC, USA.
AD  - Center for Gastrointestinal Biology and Disease, University of North Carolina,
      Chapel Hill, NC, USA.
FAU - Molkentin, Jeffery D
AU  - Molkentin JD
AD  - Howard Hughes Medical Institute, Cincinnati Children's Hospital Medical Center,
      Cincinnati, OH, USA.
FAU - Moll, Ute M
AU  - Moll UM
AD  - Department of Pathology, Stony Brook University, Stony Brook, NY, USA.
FAU - Munoz-Pinedo, Cristina
AU  - Munoz-Pinedo C
AD  - Cell Death Regulation Group, Oncobell Program, Bellvitge Biomedical Research
      Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain.
FAU - Nagata, Shigekazu
AU  - Nagata S
AD  - Laboratory of Biochemistry and Immunology, World Premier International (WPI)
      Immunology Frontier Research Center, Osaka University, Suita, Osaka, Japan.
FAU - Nunez, Gabriel
AU  - Nunez G
AD  - Department of Pathology, University of Michigan Medical School, Ann Arbor, MI,
      USA.
AD  - Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor,
      MI, USA.
FAU - Oberst, Andrew
AU  - Oberst A
AD  - Department of Immunology, University of Washington, Seattle, WA, USA.
AD  - Center for Innate Immunity and Immune Disease, Seattle, WA, USA.
FAU - Oren, Moshe
AU  - Oren M
AD  - Department of Molecular Cell Biology, Weizmann Institute, Rehovot, Israel.
FAU - Overholtzer, Michael
AU  - Overholtzer M
AD  - Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
FAU - Pagano, Michele
AU  - Pagano M
AD  - Laura and Isaac Perlmutter Cancer Center, New York University School of Medicine,
      New York, NY, USA.
AD  - Department of Biochemistry and Molecular Pharmacology, New York University School
      of Medicine, New York, NY, USA.
AD  - Howard Hughes Medical Institute, New York University School of Medicine, New
      York, NY, USA.
FAU - Panaretakis, Theocharis
AU  - Panaretakis T
AD  - Department of Genitourinary Medical Oncology, University of Texas, MD Anderson
      Cancer Center, Houston, TX, USA.
AD  - Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.
FAU - Pasparakis, Manolis
AU  - Pasparakis M
AD  - Institute for Genetics, Center for Molecular Medicine (CMMC), University of
      Cologne, Cologne, Germany.
AD  - Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated
      Diseases (CECAD), University of Cologne, Cologne, Germany.
FAU - Penninger, Josef M
AU  - Penninger JM
AD  - Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), 
      Campus Vienna BioCentre, Vienna, Austria.
FAU - Pereira, David M
AU  - Pereira DM
AD  - REQUIMTE/LAQV, Laboratory of Pharmacognosy, Department of Chemistry, Faculty of
      Pharmacy, University of Porto, Porto, Portugal.
FAU - Pervaiz, Shazib
AU  - Pervaiz S
AD  - Department of Physiology, Yong Loo Lin School of Medicine, National University of
      Singapore, Singapore, Singapore.
AD  - NUS Graduate School for Integrative Sciences and Engineering, National University
      of Singapore, Singapore, Singapore.
AD  - National University Cancer Institute, National University Health System (NUHS),
      Singapore, Singapore.
FAU - Peter, Marcus E
AU  - Peter ME
AD  - Division of Hematology/Oncology, Department of Medicine, Northwestern University 
      Feinberg School of Medicine, Chicago, IL, USA.
AD  - Department of Biochemistry and Molecular Genetics, Northwestern University
      Feinberg School of Medicine, Chicago, IL, USA.
FAU - Piacentini, Mauro
AU  - Piacentini M
AD  - Department of Biology, University of Rome "Tor Vergata", Rome, Italy.
AD  - National Institute for Infectious Diseases IRCCS "Lazzaro Spallanzani", Rome,
      Italy.
FAU - Pinton, Paolo
AU  - Pinton P
AD  - Department of Morphology, Surgery and Experimental Medicine, University of
      Ferrara, Ferrara, Italy.
AD  - LTTA center, University of Ferrara, Ferrara, Italy.
AD  - Maria Cecilia Hospital, GVM Care & Research, Health Science Foundation,
      Cotignola, Italy.
FAU - Prehn, Jochen H M
AU  - Prehn JHM
AD  - Department of Physiology, Royal College of Surgeons in Ireland, Dublin, Ireland.
FAU - Puthalakath, Hamsa
AU  - Puthalakath H
AD  - Department of Biochemistry, La Trobe University, Victoria, Australia.
FAU - Rabinovich, Gabriel A
AU  - Rabinovich GA
AD  - Laboratory of Immunopathology, Institute of Biology and Experimental Medicine
      (IBYME), National Council of Scientific and Technical Research (CONICET), Buenos 
      Aires, Argentina.
AD  - Department of Biological Chemistry, Faculty of Exact and Natural Sciences,
      University of Buenos Aires, Buenos Aires, Argentina.
FAU - Rehm, Markus
AU  - Rehm M
AD  - Institute of Cell Biology and Immunology, University of Stuttgart, Stuttgart,
      Germany.
AD  - Stuttgart Research Center Systems Biology, Stuttgart, Germany.
FAU - Rizzuto, Rosario
AU  - Rizzuto R
AD  - Department of Biomedical Sciences, University of Padua, Padua, Italy.
FAU - Rodrigues, Cecilia M P
AU  - Rodrigues CMP
AD  - Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, University 
      of Lisbon, Lisbon, Portugal.
FAU - Rubinsztein, David C
AU  - Rubinsztein DC
AD  - Department of Medical Genetics, Cambridge Institute for Medical Research (CIMR), 
      University of Cambridge, Cambridge, UK.
FAU - Rudel, Thomas
AU  - Rudel T
AD  - Department of Microbiology, Biocenter, University of Wurzburg, Wurzburg, Germany.
FAU - Ryan, Kevin M
AU  - Ryan KM
AD  - Cancer Research UK Beatson Institute, Glasgow, UK.
FAU - Sayan, Emre
AU  - Sayan E
AD  - Cancer Sciences Unit, Faculty of Medicine, University of Southampton,
      Southampton, UK.
FAU - Scorrano, Luca
AU  - Scorrano L
AD  - Department of Biology, University of Padua, Padua, Italy.
AD  - Venetian Institute of Molecular Medicine, Padua, Italy.
FAU - Shao, Feng
AU  - Shao F
AD  - National Institute of Biological Sciences, Beijing, China.
FAU - Shi, Yufang
AU  - Shi Y
AD  - Key Laboratory of Stem Cell Biology, Institute of Health Sciences, Chinese
      Academy of Sciences, Shanghai, China.
AD  - Jiangsu Key Laboratory of Stem Cells and Medicinal Biomaterials, Institutes for
      Translational Medicine, Soochow University, Suzhou, China.
AD  - The First Affiliated Hospital of Soochow University, Institutes for Translational
      Medicine, Soochow University, Suzhou, China.
FAU - Silke, John
AU  - Silke J
AD  - Department of Medical Biology, The University of Melbourne, Melbourne, Victoria, 
      Australia.
AD  - Division of Inflammation, Walter and Eliza Hall Institute of Medical Research,
      Melbourne, Victoria, Australia.
FAU - Simon, Hans-Uwe
AU  - Simon HU
AD  - Institute of Pharmacology, University of Bern, Bern, Switzerland.
FAU - Sistigu, Antonella
AU  - Sistigu A
AD  - Institute of General Pathology, Catholic University "Sacro Cuore", Rome, Italy.
AD  - Unit of Tumor Immunology and Immunotherapy, Department of Research, Advanced
      Diagnostics and Technological Innovation, Regina Elena National Cancer Institute,
      Rome, Italy.
FAU - Stockwell, Brent R
AU  - Stockwell BR
AD  - Department of Biological Sciences, Columbia University, New York, NY, USA.
AD  - Department of Chemistry, Columbia University, New York, NY, USA.
FAU - Strasser, Andreas
AU  - Strasser A
AD  - The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria,
      Australia.
FAU - Szabadkai, Gyorgy
AU  - Szabadkai G
AD  - Department of Biomedical Sciences, University of Padua, Padua, Italy.
AD  - Department of Cell and Developmental Biology, University College London
      Consortium for Mitochondrial Research, London, UK.
AD  - Francis Crick Institute, London, UK.
FAU - Tait, Stephen W G
AU  - Tait SWG
AD  - Cancer Research UK Beatson Institute, Glasgow, UK.
FAU - Tang, Daolin
AU  - Tang D
AD  - The Third Affiliated Hospital, Guangzhou Medical University, Guangzhou,
      Guangdong, China.
AD  - Center for DAMP Biology, Guangzhou Medical University, Guangzhou, Guangdong,
      China.
AD  - Key Laboratory for Major Obstetric Diseases of Guangdong Province, Guangzhou
      Medical University, Guangzhou, Guangdong, China.
AD  - Key Laboratory of Reproduction and Genetics of Guangdong Higher Education
      Institutes, Guangzhou Medical University, Guangzhou, Guangdong, China.
AD  - Key Laboratory for Protein Modification and Degradation of Guangdong Province,
      Guangzhou Medical University, Guangzhou, Guangdong, China.
AD  - Department of Surgery, University of Pittsburgh, Pittsburgh, PA, USA.
FAU - Tavernarakis, Nektarios
AU  - Tavernarakis N
AD  - Institute of Molecular Biology and Biotechnology, Foundation for Research and
      Technology-Hellas Medical School, University of Crete, Heraklion, Greece.
FAU - Thorburn, Andrew
AU  - Thorburn A
AD  - Department of Pharmacology, University of Colorado, Aurora, CO, USA.
FAU - Tsujimoto, Yoshihide
AU  - Tsujimoto Y
AD  - Research Center, Osaka International Cancer Institute, Osaka, Japan.
FAU - Turk, Boris
AU  - Turk B
AD  - Department Biochemistry and Molecular Biology, "Jozef Stefan" Institute,
      Ljubljana, Slovenia.
AD  - Faculty of Chemistry and Chemical Technology, University of Ljubljana, Ljubljana,
      Slovenia.
FAU - Vanden Berghe, Tom
AU  - Vanden Berghe T
AD  - VIB Center for Inflammation Research (IRC), Ghent, Belgium.
AD  - Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium.
FAU - Vandenabeele, Peter
AU  - Vandenabeele P
AD  - VIB Center for Inflammation Research (IRC), Ghent, Belgium.
AD  - Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium.
FAU - Vander Heiden, Matthew G
AU  - Vander Heiden MG
AD  - Koch Institute for Integrative Cancer Research, Massachusetts Institute of
      Technology, Cambridge, MA, USA.
AD  - Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical 
      School, Boston, MA, USA.
FAU - Villunger, Andreas
AU  - Villunger A
AD  - Division of Developmental Immunology, Innsbruck Medical University, Innsbruck,
      Austria.
FAU - Virgin, Herbert W
AU  - Virgin HW
AD  - Department of Pathology and Immunology, Washington University School of Medicine,
      St. Louis, MO, USA.
FAU - Vousden, Karen H
AU  - Vousden KH
AD  - Francis Crick Institute, London, UK.
FAU - Vucic, Domagoj
AU  - Vucic D
AD  - Department of Early Discovery Biochemistry, Genentech, South San Francisco, CA,
      USA.
FAU - Wagner, Erwin F
AU  - Wagner EF
AD  - Genes, Development and Disease Group, Cancer Cell Biology Program, Spanish
      National Cancer Research Centre (CNIO), Madrid, Spain.
FAU - Walczak, Henning
AU  - Walczak H
AD  - Centre for Cell Death, Cancer and Inflammation, UCL Cancer Institute, University 
      College London, London, UK.
FAU - Wallach, David
AU  - Wallach D
AD  - Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot,
      Israel.
FAU - Wang, Ying
AU  - Wang Y
AD  - Institute of Health Sciences, Shanghai Institutes for Biological Sciences,
      Chinese Academy of Sciences, Shanghai, China.
FAU - Wells, James A
AU  - Wells JA
AD  - Department of Pharmaceutical Chemistry, University of California, San Francisco, 
      San Francisco, CA, USA.
FAU - Wood, Will
AU  - Wood W
AD  - School of Cellular and Molecular Medicine, Faculty of Biomedical Sciences,
      University of Bristol, Bristol, UK.
FAU - Yuan, Junying
AU  - Yuan J
AD  - Department of Cell Biology, Harvard Medical School, Boston, MA, USA.
AD  - Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of
      Organic Chemistry, Chinese Academy of Sciences, Shanghai, China.
FAU - Zakeri, Zahra
AU  - Zakeri Z
AD  - Department of Biology, Queens College of the City University of New York, Queens,
      NY, USA.
FAU - Zhivotovsky, Boris
AU  - Zhivotovsky B
AD  - Toxicology Unit, Institute of Environmental Medicine, Karolinska Institute,
      Stockholm, Sweden.
AD  - Faculty of Fundamental Medicine, Lomonosov Moscow State University, Moscow,
      Russia.
FAU - Zitvogel, Laurence
AU  - Zitvogel L
AD  - Faculty of Medicine, Paris Sud/Paris XI University, Kremlin-Bicetre, France.
AD  - Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.
AD  - INSERM U1015, Villejuif, France.
AD  - Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428,
      Villejuif, France.
FAU - Melino, Gerry
AU  - Melino G
AD  - Medical Research Council (MRC) Toxicology Unit, Leicester University, Leicester, 
      UK.
AD  - Department of Experimental Medicine and Surgery, University of Rome "Tor
      Vergata", Rome, Italy.
FAU - Kroemer, Guido
AU  - Kroemer G
AD  - Paris Descartes/Paris V University, Paris, France. kroemer@orange.fr.
AD  - Department of Women's and Children's Health, Karolinska Institute, Stockholm,
      Sweden. kroemer@orange.fr.
AD  - Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer
      Campus, Villejuif, France. kroemer@orange.fr.
AD  - Team 11 labeled "Ligue Nationale contre le Cancer", Cordeliers Research Center,
      Paris, France. kroemer@orange.fr.
AD  - INSERM U1138, Paris, France. kroemer@orange.fr.
AD  - Pierre et Marie Curie/Paris VI University, Paris, France. kroemer@orange.fr.
AD  - Biology Pole, European Hospital George Pompidou, AP-HP, Paris, France.
      kroemer@orange.fr.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180123
PL  - England
TA  - Cell Death Differ
JT  - Cell death and differentiation
JID - 9437445
EDAT- 2018/01/25 06:00
MHDA- 2018/01/25 06:00
CRDT- 2018/01/25 06:00
PHST- 2017/10/11 00:00 [received]
PHST- 2017/10/13 00:00 [accepted]
PHST- 2018/01/25 06:00 [entrez]
PHST- 2018/01/25 06:00 [pubmed]
PHST- 2018/01/25 06:00 [medline]
AID - 10.1038/s41418-017-0012-4 [doi]
AID - 10.1038/s41418-017-0012-4 [pii]
PST - aheadofprint
SO  - Cell Death Differ. 2018 Jan 23. pii: 10.1038/s41418-017-0012-4. doi:
      10.1038/s41418-017-0012-4.

PMID- 29364879
OWN - NLM
STAT- Publisher
LR  - 20180124
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
DP  - 2018 Jan 24
TI  - Mitochondrial translation requires folate-dependent tRNA methylation.
LID - 10.1038/nature25460 [doi]
AB  - Folates enable the activation and transfer of one-carbon units for the
      biosynthesis of purines, thymidine and methionine. Antifolates are important
      immunosuppressive and anticancer agents. In proliferating lymphocytes and human
      cancers, mitochondrial folate enzymes are particularly strongly upregulated. This
      in part reflects the need for mitochondria to generate one-carbon units and
      export them to the cytosol for anabolic metabolism. The full range of uses of
      folate-bound one-carbon units in the mitochondrial compartment itself, however,
      has not been thoroughly explored. Here we show that loss of the catalytic
      activity of the mitochondrial folate enzyme serine hydroxymethyltransferase 2
      (SHMT2), but not of other folate enzymes, leads to defective oxidative
      phosphorylation in human cells due to impaired mitochondrial translation. We find
      that SHMT2, presumably by generating mitochondrial
      5,10-methylenetetrahydrofolate, provides methyl donors to produce the
      taurinomethyluridine base at the wobble position of select mitochondrial tRNAs.
      Mitochondrial ribosome profiling in SHMT2-knockout human cells reveals that the
      lack of this modified base causes defective translation, with preferential
      mitochondrial ribosome stalling at certain lysine (AAG) and leucine (UUG) codons.
      This results in the impaired expression of respiratory chain enzymes. Stalling at
      these specific codons also occurs in certain inborn errors of mitochondrial
      metabolism. Disruption of whole-cell folate metabolism, by either folate
      deficiency or antifolate treatment, also impairs the respiratory chain. In
      summary, mammalian mitochondria use folate-bound one-carbon units to methylate
      tRNA, and this modification is required for mitochondrial translation and thus
      oxidative phosphorylation.
FAU - Morscher, Raphael J
AU  - Morscher RJ
AD  - Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton,
      New Jersey 08544, USA.
AD  - Department of Chemistry, Princeton University, Princeton, New Jersey 08544, USA.
FAU - Ducker, Gregory S
AU  - Ducker GS
AD  - Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton,
      New Jersey 08544, USA.
AD  - Department of Chemistry, Princeton University, Princeton, New Jersey 08544, USA.
FAU - Li, Sophia Hsin-Jung
AU  - Li SH
AD  - Department of Molecular Biology, Princeton University, Princeton, New Jersey
      08544, USA.
FAU - Mayer, Johannes A
AU  - Mayer JA
AD  - Department of Pediatrics, Salzburger Landeskliniken and Paracelsus Medical
      University, Salzburg 5020, Austria.
FAU - Gitai, Zemer
AU  - Gitai Z
AD  - Department of Molecular Biology, Princeton University, Princeton, New Jersey
      08544, USA.
FAU - Sperl, Wolfgang
AU  - Sperl W
AD  - Department of Pediatrics, Salzburger Landeskliniken and Paracelsus Medical
      University, Salzburg 5020, Austria.
FAU - Rabinowitz, Joshua D
AU  - Rabinowitz JD
AD  - Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton,
      New Jersey 08544, USA.
AD  - Department of Chemistry, Princeton University, Princeton, New Jersey 08544, USA.
LA  - eng
PT  - Journal Article
DEP - 20180124
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
EDAT- 2018/01/25 06:00
MHDA- 2018/01/25 06:00
CRDT- 2018/01/25 06:00
PHST- 2017/06/07 00:00 [received]
PHST- 2017/12/14 00:00 [accepted]
PHST- 2018/01/25 06:00 [entrez]
PHST- 2018/01/25 06:00 [pubmed]
PHST- 2018/01/25 06:00 [medline]
AID - nature25460 [pii]
AID - 10.1038/nature25460 [doi]
PST - aheadofprint
SO  - Nature. 2018 Jan 24. pii: nature25460. doi: 10.1038/nature25460.

PMID- 29258295
OWN - NLM
STAT- In-Data-Review
LR  - 20180104
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 553
IP  - 7686
DP  - 2018 Jan 4
TI  - Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling.
PG  - 101-105
LID - 10.1038/nature25169 [doi]
AB  - Genomic sequencing has driven precision-based oncology therapy; however, the
      genetic drivers of many malignancies remain unknown or non-targetable, so
      alternative approaches to the identification of therapeutic leads are necessary. 
      Ependymomas are chemotherapy-resistant brain tumours, which, despite genomic
      sequencing, lack effective molecular targets. Intracranial ependymomas are
      segregated on the basis of anatomical location (supratentorial region or
      posterior fossa) and further divided into distinct molecular subgroups that
      reflect differences in the age of onset, gender predominance and response to
      therapy. The most common and aggressive subgroup, posterior fossa ependymoma
      group A (PF-EPN-A), occurs in young children and appears to lack recurrent
      somatic mutations. Conversely, posterior fossa ependymoma group B (PF-EPN-B)
      tumours display frequent large-scale copy number gains and losses but have
      favourable clinical outcomes. More than 70% of supratentorial ependymomas are
      defined by highly recurrent gene fusions in the NF-kappaB subunit gene RELA
      (ST-EPN-RELA), and a smaller number involve fusion of the gene encoding the
      transcriptional activator YAP1 (ST-EPN-YAP1). Subependymomas, a distinct
      histologic variant, can also be found within the supratetorial and posterior
      fossa compartments, and account for the majority of tumours in the molecular
      subgroups ST-EPN-SE and PF-EPN-SE. Here we describe mapping of active chromatin
      landscapes in 42 primary ependymomas in two non-overlapping primary ependymoma
      cohorts, with the goal of identifying essential super-enhancer-associated genes
      on which tumour cells depend. Enhancer regions revealed putative oncogenes,
      molecular targets and pathways; inhibition of these targets with small molecule
      inhibitors or short hairpin RNA diminished the proliferation of patient-derived
      neurospheres and increased survival in mouse models of ependymomas. Through
      profiling of transcriptional enhancers, our study provides a framework for target
      and drug discovery in other cancers that lack known genetic drivers and are
      therefore difficult to treat.
FAU - Mack, Stephen C
AU  - Mack SC
AD  - Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.
AD  - Department of Pediatric Hematolgy and Oncology, Texas Children's Cancer and
      Hematology Centers, Houston, Texas, USA.
AD  - Department of Stem Cell Biology and Regenerative Medicine, Lerner Research
      Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA.
AD  - Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine of 
      Case Western Reserve University, Cleveland, Ohio 44195, USA.
FAU - Pajtler, Kristian W
AU  - Pajtler KW
AD  - Hopp Children's Cancer Center at the NCT Heidelberg (KiTZ), 69120 Heidelberg,
      Germany.
AD  - Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), 69120 
      Heidelberg, Germany and German Cancer Consortium (DKTK), 69120 Heidelberg,
      Germany.
AD  - Department of Pediatric Oncology, Hematology and Immunology, Heidelberg
      University Hospital, 69120 Heidelberg, Germany.
FAU - Chavez, Lukas
AU  - Chavez L
AD  - Hopp Children's Cancer Center at the NCT Heidelberg (KiTZ), 69120 Heidelberg,
      Germany.
AD  - Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), 69120 
      Heidelberg, Germany and German Cancer Consortium (DKTK), 69120 Heidelberg,
      Germany.
AD  - Department of Medicine, Division of Medical Genetics, University of California - 
      San Diego School of Medicine, La Jolla, California 92093, USA.
FAU - Okonechnikov, Konstantin
AU  - Okonechnikov K
AD  - Hopp Children's Cancer Center at the NCT Heidelberg (KiTZ), 69120 Heidelberg,
      Germany.
AD  - Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), 69120 
      Heidelberg, Germany and German Cancer Consortium (DKTK), 69120 Heidelberg,
      Germany.
FAU - Bertrand, Kelsey C
AU  - Bertrand KC
AD  - Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.
AD  - Department of Pediatric Hematolgy and Oncology, Texas Children's Cancer and
      Hematology Centers, Houston, Texas, USA.
AD  - Department of Pediatrics, Cleveland Clinic, Cleveland, Ohio 44195, USA.
FAU - Wang, Xiuxing
AU  - Wang X
AD  - Department of Stem Cell Biology and Regenerative Medicine, Lerner Research
      Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA.
AD  - Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine of 
      Case Western Reserve University, Cleveland, Ohio 44195, USA.
AD  - Department of Medicine, Division of Regenerative Medicine, University of
      California - San Diego School of Medicine, La Jolla, California, USA.
FAU - Erkek, Serap
AU  - Erkek S
AD  - Hopp Children's Cancer Center at the NCT Heidelberg (KiTZ), 69120 Heidelberg,
      Germany.
AD  - Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), 69120 
      Heidelberg, Germany and German Cancer Consortium (DKTK), 69120 Heidelberg,
      Germany.
AD  - European Molecular Biology Laboratory, Genome Biology Unit, Heidelberg, Germany.
FAU - Federation, Alexander
AU  - Federation A
AD  - Department of Genomic Sciences, University of Washington, Seattle, Washington
      355065, USA.
FAU - Song, Anne
AU  - Song A
AD  - Department of Stem Cell Biology and Regenerative Medicine, Lerner Research
      Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA.
AD  - Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine of 
      Case Western Reserve University, Cleveland, Ohio 44195, USA.
FAU - Lee, Christine
AU  - Lee C
AD  - Department of Stem Cell Biology and Regenerative Medicine, Lerner Research
      Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA.
AD  - Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine of 
      Case Western Reserve University, Cleveland, Ohio 44195, USA.
FAU - Wang, Xin
AU  - Wang X
AD  - Division of Neurosurgery, Program in Developmental and Stem Cell Biology, Arthur 
      and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children,
      Toronto, Ontario M5G 1X8, Canada.
FAU - McDonald, Laura
AU  - McDonald L
AD  - Division of Neurosurgery, Program in Developmental and Stem Cell Biology, Arthur 
      and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children,
      Toronto, Ontario M5G 1X8, Canada.
FAU - Morrow, James J
AU  - Morrow JJ
AD  - Department of Genetics and Genome Sciences, Case Western Reserve University,
      Cleveland, Ohio 44106, USA.
FAU - Saiakhova, Alina
AU  - Saiakhova A
AD  - Department of Genetics and Genome Sciences, Case Western Reserve University,
      Cleveland, Ohio 44106, USA.
FAU - Sin-Chan, Patrick
AU  - Sin-Chan P
AD  - Division of Neurosurgery, Program in Developmental and Stem Cell Biology, Arthur 
      and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children,
      Toronto, Ontario M5G 1X8, Canada.
FAU - Wu, Qiulian
AU  - Wu Q
AD  - Department of Stem Cell Biology and Regenerative Medicine, Lerner Research
      Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA.
AD  - Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine of 
      Case Western Reserve University, Cleveland, Ohio 44195, USA.
AD  - Department of Medicine, Division of Regenerative Medicine, University of
      California - San Diego School of Medicine, La Jolla, California, USA.
FAU - Michaelraj, Kulandaimanuvel Antony
AU  - Michaelraj KA
AD  - Division of Neurosurgery, Program in Developmental and Stem Cell Biology, Arthur 
      and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children,
      Toronto, Ontario M5G 1X8, Canada.
FAU - Miller, Tyler E
AU  - Miller TE
AD  - Department of Stem Cell Biology and Regenerative Medicine, Lerner Research
      Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA.
AD  - Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine of 
      Case Western Reserve University, Cleveland, Ohio 44195, USA.
AD  - Department of Pathology, Case Western Reserve University, Cleveland, Ohio 44106, 
      USA.
FAU - Hubert, Christopher G
AU  - Hubert CG
AD  - Department of Stem Cell Biology and Regenerative Medicine, Lerner Research
      Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA.
AD  - Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine of 
      Case Western Reserve University, Cleveland, Ohio 44195, USA.
FAU - Ryzhova, Marina
AU  - Ryzhova M
AD  - Department of Neuropathology, NN Burdenko Neurosurgical Institute, 4th
      Tverskaya-Yamskaya 16, Moscow 125047, Russia.
FAU - Garzia, Livia
AU  - Garzia L
AD  - Division of Neurosurgery, Program in Developmental and Stem Cell Biology, Arthur 
      and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children,
      Toronto, Ontario M5G 1X8, Canada.
FAU - Donovan, Laura
AU  - Donovan L
AD  - Division of Neurosurgery, Program in Developmental and Stem Cell Biology, Arthur 
      and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children,
      Toronto, Ontario M5G 1X8, Canada.
FAU - Dombrowski, Stephen
AU  - Dombrowski S
AD  - Department of Stem Cell Biology and Regenerative Medicine, Lerner Research
      Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA.
AD  - Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine of 
      Case Western Reserve University, Cleveland, Ohio 44195, USA.
AD  - Rose Ella Burkhardt Brain Tumor & Neuro-Oncology Center, Cleveland Clinic
      Neurological Institute, Department of Neurosurgery, Cleveland Clinic, Cleveland, 
      Ohio 44195, USA.
FAU - Factor, Daniel C
AU  - Factor DC
AD  - Department of Genetics and Genome Sciences, Case Western Reserve University,
      Cleveland, Ohio 44106, USA.
FAU - Luu, Betty
AU  - Luu B
AD  - Division of Neurosurgery, Program in Developmental and Stem Cell Biology, Arthur 
      and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children,
      Toronto, Ontario M5G 1X8, Canada.
FAU - Valentim, Claudia L L
AU  - Valentim CLL
AD  - Department of Stem Cell Biology and Regenerative Medicine, Lerner Research
      Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA.
AD  - Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine of 
      Case Western Reserve University, Cleveland, Ohio 44195, USA.
FAU - Gimple, Ryan C
AU  - Gimple RC
AD  - Department of Stem Cell Biology and Regenerative Medicine, Lerner Research
      Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA.
AD  - Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine of 
      Case Western Reserve University, Cleveland, Ohio 44195, USA.
AD  - Department of Medicine, Division of Regenerative Medicine, University of
      California - San Diego School of Medicine, La Jolla, California, USA.
AD  - Department of Pathology, Case Western Reserve University, Cleveland, Ohio 44106, 
      USA.
FAU - Morton, Andrew
AU  - Morton A
AD  - Department of Stem Cell Biology and Regenerative Medicine, Lerner Research
      Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA.
AD  - Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine of 
      Case Western Reserve University, Cleveland, Ohio 44195, USA.
AD  - Department of Genetics and Genome Sciences, Case Western Reserve University,
      Cleveland, Ohio 44106, USA.
FAU - Kim, Leo
AU  - Kim L
AD  - Department of Stem Cell Biology and Regenerative Medicine, Lerner Research
      Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA.
AD  - Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine of 
      Case Western Reserve University, Cleveland, Ohio 44195, USA.
AD  - Department of Medicine, Division of Regenerative Medicine, University of
      California - San Diego School of Medicine, La Jolla, California, USA.
FAU - Prager, Briana C
AU  - Prager BC
AD  - Department of Stem Cell Biology and Regenerative Medicine, Lerner Research
      Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA.
AD  - Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine of 
      Case Western Reserve University, Cleveland, Ohio 44195, USA.
AD  - Department of Medicine, Division of Regenerative Medicine, University of
      California - San Diego School of Medicine, La Jolla, California, USA.
FAU - Lee, John J Y
AU  - Lee JJY
AD  - Division of Neurosurgery, Program in Developmental and Stem Cell Biology, Arthur 
      and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children,
      Toronto, Ontario M5G 1X8, Canada.
FAU - Wu, Xiaochong
AU  - Wu X
AD  - Division of Neurosurgery, Program in Developmental and Stem Cell Biology, Arthur 
      and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children,
      Toronto, Ontario M5G 1X8, Canada.
FAU - Zuccaro, Jennifer
AU  - Zuccaro J
AD  - Division of Neurosurgery, Program in Developmental and Stem Cell Biology, Arthur 
      and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children,
      Toronto, Ontario M5G 1X8, Canada.
FAU - Thompson, Yuan
AU  - Thompson Y
AD  - Division of Neurosurgery, Program in Developmental and Stem Cell Biology, Arthur 
      and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children,
      Toronto, Ontario M5G 1X8, Canada.
FAU - Holgado, Borja L
AU  - Holgado BL
AD  - Division of Neurosurgery, Program in Developmental and Stem Cell Biology, Arthur 
      and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children,
      Toronto, Ontario M5G 1X8, Canada.
FAU - Reimand, Juri
AU  - Reimand J
AD  - Computational Biology Program, Ontario Institute for Cancer Research, Toronto,
      Ontario M5G 0A3, Canada.
AD  - Department of Medical Biophysics, University of Toronto, Toronto, Ontario M5G
      1L7, Canada.
FAU - Ke, Susan Q
AU  - Ke SQ
AD  - Department of Stem Cell Biology and Regenerative Medicine, Lerner Research
      Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA.
AD  - Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine of 
      Case Western Reserve University, Cleveland, Ohio 44195, USA.
FAU - Tropper, Adam
AU  - Tropper A
AD  - Department of Stem Cell Biology and Regenerative Medicine, Lerner Research
      Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA.
AD  - Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine of 
      Case Western Reserve University, Cleveland, Ohio 44195, USA.
FAU - Lai, Sisi
AU  - Lai S
AD  - Department of Stem Cell Biology and Regenerative Medicine, Lerner Research
      Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA.
AD  - Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine of 
      Case Western Reserve University, Cleveland, Ohio 44195, USA.
FAU - Vijayarajah, Senthuran
AU  - Vijayarajah S
AD  - Department of Pediatrics, Cleveland Clinic, Cleveland, Ohio 44195, USA.
AD  - Department of Pediatrics, Division of Critical Care, University of Utah School of
      Medicine, Salt Lake City, Utah, USA.
FAU - Doan, Sylvia
AU  - Doan S
AD  - Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, 
      Utah, USA.
FAU - Mahadev, Vaidehi
AU  - Mahadev V
AD  - Department of Stem Cell Biology and Regenerative Medicine, Lerner Research
      Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA.
AD  - Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine of 
      Case Western Reserve University, Cleveland, Ohio 44195, USA.
FAU - Minan, Ana Fernandez
AU  - Minan AF
AD  - Centro Andaluz de Biologia del Desarrollo, Consejo Superior de Investigaciones
      Cientificas and Universidad Pablo de Olavide, Sevilla, Spain.
FAU - Grobner, Susanne N
AU  - Grobner SN
AD  - Hopp Children's Cancer Center at the NCT Heidelberg (KiTZ), 69120 Heidelberg,
      Germany.
AD  - Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), 69120 
      Heidelberg, Germany and German Cancer Consortium (DKTK), 69120 Heidelberg,
      Germany.
FAU - Lienhard, Matthias
AU  - Lienhard M
AD  - Department of Computational Molecular Biology, Max-Planck-Institute for Molecular
      Genetics, 14195 Berlin, Germany.
FAU - Zapatka, Marc
AU  - Zapatka M
AD  - Division of Molecular Genetics, German Cancer Research Center (DKFZ), 69121
      Heidelberg, Germany.
FAU - Huang, Zhiqin
AU  - Huang Z
AD  - Division of Molecular Genetics, German Cancer Research Center (DKFZ), 69121
      Heidelberg, Germany.
FAU - Aldape, Kenneth D
AU  - Aldape KD
AD  - Department of Pathology, University Health Network, Toronto, Ontario M5G 1L7,
      Canada.
FAU - Carcaboso, Angel M
AU  - Carcaboso AM
AD  - Preclinical Therapeutics and Drug Delivery Research Program, Fundacio Sant Joan
      de Deu, 08950 Barcelona, Spain.
FAU - Houghton, Peter J
AU  - Houghton PJ
AD  - Nationwide Children's Hospital, Center for Childhood Cancer and Blood Diseases,
      Columbus, Ohio.
FAU - Keir, Stephen T
AU  - Keir ST
AD  - Duke University Medical Center, Department of Surgery, Durham, North Carolina,
      USA.
FAU - Milde, Till
AU  - Milde T
AD  - Hopp Children's Cancer Center at the NCT Heidelberg (KiTZ), 69120 Heidelberg,
      Germany.
AD  - Department of Pediatric Oncology, Hematology and Immunology, Heidelberg
      University Hospital, 69120 Heidelberg, Germany.
AD  - Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center
      (DKFZ), INF 280, D-69120 Heidelberg, Germany.
FAU - Witt, Hendrik
AU  - Witt H
AD  - Hopp Children's Cancer Center at the NCT Heidelberg (KiTZ), 69120 Heidelberg,
      Germany.
AD  - Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), 69120 
      Heidelberg, Germany and German Cancer Consortium (DKTK), 69120 Heidelberg,
      Germany.
AD  - Department of Pediatric Oncology, Hematology and Immunology, Heidelberg
      University Hospital, 69120 Heidelberg, Germany.
FAU - Li, Yan
AU  - Li Y
AD  - Department of Genetics and Genome Sciences, Case Western Reserve University,
      Cleveland, Ohio 44106, USA.
FAU - Li, Chao-Jun
AU  - Li CJ
AD  - MOE Key Laboratory of Model Animal for Disease Study, Model Animal Research
      Center, Nanjing University, National Resource Centre for Mutant Mice, Nanjing,
      China.
FAU - Bian, Xiu-Wu
AU  - Bian XW
AD  - Institute of Pathology and Southwest Cancer Center, Southwest Hospital, The Third
      Military Medical University, and The Key Laboratory of Tumor Immunopathology, The
      Ministry of Education of China, Chongqing, China.
FAU - Jones, David T W
AU  - Jones DTW
AD  - Hopp Children's Cancer Center at the NCT Heidelberg (KiTZ), 69120 Heidelberg,
      Germany.
AD  - Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), 69120 
      Heidelberg, Germany and German Cancer Consortium (DKTK), 69120 Heidelberg,
      Germany.
FAU - Scott, Ian
AU  - Scott I
AD  - Division of Neurosurgery, Program in Developmental and Stem Cell Biology, Arthur 
      and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children,
      Toronto, Ontario M5G 1X8, Canada.
FAU - Singh, Sheila K
AU  - Singh SK
AD  - Department of Surgery, Division of Neurosurgery, Faculty of Health Sciences,
      McMaster University, Hamilton, Ontario, Canada.
FAU - Huang, Annie
AU  - Huang A
AD  - Division of Neurosurgery, Program in Developmental and Stem Cell Biology, Arthur 
      and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children,
      Toronto, Ontario M5G 1X8, Canada.
AD  - Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139, USA.
FAU - Dirks, Peter B
AU  - Dirks PB
AD  - Division of Neurosurgery, Program in Developmental and Stem Cell Biology, Arthur 
      and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children,
      Toronto, Ontario M5G 1X8, Canada.
FAU - Bouffet, Eric
AU  - Bouffet E
AD  - Division of Neurosurgery, Program in Developmental and Stem Cell Biology, Arthur 
      and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children,
      Toronto, Ontario M5G 1X8, Canada.
AD  - Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139, USA.
FAU - Bradner, James E
AU  - Bradner JE
AD  - Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139, USA.
FAU - Ramaswamy, Vijay
AU  - Ramaswamy V
AD  - Division of Neurosurgery, Program in Developmental and Stem Cell Biology, Arthur 
      and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children,
      Toronto, Ontario M5G 1X8, Canada.
AD  - Division of Hematology and Oncology, Hospital for Sick Children, Toronto, Ontario
      M5G 1X8, Canada.
FAU - Jabado, Nada
AU  - Jabado N
AD  - Departments of Paediatrics and Human Genetics, McGill University and the McGill
      University Health Centre Research Institute, Montreal, Quebec H3Z 2Z3, Canada.
FAU - Rutka, James T
AU  - Rutka JT
AD  - Division of Neurosurgery, Program in Developmental and Stem Cell Biology, Arthur 
      and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children,
      Toronto, Ontario M5G 1X8, Canada.
FAU - Northcott, Paul A
AU  - Northcott PA
AD  - Developmental Neurobiology, St Jude Children's Research Hospital, Memphis,
      Tennessee, USA.
FAU - Lupien, Mathieu
AU  - Lupien M
AD  - Department of Medical Biophysics, University of Toronto, Toronto, Ontario M5G
      1L7, Canada.
FAU - Lichter, Peter
AU  - Lichter P
AD  - Division of Molecular Genetics, German Cancer Research Center (DKFZ), 69121
      Heidelberg, Germany.
FAU - Korshunov, Andrey
AU  - Korshunov A
AD  - Department of Neuropathology, University of Heidelberg, 69120 Heidelberg,
      Germany.
AD  - Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ),
      69121 Heidelberg, Germany.
FAU - Scacheri, Peter C
AU  - Scacheri PC
AD  - Department of Genetics and Genome Sciences, Case Western Reserve University,
      Cleveland, Ohio 44106, USA.
FAU - Pfister, Stefan M
AU  - Pfister SM
AD  - Hopp Children's Cancer Center at the NCT Heidelberg (KiTZ), 69120 Heidelberg,
      Germany.
AD  - Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), 69120 
      Heidelberg, Germany and German Cancer Consortium (DKTK), 69120 Heidelberg,
      Germany.
AD  - Department of Pediatric Oncology, Hematology and Immunology, Heidelberg
      University Hospital, 69120 Heidelberg, Germany.
FAU - Kool, Marcel
AU  - Kool M
AD  - Hopp Children's Cancer Center at the NCT Heidelberg (KiTZ), 69120 Heidelberg,
      Germany.
AD  - Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), 69120 
      Heidelberg, Germany and German Cancer Consortium (DKTK), 69120 Heidelberg,
      Germany.
FAU - Taylor, Michael D
AU  - Taylor MD
AD  - Division of Neurosurgery, Program in Developmental and Stem Cell Biology, Arthur 
      and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children,
      Toronto, Ontario M5G 1X8, Canada.
FAU - Rich, Jeremy N
AU  - Rich JN
AD  - Department of Stem Cell Biology and Regenerative Medicine, Lerner Research
      Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA.
AD  - Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine of 
      Case Western Reserve University, Cleveland, Ohio 44195, USA.
AD  - Department of Medicine, Division of Regenerative Medicine, University of
      California - San Diego School of Medicine, La Jolla, California, USA.
AD  - Rose Ella Burkhardt Brain Tumor & Neuro-Oncology Center, Cleveland Clinic
      Neurological Institute, Department of Neurosurgery, Cleveland Clinic, Cleveland, 
      Ohio 44195, USA.
LA  - eng
PT  - Journal Article
DEP - 20171220
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
EDAT- 2017/12/21 06:00
MHDA- 2017/12/21 06:00
CRDT- 2017/12/21 06:00
PHST- 2016/12/19 00:00 [received]
PHST- 2017/11/22 00:00 [accepted]
PHST- 2017/12/21 06:00 [pubmed]
PHST- 2017/12/21 06:00 [medline]
PHST- 2017/12/21 06:00 [entrez]
AID - nature25169 [pii]
AID - 10.1038/nature25169 [doi]
PST - ppublish
SO  - Nature. 2018 Jan 4;553(7686):101-105. doi: 10.1038/nature25169. Epub 2017 Dec 20.

PMID- 29183089
OWN - NLM
STAT- Publisher
LR  - 20171128
IS  - 1439-4286 (Electronic)
IS  - 0018-5043 (Linking)
DP  - 2017 Nov 28
TI  - Successful Treatment of Estrogen Excess in Primary Bilateral Macronodular
      Adrenocortical Hyperplasia with Leuprolide Acetate.
LID - 10.1055/s-0043-122074 [doi]
AB  - Primary bilateral macronodular adrenocortical hyperplasia (PBMAH) is an uncommon 
      cause of adrenal Cushing syndrome (CS) in which cortisol and occasionally other
      steroid hormones can be secreted under the influence of aberrantly expressed
      G-protein coupled receptors (GPCRs) in the adrenal cortex. We describe the unique
      case of a 64-year-old postmenopausal female with PBMAH whose adrenal lesions
      expressed luteinizing hormone receptors (LHr). She presented initially with CS
      and underwent right adrenalectomy; a few years later she presented with
      macromastia and mastodynia, possibly due to estrogen excess from her remaining
      left adrenocortical masses. Testing before and after treatment with quarterly
      leuprolide acetate therapy and immunohistochemistry on tissue and targeted
      sequencing of the genes of interest were performed. Tissue from the patient's
      right adrenal was tested for P450 aromatase (CYP19A1) and LHr expression; both
      were expressed throughout the hyperplastic cortex, although expression was more
      intense in the adenomatous areas. Targeted sequencing revealed a pathogenic
      PDE11A mutation, as well as variants in the ARMC5 and INHA genes. PDE11A
      expression was decreased in the adenoma but there was no loss of heterozygosity
      for the PDE11A locus. Because of the clinical presentation and LHr expression,
      quarterly leuprolide acetate therapy was started. Shortly after initiation of
      therapy, the patient reported decreased breast size and pain; she remains well
      controlled to date, after 10 years of treatment. This is the first description of
      a patient with PBMAH presenting with severe macromastia and mastodynia from what 
      appears to be excess estrogen production from her adrenal tumor. The patient had 
      a long-lasting response to chronic leuprolide acetate treatment, showing that
      drug therapy exploiting the aberrant receptor expression in PBMAH is possible
      even in the absence of cortisol overproduction.
CI  - (c) Georg Thieme Verlag KG Stuttgart . New York.
FAU - Hannah-Shmouni, Fady
AU  - Hannah-Shmouni F
AD  - Section on Endocrinology & Genetics (SEGEN), Eunice Kennedy Shriver National
      Institute of Child Health and Human Development (NICHD), National Institutes of
      Health (NIH), Bethesda, MD, USA.
FAU - Moraitis, Andreas G
AU  - Moraitis AG
AD  - Section on Endocrinology & Genetics (SEGEN), Eunice Kennedy Shriver National
      Institute of Child Health and Human Development (NICHD), National Institutes of
      Health (NIH), Bethesda, MD, USA.
AD  - Corcept Therapeutics Incorporated, Drug Research and Development, MI, USA
      (Current address).
FAU - Romero, Vladimir Valera
AU  - Romero VV
AD  - Laboratory of Pathology, National Cancer Institute (NCI), NIH, Bethesda, MD, USA.
FAU - Faucz, Fabio R
AU  - Faucz FR
AD  - Section on Endocrinology & Genetics (SEGEN), Eunice Kennedy Shriver National
      Institute of Child Health and Human Development (NICHD), National Institutes of
      Health (NIH), Bethesda, MD, USA.
FAU - Mastroyannis, Spyridon A
AU  - Mastroyannis SA
AD  - Section on Endocrinology & Genetics (SEGEN), Eunice Kennedy Shriver National
      Institute of Child Health and Human Development (NICHD), National Institutes of
      Health (NIH), Bethesda, MD, USA.
FAU - Berthon, Annabel
AU  - Berthon A
AD  - Section on Endocrinology & Genetics (SEGEN), Eunice Kennedy Shriver National
      Institute of Child Health and Human Development (NICHD), National Institutes of
      Health (NIH), Bethesda, MD, USA.
FAU - Failor, Richard A
AU  - Failor RA
AD  - Division of Endocrinology, Metabolism, & Nutrition University of Washington,
      Seattle, WA, USA.
FAU - Merino, Maria
AU  - Merino M
AD  - Laboratory of Pathology, National Cancer Institute (NCI), NIH, Bethesda, MD, USA.
FAU - Demidowich, Andrew P
AU  - Demidowich AP
AD  - Section on Endocrinology & Genetics (SEGEN), Eunice Kennedy Shriver National
      Institute of Child Health and Human Development (NICHD), National Institutes of
      Health (NIH), Bethesda, MD, USA.
FAU - Stratakis, Constantine A
AU  - Stratakis CA
AD  - Section on Endocrinology & Genetics (SEGEN), Eunice Kennedy Shriver National
      Institute of Child Health and Human Development (NICHD), National Institutes of
      Health (NIH), Bethesda, MD, USA.
LA  - eng
PT  - Journal Article
DEP - 20171128
PL  - Germany
TA  - Horm Metab Res
JT  - Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et 
      metabolisme
JID - 0177722
COIS- Conflict of Interest: The authors declare that they have no conflict of interest.
EDAT- 2017/11/29 06:00
MHDA- 2017/11/29 06:00
CRDT- 2017/11/29 06:00
PHST- 2017/11/29 06:00 [entrez]
PHST- 2017/11/29 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
AID - 10.1055/s-0043-122074 [doi]
PST - aheadofprint
SO  - Horm Metab Res. 2017 Nov 28. doi: 10.1055/s-0043-122074.

PMID- 29291352
OWN - NLM
STAT- Publisher
LR  - 20180129
IS  - 1546-170X (Electronic)
IS  - 1078-8956 (Linking)
DP  - 2018 Jan 1
TI  - Recurrent ECSIT mutation encoding V140A triggers hyperinflammation and promotes
      hemophagocytic syndrome in extranodal NK/T cell lymphoma.
LID - 10.1038/nm.4456 [doi]
AB  - Hemophagocytic syndrome (HPS) is a fatal hyperinflammatory disease with a poorly 
      understood mechanism that occurs most frequently in extranodal natural killer/T
      cell lymphoma (ENKTL). Through exome sequencing of ENKTL tumor-normal samples, we
      have identified a hotspot mutation (c.419T>C) in the evolutionarily conserved
      signaling intermediate in Toll pathway (ECSIT) gene, encoding a V140A variant of 
      ECSIT. ECSIT-V140A activated NF-kappaB more potently than the wild-type protein
      owing to its increased affinity for the S100A8 and S100A9 heterodimer, which
      promotes NADPH oxidase activity. ECSIT-T419C knock-in mice showed higher
      peritoneal NADPH oxidase activity than mice with wild-type ECSIT in response to
      LPS. ECSIT-T419C-transfected ENKTL cell lines produced tumor necrosis factor
      (TNF)-alpha and interferon (IFN)-gamma, which induced macrophage activation and
      massive cytokine secretion in cell culture and mouse xenografts. In individuals
      with ENKTL, ECSIT-V140A was associated with activation of NF-kappaB, higher HPS
      incidence, and poor prognosis. The immunosuppressive drug thalidomide prevented
      NF-kappaB from binding to the promoters of its target genes (including TNF and
      IFNG), and combination treatment with thalidomide and dexamethasone extended
      survival of mice engrafted with ECSIT-T419C-transfected ENKTL cells. We added
      thalidomide to the conventional dexamethasone-containing therapy regimen for two 
      patients with HPS who expressed ECSIT-V140A, and we observed reversal of their
      HPS and disease-free survival for longer than 3 years. These findings provide
      mechanistic insights and a potential therapeutic strategy for ENKTL-associated
      HPS.
FAU - Wen, Haijun
AU  - Wen H
AD  - Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South
      China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
AD  - Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
AD  - State Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-sen
      University, Guangzhou, China.
FAU - Ma, Huajuan
AU  - Ma H
AD  - Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South
      China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
AD  - School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China.
FAU - Cai, Qichun
AU  - Cai Q
AD  - Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South
      China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
AD  - Department of Medical Oncology, Guangdong General Hospital, Guangdong Academy of 
      Medical Sciences, Guangzhou, China.
AD  - Lymphoma Center, Department of Medical Oncology, Sun Yat-sen University Cancer
      Center, State Key Laboratory of Oncology in South China, Guangzhou, China.
FAU - Lin, Suxia
AU  - Lin S
AD  - Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South
      China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
AD  - Department of Pathology, Sun Yat-sen University Cancer Center, State Key
      Laboratory of Oncology in South China, Guangzhou, China.
FAU - Lei, Xinxing
AU  - Lei X
AD  - Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South
      China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
FAU - He, Bin
AU  - He B
AD  - Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South
      China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
FAU - Wu, Sijin
AU  - Wu S
AUID- ORCID: http://orcid.org/0000-0003-4554-4610
AD  - Center for Molecular Medicine, School of Life Science and Biotechnology, Dalian
      University of Technology, Dalian, China.
FAU - Wang, Zifeng
AU  - Wang Z
AD  - Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South
      China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
FAU - Gao, Yan
AU  - Gao Y
AD  - Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South
      China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
AD  - Lymphoma Center, Department of Medical Oncology, Sun Yat-sen University Cancer
      Center, State Key Laboratory of Oncology in South China, Guangzhou, China.
FAU - Liu, Wensheng
AU  - Liu W
AD  - Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South
      China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
FAU - Liu, Weiping
AU  - Liu W
AD  - Department of Pathology, West-China Hospital of Sichuan University, Chengdu,
      China.
FAU - Tao, Qian
AU  - Tao Q
AD  - State Key Laboratory of Oncology in South China, Department of Clinical Oncology,
      Li Ka Shing Institute of Health Sciences, Chinese University of Hong Kong, Hong
      Kong.
FAU - Long, Zijie
AU  - Long Z
AD  - Department of Hematology, The Third Affiliated Hospital, Sun Yat-sen University, 
      Guangzhou, China.
FAU - Yan, Min
AU  - Yan M
AD  - Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South
      China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
FAU - Li, Dali
AU  - Li D
AD  - Institute of Biomedical Sciences, East China Normal University, Shanghai, China.
FAU - Kelley, Keith W
AU  - Kelley KW
AD  - Laboratory of Immunophysiology, Department of Animal Sciences, College of
      Agricultural, Consumer and Environmental Science (ACES) and Department of
      Pathology, College of Medicine, University of Illinois at Urbana-Champaign,
      Urbana, Illinois, USA.
FAU - Yang, Yongliang
AU  - Yang Y
AD  - Center for Molecular Medicine, School of Life Science and Biotechnology, Dalian
      University of Technology, Dalian, China.
FAU - Huang, Huiqiang
AU  - Huang H
AD  - Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South
      China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
AD  - Lymphoma Center, Department of Medical Oncology, Sun Yat-sen University Cancer
      Center, State Key Laboratory of Oncology in South China, Guangzhou, China.
FAU - Liu, Quentin
AU  - Liu Q
AD  - Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South
      China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
AD  - Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
AD  - Department of Hematology, The Third Affiliated Hospital, Sun Yat-sen University, 
      Guangzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20180101
PL  - United States
TA  - Nat Med
JT  - Nature medicine
JID - 9502015
EDAT- 2018/01/02 06:00
MHDA- 2018/01/02 06:00
CRDT- 2018/01/02 06:00
PHST- 2016/08/14 00:00 [received]
PHST- 2017/11/10 00:00 [accepted]
PHST- 2018/01/02 06:00 [pubmed]
PHST- 2018/01/02 06:00 [medline]
PHST- 2018/01/02 06:00 [entrez]
AID - nm.4456 [pii]
AID - 10.1038/nm.4456 [doi]
PST - aheadofprint
SO  - Nat Med. 2018 Jan 1. pii: nm.4456. doi: 10.1038/nm.4456.

PMID- 29339438
OWN - NLM
STAT- Publisher
LR  - 20180124
IS  - 1540-8140 (Electronic)
IS  - 0021-9525 (Linking)
DP  - 2018 Jan 16
TI  - Quantifying exosome secretion from single cells reveals a modulatory role for
      GPCR signaling.
LID - jcb.201703206 [pii]
LID - 10.1083/jcb.201703206 [doi]
AB  - Exosomes are small endosome-derived extracellular vesicles implicated in
      cell-cell communication and are secreted by living cells when multivesicular
      bodies (MVBs) fuse with the plasma membrane (PM). Current techniques to study
      exosome physiology are based on isolation procedures after secretion, precluding 
      direct and dynamic insight into the mechanics of exosome biogenesis and the
      regulation of their release. In this study, we propose real-time visualization of
      MVB-PM fusion to overcome these limitations. We designed tetraspanin-based
      pH-sensitive optical reporters that detect MVB-PM fusion using live total
      internal reflection fluorescence and dynamic correlative light-electron
      microscopy. Quantitative analysis demonstrates that MVB-PM fusion frequency is
      reduced by depleting the target membrane SNAREs SNAP23 and syntaxin-4 but also
      can be induced in single cells by stimulation of the histamine H1 receptor
      (H1HR). Interestingly, activation of H1R1 in HeLa cells increases Ser110
      phosphorylation of SNAP23, promoting MVB-PM fusion and the release of
      CD63-enriched exosomes. Using this single-cell resolution approach, we highlight 
      the modulatory dynamics of MVB exocytosis that will help to increase our
      understanding of exosome physiology and identify druggable targets in
      exosome-associated pathologies.
CI  - (c) 2018 Verweij et al.
FAU - Verweij, Frederik Johannes
AU  - Verweij FJ
AUID- ORCID: http://orcid.org/0000-0001-8879-1174
AD  - Department of Pathology, Cancer Center Amsterdam, VU University Medical Center,
      Amsterdam, Netherlands frederik.verweij@curie.fr.
AD  - Institut Curie, Paris Sciences et Lettres Research University, Centre National de
      la Recherche Scientifique, UMR 144, Paris, France.
AD  - Cell and Tissue Imaging Core Facility PICT-IBiSA, Institut Curie, Paris, France.
FAU - Bebelman, Maarten P
AU  - Bebelman MP
AUID- ORCID: http://orcid.org/0000-0003-4007-5093
AD  - Department of Pathology, Cancer Center Amsterdam, VU University Medical Center,
      Amsterdam, Netherlands.
AD  - Division of Medicinal Chemistry, Amsterdam Institute for Molecules Medicines and 
      Systems, VU University Amsterdam, Amsterdam, Netherlands.
FAU - Jimenez, Connie R
AU  - Jimenez CR
AD  - Department of Medical Oncology, Cancer Center Amsterdam, VU University Medical
      Center, Amsterdam, Netherlands.
FAU - Garcia-Vallejo, Juan J
AU  - Garcia-Vallejo JJ
AD  - Department of Molecular Cell Biology and Immunology, VU University Medical
      Center, Amsterdam, Netherlands.
FAU - Janssen, Hans
AU  - Janssen H
AUID- ORCID: http://orcid.org/0000-0001-7480-793X
AD  - Division of Cell Biology, Netherlands Cancer Institute, Amsterdam, Netherlands.
FAU - Neefjes, Jacques
AU  - Neefjes J
AD  - Department of Chemical Immunology, Leiden University Medical Center, Leiden,
      Netherlands.
FAU - Knol, Jaco C
AU  - Knol JC
AD  - Department of Medical Oncology, Cancer Center Amsterdam, VU University Medical
      Center, Amsterdam, Netherlands.
FAU - de Goeij-de Haas, Richard
AU  - de Goeij-de Haas R
AD  - Department of Medical Oncology, Cancer Center Amsterdam, VU University Medical
      Center, Amsterdam, Netherlands.
FAU - Piersma, Sander R
AU  - Piersma SR
AD  - Department of Medical Oncology, Cancer Center Amsterdam, VU University Medical
      Center, Amsterdam, Netherlands.
FAU - Baglio, S Rubina
AU  - Baglio SR
AD  - Department of Pathology, Cancer Center Amsterdam, VU University Medical Center,
      Amsterdam, Netherlands.
FAU - Verhage, Matthijs
AU  - Verhage M
AD  - Department of Clinical Genetics, VU University Medical Center, Amsterdam,
      Netherlands.
AD  - Department of Functional Genomics, Center for Neurogenomics and Cognitive
      Research, VU University Amsterdam, Amsterdam, Netherlands.
FAU - Middeldorp, Jaap M
AU  - Middeldorp JM
AUID- ORCID: http://orcid.org/0000-0002-0765-4125
AD  - Department of Pathology, Cancer Center Amsterdam, VU University Medical Center,
      Amsterdam, Netherlands.
FAU - Zomer, Anoek
AU  - Zomer A
AD  - Cancer Genomics Netherlands-Hubrecht Institute-Koninklijke Nederlandse Akademie
      van Wetenschappen, Utrecht, Netherlands.
AD  - University Medical Centre Utrecht, Utrecht, Netherlands.
FAU - van Rheenen, Jacco
AU  - van Rheenen J
AD  - Cancer Genomics Netherlands-Hubrecht Institute-Koninklijke Nederlandse Akademie
      van Wetenschappen, Utrecht, Netherlands.
AD  - University Medical Centre Utrecht, Utrecht, Netherlands.
FAU - Coppolino, Marc G
AU  - Coppolino MG
AD  - Department of Molecular and Cellular Biology, University of Guelph, Guelph,
      Canada.
FAU - Hurbain, Ilse
AU  - Hurbain I
AUID- ORCID: http://orcid.org/0000-0002-0097-7773
AD  - Institut Curie, Paris Sciences et Lettres Research University, Centre National de
      la Recherche Scientifique, UMR 144, Paris, France.
AD  - Centre National de la Recherche Scientifique, UMR 144, Paris, France.
AD  - Cell and Tissue Imaging Core Facility PICT-IBiSA, Institut Curie, Paris, France.
FAU - Raposo, Graca
AU  - Raposo G
AD  - Institut Curie, Paris Sciences et Lettres Research University, Centre National de
      la Recherche Scientifique, UMR 144, Paris, France.
AD  - Centre National de la Recherche Scientifique, UMR 144, Paris, France.
AD  - Cell and Tissue Imaging Core Facility PICT-IBiSA, Institut Curie, Paris, France.
FAU - Smit, Martine J
AU  - Smit MJ
AD  - Division of Medicinal Chemistry, Amsterdam Institute for Molecules Medicines and 
      Systems, VU University Amsterdam, Amsterdam, Netherlands.
FAU - Toonen, Ruud F G
AU  - Toonen RFG
AUID- ORCID: http://orcid.org/0000-0002-9900-4233
AD  - Department of Clinical Genetics, VU University Medical Center, Amsterdam,
      Netherlands.
AD  - Department of Functional Genomics, Center for Neurogenomics and Cognitive
      Research, VU University Amsterdam, Amsterdam, Netherlands.
FAU - van Niel, Guillaume
AU  - van Niel G
AUID- ORCID: http://orcid.org/0000-0002-8651-9705
AD  - Institut Curie, Paris Sciences et Lettres Research University, Centre National de
      la Recherche Scientifique, UMR 144, Paris, France.
AD  - Centre National de la Recherche Scientifique, UMR 144, Paris, France.
AD  - Cell and Tissue Imaging Core Facility PICT-IBiSA, Institut Curie, Paris, France.
FAU - Pegtel, D Michiel
AU  - Pegtel DM
AUID- ORCID: http://orcid.org/0000-0002-7357-4406
AD  - Department of Pathology, Cancer Center Amsterdam, VU University Medical Center,
      Amsterdam, Netherlands d.pegtel@vumc.nl.
LA  - eng
PT  - Journal Article
DEP - 20180116
PL  - United States
TA  - J Cell Biol
JT  - The Journal of cell biology
JID - 0375356
EIN - J Cell Biol. 2018 Jan 23;:. PMID: 29362224
EDAT- 2018/01/18 06:00
MHDA- 2018/01/18 06:00
CRDT- 2018/01/18 06:00
PHST- 2017/03/28 00:00 [received]
PHST- 2017/10/18 00:00 [revised]
PHST- 2017/12/01 00:00 [accepted]
PHST- 2018/01/18 06:00 [pubmed]
PHST- 2018/01/18 06:00 [medline]
PHST- 2018/01/18 06:00 [entrez]
AID - jcb.201703206 [pii]
AID - 10.1083/jcb.201703206 [doi]
PST - aheadofprint
SO  - J Cell Biol. 2018 Jan 16. pii: jcb.201703206. doi: 10.1083/jcb.201703206.

PMID- 29334602
OWN - NLM
STAT- Publisher
LR  - 20180115
IS  - 2005-9256 (Electronic)
IS  - 1598-2998 (Linking)
DP  - 2018 Jan 10
TI  - High-Dose Metformin Plus Temozolomide Shows Increased Anti-tumor Effects in
      Glioblastoma In Vitro and In Vivo Compared with Monotherapy.
LID - 10.4143/crt.2017.466 [doi]
AB  - Purpose: The purpose of the study is to investigate the efficacy of combined
      treatment with temozolomide (TMZ) and metformin for glioblastoma (GBM) in vitro
      and in vivo. Materials and Methods: We investigated the efficacy of combined
      treatment with TMZ and metformin using cell viability and apoptosis assays. A GBM
      orthotopic mice model was established by inoculation of 5x105 U87 cells and
      treated with metformin, TMZ, and the combination for 4 weeks. Western blotting
      and immunofluorescence of tumor specimens were analyzed to investigate
      AMP-activated protein kinase (AMPK) and AKT pathway. Results: The combination of 
      TMZ and metformin showed higher cytotoxicity than single agents in U87, U251, and
      A172 cell lines. A combination of high-dose metformin and TMZ showed the highest 
      apoptotic activity. The combination of TMZ and metformin enhanced AMPK
      phosphorylation and inhibited mammalian target of rapamycin phosphorylation, AKT 
      phosphorylation and p53 expression. The median survival of each group was 43.6,
      55.2, 53.2, 65.2, and 71.3 days for control, metformin treatment (2 mg/25 g/day
      or 10 mg/25 g/day), TMZ treatment (15 mg/kg/day), combination treatment with
      low-dose metformin and TMZ, and combination treatment with high-dose metformin
      and TMZ, respectively. Expression of fatty acid synthase (FASN) was significantly
      decreased in tumor specimens treated with metformin and TMZ. Conclusion: The
      combination of metformin and TMZ was superior to monotherapy using metformin or
      TMZ in terms of cell viability in vitro and survival in vivo. The combination of 
      high-dose metformin and TMZ inhibited FASN expression in an orthotopic model.
      Inhibition of FASN might be a potential therapeutic target of GBM.
FAU - Lee, Jung Eun
AU  - Lee JE
AD  - Department of Neurosurgery, St. Vincent's Hospital, Cell Death Disease Research
      Center, College of Medicine, The Catholic University of Korea, Suwon, Korea.
FAU - Lim, Ji Hee
AU  - Lim JH
AD  - Division of Nephrology, Department of Internal Medicine, College of Medicine, The
      Catholic University of Korea, Seoul, Korea.
FAU - Hong, Yong Kil
AU  - Hong YK
AD  - Department of Neurosurgery, Seoul St. Mary's Hospital, College of Medicine, The
      Catholic University of Korea, Seoul, Korea.
FAU - Yang, Seung Ho
AU  - Yang SH
AD  - Department of Neurosurgery, St. Vincent's Hospital, Cell Death Disease Research
      Center, College of Medicine, The Catholic University of Korea, Suwon, Korea.
LA  - eng
PT  - Journal Article
DEP - 20180110
PL  - Korea (South)
TA  - Cancer Res Treat
JT  - Cancer research and treatment : official journal of Korean Cancer Association
JID - 101155137
OTO - NOTNLM
OT  - Fatty acid synthase
OT  - Glioblastoma
OT  - Metformin
OT  - Temozolomide
EDAT- 2018/01/16 06:00
MHDA- 2018/01/16 06:00
CRDT- 2018/01/16 06:00
PHST- 2017/09/30 00:00 [received]
PHST- 2018/01/09 00:00 [accepted]
PHST- 2018/01/16 06:00 [entrez]
PHST- 2018/01/16 06:00 [pubmed]
PHST- 2018/01/16 06:00 [medline]
AID - crt.2017.466 [pii]
AID - 10.4143/crt.2017.466 [doi]
PST - aheadofprint
SO  - Cancer Res Treat. 2018 Jan 10. pii: crt.2017.466. doi: 10.4143/crt.2017.466.

PMID- 29320474
OWN - NLM
STAT- In-Data-Review
LR  - 20180123
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 553
IP  - 7688
DP  - 2018 Jan 18
TI  - High response rate to PD-1 blockade in desmoplastic melanomas.
PG  - 347-350
LID - 10.1038/nature25187 [doi]
AB  - Desmoplastic melanoma is a rare subtype of melanoma characterized by dense
      fibrous stroma, resistance to chemotherapy and a lack of actionable driver
      mutations, and is highly associated with ultraviolet light-induced DNA damage. We
      analysed sixty patients with advanced desmoplastic melanoma who had been treated 
      with antibodies to block programmed cell death 1 (PD-1) or PD-1 ligand (PD-L1).
      Objective tumour responses were observed in forty-two of the sixty patients (70%;
      95% confidence interval 57-81%), including nineteen patients (32%) with a
      complete response. Whole-exome sequencing revealed a high mutational load and
      frequent NF1 mutations (fourteen out of seventeen cases) in these tumours.
      Immunohistochemistry analysis from nineteen desmoplastic melanomas and thirteen
      non-desmoplastic melanomas revealed a higher percentage of PD-L1-positive cells
      in the tumour parenchyma in desmoplastic melanomas (P = 0.04); these cells were
      highly associated with increased CD8 density and PD-L1 expression in the tumour
      invasive margin. Therefore, patients with advanced desmoplastic melanoma derive
      substantial clinical benefit from PD-1 or PD-L1 immune checkpoint blockade
      therapy, even though desmoplastic melanoma is defined by its dense desmoplastic
      fibrous stroma. The benefit is likely to result from the high mutational burden
      and a frequent pre-existing adaptive immune response limited by PD-L1 expression.
FAU - Eroglu, Zeynep
AU  - Eroglu Z
AD  - University of California Los Angeles, Los Angeles, California, USA.
AD  - Moffitt Cancer Center and University of South Florida, Tampa, Florida, USA.
FAU - Zaretsky, Jesse M
AU  - Zaretsky JM
AD  - University of California Los Angeles, Los Angeles, California, USA.
FAU - Hu-Lieskovan, Siwen
AU  - Hu-Lieskovan S
AD  - University of California Los Angeles, Los Angeles, California, USA.
FAU - Kim, Dae Won
AU  - Kim DW
AD  - Moffitt Cancer Center and University of South Florida, Tampa, Florida, USA.
AD  - The University of Texas-MD Anderson Cancer Center, Houston, Texas, USA.
FAU - Algazi, Alain
AU  - Algazi A
AD  - University of California San Francisco, San Francisco, California, USA.
FAU - Johnson, Douglas B
AU  - Johnson DB
AD  - Vanderbilt Ingram Cancer Center, Nashville, Tennessee, USA.
FAU - Liniker, Elizabeth
AU  - Liniker E
AD  - Melanoma Institute Australia, Sydney, New South Wales, Australia.
FAU - Ben Kong
AU  - Ben Kong
AD  - Westmead Hospital, Sydney, New South Wales, Australia.
FAU - Munhoz, Rodrigo
AU  - Munhoz R
AD  - Memorial Sloan Kettering Cancer Center, New York, New York, USA.
AD  - Weill Cornell Medical College, New York, New York, USA.
FAU - Rapisuwon, Suthee
AU  - Rapisuwon S
AD  - Georgetown Lombardi Cancer Center, Washington DC, USA.
FAU - Gherardini, Pier Federico
AU  - Gherardini PF
AD  - Parker Institute for Cancer Immunotherapy, San Francisco, California, USA.
FAU - Chmielowski, Bartosz
AU  - Chmielowski B
AD  - University of California Los Angeles, Los Angeles, California, USA.
FAU - Wang, Xiaoyan
AU  - Wang X
AD  - University of California Los Angeles, Los Angeles, California, USA.
FAU - Shintaku, I Peter
AU  - Shintaku IP
AD  - University of California Los Angeles, Los Angeles, California, USA.
FAU - Wei, Cody
AU  - Wei C
AD  - University of California Los Angeles, Los Angeles, California, USA.
FAU - Sosman, Jeffrey A
AU  - Sosman JA
AD  - Vanderbilt Ingram Cancer Center, Nashville, Tennessee, USA.
FAU - Joseph, Richard W
AU  - Joseph RW
AD  - Mayo Clinic, Jacksonville, Florida, USA.
FAU - Postow, Michael A
AU  - Postow MA
AD  - Memorial Sloan Kettering Cancer Center, New York, New York, USA.
AD  - Weill Cornell Medical College, New York, New York, USA.
FAU - Carlino, Matteo S
AU  - Carlino MS
AD  - Melanoma Institute Australia, Sydney, New South Wales, Australia.
AD  - Westmead Hospital, Sydney, New South Wales, Australia.
AD  - The University of Sydney, Sydney, New South Wales, Australia.
FAU - Hwu, Wen-Jen
AU  - Hwu WJ
AD  - The University of Texas-MD Anderson Cancer Center, Houston, Texas, USA.
FAU - Scolyer, Richard A
AU  - Scolyer RA
AD  - Melanoma Institute Australia, Sydney, New South Wales, Australia.
AD  - The University of Sydney, Sydney, New South Wales, Australia.
AD  - Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
FAU - Messina, Jane
AU  - Messina J
AD  - Moffitt Cancer Center and University of South Florida, Tampa, Florida, USA.
FAU - Cochran, Alistair J
AU  - Cochran AJ
AD  - University of California Los Angeles, Los Angeles, California, USA.
FAU - Long, Georgina V
AU  - Long GV
AD  - Melanoma Institute Australia, Sydney, New South Wales, Australia.
AD  - The University of Sydney, Sydney, New South Wales, Australia.
AD  - Royal North Shore Hospital, Sydney, New South Wales, Australia.
FAU - Ribas, Antoni
AU  - Ribas A
AD  - University of California Los Angeles, Los Angeles, California, USA.
LA  - eng
GR  - T32 GM008042/GM/NIGMS NIH HHS/United States
GR  - R35 CA197633/CA/NCI NIH HHS/United States
GR  - P30 CA076292/CA/NCI NIH HHS/United States
GR  - P01 CA168585/CA/NCI NIH HHS/United States
GR  - P50 CA168536/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20180110
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
PMC - PMC5773412
MID - NIHMS924023
EDAT- 2018/01/11 06:00
MHDA- 2018/01/11 06:00
CRDT- 2018/01/11 06:00
PMCR- 2018/07/10 00:00
PHST- 2017/02/16 00:00 [received]
PHST- 2017/11/30 00:00 [accepted]
PHST- 2018/07/10 00:00 [pmc-release]
PHST- 2018/01/11 06:00 [pubmed]
PHST- 2018/01/11 06:00 [medline]
PHST- 2018/01/11 06:00 [entrez]
AID - nature25187 [pii]
AID - 10.1038/nature25187 [doi]
PST - ppublish
SO  - Nature. 2018 Jan 18;553(7688):347-350. doi: 10.1038/nature25187. Epub 2018 Jan
      10.

PMID- 29342133
OWN - NLM
STAT- In-Data-Review
LR  - 20180129
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 553
IP  - 7689
DP  - 2018 Jan 25
TI  - A Myc enhancer cluster regulates normal and leukaemic haematopoietic stem cell
      hierarchies.
PG  - 515-520
LID - 10.1038/nature25193 [doi]
AB  - The transcription factor Myc is essential for the regulation of haematopoietic
      stem cells and progenitors and has a critical function in haematopoietic
      malignancies. Here we show that an evolutionarily conserved region located 1.7
      megabases downstream of the Myc gene that has previously been labelled as a
      'super-enhancer' is essential for the regulation of Myc expression levels in both
      normal haematopoietic and leukaemic stem cell hierarchies in mice and humans.
      Deletion of this region in mice leads to a complete loss of Myc expression in
      haematopoietic stem cells and progenitors. This caused an accumulation of
      differentiation-arrested multipotent progenitors and loss of myeloid and B cells,
      mimicking the phenotype caused by Mx1-Cre-mediated conditional deletion of the
      Myc gene in haematopoietic stem cells. This super-enhancer comprises multiple
      enhancer modules with selective activity that recruits a compendium of
      transcription factors, including GFI1b, RUNX1 and MYB. Analysis of mice carrying 
      deletions of individual enhancer modules suggests that specific Myc expression
      levels throughout most of the haematopoietic hierarchy are controlled by the
      combinatorial and additive activity of individual enhancer modules, which
      collectively function as a 'blood enhancer cluster' (BENC). We show that BENC is 
      also essential for the maintenance of MLL-AF9-driven leukaemia in mice.
      Furthermore, a BENC module, which controls Myc expression in mouse haematopoietic
      stem cells and progenitors, shows increased chromatin accessibility in human
      acute myeloid leukaemia stem cells compared to blasts. This difference correlates
      with MYC expression and patient outcome. We propose that clusters of enhancers,
      such as BENC, form highly combinatorial systems that allow precise control of
      gene expression across normal cellular hierarchies and which also can be hijacked
      in malignancies.
FAU - Bahr, Carsten
AU  - Bahr C
AD  - Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ) and
      DKFZ-ZMBH Alliance, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.
AD  - Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM 
      gGmbH), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.
AD  - Faculty of Biosciences, University of Heidelberg, 69120 Heidelberg, Germany.
FAU - von Paleske, Lisa
AU  - von Paleske L
AD  - Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ) and
      DKFZ-ZMBH Alliance, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.
AD  - Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM 
      gGmbH), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.
AD  - Faculty of Biosciences, University of Heidelberg, 69120 Heidelberg, Germany.
FAU - Uslu, Veli V
AU  - Uslu VV
AD  - Developmental Biology Unit, European Molecular Biology Laboratory (EMBL), 69117
      Heidelberg, Germany.
FAU - Remeseiro, Silvia
AU  - Remeseiro S
AD  - Developmental Biology Unit, European Molecular Biology Laboratory (EMBL), 69117
      Heidelberg, Germany.
FAU - Takayama, Naoya
AU  - Takayama N
AD  - Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 
      2M9, Canada.
AD  - Department of Molecular Genetics, University of Toronto, Toronto, Ontario M5G
      1A1, Canada.
FAU - Ng, Stanley W
AU  - Ng SW
AD  - Institute of Biomaterials and Biomedical Engineering, University of Toronto,
      Toronto, Ontario M5G 1A1, Canada.
FAU - Murison, Alex
AU  - Murison A
AD  - Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 
      2M9, Canada.
AD  - Department of Medical Biophysics, University of Toronto, Toronto, Ontario M5G
      2M9, Canada.
FAU - Langenfeld, Katja
AU  - Langenfeld K
AD  - Developmental Biology Unit, European Molecular Biology Laboratory (EMBL), 69117
      Heidelberg, Germany.
FAU - Petretich, Massimo
AU  - Petretich M
AD  - Developmental Biology Unit, European Molecular Biology Laboratory (EMBL), 69117
      Heidelberg, Germany.
FAU - Scognamiglio, Roberta
AU  - Scognamiglio R
AD  - Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ) and
      DKFZ-ZMBH Alliance, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.
AD  - Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM 
      gGmbH), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.
AD  - Faculty of Biosciences, University of Heidelberg, 69120 Heidelberg, Germany.
FAU - Zeisberger, Petra
AU  - Zeisberger P
AD  - Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ) and
      DKFZ-ZMBH Alliance, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.
AD  - Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM 
      gGmbH), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.
FAU - Benk, Amelie S
AU  - Benk AS
AD  - Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ) and
      DKFZ-ZMBH Alliance, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.
AD  - Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM 
      gGmbH), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.
AD  - Faculty of Biosciences, University of Heidelberg, 69120 Heidelberg, Germany.
FAU - Amit, Ido
AU  - Amit I
AD  - Department of Immunology, Weizmann Institute of Science, Rehovot 76100, Israel.
FAU - Zandstra, Peter W
AU  - Zandstra PW
AD  - Institute of Biomaterials and Biomedical Engineering, University of Toronto,
      Toronto, Ontario M5G 1A1, Canada.
FAU - Lupien, Mathieu
AU  - Lupien M
AD  - Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 
      2M9, Canada.
AD  - Department of Medical Biophysics, University of Toronto, Toronto, Ontario M5G
      2M9, Canada.
FAU - Dick, John E
AU  - Dick JE
AD  - Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 
      2M9, Canada.
AD  - Department of Molecular Genetics, University of Toronto, Toronto, Ontario M5G
      1A1, Canada.
FAU - Trumpp, Andreas
AU  - Trumpp A
AD  - Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ) and
      DKFZ-ZMBH Alliance, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.
AD  - Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM 
      gGmbH), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.
AD  - Faculty of Biosciences, University of Heidelberg, 69120 Heidelberg, Germany.
AD  - German Cancer Consortium (DKTK), 69120 Heidelberg, Germany.
AD  - Nationales Zentrum fur Tumorerkrankungen (NCT), 69120 Heidelberg, Germany.
FAU - Spitz, Francois
AU  - Spitz F
AD  - Developmental Biology Unit, European Molecular Biology Laboratory (EMBL), 69117
      Heidelberg, Germany.
AD  - CNRS, UMR3738, 25 Rue du Dr Roux, 75015 Paris, France.
AD  - (Epi)genomics of Animal Development Unit, Developmental and Stem Cell Biology
      Department, Institut Pasteur, 75015 Paris, France.
LA  - eng
PT  - Journal Article
DEP - 20180117
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
EDAT- 2018/01/18 06:00
MHDA- 2018/01/18 06:00
CRDT- 2018/01/18 06:00
PHST- 2015/02/13 00:00 [received]
PHST- 2017/12/04 00:00 [accepted]
PHST- 2018/01/18 06:00 [pubmed]
PHST- 2018/01/18 06:00 [medline]
PHST- 2018/01/18 06:00 [entrez]
AID - nature25193 [pii]
AID - 10.1038/nature25193 [doi]
PST - ppublish
SO  - Nature. 2018 Jan 25;553(7689):515-520. doi: 10.1038/nature25193. Epub 2018 Jan
      17.

PMID- 29290617
OWN - NLM
STAT- Publisher
LR  - 20180101
IS  - 1875-9777 (Electronic)
IS  - 1875-9777 (Linking)
DP  - 2017 Dec 8
TI  - METTL14 Inhibits Hematopoietic Stem/Progenitor Differentiation and Promotes
      Leukemogenesis via mRNA m(6)A Modification.
LID - S1934-5909(17)30468-X [pii]
LID - 10.1016/j.stem.2017.11.016 [doi]
AB  - N(6)-methyladenosine (m(6)A), the most prevalent internal modification in
      eukaryotic messenger RNAs (mRNAs), plays critical roles in many bioprocesses.
      However, its functions in normal and malignant hematopoiesis remain elusive.
      Here, we report that METTL14, a key component of the m(6)A methyltransferase
      complex, is highly expressed in normal hematopoietic stem/progenitor cells
      (HSPCs) and acute myeloid leukemia (AML) cells carrying t(11q23), t(15;17), or
      t(8;21) and is downregulated during myeloid differentiation. Silencing of METTL14
      promotes terminal myeloid differentiation of normal HSPCs and AML cells and
      inhibits AML cell survival/proliferation. METTL14 is required for development and
      maintenance of AML and self-renewal of leukemia stem/initiation cells
      (LSCs/LICs). Mechanistically, METTL14 exerts its oncogenic role by regulating its
      mRNA targets (e.g., MYB and MYC) through m(6)A modification, while the protein
      itself is negatively regulated by SPI1. Collectively, our results reveal the
      SPI1-METTL14-MYB/MYC signaling axis in myelopoiesis and leukemogenesis and
      highlight the critical roles of METTL14 and m(6)A modification in normal and
      malignant hematopoiesis.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Weng, Hengyou
AU  - Weng H
AD  - Department of Cancer Biology, University of Cincinnati, Cincinnati, OH 45219,
      USA.
FAU - Huang, Huilin
AU  - Huang H
AD  - Department of Cancer Biology, University of Cincinnati, Cincinnati, OH 45219,
      USA.
FAU - Wu, Huizhe
AU  - Wu H
AD  - Department of Cancer Biology, University of Cincinnati, Cincinnati, OH 45219,
      USA; Department of Pharmacology, School of Pharmacy, China Medical University,
      Shenyang, Liaoning 110122, China.
FAU - Qin, Xi
AU  - Qin X
AD  - Department of Cancer Biology, University of Cincinnati, Cincinnati, OH 45219,
      USA.
FAU - Zhao, Boxuan Simen
AU  - Zhao BS
AD  - Department of Chemistry, Department of Biochemistry and Molecular Biology,
      Institute for Biophysical Dynamics, Howard Hughes Medical Institute, University
      of Chicago, Chicago, IL 60637, USA.
FAU - Dong, Lei
AU  - Dong L
AD  - Department of Cancer Biology, University of Cincinnati, Cincinnati, OH 45219,
      USA.
FAU - Shi, Hailing
AU  - Shi H
AD  - Department of Chemistry, Department of Biochemistry and Molecular Biology,
      Institute for Biophysical Dynamics, Howard Hughes Medical Institute, University
      of Chicago, Chicago, IL 60637, USA.
FAU - Skibbe, Jennifer
AU  - Skibbe J
AD  - Department of Cancer Biology, University of Cincinnati, Cincinnati, OH 45219,
      USA.
FAU - Shen, Chao
AU  - Shen C
AD  - Department of Cancer Biology, University of Cincinnati, Cincinnati, OH 45219,
      USA.
FAU - Hu, Chao
AU  - Hu C
AD  - Department of Cancer Biology, University of Cincinnati, Cincinnati, OH 45219,
      USA; Department of Hematology, The First Affiliated Hospital Zhejiang University,
      Hangzhou, Zhejiang 310003, China.
FAU - Sheng, Yue
AU  - Sheng Y
AD  - Department of Medicine and Cancer Research Center, The University of Illinois,
      Chicago, IL 60612, USA.
FAU - Wang, Yungui
AU  - Wang Y
AD  - Department of Cancer Biology, University of Cincinnati, Cincinnati, OH 45219,
      USA; Department of Hematology, The First Affiliated Hospital Zhejiang University,
      Hangzhou, Zhejiang 310003, China.
FAU - Wunderlich, Mark
AU  - Wunderlich M
AD  - Division of Experimental Hematology and Cancer Biology, Cincinnati Children's
      Hospital Medical Center, Cincinnati, OH 45229, USA.
FAU - Zhang, Bin
AU  - Zhang B
AD  - Department of Hematologic Malignancies Translational Science and Gehr Family
      Leukemia Center, City of Hope, Duarte, CA 91010, USA.
FAU - Dore, Louis C
AU  - Dore LC
AD  - Department of Chemistry, Department of Biochemistry and Molecular Biology,
      Institute for Biophysical Dynamics, Howard Hughes Medical Institute, University
      of Chicago, Chicago, IL 60637, USA.
FAU - Su, Rui
AU  - Su R
AD  - Department of Cancer Biology, University of Cincinnati, Cincinnati, OH 45219,
      USA.
FAU - Deng, Xiaolan
AU  - Deng X
AD  - Department of Cancer Biology, University of Cincinnati, Cincinnati, OH 45219,
      USA; Department of Pharmacology, School of Pharmacy, China Medical University,
      Shenyang, Liaoning 110122, China.
FAU - Ferchen, Kyle
AU  - Ferchen K
AD  - Department of Cancer Biology, University of Cincinnati, Cincinnati, OH 45219,
      USA.
FAU - Li, Chenying
AU  - Li C
AD  - Department of Cancer Biology, University of Cincinnati, Cincinnati, OH 45219,
      USA; Department of Hematology, The First Affiliated Hospital Zhejiang University,
      Hangzhou, Zhejiang 310003, China.
FAU - Sun, Miao
AU  - Sun M
AD  - Division of Human Genetics, Cincinnati Children's Hospital Medical Center,
      Cincinnati, OH 45229, USA.
FAU - Lu, Zhike
AU  - Lu Z
AD  - Department of Chemistry, Department of Biochemistry and Molecular Biology,
      Institute for Biophysical Dynamics, Howard Hughes Medical Institute, University
      of Chicago, Chicago, IL 60637, USA.
FAU - Jiang, Xi
AU  - Jiang X
AD  - Department of Cancer Biology, University of Cincinnati, Cincinnati, OH 45219,
      USA.
FAU - Marcucci, Guido
AU  - Marcucci G
AD  - Department of Hematologic Malignancies Translational Science and Gehr Family
      Leukemia Center, City of Hope, Duarte, CA 91010, USA.
FAU - Mulloy, James C
AU  - Mulloy JC
AD  - Division of Experimental Hematology and Cancer Biology, Cincinnati Children's
      Hospital Medical Center, Cincinnati, OH 45229, USA.
FAU - Yang, Jianhua
AU  - Yang J
AD  - Key Laboratory of Gene Engineering of the Ministry of Education, Sun Yat-sen
      University, Guangzhou 510275, China.
FAU - Qian, Zhijian
AU  - Qian Z
AD  - Department of Medicine and Cancer Research Center, The University of Illinois,
      Chicago, IL 60612, USA.
FAU - Wei, Minjie
AU  - Wei M
AD  - Department of Pharmacology, School of Pharmacy, China Medical University,
      Shenyang, Liaoning 110122, China. Electronic address: mjwei@hotmail.com.
FAU - He, Chuan
AU  - He C
AD  - Department of Chemistry, Department of Biochemistry and Molecular Biology,
      Institute for Biophysical Dynamics, Howard Hughes Medical Institute, University
      of Chicago, Chicago, IL 60637, USA. Electronic address: chuanhe@uchicago.edu.
FAU - Chen, Jianjun
AU  - Chen J
AD  - Department of Cancer Biology, University of Cincinnati, Cincinnati, OH 45219,
      USA. Electronic address: jianchen@coh.org.
LA  - eng
PT  - Journal Article
DEP - 20171208
PL  - United States
TA  - Cell Stem Cell
JT  - Cell stem cell
JID - 101311472
OTO - NOTNLM
OT  - HSC
OT  - HSPCs
OT  - LSCs/LICs
OT  - METTL14
OT  - MYB
OT  - MYC
OT  - N(6)-methyladenosine modification
OT  - SPI1
OT  - acute myeloid leukemia
OT  - myeloid differentiation block
EDAT- 2018/01/02 06:00
MHDA- 2018/01/02 06:00
CRDT- 2018/01/02 06:00
PHST- 2017/05/17 00:00 [received]
PHST- 2017/09/04 00:00 [revised]
PHST- 2017/11/20 00:00 [accepted]
PHST- 2018/01/02 06:00 [entrez]
PHST- 2018/01/02 06:00 [pubmed]
PHST- 2018/01/02 06:00 [medline]
AID - S1934-5909(17)30468-X [pii]
AID - 10.1016/j.stem.2017.11.016 [doi]
PST - aheadofprint
SO  - Cell Stem Cell. 2017 Dec 8. pii: S1934-5909(17)30468-X. doi:
      10.1016/j.stem.2017.11.016.

PMID- 29307555
OWN - NLM
STAT- In-Data-Review
LR  - 20180128
IS  - 1879-0445 (Electronic)
IS  - 0960-9822 (Linking)
VI  - 28
IP  - 2
DP  - 2018 Jan 22
TI  - Vps13D Encodes a Ubiquitin-Binding Protein that Is Required for the Regulation of
      Mitochondrial Size and Clearance.
PG  - 287-295.e6
LID - S0960-9822(17)31589-0 [pii]
LID - 10.1016/j.cub.2017.11.064 [doi]
AB  - The clearance of mitochondria by autophagy, mitophagy, is important for cell and 
      organism health [1], and known to be regulated by ubiquitin. During Drosophila
      intestine development, cells undergo a dramatic reduction in cell size and
      clearance of mitochondria that depends on autophagy, the E1 ubiquitin-activating 
      enzyme Uba1, and ubiquitin [2]. Here we screen a collection of putative
      ubiquitin-binding domain-encoding genes for cell size reduction and autophagy
      phenotypes. We identify the endosomal sorting complex required for transport
      (ESCRT) components TSG101 and Vps36, as well as the novel gene Vps13D. Vps13D is 
      an essential gene that is necessary for autophagy, mitochondrial size, and
      mitochondrial clearance in Drosophila. Interestingly, a similar mitochondrial
      phenotype is observed in VPS13D mutant human cells. The ubiquitin-associated
      (UBA) domain of Vps13D binds K63 ubiquitin chains, and mutants lacking the UBA
      domain have defects in mitochondrial size and clearance and exhibit
      semi-lethality, highlighting the importance of Vps13D ubiquitin binding in both
      mitochondrial health and development. VPS13D mutant cells possess phosphorylated 
      DRP1 and mitochondrial fission factor (MFF) as well as DRP1 association with
      mitochondria, suggesting that VPS13D functions downstream of these known
      regulators of mitochondrial fission. In addition, the large Vps13D mitochondrial 
      and cell size phenotypes are suppressed by decreased mitochondrial fusion gene
      function. Thus, these results provide a previously unknown link between
      ubiquitin, mitochondrial size regulation, and autophagy.
CI  - Copyright (c) 2017 Elsevier Ltd. All rights reserved.
FAU - Anding, Allyson L
AU  - Anding AL
AD  - Department of Molecular, Cell and Cancer Biology, University of Massachusetts
      Medical School, Worcester, MA 01605, USA.
FAU - Wang, Chunxin
AU  - Wang C
AD  - Biochemistry Section, Surgical Neurology Branch, National Institute of
      Neurological Disorders and Stroke, NIH, Bethesda, MD 20892, USA.
FAU - Chang, Tsun-Kai
AU  - Chang TK
AD  - Department of Molecular, Cell and Cancer Biology, University of Massachusetts
      Medical School, Worcester, MA 01605, USA.
FAU - Sliter, Danielle A
AU  - Sliter DA
AD  - Biochemistry Section, Surgical Neurology Branch, National Institute of
      Neurological Disorders and Stroke, NIH, Bethesda, MD 20892, USA.
FAU - Powers, Christine M
AU  - Powers CM
AD  - Department of Molecular, Cell and Cancer Biology, University of Massachusetts
      Medical School, Worcester, MA 01605, USA.
FAU - Hofmann, Kay
AU  - Hofmann K
AD  - Institute for Genetics, University of Cologne, 50674 Cologne, Germany.
FAU - Youle, Richard J
AU  - Youle RJ
AD  - Biochemistry Section, Surgical Neurology Branch, National Institute of
      Neurological Disorders and Stroke, NIH, Bethesda, MD 20892, USA.
FAU - Baehrecke, Eric H
AU  - Baehrecke EH
AD  - Department of Molecular, Cell and Cancer Biology, University of Massachusetts
      Medical School, Worcester, MA 01605, USA. Electronic address:
      eric.baehrecke@umassmed.edu.
LA  - eng
GR  - R01 GM111658/GM/NIGMS NIH HHS/United States
PT  - Journal Article
DEP - 20180104
PL  - England
TA  - Curr Biol
JT  - Current biology : CB
JID - 9107782
PMC - PMC5787036
MID - NIHMS925912
OTO - NOTNLM
OT  - Drosophila
OT  - Vps13D
OT  - autophagy
OT  - fission
OT  - mitochondria
OT  - mitophagy
OT  - ubiquitin
EDAT- 2018/01/09 06:00
MHDA- 2018/01/09 06:00
CRDT- 2018/01/09 06:00
PMCR- 2019/01/22 00:00
PHST- 2017/10/30 00:00 [received]
PHST- 2017/11/21 00:00 [revised]
PHST- 2017/11/28 00:00 [accepted]
PHST- 2019/01/22 00:00 [pmc-release]
PHST- 2018/01/09 06:00 [pubmed]
PHST- 2018/01/09 06:00 [medline]
PHST- 2018/01/09 06:00 [entrez]
AID - S0960-9822(17)31589-0 [pii]
AID - 10.1016/j.cub.2017.11.064 [doi]
PST - ppublish
SO  - Curr Biol. 2018 Jan 22;28(2):287-295.e6. doi: 10.1016/j.cub.2017.11.064. Epub
      2018 Jan 4.

PMID- 29301958
OWN - NLM
STAT- Publisher
LR  - 20180105
IS  - 1095-9203 (Electronic)
IS  - 0036-8075 (Linking)
DP  - 2018 Jan 4
TI  - A major chromatin regulator determines resistance of tumor cells to T
      cell-mediated killing.
LID - eaao1710 [pii]
LID - 10.1126/science.aao1710 [doi]
AB  - Many human cancers are resistant to immunotherapy for reasons that are poorly
      understood. We used a genome-scale CRISPR/Cas9 screen to identify mechanisms of
      tumor cell resistance to killing by cytotoxic T cells, the central effectors of
      anti-tumor immunity. Inactivation of >100 genes sensitized mouse B16F10 melanoma 
      cells to killing by T cells, including Pbrm1, Arid2 and Brd7, which encode
      components of the PBAF form of the SWI/SNF chromatin remodeling complex. Loss of 
      PBAF function increased tumor cell sensitivity to interferon-gamma, resulting in 
      enhanced secretion of chemokines that recruit effector T cells.
      Treatment-resistant tumors became responsive to immunotherapy when Pbrm1 was
      inactivated. In many human cancers, expression of PBRM1 and ARID2 inversely
      correlated with expression of T cell cytotoxicity genes, and Pbrm1-deficient
      murine melanomas were more strongly infiltrated by cytotoxic T cells.
CI  - Copyright (c) 2018, American Association for the Advancement of Science.
FAU - Pan, Deng
AU  - Pan D
AUID- ORCID: http://orcid.org/0000-0003-3305-4884
AD  - Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute,
      Boston, MA 02215, USA.
FAU - Kobayashi, Aya
AU  - Kobayashi A
AUID- ORCID: http://orcid.org/0000-0003-3408-4006
AD  - Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute,
      Boston, MA 02215, USA.
FAU - Jiang, Peng
AU  - Jiang P
AUID- ORCID: http://orcid.org/0000-0002-7828-5486
AD  - Department of Biostatistics and Computational Biology, Dana-Farber Cancer
      Institute, Boston, MA 02215, USA.
FAU - Ferrari de Andrade, Lucas
AU  - Ferrari de Andrade L
AUID- ORCID: http://orcid.org/0000-0002-2137-2271
AD  - Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute,
      Boston, MA 02215, USA.
FAU - Tay, Rong En
AU  - Tay RE
AD  - Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute,
      Boston, MA 02215, USA.
FAU - Luoma, Adrienne
AU  - Luoma A
AD  - Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute,
      Boston, MA 02215, USA.
FAU - Tsoucas, Daphne
AU  - Tsoucas D
AD  - Department of Biostatistics and Computational Biology, Dana-Farber Cancer
      Institute, Boston, MA 02215, USA.
FAU - Qiu, Xintao
AU  - Qiu X
AUID- ORCID: http://orcid.org/0000-0002-8560-7017
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Lim, Klothilda
AU  - Lim K
AUID- ORCID: http://orcid.org/0000-0002-9791-6503
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Rao, Prakash
AU  - Rao P
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Long, Henry W
AU  - Long HW
AUID- ORCID: http://orcid.org/0000-0001-6849-6629
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Yuan, Guo-Cheng
AU  - Yuan GC
AD  - Department of Biostatistics and Computational Biology, Dana-Farber Cancer
      Institute, Boston, MA 02215, USA.
FAU - Doench, John
AU  - Doench J
AUID- ORCID: http://orcid.org/0000-0002-3707-9889
AD  - Genetic Perturbation Platform, Broad Institute of MIT and Harvard, Cambridge, MA 
      02142, USA.
FAU - Brown, Myles
AU  - Brown M
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Liu, Shirley
AU  - Liu S
AUID- ORCID: http://orcid.org/0000-0003-4736-7339
AD  - Department of Biostatistics and Computational Biology, Dana-Farber Cancer
      Institute, Boston, MA 02215, USA. kai_wucherpfennig@dfci.harvard.edu
      xsliu@jimmy.harvard.edu.
FAU - Wucherpfennig, Kai W
AU  - Wucherpfennig KW
AUID- ORCID: http://orcid.org/0000-0002-1829-302X
AD  - Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute,
      Boston, MA 02215, USA. kai_wucherpfennig@dfci.harvard.edu
      xsliu@jimmy.harvard.edu.
AD  - Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 
      02115, USA.
LA  - eng
PT  - Journal Article
DEP - 20180104
PL  - United States
TA  - Science
JT  - Science (New York, N.Y.)
JID - 0404511
EDAT- 2018/01/06 06:00
MHDA- 2018/01/06 06:00
CRDT- 2018/01/06 06:00
PHST- 2017/06/21 00:00 [received]
PHST- 2017/10/30 00:00 [revised]
PHST- 2017/12/14 00:00 [accepted]
PHST- 2018/01/06 06:00 [entrez]
PHST- 2018/01/06 06:00 [pubmed]
PHST- 2018/01/06 06:00 [medline]
AID - science.aao1710 [pii]
AID - 10.1126/science.aao1710 [doi]
PST - aheadofprint
SO  - Science. 2018 Jan 4. pii: science.aao1710. doi: 10.1126/science.aao1710.

PMID- 29309059
OWN - NLM
STAT- Publisher
LR  - 20180129
IS  - 1546-170X (Electronic)
IS  - 1078-8956 (Linking)
DP  - 2018 Jan 8
TI  - High-dimensional single-cell analysis predicts response to anti-PD-1
      immunotherapy.
LID - 10.1038/nm.4466 [doi]
AB  - Immune-checkpoint blockade has revolutionized cancer therapy. In particular,
      inhibition of programmed cell death protein 1 (PD-1) has been found to be
      effective for the treatment of metastatic melanoma and other cancers. Despite a
      dramatic increase in progression-free survival, a large proportion of patients do
      not show durable responses. Therefore, predictive biomarkers of a clinical
      response are urgently needed. Here we used high-dimensional single-cell mass
      cytometry and a bioinformatics pipeline for the in-depth characterization of the 
      immune cell subsets in the peripheral blood of patients with stage IV melanoma
      before and after 12 weeks of anti-PD-1 immunotherapy. During therapy, we observed
      a clear response to immunotherapy in the T cell compartment. However, before
      commencing therapy, a strong predictor of progression-free and overall survival
      in response to anti-PD-1 immunotherapy was the frequency of
      CD14(+)CD16(-)HLA-DR(hi) monocytes. We confirmed this by conventional flow
      cytometry in an independent, blinded validation cohort, and we propose that the
      frequency of monocytes in PBMCs may serve in clinical decision support.
FAU - Krieg, Carsten
AU  - Krieg C
AUID- ORCID: http://orcid.org/0000-0002-5145-7591
AD  - Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
FAU - Nowicka, Malgorzata
AU  - Nowicka M
AD  - Institute of Molecular Life Sciences, University of Zurich, Zurich, Switzerland.
AD  - Swiss Institute of Bioinformatics (SIB), University of Zurich, Zurich,
      Switzerland.
FAU - Guglietta, Silvia
AU  - Guglietta S
AD  - Department of Experimental Oncology, European Institute of Oncology, Milan,
      Italy.
FAU - Schindler, Sabrina
AU  - Schindler S
AD  - Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
FAU - Hartmann, Felix J
AU  - Hartmann FJ
AUID- ORCID: http://orcid.org/0000-0002-4174-2276
AD  - Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
FAU - Weber, Lukas M
AU  - Weber LM
AUID- ORCID: http://orcid.org/0000-0002-3282-1730
AD  - Institute of Molecular Life Sciences, University of Zurich, Zurich, Switzerland.
AD  - Swiss Institute of Bioinformatics (SIB), University of Zurich, Zurich,
      Switzerland.
FAU - Dummer, Reinhard
AU  - Dummer R
AD  - Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
FAU - Robinson, Mark D
AU  - Robinson MD
AUID- ORCID: http://orcid.org/0000-0002-3048-5518
AD  - Institute of Molecular Life Sciences, University of Zurich, Zurich, Switzerland.
AD  - Swiss Institute of Bioinformatics (SIB), University of Zurich, Zurich,
      Switzerland.
FAU - Levesque, Mitchell P
AU  - Levesque MP
AUID- ORCID: http://orcid.org/0000-0001-5902-9420
AD  - Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
FAU - Becher, Burkhard
AU  - Becher B
AUID- ORCID: http://orcid.org/0000-0002-1541-7867
AD  - Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
LA  - eng
PT  - Journal Article
DEP - 20180108
PL  - United States
TA  - Nat Med
JT  - Nature medicine
JID - 9502015
EDAT- 2018/01/09 06:00
MHDA- 2018/01/09 06:00
CRDT- 2018/01/09 06:00
PHST- 2017/05/01 00:00 [received]
PHST- 2017/11/20 00:00 [accepted]
PHST- 2018/01/09 06:00 [pubmed]
PHST- 2018/01/09 06:00 [medline]
PHST- 2018/01/09 06:00 [entrez]
AID - nm.4466 [pii]
AID - 10.1038/nm.4466 [doi]
PST - aheadofprint
SO  - Nat Med. 2018 Jan 8. pii: nm.4466. doi: 10.1038/nm.4466.

PMID- 29301960
OWN - NLM
STAT- Publisher
LR  - 20180105
IS  - 1095-9203 (Electronic)
IS  - 0036-8075 (Linking)
DP  - 2018 Jan 4
TI  - Genomic correlates of response to immune checkpoint therapies in clear cell renal
      cell carcinoma.
LID - eaan5951 [pii]
LID - 10.1126/science.aan5951 [doi]
AB  - Immune checkpoint inhibitors targeting the programmed cell death-1 receptor
      (PD-1) improve survival in a subset of patients with clear cell renal cell
      carcinoma (ccRCC). To identify genomic alterations in ccRCC that correlate with
      response to anti-PD-1 monotherapy, we performed whole exome sequencing of
      metastatic ccRCC from 35 patients. We found that clinical benefit was associated 
      with loss-of-function mutations in the PBRM1 gene (p=0.012), which encodes a
      subunit of a SWI/SNF chromatin remodeling complex (the PBAF subtype). We
      confirmed this finding in an independent validation cohort of 63 ccRCC patients
      treated with PD-(L)1 blockade therapy alone or in combination with anti-CTLA-4
      therapies (p=0.0071). Gene expression analysis of PBAF-deficient ccRCC cell lines
      and PBRM1-deficient tumors revealed altered transcriptional output in JAK/STAT,
      hypoxia, and immune signaling pathways. PBRM1 loss in ccRCC may alter global
      tumor cell expression profiles to influence responsiveness to immune checkpoint
      therapy.
CI  - Copyright (c) 2018, American Association for the Advancement of Science.
FAU - Miao, Diana
AU  - Miao D
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
AD  - Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard,
      Cambridge, MA 02142, USA.
FAU - Margolis, Claire A
AU  - Margolis CA
AUID- ORCID: http://orcid.org/0000-0002-1019-2419
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
AD  - Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard,
      Cambridge, MA 02142, USA.
FAU - Gao, Wenhua
AU  - Gao W
AUID- ORCID: http://orcid.org/0000-0002-3020-5408
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Voss, Martin H
AU  - Voss MH
AUID- ORCID: http://orcid.org/0000-0003-0551-5807
AD  - Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
AD  - Weill Cornell Medical College, New York, NY 10065, USA.
FAU - Li, Wei
AU  - Li W
AUID- ORCID: http://orcid.org/0000-0002-2163-7903
AD  - Department of Biostatistics and Computational Biology, Dana-Farber Cancer
      Institute, Boston, MA 02215, USA.
FAU - Martini, Dylan J
AU  - Martini DJ
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Norton, Craig
AU  - Norton C
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Bosse, Dominick
AU  - Bosse D
AUID- ORCID: http://orcid.org/0000-0003-2992-5632
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Wankowicz, Stephanie M
AU  - Wankowicz SM
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
AD  - Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard,
      Cambridge, MA 02142, USA.
FAU - Cullen, Dana
AU  - Cullen D
AD  - Bristol-Myers Squibb, New York, NY 10154, USA.
FAU - Horak, Christine
AU  - Horak C
AD  - Bristol-Myers Squibb, New York, NY 10154, USA.
FAU - Wind-Rotolo, Megan
AU  - Wind-Rotolo M
AUID- ORCID: http://orcid.org/0000-0001-8063-9928
AD  - Bristol-Myers Squibb, New York, NY 10154, USA.
FAU - Tracy, Adam
AU  - Tracy A
AUID- ORCID: http://orcid.org/0000-0002-7750-0148
AD  - Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard,
      Cambridge, MA 02142, USA.
FAU - Giannakis, Marios
AU  - Giannakis M
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
AD  - Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard,
      Cambridge, MA 02142, USA.
FAU - Hodi, Frank Stephen
AU  - Hodi FS
AUID- ORCID: http://orcid.org/0000-0001-6825-091X
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Drake, Charles G
AU  - Drake CG
AD  - Columbia University Medical Center, New York, NY 10032, USA.
FAU - Ball, Mark W
AU  - Ball MW
AUID- ORCID: http://orcid.org/0000-0003-1780-2627
AD  - James Buchanan Brady Urological Institute and Department of Urology, Johns
      Hopkins University School of Medicine, Baltimore, MD 21287, USA.
FAU - Allaf, Mohamad E
AU  - Allaf ME
AUID- ORCID: http://orcid.org/0000-0003-3333-3904
AD  - James Buchanan Brady Urological Institute and Department of Urology, Johns
      Hopkins University School of Medicine, Baltimore, MD 21287, USA.
FAU - Snyder, Alexandra
AU  - Snyder A
AUID- ORCID: http://orcid.org/0000-0002-2606-3523
AD  - Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
FAU - Hellmann, Matthew D
AU  - Hellmann MD
AUID- ORCID: http://orcid.org/0000-0002-2670-9777
AD  - Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
AD  - Weill Cornell Medical College, New York, NY 10065, USA.
FAU - Ho, Thai
AU  - Ho T
AUID- ORCID: http://orcid.org/0000-0003-0023-2939
AD  - Mayo Clinic, Scottsdale, AZ 85259, USA.
FAU - Motzer, Robert J
AU  - Motzer RJ
AUID- ORCID: http://orcid.org/0000-0001-6925-2327
AD  - Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
AD  - Weill Cornell Medical College, New York, NY 10065, USA.
FAU - Signoretti, Sabina
AU  - Signoretti S
AUID- ORCID: http://orcid.org/0000-0002-5000-9105
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Kaelin, William G Jr
AU  - Kaelin WG Jr
AUID- ORCID: http://orcid.org/0000-0002-0574-4856
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
AD  - Howard Hughes Medical Institute, Dana-Farber Cancer Institute, Boston, MA 02215, 
      USA.
FAU - Choueiri, Toni K
AU  - Choueiri TK
AUID- ORCID: http://orcid.org/0000-0002-9201-3217
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA. eliezerm_vanallen@dfci.harvard.edu toni_choueiri@dfci.harvard.edu.
FAU - Van Allen, Eliezer M
AU  - Van Allen EM
AUID- ORCID: http://orcid.org/0000-0002-0201-4444
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA. eliezerm_vanallen@dfci.harvard.edu toni_choueiri@dfci.harvard.edu.
AD  - Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard,
      Cambridge, MA 02142, USA.
LA  - eng
PT  - Journal Article
DEP - 20180104
PL  - United States
TA  - Science
JT  - Science (New York, N.Y.)
JID - 0404511
EDAT- 2018/01/06 06:00
MHDA- 2018/01/06 06:00
CRDT- 2018/01/06 06:00
PHST- 2017/05/15 00:00 [received]
PHST- 2017/10/30 00:00 [revised]
PHST- 2017/12/15 00:00 [accepted]
PHST- 2018/01/06 06:00 [entrez]
PHST- 2018/01/06 06:00 [pubmed]
PHST- 2018/01/06 06:00 [medline]
AID - science.aan5951 [pii]
AID - 10.1126/science.aan5951 [doi]
PST - aheadofprint
SO  - Science. 2018 Jan 4. pii: science.aan5951. doi: 10.1126/science.aan5951.

PMID- 29334376
OWN - NLM
STAT- Publisher
LR  - 20180129
IS  - 1546-170X (Electronic)
IS  - 1078-8956 (Linking)
DP  - 2018 Jan 15
TI  - Positively selected enhancer elements endow osteosarcoma cells with metastatic
      competence.
LID - 10.1038/nm.4475 [doi]
AB  - Metastasis results from a complex set of traits acquired by tumor cells, distinct
      from those necessary for tumorigenesis. Here, we investigate the contribution of 
      enhancer elements to the metastatic phenotype of osteosarcoma. Through epigenomic
      profiling, we identify substantial differences in enhancer activity between
      primary and metastatic human tumors and between near isogenic pairs of highly
      lung metastatic and nonmetastatic osteosarcoma cell lines. We term these regions 
      metastatic variant enhancer loci (Met-VELs). Met-VELs drive coordinated waves of 
      gene expression during metastatic colonization of the lung. Met-VELs cluster
      nonrandomly in the genome, indicating that activity of these enhancers and
      expression of their associated gene targets are positively selected. As evidence 
      of this causal association, osteosarcoma lung metastasis is inhibited by global
      interruptions of Met-VEL-associated gene expression via pharmacologic BET
      inhibition, by knockdown of AP-1 transcription factors that occupy Met-VELs, and 
      by knockdown or functional inhibition of individual genes activated by Met-VELs, 
      such as that encoding coagulation factor III/tissue factor (F3). We further show 
      that genetic deletion of a single Met-VEL at the F3 locus blocks metastatic cell 
      outgrowth in the lung. These findings indicate that Met-VELs and the genes they
      regulate play a functional role in metastasis and may be suitable targets for
      antimetastatic therapies.
FAU - Morrow, James J
AU  - Morrow JJ
AD  - Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USA.
AD  - Department of Genetics and Genome Sciences, Case Western Reserve University,
      Cleveland, Ohio, USA.
FAU - Bayles, Ian
AU  - Bayles I
AD  - Department of Genetics and Genome Sciences, Case Western Reserve University,
      Cleveland, Ohio, USA.
FAU - Funnell, Alister P W
AU  - Funnell APW
AD  - Altius Institute for Biomedical Sciences, Seattle, Washington, USA.
FAU - Miller, Tyler E
AU  - Miller TE
AD  - Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USA.
FAU - Saiakhova, Alina
AU  - Saiakhova A
AD  - Department of Genetics and Genome Sciences, Case Western Reserve University,
      Cleveland, Ohio, USA.
FAU - Lizardo, Michael M
AU  - Lizardo MM
AD  - Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute,
      National Institutes of Health, Bethesda, Maryland, USA.
FAU - Bartels, Cynthia F
AU  - Bartels CF
AD  - Department of Genetics and Genome Sciences, Case Western Reserve University,
      Cleveland, Ohio, USA.
FAU - Kapteijn, Maaike Y
AU  - Kapteijn MY
AD  - Thrombosis and Hemostasis Division, Department of Internal Medicine, Leiden
      University Medical Center, Leiden, the Netherlands.
FAU - Hung, Stevephen
AU  - Hung S
AD  - Department of Genetics and Genome Sciences, Case Western Reserve University,
      Cleveland, Ohio, USA.
FAU - Mendoza, Arnulfo
AU  - Mendoza A
AD  - Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute,
      National Institutes of Health, Bethesda, Maryland, USA.
FAU - Dhillon, Gursimran
AU  - Dhillon G
AD  - Department of Genetics and Genome Sciences, Case Western Reserve University,
      Cleveland, Ohio, USA.
FAU - Chee, Daniel R
AU  - Chee DR
AD  - Department of Genome Sciences, University of Washington, Seattle, Washington,
      USA.
FAU - Myers, Jay T
AU  - Myers JT
AD  - Department of Pediatrics, Case Western Reserve University, Cleveland, Ohio, USA.
FAU - Allen, Frederick
AU  - Allen F
AD  - Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USA.
FAU - Gambarotti, Marco
AU  - Gambarotti M
AD  - Research Laboratory, Istituto Ortopedico Rizzoli, Bologna, Italy.
FAU - Righi, Alberto
AU  - Righi A
AD  - Research Laboratory, Istituto Ortopedico Rizzoli, Bologna, Italy.
FAU - DiFeo, Analisa
AU  - DiFeo A
AD  - Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland,
      Ohio, USA.
FAU - Rubin, Brian P
AU  - Rubin BP
AD  - Departments of Anatomic Pathology and Molecular Genetics, Cleveland Clinic,
      Lerner Research Institute and Taussig Cancer Center, Cleveland, Ohio, USA.
FAU - Huang, Alex Y
AU  - Huang AY
AD  - Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USA.
AD  - Department of Pediatrics, Case Western Reserve University, Cleveland, Ohio, USA.
FAU - Meltzer, Paul S
AU  - Meltzer PS
AD  - Genetics Branch, Center for Cancer Research, National Cancer Institute, National 
      Institutes of Health, Bethesda, Maryland, USA.
FAU - Helman, Lee J
AU  - Helman LJ
AD  - Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute,
      National Institutes of Health, Bethesda, Maryland, USA.
FAU - Picci, Piero
AU  - Picci P
AD  - Research Laboratory, Istituto Ortopedico Rizzoli, Bologna, Italy.
FAU - Versteeg, Henri
AU  - Versteeg H
AUID- ORCID: http://orcid.org/0000-0003-4294-175X
AD  - Thrombosis and Hemostasis Division, Department of Internal Medicine, Leiden
      University Medical Center, Leiden, the Netherlands.
FAU - Stamatoyannopolus, John
AU  - Stamatoyannopolus J
AD  - Altius Institute for Biomedical Sciences, Seattle, Washington, USA.
FAU - Khanna, Chand
AU  - Khanna C
AD  - Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute,
      National Institutes of Health, Bethesda, Maryland, USA.
FAU - Scacheri, Peter C
AU  - Scacheri PC
AD  - Department of Genetics and Genome Sciences, Case Western Reserve University,
      Cleveland, Ohio, USA.
AD  - Research Laboratory, Istituto Ortopedico Rizzoli, Bologna, Italy.
LA  - eng
PT  - Journal Article
DEP - 20180115
PL  - United States
TA  - Nat Med
JT  - Nature medicine
JID - 9502015
EDAT- 2018/01/16 06:00
MHDA- 2018/01/16 06:00
CRDT- 2018/01/16 06:00
PHST- 2017/06/30 00:00 [received]
PHST- 2017/12/18 00:00 [accepted]
PHST- 2018/01/16 06:00 [pubmed]
PHST- 2018/01/16 06:00 [medline]
PHST- 2018/01/16 06:00 [entrez]
AID - nm.4475 [pii]
AID - 10.1038/nm.4475 [doi]
PST - aheadofprint
SO  - Nat Med. 2018 Jan 15. pii: nm.4475. doi: 10.1038/nm.4475.

PMID- 29357389
OWN - NLM
STAT- Publisher
LR  - 20180125
IS  - 1553-7374 (Electronic)
IS  - 1553-7366 (Linking)
VI  - 14
IP  - 1
DP  - 2018 Jan 22
TI  - Interferon regulatory factor 8 regulates aspase-1 expression to facilitate
      Epstein-Barr virus reactivation in response to B cell receptor stimulation and
      chemical induction.
PG  - e1006868
LID - 10.1371/journal.ppat.1006868 [doi]
AB  - Interferon regulatory factor 8 (IRF8), also known as interferon consensus
      sequence-binding protein (ICSBP), is a transcription factor of the IRF family.
      IRF8 plays a key role in normal B cell differentiation, a cellular process that
      is intrinsically associated with Epstein-Barr virus (EBV) reactivation. However, 
      whether IRF8 regulates EBV lytic replication remains unknown. In this study, we
      utilized a CRISPR/Cas9 genomic editing approach to deplete IRF8 and found that
      IRF8 depletion dramatically inhibits the reactivation of EBV upon lytic
      induction. We demonstrated that IRF8 depletion suppresses the expression of a
      group of genes involved in apoptosis and thus inhibits apoptosis induction upon
      lytic induction by B cell receptor (BCR) stimulation or chemical induction. The
      protein levels of caspase-1, caspase-3 and caspase-8 all dramatically decreased
      in IRF8-depleted cells, which led to reduced caspase activation and the
      stabilization of KAP1, PAX5 and DNMT3A upon BCR stimulation. Interestingly,
      caspase inhibition blocked the degradation of KAP1, PAX5 and DNMT3A, suppressed
      EBV lytic gene expression and viral DNA replication upon lytic induction,
      suggesting that the reduced caspase expression in IRF8-depleted cells contributes
      to the suppression of EBV lytic replication. We further demonstrated that IRF8
      directly regulates CASP1 (caspase-1) gene expression through targeting its gene
      promoter and knockdown of caspase-1 abrogates EBV reactivation upon lytic
      induction, partially through the stabilization of KAP1. Together our study
      suggested that, by modulating the activation of caspases and the subsequent
      cleavage of KAP1 upon lytic induction, IRF8 plays a critical role in EBV lytic
      reactivation.
FAU - Lv, Dong-Wen
AU  - Lv DW
AUID- ORCID: http://orcid.org/0000-0003-4677-8996
AD  - Department of Oral and Craniofacial Molecular Biology and Philips Institute for
      Oral Health Research, School of Dentistry, Virginia Commonwealth University,
      Richmond, Virginia, United States of America.
FAU - Zhang, Kun
AU  - Zhang K
AUID- ORCID: http://orcid.org/0000-0001-5696-2426
AD  - Department of Oral and Craniofacial Molecular Biology and Philips Institute for
      Oral Health Research, School of Dentistry, Virginia Commonwealth University,
      Richmond, Virginia, United States of America.
FAU - Li, Renfeng
AU  - Li R
AUID- ORCID: http://orcid.org/0000-0002-9226-4470
AD  - Department of Oral and Craniofacial Molecular Biology and Philips Institute for
      Oral Health Research, School of Dentistry, Virginia Commonwealth University,
      Richmond, Virginia, United States of America.
AD  - Department of Microbiology and Immunology, School of Medicine, Virginia
      Commonwealth University, Richmond, Virginia, United States of America.
AD  - Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia,
      United States of America.
LA  - eng
GR  - K99 AI104828/AI/NIAID NIH HHS/United States
GR  - P30 CA016059/CA/NCI NIH HHS/United States
GR  - R00 AI104828/AI/NIAID NIH HHS/United States
PT  - Journal Article
DEP - 20180122
PL  - United States
TA  - PLoS Pathog
JT  - PLoS pathogens
JID - 101238921
EDAT- 2018/01/23 06:00
MHDA- 2018/01/23 06:00
CRDT- 2018/01/23 06:00
PHST- 2017/10/03 00:00 [received]
PHST- 2018/01/09 00:00 [accepted]
PHST- 2018/01/23 06:00 [entrez]
PHST- 2018/01/23 06:00 [pubmed]
PHST- 2018/01/23 06:00 [medline]
AID - 10.1371/journal.ppat.1006868 [doi]
AID - PPATHOGENS-D-17-02186 [pii]
PST - aheadofprint
SO  - PLoS Pathog. 2018 Jan 22;14(1):e1006868. doi: 10.1371/journal.ppat.1006868.

PMID- 29336889
OWN - NLM
STAT- Publisher
LR  - 20180116
IS  - 1097-4172 (Electronic)
IS  - 0092-8674 (Linking)
DP  - 2018 Jan 4
TI  - KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of
      Mutant KRAS.
LID - S0092-8674(17)31500-3 [pii]
LID - 10.1016/j.cell.2017.12.020 [doi]
AB  - The mechanism by which the wild-type KRAS allele imparts a growth inhibitory
      effect to oncogenic KRAS in various cancers, including lung adenocarcinoma
      (LUAD), is poorly understood. Here, using a genetically inducible model of KRAS
      loss of heterozygosity (LOH), we show that KRAS dimerization mediates wild-type
      KRAS-dependent fitness of human and murine KRAS mutant LUAD tumor cells and
      underlies resistance to MEK inhibition. These effects are abrogated when
      wild-type KRAS is replaced by KRAS(D154Q), a mutant that disrupts dimerization at
      the alpha4-alpha5 KRAS dimer interface without changing other fundamental
      biochemical properties of KRAS, both in vitro and in vivo. Moreover, dimerization
      has a critical role in the oncogenic activity of mutant KRAS. Our studies provide
      mechanistic and biological insights into the role of KRAS dimerization and
      highlight a role for disruption of dimerization as a therapeutic strategy for
      KRAS mutant cancers.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Ambrogio, Chiara
AU  - Ambrogio C
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA. Electronic address: chiara_ambrogio@dfci.harvard.edu.
FAU - Kohler, Jens
AU  - Kohler J
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Zhou, Zhi-Wei
AU  - Zhou ZW
AD  - Departments of Biochemistry and Radiation Oncology, the University of Texas
      Southwestern Medical Center, Dallas, TX 75390, USA.
FAU - Wang, Haiyun
AU  - Wang H
AD  - School of Life Science and Technology, Tongji University, 200092 Shanghai, China.
FAU - Paranal, Raymond
AU  - Paranal R
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Li, Jiaqi
AU  - Li J
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Capelletti, Marzia
AU  - Capelletti M
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Caffarra, Cristina
AU  - Caffarra C
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Li, Shuai
AU  - Li S
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Lv, Qi
AU  - Lv Q
AD  - School of Life Science and Technology, Tongji University, 200092 Shanghai, China.
FAU - Gondi, Sudershan
AU  - Gondi S
AD  - Departments of Biochemistry and Radiation Oncology, the University of Texas
      Southwestern Medical Center, Dallas, TX 75390, USA.
FAU - Hunter, John C
AU  - Hunter JC
AD  - Departments of Biochemistry and Radiation Oncology, the University of Texas
      Southwestern Medical Center, Dallas, TX 75390, USA.
FAU - Lu, Jia
AU  - Lu J
AD  - Departments of Biochemistry and Radiation Oncology, the University of Texas
      Southwestern Medical Center, Dallas, TX 75390, USA.
FAU - Chiarle, Roberto
AU  - Chiarle R
AD  - Department of Pathology, Boston Children's Hospital and Harvard Medical School,
      Boston, MA 02115, USA; Department of Molecular Biotechnology and Health Science, 
      University of Torino, 10126, Italy.
FAU - Santamaria, David
AU  - Santamaria D
AD  - University of Bordeaux, INSERM U1218, ACTION Laboratory, IECB, F-33600 Pessac,
      France.
FAU - Westover, Kenneth D
AU  - Westover KD
AD  - Departments of Biochemistry and Radiation Oncology, the University of Texas
      Southwestern Medical Center, Dallas, TX 75390, USA. Electronic address:
      kenneth.westover@utsouthwestern.edu.
FAU - Janne, Pasi A
AU  - Janne PA
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute,
      Boston, MA 02215, USA. Electronic address: pasi_janne@dfci.harvard.edu.
LA  - eng
PT  - Journal Article
DEP - 20180104
PL  - United States
TA  - Cell
JT  - Cell
JID - 0413066
OTO - NOTNLM
OT  - KRAS oncogene
OT  - MAPK pathway
OT  - MEK inhibitors
OT  - allelic imbalance
OT  - dimerization
OT  - drug resistance
OT  - lung adenocarcinoma
OT  - wild-type allele
EDAT- 2018/01/18 06:00
MHDA- 2018/01/18 06:00
CRDT- 2018/01/17 06:00
PHST- 2017/05/25 00:00 [received]
PHST- 2017/09/19 00:00 [revised]
PHST- 2017/12/15 00:00 [accepted]
PHST- 2018/01/17 06:00 [entrez]
PHST- 2018/01/18 06:00 [pubmed]
PHST- 2018/01/18 06:00 [medline]
AID - S0092-8674(17)31500-3 [pii]
AID - 10.1016/j.cell.2017.12.020 [doi]
PST - aheadofprint
SO  - Cell. 2018 Jan 4. pii: S0092-8674(17)31500-3. doi: 10.1016/j.cell.2017.12.020.

PMID- 29329591
OWN - NLM
STAT- In-Data-Review
LR  - 20180119
IS  - 1476-4598 (Electronic)
IS  - 1476-4598 (Linking)
VI  - 17
IP  - 1
DP  - 2018 Jan 12
TI  - Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
PG  - 7
LID - 10.1186/s12943-018-0759-3 [doi]
AB  - The potential for adoptive cell immunotherapy as a treatment against cancers has 
      been demonstrated by the remarkable response in some patients with hematological 
      malignancies using autologous T cells endowed with chimeric antigen receptors
      (CARs) specific for CD19. Clinical efficacy of CAR-T cell therapy for the
      treatment of solid tumors, however, is rare due to physical and biochemical
      factors. This review focuses on different aspects of multiple mechanisms of
      immunosuppression in solid tumors. We characterize the current state of
      CAR-modified T cell therapy and summarize the various strategies to combat the
      immunosuppressive microenvironment of solid tumors, with the aim of promoting T
      cell cytotoxicity and enhancing tumor cell eradication.
FAU - Zhang, Erhao
AU  - Zhang E
AD  - The Engineering Research Center of Peptide Drug Discovery and Development, China 
      Pharmaceutical University, Nanjing, Jiangsu, 210009, People's Republic of China.
FAU - Gu, Jieyi
AU  - Gu J
AD  - The Engineering Research Center of Peptide Drug Discovery and Development, China 
      Pharmaceutical University, Nanjing, Jiangsu, 210009, People's Republic of China.
FAU - Xu, Hanmei
AU  - Xu H
AD  - The Engineering Research Center of Peptide Drug Discovery and Development, China 
      Pharmaceutical University, Nanjing, Jiangsu, 210009, People's Republic of China. 
      haobo89@163.com.
AD  - State Key Laboratory of Natural Medicines, Ministry of Education, China
      Pharmaceutical University, Nanjing, Jiangsu, 210009, People's Republic of China. 
      haobo89@163.com.
LA  - eng
GR  - No. SKLNMBZ201403/Ministry of Science and Technology of the People's Republic of 
      China/United States
GR  - No. 2012ZX09103301-004/Ministry of Science and Technology of the People's
      Republic of China/United States
GR  - No. 2014ZX09508007/Ministry of Science and Technology of the People's Republic of
      China/United States
PT  - Journal Article
PT  - Review
DEP - 20180112
PL  - England
TA  - Mol Cancer
JT  - Molecular cancer
JID - 101147698
PMC - PMC5767005
OTO - NOTNLM
OT  - Adoptive cell therapy
OT  - Cancer immunotherapy
OT  - Chimeric antigen receptor T cell
OT  - Immunosuppressive microenvironment
OT  - Solid tumor
EDAT- 2018/01/14 06:00
MHDA- 2018/01/14 06:00
CRDT- 2018/01/14 06:00
PHST- 2017/09/24 00:00 [received]
PHST- 2018/01/02 00:00 [accepted]
PHST- 2018/01/14 06:00 [entrez]
PHST- 2018/01/14 06:00 [pubmed]
PHST- 2018/01/14 06:00 [medline]
AID - 10.1186/s12943-018-0759-3 [doi]
AID - 10.1186/s12943-018-0759-3 [pii]
PST - epublish
SO  - Mol Cancer. 2018 Jan 12;17(1):7. doi: 10.1186/s12943-018-0759-3.

PMID- 29334373
OWN - NLM
STAT- Publisher
LR  - 20180129
IS  - 1546-170X (Electronic)
IS  - 1078-8956 (Linking)
DP  - 2018 Jan 15
TI  - Prevention of tuberculosis in rhesus macaques by a cytomegalovirus-based vaccine.
LID - 10.1038/nm.4473 [doi]
AB  - Despite widespread use of the bacille Calmette-Guerin (BCG) vaccine, tuberculosis
      (TB) remains a leading cause of global mortality from a single infectious agent
      (Mycobacterium tuberculosis or Mtb). Here, over two independent Mtb challenge
      studies, we demonstrate that subcutaneous vaccination of rhesus macaques (RMs)
      with rhesus cytomegalovirus vectors encoding Mtb antigen inserts (hereafter
      referred to as RhCMV/TB)-which elicit and maintain highly
      effector-differentiated, circulating and tissue-resident Mtb-specific CD4(+) and 
      CD8(+) memory T cell responses-can reduce the overall (pulmonary and
      extrapulmonary) extent of Mtb infection and disease by 68%, as compared to that
      in unvaccinated controls, after intrabronchial challenge with the Erdman strain
      of Mtb at approximately 1 year after the first vaccination. Fourteen of 34
      RhCMV/TB-vaccinated RMs (41%) across both studies showed no TB disease by
      computed tomography scans or at necropsy after challenge (as compared to 0 of 17 
      unvaccinated controls), and ten of these RMs were Mtb-culture-negative for all
      tissues, an exceptional long-term vaccine effect in the RM challenge model with
      the Erdman strain of Mtb. These results suggest that complete vaccine-mediated
      immune control of highly pathogenic Mtb is possible if immune effector responses 
      can intercept Mtb infection at its earliest stages.
FAU - Hansen, Scott G
AU  - Hansen SG
AD  - Vaccine and Gene Therapy Institute and Oregon National Primate Research Center
      (ONPRC), Oregon Health and Science University (OHSU), Beaverton, Oregon, USA.
FAU - Zak, Daniel E
AU  - Zak DE
AD  - Center for Infectious Disease Research, Seattle, Washington, USA.
FAU - Xu, Guangwu
AU  - Xu G
AD  - Vaccine and Gene Therapy Institute and Oregon National Primate Research Center
      (ONPRC), Oregon Health and Science University (OHSU), Beaverton, Oregon, USA.
FAU - Ford, Julia C
AU  - Ford JC
AD  - Vaccine and Gene Therapy Institute and Oregon National Primate Research Center
      (ONPRC), Oregon Health and Science University (OHSU), Beaverton, Oregon, USA.
FAU - Marshall, Emily E
AU  - Marshall EE
AD  - Vaccine and Gene Therapy Institute and Oregon National Primate Research Center
      (ONPRC), Oregon Health and Science University (OHSU), Beaverton, Oregon, USA.
FAU - Malouli, Daniel
AU  - Malouli D
AD  - Vaccine and Gene Therapy Institute and Oregon National Primate Research Center
      (ONPRC), Oregon Health and Science University (OHSU), Beaverton, Oregon, USA.
FAU - Gilbride, Roxanne M
AU  - Gilbride RM
AD  - Vaccine and Gene Therapy Institute and Oregon National Primate Research Center
      (ONPRC), Oregon Health and Science University (OHSU), Beaverton, Oregon, USA.
FAU - Hughes, Colette M
AU  - Hughes CM
AD  - Vaccine and Gene Therapy Institute and Oregon National Primate Research Center
      (ONPRC), Oregon Health and Science University (OHSU), Beaverton, Oregon, USA.
FAU - Ventura, Abigail B
AU  - Ventura AB
AD  - Vaccine and Gene Therapy Institute and Oregon National Primate Research Center
      (ONPRC), Oregon Health and Science University (OHSU), Beaverton, Oregon, USA.
FAU - Ainslie, Emily
AU  - Ainslie E
AD  - Vaccine and Gene Therapy Institute and Oregon National Primate Research Center
      (ONPRC), Oregon Health and Science University (OHSU), Beaverton, Oregon, USA.
FAU - Randall, Kurt T
AU  - Randall KT
AD  - Vaccine and Gene Therapy Institute and Oregon National Primate Research Center
      (ONPRC), Oregon Health and Science University (OHSU), Beaverton, Oregon, USA.
FAU - Selseth, Andrea N
AU  - Selseth AN
AD  - Vaccine and Gene Therapy Institute and Oregon National Primate Research Center
      (ONPRC), Oregon Health and Science University (OHSU), Beaverton, Oregon, USA.
FAU - Rundstrom, Parker
AU  - Rundstrom P
AD  - Vaccine and Gene Therapy Institute and Oregon National Primate Research Center
      (ONPRC), Oregon Health and Science University (OHSU), Beaverton, Oregon, USA.
FAU - Herlache, Lauren
AU  - Herlache L
AD  - Vaccine and Gene Therapy Institute and Oregon National Primate Research Center
      (ONPRC), Oregon Health and Science University (OHSU), Beaverton, Oregon, USA.
FAU - Lewis, Matthew S
AU  - Lewis MS
AD  - Vaccine and Gene Therapy Institute and Oregon National Primate Research Center
      (ONPRC), Oregon Health and Science University (OHSU), Beaverton, Oregon, USA.
FAU - Park, Haesun
AU  - Park H
AD  - Vaccine and Gene Therapy Institute and Oregon National Primate Research Center
      (ONPRC), Oregon Health and Science University (OHSU), Beaverton, Oregon, USA.
FAU - Planer, Shannon L
AU  - Planer SL
AD  - Vaccine and Gene Therapy Institute and Oregon National Primate Research Center
      (ONPRC), Oregon Health and Science University (OHSU), Beaverton, Oregon, USA.
FAU - Turner, John M
AU  - Turner JM
AD  - Vaccine and Gene Therapy Institute and Oregon National Primate Research Center
      (ONPRC), Oregon Health and Science University (OHSU), Beaverton, Oregon, USA.
FAU - Fischer, Miranda
AU  - Fischer M
AD  - Vaccine and Gene Therapy Institute and Oregon National Primate Research Center
      (ONPRC), Oregon Health and Science University (OHSU), Beaverton, Oregon, USA.
FAU - Armstrong, Christina
AU  - Armstrong C
AD  - Vaccine and Gene Therapy Institute and Oregon National Primate Research Center
      (ONPRC), Oregon Health and Science University (OHSU), Beaverton, Oregon, USA.
FAU - Zweig, Robert C
AU  - Zweig RC
AD  - Vaccine and Gene Therapy Institute and Oregon National Primate Research Center
      (ONPRC), Oregon Health and Science University (OHSU), Beaverton, Oregon, USA.
FAU - Valvo, Joseph
AU  - Valvo J
AD  - Center for Infectious Disease Research, Seattle, Washington, USA.
FAU - Braun, Jackie M
AU  - Braun JM
AD  - Center for Infectious Disease Research, Seattle, Washington, USA.
FAU - Shankar, Smitha
AU  - Shankar S
AD  - Center for Infectious Disease Research, Seattle, Washington, USA.
FAU - Lu, Lenette
AU  - Lu L
AD  - Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of
      Technology and Harvard University, Cambridge, Massachusetts, USA.
FAU - Sylwester, Andrew W
AU  - Sylwester AW
AD  - Vaccine and Gene Therapy Institute and Oregon National Primate Research Center
      (ONPRC), Oregon Health and Science University (OHSU), Beaverton, Oregon, USA.
FAU - Legasse, Alfred W
AU  - Legasse AW
AD  - Vaccine and Gene Therapy Institute and Oregon National Primate Research Center
      (ONPRC), Oregon Health and Science University (OHSU), Beaverton, Oregon, USA.
FAU - Messerle, Martin
AU  - Messerle M
AD  - Department of Virology, Hannover Medical School, Hannover, Germany.
FAU - Jarvis, Michael A
AU  - Jarvis MA
AD  - School of Biomedical and Healthcare Sciences, University of Plymouth, Devon, UK.
FAU - Amon, Lynn M
AU  - Amon LM
AD  - Center for Infectious Disease Research, Seattle, Washington, USA.
FAU - Aderem, Alan
AU  - Aderem A
AD  - Center for Infectious Disease Research, Seattle, Washington, USA.
FAU - Alter, Galit
AU  - Alter G
AD  - Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of
      Technology and Harvard University, Cambridge, Massachusetts, USA.
FAU - Laddy, Dominick J
AU  - Laddy DJ
AD  - Aeras, Rockville, Maryland, USA.
FAU - Stone, Michele
AU  - Stone M
AD  - Aeras, Rockville, Maryland, USA.
FAU - Bonavia, Aurelio
AU  - Bonavia A
AD  - Aeras, Rockville, Maryland, USA.
FAU - Evans, Thomas G
AU  - Evans TG
AD  - Aeras, Rockville, Maryland, USA.
FAU - Axthelm, Michael K
AU  - Axthelm MK
AUID- ORCID: http://orcid.org/0000-0002-1984-5906
AD  - Vaccine and Gene Therapy Institute and Oregon National Primate Research Center
      (ONPRC), Oregon Health and Science University (OHSU), Beaverton, Oregon, USA.
FAU - Fruh, Klaus
AU  - Fruh K
AD  - Vaccine and Gene Therapy Institute and Oregon National Primate Research Center
      (ONPRC), Oregon Health and Science University (OHSU), Beaverton, Oregon, USA.
FAU - Edlefsen, Paul T
AU  - Edlefsen PT
AD  - Statistical Center for HIV-AIDS Research and Prevention, Vaccine and Infectious
      Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington,
      USA.
FAU - Picker, Louis J
AU  - Picker LJ
AD  - Vaccine and Gene Therapy Institute and Oregon National Primate Research Center
      (ONPRC), Oregon Health and Science University (OHSU), Beaverton, Oregon, USA.
LA  - eng
PT  - Journal Article
DEP - 20180115
PL  - United States
TA  - Nat Med
JT  - Nature medicine
JID - 9502015
EDAT- 2018/01/16 06:00
MHDA- 2018/01/16 06:00
CRDT- 2018/01/16 06:00
PHST- 2017/09/01 00:00 [received]
PHST- 2017/12/15 00:00 [accepted]
PHST- 2018/01/16 06:00 [pubmed]
PHST- 2018/01/16 06:00 [medline]
PHST- 2018/01/16 06:00 [entrez]
AID - nm.4473 [pii]
AID - 10.1038/nm.4473 [doi]
PST - aheadofprint
SO  - Nat Med. 2018 Jan 15. pii: nm.4473. doi: 10.1038/nm.4473.

PMID- 29342139
OWN - NLM
STAT- In-Data-Review
LR  - 20180129
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 553
IP  - 7689
DP  - 2018 Jan 25
TI  - Structure and mutagenesis reveal essential capsid protein interactions for KSHV
      replication.
PG  - 521-525
LID - 10.1038/nature25438 [doi]
AB  - Kaposi's sarcoma-associated herpesvirus (KSHV) causes Kaposi's sarcoma, a cancer 
      that commonly affects patients with AIDS and which is endemic in sub-Saharan
      Africa. The KSHV capsid is highly pressurized by its double-stranded DNA genome, 
      as are the capsids of the eight other human herpesviruses. Capsid assembly and
      genome packaging of herpesviruses are prone to interruption and can therefore be 
      targeted for the structure-guided development of antiviral agents. However,
      herpesvirus capsids-comprising nearly 3,000 proteins and over 1,300 A in
      diameter-present a formidable challenge to atomic structure determination and
      functional mapping of molecular interactions. Here we report a 4.2 A resolution
      structure of the KSHV capsid, determined by electron-counting cryo-electron
      microscopy, and its atomic model, which contains 46 unique conformers of the
      major capsid protein (MCP), the smallest capsid protein (SCP) and the triplex
      proteins Tri1 and Tri2. Our structure and mutagenesis results reveal a groove in 
      the upper domain of the MCP that contains hydrophobic residues that interact with
      the SCP, which in turn crosslinks with neighbouring MCPs in the same hexon to
      stabilize the capsid. Multiple levels of MCP-MCP interaction-including six sets
      of stacked hairpins lining the hexon channel, disulfide bonds across channel and 
      buttress domains in neighbouring MCPs, and an interaction network forged by the
      N-lasso domain and secured by the dimerization domain-define a robust capsid that
      is resistant to the pressure exerted by the enclosed genome. The triplexes, each 
      composed of two Tri2 molecules and a Tri1 molecule, anchor to the capsid floor
      via a Tri1 N-anchor to plug holes in the MCP network and rivet the capsid floor. 
      These essential roles of the MCP N-lasso and Tri1 N-anchor are verified by
      serial-truncation mutageneses. Our proof-of-concept demonstration of the use of
      polypeptides that mimic the smallest capsid protein to inhibit KSHV lytic
      replication highlights the potential for exploiting the interaction hotspots
      revealed in our atomic structure to develop antiviral agents.
FAU - Dai, Xinghong
AU  - Dai X
AD  - Department of Microbiology, Immunology and Molecular Genetics, University of
      California, Los Angeles (UCLA), Los Angeles, California 90095, USA.
AD  - The California NanoSystems Institute (CNSI), University of California, Los
      Angeles (UCLA), Los Angeles, California 90095, USA.
AD  - Department of Molecular and Medical Pharmacology, University of California, Los
      Angeles (UCLA), Los Angeles, California 90095, USA.
FAU - Gong, Danyang
AU  - Gong D
AD  - Department of Molecular and Medical Pharmacology, University of California, Los
      Angeles (UCLA), Los Angeles, California 90095, USA.
FAU - Lim, Hanyoung
AU  - Lim H
AD  - Department of Microbiology, Immunology and Molecular Genetics, University of
      California, Los Angeles (UCLA), Los Angeles, California 90095, USA.
FAU - Jih, Jonathan
AU  - Jih J
AD  - Department of Microbiology, Immunology and Molecular Genetics, University of
      California, Los Angeles (UCLA), Los Angeles, California 90095, USA.
FAU - Wu, Ting-Ting
AU  - Wu TT
AD  - Department of Molecular and Medical Pharmacology, University of California, Los
      Angeles (UCLA), Los Angeles, California 90095, USA.
FAU - Sun, Ren
AU  - Sun R
AD  - The California NanoSystems Institute (CNSI), University of California, Los
      Angeles (UCLA), Los Angeles, California 90095, USA.
AD  - Department of Molecular and Medical Pharmacology, University of California, Los
      Angeles (UCLA), Los Angeles, California 90095, USA.
FAU - Zhou, Z Hong
AU  - Zhou ZH
AD  - Department of Microbiology, Immunology and Molecular Genetics, University of
      California, Los Angeles (UCLA), Los Angeles, California 90095, USA.
AD  - The California NanoSystems Institute (CNSI), University of California, Los
      Angeles (UCLA), Los Angeles, California 90095, USA.
LA  - eng
PT  - Journal Article
DEP - 20180117
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
EDAT- 2018/01/18 06:00
MHDA- 2018/01/18 06:00
CRDT- 2018/01/18 06:00
PHST- 2017/04/24 00:00 [received]
PHST- 2017/12/06 00:00 [accepted]
PHST- 2018/01/18 06:00 [pubmed]
PHST- 2018/01/18 06:00 [medline]
PHST- 2018/01/18 06:00 [entrez]
AID - nature25438 [pii]
AID - 10.1038/nature25438 [doi]
PST - ppublish
SO  - Nature. 2018 Jan 25;553(7689):521-525. doi: 10.1038/nature25438. Epub 2018 Jan
      17.

PMID- 29341834
OWN - NLM
STAT- Publisher
LR  - 20180117
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Linking)
DP  - 2018 Jan 17
TI  - Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone
      in Patients With Relapsed or Refractory Multiple Myeloma.
PG  - JCO2017765032
LID - 10.1200/JCO.2017.76.5032 [doi]
AB  - Purpose In the ASPIRE study of carfilzomib, lenalidomide, and dexamethasone (KRd)
      versus lenalidomide plus dexamethasone (Rd) in patients with relapsed or
      refractory multiple myeloma, progression-free survival was significantly improved
      in the carfilzomib group (hazard ratio, 0.69; two-sided P < .001). This
      prespecified analysis reports final overall survival (OS) data and updated safety
      results. Patients and Methods Adults with relapsed multiple myeloma (one to three
      prior lines of therapy) were eligible and randomly assigned at a one-to-one ratio
      to receive KRd or Rd in 28-day cycles until withdrawal of consent, disease
      progression, or occurrence of unacceptable toxicity. After 18 cycles, all
      patients received Rd only. Progression-free survival was the primary end point;
      OS was a key secondary end point. OS was compared between treatment arms using a 
      stratified log-rank test. Results Median OS was 48.3 months (95% CI, 42.4 to 52.8
      months) for KRd versus 40.4 months (95% CI, 33.6 to 44.4 months) for Rd (hazard
      ratio, 0.79; 95% CI, 0.67 to 0.95; one-sided P = .0045). In patients receiving
      one prior line of therapy, median OS was 11.4 months longer for KRd versus Rd; it
      was 6.5 months longer for KRd versus Rd among patients receiving >/= two prior
      lines of therapy. Rates of treatment discontinuation because of adverse events
      (AEs) were 19.9% (KRd) and 21.5% (Rd). Grade >/= 3 AE rates were 87.0% (KRd) and 
      83.3% (Rd). Selected grade >/= 3 AEs of interest (grouped terms; KRd v Rd)
      included acute renal failure (3.8% v 3.3%), cardiac failure (4.3% v 2.1%),
      ischemic heart disease (3.8% v 2.3%), hypertension (6.4% v 2.3%), hematopoietic
      thrombocytopenia (20.2% v 14.9%), and peripheral neuropathy (2.8% v 3.1%).
      Conclusion KRd demonstrated a statistically significant and clinically meaningful
      reduction in the risk of death versus Rd, improving survival by 7.9 months. The
      KRd efficacy advantage is most pronounced at first relapse.
FAU - Siegel, David S
AU  - Siegel DS
AD  - David S. Siegel, John Theurer Cancer Center, Hackensack University Medical
      Center, Hackensack, NJ; Meletios A. Dimopoulos, National and Kapodistrian
      University of Athens, Athens, Greece; Heinz Ludwig, Wilhelminen Cancer Research
      Institute, Wilhelminenspital, Vienna, Austria; Thierry Facon, Hopital Claude
      Huriez, Centre Hospitalier Regional Universitaire de Lille, Lille, France;
      Hartmut Goldschmidt, Heidelberg Medical University and National Center of Tumor
      Diseases, Heidelberg, Germany; Andrzej Jakubowiak, University of Chicago
      Medicine, Chicago, IL; Jesus San-Miguel, Clinica Universidad de Navarra-Centro de
      Investigacion Medica Aplicada, Instituto de Investigacion Sanitaria de Navarra,
      Centro de Investigacion Biomedica en Red de Cancer, Pamplona, Spain; Mihaela
      Obreja and Julie Blaedel, Amgen, Thousand Oaks, CA; and A. Keith Stewart, Mayo
      Clinic, Scottsdale, AZ.
FAU - Dimopoulos, Meletios A
AU  - Dimopoulos MA
AD  - David S. Siegel, John Theurer Cancer Center, Hackensack University Medical
      Center, Hackensack, NJ; Meletios A. Dimopoulos, National and Kapodistrian
      University of Athens, Athens, Greece; Heinz Ludwig, Wilhelminen Cancer Research
      Institute, Wilhelminenspital, Vienna, Austria; Thierry Facon, Hopital Claude
      Huriez, Centre Hospitalier Regional Universitaire de Lille, Lille, France;
      Hartmut Goldschmidt, Heidelberg Medical University and National Center of Tumor
      Diseases, Heidelberg, Germany; Andrzej Jakubowiak, University of Chicago
      Medicine, Chicago, IL; Jesus San-Miguel, Clinica Universidad de Navarra-Centro de
      Investigacion Medica Aplicada, Instituto de Investigacion Sanitaria de Navarra,
      Centro de Investigacion Biomedica en Red de Cancer, Pamplona, Spain; Mihaela
      Obreja and Julie Blaedel, Amgen, Thousand Oaks, CA; and A. Keith Stewart, Mayo
      Clinic, Scottsdale, AZ.
FAU - Ludwig, Heinz
AU  - Ludwig H
AD  - David S. Siegel, John Theurer Cancer Center, Hackensack University Medical
      Center, Hackensack, NJ; Meletios A. Dimopoulos, National and Kapodistrian
      University of Athens, Athens, Greece; Heinz Ludwig, Wilhelminen Cancer Research
      Institute, Wilhelminenspital, Vienna, Austria; Thierry Facon, Hopital Claude
      Huriez, Centre Hospitalier Regional Universitaire de Lille, Lille, France;
      Hartmut Goldschmidt, Heidelberg Medical University and National Center of Tumor
      Diseases, Heidelberg, Germany; Andrzej Jakubowiak, University of Chicago
      Medicine, Chicago, IL; Jesus San-Miguel, Clinica Universidad de Navarra-Centro de
      Investigacion Medica Aplicada, Instituto de Investigacion Sanitaria de Navarra,
      Centro de Investigacion Biomedica en Red de Cancer, Pamplona, Spain; Mihaela
      Obreja and Julie Blaedel, Amgen, Thousand Oaks, CA; and A. Keith Stewart, Mayo
      Clinic, Scottsdale, AZ.
FAU - Facon, Thierry
AU  - Facon T
AD  - David S. Siegel, John Theurer Cancer Center, Hackensack University Medical
      Center, Hackensack, NJ; Meletios A. Dimopoulos, National and Kapodistrian
      University of Athens, Athens, Greece; Heinz Ludwig, Wilhelminen Cancer Research
      Institute, Wilhelminenspital, Vienna, Austria; Thierry Facon, Hopital Claude
      Huriez, Centre Hospitalier Regional Universitaire de Lille, Lille, France;
      Hartmut Goldschmidt, Heidelberg Medical University and National Center of Tumor
      Diseases, Heidelberg, Germany; Andrzej Jakubowiak, University of Chicago
      Medicine, Chicago, IL; Jesus San-Miguel, Clinica Universidad de Navarra-Centro de
      Investigacion Medica Aplicada, Instituto de Investigacion Sanitaria de Navarra,
      Centro de Investigacion Biomedica en Red de Cancer, Pamplona, Spain; Mihaela
      Obreja and Julie Blaedel, Amgen, Thousand Oaks, CA; and A. Keith Stewart, Mayo
      Clinic, Scottsdale, AZ.
FAU - Goldschmidt, Hartmut
AU  - Goldschmidt H
AD  - David S. Siegel, John Theurer Cancer Center, Hackensack University Medical
      Center, Hackensack, NJ; Meletios A. Dimopoulos, National and Kapodistrian
      University of Athens, Athens, Greece; Heinz Ludwig, Wilhelminen Cancer Research
      Institute, Wilhelminenspital, Vienna, Austria; Thierry Facon, Hopital Claude
      Huriez, Centre Hospitalier Regional Universitaire de Lille, Lille, France;
      Hartmut Goldschmidt, Heidelberg Medical University and National Center of Tumor
      Diseases, Heidelberg, Germany; Andrzej Jakubowiak, University of Chicago
      Medicine, Chicago, IL; Jesus San-Miguel, Clinica Universidad de Navarra-Centro de
      Investigacion Medica Aplicada, Instituto de Investigacion Sanitaria de Navarra,
      Centro de Investigacion Biomedica en Red de Cancer, Pamplona, Spain; Mihaela
      Obreja and Julie Blaedel, Amgen, Thousand Oaks, CA; and A. Keith Stewart, Mayo
      Clinic, Scottsdale, AZ.
FAU - Jakubowiak, Andrzej
AU  - Jakubowiak A
AD  - David S. Siegel, John Theurer Cancer Center, Hackensack University Medical
      Center, Hackensack, NJ; Meletios A. Dimopoulos, National and Kapodistrian
      University of Athens, Athens, Greece; Heinz Ludwig, Wilhelminen Cancer Research
      Institute, Wilhelminenspital, Vienna, Austria; Thierry Facon, Hopital Claude
      Huriez, Centre Hospitalier Regional Universitaire de Lille, Lille, France;
      Hartmut Goldschmidt, Heidelberg Medical University and National Center of Tumor
      Diseases, Heidelberg, Germany; Andrzej Jakubowiak, University of Chicago
      Medicine, Chicago, IL; Jesus San-Miguel, Clinica Universidad de Navarra-Centro de
      Investigacion Medica Aplicada, Instituto de Investigacion Sanitaria de Navarra,
      Centro de Investigacion Biomedica en Red de Cancer, Pamplona, Spain; Mihaela
      Obreja and Julie Blaedel, Amgen, Thousand Oaks, CA; and A. Keith Stewart, Mayo
      Clinic, Scottsdale, AZ.
FAU - San-Miguel, Jesus
AU  - San-Miguel J
AD  - David S. Siegel, John Theurer Cancer Center, Hackensack University Medical
      Center, Hackensack, NJ; Meletios A. Dimopoulos, National and Kapodistrian
      University of Athens, Athens, Greece; Heinz Ludwig, Wilhelminen Cancer Research
      Institute, Wilhelminenspital, Vienna, Austria; Thierry Facon, Hopital Claude
      Huriez, Centre Hospitalier Regional Universitaire de Lille, Lille, France;
      Hartmut Goldschmidt, Heidelberg Medical University and National Center of Tumor
      Diseases, Heidelberg, Germany; Andrzej Jakubowiak, University of Chicago
      Medicine, Chicago, IL; Jesus San-Miguel, Clinica Universidad de Navarra-Centro de
      Investigacion Medica Aplicada, Instituto de Investigacion Sanitaria de Navarra,
      Centro de Investigacion Biomedica en Red de Cancer, Pamplona, Spain; Mihaela
      Obreja and Julie Blaedel, Amgen, Thousand Oaks, CA; and A. Keith Stewart, Mayo
      Clinic, Scottsdale, AZ.
FAU - Obreja, Mihaela
AU  - Obreja M
AD  - David S. Siegel, John Theurer Cancer Center, Hackensack University Medical
      Center, Hackensack, NJ; Meletios A. Dimopoulos, National and Kapodistrian
      University of Athens, Athens, Greece; Heinz Ludwig, Wilhelminen Cancer Research
      Institute, Wilhelminenspital, Vienna, Austria; Thierry Facon, Hopital Claude
      Huriez, Centre Hospitalier Regional Universitaire de Lille, Lille, France;
      Hartmut Goldschmidt, Heidelberg Medical University and National Center of Tumor
      Diseases, Heidelberg, Germany; Andrzej Jakubowiak, University of Chicago
      Medicine, Chicago, IL; Jesus San-Miguel, Clinica Universidad de Navarra-Centro de
      Investigacion Medica Aplicada, Instituto de Investigacion Sanitaria de Navarra,
      Centro de Investigacion Biomedica en Red de Cancer, Pamplona, Spain; Mihaela
      Obreja and Julie Blaedel, Amgen, Thousand Oaks, CA; and A. Keith Stewart, Mayo
      Clinic, Scottsdale, AZ.
FAU - Blaedel, Julie
AU  - Blaedel J
AD  - David S. Siegel, John Theurer Cancer Center, Hackensack University Medical
      Center, Hackensack, NJ; Meletios A. Dimopoulos, National and Kapodistrian
      University of Athens, Athens, Greece; Heinz Ludwig, Wilhelminen Cancer Research
      Institute, Wilhelminenspital, Vienna, Austria; Thierry Facon, Hopital Claude
      Huriez, Centre Hospitalier Regional Universitaire de Lille, Lille, France;
      Hartmut Goldschmidt, Heidelberg Medical University and National Center of Tumor
      Diseases, Heidelberg, Germany; Andrzej Jakubowiak, University of Chicago
      Medicine, Chicago, IL; Jesus San-Miguel, Clinica Universidad de Navarra-Centro de
      Investigacion Medica Aplicada, Instituto de Investigacion Sanitaria de Navarra,
      Centro de Investigacion Biomedica en Red de Cancer, Pamplona, Spain; Mihaela
      Obreja and Julie Blaedel, Amgen, Thousand Oaks, CA; and A. Keith Stewart, Mayo
      Clinic, Scottsdale, AZ.
FAU - Stewart, A Keith
AU  - Stewart AK
AD  - David S. Siegel, John Theurer Cancer Center, Hackensack University Medical
      Center, Hackensack, NJ; Meletios A. Dimopoulos, National and Kapodistrian
      University of Athens, Athens, Greece; Heinz Ludwig, Wilhelminen Cancer Research
      Institute, Wilhelminenspital, Vienna, Austria; Thierry Facon, Hopital Claude
      Huriez, Centre Hospitalier Regional Universitaire de Lille, Lille, France;
      Hartmut Goldschmidt, Heidelberg Medical University and National Center of Tumor
      Diseases, Heidelberg, Germany; Andrzej Jakubowiak, University of Chicago
      Medicine, Chicago, IL; Jesus San-Miguel, Clinica Universidad de Navarra-Centro de
      Investigacion Medica Aplicada, Instituto de Investigacion Sanitaria de Navarra,
      Centro de Investigacion Biomedica en Red de Cancer, Pamplona, Spain; Mihaela
      Obreja and Julie Blaedel, Amgen, Thousand Oaks, CA; and A. Keith Stewart, Mayo
      Clinic, Scottsdale, AZ.
LA  - eng
PT  - Journal Article
DEP - 20180117
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of
      Clinical Oncology
JID - 8309333
EDAT- 2018/01/18 06:00
MHDA- 2018/01/18 06:00
CRDT- 2018/01/18 06:00
PHST- 2018/01/18 06:00 [entrez]
PHST- 2018/01/18 06:00 [pubmed]
PHST- 2018/01/18 06:00 [medline]
AID - 10.1200/JCO.2017.76.5032 [doi]
PST - aheadofprint
SO  - J Clin Oncol. 2018 Jan 17:JCO2017765032. doi: 10.1200/JCO.2017.76.5032.

PMID- 29298116
OWN - NLM
STAT- MEDLINE
DCOM- 20180124
LR  - 20180124
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 378
IP  - 3
DP  - 2018 Jan 18
TI  - Somatic Activating KRAS Mutations in Arteriovenous Malformations of the Brain.
PG  - 250-261
LID - 10.1056/NEJMoa1709449 [doi]
AB  - BACKGROUND: Sporadic arteriovenous malformations of the brain, which are
      morphologically abnormal connections between arteries and veins in the brain
      vasculature, are a leading cause of hemorrhagic stroke in young adults and
      children. The genetic cause of this rare focal disorder is unknown. METHODS: We
      analyzed tissue and blood samples from patients with arteriovenous malformations 
      of the brain to detect somatic mutations. We performed exome DNA sequencing of
      tissue samples of arteriovenous malformations of the brain from 26 patients in
      the main study group and of paired blood samples from 17 of those patients. To
      confirm our findings, we performed droplet digital polymerase-chain-reaction
      (PCR) analysis of tissue samples from 39 patients in the main study group (21
      with matching blood samples) and from 33 patients in an independent validation
      group. We interrogated the downstream signaling pathways, changes in gene
      expression, and cellular phenotype that were induced by activating KRAS
      mutations, which we had discovered in tissue samples. RESULTS: We detected
      somatic activating KRAS mutations in tissue samples from 45 of the 72 patients
      and in none of the 21 paired blood samples. In endothelial cell-enriched cultures
      derived from arteriovenous malformations of the brain, we detected KRAS mutations
      and observed that expression of mutant KRAS (KRAS(G12V)) in endothelial cells in 
      vitro induced increased ERK (extracellular signal-regulated kinase) activity,
      increased expression of genes related to angiogenesis and Notch signaling, and
      enhanced migratory behavior. These processes were reversed by inhibition of MAPK 
      (mitogen-activated protein kinase)-ERK signaling. CONCLUSIONS: We identified
      activating KRAS mutations in the majority of tissue samples of arteriovenous
      malformations of the brain that we analyzed. We propose that these malformations 
      develop as a result of KRAS-induced activation of the MAPK-ERK signaling pathway 
      in brain endothelial cells. (Funded by the Swiss Cancer League and others.).
FAU - Nikolaev, Sergey I
AU  - Nikolaev SI
AD  - From the Department of Genetic Medicine and Development, University of Geneva
      Medical School (S.I.N., X.B., S.E.A.), Service of Genetic Medicine, University
      Hospitals of Geneva (S.I.N., S.E.A.), and iGE3, Institute of Genetics and
      Genomics of Geneva (S.E.A.) - all in Geneva; the Department of Fundamental
      Neurobiology, Krembil Research Institute (S.V., M.T., I.R.), Toronto General
      Hospital Research Institute (E.B., N.K., P.V.D., J.E.F.), the Department of
      Pathology (T.-R.K.), the Division of Neurosurgery, Department of Surgery (V.M.P.,
      T.K., H.A.-B., T.T., T.V., G.Z., M.T., I.R.), and the Joint Division of Medical
      Imaging, Department of Medical Imaging (V.M.P., T.K.), Toronto Western Hospital, 
      University Health Network, the Department of Laboratory Medicine and
      Pathobiology, University of Toronto (E.B., N.K., P.V.D., T.-R.K., J.E.F.), and
      the Heart and Stroke Richard Lewar Centre of Excellence in Cardiovascular
      Research (E.B., N.K., P.V.D., J.E.F.) - all in Toronto; the Department of
      Molecular Medicine, AIV Institute, University of Eastern Finland (S.J., B.R.J.,
      S.S., S.Y.-H., J.F.), and the Hemorrhagic Brain Pathology Research Group,
      Department of Neurosurgery and NeuroCenter (S.J., B.R.J., S.S., T.R., J.F.), and 
      the Department of Pathology (T.R.), Kuopio University Hospital - all in Kuopio,
      Finland; and the Cardiovascular Research Institute and the Department of
      Molecular Physiology and Biophysics, Baylor College of Medicine, Houston (A.M.H.,
      J.D.W.).
FAU - Vetiska, Sandra
AU  - Vetiska S
AD  - From the Department of Genetic Medicine and Development, University of Geneva
      Medical School (S.I.N., X.B., S.E.A.), Service of Genetic Medicine, University
      Hospitals of Geneva (S.I.N., S.E.A.), and iGE3, Institute of Genetics and
      Genomics of Geneva (S.E.A.) - all in Geneva; the Department of Fundamental
      Neurobiology, Krembil Research Institute (S.V., M.T., I.R.), Toronto General
      Hospital Research Institute (E.B., N.K., P.V.D., J.E.F.), the Department of
      Pathology (T.-R.K.), the Division of Neurosurgery, Department of Surgery (V.M.P.,
      T.K., H.A.-B., T.T., T.V., G.Z., M.T., I.R.), and the Joint Division of Medical
      Imaging, Department of Medical Imaging (V.M.P., T.K.), Toronto Western Hospital, 
      University Health Network, the Department of Laboratory Medicine and
      Pathobiology, University of Toronto (E.B., N.K., P.V.D., T.-R.K., J.E.F.), and
      the Heart and Stroke Richard Lewar Centre of Excellence in Cardiovascular
      Research (E.B., N.K., P.V.D., J.E.F.) - all in Toronto; the Department of
      Molecular Medicine, AIV Institute, University of Eastern Finland (S.J., B.R.J.,
      S.S., S.Y.-H., J.F.), and the Hemorrhagic Brain Pathology Research Group,
      Department of Neurosurgery and NeuroCenter (S.J., B.R.J., S.S., T.R., J.F.), and 
      the Department of Pathology (T.R.), Kuopio University Hospital - all in Kuopio,
      Finland; and the Cardiovascular Research Institute and the Department of
      Molecular Physiology and Biophysics, Baylor College of Medicine, Houston (A.M.H.,
      J.D.W.).
FAU - Bonilla, Ximena
AU  - Bonilla X
AD  - From the Department of Genetic Medicine and Development, University of Geneva
      Medical School (S.I.N., X.B., S.E.A.), Service of Genetic Medicine, University
      Hospitals of Geneva (S.I.N., S.E.A.), and iGE3, Institute of Genetics and
      Genomics of Geneva (S.E.A.) - all in Geneva; the Department of Fundamental
      Neurobiology, Krembil Research Institute (S.V., M.T., I.R.), Toronto General
      Hospital Research Institute (E.B., N.K., P.V.D., J.E.F.), the Department of
      Pathology (T.-R.K.), the Division of Neurosurgery, Department of Surgery (V.M.P.,
      T.K., H.A.-B., T.T., T.V., G.Z., M.T., I.R.), and the Joint Division of Medical
      Imaging, Department of Medical Imaging (V.M.P., T.K.), Toronto Western Hospital, 
      University Health Network, the Department of Laboratory Medicine and
      Pathobiology, University of Toronto (E.B., N.K., P.V.D., T.-R.K., J.E.F.), and
      the Heart and Stroke Richard Lewar Centre of Excellence in Cardiovascular
      Research (E.B., N.K., P.V.D., J.E.F.) - all in Toronto; the Department of
      Molecular Medicine, AIV Institute, University of Eastern Finland (S.J., B.R.J.,
      S.S., S.Y.-H., J.F.), and the Hemorrhagic Brain Pathology Research Group,
      Department of Neurosurgery and NeuroCenter (S.J., B.R.J., S.S., T.R., J.F.), and 
      the Department of Pathology (T.R.), Kuopio University Hospital - all in Kuopio,
      Finland; and the Cardiovascular Research Institute and the Department of
      Molecular Physiology and Biophysics, Baylor College of Medicine, Houston (A.M.H.,
      J.D.W.).
FAU - Boudreau, Emilie
AU  - Boudreau E
AD  - From the Department of Genetic Medicine and Development, University of Geneva
      Medical School (S.I.N., X.B., S.E.A.), Service of Genetic Medicine, University
      Hospitals of Geneva (S.I.N., S.E.A.), and iGE3, Institute of Genetics and
      Genomics of Geneva (S.E.A.) - all in Geneva; the Department of Fundamental
      Neurobiology, Krembil Research Institute (S.V., M.T., I.R.), Toronto General
      Hospital Research Institute (E.B., N.K., P.V.D., J.E.F.), the Department of
      Pathology (T.-R.K.), the Division of Neurosurgery, Department of Surgery (V.M.P.,
      T.K., H.A.-B., T.T., T.V., G.Z., M.T., I.R.), and the Joint Division of Medical
      Imaging, Department of Medical Imaging (V.M.P., T.K.), Toronto Western Hospital, 
      University Health Network, the Department of Laboratory Medicine and
      Pathobiology, University of Toronto (E.B., N.K., P.V.D., T.-R.K., J.E.F.), and
      the Heart and Stroke Richard Lewar Centre of Excellence in Cardiovascular
      Research (E.B., N.K., P.V.D., J.E.F.) - all in Toronto; the Department of
      Molecular Medicine, AIV Institute, University of Eastern Finland (S.J., B.R.J.,
      S.S., S.Y.-H., J.F.), and the Hemorrhagic Brain Pathology Research Group,
      Department of Neurosurgery and NeuroCenter (S.J., B.R.J., S.S., T.R., J.F.), and 
      the Department of Pathology (T.R.), Kuopio University Hospital - all in Kuopio,
      Finland; and the Cardiovascular Research Institute and the Department of
      Molecular Physiology and Biophysics, Baylor College of Medicine, Houston (A.M.H.,
      J.D.W.).
FAU - Jauhiainen, Suvi
AU  - Jauhiainen S
AD  - From the Department of Genetic Medicine and Development, University of Geneva
      Medical School (S.I.N., X.B., S.E.A.), Service of Genetic Medicine, University
      Hospitals of Geneva (S.I.N., S.E.A.), and iGE3, Institute of Genetics and
      Genomics of Geneva (S.E.A.) - all in Geneva; the Department of Fundamental
      Neurobiology, Krembil Research Institute (S.V., M.T., I.R.), Toronto General
      Hospital Research Institute (E.B., N.K., P.V.D., J.E.F.), the Department of
      Pathology (T.-R.K.), the Division of Neurosurgery, Department of Surgery (V.M.P.,
      T.K., H.A.-B., T.T., T.V., G.Z., M.T., I.R.), and the Joint Division of Medical
      Imaging, Department of Medical Imaging (V.M.P., T.K.), Toronto Western Hospital, 
      University Health Network, the Department of Laboratory Medicine and
      Pathobiology, University of Toronto (E.B., N.K., P.V.D., T.-R.K., J.E.F.), and
      the Heart and Stroke Richard Lewar Centre of Excellence in Cardiovascular
      Research (E.B., N.K., P.V.D., J.E.F.) - all in Toronto; the Department of
      Molecular Medicine, AIV Institute, University of Eastern Finland (S.J., B.R.J.,
      S.S., S.Y.-H., J.F.), and the Hemorrhagic Brain Pathology Research Group,
      Department of Neurosurgery and NeuroCenter (S.J., B.R.J., S.S., T.R., J.F.), and 
      the Department of Pathology (T.R.), Kuopio University Hospital - all in Kuopio,
      Finland; and the Cardiovascular Research Institute and the Department of
      Molecular Physiology and Biophysics, Baylor College of Medicine, Houston (A.M.H.,
      J.D.W.).
FAU - Rezai Jahromi, Behnam
AU  - Rezai Jahromi B
AD  - From the Department of Genetic Medicine and Development, University of Geneva
      Medical School (S.I.N., X.B., S.E.A.), Service of Genetic Medicine, University
      Hospitals of Geneva (S.I.N., S.E.A.), and iGE3, Institute of Genetics and
      Genomics of Geneva (S.E.A.) - all in Geneva; the Department of Fundamental
      Neurobiology, Krembil Research Institute (S.V., M.T., I.R.), Toronto General
      Hospital Research Institute (E.B., N.K., P.V.D., J.E.F.), the Department of
      Pathology (T.-R.K.), the Division of Neurosurgery, Department of Surgery (V.M.P.,
      T.K., H.A.-B., T.T., T.V., G.Z., M.T., I.R.), and the Joint Division of Medical
      Imaging, Department of Medical Imaging (V.M.P., T.K.), Toronto Western Hospital, 
      University Health Network, the Department of Laboratory Medicine and
      Pathobiology, University of Toronto (E.B., N.K., P.V.D., T.-R.K., J.E.F.), and
      the Heart and Stroke Richard Lewar Centre of Excellence in Cardiovascular
      Research (E.B., N.K., P.V.D., J.E.F.) - all in Toronto; the Department of
      Molecular Medicine, AIV Institute, University of Eastern Finland (S.J., B.R.J.,
      S.S., S.Y.-H., J.F.), and the Hemorrhagic Brain Pathology Research Group,
      Department of Neurosurgery and NeuroCenter (S.J., B.R.J., S.S., T.R., J.F.), and 
      the Department of Pathology (T.R.), Kuopio University Hospital - all in Kuopio,
      Finland; and the Cardiovascular Research Institute and the Department of
      Molecular Physiology and Biophysics, Baylor College of Medicine, Houston (A.M.H.,
      J.D.W.).
FAU - Khyzha, Nadiya
AU  - Khyzha N
AD  - From the Department of Genetic Medicine and Development, University of Geneva
      Medical School (S.I.N., X.B., S.E.A.), Service of Genetic Medicine, University
      Hospitals of Geneva (S.I.N., S.E.A.), and iGE3, Institute of Genetics and
      Genomics of Geneva (S.E.A.) - all in Geneva; the Department of Fundamental
      Neurobiology, Krembil Research Institute (S.V., M.T., I.R.), Toronto General
      Hospital Research Institute (E.B., N.K., P.V.D., J.E.F.), the Department of
      Pathology (T.-R.K.), the Division of Neurosurgery, Department of Surgery (V.M.P.,
      T.K., H.A.-B., T.T., T.V., G.Z., M.T., I.R.), and the Joint Division of Medical
      Imaging, Department of Medical Imaging (V.M.P., T.K.), Toronto Western Hospital, 
      University Health Network, the Department of Laboratory Medicine and
      Pathobiology, University of Toronto (E.B., N.K., P.V.D., T.-R.K., J.E.F.), and
      the Heart and Stroke Richard Lewar Centre of Excellence in Cardiovascular
      Research (E.B., N.K., P.V.D., J.E.F.) - all in Toronto; the Department of
      Molecular Medicine, AIV Institute, University of Eastern Finland (S.J., B.R.J.,
      S.S., S.Y.-H., J.F.), and the Hemorrhagic Brain Pathology Research Group,
      Department of Neurosurgery and NeuroCenter (S.J., B.R.J., S.S., T.R., J.F.), and 
      the Department of Pathology (T.R.), Kuopio University Hospital - all in Kuopio,
      Finland; and the Cardiovascular Research Institute and the Department of
      Molecular Physiology and Biophysics, Baylor College of Medicine, Houston (A.M.H.,
      J.D.W.).
FAU - DiStefano, Peter V
AU  - DiStefano PV
AD  - From the Department of Genetic Medicine and Development, University of Geneva
      Medical School (S.I.N., X.B., S.E.A.), Service of Genetic Medicine, University
      Hospitals of Geneva (S.I.N., S.E.A.), and iGE3, Institute of Genetics and
      Genomics of Geneva (S.E.A.) - all in Geneva; the Department of Fundamental
      Neurobiology, Krembil Research Institute (S.V., M.T., I.R.), Toronto General
      Hospital Research Institute (E.B., N.K., P.V.D., J.E.F.), the Department of
      Pathology (T.-R.K.), the Division of Neurosurgery, Department of Surgery (V.M.P.,
      T.K., H.A.-B., T.T., T.V., G.Z., M.T., I.R.), and the Joint Division of Medical
      Imaging, Department of Medical Imaging (V.M.P., T.K.), Toronto Western Hospital, 
      University Health Network, the Department of Laboratory Medicine and
      Pathobiology, University of Toronto (E.B., N.K., P.V.D., T.-R.K., J.E.F.), and
      the Heart and Stroke Richard Lewar Centre of Excellence in Cardiovascular
      Research (E.B., N.K., P.V.D., J.E.F.) - all in Toronto; the Department of
      Molecular Medicine, AIV Institute, University of Eastern Finland (S.J., B.R.J.,
      S.S., S.Y.-H., J.F.), and the Hemorrhagic Brain Pathology Research Group,
      Department of Neurosurgery and NeuroCenter (S.J., B.R.J., S.S., T.R., J.F.), and 
      the Department of Pathology (T.R.), Kuopio University Hospital - all in Kuopio,
      Finland; and the Cardiovascular Research Institute and the Department of
      Molecular Physiology and Biophysics, Baylor College of Medicine, Houston (A.M.H.,
      J.D.W.).
FAU - Suutarinen, Santeri
AU  - Suutarinen S
AD  - From the Department of Genetic Medicine and Development, University of Geneva
      Medical School (S.I.N., X.B., S.E.A.), Service of Genetic Medicine, University
      Hospitals of Geneva (S.I.N., S.E.A.), and iGE3, Institute of Genetics and
      Genomics of Geneva (S.E.A.) - all in Geneva; the Department of Fundamental
      Neurobiology, Krembil Research Institute (S.V., M.T., I.R.), Toronto General
      Hospital Research Institute (E.B., N.K., P.V.D., J.E.F.), the Department of
      Pathology (T.-R.K.), the Division of Neurosurgery, Department of Surgery (V.M.P.,
      T.K., H.A.-B., T.T., T.V., G.Z., M.T., I.R.), and the Joint Division of Medical
      Imaging, Department of Medical Imaging (V.M.P., T.K.), Toronto Western Hospital, 
      University Health Network, the Department of Laboratory Medicine and
      Pathobiology, University of Toronto (E.B., N.K., P.V.D., T.-R.K., J.E.F.), and
      the Heart and Stroke Richard Lewar Centre of Excellence in Cardiovascular
      Research (E.B., N.K., P.V.D., J.E.F.) - all in Toronto; the Department of
      Molecular Medicine, AIV Institute, University of Eastern Finland (S.J., B.R.J.,
      S.S., S.Y.-H., J.F.), and the Hemorrhagic Brain Pathology Research Group,
      Department of Neurosurgery and NeuroCenter (S.J., B.R.J., S.S., T.R., J.F.), and 
      the Department of Pathology (T.R.), Kuopio University Hospital - all in Kuopio,
      Finland; and the Cardiovascular Research Institute and the Department of
      Molecular Physiology and Biophysics, Baylor College of Medicine, Houston (A.M.H.,
      J.D.W.).
FAU - Kiehl, Tim-Rasmus
AU  - Kiehl TR
AD  - From the Department of Genetic Medicine and Development, University of Geneva
      Medical School (S.I.N., X.B., S.E.A.), Service of Genetic Medicine, University
      Hospitals of Geneva (S.I.N., S.E.A.), and iGE3, Institute of Genetics and
      Genomics of Geneva (S.E.A.) - all in Geneva; the Department of Fundamental
      Neurobiology, Krembil Research Institute (S.V., M.T., I.R.), Toronto General
      Hospital Research Institute (E.B., N.K., P.V.D., J.E.F.), the Department of
      Pathology (T.-R.K.), the Division of Neurosurgery, Department of Surgery (V.M.P.,
      T.K., H.A.-B., T.T., T.V., G.Z., M.T., I.R.), and the Joint Division of Medical
      Imaging, Department of Medical Imaging (V.M.P., T.K.), Toronto Western Hospital, 
      University Health Network, the Department of Laboratory Medicine and
      Pathobiology, University of Toronto (E.B., N.K., P.V.D., T.-R.K., J.E.F.), and
      the Heart and Stroke Richard Lewar Centre of Excellence in Cardiovascular
      Research (E.B., N.K., P.V.D., J.E.F.) - all in Toronto; the Department of
      Molecular Medicine, AIV Institute, University of Eastern Finland (S.J., B.R.J.,
      S.S., S.Y.-H., J.F.), and the Hemorrhagic Brain Pathology Research Group,
      Department of Neurosurgery and NeuroCenter (S.J., B.R.J., S.S., T.R., J.F.), and 
      the Department of Pathology (T.R.), Kuopio University Hospital - all in Kuopio,
      Finland; and the Cardiovascular Research Institute and the Department of
      Molecular Physiology and Biophysics, Baylor College of Medicine, Houston (A.M.H.,
      J.D.W.).
FAU - Mendes Pereira, Vitor
AU  - Mendes Pereira V
AD  - From the Department of Genetic Medicine and Development, University of Geneva
      Medical School (S.I.N., X.B., S.E.A.), Service of Genetic Medicine, University
      Hospitals of Geneva (S.I.N., S.E.A.), and iGE3, Institute of Genetics and
      Genomics of Geneva (S.E.A.) - all in Geneva; the Department of Fundamental
      Neurobiology, Krembil Research Institute (S.V., M.T., I.R.), Toronto General
      Hospital Research Institute (E.B., N.K., P.V.D., J.E.F.), the Department of
      Pathology (T.-R.K.), the Division of Neurosurgery, Department of Surgery (V.M.P.,
      T.K., H.A.-B., T.T., T.V., G.Z., M.T., I.R.), and the Joint Division of Medical
      Imaging, Department of Medical Imaging (V.M.P., T.K.), Toronto Western Hospital, 
      University Health Network, the Department of Laboratory Medicine and
      Pathobiology, University of Toronto (E.B., N.K., P.V.D., T.-R.K., J.E.F.), and
      the Heart and Stroke Richard Lewar Centre of Excellence in Cardiovascular
      Research (E.B., N.K., P.V.D., J.E.F.) - all in Toronto; the Department of
      Molecular Medicine, AIV Institute, University of Eastern Finland (S.J., B.R.J.,
      S.S., S.Y.-H., J.F.), and the Hemorrhagic Brain Pathology Research Group,
      Department of Neurosurgery and NeuroCenter (S.J., B.R.J., S.S., T.R., J.F.), and 
      the Department of Pathology (T.R.), Kuopio University Hospital - all in Kuopio,
      Finland; and the Cardiovascular Research Institute and the Department of
      Molecular Physiology and Biophysics, Baylor College of Medicine, Houston (A.M.H.,
      J.D.W.).
FAU - Herman, Alexander M
AU  - Herman AM
AD  - From the Department of Genetic Medicine and Development, University of Geneva
      Medical School (S.I.N., X.B., S.E.A.), Service of Genetic Medicine, University
      Hospitals of Geneva (S.I.N., S.E.A.), and iGE3, Institute of Genetics and
      Genomics of Geneva (S.E.A.) - all in Geneva; the Department of Fundamental
      Neurobiology, Krembil Research Institute (S.V., M.T., I.R.), Toronto General
      Hospital Research Institute (E.B., N.K., P.V.D., J.E.F.), the Department of
      Pathology (T.-R.K.), the Division of Neurosurgery, Department of Surgery (V.M.P.,
      T.K., H.A.-B., T.T., T.V., G.Z., M.T., I.R.), and the Joint Division of Medical
      Imaging, Department of Medical Imaging (V.M.P., T.K.), Toronto Western Hospital, 
      University Health Network, the Department of Laboratory Medicine and
      Pathobiology, University of Toronto (E.B., N.K., P.V.D., T.-R.K., J.E.F.), and
      the Heart and Stroke Richard Lewar Centre of Excellence in Cardiovascular
      Research (E.B., N.K., P.V.D., J.E.F.) - all in Toronto; the Department of
      Molecular Medicine, AIV Institute, University of Eastern Finland (S.J., B.R.J.,
      S.S., S.Y.-H., J.F.), and the Hemorrhagic Brain Pathology Research Group,
      Department of Neurosurgery and NeuroCenter (S.J., B.R.J., S.S., T.R., J.F.), and 
      the Department of Pathology (T.R.), Kuopio University Hospital - all in Kuopio,
      Finland; and the Cardiovascular Research Institute and the Department of
      Molecular Physiology and Biophysics, Baylor College of Medicine, Houston (A.M.H.,
      J.D.W.).
FAU - Krings, Timo
AU  - Krings T
AD  - From the Department of Genetic Medicine and Development, University of Geneva
      Medical School (S.I.N., X.B., S.E.A.), Service of Genetic Medicine, University
      Hospitals of Geneva (S.I.N., S.E.A.), and iGE3, Institute of Genetics and
      Genomics of Geneva (S.E.A.) - all in Geneva; the Department of Fundamental
      Neurobiology, Krembil Research Institute (S.V., M.T., I.R.), Toronto General
      Hospital Research Institute (E.B., N.K., P.V.D., J.E.F.), the Department of
      Pathology (T.-R.K.), the Division of Neurosurgery, Department of Surgery (V.M.P.,
      T.K., H.A.-B., T.T., T.V., G.Z., M.T., I.R.), and the Joint Division of Medical
      Imaging, Department of Medical Imaging (V.M.P., T.K.), Toronto Western Hospital, 
      University Health Network, the Department of Laboratory Medicine and
      Pathobiology, University of Toronto (E.B., N.K., P.V.D., T.-R.K., J.E.F.), and
      the Heart and Stroke Richard Lewar Centre of Excellence in Cardiovascular
      Research (E.B., N.K., P.V.D., J.E.F.) - all in Toronto; the Department of
      Molecular Medicine, AIV Institute, University of Eastern Finland (S.J., B.R.J.,
      S.S., S.Y.-H., J.F.), and the Hemorrhagic Brain Pathology Research Group,
      Department of Neurosurgery and NeuroCenter (S.J., B.R.J., S.S., T.R., J.F.), and 
      the Department of Pathology (T.R.), Kuopio University Hospital - all in Kuopio,
      Finland; and the Cardiovascular Research Institute and the Department of
      Molecular Physiology and Biophysics, Baylor College of Medicine, Houston (A.M.H.,
      J.D.W.).
FAU - Andrade-Barazarte, Hugo
AU  - Andrade-Barazarte H
AD  - From the Department of Genetic Medicine and Development, University of Geneva
      Medical School (S.I.N., X.B., S.E.A.), Service of Genetic Medicine, University
      Hospitals of Geneva (S.I.N., S.E.A.), and iGE3, Institute of Genetics and
      Genomics of Geneva (S.E.A.) - all in Geneva; the Department of Fundamental
      Neurobiology, Krembil Research Institute (S.V., M.T., I.R.), Toronto General
      Hospital Research Institute (E.B., N.K., P.V.D., J.E.F.), the Department of
      Pathology (T.-R.K.), the Division of Neurosurgery, Department of Surgery (V.M.P.,
      T.K., H.A.-B., T.T., T.V., G.Z., M.T., I.R.), and the Joint Division of Medical
      Imaging, Department of Medical Imaging (V.M.P., T.K.), Toronto Western Hospital, 
      University Health Network, the Department of Laboratory Medicine and
      Pathobiology, University of Toronto (E.B., N.K., P.V.D., T.-R.K., J.E.F.), and
      the Heart and Stroke Richard Lewar Centre of Excellence in Cardiovascular
      Research (E.B., N.K., P.V.D., J.E.F.) - all in Toronto; the Department of
      Molecular Medicine, AIV Institute, University of Eastern Finland (S.J., B.R.J.,
      S.S., S.Y.-H., J.F.), and the Hemorrhagic Brain Pathology Research Group,
      Department of Neurosurgery and NeuroCenter (S.J., B.R.J., S.S., T.R., J.F.), and 
      the Department of Pathology (T.R.), Kuopio University Hospital - all in Kuopio,
      Finland; and the Cardiovascular Research Institute and the Department of
      Molecular Physiology and Biophysics, Baylor College of Medicine, Houston (A.M.H.,
      J.D.W.).
FAU - Tung, Takyee
AU  - Tung T
AD  - From the Department of Genetic Medicine and Development, University of Geneva
      Medical School (S.I.N., X.B., S.E.A.), Service of Genetic Medicine, University
      Hospitals of Geneva (S.I.N., S.E.A.), and iGE3, Institute of Genetics and
      Genomics of Geneva (S.E.A.) - all in Geneva; the Department of Fundamental
      Neurobiology, Krembil Research Institute (S.V., M.T., I.R.), Toronto General
      Hospital Research Institute (E.B., N.K., P.V.D., J.E.F.), the Department of
      Pathology (T.-R.K.), the Division of Neurosurgery, Department of Surgery (V.M.P.,
      T.K., H.A.-B., T.T., T.V., G.Z., M.T., I.R.), and the Joint Division of Medical
      Imaging, Department of Medical Imaging (V.M.P., T.K.), Toronto Western Hospital, 
      University Health Network, the Department of Laboratory Medicine and
      Pathobiology, University of Toronto (E.B., N.K., P.V.D., T.-R.K., J.E.F.), and
      the Heart and Stroke Richard Lewar Centre of Excellence in Cardiovascular
      Research (E.B., N.K., P.V.D., J.E.F.) - all in Toronto; the Department of
      Molecular Medicine, AIV Institute, University of Eastern Finland (S.J., B.R.J.,
      S.S., S.Y.-H., J.F.), and the Hemorrhagic Brain Pathology Research Group,
      Department of Neurosurgery and NeuroCenter (S.J., B.R.J., S.S., T.R., J.F.), and 
      the Department of Pathology (T.R.), Kuopio University Hospital - all in Kuopio,
      Finland; and the Cardiovascular Research Institute and the Department of
      Molecular Physiology and Biophysics, Baylor College of Medicine, Houston (A.M.H.,
      J.D.W.).
FAU - Valiante, Taufik
AU  - Valiante T
AD  - From the Department of Genetic Medicine and Development, University of Geneva
      Medical School (S.I.N., X.B., S.E.A.), Service of Genetic Medicine, University
      Hospitals of Geneva (S.I.N., S.E.A.), and iGE3, Institute of Genetics and
      Genomics of Geneva (S.E.A.) - all in Geneva; the Department of Fundamental
      Neurobiology, Krembil Research Institute (S.V., M.T., I.R.), Toronto General
      Hospital Research Institute (E.B., N.K., P.V.D., J.E.F.), the Department of
      Pathology (T.-R.K.), the Division of Neurosurgery, Department of Surgery (V.M.P.,
      T.K., H.A.-B., T.T., T.V., G.Z., M.T., I.R.), and the Joint Division of Medical
      Imaging, Department of Medical Imaging (V.M.P., T.K.), Toronto Western Hospital, 
      University Health Network, the Department of Laboratory Medicine and
      Pathobiology, University of Toronto (E.B., N.K., P.V.D., T.-R.K., J.E.F.), and
      the Heart and Stroke Richard Lewar Centre of Excellence in Cardiovascular
      Research (E.B., N.K., P.V.D., J.E.F.) - all in Toronto; the Department of
      Molecular Medicine, AIV Institute, University of Eastern Finland (S.J., B.R.J.,
      S.S., S.Y.-H., J.F.), and the Hemorrhagic Brain Pathology Research Group,
      Department of Neurosurgery and NeuroCenter (S.J., B.R.J., S.S., T.R., J.F.), and 
      the Department of Pathology (T.R.), Kuopio University Hospital - all in Kuopio,
      Finland; and the Cardiovascular Research Institute and the Department of
      Molecular Physiology and Biophysics, Baylor College of Medicine, Houston (A.M.H.,
      J.D.W.).
FAU - Zadeh, Gelareh
AU  - Zadeh G
AD  - From the Department of Genetic Medicine and Development, University of Geneva
      Medical School (S.I.N., X.B., S.E.A.), Service of Genetic Medicine, University
      Hospitals of Geneva (S.I.N., S.E.A.), and iGE3, Institute of Genetics and
      Genomics of Geneva (S.E.A.) - all in Geneva; the Department of Fundamental
      Neurobiology, Krembil Research Institute (S.V., M.T., I.R.), Toronto General
      Hospital Research Institute (E.B., N.K., P.V.D., J.E.F.), the Department of
      Pathology (T.-R.K.), the Division of Neurosurgery, Department of Surgery (V.M.P.,
      T.K., H.A.-B., T.T., T.V., G.Z., M.T., I.R.), and the Joint Division of Medical
      Imaging, Department of Medical Imaging (V.M.P., T.K.), Toronto Western Hospital, 
      University Health Network, the Department of Laboratory Medicine and
      Pathobiology, University of Toronto (E.B., N.K., P.V.D., T.-R.K., J.E.F.), and
      the Heart and Stroke Richard Lewar Centre of Excellence in Cardiovascular
      Research (E.B., N.K., P.V.D., J.E.F.) - all in Toronto; the Department of
      Molecular Medicine, AIV Institute, University of Eastern Finland (S.J., B.R.J.,
      S.S., S.Y.-H., J.F.), and the Hemorrhagic Brain Pathology Research Group,
      Department of Neurosurgery and NeuroCenter (S.J., B.R.J., S.S., T.R., J.F.), and 
      the Department of Pathology (T.R.), Kuopio University Hospital - all in Kuopio,
      Finland; and the Cardiovascular Research Institute and the Department of
      Molecular Physiology and Biophysics, Baylor College of Medicine, Houston (A.M.H.,
      J.D.W.).
FAU - Tymianski, Mike
AU  - Tymianski M
AD  - From the Department of Genetic Medicine and Development, University of Geneva
      Medical School (S.I.N., X.B., S.E.A.), Service of Genetic Medicine, University
      Hospitals of Geneva (S.I.N., S.E.A.), and iGE3, Institute of Genetics and
      Genomics of Geneva (S.E.A.) - all in Geneva; the Department of Fundamental
      Neurobiology, Krembil Research Institute (S.V., M.T., I.R.), Toronto General
      Hospital Research Institute (E.B., N.K., P.V.D., J.E.F.), the Department of
      Pathology (T.-R.K.), the Division of Neurosurgery, Department of Surgery (V.M.P.,
      T.K., H.A.-B., T.T., T.V., G.Z., M.T., I.R.), and the Joint Division of Medical
      Imaging, Department of Medical Imaging (V.M.P., T.K.), Toronto Western Hospital, 
      University Health Network, the Department of Laboratory Medicine and
      Pathobiology, University of Toronto (E.B., N.K., P.V.D., T.-R.K., J.E.F.), and
      the Heart and Stroke Richard Lewar Centre of Excellence in Cardiovascular
      Research (E.B., N.K., P.V.D., J.E.F.) - all in Toronto; the Department of
      Molecular Medicine, AIV Institute, University of Eastern Finland (S.J., B.R.J.,
      S.S., S.Y.-H., J.F.), and the Hemorrhagic Brain Pathology Research Group,
      Department of Neurosurgery and NeuroCenter (S.J., B.R.J., S.S., T.R., J.F.), and 
      the Department of Pathology (T.R.), Kuopio University Hospital - all in Kuopio,
      Finland; and the Cardiovascular Research Institute and the Department of
      Molecular Physiology and Biophysics, Baylor College of Medicine, Houston (A.M.H.,
      J.D.W.).
FAU - Rauramaa, Tuomas
AU  - Rauramaa T
AD  - From the Department of Genetic Medicine and Development, University of Geneva
      Medical School (S.I.N., X.B., S.E.A.), Service of Genetic Medicine, University
      Hospitals of Geneva (S.I.N., S.E.A.), and iGE3, Institute of Genetics and
      Genomics of Geneva (S.E.A.) - all in Geneva; the Department of Fundamental
      Neurobiology, Krembil Research Institute (S.V., M.T., I.R.), Toronto General
      Hospital Research Institute (E.B., N.K., P.V.D., J.E.F.), the Department of
      Pathology (T.-R.K.), the Division of Neurosurgery, Department of Surgery (V.M.P.,
      T.K., H.A.-B., T.T., T.V., G.Z., M.T., I.R.), and the Joint Division of Medical
      Imaging, Department of Medical Imaging (V.M.P., T.K.), Toronto Western Hospital, 
      University Health Network, the Department of Laboratory Medicine and
      Pathobiology, University of Toronto (E.B., N.K., P.V.D., T.-R.K., J.E.F.), and
      the Heart and Stroke Richard Lewar Centre of Excellence in Cardiovascular
      Research (E.B., N.K., P.V.D., J.E.F.) - all in Toronto; the Department of
      Molecular Medicine, AIV Institute, University of Eastern Finland (S.J., B.R.J.,
      S.S., S.Y.-H., J.F.), and the Hemorrhagic Brain Pathology Research Group,
      Department of Neurosurgery and NeuroCenter (S.J., B.R.J., S.S., T.R., J.F.), and 
      the Department of Pathology (T.R.), Kuopio University Hospital - all in Kuopio,
      Finland; and the Cardiovascular Research Institute and the Department of
      Molecular Physiology and Biophysics, Baylor College of Medicine, Houston (A.M.H.,
      J.D.W.).
FAU - Yla-Herttuala, Seppo
AU  - Yla-Herttuala S
AD  - From the Department of Genetic Medicine and Development, University of Geneva
      Medical School (S.I.N., X.B., S.E.A.), Service of Genetic Medicine, University
      Hospitals of Geneva (S.I.N., S.E.A.), and iGE3, Institute of Genetics and
      Genomics of Geneva (S.E.A.) - all in Geneva; the Department of Fundamental
      Neurobiology, Krembil Research Institute (S.V., M.T., I.R.), Toronto General
      Hospital Research Institute (E.B., N.K., P.V.D., J.E.F.), the Department of
      Pathology (T.-R.K.), the Division of Neurosurgery, Department of Surgery (V.M.P.,
      T.K., H.A.-B., T.T., T.V., G.Z., M.T., I.R.), and the Joint Division of Medical
      Imaging, Department of Medical Imaging (V.M.P., T.K.), Toronto Western Hospital, 
      University Health Network, the Department of Laboratory Medicine and
      Pathobiology, University of Toronto (E.B., N.K., P.V.D., T.-R.K., J.E.F.), and
      the Heart and Stroke Richard Lewar Centre of Excellence in Cardiovascular
      Research (E.B., N.K., P.V.D., J.E.F.) - all in Toronto; the Department of
      Molecular Medicine, AIV Institute, University of Eastern Finland (S.J., B.R.J.,
      S.S., S.Y.-H., J.F.), and the Hemorrhagic Brain Pathology Research Group,
      Department of Neurosurgery and NeuroCenter (S.J., B.R.J., S.S., T.R., J.F.), and 
      the Department of Pathology (T.R.), Kuopio University Hospital - all in Kuopio,
      Finland; and the Cardiovascular Research Institute and the Department of
      Molecular Physiology and Biophysics, Baylor College of Medicine, Houston (A.M.H.,
      J.D.W.).
FAU - Wythe, Joshua D
AU  - Wythe JD
AD  - From the Department of Genetic Medicine and Development, University of Geneva
      Medical School (S.I.N., X.B., S.E.A.), Service of Genetic Medicine, University
      Hospitals of Geneva (S.I.N., S.E.A.), and iGE3, Institute of Genetics and
      Genomics of Geneva (S.E.A.) - all in Geneva; the Department of Fundamental
      Neurobiology, Krembil Research Institute (S.V., M.T., I.R.), Toronto General
      Hospital Research Institute (E.B., N.K., P.V.D., J.E.F.), the Department of
      Pathology (T.-R.K.), the Division of Neurosurgery, Department of Surgery (V.M.P.,
      T.K., H.A.-B., T.T., T.V., G.Z., M.T., I.R.), and the Joint Division of Medical
      Imaging, Department of Medical Imaging (V.M.P., T.K.), Toronto Western Hospital, 
      University Health Network, the Department of Laboratory Medicine and
      Pathobiology, University of Toronto (E.B., N.K., P.V.D., T.-R.K., J.E.F.), and
      the Heart and Stroke Richard Lewar Centre of Excellence in Cardiovascular
      Research (E.B., N.K., P.V.D., J.E.F.) - all in Toronto; the Department of
      Molecular Medicine, AIV Institute, University of Eastern Finland (S.J., B.R.J.,
      S.S., S.Y.-H., J.F.), and the Hemorrhagic Brain Pathology Research Group,
      Department of Neurosurgery and NeuroCenter (S.J., B.R.J., S.S., T.R., J.F.), and 
      the Department of Pathology (T.R.), Kuopio University Hospital - all in Kuopio,
      Finland; and the Cardiovascular Research Institute and the Department of
      Molecular Physiology and Biophysics, Baylor College of Medicine, Houston (A.M.H.,
      J.D.W.).
FAU - Antonarakis, Stylianos E
AU  - Antonarakis SE
AD  - From the Department of Genetic Medicine and Development, University of Geneva
      Medical School (S.I.N., X.B., S.E.A.), Service of Genetic Medicine, University
      Hospitals of Geneva (S.I.N., S.E.A.), and iGE3, Institute of Genetics and
      Genomics of Geneva (S.E.A.) - all in Geneva; the Department of Fundamental
      Neurobiology, Krembil Research Institute (S.V., M.T., I.R.), Toronto General
      Hospital Research Institute (E.B., N.K., P.V.D., J.E.F.), the Department of
      Pathology (T.-R.K.), the Division of Neurosurgery, Department of Surgery (V.M.P.,
      T.K., H.A.-B., T.T., T.V., G.Z., M.T., I.R.), and the Joint Division of Medical
      Imaging, Department of Medical Imaging (V.M.P., T.K.), Toronto Western Hospital, 
      University Health Network, the Department of Laboratory Medicine and
      Pathobiology, University of Toronto (E.B., N.K., P.V.D., T.-R.K., J.E.F.), and
      the Heart and Stroke Richard Lewar Centre of Excellence in Cardiovascular
      Research (E.B., N.K., P.V.D., J.E.F.) - all in Toronto; the Department of
      Molecular Medicine, AIV Institute, University of Eastern Finland (S.J., B.R.J.,
      S.S., S.Y.-H., J.F.), and the Hemorrhagic Brain Pathology Research Group,
      Department of Neurosurgery and NeuroCenter (S.J., B.R.J., S.S., T.R., J.F.), and 
      the Department of Pathology (T.R.), Kuopio University Hospital - all in Kuopio,
      Finland; and the Cardiovascular Research Institute and the Department of
      Molecular Physiology and Biophysics, Baylor College of Medicine, Houston (A.M.H.,
      J.D.W.).
FAU - Frosen, Juhana
AU  - Frosen J
AD  - From the Department of Genetic Medicine and Development, University of Geneva
      Medical School (S.I.N., X.B., S.E.A.), Service of Genetic Medicine, University
      Hospitals of Geneva (S.I.N., S.E.A.), and iGE3, Institute of Genetics and
      Genomics of Geneva (S.E.A.) - all in Geneva; the Department of Fundamental
      Neurobiology, Krembil Research Institute (S.V., M.T., I.R.), Toronto General
      Hospital Research Institute (E.B., N.K., P.V.D., J.E.F.), the Department of
      Pathology (T.-R.K.), the Division of Neurosurgery, Department of Surgery (V.M.P.,
      T.K., H.A.-B., T.T., T.V., G.Z., M.T., I.R.), and the Joint Division of Medical
      Imaging, Department of Medical Imaging (V.M.P., T.K.), Toronto Western Hospital, 
      University Health Network, the Department of Laboratory Medicine and
      Pathobiology, University of Toronto (E.B., N.K., P.V.D., T.-R.K., J.E.F.), and
      the Heart and Stroke Richard Lewar Centre of Excellence in Cardiovascular
      Research (E.B., N.K., P.V.D., J.E.F.) - all in Toronto; the Department of
      Molecular Medicine, AIV Institute, University of Eastern Finland (S.J., B.R.J.,
      S.S., S.Y.-H., J.F.), and the Hemorrhagic Brain Pathology Research Group,
      Department of Neurosurgery and NeuroCenter (S.J., B.R.J., S.S., T.R., J.F.), and 
      the Department of Pathology (T.R.), Kuopio University Hospital - all in Kuopio,
      Finland; and the Cardiovascular Research Institute and the Department of
      Molecular Physiology and Biophysics, Baylor College of Medicine, Houston (A.M.H.,
      J.D.W.).
FAU - Fish, Jason E
AU  - Fish JE
AD  - From the Department of Genetic Medicine and Development, University of Geneva
      Medical School (S.I.N., X.B., S.E.A.), Service of Genetic Medicine, University
      Hospitals of Geneva (S.I.N., S.E.A.), and iGE3, Institute of Genetics and
      Genomics of Geneva (S.E.A.) - all in Geneva; the Department of Fundamental
      Neurobiology, Krembil Research Institute (S.V., M.T., I.R.), Toronto General
      Hospital Research Institute (E.B., N.K., P.V.D., J.E.F.), the Department of
      Pathology (T.-R.K.), the Division of Neurosurgery, Department of Surgery (V.M.P.,
      T.K., H.A.-B., T.T., T.V., G.Z., M.T., I.R.), and the Joint Division of Medical
      Imaging, Department of Medical Imaging (V.M.P., T.K.), Toronto Western Hospital, 
      University Health Network, the Department of Laboratory Medicine and
      Pathobiology, University of Toronto (E.B., N.K., P.V.D., T.-R.K., J.E.F.), and
      the Heart and Stroke Richard Lewar Centre of Excellence in Cardiovascular
      Research (E.B., N.K., P.V.D., J.E.F.) - all in Toronto; the Department of
      Molecular Medicine, AIV Institute, University of Eastern Finland (S.J., B.R.J.,
      S.S., S.Y.-H., J.F.), and the Hemorrhagic Brain Pathology Research Group,
      Department of Neurosurgery and NeuroCenter (S.J., B.R.J., S.S., T.R., J.F.), and 
      the Department of Pathology (T.R.), Kuopio University Hospital - all in Kuopio,
      Finland; and the Cardiovascular Research Institute and the Department of
      Molecular Physiology and Biophysics, Baylor College of Medicine, Houston (A.M.H.,
      J.D.W.).
FAU - Radovanovic, Ivan
AU  - Radovanovic I
AD  - From the Department of Genetic Medicine and Development, University of Geneva
      Medical School (S.I.N., X.B., S.E.A.), Service of Genetic Medicine, University
      Hospitals of Geneva (S.I.N., S.E.A.), and iGE3, Institute of Genetics and
      Genomics of Geneva (S.E.A.) - all in Geneva; the Department of Fundamental
      Neurobiology, Krembil Research Institute (S.V., M.T., I.R.), Toronto General
      Hospital Research Institute (E.B., N.K., P.V.D., J.E.F.), the Department of
      Pathology (T.-R.K.), the Division of Neurosurgery, Department of Surgery (V.M.P.,
      T.K., H.A.-B., T.T., T.V., G.Z., M.T., I.R.), and the Joint Division of Medical
      Imaging, Department of Medical Imaging (V.M.P., T.K.), Toronto Western Hospital, 
      University Health Network, the Department of Laboratory Medicine and
      Pathobiology, University of Toronto (E.B., N.K., P.V.D., T.-R.K., J.E.F.), and
      the Heart and Stroke Richard Lewar Centre of Excellence in Cardiovascular
      Research (E.B., N.K., P.V.D., J.E.F.) - all in Toronto; the Department of
      Molecular Medicine, AIV Institute, University of Eastern Finland (S.J., B.R.J.,
      S.S., S.Y.-H., J.F.), and the Hemorrhagic Brain Pathology Research Group,
      Department of Neurosurgery and NeuroCenter (S.J., B.R.J., S.S., T.R., J.F.), and 
      the Department of Pathology (T.R.), Kuopio University Hospital - all in Kuopio,
      Finland; and the Cardiovascular Research Institute and the Department of
      Molecular Physiology and Biophysics, Baylor College of Medicine, Houston (A.M.H.,
      J.D.W.).
LA  - eng
GR  - T32 HL007676/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20180103
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (KRAS protein, human)
RN  - EC 2.7.11.25 (MAP Kinase Kinase Kinases)
RN  - EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras))
SB  - AIM
SB  - IM
MH  - Adult
MH  - Cells, Cultured
MH  - DNA Mutational Analysis
MH  - Exome
MH  - Gene Expression
MH  - Human Umbilical Vein Endothelial Cells/metabolism
MH  - Humans
MH  - Intracranial Arteriovenous Malformations/etiology/*genetics/pathology
MH  - MAP Kinase Kinase Kinases/metabolism
MH  - MAP Kinase Signaling System
MH  - *Mutation
MH  - Phosphorylation
MH  - Proto-Oncogene Proteins p21(ras)/*genetics/metabolism
EDAT- 2018/01/04 06:00
MHDA- 2018/01/25 06:00
CRDT- 2018/01/04 06:00
PHST- 2018/01/04 06:00 [pubmed]
PHST- 2018/01/25 06:00 [medline]
PHST- 2018/01/04 06:00 [entrez]
AID - 10.1056/NEJMoa1709449 [doi]
AID - 10.1056/NEJMoa1709449 [pii]
PST - ppublish
SO  - N Engl J Med. 2018 Jan 18;378(3):250-261. doi: 10.1056/NEJMoa1709449. Epub 2018
      Jan 3.

PMID- 29357394
OWN - NLM
STAT- Publisher
LR  - 20180122
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Linking)
DP  - 2018 Jan 23
TI  - Associations Between Marijuana Use and Cardiovascular Risk Factors and Outcomes: 
      A Systematic Review.
LID - 10.7326/M17-1548 [doi]
AB  - Background: Marijuana use is increasing in the United States, and its effect on
      cardiovascular health is unknown. Purpose: To review harms and benefits of
      marijuana use in relation to cardiovascular risk factors and clinical outcomes.
      Data Sources: PubMed, MEDLINE, EMBASE, PsycINFO, and the Cochrane Library between
      1 January 1975 and 30 September 2017. Study Selection: Observational studies that
      were published in English, enrolled adults using any form of marijuana, and
      reported on vascular risk factors (hyperglycemia, diabetes, dyslipidemia, and
      obesity) or on outcomes (stroke, myocardial infarction, cardiovascular mortality,
      and all-cause mortality in cardiovascular cohorts). Data Extraction: Study
      characteristics and quality were assessed by 4 reviewers independently; strength 
      of evidence for each outcome was graded by consensus. Data Synthesis: 13 and 11
      studies examined associations between marijuana use and cardiovascular risk
      factors and clinical outcomes, respectively. Although 6 studies suggested a
      metabolic benefit from marijuana use, they were based on cross-sectional designs 
      and were not supported by prospective studies. Evidence examining the effect of
      marijuana on diabetes, dyslipidemia, acute myocardial infarction, stroke, or
      cardiovascular and all-cause mortality was insufficient. Although the current
      literature includes several long-term prospective studies, they are limited by
      recall bias, inadequate exposure assessment, minimal marijuana exposure, and a
      predominance of low-risk cohorts. Limitation: Poor- or moderate-quality data,
      inadequate assessment of marijuana exposure and minimal exposure in the
      populations studied, and variation in study design. Conclusion: Evidence
      examining the effect of marijuana on cardiovascular risk factors and outcomes,
      including stroke and myocardial infarction, is insufficient. Primary Funding
      Source: National Heart, Lung, and Blood Institute. (PROSPERO: CRD42016051297).
FAU - Ravi, Divya
AU  - Ravi D
AD  - From The Wright Center for Graduate Medical Education, Scranton, Pennsylvania;
      University of California, San Francisco, and San Francisco Veterans Affairs
      Medical Center, San Francisco, California; Memorial Sloan Kettering Cancer
      Center, New York, New York; and University of Michigan, Ann Arbor, Michigan.
FAU - Ghasemiesfe, Mehrnaz
AU  - Ghasemiesfe M
AD  - From The Wright Center for Graduate Medical Education, Scranton, Pennsylvania;
      University of California, San Francisco, and San Francisco Veterans Affairs
      Medical Center, San Francisco, California; Memorial Sloan Kettering Cancer
      Center, New York, New York; and University of Michigan, Ann Arbor, Michigan.
FAU - Korenstein, Deborah
AU  - Korenstein D
AD  - From The Wright Center for Graduate Medical Education, Scranton, Pennsylvania;
      University of California, San Francisco, and San Francisco Veterans Affairs
      Medical Center, San Francisco, California; Memorial Sloan Kettering Cancer
      Center, New York, New York; and University of Michigan, Ann Arbor, Michigan.
FAU - Cascino, Thomas
AU  - Cascino T
AD  - From The Wright Center for Graduate Medical Education, Scranton, Pennsylvania;
      University of California, San Francisco, and San Francisco Veterans Affairs
      Medical Center, San Francisco, California; Memorial Sloan Kettering Cancer
      Center, New York, New York; and University of Michigan, Ann Arbor, Michigan.
FAU - Keyhani, Salomeh
AU  - Keyhani S
AD  - From The Wright Center for Graduate Medical Education, Scranton, Pennsylvania;
      University of California, San Francisco, and San Francisco Veterans Affairs
      Medical Center, San Francisco, California; Memorial Sloan Kettering Cancer
      Center, New York, New York; and University of Michigan, Ann Arbor, Michigan.
LA  - eng
PT  - Journal Article
DEP - 20180123
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
EDAT- 2018/01/23 06:00
MHDA- 2018/01/23 06:00
CRDT- 2018/01/23 06:00
PHST- 2018/01/23 06:00 [entrez]
PHST- 2018/01/23 06:00 [pubmed]
PHST- 2018/01/23 06:00 [medline]
AID - 2670319 [pii]
AID - 10.7326/M17-1548 [doi]
PST - aheadofprint
SO  - Ann Intern Med. 2018 Jan 23. pii: 2670319. doi: 10.7326/M17-1548.

PMID- 29315334
OWN - NLM
STAT- In-Data-Review
LR  - 20180129
IS  - 1549-1676 (Electronic)
IS  - 1549-1277 (Linking)
VI  - 15
IP  - 1
DP  - 2018 Jan
TI  - Immune-related genetic enrichment in frontotemporal dementia: An analysis of
      genome-wide association studies.
PG  - e1002487
LID - 10.1371/journal.pmed.1002487 [doi]
AB  - BACKGROUND: Converging evidence suggests that immune-mediated dysfunction plays
      an important role in the pathogenesis of frontotemporal dementia (FTD). Although 
      genetic studies have shown that immune-associated loci are associated with
      increased FTD risk, a systematic investigation of genetic overlap between
      immune-mediated diseases and the spectrum of FTD-related disorders has not been
      performed. METHODS AND FINDINGS: Using large genome-wide association studies
      (GWASs) (total n = 192,886 cases and controls) and recently developed tools to
      quantify genetic overlap/pleiotropy, we systematically identified single
      nucleotide polymorphisms (SNPs) jointly associated with FTD-related
      disorders-namely, FTD, corticobasal degeneration (CBD), progressive supranuclear 
      palsy (PSP), and amyotrophic lateral sclerosis (ALS)-and 1 or more
      immune-mediated diseases including Crohn disease, ulcerative colitis (UC),
      rheumatoid arthritis (RA), type 1 diabetes (T1D), celiac disease (CeD), and
      psoriasis. We found up to 270-fold genetic enrichment between FTD and RA, up to
      160-fold genetic enrichment between FTD and UC, up to 180-fold genetic enrichment
      between FTD and T1D, and up to 175-fold genetic enrichment between FTD and CeD.
      In contrast, for CBD and PSP, only 1 of the 6 immune-mediated diseases produced
      genetic enrichment comparable to that seen for FTD, with up to 150-fold genetic
      enrichment between CBD and CeD and up to 180-fold enrichment between PSP and RA. 
      Further, we found minimal enrichment between ALS and the immune-mediated diseases
      tested, with the highest levels of enrichment between ALS and RA (up to 20-fold).
      For FTD, at a conjunction false discovery rate < 0.05 and after excluding SNPs in
      linkage disequilibrium, we found that 8 of the 15 identified loci mapped to the
      human leukocyte antigen (HLA) region on Chromosome (Chr) 6. We also found novel
      candidate FTD susceptibility loci within LRRK2 (leucine rich repeat kinase 2),
      TBKBP1 (TBK1 binding protein 1), and PGBD5 (piggyBac transposable element derived
      5). Functionally, we found that the expression of FTD-immune pleiotropic genes
      (particularly within the HLA region) is altered in postmortem brain tissue from
      patients with FTD and is enriched in microglia/macrophages compared to other
      central nervous system cell types. The main study limitation is that the results 
      represent only clinically diagnosed individuals. Also, given the complex
      interconnectedness of the HLA region, we were not able to define the specific
      gene or genes on Chr 6 responsible for our pleiotropic signal. CONCLUSIONS: We
      show immune-mediated genetic enrichment specifically in FTD, particularly within 
      the HLA region. Our genetic results suggest that for a subset of patients, immune
      dysfunction may contribute to FTD risk. These findings have potential
      implications for clinical trials targeting immune dysfunction in patients with
      FTD.
FAU - Broce, Iris
AU  - Broce I
AUID- ORCID: 0000-0003-4932-1430
AD  - Neuroradiology Section, Department of Radiology and Biomedical Imaging,
      University of California, San Francisco, San Francisco, California, United States
      of America.
FAU - Karch, Celeste M
AU  - Karch CM
AUID- ORCID: 0000-0002-6854-5547
AD  - Department of Psychiatry, Washington University, St. Louis, Missouri, United
      States of America.
FAU - Wen, Natalie
AU  - Wen N
AD  - Department of Psychiatry, Washington University, St. Louis, Missouri, United
      States of America.
FAU - Fan, Chun C
AU  - Fan CC
AD  - Department of Cognitive Sciences, University of California, San Diego, La Jolla, 
      California, United States of America.
FAU - Wang, Yunpeng
AU  - Wang Y
AUID- ORCID: 0000-0001-9831-1090
AD  - Norwegian Centre for Mental Disorders Research (NORMENT), Institute of Clinical
      Medicine, University of Oslo, Oslo, Norway.
AD  - Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.
FAU - Tan, Chin Hong
AU  - Tan CH
AUID- ORCID: 0000-0002-0980-9936
AD  - Neuroradiology Section, Department of Radiology and Biomedical Imaging,
      University of California, San Francisco, San Francisco, California, United States
      of America.
FAU - Kouri, Naomi
AU  - Kouri N
AUID- ORCID: 0000-0002-6841-9882
AD  - Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, United States of 
      America.
FAU - Ross, Owen A
AU  - Ross OA
AD  - Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, United States of 
      America.
FAU - Hoglinger, Gunter U
AU  - Hoglinger GU
AD  - Department of Neurology, Technical University of Munich, Munich, Germany.
AD  - German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
AD  - Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.
FAU - Muller, Ulrich
AU  - Muller U
AD  - Institut for Humangenetik, Justus-Liebig-Universitat, Giessen, Germany.
FAU - Hardy, John
AU  - Hardy J
AD  - Department of Molecular Neuroscience, Institute of Neurology, University College 
      London, London, United Kingdom.
CN  - International FTD-Genomics Consortium
FAU - Momeni, Parastoo
AU  - Momeni P
AD  - Laboratory of Neurogenetics, Department of Internal Medicine, Texas Tech
      University Health Sciences Center, Lubbock, Texas, United States of America.
FAU - Hess, Christopher P
AU  - Hess CP
AUID- ORCID: 0000-0002-5132-5302
AD  - Neuroradiology Section, Department of Radiology and Biomedical Imaging,
      University of California, San Francisco, San Francisco, California, United States
      of America.
FAU - Dillon, William P
AU  - Dillon WP
AD  - Neuroradiology Section, Department of Radiology and Biomedical Imaging,
      University of California, San Francisco, San Francisco, California, United States
      of America.
FAU - Miller, Zachary A
AU  - Miller ZA
AUID- ORCID: 0000-0002-5991-3053
AD  - Department of Neurology, University of California, San Francisco, San Francisco, 
      California, United States of America.
FAU - Bonham, Luke W
AU  - Bonham LW
AUID- ORCID: 0000-0002-2533-1266
AD  - Department of Neurology, University of California, San Francisco, San Francisco, 
      California, United States of America.
FAU - Rabinovici, Gil D
AU  - Rabinovici GD
AD  - Department of Neurology, University of California, San Francisco, San Francisco, 
      California, United States of America.
FAU - Rosen, Howard J
AU  - Rosen HJ
AD  - Department of Neurology, University of California, San Francisco, San Francisco, 
      California, United States of America.
FAU - Schellenberg, Gerard D
AU  - Schellenberg GD
AD  - Department of Pathology and Laboratory Medicine, Perelman School of Medicine,
      University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
FAU - Franke, Andre
AU  - Franke A
AD  - Institute of Clinical Molecular Biology, Christian-Albrechts-Universitat zu Kiel,
      Kiel, Germany.
FAU - Karlsen, Tom H
AU  - Karlsen TH
AD  - Norwegian PSC Research Center, Research Institute of Internal Medicine, Division 
      of Cancer Medicine, Surgery and Transplantation, Oslo University Hospital,
      Rikshospitalet, Oslo, Norway.
AD  - Division of Gastroenterology, Institute of Medicine, University of Bergen,
      Bergen, Norway.
AD  - K.G. Jebsen Inflammation Research Centre, Research Institute of Internal
      Medicine, Division of Cancer Medicine, Surgery and Transplantation, Oslo
      University Hospital, Rikshospitalet, Oslo, Norway.
FAU - Veldink, Jan H
AU  - Veldink JH
AUID- ORCID: 0000-0001-5572-9657
AD  - Department of Neurology, Brain Center Rudolf Magnus, University Medical Center
      Utrecht, Utrecht, the Netherlands.
FAU - Ferrari, Raffaele
AU  - Ferrari R
AD  - Department of Molecular Neuroscience, Institute of Neurology, University College 
      London, London, United Kingdom.
FAU - Yokoyama, Jennifer S
AU  - Yokoyama JS
AD  - Department of Neurology, University of California, San Francisco, San Francisco, 
      California, United States of America.
FAU - Miller, Bruce L
AU  - Miller BL
AD  - Department of Neurology, University of California, San Francisco, San Francisco, 
      California, United States of America.
FAU - Andreassen, Ole A
AU  - Andreassen OA
AD  - Norwegian Centre for Mental Disorders Research (NORMENT), Institute of Clinical
      Medicine, University of Oslo, Oslo, Norway.
AD  - Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.
FAU - Dale, Anders M
AU  - Dale AM
AUID- ORCID: 0000-0002-6126-2966
AD  - Department of Cognitive Sciences, University of California, San Diego, La Jolla, 
      California, United States of America.
AD  - Department of Radiology, University of California, San Diego, La Jolla,
      California, United States of America.
AD  - Department of Neurosciences, University of California, San Diego, La Jolla,
      California, United States of America.
FAU - Desikan, Rahul S
AU  - Desikan RS
AUID- ORCID: 0000-0002-4151-6017
AD  - Neuroradiology Section, Department of Radiology and Biomedical Imaging,
      University of California, San Francisco, San Francisco, California, United States
      of America.
AD  - Department of Neurology, University of California, San Francisco, San Francisco, 
      California, United States of America.
FAU - Sugrue, Leo P
AU  - Sugrue LP
AUID- ORCID: 0000-0001-7315-4519
AD  - Neuroradiology Section, Department of Radiology and Biomedical Imaging,
      University of California, San Francisco, San Francisco, California, United States
      of America.
LA  - eng
PT  - Journal Article
DEP - 20180109
PL  - United States
TA  - PLoS Med
JT  - PLoS medicine
JID - 101231360
EIN - PLoS Med. 2018 Jan 29;15(1):e1002504. PMID: 29377952
PMC - PMC5760014
IR  - Ferrari R
FIR - Ferrari, Raffaele
IR  - Hernandez DG
FIR - Hernandez, Dena
IR  - Nalls MA
FIR - Nalls, Michael
IR  - Rohrer JD
FIR - Rohrer, Jonathan
IR  - Ramasamy A
FIR - Ramasamy, Adaikalavan
IR  - Kwok JBJ
FIR - Kwok, John
IR  - Dobson-Stone C
FIR - Dobson-Stone, Carol
IR  - Brooks WS
FIR - Brooks, William
IR  - Schofield PR
FIR - Schofield, Peter
IR  - Halliday GM
FIR - Halliday, Glenda
IR  - Hodges JR
FIR - Hodges, John
IR  - Piguet O
FIR - Piguet, Olivier
IR  - Bartley L
FIR - Bartley, Lauren
IR  - Thompson E
FIR - Thompson, Elizabeth
IR  - Haan E
FIR - Haan, Eric
IR  - Hernandez I
FIR - Hernandez, Isabel
IR  - Ruiz A
FIR - Ruiz, Agustin
IR  - Boada M
FIR - Boada, Merce
IR  - Borroni B
FIR - Borroni, Barbara
IR  - Padovani A
FIR - Padovani, Alessandro
IR  - Cruchaga C
FIR - Cruchaga, Carlos
IR  - Cairns NJ
FIR - Cairns, Nigel
IR  - Benussi L
FIR - Benussi, Luisa
IR  - Binetti G
FIR - Binetti, Giuliano
IR  - Ghidoni R
FIR - Ghidoni, Roberta
IR  - Forloni G
FIR - Forloni, Gianluigi
IR  - Galimberti D
FIR - Galimberti, Daniela
IR  - Fenoglio C
FIR - Fenoglio, Chiara
IR  - Serpente M
FIR - Serpente, Maria
IR  - Scarpini E
FIR - Scarpini, Elio
IR  - Clarimon J
FIR - Clarimon, Jordi
IR  - Lleo A
FIR - Lleo, Alberto
IR  - Blesa R
FIR - Blesa, Rafael
IR  - Waldo ML
FIR - Waldo, Maria Landqvist
IR  - Nilsson K
FIR - Nilsson, Karin
IR  - Nilsson C
FIR - Nilsson, Christer
IR  - Mackenzie IRA
FIR - Mackenzie, Ian
IR  - Hsuing GYR
FIR - Hsuing, Ging-Yuek
IR  - Mann DMA
FIR - Mann, David
IR  - Grafman J
FIR - Grafman, Jordan
IR  - Morris CM
FIR - Morris, Christopher
IR  - Attems J
FIR - Attems, Johannes
IR  - Griffiths TD
FIR - Griffiths, Timothy
IR  - McKeith IG
FIR - McKeith, Ian
IR  - Thomas AJ
FIR - Thomas, Alan
IR  - Pietrini P
FIR - Pietrini, Pietro
IR  - Huey ED
FIR - Huey, Edward
IR  - Wasserman EM
FIR - Wasserman, Eric
IR  - Baborie A
FIR - Baborie, Atik
IR  - Jaros E
FIR - Jaros, Evelyn
IR  - Tierney MC
FIR - Tierney, Michael
IR  - Pastor P
FIR - Pastor, Pau
IR  - Razquin C
FIR - Razquin, Cristina
IR  - Ortega-Cubero S
FIR - Ortega-Cubero, Sara
IR  - Alonso E
FIR - Alonso, Elena
IR  - Perneczky E
FIR - Perneczky, Elisa
IR  - Diehl-Schmid J
FIR - Diehl-Schmid, Janine
IR  - Alexopoulos P
FIR - Alexopoulos, Panagiotis
IR  - Kurz A
FIR - Kurz, Alexander
IR  - Rainero I
FIR - Rainero, Innocenzo
IR  - Rubino E
FIR - Rubino, Elisa
IR  - Pinessi L
FIR - Pinessi, Lorenzo
IR  - Rogaeva E
FIR - Rogaeva, Ekaterina
IR  - St George-Hyslop P
FIR - St George-Hyslop, Peter
IR  - Rossi G
FIR - Rossi, Giacomina
IR  - Tagliavini F
FIR - Tagliavini, Fabrizio
IR  - Giaccone G
FIR - Giaccone, Giorgio
IR  - Rowe JB
FIR - Rowe, James
IR  - Schlachetzki JCM
FIR - Schlachetzki, Johannes
IR  - Uphill J
FIR - Uphill, James
IR  - Collinge J
FIR - Collinge, John
IR  - Mead S
FIR - Mead, Simon
IR  - Danek A
FIR - Danek, Adrian
IR  - Van Deerlin VM
FIR - Van Deerlin, Vivianna
IR  - Grossmann M
FIR - Grossmann, Murray
IR  - Trojanowski JQ
FIR - Trojanowski, John
IR  - van der Zee J
FIR - van der Zee, Julie
IR  - Deschamps W
FIR - Deschamps, William
IR  - Van Langenhove T
FIR - Van Langenhove, Tim
IR  - Cruts M
FIR - Cruts, Marc
IR  - Van Broeckhoven C
FIR - Van Broeckhoven, Christine
IR  - Cappa SF
FIR - Cappa, Stefano
IR  - Le Ber I
FIR - Le Ber, Isabelle
IR  - Hannequin D
FIR - Hannequin, Didier
IR  - Golfier V
FIR - Golfier, Veronique
IR  - Vercelletto M
FIR - Vercelletto, Martine
IR  - Brice A
FIR - Brice, Alexis
IR  - Nacimas B
FIR - Nacimas, Benedetta
IR  - Sorbi S
FIR - Sorbi, Sandro
IR  - Bagnoli S
FIR - Bagnoli, Silvia
IR  - Piaceri I
FIR - Piaceri, Irene
IR  - Nielsen JE
FIR - Nielsen, Jorgen
IR  - Hjermind LE
FIR - Hjermind, Lena
IR  - Riemenschneider M
FIR - Riemenschneider, Matthias
IR  - Mayhaus M
FIR - Mayhaus, Manuel
IR  - Ibach B
FIR - Ibach, Bernd
IR  - Gasparoni G
FIR - Gasparoni, Gilles
IR  - Pichler S
FIR - Pichler, Sabrina
IR  - Gu W
FIR - Gu, Wei
IR  - Rossor MN
FIR - Rossor, Martin
IR  - Fox NC
FIR - Fox, Nick
IR  - Warren JD
FIR - Warren, Jason
IR  - Spillantini MG
FIR - Spillantini, Maria Grazia
IR  - Morris HR
FIR - Morris, Huw
IR  - Rizzu P
FIR - Rizzu, Patrizia
IR  - Heutnik P
FIR - Heutnik, Peter
IR  - Snowden J
FIR - Snowden, Julie
IR  - Rollinson S
FIR - Rollinson, Sara
IR  - Richardson A
FIR - Richardson, Anna
IR  - Gerhard A
FIR - Gerhard, Alexander
IR  - Bruni AC
FIR - Bruni, Amalia
IR  - Maletta R
FIR - Maletta, Raffaele
IR  - Frangipane F
FIR - Frangipane, Francesca
IR  - Cupidi C
FIR - Cupidi, Chiara
IR  - Bernardi L
FIR - Bernardi, Livia
IR  - Anfossi M
FIR - Anfossi, Maria
IR  - Gallo M
FIR - Gallo, Maura
IR  - Conidi ME
FIR - Conidi, Maria Elena
IR  - Smirne N
FIR - Smirne, Nicoletta
IR  - Rademakers R
FIR - Rademakers, Rosa
IR  - Baker M
FIR - Baker, Matt
IR  - Dickson DW
FIR - Dickson, Dennis
IR  - Graff-Radford NR
FIR - Graff-Radford, Neill
IR  - Peterson RC
FIR - Peterson, Ronald
IR  - Knopman D
FIR - Knopman, David
IR  - Josephs KA
FIR - Josephs, Keith
IR  - Boeve BF
FIR - Boeve, Bradley
IR  - Parisi JE
FIR - Parisi, Joseph
IR  - Seeley WW
FIR - Seeley, William
IR  - Miller BL
FIR - Miller, Bruce
IR  - Karydas AM
FIR - Karydas, Anna
IR  - Rosen H
FIR - Rosen, Howard
IR  - van Swieten JC
FIR - van Swieten, John
IR  - Dopper EGP
FIR - Dopper, Elise
IR  - Seelaar H
FIR - Seelaar, Harro
IR  - Pijnenburg YAL
FIR - Pijnenburg, Yolande
IR  - Scheltens P
FIR - Scheltens, Philip
IR  - Logroscino G
FIR - Logroscino, Giancarlo
IR  - Capozzo R
FIR - Capozzo, Rosa
IR  - Novelli V
FIR - Novelli, Valeria
IR  - Puca AA
FIR - Puca, Annibale
IR  - Franceschi M
FIR - Franceschi, Massimo
IR  - Postiglione A
FIR - Postiglione, Alfredo
IR  - Milan G
FIR - Milan, Graziella
IR  - Sorrentino P
FIR - Sorrentino, Paolo
IR  - Kristiansen M
FIR - Kristiansen, Mark
IR  - Chiang HH
FIR - Chiang, Huei-Hsin
IR  - Graff C
FIR - Graff, Caroline
IR  - Pasquier F
FIR - Pasquier, Florence
IR  - Rollin A
FIR - Rollin, Adeline
IR  - Deramecourt V
FIR - Deramecourt, Vincent
IR  - Lebert F
FIR - Lebert, Florence
IR  - Kapogiannis D
FIR - Kapogiannis, Dimitiros
IR  - Ferucci L
FIR - Ferucci, Luigi
IR  - Pickering-Brown S
FIR - Pickering-Brown, Stuart
IR  - Singleton AB
FIR - Singleton, Andrew
IR  - Hardy J
FIR - Hardy, John
IR  - Momeni P
FIR - Momeni, Parastoo
EDAT- 2018/01/10 06:00
MHDA- 2018/01/10 06:00
CRDT- 2018/01/10 06:00
PHST- 2017/07/03 00:00 [received]
PHST- 2017/12/05 00:00 [accepted]
PHST- 2018/01/10 06:00 [entrez]
PHST- 2018/01/10 06:00 [pubmed]
PHST- 2018/01/10 06:00 [medline]
AID - 10.1371/journal.pmed.1002487 [doi]
AID - PMEDICINE-D-17-02291 [pii]
PST - epublish
SO  - PLoS Med. 2018 Jan 9;15(1):e1002487. doi: 10.1371/journal.pmed.1002487.
      eCollection 2018 Jan.

PMID- 29273807
OWN - NLM
STAT- In-Data-Review
LR  - 20180125
IS  - 1546-1718 (Electronic)
IS  - 1061-4036 (Linking)
VI  - 50
IP  - 1
DP  - 2018 Jan
TI  - Protein-altering variants associated with body mass index implicate pathways that
      control energy intake and expenditure in obesity.
PG  - 26-41
LID - 10.1038/s41588-017-0011-x [doi]
AB  - Genome-wide association studies (GWAS) have identified >250 loci for body mass
      index (BMI), implicating pathways related to neuronal biology. Most GWAS loci
      represent clusters of common, noncoding variants from which pinpointing causal
      genes remains challenging. Here we combined data from 718,734 individuals to
      discover rare and low-frequency (minor allele frequency (MAF) < 5%) coding
      variants associated with BMI. We identified 14 coding variants in 13 genes, of
      which 8 variants were in genes (ZBTB7B, ACHE, RAPGEF3, RAB21, ZFHX3, ENTPD6, ZFR2
      and ZNF169) newly implicated in human obesity, 2 variants were in genes (MC4R and
      KSR2) previously observed to be mutated in extreme obesity and 2 variants were in
      GIPR. The effect sizes of rare variants are ~10 times larger than those of common
      variants, with the largest effect observed in carriers of an MC4R mutation
      introducing a stop codon (p.Tyr35Ter, MAF = 0.01%), who weighed ~7 kg more than
      non-carriers. Pathway analyses based on the variants associated with BMI confirm 
      enrichment of neuronal genes and provide new evidence for adipocyte and energy
      expenditure biology, widening the potential of genetically supported therapeutic 
      targets in obesity.
FAU - Turcot, Valerie
AU  - Turcot V
AD  - Montreal Heart Institute, Universite de Montreal, Montreal, Quebec, Canada.
FAU - Lu, Yingchang
AU  - Lu Y
AD  - Division of Epidemiology, Department of Medicine, Vanderbilt-Ingram Cancer
      Center, Vanderbilt Epidemiology Center, Vanderbilt University School of Medicine,
      Nashville, TN, USA.
AD  - Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at
      Mount Sinai, New York, NY, USA.
AD  - Genetics of Obesity and Related Metabolic Traits Program, Icahn School of
      Medicine at Mount Sinai, New York, NY, USA.
FAU - Highland, Heather M
AU  - Highland HM
AD  - Department of Epidemiology, University of North Carolina, Chapel Hill, NC, USA.
AD  - Human Genetics Center, University of Texas School of Public Health, University of
      Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, 
      University of Texas Health Science Center at Houston, Houston, TX, USA.
FAU - Schurmann, Claudia
AU  - Schurmann C
AUID- ORCID: http://orcid.org/0000-0003-4158-9192
AD  - Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at
      Mount Sinai, New York, NY, USA.
AD  - Genetics of Obesity and Related Metabolic Traits Program, Icahn School of
      Medicine at Mount Sinai, New York, NY, USA.
FAU - Justice, Anne E
AU  - Justice AE
AUID- ORCID: http://orcid.org/0000-0002-8903-8712
AD  - Department of Epidemiology, University of North Carolina, Chapel Hill, NC, USA.
FAU - Fine, Rebecca S
AU  - Fine RS
AD  - Broad Institute of MIT and Harvard, Cambridge, MA, USA.
AD  - Department of Genetics, Harvard Medical School, Boston, MA, USA.
AD  - Division of Endocrinology and Center for Basic and Translational Obesity
      Research, Boston Children's Hospital, Boston, MA, USA.
FAU - Bradfield, Jonathan P
AU  - Bradfield JP
AD  - Center for Applied Genomics, Division of Human Genetics, Children's Hospital of
      Philadelphia, Philadelphia, PA, USA.
AD  - Quantinuum Research, LLC, San Diego, CA, USA.
FAU - Esko, Tonu
AU  - Esko T
AD  - Broad Institute of MIT and Harvard, Cambridge, MA, USA.
AD  - Division of Endocrinology and Center for Basic and Translational Obesity
      Research, Boston Children's Hospital, Boston, MA, USA.
AD  - Estonian Genome Center, University of Tartu, Tartu, Estonia.
FAU - Giri, Ayush
AU  - Giri A
AUID- ORCID: http://orcid.org/0000-0002-7786-4670
AD  - Division of Epidemiology, Department of Medicine, Institute for Medicine and
      Public Health, Vanderbilt Genetics Institute, Vanderbilt University, Nashville,
      TN, USA.
FAU - Graff, Mariaelisa
AU  - Graff M
AD  - Department of Epidemiology, University of North Carolina, Chapel Hill, NC, USA.
FAU - Guo, Xiuqing
AU  - Guo X
AD  - Institute for Translational Genomics and Population Sciences, LABioMed at
      Harbor-UCLA Medical Center, Torrance, CA, USA.
FAU - Hendricks, Audrey E
AU  - Hendricks AE
AD  - Wellcome Trust Sanger Institute, Hinxton, UK.
AD  - Department of Mathematical and Statistical Sciences, University of Colorado,
      Denver, CO, USA.
FAU - Karaderi, Tugce
AU  - Karaderi T
AD  - Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
AD  - Department of Biological Sciences, Faculty of Arts and Sciences, Eastern
      Mediterranean University, Famagusta, Cyprus.
FAU - Lempradl, Adelheid
AU  - Lempradl A
AD  - Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.
FAU - Locke, Adam E
AU  - Locke AE
AUID- ORCID: http://orcid.org/0000-0001-6227-198X
AD  - Department of Biostatistics and Center for Statistical Genetics, University of
      Michigan, Ann Arbor, MI, USA.
AD  - McDonnell Genome Institute, Washington University School of Medicine, St. Louis, 
      MO, USA.
FAU - Mahajan, Anubha
AU  - Mahajan A
AD  - Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
FAU - Marouli, Eirini
AU  - Marouli E
AD  - William Harvey Research Institute, Barts and The London School of Medicine and
      Dentistry, Queen Mary University of London, London, UK.
FAU - Sivapalaratnam, Suthesh
AU  - Sivapalaratnam S
AD  - Department of Vascular Medicine, AMC, Amsterdam, The Netherlands.
AD  - Massachusetts General Hospital, Boston, MA, USA.
AD  - Department of Haematology, University of Cambridge, Cambridge, UK.
FAU - Young, Kristin L
AU  - Young KL
AUID- ORCID: http://orcid.org/0000-0003-0070-6145
AD  - Department of Epidemiology, University of North Carolina, Chapel Hill, NC, USA.
FAU - Alfred, Tamuno
AU  - Alfred T
AD  - Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at
      Mount Sinai, New York, NY, USA.
FAU - Feitosa, Mary F
AU  - Feitosa MF
AD  - Division of Statistical Genomics, Department of Genetics, Washington University
      School of Medicine, St. Louis, MO, USA.
FAU - Masca, Nicholas G D
AU  - Masca NGD
AD  - Department of Cardiovascular Sciences, University of Leicester, Glenfield
      Hospital, Leicester, UK.
AD  - NIHR Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital,
      Leicester, UK.
FAU - Manning, Alisa K
AU  - Manning AK
AD  - Broad Institute of MIT and Harvard, Cambridge, MA, USA.
AD  - Massachusetts General Hospital, Boston, MA, USA.
AD  - Department of Medicine, Harvard Medical School, Boston, MA, USA.
AD  - Medical and Population Genetics Program, Broad Institute, Cambridge, MA, USA.
FAU - Medina-Gomez, Carolina
AU  - Medina-Gomez C
AUID- ORCID: http://orcid.org/0000-0001-7999-5538
AD  - Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands.
AD  - Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The
      Netherlands.
FAU - Mudgal, Poorva
AU  - Mudgal P
AD  - Center for Diabetes Research, Wake Forest School of Medicine, Winston-Salem, NC, 
      USA.
FAU - Ng, Maggie C Y
AU  - Ng MCY
AD  - Center for Diabetes Research, Wake Forest School of Medicine, Winston-Salem, NC, 
      USA.
AD  - Center for Genomics and Personalized Medicine Research, Wake Forest School of
      Medicine, Winston-Salem, NC, USA.
FAU - Reiner, Alex P
AU  - Reiner AP
AD  - Department of Epidemiology, University of Washington, Seattle, WA, USA.
AD  - Division of Public Health Sciences, Fred Hutchinson Cancer Research Center,
      Seattle, WA, USA.
FAU - Vedantam, Sailaja
AU  - Vedantam S
AD  - Broad Institute of MIT and Harvard, Cambridge, MA, USA.
AD  - Department of Genetics, Harvard Medical School, Boston, MA, USA.
AD  - Division of Endocrinology and Center for Basic and Translational Obesity
      Research, Boston Children's Hospital, Boston, MA, USA.
FAU - Willems, Sara M
AU  - Willems SM
AD  - MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine,
      Institute of Metabolic Science, Cambridge, UK.
FAU - Winkler, Thomas W
AU  - Winkler TW
AUID- ORCID: http://orcid.org/0000-0003-0292-5421
AD  - Department of Genetic Epidemiology, University of Regensburg, Regensburg,
      Germany.
FAU - Abecasis, Goncalo
AU  - Abecasis G
AD  - Department of Biostatistics and Center for Statistical Genetics, University of
      Michigan, Ann Arbor, MI, USA.
FAU - Aben, Katja K
AU  - Aben KK
AD  - Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands.
AD  - Radboud Institute for Health Sciences, Radboud University Medical Center,
      Nijmegen, The Netherlands.
FAU - Alam, Dewan S
AU  - Alam DS
AD  - School of Kinesiology and Health Science, Faculty of Health, York University,
      Toronto, Ontario, Canada.
FAU - Alharthi, Sameer E
AU  - Alharthi SE
AD  - William Harvey Research Institute, Barts and The London School of Medicine and
      Dentistry, Queen Mary University of London, London, UK.
AD  - Princess Al-Jawhara Al-Brahim Centre of Excellence in Research of Hereditary
      Disorders (PACER-HD), King Abdulaziz University, Jeddah, Saudi Arabia.
FAU - Allison, Matthew
AU  - Allison M
AD  - Department of Family Medicine and Public Health, University of California, San
      Diego, La Jolla, CA, USA.
FAU - Amouyel, Philippe
AU  - Amouyel P
AD  - INSERM U1167, Lille, France.
AD  - Institut Pasteur de Lille, U1167, Lille, France.
AD  - Universite de Lille, U1167, RID-AGE, Risk Factors and Molecular Determinants of
      Aging-Related Diseases, Lille, France.
FAU - Asselbergs, Folkert W
AU  - Asselbergs FW
AD  - Department of Cardiology, Division Heart and Lungs, University Medical Center
      Utrecht, Utrecht, The Netherlands.
AD  - Durrer Center for Cardiogenetic Research, ICIN-Netherlands Heart Institute,
      Utrecht, The Netherlands.
AD  - Institute of Cardiovascular Science, Faculty of Population Health Sciences,
      University College London, London, UK.
FAU - Auer, Paul L
AU  - Auer PL
AD  - Zilber School of Public Health, University of Wisconsin-Milwaukee, Milwaukee, WI,
      USA.
FAU - Balkau, Beverley
AU  - Balkau B
AD  - INSERM U1018, Centre de Recherche en Epidemiologie et Sante des Populations
      (CESP), Villejuif, France.
FAU - Bang, Lia E
AU  - Bang LE
AD  - Department of Cardiology, Rigshospitalet, Copenhagen University Hospital,
      Copenhagen, Denmark.
FAU - Barroso, Ines
AU  - Barroso I
AD  - Wellcome Trust Sanger Institute, Hinxton, UK.
AD  - Metabolic Research Laboratories, University of Cambridge, Cambridge, UK.
AD  - NIHR Cambridge Biomedical Research Centre, Wellcome Trust-MRC Institute of
      Metabolic Science, Addenbrooke's Hospital, Cambridge, UK.
FAU - Bastarache, Lisa
AU  - Bastarache L
AD  - Department of Biomedical Informatics, Vanderbilt University, Nashville, TN, USA.
FAU - Benn, Marianne
AU  - Benn M
AD  - Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen
      University Hospital, Herlev, Denmark.
AD  - Department of Public Health, Faculty of Health and Medical Sciences, University
      of Copenhagen, Copenhagen, Denmark.
FAU - Bergmann, Sven
AU  - Bergmann S
AD  - Department of Computational Biology, University of Lausanne, Lausanne,
      Switzerland.
AD  - Swiss Institute of Bioinformatics, Lausanne, Switzerland.
FAU - Bielak, Lawrence F
AU  - Bielak LF
AD  - Department of Epidemiology, School of Public Health, University of Michigan, Ann 
      Arbor, MI, USA.
FAU - Bluher, Matthias
AU  - Bluher M
AD  - IFB Adiposity Diseases, University of Leipzig, Leipzig, Germany.
AD  - Department of Medicine, University of Leipzig, Leipzig, Germany.
FAU - Boehnke, Michael
AU  - Boehnke M
AD  - Department of Biostatistics and Center for Statistical Genetics, University of
      Michigan, Ann Arbor, MI, USA.
FAU - Boeing, Heiner
AU  - Boeing H
AD  - Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbrucke
      (DIfE), Nuthetal, Germany.
FAU - Boerwinkle, Eric
AU  - Boerwinkle E
AD  - School of Public Health, Human Genetics Center, University of Texas Health
      Science Center at Houston, Houston, TX, USA.
AD  - Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, USA.
FAU - Boger, Carsten A
AU  - Boger CA
AD  - Department of Nephrology, University Hospital Regensburg, Regensburg, Germany.
FAU - Bork-Jensen, Jette
AU  - Bork-Jensen J
AD  - Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health
      and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
FAU - Bots, Michiel L
AU  - Bots ML
AD  - Julius Center for Health Sciences and Primary Care, University Medical Center
      Utrecht, Utrecht, The Netherlands.
FAU - Bottinger, Erwin P
AU  - Bottinger EP
AD  - Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at
      Mount Sinai, New York, NY, USA.
FAU - Bowden, Donald W
AU  - Bowden DW
AD  - Center for Diabetes Research, Wake Forest School of Medicine, Winston-Salem, NC, 
      USA.
AD  - Center for Genomics and Personalized Medicine Research, Wake Forest School of
      Medicine, Winston-Salem, NC, USA.
AD  - Department of Biochemistry, Wake Forest School of Medicine, Winston-Salem, NC,
      USA.
FAU - Brandslund, Ivan
AU  - Brandslund I
AD  - Department of Clinical Biochemistry, Lillebaelt Hospital, Vejle, Denmark.
AD  - Institute of Regional Health Research, University of Southern Denmark, Odense,
      Denmark.
FAU - Breen, Gerome
AU  - Breen G
AD  - MRC Social Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, 
      Psychology and Neuroscience, King's College London, London, UK.
AD  - NIHR Biomedical Research Centre for Mental Health, South London and Maudsley
      Hospital, London, UK.
FAU - Brilliant, Murray H
AU  - Brilliant MH
AD  - Marshfield Clinic Research Institute, Marshfield, WI, USA.
FAU - Broer, Linda
AU  - Broer L
AD  - Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The
      Netherlands.
FAU - Brumat, Marco
AU  - Brumat M
AD  - Department of Medical Sciences, University of Trieste, Trieste, Italy.
FAU - Burt, Amber A
AU  - Burt AA
AD  - Department of Medicine, University of Washington, Seattle, WA, USA.
FAU - Butterworth, Adam S
AU  - Butterworth AS
AD  - MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary
      Care, University of Cambridge, Cambridge, UK.
AD  - NIHR Blood and Transplant Research Unit in Donor Health and Genomics, Department 
      of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
FAU - Campbell, Peter T
AU  - Campbell PT
AD  - Epidemiology Research Program, American Cancer Society, Atlanta, GA, USA.
FAU - Cappellani, Stefania
AU  - Cappellani S
AD  - Institute for Maternal and Child Health, IRCCS 'Burlo Garofolo', Trieste, Italy.
FAU - Carey, David J
AU  - Carey DJ
AD  - Weis Center for Research, Geisinger Health System, Danville, PA, USA.
FAU - Catamo, Eulalia
AU  - Catamo E
AD  - Institute for Maternal and Child Health, IRCCS 'Burlo Garofolo', Trieste, Italy.
FAU - Caulfield, Mark J
AU  - Caulfield MJ
AD  - William Harvey Research Institute, Barts and The London School of Medicine and
      Dentistry, Queen Mary University of London, London, UK.
AD  - NIHR Barts Cardiovascular Research Unit, Barts and The London School of Medicine 
      and Dentistry, Queen Mary University of London, London, UK.
FAU - Chambers, John C
AU  - Chambers JC
AD  - Department of Cardiology, London North West Healthcare NHS Trust, Ealing
      Hospital, Middlesex, UK.
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Imperial
      College London, London, UK.
AD  - Imperial College Healthcare NHS Trust, London, UK.
FAU - Chasman, Daniel I
AU  - Chasman DI
AD  - Broad Institute of MIT and Harvard, Cambridge, MA, USA.
AD  - Division of Genetics, Brigham and Women's Hospital and Harvard Medical School,
      Boston, MA, USA.
AD  - Division of Preventive Medicine, Brigham and Women's Hospital and Harvard Medical
      School, Boston, MA, USA.
AD  - Harvard Medical School, Boston, MA, USA.
FAU - Chen, Yii-Der I
AU  - Chen YI
AD  - Institute for Translational Genomics and Population Sciences, LABioMed at
      Harbor-UCLA Medical Center, Torrance, CA, USA.
FAU - Chowdhury, Rajiv
AU  - Chowdhury R
AD  - MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary
      Care, University of Cambridge, Cambridge, UK.
FAU - Christensen, Cramer
AU  - Christensen C
AD  - Medical Department, Lillebaelt Hospital, Vejle, Denmark.
FAU - Chu, Audrey Y
AU  - Chu AY
AD  - NHLBI Framingham Heart Study, Framingham, MA, USA.
AD  - Genetics and Pharmacogenomics, Merck, Sharp & Dohme, Boston, MA, USA.
FAU - Cocca, Massimiliano
AU  - Cocca M
AD  - Department of Medical, Surgical and Health Sciences, University of Trieste,
      Trieste, Italy.
FAU - Collins, Francis S
AU  - Collins FS
AD  - Medical Genomics and Metabolic Genetics Branch, National Human Genome Research
      Institute, US National Institutes of Health, Bethesda, MD, USA.
FAU - Cook, James P
AU  - Cook JP
AD  - Department of Biostatistics, University of Liverpool, Liverpool, UK.
FAU - Corley, Janie
AU  - Corley J
AD  - Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, 
      Edinburgh, UK.
AD  - Department of Psychology, University of Edinburgh, Edinburgh, UK.
FAU - Corominas Galbany, Jordi
AU  - Corominas Galbany J
AD  - Department of Human Genetics, Donders Institute for Brain, Cognition and
      Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands.
AD  - Department of Ophthalmology, Donders Institute for Brain, Cognition and
      Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands.
FAU - Cox, Amanda J
AU  - Cox AJ
AD  - Center for Diabetes Research, Wake Forest School of Medicine, Winston-Salem, NC, 
      USA.
AD  - Center for Genomics and Personalized Medicine Research, Wake Forest School of
      Medicine, Winston-Salem, NC, USA.
AD  - Menzies Health Institute Queensland, Griffith University, Southport, Queensland, 
      Australia.
FAU - Crosslin, David S
AU  - Crosslin DS
AD  - Department of Biomedical Informatics and Medical Education, University of
      Washington, Seattle, WA, USA.
FAU - Cuellar-Partida, Gabriel
AU  - Cuellar-Partida G
AD  - Diamantina Institute, University of Queensland, Brisbane, Queensland, Australia.
AD  - QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
FAU - D'Eustacchio, Angela
AU  - D'Eustacchio A
AD  - Institute for Maternal and Child Health, IRCCS 'Burlo Garofolo', Trieste, Italy.
FAU - Danesh, John
AU  - Danesh J
AD  - Wellcome Trust Sanger Institute, Hinxton, UK.
AD  - MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary
      Care, University of Cambridge, Cambridge, UK.
AD  - NIHR Blood and Transplant Research Unit in Donor Health and Genomics, Department 
      of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
AD  - British Heart Foundation Cambridge Centre of Excellence, Department of Medicine, 
      University of Cambridge, Cambridge, UK.
FAU - Davies, Gail
AU  - Davies G
AD  - Department of Biostatistics, University of Liverpool, Liverpool, UK.
AD  - Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, 
      Edinburgh, UK.
FAU - Bakker, Paul I W
AU  - Bakker PIW
AD  - Julius Center for Health Sciences and Primary Care, University Medical Center
      Utrecht, Utrecht, The Netherlands.
AD  - Department of Genetics, Center for Molecular Medicine, University Medical Center 
      Utrecht, Utrecht, The Netherlands.
FAU - Groot, Mark C H
AU  - Groot MCH
AD  - Department of Clinical Chemistry and Haematology, Division of Laboratory and
      Pharmacy, University Medical Center Utrecht, Utrecht, The Netherlands.
AD  - Utrecht Institute for Pharmaceutical Sciences, Division Pharmacoepidemiology and 
      Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands.
FAU - Mutsert, Renee
AU  - Mutsert R
AD  - Department of Clinical Epidemiology, Leiden University Medical Center, Leiden,
      The Netherlands.
FAU - Deary, Ian J
AU  - Deary IJ
AD  - Department of Biostatistics, University of Liverpool, Liverpool, UK.
AD  - Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, 
      Edinburgh, UK.
FAU - Dedoussis, George
AU  - Dedoussis G
AD  - Department of Nutrition and Dietetics, School of Health Science and Education,
      Harokopio University, Athens, Greece.
FAU - Demerath, Ellen W
AU  - Demerath EW
AD  - Division of Epidemiology and Community Health, School of Public Health,
      University of Minnesota, Minneapolis, MN, USA.
FAU - Heijer, Martin
AU  - Heijer M
AD  - Department of Internal Medicine, VU University Medical Center, Amsterdam, The
      Netherlands.
FAU - Hollander, Anneke I
AU  - Hollander AI
AD  - Department of Ophthalmology, Donders Institute for Brain, Cognition and
      Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands.
FAU - Ruijter, Hester M
AU  - Ruijter HM
AD  - Laboratory of Experimental Cardiology, Division Heart and Lungs, University
      Medical Center Utrecht, Utrecht, The Netherlands.
FAU - Dennis, Joe G
AU  - Dennis JG
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary
      Care, University of Cambridge, Cambridge, UK.
FAU - Denny, Josh C
AU  - Denny JC
AD  - Department of Biomedical Informatics, Vanderbilt University, Nashville, TN, USA.
FAU - Angelantonio, Emanuele
AU  - Angelantonio E
AD  - MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary
      Care, University of Cambridge, Cambridge, UK.
AD  - NIHR Blood and Transplant Research Unit in Donor Health and Genomics, Department 
      of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
FAU - Drenos, Fotios
AU  - Drenos F
AD  - Institute of Cardiovascular Science, University College London, London, UK.
AD  - MRC Integrative Epidemiology Unit, School of Social and Community Medicine,
      University of Bristol, Bristol, UK.
FAU - Du, Mengmeng
AU  - Du M
AD  - Division of Public Health Sciences, Fred Hutchinson Cancer Research Center,
      Seattle, WA, USA.
AD  - Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer
      Center, New York, NY, USA.
FAU - Dube, Marie-Pierre
AU  - Dube MP
AD  - Montreal Heart Institute, Universite de Montreal, Montreal, Quebec, Canada.
AD  - Department of Medicine, Faculty of Medicine, Universite de Montreal, Montreal,
      Quebec, Canada.
FAU - Dunning, Alison M
AU  - Dunning AM
AD  - Centre for Cancer Genetic Epidemiology, Department of Oncology, University of
      Cambridge, Cambridge, UK.
FAU - Easton, Douglas F
AU  - Easton DF
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary
      Care, University of Cambridge, Cambridge, UK.
AD  - Centre for Cancer Genetic Epidemiology, Department of Oncology, University of
      Cambridge, Cambridge, UK.
FAU - Edwards, Todd L
AU  - Edwards TL
AD  - Division of Epidemiology, Department of Medicine, Institute for Medicine and
      Public Health, Vanderbilt Genetics Institute, Vanderbilt University, Nashville,
      TN, USA.
FAU - Ellinghaus, David
AU  - Ellinghaus D
AD  - Institute of Clinical Molecular Biology, Christian Albrechts University of Kiel, 
      Kiel, Germany.
FAU - Ellinor, Patrick T
AU  - Ellinor PT
AD  - Broad Institute of MIT and Harvard, Cambridge, MA, USA.
AD  - Massachusetts General Hospital, Boston, MA, USA.
AD  - Medical and Population Genetics Program, Broad Institute, Cambridge, MA, USA.
FAU - Elliott, Paul
AU  - Elliott P
AD  - Department of Epidemiology and Biostatistics, MRC-PHE Centre for Environment and 
      Health, School of Public Health, Imperial College London, London, UK.
FAU - Evangelou, Evangelos
AU  - Evangelou E
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Imperial
      College London, London, UK.
AD  - Department of Hygiene and Epidemiology, University of Ioannina Medical School,
      Ioannina, Greece.
FAU - Farmaki, Aliki-Eleni
AU  - Farmaki AE
AD  - Department of Nutrition and Dietetics, School of Health Science and Education,
      Harokopio University, Athens, Greece.
AD  - Department of Health Sciences, University of Leicester, Leicester, UK.
FAU - Farooqi, I Sadaf
AU  - Farooqi IS
AD  - Metabolic Research Laboratories, University of Cambridge, Cambridge, UK.
AD  - NIHR Cambridge Biomedical Research Centre, Wellcome Trust-MRC Institute of
      Metabolic Science, Addenbrooke's Hospital, Cambridge, UK.
FAU - Faul, Jessica D
AU  - Faul JD
AD  - Survey Research Center, Institute for Social Research, University of Michigan,
      Ann Arbor, MI, USA.
FAU - Fauser, Sascha
AU  - Fauser S
AD  - Department of Ophthalmology, University of Cologne, Cologne, Germany.
FAU - Feng, Shuang
AU  - Feng S
AD  - Department of Biostatistics and Center for Statistical Genetics, University of
      Michigan, Ann Arbor, MI, USA.
FAU - Ferrannini, Ele
AU  - Ferrannini E
AD  - CNR Institute of Clinical Physiology, Pisa, Italy.
AD  - Department of Clinical and Experimental Medicine, University of Pisa, Pisa,
      Italy.
FAU - Ferrieres, Jean
AU  - Ferrieres J
AD  - Toulouse University School of Medicine, Toulouse, France.
FAU - Florez, Jose C
AU  - Florez JC
AD  - Broad Institute of MIT and Harvard, Cambridge, MA, USA.
AD  - Massachusetts General Hospital, Boston, MA, USA.
AD  - Department of Medicine, Harvard Medical School, Boston, MA, USA.
AD  - Medical and Population Genetics Program, Broad Institute, Cambridge, MA, USA.
FAU - Ford, Ian
AU  - Ford I
AD  - University of Glasgow, Glasgow, UK.
FAU - Fornage, Myriam
AU  - Fornage M
AD  - Institute of Molecular Medicine, University of Texas Health Science Center at
      Houston, Houston, TX, USA.
FAU - Franco, Oscar H
AU  - Franco OH
AD  - Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands.
FAU - Franke, Andre
AU  - Franke A
AD  - Institute of Clinical Molecular Biology, Christian Albrechts University of Kiel, 
      Kiel, Germany.
FAU - Franks, Paul W
AU  - Franks PW
AD  - Department of Clinical Sciences, Genetic and Molecular Epidemiology Unit, Lund
      University, Malmo, Sweden.
AD  - Department of Nutrition, Harvard School of Public Health, Boston, MA, USA.
AD  - Department of Public Health and Clinical Medicine, Unit of Medicine, Umea
      University, Umea, Sweden.
FAU - Friedrich, Nele
AU  - Friedrich N
AD  - Institute of Clinical Chemistry and Laboratory Medicine, University Medicine
      Greifswald, Greifswald, Germany.
FAU - Frikke-Schmidt, Ruth
AU  - Frikke-Schmidt R
AD  - Department of Public Health, Faculty of Health and Medical Sciences, University
      of Copenhagen, Copenhagen, Denmark.
AD  - Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University
      Hospital, Copenhagen, Denmark.
FAU - Galesloot, Tessel E
AU  - Galesloot TE
AD  - Radboud Institute for Health Sciences, Radboud University Medical Center,
      Nijmegen, The Netherlands.
FAU - Gan, Wei
AU  - Gan W
AD  - Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
FAU - Gandin, Ilaria
AU  - Gandin I
AD  - Research Unit, AREA Science Park, Trieste, Italy.
FAU - Gasparini, Paolo
AU  - Gasparini P
AD  - Department of Medical Sciences, University of Trieste, Trieste, Italy.
AD  - Institute for Maternal and Child Health, IRCCS 'Burlo Garofolo', Trieste, Italy.
FAU - Gibson, Jane
AU  - Gibson J
AD  - Centre for Biological Sciences, Faculty of Natural and Environmental Sciences,
      University of Southampton, Southampton, UK.
FAU - Giedraitis, Vilmantas
AU  - Giedraitis V
AD  - Geriatrics, Department of Public Health, Uppsala University, Uppsala, Sweden.
FAU - Gjesing, Anette P
AU  - Gjesing AP
AD  - Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health
      and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
FAU - Gordon-Larsen, Penny
AU  - Gordon-Larsen P
AD  - Carolina Population Center, University of North Carolina, Chapel Hill, NC, USA.
AD  - Department of Nutrition, Gillings School of Global Public Health, University of
      North Carolina, Chapel Hill, NC, USA.
FAU - Gorski, Mathias
AU  - Gorski M
AD  - Department of Genetic Epidemiology, University of Regensburg, Regensburg,
      Germany.
AD  - Department of Nephrology, University Hospital Regensburg, Regensburg, Germany.
FAU - Grabe, Hans-Jorgen
AU  - Grabe HJ
AD  - Department of Psychiatry and Psychotherapy, University Medicine Greifswald,
      Greifswald, Germany.
AD  - German Center for Neurodegenerative Diseases (DZNE), Rostock/Greifswald,
      Greifswald, Germany.
FAU - Grant, Struan F A
AU  - Grant SFA
AD  - Center for Applied Genomics, Division of Human Genetics, Children's Hospital of
      Philadelphia, Philadelphia, PA, USA.
AD  - Department of Pediatrics, Perelman School of Medicine, University of
      Pennsylvania, Philadelphia, PA, USA.
AD  - Division of Endocrinology, Children's Hospital of Philadelphia, Philadelphia, PA,
      USA.
FAU - Grarup, Niels
AU  - Grarup N
AD  - Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health
      and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
FAU - Griffiths, Helen L
AU  - Griffiths HL
AD  - Vision Sciences, Clinical Neurosciences Research Group, Faculty of Medicine,
      University of Southampton, Southampton, UK.
FAU - Grove, Megan L
AU  - Grove ML
AD  - School of Public Health, Human Genetics Center, University of Texas Health
      Science Center at Houston, Houston, TX, USA.
FAU - Gudnason, Vilmundur
AU  - Gudnason V
AD  - Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
AD  - Icelandic Heart Association, Kopavogur, Iceland.
FAU - Gustafsson, Stefan
AU  - Gustafsson S
AD  - Department of Medical Sciences, Molecular Epidemiology and Science for Life
      Laboratory, Uppsala University, Uppsala, Sweden.
FAU - Haessler, Jeff
AU  - Haessler J
AD  - Division of Public Health Sciences, Fred Hutchinson Cancer Research Center,
      Seattle, WA, USA.
FAU - Hakonarson, Hakon
AU  - Hakonarson H
AD  - Center for Applied Genomics, Division of Human Genetics, Children's Hospital of
      Philadelphia, Philadelphia, PA, USA.
AD  - Department of Pediatrics, Perelman School of Medicine, University of
      Pennsylvania, Philadelphia, PA, USA.
FAU - Hammerschlag, Anke R
AU  - Hammerschlag AR
AD  - Department of Complex Trait Genetics, Center for Neurogenomics and Cognitive
      Research, Amsterdam Neuroscience, VU University Amsterdam, Amsterdam, The
      Netherlands.
FAU - Hansen, Torben
AU  - Hansen T
AD  - Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health
      and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
FAU - Harris, Kathleen Mullan
AU  - Harris KM
AD  - Carolina Population Center, University of North Carolina, Chapel Hill, NC, USA.
AD  - Department of Sociology, University of North Carolina, Chapel Hill, NC, USA.
FAU - Harris, Tamara B
AU  - Harris TB
AD  - Laboratory of Epidemiology and Population Sciences, National Institute on Aging, 
      Intramural Research Program, US National Institutes of Health, Bethesda, MD, USA.
FAU - Hattersley, Andrew T
AU  - Hattersley AT
AD  - University of Exeter Medical School, University of Exeter, Exeter, UK.
FAU - Have, Christian T
AU  - Have CT
AD  - Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health
      and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
FAU - Hayward, Caroline
AU  - Hayward C
AD  - MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University
      of Edinburgh, Edinburgh, UK.
FAU - He, Liang
AU  - He L
AD  - Biodemography of Aging Research Unit, Social Science Research Institute, Duke
      University, Durham, NC, USA.
AD  - Department of Public Health, University of Helsinki, Helsinki, Finland.
FAU - Heard-Costa, Nancy L
AU  - Heard-Costa NL
AD  - NHLBI Framingham Heart Study, Framingham, MA, USA.
AD  - Department of Neurology, Boston University School of Medicine, Boston, MA, USA.
FAU - Heath, Andrew C
AU  - Heath AC
AD  - Department of Psychiatry, Washington University, St. Louis, MO, USA.
FAU - Heid, Iris M
AU  - Heid IM
AD  - Department of Genetic Epidemiology, University of Regensburg, Regensburg,
      Germany.
AD  - Institute of Genetic Epidemiology, Helmholtz Zentrum Munchen-German Research
      Center for Environmental Health, Neuherberg, Germany.
FAU - Helgeland, Oyvind
AU  - Helgeland O
AD  - Department of Pediatrics, Haukeland University Hospital, Bergen, Norway.
AD  - KG Jebsen Center for Diabetes Research, Department of Clinical Science,
      University of Bergen, Bergen, Norway.
FAU - Hernesniemi, Jussi
AU  - Hernesniemi J
AD  - Department of Cardiology, Heart Center, Tampere University Hospital and Faculty
      of Medicine and Life Sciences, University of Tampere, Tampere, Finland.
AD  - Department of Clinical Chemistry, Fimlab Laboratories, Tampere, Finland.
AD  - Department of Clinical Chemistry, Finnish Cardiovascular Research Center-Tampere,
      Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland.
FAU - Hewitt, Alex W
AU  - Hewitt AW
AD  - Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital,
      University of Melbourne, Melbourne, Victoria, Australia.
AD  - Centre for Ophthalmology and Vision Science, Lions Eye Institute, University of
      Western Australia, Perth, Western Australia, Australia.
AD  - Menzies Research Institute Tasmania, University of Tasmania, Hobart, Tasmania,
      Australia.
FAU - Holmen, Oddgeir L
AU  - Holmen OL
AD  - KG Jebsen Center for Genetic Epidemiology, Department of Public Health, NTNU,
      Norwegian University of Science and Technology, Trondheim, Norway.
FAU - Hovingh, G Kees
AU  - Hovingh GK
AD  - Department of Vascular Medicine, AMC, Amsterdam, The Netherlands.
FAU - Howson, Joanna M M
AU  - Howson JMM
AD  - MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary
      Care, University of Cambridge, Cambridge, UK.
FAU - Hu, Yao
AU  - Hu Y
AD  - Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences,
      Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences,
      University of the Chinese Academy of Sciences, Shanghai, China.
FAU - Huang, Paul L
AU  - Huang PL
AD  - Massachusetts General Hospital, Boston, MA, USA.
FAU - Huffman, Jennifer E
AU  - Huffman JE
AD  - MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University
      of Edinburgh, Edinburgh, UK.
FAU - Ikram, M Arfan
AU  - Ikram MA
AD  - Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands.
AD  - Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands.
AD  - Department of Radiology, Erasmus Medical Center, Rotterdam, The Netherlands.
FAU - Ingelsson, Erik
AU  - Ingelsson E
AD  - Department of Medical Sciences, Molecular Epidemiology and Science for Life
      Laboratory, Uppsala University, Uppsala, Sweden.
AD  - Division of Cardiovascular Medicine, Department of Medicine, Stanford University 
      School of Medicine, Stanford, CA, USA.
FAU - Jackson, Anne U
AU  - Jackson AU
AD  - Department of Biostatistics and Center for Statistical Genetics, University of
      Michigan, Ann Arbor, MI, USA.
FAU - Jansson, Jan-Hakan
AU  - Jansson JH
AD  - Department of Public Health and Clinical Medicine, Umea University, Umea, Sweden.
AD  - Research Unit Skelleftea, Skelleftea, Sweden.
FAU - Jarvik, Gail P
AU  - Jarvik GP
AD  - Department of Medicine, University of Washington, Seattle, WA, USA.
AD  - Department of Genome Sciences, University of Washington, Seattle, WA, USA.
FAU - Jensen, Gorm B
AU  - Jensen GB
AD  - Copenhagen City Heart Study, Frederiksberg Hospital, Frederiksberg, Denmark.
FAU - Jia, Yucheng
AU  - Jia Y
AD  - Institute for Translational Genomics and Population Sciences, LABioMed at
      Harbor-UCLA Medical Center, Torrance, CA, USA.
FAU - Johansson, Stefan
AU  - Johansson S
AD  - KG Jebsen Center for Diabetes Research, Department of Clinical Science,
      University of Bergen, Bergen, Norway.
AD  - Center for Medical Genetics and Molecular Medicine, Haukeland University
      Hospital, Bergen, Norway.
FAU - Jorgensen, Marit E
AU  - Jorgensen ME
AD  - National Institute of Public Health, University of Southern Denmark, Copenhagen, 
      Denmark.
AD  - Steno Diabetes Center Copenhagen, Gentofte, Denmark.
FAU - Jorgensen, Torben
AU  - Jorgensen T
AD  - Department of Public Health, Faculty of Health and Medical Sciences, University
      of Copenhagen, Copenhagen, Denmark.
AD  - Faculty of Medicine, Aalborg University, Aalborg, Denmark.
AD  - Research Center for Prevention and Health, Capital Region of Denmark, Glostrup,
      Denmark.
FAU - Jukema, J Wouter
AU  - Jukema JW
AD  - Department of Cardiology, Leiden University Medical Center, Leiden, The
      Netherlands.
AD  - Interuniversity Cardiology Institute of the Netherlands, Utrecht, The
      Netherlands.
FAU - Kahali, Bratati
AU  - Kahali B
AD  - Department of Computational Medicine and Bioinformatics, University of Michigan, 
      Ann Arbor, MI, USA.
AD  - Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
AD  - Division of Gastroenterology, University of Michigan, Ann Arbor, MI, USA.
AD  - Centre for Brain Research, Indian Institute of Science, Bangalore, India.
FAU - Kahn, Rene S
AU  - Kahn RS
AD  - Department of Psychiatry, Brain Center Rudolf Magnus, University Medical Center
      Utrecht, Utrecht, The Netherlands.
FAU - Kahonen, Mika
AU  - Kahonen M
AD  - Department of Clinical Physiology, Faculty of Medicine and Life Sciences,
      University of Tampere, Tampere, Finland.
AD  - Department of Clinical Physiology, Tampere University Hospital, Tampere, Finland.
FAU - Kamstrup, Pia R
AU  - Kamstrup PR
AD  - Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen
      University Hospital, Herlev, Denmark.
FAU - Kanoni, Stavroula
AU  - Kanoni S
AD  - William Harvey Research Institute, Barts and The London School of Medicine and
      Dentistry, Queen Mary University of London, London, UK.
FAU - Kaprio, Jaakko
AU  - Kaprio J
AD  - Department of Public Health, University of Helsinki, Helsinki, Finland.
AD  - Institute for Molecular Medicine Finland (FIMM), University of Helsinki,
      Helsinki, Finland.
AD  - National Institute for Health and Welfare, Helsinki, Finland.
FAU - Karaleftheri, Maria
AU  - Karaleftheri M
AD  - Echinos Medical Centre, Echinos, Greece.
FAU - Kardia, Sharon L R
AU  - Kardia SLR
AD  - Department of Epidemiology, School of Public Health, University of Michigan, Ann 
      Arbor, MI, USA.
FAU - Karpe, Fredrik
AU  - Karpe F
AD  - Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of
      Medicine, University of Oxford, Oxford, UK.
AD  - Oxford NIHR Biomedical Research Centre, Oxford University Hospitals Trust,
      Oxford, UK.
FAU - Kathiresan, Sekar
AU  - Kathiresan S
AD  - Broad Institute of MIT and Harvard, Cambridge, MA, USA.
AD  - Massachusetts General Hospital, Boston, MA, USA.
AD  - Harvard Medical School, Boston, MA, USA.
FAU - Kee, Frank
AU  - Kee F
AD  - UKCRC Centre of Excellence for Public Health Research, Queens University Belfast,
      Belfast, UK.
FAU - Kiemeney, Lambertus A
AU  - Kiemeney LA
AD  - Radboud Institute for Health Sciences, Radboud University Medical Center,
      Nijmegen, The Netherlands.
FAU - Kim, Eric
AU  - Kim E
AD  - Institute for Translational Genomics and Population Sciences, LABioMed at
      Harbor-UCLA Medical Center, Torrance, CA, USA.
FAU - Kitajima, Hidetoshi
AU  - Kitajima H
AD  - Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
FAU - Komulainen, Pirjo
AU  - Komulainen P
AD  - Foundation for Research in Health Exercise and Nutrition, Kuopio Research
      Institute of Exercise Medicine, Kuopio, Finland.
AD  - Institute of Biomedicine, School of Medicine, University of Eastern Finland,
      Kuopio Campus, Kuopio, Finland.
AD  - Department of Clinical Physiology and Nuclear Medicine, Kuopio University
      Hospital, Kuopio, Finland.
FAU - Kooner, Jaspal S
AU  - Kooner JS
AD  - Department of Cardiology, London North West Healthcare NHS Trust, Ealing
      Hospital, Middlesex, UK.
AD  - Imperial College Healthcare NHS Trust, London, UK.
AD  - National Heart and Lung Institute, Imperial College London, Hammersmith Hospital 
      Campus, London, UK.
AD  - MRC-PHE Centre for Environment and Health, Imperial College London, London, UK.
FAU - Kooperberg, Charles
AU  - Kooperberg C
AD  - Division of Public Health Sciences, Fred Hutchinson Cancer Research Center,
      Seattle, WA, USA.
FAU - Korhonen, Tellervo
AU  - Korhonen T
AD  - Department of Public Health, University of Helsinki, Helsinki, Finland.
AD  - National Institute for Health and Welfare, Helsinki, Finland.
AD  - Institute of Public Health and Clinical Nutrition, University of Eastern Finland,
      Kuopio, Finland.
FAU - Kovacs, Peter
AU  - Kovacs P
AD  - IFB Adiposity Diseases, University of Leipzig, Leipzig, Germany.
FAU - Kuivaniemi, Helena
AU  - Kuivaniemi H
AD  - Weis Center for Research, Geisinger Health System, Danville, PA, USA.
AD  - Department of Psychiatry, Faculty of Medicine and Health Sciences, Stellenbosch
      University, Tygerberg, South Africa.
AD  - Division of Molecular Biology and Human Genetics, Department of Biomedical
      Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University,
      Tygerberg, South Africa.
FAU - Kutalik, Zoltan
AU  - Kutalik Z
AD  - Swiss Institute of Bioinformatics, Lausanne, Switzerland.
AD  - Institute of Social and Preventive Medicine, Lausanne University Hospital,
      Lausanne, Switzerland.
FAU - Kuulasmaa, Kari
AU  - Kuulasmaa K
AD  - National Institute for Health and Welfare, Helsinki, Finland.
FAU - Kuusisto, Johanna
AU  - Kuusisto J
AD  - Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland 
      and Kuopio University Hospital, Kuopio, Finland.
FAU - Laakso, Markku
AU  - Laakso M
AD  - Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland 
      and Kuopio University Hospital, Kuopio, Finland.
FAU - Lakka, Timo A
AU  - Lakka TA
AD  - Foundation for Research in Health Exercise and Nutrition, Kuopio Research
      Institute of Exercise Medicine, Kuopio, Finland.
AD  - Institute of Biomedicine, School of Medicine, University of Eastern Finland,
      Kuopio Campus, Kuopio, Finland.
AD  - Department of Clinical Physiology and Nuclear Medicine, Kuopio University
      Hospital, Kuopio, Finland.
FAU - Lamparter, David
AU  - Lamparter D
AD  - Department of Computational Biology, University of Lausanne, Lausanne,
      Switzerland.
AD  - Swiss Institute of Bioinformatics, Lausanne, Switzerland.
FAU - Lange, Ethan M
AU  - Lange EM
AD  - Department of Genetics, University of North Carolina, Chapel Hill, NC, USA.
FAU - Lange, Leslie A
AU  - Lange LA
AD  - Department of Genetics, University of North Carolina, Chapel Hill, NC, USA.
FAU - Langenberg, Claudia
AU  - Langenberg C
AD  - MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine,
      Institute of Metabolic Science, Cambridge, UK.
FAU - Larson, Eric B
AU  - Larson EB
AD  - Department of Medicine, University of Washington, Seattle, WA, USA.
AD  - Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA.
AD  - Department of Health Services, University of Washington, Seattle, WA, USA.
FAU - Lee, Nanette R
AU  - Lee NR
AD  - Department of Anthropology, Sociology and History, University of San Carlos, Cebu
      City, Philippines.
AD  - USC-Office of Population Studies Foundation, Inc., University of San Carlos, Cebu
      City, Philippines.
FAU - Lehtimaki, Terho
AU  - Lehtimaki T
AD  - Department of Clinical Chemistry, Fimlab Laboratories, Tampere, Finland.
AD  - Department of Clinical Chemistry, Finnish Cardiovascular Research Center-Tampere,
      Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland.
FAU - Lewis, Cora E
AU  - Lewis CE
AD  - Division of Preventive Medicine, University of Alabama at Birmingham, Birmingham,
      AL, USA.
FAU - Li, Huaixing
AU  - Li H
AD  - Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences,
      Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences,
      University of the Chinese Academy of Sciences, Shanghai, China.
FAU - Li, Jin
AU  - Li J
AD  - Division of Cardiovascular Medicine, Department of Medicine, Stanford University 
      School of Medicine, Stanford, CA, USA.
FAU - Li-Gao, Ruifang
AU  - Li-Gao R
AD  - Department of Clinical Epidemiology, Leiden University Medical Center, Leiden,
      The Netherlands.
FAU - Lin, Honghuang
AU  - Lin H
AD  - Department of Medicine, Boston University School of Medicine, Boston, MA, USA.
FAU - Lin, Keng-Hung
AU  - Lin KH
AD  - Department of Ophthalmology, Taichung Veterans General Hospital, Taichung,
      Taiwan.
FAU - Lin, Li-An
AU  - Lin LA
AD  - Institute of Molecular Medicine, University of Texas Health Science Center at
      Houston, Houston, TX, USA.
FAU - Lin, Xu
AU  - Lin X
AD  - Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences,
      Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences,
      University of the Chinese Academy of Sciences, Shanghai, China.
FAU - Lind, Lars
AU  - Lind L
AD  - Department of Medical Sciences, Cardiovascular Epidemiology, Uppsala University, 
      Uppsala, Sweden.
FAU - Lindstrom, Jaana
AU  - Lindstrom J
AD  - National Institute for Health and Welfare, Helsinki, Finland.
FAU - Linneberg, Allan
AU  - Linneberg A
AD  - Research Center for Prevention and Health, Capital Region of Denmark, Glostrup,
      Denmark.
AD  - Department of Clinical Experimental Research, Rigshospitalet, Copenhagen,
      Denmark.
AD  - Department of Clinical Medicine, Faculty of Health and Medical Sciences,
      University of Copenhagen, Copenhagen, Denmark.
FAU - Liu, Ching-Ti
AU  - Liu CT
AD  - Department of Biostatistics, Boston University School of Public Health, Boston,
      MA, USA.
FAU - Liu, Dajiang J
AU  - Liu DJ
AD  - Department of Public Health Sciences, Institute for Personalized Medicine,
      Pennsylvania State University College of Medicine, Hershey, PA, USA.
FAU - Liu, Yongmei
AU  - Liu Y
AD  - Division of Public Health Sciences, Wake Forest School of Medicine,
      Winston-Salem, NC, USA.
FAU - Lo, Ken S
AU  - Lo KS
AD  - Montreal Heart Institute, Universite de Montreal, Montreal, Quebec, Canada.
FAU - Lophatananon, Artitaya
AU  - Lophatananon A
AD  - Division of Health Sciences, Warwick Medical School, Warwick University,
      Coventry, UK.
FAU - Lotery, Andrew J
AU  - Lotery AJ
AD  - Vision Sciences, Clinical Neurosciences Research Group, Faculty of Medicine,
      University of Southampton, Southampton, UK.
FAU - Loukola, Anu
AU  - Loukola A
AD  - Department of Public Health, University of Helsinki, Helsinki, Finland.
AD  - Institute for Molecular Medicine Finland (FIMM), University of Helsinki,
      Helsinki, Finland.
FAU - Luan, Jian'an
AU  - Luan J
AD  - MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine,
      Institute of Metabolic Science, Cambridge, UK.
FAU - Lubitz, Steven A
AU  - Lubitz SA
AD  - Broad Institute of MIT and Harvard, Cambridge, MA, USA.
AD  - Massachusetts General Hospital, Boston, MA, USA.
AD  - Medical and Population Genetics Program, Broad Institute, Cambridge, MA, USA.
FAU - Lyytikainen, Leo-Pekka
AU  - Lyytikainen LP
AD  - Department of Clinical Chemistry, Fimlab Laboratories, Tampere, Finland.
AD  - Department of Clinical Chemistry, Finnish Cardiovascular Research Center-Tampere,
      Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland.
FAU - Mannisto, Satu
AU  - Mannisto S
AD  - National Institute for Health and Welfare, Helsinki, Finland.
FAU - Marenne, Gaelle
AU  - Marenne G
AD  - Wellcome Trust Sanger Institute, Hinxton, UK.
FAU - Mazul, Angela L
AU  - Mazul AL
AD  - Department of Epidemiology, University of North Carolina, Chapel Hill, NC, USA.
FAU - McCarthy, Mark I
AU  - McCarthy MI
AD  - Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
AD  - Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of
      Medicine, University of Oxford, Oxford, UK.
AD  - Oxford NIHR Biomedical Research Centre, Oxford University Hospitals Trust,
      Oxford, UK.
FAU - McKean-Cowdin, Roberta
AU  - McKean-Cowdin R
AD  - Department of Preventive Medicine, Keck School of Medicine of the University of
      Southern California, Los Angeles, CA, USA.
FAU - Medland, Sarah E
AU  - Medland SE
AD  - QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
FAU - Meidtner, Karina
AU  - Meidtner K
AD  - Department of Molecular Epidemiology, German Institute of Human Nutrition
      Potsdam-Rehbrucke (DIfE), Nuthetal, Germany.
AD  - German Center for Diabetes Research, Neuherberg, Germany.
FAU - Milani, Lili
AU  - Milani L
AD  - Estonian Genome Center, University of Tartu, Tartu, Estonia.
FAU - Mistry, Vanisha
AU  - Mistry V
AD  - Metabolic Research Laboratories, University of Cambridge, Cambridge, UK.
AD  - NIHR Cambridge Biomedical Research Centre, Wellcome Trust-MRC Institute of
      Metabolic Science, Addenbrooke's Hospital, Cambridge, UK.
FAU - Mitchell, Paul
AU  - Mitchell P
AD  - Westmead Millennium Institute of Medical Research, Centre for Vision Research and
      Department of Ophthalmology, University of Sydney, Sydney, New South Wales,
      Australia.
FAU - Mohlke, Karen L
AU  - Mohlke KL
AD  - Department of Genetics, University of North Carolina, Chapel Hill, NC, USA.
FAU - Moilanen, Leena
AU  - Moilanen L
AD  - Department of Medicine, Kuopio University Hospital, Kuopio, Finland.
FAU - Moitry, Marie
AU  - Moitry M
AD  - Department of Epidemiology and Public Health, University of Strasbourg,
      Strasbourg, France.
AD  - Department of Public Health, University Hospital of Strasbourg, Strasbourg,
      France.
FAU - Montgomery, Grant W
AU  - Montgomery GW
AD  - QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
AD  - Institute for Molecular Bioscience, University of Queensland, Brisbane,
      Queensland, Australia.
FAU - Mook-Kanamori, Dennis O
AU  - Mook-Kanamori DO
AD  - Department of Clinical Epidemiology, Leiden University Medical Center, Leiden,
      The Netherlands.
AD  - Department of Public Health and Primary Care, Leiden University Medical Center,
      Leiden, The Netherlands.
FAU - Moore, Carmel
AU  - Moore C
AD  - NIHR Blood and Transplant Research Unit in Donor Health and Genomics, Department 
      of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
AD  - INTERVAL Coordinating Centre, Department of Public Health and Primary Care,
      University of Cambridge, Cambridge, UK.
FAU - Mori, Trevor A
AU  - Mori TA
AD  - School of Medicine and Pharmacology, University of Western Australia, Perth,
      Western Australia, Australia.
FAU - Morris, Andrew D
AU  - Morris AD
AD  - Centre for Global Health Research, Usher Institute of Population Health Sciences 
      and Informatics, University of Edinburgh, Edinburgh, UK.
FAU - Morris, Andrew P
AU  - Morris AP
AD  - Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
AD  - Department of Biostatistics, University of Liverpool, Liverpool, UK.
FAU - Muller-Nurasyid, Martina
AU  - Muller-Nurasyid M
AD  - Institute of Genetic Epidemiology, Helmholtz Zentrum Munchen-German Research
      Center for Environmental Health, Neuherberg, Germany.
AD  - Department of Medicine I, University Hospital Grosshadern,
      Ludwig-Maximilians-Universitat, Munich, Germany.
AD  - German Centre for Cardiovascular Research (DZHK), partner site Munich Heart
      Alliance, Munich, Germany.
FAU - Munroe, Patricia B
AU  - Munroe PB
AD  - William Harvey Research Institute, Barts and The London School of Medicine and
      Dentistry, Queen Mary University of London, London, UK.
AD  - NIHR Barts Cardiovascular Research Unit, Barts and The London School of Medicine 
      and Dentistry, Queen Mary University of London, London, UK.
FAU - Nalls, Mike A
AU  - Nalls MA
AD  - Laboratory of Neurogenetics, National Institute on Aging, US National Institutes 
      of Health, Bethesda, MD, USA.
AD  - Data Tecnica International, Glen Echo, MD, USA.
FAU - Narisu, Narisu
AU  - Narisu N
AD  - Medical Genomics and Metabolic Genetics Branch, National Human Genome Research
      Institute, US National Institutes of Health, Bethesda, MD, USA.
FAU - Nelson, Christopher P
AU  - Nelson CP
AD  - Department of Cardiovascular Sciences, University of Leicester, Glenfield
      Hospital, Leicester, UK.
AD  - NIHR Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital,
      Leicester, UK.
FAU - Neville, Matt
AU  - Neville M
AD  - Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of
      Medicine, University of Oxford, Oxford, UK.
AD  - Oxford NIHR Biomedical Research Centre, Oxford University Hospitals Trust,
      Oxford, UK.
FAU - Nielsen, Sune F
AU  - Nielsen SF
AD  - Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen
      University Hospital, Herlev, Denmark.
AD  - Department of Public Health, Faculty of Health and Medical Sciences, University
      of Copenhagen, Copenhagen, Denmark.
FAU - Nikus, Kjell
AU  - Nikus K
AD  - Department of Cardiology, Heart Center, Tampere University Hospital and Faculty
      of Medicine and Life Sciences, University of Tampere, Tampere, Finland.
FAU - Njolstad, Pal R
AU  - Njolstad PR
AD  - Department of Pediatrics, Haukeland University Hospital, Bergen, Norway.
AD  - KG Jebsen Center for Diabetes Research, Department of Clinical Science,
      University of Bergen, Bergen, Norway.
FAU - Nordestgaard, Borge G
AU  - Nordestgaard BG
AD  - Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen
      University Hospital, Herlev, Denmark.
AD  - Department of Public Health, Faculty of Health and Medical Sciences, University
      of Copenhagen, Copenhagen, Denmark.
FAU - Nyholt, Dale R
AU  - Nyholt DR
AD  - QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
AD  - Institute of Health and Biomedical Innovation, Queensland University of
      Technology, Brisbane, Queensland, Australia.
FAU - O'Connel, Jeffrey R
AU  - O'Connel JR
AD  - Program for Personalized and Genomic Medicine, Department of Medicine, University
      of Maryland School of Medicine, Baltimore, MD, USA.
FAU - O'Donoghue, Michelle L
AU  - O'Donoghue ML
AD  - Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard
      Medical School, Boston, MA, USA.
FAU - Olde Loohuis, Loes M
AU  - Olde Loohuis LM
AD  - Center for Neurobehavioral Genetics, University of California, Los Angeles, Los
      Angeles, CA, USA.
FAU - Ophoff, Roel A
AU  - Ophoff RA
AD  - Department of Psychiatry, Brain Center Rudolf Magnus, University Medical Center
      Utrecht, Utrecht, The Netherlands.
AD  - Center for Neurobehavioral Genetics, University of California, Los Angeles, Los
      Angeles, CA, USA.
FAU - Owen, Katharine R
AU  - Owen KR
AD  - Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of
      Medicine, University of Oxford, Oxford, UK.
AD  - Oxford NIHR Biomedical Research Centre, Oxford University Hospitals Trust,
      Oxford, UK.
FAU - Packard, Chris J
AU  - Packard CJ
AD  - University of Glasgow, Glasgow, UK.
FAU - Padmanabhan, Sandosh
AU  - Padmanabhan S
AD  - University of Glasgow, Glasgow, UK.
FAU - Palmer, Colin N A
AU  - Palmer CNA
AD  - Pat Macpherson Centre for Pharmacogenetics and Pharmacogenomics, Medical Research
      Institute, Ninewells Hospital and Medical School, Dundee, UK.
FAU - Palmer, Nicholette D
AU  - Palmer ND
AD  - Department of Biochemistry, Wake Forest School of Medicine, Winston-Salem, NC,
      USA.
FAU - Pasterkamp, Gerard
AU  - Pasterkamp G
AD  - Laboratory of Experimental Cardiology, Division Heart and Lungs, University
      Medical Center Utrecht, Utrecht, The Netherlands.
AD  - Laboratory of Clinical Chemistry and Hematology, Division of Laboratories and
      Pharmacy, University Medical Center Utrecht, Utrecht, The Netherlands.
FAU - Patel, Aniruddh P
AU  - Patel AP
AD  - Broad Institute of MIT and Harvard, Cambridge, MA, USA.
AD  - Massachusetts General Hospital, Boston, MA, USA.
AD  - Harvard Medical School, Boston, MA, USA.
FAU - Pattie, Alison
AU  - Pattie A
AD  - Department of Psychology, University of Edinburgh, Edinburgh, UK.
FAU - Pedersen, Oluf
AU  - Pedersen O
AD  - Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health
      and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
FAU - Peissig, Peggy L
AU  - Peissig PL
AD  - Marshfield Clinic Research Institute, Marshfield, WI, USA.
FAU - Peloso, Gina M
AU  - Peloso GM
AD  - Department of Biostatistics, Boston University School of Public Health, Boston,
      MA, USA.
FAU - Pennell, Craig E
AU  - Pennell CE
AD  - School of Women's and Infants' Health, University of Western Australia, Perth,
      Western Australia, Australia.
FAU - Perola, Markus
AU  - Perola M
AD  - Estonian Genome Center, University of Tartu, Tartu, Estonia.
AD  - Institute for Molecular Medicine Finland (FIMM), University of Helsinki,
      Helsinki, Finland.
AD  - National Institute for Health and Welfare, Helsinki, Finland.
AD  - Diabetes and Obesity Research Program, University of Helsinki, Helsinki, Finland.
FAU - Perry, James A
AU  - Perry JA
AD  - Program for Personalized and Genomic Medicine, Department of Medicine, University
      of Maryland School of Medicine, Baltimore, MD, USA.
FAU - Perry, John R B
AU  - Perry JRB
AD  - MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine,
      Institute of Metabolic Science, Cambridge, UK.
FAU - Pers, Tune H
AU  - Pers TH
AD  - Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health
      and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
AD  - Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark.
FAU - Person, Thomas N
AU  - Person TN
AD  - Marshfield Clinic Research Institute, Marshfield, WI, USA.
FAU - Peters, Annette
AU  - Peters A
AD  - German Center for Diabetes Research, Neuherberg, Germany.
AD  - German Centre for Cardiovascular Research (DZHK), partner site Munich Heart
      Alliance, Munich, Germany.
AD  - Institute of Epidemiology II, Helmholtz Zentrum Munchen-German Research Center
      for Environmental Health, Neuherberg, Germany.
FAU - Petersen, Eva R B
AU  - Petersen ERB
AD  - Department of Clinical Immunology and Biochemistry, Lillebaelt Hospital, Vejle,
      Denmark.
FAU - Peyser, Patricia A
AU  - Peyser PA
AD  - Department of Epidemiology, School of Public Health, University of Michigan, Ann 
      Arbor, MI, USA.
FAU - Pirie, Ailith
AU  - Pirie A
AD  - Centre for Cancer Genetic Epidemiology, Department of Oncology, University of
      Cambridge, Cambridge, UK.
FAU - Polasek, Ozren
AU  - Polasek O
AD  - Centre for Global Health Research, Usher Institute of Population Health Sciences 
      and Informatics, University of Edinburgh, Edinburgh, UK.
AD  - School of Medicine, University of Split, Split, Croatia.
FAU - Polderman, Tinca J
AU  - Polderman TJ
AD  - Department of Complex Trait Genetics, Center for Neurogenomics and Cognitive
      Research, Amsterdam Neuroscience, VU University Amsterdam, Amsterdam, The
      Netherlands.
FAU - Puolijoki, Hannu
AU  - Puolijoki H
AD  - Central Hospital of Southern Ostrobothnia, Seinajoki, Finland.
FAU - Raitakari, Olli T
AU  - Raitakari OT
AD  - Department of Clinical Physiology and Nuclear Medicine, Turku University
      Hospital, Turku, Finland.
AD  - Research Centre of Applied and Preventive Cardiovascular Medicine, University of 
      Turku, Turku, Finland.
FAU - Rasheed, Asif
AU  - Rasheed A
AD  - Centre for Non-Communicable Diseases, Karachi, Pakistan.
FAU - Rauramaa, Rainer
AU  - Rauramaa R
AD  - Foundation for Research in Health Exercise and Nutrition, Kuopio Research
      Institute of Exercise Medicine, Kuopio, Finland.
AD  - Institute of Biomedicine, School of Medicine, University of Eastern Finland,
      Kuopio Campus, Kuopio, Finland.
FAU - Reilly, Dermot F
AU  - Reilly DF
AD  - Genetics and Pharmacogenomics, Merck, Sharp & Dohme, Boston, MA, USA.
FAU - Renstrom, Frida
AU  - Renstrom F
AD  - Department of Clinical Sciences, Genetic and Molecular Epidemiology Unit, Lund
      University, Malmo, Sweden.
AD  - Department of Biobank Research, Umea University, Umea, Sweden.
FAU - Rheinberger, Myriam
AU  - Rheinberger M
AD  - Department of Nephrology, University Hospital Regensburg, Regensburg, Germany.
FAU - Ridker, Paul M
AU  - Ridker PM
AD  - Division of Preventive Medicine, Brigham and Women's Hospital and Harvard Medical
      School, Boston, MA, USA.
AD  - Harvard Medical School, Boston, MA, USA.
AD  - Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard
      Medical School, Boston, MA, USA.
FAU - Rioux, John D
AU  - Rioux JD
AD  - Montreal Heart Institute, Universite de Montreal, Montreal, Quebec, Canada.
AD  - Department of Medicine, Faculty of Medicine, Universite de Montreal, Montreal,
      Quebec, Canada.
FAU - Rivas, Manuel A
AU  - Rivas MA
AD  - Broad Institute of MIT and Harvard, Cambridge, MA, USA.
AD  - Wellcome Trust Centre for Human Genetics, Nuffield Department of Clinical
      Medicine, University of Oxford, Oxford, UK.
FAU - Roberts, David J
AU  - Roberts DJ
AD  - NIHR Blood and Transplant Research Unit in Donor Health and Genomics, Department 
      of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
AD  - NHS Blood and Transplant-Oxford Centre, Oxford, UK.
AD  - BRC Haematology Theme and Radcliffe Department of Medicine, University of Oxford,
      Oxford, UK.
FAU - Robertson, Neil R
AU  - Robertson NR
AD  - Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
AD  - Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of
      Medicine, University of Oxford, Oxford, UK.
FAU - Robino, Antonietta
AU  - Robino A
AD  - Institute for Maternal and Child Health, IRCCS 'Burlo Garofolo', Trieste, Italy.
FAU - Rolandsson, Olov
AU  - Rolandsson O
AD  - Department of Public Health and Clinical Medicine, Umea University, Umea, Sweden.
AD  - Department of Public Health and Clinical Medicine, Unit of Family Medicine, Umea 
      University, Umea, Sweden.
FAU - Rudan, Igor
AU  - Rudan I
AD  - Centre for Global Health Research, Usher Institute of Population Health Sciences 
      and Informatics, University of Edinburgh, Edinburgh, UK.
FAU - Ruth, Katherine S
AU  - Ruth KS
AD  - Genetics of Complex Traits, University of Exeter Medical School, University of
      Exeter, Exeter, UK.
FAU - Saleheen, Danish
AU  - Saleheen D
AD  - Centre for Non-Communicable Diseases, Karachi, Pakistan.
AD  - Department of Biostatistics and Epidemiology, Perelman School of Medicine,
      University of Pennsylvania, Philadelphia, PA, USA.
FAU - Salomaa, Veikko
AU  - Salomaa V
AD  - National Institute for Health and Welfare, Helsinki, Finland.
FAU - Samani, Nilesh J
AU  - Samani NJ
AD  - Department of Cardiovascular Sciences, University of Leicester, Glenfield
      Hospital, Leicester, UK.
AD  - NIHR Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital,
      Leicester, UK.
FAU - Sapkota, Yadav
AU  - Sapkota Y
AD  - QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
FAU - Sattar, Naveed
AU  - Sattar N
AD  - University of Glasgow, Glasgow, UK.
FAU - Schoen, Robert E
AU  - Schoen RE
AD  - Departments of Medicine and Epidemiology, University of Pittsburgh Medical
      Center, Pittsburgh, PA, USA.
FAU - Schreiner, Pamela J
AU  - Schreiner PJ
AD  - Division of Epidemiology and Community Health, School of Public Health,
      University of Minnesota, Minneapolis, MN, USA.
FAU - Schulze, Matthias B
AU  - Schulze MB
AD  - Department of Molecular Epidemiology, German Institute of Human Nutrition
      Potsdam-Rehbrucke (DIfE), Nuthetal, Germany.
AD  - German Center for Diabetes Research, Neuherberg, Germany.
FAU - Scott, Robert A
AU  - Scott RA
AD  - MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine,
      Institute of Metabolic Science, Cambridge, UK.
FAU - Segura-Lepe, Marcelo P
AU  - Segura-Lepe MP
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Imperial
      College London, London, UK.
FAU - Shah, Svati H
AU  - Shah SH
AD  - Duke Molecular Physiology Institute, Duke University, Durham, NC, USA.
FAU - Sheu, Wayne H-H
AU  - Sheu WH
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine,
      Taichung Veterans General Hospital, Taichung, Taiwan.
AD  - School of Medicine, National Defense Medical Center, Taipei, Taiwan.
AD  - School of Medicine, National Yang-Ming University, Taipei, Taiwan.
FAU - Sim, Xueling
AU  - Sim X
AD  - Department of Biostatistics and Center for Statistical Genetics, University of
      Michigan, Ann Arbor, MI, USA.
AD  - Saw Swee Hock School of Public Health, National University Health System,
      National University of Singapore, Singapore, Singapore.
FAU - Slater, Andrew J
AU  - Slater AJ
AD  - Genetics, Target Sciences, GlaxoSmithKline, Research Triangle Park, NC, USA.
AD  - OmicSoft at Qiagen Company, Cary, NC, USA.
FAU - Small, Kerrin S
AU  - Small KS
AD  - Department of Twin Research and Genetic Epidemiology, King's College London,
      London, UK.
FAU - Smith, Albert V
AU  - Smith AV
AD  - Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
AD  - Icelandic Heart Association, Kopavogur, Iceland.
FAU - Southam, Lorraine
AU  - Southam L
AD  - Wellcome Trust Sanger Institute, Hinxton, UK.
AD  - Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
FAU - Spector, Timothy D
AU  - Spector TD
AD  - Department of Twin Research and Genetic Epidemiology, King's College London,
      London, UK.
FAU - Speliotes, Elizabeth K
AU  - Speliotes EK
AD  - Department of Computational Medicine and Bioinformatics, University of Michigan, 
      Ann Arbor, MI, USA.
AD  - Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
AD  - Division of Gastroenterology, University of Michigan, Ann Arbor, MI, USA.
FAU - Starr, John M
AU  - Starr JM
AD  - Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, 
      Edinburgh, UK.
AD  - Alzheimer Scotland Dementia Research Centre, University of Edinburgh, Edinburgh, 
      UK.
FAU - Stefansson, Kari
AU  - Stefansson K
AD  - Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
AD  - deCODE Genetics/Amgen, Inc., Reykjavik, Iceland.
FAU - Steinthorsdottir, Valgerdur
AU  - Steinthorsdottir V
AD  - deCODE Genetics/Amgen, Inc., Reykjavik, Iceland.
FAU - Stirrups, Kathleen E
AU  - Stirrups KE
AD  - William Harvey Research Institute, Barts and The London School of Medicine and
      Dentistry, Queen Mary University of London, London, UK.
AD  - Department of Haematology, University of Cambridge, Cambridge, UK.
FAU - Strauch, Konstantin
AU  - Strauch K
AD  - Institute of Genetic Epidemiology, Helmholtz Zentrum Munchen-German Research
      Center for Environmental Health, Neuherberg, Germany.
AD  - Chair of Genetic Epidemiology, IBE, Faculty of Medicine, LMU Munich, Munich,
      Germany.
FAU - Stringham, Heather M
AU  - Stringham HM
AD  - Department of Biostatistics and Center for Statistical Genetics, University of
      Michigan, Ann Arbor, MI, USA.
FAU - Stumvoll, Michael
AU  - Stumvoll M
AD  - IFB Adiposity Diseases, University of Leipzig, Leipzig, Germany.
AD  - Department of Medicine, University of Leipzig, Leipzig, Germany.
FAU - Sun, Liang
AU  - Sun L
AD  - Biodemography of Aging Research Unit, Social Science Research Institute, Duke
      University, Durham, NC, USA.
AD  - Department of Public Health, University of Helsinki, Helsinki, Finland.
FAU - Surendran, Praveen
AU  - Surendran P
AD  - MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary
      Care, University of Cambridge, Cambridge, UK.
FAU - Swift, Amy J
AU  - Swift AJ
AD  - Medical Genomics and Metabolic Genetics Branch, National Human Genome Research
      Institute, US National Institutes of Health, Bethesda, MD, USA.
FAU - Tada, Hayato
AU  - Tada H
AD  - Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard
      Medical School, Boston, MA, USA.
AD  - Kanazawa University, Kanazawa, Japan.
FAU - Tansey, Katherine E
AU  - Tansey KE
AD  - MRC Integrative Epidemiology Unit, School of Social and Community Medicine,
      University of Bristol, Bristol, UK.
AD  - College of Biomedical and Life Sciences, Cardiff University, Cardiff, UK.
FAU - Tardif, Jean-Claude
AU  - Tardif JC
AD  - Montreal Heart Institute, Universite de Montreal, Montreal, Quebec, Canada.
FAU - Taylor, Kent D
AU  - Taylor KD
AD  - Institute for Translational Genomics and Population Sciences, LABioMed at
      Harbor-UCLA Medical Center, Torrance, CA, USA.
FAU - Teumer, Alexander
AU  - Teumer A
AD  - Institute for Community Medicine, University Medicine Greifswald, Greifswald,
      Germany.
FAU - Thompson, Deborah J
AU  - Thompson DJ
AD  - Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary
      Care, University of Cambridge, Cambridge, UK.
FAU - Thorleifsson, Gudmar
AU  - Thorleifsson G
AD  - deCODE Genetics/Amgen, Inc., Reykjavik, Iceland.
FAU - Thorsteinsdottir, Unnur
AU  - Thorsteinsdottir U
AD  - Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
AD  - deCODE Genetics/Amgen, Inc., Reykjavik, Iceland.
FAU - Thuesen, Betina H
AU  - Thuesen BH
AD  - Research Center for Prevention and Health, Capital Region of Denmark, Glostrup,
      Denmark.
FAU - Tonjes, Anke
AU  - Tonjes A
AD  - Center for Pediatric Research, Department for Women's and Child Health,
      University of Leipzig, Leipzig, Germany.
FAU - Tromp, Gerard
AU  - Tromp G
AD  - Weis Center for Research, Geisinger Health System, Danville, PA, USA.
AD  - Division of Molecular Biology and Human Genetics, Department of Biomedical
      Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University,
      Tygerberg, South Africa.
FAU - Trompet, Stella
AU  - Trompet S
AD  - Department of Cardiology, Leiden University Medical Center, Leiden, The
      Netherlands.
AD  - Department of Gerontology and Geriatrics, Leiden University Medical Center,
      Leiden, The Netherlands.
FAU - Tsafantakis, Emmanouil
AU  - Tsafantakis E
AD  - Anogia Medical Centre, Anogia, Greece.
FAU - Tuomilehto, Jaakko
AU  - Tuomilehto J
AD  - National Institute for Health and Welfare, Helsinki, Finland.
AD  - Centre for Vascular Prevention, Danube University Krems, Krems, Austria.
AD  - Dasman Diabetes Institute, Dasman, Kuwait.
AD  - Diabetes Research Group, King Abdulaziz University, Jeddah, Saudi Arabia.
FAU - Tybjaerg-Hansen, Anne
AU  - Tybjaerg-Hansen A
AD  - Department of Public Health, Faculty of Health and Medical Sciences, University
      of Copenhagen, Copenhagen, Denmark.
AD  - Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University
      Hospital, Copenhagen, Denmark.
FAU - Tyrer, Jonathan P
AU  - Tyrer JP
AD  - Centre for Cancer Genetic Epidemiology, Department of Oncology, University of
      Cambridge, Cambridge, UK.
FAU - Uher, Rudolf
AU  - Uher R
AD  - Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia, Canada.
FAU - Uitterlinden, Andre G
AU  - Uitterlinden AG
AD  - Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands.
AD  - Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The
      Netherlands.
FAU - Uusitupa, Matti
AU  - Uusitupa M
AD  - Department of Public Health and Clinical Nutrition, University of Eastern
      Finland, Kuopio, Finland.
FAU - Laan, Sander W
AU  - Laan SW
AD  - Laboratory of Experimental Cardiology, Division Heart and Lungs, University
      Medical Center Utrecht, Utrecht, The Netherlands.
FAU - Duijn, Cornelia M
AU  - Duijn CM
AD  - Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands.
FAU - Leeuwen, Nienke
AU  - Leeuwen N
AD  - Department of Epidemiology and Biostatistics, VU University Medical Center,
      Amsterdam, The Netherlands.
AD  - Department of Molecular Cell Biology, Leiden University Medical Center, Leiden,
      The Netherlands.
FAU - van Setten, Jessica
AU  - van Setten J
AD  - Department of Cardiology, Division Heart and Lungs, University Medical Center
      Utrecht, Utrecht, The Netherlands.
FAU - Vanhala, Mauno
AU  - Vanhala M
AD  - Primary Health Care Unit, Central Hospital of Central Finland, Jyvaskyla,
      Finland.
AD  - Primary Health Care Unit, Kuopio University Hospital, Kuopio, Finland.
FAU - Varbo, Anette
AU  - Varbo A
AD  - Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen
      University Hospital, Herlev, Denmark.
AD  - Department of Public Health, Faculty of Health and Medical Sciences, University
      of Copenhagen, Copenhagen, Denmark.
FAU - Varga, Tibor V
AU  - Varga TV
AD  - Department of Clinical Sciences, Genetic and Molecular Epidemiology Unit, Lund
      University, Malmo, Sweden.
FAU - Varma, Rohit
AU  - Varma R
AD  - USC Roski Eye Institute, Department of Ophthalmology, Keck School of Medicine of 
      the University of Southern California, Los Angeles, CA, USA.
FAU - Velez Edwards, Digna R
AU  - Velez Edwards DR
AD  - Department of Obstetrics and Gynecology, Institute for Medicine and Public
      Health, Vanderbilt Genetics Institute, Vanderbilt University, Nashville, TN, USA.
FAU - Vermeulen, Sita H
AU  - Vermeulen SH
AD  - Radboud Institute for Health Sciences, Radboud University Medical Center,
      Nijmegen, The Netherlands.
FAU - Veronesi, Giovanni
AU  - Veronesi G
AD  - Research Center on Epidemiology and Preventive Medicine, Department of Medicine
      and Surgery, University of Insubria, Varese, Italy.
FAU - Vestergaard, Henrik
AU  - Vestergaard H
AD  - Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health
      and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
AD  - Steno Diabetes Center Copenhagen, Gentofte, Denmark.
FAU - Vitart, Veronique
AU  - Vitart V
AD  - MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University
      of Edinburgh, Edinburgh, UK.
FAU - Vogt, Thomas F
AU  - Vogt TF
AD  - Cardiometabolic Disease, Merck, Sharp & Dohme, Kenilworth, NJ, USA.
FAU - Volker, Uwe
AU  - Volker U
AD  - German Centre for Cardiovascular Research (DZHK), partner site Greifswald,
      Greifswald, Germany.
AD  - Interfaculty Institute for Genetics and Functional Genomics, University Medicine 
      Greifswald, Greifswald, Germany.
FAU - Vuckovic, Dragana
AU  - Vuckovic D
AD  - Department of Medical Sciences, University of Trieste, Trieste, Italy.
AD  - Institute for Maternal and Child Health, IRCCS 'Burlo Garofolo', Trieste, Italy.
FAU - Wagenknecht, Lynne E
AU  - Wagenknecht LE
AD  - Division of Public Health Sciences, Wake Forest School of Medicine,
      Winston-Salem, NC, USA.
FAU - Walker, Mark
AU  - Walker M
AD  - Institute of Cellular Medicine, Medical School, Newcastle University, Newcastle, 
      UK.
FAU - Wallentin, Lars
AU  - Wallentin L
AD  - Department of Medical Sciences, Cardiology, Uppsala Clinical Research Center,
      Uppsala University, Uppsala, Sweden.
FAU - Wang, Feijie
AU  - Wang F
AD  - Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences,
      Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences,
      University of the Chinese Academy of Sciences, Shanghai, China.
FAU - Wang, Carol A
AU  - Wang CA
AD  - School of Women's and Infants' Health, University of Western Australia, Perth,
      Western Australia, Australia.
FAU - Wang, Shuai
AU  - Wang S
AD  - Department of Biostatistics, Boston University School of Public Health, Boston,
      MA, USA.
FAU - Wang, Yiqin
AU  - Wang Y
AD  - Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences,
      Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences,
      University of the Chinese Academy of Sciences, Shanghai, China.
FAU - Ware, Erin B
AU  - Ware EB
AD  - Department of Epidemiology, School of Public Health, University of Michigan, Ann 
      Arbor, MI, USA.
AD  - Survey Research Center, Institute for Social Research, University of Michigan,
      Ann Arbor, MI, USA.
FAU - Wareham, Nicholas J
AU  - Wareham NJ
AD  - MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine,
      Institute of Metabolic Science, Cambridge, UK.
FAU - Warren, Helen R
AU  - Warren HR
AD  - William Harvey Research Institute, Barts and The London School of Medicine and
      Dentistry, Queen Mary University of London, London, UK.
AD  - NIHR Barts Cardiovascular Research Unit, Barts and The London School of Medicine 
      and Dentistry, Queen Mary University of London, London, UK.
FAU - Waterworth, Dawn M
AU  - Waterworth DM
AD  - Genetics, Target Sciences, GlaxoSmithKline, King of Prussia, PA, USA.
FAU - Wessel, Jennifer
AU  - Wessel J
AD  - Departments of Epidemiology and Medicine, Diabetes Translational Research Center,
      Fairbanks School of Public Health and School of Medicine, Indiana University,
      Indianapolis, IN, USA.
FAU - White, Harvey D
AU  - White HD
AD  - Green Lane Cardiovascular Service, Auckland City Hospital and University of
      Auckland, Auckland, New Zealand.
FAU - Willer, Cristen J
AU  - Willer CJ
AD  - Department of Computational Medicine and Bioinformatics, University of Michigan, 
      Ann Arbor, MI, USA.
AD  - Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
AD  - Department of Human Genetics, University of Michigan, Ann Arbor, MI, USA.
FAU - Wilson, James G
AU  - Wilson JG
AD  - Department of Physiology and Biophysics, University of Mississippi Medical
      Center, Jackson, MS, USA.
FAU - Witte, Daniel R
AU  - Witte DR
AD  - Danish Diabetes Academy, Odense, Denmark.
AD  - Department of Public Health, Aarhus University, Aarhus, Denmark.
FAU - Wood, Andrew R
AU  - Wood AR
AD  - Genetics of Complex Traits, University of Exeter Medical School, University of
      Exeter, Exeter, UK.
FAU - Wu, Ying
AU  - Wu Y
AD  - Department of Genetics, University of North Carolina, Chapel Hill, NC, USA.
FAU - Yaghootkar, Hanieh
AU  - Yaghootkar H
AD  - Genetics of Complex Traits, University of Exeter Medical School, University of
      Exeter, Exeter, UK.
FAU - Yao, Jie
AU  - Yao J
AD  - Institute for Translational Genomics and Population Sciences, LABioMed at
      Harbor-UCLA Medical Center, Torrance, CA, USA.
FAU - Yao, Pang
AU  - Yao P
AD  - Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences,
      Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences,
      University of the Chinese Academy of Sciences, Shanghai, China.
FAU - Yerges-Armstrong, Laura M
AU  - Yerges-Armstrong LM
AD  - Program for Personalized and Genomic Medicine, Department of Medicine, University
      of Maryland School of Medicine, Baltimore, MD, USA.
AD  - GlaxoSmithKline, King of Prussia, PA, USA.
FAU - Young, Robin
AU  - Young R
AD  - MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary
      Care, University of Cambridge, Cambridge, UK.
AD  - University of Glasgow, Glasgow, UK.
FAU - Zeggini, Eleftheria
AU  - Zeggini E
AUID- ORCID: http://orcid.org/0000-0003-4238-659X
AD  - Wellcome Trust Sanger Institute, Hinxton, UK.
FAU - Zhan, Xiaowei
AU  - Zhan X
AD  - Department of Clinical Sciences, Quantitative Biomedical Research Center, Center 
      for the Genetics of Host Defense, University of Texas Southwestern Medical
      Center, Dallas, TX, USA.
FAU - Zhang, Weihua
AU  - Zhang W
AD  - Department of Cardiology, London North West Healthcare NHS Trust, Ealing
      Hospital, Middlesex, UK.
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Imperial
      College London, London, UK.
FAU - Zhao, Jing Hua
AU  - Zhao JH
AD  - MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine,
      Institute of Metabolic Science, Cambridge, UK.
FAU - Zhao, Wei
AU  - Zhao W
AD  - Department of Epidemiology, School of Public Health, University of Michigan, Ann 
      Arbor, MI, USA.
AD  - Department of Biostatistics and Epidemiology, Perelman School of Medicine,
      University of Pennsylvania, Philadelphia, PA, USA.
FAU - Zhou, Wei
AU  - Zhou W
AUID- ORCID: http://orcid.org/0000-0002-8301-9297
AD  - Department of Computational Medicine and Bioinformatics, University of Michigan, 
      Ann Arbor, MI, USA.
AD  - Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
FAU - Zondervan, Krina T
AU  - Zondervan KT
AUID- ORCID: http://orcid.org/0000-0002-0275-9905
AD  - Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
AD  - Endometriosis CaRe Centre, Nuffield Department of Obstetrics and Gynaecology,
      University of Oxford, Oxford, UK.
CN  - CHD Exome+ Consortium
CN  - EPIC-CVD Consortium
CN  - ExomeBP Consortium
CN  - Global Lipids Genetic Consortium
CN  - GoT2D Genes Consortium
CN  - EPIC InterAct Consortium
CN  - INTERVAL Study
CN  - ReproGen Consortium
CN  - T2D-Genes Consortium
CN  - MAGIC Investigators
CN  - Understanding Society Scientific Group
FAU - Rotter, Jerome I
AU  - Rotter JI
AD  - Institute for Translational Genomics and Population Sciences, LABioMed at
      Harbor-UCLA Medical Center, Torrance, CA, USA.
FAU - Pospisilik, John A
AU  - Pospisilik JA
AUID- ORCID: http://orcid.org/0000-0002-9745-0977
AD  - Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.
FAU - Rivadeneira, Fernando
AU  - Rivadeneira F
AUID- ORCID: http://orcid.org/0000-0001-9435-9441
AD  - Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands.
AD  - Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The
      Netherlands.
FAU - Borecki, Ingrid B
AU  - Borecki IB
AD  - Division of Statistical Genomics, Department of Genetics, Washington University
      School of Medicine, St. Louis, MO, USA.
FAU - Deloukas, Panos
AU  - Deloukas P
AUID- ORCID: http://orcid.org/0000-0001-9251-070X
AD  - William Harvey Research Institute, Barts and The London School of Medicine and
      Dentistry, Queen Mary University of London, London, UK.
AD  - Princess Al-Jawhara Al-Brahim Centre of Excellence in Research of Hereditary
      Disorders (PACER-HD), King Abdulaziz University, Jeddah, Saudi Arabia.
FAU - Frayling, Timothy M
AU  - Frayling TM
AD  - Genetics of Complex Traits, University of Exeter Medical School, University of
      Exeter, Exeter, UK.
FAU - Lettre, Guillaume
AU  - Lettre G
AD  - Montreal Heart Institute, Universite de Montreal, Montreal, Quebec, Canada.
AD  - Department of Medicine, Faculty of Medicine, Universite de Montreal, Montreal,
      Quebec, Canada.
FAU - North, Kari E
AU  - North KE
AD  - Department of Epidemiology and Carolina Center of Genome Sciences, Chapel Hill,
      NC, USA.
FAU - Lindgren, Cecilia M
AU  - Lindgren CM
AD  - Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
AD  - Li Ka Shing Centre for Health Information and Discovery, Big Data Institute,
      University of Oxford, Oxford, UK.
FAU - Hirschhorn, Joel N
AU  - Hirschhorn JN
AD  - Broad Institute of MIT and Harvard, Cambridge, MA, USA. joelh@broadinstitute.org.
AD  - Department of Genetics, Harvard Medical School, Boston, MA, USA.
      joelh@broadinstitute.org.
AD  - Division of Endocrinology and Center for Basic and Translational Obesity
      Research, Boston Children's Hospital, Boston, MA, USA. joelh@broadinstitute.org.
AD  - Department of Pediatrics, Harvard Medical School, Boston, MA, USA.
      joelh@broadinstitute.org.
FAU - Loos, Ruth J F
AU  - Loos RJF
AD  - Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at
      Mount Sinai, New York, NY, USA. ruth.loos@mssm.edu.
AD  - Genetics of Obesity and Related Metabolic Traits Program, Icahn School of
      Medicine at Mount Sinai, New York, NY, USA. ruth.loos@mssm.edu.
AD  - Mindich Child Health and Development Institute, Icahn School of Medicine at Mount
      Sinai, New York, NY, USA. ruth.loos@mssm.edu.
LA  - eng
GR  - RG/13/13/30194/British Heart Foundation/United Kingdom
GR  - RG/08/014/24067/British Heart Foundation/United Kingdom
GR  - MR/L01632X/1/Medical Research Council/United Kingdom
GR  - MC_UU_12015/7/Medical Research Council/United Kingdom
GR  - MR/L01341X/1/Medical Research Council/United Kingdom
GR  - G0601966/Medical Research Council/United Kingdom
GR  - MC_UU_12015/1/Medical Research Council/United Kingdom
GR  - MC_UU_12015/2/Medical Research Council/United Kingdom
PT  - Journal Article
DEP - 20171222
PL  - United States
TA  - Nat Genet
JT  - Nature genetics
JID - 9216904
EDAT- 2017/12/24 06:00
MHDA- 2017/12/24 06:00
CRDT- 2017/12/24 06:00
PHST- 2017/08/14 00:00 [received]
PHST- 2017/11/15 00:00 [accepted]
PHST- 2017/12/24 06:00 [entrez]
PHST- 2017/12/24 06:00 [pubmed]
PHST- 2017/12/24 06:00 [medline]
AID - 10.1038/s41588-017-0011-x [doi]
AID - 10.1038/s41588-017-0011-x [pii]
PST - ppublish
SO  - Nat Genet. 2018 Jan;50(1):26-41. doi: 10.1038/s41588-017-0011-x. Epub 2017 Dec
      22.

PMID- 29307491
OWN - NLM
STAT- In-Data-Review
LR  - 20180124
IS  - 1097-4172 (Electronic)
IS  - 0092-8674 (Linking)
VI  - 172
IP  - 1-2
DP  - 2018 Jan 11
TI  - Structure of the Nanobody-Stabilized Active State of the Kappa Opioid Receptor.
PG  - 55-67.e15
LID - S0092-8674(17)31491-5 [pii]
LID - 10.1016/j.cell.2017.12.011 [doi]
AB  - The kappa-opioid receptor (KOP) mediates the actions of opioids with
      hallucinogenic, dysphoric, and analgesic activities. The design of KOP analgesics
      devoid of hallucinatory and dysphoric effects has been hindered by an incomplete 
      structural and mechanistic understanding of KOP agonist actions. Here, we provide
      a crystal structure of human KOP in complex with the potent epoxymorphinan opioid
      agonist MP1104 and an active-state-stabilizing nanobody. Comparisons between
      inactive- and active-state opioid receptor structures reveal substantial
      conformational changes in the binding pocket and intracellular and extracellular 
      regions. Extensive structural analysis and experimental validation illuminate key
      residues that propagate larger-scale structural rearrangements and transducer
      binding that, collectively, elucidate the structural determinants of KOP
      pharmacology, function, and biased signaling. These molecular insights promise to
      accelerate the structure-guided design of safer and more effective kappa-opioid
      receptor therapeutics.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Che, Tao
AU  - Che T
AD  - Department of Pharmacology, University of North Carolina at Chapel Hill School of
      Medicine, Chapel Hill, NC 27599, USA.
FAU - Majumdar, Susruta
AU  - Majumdar S
AD  - Molecular Pharmacology Program and Department of Neurology, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA.
FAU - Zaidi, Saheem A
AU  - Zaidi SA
AD  - Department of Biological Sciences, Bridge Institute, University of Southern
      California, Los Angeles, CA 90089, USA.
FAU - Ondachi, Pauline
AU  - Ondachi P
AD  - Center for Organic and Medicinal Chemistry, Research Triangle Institute, Research
      Triangle Park, NC 27709, USA.
FAU - McCorvy, John D
AU  - McCorvy JD
AD  - Department of Pharmacology, University of North Carolina at Chapel Hill School of
      Medicine, Chapel Hill, NC 27599, USA.
FAU - Wang, Sheng
AU  - Wang S
AD  - Department of Pharmacology, University of North Carolina at Chapel Hill School of
      Medicine, Chapel Hill, NC 27599, USA.
FAU - Mosier, Philip D
AU  - Mosier PD
AD  - Department of Medicinal Chemistry and Institute for Structural Biology, Drug
      Discovery and Development, Virginia Commonweath University, Richmond, VA 23298,
      USA.
FAU - Uprety, Rajendra
AU  - Uprety R
AD  - Molecular Pharmacology Program and Department of Neurology, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA.
FAU - Vardy, Eyal
AU  - Vardy E
AD  - Department of Pharmacology, University of North Carolina at Chapel Hill School of
      Medicine, Chapel Hill, NC 27599, USA.
FAU - Krumm, Brian E
AU  - Krumm BE
AD  - Department of Pharmacology, University of North Carolina at Chapel Hill School of
      Medicine, Chapel Hill, NC 27599, USA.
FAU - Han, Gye Won
AU  - Han GW
AD  - Department of Chemistry, Bridge Institute, University of Southern California, Los
      Angeles, CA 90089, USA.
FAU - Lee, Ming-Yue
AU  - Lee MY
AD  - Department of Chemistry, Bridge Institute, University of Southern California, Los
      Angeles, CA 90089, USA; School of Molecular Sciences, Biodesign Center for
      Applied Structural Discovery, Biodesign Institute, Arizona State University,
      Tempe, AZ 85287, USA; Institute of Natural Resources and Environmental Audits,
      Nanjing Audit University, Nanjing, China.
FAU - Pardon, Els
AU  - Pardon E
AD  - Structural Biology Brussels, Vrije Universiteit Brussel, 1050 Brussels, Belgium; 
      VIB-VUB Center for Structural Biology, VIB, 1050 Brussels, Belgium.
FAU - Steyaert, Jan
AU  - Steyaert J
AD  - Structural Biology Brussels, Vrije Universiteit Brussel, 1050 Brussels, Belgium; 
      VIB-VUB Center for Structural Biology, VIB, 1050 Brussels, Belgium.
FAU - Huang, Xi-Ping
AU  - Huang XP
AD  - National Institute of Mental Health Psychoactive Drug Screening Program (NIMH
      PDSP), School of Medicine, University of North Carolina at Chapel Hill School of 
      Medicine, Chapel Hill, NC 27599, USA.
FAU - Strachan, Ryan T
AU  - Strachan RT
AD  - Department of Pharmacology, University of North Carolina at Chapel Hill School of
      Medicine, Chapel Hill, NC 27599, USA.
FAU - Tribo, Alexandra R
AU  - Tribo AR
AD  - Department of Pharmacology, University of North Carolina at Chapel Hill School of
      Medicine, Chapel Hill, NC 27599, USA.
FAU - Pasternak, Gavril W
AU  - Pasternak GW
AD  - Molecular Pharmacology Program and Department of Neurology, Memorial Sloan
      Kettering Cancer Center, New York, NY 10065, USA.
FAU - Carroll, F Ivy
AU  - Carroll FI
AD  - Center for Organic and Medicinal Chemistry, Research Triangle Institute, Research
      Triangle Park, NC 27709, USA.
FAU - Stevens, Raymond C
AU  - Stevens RC
AD  - Department of Biological Sciences, Bridge Institute, University of Southern
      California, Los Angeles, CA 90089, USA; Department of Chemistry, Bridge
      Institute, University of Southern California, Los Angeles, CA 90089, USA.
FAU - Cherezov, Vadim
AU  - Cherezov V
AD  - Department of Chemistry, Bridge Institute, University of Southern California, Los
      Angeles, CA 90089, USA.
FAU - Katritch, Vsevolod
AU  - Katritch V
AD  - Department of Biological Sciences, Bridge Institute, University of Southern
      California, Los Angeles, CA 90089, USA; Department of Chemistry, Bridge
      Institute, University of Southern California, Los Angeles, CA 90089, USA.
FAU - Wacker, Daniel
AU  - Wacker D
AD  - Department of Pharmacology, University of North Carolina at Chapel Hill School of
      Medicine, Chapel Hill, NC 27599, USA. Electronic address: dwacker@email.unc.edu.
FAU - Roth, Bryan L
AU  - Roth BL
AD  - Department of Pharmacology, University of North Carolina at Chapel Hill School of
      Medicine, Chapel Hill, NC 27599, USA; National Institute of Mental Health
      Psychoactive Drug Screening Program (NIMH PDSP), School of Medicine, University
      of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA; 
      Division of Chemical Biology and Medicinal Chemistry, Eshelman School of
      Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599,
      USA. Electronic address: bryan_roth@med.unc.edu.
LA  - eng
GR  - P01 DA035764/DA/NIDA NIH HHS/United States
PT  - Journal Article
DEP - 20180104
PL  - United States
TA  - Cell
JT  - Cell
JID - 0413066
OTO - NOTNLM
OT  - GPCR
OT  - active state
OT  - addiction
OT  - crystallography
OT  - morphinan
OT  - nanobody
OT  - opioid receptor
OT  - structure-function
EDAT- 2018/01/09 06:00
MHDA- 2018/01/09 06:00
CRDT- 2018/01/09 06:00
PHST- 2017/07/10 00:00 [received]
PHST- 2017/10/11 00:00 [revised]
PHST- 2017/12/06 00:00 [accepted]
PHST- 2018/01/09 06:00 [pubmed]
PHST- 2018/01/09 06:00 [medline]
PHST- 2018/01/09 06:00 [entrez]
AID - S0092-8674(17)31491-5 [pii]
AID - 10.1016/j.cell.2017.12.011 [doi]
PST - ppublish
SO  - Cell. 2018 Jan 11;172(1-2):55-67.e15. doi: 10.1016/j.cell.2017.12.011. Epub 2018 
      Jan 4.

PMID- 29275859
OWN - NLM
STAT- In-Data-Review
LR  - 20180126
IS  - 1097-4172 (Electronic)
IS  - 0092-8674 (Linking)
VI  - 172
IP  - 3
DP  - 2018 Jan 25
TI  - Microbiome Influences Prenatal and Adult Microglia in a Sex-Specific Manner.
PG  - 500-516.e16
LID - S0092-8674(17)31432-0 [pii]
LID - 10.1016/j.cell.2017.11.042 [doi]
AB  - Microglia are embryonically seeded macrophages that contribute to brain
      development, homeostasis, and pathologies. It is thus essential to decipher how
      microglial properties are temporally regulated by intrinsic and extrinsic
      factors, such as sexual identity and the microbiome. Here, we found that
      microglia undergo differentiation phases, discernable by transcriptomic
      signatures and chromatin accessibility landscapes, which can diverge in adult
      males and females. Remarkably, the absence of microbiome in germ-free mice had a 
      time and sexually dimorphic impact both prenatally and postnatally: microglia
      were more profoundly perturbed in male embryos and female adults. Antibiotic
      treatment of adult mice triggered sexually biased microglial responses revealing 
      both acute and long-term effects of microbiota depletion. Finally, human fetal
      microglia exhibited significant overlap with the murine transcriptomic signature.
      Our study shows that microglia respond to environmental challenges in a sex- and 
      time-dependent manner from prenatal stages, with major implications for our
      understanding of microglial contributions to health and disease.
CI  - Copyright (c) 2017 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Thion, Morgane Sonia
AU  - Thion MS
AD  - Institut de Biologie de l'Ecole normale superieure (IBENS), Ecole Normale
      Superieure, CNRS, INSERM, PSL Research University, 75005 Paris, France.
FAU - Low, Donovan
AU  - Low D
AD  - Singapore Immunology Network (SIgN), Agency for Science, Technology and Research 
      (A( *)STAR), Singapore 138648, Singapore.
FAU - Silvin, Aymeric
AU  - Silvin A
AD  - Singapore Immunology Network (SIgN), Agency for Science, Technology and Research 
      (A( *)STAR), Singapore 138648, Singapore.
FAU - Chen, Jinmiao
AU  - Chen J
AD  - Singapore Immunology Network (SIgN), Agency for Science, Technology and Research 
      (A( *)STAR), Singapore 138648, Singapore.
FAU - Grisel, Pauline
AU  - Grisel P
AD  - Institut de Biologie de l'Ecole normale superieure (IBENS), Ecole Normale
      Superieure, CNRS, INSERM, PSL Research University, 75005 Paris, France.
FAU - Schulte-Schrepping, Jonas
AU  - Schulte-Schrepping J
AD  - Genomics and Immunoregulation, Life and Medical Sciences (LIMES) Institute,
      University of Bonn, 53115 Bonn, Germany.
FAU - Blecher, Ronnie
AU  - Blecher R
AD  - Department of Immunology, Weizmann Institute of Science, 76100 Rehovot, Israel.
FAU - Ulas, Thomas
AU  - Ulas T
AD  - Genomics and Immunoregulation, Life and Medical Sciences (LIMES) Institute,
      University of Bonn, 53115 Bonn, Germany.
FAU - Squarzoni, Paola
AU  - Squarzoni P
AD  - Institut de Biologie de l'Ecole normale superieure (IBENS), Ecole Normale
      Superieure, CNRS, INSERM, PSL Research University, 75005 Paris, France.
FAU - Hoeffel, Guillaume
AU  - Hoeffel G
AD  - Singapore Immunology Network (SIgN), Agency for Science, Technology and Research 
      (A( *)STAR), Singapore 138648, Singapore; Aix-Marseille Universite, CNRS, INSERM,
      Centre d'Immunologie de Marseille-Luminy (CIML), 13288 Marseille, France.
FAU - Coulpier, Fanny
AU  - Coulpier F
AD  - Institut de Biologie de l'Ecole normale superieure (IBENS), Ecole Normale
      Superieure, CNRS, INSERM, PSL Research University, 75005 Paris, France.
FAU - Siopi, Eleni
AU  - Siopi E
AD  - Institut Pasteur, Unite Perception et Memoire, CNRS, UMR 3571, F-75015 Paris,
      France.
FAU - David, Friederike Sophie
AU  - David FS
AD  - Genomics and Immunoregulation, Life and Medical Sciences (LIMES) Institute,
      University of Bonn, 53115 Bonn, Germany.
FAU - Scholz, Claus
AU  - Scholz C
AD  - Genomics and Immunoregulation, Life and Medical Sciences (LIMES) Institute,
      University of Bonn, 53115 Bonn, Germany.
FAU - Shihui, Foo
AU  - Shihui F
AD  - Singapore Immunology Network (SIgN), Agency for Science, Technology and Research 
      (A( *)STAR), Singapore 138648, Singapore.
FAU - Lum, Josephine
AU  - Lum J
AD  - Singapore Immunology Network (SIgN), Agency for Science, Technology and Research 
      (A( *)STAR), Singapore 138648, Singapore.
FAU - Amoyo, Arlaine Anne
AU  - Amoyo AA
AD  - National Cancer Centre, Singapore 169610, Singapore.
FAU - Larbi, Anis
AU  - Larbi A
AD  - Singapore Immunology Network (SIgN), Agency for Science, Technology and Research 
      (A( *)STAR), Singapore 138648, Singapore.
FAU - Poidinger, Michael
AU  - Poidinger M
AD  - Singapore Immunology Network (SIgN), Agency for Science, Technology and Research 
      (A( *)STAR), Singapore 138648, Singapore.
FAU - Buttgereit, Anne
AU  - Buttgereit A
AD  - Institute of Experimental Immunology, University of Zurich, 8057 Zurich,
      Switzerland.
FAU - Lledo, Pierre-Marie
AU  - Lledo PM
AD  - Institut Pasteur, Unite Perception et Memoire, CNRS, UMR 3571, F-75015 Paris,
      France.
FAU - Greter, Melanie
AU  - Greter M
AD  - Institute of Experimental Immunology, University of Zurich, 8057 Zurich,
      Switzerland.
FAU - Chan, Jerry Kok Yen
AU  - Chan JKY
AD  - Department of Reproductive Medicine, KK Women's and Children's Hospital,
      Singapore 229899, Singapore; KK Research Centre, KK Women's and Children's
      Hospital, 100 Bukit Timah Road, Singapore 229899, Singapore.
FAU - Amit, Ido
AU  - Amit I
AD  - Department of Immunology, Weizmann Institute of Science, 76100 Rehovot, Israel.
FAU - Beyer, Marc
AU  - Beyer M
AD  - Genomics and Immunoregulation, Life and Medical Sciences (LIMES) Institute,
      University of Bonn, 53115 Bonn, Germany; Molecular Immunology in
      Neurodegeneration, German Center for Neurodegenerative Diseases (DZNE), 53127
      Bonn, Germany.
FAU - Schultze, Joachim Ludwig
AU  - Schultze JL
AD  - Genomics and Immunoregulation, Life and Medical Sciences (LIMES) Institute,
      University of Bonn, 53115 Bonn, Germany; Platform of Single Cell Genomics and
      Epigenomics at the German Center for Neurodegenerative Diseases and the
      University of Bonn, 53175 Bonn, Germany.
FAU - Schlitzer, Andreas
AU  - Schlitzer A
AD  - Singapore Immunology Network (SIgN), Agency for Science, Technology and Research 
      (A( *)STAR), Singapore 138648, Singapore; Myeloid Cell Biology, LIMES-Institute, 
      University of Bonn, 53115 Bonn, Germany.
FAU - Pettersson, Sven
AU  - Pettersson S
AD  - Lee Kong Chian School of Medicine and School of Biological Sciences, Nanyang
      Technological University, Singapore 639798, Singapore; Department of
      Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm 17165,
      Sweden.
FAU - Ginhoux, Florent
AU  - Ginhoux F
AD  - Singapore Immunology Network (SIgN), Agency for Science, Technology and Research 
      (A( *)STAR), Singapore 138648, Singapore. Electronic address:
      florent_ginhoux@immunol.a-star.edu.sg.
FAU - Garel, Sonia
AU  - Garel S
AD  - Institut de Biologie de l'Ecole normale superieure (IBENS), Ecole Normale
      Superieure, CNRS, INSERM, PSL Research University, 75005 Paris, France.
      Electronic address: garel@biologie.ens.fr.
LA  - eng
PT  - Journal Article
DEP - 20171221
PL  - United States
TA  - Cell
JT  - Cell
JID - 0413066
OTO - NOTNLM
OT  - CXCR4
OT  - antibiotics
OT  - embryogenesis
OT  - germ-free
OT  - microbiome
OT  - microglia
OT  - neurodevelopmental disorders
OT  - neuroinflammation
OT  - prenatal
OT  - sex
EDAT- 2017/12/26 06:00
MHDA- 2017/12/26 06:00
CRDT- 2017/12/26 06:00
PHST- 2017/06/10 00:00 [received]
PHST- 2017/11/15 00:00 [revised]
PHST- 2017/11/22 00:00 [accepted]
PHST- 2017/12/26 06:00 [pubmed]
PHST- 2017/12/26 06:00 [medline]
PHST- 2017/12/26 06:00 [entrez]
AID - S0092-8674(17)31432-0 [pii]
AID - 10.1016/j.cell.2017.11.042 [doi]
PST - ppublish
SO  - Cell. 2018 Jan 25;172(3):500-516.e16. doi: 10.1016/j.cell.2017.11.042. Epub 2017 
      Dec 21.

PMID- 29302060
OWN - NLM
STAT- In-Data-Review
LR  - 20180114
IS  - 2041-1723 (Electronic)
IS  - 2041-1723 (Linking)
VI  - 9
IP  - 1
DP  - 2018 Jan 4
TI  - C9ORF72 GGGGCC repeat-associated non-AUG translation is upregulated by stress
      through eIF2alpha phosphorylation.
PG  - 51
LID - 10.1038/s41467-017-02495-z [doi]
AB  - Hexanucleotide repeat expansion in C9ORF72 is the most frequent cause of both
      amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Here we
      demonstrate that the repeat-associated non-AUG (RAN) translation of (GGGGCC) n
      -containing RNAs into poly-dipeptides can initiate in vivo without a 5'-cap. The 
      primary RNA substrate for RAN translation of C9ORF72 sense repeats is shown to be
      the spliced first intron, following its excision from the initial pre-mRNA and
      transport to the cytoplasm. Cap-independent RAN translation is shown to be
      upregulated by various stress stimuli through phosphorylation of the alpha
      subunit of eukaryotic initiation factor-2 (eIF2alpha), the core event of an
      integrated stress response (ISR). Compounds inhibiting
      phospho-eIF2alpha-signaling pathways are shown to suppress RAN translation. Since
      the poly-dipeptides can themselves induce stress, these findings support a
      feedforward loop with initial repeat-mediated toxicity enhancing RAN translation 
      and subsequent production of additional poly-dipeptides through ISR, thereby
      promoting progressive disease.
FAU - Cheng, Weiwei
AU  - Cheng W
AD  - Department of Pathology and Brain Science Institute, Johns Hopkins University
      School of Medicine, Baltimore, MD, 21205, USA.
FAU - Wang, Shaopeng
AU  - Wang S
AD  - Department of Pathology and Brain Science Institute, Johns Hopkins University
      School of Medicine, Baltimore, MD, 21205, USA.
FAU - Mestre, Alexander A
AU  - Mestre AA
AD  - Department of Pathology and Brain Science Institute, Johns Hopkins University
      School of Medicine, Baltimore, MD, 21205, USA.
FAU - Fu, Chenglai
AU  - Fu C
AUID- ORCID: http://orcid.org/0000-0003-4300-9948
AD  - The Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School
      of Medicine, Baltimore, MD, 21205, USA.
FAU - Makarem, Andres
AU  - Makarem A
AD  - Department of Pathology and Brain Science Institute, Johns Hopkins University
      School of Medicine, Baltimore, MD, 21205, USA.
FAU - Xian, Fengfan
AU  - Xian F
AD  - Department of Pathology and Brain Science Institute, Johns Hopkins University
      School of Medicine, Baltimore, MD, 21205, USA.
FAU - Hayes, Lindsey R
AU  - Hayes LR
AD  - Brain Science Institute and Department of Neurology, Johns Hopkins University
      School of Medicine, Baltimore, MD, 21205, USA.
FAU - Lopez-Gonzalez, Rodrigo
AU  - Lopez-Gonzalez R
AD  - Department of Neurology, University of Massachusetts Medical School, Worcester,
      MA, 01605, USA.
FAU - Drenner, Kevin
AU  - Drenner K
AD  - Ludwig Institute for Cancer Research and Department of Cellular and Molecular
      Medicine, University of California at San Diego, La Jolla, CA, 92093, USA.
FAU - Jiang, Jie
AU  - Jiang J
AD  - Ludwig Institute for Cancer Research and Department of Cellular and Molecular
      Medicine, University of California at San Diego, La Jolla, CA, 92093, USA.
FAU - Cleveland, Don W
AU  - Cleveland DW
AD  - Ludwig Institute for Cancer Research and Department of Cellular and Molecular
      Medicine, University of California at San Diego, La Jolla, CA, 92093, USA.
FAU - Sun, Shuying
AU  - Sun S
AD  - Department of Pathology and Brain Science Institute, Johns Hopkins University
      School of Medicine, Baltimore, MD, 21205, USA. shuying.sun@jhmi.edu.
LA  - eng
PT  - Journal Article
DEP - 20180104
PL  - England
TA  - Nat Commun
JT  - Nature communications
JID - 101528555
PMC - PMC5754368
EDAT- 2018/01/06 06:00
MHDA- 2018/01/06 06:00
CRDT- 2018/01/06 06:00
PHST- 2017/04/28 00:00 [received]
PHST- 2017/12/01 00:00 [accepted]
PHST- 2018/01/06 06:00 [entrez]
PHST- 2018/01/06 06:00 [pubmed]
PHST- 2018/01/06 06:00 [medline]
AID - 10.1038/s41467-017-02495-z [doi]
AID - 10.1038/s41467-017-02495-z [pii]
PST - epublish
SO  - Nat Commun. 2018 Jan 4;9(1):51. doi: 10.1038/s41467-017-02495-z.

PMID- 29279357
OWN - NLM
STAT- Publisher
LR  - 20171227
IS  - 1528-0020 (Electronic)
IS  - 0006-4971 (Linking)
DP  - 2017 Dec 26
TI  - Successful outcome following allogeneic hematopoietic stem cell transplantation
      in adults with primary immunodeficiency.
LID - blood-2017-09-807487 [pii]
LID - 10.1182/blood-2017-09-807487 [doi]
AB  - INTRODUCTION: The primary immunodeficiencies (PID), rare inherited diseases
      characterised by severe dysfunction of immunity have been successfully treated by
      allogeneic hematopoietic stem cell transplantation (Allo-HSCT) in childhood.
      Controversy exists regarding optimal timing and use of Allo-HSCT in adults, due
      to lack of experience and previous poor outcomes. MATERIALS AND METHODS: 29
      consecutive adult patients, with a mean age at transplant of 24 years (range
      17-50) underwent Allo-HSCT. Reduced intensity conditioning included
      Flu/Mel/Alemtuzumab (n=20), Flu/Bu/Alemtuzumab (n=8) and Flu/Bu/ATG (n=1). Stem
      cell donors were matched or mismatched unrelated (MUD/MMUD) (n=18) and matched
      related donors (MRD) (n=11). Overall survival, event free survival, transplant
      related mortality, acute and chronic GVHD incidence and severity, time to
      engraftment, lineage specific chimerism, immune reconstitution and
      discontinuation of immunoglobulin replacement therapy were recorded. RESULTS:
      Overall survival (OS) at 3 years for the whole cohort was 85.2%. The rarer,
      non-CGD PID patients achieved an OS at 3 years of 88.9% (n=18), compared to 81.8%
      for CGD patients (n=11). Transplant related mortality (TRM) was low with only
      four deaths observed at a median follow-up of 3.5 years. There were no cases of
      early or late rejection. In all surviving patients either stable mixed chimerism 
      or full donor chimerism were observed. At last follow-up 87% of the surviving
      patients had no evidence of persistent or recurrent infections. CONCLUSION:
      Allo-HSCT is safe and effective in young adult patients with severe PID and
      should be considered the treatment of choice where an appropriate donor is
      available.
CI  - Copyright (c) 2017 American Society of Hematology.
FAU - Fox, Thomas A
AU  - Fox TA
AD  - Institute of Immunity and Transplantation, UCL, London, United Kingdom.
FAU - Chakraverty, Ronjon
AU  - Chakraverty R
AD  - BMT Programme, University College London Hospital NHS FT, London, United Kingdom.
FAU - Burns, Siobhan
AU  - Burns S
AD  - Institute of Immunity and Transplantation, UCL, London, United Kingdom.
FAU - Carpenter, Benjamin
AU  - Carpenter B
AD  - TYA BMT Programme, University College London Hospital NHS FT, London, United
      Kingdom.
FAU - Thomson, Kirsty
AU  - Thomson K
AD  - BMT Programme, University College London Hospital NHS FT, London, United Kingdom.
FAU - Lowe, David
AU  - Lowe D
AD  - Department of Immunology, Royal Free London NHS FT, London, United Kingdom.
FAU - Fielding, Adele
AU  - Fielding A
AD  - Department of Haematology, Royal Free London NHS FT, London, United Kingdom.
FAU - Peggs, Karl
AU  - Peggs K
AD  - UCL Cancer Institute, Department of Haematology, University College London,
      London, United Kingdom.
FAU - Kottaridis, Panagiotis
AU  - Kottaridis P
AD  - BMT Programme, University College London Hospital NHS FT, London, United Kingdom.
FAU - Uttenthal, Benjamin
AU  - Uttenthal B
AD  - Department of Haematology, Addenbrookes' Hospital, Cambridge, United Kingdom.
FAU - Bigley, Venetia
AU  - Bigley V
AD  - Institute of Cellular Medicine, Newcastle University, Newcastle, United Kingdom.
FAU - Buckland, Matthew
AU  - Buckland M
AD  - Department of Immunology, Royal Free London NHS FT, London, United Kingdom.
FAU - Grandage, Victoria
AU  - Grandage V
AD  - TYA BMT Programme, University College London Hospital NHS FT, London, United
      Kingdom.
FAU - Denovan, Shari
AU  - Denovan S
AD  - BMT Programme, University College London Hospital NHS FT, London, United Kingdom.
FAU - Grace, Sarah
AU  - Grace S
AD  - BMT Programme, University College London Hospital NHS FT, London, United Kingdom.
FAU - Dahlstrom, Julia
AU  - Dahlstrom J
AD  - BMT Programme, University College London Hospital NHS FT, London, United Kingdom.
FAU - Workman, Sarita
AU  - Workman S
AD  - Department of Immunology, Royal Free London NHS FT, London, United Kingdom.
FAU - Symes, Andrew
AU  - Symes A
AD  - Department of Immunology, Royal Free London NHS FT, London, United Kingdom.
FAU - Mackinnon, Stephen
AU  - Mackinnon S
AD  - BMT Programme, University College London Hospital NHS FT, London, United Kingdom.
FAU - Hough, Rachael
AU  - Hough R
AD  - TYA BMT Programme, University College London Hospital NHS FT, London, United
      Kingdom.
FAU - Morris, Emma
AU  - Morris E
AD  - Institute of Immunity and Transplantation, UCL, London, United Kingdom;
      e.morris@ucl.ac.uk.
LA  - eng
PT  - Journal Article
DEP - 20171226
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
EDAT- 2017/12/28 06:00
MHDA- 2017/12/28 06:00
CRDT- 2017/12/28 06:00
PHST- 2017/09/20 00:00 [received]
PHST- 2017/12/14 00:00 [accepted]
PHST- 2017/12/28 06:00 [entrez]
PHST- 2017/12/28 06:00 [pubmed]
PHST- 2017/12/28 06:00 [medline]
AID - blood-2017-09-807487 [pii]
AID - 10.1182/blood-2017-09-807487 [doi]
PST - aheadofprint
SO  - Blood. 2017 Dec 26. pii: blood-2017-09-807487. doi: 10.1182/blood-2017-09-807487.

PMID- 29342135
OWN - NLM
STAT- In-Data-Review
LR  - 20180129
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 553
IP  - 7689
DP  - 2018 Jan 25
TI  - Structures of beta-klotho reveal a 'zip code'-like mechanism for endocrine FGF
      signalling.
PG  - 501-505
LID - 10.1038/nature25010 [doi]
AB  - Canonical fibroblast growth factors (FGFs) activate FGF receptors (FGFRs) through
      paracrine or autocrine mechanisms in a process that requires cooperation with
      heparan sulfate proteoglycans, which function as co-receptors for FGFR
      activation. By contrast, endocrine FGFs (FGF19, FGF21 and FGF23) are circulating 
      hormones that regulate critical metabolic processes in a variety of tissues.
      FGF19 regulates bile acid synthesis and lipogenesis, whereas FGF21 stimulates
      insulin sensitivity, energy expenditure and weight loss. Endocrine FGFs signal
      through FGFRs in a manner that requires klothos, which are cell-surface proteins 
      that possess tandem glycosidase domains. Here we describe the crystal structures 
      of free and ligand-bound beta-klotho extracellular regions that reveal the
      molecular mechanism that underlies the specificity of FGF21 towards beta-klotho
      and demonstrate how the FGFR is activated in a klotho-dependent manner.
      beta-Klotho serves as a primary 'zip code'-like receptor that acts as a targeting
      signal for FGF21, and FGFR functions as a catalytic subunit that mediates
      intracellular signalling. Our structures also show how the sugar-cutting enzyme
      glycosidase has evolved to become a specific receptor for hormones that regulate 
      metabolic processes, including the lowering of blood sugar levels. Finally, we
      describe an agonistic variant of FGF21 with enhanced biological activity and
      present structural insights into the potential development of therapeutic agents 
      for diseases linked to endocrine FGFs.
FAU - Lee, Sangwon
AU  - Lee S
AD  - Department of Pharmacology and Yale Cancer Biology Institute, Yale School of
      Medicine, 333 Cedar Street, New Haven, Connecticut 06520, USA.
FAU - Choi, Jungyuen
AU  - Choi J
AD  - Department of Pharmacology and Yale Cancer Biology Institute, Yale School of
      Medicine, 333 Cedar Street, New Haven, Connecticut 06520, USA.
FAU - Mohanty, Jyotidarsini
AU  - Mohanty J
AD  - Department of Pharmacology and Yale Cancer Biology Institute, Yale School of
      Medicine, 333 Cedar Street, New Haven, Connecticut 06520, USA.
FAU - Sousa, Leiliane P
AU  - Sousa LP
AD  - Department of Pharmacology and Yale Cancer Biology Institute, Yale School of
      Medicine, 333 Cedar Street, New Haven, Connecticut 06520, USA.
FAU - Tome, Francisco
AU  - Tome F
AD  - Department of Pharmacology and Yale Cancer Biology Institute, Yale School of
      Medicine, 333 Cedar Street, New Haven, Connecticut 06520, USA.
FAU - Pardon, Els
AU  - Pardon E
AD  - VIB Center for Structural Biology, Vrije Universiteit Brussel, Pleinlaan 2, 1050 
      Brussels, Belgium.
FAU - Steyaert, Jan
AU  - Steyaert J
AD  - VIB Center for Structural Biology, Vrije Universiteit Brussel, Pleinlaan 2, 1050 
      Brussels, Belgium.
FAU - Lemmon, Mark A
AU  - Lemmon MA
AD  - Department of Pharmacology and Yale Cancer Biology Institute, Yale School of
      Medicine, 333 Cedar Street, New Haven, Connecticut 06520, USA.
FAU - Lax, Irit
AU  - Lax I
AD  - Department of Pharmacology and Yale Cancer Biology Institute, Yale School of
      Medicine, 333 Cedar Street, New Haven, Connecticut 06520, USA.
FAU - Schlessinger, Joseph
AU  - Schlessinger J
AD  - Department of Pharmacology and Yale Cancer Biology Institute, Yale School of
      Medicine, 333 Cedar Street, New Haven, Connecticut 06520, USA.
LA  - eng
PT  - Journal Article
DEP - 20180117
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
EDAT- 2018/01/18 06:00
MHDA- 2018/01/18 06:00
CRDT- 2018/01/18 06:00
PHST- 2017/07/11 00:00 [received]
PHST- 2017/11/03 00:00 [accepted]
PHST- 2018/01/18 06:00 [pubmed]
PHST- 2018/01/18 06:00 [medline]
PHST- 2018/01/18 06:00 [entrez]
AID - nature25010 [pii]
AID - 10.1038/nature25010 [doi]
PST - ppublish
SO  - Nature. 2018 Jan 25;553(7689):501-505. doi: 10.1038/nature25010. Epub 2018 Jan
      17.

PMID- 29298421
OWN - NLM
STAT- In-Data-Review
LR  - 20180103
IS  - 2211-1247 (Electronic)
VI  - 22
IP  - 1
DP  - 2018 Jan 2
TI  - Primary Cilium-Mediated Retinal Pigment Epithelium Maturation Is Disrupted in
      Ciliopathy Patient Cells.
PG  - 189-205
LID - S2211-1247(17)31847-8 [pii]
LID - 10.1016/j.celrep.2017.12.038 [doi]
AB  - Primary cilia are sensory organelles that protrude from the cell membrane.
      Defects in the primary cilium cause ciliopathy disorders, with retinal
      degeneration as a prominent phenotype. Here, we demonstrate that the retinal
      pigment epithelium (RPE), essential for photoreceptor development and function,
      requires a functional primary cilium for complete maturation and that RPE
      maturation defects in ciliopathies precede photoreceptor degeneration.
      Pharmacologically enhanced ciliogenesis in wild-type induced pluripotent stem
      cells (iPSC)-RPE leads to fully mature and functional cells. In contrast,
      ciliopathy patient-derived iPSC-RPE and iPSC-RPE with a knockdown of
      ciliary-trafficking protein remain immature, with defective apical processes,
      reduced functionality, and reduced adult-specific gene expression. Proteins of
      the primary cilium regulate RPE maturation by simultaneously suppressing
      canonical WNT and activating PKCdelta pathways. A similar cilium-dependent
      maturation pathway exists in lung epithelium. Our results provide insights into
      ciliopathy-induced retinal degeneration, demonstrate a developmental role for
      primary cilia in epithelial maturation, and provide a method to mature iPSC
      epithelial cells for clinical applications.
CI  - Published by Elsevier Inc.
FAU - May-Simera, Helen Louise
AU  - May-Simera HL
AD  - Institute of Molecular Physiology, Johannes-Gutenberg University, Mainz, Germany.
FAU - Wan, Qin
AU  - Wan Q
AD  - National Eye Institute, NIH, Bethesda, MD, USA.
FAU - Jha, Balendu Shekhar
AU  - Jha BS
AD  - National Eye Institute, NIH, Bethesda, MD, USA.
FAU - Hartford, Juliet
AU  - Hartford J
AD  - National Eye Institute, NIH, Bethesda, MD, USA.
FAU - Khristov, Vladimir
AU  - Khristov V
AD  - National Eye Institute, NIH, Bethesda, MD, USA.
FAU - Dejene, Roba
AU  - Dejene R
AD  - National Eye Institute, NIH, Bethesda, MD, USA.
FAU - Chang, Justin
AU  - Chang J
AD  - National Eye Institute, NIH, Bethesda, MD, USA.
FAU - Patnaik, Sarita
AU  - Patnaik S
AD  - Institute of Molecular Physiology, Johannes-Gutenberg University, Mainz, Germany.
FAU - Lu, Quanlong
AU  - Lu Q
AD  - National Cancer Institute, NIH, Frederick, MD, USA.
FAU - Banerjee, Poulomi
AU  - Banerjee P
AD  - School of Regenerative Medicine, Manipal University, Bangalore, India.
FAU - Silver, Jason
AU  - Silver J
AD  - National Eye Institute, NIH, Bethesda, MD, USA.
FAU - Insinna-Kettenhofen, Christine
AU  - Insinna-Kettenhofen C
AD  - National Cancer Institute, NIH, Frederick, MD, USA.
FAU - Patel, Dishita
AU  - Patel D
AD  - National Eye Institute, NIH, Bethesda, MD, USA.
FAU - Lotfi, Mostafa
AU  - Lotfi M
AD  - National Eye Institute, NIH, Bethesda, MD, USA.
FAU - Malicdan, May
AU  - Malicdan M
AD  - National Human Genome Research Institute, NIH, Bethesda, MD, USA.
FAU - Hotaling, Nathan
AU  - Hotaling N
AD  - National Eye Institute, NIH, Bethesda, MD, USA.
FAU - Maminishkis, Arvydas
AU  - Maminishkis A
AD  - National Eye Institute, NIH, Bethesda, MD, USA.
FAU - Sridharan, Rupa
AU  - Sridharan R
AD  - University of Wisconsin, Madison, WI, USA.
FAU - Brooks, Brian
AU  - Brooks B
AD  - National Eye Institute, NIH, Bethesda, MD, USA.
FAU - Miyagishima, Kiyoharu
AU  - Miyagishima K
AD  - National Eye Institute, NIH, Bethesda, MD, USA.
FAU - Gunay-Aygun, Meral
AU  - Gunay-Aygun M
AD  - National Human Genome Research Institute, NIH, Bethesda, MD, USA.
FAU - Pal, Rajarshi
AU  - Pal R
AD  - School of Regenerative Medicine, Manipal University, Bangalore, India.
FAU - Westlake, Christopher
AU  - Westlake C
AD  - National Cancer Institute, NIH, Frederick, MD, USA.
FAU - Miller, Sheldon
AU  - Miller S
AD  - National Eye Institute, NIH, Bethesda, MD, USA.
FAU - Sharma, Ruchi
AU  - Sharma R
AD  - National Eye Institute, NIH, Bethesda, MD, USA.
FAU - Bharti, Kapil
AU  - Bharti K
AD  - National Eye Institute, NIH, Bethesda, MD, USA. Electronic address:
      kapilbharti@mail.nih.gov.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cell Rep
JT  - Cell reports
JID - 101573691
OTO - NOTNLM
OT  - CEP290
OT  - RPE
OT  - WNT signaling
OT  - apical-basal polarity
OT  - cell maturation
OT  - cilia
OT  - ciliopathy
OT  - iPS cells
OT  - primary cilium
OT  - retinal pigment epithelium
EDAT- 2018/01/04 06:00
MHDA- 2018/01/04 06:00
CRDT- 2018/01/04 06:00
PHST- 2017/07/19 00:00 [received]
PHST- 2017/11/08 00:00 [revised]
PHST- 2017/12/11 00:00 [accepted]
PHST- 2018/01/04 06:00 [entrez]
PHST- 2018/01/04 06:00 [pubmed]
PHST- 2018/01/04 06:00 [medline]
AID - S2211-1247(17)31847-8 [pii]
AID - 10.1016/j.celrep.2017.12.038 [doi]
PST - ppublish
SO  - Cell Rep. 2018 Jan 2;22(1):189-205. doi: 10.1016/j.celrep.2017.12.038.

PMID- 29326266
OWN - NLM
STAT- In-Process
LR  - 20180117
IS  - 1095-9203 (Electronic)
IS  - 0036-8075 (Linking)
VI  - 359
IP  - 6372
DP  - 2018 Jan 12
TI  - The epigenetic control of stemness in CD8(+) T cell fate commitment.
PG  - 177-186
LID - 10.1126/science.aah6499 [doi]
AB  - After priming, naive CD8(+) T lymphocytes establish specific heritable
      transcription programs that define progression to long-lasting memory cells or to
      short-lived effector cells. Although lineage specification is critical for
      protection, it remains unclear how chromatin dynamics contributes to the control 
      of gene expression programs. We explored the role of gene silencing by the
      histone methyltransferase Suv39h1. In murine CD8(+) T cells activated after
      Listeria monocytogenes infection, Suv39h1-dependent trimethylation of histone H3 
      lysine 9 controls the expression of a set of stem cell-related memory genes.
      Single-cell RNA sequencing revealed a defect in silencing of stem/memory genes
      selectively in Suv39h1-defective T cell effectors. As a result, Suv39h1-defective
      CD8(+) T cells show sustained survival and increased long-term memory
      reprogramming capacity. Thus, Suv39h1 plays a critical role in marking chromatin 
      to silence stem/memory genes during CD8(+) T effector terminal differentiation.
CI  - Copyright (c) 2018 The Authors, some rights reserved; exclusive licensee American
      Association for the Advancement of Science. No claim to original U.S. Government 
      Works.
FAU - Pace, Luigia
AU  - Pace L
AUID- ORCID: http://orcid.org/0000-0002-1694-2401
AD  - Institut Curie, PSL Research University, F-75005 Paris, France.
      luigia.pace@iigm.it genevieve.almouzni@curie.fr sebastian.amigorena@curie.fr.
AD  - INSERM U932, Equipes Labellisees Ligue contre le Cancer, F-75005 Paris, France.
AD  - Armenise-Harvard Laboratory, Italian Institute for Genomic Medicine, Turin,
      Italy.
FAU - Goudot, Christel
AU  - Goudot C
AD  - Institut Curie, PSL Research University, F-75005 Paris, France.
AD  - INSERM U932, Equipes Labellisees Ligue contre le Cancer, F-75005 Paris, France.
FAU - Zueva, Elina
AU  - Zueva E
AD  - Institut Curie, PSL Research University, F-75005 Paris, France.
AD  - INSERM U932, Equipes Labellisees Ligue contre le Cancer, F-75005 Paris, France.
FAU - Gueguen, Paul
AU  - Gueguen P
AUID- ORCID: http://orcid.org/0000-0003-2930-6073
AD  - Institut Curie, PSL Research University, F-75005 Paris, France.
AD  - INSERM U932, Equipes Labellisees Ligue contre le Cancer, F-75005 Paris, France.
FAU - Burgdorf, Nina
AU  - Burgdorf N
AD  - Institut Curie, PSL Research University, F-75005 Paris, France.
AD  - INSERM U932, Equipes Labellisees Ligue contre le Cancer, F-75005 Paris, France.
FAU - Waterfall, Joshua J
AU  - Waterfall JJ
AUID- ORCID: http://orcid.org/0000-0002-3762-5050
AD  - Institut Curie, PSL Research University, F-75005 Paris, France.
AD  - INSERM U830, F-75005 Paris, France.
AD  - Institut Curie, Translational Research Department, F-75005 Paris, France.
FAU - Quivy, Jean-Pierre
AU  - Quivy JP
AUID- ORCID: http://orcid.org/0000-0001-6557-7204
AD  - Institut Curie, PSL Research University, F-75005 Paris, France.
AD  - CNRS, UMR3664, Equipe Labellisee Ligue contre le Cancer, F-75005 Paris, France.
AD  - Sorbonne Universites, UPMC University Paris 06, CNRS, UMR3664, F-75005 Paris,
      France.
FAU - Almouzni, Genevieve
AU  - Almouzni G
AUID- ORCID: http://orcid.org/0000-0001-5570-0723
AD  - Institut Curie, PSL Research University, F-75005 Paris, France.
AD  - CNRS, UMR3664, Equipe Labellisee Ligue contre le Cancer, F-75005 Paris, France.
AD  - Sorbonne Universites, UPMC University Paris 06, CNRS, UMR3664, F-75005 Paris,
      France.
FAU - Amigorena, Sebastian
AU  - Amigorena S
AUID- ORCID: http://orcid.org/0000-0001-8583-8416
AD  - Institut Curie, PSL Research University, F-75005 Paris, France.
AD  - INSERM U932, Equipes Labellisees Ligue contre le Cancer, F-75005 Paris, France.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Science
JT  - Science (New York, N.Y.)
JID - 0404511
CIN - Science. 2018 Jan 12;359(6372):163-164. PMID: 29326263
EDAT- 2018/01/13 06:00
MHDA- 2018/01/13 06:00
CRDT- 2018/01/13 06:00
PHST- 2016/07/27 00:00 [received]
PHST- 2017/08/01 00:00 [revised]
PHST- 2017/11/16 00:00 [accepted]
PHST- 2018/01/13 06:00 [entrez]
PHST- 2018/01/13 06:00 [pubmed]
PHST- 2018/01/13 06:00 [medline]
AID - 359/6372/177 [pii]
AID - 10.1126/science.aah6499 [doi]
PST - ppublish
SO  - Science. 2018 Jan 12;359(6372):177-186. doi: 10.1126/science.aah6499.

PMID- 29323119
OWN - NLM
STAT- In-Data-Review
LR  - 20180119
IS  - 2041-1723 (Electronic)
IS  - 2041-1723 (Linking)
VI  - 9
IP  - 1
DP  - 2018 Jan 11
TI  - CUG initiation and frameshifting enable production of dipeptide repeat proteins
      from ALS/FTD C9ORF72 transcripts.
PG  - 152
LID - 10.1038/s41467-017-02643-5 [doi]
AB  - Expansion of G4C2 repeats in the C9ORF72 gene is the most prevalent inherited
      form of amyotrophic lateral sclerosis and frontotemporal dementia. Expanded
      transcripts undergo repeat-associated non-AUG (RAN) translation producing
      dipeptide repeat proteins from all reading frames. We determined cis-factors and 
      trans-factors influencing translation of the human C9ORF72 transcripts. G4C2
      translation operates through a 5'-3' cap-dependent scanning mechanism, requiring 
      a CUG codon located upstream of the repeats and an initiator Met-tRNA(Met)i.
      Production of poly-GA, poly-GP, and poly-GR proteins from the three frames is
      influenced by mutation of the same CUG start codon supporting a frameshifting
      mechanism. RAN translation is also regulated by an upstream open reading frame
      (uORF) present in mis-spliced C9ORF72 transcripts. Inhibitors of the
      pre-initiation ribosomal complex and RNA antisense oligonucleotides selectively
      targeting the 5'-flanking G4C2 sequence block ribosomal scanning and prevent
      translation. Finally, we identified an unexpected affinity of expanded
      transcripts for the ribosomal subunits independently from translation.
FAU - Tabet, Ricardos
AU  - Tabet R
AD  - Department of Neurology, MassGeneral Institute for Neurodegenerative Disease
      (MIND), Massachusetts General Hospital and Harvard Medical School, Boston, MA,
      02114, USA.
AD  - Broad Institute of Harvard University and MIT, Cambridge, MA, 02142, USA.
FAU - Schaeffer, Laure
AU  - Schaeffer L
AD  - Architecture et Reactivite de l'ARN, UPR 9002, Universite de Strasbourg, CNRS,
      F-67000, Strasbourg, France.
FAU - Freyermuth, Fernande
AU  - Freyermuth F
AD  - Department of Neurology, MassGeneral Institute for Neurodegenerative Disease
      (MIND), Massachusetts General Hospital and Harvard Medical School, Boston, MA,
      02114, USA.
AD  - Broad Institute of Harvard University and MIT, Cambridge, MA, 02142, USA.
FAU - Jambeau, Melanie
AU  - Jambeau M
AD  - Department of Neurology, MassGeneral Institute for Neurodegenerative Disease
      (MIND), Massachusetts General Hospital and Harvard Medical School, Boston, MA,
      02114, USA.
AD  - Broad Institute of Harvard University and MIT, Cambridge, MA, 02142, USA.
FAU - Workman, Michael
AU  - Workman M
AD  - Department of Neurology, MassGeneral Institute for Neurodegenerative Disease
      (MIND), Massachusetts General Hospital and Harvard Medical School, Boston, MA,
      02114, USA.
FAU - Lee, Chao-Zong
AU  - Lee CZ
AD  - Department of Neurology, MassGeneral Institute for Neurodegenerative Disease
      (MIND), Massachusetts General Hospital and Harvard Medical School, Boston, MA,
      02114, USA.
FAU - Lin, Chun-Chia
AU  - Lin CC
AD  - Department of Neurology, MassGeneral Institute for Neurodegenerative Disease
      (MIND), Massachusetts General Hospital and Harvard Medical School, Boston, MA,
      02114, USA.
FAU - Jiang, Jie
AU  - Jiang J
AD  - Ludwig Institute for Cancer Research, University of California San Diego, La
      Jolla, CA, 92093, USA.
FAU - Jansen-West, Karen
AU  - Jansen-West K
AD  - Department of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.
FAU - Abou-Hamdan, Hussein
AU  - Abou-Hamdan H
AD  - Therapeutic Innovation Laboratory (UMR 7200), Faculty of Pharmacy,
      CNRS/University of Strasbourg, 67401, Illkirch, Cedex, France.
FAU - Desaubry, Laurent
AU  - Desaubry L
AD  - Therapeutic Innovation Laboratory (UMR 7200), Faculty of Pharmacy,
      CNRS/University of Strasbourg, 67401, Illkirch, Cedex, France.
FAU - Gendron, Tania
AU  - Gendron T
AD  - Department of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.
FAU - Petrucelli, Leonard
AU  - Petrucelli L
AD  - Department of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.
FAU - Martin, Franck
AU  - Martin F
AUID- ORCID: http://orcid.org/0000-0001-9724-4025
AD  - Architecture et Reactivite de l'ARN, UPR 9002, Universite de Strasbourg, CNRS,
      F-67000, Strasbourg, France. f.martin@ibmc-cnrs.unistra.fr.
FAU - Lagier-Tourenne, Clotilde
AU  - Lagier-Tourenne C
AUID- ORCID: http://orcid.org/0000-0002-3058-8322
AD  - Department of Neurology, MassGeneral Institute for Neurodegenerative Disease
      (MIND), Massachusetts General Hospital and Harvard Medical School, Boston, MA,
      02114, USA. clagier-tourenne@mgh.harvard.edu.
AD  - Broad Institute of Harvard University and MIT, Cambridge, MA, 02142, USA.
      clagier-tourenne@mgh.harvard.edu.
LA  - eng
GR  - R01 NS087227/NS/NINDS NIH HHS/United States
PT  - Journal Article
DEP - 20180111
PL  - England
TA  - Nat Commun
JT  - Nature communications
JID - 101528555
PMC - PMC5764992
EDAT- 2018/01/13 06:00
MHDA- 2018/01/13 06:00
CRDT- 2018/01/12 06:00
PHST- 2017/04/28 00:00 [received]
PHST- 2017/12/14 00:00 [accepted]
PHST- 2018/01/12 06:00 [entrez]
PHST- 2018/01/13 06:00 [pubmed]
PHST- 2018/01/13 06:00 [medline]
AID - 10.1038/s41467-017-02643-5 [doi]
AID - 10.1038/s41467-017-02643-5 [pii]
PST - epublish
SO  - Nat Commun. 2018 Jan 11;9(1):152. doi: 10.1038/s41467-017-02643-5.

PMID- 29330221
OWN - NLM
STAT- Publisher
LR  - 20180113
IS  - 1528-0020 (Electronic)
IS  - 0006-4971 (Linking)
DP  - 2018 Jan 12
TI  - Minimal/measurable residual disease in AML: consensus document from ELN MRD
      Working Party.
LID - blood-2017-09-801498 [pii]
LID - 10.1182/blood-2017-09-801498 [doi]
AB  - Measurable residual disease (MRD, previously termed minimal residual disease) is 
      an independent, post-diagnosis, prognostic indicator in acute myeloid leukemia
      (AML) that is important for risk stratification and treatment planning, in
      conjunction with other well-established clinical, cytogenetic, and molecular data
      assessed at diagnosis. MRD can be evaluated using a variety of multi-parameter
      flow cytometry (MFC) and molecular protocols but, to date, these approaches have 
      not been qualitatively or quantitatively standardized, making their use in
      clinical practice challenging. The objective of this work was to identify key
      clinical and scientific issues in the measurement and application of MRD in AML, 
      to achieve consensus on these issues, and to provide guidelines for the current
      and future use of MRD in clinical practice. The work was accomplished over two
      years, during four meetings by a specially designated MRD working party of the
      European LeukemiaNet (ELN). The group included 24 faculty with expertise in AML
      hematopathology, molecular diagnostics, clinical trials, and clinical medicine,
      from 19 institutions in Europe and the USA. The manuscript is dedicated to the
      memory of our esteemed colleague David Grimwade, a pioneer in the field of MRD in
      AML, and an active participant in the present work.
CI  - Copyright (c) 2018 American Society of Hematology.
FAU - Schuurhuis, Gerrit J
AU  - Schuurhuis GJ
AUID- ORCID: http://orcid.org/0000-0002-0977-6185
AD  - Department of Hematology, VU University Medical Center, Amsterdam, Netherlands;
      gj.schuurhuis@vumc.nl.
FAU - Heuser, Michael
AU  - Heuser M
AD  - Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation,
      Hannover Medical School, Hannover, Germany.
FAU - Freeman, Sylvie
AU  - Freeman S
AD  - Department of Clinical Immunology, Institute of Immunology and Immunotherapy,
      College of Medical and Dental Sciences, University of Birmingham, Birmingham,
      United Kingdom.
FAU - Bene, Marie-Christine
AU  - Bene MC
AUID- ORCID: http://orcid.org/0000-0002-6569-7414
AD  - Hematology Biology, University Hospital Nantes, Nantes, France.
FAU - Buccisano, Francesco
AU  - Buccisano F
AUID- ORCID: http://orcid.org/0000-0003-4320-9253
AD  - Department of Biomedicine and Prevention, University of Rome, Tor Vergata, Rome, 
      Italy.
FAU - Cloos, Jacqueline
AU  - Cloos J
AUID- ORCID: http://orcid.org/0000-0001-9150-8026
AD  - Department of Pediatric Oncology, VU University Medical Center, Amsterdam,
      Netherlands.
FAU - Grimwade, David
AU  - Grimwade D
AD  - Division of Genetics & Molecular Medicine, King's College, London, United
      Kingdom.
FAU - Haferlach, Torsten
AU  - Haferlach T
AD  - Munich Leukemia Laboratory, Munich, Germany.
FAU - Hills, Robert K
AU  - Hills RK
AD  - Centre for Trials Research, Cardiff University, Cardiff, United Kingdom.
FAU - Hourigan, Christopher S
AU  - Hourigan CS
AUID- ORCID: http://orcid.org/0000-0002-6189-8067
AD  - Myeloid Malignancies Section, National Institutes of Health, Bethesda, MD, United
      States.
FAU - Jorgensen, Jeffrey L
AU  - Jorgensen JL
AD  - Division Pathology/Lab Medicine, Department of Hematopathology, MD Anderson
      Cancer Center, Houston, TX, United States.
FAU - Kern, Wolfgang
AU  - Kern W
AUID- ORCID: http://orcid.org/0000-0003-3945-9153
AD  - Munich Leukemia Laboratory, Munich, Germany.
FAU - Lacombe, Francis
AU  - Lacombe F
AD  - Flow cytometry Platform, University Hospital, Bordeaux, France.
FAU - Maurillo, Luca
AU  - Maurillo L
AD  - Department of Biomedicine and Prevention, University of Rome, Tor Vergata, Rome, 
      Italy.
FAU - Preudhomme, Claude
AU  - Preudhomme C
AD  - Center of Pathology, Laboratory of Hematology, University Hospital of Lille,
      Lille, France.
FAU - van der Reijden, Bert A
AU  - van der Reijden BA
AUID- ORCID: http://orcid.org/0000-0001-7804-8643
AD  - Department of Laboratory Medicine, Laboratory of Hematology, Radboud University
      Medical Center, Nijmegen, Netherlands.
FAU - Thiede, Christian
AU  - Thiede C
AUID- ORCID: http://orcid.org/0000-0003-1241-2048
AD  - Universitaetsklinikum Carl Gustav Garus an der Technischen Universitaet Dresden, 
      Dresden, Germany.
FAU - Venditti, Adriano
AU  - Venditti A
AUID- ORCID: http://orcid.org/0000-0002-0245-0553
AD  - Department of Biomedicine and Prevention, University of Rome, Tor Vergata, Rome, 
      Italy.
FAU - Vyas, Paresh
AU  - Vyas P
AD  - MRC Molecular Haematology Unit, Oxford Centre for Haematology, University of
      Oxford and Oxford University Hospitals NHS Trust Oxford, Oxford, United Kingdom.
FAU - Wood, Brent L
AU  - Wood BL
AUID- ORCID: http://orcid.org/0000-0001-7414-3969
AD  - Fred Hutchinson Cancer Research Center, Seattle, WA, United States.
FAU - Walter, Roland B
AU  - Walter RB
AUID- ORCID: http://orcid.org/0000-0002-9268-3341
AD  - University of Washington, Seattle, WA, United States.
FAU - Dohner, Konstanze
AU  - Dohner K
AD  - Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.
FAU - Roboz, Gail J
AU  - Roboz GJ
AD  - Weill Cornell Medicine and The New York Presbyterian Hospital, New York, NY,
      United States.
FAU - Ossenkoppele, Gert J
AU  - Ossenkoppele GJ
AD  - Department of Hematology, VU University Medical Center, Amsterdam, Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20180112
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
EDAT- 2018/01/14 06:00
MHDA- 2018/01/14 06:00
CRDT- 2018/01/14 06:00
PHST- 2017/09/05 00:00 [received]
PHST- 2018/01/03 00:00 [accepted]
PHST- 2018/01/14 06:00 [entrez]
PHST- 2018/01/14 06:00 [pubmed]
PHST- 2018/01/14 06:00 [medline]
AID - blood-2017-09-801498 [pii]
AID - 10.1182/blood-2017-09-801498 [doi]
PST - aheadofprint
SO  - Blood. 2018 Jan 12. pii: blood-2017-09-801498. doi: 10.1182/blood-2017-09-801498.

PMID- 29335608
OWN - NLM
STAT- Publisher
LR  - 20180116
IS  - 1546-1726 (Electronic)
IS  - 1097-6256 (Linking)
DP  - 2018 Jan 15
TI  - N(6)-methyladenosine RNA modification regulates embryonic neural stem cell
      self-renewal through histone modifications.
LID - 10.1038/s41593-017-0057-1 [doi]
AB  - Internal N(6)-methyladenosine (m(6)A) modification is widespread in messenger
      RNAs (mRNAs) and is catalyzed by heterodimers of methyltransferase-like protein 3
      (Mettl3) and Mettl14. To understand the role of m(6)A in development, we deleted 
      Mettl14 in embryonic neural stem cells (NSCs) in a mouse model. Phenotypically,
      NSCs lacking Mettl14 displayed markedly decreased proliferation and premature
      differentiation, suggesting that m(6)A modification enhances NSC self-renewal.
      Decreases in the NSC pool led to a decreased number of late-born neurons during
      cortical neurogenesis. Mechanistically, we discovered a genome-wide increase in
      specific histone modifications in Mettl14 knockout versus control NSCs. These
      changes correlated with altered gene expression and observed cellular phenotypes,
      suggesting functional significance of altered histone modifications in knockout
      cells. Finally, we found that m(6)A regulates histone modification in part by
      destabilizing transcripts that encode histone-modifying enzymes. Our results
      suggest an essential role for m(6)A in development and reveal m(6)A-regulated
      histone modifications as a previously unknown mechanism of gene regulation in
      mammalian cells.
FAU - Wang, Yang
AU  - Wang Y
AD  - Tumor Initiation and Maintenance Program, NCI-designated Cancer Center, Sanford
      Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
FAU - Li, Yue
AU  - Li Y
AUID- ORCID: http://orcid.org/0000-0002-1163-3634
AD  - Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute 
      of Technology, Cambridge, MA, USA.
FAU - Yue, Minghui
AU  - Yue M
AD  - Division of Reproductive Sciences, Division of Developmental Biology, Perinatal
      Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
AD  - Department of Pediatrics, University of Cincinnati, Cincinnati, OH, USA.
FAU - Wang, Jun
AU  - Wang J
AD  - Tumor Initiation and Maintenance Program, NCI-designated Cancer Center, Sanford
      Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
FAU - Kumar, Sandeep
AU  - Kumar S
AD  - Development, Aging, and Regeneration Program, Sanford Burnham Prebys Medical
      Discovery Institute, La Jolla, CA, USA.
FAU - Wechsler-Reya, Robert J
AU  - Wechsler-Reya RJ
AD  - Tumor Initiation and Maintenance Program, NCI-designated Cancer Center, Sanford
      Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
FAU - Zhang, Zhaolei
AU  - Zhang Z
AD  - Department of Molecular Genetics, The Donnelly Centre, University of Toronto,
      Toronto, Ontario, Canada.
FAU - Ogawa, Yuya
AU  - Ogawa Y
AD  - Division of Reproductive Sciences, Division of Developmental Biology, Perinatal
      Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
AD  - Department of Pediatrics, University of Cincinnati, Cincinnati, OH, USA.
FAU - Kellis, Manolis
AU  - Kellis M
AD  - Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute 
      of Technology, Cambridge, MA, USA.
FAU - Duester, Gregg
AU  - Duester G
AUID- ORCID: http://orcid.org/0000-0003-4335-3650
AD  - Development, Aging, and Regeneration Program, Sanford Burnham Prebys Medical
      Discovery Institute, La Jolla, CA, USA.
FAU - Zhao, Jing Crystal
AU  - Zhao JC
AUID- ORCID: http://orcid.org/0000-0002-0446-0456
AD  - Tumor Initiation and Maintenance Program, NCI-designated Cancer Center, Sanford
      Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
      czhao@sbpdiscovery.org.
LA  - eng
PT  - Journal Article
DEP - 20180115
PL  - United States
TA  - Nat Neurosci
JT  - Nature neuroscience
JID - 9809671
EDAT- 2018/01/18 06:00
MHDA- 2018/01/18 06:00
CRDT- 2018/01/17 06:00
PHST- 2017/07/04 00:00 [received]
PHST- 2017/12/04 00:00 [accepted]
PHST- 2018/01/17 06:00 [entrez]
PHST- 2018/01/18 06:00 [pubmed]
PHST- 2018/01/18 06:00 [medline]
AID - 10.1038/s41593-017-0057-1 [doi]
AID - 10.1038/s41593-017-0057-1 [pii]
PST - aheadofprint
SO  - Nat Neurosci. 2018 Jan 15. pii: 10.1038/s41593-017-0057-1. doi:
      10.1038/s41593-017-0057-1.

PMID- 29302039
OWN - NLM
STAT- In-Data-Review
LR  - 20180119
IS  - 2041-1723 (Electronic)
IS  - 2041-1723 (Linking)
VI  - 9
IP  - 1
DP  - 2018 Jan 4
TI  - Targeting the CoREST complex with dual histone deacetylase and demethylase
      inhibitors.
PG  - 53
LID - 10.1038/s41467-017-02242-4 [doi]
AB  - Here we report corin, a synthetic hybrid agent derived from the class I HDAC
      inhibitor (entinostat) and an LSD1 inhibitor (tranylcypromine analog).
      Enzymologic analysis reveals that corin potently targets the CoREST complex and
      shows more sustained inhibition of CoREST complex HDAC activity compared with
      entinostat. Cell-based experiments demonstrate that corin exhibits a superior
      anti-proliferative profile against several melanoma lines and cutaneous squamous 
      cell carcinoma lines compared to its parent monofunctional inhibitors but is less
      toxic to melanocytes and keratinocytes. CoREST knockdown, gene expression, and
      ChIP studies suggest that corin's favorable pharmacologic effects may rely on an 
      intact CoREST complex. Corin was also effective in slowing tumor growth in a
      melanoma mouse xenograft model. These studies highlight the promise of a new
      class of two-pronged hybrid agents that may show preferential targeting of
      particular epigenetic regulatory complexes and offer unique therapeutic
      opportunities.
FAU - Kalin, Jay H
AU  - Kalin JH
AD  - Division of Genetics, Departments of Medicine and Biological Chemistry and
      Molecular Pharmacology, Harvard Medical School and Brigham and Women's Hospital, 
      Boston, MA, 02115, USA.
AD  - Department of Pharmacology and Molecular Sciences, Johns Hopkins University
      School of Medicine, Baltimore, MD, 21205, USA.
FAU - Wu, Muzhou
AU  - Wu M
AD  - Department of Dermatology, Boston University School of Medicine, Boston, MA,
      02118, USA.
FAU - Gomez, Andrea V
AU  - Gomez AV
AD  - Department of Biology and Biotechnology, University of Pavia, 27100, Pavia,
      Italy.
FAU - Song, Yun
AU  - Song Y
AD  - Department of Molecular and Cell Biology, University of Leicester, Leicester, LE1
      9HN, UK.
FAU - Das, Jayanta
AU  - Das J
AD  - Department of Pharmacology and Molecular Sciences, Johns Hopkins University
      School of Medicine, Baltimore, MD, 21205, USA.
FAU - Hayward, Dawn
AU  - Hayward D
AD  - Department of Pharmacology and Molecular Sciences, Johns Hopkins University
      School of Medicine, Baltimore, MD, 21205, USA.
FAU - Adejola, Nkosi
AU  - Adejola N
AD  - Department of Pharmacology and Molecular Sciences, Johns Hopkins University
      School of Medicine, Baltimore, MD, 21205, USA.
FAU - Wu, Mingxuan
AU  - Wu M
AD  - Division of Genetics, Departments of Medicine and Biological Chemistry and
      Molecular Pharmacology, Harvard Medical School and Brigham and Women's Hospital, 
      Boston, MA, 02115, USA.
AD  - Department of Pharmacology and Molecular Sciences, Johns Hopkins University
      School of Medicine, Baltimore, MD, 21205, USA.
FAU - Panova, Izabela
AU  - Panova I
AD  - Department of Dermatology, Boston University School of Medicine, Boston, MA,
      02118, USA.
FAU - Chung, Hye Jin
AU  - Chung HJ
AD  - Department of Dermatology, Boston University School of Medicine, Boston, MA,
      02118, USA.
FAU - Kim, Edward
AU  - Kim E
AD  - Department of Dermatology, Boston University School of Medicine, Boston, MA,
      02118, USA.
FAU - Roberts, Holly J
AU  - Roberts HJ
AUID- ORCID: http://orcid.org/0000-0001-6112-7476
AD  - Department of Dermatology, Boston University School of Medicine, Boston, MA,
      02118, USA.
FAU - Roberts, Justin M
AU  - Roberts JM
AUID- ORCID: http://orcid.org/0000-0001-6112-7476
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, 
      USA.
FAU - Prusevich, Polina
AU  - Prusevich P
AD  - Department of Pharmacology and Molecular Sciences, Johns Hopkins University
      School of Medicine, Baltimore, MD, 21205, USA.
FAU - Jeliazkov, Jeliazko R
AU  - Jeliazkov JR
AD  - Program in Molecular Biophysics, Johns Hopkins University, Baltimore, MD, 21218, 
      USA.
FAU - Roy Burman, Shourya S
AU  - Roy Burman SS
AD  - Department of Chemical and Biomolecular Engineering, Johns Hopkins University,
      Baltimore, MD, 21218, USA.
FAU - Fairall, Louise
AU  - Fairall L
AD  - Department of Molecular and Cell Biology, University of Leicester, Leicester, LE1
      9HN, UK.
FAU - Milano, Charles
AU  - Milano C
AD  - Department of Molecular and Cell Biology, University of Leicester, Leicester, LE1
      9HN, UK.
FAU - Eroglu, Abdulkerim
AU  - Eroglu A
AD  - Department of Pharmacology and Molecular Sciences, Johns Hopkins University
      School of Medicine, Baltimore, MD, 21205, USA.
FAU - Proby, Charlotte M
AU  - Proby CM
AD  - Division of Cancer Research, Jacqui Wood Cancer Centre, University of Dundee,
      Dundee, DD1 9SY, UK.
FAU - Dinkova-Kostova, Albena T
AU  - Dinkova-Kostova AT
AD  - Department of Pharmacology and Molecular Sciences, Johns Hopkins University
      School of Medicine, Baltimore, MD, 21205, USA.
AD  - Division of Cancer Research, Jacqui Wood Cancer Centre, University of Dundee,
      Dundee, DD1 9SY, UK.
FAU - Hancock, Wayne W
AU  - Hancock WW
AD  - Department of Pathology and Laboratory Medicine, University of Pennsylvania
      School of Medicine, Philadelphia, PA, 19104, USA.
FAU - Gray, Jeffrey J
AU  - Gray JJ
AUID- ORCID: http://orcid.org/0000-0001-6380-2324
AD  - Program in Molecular Biophysics, Johns Hopkins University, Baltimore, MD, 21218, 
      USA.
AD  - Department of Chemical and Biomolecular Engineering, Johns Hopkins University,
      Baltimore, MD, 21218, USA.
AD  - Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of
      Medicine, Baltimore, MD, 21205, USA.
FAU - Bradner, James E
AU  - Bradner JE
AUID- ORCID: http://orcid.org/0000-0002-2718-4415
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, 
      USA.
FAU - Valente, Sergio
AU  - Valente S
AD  - Pasteur Institute, Cenci-Bolognetti Foundation, Department of Drug Chemistry and 
      Technologies, Sapienza University of Rome, 00185, Rome, Italy.
FAU - Mai, Antonello
AU  - Mai A
AD  - Pasteur Institute, Cenci-Bolognetti Foundation, Department of Drug Chemistry and 
      Technologies, Sapienza University of Rome, 00185, Rome, Italy.
FAU - Anders, Nicole M
AU  - Anders NM
AD  - Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of
      Medicine, Baltimore, MD, 21205, USA.
FAU - Rudek, Michelle A
AU  - Rudek MA
AD  - Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of
      Medicine, Baltimore, MD, 21205, USA.
FAU - Hu, Yong
AU  - Hu Y
AD  - Department of Oncology, BioDuro LLC, Shanghai, 200131, China.
FAU - Ryu, Byungwoo
AU  - Ryu B
AD  - Department of Dermatology, Boston University School of Medicine, Boston, MA,
      02118, USA.
FAU - Schwabe, John W R
AU  - Schwabe JWR
AD  - Department of Molecular and Cell Biology, University of Leicester, Leicester, LE1
      9HN, UK. js336@leicester.ac.uk.
FAU - Mattevi, Andrea
AU  - Mattevi A
AUID- ORCID: http://orcid.org/0000-0002-9523-7128
AD  - Department of Biology and Biotechnology, University of Pavia, 27100, Pavia,
      Italy. andrea.mattevi@unipv.it.
FAU - Alani, Rhoda M
AU  - Alani RM
AD  - Department of Dermatology, Boston University School of Medicine, Boston, MA,
      02118, USA. alani@bu.edu.
FAU - Cole, Philip A
AU  - Cole PA
AD  - Division of Genetics, Departments of Medicine and Biological Chemistry and
      Molecular Pharmacology, Harvard Medical School and Brigham and Women's Hospital, 
      Boston, MA, 02115, USA. pacole@bwh.harvard.edu.
AD  - Department of Pharmacology and Molecular Sciences, Johns Hopkins University
      School of Medicine, Baltimore, MD, 21205, USA. pacole@bwh.harvard.edu.
LA  - eng
GR  - R01 CA074305/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20180104
PL  - England
TA  - Nat Commun
JT  - Nature communications
JID - 101528555
PMC - PMC5754352
EDAT- 2018/01/06 06:00
MHDA- 2018/01/06 06:00
CRDT- 2018/01/06 06:00
PHST- 2017/10/09 00:00 [received]
PHST- 2017/11/14 00:00 [accepted]
PHST- 2018/01/06 06:00 [entrez]
PHST- 2018/01/06 06:00 [pubmed]
PHST- 2018/01/06 06:00 [medline]
AID - 10.1038/s41467-017-02242-4 [doi]
AID - 10.1038/s41467-017-02242-4 [pii]
PST - epublish
SO  - Nat Commun. 2018 Jan 4;9(1):53. doi: 10.1038/s41467-017-02242-4.

PMID- 29342136
OWN - NLM
STAT- In-Data-Review
LR  - 20180129
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 553
IP  - 7689
DP  - 2018 Jan 25
TI  - Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic
      leukaemia.
PG  - 511-514
LID - 10.1038/nature25186 [doi]
AB  - Relapsed acute lymphoblastic leukaemia (ALL) is associated with resistance to
      chemotherapy and poor prognosis. Gain-of-function mutations in the
      5'-nucleotidase, cytosolic II (NT5C2) gene induce resistance to 6-mercaptopurine 
      and are selectively present in relapsed ALL. Yet, the mechanisms involved in
      NT5C2 mutation-driven clonal evolution during the initiation of leukaemia,
      disease progression and relapse remain unknown. Here we use a
      conditional-and-inducible leukaemia model to demonstrate that expression of
      NT5C2(R367Q), a highly prevalent relapsed-ALL NT5C2 mutation, induces resistance 
      to chemotherapy with 6-mercaptopurine at the cost of impaired leukaemia cell
      growth and leukaemia-initiating cell activity. The loss-of-fitness phenotype of
      NT5C2(+/R367Q) mutant cells is associated with excess export of purines to the
      extracellular space and depletion of the intracellular purine-nucleotide pool.
      Consequently, blocking guanosine synthesis by inhibition of
      inosine-5'-monophosphate dehydrogenase (IMPDH) induced increased cytotoxicity
      against NT5C2-mutant leukaemia lymphoblasts. These results identify the fitness
      cost of NT5C2 mutation and resistance to chemotherapy as key evolutionary drivers
      that shape clonal evolution in relapsed ALL and support a role for IMPDH
      inhibition in the treatment of ALL.
FAU - Tzoneva, Gannie
AU  - Tzoneva G
AD  - Institute for Cancer Genetics, Columbia University, New York, New York 10032,
      USA.
FAU - Dieck, Chelsea L
AU  - Dieck CL
AD  - Institute for Cancer Genetics, Columbia University, New York, New York 10032,
      USA.
FAU - Oshima, Koichi
AU  - Oshima K
AD  - Institute for Cancer Genetics, Columbia University, New York, New York 10032,
      USA.
FAU - Ambesi-Impiombato, Alberto
AU  - Ambesi-Impiombato A
AD  - Institute for Cancer Genetics, Columbia University, New York, New York 10032,
      USA.
FAU - Sanchez-Martin, Marta
AU  - Sanchez-Martin M
AD  - Institute for Cancer Genetics, Columbia University, New York, New York 10032,
      USA.
FAU - Madubata, Chioma J
AU  - Madubata CJ
AD  - Department of Systems Biology, Columbia University, New York, New York 10032,
      USA.
FAU - Khiabanian, Hossein
AU  - Khiabanian H
AD  - Rutgers Cancer Institute, Rutgers University, New Brunswick, New Jersey 08903,
      USA.
FAU - Yu, Jiangyan
AU  - Yu J
AD  - Princess Maxima Center for Pediatric Oncology, Utrecht, 3584 CT, the Netherlands.
AD  - Department of Human Genetics, Radboud University Medical Center and Radboud
      Institute for Molecular Life Sciences, Nijmegen, 6525 GA, the Netherlands.
FAU - Waanders, Esme
AU  - Waanders E
AD  - Princess Maxima Center for Pediatric Oncology, Utrecht, 3584 CT, the Netherlands.
FAU - Iacobucci, Ilaria
AU  - Iacobucci I
AD  - Department of Pathology, St. Jude Children's Research Hospital, Memphis,
      Tennessee 38105, USA.
FAU - Sulis, Maria Luisa
AU  - Sulis ML
AD  - Department of Pediatrics, Columbia University Medical Center, New York, New York 
      10032, USA.
FAU - Kato, Motohiro
AU  - Kato M
AD  - Department of Hematology-Oncology, Saitama Children's Medical Center, Saitama
      339-8551, Japan.
FAU - Koh, Katsuyoshi
AU  - Koh K
AD  - Department of Hematology-Oncology, Saitama Children's Medical Center, Saitama
      339-8551, Japan.
FAU - Paganin, Maddalena
AU  - Paganin M
AD  - Onco-Hematology Division, Department, Salute della Donna e del Bambino (SDB),
      University of Padua, 35128 Padua, Italy.
FAU - Basso, Giuseppe
AU  - Basso G
AD  - Onco-Hematology Division, Department, Salute della Donna e del Bambino (SDB),
      University of Padua, 35128 Padua, Italy.
FAU - Gastier-Foster, Julie M
AU  - Gastier-Foster JM
AD  - Department of Pathology and Laboratory Medicine, Nationwide Children's Hospital, 
      Columbus, Ohio 43205, USA.
AD  - Department of Pathology, Ohio State University School of Medicine, Columbus, Ohio
      43210, USA.
AD  - Department of Pediatrics, Ohio State University School of Medicine, Columbus,
      Ohio 43210, USA.
AD  - Children's Oncology Group, Arcadia, California 91006, USA.
FAU - Loh, Mignon L
AU  - Loh ML
AD  - Department of Pediatrics, University of California, San Francisco, California
      94143, USA.
AD  - Helen Diller Family Comprehensive Cancer Center, San Francisco, California 94115,
      USA.
FAU - Kirschner-Schwabe, Renate
AU  - Kirschner-Schwabe R
AD  - Department of Pediatric Oncology/Hematology, Charite-Universitatsmedizin Berlin, 
      Berlin, 10117, Germany.
FAU - Mullighan, Charles G
AU  - Mullighan CG
AD  - Department of Pathology, St. Jude Children's Research Hospital, Memphis,
      Tennessee 38105, USA.
FAU - Rabadan, Raul
AU  - Rabadan R
AD  - Department of Systems Biology, Columbia University, New York, New York 10032,
      USA.
AD  - Department of Biomedical Informatics, Columbia University, New York, New York
      10032, USA.
FAU - Ferrando, Adolfo A
AU  - Ferrando AA
AD  - Institute for Cancer Genetics, Columbia University, New York, New York 10032,
      USA.
AD  - Department of Systems Biology, Columbia University, New York, New York 10032,
      USA.
AD  - Department of Pediatrics, Columbia University Medical Center, New York, New York 
      10032, USA.
AD  - Department of Pathology and Cell Biology, Columbia University Medical Center, New
      York, New York 10032, USA.
LA  - eng
PT  - Journal Article
DEP - 20180117
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
EDAT- 2018/01/18 06:00
MHDA- 2018/01/18 06:00
CRDT- 2018/01/18 06:00
PHST- 2016/12/07 00:00 [received]
PHST- 2017/11/30 00:00 [accepted]
PHST- 2018/01/18 06:00 [pubmed]
PHST- 2018/01/18 06:00 [medline]
PHST- 2018/01/18 06:00 [entrez]
AID - nature25186 [pii]
AID - 10.1038/nature25186 [doi]
PST - ppublish
SO  - Nature. 2018 Jan 25;553(7689):511-514. doi: 10.1038/nature25186. Epub 2018 Jan
      17.

PMID- 29334369
OWN - NLM
STAT- Publisher
LR  - 20180122
IS  - 1546-1696 (Electronic)
IS  - 1087-0156 (Linking)
DP  - 2018 Jan 15
TI  - Dual gene activation and knockout screen reveals directional dependencies in
      genetic networks.
LID - 10.1038/nbt.4062 [doi]
AB  - Understanding the direction of information flow is essential for characterizing
      how genetic networks affect phenotypes. However, methods to find genetic
      interactions largely fail to reveal directional dependencies. We combine two
      orthogonal Cas9 proteins from Streptococcus pyogenes and Staphylococcus aureus to
      carry out a dual screen in which one gene is activated while a second gene is
      deleted in the same cell. We analyze the quantitative effects of activation and
      knockout to calculate genetic interaction and directionality scores for each gene
      pair. Based on the results from over 100,000 perturbed gene pairs, we reconstruct
      a directional dependency network for human K562 leukemia cells and demonstrate
      how our approach allows the determination of directionality in activating genetic
      interactions. Our interaction network connects previously uncharacterized genes
      to well-studied pathways and identifies targets relevant for therapeutic
      intervention.
FAU - Boettcher, Michael
AU  - Boettcher M
AUID- ORCID: http://orcid.org/0000-0003-0986-4465
AD  - Department of Microbiology and Immunology, University of California San Francisco
      Diabetes Center, WM Keck Center for Noncoding RNAs, University of California, San
      Francisco, San Francisco, California, USA.
FAU - Tian, Ruilin
AU  - Tian R
AD  - Institute for Neurodegenerative Diseases, Department of Biochemistry and
      Biophysics, University of California, San Francisco and Chan Zuckerberg Biohub,
      San Francisco, California, USA.
FAU - Blau, James A
AU  - Blau JA
AD  - Department of Microbiology and Immunology, University of California San Francisco
      Diabetes Center, WM Keck Center for Noncoding RNAs, University of California, San
      Francisco, San Francisco, California, USA.
FAU - Markegard, Evan
AU  - Markegard E
AD  - Helen Diller Family Comprehensive Cancer Center, Department of Microbiology and
      Immunology, University of California, San Francisco, San Francisco, California,
      USA.
FAU - Wagner, Ryan T
AU  - Wagner RT
AD  - Department of Microbiology and Immunology, University of California San Francisco
      Diabetes Center, WM Keck Center for Noncoding RNAs, University of California, San
      Francisco, San Francisco, California, USA.
FAU - Wu, David
AU  - Wu D
AD  - Department of Microbiology and Immunology, University of California San Francisco
      Diabetes Center, WM Keck Center for Noncoding RNAs, University of California, San
      Francisco, San Francisco, California, USA.
FAU - Mo, Xiulei
AU  - Mo X
AD  - Department of Pharmacology and Emory Chemical Biology Discovery Center, Emory
      University School of Medicine, Atlanta, Georgia, USA.
FAU - Biton, Anne
AU  - Biton A
AD  - Department of Medicine, Lung Biology Center, University of California, San
      Francisco, San Francisco, California, USA.
AD  - Centre de Bioinformatique, Biostatistique et Biologie Integrative (C3BI, USR 3756
      Institut Pasteur et CNRS), Paris, France.
FAU - Zaitlen, Noah
AU  - Zaitlen N
AD  - Department of Medicine, Lung Biology Center, University of California, San
      Francisco, San Francisco, California, USA.
FAU - Fu, Haian
AU  - Fu H
AUID- ORCID: http://orcid.org/0000-0002-2362-7979
AD  - Department of Pharmacology and Emory Chemical Biology Discovery Center, Emory
      University School of Medicine, Atlanta, Georgia, USA.
FAU - McCormick, Frank
AU  - McCormick F
AD  - Helen Diller Family Comprehensive Cancer Center, Department of Microbiology and
      Immunology, University of California, San Francisco, San Francisco, California,
      USA.
FAU - Kampmann, Martin
AU  - Kampmann M
AUID- ORCID: http://orcid.org/0000-0002-3819-7019
AD  - Institute for Neurodegenerative Diseases, Department of Biochemistry and
      Biophysics, University of California, San Francisco and Chan Zuckerberg Biohub,
      San Francisco, California, USA.
FAU - McManus, Michael T
AU  - McManus MT
AUID- ORCID: http://orcid.org/0000-0003-3013-6569
AD  - Department of Microbiology and Immunology, University of California San Francisco
      Diabetes Center, WM Keck Center for Noncoding RNAs, University of California, San
      Francisco, San Francisco, California, USA.
LA  - eng
PT  - Journal Article
DEP - 20180115
PL  - United States
TA  - Nat Biotechnol
JT  - Nature biotechnology
JID - 9604648
EDAT- 2018/01/16 06:00
MHDA- 2018/01/16 06:00
CRDT- 2018/01/16 06:00
PHST- 2017/08/14 00:00 [received]
PHST- 2017/12/20 00:00 [accepted]
PHST- 2018/01/16 06:00 [pubmed]
PHST- 2018/01/16 06:00 [medline]
PHST- 2018/01/16 06:00 [entrez]
AID - nbt.4062 [pii]
AID - 10.1038/nbt.4062 [doi]
PST - aheadofprint
SO  - Nat Biotechnol. 2018 Jan 15. pii: nbt.4062. doi: 10.1038/nbt.4062.

PMID- 29342141
OWN - NLM
STAT- In-Data-Review
LR  - 20180129
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 553
IP  - 7689
DP  - 2018 Jan 25
TI  - Monitoring T cell-dendritic cell interactions in vivo by intercellular enzymatic 
      labelling.
PG  - 496-500
LID - 10.1038/nature25442 [doi]
AB  - Interactions between different cell types are essential for multiple biological
      processes, including immunity, embryonic development and neuronal signalling.
      Although the dynamics of cell-cell interactions can be monitored in vivo by
      intravital microscopy, this approach does not provide any information on the
      receptors and ligands involved or enable the isolation of interacting cells for
      downstream analysis. Here we describe a complementary approach that uses
      bacterial sortase A-mediated cell labelling across synapses of immune cells to
      identify receptor-ligand interactions between cells in living mice, by generating
      a signal that can subsequently be detected ex vivo by flow cytometry. We call
      this approach for the labelling of 'kiss-and-run' interactions between immune
      cells 'Labelling Immune Partnerships by SorTagging Intercellular Contacts'
      (LIPSTIC). Using LIPSTIC, we show that interactions between dendritic cells and
      CD4(+) T cells during T-cell priming in vivo occur in two distinct modalities: an
      early, cognate stage, during which CD40-CD40L interactions occur specifically
      between T cells and antigen-loaded dendritic cells; and a later, non-cognate
      stage during which these interactions no longer require prior engagement of the
      T-cell receptor. Therefore, LIPSTIC enables the direct measurement of dynamic
      cell-cell interactions both in vitro and in vivo. Given its flexibility for use
      with different receptor-ligand pairs and a range of detectable labels, we expect 
      that this approach will be of use to any field of biology requiring
      quantification of intercellular communication.
FAU - Pasqual, Giulia
AU  - Pasqual G
AD  - Laboratory of Lymphocyte Dynamics, The Rockefeller University, 1230 York Avenue, 
      New York, New York, USA.
FAU - Chudnovskiy, Aleksey
AU  - Chudnovskiy A
AD  - Laboratory of Lymphocyte Dynamics, The Rockefeller University, 1230 York Avenue, 
      New York, New York, USA.
FAU - Tas, Jeroen M J
AU  - Tas JMJ
AD  - Laboratory of Lymphocyte Dynamics, The Rockefeller University, 1230 York Avenue, 
      New York, New York, USA.
FAU - Agudelo, Marianna
AU  - Agudelo M
AD  - Laboratory of Lymphocyte Dynamics, The Rockefeller University, 1230 York Avenue, 
      New York, New York, USA.
FAU - Schweitzer, Lawrence D
AU  - Schweitzer LD
AD  - Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
AD  - Center for Cancer Research, Massachusetts General Hospital, Department of
      Medicine, Boston, Massachusetts, USA.
FAU - Cui, Ang
AU  - Cui A
AD  - Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
AD  - Center for Cancer Research, Massachusetts General Hospital, Department of
      Medicine, Boston, Massachusetts, USA.
FAU - Hacohen, Nir
AU  - Hacohen N
AD  - Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
AD  - Center for Cancer Research, Massachusetts General Hospital, Department of
      Medicine, Boston, Massachusetts, USA.
FAU - Victora, Gabriel D
AU  - Victora GD
AD  - Laboratory of Lymphocyte Dynamics, The Rockefeller University, 1230 York Avenue, 
      New York, New York, USA.
LA  - eng
PT  - Journal Article
DEP - 20180117
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
EDAT- 2018/01/18 06:00
MHDA- 2018/01/18 06:00
CRDT- 2018/01/18 06:00
PHST- 2017/06/14 00:00 [received]
PHST- 2017/12/08 00:00 [accepted]
PHST- 2018/01/18 06:00 [pubmed]
PHST- 2018/01/18 06:00 [medline]
PHST- 2018/01/18 06:00 [entrez]
AID - nature25442 [pii]
AID - 10.1038/nature25442 [doi]
PST - ppublish
SO  - Nature. 2018 Jan 25;553(7689):496-500. doi: 10.1038/nature25442. Epub 2018 Jan
      17.

PMID- 29364875
OWN - NLM
STAT- Publisher
LR  - 20180124
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
DP  - 2018 Jan 24
TI  - Tissue-selective effects of nucleolar stress and rDNA damage in developmental
      disorders.
LID - 10.1038/nature25449 [doi]
AB  - Many craniofacial disorders are caused by heterozygous mutations in general
      regulators of housekeeping cellular functions such as transcription or ribosome
      biogenesis. Although it is understood that many of these malformations are a
      consequence of defects in cranial neural crest cells, a cell type that gives rise
      to most of the facial structures during embryogenesis, the mechanism underlying
      cell-type selectivity of these defects remains largely unknown. By exploring
      molecular functions of DDX21, a DEAD-box RNA helicase involved in control of both
      RNA polymerase (Pol) I- and II-dependent transcriptional arms of ribosome
      biogenesis, we uncovered a previously unappreciated mechanism linking nucleolar
      dysfunction, ribosomal DNA (rDNA) damage, and craniofacial malformations. Here we
      demonstrate that genetic perturbations associated with Treacher Collins syndrome,
      a craniofacial disorder caused by heterozygous mutations in components of the Pol
      I transcriptional machinery or its cofactor TCOF1 (ref. 1), lead to
      relocalization of DDX21 from the nucleolus to the nucleoplasm, its loss from the 
      chromatin targets, as well as inhibition of rRNA processing and downregulation of
      ribosomal protein gene transcription. These effects are cell-type-selective,
      cell-autonomous, and involve activation of p53 tumour-suppressor protein. We
      further show that cranial neural crest cells are sensitized to p53-mediated
      apoptosis, but blocking DDX21 loss from the nucleolus and chromatin rescues both 
      the susceptibility to apoptosis and the craniofacial phenotypes associated with
      Treacher Collins syndrome. This mechanism is not restricted to cranial neural
      crest cells, as blood formation is also hypersensitive to loss of DDX21
      functions. Accordingly, ribosomal gene perturbations associated with
      Diamond-Blackfan anaemia disrupt DDX21 localization. At the molecular level, we
      demonstrate that impaired rRNA synthesis elicits a DNA damage response, and that 
      rDNA damage results in tissue-selective and dosage-dependent effects on
      craniofacial development. Taken together, our findings illustrate how disruption 
      in general regulators that compromise nucleolar homeostasis can result in
      tissue-selective malformations.
FAU - Calo, Eliezer
AU  - Calo E
AD  - Department of Biology, Massachusetts Institute of Technology, Cambridge,
      Massachusetts 02139, USA.
AD  - David H. Koch Institute for Integrative Cancer Research, Cambridge, Massachusetts
      02139, USA.
FAU - Gu, Bo
AU  - Gu B
AD  - Department of Chemical and Systems Biology, Stanford University School of
      Medicine, Stanford, California 94305, USA.
FAU - Bowen, Margot E
AU  - Bowen ME
AD  - Department of Radiation Oncology, Division of Radiation and Cancer Biology,
      Stanford University School of Medicine, Stanford, California 94305, USA.
FAU - Aryan, Fardin
AU  - Aryan F
AD  - Department of Biology, Massachusetts Institute of Technology, Cambridge,
      Massachusetts 02139, USA.
FAU - Zalc, Antoine
AU  - Zalc A
AD  - Department of Chemical and Systems Biology, Stanford University School of
      Medicine, Stanford, California 94305, USA.
FAU - Liang, Jialiang
AU  - Liang J
AD  - Department of Biology, Massachusetts Institute of Technology, Cambridge,
      Massachusetts 02139, USA.
FAU - Flynn, Ryan A
AU  - Flynn RA
AD  - Department of Chemistry, Stanford University, Stanford, California 94305, USA.
FAU - Swigut, Tomek
AU  - Swigut T
AD  - Department of Chemical and Systems Biology, Stanford University School of
      Medicine, Stanford, California 94305, USA.
FAU - Chang, Howard Y
AU  - Chang HY
AD  - Center for Personal Dynamic Regulomes, Stanford University, 269 Campus Drive,
      Stanford, California 94305, USA.
FAU - Attardi, Laura D
AU  - Attardi LD
AD  - Department of Radiation Oncology, Division of Radiation and Cancer Biology,
      Stanford University School of Medicine, Stanford, California 94305, USA.
AD  - Department of Genetics, Stanford University School of Medicine, Stanford,
      California 94305, USA.
FAU - Wysocka, Joanna
AU  - Wysocka J
AD  - Department of Chemical and Systems Biology, Stanford University School of
      Medicine, Stanford, California 94305, USA.
AD  - Department of Developmental Biology, Stanford University School of Medicine,
      Stanford, California 94305, USA.
AD  - Howard Hughes Medical Institute, Stanford School of Medicine, Stanford
      University, Stanford, California 94305, USA.
LA  - eng
PT  - Journal Article
DEP - 20180124
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
EDAT- 2018/01/25 06:00
MHDA- 2018/01/25 06:00
CRDT- 2018/01/25 06:00
PHST- 2016/11/01 00:00 [received]
PHST- 2017/12/11 00:00 [accepted]
PHST- 2018/01/25 06:00 [entrez]
PHST- 2018/01/25 06:00 [pubmed]
PHST- 2018/01/25 06:00 [medline]
AID - nature25449 [pii]
AID - 10.1038/nature25449 [doi]
PST - aheadofprint
SO  - Nature. 2018 Jan 24. pii: nature25449. doi: 10.1038/nature25449.

PMID- 29275860
OWN - NLM
STAT- In-Data-Review
LR  - 20180128
IS  - 1097-4172 (Electronic)
IS  - 0092-8674 (Linking)
VI  - 172
IP  - 3
DP  - 2018 Jan 25
TI  - Antigen Identification for Orphan T Cell Receptors Expressed on
      Tumor-Infiltrating Lymphocytes.
PG  - 549-563.e16
LID - S0092-8674(17)31433-2 [pii]
LID - 10.1016/j.cell.2017.11.043 [doi]
AB  - The immune system can mount T cell responses against tumors; however, the antigen
      specificities of tumor-infiltrating lymphocytes (TILs) are not well understood.
      We used yeast-display libraries of peptide-human leukocyte antigen (pHLA) to
      screen for antigens of "orphan" T cell receptors (TCRs) expressed on TILs from
      human colorectal adenocarcinoma. Four TIL-derived TCRs exhibited strong selection
      for peptides presented in a highly diverse pHLA-A( *)02:01 library. Three of the 
      TIL TCRs were specific for non-mutated self-antigens, two of which were present
      in separate patient tumors, and shared specificity for a non-mutated self-antigen
      derived from U2AF2. These results show that the exposed recognition surface of
      MHC-bound peptides accessible to the TCR contains sufficient structural
      information to enable the reconstruction of sequences of peptide targets for
      pathogenic TCRs of unknown specificity. This finding underscores the surprising
      specificity of TCRs for their cognate antigens and enables the facile
      indentification of tumor antigens through unbiased screening.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Gee, Marvin H
AU  - Gee MH
AD  - Program in Immunology, Stanford University School of Medicine, Stanford, CA
      94305, USA; Departments of Molecular and Cellular Physiology and Structural
      Biology, Stanford University School of Medicine, Stanford, CA 94305, USA.
FAU - Han, Arnold
AU  - Han A
AD  - Institute for Immunity, Transplantation, and Infection, Stanford University
      School of Medicine, Stanford, CA 94305, USA; Department of Microbiology and
      Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA.
FAU - Lofgren, Shane M
AU  - Lofgren SM
AD  - Institute for Immunity, Transplantation, and Infection, Stanford University
      School of Medicine, Stanford, CA 94305, USA; Department of Medicine, Stanford
      University School of Medicine, Stanford, CA 94305, USA.
FAU - Beausang, John F
AU  - Beausang JF
AD  - Department of Bioengineering, Stanford University School of Medicine, Stanford,
      CA 94305, USA.
FAU - Mendoza, Juan L
AU  - Mendoza JL
AD  - Departments of Molecular and Cellular Physiology and Structural Biology, Stanford
      University School of Medicine, Stanford, CA 94305, USA.
FAU - Birnbaum, Michael E
AU  - Birnbaum ME
AD  - Program in Immunology, Stanford University School of Medicine, Stanford, CA
      94305, USA; Departments of Molecular and Cellular Physiology and Structural
      Biology, Stanford University School of Medicine, Stanford, CA 94305, USA.
FAU - Bethune, Michael T
AU  - Bethune MT
AD  - Division of Biology and Biological Engineering, California Institute of
      Technology, Pasadena, CA 91125, USA.
FAU - Fischer, Suzanne
AU  - Fischer S
AD  - Departments of Molecular and Cellular Physiology and Structural Biology, Stanford
      University School of Medicine, Stanford, CA 94305, USA.
FAU - Yang, Xinbo
AU  - Yang X
AD  - Departments of Molecular and Cellular Physiology and Structural Biology, Stanford
      University School of Medicine, Stanford, CA 94305, USA.
FAU - Gomez-Eerland, Raquel
AU  - Gomez-Eerland R
AD  - Division of Immunology, The Netherlands Cancer Institute, Amsterdam, the
      Netherlands.
FAU - Bingham, David B
AU  - Bingham DB
AD  - Department of Medicine, Stanford University School of Medicine, Stanford, CA
      94305, USA.
FAU - Sibener, Leah V
AU  - Sibener LV
AD  - Program in Immunology, Stanford University School of Medicine, Stanford, CA
      94305, USA; Departments of Molecular and Cellular Physiology and Structural
      Biology, Stanford University School of Medicine, Stanford, CA 94305, USA.
FAU - Fernandes, Ricardo A
AU  - Fernandes RA
AD  - Departments of Molecular and Cellular Physiology and Structural Biology, Stanford
      University School of Medicine, Stanford, CA 94305, USA.
FAU - Velasco, Andrew
AU  - Velasco A
AD  - Departments of Molecular and Cellular Physiology and Structural Biology, Stanford
      University School of Medicine, Stanford, CA 94305, USA.
FAU - Baltimore, David
AU  - Baltimore D
AD  - Division of Biology and Biological Engineering, California Institute of
      Technology, Pasadena, CA 91125, USA.
FAU - Schumacher, Ton N
AU  - Schumacher TN
AD  - Division of Immunology, The Netherlands Cancer Institute, Amsterdam, the
      Netherlands.
FAU - Khatri, Purvesh
AU  - Khatri P
AD  - Institute for Immunity, Transplantation, and Infection, Stanford University
      School of Medicine, Stanford, CA 94305, USA; Department of Medicine, Stanford
      University School of Medicine, Stanford, CA 94305, USA.
FAU - Quake, Stephen R
AU  - Quake SR
AD  - Department of Bioengineering, Stanford University School of Medicine, Stanford,
      CA 94305, USA; Chan Zuckerberg Biohub, San Francisco, CA 94158, USA.
FAU - Davis, Mark M
AU  - Davis MM
AD  - Institute for Immunity, Transplantation, and Infection, Stanford University
      School of Medicine, Stanford, CA 94305, USA; Department of Microbiology and
      Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA; The 
      Howard Hughes Medical Institute, Stanford University School of Medicine,
      Stanford, CA 94305, USA.
FAU - Garcia, K Christopher
AU  - Garcia KC
AD  - Departments of Molecular and Cellular Physiology and Structural Biology, Stanford
      University School of Medicine, Stanford, CA 94305, USA; The Howard Hughes Medical
      Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.
      Electronic address: kcgarcia@stanford.edu.
LA  - eng
GR  - Howard Hughes Medical Institute/United States
GR  - R01 AI048540/AI/NIAID NIH HHS/United States
GR  - U19 AI057229/AI/NIAID NIH HHS/United States
PT  - Journal Article
DEP - 20171221
PL  - United States
TA  - Cell
JT  - Cell
JID - 0413066
PMC - PMC5786495
MID - NIHMS929818
OTO - NOTNLM
OT  - T cell
OT  - T cell receptor
OT  - antigens
OT  - cancer
OT  - combinatorial biology
OT  - human leukocyte antigen
OT  - ligand identification
OT  - peptide library
OT  - peptides
OT  - single-cell sequencing
EDAT- 2017/12/26 06:00
MHDA- 2017/12/26 06:00
CRDT- 2017/12/26 06:00
PMCR- 2019/01/25 00:00
PHST- 2017/07/07 00:00 [received]
PHST- 2017/10/30 00:00 [revised]
PHST- 2017/11/22 00:00 [accepted]
PHST- 2019/01/25 00:00 [pmc-release]
PHST- 2017/12/26 06:00 [pubmed]
PHST- 2017/12/26 06:00 [medline]
PHST- 2017/12/26 06:00 [entrez]
AID - S0092-8674(17)31433-2 [pii]
AID - 10.1016/j.cell.2017.11.043 [doi]
PST - ppublish
SO  - Cell. 2018 Jan 25;172(3):549-563.e16. doi: 10.1016/j.cell.2017.11.043. Epub 2017 
      Dec 21.

PMID- 29313530
OWN - NLM
STAT- Publisher
LR  - 20180119
IS  - 1748-7838 (Electronic)
IS  - 1001-0602 (Linking)
DP  - 2018 Jan 9
TI  - Histone H3 lysine 4 monomethylation modulates long-range chromatin interactions
      at enhancers.
LID - 10.1038/cr.2018.1 [doi]
AB  - Long-range chromatin interactions between enhancers and promoters are essential
      for transcription of many developmentally controlled genes in mammals and other
      metazoans. Currently, the exact mechanisms that connect distal enhancers to their
      specific target promoters remain to be fully elucidated. Here, we show that the
      enhancer-specific histone H3 lysine 4 monomethylation (H3K4me1) and the histone
      methyltransferases MLL3 and MLL4 (MLL3/4) play an active role in this process. We
      demonstrate that in differentiating mouse embryonic stem cells, MLL3/4-dependent 
      deposition of H3K4me1 at enhancers correlates with increased levels of chromatin 
      interactions, whereas loss of this histone modification leads to reduced levels
      of chromatin interactions and defects in gene activation during differentiation. 
      H3K4me1 facilitates recruitment of the Cohesin complex, a known regulator of
      chromatin organization, to chromatin in vitro and in vivo, providing a potential 
      mechanism for MLL3/4 to promote chromatin interactions between enhancers and
      promoters. Taken together, our results support a role for MLL3/4-dependent
      H3K4me1 in orchestrating long-range chromatin interactions at enhancers in
      mammalian cells.Cell Research advance online publication 9 January 2018;
      doi:10.1038/cr.2018.1.
FAU - Yan, Jian
AU  - Yan J
AD  - Ludwig Institute for Cancer Research, 9500 Gilman Dr., La Jolla, CA 92093, USA.
AD  - Department of Medical Biochemistry and Biophysics, Division of Functional
      Genomics and Systems Biology, Karolinska Institutet, 171 65 Stockholm, Sweden.
FAU - Chen, Shi-An A
AU  - Chen SA
AD  - Ludwig Institute for Cancer Research, 9500 Gilman Dr., La Jolla, CA 92093, USA.
FAU - Local, Andrea
AU  - Local A
AD  - Ludwig Institute for Cancer Research, 9500 Gilman Dr., La Jolla, CA 92093, USA.
AD  - Current address: Aptose Biosciences Inc., 3550 General Atomics Ct, San Diego, CA 
      92122, USA.
FAU - Liu, Tristin
AU  - Liu T
AD  - Ludwig Institute for Cancer Research, 9500 Gilman Dr., La Jolla, CA 92093, USA.
FAU - Qiu, Yunjiang
AU  - Qiu Y
AD  - Ludwig Institute for Cancer Research, 9500 Gilman Dr., La Jolla, CA 92093, USA.
FAU - Dorighi, Kristel M
AU  - Dorighi KM
AD  - Department of Chemical and Systems Biology, Stanford University School of
      Medicine, Stanford, CA 94305, USA.
FAU - Preissl, Sebastian
AU  - Preissl S
AD  - Ludwig Institute for Cancer Research, 9500 Gilman Dr., La Jolla, CA 92093, USA.
FAU - Rivera, Chloe M
AU  - Rivera CM
AD  - Ludwig Institute for Cancer Research, 9500 Gilman Dr., La Jolla, CA 92093, USA.
FAU - Wang, Chaochen
AU  - Wang C
AD  - Laboratory of Endocrinology and Receptor Biology, National Institute of Diabetes 
      and Digestive and Kidney Diseases, NIH, Bethesda, MD 20892, USA.
FAU - Ye, Zhen
AU  - Ye Z
AD  - Ludwig Institute for Cancer Research, 9500 Gilman Dr., La Jolla, CA 92093, USA.
FAU - Ge, Kai
AU  - Ge K
AD  - Laboratory of Endocrinology and Receptor Biology, National Institute of Diabetes 
      and Digestive and Kidney Diseases, NIH, Bethesda, MD 20892, USA.
FAU - Hu, Ming
AU  - Hu M
AD  - Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland 
      Clinic Foundation, Cleveland, OH 44195, USA.
FAU - Wysocka, Joanna
AU  - Wysocka J
AD  - Department of Chemical and Systems Biology, Stanford University School of
      Medicine, Stanford, CA 94305, USA.
FAU - Ren, Bing
AU  - Ren B
AD  - Ludwig Institute for Cancer Research, 9500 Gilman Dr., La Jolla, CA 92093, USA.
AD  - Department of Cellular and Molecular Medicine, University of California San
      Diego, School of Medicine, Institute of Genomic Medicine, 9500 Gilman Dr., La
      Jolla, CA 92093, USA.
LA  - eng
GR  - P50 GM085764/GM/NIGMS NIH HHS/United States
GR  - U54 DK107977/DK/NIDDK NIH HHS/United States
PT  - Journal Article
DEP - 20180109
PL  - England
TA  - Cell Res
JT  - Cell research
JID - 9425763
EDAT- 2018/01/10 06:00
MHDA- 2018/01/10 06:00
CRDT- 2018/01/10 06:00
PHST- 2017/02/17 00:00 [received]
PHST- 2017/04/05 00:00 [revised]
PHST- 2017/11/14 00:00 [accepted]
PHST- 2018/01/10 06:00 [entrez]
PHST- 2018/01/10 06:00 [pubmed]
PHST- 2018/01/10 06:00 [medline]
AID - cr20181 [pii]
AID - 10.1038/cr.2018.1 [doi]
PST - aheadofprint
SO  - Cell Res. 2018 Jan 9. pii: cr20181. doi: 10.1038/cr.2018.1.
